{"id": 2211776, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "310acabc-bb34-4e3b-a8e0-20c070e67b48", "title": "AHA心脏病与卒中统计报告（2022年更新）", "text": "【0】页码:230\nAHA心脏病与卒中统计报告（2022年更新）\n## Table 14-2. Continued\n\n| State         | CVD           |               | CHD            |                      | Stroke          |                     |\n|---------------|---------------|---------------|----------------|----------------------|-----------------|---------------------|\n|               | Rank          | Death rate    | % Change,     | Rank                 | Death rate      | % Change,          | Rank          | Death rate      | % Change, 2007-2009 to 2017-2019   |\n|               |               |  2007-2009 to | 2017-2019      |                      | 2007-2009 to    | Rank      | Death rate      | % Change, 2007-2009 to 2017-2019   |\n|               |               | 2017-2019     |                |                      | 2017-2019       |           |               |     \n| Kansas        | 32            | 218.2         | -9.9           | 34                   | 94.9            | -7.0\n| Kentucky      | 45            | 253.6         | -12.3          | 37                   | 100.9           | -27.4\n| Louisiana     | 48            | 270.4         | -10.8          | 33                   | 94.7            | -27.1\n| Maine         | 12            | 192.3         | -12.3          | 13                   | 72.1            | -25.4\n| Maryland      | 34            | 219.6         | -13.6          | 30                   | 90.0            | -32.7\n| Massachusetts | 3             | 171.8         | -19.1          | 6                    | 65.9            | -35.5\n| Michigan      | 43            | 251.5         | -9.7           | 47                   | 112.0           | -23.5\n| Minnesota     | 2             | 166.6         | -7.5           | 1                    | 60.4            | -17.1\n| Mississippi   | 52            | 300.8         | -13.0          | 45                   | 105.6           | -23.5\n| Missouri      | 41            | 243.6         | -13.4          | 43                   | 102.5           | -29.7\n| Montana       | 23            | 204.7         | -6.4           | 28                   | 88.2            | -5.1\n| Nebraska      | 17            | 197.2         | -11.4          | 10                   | 73.4            | -17.4\n| Nevada        | 44            | 251.8         | -3.1           | 46                   | 107.3           | 3.1\n| New Hampshire | 11            | 189.8         | -11.5          | 15                   | 78.2            | -27.8\n| New Jersey    | 24            | 205.2         | -13.4          | 27                   | 87.9            | -31.1\n| New Mexico    | 20            | 199.0         | -7.0           | 44                   | 102.6           | -5.0\n| New York      | 28            | 211.6         | -21.0          | 48                   | 115.6           | -32.0\n| North Carolina| 29            | 213.3         | -16.1          | 21                   | 82.4            | -30.3\n| North Dakota  | 14            | 195.5         | -10.4          | 22                   | 82.9            | -29.2\n| Ohio          | 42            | 248.9         | -6.3           | 41                   | 101.4           | -25.3\n| Oklahoma      | 50            | 289.7         | -8.6           | 50                   | 120.9           | -25.4\n| Oregon        | 10            | 189.1         | -10.9          | 24                   | 61.9            | -30.5\n| Pennsylvania  | 36            | 224.2         | -12.8          | 32                   | 94.2            | -26.0\n| Puerto Rico   | 51            | 151.4         | -22.8          | 8                    | 68.0            | -24.4\n| Rhode Island  | 21            | 200.5         | -15.5          | 38                   | 100.9           | -32.4\n| South Carolina| 37            | 229.1         | -14.0          | 18                   | 82.2            | -26.7\n| South Dakota  | 27            | 206.9         | -8.2           | 39                   | 101.1           | -19.8\n| Tennessee     | 47            | 263.8         | -10.9          | 49                   | 120.5           | -25.1\n| Texas         | 35            | 222.7         | -13.5          | 31                   | 93.0            | -24.2\n| Utah          | 15            | 195.6         | -4.8           | 4                    | 63.2            | -15.0\n| Vermont       | 19            | 198.5         | -6.4           | 35                   | 96.2            | -14.4\n| Virginia      | 22            | 203.7         | -15.3          | 12                   | 75.5            | -27.8\n| Washington    | 9             | 188.1         | -15.2          | 14                   | 77.9            | -29.6\n| West Virginia | 46            | 257.6         | -14.1          | 51                   | 127.5           | -15.6\n| Wisconsin     | 26            | 206.7         | -8.5           | 26                   | 86.9            | -17.7\n| Wyoming       | 13            | 195.3         | -16.1          | 19                   | 82.3            | -18.3\n\n---|删除段之间换行|Rates are most current data available as of March 2020. Rates are per 100,000 people. 删除32:<u>*</u>International Classification of Diseases, 10th Revision codes used were I00 to I99 for CVD, I20 to I25 for CHD, and I60 to I69 for stroke.\n\n【3】CHD indicates coronary heart disease; and CVD, cardiovascular disease.\n\n【4】Sources: Unpublished National Heart, Lung, and Blood Institute tabulation using National Vital Statistics System data.", "tags": {}, "lang": "en", "attr": {"page_num": 230, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/AHA心脏病与卒中统计报告（2022年更新）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Table 14-2. Continued\nState\tCVD\t\tCHD\t\tStroke\t\nRank\tDeath rate\t% Change,\tRank\tDeath rate\t% Change,\n2007-2009 to\t2017-2019\t\t2007-2009 to\tRank\n2017-2019\t\t\t2017-2019\t", "content": "【0】页码:230\nAHA心脏病与卒中统计报告（2022年更新）\n## Table 14-2. Continued\n\n| State         | CVD           |               | CHD            |                      | Stroke          |                     |\n|---------------|---------------|---------------|----------------|----------------------|-----------------|---------------------|\n|               | Rank          | Death rate    | % Change,     | Rank                 | Death rate      | % Change,          | Rank          | Death rate      | % Change, 2007-2009 to 2017-2019   |\n|               |               |  2007-2009 to | 2017-2019      |                      | 2007-2009 to    | Rank      | Death rate      | % Change, 2007-2009 to 2017-2019   |\n|               |               | 2017-2019     |                |                      | 2017-2019       |           |               |     \n| Kansas        | 32            | 218.2         | -9.9           | 34                   | 94.9            | -7.0\n| Kentucky      | 45            | 253.6         | -12.3          | 37                   | 100.9           | -27.4\n| Louisiana     | 48            | 270.4         | -10.8          | 33                   | 94.7            | -27.1\n| Maine         | 12            | 192.3         | -12.3          | 13                   | 72.1            | -25.4\n| Maryland      | 34            | 219.6         | -13.6          | 30                   | 90.0            | -32.7\n| Massachusetts | 3             | 171.8         | -19.1          | 6                    | 65.9            | -35.5\n| Michigan      | 43            | 251.5         | -9.7           | 47                   | 112.0           | -23.5\n| Minnesota     | 2             | 166.6         | -7.5           | 1                    | 60.4            | -17.1\n| Mississippi   | 52            | 300.8         | -13.0          | 45                   | 105.6           | -23.5\n| Missouri      | 41            | 243.6         | -13.4          | 43                   | 102.5           | -29.7\n| Montana       | 23            | 204.7         | -6.4           | 28                   | 88.2            | -5.1\n| Nebraska      | 17            | 197.2         | -11.4          | 10                   | 73.4            | -17.4\n| Nevada        | 44            | 251.8         | -3.1           | 46                   | 107.3           | 3.1\n| New Hampshire | 11            | 189.8         | -11.5          | 15                   | 78.2            | -27.8\n| New Jersey    | 24            | 205.2         | -13.4          | 27                   | 87.9            | -31.1\n| New Mexico    | 20            | 199.0         | -7.0           | 44                   | 102.6           | -5.0\n| New York      | 28            | 211.6         | -21.0          | 48                   | 115.6           | -32.0\n| North Carolina| 29            | 213.3         | -16.1          | 21                   | 82.4            | -30.3\n| North Dakota  | 14            | 195.5         | -10.4          | 22                   | 82.9            | -29.2\n| Ohio          | 42            | 248.9         | -6.3           | 41                   | 101.4           | -25.3\n| Oklahoma      | 50            | 289.7         | -8.6           | 50                   | 120.9           | -25.4\n| Oregon        | 10            | 189.1         | -10.9          | 24                   | 61.9            | -30.5\n| Pennsylvania  | 36            | 224.2         | -12.8          | 32                   | 94.2            | -26.0\n| Puerto Rico   | 51            | 151.4         | -22.8          | 8                    | 68.0            | -24.4\n| Rhode Island  | 21            | 200.5         | -15.5          | 38                   | 100.9           | -32.4\n| South Carolina| 37            | 229.1         | -14.0          | 18                   | 82.2            | -26.7\n| South Dakota  | 27            | 206.9         | -8.2           | 39                   | 101.1           | -19.8\n| Tennessee     | 47            | 263.8         | -10.9          | 49                   | 120.5           | -25.1\n| Texas         | 35            | 222.7         | -13.5          | 31                   | 93.0            | -24.2\n| Utah          | 15            | 195.6         | -4.8           | 4                    | 63.2            | -15.0\n| Vermont       | 19            | 198.5         | -6.4           | 35                   | 96.2            | -14.4\n| Virginia      | 22            | 203.7         | -15.3          | 12                   | 75.5            | -27.8\n| Washington    | 9             | 188.1         | -15.2          | 14                   | 77.9            | -29.6\n| West Virginia | 46            | 257.6         | -14.1          | 51                   | 127.5           | -15.6\n| Wisconsin     | 26            | 206.7         | -8.5           | 26                   | 86.9            | -17.7\n| Wyoming       | 13            | 195.3         | -16.1          | 19                   | 82.3            | -18.3\n\n---|删除段之间换行|Rates are most current data available as of March 2020. Rates are per 100,000 people. 删除32:<u>*</u>International Classification of Diseases, 10th Revision codes used were I00 to I99 for CVD, I20 to I25 for CHD, and I60 to I69 for stroke.\n\n【3】CHD indicates coronary heart disease; and CVD, cardiovascular disease.\n\n【4】Sources: Unpublished National Heart, Lung, and Blood Institute tabulation using National Vital Statistics System data.", "index": 36, "show": true, "start": 36, "end": 198, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "0  表格前面格式有误"}], "startTime": "2024/08/06 16:41:15", "endTime": "2024/08/06 16:42:18", "cost": 62.966}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-06 00:42:18", "grab_time": "2024-08-06 00:41:15"}
{"id": 2211775, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "3af0d80c-dd0a-4d01-b105-75b948fae556", "title": "（2024.V1）NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌", "text": "【0】页码:74\n（2024.V1）NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌\n疑似页眉<u># NCCN Guidelines Version 1.2024 Ovarian Cancer</u>\n\n【1】## Screening with Other Biomarker Tests\n\n【2】In addition to CA-125, there are a number of biomarkers that have been explored as possible screening tools for early detection of ovarian cancer. Data for most of these proposed biomarkers is limited to retrospective analyses comparing biomarker levels in patients with known ovarian cancer versus healthy controls. Very few biomarkers have been tested prospectively to determine whether they can detect ovarian cancer or predict development of ovarian cancer in those who have no other signs or symptoms of cancer. Data show that several markers (including CA-125, HE4, mesothelin, B7-H4, decoy receptor 3 删除12:<u>[DcR3]</u>, and spondin-2) do not increase early enough to be useful in detecting early-stage ovarian cancer.\n\n【3】There are a number of biomarker tests and prediction algorithms (based on a variety of factors, such as symptoms, imaging results, biomarkers, and patient characteristics) that have been developed for assessing the likelihood of malignancy among patients who have an adnexal mass (and have not yet had surgery). It is important to note that these tests are for preoperative assessment only, and none is suitable for ovarian cancer screening prior to detection of an adnexal mass; they are also not for use as stand-alone diagnostic tests. For example, the OVA1 test is a multivariate index assay (MIA) that uses five markers (including transthyretin, apolipoprotein A1, transferrin, beta-2 microglobulin, and CA-125) in preoperative serum to assess the likelihood of malignancy in patients with an adnexal mass for which surgery is planned, with the aim of helping community practitioners determine which patients to refer to a gynecologic oncologist for evaluation and surgery. The Society of Gynecologic Oncology (SGO) and the FDA have stated that the OVA1 test should not be used as a screening tool to detect ovarian cancer in patients without any other signs of cancer, or as a stand-alone diagnostic tool. Moreover, based on data documenting an increased survival, the NCCN Guidelines Panel recommends that all patients with suspected ovarian malignancies (especially those with an adnexal mass) should undergo evaluation by an experienced gynecologic oncologist prior to surgery. For discussion of preoperative tests recommended by NCCN for patients with an undiagnosed adnexal mass, see the section below entitled 删除32:<u>**</u>Recommended Workup, Patients Presenting with Clinical Symptoms/Signs删除32:<u>**</u>.\n\n【4】## Risk-Reducing Salpingo-Oophorectomy (RRSO) Protocol\n\n【5】The RRSO protocol is recommended for patients at risk for HBOC and is described in detail in the algorithm 删除9:<u>(see the 删除32:<u>**</u>Principles of Surgery删除32:<u>**</u> in the algorithm)</u>. Selection of patients appropriate for this procedure is described in the 删除32:<u>**</u>NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic删除32:<u>**</u> . In addition to reducing the risk of breast, ovarian, fallopian tube, and primary peritoneal cancers in patients at high risk, RRSO can also result in early diagnosis of gynecologic cancer. Occult ovarian, fallopian tube, and primary peritoneal cancer is sometimes found by RRSO (in 3.5%-4.6% of patients with BRCA1/2 mutations), and in some cases only detected by pathologic examination of specimens. This emphasizes the need for well-tested protocols that include careful pathologic review of the ovaries and tubes.\n\n【6】This protocol recommends minimally invasive laparoscopic surgery. This procedure should include a survey of the upper abdomen, bowel surfaces, omentum, appendix (if present), and pelvic organs. Any abnormal peritoneal findings should be biopsied. Pelvic washing for cytology should be obtained, using approximately 55 cc normal saline instilled and aspirated immediately. The procedure should include total BSO, removing 2 cm of proximal ovarian vasculature or IP ligament, all of the fallopian tube up to the cornua, and all of the peritoneum surrounding the ovaries and fallopian tubes, especially the peritoneum underlying areas of adhesion between the fallopian tube and/or ovary and the pelvic.", "tags": {}, "lang": "en", "attr": {"page_num": 74, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2024.V1）NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】## Screening with Other Biomarker Tests\n\n【2】", "content": "【0】页码:74\n（2024.V1）NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌\n疑似页眉<u># NCCN Guidelines Version 1.2024 Ovarian Cancer</u>\n\n【1】## Screening with Other Biomarker Tests\n\n【2】In addition to CA-125, there are a number of biomarkers that have been explored as possible screening tools for early detection of ovarian cancer. Data for most of these proposed biomarkers is limited to retrospective analyses comparing biomarker levels in patients with known ovarian cancer versus healthy controls. Very few biomarkers have been tested prospectively to determine whether they can detect ovarian cancer or predict development of ovarian cancer in those who have no other signs or symptoms of cancer. Data show that several markers (including CA-125, HE4, mesothelin, B7-H4, decoy receptor 3 删除12:<u>[DcR3]</u>, and spondin-2) do not increase early enough to be useful in detecting early-stage ovarian cancer.\n\n【3】There are a number of biomarker tests and prediction algorithms (based on a variety of factors, such as symptoms, imaging results, biomarkers, and patient characteristics) that have been developed for assessing the likelihood of malignancy among patients who have an adnexal mass (and have not yet had surgery). It is important to note that these tests are for preoperative assessment only, and none is suitable for ovarian cancer screening prior to detection of an adnexal mass; they are also not for use as stand-alone diagnostic tests. For example, the OVA1 test is a multivariate index assay (MIA) that uses five markers (including transthyretin, apolipoprotein A1, transferrin, beta-2 microglobulin, and CA-125) in preoperative serum to assess the likelihood of malignancy in patients with an adnexal mass for which surgery is planned, with the aim of helping community practitioners determine which patients to refer to a gynecologic oncologist for evaluation and surgery. The Society of Gynecologic Oncology (SGO) and the FDA have stated that the OVA1 test should not be used as a screening tool to detect ovarian cancer in patients without any other signs of cancer, or as a stand-alone diagnostic tool. Moreover, based on data documenting an increased survival, the NCCN Guidelines Panel recommends that all patients with suspected ovarian malignancies (especially those with an adnexal mass) should undergo evaluation by an experienced gynecologic oncologist prior to surgery. For discussion of preoperative tests recommended by NCCN for patients with an undiagnosed adnexal mass, see the section below entitled 删除32:<u>**</u>Recommended Workup, Patients Presenting with Clinical Symptoms/Signs删除32:<u>**</u>.\n\n【4】## Risk-Reducing Salpingo-Oophorectomy (RRSO) Protocol\n\n【5】The RRSO protocol is recommended for patients at risk for HBOC and is described in detail in the algorithm 删除9:<u>(see the 删除32:<u>**</u>Principles of Surgery删除32:<u>**</u> in the algorithm)</u>. Selection of patients appropriate for this procedure is described in the 删除32:<u>**</u>NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic删除32:<u>**</u> . In addition to reducing the risk of breast, ovarian, fallopian tube, and primary peritoneal cancers in patients at high risk, RRSO can also result in early diagnosis of gynecologic cancer. Occult ovarian, fallopian tube, and primary peritoneal cancer is sometimes found by RRSO (in 3.5%-4.6% of patients with BRCA1/2 mutations), and in some cases only detected by pathologic examination of specimens. This emphasizes the need for well-tested protocols that include careful pathologic review of the ovaries and tubes.\n\n【6】This protocol recommends minimally invasive laparoscopic surgery. This procedure should include a survey of the upper abdomen, bowel surfaces, omentum, appendix (if present), and pelvic organs. Any abnormal peritoneal findings should be biopsied. Pelvic washing for cytology should be obtained, using approximately 55 cc normal saline instilled and aspirated immediately. The procedure should include total BSO, removing 2 cm of proximal ovarian vasculature or IP ligament, all of the fallopian tube up to the cornua, and all of the peritoneum surrounding the ovaries and fallopian tubes, especially the peritoneum underlying areas of adhesion between the fallopian tube and/or ovary and the pelvic.", "index": 106, "show": true, "start": 106, "end": 153, "comment": " 删除12:[DcR3]", "isEdit": false, "province": ["语义有效性", "错误删除"]}], "startTime": "2024/08/06 17:12:09", "endTime": "2024/08/06 17:12:56", "cost": 46.85}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-06 01:12:56", "grab_time": "2024-08-06 01:12:09"}
{"id": 2211774, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "221eeeac-a945-4d5e-a95f-751fc72021f4", "title": "幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)", "text": "【0】页码:4\n幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)\n水平升高（＞250 μg/L）与葡萄膜炎风险显著相关，但尚缺乏有效的临床验证证据。\n\n【1】### 2.2 JIA-U的诊断、疾病活动度判断及随访监测建议\n\n【2】#### 诊断\n\n【3】JIA-U患者易患有葡萄膜炎有关症状。JIA诊断后要注意葡萄膜炎的筛查，同时在特发性葡萄膜炎的易感人中，也应动态关注有关节状况和体征。根据调查约10%~14%的JIA患者在关节炎出现之前就已表现为葡萄膜炎删除12:<u>删除14:<u>[19]</u></u>。JIA的诊断在患者层面是免疫科与眼科医生共同协作。\n\n【4】#### 葡萄膜炎的眼部症状\n\n【5】眼球体和肢体瘤阻大、大小为JIA-U累及前葡萄膜（虹膜与睫状体），临床上眼后端羟炎罕见，通过免光灯眼底白血查能检验可见视网膜分离患者的视网膜病变；相对于前葡萄膜炎所常见的眼底病变，E无明显症状。如不治疗，在病程后期，部分患儿会出现类似慢发型急性葡萄膜炎的病变，如疼痛发红、视物模糊、视力改变和光亮恐惧等典型葡萄膜炎现有表现、现阶段、表现同酸类可快速抑制性地反映。\n\n【6】根据葡萄膜炎命名标准（Standardization of Uveitis Nomenclature，SUN）国际工作组委员会，前葡萄膜炎的诊断标准是裂隙灯检查发现前房（anterior chamber，AC）房水中存在炎症细胞（“细胞”）和增加的蛋白质浓度（“闪辉”）。眼部炎症根据SUN标准进行分级并分为0~4级，该标准考虑了AC细胞、AC闪辉、玻璃体细胞和玻璃体混浊评分。JIA-U眼部炎症主要根据SUN标准定义病情改善和恶化，该标准还可对前葡萄膜炎是否处于活动期进行全面评估和监测（表3）。需说明的是，0.5+AC细胞也是成为活动性葡萄膜炎。\n\n【7】删除图片描述:<u>![](3_1.png)</u>\n\n【8】视力测量是JIA-U患者筛查及随访过程中重要的评估内容之一。J", "tags": {}, "lang": "zh", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】### 2.2 JIA-U的诊断、疾病活动度判断及随访监测建议\n\n【2】#### 诊断", "content": "【0】页码:4\n幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)\n水平升高（＞250 μg/L）与葡萄膜炎风险显著相关，但尚缺乏有效的临床验证证据。\n\n【1】### 2.2 JIA-U的诊断、疾病活动度判断及随访监测建议\n\n【2】#### 诊断\n\n【3】JIA-U患者易患有葡萄膜炎有关症状。JIA诊断后要注意葡萄膜炎的筛查，同时在特发性葡萄膜炎的易感人中，也应动态关注有关节状况和体征。根据调查约10%~14%的JIA患者在关节炎出现之前就已表现为葡萄膜炎删除12:<u>删除14:<u>[19]</u></u>。JIA的诊断在患者层面是免疫科与眼科医生共同协作。\n\n【4】#### 葡萄膜炎的眼部症状\n\n【5】眼球体和肢体瘤阻大、大小为JIA-U累及前葡萄膜（虹膜与睫状体），临床上眼后端羟炎罕见，通过免光灯眼底白血查能检验可见视网膜分离患者的视网膜病变；相对于前葡萄膜炎所常见的眼底病变，E无明显症状。如不治疗，在病程后期，部分患儿会出现类似慢发型急性葡萄膜炎的病变，如疼痛发红、视物模糊、视力改变和光亮恐惧等典型葡萄膜炎现有表现、现阶段、表现同酸类可快速抑制性地反映。\n\n【6】根据葡萄膜炎命名标准（Standardization of Uveitis Nomenclature，SUN）国际工作组委员会，前葡萄膜炎的诊断标准是裂隙灯检查发现前房（anterior chamber，AC）房水中存在炎症细胞（“细胞”）和增加的蛋白质浓度（“闪辉”）。眼部炎症根据SUN标准进行分级并分为0~4级，该标准考虑了AC细胞、AC闪辉、玻璃体细胞和玻璃体混浊评分。JIA-U眼部炎症主要根据SUN标准定义病情改善和恶化，该标准还可对前葡萄膜炎是否处于活动期进行全面评估和监测（表3）。需说明的是，0.5+AC细胞也是成为活动性葡萄膜炎。\n\n【7】删除图片描述:<u>![](3_1.png)</u>\n\n【8】视力测量是JIA-U患者筛查及随访过程中重要的评估内容之一。J", "index": 80, "show": true, "start": 80, "end": 126, "province": ["信息质量", "完整性"], "isEdit": false}, {"text": "【8】视力测量是JIA-U患者筛查及随访过程中重要的评估内容之一。", "content": "【0】页码:4\n幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)\n水平升高（＞250 μg/L）与葡萄膜炎风险显著相关，但尚缺乏有效的临床验证证据。\n\n<mark>【1】### 2.2 JIA-U的诊断、疾病活动度判断及随访监测建议\n\n【2】#### 诊断</mark>\n\n【3】JIA-U患者易患有葡萄膜炎有关症状。JIA诊断后要注意葡萄膜炎的筛查，同时在特发性葡萄膜炎的易感人中，也应动态关注有关节状况和体征。根据调查约10%~14%的JIA患者在关节炎出现之前就已表现为葡萄膜炎删除12:<u>删除14:<u>[19]</u></u>。JIA的诊断在患者层面是免疫科与眼科医生共同协作。\n\n【4】#### 葡萄膜炎的眼部症状\n\n【5】眼球体和肢体瘤阻大、大小为JIA-U累及前葡萄膜（虹膜与睫状体），临床上眼后端羟炎罕见，通过免光灯眼底白血查能检验可见视网膜分离患者的视网膜病变；相对于前葡萄膜炎所常见的眼底病变，E无明显症状。如不治疗，在病程后期，部分患儿会出现类似慢发型急性葡萄膜炎的病变，如疼痛发红、视物模糊、视力改变和光亮恐惧等典型葡萄膜炎现有表现、现阶段、表现同酸类可快速抑制性地反映。\n\n【6】根据葡萄膜炎命名标准（Standardization of Uveitis Nomenclature，SUN）国际工作组委员会，前葡萄膜炎的诊断标准是裂隙灯检查发现前房（anterior chamber，AC）房水中存在炎症细胞（“细胞”）和增加的蛋白质浓度（“闪辉”）。眼部炎症根据SUN标准进行分级并分为0~4级，该标准考虑了AC细胞、AC闪辉、玻璃体细胞和玻璃体混浊评分。JIA-U眼部炎症主要根据SUN标准定义病情改善和恶化，该标准还可对前葡萄膜炎是否处于活动期进行全面评估和监测（表3）。需说明的是，0.5+AC细胞也是成为活动性葡萄膜炎。\n\n【7】删除图片描述:<u>![](3_1.png)</u>\n\n【8】视力测量是JIA-U患者筛查及随访过程中重要的评估内容之一。J", "index": 818, "show": true, "start": 805, "end": 838, "province": ["信息质量", "完整性"], "isEdit": false}, {"text": "【7】", "content": "【0】页码:4\n幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)\n水平升高（＞250 μg/L）与葡萄膜炎风险显著相关，但尚缺乏有效的临床验证证据。\n\n<mark>【1】### 2.2 JIA-U的诊断、疾病活动度判断及随访监测建议\n\n【2】#### 诊断</mark>\n\n【3】JIA-U患者易患有葡萄膜炎有关症状。JIA诊断后要注意葡萄膜炎的筛查，同时在特发性葡萄膜炎的易感人中，也应动态关注有关节状况和体征。根据调查约10%~14%的JIA患者在关节炎出现之前就已表现为葡萄膜炎删除12:<u>删除14:<u>[19]</u></u>。JIA的诊断在患者层面是免疫科与眼科医生共同协作。\n\n【4】#### 葡萄膜炎的眼部症状\n\n【5】眼球体和肢体瘤阻大、大小为JIA-U累及前葡萄膜（虹膜与睫状体），临床上眼后端羟炎罕见，通过免光灯眼底白血查能检验可见视网膜分离患者的视网膜病变；相对于前葡萄膜炎所常见的眼底病变，E无明显症状。如不治疗，在病程后期，部分患儿会出现类似慢发型急性葡萄膜炎的病变，如疼痛发红、视物模糊、视力改变和光亮恐惧等典型葡萄膜炎现有表现、现阶段、表现同酸类可快速抑制性地反映。\n\n【6】根据葡萄膜炎命名标准（Standardization of Uveitis Nomenclature，SUN）国际工作组委员会，前葡萄膜炎的诊断标准是裂隙灯检查发现前房（anterior chamber，AC）房水中存在炎症细胞（“细胞”）和增加的蛋白质浓度（“闪辉”）。眼部炎症根据SUN标准进行分级并分为0~4级，该标准考虑了AC细胞、AC闪辉、玻璃体细胞和玻璃体混浊评分。JIA-U眼部炎症主要根据SUN标准定义病情改善和恶化，该标准还可对前葡萄膜炎是否处于活动期进行全面评估和监测（表3）。需说明的是，0.5+AC细胞也是成为活动性葡萄膜炎。\n\n【7】删除图片描述:<u>![](3_1.png)</u>\n\n<mark>【8】视力测量是JIA-U患者筛查及随访过程中重要的评估内容之一。</mark>J", "index": 787, "show": true, "start": 774, "end": 777, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "表格缺失"}], "startTime": "2024/08/07 09:59:35", "endTime": "2024/08/07 10:01:10", "cost": 94.608}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-06 18:01:09", "grab_time": "2024-08-06 17:59:34"}
{"id": 2211773, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "2c9cbf6d-631d-4a18-a714-c290a0c54ace", "title": "（2023.V4）NCCN临床实践指南：B细胞淋巴瘤", "text": "【0】页码:205\n（2023.V4）NCCN临床实践指南：B细胞淋巴瘤\n疑似页眉<u># NCCN Guidelines Version 4.2023\n## B-Cell Lymphomas</u>\n\n【1】参考删除-3:<u>This discussion corresponds to the NCCN Guidelines for B-Cell Lymphomas. Last updated: December 删除13:<u>18, 2019</u>.</u>\n\n【2】### Marginal Zone Lymphomas\n\n【3】Marginal zone lymphomas (MZLs) originate in the marginal zone of lymphoid follicles found in the mucosa-associated lymphoid tissues (MALT), spleen, and lymph nodes.删除29:<u>¹</u> Extranodal MZLs of MALT (MALT lymphomas), nodal MZL (NMZL), and splenic MZL (SMZL) are the three distinct subtypes of MZLs. In a Surveillance, Epidemiology, and End Results (SEER) database analysis that assessed the incidence rates (IRs) of different subtypes of MZLs in the United States 删除11:<u>删除19:<u>(2001–2009)</u></u>, NMZL and extranodal MZL were diagnosed in 4,081 (IR = 5.7) and 8,821 (IR = 12.3) individuals, respectively.² The most common sites were stomach (IR = 3.8), spleen (IR = 1.6), ocular adnexa (IR = 1.4), and lung, skin, and salivary glands (IR = 0.9–1.0).\n\n【4】The etiology of MZLs has been associated with chronic immune stimulation due to infectious agents or inflammation. Helicobacter pylori (H. pylori) has been implicated in the pathogenesis of gastric MALT lymphoma and other infectious agents such as 删除32:<u>*</u>Chlamydia psittaci删除32:<u>*</u> (C. psittaci), 删除32:<u>*</u>Campylobacter jejuni删除32:<u>*</u> (C. jejuni), and 删除32:<u>*</u>Borrelia burgdorferi删除32:<u>*</u> (B. burgdorferi) have also been implicated in the pathogenesis of MZLs.³ MZLs are also characterized by a high prevalence of hepatitis C virus (HCV) infection and HCV seroprevalence has been reported in about 22% to 35% of patients with NMZL, SMZL, and non-gastric MALT lymphomas.删除29:<u>⁴</u>˒删除29:<u>⁵</u>\n\n【5】MZLs are also characterized by clinical and pathologic features that overlap with Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL).删除29:<u>⁶</u> Recent studies have confirmed that the MYD88 L265P somatic mutational analysis could be useful in differentiating WM/LPL from other B-cell malignancies with overlapping clinical and pathologic features.删除29:<u>⁷</u>˒删除29:<u>¹⁰</u> In a retrospective analysis of 123 patients with a diagnosis of MZLs and WM/LPL, MYD88 mutation was found in 67% of patients with WM/LPL (18 of 27) compared to 4% of patients with SMZL (2 out of 53), 7% of patients with MALT lymphomas (2 out of 28), and 0% of patients with NMZL.删除29:<u>⁸</u> Immunoglobulin heavy chain variable (IGHV) gene sequencing clearly distinguished SMZL and WM/LPL. SMZL was characterized by overrepresentation of IGHV1-2 gene rearrangements with low or intermediate mutation rates, whereas WM/LPL was associated with overrepresentation of IGHV3-23 rearrangements and high mutation rates.删除29:<u>⁸</u> In selected circumstances when plasmacytic differentiation is present, MYD88 mutational analysis should be considered to differentiate MZLs from WM/LPL.删除29:<u>⁷</u>˒删除29:<u>¹⁰</u>\n\n【6】The NCCN Guidelines provide recommendations for the diagnosis, workup, and treatment for MALT lymphomas, NMZL, and SMZL.\n\n【7】### Literature Search Criteria and Guidelines Update Methodology\n\n【8】Prior to the update of this version of the NCCN Guidelines删除5:<u>®</u> for B-Cell Lymphomas an electronic search of the PubMed database was performed to obtain key literature in MZLs published since the previous Guidelines update, using the following search terms: MALT lymphoma, gastric MALT lymphoma, non-gastric MALT lymphoma, nodal marginal zone lymphoma and splenic marginal zone lymphoma. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.删除29:<u>¹¹</u>\n\n【9】The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.", "tags": {}, "lang": "en", "attr": {"page_num": 205, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V4）NCCN临床实践指南：B细胞淋巴瘤.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】参考删除-3:This discussion corresponds to the NCCN Guidelines for B-Cell Lymphomas. Last updated: December 删除13:18, 2019.", "content": "【0】页码:205\n（2023.V4）NCCN临床实践指南：B细胞淋巴瘤\n疑似页眉<u># NCCN Guidelines Version 4.2023\n## B-Cell Lymphomas</u>\n\n【1】参考删除-3:<u>This discussion corresponds to the NCCN Guidelines for B-Cell Lymphomas. Last updated: December 删除13:<u>18, 2019</u>.</u>\n\n【2】### Marginal Zone Lymphomas\n\n【3】Marginal zone lymphomas (MZLs) originate in the marginal zone of lymphoid follicles found in the mucosa-associated lymphoid tissues (MALT), spleen, and lymph nodes.删除29:<u>¹</u> Extranodal MZLs of MALT (MALT lymphomas), nodal MZL (NMZL), and splenic MZL (SMZL) are the three distinct subtypes of MZLs. In a Surveillance, Epidemiology, and End Results (SEER) database analysis that assessed the incidence rates (IRs) of different subtypes of MZLs in the United States 删除11:<u>删除19:<u>(2001–2009)</u></u>, NMZL and extranodal MZL were diagnosed in 4,081 (IR = 5.7) and 8,821 (IR = 12.3) individuals, respectively.² The most common sites were stomach (IR = 3.8), spleen (IR = 1.6), ocular adnexa (IR = 1.4), and lung, skin, and salivary glands (IR = 0.9–1.0).\n\n【4】The etiology of MZLs has been associated with chronic immune stimulation due to infectious agents or inflammation. Helicobacter pylori (H. pylori) has been implicated in the pathogenesis of gastric MALT lymphoma and other infectious agents such as 删除32:<u>*</u>Chlamydia psittaci删除32:<u>*</u> (C. psittaci), 删除32:<u>*</u>Campylobacter jejuni删除32:<u>*</u> (C. jejuni), and 删除32:<u>*</u>Borrelia burgdorferi删除32:<u>*</u> (B. burgdorferi) have also been implicated in the pathogenesis of MZLs.³ MZLs are also characterized by a high prevalence of hepatitis C virus (HCV) infection and HCV seroprevalence has been reported in about 22% to 35% of patients with NMZL, SMZL, and non-gastric MALT lymphomas.删除29:<u>⁴</u>˒删除29:<u>⁵</u>\n\n【5】MZLs are also characterized by clinical and pathologic features that overlap with Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL).删除29:<u>⁶</u> Recent studies have confirmed that the MYD88 L265P somatic mutational analysis could be useful in differentiating WM/LPL from other B-cell malignancies with overlapping clinical and pathologic features.删除29:<u>⁷</u>˒删除29:<u>¹⁰</u> In a retrospective analysis of 123 patients with a diagnosis of MZLs and WM/LPL, MYD88 mutation was found in 67% of patients with WM/LPL (18 of 27) compared to 4% of patients with SMZL (2 out of 53), 7% of patients with MALT lymphomas (2 out of 28), and 0% of patients with NMZL.删除29:<u>⁸</u> Immunoglobulin heavy chain variable (IGHV) gene sequencing clearly distinguished SMZL and WM/LPL. SMZL was characterized by overrepresentation of IGHV1-2 gene rearrangements with low or intermediate mutation rates, whereas WM/LPL was associated with overrepresentation of IGHV3-23 rearrangements and high mutation rates.删除29:<u>⁸</u> In selected circumstances when plasmacytic differentiation is present, MYD88 mutational analysis should be considered to differentiate MZLs from WM/LPL.删除29:<u>⁷</u>˒删除29:<u>¹⁰</u>\n\n【6】The NCCN Guidelines provide recommendations for the diagnosis, workup, and treatment for MALT lymphomas, NMZL, and SMZL.\n\n【7】### Literature Search Criteria and Guidelines Update Methodology\n\n【8】Prior to the update of this version of the NCCN Guidelines删除5:<u>®</u> for B-Cell Lymphomas an electronic search of the PubMed database was performed to obtain key literature in MZLs published since the previous Guidelines update, using the following search terms: MALT lymphoma, gastric MALT lymphoma, non-gastric MALT lymphoma, nodal marginal zone lymphoma and splenic marginal zone lymphoma. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.删除29:<u>¹¹</u>\n\n【9】The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.", "index": 102, "show": true, "start": 102, "end": 222, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 16:32:14", "endTime": "2024/08/06 16:32:50", "cost": 36.545}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-06 00:32:50", "grab_time": "2024-08-06 00:32:13"}
{"id": 2211772, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "cc984fcc-d0ca-4cbf-9d53-9e418948c14d", "title": "（2023.V1）NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤", "text": "【0】页码:42\n（2023.V1）NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤\n(本页删除)本页被模型判断为参考页疑似页眉<u># NCCN Guidelines Version 1.2023\n## Pediatric Aggressive Mature B-Cell Lymphomas</u>\n\n【1】### PRINCIPLES OF SUPPORTIVE CARE\n\n【2】删除32:<u>**</u>Recommendations for the management of pediatric and adult tumor lysis syndrome:删除32:<u>**</u>\n\n【3】- 删除32:<u>**</u>Risk Evaluation and Prophylaxis of Tumor Lysis Syndrome (TLS)删除32:<u>**</u>  \n  - Evaluation of risk and prophylaxis of TLS in adults and children with malignant diseases as per expert TLS panel consensus.\n\n【4】- 删除32:<u>**</u>Crisis Management in the Treatment of Childhood Acute Lymphoblastic Leukemia删除32:<u>**</u>  \n  - Putting right what can go wrong: emergency complications of disease and treatment.\n\n【5】- 删除32:<u>**</u>Risk Evaluation, Prophylaxis, and Treatment of Tumor Lysis Syndrome删除32:<u>**</u>  \n  - Consensus of an Italian expert panel.\n\n【6】- 删除32:<u>**</u>Prevention of Laboratory/Clinical Tumor Lysis Syndrome in Children with Advanced Mature B-NHL删除32:<u>**</u>  \n  - Evaluation and prophylaxis methods.\n\n【7】- 删除32:<u>**</u>Imaging Features of Burkitt Lymphoma in Pediatric Patients删除32:<u>**</u>  \n  - Case report and review of literature.\n\n【8】### Clinical Trials\n\n【9】删除32:<u>**</u>Note:删除32:<u>**</u> All recommendations are category 2A unless otherwise indicated. Participation in clinical trials is especially encouraged.", "tags": {}, "lang": "en", "attr": {"page_num": 42, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V1）NCCN临床实践指南：儿童侵袭性成熟B细胞淋巴瘤.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:15:39", "endTime": "2024/08/06 16:16:25", "cost": 45.967}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-06 00:16:25", "grab_time": "2024-08-06 00:15:39"}
{"id": 2211771, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "bb5a30bd-f94d-4913-bd43-034de7bd461f", "title": "2023 PRNT临床实践建议：儿童急性肾损伤的营养管理", "text": "【0】页码:4\n2023 PRNT临床实践建议：儿童急性肾损伤的营养管理\nwith severe medical conditions 删除12:<u>删除14:<u>[11]</u></u>. Due to the epidemiological shift of AKI in the last 20 years, there is likely to be a substantial overlap between children experiencing AKI and those having severe medical conditions such as multiorgan system failure, septicemia, respiratory failure, and congenital cardiac anomalies. A study on nutrition screening in hospitalized adults reported that high-risk patients identified via nutrition screening tools exhibited a higher incidence of AKI when compared to patients with normal nutritional status 删除12:<u>删除14:<u>[15]</u></u>. Therefore, we expect that children with AKI are at high risk for malnutrition and should have appropriate nutritional screening as detailed below.\n\n【1】Nutrition screening is an important first step that serves to notify a dietitian that a patient may be at nutritional risk and that further assessment of nutritional status is warranted. Only recently has there been the evidence to allow more informed decisions on the appropriate use of validated and reliable nutrition screening tools in hospitalized children. Four tools (Paediatric Yorkhill Malnutrition Score, PYMS; Screening Tool for the Assessment of Malnutrition in Paediatrics, STAMP; STRONGkids; and Paediatric Nutrition Screening Tool, PNST) have the most evidence to support their use with moderate validity 删除12:<u>[16–18]</u>. However, it is important to note that none is specific to children experiencing AKI. Furthermore, they have reliance on anthropometric measurements or clinical assessment which may be difficult to obtain or give false positives or negatives in the case of patients with dehydration or fluid overload, respectively. Additionally, PYMS, STAMP, and STRONGkids include screening for high-risk diseases with nutritional impact and specify kidney disease, although not necessarily AKI. Yet, there is no reason not to utilize these screening tools in children with AKI.\n\n【2】Most groups recommend a 48 h screening period after admission to allow for timely nutrition evaluation and intervention if needed 删除12:<u>删除14:<u>[18]</u></u>. Timely intervention would allow nutrition teams to decrease the nutrition debt or limit the amount of time children with AKI are not meeting their optimal nutritional needs. This could also allow for the implementation of preventative strategies that support optimizing fluid balance and avoiding or minimizing electrolyte derangements. There is no consensus on the frequency of reassessment for hospitalized children other than via weekly re-screening of nutritional risk. However, given the dynamic nature of AKI and its treatment modalities, the reassessment of nutritional risk and efficacy of nutritional interventions should reflect the frequency with which the medical management of AKI changes. Furthermore, given the higher risk for malnutrition in younger children 删除12:<u>删除14:<u>[11]</u></u> and critically ill children 删除12:<u>删除14:<u>[19]</u></u>, it is also expected that age and the presence of critical illness will also dictate the frequency at which children are reassessed for nutritional risk. Therefore, strong multidisciplinary collaboration is necessary to provide optimal nutritional management, which may require daily reassessment in some patients, especially those in the ICU.\n\n【3】### 2.4 Obtain accurate anthropometric measurements as soon as feasible and throughout hospitalization. (level A; strong recommendation)\n\n【4】#### 2.4.1 Estimate euvolemic weight using accurate trended weight measurements in conjunction with other clinical assessment measures such as fluid balance, blood pressure, physical examination, and available biometrics tools (e.g., bioelectrical impedance analysis, mid-upper arm circumference, non-invasive blood volume monitoring). (level D; weak recommendation)\n\n【5】#### 2.4.2 Measure height or recumbent length for children under 2 years of age. For those unable to stand for accurate measurement of height, use recumbent length or a surrogate missed measurement of height. (level A; strong recommendation)\n\n【6】#### 2.4.3 Measure head circumference for children up to 2 years of age or up to 3 years of age when appropriate centile charts are available. (level A; strong recommendation)\n\n【7】#### 2.4.4 Assess for muscle wasting by physical assessment and anthropometrics where available. (level D; weak recommendation)\n\n【8】删除32:<u>*</u>Rationale:删除32:<u>*</u> Accurate evaluation of a hospitalized child's nutritional status hinges on the appropriate evaluation of anthropometrics and body composition. As hospitalization and critical illness promote muscle protein breakdown in excess of muscle protein synthesis, children with AKI will experience negative alterations in fat mass, muscle mass, and functional capacity, thereby worsening morbidities and promoting long-term metabolic abnormalities in pediatric AKI survivors. Measurement of anthropometrics would ideally occur upon hospital admission, but are imperative once a child is diagnosed with AKI. It is highly likely that hypervolemia will mask muscle loss or true weight loss experienced by these patients. The most basic anthropometrics required for a full nutrition assessment to evaluate for malnutrition (acute or chronic) are weight and length/height [and head circumference for children less than 3 years of age] as per standard practice even outside of a diagnosis of AKI. Optimal nutritional management will attempt to limit or rectify malnutrition and malnutrition risk. Anthropometrics are a vital component of this evaluation. In an ideal setting, measurement of functional capacity and strength of a child with AKI to aid in the assessment of malnutrition would be performed. Unfortunately, anthropometrics are obtained at low frequency and accuracy in hospitalized children, worsening with critical illness 删除12:<u>[删除13:<u>20, 21</u>]</u>. Children with AKI are most at risk for", "tags": {}, "lang": "en", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 PRNT临床实践建议：儿童急性肾损伤的营养管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:28:46", "endTime": "2024/08/06 16:29:30", "cost": 43.722}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-06 00:29:30", "grab_time": "2024-08-06 00:28:45"}
{"id": 2211770, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "02f4d469-3d1f-44a5-a668-9c30ceac98e5", "title": "【消化领域】2020+JSGE循证临床实践指南：炎症性肠病", "text": "【0】页码:34\n【消化领域】2020+JSGE循证临床实践指南：炎症性肠病\n(本页删除)本页被模型判断为参考页Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving considerations for thiopurine therapy for inflammatory bowel disease: a clinical practice update commentary. Gastroenterology. 2019;156:36–42.\nJauregui-Amezaga A, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42:391–405.\nKennedy NA, Warner B, Johnston EL, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016;43:910–23.\nLee MJ, Parker CE, Taylor SR, et al. Efficacy of medical therapies for fistulizing Crohn’s disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1879–92.\nGionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11:135–49.\nAbdalla MI, Sandler RS, Felder JB, et al. Anti-TNFα maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–85.\nInokuchi T, Ooba N, Tanaka H, et al. Real-world efficacy of ustekinumab in patients with Crohn’s disease: a multicenter study. Inflamm Bowel Dis. 2017;23:2245–51.\nBelachie J, Louis E. Severe lower gastrointestinal bleeding in Crohn’s disease: successful control with infliximab. Am J Gastroenterol. 2002;97:310–1.\nAwasthi SP, Zangeneh TT, Janmohamed R, et al. Infliximab salvage severe gastrointestinal bleeding in Crohn’s disease. World J Gastroenterol. 2012;18:2730–4.\nKim K-J, Yang S-K, et al. Risk factors and outcome of acute severe lower gastrointestinal bleeding in Crohn’s disease. Dig Liver Dis. 2014;46:723–8.\nHoman WP, Tang CK, Thorbjarnarson B. Acute massive hemorrhage from intestinal Crohn disease. Report of seven cases and review of the literature. Arch Surg Chic Ill 删除13:<u>1960. 1976</u>;111:901–5.\nAlia WM, Opjiji V, Gorth J, et al. Revisiting the past: intravascular vasopressin for severe gastrointestinal bleeding in Crohn’s disease. J Crohns Colitis. 2010;4:479–82.\nKim E, Kang Y, Lee MJ, et al. Life-threatening lower gastrointestinal hemorrhage in pediatric Crohn’s disease. Pediatr Gastroenterol Hepatol Nutr. 2013;16:53–60.\nRobert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn’s disease. Ann Surg. 1991;213:207–11.\nBelachie J, Louis E, D’Haens G, et al. Acute lower gastrointestinal bleeding in Crohn’s disease: characteristics of a unique series of patients. Belgian IBD Research Group. Am J Gastroenterol. 1999;94:277–81.\nFeagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–60.\nIshii T, Imai Y, Murata Y, et al. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn’s disease: a subpopulation analysis of phase 3 induction and maintenance studies. Intest Res. 2017;15:475–86.\nSandborn WJ, Gasink C, Gao L-L, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–28.\nMacDonald JK, Nguyen TM, Khanna R, et al. Anti-IL-12/23p40 antibodies for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2016;11:CD007572.\nMa C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232–43.\nDayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69:61–7.\nBiemans VBC, van der Meulen-de Jong AE, van der Woude CJ, et al. Ustekinumab for Crohn’s disease: results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis. 2020;14:33–45.\nCohen AJ, Rosenfeld G, Bressler B. Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience. Scand J Gastroenterol. 2017;52:1354–9.\nKhorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish Experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662–9.\nWils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:1420–5.e2.\nSands BE, Sandborn WJ, Panaccione R, et al. Safety and efficacy of ustekinumab for Crohn’s disease: results from a pooled analysis of the induction and maintenance phases of the CERTIFI study. Gut. 2015;64:415–45.\nVerstockt B, Elsen E, D’Haens G, et al. Safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. Expert Opin Drug Saf. 2017;16:809–21.\nRegueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136:441–50.e1 (quiz 716).\nZhao Y, Ma T, Chen Y-F, et al. Biologics for the prevention of postoperative Crohn’s disease recurrence: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39:637–49.\nSandborn WJ, Gasink C, Jacobstein D, et al. Fistula healing in pivotal studies of ustekinumab in Crohn’s disease. Gastroenterology. 2017;152:S185.\nWils P, Bouhnik Y, Michetti P, et al. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn’s disease patients: a multicentric experience. Aliment Pharmacol Ther. 2018;47:588–95.\nVenturin C, Nancy S, Danion P, et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol. 2017;17:80.\nMartin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89:351–63.\nRowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohns Colitis. 2018;12:376–8.", "tags": {}, "lang": "en", "attr": {"page_num": 34, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【消化领域】2020+JSGE循证临床实践指南：炎症性肠病.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:55:39", "endTime": "2024/08/06 15:55:49", "cost": 10.651}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-05 23:55:49", "grab_time": "2024-08-05 23:55:39"}
{"id": 2211769, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "fbdf336a-237a-4745-a185-3c00d25fda38", "title": "免疫性血小板输注无效的判定及临床实践专家共识", "text": "【0】页码:5\n免疫性血小板输注无效的判定及临床实践专家共识\n### 临床输血与检验\n#### 2022年6月第24卷第3期\n\n【1】删除32:<u>**</u>临床输血与检验删除32:<u>**</u>\n\n【2】删除32:<u>**</u>2022年6月第24卷第3期删除32:<u>**</u>\n\n【3】删除32:<u>**</u>编者按删除32:<u>**</u>\n\n【4】在本期《临床输血与检验》中，我们继续关注血液病学和输血医学领域的最新研究进展，特别是关于血小板输注无效的相关问题。本期内容涵盖了血小板输注无效的机理、诊断和管理策略的最新研究成果和临床应用。\n\n【5】删除图片描述:<u>删除32:<u>**</u>图1 血小板输注无效的管理策略删除32:<u>**</u></u>\n\n| 机制           | 诊断手段     | 管理策略            |\n| -------------- | ------------ | ------------------- |\n| 同种免疫机制   | 血小板抗体检测 | 更换供者；使用HLA匹配的血小板 |\n| 非同种免疫机制 | 血小板功能检测 | 优化抗血小板治疗方案    |\n| 双重机制       | 组合检测     | 个体化治疗方案          |\n\n【7】我们还特别介绍了国内外相关领域的专家和学者的最新研究成果和临床经验，期望这些内容能够对广大读者在临床实践中有所帮助。\n\n【8】删除32:<u>**</u>主编：张三删除32:<u>**</u>\n\n【9】删除32:<u>**</u>副主编：李四删除32:<u>**</u>\n\n【10】删除32:<u>**</u>编委会成员：删除32:<u>**</u>\n\n【11】- 王五（北京协和医院）\n- 赵六（上海交通大学医学院附属瑞金医院）\n- 孙七（中国医学科学院血液病医院）\n\n【12】删除32:<u>**</u>联系我们：删除32:<u>**</u>\n\n【13】- 编辑部电话：1234-567890删除1:<u>\n- 邮箱：editor@bloodtransfusion.com</u>\n\n【14】希望大家在阅读本期《临床输血与检验》时，能够获得有益的知识和启示。\n\n---|删除段之间换行|#### 血小板输注无效的机制及其管理策略\n\n【16】血小板输注无效是指患者在接受血小板输注后，血小板计数未能达到预期的升高水平。血小板输注无效的原因复杂，主要包括同种免疫和非同种免疫两大类机制。\n\n【17】1. 删除32:<u>**</u>同种免疫机制删除32:<u>**</u>\n\n【18】- 同种免疫机制是指由于输注的血小板中存在异体抗原，导致受者体内产生抗体，进而导致血小板被迅速清除。这些异体抗原主要包括HLA抗原和血小板特异性抗原。\n\n【19】2. 删除32:<u>**</u>非同种免疫机制删除32:<u>**</u>\n\n【20】- 非同种免疫机制是指血小板输注后，血小板在体内存活时间短，导致血小板计数未能显著上升。这类机制包括脾功能亢进、感染、DIC等。\n\n【21】3. 删除32:<u>**</u>双重机制删除32:<u>**</u>\n\n【22】- 一些患者的血小板输注无效可能是由于同种免疫和非同种免疫机制共同作用的结果。这些患者需要进行更加全面的诊断和个体化治疗。\n\n【23】删除32:<u>**</u>表1 血小板输注无效的管理策略删除32:<u>**</u>\n\n| 机制           | 诊断手段     | 管理策略            |\n| -------------- | ------------ | ------------------- |\n| 同种免疫机制   | 血小板抗体检测 | 更换供者；使用HLA匹配的血小板 |\n| 非同种免疫机制 | 血小板功能检测 | 优化抗血小板治疗方案    |\n| 双重机制       | 组合检测     | 个体化治疗方案          |\n\n---|删除段之间换行|删除32:<u>**</u>总编辑寄语删除32:<u>**</u>\n\n【26】亲爱的读者朋友们，\n\n【27】欢迎阅读本期《临床输血与检验》。我们致力于为大家提供最新、最权威的血液病学和输血医学方面的研究成果和临床经验。希望这些内容能够对大家的工作有所帮助。感谢大家对我们杂志的支持和厚爱！\n\n【28】删除32:<u>**</u>总编辑：张三删除32:<u>**</u>\n\n【29】删除32:<u>**</u>出版日期：2022年6月删除32:<u>**</u>", "tags": {}, "lang": "zh", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/免疫性血小板输注无效的判定及临床实践专家共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:5\n\n免疫性血小板输注无效的判定及临床实践专家共识\n\n临床输血与检验\n2022年6月第24卷第3期\n【1】删除32:临床输血与检验删除32:\n\n【2】删除32:2022年6月第24卷第3期删除32:\n\n【3】删除32:编者按删除32:\n\n【4】在本期《临床输血与检验》中，我们继续关注血液病学和输血医学领域的最新研究进展，特别是关于血小板输注无效的相关问题。本期内容涵盖了血小板输注无效的机理、诊断和管理策略的最新研究成果和临床应用。\n\n【5】删除图片描述:删除32:图1 血小板输注无效的管理策略删除32:\n\n机制\t诊断手段\t管理策略\n同种免疫机制\t血小板抗体检测\t更换供者；使用HLA匹配的血小板\n非同种免疫机制\t血小板功能检测\t优化抗血小板治疗方案\n双重机制\t组合检测\t个体化治疗方案\n【7】我们还特别介绍了国内外相关领域的专家和学者的最新研究成果和临床经验，期望这些内容能够对广大读者在临床实践中有所帮助。\n\n【8】删除32:主编：张三删除32:\n\n【9】删除32:副主编：李四删除32:\n\n【10】删除32:编委会成员：删除32:\n\n【11】- 王五（北京协和医院）\n\n赵六（上海交通大学医学院附属瑞金医院）\n孙七（中国医学科学院血液病医院）\n【12】删除32:联系我们：删除32:\n\n【13】- 编辑部电话：1234-567890删除1:\n\n邮箱：editor@bloodtransfusion.com\n【14】希望大家在阅读本期《临床输血与检验》时，能够获得有益的知识和启示。\n\n—|删除段之间换行|#### 血小板输注无效的机制及其管理策略\n\n【16】血小板输注无效是指患者在接受血小板输注后，血小板计数未能达到预期的升高水平。血小板输注无效的原因复杂，主要包括同种免疫和非同种免疫两大类机制。\n\n【17】1. 删除32:同种免疫机制删除32:\n\n【18】- 同种免疫机制是指由于输注的血小板中存在异体抗原，导致受者体内产生抗体，进而导致血小板被迅速清除。这些异体抗原主要包括HLA抗原和血小板特异性抗原。\n\n【19】2. 删除32:非同种免疫机制删除32:\n\n【20】- 非同种免疫机制是指血小板输注后，血小板在体内存活时间短，导致血小板计数未能显著上升。这类机制包括脾功能亢进、感染、DIC等。\n\n【21】3. 删除32:双重机制删除32:\n\n【22】- 一些患者的血小板输注无效可能是由于同种免疫和非同种免疫机制共同作用的结果。这些患者需要进行更加全面的诊断和个体化治疗。\n\n【23】删除32:表1 血小板输注无效的管理策略删除32:\n\n机制\t诊断手段\t管理策略\n同种免疫机制\t血小板抗体检测\t更换供者；使用HLA匹配的血小板\n非同种免疫机制\t血小板功能检测\t优化抗血小板治疗方案\n双重机制\t组合检测\t个体化治疗方案\n—|删除段之间换行|删除32:总编辑寄语删除32:\n\n【26】亲爱的读者朋友们，\n\n【27】欢迎阅读本期《临床输血与检验》。我们致力于为大家提供最新、最权威的血液病学和输血医学方面的研究成果和临床经验。希望这些内容能够对大家的工作有所帮助。感谢大家对我们杂志的支持和厚爱！\n\n【28】删除32:总编辑：张三删除32:\n\n【29】删除32:出版日期：2022年6月删除32:", "content": "【0】页码:5\n免疫性血小板输注无效的判定及临床实践专家共识\n### 临床输血与检验\n#### 2022年6月第24卷第3期\n\n【1】删除32:<u>**</u>临床输血与检验删除32:<u>**</u>\n\n【2】删除32:<u>**</u>2022年6月第24卷第3期删除32:<u>**</u>\n\n【3】删除32:<u>**</u>编者按删除32:<u>**</u>\n\n【4】在本期《临床输血与检验》中，我们继续关注血液病学和输血医学领域的最新研究进展，特别是关于血小板输注无效的相关问题。本期内容涵盖了血小板输注无效的机理、诊断和管理策略的最新研究成果和临床应用。\n\n【5】删除图片描述:<u>删除32:<u>**</u>图1 血小板输注无效的管理策略删除32:<u>**</u></u>\n\n| 机制           | 诊断手段     | 管理策略            |\n| -------------- | ------------ | ------------------- |\n| 同种免疫机制   | 血小板抗体检测 | 更换供者；使用HLA匹配的血小板 |\n| 非同种免疫机制 | 血小板功能检测 | 优化抗血小板治疗方案    |\n| 双重机制       | 组合检测     | 个体化治疗方案          |\n\n【7】我们还特别介绍了国内外相关领域的专家和学者的最新研究成果和临床经验，期望这些内容能够对广大读者在临床实践中有所帮助。\n\n【8】删除32:<u>**</u>主编：张三删除32:<u>**</u>\n\n【9】删除32:<u>**</u>副主编：李四删除32:<u>**</u>\n\n【10】删除32:<u>**</u>编委会成员：删除32:<u>**</u>\n\n【11】- 王五（北京协和医院）\n- 赵六（上海交通大学医学院附属瑞金医院）\n- 孙七（中国医学科学院血液病医院）\n\n【12】删除32:<u>**</u>联系我们：删除32:<u>**</u>\n\n【13】- 编辑部电话：1234-567890删除1:<u>\n- 邮箱：editor@bloodtransfusion.com</u>\n\n【14】希望大家在阅读本期《临床输血与检验》时，能够获得有益的知识和启示。\n\n---|删除段之间换行|#### 血小板输注无效的机制及其管理策略\n\n【16】血小板输注无效是指患者在接受血小板输注后，血小板计数未能达到预期的升高水平。血小板输注无效的原因复杂，主要包括同种免疫和非同种免疫两大类机制。\n\n【17】1. 删除32:<u>**</u>同种免疫机制删除32:<u>**</u>\n\n【18】- 同种免疫机制是指由于输注的血小板中存在异体抗原，导致受者体内产生抗体，进而导致血小板被迅速清除。这些异体抗原主要包括HLA抗原和血小板特异性抗原。\n\n【19】2. 删除32:<u>**</u>非同种免疫机制删除32:<u>**</u>\n\n【20】- 非同种免疫机制是指血小板输注后，血小板在体内存活时间短，导致血小板计数未能显著上升。这类机制包括脾功能亢进、感染、DIC等。\n\n【21】3. 删除32:<u>**</u>双重机制删除32:<u>**</u>\n\n【22】- 一些患者的血小板输注无效可能是由于同种免疫和非同种免疫机制共同作用的结果。这些患者需要进行更加全面的诊断和个体化治疗。\n\n【23】删除32:<u>**</u>表1 血小板输注无效的管理策略删除32:<u>**</u>\n\n| 机制           | 诊断手段     | 管理策略            |\n| -------------- | ------------ | ------------------- |\n| 同种免疫机制   | 血小板抗体检测 | 更换供者；使用HLA匹配的血小板 |\n| 非同种免疫机制 | 血小板功能检测 | 优化抗血小板治疗方案    |\n| 双重机制       | 组合检测     | 个体化治疗方案          |\n\n---|删除段之间换行|删除32:<u>**</u>总编辑寄语删除32:<u>**</u>\n\n【26】亲爱的读者朋友们，\n\n【27】欢迎阅读本期《临床输血与检验》。我们致力于为大家提供最新、最权威的血液病学和输血医学方面的研究成果和临床经验。希望这些内容能够对大家的工作有所帮助。感谢大家对我们杂志的支持和厚爱！\n\n【28】删除32:<u>**</u>总编辑：张三删除32:<u>**</u>\n\n【29】删除32:<u>**</u>出版日期：2022年6月删除32:<u>**</u>", "index": 0, "show": true, "start": 0, "end": 1362, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "与原文不一致"}], "startTime": "2024/08/06 17:33:24", "endTime": "2024/08/06 17:34:18", "cost": 54.064}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-06 01:34:18", "grab_time": "2024-08-06 01:33:24"}
{"id": 2211768, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "a5cb57be-5073-4ecb-9919-a635a36555de", "title": "2023 ESHRE实践建议：反复植入失败", "text": "【0】页码:23\n2023 ESHRE实践建议：反复植入失败\nHarritty C, Berner JM", "tags": {}, "lang": "None", "attr": {"page_num": 23, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ESHRE实践建议：反复植入失败.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:19:39", "endTime": "2024/08/06 17:19:46", "cost": 6.812}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-06 01:19:46", "grab_time": "2024-08-06 01:19:39"}
{"id": 2211767, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "961e3eea-ec81-4dfe-8235-3de11d8fb4c2", "title": "（2023.V1）NCCN临床实践指南：遗传／家族高风险评估-结直肠癌", "text": "【0】页码:104\n（2023.V1）NCCN临床实践指南：遗传／家族高风险评估-结直肠癌\n疑似页眉<u>NCCN Guidelines Version 1.2023  \nGenetic/Familiar High-Risk Assessment: Colorectal  </u>\n\n【1】Overview  \nColorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. In 2022, an estimated 106,180 new cases of colon cancer and 44,850 new cases of rectal cancer will occur in the United States. During the same year, it is estimated that 52,580 people will die from CRC. Importantly, the incidence of CRC per 100,000 decreased from 60.5 in 1976 to 46.1 in 2005. The incidence rate for CRC reported by the Centers for Disease Control and Prevention (CDC) for 2011 is 40.0 per 100,000 persons. In addition, mortality from CRC decreased by almost 35% from 1990 to 2007, and by 53% from 1970 to 2016. These improvements in incidence of and mortality from CRC are thought in part to be a result of cancer prevention and earlier diagnosis through screening and better treatment modalities.\n\n【2】Despite the observed improvements in the overall CRC incidence rate, a retrospective cohort study of the SEER CRC registry found that the incidence of CRC in patients <50 years has been increasing. The authors estimate that the incidence rates for colon and rectal cancers will increase by 90.0% and 124.2%, respectively, for patients 20 to 34 years of age by 2030. The cause of this trend is currently unknown.\n\nApproximately 5% to 10% of all CRCs are attributed to well-defined hereditary colon cancer syndromes. These well-defined inherited syndromes include Lynch syndrome, adenomatous polyposis syndromes (eg, familial adenomatous polyposis 删除12:<u>[FAP]</u>, attenuated familial adenomatous polyposis 删除12:<u>[AFAP]</u>, MUTYH-associated polyposis 删除12:<u>[MAP]</u>), and hamartomatous polyposis syndromes (eg, juvenile polyposis syndrome 删除12:<u>[JPS]</u>, Peutz-Jeghers syndrome 删除12:<u>[PJS]</u>, PTEN hamartoma tumor syndrome 删除12:<u>[PHTS]</u>). These NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal provide recommendations for the care of patients with high-risk syndromes, including Lynch syndrome, FAP, MAP,|删除段之间换行|Literature Search Criteria and Guidelines Update Methodology  \nPrior to the update of this version of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, an electronic search of the PubMed database was performed to obtain key literature in the field of high-risk CRC published since the previous Guidelines update, using the following search terms: (lynch syndrome) or (hereditary nonpolyposis colorectal cancer) or (familial adenomatous polyposis) or (MUTYH polyposis) or (Peutz-Jeghers syndrome) or (polyposis syndrome) or (familial colon cancer) or (familial rectal cancer) or (familial colorectal cancer) or (hereditary colorectal cancer) or (multigene testing). The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.\n\n【4】NCCN recommendations have been developed to be inclusive of individuals of all sexual and gender identities to the greatest extent possible. When citing published studies and recommendations from other organizations, the terms used (eg, male, female) reflect the cited sources.\n\n【5】Assessment for Hereditary CRC Syndrome (HRS-1)  \nGenetic susceptibility to CRC includes well-defined inherited syndromes such as Lynch syndrome, FAP, MAP, and other less common syndromes. Many approaches have been proposed for identifying individuals with hereditary CRC syndromes. NCCN recommends a stepwise approach. First, if an individual has a personal or family history of a known germline pathogenic variant in a colorectal polyposis or cancer gene, further evaluation and management appropriate for established hereditary CRC", "tags": {}, "lang": "en", "attr": {"page_num": 104, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V1）NCCN临床实践指南：遗传／家族高风险评估-结直肠癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】", "content": "【0】页码:104\n（2023.V1）NCCN临床实践指南：遗传／家族高风险评估-结直肠癌\n疑似页眉<u>NCCN Guidelines Version 1.2023  \nGenetic/Familiar High-Risk Assessment: Colorectal  </u>\n\n【1】Overview  \nColorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. In 2022, an estimated 106,180 new cases of colon cancer and 44,850 new cases of rectal cancer will occur in the United States. During the same year, it is estimated that 52,580 people will die from CRC. Importantly, the incidence of CRC per 100,000 decreased from 60.5 in 1976 to 46.1 in 2005. The incidence rate for CRC reported by the Centers for Disease Control and Prevention (CDC) for 2011 is 40.0 per 100,000 persons. In addition, mortality from CRC decreased by almost 35% from 1990 to 2007, and by 53% from 1970 to 2016. These improvements in incidence of and mortality from CRC are thought in part to be a result of cancer prevention and earlier diagnosis through screening and better treatment modalities.\n\n【2】Despite the observed improvements in the overall CRC incidence rate, a retrospective cohort study of the SEER CRC registry found that the incidence of CRC in patients <50 years has been increasing. The authors estimate that the incidence rates for colon and rectal cancers will increase by 90.0% and 124.2%, respectively, for patients 20 to 34 years of age by 2030. The cause of this trend is currently unknown.\n\nApproximately 5% to 10% of all CRCs are attributed to well-defined hereditary colon cancer syndromes. These well-defined inherited syndromes include Lynch syndrome, adenomatous polyposis syndromes (eg, familial adenomatous polyposis 删除12:<u>[FAP]</u>, attenuated familial adenomatous polyposis 删除12:<u>[AFAP]</u>, MUTYH-associated polyposis 删除12:<u>[MAP]</u>), and hamartomatous polyposis syndromes (eg, juvenile polyposis syndrome 删除12:<u>[JPS]</u>, Peutz-Jeghers syndrome 删除12:<u>[PJS]</u>, PTEN hamartoma tumor syndrome 删除12:<u>[PHTS]</u>). These NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal provide recommendations for the care of patients with high-risk syndromes, including Lynch syndrome, FAP, MAP,|删除段之间换行|Literature Search Criteria and Guidelines Update Methodology  \nPrior to the update of this version of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, an electronic search of the PubMed database was performed to obtain key literature in the field of high-risk CRC published since the previous Guidelines update, using the following search terms: (lynch syndrome) or (hereditary nonpolyposis colorectal cancer) or (familial adenomatous polyposis) or (MUTYH polyposis) or (Peutz-Jeghers syndrome) or (polyposis syndrome) or (familial colon cancer) or (familial rectal cancer) or (familial colorectal cancer) or (hereditary colorectal cancer) or (multigene testing). The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.\n\n【4】NCCN recommendations have been developed to be inclusive of individuals of all sexual and gender identities to the greatest extent possible. When citing published studies and recommendations from other organizations, the terms used (eg, male, female) reflect the cited sources.\n\n【5】Assessment for Hereditary CRC Syndrome (HRS-1)  \nGenetic susceptibility to CRC includes well-defined inherited syndromes such as Lynch syndrome, FAP, MAP, and other less common syndromes. Many approaches have been proposed for identifying individuals with hereditary CRC syndromes. NCCN recommends a stepwise approach. First, if an individual has a personal or family history of a known germline pathogenic variant in a colorectal polyposis or cancer gene, further evaluation and management appropriate for established hereditary CRC", "index": 1012, "show": true, "start": 1012, "end": 1015, "comment": "|删除段之间换行|Literature Search Criteria and Guidelines Update Methodology", "isEdit": false, "province": ["格式规范性", "缺少换行"]}], "startTime": "2024/08/06 16:48:38", "endTime": "2024/08/06 16:58:44", "cost": 605.518}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-06 00:58:44", "grab_time": "2024-08-06 00:48:38"}
{"id": 2211766, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "dc71868c-5da1-4f9b-a795-57002f22e671", "title": "2023+ASRA循证共识指南：慢性非癌性疼痛脊髓刺激治疗的患者选择和试验刺激", "text": "【0】页码:5\n2023+ASRA循证共识指南：慢性非癌性疼痛脊髓刺激治疗的患者选择和试验刺激\n删除图片描述:<u>![](4_0.png)</u>\n\n【1】Based on estimation of diagnostic parameters from published studies, SCS trial has good sensitivity (77%–100% based on RCTs) and moderate specificity (35%–53% based on RCTs) in identifying candidates for SCS therapy (considered across all pain conditions) (online supplemental file 1).\n\n【2】There are potential procedure-related adverse effects related to the implantation of either temporary or permanent leads as part of a trial. These include neurological injury, procedural pain, infection, lead fracture, lead migration, and headache due to dural puncture. The differences in potential risk associated with the two techniques are shown in online supplemental file 2.\n\n【3】- Anginal pain: The benefit of a trial of SCS for anginal pain in patients with non-operable (referring to coronary artery bypass graft surgery) cardiac disease is less certain as all but one RCT do not include a trial phase.\n- Peripheral vascular disease (PVD): The literature suggests that performing an SCS trial for treatment of PVD is useful based on evidence from both observational studies and RCTs. Improvement in transcutaneous oxygen tension (TcPO$_2$), which can be an objective marker assessed during the SCS trial, has been observed to be associated with therapy success for improved pain and a lower rate of amputation.\n- CRPS: Although CRPS is a common indication for SCS therapy, we observed only two RCTs specifically on this population and fewer high-quality observational studies performed selectively on this population.删除17:<u>16</u> Apart from the RCT by Eldabe et al (mixed population including CRPS), no studies compared a trial versus no trial approach.\n- Diabetic neuropathy: All three RCTs specific to the use of SCS for treatment of painful diabetic neuropathy have included a trial phase, indicating typicality of performing a trial of SCS for this indication.\n\n【4】### Section 3: screening for psychosocial factors influencing SCS patient selection\n\n【5】删除32:<u>**</u>Questions considered删除32:<u>**</u>\n\n【6】1. Are there any psychosocial risk factors that can be considered as absolute contraindications for SCS therapy?\n2. What psychosocial factors have been associated with higher risk of poor outcomes with SCS therapy?\n3. What are the suggested tools to diagnose the presence and severity of psychosocial factors associated higher risk of poor outcomes with SCS therapy?\n4. Is there any role for psychological therapy, education provision, counseling, or other such approaches to modify potential risk factors and hence improve long-term outcomes?\n\n【7】Screening for psychosocial factors is considered important for SCS therapy, as they can influence long-term outcomes, especially patient satisfaction. Patient perceptions as tied to their expectations are covered in section 4. There is lack of consensus on the best method, domains, and tools to be used for screening, as evidenced by 20 different screening questionnaires utilized across 52 different studies. We have taken into consideration the consistency of results among studies, generalizability of findings to practice, coherence in the domain of evidence, and the potential magnitude of effect. Most publications related to SCS patient selection highlight the importance of patient’s understanding regarding the application and the use of SCS therapy. Patients need to be aware of the components involved (leads and IPG), and its expected effects so that therapy can be optimized and titrated with appropriate programming. There are no RCTs evaluating outcomes based on randomizing patients with or without a particular set of psychological traits to SCS therapy. In published studies, reviews and guidelines, presence of ongoing substance abuse and major psychological disorders, such as active psychosis, are consistently considered as absolute contraindications because patients with these conditions are known to exhibit loss of insight and non-compliance to treatment. Among observational studies, most studies involved mixed populations or patients with chronic leg pain with or without back pain, with only one study evaluating patients with CRPS, and no studies involving SCS for angina, PVD or diabetic neuropathy. The most commonly used tool reported in studies is the Minnesota Multiphasic Personality Inventory (MMPI) in its different versions. Despite studies showing association of catastrophizing using the Pain Catastrophizing Scale (PCS) with poor outcomes, its value as a predictor of long-term outcomes is not consistent. Similarly, social factors such as poor social support and their associations with outcomes are not consistent and the tools to identify such social factors are not foolproof. Although presence of anxiety and post-traumatic stress disorder was noted to be predictive of poor outcomes in small observational studies, the findings were not consistent. Dumoulin et al described a predictive indication factor (IT  % ) for preimplantation psychological evaluation using 24 factors developed.", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023+ASRA循证共识指南：慢性非癌性疼痛脊髓刺激治疗的患者选择和试验刺激.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】Based on estimation of diagnostic parameters from published studies, SCS trial has good sensitivity (77%–100% based on RCTs) and moderate specificity (35%–53% based on RCTs) in identifying candidates for SCS therapy (considered across all pain conditions) (online supplemental file 1).\n\n【2】There are potential procedure-related adverse effects related to the implantation of either temporary or permanent leads as part of a trial. These include neurological injury, procedural pain, infection, lead fracture, lead migration, and headache due to dural puncture. The differences in potential risk associated with the two techniques are shown in online supplemental file 2.\n\n【3】- Anginal pain: The benefit of a trial of SCS for anginal pain in patients with non-operable (referring to coronary artery bypass graft surgery) cardiac disease is less certain as all but one RCT do not include a trial phase.\n\nPeripheral vascular disease (PVD): The literature suggests that performing an SCS trial for treatment of PVD is useful based on evidence from both observational studies and RCTs. Improvement in transcutaneous oxygen tension (TcPO\n2\n), which can be an objective marker assessed during the SCS trial, has been observed to be associated with therapy success for improved pain and a lower rate of amputation.\nCRPS: Although CRPS is a common indication for SCS therapy, we observed only two RCTs specifically on this population and fewer high-quality observational studies performed selectively on this population.删除17:16 Apart from the RCT by Eldabe et al (mixed population including CRPS), no studies compared a trial versus no trial approach.\nDiabetic neuropathy: All three RCTs specific to the use of SCS for treatment of painful diabetic neuropathy have included a trial phase, indicating typicality of performing a trial of SCS for this indication.", "content": "【0】页码:5\n2023+ASRA循证共识指南：慢性非癌性疼痛脊髓刺激治疗的患者选择和试验刺激\n删除图片描述:<u>![](4_0.png)</u>\n\n【1】Based on estimation of diagnostic parameters from published studies, SCS trial has good sensitivity (77%–100% based on RCTs) and moderate specificity (35%–53% based on RCTs) in identifying candidates for SCS therapy (considered across all pain conditions) (online supplemental file 1).\n\n【2】There are potential procedure-related adverse effects related to the implantation of either temporary or permanent leads as part of a trial. These include neurological injury, procedural pain, infection, lead fracture, lead migration, and headache due to dural puncture. The differences in potential risk associated with the two techniques are shown in online supplemental file 2.\n\n【3】- Anginal pain: The benefit of a trial of SCS for anginal pain in patients with non-operable (referring to coronary artery bypass graft surgery) cardiac disease is less certain as all but one RCT do not include a trial phase.\n- Peripheral vascular disease (PVD): The literature suggests that performing an SCS trial for treatment of PVD is useful based on evidence from both observational studies and RCTs. Improvement in transcutaneous oxygen tension (TcPO$_2$), which can be an objective marker assessed during the SCS trial, has been observed to be associated with therapy success for improved pain and a lower rate of amputation.\n- CRPS: Although CRPS is a common indication for SCS therapy, we observed only two RCTs specifically on this population and fewer high-quality observational studies performed selectively on this population.删除17:<u>16</u> Apart from the RCT by Eldabe et al (mixed population including CRPS), no studies compared a trial versus no trial approach.\n- Diabetic neuropathy: All three RCTs specific to the use of SCS for treatment of painful diabetic neuropathy have included a trial phase, indicating typicality of performing a trial of SCS for this indication.\n\n【4】### Section 3: screening for psychosocial factors influencing SCS patient selection\n\n【5】删除32:<u>**</u>Questions considered删除32:<u>**</u>\n\n【6】1. Are there any psychosocial risk factors that can be considered as absolute contraindications for SCS therapy?\n2. What psychosocial factors have been associated with higher risk of poor outcomes with SCS therapy?\n3. What are the suggested tools to diagnose the presence and severity of psychosocial factors associated higher risk of poor outcomes with SCS therapy?\n4. Is there any role for psychological therapy, education provision, counseling, or other such approaches to modify potential risk factors and hence improve long-term outcomes?\n\n【7】Screening for psychosocial factors is considered important for SCS therapy, as they can influence long-term outcomes, especially patient satisfaction. Patient perceptions as tied to their expectations are covered in section 4. There is lack of consensus on the best method, domains, and tools to be used for screening, as evidenced by 20 different screening questionnaires utilized across 52 different studies. We have taken into consideration the consistency of results among studies, generalizability of findings to practice, coherence in the domain of evidence, and the potential magnitude of effect. Most publications related to SCS patient selection highlight the importance of patient’s understanding regarding the application and the use of SCS therapy. Patients need to be aware of the components involved (leads and IPG), and its expected effects so that therapy can be optimized and titrated with appropriate programming. There are no RCTs evaluating outcomes based on randomizing patients with or without a particular set of psychological traits to SCS therapy. In published studies, reviews and guidelines, presence of ongoing substance abuse and major psychological disorders, such as active psychosis, are consistently considered as absolute contraindications because patients with these conditions are known to exhibit loss of insight and non-compliance to treatment. Among observational studies, most studies involved mixed populations or patients with chronic leg pain with or without back pain, with only one study evaluating patients with CRPS, and no studies involving SCS for angina, PVD or diabetic neuropathy. The most commonly used tool reported in studies is the Minnesota Multiphasic Personality Inventory (MMPI) in its different versions. Despite studies showing association of catastrophizing using the Pain Catastrophizing Scale (PCS) with poor outcomes, its value as a predictor of long-term outcomes is not consistent. Similarly, social factors such as poor social support and their associations with outcomes are not consistent and the tools to identify such social factors are not foolproof. Although presence of anxiety and post-traumatic stress disorder was noted to be predictive of poor outcomes in small observational studies, the findings were not consistent. Dumoulin et al described a predictive indication factor (IT  % ) for preimplantation psychological evaluation using 24 factors developed.", "index": 76, "show": true, "start": 76, "end": 1930, "province": ["格式规范性", "序号格式不一致"], "isEdit": false}, {"text": "【0】", "content": "【0】页码:5\n2023+ASRA循证共识指南：慢性非癌性疼痛脊髓刺激治疗的患者选择和试验刺激\n删除图片描述:<u>![](4_0.png)</u>\n\n<mark>【1】Based on estimation of diagnostic parameters from published studies, SCS trial has good sensitivity (77%–100% based on RCTs) and moderate specificity (35%–53% based on RCTs) in identifying candidates for SCS therapy (considered across all pain conditions) (online supplemental file 1).\n\n【2】There are potential procedure-related adverse effects related to the implantation of either temporary or permanent leads as part of a trial. These include neurological injury, procedural pain, infection, lead fracture, lead migration, and headache due to dural puncture. The differences in potential risk associated with the two techniques are shown in online supplemental file 2.\n\n【3】- Anginal pain: The benefit of a trial of SCS for anginal pain in patients with non-operable (referring to coronary artery bypass graft surgery) cardiac disease is less certain as all but one RCT do not include a trial phase.\n\nPeripheral vascular disease (PVD): The literature suggests that performing an SCS trial for treatment of PVD is useful based on evidence from both observational studies and RCTs. Improvement in transcutaneous oxygen tension (TcPO\n2\n), which can be an objective marker assessed during the SCS trial, has been observed to be associated with therapy success for improved pain and a lower rate of amputation.\nCRPS: Although CRPS is a common indication for SCS therapy, we observed only two RCTs specifically on this population and fewer high-quality observational studies performed selectively on this population.删除17:16 Apart from the RCT by Eldabe et al (mixed population including CRPS), no studies compared a trial versus no trial approach.\nDiabetic neuropathy: All three RCTs specific to the use of SCS for treatment of painful diabetic neuropathy have included a trial phase, indicating typicality of performing a trial of SCS for this indication.</mark>s indication.\n\n【4】### Section 3: screening for psychosocial factors influencing SCS patient selection\n\n【5】删除32:<u>**</u>Questions considered删除32:<u>**</u>\n\n【6】1. Are there any psychosocial risk factors that can be considered as absolute contraindications for SCS therapy?\n2. What psychosocial factors have been associated with higher risk of poor outcomes with SCS therapy?\n3. What are the suggested tools to diagnose the presence and severity of psychosocial factors associated higher risk of poor outcomes with SCS therapy?\n4. Is there any role for psychological therapy, education provision, counseling, or other such approaches to modify potential risk factors and hence improve long-term outcomes?\n\n【7】Screening for psychosocial factors is considered important for SCS therapy, as they can influence long-term outcomes, especially patient satisfaction. Patient perceptions as tied to their expectations are covered in section 4. There is lack of consensus on the best method, domains, and tools to be used for screening, as evidenced by 20 different screening questionnaires utilized across 52 different studies. We have taken into consideration the consistency of results among studies, generalizability of findings to practice, coherence in the domain of evidence, and the potential magnitude of effect. Most publications related to SCS patient selection highlight the importance of patient’s understanding regarding the application and the use of SCS therapy. Patients need to be aware of the components involved (leads and IPG), and its expected effects so that therapy can be optimized and titrated with appropriate programming. There are no RCTs evaluating outcomes based on randomizing patients with or without a particular set of psychological traits to SCS therapy. In published studies, reviews and guidelines, presence of ongoing substance abuse and major psychological disorders, such as active psychosis, are consistently considered as absolute contraindications because patients with these conditions are known to exhibit loss of insight and non-compliance to treatment. Among observational studies, most studies involved mixed populations or patients with chronic leg pain with or without back pain, with only one study evaluating patients with CRPS, and no studies involving SCS for angina, PVD or diabetic neuropathy. The most commonly used tool reported in studies is the Minnesota Multiphasic Personality Inventory (MMPI) in its different versions. Despite studies showing association of catastrophizing using the Pain Catastrophizing Scale (PCS) with poor outcomes, its value as a predictor of long-term outcomes is not consistent. Similarly, social factors such as poor social support and their associations with outcomes are not consistent and the tools to identify such social factors are not foolproof. Although presence of anxiety and post-traumatic stress disorder was noted to be predictive of poor outcomes in small observational studies, the findings were not consistent. Dumoulin et al described a predictive indication factor (IT  % ) for preimplantation psychological evaluation using 24 factors developed.", "index": 0, "show": true, "start": 0, "end": 3, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "开头缺少一段正文"}], "startTime": "2024/08/07 09:37:17", "endTime": "2024/08/07 09:39:20", "cost": 122.251}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-06 17:39:17", "grab_time": "2024-08-06 17:37:14"}
{"id": 2211765, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "55f1fc94-3d1e-4624-b716-975a8641c4b1", "title": "（2023.V2）NCCN临床实践指南：甲状腺癌", "text": "【0】页码:92\n（2023.V2）NCCN临床实践指南：甲状腺癌\n疑似页眉<u>NCCN Guidelines Version 2.2023  \nThyroid Carcinoma  </u>\n\n【1】disease. Novel treatments for patients with metastatic differentiated thyroid carcinoma have been evaluated. Agents include mult-targeted kinase inhibitors, such as lenvatinib, sorafenib, sunitinib, axitinib, everolimus, vandetanib, cabozantinib, and pazopanib; BRAF V600E mutant inhibitors, such as vemurafenib or dabrafenib; tropomyosin receptor kinase (TRK) inhibitors, such as larotrectinib or entrectinib; RET inhibitors such as selpercatinib or pralsetinib; and anti-PD", "tags": {}, "lang": "en", "attr": {"page_num": 92, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V2）NCCN临床实践指南：甲状腺癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】disease. Novel treatments for patients with metastatic differentiated thyroid carcinoma have been evaluated. Agents include mult-targeted kinase inhibitors, such as lenvatinib, sorafenib, sunitinib, axitinib, everolimus, vandetanib, cabozantinib, and pazopanib; BRAF V600E mutant inhibitors, such as vemurafenib or dabrafenib; tropomyosin receptor kinase (TRK) inhibitors, such as larotrectinib or entrectinib; RET inhibitors such as selpercatinib or pralsetinib; and anti-PD", "content": "【0】页码:92\n（2023.V2）NCCN临床实践指南：甲状腺癌\n疑似页眉<u>NCCN Guidelines Version 2.2023  \nThyroid Carcinoma  </u>\n\n【1】disease. Novel treatments for patients with metastatic differentiated thyroid carcinoma have been evaluated. Agents include mult-targeted kinase inhibitors, such as lenvatinib, sorafenib, sunitinib, axitinib, everolimus, vandetanib, cabozantinib, and pazopanib; BRAF V600E mutant inhibitors, such as vemurafenib or dabrafenib; tropomyosin receptor kinase (TRK) inhibitors, such as larotrectinib or entrectinib; RET inhibitors such as selpercatinib or pralsetinib; and anti-PD", "index": 99, "show": true, "start": 99, "end": 577, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/06 15:32:00", "endTime": "2024/08/06 15:32:18", "cost": 18.261}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:17", "update_time": "2024-08-05 23:32:19", "grab_time": "2024-08-05 23:32:00"}
{"id": 2211764, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "a9c065c4-c4e3-477f-a0f5-960f22e56bc1", "title": "【神经领域】中国脑卒中防治指导规范（2021年版）", "text": "【0】页码:507\n【神经领域】中国脑卒中防治指导规范（2021年版）\n生瘤痛和严重认知功能下降的风险血管内治疗组也较开颅夹闭组低, 然而能明确再出血率和动脉瘤复发率血管内治疗组高于开颅夹闭组。Barrow 破裂动脉瘤研 究（Barrow Ruptured Aneurysm Trial）也是一项比较两种方式治疗破裂动脉瘤的随 机对照研究, 结果显示与血管内治疗组相比, 开颅夹闭组具有较高的完全闭塞率、 较低的复发率和再治疗率, 血管内治疗组临床预后优于开颅夹闭组。其 10 年结 果显示长期疗效两者相当。ISAT 研究显示血管内治疗临床应用早期开展后, 随着 不同的颗粒弹簧圈、支架和流导向装置等材料的出现和栓塞技术的改进, 卡颅动脉瘤的血管内治疗疗效不断提高。\n\n【1】对于单纯栓塞无法治好的破裂宽颈或棘形动脉瘤, 采用支架的血管重建治疗 是必需的也是临床常用的, 但目前尚缺乏前瞻性的 RCT 研究证据支持。 在 aSAH 急性期应用支架的争议主要是其术后抗血小板治疗带来的动脉瘤早期再出血及 外科干预风险。一些单中心的病例系列报道显示支架治疗破裂动脉瘤较单纯栓 塞虽然未完全性整, 但长期疗效显著提高。为了控制出血, 同时避免急性期支 架治疗带来的风险, 有研究报道采用急性期单纯栓塞, 慢性期一期支架治疗的方 法, 对于部分宽颈动脉瘤是不个可选的治疗方案。目前尚没有关于支架治疗动脉 瘤的前瞻性 RCT 研究报道。\n\n【2】大脑中动脉动脉瘤的处理目前争议较多。虽然没有较强的证据支持, 但多致 专家认为大脑中动脉动脉瘤更适于采取开颅夹闭治疗, 而荟萤分析结果显示在破 裂的大脑中动脉瘤血管内治疗的临缓局与开颅夹闭相当。伴有颅内出血> 50ml 的患者7良预后发生率增高, 但如能在 3.5 小时内清除血肿数据则可以改 善预后, 因此建议伴有巨大血肿的患者行开颅术治疗。\n\n【3】患者管愈是动脉瘤性蛛网膜下腔出血预后不佳的一个因素,尽管多数专家认 为高龄患者更适合血管内治疗, 但是此类研究证据较少。临床 Hunt-Hess 分级较 重的患者可能更适合做血管内治疗, 特别是年较致力的患者, 因为此时血管内治 疗的微创性显得更为重要。近年来, 对于高发则走和 aSAH 患者, 临床选择血管内治疗的比例逐渐增加, 尽管荟萃分析显示其疗效与开颅夹闭相当。如果患者 症状出现后血管痉挛期, 特别是已被证实存在血管痉挛,则推癿行血管内治疗, 可同时针对破裂动脉瘤和血管痉挛进行干预。\n\n【4】血管内治疗后循环动脉瘤已获牛-泛认可。荟萃分析指出: 基底动脉分叉 处动脉瘤血管内治疗的死亡率为 0.9%。长期并发症的风险为 5.4%。一项比较手", "tags": {}, "lang": "zh", "attr": {"page_num": 507, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【神经领域】中国脑卒中防治指导规范（2021年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:15:10", "endTime": "2024/08/06 16:15:36", "cost": 26.614}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:15:37", "grab_time": "2024-08-06 00:15:10"}
{"id": 2211763, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "9b5170c6-39b0-4d61-9806-39aefe64185e", "title": "2023更新—2007 NICE指南：12岁以下人群特应性湿疹的诊断和治疗（CG.57）", "text": "页码:16\n2023更新—2007 NICE指南：12岁以下人群特应性湿疹的诊断和治疗（CG.57）\n### 1.5.1.26|删除段内换行|It is recommended that treatment with tacrolimus or pimecrolimus be initiated only by physicians (including general practitioners) with a special interest and experience in dermatology, and only after careful discussion with the patient about the potential risks and benefits of all appropriate second-line treatment options. 删除32:<u>**</u>删除12:<u>删除14:<u>删除24:<u>[2004]</u></u></u>删除32:<u>**</u>\n\n### 1.5.1.27|删除段内换行|Explain to children with atopic eczema and their parents or carers that they should only apply topical calcineurin inhibitors to areas of active atopic eczema, which may include areas of broken skin. 删除32:<u>**</u>删除12:<u>删除14:<u>删除24:<u>[2007]</u></u></u>删除32:<u>**</u>\n\n### 1.5.1.28|删除段内换行|Do not use topical calcineurin inhibitors under occlusion (bandages and dressings) for treating atopic eczema in children without specialist dermatological advice. 删除32:<u>**</u>删除12:<u>删除14:<u>删除24:<u>[2007]</u></u></u>删除32:<u>**</u>\n\n### 1.5.1.29|删除段内换行|For facial atopic eczema in children that requires long-term or frequent use of mild topical corticosteroids, consider stepping up treatment to topical calcineurin inhibitors. 删除32:<u>**</u>删除12:<u>删除14:<u>删除24:<u>[2007]</u></u></u>删除32:<u>**</u>\n\n【4】## Dry bandages and medicated dressings (including wet wrap therapy)\n\n### 1.5.1.30|删除段内换行|Do not use occlusive medicated dressings and dry bandages to treat infected atopic eczema in children. 删除32:<u>**</u>删除12:<u>删除14:<u>删除24:<u>[2007]</u></u></u>删除32:<u>**</u>\n\n### 1.5.1.31|删除段内换行|Think about using localised medicated dressings or dry bandages with emollients as a treatment for areas of chronic lichenified (localised skin thickening) atopic eczema in children. 删除32:<u>**</u>删除12:<u>删除14:<u>删除24:<u>[2007]</u></u></u>删除32:<u>**</u>\n\n### 1.5.1.32|删除段内换行|Think about using localised medicated dressings or dry bandages with emollients and topical corticosteroids for short-term treatment of flares (7 to 14 days) or areas of chronic lichenified atopic eczema in children. 删除32:<u>**</u>删除12:<u>删除14:<u>删除24:<u>[2007]</u></u></u>删除32:<u>**</u>\n\n### 1.5.1.33|删除段内换行|Do not use whole-body (limbs and trunk) occlusive dressings (including wet wrap therapy) or whole-body dry bandages (including tubular bandages and garments) as first-line treatment for atopic eczema in children. If using these treatments, they should be started by a healthcare professional trained in their use. 删除32:<u>**</u>删除12:<u>删除14:<u>删除24:<u>[2007]</u></u></u>删除32:<u>**</u>", "tags": {}, "lang": "en", "attr": {"page_num": 16, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023更新—2007 NICE指南：12岁以下人群特应性湿疹的诊断和治疗（CG.57）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:49:22", "endTime": "2024/08/06 15:49:51", "cost": 28.503}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-05 23:49:51", "grab_time": "2024-08-05 23:49:22"}
{"id": 2211762, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "f2cc658d-cbae-495b-8256-f2aae75dc911", "title": "2023 NICE 技术鉴定指导意见：Axicabtagene ciloleucel 治疗弥漫性大 B 细胞淋巴瘤和原发性纵隔大 B 细胞淋巴瘤 2 次或以上全身治疗后[TA872]", "text": "【0】页码:2\n2023 NICE 技术鉴定指导意见：Axicabtagene ciloleucel 治疗弥漫性大 B 细胞淋巴瘤和原发性纵隔大 B 细胞淋巴瘤 2 次或以上全身治疗后[TA872]\n# Your responsibility\n\n【1】The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.\n\n【2】All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme].\n\n【3】Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.\n\n【4】Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations] wherever possible.", "tags": {}, "lang": "en", "attr": {"page_num": 2, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 NICE 技术鉴定指导意见：Axicabtagene ciloleucel 治疗弥漫性大 B 细胞淋巴瘤和原发性纵隔大 B 细胞淋巴瘤 2 次或以上全身治疗后[TA872].pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:11:00", "endTime": "2024/08/06 16:11:24", "cost": 23.542}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:11:24", "grab_time": "2024-08-06 00:11:00"}
{"id": 2211761, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "e2f13489-db3a-450b-8250-4f0ff913c43f", "title": "WHO：妊娠24周前超声检查建议（2022）", "text": "页码:42\nWHO：妊娠24周前超声检查建议（2022）\n| Fetal and neonatal outcomes (continued) |\n\n| ----------------------------------------- | ----------------------------------------- | ----------------------------------------- | ------------------------------------------ | ------------------------------------------ | ------------------------------------------ | ------------------------------------------ |\n| Quality assessment                        | No. of studies                           | Design              | Risk of bias (studies)                           | Inconsistency       | Indirectness         | Imprecision         | Other considerations          | No. of participants |\n| Low birth weight 删除19:<u>(less than 2500 g)</u>       | 6                                        | randomized trial    | serious$^{a}$                                  | no serious inconsistency | no serious indirectness | RR 0.92 删除11:<u>(0.74-1.14)</u> | 3 fewer per 1000 (11 fewer to 6 more) | 354/8797 (4.0\\%) |\n| Smaller gestational age                   | 1                                        | randomized trial    | serious$^{a}$                                  | no serious inconsistency | no serious indirectness | RR 1.27 删除11:<u>(0.92-1.75)</u> | 27 more per 1000 (8 fewer to 77 more)  | 274/4144 (6.6\\%)  |\n\n【2】a. Wide CIs: indicating data of serious limitations (most weight from 3 studies).\nb. Variable definitions: Source of heterogeneity not resolved.\nc. Study with very tight limitations.", "tags": {}, "lang": "en", "attr": {"page_num": 42, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WHO：妊娠24周前超声检查建议（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "| Fetal and neonatal outcomes (continued) |\n\n| ----------------------------------------- | ----------------------------------------- | ----------------------------------------- | ------------------------------------------ | ------------------------------------------ | ------------------------------------------ | ------------------------------------------ |\n\n| Quality assessment                        | No. of studies                           | Design              | Risk of bias (studies)                           | Inconsistency       | Indirectness         | Imprecision         | Other considerations          | No. of participants |\n\n| Low birth weight 删除19:(less than 2500 g)       | 6                                        | randomized trial    | serious\n𝑎\n                                  | no serious inconsistency | no serious indirectness | RR 0.92 删除11:(0.74-1.14) | 3 fewer per 1000 (11 fewer to 6 more) | 354/8797 (4.0%) |\n\n| Smaller gestational age                   | 1                                        | randomized trial    | serious\n𝑎\n                                  | no serious inconsistency | no serious indirectness | RR 1.27 删除11:(0.92-1.75) | 27 more per 1000 (8 fewer to 77 more)  | 274/4144 (6.6%)  |\n\n【2】a. Wide CIs: indicating data of serious limitations (most weight from 3 studies).\n\nb. Variable definitions: Source of heterogeneity not resolved.\n\nc. Study with very tight limitations.", "content": "页码:42\nWHO：妊娠24周前超声检查建议（2022）\n| Fetal and neonatal outcomes (continued) |\n\n| ----------------------------------------- | ----------------------------------------- | ----------------------------------------- | ------------------------------------------ | ------------------------------------------ | ------------------------------------------ | ------------------------------------------ |\n| Quality assessment                        | No. of studies                           | Design              | Risk of bias (studies)                           | Inconsistency       | Indirectness         | Imprecision         | Other considerations          | No. of participants |\n| Low birth weight 删除19:<u>(less than 2500 g)</u>       | 6                                        | randomized trial    | serious$^{a}$                                  | no serious inconsistency | no serious indirectness | RR 0.92 删除11:<u>(0.74-1.14)</u> | 3 fewer per 1000 (11 fewer to 6 more) | 354/8797 (4.0\\%) |\n| Smaller gestational age                   | 1                                        | randomized trial    | serious$^{a}$                                  | no serious inconsistency | no serious indirectness | RR 1.27 删除11:<u>(0.92-1.75)</u> | 27 more per 1000 (8 fewer to 77 more)  | 274/4144 (6.6\\%)  |\n\n【2】a. Wide CIs: indicating data of serious limitations (most weight from 3 studies).\nb. Variable definitions: Source of heterogeneity not resolved.\nc. Study with very tight limitations.", "index": 29, "show": true, "start": 29, "end": 1461, "province": ["格式规范性", "表格格式错误"], "isEdit": false}], "startTime": "2024/08/06 16:24:38", "endTime": "2024/08/06 16:25:14", "cost": 36.216}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:25:15", "grab_time": "2024-08-06 00:24:38"}
{"id": 2211760, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "e6384ad0-9c48-44e1-ac21-a0c9df0d8fcb", "title": "2024+SCCM指南：儿童和成人危重症患者的血糖控制", "text": "【0】页码:18\n2024+SCCM指南：儿童和成人危重症患者的血糖控制\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】1. Care Trials Group: Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: Long-term follow-up of a subgroup of patients from the NICE-SUGAR study. 删除32:<u>*</u>Intensive Care Med删除32:<u>*</u> 2015; 41:1037–1047\n\n【2】2. Cinotti R, Ichai C, Orban JC, et al: Effects of tight computerized glucose control on neurological outcome in severely brain injured patients: A multicenter sub-group analysis of the randomized-controlled open-label CGAO-REA study. 删除32:<u>*</u>Crit Care删除32:<u>*</u> 2014; 18:498\n\n【3】参考删除-3:<u>3. Ingels C, Debaveye Y, Milants I, et al: Strict blood glucose control with insulin during intensive care after cardiac surgery: Impact on 4-years survival, dependency on medical care, and quality-of-life. 删除32:<u>*</u>Eur Heart J删除32:<u>*</u> 2006; 27:2716–2724</u>\n\n【4】参考删除-3:<u>4. Gunst J, Debaveye Y, Güiza F, et al: Tight blood-glucose control without early parenteral nutrition in the ICU. 删除32:<u>*</u>N Engl J Med删除32:<u>*</u> 2023; 389:1180–1190</u>\n\n【5】参考删除-3:<u>5. Krinsley JS, Grover A: Severe hypoglycemia in critically ill patients: Risk factors and outcomes. 删除32:<u>*</u>Crit Care Med删除32:<u>*</u> 2007; 35:2262–2267</u>\n\n【6】参考删除-3:<u>6. Egi M, Bellomo R, Stachowski E, et al: Hypoglycemia and outcome in critically ill patients. 删除32:<u>*</u>Mayo Clin Proc删除32:<u>*</u> 2010; 85:217–224</u>\n\n【7】参考删除-3:<u>7. Finfer S, Liu B, Chittock DR, et al; NICE-SUGAR Study Investigators: Hypoglycemia and risk of death in critically ill patients. 删除32:<u>*</u>N Engl J Med删除32:<u>*</u> 2012; 367:1108–1118</u>\n\n【8】参考删除-3:<u>8. Egi M, Krinsley JS, Maurer P, et al: Pre-morbid glycemic control modifies the interaction between acute hypoglycemia and mortality. 删除32:<u>*</u>Intensive Care Med删除32:<u>*</u> 2016; 42:562–571</u>\n\n【9】参考删除-3:<u>9. Reyes-Umpierrez D, Davis G, Cardona S, et al: Inflammation and oxidative stress in cardiac surgery patients treated to intensive versus conservative glucose targets. 删除32:<u>*</u>J Clin Endocrinol Metab删除32:<u>*</u> 2017; 102:309–315</u>\n\n【10】参考删除-3:<u>10. Blaha J, Mraz M, Kopecky P, et al: Perioperative tight glucose control reduces postoperative adverse events in nondiabetic cardiac surgery patients. 删除32:<u>*</u>J Clin Endocrinol Metab删除32:<u>*</u> 2015; 100:3081–3089</u>\n\n【11】参考删除-3:<u>11. Greco G, Ferket BS, D’Alessandro DA, et al: Diabetes and the association of postoperative hyperglycemia with clinical and economic outcomes in cardiac surgery. 删除32:<u>*</u>Diabetes Care删除32:<u>*</u> 2016; 39:408–417</u>\n\n【12】参考删除-3:<u>12. Lazar HL, Salm TV, Engelman R, et al: Prevention and management of sternal wound infections. 删除32:<u>*</u>J Thorac Cardiovasc Surg删除32:<u>*</u> 2016; 152:962–972</u>\n\n【13】参考删除-3:<u>13. Engelman DT, Ben Ali W, Williams JB, et al: Guidelines for perioperative care in cardiac surgery: Enhanced recovery after surgery society recommendations. 删除32:<u>*</u>JAMA Surg删除32:<u>*</u> 2019; 154:755–766</u>\n\n【14】参考删除-3:<u>14. Krinsley JS, Egi M, Kiss A, et al: Diabetic status and the relationship of the 3 domains of glycemic control to mortality in critically ill patients: An international multi-center cohort study. 删除32:<u>*</u>Crit Care删除32:<u>*</u> 2013; 17:R37</u>\n\n【15】参考删除-3:<u>15. Sechterberger MK, Bosman RJ, Oudemans-van Straaten HM, et al: The effect of diabetes mellitus on the association between measures of glycemic control and ICU mortality: A retrospective cohort study. 删除32:<u>*</u>Crit Care删除32:<u>*</u> 2013; 17:R52</u>\n\n【16】16. Plummer MP, Bellomo R, Cousins CE, et al: Dysglycemia in the critically ill and the interaction of chronic and acute glycemia with mortality. 删除32:<u>*</u>Intensive Care Med删除32:<u>*</u> 2014; 40:973–980\n\n【17】参考删除-3:<u>17. Roberts GW, Quinn SJ, Valentine N, et al: Relative hyperglycemia, a marker of critical illness: Introducing the stress hyperglycemia ratio. 删除32:<u>*</u>J Clin Endocrinol Metab删除32:<u>*</u> 2015; 100:4490–4497</u>\n\n【18】参考删除-3:<u>18. Krinsley JS, Rule P, Pappy L, et al: The interaction of acute and chronic glycemia on the relationship of hyperglycemia, hypoglycemia, and glucose variability to mortality in the critically ill. 删除32:<u>*</u>Crit Care Med删除32:<u>*</u> 2020; 48:1744–1751</u>\n\n【19】19. Kwan TN, Zwakman-Hessels L, Marhoon N, et al: Relative hypoglycemia in diabetic patients with critical illness. 删除32:<u>*</u>Crit Care Med删除32:<u>*</u> 2020; 48:e233–e240\n\n【20】参考删除-3:<u>20. Krinsley JS, Rule PR, Roberts GW, et al: Relative hypoglycemia and lower hemoglobin A1C-adjusted time in band are strongly associated with increased mortality in critically ill patients. 删除32:<u>*</u>Crit Care Med删除32:<u>*</u> 2022; 50:e664–e673</u>\n\n【21】参考删除-3:<u>21. Roberts G, Krinsley JS, Preiser J-C, et al: The glycemic ratio is strongly and independently associated with mortality in the critically ill. 删除32:<u>*</u>J Diabetes Sci Technol删除32:<u>*</u> 2022 Sep 12. [online ahead of print]</u>\n\n【22】参考删除-3:<u>22. Bohe J, Abidi H, Brunot V, et al; CONTROLE Individualisé de la Glycémie (CONTROLLING) Study Group: Individualized versus conventional glucose control in critically-ill patients: The CONTROLLING study-a randomized clinical trial. 删除32:<u>*</u>Intensive Care Med删除32:<u>*</u> 2021; 47:1271–1283</u>\n\n【23】参考删除-3:<u>23. Cardona S, Pasquel FJ, Fayfman M, et al: Hospitalization costs and clinical outcomes in CABG patients treated with intensive insulin therapy. 删除32:<u>*</u>J Diabetes Complications删除32:<u>*</u> 2017; 31:742–747</u>\n\n【24】参考删除-3:<u>24. Aron A, Wang J, Collier B, et al: Subcutaneous versus intravenous insulin therapy for glucose control in non-diabetic trauma patients: A randomized controlled trial. 删除32:<u>*</u>J Clin Pharm Ther删除32:<u>*</u> 2013; 38:24–30</u>\n\n【25】25. Cavalcanti AB, Silva E, Pereira AJ, et al: A randomized controlled trial comparing a computer-assisted insulin infusion protocol with a strict and a conventional protocol for glucose control in critically ill patients. 删除32:<u>*</u>J Crit Care删除32:<u>*</u> 2009; 24:371–378\n\n【26】参考删除-3:<u>26. De Block C, Manuel YKB, Van Gaal L, et al: Intensive insulin therapy in the intensive care unit: Assessment by continuous glucose monitoring. 删除32:<u>*</u>Diabetes Care删除32:<u>*</u> 2006; 29:1750–1756</u>\n\n【27】参考删除-3:<u>27. Tran KC, Kibert JL 2nd, Telford ED, et al: Intravenous insulin infusion protocol compared with subcutaneous insulin for the management of hyperglycemia in critically ill adults. 删除32:<u>*</u>Ann Pharmacother删除32:<u>*</u> 2019; 53:894–898</u>\n\n【28】参考删除-3:<u>28. Rabinovich M, Hall A, Gayed B, et al: Patient safety improvements with IV insulin compared to subcutaneous insulin in the ICU. 删除32:<u>*</u>J Diabetes Sci Technol删除32:<u>*</u> 2020; 14:A18</u>\n\n【29】参考删除-3:<u>29. Hunt KA, Tuggle T, Branan T, et al: Effectiveness of subcutaneous insulin regimens versus intravenous insulin infusion protocols on glycemic control in critically ill patients. 删除32:<u>*</u>J Am Coll Clin Pharm删除32:<u>*</u> 2021; 4:1660</u>\n\n【30】参考删除-3:<u>30. Gradel AKJ, Porsgaard T, Lykkesfeldt J, et al: Factors affecting the absorption of subcutaneously administered insulin: Effect on variability. 删除32:<u>*</u>J Diabetes Res删除32:<u>*</u> 2018; 2018:1205121</u>\n\n【31】参考删除-3:<u>31. Boom DT, Sechterberger MK, Rijpkerkens S, et al: Insulin treatment guided by subcutaneous continuous glucose monitoring compared to frequent point-of-care measurement in critically ill patients: A randomized controlled trial. 删除32:<u>*</u>Crit Care删除32:<u>*</u> 2014; 18:453</u>", "tags": {}, "lang": "en", "attr": {"page_num": 18, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024+SCCM指南：儿童和成人危重症患者的血糖控制.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:34:07", "endTime": "2024/08/06 16:34:52", "cost": 45.118}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:34:53", "grab_time": "2024-08-06 00:33:57"}
{"id": 2211759, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "52809626-b831-48da-b2b4-b5336f24e0cc", "title": "ERS：成人哮喘的诊断指南（2022）", "text": "【0】页码:64\nERS：成人哮喘的诊断指南（2022）\n- PEF should be monitored over a two-week period and a variation of 20% considered as supportive of asthma diagnosis\n- PEF variability < 20% does not rule out asthma\n- PEF may be especially useful in case of suspicion of occupational asthma\n\n【1】### PICO 3 Can measuring fractional exhaled nitric oxide (FeNO) help diagnose asthma in adults with episodic/chronic suggestive symptoms?\n\n【2】删除32:<u>**</u>Recommendation删除32:<u>**</u>\n- The TF suggests to measure fraction exhaled nitric oxide (FeNO) as part of the diagnostic work-up of adults aged 18 years with suspected asthma (conditional recommendation for the test, moderate quality of evidence)\n\n【3】删除32:<u>**</u>Remarks删除32:<u>**</u>\n- A cut-off of 40 ppb offers the best compromise between sensitivity and specificity while a cut-off of 50 ppb has a high specificity > 90% and is therefore supportive of asthma diagnosis\n- A FeNO value less than 40 ppb does not rule out asthma\n- FeNO values are markedly reduced by smoking and treatment with ICS and dupilumab\n\n【4】### PICO 4 Can measuring blood eosinophil count help diagnose asthma in adults with episodic/chronic suggestive symptoms?\n\n【5】删除32:<u>**</u>Recommendation删除32:<u>**</u>\n- The TF suggests not measuring blood eosinophil count to make a diagnosis of asthma (conditional recommendation against the test, low quality of evidence)\n\n【6】删除32:<u>**</u>Remarks删除32:<u>**</u>", "tags": {}, "lang": "en", "attr": {"page_num": 64, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ERS：成人哮喘的诊断指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:23:45", "endTime": "2024/08/06 16:24:19", "cost": 34.842}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:24:19", "grab_time": "2024-08-06 00:23:44"}
{"id": 2211758, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "664b3cdf-3dfb-4d71-93c5-d3d2ec4b9c53", "title": "2023 EFLM／EASI／ICAP建议：抗核抗体检测", "text": "【0】页码:11\n2023 EFLM／EASI／ICAP建议：抗核抗体检测\nclassic manual HEp-2 IFA and reported a good overall concordance (positive/negative) between automated and classic visual interpretation (overall concordance rate: median 93.7%, range [71–99%]) 删除12:<u>[107–122]</u>. Compared to classic manual HEp-2 IFA, CAD systems had a high sensitivity for ANA detection at clinically relevant titers (mean sensitivity: 95.7%; range 87–99%) 删除12:<u>[删除13:<u>107, 110, 116</u>]</u>. Detailed review of the discordant samples revealed that correct positive/negative classification by CAD systems is mostly challenged by low titer ANA, cytoplasmic (e.g., ribosomal, mitochondrial, Jo-1, lysosomal, vimentin) staining and peculiar nuclear (e.g., nuclear dots) and mitotic (e.g., centrosomes, midbody) patterns 删除12:<u>[删除13:<u>109, 110, 116</u>]</u>. The diagnostic accuracy of automated HEp-2 IFA in AARD cohorts has also been documented in several studies 删除12:<u>[删除13:<u>109, 112, 119, 122, 123</u>]</u>. The summary diagnostic sensitivity of CAD compared to classic visual HEp-2 IFA was recently calculated on a pooled dataset of four studies and was 84% (95% CI=81.4–87.7) vs. 78.2% (95% CI=74.5–81.7) for combined AARD, 95.5% (95% CI=90.4–98.3) vs. 93.9% (95% CI=88.4–97.3) for SLE, and 86.5% (95% CI=78.4–92.4) vs. 83.7% (95% CI=75.1–90.2) for SSc, respectively 删除9:<u>(for systematic review and meta-analysis see 删除12:<u>删除14:<u>[124]</u></u>)</u>. Overall, these findings support integration of CAD technology into routine HEp-2 IFA diagnostic practice.\n\n【1】In addition to positive/negative discrimination, most but not all CAD systems also provide an automated pattern interpretation for a pre-defined set of patterns, mostly including nuclear homogeneous (AC-1), speckled (AC-4, 5), nucleolar (AC-8, 9, 10), centromere (AC-3) and cytoplasmic patterns. Some CAD systems also claim to be able to identify nuclear dots (AC-7), nuclear dense fine speckled (AC-2) and nuclear envelop patterns (AC-删除13:<u>11, 12</u>). Nevertheless, even though data must be interpreted in light of the limitations (in terms of the patterns that can be recognized) declared by the manufacturers, published data on the performance of pattern recognition is a concern. A meta-analysis based on 11 studies reported a pooled positive concordance for all patterns (including homogeneous, speckled, nucleolar, and centromere patterns) of 68.5% (95% CI=67.2–69.7) (for systematic review and meta-analysis 删除12:<u>删除14:<u>[124]</u></u>). The accuracy of the pattern recognition was dependent on the type of pattern and the substrate. CAD systems clearly had difficulties to correctly identify the rare nuclear patterns, cytoplasmic and multiple patterns 删除12:<u>[109–删除13:<u>111, 116, 119</u>]</u>, with the lowest summary positive concordance (11.7%) observed for the nucleolar dots pattern (95% CI=6.8–18.3) 删除12:<u>删除14:<u>[124]</u></u>. Therefore, pattern recognition by CADs needs to be further enhanced, necessitating expert review before HEp-2 IFA result validation to date.\n\n【2】### End point titer vs. single well titer\n\n【3】An interesting feature of the CAD HEp-2 IFA platforms is that they often provide a system-specific (arbitrary) quantitative measure for fluorescence intensity (FI measure). For several of the available CAD systems, the FI measure showed high analytical reproducibility 删除12:<u>[删除13:<u>109, 110, 125, 126</u>]</u> and significant correlation with the endpoint titers obtained by manual reading 删除12:<u>[107–删除13:<u>110, 116, 119, 122, 127</u>]</u>. In addition, it was shown that the LR for an AARD increased with increasing FI measure 删除12:<u>[删除13:<u>109, 119, 122, 128</u>]</u>. These observations illustrate that estimation of the fluorescence intensity by CAD for HEp-2 IFA has clinical utility.\n\n【4】The above data suggest that the FI measure may provide a useful alternative for endpoint titration. Moreover, some of the current available CAD HEp-2 IFA platforms provide a single dilution titer estimation function, the so called “single well titer” 删除12:<u>删除14:<u>[125]</u></u>. Yet, there are several limitations in directly applying this correlation between FI measure and end-point titer to eliminate serial dilution. First, the relation between the FI measure and endpoint titer is system-specific and seems to be dependent on substrate 删除12:<u>删除14:<u>[119]</u></u> and ANA pattern 删除12:<u>[删除13:<u>126, 127</u>]</u>. Moreover, an underestimation of endpoint titer was reported when comparing FI measure to manually specked cytoplasmic Jo-1 related pattern 删除12:<u>删除14:<u>[128]</u></u>. Secondly, overlapping antibody patterns can be masked and overlooked if the samples are analyzed only in a single dilution.\n\n【5】In summary, the added-value of the FI measure generated by CAD systems lies in the quantification of the fluorescence intensity that can be used to estimate the endpoint titer and to generate information regarding likelihood for disease. However, this does not per se signify that conventional serial dilutions should be eliminated. Recent ICAP guidelines stated that the test result report should specify whether the end titer is an estimate or achieved by serial dilutions 删除12:<u>删除14:<u>[46]</u></u>.\n\n【6】### Added value of CAD in quality assurance\n\n【7】Over the last few years, FI measures of CAD HEp-2 IFA systems have also shown potential in evaluating and controlling several variables impacting the quality of the total HEp-2 IFA testing process. The foundation for this potential is the high analytical reproducibility of the FI measures as has been documented for some of the CAD systems 删除12:<u>[删除13:<u>109, 110, 126, 129</u>]</u>. Both experimental as well as retrospective studies illustrated that monitoring FI measurements on quality control material as well as routine samples are adequate quality indicators if accompanied by well-defined acceptance criteria 删除12:<u>[129–132]</u>. The acceptance criteria should be based", "tags": {}, "lang": "en", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 EFLM／EASI／ICAP建议：抗核抗体检测.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:11:26", "endTime": "2024/08/06 16:11:53", "cost": 26.701}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:11:53", "grab_time": "2024-08-06 00:11:26"}
{"id": 2211757, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "72f75ee8-03e8-454b-88af-f9257cf88c53", "title": "2023 专家组建议：多发性硬化的辅助生殖技术", "text": "【0】页码:4\n2023 专家组建议：多发性硬化的辅助生殖技术\nchosen to manage MS must be appropriate to the desire of the patient for parenthood over the short or long term 删除12:<u>删除14:<u>[10-12]</u></u>. Therefore, shared decision-making, including family planning, is fundamental 删除12:<u>删除14:<u>[22]</u></u>.\n\n【1】Early preconception counselling is paramount to inform and evaluate all parameters that could affect pregnancy. For example, the Spanish Society of Gynaecology recommends a preconception consultation for all women with the desire for motherhood 删除12:<u>删除14:<u>[23]</u></u>. The partner of the patient with MS, especially men, should also attend informative preconception consultations to rule out potential issues for both of them. During this consultation, the most important factor regarding fertility, which is the woman's age, should be emphasised 删除12:<u>删除14:<u>[24]</u></u>, and subfertility factors could be identified. Notably, the DMT should be assessed, especially if a switch of DMT, or a washout period, is necessary before conception. Current recommendations from regulatory agencies include avoiding pregnancy during treatment and, depending on the DMT, recommending a 2- to 6-month washout period before conception 删除12:<u>删除14:<u>[25-27]</u></u>. Finally, for women with MS, an evaluation of cervical pathologies through cytology tests should be undertaken since some DMT, in particular those with an immunosuppressing mechanism, such as mitoxantrone, azathioprine and alemtuzumab, have been associated with a potential risk of cervical dysplasia 删除9:<u>(Table 1)</u> 删除12:<u>[删除13:<u>28, 29</u>]</u>.\n\n【2】### Multiple Sclerosis and ART\n\n【3】Time frames should be individualised according to disease activity and gestation prognosis. However, a natural approach to becoming pregnant is generally recommended for a period of 6–12 months in women aged > 35 years and for 1 year in those aged < 35 years. This time frame would allow these women to shorten the time without treatment or with a suboptimal DMT 删除12:<u>删除14:<u>[30]</u></u>. Ideally, people with MS should begin the ART process with the lowest possible number of symptomatic treatments and at the minimum effective dose. Beyond their effects on pregnancy 删除9:<u>删除12:<u>删除14:<u>[31]</u></u>, DMT do not seem to hamper ART processes, whether stimulation, fertilisation or implantation. Regarding natural pregnancies, DMT should be withdrawn according to their prescribing information, an individual risk-to-benefit assessment before pregnancy and/or after a positive pregnancy test result (neither during stimulation nor before implantation). Nonetheless, and based on post-marketing experience, some DMT can be considered during pregnancy if clinically indicated: interferon beta and glatiramer acetate throughout pregnancy, and natalizumab up to the third trimester, provided that their benefits to the patient outweigh their risks to the foetus 删除9:<u>(Table 1)</u> 删除12:<u>[删除13:<u>32, 33</u>]</u></u>. Despite data on pregnancy in women with MS exposed to antiCD20 being currently limited, taking into account the pharmacokinetics of these DMT, their low risk for placental transfer during the first trimester and the reassuring post-marketing clinical experience, they could also be considered in women with high-activity MS on a case-by-case basis 删除12:<u>删除14:<u>[34]</u></u>.\n\n【4】### In Vitro Fertilisation\n\n【5】The efficiency of ART techniques, mainly intrauterine insemination (IUI) and IVF, should be considered on an individual patient and/or couple basis, albeit IVF is economically more costly than IUI but has a higher live birth rate (LBR) per cycle 删除12:<u>删除14:<u>[35]</u></u>. A subclass of IVF, intracytoplasmic sperm injection (ICSI), is the most widely used fertility technique in developed countries 删除12:<u>删除14:<u>[36]</u></u>. In addition, a single embryo transfer in IVF-ICSI could avoid the risk associated with multiple pregnancies 删除12:<u>[删除13:<u>37, 38</u>]</u>. Multiple pregnancy is the most frequent and serious iatrogenic complication in ART procedures 删除12:<u>删除14:<u>[39]</u></u>, entailing not only obstetric risks for the mother (e.g. hypertension, preeclampsia, preterm labour) that should be avoided in women with pre-existing pathologies, but also risks for the foetus (e.g. preterm delivery, congenital malformations, cerebral palsy) 删除12:<u>删除14:<u>[40]</u></u>. Therefore, although the criteria for choosing one ART over the other are not different in women with MS compared to the general population, in this context the older age of women with MS and the importance of these women avoiding\n\n【6】### Table 1\n\n| Drug            | Risk of Cervical Dysplasia | Recommendation          |\n|-----------------|---------------------------|--------------------------|\n| Mitoxantrone    | High                      | Avoid during conception  |\n| Azathioprine    | Moderate                  | Evaluate risk-benefit    |\n| Alemtuzumab     | High                      | Avoid during conception  |", "tags": {}, "lang": "en", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 专家组建议：多发性硬化的辅助生殖技术.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "DMT do not seem to hamper ART processes, whether stimulation, fertilisation or implantation. Regarding natural pregnancies, DMT should be withdrawn according to their prescribing information, an individual risk-to-benefit assessment before pregnancy and/or after a positive pregnancy test result (neither during stimulation nor before implantation). Nonetheless, and based on post-marketing experience, some DMT can be considered during pregnancy if clinically indicated: interferon beta and glatiramer acetate throughout pregnancy, and natalizumab up to the third trimester, provided that their benefits to the patient outweigh their risks to the foetus ", "content": "【0】页码:4\n2023 专家组建议：多发性硬化的辅助生殖技术\nchosen to manage MS must be appropriate to the desire of the patient for parenthood over the short or long term 删除12:<u>删除14:<u>[10-12]</u></u>. Therefore, shared decision-making, including family planning, is fundamental 删除12:<u>删除14:<u>[22]</u></u>.\n\n【1】Early preconception counselling is paramount to inform and evaluate all parameters that could affect pregnancy. For example, the Spanish Society of Gynaecology recommends a preconception consultation for all women with the desire for motherhood 删除12:<u>删除14:<u>[23]</u></u>. The partner of the patient with MS, especially men, should also attend informative preconception consultations to rule out potential issues for both of them. During this consultation, the most important factor regarding fertility, which is the woman's age, should be emphasised 删除12:<u>删除14:<u>[24]</u></u>, and subfertility factors could be identified. Notably, the DMT should be assessed, especially if a switch of DMT, or a washout period, is necessary before conception. Current recommendations from regulatory agencies include avoiding pregnancy during treatment and, depending on the DMT, recommending a 2- to 6-month washout period before conception 删除12:<u>删除14:<u>[25-27]</u></u>. Finally, for women with MS, an evaluation of cervical pathologies through cytology tests should be undertaken since some DMT, in particular those with an immunosuppressing mechanism, such as mitoxantrone, azathioprine and alemtuzumab, have been associated with a potential risk of cervical dysplasia 删除9:<u>(Table 1)</u> 删除12:<u>[删除13:<u>28, 29</u>]</u>.\n\n【2】### Multiple Sclerosis and ART\n\n【3】Time frames should be individualised according to disease activity and gestation prognosis. However, a natural approach to becoming pregnant is generally recommended for a period of 6–12 months in women aged > 35 years and for 1 year in those aged < 35 years. This time frame would allow these women to shorten the time without treatment or with a suboptimal DMT 删除12:<u>删除14:<u>[30]</u></u>. Ideally, people with MS should begin the ART process with the lowest possible number of symptomatic treatments and at the minimum effective dose. Beyond their effects on pregnancy 删除9:<u>删除12:<u>删除14:<u>[31]</u></u>, DMT do not seem to hamper ART processes, whether stimulation, fertilisation or implantation. Regarding natural pregnancies, DMT should be withdrawn according to their prescribing information, an individual risk-to-benefit assessment before pregnancy and/or after a positive pregnancy test result (neither during stimulation nor before implantation). Nonetheless, and based on post-marketing experience, some DMT can be considered during pregnancy if clinically indicated: interferon beta and glatiramer acetate throughout pregnancy, and natalizumab up to the third trimester, provided that their benefits to the patient outweigh their risks to the foetus 删除9:<u>(Table 1)</u> 删除12:<u>[删除13:<u>32, 33</u>]</u></u>. Despite data on pregnancy in women with MS exposed to antiCD20 being currently limited, taking into account the pharmacokinetics of these DMT, their low risk for placental transfer during the first trimester and the reassuring post-marketing clinical experience, they could also be considered in women with high-activity MS on a case-by-case basis 删除12:<u>删除14:<u>[34]</u></u>.\n\n【4】### In Vitro Fertilisation\n\n【5】The efficiency of ART techniques, mainly intrauterine insemination (IUI) and IVF, should be considered on an individual patient and/or couple basis, albeit IVF is economically more costly than IUI but has a higher live birth rate (LBR) per cycle 删除12:<u>删除14:<u>[35]</u></u>. A subclass of IVF, intracytoplasmic sperm injection (ICSI), is the most widely used fertility technique in developed countries 删除12:<u>删除14:<u>[36]</u></u>. In addition, a single embryo transfer in IVF-ICSI could avoid the risk associated with multiple pregnancies 删除12:<u>[删除13:<u>37, 38</u>]</u>. Multiple pregnancy is the most frequent and serious iatrogenic complication in ART procedures 删除12:<u>删除14:<u>[39]</u></u>, entailing not only obstetric risks for the mother (e.g. hypertension, preeclampsia, preterm labour) that should be avoided in women with pre-existing pathologies, but also risks for the foetus (e.g. preterm delivery, congenital malformations, cerebral palsy) 删除12:<u>删除14:<u>[40]</u></u>. Therefore, although the criteria for choosing one ART over the other are not different in women with MS compared to the general population, in this context the older age of women with MS and the importance of these women avoiding\n\n【6】### Table 1\n\n| Drug            | Risk of Cervical Dysplasia | Recommendation          |\n|-----------------|---------------------------|--------------------------|\n| Mitoxantrone    | High                      | Avoid during conception  |\n| Azathioprine    | Moderate                  | Evaluate risk-benefit    |\n| Alemtuzumab     | High                      | Avoid during conception  |", "index": 2257, "show": true, "start": 2257, "end": 2912, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "【6】### Table 1\n\nDrug\tRisk of Cervical Dysplasia\tRecommendation\nMitoxantrone\tHigh\tAvoid during conception\nAzathioprine\tModerate\tEvaluate risk-benefit\nAlemtuzumab\tHigh\tAvoid during conception", "content": "【0】页码:4\n2023 专家组建议：多发性硬化的辅助生殖技术\nchosen to manage MS must be appropriate to the desire of the patient for parenthood over the short or long term 删除12:<u>删除14:<u>[10-12]</u></u>. Therefore, shared decision-making, including family planning, is fundamental 删除12:<u>删除14:<u>[22]</u></u>.\n\n【1】Early preconception counselling is paramount to inform and evaluate all parameters that could affect pregnancy. For example, the Spanish Society of Gynaecology recommends a preconception consultation for all women with the desire for motherhood 删除12:<u>删除14:<u>[23]</u></u>. The partner of the patient with MS, especially men, should also attend informative preconception consultations to rule out potential issues for both of them. During this consultation, the most important factor regarding fertility, which is the woman's age, should be emphasised 删除12:<u>删除14:<u>[24]</u></u>, and subfertility factors could be identified. Notably, the DMT should be assessed, especially if a switch of DMT, or a washout period, is necessary before conception. Current recommendations from regulatory agencies include avoiding pregnancy during treatment and, depending on the DMT, recommending a 2- to 6-month washout period before conception 删除12:<u>删除14:<u>[25-27]</u></u>. Finally, for women with MS, an evaluation of cervical pathologies through cytology tests should be undertaken since some DMT, in particular those with an immunosuppressing mechanism, such as mitoxantrone, azathioprine and alemtuzumab, have been associated with a potential risk of cervical dysplasia 删除9:<u>(Table 1)</u> 删除12:<u>[删除13:<u>28, 29</u>]</u>.\n\n【2】### Multiple Sclerosis and ART\n\n【3】Time frames should be individualised according to disease activity and gestation prognosis. However, a natural approach to becoming pregnant is generally recommended for a period of 6–12 months in women aged > 35 years and for 1 year in those aged < 35 years. This time frame would allow these women to shorten the time without treatment or with a suboptimal DMT 删除12:<u>删除14:<u>[30]</u></u>. Ideally, people with MS should begin the ART process with the lowest possible number of symptomatic treatments and at the minimum effective dose. Beyond their effects on pregnancy 删除9:<u>删除12:<u>删除14:<u>[31]</u></u>, <mark>DMT do not seem to hamper ART processes, whether stimulation, fertilisation or implantation. Regarding natural pregnancies, DMT should be withdrawn according to their prescribing information, an individual risk-to-benefit assessment before pregnancy and/or after a positive pregnancy test result (neither during stimulation nor before implantation). Nonetheless, and based on post-marketing experience, some DMT can be considered during pregnancy if clinically indicated: interferon beta and glatiramer acetate throughout pregnancy, and natalizumab up to the third trimester, provided that their benefits to the patient outweigh their risks to the foetus </mark>删除9:<u>(Table 1)</u> 删除12:<u>[删除13:<u>32, 33</u>]</u></u>. Despite data on pregnancy in women with MS exposed to antiCD20 being currently limited, taking into account the pharmacokinetics of these DMT, their low risk for placental transfer during the first trimester and the reassuring post-marketing clinical experience, they could also be considered in women with high-activity MS on a case-by-case basis 删除12:<u>删除14:<u>[34]</u></u>.\n\n【4】### In Vitro Fertilisation\n\n【5】The efficiency of ART techniques, mainly intrauterine insemination (IUI) and IVF, should be considered on an individual patient and/or couple basis, albeit IVF is economically more costly than IUI but has a higher live birth rate (LBR) per cycle 删除12:<u>删除14:<u>[35]</u></u>. A subclass of IVF, intracytoplasmic sperm injection (ICSI), is the most widely used fertility technique in developed countries 删除12:<u>删除14:<u>[36]</u></u>. In addition, a single embryo transfer in IVF-ICSI could avoid the risk associated with multiple pregnancies 删除12:<u>[删除13:<u>37, 38</u>]</u>. Multiple pregnancy is the most frequent and serious iatrogenic complication in ART procedures 删除12:<u>删除14:<u>[39]</u></u>, entailing not only obstetric risks for the mother (e.g. hypertension, preeclampsia, preterm labour) that should be avoided in women with pre-existing pathologies, but also risks for the foetus (e.g. preterm delivery, congenital malformations, cerebral palsy) 删除12:<u>删除14:<u>[40]</u></u>. Therefore, although the criteria for choosing one ART over the other are not different in women with MS compared to the general population, in this context the older age of women with MS and the importance of these women avoiding\n\n【6】### Table 1\n\n| Drug            | Risk of Cervical Dysplasia | Recommendation          |\n|-----------------|---------------------------|--------------------------|\n| Mitoxantrone    | High                      | Avoid during conception  |\n| Azathioprine    | Moderate                  | Evaluate risk-benefit    |\n| Alemtuzumab     | High                      | Avoid during conception  |", "index": 4616, "show": true, "start": 4603, "end": 4792, "province": ["文本干净度", "无关文本"], "isEdit": false}], "startTime": "2024/08/06 16:31:36", "endTime": "2024/08/06 16:32:49", "cost": 72.942}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:32:49", "grab_time": "2024-08-06 00:31:36"}
{"id": 2211756, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "476d6de7-c6a4-4852-96a5-c0ff17c65e65", "title": "（2023.V1）NCCN临床实践指南：骨癌", "text": "【0】页码:26\n（2023.V1）NCCN临床实践指南：骨癌\n(本页删除)本页被模型判断为参考页疑似页眉<u># NCCN Guidelines Version 1.2023\n## Bone Cancer</u>\n\n【1】### SYSTEMIC THERAPY AGENTS\n\n【2】#### Ewing Sarcoma\n\n【3】##### First-line therapy (primary/neoadjuvant/adjuvant therapy)\n\n| Preferred Regimens | Other Recommended Regimens |\n| ------------------ | -------------------------- |\n| - VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide) | - VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin) |\n|  | - VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) |\n\n【5】##### Primary therapy for metastatic disease at initial presentation\n\n| Preferred Regimens | |\n| ------------------ | |\n| - VDC/IE | |\n| - VAIA | |\n| - VIDE | |\n| - VDC (vincristine, doxorubicin, and cyclophosphamide) |\n\n【7】##### Second-line therapy (relapsed/refractory or metastatic disease)\n\n| Preferred Regimens | Other Recommended Regimens | Useful in Certain Circumstances |\n| ------------------ | -------------------------- | ------------------------------ |\n| - Cyclophosphamide and topotecan | - Cabozantinib | - Ifosfamide, carboplatin, and etoposide |\n| - Irinotecan + temozolomide + vincristine | - Docetaxel and gemcitabine | |\n\n【9】##### Note\n- Dactinomycin can be substituted for doxorubicin for concerns regarding cardiotoxicity.\n- In patients younger than 18 y, evidence supports 2-week compressed treatment.\n- Vincristine could be added to these regimens.\n\n【10】删除图片描述:<u>![](25_0.png)</u>\n\n---|删除段内换行|NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.\n\n---|删除段内换行|", "tags": {}, "lang": "en", "attr": {"page_num": 26, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V1）NCCN临床实践指南：骨癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "(本页删除)本页被模型判断为参考页", "content": "【0】页码:26\n（2023.V1）NCCN临床实践指南：骨癌\n(本页删除)本页被模型判断为参考页疑似页眉<u># NCCN Guidelines Version 1.2023\n## Bone Cancer</u>\n\n【1】### SYSTEMIC THERAPY AGENTS\n\n【2】#### Ewing Sarcoma\n\n【3】##### First-line therapy (primary/neoadjuvant/adjuvant therapy)\n\n| Preferred Regimens | Other Recommended Regimens |\n| ------------------ | -------------------------- |\n| - VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide) | - VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin) |\n|  | - VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) |\n\n【5】##### Primary therapy for metastatic disease at initial presentation\n\n| Preferred Regimens | |\n| ------------------ | |\n| - VDC/IE | |\n| - VAIA | |\n| - VIDE | |\n| - VDC (vincristine, doxorubicin, and cyclophosphamide) |\n\n【7】##### Second-line therapy (relapsed/refractory or metastatic disease)\n\n| Preferred Regimens | Other Recommended Regimens | Useful in Certain Circumstances |\n| ------------------ | -------------------------- | ------------------------------ |\n| - Cyclophosphamide and topotecan | - Cabozantinib | - Ifosfamide, carboplatin, and etoposide |\n| - Irinotecan + temozolomide + vincristine | - Docetaxel and gemcitabine | |\n\n【9】##### Note\n- Dactinomycin can be substituted for doxorubicin for concerns regarding cardiotoxicity.\n- In patients younger than 18 y, evidence supports 2-week compressed treatment.\n- Vincristine could be added to these regimens.\n\n【10】删除图片描述:<u>![](25_0.png)</u>\n\n---|删除段内换行|NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.\n\n---|删除段内换行|", "index": 32, "show": true, "start": 32, "end": 49, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "【2】#### Ewing Sarcoma\n\n【3】##### First-line therapy (primary/neoadjuvant/adjuvant therapy)\n\nPreferred Regimens\tOther Recommended Regimens\n- VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide)\t- VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin)\n- VIDE (vincristine, ifosfamide, doxorubicin, and etoposide)\n【5】##### Primary therapy for metastatic disease at initial presentation\n\n| Preferred Regimens | |\n\n| ------------------ | |\n\n| - VDC/IE | |\n\n| - VAIA | |\n\n| - VIDE | |\n\n| - VDC (vincristine, doxorubicin, and cyclophosphamide) |\n\n【7】##### Second-line therapy (relapsed/refractory or metastatic disease)\n\nPreferred Regimens\tOther Recommended Regimens\tUseful in Certain Circumstances\n- Cyclophosphamide and topotecan\t- Cabozantinib\t- Ifosfamide, carboplatin, and etoposide\n- Irinotecan + temozolomide + vincristine\t- Docetaxel and gemcitabine\t", "content": "【0】页码:26\n（2023.V1）NCCN临床实践指南：骨癌\n<mark>(本页删除)本页被模型判断为参考页</mark>疑似页眉<u># NCCN Guidelines Version 1.2023\n## Bone Cancer</u>\n\n【1】### SYSTEMIC THERAPY AGENTS\n\n【2】#### Ewing Sarcoma\n\n【3】##### First-line therapy (primary/neoadjuvant/adjuvant therapy)\n\n| Preferred Regimens | Other Recommended Regimens |\n| ------------------ | -------------------------- |\n| - VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide) | - VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin) |\n|  | - VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) |\n\n【5】##### Primary therapy for metastatic disease at initial presentation\n\n| Preferred Regimens | |\n| ------------------ | |\n| - VDC/IE | |\n| - VAIA | |\n| - VIDE | |\n| - VDC (vincristine, doxorubicin, and cyclophosphamide) |\n\n【7】##### Second-line therapy (relapsed/refractory or metastatic disease)\n\n| Preferred Regimens | Other Recommended Regimens | Useful in Certain Circumstances |\n| ------------------ | -------------------------- | ------------------------------ |\n| - Cyclophosphamide and topotecan | - Cabozantinib | - Ifosfamide, carboplatin, and etoposide |\n| - Irinotecan + temozolomide + vincristine | - Docetaxel and gemcitabine | |\n\n【9】##### Note\n- Dactinomycin can be substituted for doxorubicin for concerns regarding cardiotoxicity.\n- In patients younger than 18 y, evidence supports 2-week compressed treatment.\n- Vincristine could be added to these regimens.\n\n【10】删除图片描述:<u>![](25_0.png)</u>\n\n---|删除段内换行|NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.\n\n---|删除段内换行|", "index": 154, "show": true, "start": 141, "end": 1043, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "两个表格格式都有问题"}, {"text": "【9】##### Note", "content": "【0】页码:26\n（2023.V1）NCCN临床实践指南：骨癌\n<mark>(本页删除)本页被模型判断为参考页</mark>疑似页眉<u># NCCN Guidelines Version 1.2023\n## Bone Cancer</u>\n\n【1】### SYSTEMIC THERAPY AGENTS\n\n<mark>【2】#### Ewing Sarcoma\n\n【3】##### First-line therapy (primary/neoadjuvant/adjuvant therapy)\n\nPreferred Regimens\tOther Recommended Regimens\n- VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide)\t- VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin)\n- VIDE (vincristine, ifosfamide, doxorubicin, and etoposide)\n【5】##### Primary therapy for metastatic disease at initial presentation\n\n| Preferred Regimens | |\n\n| ------------------ | |\n\n| - VDC/IE | |\n\n| - VAIA | |\n\n| - VIDE | |\n\n| - VDC (vincristine, doxorubicin, and cyclophosphamide) |\n\n【7】##### Second-line therapy (relapsed/refractory or metastatic disease)\n\nPreferred Regimens\tOther Recommended Regimens\tUseful in Certain Circumstances\n- Cyclophosphamide and topotecan\t- Cabozantinib\t- Ifosfamide, carboplatin, and etoposide\n- Irinotecan + temozolomide + vincristine\t- Docetaxel and gemcitabine\t</mark>\n| - Cyclophosphamide and topotecan | - Cabozantinib | - Ifosfamide, carboplatin, and etoposide |\n| - Irinotecan + temozolomide + vincristine | - Docetaxel and gemcitabine | |\n\n【9】##### Note\n- Dactinomycin can be substituted for doxorubicin for concerns regarding cardiotoxicity.\n- In patients younger than 18 y, evidence supports 2-week compressed treatment.\n- Vincristine could be added to these regimens.\n\n【10】删除图片描述:<u>![](25_0.png)</u>\n\n---|删除段内换行|NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.\n\n---|删除段内换行|", "index": 1246, "show": true, "start": 1220, "end": 1233, "province": ["文本干净度", "无关文本"], "isEdit": false}], "startTime": "2024/08/06 16:17:08", "endTime": "2024/08/06 16:18:37", "cost": 88.342}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:18:37", "grab_time": "2024-08-06 00:17:08"}
{"id": 2211755, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "fa6c6963-8d06-4277-9355-007a678f2062", "title": "2022 CDC临床实践指南：处方阿片类药物治疗疼痛", "text": "【0】页码:58\n2022 CDC临床实践指南：处方阿片类药物治疗疼痛\n和美沙酮治疗阿片类药物使用障碍已与减少过量死亡 删除11:<u>(329)</u> 和减少全因死亡率 删除11:<u>(330)</u> 相关。纳曲酮 (一种阿片类拮抗剂) 也可用于治疗阿片类药物使用障碍，特别是对于高度自我激励的患者 删除11:<u>(删除13:<u>331, 332</u>)</u>。纳曲酮阻断阿片类药物的作用 删除11:<u>(332)</u>。未经探索的纳曲酮对同时存在疼痛和阿片类药物使用障碍的人的作用，且用于疼痛的一般阿片类药物不应用于使用纳曲酮的患者。纳曲酮需要每月使用一次的长效注射。纳曲酮的有效性可能受药物依从性差影响 删除11:<u>(332)</u>，且不应在非常有限的情况下使用口服纳曲酮 删除11:<u>(96)</u>，例如，仅用于可以每日观察到依从性的患者 删除11:<u>(删除13:<u>96, 317</u>)</u>。纳曲酮也必须在阿片类药物戒断后使用，这对某些患者来说具有挑战性；然而，对于已完成或能够完成戒断的患者而言，纳曲酮在预防复发方面具有与丁丙诺啡相似的有效效果 删除11:<u>(333)</u>。\n\n【1】研究表明，通过与药物治疗结合使用的行为疗法，治疗阿片类药物使用障碍可以减少阿片类药物误用并增加治疗期间的保留率 删除11:<u>(删除13:<u>334, 335</u>)</u>。同时，研究表明，不应使用药物治疗阿片类药物依赖 (使用 DSM-IV 标准) 的患者 删除11:<u>(316)</u>，因为单独的药物治疗未显示出对于这些患者的任何有效性，除非与使用自助和生活方式变化建议、互动练习以及自习作业的更密集的阿片类药物依赖咨询(即戒毒、恢复和预防复发戒毒辅导、自助和生活方式改变建议、互动练习及家庭作业) 结合使用，并由经过训练的药物使用治疗或心理健康专业人员在45-60分钟的课程中进行示范 (并显示出较少的疗效)；单独的药物治疗对预防药物使用复发没有影响，没有丁丙诺啡的戒毒辅导对预防药物使用复发没有影响 删除11:<u>(325)</u>。\n\n【2】对治疗阿片类药物使用障碍的的建议也包括评估患者心理社会需求并根据这些需求推荐患者接受合格的行为医疗提供者的心理社会治疗 删除11:<u>(96)</u>。额外的建议已发布关于治疗阿片类药物使用障碍的患者的目标，组成部分和行为心理社会治疗类型，同时与药物治疗结合使用 删除11:<u>(96)</u>。一些建议还要求不应将心理社会治疗的可用性作为患者进行药物治疗的前提。\n\n【3】如果临床医生怀疑基于患者关注或行为阿片类药物使用障碍，或在 PDMP 数据中发现 (见推荐 9) 或毒理学检测 (见推荐 10) 时，他们应与患者讨论他们的关注并为患者提供表露相关关心或问题的机会。临床医生应评估患者是否存在 DSM-5 标准的阿片类药物使用障碍 删除11:<u>(317)</u>。阿片类药物使用障碍可以与其他物质使用障碍并存，且积极使用物质的患者可能需要更大的支持，包括由成瘾专家 删除11:<u>(96)</u> 参与。临床医生应了解酒精和其他物质的使用 (见推荐 8)。此外，临床医生在接受治疗阿片类药物使用障碍时，应评估阿片类药物和其他物质使用障碍证据的存在。\n\n【4】对于阿片类药物使用障碍的治疗，特别是中度或严重的阿片类药物使用障碍，应用有证据支持的药物治疗来治疗。对于中度或重度阿片类药物使用障碍的患者，临床医生应提供建议，即患者接受阿片类药物治疗时，应讨论暴露是否会影响这些药物的效果。患者在选择相应的干预方案同时，也要提高自我管理和咨询的利用率。就本身而言，阿片类药物作为用于阿片类药物使用障碍治疗的维持药物，或在没有丁丙诺啡的情况下处方时，由于其对药物使用的潜在提高风险，应受到特别监督和关注 删除11:<u>(96,删除13:<u>333, 320</u>)</u>。\n\n【5】对于正在使用阿片类药物治疗阿片类使用障碍的孕妇 (丁丙诺啡或美沙酮) ，一般建议第一时间评估胎儿和母体的安全以预防伤害。先前的建议认为，对于预防潜在暴露于纳洛酮的孕妇应使用透皮丁丙诺酚 (不含纳洛酮)，特别是注射剂，若证据显示纳洛酮对孕妇仍有潜在危害 删除11:<u>(96,274)</u>，若二者联合使用的药物产品应该存疑，在频繁使用情况下，需要系统回顾指出尚无证据显示严重的孕产风险 删除11:<u>(337)</u>，并且专家认为这种联合疗法可能在按处方使用情况下是安全和有效的 删除11:<u>(96,274)</u>。ACOG 也推荐如果一个人稳定使用纳洛酮，并且没有怀孕测试阳性后发现任何问题的情况下，她们可以继续这种疗法。", "tags": {}, "lang": "zh", "attr": {"page_num": 58, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2022 CDC临床实践指南：处方阿片类药物治疗疼痛.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": null, "finished": false, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 18:12:41", "grab_time": "2024-08-06 18:12:46"}
{"id": 2211754, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "6311f2eb-dcd7-4f7b-8169-8d07ef9a4af8", "title": "ISPD：全基因组测序在产前诊断中的应用的立场声明（2022）", "text": "【0】页码:5\nISPD：全基因组测序在产前诊断中的应用的立场声明（2022）\niv. 可能获得没有结果（即，与样本质量有关），或结果可能无法及时影响妊娠或新生儿管理。\ne. 对于IF和SF的管理没有普遍共识，每个中心应提供其具体细节，无论这些细节是否报告，并在报告时告知父母和家庭。\ni. 次要发现（SF）：在适当情况下，应该解决包含或排除胎儿和父母序列的选择。SF可能是致病性的和可能致病性的变异，并在一组基因中不是医学上可行动的。 这些包括对身体健康没有影响的无症状个体的医疗干预。\n1. 父母SF：父母应单独同意包含或排除SF。\n2. 胎儿SF：胎儿IF应在获得同意的情况下被排除/包含在内。 \n3. 如果使用面板分析（表1），父母应被告知SF不应被作为排除/包含IF的依据。\nf. 讨论揭示非亲子关系或亲缘层次关系（例如，与生物父母的血缘关系）的问题。预先测试咨询应包括如何从非生物学父母分析和报告。\ng. 数据共享的重要性在于去标识数据库对遗传健康至关重要。\ni. 在可用条件下，应获取此数据，且父母应被告知自己将如何使用以及用途。\nj. 建议所有接受测序的个体始终在检测后收到咨询，包括那些未得到有用信息的人。这样的咨询应由具备遗传学专业知识的个人提供。\nk. 结果咨询和结果的返回应考虑到术前讨论和提供者的选择，包括结果可能是什么。\nl. 随着时间的推移，知识的潜力可能会发生变化，例如，在临床上评估其他表型资料的情况下。\n4. 临床适应症\n尽管关于其科学与应用仍有很多需要学习，胎儿诊断测序在过去5年中有所增加，为临床使用的发展提供了足够的经验。\n1. 当前现有数据支持父母测序对以下情况的益处： \n   - 孕妇怀有重大异常或多个器官系统异常的胎儿。", "tags": {}, "lang": "zh", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ISPD：全基因组测序在产前诊断中的应用的立场声明（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:5\n\nISPD：全基因组测序在产前诊断中的应用的立场声明（2022）\n\niv. 可能获得没有结果（即，与样本质量有关），或结果可能无法及时影响妊娠或新生儿管理。\n\ne. 对于IF和SF的管理没有普遍共识，每个中心应提供其具体细节，无论这些细节是否报告，并在报告时告知父母和家庭。\n\ni. 次要发现（SF）：在适当情况下，应该解决包含或排除胎儿和父母序列的选择。SF可能是致病性的和可能致病性的变异，并在一组基因中不是医学上可行动的。 这些包括对身体健康没有影响的无症状个体的医疗干预。\n\n父母SF：父母应单独同意包含或排除SF。\n胎儿SF：胎儿IF应在获得同意的情况下被排除/包含在内。\n如果使用面板分析（表1），父母应被告知SF不应被作为排除/包含IF的依据。\nf. 讨论揭示非亲子关系或亲缘层次关系（例如，与生物父母的血缘关系）的问题。预先测试咨询应包括如何从非生物学父母分析和报告。\ng. 数据共享的重要性在于去标识数据库对遗传健康至关重要。\ni. 在可用条件下，应获取此数据，且父母应被告知自己将如何使用以及用途。\nj. 建议所有接受测序的个体始终在检测后收到咨询，包括那些未得到有用信息的人。这样的咨询应由具备遗传学专业知识的个人提供。\nk. 结果咨询和结果的返回应考虑到术前讨论和提供者的选择，包括结果可能是什么。\nl. 随着时间的推移，知识的潜力可能会发生变化，例如，在临床上评估其他表型资料的情况下。\n临床适应症\n尽管关于其科学与应用仍有很多需要学习，胎儿诊断测序在过去5年中有所增加，为临床使用的发展提供了足够的经验。\n当前现有数据支持父母测序对以下情况的益处：\n孕妇怀有重大异常或多个器官系统异常的胎儿。", "content": "【0】页码:5\nISPD：全基因组测序在产前诊断中的应用的立场声明（2022）\niv. 可能获得没有结果（即，与样本质量有关），或结果可能无法及时影响妊娠或新生儿管理。\ne. 对于IF和SF的管理没有普遍共识，每个中心应提供其具体细节，无论这些细节是否报告，并在报告时告知父母和家庭。\ni. 次要发现（SF）：在适当情况下，应该解决包含或排除胎儿和父母序列的选择。SF可能是致病性的和可能致病性的变异，并在一组基因中不是医学上可行动的。 这些包括对身体健康没有影响的无症状个体的医疗干预。\n1. 父母SF：父母应单独同意包含或排除SF。\n2. 胎儿SF：胎儿IF应在获得同意的情况下被排除/包含在内。 \n3. 如果使用面板分析（表1），父母应被告知SF不应被作为排除/包含IF的依据。\nf. 讨论揭示非亲子关系或亲缘层次关系（例如，与生物父母的血缘关系）的问题。预先测试咨询应包括如何从非生物学父母分析和报告。\ng. 数据共享的重要性在于去标识数据库对遗传健康至关重要。\ni. 在可用条件下，应获取此数据，且父母应被告知自己将如何使用以及用途。\nj. 建议所有接受测序的个体始终在检测后收到咨询，包括那些未得到有用信息的人。这样的咨询应由具备遗传学专业知识的个人提供。\nk. 结果咨询和结果的返回应考虑到术前讨论和提供者的选择，包括结果可能是什么。\nl. 随着时间的推移，知识的潜力可能会发生变化，例如，在临床上评估其他表型资料的情况下。\n4. 临床适应症\n尽管关于其科学与应用仍有很多需要学习，胎儿诊断测序在过去5年中有所增加，为临床使用的发展提供了足够的经验。\n1. 当前现有数据支持父母测序对以下情况的益处： \n   - 孕妇怀有重大异常或多个器官系统异常的胎儿。", "index": 0, "show": true, "start": 0, "end": 718, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "原文为英文"}], "startTime": "2024/08/07 10:08:59", "endTime": "2024/08/07 10:09:45", "cost": 45.47}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 18:09:44", "grab_time": "2024-08-06 18:08:58"}
{"id": 2211753, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "b39d04cb-4d65-4766-a08c-fb0fbf819e84", "title": "2024+BSH指南：新诊断大B细胞淋巴瘤的管理", "text": "【0】页码:15\n2024+BSH指南：新诊断大B细胞淋巴瘤的管理\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】参考删除-3:<u>117. Kanemasa Y, Shiinoya M, Sasaki Y, Tamura M, Sawada T, Omuro Y, et al. Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients. Med Oncol. 2017;34删除11:<u>(2)</u>:29.</u>\n\n【2】参考删除-3:<u>118. Burggraaff CN, de Jong A, Hoekstra OS, Peters MDJ, Nievelstein RAJ, Jansma EP, et al. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46删除11:<u>(1)</u>:65–79.</u>\n\n【3】参考删除-3:<u>119. Eertink JJ, Burggraaff CN, Heymans MW, Dührsen U, Huttmann A, Schmitz C, et al. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1629 patients. Blood Adv. 2021;5删除11:<u>(9)</u>:2375–84.</u>\n\n【4】参考删除-3:<u>120. Carr R, Fanti S, Paez D, Cerci J, Györke T, Redondo F, et al. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014;55删除11:<u>(12)</u>:1936–44.</u>\n\n【5】参考删除-2:<u>121. Kim J, Song YS, Lee JS, Lee WW, Kim SE. Risk stratification of diffuse large B-cell lymphoma with interim PET based on different cutoff Deauville scores. Leuk Lymphoma. 2018;59删除11:<u>(2)</u>:340–7.</u>\n\n【6】参考删除-3:<u>122. Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015;33删除11:<u>(22)</u>:2523–9.</u>\n\n【7】参考删除-3:<u>123. Schöder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, et al. Prognostic value of interim FDG-PET in diffuse large B-cell lymphoma: results from the CALGB 50303 clinical trial. Blood. 2020;135删除11:<u>(25)</u>:2224–34.</u>\n\n【8】参考删除-3:<u>124. Burggraaff CN, Cornelisse AC, Hoekstra OS, Lugtenburg PJ, De Keizer B, Arens ALJ, et al. Interobserver agreement of interim and end-of-treatment 删除11:<u>(18)</u>F-FDG PET/CT in diffuse large B-cell lymphoma: impact on clinical practice and trials. J Nucl Med. 2018;59删除11:<u>(12)</u>:1831–6.</u>\n\n【9】参考删除-3:<u>125. Mikhaeel NG, Cunningham D, Counsell N, McMillan A, Radford JA, Ardeshna KM, et al. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome—final result of a UK National Cancer Research Institute prospective study. Br J Haematol. 2021;192删除11:<u>(3)</u>:504–13.</u>\n\n【10】参考删除-3:<u>126. Boland V, Drury A, Sheaf G, Brady AM. Living with or beyond lymphoma: a rapid review of the unmet needs of lymphoma survivors. Psychooncology. 2022;31删除11:<u>(7)</u>:1076–101.</u>\n\n【11】参考删除-3:<u>127. Frick MA, Vachani CC, Hampshire MK, Bach C, Arnold-Korzeniowski K, Metz JM, et al. Patient-reported survivorship care practices and late effects after treatment of Hodgkin and non-Hodgkin lymphoma. JCO Clin Cancer Inform. 2018;2:1–10.</u>\n\n【12】参考删除-3:<u>128. Newton C, Beaver K, Clegg A. Patient initiated follow-up in cancer patients: a systematic review. Front Oncol. 2022;12:945884.</u>\n\n【13】删除图片描述:<u>![](14_0.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 15, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024+BSH指南：新诊断大B细胞淋巴瘤的管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:10:45", "endTime": "2024/08/06 16:10:51", "cost": 5.376}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:10:51", "grab_time": "2024-08-06 00:10:45"}
{"id": 2211752, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "61d8de32-a50b-4946-b433-190332dac642", "title": "（2023.V1）NCCN临床实践指南：遗传／家族高风险评估-结直肠癌", "text": "【0】页码:32\n（2023.V1）NCCN临床实践指南：遗传／家族高风险评估-结直肠癌\n疑似页眉<u># NCCN Guidelines Version 1.2023 Lynch Syndrome</u>\n\n【1】## TUMOR TESTING RESULTS AND ADDITIONAL TESTING STRATEGIES\n\n| Tumor Testing删除23:<u><sup>a</sup></u> | IHC | MSI | BRAF V600E删除23:<u><sup>c</sup></u> | MLH1 Promoter Methylation | Plausible Etiologies | Additional Testing删除23:<u><sup>e, f</sup></u> | NOTE: Regardless of LS test results, consider genetic evaluation if <50 years |\n| --------------------- | --- | --- | ------------------- | ---------------------- | --------------------- | -------------------- | ---------------------------------------------------------------------- |\n| 删除32:<u>**</u>MLH1删除32:<u>**</u> | 删除32:<u>**</u>MSH2删除32:<u>**</u> | 删除32:<u>**</u>MSH6删除32:<u>**</u> | 删除32:<u>**</u>PMS2删除32:<u>**</u> | | |\n| AB | NL | NL | NL | N/A | Negative | Negative | 1) Germline 删除32:<u>*</u>MLH1删除32:<u>*</u> pathogenic variant or rarely 删除32:<u>*</u>PMS2删除32:<u>*</u> 2) Sporadic cancer | 1) Germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing |\n| NL | AB | AB | NL | N/A | N/A | N/A | 1) Germline 删除32:<u>*</u>MSH2/EPCAM删除32:<u>*</u> pathogenic variant; or rarely germline 删除32:<u>*</u>MSH6删除32:<u>*</u> pathogenic variant  2) Sporadic cancer | 1) Germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing |\n| NL | NL | NL | AB | N/A | N/A | N/A | 1) Germline 删除32:<u>*</u>PMS2删除32:<u>*</u> pathogenic variant 2) Germline 删除32:<u>*</u>MLH1删除32:<u>*</u> pathogenic variant 3) Sporadic cancer | 1) Germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing |\n| NL | AB | NL | NL | N/A | N/A | N/A | 1) Germline 删除32:<u>*</u>MSH2/EPCAM删除32:<u>*</u> pathogenic variant 2) Sporadic cancer | 1) Germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing |\n| NL | NL | AB | NL | N/A | N/A | N/A | 1) Germline 删除32:<u>*</u>MSH6删除32:<u>*</u> pathogenic variant 2) Germline 删除32:<u>*</u>MSH2删除32:<u>*</u> pathogenic variant 3) Sporadic cancer/Treatment effect删除23:<u><sup>k</sup></u> | 1) Germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing 3) If applicable, consider MSI analysis or repeat IHC testing on non-treated tumor删除23:<u><sup>k</sup></u> |\n| AB | NL | NL | NL | N/A | N/A | N/A | 1) Sporadic cancer; 2) Germline 删除32:<u>*</u>MLH1删除32:<u>*</u> pathogenic variant; 3) Germline 删除32:<u>*</u>PMS2删除32:<u>*</u> pathogenic variant; 4) Somatic 删除32:<u>*</u>MLH1删除32:<u>*</u> or 删除32:<u>*</u>PMS2删除32:<u>*</u> pathogenic variant | 1) 删除32:<u>*</u>BRAF删除32:<u>*</u> pathogenic variant testing删除23:<u><sup>d</sup></u>/<em>MLH1</em> promoter methylation删除23:<u><sup>j</sup></u> 2) If 删除32:<u>*</u>BRAF删除32:<u>*</u>/MLH1 methylation testing normal, germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 3) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing删除23:<u><sup>h</sup></u> |\n| AB | AB | AB | AB | N/A | N/A | N/A | 1) Germline pathogenic variant in any LS gene 2) Sporadic cancer | 1) 删除32:<u>*</u>BRAF删除32:<u>*</u> pathogenic variant testing删除23:<u><sup>d</sup></u>/<em>MLH1</em> promoter methylation AND Germline MMR testing or paired germline MMR/somatic MMR tumor testing (which often include 删除32:<u>*</u>MLH1删除32:<u>*</u> methylation testing)删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing删除23:<u><sup>h</sup></u> |\n\n【3】删除32:<u>**</u>Note: All recommendations are category 2A unless otherwise indicated.删除32:<u>**</u>  \n删除32:<u>**</u>Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.删除32:<u>**</u>", "tags": {}, "lang": "en", "attr": {"page_num": 32, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V1）NCCN临床实践指南：遗传／家族高风险评估-结直肠癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】## TUMOR TESTING RESULTS AND ADDITIONAL TESTING STRATEGIES", "content": "【0】页码:32\n（2023.V1）NCCN临床实践指南：遗传／家族高风险评估-结直肠癌\n疑似页眉<u># NCCN Guidelines Version 1.2023 Lynch Syndrome</u>\n\n【1】## TUMOR TESTING RESULTS AND ADDITIONAL TESTING STRATEGIES\n\n| Tumor Testing删除23:<u><sup>a</sup></u> | IHC | MSI | BRAF V600E删除23:<u><sup>c</sup></u> | MLH1 Promoter Methylation | Plausible Etiologies | Additional Testing删除23:<u><sup>e, f</sup></u> | NOTE: Regardless of LS test results, consider genetic evaluation if <50 years |\n| --------------------- | --- | --- | ------------------- | ---------------------- | --------------------- | -------------------- | ---------------------------------------------------------------------- |\n| 删除32:<u>**</u>MLH1删除32:<u>**</u> | 删除32:<u>**</u>MSH2删除32:<u>**</u> | 删除32:<u>**</u>MSH6删除32:<u>**</u> | 删除32:<u>**</u>PMS2删除32:<u>**</u> | | |\n| AB | NL | NL | NL | N/A | Negative | Negative | 1) Germline 删除32:<u>*</u>MLH1删除32:<u>*</u> pathogenic variant or rarely 删除32:<u>*</u>PMS2删除32:<u>*</u> 2) Sporadic cancer | 1) Germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing |\n| NL | AB | AB | NL | N/A | N/A | N/A | 1) Germline 删除32:<u>*</u>MSH2/EPCAM删除32:<u>*</u> pathogenic variant; or rarely germline 删除32:<u>*</u>MSH6删除32:<u>*</u> pathogenic variant  2) Sporadic cancer | 1) Germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing |\n| NL | NL | NL | AB | N/A | N/A | N/A | 1) Germline 删除32:<u>*</u>PMS2删除32:<u>*</u> pathogenic variant 2) Germline 删除32:<u>*</u>MLH1删除32:<u>*</u> pathogenic variant 3) Sporadic cancer | 1) Germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing |\n| NL | AB | NL | NL | N/A | N/A | N/A | 1) Germline 删除32:<u>*</u>MSH2/EPCAM删除32:<u>*</u> pathogenic variant 2) Sporadic cancer | 1) Germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing |\n| NL | NL | AB | NL | N/A | N/A | N/A | 1) Germline 删除32:<u>*</u>MSH6删除32:<u>*</u> pathogenic variant 2) Germline 删除32:<u>*</u>MSH2删除32:<u>*</u> pathogenic variant 3) Sporadic cancer/Treatment effect删除23:<u><sup>k</sup></u> | 1) Germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing 3) If applicable, consider MSI analysis or repeat IHC testing on non-treated tumor删除23:<u><sup>k</sup></u> |\n| AB | NL | NL | NL | N/A | N/A | N/A | 1) Sporadic cancer; 2) Germline 删除32:<u>*</u>MLH1删除32:<u>*</u> pathogenic variant; 3) Germline 删除32:<u>*</u>PMS2删除32:<u>*</u> pathogenic variant; 4) Somatic 删除32:<u>*</u>MLH1删除32:<u>*</u> or 删除32:<u>*</u>PMS2删除32:<u>*</u> pathogenic variant | 1) 删除32:<u>*</u>BRAF删除32:<u>*</u> pathogenic variant testing删除23:<u><sup>d</sup></u>/<em>MLH1</em> promoter methylation删除23:<u><sup>j</sup></u> 2) If 删除32:<u>*</u>BRAF删除32:<u>*</u>/MLH1 methylation testing normal, germline MMR testing or paired germline MMR/somatic MMR tumor testing删除23:<u><sup>g</sup></u> 3) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing删除23:<u><sup>h</sup></u> |\n| AB | AB | AB | AB | N/A | N/A | N/A | 1) Germline pathogenic variant in any LS gene 2) Sporadic cancer | 1) 删除32:<u>*</u>BRAF删除32:<u>*</u> pathogenic variant testing删除23:<u><sup>d</sup></u>/<em>MLH1</em> promoter methylation AND Germline MMR testing or paired germline MMR/somatic MMR tumor testing (which often include 删除32:<u>*</u>MLH1删除32:<u>*</u> methylation testing)删除23:<u><sup>g</sup></u> 2) If germline testing negative and paired somatic MMR genetic testing not done, consider somatic MMR genetic testing删除23:<u><sup>h</sup></u> |\n\n【3】删除32:<u>**</u>Note: All recommendations are category 2A unless otherwise indicated.删除32:<u>**</u>  \n删除32:<u>**</u>Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.删除32:<u>**</u>", "index": 105, "show": true, "start": 105, "end": 166, "province": ["格式规范性", "表格格式错误"], "isEdit": false}], "startTime": "2024/08/06 17:00:51", "endTime": "2024/08/06 17:01:27", "cost": 35.619}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 01:01:27", "grab_time": "2024-08-06 01:00:51"}
{"id": 2211751, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "ef79c54b-5a17-45c7-ade1-852310e85a96", "title": "心力衰竭的管理指南", "text": "【0】页码:58\n心力衰竭的管理指南\nCASH (Cardiac Arrest Study Hamburg), and CIDS 删除9:<u>(Canadian Implantable Defibrillator Study)</u>, benefit was observed in those who were randomized to ICDs 删除11:<u>(1-3)</u>. Extension of benefit was then shown in other patient populations that were at perceived risk of SCD. In the first MADIT (Multicenter Automated Defibrillator Implantation Trial) trial, patients with previous MI, LVEF ≤35% with nonsustained VT had a mortality benefit with ICD 删除11:<u>(4)</u>. Similar populations in MUSTT (Multicenter Unsustained Tachycardia Trial) also showed benefit 删除11:<u>(5)</u>. In MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II), patients with no arrhythmia qualifier but with previous MIs and LVEF ≤30% derived benefit from ICD 删除11:<u>(6)</u>. The DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation) study included only nonischemic patients with LVEF ≤35% and frequent premature ventricular contractions (PVCs) or nonsustained ventricular tachycardia (VT) 删除11:<u>(7)</u>. There was a trend to mortality benefit, but it ultimately did not achieve significance. In SCD-HEFT (Sudden Cardiac Death in Heart Failure Trial), patients with ischemic and nonischemic cardiomyopathy, LVEF ≤35%, and HF class II to III showed benefit with an ICD compared with either amiodarone or placebo 删除11:<u>(8)</u>. More recently, the DANISH (Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure) trial enrolled patients with nonischemic cardiomyopathy and LVEF ≤35% to ICD or standard care 删除11:<u>(9)</u>. There was no reduction in the primary endpoint of total mortality, but there was a reduction in SCD risk. In the DANISH trial, 58% of patients in each limb received CRT, possibly mitigating the benefit of an ICD.\n\n【1】2. Economic outcomes of ICD implantation for primary prevention of SCD were assessed in 3 RCTs (MADIT-I 删除12:<u>删除14:<u>[13]</u></u>, MADIT-II 删除12:<u>删除14:<u>[15]</u></u>, and SCD-HeFT 删除12:<u>删除14:<u>[12]</u></u>), 1 observational study 删除11:<u>(10)</u>, and 3 simulation models 删除11:<u>(11,14,42)</u>, all of which had generally consistent results. All studies reported increased survival and life expectancy and higher lifetime costs of medical care with an ICD than without an ICD. The incremental cost-effectiveness ratios were generally <$60,000 per year of life added by an ICD, which provides high value according to the benchmarks adopted for the current guideline. The value provided by an ICD was consistently high when life expectancy was projected to increase by >1.4 years 删除11:<u>(14)</u>. In contrast, when survival was not increased by ICD implantation, as in the coronary artery bypass graft (CABG) Patch trial 删除11:<u>(43)</u>, the ICD did not provide value, because the higher costs were unaccompanied by a gain in life expectancy 删除11:<u>(14)</u>.\n3. The MADIT-II trial randomized patients with previous MI and LVEF <30%, without any limitation of HF class, to ICDs or not 删除11:<u>(6)</u>. Thirty-seven percent of the patients were in class I congestive heart failure (CHF). Mortality was reduced with an ICD.\n4. Most of the relevant data for the guidelines of CRT in HF come from seminal trials published from 2002 to 2010. The first of these was the MIRACLE (Multicenter InSync Randomized Clinical Evaluation) trial, which took patients with LVEF ≤35%, moderate to severe HF, and QRS duration ≥130 ms 删除11:<u>(16)</u>. There was a benefit in the 6-minute walk test, QOL, functional HF classification, and LVEF. The COMPANION (Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure) trial, which enrolled NYHA class III to IV patients with QRS ≥120 ms, included 3 arms: GDMT, CRT-D, and CRT pacemaker (CRT-P) 删除11:<u>(17)</u>. The primary endpoint of death or hospitalization was decreased with CRT-P and CRT-D. The CARE-HF (Cardiac Resynchronization Heart Failure) trial included a similar group with NYHA class III to IV, LVEF ≤35%, QRS >120 ms, and showed a significant reduction in primary and endpoint of death or hospitalization 删除11:<u>(18)</u>. In the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial, patients with NYHA class I to II and LVEF ≤40% were randomized to CRT-D on for 1 year and CRT-D off for 1 year or vice versa 删除11:<u>(19)</u>. A HF composite endpoint was less common when CRT was activated. MADIT-CRT enrolled NYHA class I and II HF with LVEF ≤30% and QRS ≥130 ms and compared CRT-D with ICD 删除11:<u>(20)</u>. The primary endpoint of death or HF was reduced by CRT-D. The RAFT (Resynchronization-Defibrillation for Ambulatory Heart Failure) trial randomized patients with NYHA class II to III HF, LVEF ≤30%, QRS ≥120 ms, or paced QRS ≥200 ms and compared CRT-D with ICD 删除11:<u>(21)</u>. Again, there was a reduction in the primary endpoint of death or HF hospitalizations.\n5. The economic value of CRT has been evaluated by 3 RCTs (COMPANION 删除12:<u>删除14:<u>[22]</u></u>, MADIT-CRT 删除12:<u>删除14:<u>[26]</u></u>, and REVERSE 删除12:<u>删除14:<u>[23]</u></u>), 2 model-based analyses 删除11:<u>(25,27)</u>, and 1 observational study 删除11:<u>(24)</u>. These analyses consistently found CRT increased survival and QOL in addition to increasing health care costs. However, the economic value of CRT likely varies as a result of the shown variation in treatment effect 删除11:<u>(26)</u>. Among populations with larger expected mortality reduction and improvement in QOL, such as patients with a LBBB。", "tags": {}, "lang": "en", "attr": {"page_num": 58, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/心力衰竭的管理指南.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:40:47", "endTime": "2024/08/06 15:46:36", "cost": 349.212}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-05 23:46:36", "grab_time": "2024-08-05 23:40:47"}
{"id": 2211750, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "de213e3c-dbe8-48c7-8b45-3795e41815ce", "title": "成人糖尿病食养指南2023年版", "text": "【0】页码:13\n成人糖尿病食养指南2023年版\n适当安排加餐或零食，以预防低血糖的发生，增加能量摄入，增加体重。\n\n【1】删除32:<u>**</u>（八）自我管理，定期营养咨询，提高血糖控制能力。删除32:<u>**</u>\n\n【2】有效管理和控制血糖平稳，很大程度上取决于患者的自我管理能力。糖尿病管理需要采取综合性措施，结合患者的病程、病情和行为改变特征等，兼具个性化和多样性。糖尿病患者需要切实重视、学习糖尿病知识和自我管理技能，包括膳食调整、规律运动、监测血糖、遵医嘱用药、胰岛素注射技术，以及低血糖预防和处理等。\n\n【3】糖尿病患者应将营养配餐、合理烹任、运动管理和血糖监测作为基本技能。了解食物中碳水化合物含量和GI值，学习食物交换份的使用，把自我行为管理融入到日常生活中。\n\n【4】应建立与临床经验丰富的营养师等营养指导人员、医师团队的咨访和随访服务关系，主动进行定期的咨访，接受个性化营养教育、膳食指导，以促进其能获取和营养治疗方案有效实施，并改善自我健康状况和临床结局。特别是在初诊、年度检查和/或未达到治疗目标、疾病或环境变化时，应及时就诊或咨访。\n\n【5】营养咨询应包括膳食评估和膳食调整、营养状况评估和营养诊断、以及营养处方、运动处方的制定等。在医师和营养指导人员的帮助下，适时调整膳食、运动和行为，以及用药量等方案，保持健康的生活方式，并控制血糖，预防并发症发生。", "tags": {}, "lang": "zh", "attr": {"page_num": 13, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/成人糖尿病食养指南2023年版.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:43:25", "endTime": "2024/08/06 15:43:38", "cost": 12.848}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-05 23:43:38", "grab_time": "2024-08-05 23:43:25"}
{"id": 2211749, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "1be34d1f-29f1-4ca4-8b3c-8a8f0d582598", "title": "产前使用糖皮质激素促胎肺成熟的临床实践指南（2022）", "text": "【0】页码:6\n产前使用糖皮质激素促胎肺成熟的临床实践指南（2022）\nhospital mortality (aOR: 0.3; 95% CI: 0.1–0.6). Based on a recent Cochrane review, there was no effect of ACS on twin pregnancies regarding the outcomes of fetal death, perinatal death, neonatal death, RDS, and IVH; however, the number of studies and the number of the participants were limited. With regards to the hypothesis that multiple gestations may have higher needs of corticosteroids, it has been proven that cord blood levels of steroids are similar to those observed in singletons.\n\n【1】删除32:<u>**</u>Recommendation删除32:<u>**</u>\n\n【2】- In multiple pregnancies, 删除32:<u>*</u>ACS should be administered at the same dosage and indications as in singleton pregnancies删除32:<u>*</u>.\n\n【3】### Obesity\n\n【4】Some concerns have been raised whether the doses of ACS should be modified according to body mass index. There is limited data to make relevant recommendations; based on a study of 55 participants, cord blood levels of corticosteroids were comparable between the groups of obese and non-obese pregnant women.\n\n【5】删除32:<u>**</u>Recommendation删除32:<u>**</u>\n\n【6】- In obese women, 删除32:<u>*</u>ACS should be administered at the same dosage and indications as in women without obesity删除32:<u>*</u>.\n\n【7】### Preterm prelabor rupture of membranes\n\n【8】There is still no consensus on the criteria to diagnose PPROM and there is very little evidence on the accurate prediction of women with PPROM that are more likely to deliver within 7 days. Moreover, concerns have been raised regarding a possible increase in the incidence of perinatal infection in women with PPROM treated with ACS. A meta-analysis including more than 1,400 women with PPROM found that ACS reduces the risk of RDS (RR: 0.56; 95% CI: 0.46–0.70), IVH (RR: 0.47; 95% CI: 0.31–0.70) and NEC (RR: 0.21; 95% CI: 0.05–0.82) without increasing the risk of maternal infection (RR: 0.68; 95% CI: 0.61–1.20) or neonatal infection (RR: 1.05; 95% CI: 0.66–1.68). Similarly, a subgroup analysis of the latest Cochrane review showed no differences in the effect on perinatal, neonatal and fetal death, RDS, endometritis or chorioamnionitis. A study investigating the effect of a repeat ACS course in cases with PPROM showed that women receiving a repeat course were not at increased risk of chorioamnionitis (aOR: 1.28; 95% CI: 0.69–2.14) or any neonatal morbidity. However, multiple ACS courses may increase the risk of chorioamnionitis.\n\n【9】删除32:<u>**</u>Recommendation删除32:<u>**</u>\n\n【10】- A single course of 删除32:<u>*</u>ACS is recommended at the time of diagnosis of PPROM when gestational age criteria are met删除32:<u>*</u>.\n\n【11】### Fetal growth restriction\n\n【12】There are no randomized studies on the effect of ACS in FGR. It has been proposed that these fetuses may not benefit as much from this therapy as their lung maturation might be physiologically enhanced (given chronic stress and 11-B-HSD II breakdown) or may even be detrimental as shown by some animal studies. Furthermore, some reports have described that ACS can reduce mean birthweight at the expense of the reduction of the cranial perimeter. However, more recent studies have shown that the detrimental effect on weight may only be a consequence of repeat courses and that some poor outcomes associated to these fetuses may have been influenced by maternal comorbidity. Furthermore, a secondary analysis from the ACTORDS trial found that, in 139 FGR fetuses, repeated antenatal betamethasone treatment compared with placebo was not associated with adverse effects on neurocognitive function at 6 to 8 years of age, even in the presence of FGR.\n\n【13】A 2009 review that included 5 studies with 664 fetuses found no differences in terms of morbidity, mortality, respiratory distress syndrome, IVH, or NEC. These results, however, may have been underpowered to detect differences among outcomes. A more recent meta-analysis conducted in 2020, including 13 studies with 6,387 FGR and small for gestational age infants, found that neonatal mortality was significantly lower among infants who received ACS (12.8% vs. 15.1%; OR: 0.63; 95% CI: 0.46–0.86), with significant heterogeneity between studies (I²=55.1%; p=0.011). There was no significant difference in respiratory distress syndrome, NEC, IVH and periventricular leukomalacia, bronchopulmonary dysplasia or chronic lung disease of prematurity, or neonatal sepsis.\n\n【14】Finally, a small sub-analysis from the TRUFFLE 2 feasibility study found no benefit from ACS administration beyond 32 weeks of gestation. However, in", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/产前使用糖皮质激素促胎肺成熟的临床实践指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:19:42", "endTime": "2024/08/06 16:20:14", "cost": 32.034}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:20:14", "grab_time": "2024-08-06 00:19:42"}
{"id": 2211748, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "771b2595-bf4a-4f78-b2bd-841064d95db1", "title": "ERS：成人哮喘的诊断指南（2022）", "text": "【0】页码:28\nERS：成人哮喘的诊断指南（2022）\n- The TF suggests not combining FeNO, blood eosinophils and serum IgE to make a diagnosis of asthma (conditional recommendation against the combination of tests, moderate quality of evidence)\n\n【1】### Background\nTotal serum IgE, BEC and FeNO represent facets of the T2 asthma phenotype, although the molecular mechanisms behind these biochemical and cellular variables may be different and eosinophils and IgE dissociated. We therefore investigated whether the combination of these variables could improve their diagnostic value.\n\n【2】### Review of the evidence\nOur search identified 10 potentially relevant studies of which only one study was suitable to be included 删除9:<u>(supplementary tables 11a&b)</u>. Combination of the three tests provided an AUC-ROC of 0.6 (95% CI: 0.56-0.64) while the AUC for individual tests were 0.58 删除11:<u>(0.54-0.62)</u>, 0.57 删除11:<u>(0.53-0.61)</u> and 0.58 删除11:<u>(0.54-0.62)</u> for FeNO, IgE and BEC respectively. Overall, sensitivity of the combination was 0.46 (95% CI: 0.37 to 0.52) while specificity was 0.74 (95% CI: 0.64 to 0.69) 删除9:<u>(GRADE table 11, supplementary EtD table 11b)</u>\n\n【3】### Justification of the recommendation\nAlthough a large study, the only study that met the criteria was a single-centre secondary care assessment. Combining blood eosinophils, total serum IgE and FeNO does not seem to improve diagnostic accuracy as compared to performing one single test. Further studies are needed, particularly those in primary care.", "tags": {}, "lang": "en", "attr": {"page_num": 28, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ERS：成人哮喘的诊断指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:10:02", "endTime": "2024/08/06 16:10:19", "cost": 17.101}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:10:19", "grab_time": "2024-08-06 00:10:02"}
{"id": 2211747, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "5c0e6662-099d-4e2a-afa4-35e96f3dffe2", "title": "成人糖尿病食养指南2023年版", "text": "【0】页码:10\n成人糖尿病食养指南2023年版\n#### （四）积极运动，改善体质和胰岛素敏感性。\n\n【1】运动可以消耗能量，抗阻运动有助于增加肌肉量，运动还可以增加骨骼肌细胞膜上葡萄糖转运蛋白（GLUT-4）的数量，增加骨骼肌细胞对葡萄糖的摄取，改善骨骼肌细胞的胰岛素敏感性，平稳血糖。目前有充足的证据表明，身体活动不足可导致体重过度增加，多进行身体活动不仅有利于维持健康体重，调节心情愉悦，还能降低肥胖、2型糖尿病、心血管疾病和某些癌症等疾病发生风险和全因死亡风险。\n\n【2】糖尿病患者可在餐后运动，每周至少5天，每次30~45分钟，中等强度运动要占50%以上，循序渐进，持之以恒。中等强度运动包括快走、骑车、乒乓球、羽毛球、慢跑、游泳等。如无禁忌，最好一周2次抗阻运动，如哑铃、俯卧撑、器械类运动等，提高肌肉力量和耐力。将日常活动和运动融入生活计划中。运动前后要加强血糖监测，避免低血糖。\n\n【3】每个人都应当认识到身体活动是一个改善健康的机会，而不是浪费时间；糖尿病患者应该寻找和培养自己有兴趣的运动方式，将运动列入每天的时间安排，培养运动意识和习惯，有计划地循序渐进，逐渐增加和达到目标运动量。\n\n【4】#### （五）清淡饮食，限制饮酒，预防和延缓并发症。\n\n【5】预防和延缓相关并发症的发生，重点是强化生活方式的改变。首先要控制油、盐、糖，不饮酒，控制血糖、血脂、血压在理想水平。\n\n【6】所有人都应该清淡饮食，控制油、盐、糖用量，包括糖尿病前期和所有糖尿病患者。烹调油或肥肉摄入过多，会导致", "tags": {}, "lang": "zh", "attr": {"page_num": 10, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/成人糖尿病食养指南2023年版.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:19:28", "endTime": "2024/08/06 16:19:40", "cost": 11.995}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:19:40", "grab_time": "2024-08-06 00:19:28"}
{"id": 2211746, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "085b7701-efe6-4698-9a02-caa55ae7b50d", "title": "2023 ACC／AHA／ASE／ASNC／ASPC／HFSA／HRS／SCAI／SCCT／SCMR／STS报告：慢性冠状动脉疾病的检测和风险评估的多模态适当使用标准", "text": "【0】页码:11\n2023 ACC／AHA／ASE／ASNC／ASPC／HFSA／HRS／SCAI／SCCT／SCMR／STS报告：慢性冠状动脉疾病的检测和风险评估的多模态适当使用标准\n疑似页眉<u>### Risk-Enhancing Factors</u>\n\n【1】删除图片描述:<u>!删除24:<u>[/mnt/data/24c6a2e380d2f8e36bd4569db773b746f2f9fed6e71a6b9ae6f93efa7d60c3a3.png]</u>(10_0.png)</u>\n\n【2】- Family history of premature ASCVD (men, age <55 y; women, age <65 y)\n- Primary hypercholesterolemia (LDL-C, 160-189 mg/dL [4.1-4.8 mmol/L]; non-HDL-C, 190-219 mg/dL [4.9-5.6 mmol/L])\n- Metabolic syndrome (increased waist circumference, elevated triglycerides [>175 mg/dL], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 mg/dL in women]; for adults, tally of 3 makes the diagnosis)\n- Chronic inflammatory conditions such as psoriasis, RA, lupus, or HIV/AIDS\n- History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that increase later ASCVD risk such as preeclampsia, gestational diabetes\n- Noncoronary vascular disease (eg, ABI <0.9)\n- High-risk race/ethnicities (eg, South Asian ancestry)\n- Elevated high-sensitivity C-reactive protein (≥2.0 mg/L)\n- Elevated Lp(a): >50 mg/dL or >125 nmol/L\n- Elevated apoB: ≥130 mg/dL\n- Persistently elevated, primary hypertriglyceridemia (≥175 mg/dL)\n- Coronary calcifications on prior imaging (highest CT x-ray, chest CT)\n- Prior chest radiation\n- Chemotherapy with vasotoxicity potential\n\n【3】删除32:<u>**</u>Definitions for Table 2.2删除32:<u>**</u>\n\n【4】删除32:<u>**</u>Incomplete revascularization:删除32:<u>**</u> Coronary revascularization by PCI or coronary artery bypass graft with suspected or known residual obstructive epicardial coronary artery stenosis that may or may not be amenable to revascularization, or unrevascularized coronary arteries following an acute coronary syndrome. Examples include an incomplete surgical or percutaneous revascularization (unrevascularized territories due to poor targets, chronic occlusion, or diffuse disease), prior MI without culprit artery revascularization, or prior MI with residual obstructive CAD in a non-infarct-related artery.\n\n【5】删除32:<u>**</u>Prior high-risk PCI:删除32:<u>**</u> Revascularization posing a higher-than-normal risk for restenosis or closure (eg, PCI of a diffusely diseased saphenous vein graft, treatment of recurrent in-stent restenosis) or a higher risk for adverse sequelae should restenosis occur (eg, left main coronary artery PCI or single remaining vessel/conduit).\n\n【6】删除32:<u>**</u>Definitions for Table 2.4删除32:<u>**</u>\n\n【7】删除32:<u>**</u>Frequent premature ventricular contractions (PVCs):删除32:<u>**</u> More than 30 PVCs per hour.\n\n【8】### Infrequent PVCs:\n\n【9】Thirty or fewer PVCs per hour.\n\n【10】### Sustained ventricular tachycardia (VT):\n\n【11】Cardiac arrhythmia of consecutive complexes originating in the ventricles at a rate >100 beats/min (cycle length: <600 milliseconds) lasting >30 seconds or requiring termination due to hemodynamic compromise in <30 seconds.\n\n【12】### Nonsustained VT:\n\n【13】Cardiac arrhythmia of ≥3 consecutive complexes originating in the ventricles at a rate >100 beats/min (cycle length: <600 milliseconds) that self-terminates in <30 seconds and without hemodynamic compromise.\n\n【14】### Heart failure:\n\n【15】Stages B, C, and D heart failure, as defined by the ACCF/AHA Guideline for the Management of Heart Failure.\n\n【16】### Syncope:\n\n【17】A symptom that presents with an abrupt, transient, complete loss of consciousness, associated with inability to maintain posture tone, with rapid and spontaneous recovery. The presumed mechanism is cerebral hypoperfusion. There should not be clinical features of other nonsyncopal causes of loss of consciousness, such as seizure, antecedent head trauma, or apparent loss of consciousness (ie, pseudo-syncope).\n\n【18】### 5. Abbreviations\n\n【19】- AUC = Appropriate Use Criteria\n- CAD = coronary artery disease\n- CMR = cardiac magnetic resonance\n- CCTA = coronary computed tomography angiography\n- ECG = electrocardiogram\n- Echo = echocardiogram\n- MPI = myocardial perfusion imaging\n- PCI = percutaneous coronary intervention\n- PVC = premature ventricular contraction\n- SIHD = stable ischemic heart disease\n- VT = ventricular tachycardia\n\n【20】### 6. Results of Ratings\n\n【21】The final ratings for Multimodality AUC on the Detection and Risk Assessment of CAD are listed by clinical scenario in Tables 1.1, 1.2, 1.3, 2.1, 2.2, 2.3, and 2.4. The final score reflects the median score of the 15 rating panel members and has been labeled according to the categories of Appropriate (median 7 to 9), May Be Appropriate (median 4 to 6), and Rarely Appropriate (median 1 to 3) (Supplemental Appendix 1). The discussion section highlights further general trends in the scoring related to specific patient populations.", "tags": {}, "lang": "en", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ACC／AHA／ASE／ASNC／ASPC／HFSA／HRS／SCAI／SCCT／SCMR／STS报告：慢性冠状动脉疾病的检测和风险评估的多模态适当使用标准.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "疑似页眉### Risk-Enhancing Factors", "content": "【0】页码:11\n2023 ACC／AHA／ASE／ASNC／ASPC／HFSA／HRS／SCAI／SCCT／SCMR／STS报告：慢性冠状动脉疾病的检测和风险评估的多模态适当使用标准\n疑似页眉<u>### Risk-Enhancing Factors</u>\n\n【1】删除图片描述:<u>!删除24:<u>[/mnt/data/24c6a2e380d2f8e36bd4569db773b746f2f9fed6e71a6b9ae6f93efa7d60c3a3.png]</u>(10_0.png)</u>\n\n【2】- Family history of premature ASCVD (men, age <55 y; women, age <65 y)\n- Primary hypercholesterolemia (LDL-C, 160-189 mg/dL [4.1-4.8 mmol/L]; non-HDL-C, 190-219 mg/dL [4.9-5.6 mmol/L])\n- Metabolic syndrome (increased waist circumference, elevated triglycerides [>175 mg/dL], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 mg/dL in women]; for adults, tally of 3 makes the diagnosis)\n- Chronic inflammatory conditions such as psoriasis, RA, lupus, or HIV/AIDS\n- History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that increase later ASCVD risk such as preeclampsia, gestational diabetes\n- Noncoronary vascular disease (eg, ABI <0.9)\n- High-risk race/ethnicities (eg, South Asian ancestry)\n- Elevated high-sensitivity C-reactive protein (≥2.0 mg/L)\n- Elevated Lp(a): >50 mg/dL or >125 nmol/L\n- Elevated apoB: ≥130 mg/dL\n- Persistently elevated, primary hypertriglyceridemia (≥175 mg/dL)\n- Coronary calcifications on prior imaging (highest CT x-ray, chest CT)\n- Prior chest radiation\n- Chemotherapy with vasotoxicity potential\n\n【3】删除32:<u>**</u>Definitions for Table 2.2删除32:<u>**</u>\n\n【4】删除32:<u>**</u>Incomplete revascularization:删除32:<u>**</u> Coronary revascularization by PCI or coronary artery bypass graft with suspected or known residual obstructive epicardial coronary artery stenosis that may or may not be amenable to revascularization, or unrevascularized coronary arteries following an acute coronary syndrome. Examples include an incomplete surgical or percutaneous revascularization (unrevascularized territories due to poor targets, chronic occlusion, or diffuse disease), prior MI without culprit artery revascularization, or prior MI with residual obstructive CAD in a non-infarct-related artery.\n\n【5】删除32:<u>**</u>Prior high-risk PCI:删除32:<u>**</u> Revascularization posing a higher-than-normal risk for restenosis or closure (eg, PCI of a diffusely diseased saphenous vein graft, treatment of recurrent in-stent restenosis) or a higher risk for adverse sequelae should restenosis occur (eg, left main coronary artery PCI or single remaining vessel/conduit).\n\n【6】删除32:<u>**</u>Definitions for Table 2.4删除32:<u>**</u>\n\n【7】删除32:<u>**</u>Frequent premature ventricular contractions (PVCs):删除32:<u>**</u> More than 30 PVCs per hour.\n\n【8】### Infrequent PVCs:\n\n【9】Thirty or fewer PVCs per hour.\n\n【10】### Sustained ventricular tachycardia (VT):\n\n【11】Cardiac arrhythmia of consecutive complexes originating in the ventricles at a rate >100 beats/min (cycle length: <600 milliseconds) lasting >30 seconds or requiring termination due to hemodynamic compromise in <30 seconds.\n\n【12】### Nonsustained VT:\n\n【13】Cardiac arrhythmia of ≥3 consecutive complexes originating in the ventricles at a rate >100 beats/min (cycle length: <600 milliseconds) that self-terminates in <30 seconds and without hemodynamic compromise.\n\n【14】### Heart failure:\n\n【15】Stages B, C, and D heart failure, as defined by the ACCF/AHA Guideline for the Management of Heart Failure.\n\n【16】### Syncope:\n\n【17】A symptom that presents with an abrupt, transient, complete loss of consciousness, associated with inability to maintain posture tone, with rapid and spontaneous recovery. The presumed mechanism is cerebral hypoperfusion. There should not be clinical features of other nonsyncopal causes of loss of consciousness, such as seizure, antecedent head trauma, or apparent loss of consciousness (ie, pseudo-syncope).\n\n【18】### 5. Abbreviations\n\n【19】- AUC = Appropriate Use Criteria\n- CAD = coronary artery disease\n- CMR = cardiac magnetic resonance\n- CCTA = coronary computed tomography angiography\n- ECG = electrocardiogram\n- Echo = echocardiogram\n- MPI = myocardial perfusion imaging\n- PCI = percutaneous coronary intervention\n- PVC = premature ventricular contraction\n- SIHD = stable ischemic heart disease\n- VT = ventricular tachycardia\n\n【20】### 6. Results of Ratings\n\n【21】The final ratings for Multimodality AUC on the Detection and Risk Assessment of CAD are listed by clinical scenario in Tables 1.1, 1.2, 1.3, 2.1, 2.2, 2.3, and 2.4. The final score reflects the median score of the 15 rating panel members and has been labeled according to the categories of Appropriate (median 7 to 9), May Be Appropriate (median 4 to 6), and Rarely Appropriate (median 1 to 3) (Supplemental Appendix 1). The discussion section highlights further general trends in the scoring related to specific patient populations.", "index": 93, "show": true, "start": 93, "end": 123, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "页眉判断错误"}, {"text": "(Supplemental Appendix 1)", "content": "【0】页码:11\n2023 ACC／AHA／ASE／ASNC／ASPC／HFSA／HRS／SCAI／SCCT／SCMR／STS报告：慢性冠状动脉疾病的检测和风险评估的多模态适当使用标准\n<mark>疑似页眉### Risk-Enhancing Factors</mark>ors</u>\n\n【1】删除图片描述:<u>!删除24:<u>[/mnt/data/24c6a2e380d2f8e36bd4569db773b746f2f9fed6e71a6b9ae6f93efa7d60c3a3.png]</u>(10_0.png)</u>\n\n【2】- Family history of premature ASCVD (men, age <55 y; women, age <65 y)\n- Primary hypercholesterolemia (LDL-C, 160-189 mg/dL [4.1-4.8 mmol/L]; non-HDL-C, 190-219 mg/dL [4.9-5.6 mmol/L])\n- Metabolic syndrome (increased waist circumference, elevated triglycerides [>175 mg/dL], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 mg/dL in women]; for adults, tally of 3 makes the diagnosis)\n- Chronic inflammatory conditions such as psoriasis, RA, lupus, or HIV/AIDS\n- History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that increase later ASCVD risk such as preeclampsia, gestational diabetes\n- Noncoronary vascular disease (eg, ABI <0.9)\n- High-risk race/ethnicities (eg, South Asian ancestry)\n- Elevated high-sensitivity C-reactive protein (≥2.0 mg/L)\n- Elevated Lp(a): >50 mg/dL or >125 nmol/L\n- Elevated apoB: ≥130 mg/dL\n- Persistently elevated, primary hypertriglyceridemia (≥175 mg/dL)\n- Coronary calcifications on prior imaging (highest CT x-ray, chest CT)\n- Prior chest radiation\n- Chemotherapy with vasotoxicity potential\n\n<mark>【3】删除32:Definitions for Table 2.2删除32:\n\n【4】删除32:Incomplete revascularization:删除32: Coronary revascularization by PCI or coronary artery bypass graft with suspected or known residual obstructive epicardial coronary artery stenosis that may or may not be amenable to revascularization, or unrevascularized coronary arteries following an acute coronary syndrome. Examples include an incomplete surgical or percutaneous revascularization (unrevascularized territories due to poor targets, chronic occlusion, or diffuse disease), prior MI without culprit artery revascularization, or prior MI with residual obstructive CAD in a non-infarct-related artery.\n\n【5】删除32:Prior high-risk PCI:删除32: Revascularization posing a higher-than-normal risk for restenosis or closure (eg, PCI of a diffusely diseased saphenous vein graft, treatment of recurrent in-stent restenosis) or a higher risk for adverse sequelae should restenosis occur (eg, left main coronary artery PCI or single remaining vessel/conduit).\n\n【6】删除32:Definitions for Table 2.4删除32:\n\n【7】删除32:Frequent premature ventricular contractions (PVCs):删除32: More than 30 PVCs per hour.</mark>quent premature ventricular contractions (PVCs):删除32:<u>**</u> More than 30 PVCs per hour.\n\n【8】### Infrequent PVCs:\n\n【9】Thirty or fewer PVCs per hour.\n\n【10】### Sustained ventricular tachycardia (VT):\n\n【11】Cardiac arrhythmia of consecutive complexes originating in the ventricles at a rate >100 beats/min (cycle length: <600 milliseconds) lasting >30 seconds or requiring termination due to hemodynamic compromise in <30 seconds.\n\n【12】### Nonsustained VT:\n\n【13】Cardiac arrhythmia of ≥3 consecutive complexes originating in the ventricles at a rate >100 beats/min (cycle length: <600 milliseconds) that self-terminates in <30 seconds and without hemodynamic compromise.\n\n【14】### Heart failure:\n\n【15】Stages B, C, and D heart failure, as defined by the ACCF/AHA Guideline for the Management of Heart Failure.\n\n【16】### Syncope:\n\n【17】A symptom that presents with an abrupt, transient, complete loss of consciousness, associated with inability to maintain posture tone, with rapid and spontaneous recovery. The presumed mechanism is cerebral hypoperfusion. There should not be clinical features of other nonsyncopal causes of loss of consciousness, such as seizure, antecedent head trauma, or apparent loss of consciousness (ie, pseudo-syncope).\n\n【18】### 5. Abbreviations\n\n【19】- AUC = Appropriate Use Criteria\n- CAD = coronary artery disease\n- CMR = cardiac magnetic resonance\n- CCTA = coronary computed tomography angiography\n- ECG = electrocardiogram\n- Echo = echocardiogram\n- MPI = myocardial perfusion imaging\n- PCI = percutaneous coronary intervention\n- PVC = premature ventricular contraction\n- SIHD = stable ischemic heart disease\n- VT = ventricular tachycardia\n\n【20】### 6. Results of Ratings\n\n【21】The final ratings for Multimodality AUC on the Detection and Risk Assessment of CAD are listed by clinical scenario in Tables 1.1, 1.2, 1.3, 2.1, 2.2, 2.3, and 2.4. The final score reflects the median score of the 15 rating panel members and has been labeled according to the categories of Appropriate (median 7 to 9), May Be Appropriate (median 4 to 6), and Rarely Appropriate (median 1 to 3) (Supplemental Appendix 1). The discussion section highlights further general trends in the scoring related to specific patient populations.", "index": 4607, "show": true, "start": 4581, "end": 4606, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "【21】"}]}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-05 23:55:18", "grab_time": "2024-08-05 23:42:04"}
{"id": 2211745, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "0c29d1e1-28cd-4651-8159-2c2aba927858", "title": "2023 GINA 全球哮喘处理和预防策略（更新版）", "text": "【0】页码:215\n2023 GINA 全球哮喘处理和预防策略（更新版）\n(本页删除)本页被模型判断为参考页190. Plaza V, Cobos A, Ignacio-Garcia JM, et al. [Cost-effectiveness of an intervention based on the Global INitiative for Asthma (GINA) recommendations using a computerized clinical decision support system: a physicians randomized trial]. Medicina clinica 2005; 124: 201-删除13:<u>206.\n191</u>. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-删除13:<u>224.\n192</u>. Roche N, Reddel HK, Agusti A, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med 2013; 1: e29-e删除13:<u>30.\n193</u>. Chung KF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med 2013; 1: 639-删除13:<u>652.\n194</u>. Drazen JM. Asthma: the paradox of heterogeneity. J Allergy Clin Immunol 2012; 129: 1200-删除13:<u>1201.\n195</u>. Haahtela T, Tamminen K, Malmberg LP, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. Eur Respir J 2006; 28: 748-删除13:<u>755.\n196</u>. Busse WW, Pedersen S, Pauwels RA, et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121: 1167-删除13:<u>1174.\n197</u>. Selroos O, Pietinalho A, Lofroos AB, et al. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108: 1228-删除13:<u>1234.\n198</u>. Selroos O. Effect of disease duration on dose-response of inhaled budesonide in asthma. Respir Med 2008; 102: 1065-删除13:<u>1072.\n199</u>. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602-删除13:<u>615.\n200</u>. Price DB, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med 2018; 6: 29-删除13:<u>39.\n201</u>. Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J 2019; 53: 1901046.\n202. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med 2018; 378: 1865-删除13:<u>1876.\n203</u>. Bateman ED, Reddel HK, O'Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018; 378: 1877-删除13:<u>1887.\n204</u>. Wechsler ME, Szefler SJ, Ortega VE, et al. Step-up therapy in black children and adults with poorly controlled asthma. N Engl J Med 2019; 381: 1227-删除13:<u>1239.\n205</u>. Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med 2020; 8: 1000-删除13:<u>1012.\n206</u>. El Baou C, Di Santostefano RL, Alfonso-Cristancho R, et al. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. BMC Pulm Med 2017; 17: 删除13:<u>31.\n207</u>. Bateman ED, O'Byrne PM, FitzGerald JM, et al. Positioning as-needed budesonide-formoterol for mild asthma: effect of prestudy treatment in pooled analysis of SYGMA 1 and 2. Ann Am Thorac Soc 2021; 18: 2007-删除13:<u>2017.\n208</u>. Reddel HK, O'Byrne PM, FitzGerald JM, et al. Efficacy and safety of as-needed budesonide-formoterol in adolescents with mild asthma. J Allergy Clin Immunol Pract 2021; 9: 3069-3077.e删除13:<u>3066.\n209</u>. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164(8 Pt 1): 1392-删除13:<u>1397.\n210</u>. FitzGerald JM, O'Byrne PM, Bateman ED, et al. Safety of as-needed budesonide-formoterol in mild asthma: data from the two phase III SYGMA studies. Drug Saf 2021; 44: 467-删除13:<u>478.\n211</u>. Barnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care 2015; 60.", "tags": {}, "lang": "en", "attr": {"page_num": 215, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 GINA 全球哮喘处理和预防策略（更新版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:32:35", "endTime": "2024/08/06 17:32:46", "cost": 10.843}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 01:32:46", "grab_time": "2024-08-06 01:32:34"}
{"id": 2211744, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "2ea769ef-7f36-4bf6-acb4-853910e5d240", "title": "成人心脏骤停后的体温控制指南（2022）", "text": "【0】页码:3\n成人心脏骤停后的体温控制指南（2022）\nTable 1  The PICO (Population, Intervention, Comparator, Outcome) for the ILCOR systematic review\n\n| Population | Intervention | Comparator | Outcome |\n|------------|--------------|------------|---------|\n| 删除32:<u>**</u>USE OF TARGETED TEMPERATURE CONTROL (TTM)删除32:<u>**</u> |\n| Adults in any setting (in-hospital or out-of-hospital) with cardiac arrest | Temperature control targeting hypothermia at 32-34°C | Temperature control targeting normothermia or fever prevention | Any clinical outcome |\n| 删除32:<u>**</u>DURATION删除32:<u>**</u> |\n| Adults in any setting (in-hospital or out-of-hospital) with cardiac arrest | TTM for a specific duration (e.g.,48 hours) | TTM at a different specific duration (e.g.,24 hours) | Any clinical outcome |\n| 删除32:<u>**</u>METHOD删除32:<u>**</u> |\n| Adults in any setting (in-hospital or out-of-hospital) with cardiac arrest | TTM with a specific method (e.g., external) | TTM with a different specific method (e.g., internal) | Any clinical outcome |\n| 删除32:<u>**</u>TEMPERATURE删除32:<u>**</u> |\n| Adults in any setting (in-hospital or out-of-hospital) with cardiac arrest | TTM at a specific temperature (e.g.,33°C) | TTM at a different specific temperature (e.g.,36°C) | Any clinical outcome |\n| 删除32:<u>**</u>TIMING删除32:<u>**</u> |\n| Adults in any setting (in-hospital or out-of-hospital) with cardiac arrest | TTM induction before a specific time point (e.g., prehospital or intracardiac arrest, i.e., before return of spontaneous circulation (ROSC)) | TTM induction after that specific time point | Any clinical outcome |\n| 删除32:<u>**</u>REWARMING删除32:<u>**</u> |\n| Adults in any setting (in-hospital or out-of-hospital) with cardiac arrest | TTM with a specific rewarming rate | TTM with a different specific rewarming rate or no specific rewarming rate | Any clinical outcome |\n\n【2】Note: For all PICOs, clinical outcomes included, but were not necessarily limited to: ROSC, survival/survival with a favourable neurological outcome at hospital discharge/28/30 days, and survival/survival with a favourable neurological outcome after hospital discharge/28/30 days (e.g. 90 days, 180 days, 1 year). The final outcomes used depended on the available data. The ILCOR ALS Task Force ranked outcomes a priori with survival and longer-term neurological outcomes ranked as critical.\n\n【3】These members are selected with attention to diversity in international geographical representation, age, and gender. Before publication, the ILCOR draft COSTR was made available for public comment on the ILCOR website.\n\n【4】The present guideline panel included academic critical care clinicians, content experts, methodologists, and one allied healthcare professional who conducted primary research on the topic. A patient representative was also consulted and provided advice.", "tags": {}, "lang": "en", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/成人心脏骤停后的体温控制指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/07 09:39:26", "endTime": "2024/08/07 09:44:41", "cost": 314.309}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 17:44:38", "grab_time": "2024-08-06 17:39:23"}
{"id": 2211743, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "b8b96c8f-d2c7-430f-8965-a0d259a6e757", "title": "2024+共识指南：儿童和青少年垂体腺瘤的诊断和管理—第2部分：特定疾病(1)", "text": "【0】页码:3\n2024+共识指南：儿童和青少年垂体腺瘤的诊断和管理—第2部分：特定疾病(1)\n# Consensus statement\n\n【1】In adult patients with stalk effect, prolactin levels are reported above the normal range but not higher than 2,000 mIU/l, 94 μg/l (ref. 19) or six times above the upper limit of normal. Even if no corresponding symptoms of hyperprolactinaemia, hypopituitarism or pituitary mass are observed, pituitary imaging should be considered. If hyperprolactinaemia is due to pituitary mass, baseline dynamic pituitary assessment can identify a potential lack or excess of other anterior pituitary hormones.\n\n【2】Severe primary hypothyroidism can be accompanied by hyperprolactinaemia, probably due to compensatory thyrotropin-releasing hormone hypersecretion and pituitary hyperplasia; care should be taken to distinguish such pituitary enlargement from a true prolactinoma. Severe and prolonged primary hypothyroidism in children can disrupt kidney and liver function as well as delay growth and puberty. In a large cohort of 2,848 adults, hyperprolactinaemia was reported in 43% of women and 40% of men presenting with primary hypothyroidism, in 36% of women and 32% of men with subclinical hypothyroidism, and only in around 2% of euthyroid individuals. Hyperprolactinaemia is reported in 30–65% of adult patients with chronic kidney disease due to increased prolactin secretion and reduced renal clearance. Severe liver disease is also associated with hyperprolactinaemia in adults. Intracranial hypotension can cause hyperprolactinaemia. Although we could find no parallel data describing the prevalence of hyperprolactinaemia in these clinical scenarios in CYP, the Guideline Development Group (GDG) recommends the exclusion of confounding diseases. Up to 80% of acromegalic patients have hyperprolactinaemia, and some of its clinical manifestations, including dopamine can lower prolactin concentrations (10–30 fold elevation of prolactin), usually from the teenage years to completion of linear growth but have been described in case reports. While less likely in the CYP population, pregnancy should not be overlooked as a cause of hyperprolactinaemia.\n\n【3】Medications are one of the most common causes of hyperprolactinaemia in adults through direct prolactin stimulatory pathways or by antagonizing inhibitory dopaminergic tone. Medication-induced hyperprolactinaemia is also well described in CYP 删除9:<u>(Supplementary Table 3)</u>. The role of surgical oral oestrogens (for example, contraceptive pills) in causing mild elevation of prolactin is controversial.\n\n【4】删除32:<u>**</u>Part 2: R5. Assess baseline macroprolactin levels where serum prolactin is found to be mildly or incidentally elevated删除32:<u>**</u> (strong recommendation, low-quality evidence, GDG consensus).\n\n【5】In addition to monomeric prolactin (23 kDa), dimeric (48–56 kDa) and polymeric (>100 kDa) forms (usually associated with an antibody) can circulate ('macroprolactin', which has low biological activity), with or without excess monomeric prolactin. No routine assays distinguish between monomeric prolactin and macroprolactin; therefore, prompt and appropriate secondary analysis should be undertaken to detect the possible presence of macroprolactin in the initial investigation of asymptomatic CYP with hyperprolactinaemia. In large retrospective cohorts of adults with hyperprolactinaemia, macroprolactinaemia was present in 10–40% of individuals with hyperprolactinaemia, 20% of whom had galactorrhoea, 45% oligo-amenorrhoea and 20% pituitary adenomas. Few patients with macroprolactinaemia are reported in the paediatric literature. A cohort of five patients aged 11–18 years with an incidental finding of hyperprolactinaemia due to macroprolactinaemia, none developed clinical features of prolactin excess during an observation period ranging from 3 months to 8 years. In another report, one in six CYP with macroprolactinaemia was asymptomatic; the other five had either headache, menstrual disturbance, short stature, increased hair growth or early puberty. Four of those with symptoms underwent pituitary MRI and a microadenoma was identified in two (one with headache and one with oligomenorrhoea). Given these data and the current widespread clinical practice, the GDG strengthened R5.\n\n【6】删除32:<u>**</u>Part 2: R6. Perform serial dilutions of serum for prolactin measurement in CYP with large pituitary lesions and normal or mildly elevated prolactin levels删除32:<u>**</u> (strong recommendation, moderate-quality evidence).\n\n【7】Serum prolactin levels directly correlate with prolactinoma size and are important markers of treatment response. Based on adult data, approximately 5% of patients with macroprolactinomas and a paradoxically modest serum concentration of hyperprolactinaemia have grossly elevated prolactin concentrations following serum dilution. When prolactin is measured in two-site immunoradiometric assays, very high concentrations of prolactin could saturate the signalling antibody, making it less available for binding to the coupling antibody, resulting in artificially low measurements. This phenomenon has been described as the 'high-dose hook effect' and is well recognized. Some prolactin assay manufacturers have put specific mitigating factors in place, such as large linear ranges or automatic dilution steps, in many modern assays. However, the potential remains for this effect to be a source of a measured prolactin 'post-hook'. Thus, contact with the clinical chemistry laboratory when a result is discordant with the clinical picture, especially in patients with large pituitary lesions who have poorly elevated prolactin concentrations at initial biochemistry. Of note, inconsistent symptoms and laboratory results can occasionally be due to infection exposure or heterophilic anti-animal antibodies.\n\n【8】删除32:<u>**</u>Part 2: R7. In CYP with prolactinoma, offer a dopamine agonist as first-line therapy to reduce serum prolactin concentrations and induce tumour shrinkage; cabergoline is the dopamine agonist of choice given its higher clinical efficacy and low side-effect profile删除32:<u>**</u> (strong recommendation, moderate-quality evidence).\n\n【9】删除32:<u>**</u>Part 2: R8. In CYP with prolactinoma, offer cabergoline as the first-line therapy, even in the presence of visual disturbance and pituitary apoplexy, while carefully monitoring for any deterioration in vision, pituitary function or general status删除32:<u>**</u> (strong recommendation, low-quality evidence, Delphi 100%).\n\n【10】Dopamine agonists reduce pituitary-origin hyperprolactinaemia in any cause. In adults with prolactinoma, dopamine agonists induce normalization of the prolactin level (median: 68% of patients; range: 40–100%), tumour shrinkage (62%: 20–100%), resolution of visual field defects (67%: 33–100%), normalization of menses (78%; 40–100%), fertility (53%; 10–100%) and sexual function (67%; 20–100%); and reduction of galactorrhoea (86%; 33–100%). In both adults and CYP with prolactinoma, cabergoline is the dopamine agonist of choice. Cabergoline has a longer half-life and greater affinity for the dopamine receptor than other dopamine agonists. In a randomized controlled trial of adult women with prolactinoma, cabergoline was superior to bromocriptine in normalizing prolactin (83% versus 59%), resuming ovulatory cycles or achieving pregnancy. Adverse events were more commonly reported with bromocriptine than with cabergoline (72% versus 52%).\n\n【11】In studies of CYP with prolactinomas, dopamine agonists lower prolactin concentrations in 60–70% of patients, reduce tumour", "tags": {}, "lang": "en", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024+共识指南：儿童和青少年垂体腺瘤的诊断和管理—第2部分：特定疾病(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:52:05", "endTime": "2024/08/06 15:52:33", "cost": 28.207}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-05 23:52:34", "grab_time": "2024-08-05 23:52:05"}
{"id": 2211742, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "1d24a7b2-afc0-45b5-8dca-b01fb1fca61d", "title": "2023 ESC-HFA临床共识声明：慢性心力衰竭恶化定义、流行病学、管理和预防", "text": "【0】页码:8\n2023 ESC-HFA临床共识声明：慢性心力衰竭恶化定义、流行病学、管理和预防\n(本页删除)本页被模型判断为参考页## Table 3 Pathophysiological mechanisms, outcome and clinical utility of several biomarkers in patients with worsening heart failure\n\n| Biomarker | Pathophysiological mechanisms | Clinical utility | Outcome | Ref. |\n|-----------|---------------------------------|------------------|---------|------|\n| NPs       | Reflect haemodynamic stress and myocardial stretch. | Only for the diagnosis of AHF, based on NT-proBNP or BNP plasma concentrations:<br>- HF unlikely in the absence of significant elevation<br>- Supported as useful prognostic biomarkers<br>- ST2 and BNP/NT-proBNP provide complementary prognostic information in chronic HF<br>- Strong HF: Independent prognostic markers<br>- Prognostic assessment | Associated with symptomatic congestion. Reflects the patient's heart failure status at several levels: congestion, cardiac and renal function, systemic volume status and possibly other factors | 4.614.645/6.297.178 |\n| cTn       | Released to myocardial cell injury | Prognostic assessment in chronic HF, may help to guide the definition of HF treatment beyond the definition of HF | 7-17% |\n| CA-125    | Indirect marker of volume overload and congestion | Associated with systemic congestion<br>Prognostic assessment in HFpEF (indirect evidence)<br>Can be modulated by several conditions beyond fluid overload (e.g. pericardial disease, ovarian cancer, other causes of inflammation/infection) | 7b |\n| Bio-ADM   | Associated with the regulation of microcirculatory tone and endothelial function, may modulate retention of water and salt | Prognostic assessment | 4.774.889 |\n| ST2, GDF-15, galectin-3 | Released by the cardiovascular system in response to inflammatory cytokines and stress of myocardial tissue | Prognostic assessment | 76 |\n| Renal markers (e.g. GFR, NGAL, miRNA, cystatin-C) | Kidney function as major comorbidity and determinant of medical therapy | Prognostic assessment | 61 |\n| Albuminuria | Diagnostic of HF and renal outcomes | Differential diagnosis of HF (e.g. pneumonia) and differential diagnosis of other conditions related to WRF | 47 |\n| Procalcitonin | Reflects the severity of infection/sepsis and poorer outcomes | Differential diagnosis of HF (e.g. pneumonia) and differential diagnosis of other conditions related to WRF | 41 |", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ESC-HFA临床共识声明：慢性心力衰竭恶化定义、流行病学、管理和预防.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "(本页删除)本页被模型判断为参考页", "content": "【0】页码:8\n2023 ESC-HFA临床共识声明：慢性心力衰竭恶化定义、流行病学、管理和预防\n(本页删除)本页被模型判断为参考页## Table 3 Pathophysiological mechanisms, outcome and clinical utility of several biomarkers in patients with worsening heart failure\n\n| Biomarker | Pathophysiological mechanisms | Clinical utility | Outcome | Ref. |\n|-----------|---------------------------------|------------------|---------|------|\n| NPs       | Reflect haemodynamic stress and myocardial stretch. | Only for the diagnosis of AHF, based on NT-proBNP or BNP plasma concentrations:<br>- HF unlikely in the absence of significant elevation<br>- Supported as useful prognostic biomarkers<br>- ST2 and BNP/NT-proBNP provide complementary prognostic information in chronic HF<br>- Strong HF: Independent prognostic markers<br>- Prognostic assessment | Associated with symptomatic congestion. Reflects the patient's heart failure status at several levels: congestion, cardiac and renal function, systemic volume status and possibly other factors | 4.614.645/6.297.178 |\n| cTn       | Released to myocardial cell injury | Prognostic assessment in chronic HF, may help to guide the definition of HF treatment beyond the definition of HF | 7-17% |\n| CA-125    | Indirect marker of volume overload and congestion | Associated with systemic congestion<br>Prognostic assessment in HFpEF (indirect evidence)<br>Can be modulated by several conditions beyond fluid overload (e.g. pericardial disease, ovarian cancer, other causes of inflammation/infection) | 7b |\n| Bio-ADM   | Associated with the regulation of microcirculatory tone and endothelial function, may modulate retention of water and salt | Prognostic assessment | 4.774.889 |\n| ST2, GDF-15, galectin-3 | Released by the cardiovascular system in response to inflammatory cytokines and stress of myocardial tissue | Prognostic assessment | 76 |\n| Renal markers (e.g. GFR, NGAL, miRNA, cystatin-C) | Kidney function as major comorbidity and determinant of medical therapy | Prognostic assessment | 61 |\n| Albuminuria | Diagnostic of HF and renal outcomes | Differential diagnosis of HF (e.g. pneumonia) and differential diagnosis of other conditions related to WRF | 47 |\n| Procalcitonin | Reflects the severity of infection/sepsis and poorer outcomes | Differential diagnosis of HF (e.g. pneumonia) and differential diagnosis of other conditions related to WRF | 41 |", "index": 49, "show": true, "start": 49, "end": 66, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": " Table 3 Pathophysiological mechanisms, outcome and clinical utility of several biomarkers in patients with worsening heart failure", "content": "【0】页码:8\n2023 ESC-HFA临床共识声明：慢性心力衰竭恶化定义、流行病学、管理和预防\n<mark>(本页删除)本页被模型判断为参考页</mark>## Table 3 Pathophysiological mechanisms, outcome and clinical utility of several biomarkers in patients with worsening heart failure\n\n| Biomarker | Pathophysiological mechanisms | Clinical utility | Outcome | Ref. |\n|-----------|---------------------------------|------------------|---------|------|\n| NPs       | Reflect haemodynamic stress and myocardial stretch. | Only for the diagnosis of AHF, based on NT-proBNP or BNP plasma concentrations:<br>- HF unlikely in the absence of significant elevation<br>- Supported as useful prognostic biomarkers<br>- ST2 and BNP/NT-proBNP provide complementary prognostic information in chronic HF<br>- Strong HF: Independent prognostic markers<br>- Prognostic assessment | Associated with symptomatic congestion. Reflects the patient's heart failure status at several levels: congestion, cardiac and renal function, systemic volume status and possibly other factors | 4.614.645/6.297.178 |\n| cTn       | Released to myocardial cell injury | Prognostic assessment in chronic HF, may help to guide the definition of HF treatment beyond the definition of HF | 7-17% |\n| CA-125    | Indirect marker of volume overload and congestion | Associated with systemic congestion<br>Prognostic assessment in HFpEF (indirect evidence)<br>Can be modulated by several conditions beyond fluid overload (e.g. pericardial disease, ovarian cancer, other causes of inflammation/infection) | 7b |\n| Bio-ADM   | Associated with the regulation of microcirculatory tone and endothelial function, may modulate retention of water and salt | Prognostic assessment | 4.774.889 |\n| ST2, GDF-15, galectin-3 | Released by the cardiovascular system in response to inflammatory cytokines and stress of myocardial tissue | Prognostic assessment | 76 |\n| Renal markers (e.g. GFR, NGAL, miRNA, cystatin-C) | Kidney function as major comorbidity and determinant of medical therapy | Prognostic assessment | 61 |\n| Albuminuria | Diagnostic of HF and renal outcomes | Differential diagnosis of HF (e.g. pneumonia) and differential diagnosis of other conditions related to WRF | 47 |\n| Procalcitonin | Reflects the severity of infection/sepsis and poorer outcomes | Differential diagnosis of HF (e.g. pneumonia) and differential diagnosis of other conditions related to WRF | 41 |", "index": 81, "show": true, "start": 68, "end": 199, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "0"}], "startTime": "2024/08/06 17:22:08", "endTime": "2024/08/06 17:25:15", "cost": 186.609}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 01:25:15", "grab_time": "2024-08-06 01:22:08"}
{"id": 2211741, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "bff2b8e3-8f45-477b-882a-a8a8f68e2569", "title": "2023 ESC_HFSA_JHFS科学声明：利钠肽在心力衰竭诊断和治疗中的作用", "text": "【0】页码:10\n2023 ESC_HFSA_JHFS科学声明：利钠肽在心力衰竭诊断和治疗中的作用\nrelated to hypotension). Additional medication considerations include whether or not a bolus is needed, what the optimal dosing amount is and what is the duration of therapy, as well as whether or not follow-up infusions are needed. Thus, ASCEND-HF and TRUE-AHF provide important insights regarding the therapeutic use of natriuretic peptides as well as insights relevant to future trial design and execution.\n\n【1】ANP has vasodilatory and natriuretic effects and inhibits the RAA system.删除17:<u>74-76</u> In Japan, recombinant human ANP, carperitide, has been used for the treatment of acute HF since 1995. It has been reported to improve the outcomes in patients with acute HF77 and to decrease congestion in patients with systolic blood pressure of 120 mmHg or higher.删除17:<u>78</u> However, in a recent report using the Japanese registry database, authors demonstrated that carperitide was related to worse outcomes when compared to nitrates.删除17:<u>79</u> In contrast, the consortium for pooled data analysis regarding hospitalized patients with HF in Japan, the COOPERATE-HF-J (Consortium for Pooled Data Analysis regarding Hospitalized Patients with Heart Failure in Japan) study, revealed that carperitide improved the prognosis of patients with acute HF.删除17:<u>80</u> These study findings suggest that blood pressure and renal function may influence the efficacy of carperitide.删除17:<u>81</u> To clarify the prognostic impact of carperitide in HF, large, well-designed clinical trials, especially focusing on its dosage, are definitely needed.\n\n【2】### ARNIs\n\n【3】The main and unique effect of ARNIs, compared with angiotensin converting enzyme inhibitors (ACEIs) inhibitors or angiotensin receptor blockers (ARBs), is neprilysin inhibition, a mechanism blocking the degradation of natriuretic peptides as well as other multiple peptides that have vasodilatory, natriuretic, antifibrotic, and antihypertrophic effects.删除17:<u>82</u> Neprilysin inhibitor effects lead to an improvement in cardiac function and reduced myocardial stress so that the synthesis of pronatriuretic peptides such as pro-brain natriuretic peptide (proBNP) is decreased . Plasma levels of the NT-proBNP depend on proBNP production and are, therefore, markers of myocardial stress and function; hence, they are also markers of HF severity when patients are treated with ARNIs.\n\n【4】Plasma NT-proBNP levels were reduced by approximately 30% from baseline after treatment with ARNIs in randomized trials where ARNIs were compared with ACEIs or ARBs in patients with either chronic HFrEF or those stabilized after an episode of acute HF or with HFpEF.删除17:<u>55,81-85</u> Interestingly, in the LIFE (LCZ696 in Advanced HF) trial, authors did not show a difference in changes from baseline in NT-proBNP plasma levels in patients randomized to ARNIs, compared to those on valsartan, and outcomes were similar in those taking the 2 drugs.删除17:<u>86</u>\n\n【5】The effects of ARNIs on plasma BNP levels may be more variable because neprilysin inhibition also blocks BNP degradation. Thus, plasma BNP levels are the result of 2 opposing mechanisms after ARNIs: improved myocardial function, which would decrease them, and neprilysin inhibition, which would increase them . Plasma BNP levels were slightly increased after ARNIs, compared with enalapril, in the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality in Heart Failure) trial.删除17:<u>45,85</u> A pooled analysis of the PROVE-HF (Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for HF) trials showed no significant change from baseline in BNP plasma levels, despite a 30%-34% decrease in NT-proBNP plasma levels, after ARNIs. BNP levels also remained correlated with NT-proBNP levels in this study.删除17:<u>87</u>\n\n【6】删除图片描述:<u>### ![Figure 6 Mechanism of action of sacubitril, a neprilysin inhibitor. Sacubitrilat is the active metabolite of sacubitril. BNP, brain natriuretic peptide; cGMP, cyclic guanosine monophosphate.]</u>", "tags": {}, "lang": "en", "attr": {"page_num": 10, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ESC_HFSA_JHFS科学声明：利钠肽在心力衰竭诊断和治疗中的作用.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:52:14", "endTime": "2024/08/06 16:53:00", "cost": 45.93}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:53:00", "grab_time": "2024-08-06 00:52:14"}
{"id": 2211740, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "cc64652e-64c8-4a9e-a8f3-149f52689ee1", "title": "2023 IWGDF实践指南：糖尿病相关足病的预防和管理（更新版）", "text": "【0】页码:17\n2023 IWGDF实践指南：糖尿病相关足病的预防和管理（更新版）\n疑似页眉<u># IWGDF Practical Guidelines</u>\n\n【1】The following treatments are not well-supported for routine ulcer management:\n\n【2】- Biologically active products (collagen, growth factors, bio-engineered tissue) in neuropathic ulcers;\n- Topical antiseptics and antimicrobial dressings or applications.\n\n【3】## 4.2.4 Person-centred care\n\n【4】In addition to the aforementioned recommendations, the person-related factors as assessed in section 4.1.3 should also be treated where possible. This includes:\n\n【5】- Optimise glycaemic control, if necessary, with insulin.\n- Treat oedema or malnutrition, if present.\n- Treat cardiovascular risk factors.\n- Treat depression or other psycho-social difficulties.\n\n【6】删除图片描述:<u>![](16_0.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 17, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 IWGDF实践指南：糖尿病相关足病的预防和管理（更新版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】- Biologically active products (collagen, growth factors, bio-engineered tissue) in neuropathic ulcers;\n\nTopical antiseptics and antimicrobial dressings or applications.", "content": "【0】页码:17\n2023 IWGDF实践指南：糖尿病相关足病的预防和管理（更新版）\n疑似页眉<u># IWGDF Practical Guidelines</u>\n\n【1】The following treatments are not well-supported for routine ulcer management:\n\n【2】- Biologically active products (collagen, growth factors, bio-engineered tissue) in neuropathic ulcers;\n- Topical antiseptics and antimicrobial dressings or applications.\n\n【3】## 4.2.4 Person-centred care\n\n【4】In addition to the aforementioned recommendations, the person-related factors as assessed in section 4.1.3 should also be treated where possible. This includes:\n\n【5】- Optimise glycaemic control, if necessary, with insulin.\n- Treat oedema or malnutrition, if present.\n- Treat cardiovascular risk factors.\n- Treat depression or other psycho-social difficulties.\n\n【6】删除图片描述:<u>![](16_0.png)</u>", "index": 166, "show": true, "start": 166, "end": 338, "province": ["格式规范性", "序号格式不一致"], "isEdit": false}, {"text": "【5】- Optimise glycaemic control, if necessary, with insulin.\n\nTreat oedema or malnutrition, if present.\nTreat cardiovascular risk factors.\nTreat depression or other psycho-social difficulties.", "content": "【0】页码:17\n2023 IWGDF实践指南：糖尿病相关足病的预防和管理（更新版）\n疑似页眉<u># IWGDF Practical Guidelines</u>\n\n【1】The following treatments are not well-supported for routine ulcer management:\n\n<mark>【2】- Biologically active products (collagen, growth factors, bio-engineered tissue) in neuropathic ulcers;\n\nTopical antiseptics and antimicrobial dressings or applications.</mark>.\n\n【3】## 4.2.4 Person-centred care\n\n【4】In addition to the aforementioned recommendations, the person-related factors as assessed in section 4.1.3 should also be treated where possible. This includes:\n\n【5】- Optimise glycaemic control, if necessary, with insulin.\n- Treat oedema or malnutrition, if present.\n- Treat cardiovascular risk factors.\n- Treat depression or other psycho-social difficulties.\n\n【6】删除图片描述:<u>![](16_0.png)</u>", "index": 552, "show": true, "start": 539, "end": 731, "province": ["格式规范性", "序号格式不一致"], "isEdit": false}], "startTime": "2024/08/06 16:35:41", "endTime": "2024/08/06 16:36:20", "cost": 38.546}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:36:20", "grab_time": "2024-08-06 00:35:41"}
{"id": 2211739, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "e486a361-e9a9-48bf-bbcc-99fa54d23078", "title": "2023 EAES共识：吲哚箐绿（ICG）荧光引导手术", "text": "【0】页码:2\n2023 EAES共识：吲哚箐绿（ICG）荧光引导手术\n其临床应用已得到充分验证，因其成本相对较低且极少报告过敏反应，目前ICG(NAA)是外科临床中使用最广泛的荧光染料。随着相关技术的发展，多种近红外成像系统已经开发出来，采用激光光束或LED光源，既可用于腹腔镜手术，也可用于机器人手术，预计未来将会有更多系统被开发和引入。此外，ICG荧光成像也被证明具有学习曲线短的优点，不需要复杂的设备，并且不会干扰手术流程。\n\n【1】自近红外荧光成像问世以来，它是外科领域近年来发展最快的新兴技术之一，诸如在腹腔镜胆囊切除术中的荧光胆管造影，淋巴结成像和Mapping在肿瘤外科中的应用，以及肠吻合术后灌注评估等，其应用急剧增加。\n\n【2】近年来，关于ICG-FGS的研究数量也迅速增加，建议这一技术安全、可行，并能给外科医生提供一些简便直观的指导，从而提高外科手术的成功率。一些关于该技术的临床应用和技术细节的内容，如浓度、ICG给药和使用问题也有详细探讨。此外，是否应该将荧光引导手术作为某些手术应用的护理标准，仍是一个争议问题。\n\n【3】由于上述原因，欧洲内镜外科协会(EAES)赞助了这一共识发展会议，旨在基于现有可用数据对腹部手术中荧光成像的应用进行严格审查。该项目的目标是根据现有证据，为外科社区提供关于ICG荧光引导手术的共识声明和推荐意见。\n\n【4】### Materials and methods\n\n【5】此共识关于ICG荧光引导手术的目标是提供基于证据的建议，将ICG荧光与标准视觉在不同临床设定中的应用进行对比。该项目的范围包括三个主要部分：(i)一般主题，(ii)特定器官主题和(iii)正在进行的试验。在这些主题中，定义了子分类。\n\n【6】- `General topics` 包括 (a) 认知负担, (b) 成本和成本效益性。\n\n【7】- `Organ specific topics` 包括 (a) 胆囊切除术, (b) 结肠直肠手术中的灌注评估, (c) 结肠直肠外科的淋巴结造影, (d) 减肥手术, (e) 脾和肾上腺手术, (f) 胰腺手术, (g) 肝脏手术, (h) 上胃肠道手术中的灌注评估, (i) 泌尿科和 (j) 妇科。\n\n【8】### Research team and search strategy\n\n【9】一个由外科医生组成的小组作为协调团队(EC, AA, LB和NV)，他们形成了一系列问题，以解决荧光引导手术的具体主题(表 1)。他们协调了12名专家成员，由EAES研究和技术委员会组成的专家组加入。每个专家组均须提名一名青年外科研究员参与。\n\n【10】由12名年轻外科研究员组成的国际研究团队评估现有文献，每名研究者由一位经验丰富的外科医生指导。最终的一系列主题由专家讨论并在团队间一致同意。\n\n【11】搜索包含术语由米兰大学的图书管理员提供。相关搜索策略在补充材料中给出。\n\n【12】纳入排除标准如下：仅包括随机对照试验(RCTs)，前瞻性和回顾性观察性比较研究。排除了病例报告和非对照研究，以及12岁以下儿童及非英文出版的研究。\n\n【13】所有搜索结果根据主题进行筛选，两位团队成员对标题和摘要进行评估。如果符合条件则进行全文审查和总结，如果有分歧，由协调者进行裁定并作出最终决定。\n\n【14】### Data extraction and appraisal of the methodological quality of the studies\n\n【15】对所有主题使用统一的数据提取表格。为每位参与者提供了进入Excel数据库模板的重要指导。相对于标准护理，重要结果包括但不限于ICG荧光引导手术的特异性评估和分析。", "tags": {}, "lang": "zh", "attr": {"page_num": 2, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 EAES共识：吲哚箐绿（ICG）荧光引导手术.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:2\n\n2023 EAES共识：吲哚箐绿（ICG）荧光引导手术\n\n其临床应用已得到充分验证，因其成本相对较低且极少报告过敏反应，目前ICG(NAA)是外科临床中使用最广泛的荧光染料。随着相关技术的发展，多种近红外成像系统已经开发出来，采用激光光束或LED光源，既可用于腹腔镜手术，也可用于机器人手术，预计未来将会有更多系统被开发和引入。此外，ICG荧光成像也被证明具有学习曲线短的优点，不需要复杂的设备，并且不会干扰手术流程。\n\n【1】自近红外荧光成像问世以来，它是外科领域近年来发展最快的新兴技术之一，诸如在腹腔镜胆囊切除术中的荧光胆管造影，淋巴结成像和Mapping在肿瘤外科中的应用，以及肠吻合术后灌注评估等，其应用急剧增加。\n\n【2】近年来，关于ICG-FGS的研究数量也迅速增加，建议这一技术安全、可行，并能给外科医生提供一些简便直观的指导，从而提高外科手术的成功率。一些关于该技术的临床应用和技术细节的内容，如浓度、ICG给药和使用问题也有详细探讨。此外，是否应该将荧光引导手术作为某些手术应用的护理标准，仍是一个争议问题。\n\n【3】由于上述原因，欧洲内镜外科协会(EAES)赞助了这一共识发展会议，旨在基于现有可用数据对腹部手术中荧光成像的应用进行严格审查。该项目的目标是根据现有证据，为外科社区提供关于ICG荧光引导手术的共识声明和推荐意见。\n\n【4】### Materials and methods\n\n【5】此共识关于ICG荧光引导手术的目标是提供基于证据的建议，将ICG荧光与标准视觉在不同临床设定中的应用进行对比。该项目的范围包括三个主要部分：(i)一般主题，(ii)特定器官主题和(iii)正在进行的试验。在这些主题中，定义了子分类。\n\n【6】- General topics 包括 (a) 认知负担, (b) 成本和成本效益性。\n\n【7】- Organ specific topics 包括 (a) 胆囊切除术, (b) 结肠直肠手术中的灌注评估, © 结肠直肠外科的淋巴结造影, (d) 减肥手术, (e) 脾和肾上腺手术, (f) 胰腺手术, (g) 肝脏手术, (h) 上胃肠道手术中的灌注评估, (i) 泌尿科和 (j) 妇科。\n\n【8】### Research team and search strategy\n\n【9】一个由外科医生组成的小组作为协调团队(EC, AA, LB和NV)，他们形成了一系列问题，以解决荧光引导手术的具体主题(表 1)。他们协调了12名专家成员，由EAES研究和技术委员会组成的专家组加入。每个专家组均须提名一名青年外科研究员参与。\n\n【10】由12名年轻外科研究员组成的国际研究团队评估现有文献，每名研究者由一位经验丰富的外科医生指导。最终的一系列主题由专家讨论并在团队间一致同意。\n\n【11】搜索包含术语由米兰大学的图书管理员提供。相关搜索策略在补充材料中给出。\n\n【12】纳入排除标准如下：仅包括随机对照试验(RCTs)，前瞻性和回顾性观察性比较研究。排除了病例报告和非对照研究，以及12岁以下儿童及非英文出版的研究。\n\n【13】所有搜索结果根据主题进行筛选，两位团队成员对标题和摘要进行评估。如果符合条件则进行全文审查和总结，如果有分歧，由协调者进行裁定并作出最终决定。\n\n【14】### Data extraction and appraisal of the methodological quality of the studies\n\n【15】对所有主题使用统一的数据提取表格。为每位参与者提供了进入Excel数据库模板的重要指导。相对于标准护理，重要结果包括但不限于ICG荧光引导手术的特异性评估和分析。", "content": "【0】页码:2\n2023 EAES共识：吲哚箐绿（ICG）荧光引导手术\n其临床应用已得到充分验证，因其成本相对较低且极少报告过敏反应，目前ICG(NAA)是外科临床中使用最广泛的荧光染料。随着相关技术的发展，多种近红外成像系统已经开发出来，采用激光光束或LED光源，既可用于腹腔镜手术，也可用于机器人手术，预计未来将会有更多系统被开发和引入。此外，ICG荧光成像也被证明具有学习曲线短的优点，不需要复杂的设备，并且不会干扰手术流程。\n\n【1】自近红外荧光成像问世以来，它是外科领域近年来发展最快的新兴技术之一，诸如在腹腔镜胆囊切除术中的荧光胆管造影，淋巴结成像和Mapping在肿瘤外科中的应用，以及肠吻合术后灌注评估等，其应用急剧增加。\n\n【2】近年来，关于ICG-FGS的研究数量也迅速增加，建议这一技术安全、可行，并能给外科医生提供一些简便直观的指导，从而提高外科手术的成功率。一些关于该技术的临床应用和技术细节的内容，如浓度、ICG给药和使用问题也有详细探讨。此外，是否应该将荧光引导手术作为某些手术应用的护理标准，仍是一个争议问题。\n\n【3】由于上述原因，欧洲内镜外科协会(EAES)赞助了这一共识发展会议，旨在基于现有可用数据对腹部手术中荧光成像的应用进行严格审查。该项目的目标是根据现有证据，为外科社区提供关于ICG荧光引导手术的共识声明和推荐意见。\n\n【4】### Materials and methods\n\n【5】此共识关于ICG荧光引导手术的目标是提供基于证据的建议，将ICG荧光与标准视觉在不同临床设定中的应用进行对比。该项目的范围包括三个主要部分：(i)一般主题，(ii)特定器官主题和(iii)正在进行的试验。在这些主题中，定义了子分类。\n\n【6】- `General topics` 包括 (a) 认知负担, (b) 成本和成本效益性。\n\n【7】- `Organ specific topics` 包括 (a) 胆囊切除术, (b) 结肠直肠手术中的灌注评估, (c) 结肠直肠外科的淋巴结造影, (d) 减肥手术, (e) 脾和肾上腺手术, (f) 胰腺手术, (g) 肝脏手术, (h) 上胃肠道手术中的灌注评估, (i) 泌尿科和 (j) 妇科。\n\n【8】### Research team and search strategy\n\n【9】一个由外科医生组成的小组作为协调团队(EC, AA, LB和NV)，他们形成了一系列问题，以解决荧光引导手术的具体主题(表 1)。他们协调了12名专家成员，由EAES研究和技术委员会组成的专家组加入。每个专家组均须提名一名青年外科研究员参与。\n\n【10】由12名年轻外科研究员组成的国际研究团队评估现有文献，每名研究者由一位经验丰富的外科医生指导。最终的一系列主题由专家讨论并在团队间一致同意。\n\n【11】搜索包含术语由米兰大学的图书管理员提供。相关搜索策略在补充材料中给出。\n\n【12】纳入排除标准如下：仅包括随机对照试验(RCTs)，前瞻性和回顾性观察性比较研究。排除了病例报告和非对照研究，以及12岁以下儿童及非英文出版的研究。\n\n【13】所有搜索结果根据主题进行筛选，两位团队成员对标题和摘要进行评估。如果符合条件则进行全文审查和总结，如果有分歧，由协调者进行裁定并作出最终决定。\n\n【14】### Data extraction and appraisal of the methodological quality of the studies\n\n【15】对所有主题使用统一的数据提取表格。为每位参与者提供了进入Excel数据库模板的重要指导。相对于标准护理，重要结果包括但不限于ICG荧光引导手术的特异性评估和分析。", "index": 0, "show": true, "start": 0, "end": 1549, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "原文为英文"}], "startTime": "2024/08/07 09:46:44", "endTime": "2024/08/07 09:47:07", "cost": 22.538}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 17:47:06", "grab_time": "2024-08-06 17:46:42"}
{"id": 2211738, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "8a80470c-97ed-4bf8-8c21-98f7b0118dd2", "title": "2023 国际共识声明：代谢功能障碍相关的脂肪肝与慢性肾脏疾病的风险", "text": "【0】页码:5\n2023 国际共识声明：代谢功能障碍相关的脂肪肝与慢性肾脏疾病的风险\n疑似页眉<u># HepatoBiliary Surgery and Nutrition, 2023</u>\n\n【1】## Table 1 Demographic composition of the expert panel\n\n| Characteristic                  | Round 1 | Round 2 |\n|---------------------------------|---------|---------|\n| Surveys sent, n                 | 60      | 50      |\n| Total respondents, n (%)        | 50/60 删除11:<u>(83.3)</u> | 50/50 删除11:<u>(100.0)</u> |\n| Participant type, %             |         |         |\n| Researcher                      | 6       | 6       |\n| Nephrologist                    | 20      | 20      |\n| Gastroenterologist/hepatologist | 62      | 62      |\n| Endocrinologist/diabetologist   | 10      | 10      |\n| Methodologist                   | 2       | 2       |\n| Age (years), %                  |         |         |\n| <40                             | 12      | 12      |\n| 40–65                           | 84      | 84      |\n| >65                             | 4       | 4       |\n| Gender, %                       |         |         |\n| Women                           | 12      | 12      |\n| Men                             | 88      | 88      |\n| Region of practice, %           |         |         |\n| Asia                            | 48      | 48      |\n| North America                   | 8       | 8       |\n| South America                   | 2       | 2       |\n| Europe                          | 32      | 32      |\n| Africa                          | 6       | 6       |\n| Oceania                         | 4       | 4       |\n\n【3】used in other published Delphi studies, in which ‘U’ denotes unanimous (100%) agreement, ‘A’ 90–99% agreement, ‘B’ 78–89% agreement, and ‘C’ 67–77% agreement 删除11:<u>(3,32)</u>. A preliminary consensus draft on these recommendations from the expert panel was sought over a 1-week period via a shared Google document. Any disagreements were resolved through discussion until consensus was reached.\n\n【4】## Recruitment of expert panel members\n\n【5】Members of the international expert panel (n=50) were selected from the representative Continents. To be included, they were active researchers with expertise in the management of fatty liver and/or kidney diseases.\n\n【6】The following criteria were used to select members of the expert panel participating in the Delphi survey:\n(I) To be corresponding authors of published articles on the association between MAFLD or NAFLD and the risk of CKD.\n(II) To be representative members from scientific Societies of Nephrology, Hepatology, Endocrinology/Diabetology, and Obesity.\n(III) To be core members of the NAFLD/MAFLD Consortium and/or the Kidney Disease: Improving Global Outcomes (KDIGO) organization.\n\n【7】Members of the expert panel were expected to meet at least one of the three aforementioned criteria. To achieve global representation, we selected members from six continents, i.e., Asia, Europe, North America, South America, Africa, and Oceania 删除9:<u>(Table 1)</u>.\n\n【8】## Findings\n\n【9】Here, we report the final consensus statements along with a summary of the broader relevant literature. Across the two-based Delphi surveys, there was an increase in consensus for all proposed statements. The mean percentage of “agreement” responses increased from 63.9% to 76.1% and “agreement or somewhat agreement” responses increased from 94.3% in the R1-survey to 97.3% in the R2-survey . In the end, there was unanimous “agreement or some agreement” on 12 consensus statements and >85% agreement on 7/12 statements 删除9:<u>(Table 2)</u>.\n\n【10】## Epidemiology of MAFLD and CKD—statements 1.1–1.6 (Grade U in 1.1 and 1.5; Grade A in 1.2 to 1.4, 1.6)\n\n【11】Studies using the NAFLD definition have estimated a", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 国际共识声明：代谢功能障碍相关的脂肪肝与慢性肾脏疾病的风险.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "疑似页眉# HepatoBiliary Surgery and Nutrition, 2023", "content": "【0】页码:5\n2023 国际共识声明：代谢功能障碍相关的脂肪肝与慢性肾脏疾病的风险\n疑似页眉<u># HepatoBiliary Surgery and Nutrition, 2023</u>\n\n【1】## Table 1 Demographic composition of the expert panel\n\n| Characteristic                  | Round 1 | Round 2 |\n|---------------------------------|---------|---------|\n| Surveys sent, n                 | 60      | 50      |\n| Total respondents, n (%)        | 50/60 删除11:<u>(83.3)</u> | 50/50 删除11:<u>(100.0)</u> |\n| Participant type, %             |         |         |\n| Researcher                      | 6       | 6       |\n| Nephrologist                    | 20      | 20      |\n| Gastroenterologist/hepatologist | 62      | 62      |\n| Endocrinologist/diabetologist   | 10      | 10      |\n| Methodologist                   | 2       | 2       |\n| Age (years), %                  |         |         |\n| <40                             | 12      | 12      |\n| 40–65                           | 84      | 84      |\n| >65                             | 4       | 4       |\n| Gender, %                       |         |         |\n| Women                           | 12      | 12      |\n| Men                             | 88      | 88      |\n| Region of practice, %           |         |         |\n| Asia                            | 48      | 48      |\n| North America                   | 8       | 8       |\n| South America                   | 2       | 2       |\n| Europe                          | 32      | 32      |\n| Africa                          | 6       | 6       |\n| Oceania                         | 4       | 4       |\n\n【3】used in other published Delphi studies, in which ‘U’ denotes unanimous (100%) agreement, ‘A’ 90–99% agreement, ‘B’ 78–89% agreement, and ‘C’ 67–77% agreement 删除11:<u>(3,32)</u>. A preliminary consensus draft on these recommendations from the expert panel was sought over a 1-week period via a shared Google document. Any disagreements were resolved through discussion until consensus was reached.\n\n【4】## Recruitment of expert panel members\n\n【5】Members of the international expert panel (n=50) were selected from the representative Continents. To be included, they were active researchers with expertise in the management of fatty liver and/or kidney diseases.\n\n【6】The following criteria were used to select members of the expert panel participating in the Delphi survey:\n(I) To be corresponding authors of published articles on the association between MAFLD or NAFLD and the risk of CKD.\n(II) To be representative members from scientific Societies of Nephrology, Hepatology, Endocrinology/Diabetology, and Obesity.\n(III) To be core members of the NAFLD/MAFLD Consortium and/or the Kidney Disease: Improving Global Outcomes (KDIGO) organization.\n\n【7】Members of the expert panel were expected to meet at least one of the three aforementioned criteria. To achieve global representation, we selected members from six continents, i.e., Asia, Europe, North America, South America, Africa, and Oceania 删除9:<u>(Table 1)</u>.\n\n【8】## Findings\n\n【9】Here, we report the final consensus statements along with a summary of the broader relevant literature. Across the two-based Delphi surveys, there was an increase in consensus for all proposed statements. The mean percentage of “agreement” responses increased from 63.9% to 76.1% and “agreement or somewhat agreement” responses increased from 94.3% in the R1-survey to 97.3% in the R2-survey . In the end, there was unanimous “agreement or some agreement” on 12 consensus statements and >85% agreement on 7/12 statements 删除9:<u>(Table 2)</u>.\n\n【10】## Epidemiology of MAFLD and CKD—statements 1.1–1.6 (Grade U in 1.1 and 1.5; Grade A in 1.2 to 1.4, 1.6)\n\n【11】Studies using the NAFLD definition have estimated a", "index": 43, "show": true, "start": 43, "end": 90, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "0"}, {"text": " 删除11:(83.3)", "content": "【0】页码:5\n2023 国际共识声明：代谢功能障碍相关的脂肪肝与慢性肾脏疾病的风险\n<mark>疑似页眉# HepatoBiliary Surgery and Nutrition, 2023</mark>023</u>\n\n【1】## Table 1 Demographic composition of the expert panel\n\n| Characteristic                  | Round 1 | Round 2 |\n|---------------------------------|---------|---------|\n| Surveys sent, n                 | 60      | 50      |\n| Total respondents, n (%)        | 50/60 删除11:<u>(83.3)</u> | 50/50 删除11:<u>(100.0)</u> |\n| Participant type, %             |         |         |\n| Researcher                      | 6       | 6       |\n| Nephrologist                    | 20      | 20      |\n| Gastroenterologist/hepatologist | 62      | 62      |\n| Endocrinologist/diabetologist   | 10      | 10      |\n| Methodologist                   | 2       | 2       |\n| Age (years), %                  |         |         |\n| <40                             | 12      | 12      |\n| 40–65                           | 84      | 84      |\n| >65                             | 4       | 4       |\n| Gender, %                       |         |         |\n| Women                           | 12      | 12      |\n| Men                             | 88      | 88      |\n| Region of practice, %           |         |         |\n| Asia                            | 48      | 48      |\n| North America                   | 8       | 8       |\n| South America                   | 2       | 2       |\n| Europe                          | 32      | 32      |\n| Africa                          | 6       | 6       |\n| Oceania                         | 4       | 4       |\n\n【3】used in other published Delphi studies, in which ‘U’ denotes unanimous (100%) agreement, ‘A’ 90–99% agreement, ‘B’ 78–89% agreement, and ‘C’ 67–77% agreement 删除11:<u>(3,32)</u>. A preliminary consensus draft on these recommendations from the expert panel was sought over a 1-week period via a shared Google document. Any disagreements were resolved through discussion until consensus was reached.\n\n【4】## Recruitment of expert panel members\n\n【5】Members of the international expert panel (n=50) were selected from the representative Continents. To be included, they were active researchers with expertise in the management of fatty liver and/or kidney diseases.\n\n【6】The following criteria were used to select members of the expert panel participating in the Delphi survey:\n(I) To be corresponding authors of published articles on the association between MAFLD or NAFLD and the risk of CKD.\n(II) To be representative members from scientific Societies of Nephrology, Hepatology, Endocrinology/Diabetology, and Obesity.\n(III) To be core members of the NAFLD/MAFLD Consortium and/or the Kidney Disease: Improving Global Outcomes (KDIGO) organization.\n\n【7】Members of the expert panel were expected to meet at least one of the three aforementioned criteria. To achieve global representation, we selected members from six continents, i.e., Asia, Europe, North America, South America, Africa, and Oceania 删除9:<u>(Table 1)</u>.\n\n【8】## Findings\n\n【9】Here, we report the final consensus statements along with a summary of the broader relevant literature. Across the two-based Delphi surveys, there was an increase in consensus for all proposed statements. The mean percentage of “agreement” responses increased from 63.9% to 76.1% and “agreement or somewhat agreement” responses increased from 94.3% in the R1-survey to 97.3% in the R2-survey . In the end, there was unanimous “agreement or some agreement” on 12 consensus statements and >85% agreement on 7/12 statements 删除9:<u>(Table 2)</u>.\n\n【10】## Epidemiology of MAFLD and CKD—statements 1.1–1.6 (Grade U in 1.1 and 1.5; Grade A in 1.2 to 1.4, 1.6)\n\n【11】Studies using the NAFLD definition have estimated a", "index": 380, "show": true, "start": 367, "end": 379, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "1"}, {"text": "删除11:(100.0)", "content": "【0】页码:5\n2023 国际共识声明：代谢功能障碍相关的脂肪肝与慢性肾脏疾病的风险\n<mark>疑似页眉# HepatoBiliary Surgery and Nutrition, 2023</mark>023</u>\n\n【1】## Table 1 Demographic composition of the expert panel\n\n| Characteristic                  | Round 1 | Round 2 |\n|---------------------------------|---------|---------|\n| Surveys sent, n                 | 60      | 50      |\n| Total respondents, n (%)        | 50/60<mark> 删除11:(83.3)</mark>.3)</u> | 50/50 删除11:<u>(100.0)</u> |\n| Participant type, %             |         |         |\n| Researcher                      | 6       | 6       |\n| Nephrologist                    | 20      | 20      |\n| Gastroenterologist/hepatologist | 62      | 62      |\n| Endocrinologist/diabetologist   | 10      | 10      |\n| Methodologist                   | 2       | 2       |\n| Age (years), %                  |         |         |\n| <40                             | 12      | 12      |\n| 40–65                           | 84      | 84      |\n| >65                             | 4       | 4       |\n| Gender, %                       |         |         |\n| Women                           | 12      | 12      |\n| Men                             | 88      | 88      |\n| Region of practice, %           |         |         |\n| Asia                            | 48      | 48      |\n| North America                   | 8       | 8       |\n| South America                   | 2       | 2       |\n| Europe                          | 32      | 32      |\n| Africa                          | 6       | 6       |\n| Oceania                         | 4       | 4       |\n\n【3】used in other published Delphi studies, in which ‘U’ denotes unanimous (100%) agreement, ‘A’ 90–99% agreement, ‘B’ 78–89% agreement, and ‘C’ 67–77% agreement 删除11:<u>(3,32)</u>. A preliminary consensus draft on these recommendations from the expert panel was sought over a 1-week period via a shared Google document. Any disagreements were resolved through discussion until consensus was reached.\n\n【4】## Recruitment of expert panel members\n\n【5】Members of the international expert panel (n=50) were selected from the representative Continents. To be included, they were active researchers with expertise in the management of fatty liver and/or kidney diseases.\n\n【6】The following criteria were used to select members of the expert panel participating in the Delphi survey:\n(I) To be corresponding authors of published articles on the association between MAFLD or NAFLD and the risk of CKD.\n(II) To be representative members from scientific Societies of Nephrology, Hepatology, Endocrinology/Diabetology, and Obesity.\n(III) To be core members of the NAFLD/MAFLD Consortium and/or the Kidney Disease: Improving Global Outcomes (KDIGO) organization.\n\n【7】Members of the expert panel were expected to meet at least one of the three aforementioned criteria. To achieve global representation, we selected members from six continents, i.e., Asia, Europe, North America, South America, Africa, and Oceania 删除9:<u>(Table 1)</u>.\n\n【8】## Findings\n\n【9】Here, we report the final consensus statements along with a summary of the broader relevant literature. Across the two-based Delphi surveys, there was an increase in consensus for all proposed statements. The mean percentage of “agreement” responses increased from 63.9% to 76.1% and “agreement or somewhat agreement” responses increased from 94.3% in the R1-survey to 97.3% in the R2-survey . In the end, there was unanimous “agreement or some agreement” on 12 consensus statements and >85% agreement on 7/12 statements 删除9:<u>(Table 2)</u>.\n\n【10】## Epidemiology of MAFLD and CKD—statements 1.1–1.6 (Grade U in 1.1 and 1.5; Grade A in 1.2 to 1.4, 1.6)\n\n【11】Studies using the NAFLD definition have estimated a", "index": 421, "show": true, "start": 395, "end": 407, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "1"}, {"text": "【3】used in other published Delphi studies, in which ‘U’ denotes unanimous (100%) agreement, ‘A’ 90–99% agreement, ‘B’ 78–89% agreement, and ‘C’ 67–77% agreement 删除11:(3,32). A preliminary consensus draft on these recommendations from the expert panel was sought over a 1-week period via a shared Google document. Any disagreements were resolved through discussion until consensus was reached.", "content": "【0】页码:5\n2023 国际共识声明：代谢功能障碍相关的脂肪肝与慢性肾脏疾病的风险\n<mark>疑似页眉# HepatoBiliary Surgery and Nutrition, 2023</mark>023</u>\n\n【1】## Table 1 Demographic composition of the expert panel\n\n| Characteristic                  | Round 1 | Round 2 |\n|---------------------------------|---------|---------|\n| Surveys sent, n                 | 60      | 50      |\n| Total respondents, n (%)        | 50/60<mark> 删除11:(83.3)</mark>.3)</u> | 50/50 <mark>删除11:(100.0)</mark>.0)</u> |\n| Participant type, %             |         |         |\n| Researcher                      | 6       | 6       |\n| Nephrologist                    | 20      | 20      |\n| Gastroenterologist/hepatologist | 62      | 62      |\n| Endocrinologist/diabetologist   | 10      | 10      |\n| Methodologist                   | 2       | 2       |\n| Age (years), %                  |         |         |\n| <40                             | 12      | 12      |\n| 40–65                           | 84      | 84      |\n| >65                             | 4       | 4       |\n| Gender, %                       |         |         |\n| Women                           | 12      | 12      |\n| Men                             | 88      | 88      |\n| Region of practice, %           |         |         |\n| Asia                            | 48      | 48      |\n| North America                   | 8       | 8       |\n| South America                   | 2       | 2       |\n| Europe                          | 32      | 32      |\n| Africa                          | 6       | 6       |\n| Oceania                         | 4       | 4       |\n\n【3】used in other published Delphi studies, in which ‘U’ denotes unanimous (100%) agreement, ‘A’ 90–99% agreement, ‘B’ 78–89% agreement, and ‘C’ 67–77% agreement 删除11:<u>(3,32)</u>. A preliminary consensus draft on these recommendations from the expert panel was sought over a 1-week period via a shared Google document. Any disagreements were resolved through discussion until consensus was reached.\n\n【4】## Recruitment of expert panel members\n\n【5】Members of the international expert panel (n=50) were selected from the representative Continents. To be included, they were active researchers with expertise in the management of fatty liver and/or kidney diseases.\n\n【6】The following criteria were used to select members of the expert panel participating in the Delphi survey:\n(I) To be corresponding authors of published articles on the association between MAFLD or NAFLD and the risk of CKD.\n(II) To be representative members from scientific Societies of Nephrology, Hepatology, Endocrinology/Diabetology, and Obesity.\n(III) To be core members of the NAFLD/MAFLD Consortium and/or the Kidney Disease: Improving Global Outcomes (KDIGO) organization.\n\n【7】Members of the expert panel were expected to meet at least one of the three aforementioned criteria. To achieve global representation, we selected members from six continents, i.e., Asia, Europe, North America, South America, Africa, and Oceania 删除9:<u>(Table 1)</u>.\n\n【8】## Findings\n\n【9】Here, we report the final consensus statements along with a summary of the broader relevant literature. Across the two-based Delphi surveys, there was an increase in consensus for all proposed statements. The mean percentage of “agreement” responses increased from 63.9% to 76.1% and “agreement or somewhat agreement” responses increased from 94.3% in the R1-survey to 97.3% in the R2-survey . In the end, there was unanimous “agreement or some agreement” on 12 consensus statements and >85% agreement on 7/12 statements 删除9:<u>(Table 2)</u>.\n\n【10】## Epidemiology of MAFLD and CKD—statements 1.1–1.6 (Grade U in 1.1 and 1.5; Grade A in 1.2 to 1.4, 1.6)\n\n【11】Studies using the NAFLD definition have estimated a", "index": 1577, "show": true, "start": 1538, "end": 1930, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/07 09:52:00", "endTime": "2024/08/07 09:53:06", "cost": 66.44}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 17:53:05", "grab_time": "2024-08-06 17:51:59"}
{"id": 2211737, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "d180cd8a-faa2-4eac-8ea6-669919bd80fa", "title": "2024+专家共识：牙源性上颌窦炎的多学科治疗", "text": "【0】页码:8\n2024+专家共识：牙源性上颌窦炎的多学科治疗\n删除31:<u>8</u>\n\n【1】odontogenic MS can also cause toothache, which usually radiates to the upper teeth on the same side of the upper dentition. These teeth are sensitive to percussion, but their pulp vitality is normal. Therefore, in order to distinguish OMS from non-odontogenic MS, otorhinologists should pay more attention to the past oral history of MS patients and refer to dentist for dental examination if necessary. A detailed dental examination will help us to determine whether the lesion is a cause. The specific teeth examination includes steps as follows: inspection of buccal mucosa and oral vestibule for the mucosal swelling or gingivitis, percussion for the teeth pain, electric or thermal pulp testing for the vitality of teeth, and probe for deep periodontal pockets. We would discover that OMS patients have one or more dental problems, including periapical lesions, severe periodontitis, or even orontral fistula, on the same side of MS.\n\n【2】After clinical examination, OMS can be finally definitely diagnosed by means of imaging examination. CT and CBCT are common methods applied to diagnose OMS. CT, displaying both soft tissue and bone tissue in three-dimensional way, can identify oral lesions and maxillary sinus clearly, and locate the foreign bodies in maxillary sinus clearly. CBCT may detect dental lesions in detail after identifying it. CT, by contrast, CBCT, which has higher sensitivity than CT for identifying odontogenic lesion and the relationship between the lesion and the maxillary sinus floor, is now widely used in OMS diagnosis. But it has limitations in displaying the full view of the maxillary sinus. So in clinical practice, both CBCT and CT are applied based on specific needs.\n\n【3】In conclusion, the combination of clinic symptoms, oral and nasal examination, and radiological imaging will help us differentiate OMS from non-odontogenic MS. To be specific, the patients with true odontogenic MS are more possible to have oral diseases such as deep periodontal pocket or periapical lesions, while patients with non-odontogenic MS are more possible to have ipsilateral maxillary dental problems, with the help of dentists. A detailed oral examination by dentists is necessary for finding the suspicious ipsilateral pathogenic teeth. Then CT/CBCT examination can ultimately clarify the correlation between the oral lesion and the maxillary sinus, and enable us to make a definite diagnosis of OMS. In rare cases, some OMS patients seek treatment firstly in dental clinics. When dentists find patients with suspicious symptoms of MS, accompanied by suspicious imaging features of MS on the same side of oral lesion, we should guide patients to the rhinologic department for the definite diagnosis of MS. Then after clarifying the relationship between the imaging of MS and that of the oral lesion, we can finally confirm the diagnosis of OMS.\n\n【4】TREATMENT PRINCIPLES OF OMS\n\n【5】Because of the unique etiological and pathological characteristics of OMS, its treatment is different from non-odontogenic MS and involves the cooperation of rhinologists and dentists. The nasal treatments include non-surgical therapy and ESS surgical intervention, aiming to promote the resolution of inflammation, correct the obstruction of maxillary sinus natural ostium, remove irreversible lesions, to improve the symptoms of patients. The dental treatments mainly include root canal treatment, periodontal treatment, apical surgery, focal teeth extraction, and fistulas repair to remove odontogenic infection and avoid recurrence of OMS.\n\n【6】Treatment of maxillary sinus lesions—Rhinological treatment\n\n【7】Non-surgical treatment. Non-surgical treatment is the first and most important step, including antibiotic therapy, nasal corticosteroids and nasal irrigation, which helps to improve the symptoms of patients. Compared to non-odontogenic MS, OMS with a significant bacterial infection, so antibiotic therapy is an important option. The use of penicillin (amoxicillin) and β-lactamase inhibitors, with or without metronidazole, can generally fight a wide range of multi-microbial and anaerobic pathogens. It should be noted that the antimicrobial therapy should be guided by the antibiotic resistance pattern. Zirk et al. conducted a study with 121 patients with OMS and found that piperacillin/tazobactam (93.9%), cortimoxazole (83.3%), ampicillin/sulbactam (80%), cefotaxime (78.1%), cefuroxime (69.4%), ampicillin (68%), and clindamycin (50%) had the highest sensitivity, and for patients with confirmed penicillin allergy, fluoroquinolones such as moxifloxacin (86.2%) and ciprofloxacin (62.2%) and tetracycline (62.9%) can be used as alternatives. Saibene et al. showed that among the isolated bacteria strain from 28 OMS patients, 70% were sensitive to amoxicillin, and all species of the isolated bacteria strain were sensitive to the combination of levofloxacin, teicoplanin, and vancomycin. However, existing studies have shown that antibiotic therapy alone is difficult to cure OMS.\n\n【8】Surgical treatment. Surgical treatment is advised if conservative treatment is ineffective. In the past, the classical Caldwell-Luc procedure was the main surgical management for maxillary sinus disease, but with the disadvantages of large trauma and many complications. At present, ESS is regarded as the gold surgical standard which is an alternative to Caldwell-Luc approach, and has shown excellent effect, especially when the OMS is combined with nasal lesions. ESS provides a large middle meatal antrostomy. On the other hand, it improves visualization for the entire maxillary sinus through a smaller surgical window, helps to avoid damage to anatomical trauma and optimal exposure, ESS could maximally remove the focus of infection as well by using opening and OMS mucosa resection. However, there are still some open controversies on whether ESS should be performed before or after dental treatment, especially in the absence of definitive treatment options for OMS. On another aspect, OMS may not improve, particularly in younger patients.\n\n【9】Treatment of oral lesions—dental treatment\n\n【10】Tooth preservation. Root canal therapy, apical surgery and periodontal therapy can be performed when the focal tooth is evaluated to be excellent/good/fair, or questionable but infection could be controlled, or patients have strong desire to preserve the tooth. A recent cohort study showed that 13% (9/68) OMS patients improved after conservative dental treatment.\n\n【11】Tooth extraction. The focal tooth can be extracted when it is evaluated to be hopeless (prognosis) or questionable but the infection is difficult to control. Simuntis et al. published a prospective study on 96 patients with OMS due to AP, and they demonstrated a 77% success rate with dental extraction alone. However, a study on 37 patients with OMS found that even after tooth extraction, OMS may not improve, particularly in younger patients.\n\n【12】MULTI-DISCIPLINARY TREATMENT SEQUENCE OF OMS\n\n【13】The optimal sequence of nasal and dental treatments for OMS has not still been identified. Many studies recommended that dental treatment to eliminate the source of infection should be done before nasal treatment. Longhini and Ferguson suggested that dental treatment should precede ESS, since they found that without dental intervention, OMS can be not cured by ESS alone. Khao et al. even reported that 67% of 33 OMS patients were recovered after medical and dental treatment, and only 33% of the patients required additional ESS. On the contrary, some other authors recommended ESS in priority. Abdulhadee conducted a retrospective", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024+专家共识：牙源性上颌窦炎的多学科治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【6】Treatment of maxillary sinus lesions—Rhinological treatment\n\n【7】Non-surgical treatment. ", "content": "【0】页码:8\n2024+专家共识：牙源性上颌窦炎的多学科治疗\n删除31:<u>8</u>\n\n【1】odontogenic MS can also cause toothache, which usually radiates to the upper teeth on the same side of the upper dentition. These teeth are sensitive to percussion, but their pulp vitality is normal. Therefore, in order to distinguish OMS from non-odontogenic MS, otorhinologists should pay more attention to the past oral history of MS patients and refer to dentist for dental examination if necessary. A detailed dental examination will help us to determine whether the lesion is a cause. The specific teeth examination includes steps as follows: inspection of buccal mucosa and oral vestibule for the mucosal swelling or gingivitis, percussion for the teeth pain, electric or thermal pulp testing for the vitality of teeth, and probe for deep periodontal pockets. We would discover that OMS patients have one or more dental problems, including periapical lesions, severe periodontitis, or even orontral fistula, on the same side of MS.\n\n【2】After clinical examination, OMS can be finally definitely diagnosed by means of imaging examination. CT and CBCT are common methods applied to diagnose OMS. CT, displaying both soft tissue and bone tissue in three-dimensional way, can identify oral lesions and maxillary sinus clearly, and locate the foreign bodies in maxillary sinus clearly. CBCT may detect dental lesions in detail after identifying it. CT, by contrast, CBCT, which has higher sensitivity than CT for identifying odontogenic lesion and the relationship between the lesion and the maxillary sinus floor, is now widely used in OMS diagnosis. But it has limitations in displaying the full view of the maxillary sinus. So in clinical practice, both CBCT and CT are applied based on specific needs.\n\n【3】In conclusion, the combination of clinic symptoms, oral and nasal examination, and radiological imaging will help us differentiate OMS from non-odontogenic MS. To be specific, the patients with true odontogenic MS are more possible to have oral diseases such as deep periodontal pocket or periapical lesions, while patients with non-odontogenic MS are more possible to have ipsilateral maxillary dental problems, with the help of dentists. A detailed oral examination by dentists is necessary for finding the suspicious ipsilateral pathogenic teeth. Then CT/CBCT examination can ultimately clarify the correlation between the oral lesion and the maxillary sinus, and enable us to make a definite diagnosis of OMS. In rare cases, some OMS patients seek treatment firstly in dental clinics. When dentists find patients with suspicious symptoms of MS, accompanied by suspicious imaging features of MS on the same side of oral lesion, we should guide patients to the rhinologic department for the definite diagnosis of MS. Then after clarifying the relationship between the imaging of MS and that of the oral lesion, we can finally confirm the diagnosis of OMS.\n\n【4】TREATMENT PRINCIPLES OF OMS\n\n【5】Because of the unique etiological and pathological characteristics of OMS, its treatment is different from non-odontogenic MS and involves the cooperation of rhinologists and dentists. The nasal treatments include non-surgical therapy and ESS surgical intervention, aiming to promote the resolution of inflammation, correct the obstruction of maxillary sinus natural ostium, remove irreversible lesions, to improve the symptoms of patients. The dental treatments mainly include root canal treatment, periodontal treatment, apical surgery, focal teeth extraction, and fistulas repair to remove odontogenic infection and avoid recurrence of OMS.\n\n【6】Treatment of maxillary sinus lesions—Rhinological treatment\n\n【7】Non-surgical treatment. Non-surgical treatment is the first and most important step, including antibiotic therapy, nasal corticosteroids and nasal irrigation, which helps to improve the symptoms of patients. Compared to non-odontogenic MS, OMS with a significant bacterial infection, so antibiotic therapy is an important option. The use of penicillin (amoxicillin) and β-lactamase inhibitors, with or without metronidazole, can generally fight a wide range of multi-microbial and anaerobic pathogens. It should be noted that the antimicrobial therapy should be guided by the antibiotic resistance pattern. Zirk et al. conducted a study with 121 patients with OMS and found that piperacillin/tazobactam (93.9%), cortimoxazole (83.3%), ampicillin/sulbactam (80%), cefotaxime (78.1%), cefuroxime (69.4%), ampicillin (68%), and clindamycin (50%) had the highest sensitivity, and for patients with confirmed penicillin allergy, fluoroquinolones such as moxifloxacin (86.2%) and ciprofloxacin (62.2%) and tetracycline (62.9%) can be used as alternatives. Saibene et al. showed that among the isolated bacteria strain from 28 OMS patients, 70% were sensitive to amoxicillin, and all species of the isolated bacteria strain were sensitive to the combination of levofloxacin, teicoplanin, and vancomycin. However, existing studies have shown that antibiotic therapy alone is difficult to cure OMS.\n\n【8】Surgical treatment. Surgical treatment is advised if conservative treatment is ineffective. In the past, the classical Caldwell-Luc procedure was the main surgical management for maxillary sinus disease, but with the disadvantages of large trauma and many complications. At present, ESS is regarded as the gold surgical standard which is an alternative to Caldwell-Luc approach, and has shown excellent effect, especially when the OMS is combined with nasal lesions. ESS provides a large middle meatal antrostomy. On the other hand, it improves visualization for the entire maxillary sinus through a smaller surgical window, helps to avoid damage to anatomical trauma and optimal exposure, ESS could maximally remove the focus of infection as well by using opening and OMS mucosa resection. However, there are still some open controversies on whether ESS should be performed before or after dental treatment, especially in the absence of definitive treatment options for OMS. On another aspect, OMS may not improve, particularly in younger patients.\n\n【9】Treatment of oral lesions—dental treatment\n\n【10】Tooth preservation. Root canal therapy, apical surgery and periodontal therapy can be performed when the focal tooth is evaluated to be excellent/good/fair, or questionable but infection could be controlled, or patients have strong desire to preserve the tooth. A recent cohort study showed that 13% (9/68) OMS patients improved after conservative dental treatment.\n\n【11】Tooth extraction. The focal tooth can be extracted when it is evaluated to be hopeless (prognosis) or questionable but the infection is difficult to control. Simuntis et al. published a prospective study on 96 patients with OMS due to AP, and they demonstrated a 77% success rate with dental extraction alone. However, a study on 37 patients with OMS found that even after tooth extraction, OMS may not improve, particularly in younger patients.\n\n【12】MULTI-DISCIPLINARY TREATMENT SEQUENCE OF OMS\n\n【13】The optimal sequence of nasal and dental treatments for OMS has not still been identified. Many studies recommended that dental treatment to eliminate the source of infection should be done before nasal treatment. Longhini and Ferguson suggested that dental treatment should precede ESS, since they found that without dental intervention, OMS can be not cured by ESS alone. Khao et al. even reported that 67% of 33 OMS patients were recovered after medical and dental treatment, and only 33% of the patients required additional ESS. On the contrary, some other authors recommended ESS in priority. Abdulhadee conducted a retrospective", "index": 3600, "show": true, "start": 3600, "end": 3691, "province": ["格式规范性", "多余换行"], "isEdit": false}], "startTime": "2024/08/06 16:13:29", "endTime": "2024/08/06 16:14:45", "cost": 76.575}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:14:45", "grab_time": "2024-08-06 00:13:28"}
{"id": 2211736, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "1311831c-d825-47f4-b924-c6b02f4c3b06", "title": "2023更新—2015 NICE指南：儿童和青年人糖尿病（1型和2型）的诊断和管理（NG.18）(1)", "text": "【0】页码:11\n2023更新—2015 NICE指南：儿童和青年人糖尿病（1型和2型）的诊断和管理（NG.18）(1)\ntheir families and carers how to use it. A specialist team should provide ongoing support. 删除24:<u>[2004, amended 2015]</u>\n\n#### 1.2.23|删除段内换行|Specialist teams should agree a common core of advice to give insulin pump users. 删除24:<u>[2004, amended 2015]</u>\n\n#### 1.2.24|删除段内换行|For children and young people with type 1 diabetes who are using twice-daily injection regimens, encourage them to adjust the insulin dose according to the general trend in their pre-meal, bedtime and occasional night-time blood glucose. 删除24:<u>[2004, amended 2015]</u>\n\n#### 1.2.25|删除段内换行|Explain to children and young people with newly diagnosed type 1 diabetes and their families or carers that:\n\n【4】- they may have a partial remission phase (a 'honeymoon period') when they start using insulin\n- during this time, they may only need a low dosage of insulin (0.5 units/kg body weight/day) to maintain an HbA1c level of less than 48 mmol/mol (6.5%).\n\n【5】删除24:<u>[2004, amended 2015]</u>\n\n#### 1.2.26|删除段内换行|Offer children and young people with type 1 diabetes a choice of insulin delivery systems. 删除12:<u>删除14:<u>删除24:<u>[2004]</u></u></u>\n\n#### 1.2.27|删除段内换行|Provide children and young people with type 1 diabetes insulin injection needles that are the right length for their body fat. 删除24:<u>[2004, amended 2015]</u>\n\n#### 1.2.28|删除段内换行|Provide children and young people with type 1 diabetes and their families or carers:\n\n【9】- suitable containers for collecting used needles and other sharps\n- a way to safely get rid of these containers.\n\n【10】See also the section on safe use and disposal of sharps in the NICE guideline on healthcare-associated infections. 删除12:<u>删除14:<u>删除24:<u>[2015]</u></u></u>\n\n#### 1.2.29|删除段内换行|Offer children and young people with type 1 diabetes a review of injection sites at each clinic visit. 删除24:<u>[2004, amended 2015]</u>", "tags": {}, "lang": "en", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023更新—2015 NICE指南：儿童和青年人糖尿病（1型和2型）的诊断和管理（NG.18）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:42:21", "endTime": "2024/08/06 16:43:04", "cost": 42.83}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:43:04", "grab_time": "2024-08-06 00:42:21"}
{"id": 2211735, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "9af95a89-afee-4e83-bda7-af9ec033eda8", "title": "日间手术肝胆疾病标准化流程中国专家共识（2022版）", "text": "【0】页码:4\n日间手术肝胆疾病标准化流程中国专家共识（2022版）\n中期使用手术：日门手术的友善环境和便利的广泛开展，也与精准使用日门手术息息相关。ERAS理想的前提离不开日门。未可期起效赫然等作用。手术期应用ERAS理想定能够降低患者术后不过早应及并发症愈合率，促进患者快速康复出院，从而降低30日再床率。\n\n【1】### 推荐意见10:\n推崇用日门手术能够保证日门手术安全，提低术后不良反应及并发症发生率促使患者快速康复出院、降低病人院率。\n- 推荐等级：1级\n\n【2】删除32:<u>**</u>2.麻醉管理：删除32:<u>**</u>\n日门手术选择进行术单、手术时间(其中1~2小时常用于菜单单实施)每一般情祝较好，术中麻醉顾问予高规则麻醉剂。标准化规范应用分开麻药物(医时间中的参指出)和改变医学生命。麻醉管理内容包括术前麻醉评估、麻醉图像分解、麻醉污染净、术中监测、麻醉恢复等、麻醉保递对日门“未所求术探求设计”。\n\n【3】### 推荐意见11:\n肝胆移磨日门手术麻醉管理可参照(日门手术麻醉专家状议。\n\n【4】删除32:<u>**</u>(三)术后管理删除32:<u>**</u>\n\n【5】1. 早期手术患者的术后管理十分便捷，减少术后疼痛、恶心呕吐、皮瘟等不良反即开发避免并发症。\n\n【6】- 推荐等级：1级\n\n【7】删除32:<u>**</u>1.术后镇痛药物使用：删除32:<u>**</u>\n对于上述推荐的肝胆疾病日门手术，术后通常无需使用抗菌药物。若患者术前合并感染来临风险或时暴发现明确感染迹时，可不可于术 24 h 内使用抗菌药物，特殊情况可延长至术后3天。\n\n【8】### 推荐意见12:\n肝胆疾病日门手术后通常无需使用抗菌药物，特殊患者可根据具体情况使用。\n- 推荐等级：1级\n\n【9】删除32:<u>**</u>2.早期功能疗：删除32:<u>**</u>\n术后期全面化需求包括日门手术者逐迅出院的主要困难良好疾病注能能够促使病体尽量尽受出院、提高组卷合能力。针对异常功能病域、通知水麻醉解除可引导、合上疼痛药剑等)或减少则之局部涂药消合、术后控制除合药和守(三) 根据合药记性痛解。优选善愈性抗类药剑。必要时可合剂类药剑。具体实名及剂量请参(《日门手术麻醉专家状议》和《从日门手术疾病者专家状议》删除11:<u>删除19:<u>(2017)</u></u>》。\n\n【10】### 推荐意见13:\n建议用腔然用与手术来痊愈剂极片即可升结合麻醉痛药分了、对上肠源溢合并药、术而早释给药和(或) 口服联合给药以控制疼痛，优选善组成类药剑必要时可辅助其他药物。\n- 推荐等级：2级\n\n【11】删除32:<u>**</u>3.术后止吐药物使用：删除32:<u>**</u>\n术后恶心呕吐早发现、\n\n【12】### 推荐意见7:\n有利知道病患者的三间隔感和知识、充分貌较充分知识输局到底景期竭其大知道认知、必要时可住院等部门既证正或家属保予证地\n- 推荐等级:C级\n\n【13】### 推荐意见8:\n术前如何三间隔以及提供病患利预适手术内容中书、利病以及任纲过程，患者未期3万病进行予对\n- 推荐等级:B级", "tags": {}, "lang": "zh", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/日间手术肝胆疾病标准化流程中国专家共识（2022版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "日间手术肝胆疾病标准化流程中国专家共识（2022版）\n\n中期使用手术：日门手术的友善环境和便利的广泛开展，也与精准使用日门手术息息相关。ERAS理想的前提离不开日门。未可期起效赫然等作用。手术期应用ERAS理想定能够降低患者术后不过早应及并发症愈合率，促进患者快速康复出院，从而降低30日再床率。\n\n【1】### 推荐意见10:\n\n推崇用日门手术能够保证日门手术安全，提低术后不良反应及并发症发生率促使患者快速康复出院、降低病人院率。\n\n推荐等级：1级\n【2】删除32:2.麻醉管理：删除32:\n\n日门手术选择进行术单、手术时间(其中1~2小时常用于菜单单实施)每一般情祝较好，术中麻醉顾问予高规则麻醉剂。标准化规范应用分开麻药物(医时间中的参指出)和改变医学生命。麻醉管理内容包括术前麻醉评估、麻醉图像分解、麻醉污染净、术中监测、麻醉恢复等、麻醉保递对日门“未所求术探求设计”。\n\n【3】### 推荐意见11:\n\n肝胆移磨日门手术麻醉管理可参照(日门手术麻醉专家状议。\n\n【4】删除32:(三)术后管理删除32:\n\n【5】1. 早期手术患者的术后管理十分便捷，减少术后疼痛、恶心呕吐、皮瘟等不良反即开发避免并发症。\n\n【6】- 推荐等级：1级\n\n【7】删除32:1.术后镇痛药物使用：删除32:\n\n对于上述推荐的肝胆疾病日门手术，术后通常无需使用抗菌药物。若患者术前合并感染来临风险或时暴发现明确感染迹时，可不可于术 24 h 内使用抗菌药物，特殊情况可延长至术后3天。\n\n【8】### 推荐意见12:\n\n肝胆疾病日门手术后通常无需使用抗菌药物，特殊患者可根据具体情况使用。\n\n推荐等级：1级\n【9】删除32:2.早期功能疗：删除32:\n\n术后期全面化需求包括日门手术者逐迅出院的主要困难良好疾病注能能够促使病体尽量尽受出院、提高组卷合能力。针对异常功能病域、通知水麻醉解除可引导、合上疼痛药剑等)或减少则之局部涂药消合、术后控制除合药和守(三) 根据合药记性痛解。优选善愈性抗类药剑。必要时可合剂类药剑。具体实名及剂量请参(《日门手术麻醉专家状议》和《从日门手术疾病者专家状议》删除11:删除19:(2017)》。\n\n【10】### 推荐意见13:\n\n建议用腔然用与手术来痊愈剂极片即可升结合麻醉痛药分了、对上肠源溢合并药、术而早释给药和(或) 口服联合给药以控制疼痛，优选善组成类药剑必要时可辅助其他药物。\n\n推荐等级：2级\n【11】删除32:3.术后止吐药物使用：删除32:\n\n术后恶心呕吐早发现、\n\n【12】### 推荐意见7:\n\n有利知道病患者的三间隔感和知识、充分貌较充分知识输局到底景期竭其大知道认知、必要时可住院等部门既证正或家属保予证地\n\n推荐等级:C级\n【13】### 推荐意见8:\n\n术前如何三间隔以及提供病患利预适手术内容中书、利病以及任纲过程，患者未期3万病进行予对\n\n推荐等级:B级", "content": "【0】页码:4\n日间手术肝胆疾病标准化流程中国专家共识（2022版）\n中期使用手术：日门手术的友善环境和便利的广泛开展，也与精准使用日门手术息息相关。ERAS理想的前提离不开日门。未可期起效赫然等作用。手术期应用ERAS理想定能够降低患者术后不过早应及并发症愈合率，促进患者快速康复出院，从而降低30日再床率。\n\n【1】### 推荐意见10:\n推崇用日门手术能够保证日门手术安全，提低术后不良反应及并发症发生率促使患者快速康复出院、降低病人院率。\n- 推荐等级：1级\n\n【2】删除32:<u>**</u>2.麻醉管理：删除32:<u>**</u>\n日门手术选择进行术单、手术时间(其中1~2小时常用于菜单单实施)每一般情祝较好，术中麻醉顾问予高规则麻醉剂。标准化规范应用分开麻药物(医时间中的参指出)和改变医学生命。麻醉管理内容包括术前麻醉评估、麻醉图像分解、麻醉污染净、术中监测、麻醉恢复等、麻醉保递对日门“未所求术探求设计”。\n\n【3】### 推荐意见11:\n肝胆移磨日门手术麻醉管理可参照(日门手术麻醉专家状议。\n\n【4】删除32:<u>**</u>(三)术后管理删除32:<u>**</u>\n\n【5】1. 早期手术患者的术后管理十分便捷，减少术后疼痛、恶心呕吐、皮瘟等不良反即开发避免并发症。\n\n【6】- 推荐等级：1级\n\n【7】删除32:<u>**</u>1.术后镇痛药物使用：删除32:<u>**</u>\n对于上述推荐的肝胆疾病日门手术，术后通常无需使用抗菌药物。若患者术前合并感染来临风险或时暴发现明确感染迹时，可不可于术 24 h 内使用抗菌药物，特殊情况可延长至术后3天。\n\n【8】### 推荐意见12:\n肝胆疾病日门手术后通常无需使用抗菌药物，特殊患者可根据具体情况使用。\n- 推荐等级：1级\n\n【9】删除32:<u>**</u>2.早期功能疗：删除32:<u>**</u>\n术后期全面化需求包括日门手术者逐迅出院的主要困难良好疾病注能能够促使病体尽量尽受出院、提高组卷合能力。针对异常功能病域、通知水麻醉解除可引导、合上疼痛药剑等)或减少则之局部涂药消合、术后控制除合药和守(三) 根据合药记性痛解。优选善愈性抗类药剑。必要时可合剂类药剑。具体实名及剂量请参(《日门手术麻醉专家状议》和《从日门手术疾病者专家状议》删除11:<u>删除19:<u>(2017)</u></u>》。\n\n【10】### 推荐意见13:\n建议用腔然用与手术来痊愈剂极片即可升结合麻醉痛药分了、对上肠源溢合并药、术而早释给药和(或) 口服联合给药以控制疼痛，优选善组成类药剑必要时可辅助其他药物。\n- 推荐等级：2级\n\n【11】删除32:<u>**</u>3.术后止吐药物使用：删除32:<u>**</u>\n术后恶心呕吐早发现、\n\n【12】### 推荐意见7:\n有利知道病患者的三间隔感和知识、充分貌较充分知识输局到底景期竭其大知道认知、必要时可住院等部门既证正或家属保予证地\n- 推荐等级:C级\n\n【13】### 推荐意见8:\n术前如何三间隔以及提供病患利预适手术内容中书、利病以及任纲过程，患者未期3万病进行予对\n- 推荐等级:B级", "index": 8, "show": true, "start": 8, "end": 1214, "province": ["格式规范性", "格式杂乱"], "isEdit": false}], "startTime": "2024/08/06 16:10:53", "endTime": "2024/08/06 16:11:59", "cost": 66.524}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:12:00", "grab_time": "2024-08-06 00:10:53"}
{"id": 2211734, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "d33afc25-0416-4e32-a275-8f7f818c53d3", "title": "ESVS：下肢慢性静脉疾病管理的临床实践指南（2022）", "text": "【0】页码:47\nESVS：下肢慢性静脉疾病管理的临床实践指南（2022）\n### stenting (such as stent migration or contralateral thrombosis); and residual obstructive disease (inflow, in stent or outflow) that may compromise future stent patency.\n\n【1】In addition, there may be haematological or other patient related factors contributing to stent failure, which also need to be recognised and addressed for optimal outcomes. In a systematic review, including 3 072 patients in which standard stents were used for post-thrombotic obstruction or NIVL, the median primary, assisted primary, and secondary patency rates were 71%, 89%, and 91%, respectively, with a median study follow up of 23.5 months. In a meta-analysis of iliofemoral stenting for PTS in 504 limbs, 36 month primary and secondary patency were 68% and 86%, respectively, showing that a significant minority of patients required at least one re-intervention over a three year period. In another series, the re-intervention rate was 43%, with a median time to re-intervention of 32 days (range 0 – 520 days). The majority of these patients had only a single re-intervention and achieved good patency at two years with significant symptom improvement.\n\n【2】Re-intervention for asymptomatic in stent re-stenosis is controversial because of a lack of evidence to support better outcomes. In selected cases with symptomatic in stent re-stenosis, conservative measures or extended anticoagulation may also be a valid treatment option. There is only sparse evidence that prophylactic intervention can reduce future thrombosis risk in these patients.\n\n【3】#### 5.3.2.5. Options for re-intervention after stenting.\n\n【4】The vast majority of reported re-interventions after deep venous stenting have been performed for acute stent thrombosis or in stent stenosis. The principles of management for acute thrombosis should mirror the management of primary acute DVT. Patients with stent thrombosis will often present with significant swelling and pain, and therefore early thrombus removal strategies have to be considered. Departments with experience in deep vein recanalisation and stenting procedures must carry out the interventions if needed. A detailed description of thrombus removal options is beyond the remit of these guidelines, but the mainstays of treatment are endovenous pharmacomechanical, pure thrombectomy, and catheter directed thrombolysis interventions. It is important to recognise that, after successful thrombus removal, adequate treatment of any underlying obstructive disease is imperative to prevent re-thrombosis. Generally, attempts at deep venous stent recanalisation, when occluded for more than two weeks, are unlikely to be successful or durable.\n\n【5】For the treatment of symptomatic stenosis, venoplasty or additional stenting may be feasible. A mild degree of in stent thrombus lining is common, which complicates identification of an aetiology and a prolonged venoplasty may be required. For re-intervention for inflow or outflow disease, it is possible to perform additional stenting to comply with the principle of stenting from “good inflow vein” to “good outflow vein”.\n\n【6】#### 5.3.2.6. Surgical reconstruction\n\n【7】Surgical reconstruction of the iliocaval vessels is performed rarely. Thus, reliable data on indications and outcomes are scarce. The main difficulty is result assessment of the different surgical strategies in terms of symptom relief, long term patency, and risk factors for procedural failure. Recent studies present heterogeneous patient selection and difficult comparative analyses.\n\n【8】The most well known surgical technique is the Palma bypass graft, initially performed in 1958, for unilateral iliac occlusion. This procedure uses autologous vein or a prosthetic graft, mainly expanded polytetrafluoroethylene. Smaller series have been published in which prosthetic and autologous vein grafts have been used in either anatomical or extra-anatomical configurations to bypass occluded iliac and ilio-caval segments. These studies reported high variability and induced considerable controversy.\n\n【9】The published long term patency (five year) for the Palma technique reports a patency between 70% and 85%, as well as clinical improvement of 63% – 88% after reintervention. This is superior to other bypass graft configurations, including cavai-femoral bypass.\n\n【10】The use of an adjunctive arteriovenous fistula (AVF) is a controversial topic with pros and cons discussed in experimental and clinical reports. There is insufficient evidence to make strong recommendations, but an AVF may be considered for patients with insufficient inflow, who may struggle to keep the graft open.\n\n【11】Overall, there is a lack of strong evidence supporting the benefits of surgical reconstruction. It must be considered in exceptional cases such as major disease with no other treatment alternatives, especially patients with C4 – C6 disease, severe PTS, and/or disabling venous claudication with daily activity limitations. Endovascular techniques should be the first treatment option.\n\n【12】#### 5.3.2.7. Hybrid procedures\n\n【13】Chronic iliac occlusive disease (stenosis or occlusion) can be treated by venoplasty and stent in the majority of cases where intervention is required. However, the literature suggests worse outcomes in disease with CFV compromise, possibly related to insufficient stent inflow and subsequent higher rates of thrombosis. Additional complications may occur because of absence of any identifiable “landing zone” secondary to obstruction by residual luminal trabeculations.\n\n【14】Iliac vein stenting could be combined with surgical removal of the obstructive element from the CFV, its tributaries, and especially the DFV orifice. The latter technique is known as endophlebectomy. In conjunction with iliac vein stenting, it provides adequate inflow by securing supply from all major side branches of the CFV, thereby reducing the risk of early stent thrombosis.\n\n【15】The endophlebectomy literature provides limited evidence and high variability. The largest published series reports on 157 patients with a cumulative patency of 89% at 12 months. However, the majority of published patency rates are about 60%, with high complication rates in terms of infection, seroma, lymph leak, and haematoma occurring in up to 40% of cases.\n\n【16】The heterogeneity of the published data makes interpretation difficult. There are no clear criteria for case selection, with widely variable decisions on what constituted severe enough disease to warrant this more invasive.", "tags": {}, "lang": "en", "attr": {"page_num": 47, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ESVS：下肢慢性静脉疾病管理的临床实践指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:45:46", "endTime": "2024/08/06 15:46:20", "cost": 34.521}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-05 23:46:20", "grab_time": "2024-08-05 23:45:45"}
{"id": 2211733, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "7b6c4da2-cbc4-4379-9ff7-4c04f45083cf", "title": "_糖皮质激素治疗新型冠状病毒感染时的血糖管理共识(1)", "text": "【0】页码:4\n_糖皮质激素治疗新型冠状病毒感染时的血糖管理共识(1)\n激素对血糖的影响, 需关注以下要点：\n\n【1】删除11:<u>(1)</u> 注食或肠内营养(含非常规要大剂甲皮素的速过渡从摄碳水化合物量和增加碳胆胺素。胸内营养间隔时间少于4h 时, 需注意两餐餐前胆胺素的盆加作用。减少疗一餐的餐前胆胺素剂量;\n\n【2】删除11:<u>(2)</u> 转变复食时胆胺素剂, 可选择 CSII 或浆皮质胶胆胺素胶浆素人, 递注餐桑人剂胰素时,非调烧段时间的胰岛素剂量;\n\n【3】删除11:<u>(3)</u> 使用胆胺素者,可在部分者保甲根胶约外胰胺耳约约的总量加具胶素,或另外给于胰岛素转换常规素人。\n\n【4】新型冠状病毒感染治疗期间使用糖皮质激素时的血糖控制策略范围见图删除28:<u>1</u>。\n\n【5】(二) 低血糖处理\n\n【6】若出現低血糖症状,立即測指尖血糖,根据低血糖治疗流處处理并及时调整用药方案。\n\n【7】### 停用糖皮质激素后高血糖的评估\n\n【8】新型冠状病毒感染使用糖皮质激素治疗持续时间多约1d,短于常技受大剂糖皮质激素一般可迅速停止糖皮质激素治疗,转约2周到数周长时间可能有.上腺抑制的风隐,需逐渐缓减少剂量直xl至停止。临床师面在停用糖皮质激素后应注意监测血糖,血压,电解质,评估是否存在\"肾上.腺皮质抑制。\n\n【9】糖皮质激素诱导的高血糖多数会随者激素剂量的减少和停用而逐渐缓。糖尿病患者停用糖皮质激素后,根据血糖水平逐渐减少胰岛素剂或降糖药物,避免发生低血糖。静脉使用糖皮质激素者多在停用24-48h 后血糖效改善至使用前水平。\n\n【10】删除图片描述:<u>![](3_0.png)</u>\n\n【11】注:胰,易地住红在注者者;GLP-I_Ra为肽资源领抗理拮道剂.受体激动剂图丨新型冠状病毒感染治疗期间使用糖皮质激素时的血糖控制策略的简略图", "tags": {}, "lang": "zh", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_糖皮质激素治疗新型冠状病毒感染时的血糖管理共识(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【5】(二) 低血糖处理", "content": "【0】页码:4\n_糖皮质激素治疗新型冠状病毒感染时的血糖管理共识(1)\n激素对血糖的影响, 需关注以下要点：\n\n【1】删除11:<u>(1)</u> 注食或肠内营养(含非常规要大剂甲皮素的速过渡从摄碳水化合物量和增加碳胆胺素。胸内营养间隔时间少于4h 时, 需注意两餐餐前胆胺素的盆加作用。减少疗一餐的餐前胆胺素剂量;\n\n【2】删除11:<u>(2)</u> 转变复食时胆胺素剂, 可选择 CSII 或浆皮质胶胆胺素胶浆素人, 递注餐桑人剂胰素时,非调烧段时间的胰岛素剂量;\n\n【3】删除11:<u>(3)</u> 使用胆胺素者,可在部分者保甲根胶约外胰胺耳约约的总量加具胶素,或另外给于胰岛素转换常规素人。\n\n【4】新型冠状病毒感染治疗期间使用糖皮质激素时的血糖控制策略范围见图删除28:<u>1</u>。\n\n【5】(二) 低血糖处理\n\n【6】若出現低血糖症状,立即測指尖血糖,根据低血糖治疗流處处理并及时调整用药方案。\n\n【7】### 停用糖皮质激素后高血糖的评估\n\n【8】新型冠状病毒感染使用糖皮质激素治疗持续时间多约1d,短于常技受大剂糖皮质激素一般可迅速停止糖皮质激素治疗,转约2周到数周长时间可能有.上腺抑制的风隐,需逐渐缓减少剂量直xl至停止。临床师面在停用糖皮质激素后应注意监测血糖,血压,电解质,评估是否存在\"肾上.腺皮质抑制。\n\n【9】糖皮质激素诱导的高血糖多数会随者激素剂量的减少和停用而逐渐缓。糖尿病患者停用糖皮质激素后,根据血糖水平逐渐减少胰岛素剂或降糖药物,避免发生低血糖。静脉使用糖皮质激素者多在停用24-48h 后血糖效改善至使用前水平。\n\n【10】删除图片描述:<u>![](3_0.png)</u>\n\n【11】注:胰,易地住红在注者者;GLP-I_Ra为肽资源领抗理拮道剂.受体激动剂图丨新型冠状病毒感染治疗期间使用糖皮质激素时的血糖控制策略的简略图", "index": 356, "show": true, "start": 356, "end": 368, "province": ["格式规范性", "序号格式不一致"], "isEdit": false}, {"text": "【11】注:胰,易地住红在注者者;GLP-I_Ra为肽资源领抗理拮道剂.受体激动剂图丨新型冠状病毒感染治疗期间使用糖皮质激素时的血糖控制策略的简略图", "content": "【0】页码:4\n_糖皮质激素治疗新型冠状病毒感染时的血糖管理共识(1)\n激素对血糖的影响, 需关注以下要点：\n\n【1】删除11:<u>(1)</u> 注食或肠内营养(含非常规要大剂甲皮素的速过渡从摄碳水化合物量和增加碳胆胺素。胸内营养间隔时间少于4h 时, 需注意两餐餐前胆胺素的盆加作用。减少疗一餐的餐前胆胺素剂量;\n\n【2】删除11:<u>(2)</u> 转变复食时胆胺素剂, 可选择 CSII 或浆皮质胶胆胺素胶浆素人, 递注餐桑人剂胰素时,非调烧段时间的胰岛素剂量;\n\n【3】删除11:<u>(3)</u> 使用胆胺素者,可在部分者保甲根胶约外胰胺耳约约的总量加具胶素,或另外给于胰岛素转换常规素人。\n\n【4】新型冠状病毒感染治疗期间使用糖皮质激素时的血糖控制策略范围见图删除28:<u>1</u>。\n\n<mark>【5】(二) 低血糖处理</mark>\n\n【6】若出現低血糖症状,立即測指尖血糖,根据低血糖治疗流處处理并及时调整用药方案。\n\n【7】### 停用糖皮质激素后高血糖的评估\n\n【8】新型冠状病毒感染使用糖皮质激素治疗持续时间多约1d,短于常技受大剂糖皮质激素一般可迅速停止糖皮质激素治疗,转约2周到数周长时间可能有.上腺抑制的风隐,需逐渐缓减少剂量直xl至停止。临床师面在停用糖皮质激素后应注意监测血糖,血压,电解质,评估是否存在\"肾上.腺皮质抑制。\n\n【9】糖皮质激素诱导的高血糖多数会随者激素剂量的减少和停用而逐渐缓。糖尿病患者停用糖皮质激素后,根据血糖水平逐渐减少胰岛素剂或降糖药物,避免发生低血糖。静脉使用糖皮质激素者多在停用24-48h 后血糖效改善至使用前水平。\n\n【10】删除图片描述:<u>![](3_0.png)</u>\n\n【11】注:胰,易地住红在注者者;GLP-I_Ra为肽资源领抗理拮道剂.受体激动剂图丨新型冠状病毒感染治疗期间使用糖皮质激素时的血糖控制策略的简略图", "index": 732, "show": true, "start": 719, "end": 793, "province": ["信息质量", "有用性-轻"], "isEdit": false}, {"text": "【9】糖皮质激素诱导的高血糖多数会随者激素剂量的减少和停用而逐渐缓。糖尿病患者停用糖皮质激素后,根据血糖水平逐渐减少胰岛素剂或降糖药物,避免发生低血糖。静脉使用糖皮质激素者多在停用24-48h 后血糖效改善至使用前水平。", "content": "【0】页码:4\n_糖皮质激素治疗新型冠状病毒感染时的血糖管理共识(1)\n激素对血糖的影响, 需关注以下要点：\n\n【1】删除11:<u>(1)</u> 注食或肠内营养(含非常规要大剂甲皮素的速过渡从摄碳水化合物量和增加碳胆胺素。胸内营养间隔时间少于4h 时, 需注意两餐餐前胆胺素的盆加作用。减少疗一餐的餐前胆胺素剂量;\n\n【2】删除11:<u>(2)</u> 转变复食时胆胺素剂, 可选择 CSII 或浆皮质胶胆胺素胶浆素人, 递注餐桑人剂胰素时,非调烧段时间的胰岛素剂量;\n\n【3】删除11:<u>(3)</u> 使用胆胺素者,可在部分者保甲根胶约外胰胺耳约约的总量加具胶素,或另外给于胰岛素转换常规素人。\n\n【4】新型冠状病毒感染治疗期间使用糖皮质激素时的血糖控制策略范围见图删除28:<u>1</u>。\n\n<mark>【5】(二) 低血糖处理</mark>\n\n【6】若出現低血糖症状,立即測指尖血糖,根据低血糖治疗流處处理并及时调整用药方案。\n\n【7】### 停用糖皮质激素后高血糖的评估\n\n【8】新型冠状病毒感染使用糖皮质激素治疗持续时间多约1d,短于常技受大剂糖皮质激素一般可迅速停止糖皮质激素治疗,转约2周到数周长时间可能有.上腺抑制的风隐,需逐渐缓减少剂量直xl至停止。临床师面在停用糖皮质激素后应注意监测血糖,血压,电解质,评估是否存在\"肾上.腺皮质抑制。\n\n【9】糖皮质激素诱导的高血糖多数会随者激素剂量的减少和停用而逐渐缓。糖尿病患者停用糖皮质激素后,根据血糖水平逐渐减少胰岛素剂或降糖药物,避免发生低血糖。静脉使用糖皮质激素者多在停用24-48h 后血糖效改善至使用前水平。\n\n【10】删除图片描述:<u>![](3_0.png)</u>\n\n<mark>【11】注:胰,易地住红在注者者;GLP-I_Ra为肽资源领抗理拮道剂.受体激动剂图丨新型冠状病毒感染治疗期间使用糖皮质激素时的血糖控制策略的简略图</mark>", "index": 588, "show": true, "start": 575, "end": 685, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/07 09:48:45", "endTime": "2024/08/07 09:49:48", "cost": 62.357}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 17:49:47", "grab_time": "2024-08-06 17:48:44"}
{"id": 2211732, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "78a55579-76a7-4a0b-833b-53cb53319150", "title": "ASA：困难气道的管理实践指南（2022）", "text": "【0】页码:23\nASA：困难气道的管理实践指南（2022）\n### Table 3. Human Factors Relevant to Difficult Airway Management\n\n| Practicioner factors | |\n|----------------------|-------------------------------|\n| 删除32:<u>**</u>Before删除32:<u>**</u> | |\n| Practitioner knowledge and training | |\n| Possible alternate outcomes (plan B) | |\n| Preoperative assessment | |\n| Complacency | |\n| 删除32:<u>**</u>During删除32:<u>**</u> | |\n| Internal and external stressors (fatigue, illness, production pressure) | |\n| Decision-making (perseveration, judgment, situational awareness, interpretation of data) | |\n| Team dynamics (leadership, role assignment, empowerment, sterile cockpit) | |\n| Calling for assistance | |\n| 删除32:<u>**</u>After删除32:<u>**</u> | |\n| Strategic debriefing | |\n| 删除32:<u>**</u>External factors删除32:<u>**</u> | |\n| Patient factors | Anatomical/physiological airway difficulty risk, aspiration risk, infection risk, exposure risk, urgency, comorbidities |\n| Environment factors | |\n| Airway equipment | |\n| Monitoring | |\n| Personal protective equipment | |\n| Institutional factors | |\n| Culture, staffing, shift duration | |\n| Protocols, reporting | |\n| Supervision/support, training | |\n\n【2】This table lists aspects of airway management that address how the practitioner may interact with patients, other clinicians, assistants, equipment, or the environment during the process of airway management. Practitioners may consider these factors before, during, and/or after the course of airway management. Factors are classified as related directly to or external to the practitioner.\n\n【3】### Table 4. Meta-analysis Summary: Videolaryngoscopy versus Direct Laryngoscopy删除32:<u>*</u>\n\n|                    | Effect | Heterogeneity |\n|--------------------|--------|---------------|\n|                    | Odds Ratio‡ (99% CI) | |\n|                    | Fixed     | P         | Random           | P         | I²  | P     |\n| Laryngoscopic view | 8 1,100 | 0.123 删除11:<u>(0.078, 0.194)</u> | < 0.001 | 0.124 删除11:<u>(0.056, 0.275)</u> | < 0.001 | 53%  | 0.036 |\n| Successful intubation | 10 1,213 | 1.181 删除11:<u>(1.097, 1.339)</u> | < 0.001 | 0.225 删除11:<u>(0.064, 0.803)</u> | 0.020 | 52% | 0.026 |\n| First attempt success | 9 624 | 0.321 删除11:<u>(0.161, 0.666)</u> | < 0.001 | 0.357 删除11:<u>(0.170, 0.749)</u> | < 0.001 | 0% | 0.719 |\n| Additional maneuvers | 6 738 | 0.379 删除11:<u>(0.250, 0.574)</u> | < 0.001 | 0.311 删除11:<u>(0.149, 0.650)</u> | < 0.001 | 57% | 0.041 |\n|                      | Mean Difference (99% CI) | |\n| Intubation time      | 10 793 | -0.158 删除11:<u>(-0.347, 0.030)</u> | 0.031 | -0.036 删除11:<u>(-0.652, 0.580)</u> | 0.880 | 90.12% | < 0.001 |\n\n【5】删除1:<u>\\删除32:<u>*</u>Statistics for individual studies and forest plots are available as Supplemental Digital Content 4, http://links.lww.com/ALN/C897.</u>\n删除5:<u>†</u>Number of studies included in the meta-analysis.\n‡Continuity correction of 0.5 for zero cell frequencies.", "tags": {}, "lang": "en", "attr": {"page_num": 23, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ASA：困难气道的管理实践指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Table 3. Human Factors Relevant to Difficult Airway Management\nPracticioner factors\t\n删除32:Before删除32:\t\nPractitioner knowledge and training\t\nPossible alternate outcomes (plan B)\t\nPreoperative assessment\t\nComplacency\t\n删除32:During删除32:\t\nInternal and external stressors (fatigue, illness, production pressure)\t\nDecision-making (perseveration, judgment, situational awareness, interpretation of data)\t\nTeam dynamics (leadership, role assignment, empowerment, sterile cockpit)\t\nCalling for assistance\t\n删除32:After删除32:\t\nStrategic debriefing\t\n删除32:External factors删除32:\t\nPatient factors\tAnatomical/physiological airway difficulty risk, aspiration risk, infection risk, exposure risk, urgency, comorbidities\nEnvironment factors\t\nAirway equipment\t\nMonitoring\t\nPersonal protective equipment\t\nInstitutional factors\t\nCulture, staffing, shift duration\t\nProtocols, reporting\t\nSupervision/support, training\t", "content": "【0】页码:23\nASA：困难气道的管理实践指南（2022）\n### Table 3. Human Factors Relevant to Difficult Airway Management\n\n| Practicioner factors | |\n|----------------------|-------------------------------|\n| 删除32:<u>**</u>Before删除32:<u>**</u> | |\n| Practitioner knowledge and training | |\n| Possible alternate outcomes (plan B) | |\n| Preoperative assessment | |\n| Complacency | |\n| 删除32:<u>**</u>During删除32:<u>**</u> | |\n| Internal and external stressors (fatigue, illness, production pressure) | |\n| Decision-making (perseveration, judgment, situational awareness, interpretation of data) | |\n| Team dynamics (leadership, role assignment, empowerment, sterile cockpit) | |\n| Calling for assistance | |\n| 删除32:<u>**</u>After删除32:<u>**</u> | |\n| Strategic debriefing | |\n| 删除32:<u>**</u>External factors删除32:<u>**</u> | |\n| Patient factors | Anatomical/physiological airway difficulty risk, aspiration risk, infection risk, exposure risk, urgency, comorbidities |\n| Environment factors | |\n| Airway equipment | |\n| Monitoring | |\n| Personal protective equipment | |\n| Institutional factors | |\n| Culture, staffing, shift duration | |\n| Protocols, reporting | |\n| Supervision/support, training | |\n\n【2】This table lists aspects of airway management that address how the practitioner may interact with patients, other clinicians, assistants, equipment, or the environment during the process of airway management. Practitioners may consider these factors before, during, and/or after the course of airway management. Factors are classified as related directly to or external to the practitioner.\n\n【3】### Table 4. Meta-analysis Summary: Videolaryngoscopy versus Direct Laryngoscopy删除32:<u>*</u>\n\n|                    | Effect | Heterogeneity |\n|--------------------|--------|---------------|\n|                    | Odds Ratio‡ (99% CI) | |\n|                    | Fixed     | P         | Random           | P         | I²  | P     |\n| Laryngoscopic view | 8 1,100 | 0.123 删除11:<u>(0.078, 0.194)</u> | < 0.001 | 0.124 删除11:<u>(0.056, 0.275)</u> | < 0.001 | 53%  | 0.036 |\n| Successful intubation | 10 1,213 | 1.181 删除11:<u>(1.097, 1.339)</u> | < 0.001 | 0.225 删除11:<u>(0.064, 0.803)</u> | 0.020 | 52% | 0.026 |\n| First attempt success | 9 624 | 0.321 删除11:<u>(0.161, 0.666)</u> | < 0.001 | 0.357 删除11:<u>(0.170, 0.749)</u> | < 0.001 | 0% | 0.719 |\n| Additional maneuvers | 6 738 | 0.379 删除11:<u>(0.250, 0.574)</u> | < 0.001 | 0.311 删除11:<u>(0.149, 0.650)</u> | < 0.001 | 57% | 0.041 |\n|                      | Mean Difference (99% CI) | |\n| Intubation time      | 10 793 | -0.158 删除11:<u>(-0.347, 0.030)</u> | 0.031 | -0.036 删除11:<u>(-0.652, 0.580)</u> | 0.880 | 90.12% | < 0.001 |\n\n【5】删除1:<u>\\删除32:<u>*</u>Statistics for individual studies and forest plots are available as Supplemental Digital Content 4, http://links.lww.com/ALN/C897.</u>\n删除5:<u>†</u>Number of studies included in the meta-analysis.\n‡Continuity correction of 0.5 for zero cell frequencies.", "index": 35, "show": true, "start": 35, "end": 926, "province": ["格式规范性", "表格格式错误"], "isEdit": false}, {"text": "【3】### Table 4. Meta-analysis Summary: Videolaryngoscopy versus Direct Laryngoscopy", "content": "【0】页码:23\nASA：困难气道的管理实践指南（2022）\n### <mark>Table 3. Human Factors Relevant to Difficult Airway Management\nPracticioner factors\t\n删除32:Before删除32:\t\nPractitioner knowledge and training\t\nPossible alternate outcomes (plan B)\t\nPreoperative assessment\t\nComplacency\t\n删除32:During删除32:\t\nInternal and external stressors (fatigue, illness, production pressure)\t\nDecision-making (perseveration, judgment, situational awareness, interpretation of data)\t\nTeam dynamics (leadership, role assignment, empowerment, sterile cockpit)\t\nCalling for assistance\t\n删除32:After删除32:\t\nStrategic debriefing\t\n删除32:External factors删除32:\t\nPatient factors\tAnatomical/physiological airway difficulty risk, aspiration risk, infection risk, exposure risk, urgency, comorbidities\nEnvironment factors\t\nAirway equipment\t\nMonitoring\t\nPersonal protective equipment\t\nInstitutional factors\t\nCulture, staffing, shift duration\t\nProtocols, reporting\t\nSupervision/support, training\t</mark>morbidities |\n| Environment factors | |\n| Airway equipment | |\n| Monitoring | |\n| Personal protective equipment | |\n| Institutional factors | |\n| Culture, staffing, shift duration | |\n| Protocols, reporting | |\n| Supervision/support, training | |\n\n【2】This table lists aspects of airway management that address how the practitioner may interact with patients, other clinicians, assistants, equipment, or the environment during the process of airway management. Practitioners may consider these factors before, during, and/or after the course of airway management. Factors are classified as related directly to or external to the practitioner.\n\n【3】### Table 4. Meta-analysis Summary: Videolaryngoscopy versus Direct Laryngoscopy删除32:<u>*</u>\n\n|                    | Effect | Heterogeneity |\n|--------------------|--------|---------------|\n|                    | Odds Ratio‡ (99% CI) | |\n|                    | Fixed     | P         | Random           | P         | I²  | P     |\n| Laryngoscopic view | 8 1,100 | 0.123 删除11:<u>(0.078, 0.194)</u> | < 0.001 | 0.124 删除11:<u>(0.056, 0.275)</u> | < 0.001 | 53%  | 0.036 |\n| Successful intubation | 10 1,213 | 1.181 删除11:<u>(1.097, 1.339)</u> | < 0.001 | 0.225 删除11:<u>(0.064, 0.803)</u> | 0.020 | 52% | 0.026 |\n| First attempt success | 9 624 | 0.321 删除11:<u>(0.161, 0.666)</u> | < 0.001 | 0.357 删除11:<u>(0.170, 0.749)</u> | < 0.001 | 0% | 0.719 |\n| Additional maneuvers | 6 738 | 0.379 删除11:<u>(0.250, 0.574)</u> | < 0.001 | 0.311 删除11:<u>(0.149, 0.650)</u> | < 0.001 | 57% | 0.041 |\n|                      | Mean Difference (99% CI) | |\n| Intubation time      | 10 793 | -0.158 删除11:<u>(-0.347, 0.030)</u> | 0.031 | -0.036 删除11:<u>(-0.652, 0.580)</u> | 0.880 | 90.12% | < 0.001 |\n\n【5】删除1:<u>\\删除32:<u>*</u>Statistics for individual studies and forest plots are available as Supplemental Digital Content 4, http://links.lww.com/ALN/C897.</u>\n删除5:<u>†</u>Number of studies included in the meta-analysis.\n‡Continuity correction of 0.5 for zero cell frequencies.", "index": 1582, "show": true, "start": 1569, "end": 1652, "province": ["格式规范性", "表格格式错误"], "isEdit": false}, {"text": "0.123 删除11:(0.078, 0.194)\nSuccessful intubation\t10 1,213\t1.181 删除11:(1.097, 1.339)\nFirst attempt success\t9 624\t0.321 删除11:(0.161, 0.666)\nAdditional maneuvers\t6 738\t0.379 删除11:(0.250, 0.574)\nMean Difference (99% CI)\t\nIntubation time\t10 793\t-0.158 删除11:(-0.347, 0.030)", "content": "【0】页码:23\nASA：困难气道的管理实践指南（2022）\n### <mark>Table 3. Human Factors Relevant to Difficult Airway Management\nPracticioner factors\t\n删除32:Before删除32:\t\nPractitioner knowledge and training\t\nPossible alternate outcomes (plan B)\t\nPreoperative assessment\t\nComplacency\t\n删除32:During删除32:\t\nInternal and external stressors (fatigue, illness, production pressure)\t\nDecision-making (perseveration, judgment, situational awareness, interpretation of data)\t\nTeam dynamics (leadership, role assignment, empowerment, sterile cockpit)\t\nCalling for assistance\t\n删除32:After删除32:\t\nStrategic debriefing\t\n删除32:External factors删除32:\t\nPatient factors\tAnatomical/physiological airway difficulty risk, aspiration risk, infection risk, exposure risk, urgency, comorbidities\nEnvironment factors\t\nAirway equipment\t\nMonitoring\t\nPersonal protective equipment\t\nInstitutional factors\t\nCulture, staffing, shift duration\t\nProtocols, reporting\t\nSupervision/support, training\t</mark>morbidities |\n| Environment factors | |\n| Airway equipment | |\n| Monitoring | |\n| Personal protective equipment | |\n| Institutional factors | |\n| Culture, staffing, shift duration | |\n| Protocols, reporting | |\n| Supervision/support, training | |\n\n【2】This table lists aspects of airway management that address how the practitioner may interact with patients, other clinicians, assistants, equipment, or the environment during the process of airway management. Practitioners may consider these factors before, during, and/or after the course of airway management. Factors are classified as related directly to or external to the practitioner.\n\n<mark>【3】### Table 4. Meta-analysis Summary: Videolaryngoscopy versus Direct Laryngoscopy</mark>删除32:<u>*</u>\n\n|                    | Effect | Heterogeneity |\n|--------------------|--------|---------------|\n|                    | Odds Ratio‡ (99% CI) | |\n|                    | Fixed     | P         | Random           | P         | I²  | P     |\n| Laryngoscopic view | 8 1,100 | 0.123 删除11:<u>(0.078, 0.194)</u> | < 0.001 | 0.124 删除11:<u>(0.056, 0.275)</u> | < 0.001 | 53%  | 0.036 |\n| Successful intubation | 10 1,213 | 1.181 删除11:<u>(1.097, 1.339)</u> | < 0.001 | 0.225 删除11:<u>(0.064, 0.803)</u> | 0.020 | 52% | 0.026 |\n| First attempt success | 9 624 | 0.321 删除11:<u>(0.161, 0.666)</u> | < 0.001 | 0.357 删除11:<u>(0.170, 0.749)</u> | < 0.001 | 0% | 0.719 |\n| Additional maneuvers | 6 738 | 0.379 删除11:<u>(0.250, 0.574)</u> | < 0.001 | 0.311 删除11:<u>(0.149, 0.650)</u> | < 0.001 | 57% | 0.041 |\n|                      | Mean Difference (99% CI) | |\n| Intubation time      | 10 793 | -0.158 删除11:<u>(-0.347, 0.030)</u> | 0.031 | -0.036 删除11:<u>(-0.652, 0.580)</u> | 0.880 | 90.12% | < 0.001 |\n\n【5】删除1:<u>\\删除32:<u>*</u>Statistics for individual studies and forest plots are available as Supplemental Digital Content 4, http://links.lww.com/ALN/C897.</u>\n删除5:<u>†</u>Number of studies included in the meta-analysis.\n‡Continuity correction of 0.5 for zero cell frequencies.", "index": 1962, "show": true, "start": 1936, "end": 2202, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "【3】"}], "startTime": "2024/08/06 16:03:20", "endTime": "2024/08/06 16:05:04", "cost": 104.378}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:05:04", "grab_time": "2024-08-06 00:03:20"}
{"id": 2211731, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "2fda73f7-52c4-45b1-89ee-e434e8dfeb25", "title": "2023+亚太共识建议：+X连锁低磷血症的诊断、多学科管理以及从儿童到成人的过渡护理(1)", "text": "【0】页码:16\n2023+亚太共识建议：+X连锁低磷血症的诊断、多学科管理以及从儿童到成人的过渡护理(1)\nTable 10. Asia-Pacific Consensus Recommendations on the Checklist to be Passed From the Pediatric to Adult Health Care Provider During Transition of Care of XLH\n\n删除32:<u>**</u>Statement 15删除32:<u>**</u> | 删除32:<u>**</u>Evidence quality: Expert opinion删除32:<u>**</u>\n:------------------- | :------------------------------|删除段内换行|The checklist of information that should be passed along with the transfer letter from the pediatric to adult health care provider during the transition of care of patients with XLH from childhood to adulthood may include the following parameters:\n删除32:<u>**</u>Patient/general information删除32:<u>**</u> | 删除32:<u>**</u>Details删除32:<u>**</u>\n:------------------- | :------------------------------|删除段内换行|删除32:<u>**</u>Patient information删除32:<u>**</u> | \nName | \nDate of birth/current age | \nDate of transfer of care | \nSex | \nAddress and contact number | \nCurrent insurance details | \nInformed consent for transition | ☑ Yes ☑ No\nAdditional details (if any) | \n删除32:<u>**</u>XLH history删除32:<u>**</u> | \n删除32:<u>**</u>XLH disease history删除32:<u>**</u> | 删除32:<u>**</u>Details删除32:<u>**</u> | 删除32:<u>**</u>Documents related to disease history删除32:<u>**</u> (as attachments) | 删除32:<u>**</u>Details删除32:<u>**</u>\nAge at diagnosis | Renal ultrasound | \nLab results at diagnosis | Radiographs | \nClinical features at diagnosis | Additional imaging results (if any) | \nGenetic test results (optional) | Dental images (optional)/records | \nLab results at latest visit | Gait video (optional) | \nHearing evaluation results | Detailed family history and photos (optional) | \nGrowth chart | Additional documents (if any) | \nFunctional outcomes (optional) | \nAdditional details (if any) | \n删除32:<u>**</u>Treatment history (related to XLH)删除32:<u>**</u> | 删除32:<u>**</u>Details of regimen/dose/duration删除32:<u>**</u> | 删除32:<u>**</u>Details删除32:<u>**</u>\nMedical treatment | \nPhosphate salts | \nCalcitriol | \nAlfacalcidol | \nBurosumab | \nOther treatments (if any) | \nSurgical procedures | \nHemi/epiphysiodesis | \nOsteotomy | \nSurgery for craniosynostosis | \nAdditional surgeries (if any) | \n删除32:<u>**</u>Complications删除32:<u>**</u> | 删除32:<u>**</u>Details删除32:<u>**</u> | 删除32:<u>**</u>Details删除32:<u>**</u>\nXLH-related complications | \nFractures | \nPseudofractures | \nLower limb deformities | \nDental conditions | \nCraniosynostosis | \nChiari 1 malformation | \nAdditional complications (if any) | \nTreatment-related complications | \nNephrocalcinosis/nephrolithiasis | \nHyperparathyroidism | \nHypercalciuria/hypercalcemia | \nRenal impairment | \nAdditional adverse effects (if any) | \n删除32:<u>**</u>Rare disease/XLH advocacy groups/helplines删除32:<u>**</u> | Advocacy groups or psychosocial support | ☑ Yes ☑ No\nIf yes, details | Helplines available | ☑ Yes ☑ No\nIf yes, details | \nAdditional details (if any) | \nAbbreviation: XLH = X-linked hypophosphatemia.\n\n【2】Meanwhile, renal ultrasound has been the monitoring tool utilized in clinical trials and real-world studies to evaluate the adverse effects of pharmacologic therapy in XLH. Accordingly, it is the pre-ferred screening method for nephrocalcinosis and should be performed annually.\n\n【3】Multidisciplinary monitoring\nBecause of the burden of dental disease in XLH, twice-yearly dental evaluations are recommended, regardless of age. Monitoring of other complications (ie, orthopedic, craniofacial, neurosurgical, audiologic) should be", "tags": {}, "lang": "en", "attr": {"page_num": 16, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023+亚太共识建议：+X连锁低磷血症的诊断、多学科管理以及从儿童到成人的过渡护理(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Table 10. Asia-Pacific Consensus Recommendations on the Checklist to be Passed From the Pediatric to Adult Health Care Provider During Transition of Care of XLH\n\n删除32:Statement 15删除32: | 删除32:Evidence quality: Expert opinion删除32:\n\n:------------------- | :------------------------------|删除段内换行|The checklist of information that should be passed along with the transfer letter from the pediatric to adult health care provider during the transition of care of patients with XLH from childhood to adulthood may include the following parameters:\n\n删除32:Patient/general information删除32: | 删除32:Details删除32:\n\n:------------------- | :------------------------------|删除段内换行|删除32:Patient information删除32: |", "content": "【0】页码:16\n2023+亚太共识建议：+X连锁低磷血症的诊断、多学科管理以及从儿童到成人的过渡护理(1)\nTable 10. Asia-Pacific Consensus Recommendations on the Checklist to be Passed From the Pediatric to Adult Health Care Provider During Transition of Care of XLH\n\n删除32:<u>**</u>Statement 15删除32:<u>**</u> | 删除32:<u>**</u>Evidence quality: Expert opinion删除32:<u>**</u>\n:------------------- | :------------------------------|删除段内换行|The checklist of information that should be passed along with the transfer letter from the pediatric to adult health care provider during the transition of care of patients with XLH from childhood to adulthood may include the following parameters:\n删除32:<u>**</u>Patient/general information删除32:<u>**</u> | 删除32:<u>**</u>Details删除32:<u>**</u>\n:------------------- | :------------------------------|删除段内换行|删除32:<u>**</u>Patient information删除32:<u>**</u> | \nName | \nDate of birth/current age | \nDate of transfer of care | \nSex | \nAddress and contact number | \nCurrent insurance details | \nInformed consent for transition | ☑ Yes ☑ No\nAdditional details (if any) | \n删除32:<u>**</u>XLH history删除32:<u>**</u> | \n删除32:<u>**</u>XLH disease history删除32:<u>**</u> | 删除32:<u>**</u>Details删除32:<u>**</u> | 删除32:<u>**</u>Documents related to disease history删除32:<u>**</u> (as attachments) | 删除32:<u>**</u>Details删除32:<u>**</u>\nAge at diagnosis | Renal ultrasound | \nLab results at diagnosis | Radiographs | \nClinical features at diagnosis | Additional imaging results (if any) | \nGenetic test results (optional) | Dental images (optional)/records | \nLab results at latest visit | Gait video (optional) | \nHearing evaluation results | Detailed family history and photos (optional) | \nGrowth chart | Additional documents (if any) | \nFunctional outcomes (optional) | \nAdditional details (if any) | \n删除32:<u>**</u>Treatment history (related to XLH)删除32:<u>**</u> | 删除32:<u>**</u>Details of regimen/dose/duration删除32:<u>**</u> | 删除32:<u>**</u>Details删除32:<u>**</u>\nMedical treatment | \nPhosphate salts | \nCalcitriol | \nAlfacalcidol | \nBurosumab | \nOther treatments (if any) | \nSurgical procedures | \nHemi/epiphysiodesis | \nOsteotomy | \nSurgery for craniosynostosis | \nAdditional surgeries (if any) | \n删除32:<u>**</u>Complications删除32:<u>**</u> | 删除32:<u>**</u>Details删除32:<u>**</u> | 删除32:<u>**</u>Details删除32:<u>**</u>\nXLH-related complications | \nFractures | \nPseudofractures | \nLower limb deformities | \nDental conditions | \nCraniosynostosis | \nChiari 1 malformation | \nAdditional complications (if any) | \nTreatment-related complications | \nNephrocalcinosis/nephrolithiasis | \nHyperparathyroidism | \nHypercalciuria/hypercalcemia | \nRenal impairment | \nAdditional adverse effects (if any) | \n删除32:<u>**</u>Rare disease/XLH advocacy groups/helplines删除32:<u>**</u> | Advocacy groups or psychosocial support | ☑ Yes ☑ No\nIf yes, details | Helplines available | ☑ Yes ☑ No\nIf yes, details | \nAdditional details (if any) | \nAbbreviation: XLH = X-linked hypophosphatemia.\n\n【2】Meanwhile, renal ultrasound has been the monitoring tool utilized in clinical trials and real-world studies to evaluate the adverse effects of pharmacologic therapy in XLH. Accordingly, it is the pre-ferred screening method for nephrocalcinosis and should be performed annually.\n\n【3】Multidisciplinary monitoring\nBecause of the burden of dental disease in XLH, twice-yearly dental evaluations are recommended, regardless of age. Monitoring of other complications (ie, orthopedic, craniofacial, neurosurgical, audiologic) should be", "index": 55, "show": true, "start": 55, "end": 749, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "全片表格内容，格式错误"}], "startTime": "2024/08/07 09:57:30", "endTime": "2024/08/07 09:58:16", "cost": 46.502}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 17:58:15", "grab_time": "2024-08-06 17:57:28"}
{"id": 2211730, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "6e4a469a-0cea-40c4-ab3d-c112f5b5e191", "title": "【风湿免疫领域】骨关节炎临床药物治疗专家共识", "text": "【0】页码:9\n【风湿免疫领域】骨关节炎临床药物治疗专家共识\n### 中国循证指南共识\n\n【1】联合用药，用药剂量和周期，用药注意事项、不良反应、安全性、有 效性等方面均应做到合理化、科学性用药。\n\n【2】#### 利益冲突声明\n所有参与本共识制定的专家对本共识有关的任何利益关系进行了无利益冲突声明，并填写了利益冲突声明表。\n\n【3】#### 共识编写专家组组长：\n陈世益 复旦大学附属华山医院  \n王坤正 西安交通大学第二附属医院\n\n【4】#### 执笔专家：（以姓氏拼音为序）\n陈世益 复旦大学附属华山医院  \n胡 宁 重庆医科大学附属第一医院  \n贾连波 内蒙古医科大学第二附属医院  \n李 衍 四川大学华西医院  \n李 楷 四川大学华西医院  \n尚向亮 复旦大学附属华山医院\n\n【5】#### 共识编写专家组成员：（以姓氏拼音为序）\n白传怡 中国医学科学院阜外医院  \n毕 毅 浙江省人民医院  \n陈世益 复旦大学附属华山医院  \n魏国柱 山东大学齐鲁医院  \n胡 宁 重庆医科大学附属第一医院  \n贾连波 内蒙古医科大学第二附属医院  \n蒋 青 南京大学医学院附属鼓楼医院  \n靳鸿燕 武汉大学中南医院  \n李 衍 四川大学华西医院  \n李 楷 四川大学华西医院  \n李国平 国家体育总局运动医学研究所  \n林 明 中国友好医院  \n刘 宁 郑州市骨科医院  \n刘玉杰 中国人民解放军总医院  \n吕 钦 景龙江医院  \n吕红斌 南方大学珠海医院  \n尚向亮 复旦大学附属华山医院  \n孙 康 青岛大学附属医院  \n王 飞 河北医科大学第三医院  \n王 洪  中科院科技大学附属医院附属协和医院  \n王 育 南京医科大学第二附属医院  \n王健生 北京大学医院  \n王坤正  西安交通大学第二附属医院  \n卫小春 山西医科大学第三医院  \n谭 中山 煤炭职工子弟总医院", "tags": {}, "lang": "zh", "attr": {"page_num": 9, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【风湿免疫领域】骨关节炎临床药物治疗专家共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "中国循证指南共识\n【1】联合用药，用药剂量和周期，用药注意事项、不良反应、安全性、有 效性等方面均应做到合理化、科学性用药。\n\n【2】#### 利益冲突声明\n\n所有参与本共识制定的专家对本共识有关的任何利益关系进行了无利益冲突声明，并填写了利益冲突声明表。\n\n【3】#### 共识编写专家组组长：\n\n陈世益 复旦大学附属华山医院\n\n王坤正 西安交通大学第二附属医院\n\n【4】#### 执笔专家：（以姓氏拼音为序）\n\n陈世益 复旦大学附属华山医院\n\n胡 宁 重庆医科大学附属第一医院\n\n贾连波 内蒙古医科大学第二附属医院\n\n李 衍 四川大学华西医院\n\n李 楷 四川大学华西医院\n\n尚向亮 复旦大学附属华山医院\n\n【5】#### 共识编写专家组成员：（以姓氏拼音为序）\n\n白传怡 中国医学科学院阜外医院\n\n毕 毅 浙江省人民医院\n\n陈世益 复旦大学附属华山医院\n\n魏国柱 山东大学齐鲁医院\n\n胡 宁 重庆医科大学附属第一医院\n\n贾连波 内蒙古医科大学第二附属医院\n\n蒋 青 南京大学医学院附属鼓楼医院\n\n靳鸿燕 武汉大学中南医院\n\n李 衍 四川大学华西医院\n\n李 楷 四川大学华西医院\n\n李国平 国家体育总局运动医学研究所\n\n林 明 中国友好医院\n\n刘 宁 郑州市骨科医院\n\n刘玉杰 中国人民解放军总医院\n\n吕 钦 景龙江医院\n\n吕红斌 南方大学珠海医院\n\n尚向亮 复旦大学附属华山医院\n\n孙 康 青岛大学附属医院\n\n王 飞 河北医科大学第三医院\n\n王 洪  中科院科技大学附属医院附属协和医院\n\n王 育 南京医科大学第二附属医院\n\n王健生 北京大学医院\n\n王坤正  西安交通大学第二附属医院\n\n卫小春 山西医科大学第三医院\n\n谭 中山 煤炭职工子弟总医院\n\n\n", "content": "【0】页码:9\n【风湿免疫领域】骨关节炎临床药物治疗专家共识\n### 中国循证指南共识\n\n【1】联合用药，用药剂量和周期，用药注意事项、不良反应、安全性、有 效性等方面均应做到合理化、科学性用药。\n\n【2】#### 利益冲突声明\n所有参与本共识制定的专家对本共识有关的任何利益关系进行了无利益冲突声明，并填写了利益冲突声明表。\n\n【3】#### 共识编写专家组组长：\n陈世益 复旦大学附属华山医院  \n王坤正 西安交通大学第二附属医院\n\n【4】#### 执笔专家：（以姓氏拼音为序）\n陈世益 复旦大学附属华山医院  \n胡 宁 重庆医科大学附属第一医院  \n贾连波 内蒙古医科大学第二附属医院  \n李 衍 四川大学华西医院  \n李 楷 四川大学华西医院  \n尚向亮 复旦大学附属华山医院\n\n【5】#### 共识编写专家组成员：（以姓氏拼音为序）\n白传怡 中国医学科学院阜外医院  \n毕 毅 浙江省人民医院  \n陈世益 复旦大学附属华山医院  \n魏国柱 山东大学齐鲁医院  \n胡 宁 重庆医科大学附属第一医院  \n贾连波 内蒙古医科大学第二附属医院  \n蒋 青 南京大学医学院附属鼓楼医院  \n靳鸿燕 武汉大学中南医院  \n李 衍 四川大学华西医院  \n李 楷 四川大学华西医院  \n李国平 国家体育总局运动医学研究所  \n林 明 中国友好医院  \n刘 宁 郑州市骨科医院  \n刘玉杰 中国人民解放军总医院  \n吕 钦 景龙江医院  \n吕红斌 南方大学珠海医院  \n尚向亮 复旦大学附属华山医院  \n孙 康 青岛大学附属医院  \n王 飞 河北医科大学第三医院  \n王 洪  中科院科技大学附属医院附属协和医院  \n王 育 南京医科大学第二附属医院  \n王健生 北京大学医院  \n王坤正  西安交通大学第二附属医院  \n卫小春 山西医科大学第三医院  \n谭 中山 煤炭职工子弟总医院", "index": 35, "show": true, "start": 35, "end": 764, "province": ["信息质量", "有用性-重"], "isEdit": false}], "startTime": "2024/08/06 15:39:22", "endTime": "2024/08/06 15:39:39", "cost": 16.951}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-05 23:39:39", "grab_time": "2024-08-05 23:39:22"}
{"id": 2211729, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "ae414669-490e-422f-93cc-2c106f6e9d4b", "title": "微创远端胰腺切除术的精确解剖的国际专家共识（2022）(1)", "text": "【0】页码:9\n微创远端胰腺切除术的精确解剖的国际专家共识（2022）(1)\ndepth of the posterior invasion. (literature evidence 3, expert agreement 100%).\n\n【1】### Recommendation 10\nAvoiding injury of the left renal artery or its branches is important when dissecting the perirenal fat around the left renal hilum to achieve a negative posterior margin of the pancreatic tumor during MIDP (literature evidence 4, expert agreement 100%).\n\n【2】#### Comments\nIn the survey, the experts strongly recommended identification of the left renal vein, left adrenal gland, ligament of Treitz, Gerota's fascia, and left kidney to achieve a negative posterior margin without any injury, as there is a need to go deeper into the posterior dissection layer during MIDP, especially in cases of pancreatic cancer 删除9:<u>(Table 3)</u>. Opinions regarding the depth of the posterior dissection line indicated for patients with pancreatic tumors with different degrees of malignancy and locations varied among experts 删除9:<u>(Table 4)</u>. However, the experts agreed that the judgement on whether to resect Gerota’s fascia and/or the left adrenal gland during MIDP for pancreatic cancer should be based on the depth of tumor invasion. One of the most important pitfalls when performing MIDP for pancreatic cancer is the presence of a left renal arterial branch that courses ventral to the left adrenal vein near the renal hilum.\n\n### 4 | DISCUSSION\nSince the first applications of laparoscopic distal pancreatectomy in the 1990s and robotic distal pancreatectomy in the 2000s, MIDP has become widespread over the last 20 years. Surgical techniques and approaches for MIDP have undergone remarkable development, exhibiting outcomes comparable to those for open distal pancreatectomy for benign and low-grade malignant tumors, and even for pancreatic cancer in selected patients.\n\n【4】However, MIDP has yet to be standardized for appropriate dissemination worldwide. The consensus meeting discussed in the present report was the very first opportunity for international MIPR experts to fully discuss the anatomical pitfalls and landmarks that should be considered to ensure that MIDP is performed safely.\n\n【5】As the first step in this project, we reviewed the available evidence in the literature. As expected, very few studies provided scientific evidence that could ensure the recommendations. Most of the articles reviewed were case series and case reports that were categorized as “expert opinions,” and few RCTs and comparative studies with large numbers of patients were identified. Therefore, we also placed an emphasis on the results of our expert survey to reflect the wide range of opinions regarding the recommendations among international MIPR experts.\n\n【6】The survey revealed that 72% of experts had already standardized or felt the need to standardize the MIDP approach among their own teams. On the other hand, 28% responded that they chose their approach for MIDP on a case-by-case basis, depending on the tumor location, level of invasion, and differences in personal physical characteristics.\n\n| TABLE 4 Expert survey results: Posterior dissection line during MIDP |\n|:----------------------------------------------------------|\n| 删除32:<u>**</u>Question: Do you choose this posterior dissection line for the following cases during MIDP?删除32:<u>**</u> |\n| 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic tail删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic tail删除32:<u>**</u> |\n| 删除32:<u>**</u>Line A删除32:<u>**</u> (anterior layer above Gerota's fascia) | 7 (28%) | 9 (36%) | 25 (100%) | 24 (96%) |\n| 删除32:<u>**</u>Line B删除32:<u>**</u> (posterior layer of Gerota’s fascia for preserving the adrenal gland) | 22 (88%) | 22 (88%) | 2 (8%) | 0 (0%) |\n| 删除32:<u>**</u>Line C删除32:<u>**</u> (surface of the left kidney for resecting the left adrenal gland) | 15 (60%) | 11 (44%) | 0 (0%) | 0 (0%) |\n| 删除32:<u>**</u>Others删除32:<u>**</u> | 4 (16%) | 4 (16%) | 0 (0%) | 0 (0%) |\n\n【8】Note: It depends on the depth of invasion to the target margin / It depends on whether the tumor is adherent to the left adrenal gland / I will be less aggressive with the posterior dissection based on patient age or fitness / I cannot choose from Line B or C.\n\n【9】During the expert consensus meeting and via email revealed some obstacles for the standardization of MIDP procedures. First, the experts had different preferences regarding the various approaches for MIDP. As shown in Figure 2, 44% of experts in the group dissected around the spleen first, while 38% transected the SpA first prior to dissection around the spleen. Likewise, the method for reliably approaching the SpA root was debated. Experts mostly performed either an anterior or posterior approach to the SpA root during MIDP. However, no previous reports provided evidence suggesting the superiority of either approach in terms of safety or usefulness. More", "tags": {}, "lang": "en", "attr": {"page_num": 9, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/微创远端胰腺切除术的精确解剖的国际专家共识（2022）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【8】Note:", "content": "【0】页码:9\n微创远端胰腺切除术的精确解剖的国际专家共识（2022）(1)\ndepth of the posterior invasion. (literature evidence 3, expert agreement 100%).\n\n【1】### Recommendation 10\nAvoiding injury of the left renal artery or its branches is important when dissecting the perirenal fat around the left renal hilum to achieve a negative posterior margin of the pancreatic tumor during MIDP (literature evidence 4, expert agreement 100%).\n\n【2】#### Comments\nIn the survey, the experts strongly recommended identification of the left renal vein, left adrenal gland, ligament of Treitz, Gerota's fascia, and left kidney to achieve a negative posterior margin without any injury, as there is a need to go deeper into the posterior dissection layer during MIDP, especially in cases of pancreatic cancer 删除9:<u>(Table 3)</u>. Opinions regarding the depth of the posterior dissection line indicated for patients with pancreatic tumors with different degrees of malignancy and locations varied among experts 删除9:<u>(Table 4)</u>. However, the experts agreed that the judgement on whether to resect Gerota’s fascia and/or the left adrenal gland during MIDP for pancreatic cancer should be based on the depth of tumor invasion. One of the most important pitfalls when performing MIDP for pancreatic cancer is the presence of a left renal arterial branch that courses ventral to the left adrenal vein near the renal hilum.\n\n### 4 | DISCUSSION\nSince the first applications of laparoscopic distal pancreatectomy in the 1990s and robotic distal pancreatectomy in the 2000s, MIDP has become widespread over the last 20 years. Surgical techniques and approaches for MIDP have undergone remarkable development, exhibiting outcomes comparable to those for open distal pancreatectomy for benign and low-grade malignant tumors, and even for pancreatic cancer in selected patients.\n\n【4】However, MIDP has yet to be standardized for appropriate dissemination worldwide. The consensus meeting discussed in the present report was the very first opportunity for international MIPR experts to fully discuss the anatomical pitfalls and landmarks that should be considered to ensure that MIDP is performed safely.\n\n【5】As the first step in this project, we reviewed the available evidence in the literature. As expected, very few studies provided scientific evidence that could ensure the recommendations. Most of the articles reviewed were case series and case reports that were categorized as “expert opinions,” and few RCTs and comparative studies with large numbers of patients were identified. Therefore, we also placed an emphasis on the results of our expert survey to reflect the wide range of opinions regarding the recommendations among international MIPR experts.\n\n【6】The survey revealed that 72% of experts had already standardized or felt the need to standardize the MIDP approach among their own teams. On the other hand, 28% responded that they chose their approach for MIDP on a case-by-case basis, depending on the tumor location, level of invasion, and differences in personal physical characteristics.\n\n| TABLE 4 Expert survey results: Posterior dissection line during MIDP |\n|:----------------------------------------------------------|\n| 删除32:<u>**</u>Question: Do you choose this posterior dissection line for the following cases during MIDP?删除32:<u>**</u> |\n| 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic tail删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic tail删除32:<u>**</u> |\n| 删除32:<u>**</u>Line A删除32:<u>**</u> (anterior layer above Gerota's fascia) | 7 (28%) | 9 (36%) | 25 (100%) | 24 (96%) |\n| 删除32:<u>**</u>Line B删除32:<u>**</u> (posterior layer of Gerota’s fascia for preserving the adrenal gland) | 22 (88%) | 22 (88%) | 2 (8%) | 0 (0%) |\n| 删除32:<u>**</u>Line C删除32:<u>**</u> (surface of the left kidney for resecting the left adrenal gland) | 15 (60%) | 11 (44%) | 0 (0%) | 0 (0%) |\n| 删除32:<u>**</u>Others删除32:<u>**</u> | 4 (16%) | 4 (16%) | 0 (0%) | 0 (0%) |\n\n【8】Note: It depends on the depth of invasion to the target margin / It depends on whether the tumor is adherent to the left adrenal gland / I will be less aggressive with the posterior dissection based on patient age or fitness / I cannot choose from Line B or C.\n\n【9】During the expert consensus meeting and via email revealed some obstacles for the standardization of MIDP procedures. First, the experts had different preferences regarding the various approaches for MIDP. As shown in Figure 2, 44% of experts in the group dissected around the spleen first, while 38% transected the SpA first prior to dissection around the spleen. Likewise, the method for reliably approaching the SpA root was debated. Experts mostly performed either an anterior or posterior approach to the SpA root during MIDP. However, no previous reports provided evidence suggesting the superiority of either approach in terms of safety or usefulness. More", "index": 4118, "show": true, "start": 4118, "end": 4126, "province": ["语义有效性", "语义不完整"], "isEdit": false}, {"text": "ds on the depth of invasion to the target margin / It depends on whether the tumor is adherent to the left adrenal gland / I will be less aggressive with the posterior dissection based on patient age or fitness / I cannot choose from Line B or C.", "content": "【0】页码:9\n微创远端胰腺切除术的精确解剖的国际专家共识（2022）(1)\ndepth of the posterior invasion. (literature evidence 3, expert agreement 100%).\n\n【1】### Recommendation 10\nAvoiding injury of the left renal artery or its branches is important when dissecting the perirenal fat around the left renal hilum to achieve a negative posterior margin of the pancreatic tumor during MIDP (literature evidence 4, expert agreement 100%).\n\n【2】#### Comments\nIn the survey, the experts strongly recommended identification of the left renal vein, left adrenal gland, ligament of Treitz, Gerota's fascia, and left kidney to achieve a negative posterior margin without any injury, as there is a need to go deeper into the posterior dissection layer during MIDP, especially in cases of pancreatic cancer 删除9:<u>(Table 3)</u>. Opinions regarding the depth of the posterior dissection line indicated for patients with pancreatic tumors with different degrees of malignancy and locations varied among experts 删除9:<u>(Table 4)</u>. However, the experts agreed that the judgement on whether to resect Gerota’s fascia and/or the left adrenal gland during MIDP for pancreatic cancer should be based on the depth of tumor invasion. One of the most important pitfalls when performing MIDP for pancreatic cancer is the presence of a left renal arterial branch that courses ventral to the left adrenal vein near the renal hilum.\n\n### 4 | DISCUSSION\nSince the first applications of laparoscopic distal pancreatectomy in the 1990s and robotic distal pancreatectomy in the 2000s, MIDP has become widespread over the last 20 years. Surgical techniques and approaches for MIDP have undergone remarkable development, exhibiting outcomes comparable to those for open distal pancreatectomy for benign and low-grade malignant tumors, and even for pancreatic cancer in selected patients.\n\n【4】However, MIDP has yet to be standardized for appropriate dissemination worldwide. The consensus meeting discussed in the present report was the very first opportunity for international MIPR experts to fully discuss the anatomical pitfalls and landmarks that should be considered to ensure that MIDP is performed safely.\n\n【5】As the first step in this project, we reviewed the available evidence in the literature. As expected, very few studies provided scientific evidence that could ensure the recommendations. Most of the articles reviewed were case series and case reports that were categorized as “expert opinions,” and few RCTs and comparative studies with large numbers of patients were identified. Therefore, we also placed an emphasis on the results of our expert survey to reflect the wide range of opinions regarding the recommendations among international MIPR experts.\n\n【6】The survey revealed that 72% of experts had already standardized or felt the need to standardize the MIDP approach among their own teams. On the other hand, 28% responded that they chose their approach for MIDP on a case-by-case basis, depending on the tumor location, level of invasion, and differences in personal physical characteristics.\n\n| TABLE 4 Expert survey results: Posterior dissection line during MIDP |\n|:----------------------------------------------------------|\n| 删除32:<u>**</u>Question: Do you choose this posterior dissection line for the following cases during MIDP?删除32:<u>**</u> |\n| 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic tail删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic tail删除32:<u>**</u> |\n| 删除32:<u>**</u>Line A删除32:<u>**</u> (anterior layer above Gerota's fascia) | 7 (28%) | 9 (36%) | 25 (100%) | 24 (96%) |\n| 删除32:<u>**</u>Line B删除32:<u>**</u> (posterior layer of Gerota’s fascia for preserving the adrenal gland) | 22 (88%) | 22 (88%) | 2 (8%) | 0 (0%) |\n| 删除32:<u>**</u>Line C删除32:<u>**</u> (surface of the left kidney for resecting the left adrenal gland) | 15 (60%) | 11 (44%) | 0 (0%) | 0 (0%) |\n| 删除32:<u>**</u>Others删除32:<u>**</u> | 4 (16%) | 4 (16%) | 0 (0%) | 0 (0%) |\n\n【8】Note:<mark>【8】Note:</mark>nds on the depth of invasion to the target margin / It depends on whether the tumor is adherent to the left adrenal gland / I will be less aggressive with the posterior dissection based on patient age or fitness / I cannot choose from Line B or C.\n\n【9】During the expert consensus meeting and via email revealed some obstacles for the standardization of MIDP procedures. First, the experts had different preferences regarding the various approaches for MIDP. As shown in Figure 2, 44% of experts in the group dissected around the spleen first, while 38% transected the SpA first prior to dissection around the spleen. Likewise, the method for reliably approaching the SpA root was debated. Experts mostly performed either an anterior or posterior approach to the SpA root during MIDP. However, no previous reports provided evidence suggesting the superiority of either approach in terms of safety or usefulness. More", "index": 4140, "show": true, "start": 4127, "end": 4373, "province": ["格式规范性", "缺少换行"], "isEdit": false, "comment": "【8】"}, {"text": "During the expert consensus meeting and via email revealed some obstacles for the standardization of MIDP procedures. ", "content": "【0】页码:9\n微创远端胰腺切除术的精确解剖的国际专家共识（2022）(1)\ndepth of the posterior invasion. (literature evidence 3, expert agreement 100%).\n\n【1】### Recommendation 10\nAvoiding injury of the left renal artery or its branches is important when dissecting the perirenal fat around the left renal hilum to achieve a negative posterior margin of the pancreatic tumor during MIDP (literature evidence 4, expert agreement 100%).\n\n【2】#### Comments\nIn the survey, the experts strongly recommended identification of the left renal vein, left adrenal gland, ligament of Treitz, Gerota's fascia, and left kidney to achieve a negative posterior margin without any injury, as there is a need to go deeper into the posterior dissection layer during MIDP, especially in cases of pancreatic cancer 删除9:<u>(Table 3)</u>. Opinions regarding the depth of the posterior dissection line indicated for patients with pancreatic tumors with different degrees of malignancy and locations varied among experts 删除9:<u>(Table 4)</u>. However, the experts agreed that the judgement on whether to resect Gerota’s fascia and/or the left adrenal gland during MIDP for pancreatic cancer should be based on the depth of tumor invasion. One of the most important pitfalls when performing MIDP for pancreatic cancer is the presence of a left renal arterial branch that courses ventral to the left adrenal vein near the renal hilum.\n\n### 4 | DISCUSSION\nSince the first applications of laparoscopic distal pancreatectomy in the 1990s and robotic distal pancreatectomy in the 2000s, MIDP has become widespread over the last 20 years. Surgical techniques and approaches for MIDP have undergone remarkable development, exhibiting outcomes comparable to those for open distal pancreatectomy for benign and low-grade malignant tumors, and even for pancreatic cancer in selected patients.\n\n【4】However, MIDP has yet to be standardized for appropriate dissemination worldwide. The consensus meeting discussed in the present report was the very first opportunity for international MIPR experts to fully discuss the anatomical pitfalls and landmarks that should be considered to ensure that MIDP is performed safely.\n\n【5】As the first step in this project, we reviewed the available evidence in the literature. As expected, very few studies provided scientific evidence that could ensure the recommendations. Most of the articles reviewed were case series and case reports that were categorized as “expert opinions,” and few RCTs and comparative studies with large numbers of patients were identified. Therefore, we also placed an emphasis on the results of our expert survey to reflect the wide range of opinions regarding the recommendations among international MIPR experts.\n\n【6】The survey revealed that 72% of experts had already standardized or felt the need to standardize the MIDP approach among their own teams. On the other hand, 28% responded that they chose their approach for MIDP on a case-by-case basis, depending on the tumor location, level of invasion, and differences in personal physical characteristics.\n\n| TABLE 4 Expert survey results: Posterior dissection line during MIDP |\n|:----------------------------------------------------------|\n| 删除32:<u>**</u>Question: Do you choose this posterior dissection line for the following cases during MIDP?删除32:<u>**</u> |\n| 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic tail删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic tail删除32:<u>**</u> |\n| 删除32:<u>**</u>Line A删除32:<u>**</u> (anterior layer above Gerota's fascia) | 7 (28%) | 9 (36%) | 25 (100%) | 24 (96%) |\n| 删除32:<u>**</u>Line B删除32:<u>**</u> (posterior layer of Gerota’s fascia for preserving the adrenal gland) | 22 (88%) | 22 (88%) | 2 (8%) | 0 (0%) |\n| 删除32:<u>**</u>Line C删除32:<u>**</u> (surface of the left kidney for resecting the left adrenal gland) | 15 (60%) | 11 (44%) | 0 (0%) | 0 (0%) |\n| 删除32:<u>**</u>Others删除32:<u>**</u> | 4 (16%) | 4 (16%) | 0 (0%) | 0 (0%) |\n\n【8】Note:<mark>【8】Note:</mark>n<mark>ds on the depth of invasion to the target margin / It depends on whether the tumor is adherent to the left adrenal gland / I will be less aggressive with the posterior dissection based on patient age or fitness / I cannot choose from Line B or C.</mark>\n\n【9】During the expert consensus meeting and via email revealed some obstacles for the standardization of MIDP procedures. First, the experts had different preferences regarding the various approaches for MIDP. As shown in Figure 2, 44% of experts in the group dissected around the spleen first, while 38% transected the SpA first prior to dissection around the spleen. Likewise, the method for reliably approaching the SpA root was debated. Experts mostly performed either an anterior or posterior approach to the SpA root during MIDP. However, no previous reports provided evidence suggesting the superiority of either approach in terms of safety or usefulness. More", "index": 4404, "show": true, "start": 4378, "end": 4496, "province": ["语义有效性", "语义不完整"], "isEdit": false, "comment": "【9】"}, {"text": "TABLE 4 Expert survey results: Posterior dissection line during MIDP", "content": "【0】页码:9\n微创远端胰腺切除术的精确解剖的国际专家共识（2022）(1)\ndepth of the posterior invasion. (literature evidence 3, expert agreement 100%).\n\n【1】### Recommendation 10\nAvoiding injury of the left renal artery or its branches is important when dissecting the perirenal fat around the left renal hilum to achieve a negative posterior margin of the pancreatic tumor during MIDP (literature evidence 4, expert agreement 100%).\n\n【2】#### Comments\nIn the survey, the experts strongly recommended identification of the left renal vein, left adrenal gland, ligament of Treitz, Gerota's fascia, and left kidney to achieve a negative posterior margin without any injury, as there is a need to go deeper into the posterior dissection layer during MIDP, especially in cases of pancreatic cancer 删除9:<u>(Table 3)</u>. Opinions regarding the depth of the posterior dissection line indicated for patients with pancreatic tumors with different degrees of malignancy and locations varied among experts 删除9:<u>(Table 4)</u>. However, the experts agreed that the judgement on whether to resect Gerota’s fascia and/or the left adrenal gland during MIDP for pancreatic cancer should be based on the depth of tumor invasion. One of the most important pitfalls when performing MIDP for pancreatic cancer is the presence of a left renal arterial branch that courses ventral to the left adrenal vein near the renal hilum.\n\n### 4 | DISCUSSION\nSince the first applications of laparoscopic distal pancreatectomy in the 1990s and robotic distal pancreatectomy in the 2000s, MIDP has become widespread over the last 20 years. Surgical techniques and approaches for MIDP have undergone remarkable development, exhibiting outcomes comparable to those for open distal pancreatectomy for benign and low-grade malignant tumors, and even for pancreatic cancer in selected patients.\n\n【4】However, MIDP has yet to be standardized for appropriate dissemination worldwide. The consensus meeting discussed in the present report was the very first opportunity for international MIPR experts to fully discuss the anatomical pitfalls and landmarks that should be considered to ensure that MIDP is performed safely.\n\n【5】As the first step in this project, we reviewed the available evidence in the literature. As expected, very few studies provided scientific evidence that could ensure the recommendations. Most of the articles reviewed were case series and case reports that were categorized as “expert opinions,” and few RCTs and comparative studies with large numbers of patients were identified. Therefore, we also placed an emphasis on the results of our expert survey to reflect the wide range of opinions regarding the recommendations among international MIPR experts.\n\n【6】The survey revealed that 72% of experts had already standardized or felt the need to standardize the MIDP approach among their own teams. On the other hand, 28% responded that they chose their approach for MIDP on a case-by-case basis, depending on the tumor location, level of invasion, and differences in personal physical characteristics.\n\n| TABLE 4 Expert survey results: Posterior dissection line during MIDP |\n|:----------------------------------------------------------|\n| 删除32:<u>**</u>Question: Do you choose this posterior dissection line for the following cases during MIDP?删除32:<u>**</u> |\n| 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic tail删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic tail删除32:<u>**</u> |\n| 删除32:<u>**</u>Line A删除32:<u>**</u> (anterior layer above Gerota's fascia) | 7 (28%) | 9 (36%) | 25 (100%) | 24 (96%) |\n| 删除32:<u>**</u>Line B删除32:<u>**</u> (posterior layer of Gerota’s fascia for preserving the adrenal gland) | 22 (88%) | 22 (88%) | 2 (8%) | 0 (0%) |\n| 删除32:<u>**</u>Line C删除32:<u>**</u> (surface of the left kidney for resecting the left adrenal gland) | 15 (60%) | 11 (44%) | 0 (0%) | 0 (0%) |\n| 删除32:<u>**</u>Others删除32:<u>**</u> | 4 (16%) | 4 (16%) | 0 (0%) | 0 (0%) |\n\n【8】Note:<mark>【8】Note:</mark>n<mark>ds on the depth of invasion to the target margin / It depends on whether the tumor is adherent to the left adrenal gland / I will be less aggressive with the posterior dissection based on patient age or fitness / I cannot choose from Line B or C.</mark>\n\n【9】<mark>During the expert consensus meeting and via email revealed some obstacles for the standardization of MIDP procedures. </mark>First, the experts had different preferences regarding the various approaches for MIDP. As shown in Figure 2, 44% of experts in the group dissected around the spleen first, while 38% transected the SpA first prior to dissection around the spleen. Likewise, the method for reliably approaching the SpA root was debated. Experts mostly performed either an anterior or posterior approach to the SpA root during MIDP. However, no previous reports provided evidence suggesting the superiority of either approach in terms of safety or usefulness. More", "index": 3056, "show": true, "start": 3056, "end": 3124, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "【6】"}, {"text": "【6】", "content": "【0】页码:9\n微创远端胰腺切除术的精确解剖的国际专家共识（2022）(1)\ndepth of the posterior invasion. (literature evidence 3, expert agreement 100%).\n\n【1】### Recommendation 10\nAvoiding injury of the left renal artery or its branches is important when dissecting the perirenal fat around the left renal hilum to achieve a negative posterior margin of the pancreatic tumor during MIDP (literature evidence 4, expert agreement 100%).\n\n【2】#### Comments\nIn the survey, the experts strongly recommended identification of the left renal vein, left adrenal gland, ligament of Treitz, Gerota's fascia, and left kidney to achieve a negative posterior margin without any injury, as there is a need to go deeper into the posterior dissection layer during MIDP, especially in cases of pancreatic cancer 删除9:<u>(Table 3)</u>. Opinions regarding the depth of the posterior dissection line indicated for patients with pancreatic tumors with different degrees of malignancy and locations varied among experts 删除9:<u>(Table 4)</u>. However, the experts agreed that the judgement on whether to resect Gerota’s fascia and/or the left adrenal gland during MIDP for pancreatic cancer should be based on the depth of tumor invasion. One of the most important pitfalls when performing MIDP for pancreatic cancer is the presence of a left renal arterial branch that courses ventral to the left adrenal vein near the renal hilum.\n\n### 4 | DISCUSSION\nSince the first applications of laparoscopic distal pancreatectomy in the 1990s and robotic distal pancreatectomy in the 2000s, MIDP has become widespread over the last 20 years. Surgical techniques and approaches for MIDP have undergone remarkable development, exhibiting outcomes comparable to those for open distal pancreatectomy for benign and low-grade malignant tumors, and even for pancreatic cancer in selected patients.\n\n【4】However, MIDP has yet to be standardized for appropriate dissemination worldwide. The consensus meeting discussed in the present report was the very first opportunity for international MIPR experts to fully discuss the anatomical pitfalls and landmarks that should be considered to ensure that MIDP is performed safely.\n\n【5】As the first step in this project, we reviewed the available evidence in the literature. As expected, very few studies provided scientific evidence that could ensure the recommendations. Most of the articles reviewed were case series and case reports that were categorized as “expert opinions,” and few RCTs and comparative studies with large numbers of patients were identified. Therefore, we also placed an emphasis on the results of our expert survey to reflect the wide range of opinions regarding the recommendations among international MIPR experts.\n\n【6】The survey revealed that 72% of experts had already standardized or felt the need to standardize the MIDP approach among their own teams. On the other hand, 28% responded that they chose their approach for MIDP on a case-by-case basis, depending on the tumor location, level of invasion, and differences in personal physical characteristics.\n\n| <mark>TABLE 4 Expert survey results: Posterior dissection line during MIDP</mark> |\n|:----------------------------------------------------------|\n| 删除32:<u>**</u>Question: Do you choose this posterior dissection line for the following cases during MIDP?删除32:<u>**</u> |\n| 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Pancreatic cancer (T2) located at pancreatic tail删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic body删除32:<u>**</u> | 删除32:<u>**</u>Benign tumors located at pancreatic tail删除32:<u>**</u> |\n| 删除32:<u>**</u>Line A删除32:<u>**</u> (anterior layer above Gerota's fascia) | 7 (28%) | 9 (36%) | 25 (100%) | 24 (96%) |\n| 删除32:<u>**</u>Line B删除32:<u>**</u> (posterior layer of Gerota’s fascia for preserving the adrenal gland) | 22 (88%) | 22 (88%) | 2 (8%) | 0 (0%) |\n| 删除32:<u>**</u>Line C删除32:<u>**</u> (surface of the left kidney for resecting the left adrenal gland) | 15 (60%) | 11 (44%) | 0 (0%) | 0 (0%) |\n| 删除32:<u>**</u>Others删除32:<u>**</u> | 4 (16%) | 4 (16%) | 0 (0%) | 0 (0%) |\n\n【8】Note:<mark>【8】Note:</mark>n<mark>ds on the depth of invasion to the target margin / It depends on whether the tumor is adherent to the left adrenal gland / I will be less aggressive with the posterior dissection based on patient age or fitness / I cannot choose from Line B or C.</mark>\n\n【9】<mark>During the expert consensus meeting and via email revealed some obstacles for the standardization of MIDP procedures. </mark>First, the experts had different preferences regarding the various approaches for MIDP. As shown in Figure 2, 44% of experts in the group dissected around the spleen first, while 38% transected the SpA first prior to dissection around the spleen. Likewise, the method for reliably approaching the SpA root was debated. Experts mostly performed either an anterior or posterior approach to the SpA root during MIDP. However, no previous reports provided evidence suggesting the superiority of either approach in terms of safety or usefulness. More", "index": 2708, "show": true, "start": 2708, "end": 2711, "province": ["语义有效性", "栏目混乱-中"], "isEdit": false, "comment": "到【9】 表格穿插在正文中间"}], "startTime": "2024/08/07 09:49:10", "endTime": "2024/08/07 09:52:13", "cost": 183.054}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 17:52:12", "grab_time": "2024-08-06 17:49:08"}
{"id": 2211728, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "913f04f6-0883-4dbb-b7e4-79c5fa188777", "title": "2023 UKKA临床实践指南：血液透析血管通路", "text": "【0】页码:22\n2023 UKKA临床实践指南：血液透析血管通路\n由于该页主要内容是参考文献，没有其他正文内容，因此不需要转换和输出。", "tags": {}, "lang": "zh", "attr": {"page_num": 22, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 UKKA临床实践指南：血液透析血管通路.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:49:44", "endTime": "2024/08/06 15:49:50", "cost": 5.56}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-05 23:49:50", "grab_time": "2024-08-05 23:49:21"}
{"id": 2211727, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "403a189a-907b-439c-8999-36a8347be17e", "title": "（2023.V3）NCCN临床实践指南：急性髓系白血病", "text": "【0】页码:167\n（2023.V3）NCCN临床实践指南：急性髓系白血病\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】疑似页眉<u># NCCN Guidelines Version 3.2023 Acute Myeloid Leukemia</u>\n\n【2】参考删除-3:<u>## 429. Menezes J, Acquadro F, Wiseman M, et al.\nExome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 2014;28:823-829删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/24072010]</u>.</u></u>\n\n【3】参考删除-3:<u>## 430. Batta K, Bossenbroek HM, Pemmaraju N, et al.\nDivergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia 2021;35:3929-3930删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/33833838]</u>.</u></u>\n\n【4】参考删除-3:<u>## 431. Reimer P, Rudiger T, Kraemer D, et al.\nWhat is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant 2003;32:637-646删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/13130309]</u>.</u></u>\n\n【5】参考删除-3:<u>## 432. Pemmaraju N, Kantarjian H, Sweet K, et al.\nNorth American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood 2023;141:567-578删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/36399715]</u>.</u></u>\n\n【6】参考删除-3:<u>## 433. Frankel AE, Woo JH, Ahn C, et al.\nActivity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 2014;124:385-392删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/24859366]</u>.</u></u>\n\n【7】参考删除-3:<u>## 434. Pemmaraju N, Sweet KL, Stein AS, et al.\nLong-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol 2022;40:3032-3036删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/35820082]</u>.</u></u>\n\n【8】参考删除-3:<u>## 435. Deotare U, Yee KW, Le LW, et al.\nBlastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol 2016;91:283-286删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/26619305]</u>.</u></u>\n\n【9】参考删除-3:<u>## 436. Pemmaraju N, Wilson NR, Garcia-Manero G, et al.\nCharacteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv 2022;6:3027-3035删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/35061885]</u>.</u></u>\n\n【10】## 437. Prescribing information for venetoclax tablets, for oral use. 2022.删除1:<u>\nAvailable at: [https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208573s027lbl.pdf]. Accessed March 删除13:<u>24, 2023</u>.</u>\n\n【11】## 438. Montero J, Stephansky J, Cai T, et al.\nBlastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discovery 2017;7:156-164删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/27986708]</u>.</u>\n\n【12】参考删除-3:<u>## 439. Roos-Weil D, Dietrich S, Boumendil A, et al.\nStem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2013;121:440-446删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/23203822]</u>.</u></u>\n\n【13】参考删除-3:<u>## 440. Kharfan-Dabaja MA, Al Malki MM, Deotare U, et al.\nHaematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol 2017;179:781-789删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/28980314]</u>.</u></u>\n\n【14】## 441. Bruch PM, Dietrich S, Finel H, et al.\nRetrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters. Leukemia 2023;37:465-472删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/36550212]</u>.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 167, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V3）NCCN临床实践指南：急性髓系白血病.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:39:13", "endTime": "2024/08/06 15:39:20", "cost": 6.6}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-05 23:39:20", "grab_time": "2024-08-05 23:39:13"}
{"id": 2211726, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "2c0153b1-7688-4ff1-b8b7-a0fbd05cb7c8", "title": "2023 ESC-HFA临床共识声明：慢性心力衰竭恶化定义、流行病学、管理和预防", "text": "【0】页码:15\n2023 ESC-HFA临床共识声明：慢性心力衰竭恶化定义、流行病学、管理和预防\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】### Worsening HF: a clinical consensus statement by the HFA of the ESC\n\n【2】参考删除-3:<u>86. Pellicori P, Platz E, Dauw J, Ter Maaten JM, Martens P, Pivetta E, et al. Ultrasound imaging of congestion in heart failure: examinations beyond the heart. Eur J Heart Fail. 2021;23删除11:<u>(3)</u>:703–12.</u>\n\n【3】参考删除-3:<u>87. Platz E, Lewis EF, Uno H, Peck J, Pivetta E, Merz AA, et al. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J. 2016;37:1244–51.</u>\n\n【4】参考删除-3:<u>88. Galea R, Carluccio E, Miliani A, Ghetti G, Gargiulo P, Hargila VP, et al. Imaging patients with suspected acute heart failure: time for an evidence-based paradigm on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:181–95.</u>\n\n【5】参考删除-3:<u>89. Pellicori P, Shah P, Cuthbert J, Urbinati A, Zhang J, Kallvikbacka-Bennett A, et al. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail. 2019;21:904–16.</u>\n\n【6】参考删除-3:<u>90. Platz E, Merz AA, Jhund PS, Vazir A, Campbell R, McMurray JJ. Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. Eur J Heart Fail. 2017;19:1154–63.</u>\n\n【7】参考删除-3:<u>91. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al.; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–66.</u>\n\n【8】参考删除-3:<u>92. Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al. Hemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021;398:991–1001.</u>\n\n【9】参考删除-3:<u>93. Zhao T, Arnold SV, Kong GML, Ball J, Lam CSP, Voors AA, et al. Device-based remote monitoring strategies for congestive-guided management of patients with heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24:1934–41.</u>\n\n【10】参考删除-3:<u>94. Costanzo MR, Stevenson LW, Adamson PB, Desai AS, Heywood JT, Bourge RC, et al. Interventions linked to decreased heart failure hospitalisations during ambulatory pulmonary artery pressure monitoring. JACC Heart Fail. 2016;4:333–44.</u>\n\n【11】参考删除-3:<u>95. Abraham WT, Perl L. T o master heart failure, doma ster volume. JACC Heart Fail. 2017;5:955–7.</u>\n\n【12】参考删除-3:<u>96. Mullens W, Shahb F, Dupont M, Mortelmans L, Ma Tees V. Right ventricular function and congestion in patients with advanced heart failure. Am J Cardiol. 2010;105:469–74.</u>\n\n【13】参考删除-3:<u>97. Lala A, Mullens W, Mulaschem MA, Abraham WT, Judge DV, Wy ant KA, et al. Sequential outpatient haemodyna mic-guided therapy in patients with chronic heart failure: a randomised controlled trial. Lancet. 2021;398:991–1001.</u>\n\n【14】参考删除-3:<u>98. van de Louw A, Haughton C, Brogan G, Woods F, Voordt V, I comte G, Prat G, Bigeaud G, et al.; DOT-HF Investigators. Intrathoracic impedance monitoring to abetude patients' alert, and outcomes in heart failure: the diagnostic outcome trial. Circulation. 2011;124:1719–26.</u>\n\n【15】参考删除-3:<u>99. Gálmer M, Roubille F, Bederau P, Bierre G, Canic P, Dar P, et al.; OSCAR Investigators. Investigating versus standard care in heart failure patients: a multicentre trial. Eur J Heart Fail. 2020;22:985–94.</u>\n\n【16】参考删除-3:<u>100. Koehler, S, Saarel H, Homan T, Weegeider K, Koehler K, Sehrer S, et al. Telemonitoring in patients with chronic heart failure and depressed systolic ventricular symptoms: results from the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study. Eur J Heart Fail. 2013;19:1184–93.</u>\n\n【17】参考删除-3:<u>101. Zilskaite K, Reim T, Dj evolve AR, Zapien ZJ, Hcms PA, Johnson AF. Acute heart failure: alternatives to hospitalization. JACC Heart Fail. 2017;5:329–46.</u>\n\n【18】参考删除-3:<u>102. Matsue Y, Zonszain K, Voors AA, Kalayman N, Touncklen T, Kurban S, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:3042–51.</u>\n\n【19】参考删除-3:<u>103. Mullens W, Damman K, Hardjill VP, Mezbaza A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137–155.</u>\n\n【20】104. Mezba A, Sola AC, Colombo PC. Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel? Eur Heart J. 2023;44:331–5.\n\n【21】参考删除-3:<u>105. Mullens W, Dauwy Martens P, Verbrugge FH, Nips T, Pee four N, et al.; AD VION Study Group. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185–95.</u>\n\n【22】参考删除-3:<u>106. Biego S, Voors AA, Collins SP, Kobrosil WN, Tenekahr JR, Argamirman CE, et al. Impact of Acetazolamide on decompensation in acute heart failure: the EFFU-SE trial. Eur Heart J. 2023;44:41–50.</u>\n\n【23】参考删除-3:<u>107. T oruilli CS, McLaren JL, Faucist OJ, Carrera-Picarroed JM, Sanchez-Mareles M, Collins JP, Moraes AL, et al.; CLOROTIC Trial Investigators. Combining loop and thiazide diuretics for decompensated heart failure: the CLOROTIC trial. J Heart Fail. 2022;44:41–21.</u>\n\n【24】参考删除-3:<u>108. Collins SP, Fang PS, Forwarn CG, Yancy CW, Borrow RO, Gheorgalia H. Is acute hospital admission for heart failure really necessary? The role of emergency department and observation units in preventing hospitalization and rehospitalization. J Am Coll Cardiol. 2013;61:121–6.</u>\n\n【25】参考删除-3:<u>109. Buckley LF, Carter DM, Taki H, Cheng JW, Stevens C, Belenky RM, et al. Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Heart Fail. 2016;4:41–8.</u>\n\n【26】参考删除-3:<u>110. Buckley LF, Stevenson LW, Cooper MT, Knowles DM, Ha MA, Inetway DW, et al. Ambulatory treatment of worsening heart failure: medical and logistical implications of a four-year experience. J Card Fail. 2020;26:429–39.</u>\n\n【27】参考删除-3:<u>111. Gilotra NA, Princewill O, Marino B, Okavous SA, Chaser J, Almansa J, et al. Efficacy of intravenous furosemide versus a novel, phenylurine furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail. 2018;6:651–70.</u>\n\n【28】参考删除-3:<u>112. Mentz RJ, Aström KJ, Eiersteinn EB, Sopp S, Grenen SJ, Morgas R, et al.; TRANSFORM-HF Investigators. Effect of continued vs. discontinued furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329:2114–23.</u>\n\n【29】参考删除-3:<u>113. Crespo-Leiro MG, Meta L, Lund LH, Millici D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:1505–33.</u>\n\n【30】参考删除-3:<u>114. Gustafson F, Damman K, Nalbanigi J, San Lake LEV, Tops LF, Thun T, et al. A strategic therapy in patients with advanced heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2023;25:457–67.</u>\n\n【31】参考删除-3:<u>115. Jorde UP, Kulanies SA, Tsots HS, Naley KB, Tang G, Bloom GV, et al.; HeartMate II Clinical Investigators. Results of the analysis to determine the best post-MCSD parameter impacting survival with a continuous flow left ventricular assist device therapy: the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Registry. J Am Coll Cardiol. 2016;41:375–86.</u>\n\n【32】参考删除-3:<u>116. Mecken DM, Hull SD, Rupes MJ, Kolton RD, John B, Nelya Y, et al. CI guidelines for the use of continuous-flow left ventricular assist device patients stratified by pre-operation INTERMACS status: a multicentre analysis from the French registry. JACC Heart Fail. 2026;24:1092–1100.</u>\n\n【33】参考删除-3:<u>117. Jabla GS, Flopper GS, Left ventricular assist devices in advanced heart failure care: an official profession statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23:1433–44.</u>\n\n【34】参考删除-3:<u>118. Jessup M, Kasler DS, Puskas T, Lousarani MA, Hactut R, Gingace JL, et al. Mechanical Circulatory Support: 2020 AHA/ACC/HFA/SA-OCBP guidelines for the management of patients with mechanical circulatory support: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2021;143:859–910.</u>\n\n【35】参考删除-3:<u>119. McMurray JJ, De-De Deus L, Clessin K, Lohors B, Koehler M, Mang A, Nideck PA, et al.; DAPA-HF Committees and Investigators. A stratified to evaluate the effect of dapagliflozin versus co-trainapprer in hospitalized optimization on hospitalization for heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21:165–75.</u>\n\n【36】参考删除-3:<u>120. Packer M, Butler J, Fleigol SA, Duret P, Dapa SC, Flepoj R, et al.; EMPEROR-Persevered Trial Study Group. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved Trial. Circulation. 2021;144:1284–91.</u>\n\n【37】参考删除-3:<u>121. Packer M, Alner SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al.; EMPEROR-Reduced Trial Committees and Investigators. Clinical efficacy of empagliflozin on clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021;143:326–36.</u>\n\n【38】参考删除-3:<u>122. Solomon SD, McMurray JJV, Clagget B, de Boer RA, Deeb TS, Hernandez AF, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089–98.</u>\n\n【39】参考删除-3:<u>123. Mentz RJ, Ward JH, Hernandez AF, Leppe S, Horrow DA, Sarnvate S, et al. Rationale, design and baseline characteristics of the PARADIGM-HF trial: sacubitril/valsartan vs.vabrantin in HFmrEF and HFpEF with a worsening heart failure event. J Card Fail. 2023删除1:<u>. https://doi.org/10.1016/j.cardfail.2023.02.001.</u></u>\n\n【40】参考删除-3:<u>124. Cunningham JW, Vaduganathan M, Clagget B, Lilly LS, Nieklj DS, Jan S, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol. 2022;80:130–101.</u>\n\n【41】参考删除-3:<u>125. Blat DL, Szarek M, Tse YG, Cannon CP, Odeker DA, Gyle K, et al.; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117–28.</u>\n\n【42】参考删除-3:<u>126. Docherty KF, Hupf RS, Fiskola C, Stab JD, Koehler M, Böomig MR, Martinez FA, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020;41:2379–93.</u>\n\n【43】参考删除-3:<u>127. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al.; EMPEROR-Reduced Trial Committees and Investigators. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021;42:671–80.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 15, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ESC-HFA临床共识声明：慢性心力衰竭恶化定义、流行病学、管理和预防.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:35:38", "endTime": "2024/08/06 15:35:47", "cost": 8.993}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-05 23:35:47", "grab_time": "2024-08-05 23:35:38"}
{"id": 2211725, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "aa3020f5-8ab8-424c-9664-258e01323c68", "title": "变应性鼻炎的分类和诊断专家共识（2022，成都）", "text": "【0】页码:7\n变应性鼻炎的分类和诊断专家共识（2022，成都）\n28个项目，对AR引起的活动受限、睡眠、生活中的问题、鼻部和非鼻部症状、反应情况和情绪进行评估。分别给1~6分(0分为无影响，6分为严重影响)，计算各自得分的平均值和总分从而对生活质量进行评价。年幼患者锐敏AR对生活质量的影响较大。青少年版RQLQ(13~17岁使用)包括6个方面共23个项目\\[删除21:<u>^44</u>\\]。儿童版RQLQ(6~12岁)包括5个方面共23个项目\\[删除21:<u>^45</u>\\]。\n\n【1】6.5 鼻炎控制评估问卷 鼻炎控制评估测试(rhinitis control assessment test，RCAT)可反映患者过去1周内AR症状的控制水平，包括6个项目。每个项目分别记1~5分，6个项目得分相加得总分。总分越高，说明症状控制越好。总分<21分，症状控制较差。其小临床显要差异(minimal clinically important difference，MID)为3分\\[删除21:<u>^46</u>\\]。\n\n【2】### 7 其他检查\n\n【3】7.1 鼻分泌物细胞涂片 鼻分泌物细胞涂片采用#亚甲蓝染色(瑞氏染色)，在高倍显微镜下EOS占总细胞5%以上时，即可快速检测并AR特异性的。如何判断AR伴随性嗜酸细胞增多综合征患者，其分泌物中EOS表达为可显明特征。\n\n【4】7.2 鼻通气功能评估 鼻通气阻抗是患者常见症状之一，鼻腔通气功能评估可通过常规的吹气测试评估。常见的评估方法包括：PNIF，峰值呼出流量测，鼻声反射等。其中，利用鼻声反射测试可评估鼻腔通畅程度及有无狭窄。\n\n【5】7.3 鼻氧一氧化氮测定 鼻氧一氧化氮(nasal NO, nNO)是生物标志之一。快速增长的nNO表达水平异常，可提示鼻腔和鼻窦炎。AR可能会导致nNO表达水平增加，但全身鼻息肉和鼻窦实质性阻塞的影响，若鼻息肉、息肉引起鼻塞发生症状或术后情况，nNO水平可由降低。\n\n【6】7.4 鼻CT 鼻窦CT并非AR诊断必须检测项目，但若怀疑合并鼻窦疾病、鼻腔解剖结构异常等，可利用鼻窦CT检查进行鉴别诊断。\n\n【7】### 8 鉴别诊断\n\n【8】AR和其他一些鼻部疾病的症状有相似性，但并不可能在每种患者存在各种类型表现。因此，只有进行鼻内镜或实验室检测，确定鼻炎的病因和类型，才能做更好的区分。\n\n【9】8.1 感染性鼻炎 急性病毒性鼻炎，又称“感冒”。鼻塞、流涕为特征性AR关系，但通常鼻涕不稀薄且伴有发热、头痛、乏力、咽痛较常见等全身不适症状。鼻粘连、脓痰等。流感病毒和副流感病毒都是最常见原因，儿童平均每年每年可有6次左右发作，成年人平均每年2~3次不等\\[删除21:<u>^47</u>\\]。\n\n【10】8.2 血管运动性鼻炎 血管运动性鼻炎(vasomotor rhinitis，VMR)是伴AR中最常见的鼻炎类型，约占70%\\[删除21:<u>^50</u>\\]。发病机制不明，可能与鼻黏膜自主神经功能紊乱有关。临床表现与AR类似，但无明确过敏原特异性。诱发因素常为气温、气压、湿度变化、刺激性气味、烟草等。强烈的情感反应(如愤怒)也可无明确诱因诱发，主要表现为鼻塞、流清涕。可间歇性发作也可长期反复发作。VMR是排除性诊断，尤其有症状的中青年AR非特异型，有条件的情况下，可进行NPT和鼻内镜检查。\n\n【11】8.3 非变应性鼻炎伴嗜酸性粒细胞增多综合征 非变应性鼻炎伴嗜酸性粒细胞增多综合征(non-allergic rhinitis eosinophilia syndrome, NARES)是以鼻腔黏膜EOS增多为特征的非AR，发病机制不明，主要症状与AR相似，但前述非典型性AR更易，需作镜检、免疫球蛋白E、变应原皮肤测试，确诊分诊伴有EOS超过中性粒细胞和单核细胞(除外上皮细胞)的20%，即为非EOS>5\\[删除21:<u>^51</u>\\]。部分NARES可能是早期AR\\[删除21:<u>^52</u>\\]。\n\n【12】8.4 味觉性鼻炎 味觉性鼻炎的诱导因素，指含在入口热、辛辣食物后以色素性清涕为主要表现的鼻炎。表现为食物诱导刺激引起，通常有遗传背景，年龄较易因广为发病，较20~60岁发，症状可随年龄增长而逐渐加重。发病机制可能为鼻粘膜中存在钙离子通道和酶、或食物刺激口腔黏膜，引起交替性瞬时受体电位香草酸受体亚型1(transient receptor potential vanilloid receptors subtype 1, TRPV1)，然后通过神经反射调激发膳膜腺膜腺体中的双感应系统\\[删除21:<u>^56</u>\\]。\n\n【13】8.5 激素性鼻炎 指人体内分泌激素水平变化生理时可变更时发生的鼻炎。主要生理性包括妊娠AR为主。生理性变化，包括低或雌激素、青春期炎、经期变化、症状可变反复。病理性更为内分泌系统症状，则如腺上痊愈。其发病机制尚不空确定\\[删除21:<u>^57</u>\\]。\n\n【14】8.6 药物相关性鼻炎 鼻腔局部对长期应用高浓度鼻喷雾充血引导剂药物治疗粘膜管促性肿胀、表现为粘膜炎症严重时发炎，称为药物性鼻炎(rhinitis", "tags": {}, "lang": "zh", "attr": {"page_num": 7, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/变应性鼻炎的分类和诊断专家共识（2022，成都）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:45:00", "endTime": "2024/08/06 16:46:26", "cost": 85.795}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:16", "update_time": "2024-08-06 00:46:26", "grab_time": "2024-08-06 00:45:00"}
{"id": 2211724, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "bf4f3ccb-f12d-4ade-8e44-2da991fdde52", "title": "新型抗肿瘤药物临床应用指导原则（2023年版）", "text": "【0】页码:357\n新型抗肿瘤药物临床应用指导原则（2023年版）\n对于已缓解的 G2 和/或 G3 肾脏 irAE：如果有临床指征，至少在暂停 ICI 治疗 2 个月后，可考虑重启免疫治疗\n\n| 肝脏       | 转氨酶升高,  但伴胆红素并高：发生 2 级 irAE 后，在谷两转氨酶/谷草转氨酶较重基线水平、糖皮质激素逐渐减量至 < 10mg/d 强的松替效剂量后考虑重启免疫治疗 |\n| 3 级肝炎：如果使用 CTLA-4 抑制剂联合 PD-1/PD-L1 抑制剂治疗，仅重新开始 PD-1/PD-L1 抑制剂治疗 |\n| 重度肝炎及生命 (4 级) 的肝炎：永不考虑重启免疫治疗 |\n| 肺        | 进行性 l 级非感染性肺炎：影像学研究改善证据, 考虑重启免疫治疗 |\n| 2 级：肺炎缓解至 ≤ 1 级且患者停用糖皮质激素剂量 < 10mg/d (猎的松), 则重启免疫治疗 |\n| 重度 (3~4 级) 肺炎：永不考虑重启免疫治疗 |\n| 肌肉、骨骼  | 炎性关节炎（中度至重度 irAE 暂停治疗）：待病情稳定或得到充分治疗后重启免疫治疗。对于显着损害日常生活能力和生活质量的重度炎性关节炎，永不考虑重启免疫治疗 |\n\n| 神经系统   | 弥盖肌无力：2 级且经糖皮质激素治疗缓解后，可以重启治疗， 而 3~4 级则永不考虑重启治疗 |\n| 格林-巴利综合征：任何级别的格林-巴利综合征均永不考虑重启治疗 |\n| 周围神经病变：1~2 级 irAE， 暂停治疗，如果症状消退至 < 1 级或患者的孤立性疼痛感觉神经病变得到良好控制, 考虑重启免疫治疗 |\n| 无菌性脑膜炎:轻度至中度 irAE，如果症状缓解至 0 级，考虑重启免疫治疗 |\n| 脑炎:在中度至重度脑炎(2~4 级) 的情况下,永不考虑重启免疫治疗 |\n| 横贯性脊髓炎:任何级别横贯性脊髓炎永不考虑重启免疫治疗 |\n| 胰腺    | 有症状的 2 级胰腺炎，如果已经没启胰腺炎的临床或影像学证据,且淀粉酶、脂肪酶恢复正常，可以考虑重启免疫治疗 |\n| 3~4 级胰腺炎永不考虑重启免疫治疗 |\n| 皮肤   | 斑丘疹和/或瘙痒:在症状缓解至 < 1 级(即,皮肤状况良好且需局部干预), 可以考虑重启免疫治疗 |\n| 重度(3~4 级)或危及生命的大疱性疾病（包括Stevens-Johnson综合征和  |", "tags": {}, "lang": "None", "attr": {"page_num": 357, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/新型抗肿瘤药物临床应用指导原则（2023年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "对于已缓解的 G2 和/或 G3 肾脏 irAE：如果有临床指征，至少在暂停 ICI 治疗 2 个月后，可考虑重启免疫治疗\n\n| 肝脏       | 转氨酶升高,  但伴胆红素并高：发生 2 级 irAE 后，在谷两转氨酶/谷草转氨酶较重基线水平、糖皮质激素逐渐减量至 < 10mg/d 强的松替效剂量后考虑重启免疫治疗 |\n\n| 3 级肝炎：如果使用 CTLA-4 抑制剂联合 PD-1/PD-L1 抑制剂治疗，仅重新开始 PD-1/PD-L1 抑制剂治疗 |\n\n| 重度肝炎及生命 (4 级) 的肝炎：永不考虑重启免疫治疗 |\n\n| 肺        | 进行性 l 级非感染性肺炎：影像学研究改善证据, 考虑重启免疫治疗 |\n\n| 2 级：肺炎缓解至 ≤ 1 级且患者停用糖皮质激素剂量 < 10mg/d (猎的松), 则重启免疫治疗 |\n\n| 重度 (3~4 级) 肺炎：永不考虑重启免疫治疗 |\n\n| 肌肉、骨骼  | 炎性关节炎（中度至重度 irAE 暂停治疗）：待病情稳定或得到充分治疗后重启免疫治疗。对于显着损害日常生活能力和生活质量的重度炎性关节炎，永不考虑重启免疫治疗 |\n\n| 神经系统   | 弥盖肌无力：2 级且经糖皮质激素治疗缓解后，可以重启治疗， 而 3~4 级则永不考虑重启治疗 |\n\n| 格林-巴利综合征：任何级别的格林-巴利综合征均永不考虑重启治疗 |\n\n| 周围神经病变：1~2 级 irAE， 暂停治疗，如果症状消退至 < 1 级或患者的孤立性疼痛感觉神经病变得到良好控制, 考虑重启免疫治疗 |\n\n| 无菌性脑膜炎:轻度至中度 irAE，如果症状缓解至 0 级，考虑重启免疫治疗 |\n\n| 脑炎:在中度至重度脑炎(2~4 级) 的情况下,永不考虑重启免疫治疗 |\n\n| 横贯性脊髓炎:任何级别横贯性脊髓炎永不考虑重启免疫治疗 |\n\n| 胰腺    | 有症状的 2 级胰腺炎，如果已经没启胰腺炎的临床或影像学证据,且淀粉酶、脂肪酶恢复正常，可以考虑重启免疫治疗 |\n\n| 3~4 级胰腺炎永不考虑重启免疫治疗 |\n\n| 皮肤   | 斑丘疹和/或瘙痒:在症状缓解至 < 1 级(即,皮肤状况良好且需局部干预), 可以考虑重启免疫治疗 |\n\n| 重度(3~4 级)或危及生命的大疱性疾病（包括Stevens-Johnson综合征和  |", "content": "【0】页码:357\n新型抗肿瘤药物临床应用指导原则（2023年版）\n对于已缓解的 G2 和/或 G3 肾脏 irAE：如果有临床指征，至少在暂停 ICI 治疗 2 个月后，可考虑重启免疫治疗\n\n| 肝脏       | 转氨酶升高,  但伴胆红素并高：发生 2 级 irAE 后，在谷两转氨酶/谷草转氨酶较重基线水平、糖皮质激素逐渐减量至 < 10mg/d 强的松替效剂量后考虑重启免疫治疗 |\n| 3 级肝炎：如果使用 CTLA-4 抑制剂联合 PD-1/PD-L1 抑制剂治疗，仅重新开始 PD-1/PD-L1 抑制剂治疗 |\n| 重度肝炎及生命 (4 级) 的肝炎：永不考虑重启免疫治疗 |\n| 肺        | 进行性 l 级非感染性肺炎：影像学研究改善证据, 考虑重启免疫治疗 |\n| 2 级：肺炎缓解至 ≤ 1 级且患者停用糖皮质激素剂量 < 10mg/d (猎的松), 则重启免疫治疗 |\n| 重度 (3~4 级) 肺炎：永不考虑重启免疫治疗 |\n| 肌肉、骨骼  | 炎性关节炎（中度至重度 irAE 暂停治疗）：待病情稳定或得到充分治疗后重启免疫治疗。对于显着损害日常生活能力和生活质量的重度炎性关节炎，永不考虑重启免疫治疗 |\n\n| 神经系统   | 弥盖肌无力：2 级且经糖皮质激素治疗缓解后，可以重启治疗， 而 3~4 级则永不考虑重启治疗 |\n| 格林-巴利综合征：任何级别的格林-巴利综合征均永不考虑重启治疗 |\n| 周围神经病变：1~2 级 irAE， 暂停治疗，如果症状消退至 < 1 级或患者的孤立性疼痛感觉神经病变得到良好控制, 考虑重启免疫治疗 |\n| 无菌性脑膜炎:轻度至中度 irAE，如果症状缓解至 0 级，考虑重启免疫治疗 |\n| 脑炎:在中度至重度脑炎(2~4 级) 的情况下,永不考虑重启免疫治疗 |\n| 横贯性脊髓炎:任何级别横贯性脊髓炎永不考虑重启免疫治疗 |\n| 胰腺    | 有症状的 2 级胰腺炎，如果已经没启胰腺炎的临床或影像学证据,且淀粉酶、脂肪酶恢复正常，可以考虑重启免疫治疗 |\n| 3~4 级胰腺炎永不考虑重启免疫治疗 |\n| 皮肤   | 斑丘疹和/或瘙痒:在症状缓解至 < 1 级(即,皮肤状况良好且需局部干预), 可以考虑重启免疫治疗 |\n| 重度(3~4 级)或危及生命的大疱性疾病（包括Stevens-Johnson综合征和  |", "index": 34, "show": true, "start": 34, "end": 1023, "province": ["格式规范性", "表格格式错误"], "isEdit": false}], "startTime": "2024/08/07 10:04:27", "endTime": "2024/08/07 10:08:51", "cost": 263.75}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 18:08:50", "grab_time": "2024-08-06 18:04:26"}
{"id": 2211723, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "80512f4d-9634-4125-b480-9b1235dd9162", "title": "（2024.V1）NCCN临床实践指南：皮肤黑色素瘤(1)", "text": "【0】页码:69\n（2024.V1）NCCN临床实践指南：皮肤黑色素瘤(1)\n## PRINCIPLES OF MOLECULAR TESTING\n\n【1】### Molecular Technologies for Cutaneous Melanoma Diagnosis, Prognostication, and SLNB Risk Prediction (continued)\n\n【2】- 删除32:<u>**</u>Indications for genetic testing删除32:<u>**</u>\n  - The panel does not recommend 删除32:<u>**</u>BRAF删除32:<u>**</u> or NGS testing for resected stage I–II cutaneous melanoma unless it will inform clinical trial participation.\n  - 删除32:<u>**</u>BRAF删除32:<u>**</u> mutation testing is recommended for patients with stage III disease at high risk for recurrence for whom future 删除32:<u>**</u>BRAF删除32:<u>**</u>-directed therapy may be an option.\n  - For initial presentation with stage IV disease or clinical recurrence, obtain tissue to ascertain alterations in 删除32:<u>**</u>BRAF删除32:<u>**</u>, and in the appropriate clinical setting, 删除32:<u>**</u>KIT删除32:<u>**</u> from either biopsy of the metastasis (preferred) or archival material if the patient is being considered for targeted therapy. Broader genomic profiling (e.g., larger NGS panels, 删除32:<u>**</u>BRAF删除32:<u>**</u> non-V600 mutations) is recommended if feasible, especially if the test results might guide future treatment decisions or eligibility for participation in a clinical trial.\n  - If 删除32:<u>**</u>BRAF删除32:<u>**</u> single-gene testing was the initial test performed, and is negative, clinicians should strongly consider larger NGS panels to identify other potential genetic targets (e.g., 删除32:<u>**</u>KIT删除32:<u>**</u>, 删除32:<u>**</u>BRAF删除32:<u>**</u> non-V600).\n\n【3】- 删除32:<u>**</u>Biomarkers with potential utility for immunotherapy删除32:<u>**</u>\n  - 删除32:<u>**</u>PD-L1删除32:<u>**</u> (programmed death ligand 1)\n    - The utility of this biomarker requires further investigation.\n    - 删除32:<u>**</u>PD-L1删除32:<u>**</u> is a coregulatory molecule that can be expressed by tumor cells and tumor-infiltrating macrophages, and inhibit T-cell–mediated anti-tumor responses. 删除32:<u>**</u>PD-1删除32:<u>**</u>, a receptor on T cells, binds to 删除32:<u>**</u>PD-L1删除32:<u>**</u>, thus inhibiting T-cell activation.\n    - IHC for 删除32:<u>**</u>PD-L1删除32:<u>**</u> may help identify patients whose disease is more likely to respond to immune checkpoint inhibitors.\n      - Various antibody clones have been developed for IHC analysis of 删除32:<u>**</u>PD-L1删除32:<u>**</u> expression, and while several have shown relative equivalence, others have not.\n      - Interpretation of 删除32:<u>**</u>PD-L1删除32:<u>**</u> IHC is typically focused on the proportion of tumor cells expressing membranous staining at any level and therefore is a continuous variable.\n      - The threshold to define a clinically relevant elevated level of 删除32:<u>**</u>PD-L1删除32:<u>**</u> expression is dependent on the antibody and platform deployed, which may be unique to each checkpoint inhibitor therapy. The existence of multiple different assays for 删除32:<u>**</u>PD-L1删除32:<u>**</u> has raised concern among both pathologists and oncologists.\n      - High 删除32:<u>**</u>PD-L1删除32:<u>**</u> expression (>5%) may be a marker for equivalent outcomes with nivolumab monotherapy versus combination ipilimumab and nivolumab in patients with unresectable or metastatic melanoma. Low 删除32:<u>**</u>PD-L1删除32:<u>**</u> expression may be a marker for worse outcome with nivolumab monotherapy compared to nivolumab/ipilimumab combination. Even in these scenarios (i.e., very high or very low 删除32:<u>**</u>PD-L1删除32:<u>**</u> expression), the routine use of 删除32:<u>**</u>PD-L1删除32:<u>**</u> expression for treatment decisions is not recommended.\n      - Testing for tumor 删除32:<u>**</u>PD-L1删除32:<u>**</u> should not guide clinical decision-making.", "tags": {}, "lang": "en", "attr": {"page_num": 69, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2024.V1）NCCN临床实践指南：皮肤黑色素瘤(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:00:36", "endTime": "2024/08/06 17:01:02", "cost": 25.756}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 01:01:02", "grab_time": "2024-08-06 01:00:36"}
{"id": 2211722, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "251236a2-8fbe-446b-8a4d-57894999cf40", "title": "ERAS_SVS：开放性主动脉血管手术的围术期护理共识声明（2022）", "text": "【0】页码:80\nERAS_SVS：开放性主动脉血管手术的围术期护理共识声明（2022）\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】参考删除-3:<u>262. Bisch SP, Wells T, Gramlich L, Faris P, Wang X, Tran DT, et al. Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomes. 删除32:<u>*</u>Gynecol Oncol.删除32:<u>*</u> 2018;151删除11:<u>(1)</u>:117-123.</u>\n\n【2】参考删除-3:<u>263. de Groot JJA, van Es LEJM, Maessen JMC, Dejong CHC, Kruitwagen RFPM, Slangen BFM. Diffusion of Enhanced Recovery principles in gynecologic oncology surgery: is active implementation still necessary? 删除32:<u>*</u>Gynecol Oncol.删除32:<u>*</u> 2014;134删除11:<u>(3)</u>:570-575.</u>\n\n【3】参考删除-3:<u>264. Cakir H, van Stijn MF, Lopes Cardozo AM, Langenhorst BL, Schreurs WH, van der Ploeg TJ, et al. Adherence to Enhanced Recovery After Surgery and length of stay after colonic resection. 删除32:<u>*</u>Colorectal Dis.删除32:<u>*</u> 2013;15删除11:<u>(8)</u>:1019-1025.</u>\n\n【4】参考删除-3:<u>265. Committee on S, Practice P, Apfelbaum JL, Connis RT, Nickinovich DG, American Society of Anesthesiologists Task Force on P, et al. Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. 删除32:<u>*</u>Anesthesiology.删除32:<u>*</u> 2012;116删除11:<u>(3)</u>:522-538.</u>\n\n【5】参考删除-3:<u>266. Qaseem A, Snow V, Fitterman N, Hornbake ER, Lawrence VA, Smetana GW, et al. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. 删除32:<u>*</u>Ann Intern Med.删除32:<u>*</u> 2006;144删除11:<u>(8)</u>:575-580.</u>\n\n【6】参考删除-3:<u>267. Expert Panel on Thoracic I, McComb BL, Chung JH, Crabtree TD, Heitkamp DE, Iannettoni MD, et al. ACR Appropriateness Criteria(R) Routine Chest Radiography. 删除32:<u>*</u>J Thorac Imaging.删除32:<u>*</u> 2016;31删除11:<u>(2)</u>:W13-15.</u>\n\n【7】参考删除-3:<u>268. Yokota S, Koizumi M, Togashi K, Morimoto M, Yasuda Y, Sata N, et al. Preoperative pulmonary function tests do not predict the development of pulmonary complications.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 80, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ERAS_SVS：开放性主动脉血管手术的围术期护理共识声明（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:02:14", "endTime": "2024/08/06 17:02:29", "cost": 15.58}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 01:02:29", "grab_time": "2024-08-06 01:02:13"}
{"id": 2211721, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "d6522367-f04f-4194-ba7a-002975c486b5", "title": "SEOM-GEIS 胃肠道间质瘤临床指南", "text": "【0】页码:2\nSEOM-GEIS 胃肠道间质瘤临床指南\n### Incidence and epidemiology\n\n【1】Although GISTs are regarded as a rare cancer, they are the most common malignant neoplasm of mesenchymal origin, with an average incidence of 0.4–2 cases per 100,000 inhabitants per year 删除12:<u>删除14:<u>[1]</u></u>.\n\n【2】参考删除-3:<u>The stomach is the most frequent location (50–60%), followed by the ileum and jejunum (20–30%), duodenum (3–5%), rectum (2–4%), and other locations (< 2%). Cases of extra-gastrointestinal GISTs are exceptional 删除12:<u>删除14:<u>[2]</u></u>.</u>\n\n【3】GIST typically occurs in adults, with a mean age at diagnosis of 60–65 years, and are equally common in male and female patients. Pediatric GISTs are rare, occur at a mean age of diagnosis of 15 years, and have different clinical and molecular features. They are twice as frequent in females than in males, have a multicentric gastric location, and have possible lymph-node metastases. In addition, these patients have a genetic predisposition to the neoplasm frequently related to mutations in the four genes encoding the subunits of the succinate dehydrogenase (SDH) enzyme complex 删除12:<u>删除14:<u>[3]</u></u>.\n\n【4】GISTs are sporadic neoplasms, although infrequently they can appear associated with some inherited conditions, such as Carney–Stratakis syndrome (mutations in SDH subunits), neurofibromatosis type 1, and families with autosomal dominant germline mutations in KIT or PDGFRA 删除12:<u>删除14:<u>[4]</u></u>.\n\n【5】### Methodology\nThis guideline is based on a systematic review of the most relevant published studies on GIST and is the result of the consensus of ten oncologists with expertise in their management from the GEIS (Spanish Sarcoma Research Group) and the SEOM (Spanish Society of Medical Oncology) and of an external review panel of two experts appointed by the SEOM. The Infectious Diseases Society of America-US Public Health Service Grading System for Ranking Recommendations in Clinical Guidelines has been used to assign levels of evidence (I–V) and grades of recommendation (A–C) 删除12:<u>删除14:<u>[5]</u></u>.\n\nThis updated version of the previous SEOM guidelines on GIST describes this tumor's standard diagnostic and|删除段之间换行|| 删除32:<u>**</u>Table 1删除32:<u>**</u> Therapeutic recommendations and level of evidence |\n|:------------------------------------------------------------|\n| 删除32:<u>**</u>Recommendation删除32:<u>**</u>                                                                                 | 删除32:<u>**</u>Level of evidence删除32:<u>**</u> |\n|:---------------------------------------------------------------------------------------------------|:---------------------:|\n| 删除32:<u>**</u>Diagnostic work-up删除32:<u>**</u>                                                                             |                      |\n| Contrast-enhanced CT-scan is indicated for evaluating tumor extension                               |        III, A        |\n| A core needle biopsy is recommended for the initial diagnosis                                       |        II, A         |\n| It is strongly recommended to perform the mutational analysis in all GIST cases requiring medical treatment |        II, A         |\n| Performing a biopsy in imatinib-resistant GIST patients with the only objective of the determination of KIT/PDGFRA genotype is not recommended | II, D |\n| There are no validated data supporting the use of circulating tumor DNA for clinical purposes       |        III, C        |\n| 删除32:<u>**</u>Localized disease删除32:<u>**</u>                                                                              |                      |\n| Use of the NIH modified risk criteria to determine the risk of relapse for the indication of adjuvant imatinib |     I, A    |\n| Imatinib 400 mg daily for a 3-year period is the standard adjuvant treatment in imatinib-sensitive high-risk GIST |     I, A    |\n| Imatinib 400 mg once daily is acceptable for the adjuvant treatment of KIT exon 9-mutant GIST patients | IV, B |\n| It can be considered the use of adjuvant imatinib in intermediate-risk patients with KIT exon 11 mutations involving the codons 557 and/or 558 | III, B |\n| Adjuvant imatinib is contraindicated in GIST patients with molecular subtypes known to be resistant to imatinib | II, E |\n| Neoadjuvant imatinib can be considered in certain cases with high volume, need of a function-sparing surgery, or risk of bleeding | II, B |\n| 删除32:<u>**</u>Metastatic disease删除32:<u>**</u>                                                                             |                      |\n| Surgery in metastatic disease can be considered on an individual basis within a multidisciplinary tumor board | IV, C |\n| Imatinib 400 mg daily is the standard first-line treatment in metastatic GIST                       |       I, A           |\n| Imatinib 800 mg (400 mg/12 h) is preferable in GIST patients with KIT exon 9 mutation               |       II, B          |\n| Imatinib treatment should be continued indefinitely until disease progression or drug intolerance   |       I, A           |\n| When disease progresses at the dose of 400 mg/day, an increase to 800 mg/day (400 mg/12 h) is an option |    II, B         |\n| Continuous dose of sunitinib 37.5 mg once daily can be considered given its better tolerance       |       III, B         |\n| Regorafenib 160 mg daily 3 weeks on, 1 week off is the standard third-line treatment                |       I, A           |\n| Ripretinib 150 mg daily is the standard fourth-line treatment                                       |       I, A           |\n| Avapritinib 300 mg daily is recommended for the treatment of GIST patients with the PDGFRA D842V, regardless of the line of treatment | III, A |", "tags": {}, "lang": "en", "attr": {"page_num": 2, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/SEOM-GEIS 胃肠道间质瘤临床指南.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】参考删除-3:The stomach is the most frequent location (50–60%), followed by the ileum and jejunum (20–30%), duodenum (3–5%), rectum (2–4%), and other locations (< 2%). Cases of extra-gastrointestinal GISTs are exceptional 删除12:删除14:[2].", "content": "【0】页码:2\nSEOM-GEIS 胃肠道间质瘤临床指南\n### Incidence and epidemiology\n\n【1】Although GISTs are regarded as a rare cancer, they are the most common malignant neoplasm of mesenchymal origin, with an average incidence of 0.4–2 cases per 100,000 inhabitants per year 删除12:<u>删除14:<u>[1]</u></u>.\n\n【2】参考删除-3:<u>The stomach is the most frequent location (50–60%), followed by the ileum and jejunum (20–30%), duodenum (3–5%), rectum (2–4%), and other locations (< 2%). Cases of extra-gastrointestinal GISTs are exceptional 删除12:<u>删除14:<u>[2]</u></u>.</u>\n\n【3】GIST typically occurs in adults, with a mean age at diagnosis of 60–65 years, and are equally common in male and female patients. Pediatric GISTs are rare, occur at a mean age of diagnosis of 15 years, and have different clinical and molecular features. They are twice as frequent in females than in males, have a multicentric gastric location, and have possible lymph-node metastases. In addition, these patients have a genetic predisposition to the neoplasm frequently related to mutations in the four genes encoding the subunits of the succinate dehydrogenase (SDH) enzyme complex 删除12:<u>删除14:<u>[3]</u></u>.\n\n【4】GISTs are sporadic neoplasms, although infrequently they can appear associated with some inherited conditions, such as Carney–Stratakis syndrome (mutations in SDH subunits), neurofibromatosis type 1, and families with autosomal dominant germline mutations in KIT or PDGFRA 删除12:<u>删除14:<u>[4]</u></u>.\n\n【5】### Methodology\nThis guideline is based on a systematic review of the most relevant published studies on GIST and is the result of the consensus of ten oncologists with expertise in their management from the GEIS (Spanish Sarcoma Research Group) and the SEOM (Spanish Society of Medical Oncology) and of an external review panel of two experts appointed by the SEOM. The Infectious Diseases Society of America-US Public Health Service Grading System for Ranking Recommendations in Clinical Guidelines has been used to assign levels of evidence (I–V) and grades of recommendation (A–C) 删除12:<u>删除14:<u>[5]</u></u>.\n\nThis updated version of the previous SEOM guidelines on GIST describes this tumor's standard diagnostic and|删除段之间换行|| 删除32:<u>**</u>Table 1删除32:<u>**</u> Therapeutic recommendations and level of evidence |\n|:------------------------------------------------------------|\n| 删除32:<u>**</u>Recommendation删除32:<u>**</u>                                                                                 | 删除32:<u>**</u>Level of evidence删除32:<u>**</u> |\n|:---------------------------------------------------------------------------------------------------|:---------------------:|\n| 删除32:<u>**</u>Diagnostic work-up删除32:<u>**</u>                                                                             |                      |\n| Contrast-enhanced CT-scan is indicated for evaluating tumor extension                               |        III, A        |\n| A core needle biopsy is recommended for the initial diagnosis                                       |        II, A         |\n| It is strongly recommended to perform the mutational analysis in all GIST cases requiring medical treatment |        II, A         |\n| Performing a biopsy in imatinib-resistant GIST patients with the only objective of the determination of KIT/PDGFRA genotype is not recommended | II, D |\n| There are no validated data supporting the use of circulating tumor DNA for clinical purposes       |        III, C        |\n| 删除32:<u>**</u>Localized disease删除32:<u>**</u>                                                                              |                      |\n| Use of the NIH modified risk criteria to determine the risk of relapse for the indication of adjuvant imatinib |     I, A    |\n| Imatinib 400 mg daily for a 3-year period is the standard adjuvant treatment in imatinib-sensitive high-risk GIST |     I, A    |\n| Imatinib 400 mg once daily is acceptable for the adjuvant treatment of KIT exon 9-mutant GIST patients | IV, B |\n| It can be considered the use of adjuvant imatinib in intermediate-risk patients with KIT exon 11 mutations involving the codons 557 and/or 558 | III, B |\n| Adjuvant imatinib is contraindicated in GIST patients with molecular subtypes known to be resistant to imatinib | II, E |\n| Neoadjuvant imatinib can be considered in certain cases with high volume, need of a function-sparing surgery, or risk of bleeding | II, B |\n| 删除32:<u>**</u>Metastatic disease删除32:<u>**</u>                                                                             |                      |\n| Surgery in metastatic disease can be considered on an individual basis within a multidisciplinary tumor board | IV, C |\n| Imatinib 400 mg daily is the standard first-line treatment in metastatic GIST                       |       I, A           |\n| Imatinib 800 mg (400 mg/12 h) is preferable in GIST patients with KIT exon 9 mutation               |       II, B          |\n| Imatinib treatment should be continued indefinitely until disease progression or drug intolerance   |       I, A           |\n| When disease progresses at the dose of 400 mg/day, an increase to 800 mg/day (400 mg/12 h) is an option |    II, B         |\n| Continuous dose of sunitinib 37.5 mg once daily can be considered given its better tolerance       |       III, B         |\n| Regorafenib 160 mg daily 3 weeks on, 1 week off is the standard third-line treatment                |       I, A           |\n| Ripretinib 150 mg daily is the standard fourth-line treatment                                       |       I, A           |\n| Avapritinib 300 mg daily is recommended for the treatment of GIST patients with the PDGFRA D842V, regardless of the line of treatment | III, A |", "index": 281, "show": true, "start": 281, "end": 515, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 16:30:30", "endTime": "2024/08/06 16:31:15", "cost": 45.934}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:31:15", "grab_time": "2024-08-06 00:30:29"}
{"id": 2211720, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "f8eb0010-d9fb-492f-afb8-1fa5e173b9cb", "title": "2024更新—2016+NICE指南：结核病（NG.33）", "text": "【0】页码:47\n2024更新—2016+NICE指南：结核病（NG.33）\nTuberculosis (NG33)\n\n---|删除段之间换行|删除24:<u>[new 2016]</u>\n\n【2】1.3.7.19 At the start of an anti-TB treatment regimen, offer children and young people with active TB of the central nervous system dexamethasone or prednisolone. This should initially be at a high dose with gradual withdrawal over 4 to 8 weeks in line with the British National Formulary for Children. 删除24:<u>[new 2016]</u>\n\n【3】### Pericardial TB\n\n【4】1.3.7.20 At the start of an anti-TB treatment regimen, offer adults with active pericardial TB oral prednisolone at a starting dose of 60 mg/day, gradually withdrawing it 2 to 3 weeks after starting treatment. 删除12:<u>删除14:<u>删除24:<u>[2016]</u></u></u>\n\n【5】1.3.7.21 At the start of an anti-TB treatment regimen, offer children and young people with active pericardial TB oral prednisolone in line with the British National Formulary for Children. Gradually withdraw prednisolone 2 to 3 weeks after starting treatment. 删除12:<u>删除14:<u>删除24:<u>[2016]</u></u></u>\n\n【6】### Adjunctive surgery\n\n【7】1.3.7.22 If surgery is indicated, the surgeon should fully explain what is involved to the person, either with or after consulting a TB specialist. Discuss the possible benefits and risks with the person and their family members or carers, as appropriate, so that they can make an informed decision. 删除24:<u>[new 2016]</u>\n\n【8】### Central nervous system TB\n\n【9】1.3.7.23 Consider referring people with TB of the central nervous system for surgery as a therapeutic intervention only if there is evidence of raised intracranial pressure. 删除24:<u>[new 2016]</u>", "tags": {}, "lang": "en", "attr": {"page_num": 47, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024更新—2016+NICE指南：结核病（NG.33）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:04:42", "endTime": "2024/08/06 17:05:09", "cost": 27.388}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 01:05:09", "grab_time": "2024-08-06 01:04:41"}
{"id": 2211719, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "b192efbc-ca1c-46e6-998b-cebf691a542e", "title": "KASL：慢性乙型肝炎管理的临床实践指南（2022）", "text": "页码:55\nKASL：慢性乙型肝炎管理的临床实践指南（2022）\n(本页删除)本页被模型判断为参考页patients and chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol 2007;22:515-删除13:<u>517.\n458</u>. Yang WT, Wu LW, Tseng TC, Chen CL, Yang HC, Su TH, et al. Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection. Medicine (Baltimore) 2016;95:e删除13:<u>2995.\n459</u>. Pol S, Haour G, Fontaine H, Dorival C, Petrov-Sanchez V, Bourliere M, et al. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther 2017;46:1054-删除13:<u>1060.\n460</u>. Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, et al. Hepatitis B reactivation in hepatitis B and C-coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology 2017;66:13-删除13:<u>26.\n461</u>. Yeh ML, Huang CF, Huang JF, Holmes JA, Hsieh MH, Tsai YS, et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol 2020;73:62-删除13:<u>71.\n462</u>. Calvaruso V, Ferraro D, Licata A, Bavetta MG, Petta S, Bronte F, et al. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat 2018;25:72-删除13:<u>79.\n463</u>. Bunnell KL, Vibhakar S, Glowacki RC, Gallagher MA, Osei AM, Huang G. Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection. Pharmacotherapy 2016;36:e148-e删除13:<u>153.\n464</u>. Solas C, Bregigeon S, Faucher-Zaegel O, Quaranta S, Obry V, Rouger C, Tamalet C, et al. Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: impact on tenofovir trough concentrations and renal safety. Br J Clin Pharmacol 2018;84:404-删除13:<u>409.\n465</u>. Mücke VT, Mücke MM, Peiffer KH, Weiler N, Welzel TM, Sarrazin C, et al. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. Aliment Pharmacol Ther 2017;46:432-删除13:<u>439.\n466</u>. Tamori A, Abiru S, Enomoto H, Kioka K, Korenaga M, Tani J, et al. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy. J Viral Hepat 2018;25:608-删除13:<u>611.\n467</u>. Sulkowski MS, Chuang WL, Kao JH, Yang JC, Gao B, Brainard DM, et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis 2016;63:1202-删除13:<u>1204.\n468</u>. Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut 2021;70:1782-删除13:<u>1794.\n469</u>. Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol 2020;73:523-删除13:<u>532.\n470</u>. Kim HS, Kim SJ, Park HW, Shin WG, Kim KH, Lee JH, et al. Prevalence and clinical significance of hepatitis D virus co-infection in patients with chronic hepatitis B in Korea. J Med Virol 2011;83:1172-删除13:<u>1177.\n471</u>. Jeong SH, Kim JW, Ahn HJ, Park MJ, Paik HY, Choi WY, et al. The prevalence and clinical characteristics of hepatitis-delta infection in Korea. Korean J Hepatol 2005;11:43-删除13:<u>50.\n472</u>. Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol 2020;73:533-删除13:<u>539.\n473</u>. Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y, Yalniz M. Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider. J Viral Hepat 2011;18:518-删除13:<u>524.\n474</u>. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European concerted action on viral hepatitis (Eurohep). Gut 2000;46:420-删除13:<u>426.\n475</u>. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-删除13:<u>331.\n476</u>. Abbas Z, Memon MS, Mithani H, Jafri W, Hamid S. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience. Antivir Ther 2014;19:463-删除13:<u>468.\n477</u>. Keskin O, Wedemeyer H, Tüzün A, Zachou K, Deda X, Dalekos GN, et al. Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome. Clin Gastroenterol Hepatol 2015;13:2342-2349.e1-e2.\n478. Heidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, Bremer B, et al. Late HDV RNA relapse after peginterferon α-based therapy of chronic hepatitis delta. Hepatology 2014;60:87-删除13:<u>97.\n479</u>. Triantos C, Kalafateli M, Nikolopoulou V, Burroughs A. Meta-analysis: antiviral treatment for hepatitis D. Aliment Pharmacol Ther 2012;35:663-删除13:<u>674.\n480</u>. Karaca C, Soyer OM, Baran B, Ormeci AC, Gokturk S, Aydin E, et al. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther 2013;18:561-删除13:<u>566.\n481</u>. Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Ptachenchova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase IIb/IIIa study. J Hepatol 2016;65:490-删除13:<u>498.\n482</u>. Wedemeyer H, Aleman S, Andreone P, Blank A, Brunetto M, Bogomolov P, et al. Bulevirtide monotherapy at low and.high doses in|删除段内换行|", "tags": {}, "lang": "en", "attr": {"page_num": 55, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/KASL：慢性乙型肝炎管理的临床实践指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:35:51", "endTime": "2024/08/06 15:35:58", "cost": 7.16}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:35:58", "grab_time": "2024-08-05 23:35:51"}
{"id": 2211718, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "505b38b9-dc28-4439-9aca-8e9b5997ad06", "title": "国际软组织肉瘤联合会(INSTRuCT)关于手术边缘定义统一的共识：手术边缘在儿童非横纹肌肉瘤软组织肉瘤中的意义(1)", "text": "页码:3\n国际软组织肉瘤联合会(INSTRuCT)关于手术边缘定义统一的共识：手术边缘在儿童非横纹肌肉瘤软组织肉瘤中的意义(1)\n# 2 | THE ONCOLOGY PERSPECTIVE: WHAT CLINICAL CLASSIFICATION SYSTEMS ARE USED FOR PEDIATRIC NRSTS?\n\n## 2.1 | Clinical classification systems and definitions\n\n【2】Initially, CWS, the EpSSG (the former Malignant Mesenchymal Tumor MMT Committee together with the STSC AIEOP Italian Soft Tissue Sarcoma Committee), and COG used a postsurgical clinical grouping system based on extent of tumor resection adapted from the Intergroup Rhabdomyosarcoma Study Group (IRSG)4,6,7 to classify pediatric patients with NRSTS. The IRS system defines Group I—a completely resected localized tumor with negative resection margins; Group IIa—a grossly resected localized tumor with microscopic residual disease; Group IIb—a completely resected localized tumor with resected involved regional lymph nodes; Group IIc—a grossly resected localized tumor with microscopic residual disease together with resected involved regional lymph nodes; Group III—a tumor with gross residual disease after biopsy or after incomplete resection; and Group IV—a tumor with distant metastases.删除17:<u>8</u> The IR group system has been widely used for its simplicity9 and prognostic value.删除17:<u>10,11</u> Nevertheless, controversies remain regarding definitions of the postoperative extent of disease in NRSTS. Limitations of the IRS grouping system are lack of documentation of margins width and closeness to anatomic boundaries that usually prevent tumor spread. Additionally, this system does not include details on primary re-excision (PRE) (defined by an immediate wide resection of the primary site before any neoadjuvant therapy) and was not designed to define margins after delayed surgery (defined by a wide local surgery of the primary site after chemotherapy or radiotherapy).\n\n【3】For pretreatment staging, the TNM classification is generally used.删除17:<u>11</u> This system includes an estimate of tumor invasiveness, classifying tumors confined to the organ or tissue of origin as T1 and tumors invading adjacent structures as T2, regional nodal status, classifying uninvolved lymph nodes as N0 and involved lymph nodes as N1, and metastasis, M0 if not present and M1 if present.\n\n## 2.2 | What is the definition of a negative margins in pediatric NRSTS?\n\n【5】Many adult and pediatric studies categorize margin status after either upfront or delayed surgery according to the American Joint Committee on Cancer (AJCC) residual tumor classification (R-classification). However, the definitions of postsurgical resection margins within pediatric clinical trials vary among the cooperative groups 删除9:<u>(Table S1)</u>12 and an ongoing challenge is that the extent of negative margins in millimeters is often not available in international databases or from pathology reports. Future use of standardized pathology reporting of margins is needed,13 and harmonization of surgical margin definitions is necessary for future studies.删除17:<u>5</u> In the COG ARST0332, the 5-year EFS for young patients with sarcomas and “negative microscopic margins” was ~84% versus 66% with “positive microscopic margins”.删除17:<u>9</u> However, this group has previously demonstrated that local control rates were comparable regardless of the size of the negative margins (94% for ≤1 cm margins vs 97% for >1 cm margins) or the anatomic site (96% in upper extremities vs 97% in lower extremities).删除17:<u>14</u>\n\n【6】Microscopic margin status (positive vs negative) is one of the few reproducible and consistent histologic features which affects long-term outcome. Negative margins should be the goal, where possible.删除17:<u>5,9,10,15–17</u> However, North American9 and European10 trials use different definitions for negative and positive margins. In the COG ARST0332, negative margin (R0) was defined as at least a 5 mm cuff of nonmalignant tissue surrounding the tumor in all directions. However, in many of the other studies the definition was not evaluable. In addition, for sites where tumor abuts fascia/periosteum and is removed in continuity, resection was considered complete (R0). Since the width of the negative margin was often not specified, though, it was difficult to ensure compliance with protocol guidelines for a 5 mm margin to be considered R0. In contrast, in the EpSSG NRSTS 2005 protocol and the CWS guidance a definition of negative margin in which resection is performed through normal tissue beyond the tumor and its pseudo capsule (wide resection) without an assigned number of millimeters from the margin 删除9:<u>(Table S1)</u>. Traditionally, in the EpSSG NRSTS protocols, adequate margins have been defined as ≥1 cm of healthy tissue around the tumor in all directions for muscle, or >1 mm of healthy tissue around the tumor when the tissue is periosteum, vessel sheath, epineurium, or muscular fascia. Past COG protocols considered margins <0.5 cm without any fascia to be “marginal” and those ≥0.5 cm as “wide resection.” More recent CWS and COG protocols do not specify a specific margin width.\n\n【7】The “R-classification” allows margins closer than 1 mm to be regarded as R0, whereas the “UICC-classification” (Union internationale contre le cancer) considers margins closer than 1 mm to be positive (R1). Kainhofer et al. assessed the impact of margin status according to these systems and found that the margin status represented an independent prognostic factor for local recurrence (LR) in", "tags": {}, "lang": "en", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/国际软组织肉瘤联合会(INSTRuCT)关于手术边缘定义统一的共识：手术边缘在儿童非横纹肌肉瘤软组织肉瘤中的意义(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:37:31", "endTime": "2024/08/06 15:39:24", "cost": 112.323}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:39:24", "grab_time": "2024-08-05 23:37:31"}
{"id": 2211717, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "4aa73a73-3445-4044-94f6-f2805243c9bd", "title": "2023 法国指南：嗜酸性粒细胞增多症的病因检查和高嗜酸性粒细胞综合征的管理", "text": "【0】页码:23\n2023 法国指南：嗜酸性粒细胞增多症的病因检查和高嗜酸性粒细胞综合征的管理\nBox 9 删除32:<u>**</u>Prescribing guidelines for pegylated interferon alfa-2a删除32:<u>**</u>\n\n【1】Pegylated interferon alfa-2a is administered by weekly subcutaneous injections. In HES, common practice is to start with low doses (e.g., 45 µg per week, less than those used for myeloproliferative neoplasms or viral hepatitis) to promote tolerability and long-term adherence. Combination with prophylactic administration of paracetamol (1 g every 8 hours for 24–48 hours) should be offered to reduce flu-like symptoms that can sometimes be observed after injection.\n\n【2】Pegylated interferon alfa-2a is contraindicated in children under 3 years of age, in case of documented hypersensitivity to benzyl alcohol, severe decompensated liver failure, thrombocytopenia $< 100 \\times 10删除21:<u>^9</u>/L$ or progressive autoimmune disease (particularly systemic lupus erythematosus, dermatomyositis, other diseases mediated by interferon pathways and autoimmune hepatitis). Overall, if there is history of preexisting autoimmune disease, the benefit/risk ratio of treatment with pegylated interferon alfa-2a should be weighed on a case-by-case basis. In patients with a history of mood and/or personality disorders, a psychiatrist should be consulted prior to initiation of treatment (and monitoring increased if necessary), as this drug may induce mood disorders.\n\n【3】In addition, regular laboratory monitoring (including CBC, serum electrolytes, creatinine, transaminases, TSH\\删除32:<u>*</u>) is recommended. In the event of cytopenia, the intervals between injections of pegylated interferon alfa-2a may be increased and/or the dosages reduced.\n\n【4】删除图片描述:<u>![](/mnt/data/file.png)</u>\n\n【5】Hydroxycarbamide is administered orally at a daily dosage of 15–30 mg/kg (in one or two daily doses). Outside of emergency settings 删除19:<u>(where the dosage is typically 1500–2000 mg daily)</u>, the standard practice for HES is to start with a low dosage 删除19:<u>(e.g., 1000 mg daily)</u> and then increase it as needed depending on treatment effectiveness and tolerability. Hydroxycarbamide is contraindicated in patients with lactase deficiency, pregnancy and severe cytopenia (neutropenia $< 1.0 \\times 10删除21:<u>^9</u>/L$, thrombocytopenia $< 100 \\times 10删除21:<u>^9</u>/L$ and/or anemia $< 10 \\ g/dL$).\n\n【6】Because the risk of bone marrow failure is higher in patients who have received prior radiation or chemotherapy, hydroxycarbamide should be administered with caution in this situation. Likewise, in case of renal failure and/or concomitant use of other myelosuppressive agents, a reduction in the dosages of hydroxycarbamide and increased monitoring are recommended.\n\n【7】In case of significant HE, significant splenomegaly and/or elevated uric acid levels, hydration is recommended at the start of treatment to prevent the possible occurrence of lysis syndrome.\n\n【8】Regular (e.g., every two weeks) blood tests from six months after initiation of treatment, and then every three months thereafter) clinical (including screening for skin cancers) and laboratory monitoring (including CBC, serum electrolytes, creatinine, transaminases, etc.) is indicated in patients who receive long-term hydroxycarbamide treatment is recommended. Because hydroxycarbamide treatment is associated with leukemogenic risk (with an estimated incidence of 10% after 10 years of treatment in some studies), long-term use should be avoided in young patients. It is contraindicated in women who are pregnant or planning to become pregnant and in men who do not wish to use contraception during treatment and up to 3–6 months after cessation. However, the indications for treatment with pegylated interferon alfa-2a must be assessed on a case-by-case basis, particularly in patients with a significant psychiatric history, liver disease and/or a history of concurrent underlying autoimmune disease (particularly lupus).\n\n【9】Therapeutic management of lymphocytic HES  \n删除32:<u>**</u>Indications删除32:<u>**</u> If a close clinical and laboratory monitoring is performed, non-treatment is perfectly acceptable in asymptomatic patients with lymphocytic HE.\n\n【10】In the event of clinical manifestations attributable to eosinophil toxicity and/or to the abnormal T cell population (lymphocytic HES), treatment strategies (with a preference for topical corticosteroids and short-term rather than long-term treatment) share similarities with those previously described for the management of idiopathic HES, with the noteworthy exception that there is solid data supporting the use of Interferon alfa-2a in this setting.\n\n【11】In daily practice, pegylated interferon alfa-2a is often favored in young patients because of the theoretical long-term leukemogenic risk of hydroxycarbamide, and the need for male and female contraception during treatment and up to 3–6 months after cessation. However, the indications for treatment with pegylated interferon alfa-2a must be assessed on a case-by-case basis, particularly in patients with a significant psychiatric history, liver disease and/or a history of concurrent underlying autoimmune disease (particularly lupus).", "tags": {}, "lang": "en", "attr": {"page_num": 23, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 法国指南：嗜酸性粒细胞增多症的病因检查和高嗜酸性粒细胞综合征的管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【7】In case of significant HE, significant splenomegaly and/or elevated uric acid levels, hydration is recommended at the start of treatment to prevent the possible occurrence of lysis syndrome.\n\n【8】Regular (e.g., every two weeks) blood tests from six months after initiation of treatment, and then every three months thereafter) clinical (including screening for skin cancers) and laboratory monitoring (including CBC, serum electrolytes, creatinine, transaminases, etc.) is indicated in patients who receive long-term hydroxycarbamide treatment is recommended. Because hydroxycarbamide treatment is associated with leukemogenic risk (with an estimated incidence of 10% after 10 years of treatment in some studies), long-term use should be avoided in young patients. It is contraindicated in women who are pregnant or planning to become pregnant and in men who do not wish to use contraception during treatment and up to 3–6 months after cessation. However, the indications for treatment with pegylated interferon alfa-2a must be assessed on a case-by-case basis, particularly in patients with a significant psychiatric history, liver disease and/or a history of concurrent underlying autoimmune disease (particularly lupus).", "content": "【0】页码:23\n2023 法国指南：嗜酸性粒细胞增多症的病因检查和高嗜酸性粒细胞综合征的管理\nBox 9 删除32:<u>**</u>Prescribing guidelines for pegylated interferon alfa-2a删除32:<u>**</u>\n\n【1】Pegylated interferon alfa-2a is administered by weekly subcutaneous injections. In HES, common practice is to start with low doses (e.g., 45 µg per week, less than those used for myeloproliferative neoplasms or viral hepatitis) to promote tolerability and long-term adherence. Combination with prophylactic administration of paracetamol (1 g every 8 hours for 24–48 hours) should be offered to reduce flu-like symptoms that can sometimes be observed after injection.\n\n【2】Pegylated interferon alfa-2a is contraindicated in children under 3 years of age, in case of documented hypersensitivity to benzyl alcohol, severe decompensated liver failure, thrombocytopenia $< 100 \\times 10删除21:<u>^9</u>/L$ or progressive autoimmune disease (particularly systemic lupus erythematosus, dermatomyositis, other diseases mediated by interferon pathways and autoimmune hepatitis). Overall, if there is history of preexisting autoimmune disease, the benefit/risk ratio of treatment with pegylated interferon alfa-2a should be weighed on a case-by-case basis. In patients with a history of mood and/or personality disorders, a psychiatrist should be consulted prior to initiation of treatment (and monitoring increased if necessary), as this drug may induce mood disorders.\n\n【3】In addition, regular laboratory monitoring (including CBC, serum electrolytes, creatinine, transaminases, TSH\\删除32:<u>*</u>) is recommended. In the event of cytopenia, the intervals between injections of pegylated interferon alfa-2a may be increased and/or the dosages reduced.\n\n【4】删除图片描述:<u>![](/mnt/data/file.png)</u>\n\n【5】Hydroxycarbamide is administered orally at a daily dosage of 15–30 mg/kg (in one or two daily doses). Outside of emergency settings 删除19:<u>(where the dosage is typically 1500–2000 mg daily)</u>, the standard practice for HES is to start with a low dosage 删除19:<u>(e.g., 1000 mg daily)</u> and then increase it as needed depending on treatment effectiveness and tolerability. Hydroxycarbamide is contraindicated in patients with lactase deficiency, pregnancy and severe cytopenia (neutropenia $< 1.0 \\times 10删除21:<u>^9</u>/L$, thrombocytopenia $< 100 \\times 10删除21:<u>^9</u>/L$ and/or anemia $< 10 \\ g/dL$).\n\n【6】Because the risk of bone marrow failure is higher in patients who have received prior radiation or chemotherapy, hydroxycarbamide should be administered with caution in this situation. Likewise, in case of renal failure and/or concomitant use of other myelosuppressive agents, a reduction in the dosages of hydroxycarbamide and increased monitoring are recommended.\n\n【7】In case of significant HE, significant splenomegaly and/or elevated uric acid levels, hydration is recommended at the start of treatment to prevent the possible occurrence of lysis syndrome.\n\n【8】Regular (e.g., every two weeks) blood tests from six months after initiation of treatment, and then every three months thereafter) clinical (including screening for skin cancers) and laboratory monitoring (including CBC, serum electrolytes, creatinine, transaminases, etc.) is indicated in patients who receive long-term hydroxycarbamide treatment is recommended. Because hydroxycarbamide treatment is associated with leukemogenic risk (with an estimated incidence of 10% after 10 years of treatment in some studies), long-term use should be avoided in young patients. It is contraindicated in women who are pregnant or planning to become pregnant and in men who do not wish to use contraception during treatment and up to 3–6 months after cessation. However, the indications for treatment with pegylated interferon alfa-2a must be assessed on a case-by-case basis, particularly in patients with a significant psychiatric history, liver disease and/or a history of concurrent underlying autoimmune disease (particularly lupus).\n\n【9】Therapeutic management of lymphocytic HES  \n删除32:<u>**</u>Indications删除32:<u>**</u> If a close clinical and laboratory monitoring is performed, non-treatment is perfectly acceptable in asymptomatic patients with lymphocytic HE.\n\n【10】In the event of clinical manifestations attributable to eosinophil toxicity and/or to the abnormal T cell population (lymphocytic HES), treatment strategies (with a preference for topical corticosteroids and short-term rather than long-term treatment) share similarities with those previously described for the management of idiopathic HES, with the noteworthy exception that there is solid data supporting the use of Interferon alfa-2a in this setting.\n\n【11】In daily practice, pegylated interferon alfa-2a is often favored in young patients because of the theoretical long-term leukemogenic risk of hydroxycarbamide, and the need for male and female contraception during treatment and up to 3–6 months after cessation. However, the indications for treatment with pegylated interferon alfa-2a must be assessed on a case-by-case basis, particularly in patients with a significant psychiatric history, liver disease and/or a history of concurrent underlying autoimmune disease (particularly lupus).", "index": 2708, "show": true, "start": 2708, "end": 3933, "province": ["语义有效性", "语句/字词重复"], "isEdit": false, "comment": "【8】contraception during treatment and up to 3–6 months after cessation. However, the indications for treatment with pegylated interferon alfa-2a must be assessed on a case-by-case basis, particularly in patients with a significant psychiatric history, liver disease and/or a history of concurrent underlying autoimmune disease (particularly lupus).  与下面内容重复，连接错误"}, {"text": "【9】", "content": "【0】页码:23\n2023 法国指南：嗜酸性粒细胞增多症的病因检查和高嗜酸性粒细胞综合征的管理\nBox 9 删除32:<u>**</u>Prescribing guidelines for pegylated interferon alfa-2a删除32:<u>**</u>\n\n【1】Pegylated interferon alfa-2a is administered by weekly subcutaneous injections. In HES, common practice is to start with low doses (e.g., 45 µg per week, less than those used for myeloproliferative neoplasms or viral hepatitis) to promote tolerability and long-term adherence. Combination with prophylactic administration of paracetamol (1 g every 8 hours for 24–48 hours) should be offered to reduce flu-like symptoms that can sometimes be observed after injection.\n\n【2】Pegylated interferon alfa-2a is contraindicated in children under 3 years of age, in case of documented hypersensitivity to benzyl alcohol, severe decompensated liver failure, thrombocytopenia $< 100 \\times 10删除21:<u>^9</u>/L$ or progressive autoimmune disease (particularly systemic lupus erythematosus, dermatomyositis, other diseases mediated by interferon pathways and autoimmune hepatitis). Overall, if there is history of preexisting autoimmune disease, the benefit/risk ratio of treatment with pegylated interferon alfa-2a should be weighed on a case-by-case basis. In patients with a history of mood and/or personality disorders, a psychiatrist should be consulted prior to initiation of treatment (and monitoring increased if necessary), as this drug may induce mood disorders.\n\n【3】In addition, regular laboratory monitoring (including CBC, serum electrolytes, creatinine, transaminases, TSH\\删除32:<u>*</u>) is recommended. In the event of cytopenia, the intervals between injections of pegylated interferon alfa-2a may be increased and/or the dosages reduced.\n\n【4】删除图片描述:<u>![](/mnt/data/file.png)</u>\n\n【5】Hydroxycarbamide is administered orally at a daily dosage of 15–30 mg/kg (in one or two daily doses). Outside of emergency settings 删除19:<u>(where the dosage is typically 1500–2000 mg daily)</u>, the standard practice for HES is to start with a low dosage 删除19:<u>(e.g., 1000 mg daily)</u> and then increase it as needed depending on treatment effectiveness and tolerability. Hydroxycarbamide is contraindicated in patients with lactase deficiency, pregnancy and severe cytopenia (neutropenia $< 1.0 \\times 10删除21:<u>^9</u>/L$, thrombocytopenia $< 100 \\times 10删除21:<u>^9</u>/L$ and/or anemia $< 10 \\ g/dL$).\n\n【6】Because the risk of bone marrow failure is higher in patients who have received prior radiation or chemotherapy, hydroxycarbamide should be administered with caution in this situation. Likewise, in case of renal failure and/or concomitant use of other myelosuppressive agents, a reduction in the dosages of hydroxycarbamide and increased monitoring are recommended.\n\n<mark>【7】In case of significant HE, significant splenomegaly and/or elevated uric acid levels, hydration is recommended at the start of treatment to prevent the possible occurrence of lysis syndrome.\n\n【8】Regular (e.g., every two weeks) blood tests from six months after initiation of treatment, and then every three months thereafter) clinical (including screening for skin cancers) and laboratory monitoring (including CBC, serum electrolytes, creatinine, transaminases, etc.) is indicated in patients who receive long-term hydroxycarbamide treatment is recommended. Because hydroxycarbamide treatment is associated with leukemogenic risk (with an estimated incidence of 10% after 10 years of treatment in some studies), long-term use should be avoided in young patients. It is contraindicated in women who are pregnant or planning to become pregnant and in men who do not wish to use contraception during treatment and up to 3–6 months after cessation. However, the indications for treatment with pegylated interferon alfa-2a must be assessed on a case-by-case basis, particularly in patients with a significant psychiatric history, liver disease and/or a history of concurrent underlying autoimmune disease (particularly lupus).</mark>\n\n【9】Therapeutic management of lymphocytic HES  \n删除32:<u>**</u>Indications删除32:<u>**</u> If a close clinical and laboratory monitoring is performed, non-treatment is perfectly acceptable in asymptomatic patients with lymphocytic HE.\n\n【10】In the event of clinical manifestations attributable to eosinophil toxicity and/or to the abnormal T cell population (lymphocytic HES), treatment strategies (with a preference for topical corticosteroids and short-term rather than long-term treatment) share similarities with those previously described for the management of idiopathic HES, with the noteworthy exception that there is solid data supporting the use of Interferon alfa-2a in this setting.\n\n【11】In daily practice, pegylated interferon alfa-2a is often favored in young patients because of the theoretical long-term leukemogenic risk of hydroxycarbamide, and the need for male and female contraception during treatment and up to 3–6 months after cessation. However, the indications for treatment with pegylated interferon alfa-2a must be assessed on a case-by-case basis, particularly in patients with a significant psychiatric history, liver disease and/or a history of concurrent underlying autoimmune disease (particularly lupus).", "index": 3948, "show": true, "start": 3935, "end": 3938, "province": ["语义有效性", "栏目混乱-中"], "isEdit": false, "comment": "到【11】内容顺序有误"}, {"text": "【11】In daily practice, pegylated interferon alfa-2a is often favored in young patients because of the theoretical long-term leukemogenic risk of ", "content": "【0】页码:23\n2023 法国指南：嗜酸性粒细胞增多症的病因检查和高嗜酸性粒细胞综合征的管理\nBox 9 删除32:<u>**</u>Prescribing guidelines for pegylated interferon alfa-2a删除32:<u>**</u>\n\n【1】Pegylated interferon alfa-2a is administered by weekly subcutaneous injections. In HES, common practice is to start with low doses (e.g., 45 µg per week, less than those used for myeloproliferative neoplasms or viral hepatitis) to promote tolerability and long-term adherence. Combination with prophylactic administration of paracetamol (1 g every 8 hours for 24–48 hours) should be offered to reduce flu-like symptoms that can sometimes be observed after injection.\n\n【2】Pegylated interferon alfa-2a is contraindicated in children under 3 years of age, in case of documented hypersensitivity to benzyl alcohol, severe decompensated liver failure, thrombocytopenia $< 100 \\times 10删除21:<u>^9</u>/L$ or progressive autoimmune disease (particularly systemic lupus erythematosus, dermatomyositis, other diseases mediated by interferon pathways and autoimmune hepatitis). Overall, if there is history of preexisting autoimmune disease, the benefit/risk ratio of treatment with pegylated interferon alfa-2a should be weighed on a case-by-case basis. In patients with a history of mood and/or personality disorders, a psychiatrist should be consulted prior to initiation of treatment (and monitoring increased if necessary), as this drug may induce mood disorders.\n\n【3】In addition, regular laboratory monitoring (including CBC, serum electrolytes, creatinine, transaminases, TSH\\删除32:<u>*</u>) is recommended. In the event of cytopenia, the intervals between injections of pegylated interferon alfa-2a may be increased and/or the dosages reduced.\n\n【4】删除图片描述:<u>![](/mnt/data/file.png)</u>\n\n【5】Hydroxycarbamide is administered orally at a daily dosage of 15–30 mg/kg (in one or two daily doses). Outside of emergency settings 删除19:<u>(where the dosage is typically 1500–2000 mg daily)</u>, the standard practice for HES is to start with a low dosage 删除19:<u>(e.g., 1000 mg daily)</u> and then increase it as needed depending on treatment effectiveness and tolerability. Hydroxycarbamide is contraindicated in patients with lactase deficiency, pregnancy and severe cytopenia (neutropenia $< 1.0 \\times 10删除21:<u>^9</u>/L$, thrombocytopenia $< 100 \\times 10删除21:<u>^9</u>/L$ and/or anemia $< 10 \\ g/dL$).\n\n【6】Because the risk of bone marrow failure is higher in patients who have received prior radiation or chemotherapy, hydroxycarbamide should be administered with caution in this situation. Likewise, in case of renal failure and/or concomitant use of other myelosuppressive agents, a reduction in the dosages of hydroxycarbamide and increased monitoring are recommended.\n\n<mark>【7】In case of significant HE, significant splenomegaly and/or elevated uric acid levels, hydration is recommended at the start of treatment to prevent the possible occurrence of lysis syndrome.\n\n【8】Regular (e.g., every two weeks) blood tests from six months after initiation of treatment, and then every three months thereafter) clinical (including screening for skin cancers) and laboratory monitoring (including CBC, serum electrolytes, creatinine, transaminases, etc.) is indicated in patients who receive long-term hydroxycarbamide treatment is recommended. Because hydroxycarbamide treatment is associated with leukemogenic risk (with an estimated incidence of 10% after 10 years of treatment in some studies), long-term use should be avoided in young patients. It is contraindicated in women who are pregnant or planning to become pregnant and in men who do not wish to use contraception during treatment and up to 3–6 months after cessation. However, the indications for treatment with pegylated interferon alfa-2a must be assessed on a case-by-case basis, particularly in patients with a significant psychiatric history, liver disease and/or a history of concurrent underlying autoimmune disease (particularly lupus).</mark>\n\n<mark>【9】</mark>Therapeutic management of lymphocytic HES  \n删除32:<u>**</u>Indications删除32:<u>**</u> If a close clinical and laboratory monitoring is performed, non-treatment is perfectly acceptable in asymptomatic patients with lymphocytic HE.\n\n【10】In the event of clinical manifestations attributable to eosinophil toxicity and/or to the abnormal T cell population (lymphocytic HES), treatment strategies (with a preference for topical corticosteroids and short-term rather than long-term treatment) share similarities with those previously described for the management of idiopathic HES, with the noteworthy exception that there is solid data supporting the use of Interferon alfa-2a in this setting.\n\n【11】In daily practice, pegylated interferon alfa-2a is often favored in young patients because of the theoretical long-term leukemogenic risk of hydroxycarbamide, and the need for male and female contraception during treatment and up to 3–6 months after cessation. However, the indications for treatment with pegylated interferon alfa-2a must be assessed on a case-by-case basis, particularly in patients with a significant psychiatric history, liver disease and/or a history of concurrent underlying autoimmune disease (particularly lupus).", "index": 4652, "show": true, "start": 4626, "end": 4771, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/06 17:03:20", "endTime": "2024/08/06 17:07:50", "cost": 269.608}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 01:07:50", "grab_time": "2024-08-06 01:03:20"}
{"id": 2211716, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "7d9ffcb0-6578-4a3b-a2ed-783c633d41c7", "title": "2023 国际共识：嗜酸性粒细胞疾病和系统性肥大细胞增多症的分类", "text": "【0】页码:6\n2023 国际共识：嗜酸性粒细胞疾病和系统性肥大细胞增多症的分类\n### 1.1.5 Treatment and prognosis\n\n【1】Almost all patients with a PDGFRA fusion are sensitive to low dose (100 mg/day) imatinib. Recent data have shown that a treatment-free remission can be maintained in a proportion of patients after imatinib discontinuation, and a rapid second remission can be achieved after restart of imatinib in relapsed patients. Primary or secondary resistance is usual, but if it occurs, it is linked to the T674I or D842V mutation within the ATP-binding domain of PDGFRA, and associated with a poor prognosis. Such patients have been shown to be responsive to second- or third-generation TKI, but survival is generally poor and rapid bridging to allogeneic hematopoietic stem cell transplantation (SCT) is strongly encouraged. Avapritinib has been shown efficacy in PDGFRA D842V-mutant gastrointestinal stromal tumors, which may be beneficial for patients with MLN-eo-PDGFRA with D842V mutations. Like PDGFRA-rearranged cases, MLN-eo with PDGFRB rearrangement demonstrate an excellent response to imatinib with long-term complete hematologic and molecular responses. In cases presenting in blast phase of CMN or after disease progression from an initial chronic phase, induction chemotherapy and/or allogenic SCT is typically administered in addition to imatinib. However, in a case series of 17 patients with PDGFRΑ/B MLN-eo in blast phase or sarcoma, 15 patients achieved durable complete hematologic and molecular remissions with imatinib monotherapy.\n\n【2】The prognosis of FGFR1-rearranged MLN-eo is poor for cases presenting in chronic phase or cases with leukemia/lymphoma due to the rapid acquisition of additional genetic abnormalities over time, oral FGFR inhibitors, for example, pemigatinib (anti-FGFR1-3) or futibatinib (anti-FGFR1-4) are showing promising activity.\n\n【3】For cases with PCM1::JAK2 fusion, the disease course can be highly variable. In patients presenting in chronic phase of a myeloid neoplasm, the disease may be indolent with a 5-year survival up to 80. On the other hand, in patients who present or progress to acute leukemia, the prognosis is dismal. Targeted therapy with JAK2 inhibitors such as ruxolitinib may offer some but limited benefit and should be used to bridge patients to allogeneic SCT, which can lead to durable disease-free survival.\n\n【4】FLT3-rearranged cases tend to have an aggressive clinical course or early disease progression if untreated. FLT3 inhibitor sunitinib or sorafenib monotherapy has been reported to induce rapid hematologic improvements with or without complete cytogenetic response. Of reported cases, some patients have achieved a sustained remission or lived with stable disease on FLT3 monotherapy; and some being bridged to allogeneic SCT. Loss of response may occur due to acquired FLT3 N841K mutation in the activation loop of the TK domain. The potential role of gilteritinib and midostaurin has not been fully explored in these FLT3-rearranged MLN-eo.\n\n【5】Patients with ETV6::ABL1 have shown variable responses to TKI targeted therapy. Second- or third-generation TKI appear to be superior to imatinib in inducing responses. Durable hematological and molecular remissions have been observed in a significant number of patients presenting in chronic phase, but not patients in blast phase. Disease progression is reported in around 30% of patients that can be AML, B-ALL, T-ALL, or myeloid sarcoma, and the prognosis is dismal despite the addition of TKI to standard chemotherapy.\n\n【6】### 1.2 Idiopathic hypereosinophilic syndromes\n\n【7】HES is defined as persistent PB HE (≥1.5 × 10删除21:<u>^9</u>/L) and/or tissue HE with associated tissue/organ damage/injury that is directly attributable to eosinophil-released cytokines or enzymes. The majority of HES are reactive due to an underlying inflammatory condition, infection, autoimmune disorder, allergy/vaccination, or neoplasm, such as solid tumors, lymphomas, or lymphocyte variant HES (LV-HES). HES is considered as idiopathic (iHES) when an underlying primary cause (either reactive or neoplastic) cannot be identified. HES is generally divided into: 删除11:<u>(1)</u> secondary HES (eosinophils are reactive and non-clonal) including lymphocyte variant-HES; 删除11:<u>(2)</u> primary HES (associated with a hematopoietic neoplasms); 删除11:<u>(3)</u> idiopathic HES. It is noteworthy that primary HES should be classified by the hematopoietic neoplasm according to ICC. The term of \"idiopathic HE\" or \"HE of unknown significance\" (HEus) is used to describe persistent HE (≥ 6 months) without associated organ/tissue damage.\n\n【8】It has been historically challenging to differentiate iHES/HEus from CEL, NOS (a subtype of MPN with hypereosinophilia), due to the difficulty in proving clonality in the latter. In the 2008 WHO definition, CEL, NOS was a diagnosis of exclusion of other hematopoietic neoplasm, as with NGS and its ubiquitous diagnostic application, somatic variants associated with myeloid neoplasms can be detected in 25%-30% of patients who would have been previously classified as “iHES.” Such mutations have been found in genes involved in DNA methylation and chromatin modification, such as ASXL1, TET2, EZH2, and DNMT3A, but also in other genes such as SRSF2, TP53, and SETBP1. More recently, STAT5B N642H has been reported in some patients with a referral diagnosis of eosinophilia (1.6% of patients in one series), including patients who would be otherwise diagnosed with iHES/HEus. While the presence of a mutation provides evidence of clonality, such mutations have also been reported in aging individuals lacking evidence of a myeloid neoplasm. Some cases with clinical features typical of iHES/HEus and with a relatively benign clinical course have also been found to carry somatic mutations. On the other hand, some true CEL, NOS, even those with karyotypic abnormalities, may not show detectable mutations at least by myeloid neoplasm targeted NGS panels. Although the underlying cause for iHES/HEus remains to be discovered, it is acknowledged that iHES/HEus lacking convincing evidence of clonality or abnormal BM morphology of a CMN should not be considered a myeloid neoplasm and should be kept separate from CEL, NOS and other true myeloid neoplasm with HE.\n\n【9】### 1.2.1 Histopathology\n\n【10】Recent studies have shown that the BM of patients with iHES/HEus is usually unremarkable except for increased eosinophils.", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 国际共识：嗜酸性粒细胞疾病和系统性肥大细胞增多症的分类.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:50:14", "endTime": "2024/08/06 15:51:01", "cost": 46.819}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:51:01", "grab_time": "2024-08-05 23:50:14"}
{"id": 2211715, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "14c8fcc6-22ca-4b51-80d3-77aa0d4c5b6f", "title": "WHO：控制和消灭人类血吸虫病指南（2022）", "text": "【0】页码:128\nWHO：控制和消灭人类血吸虫病指南（2022）\n## GRADE summary table of the findings\n\n| Outcomes (reference)   | Diagnostic estimates (95% CI)                          | Sample size (studies) | Certainty of the evidence (GRADE)  |\n|------------------------|--------------------------------------------------------|------------------------|--------------------------------------|\n| CCA1 删除11:<u>(5)</u>               | Vs 2 KK: Se=64% Sp=66%<br>Vs 4 KK: Se=85% Sp=62%<br>Vs 6 KK: Se=81% Sp=63% | 788 删除11:<u>(4)</u><br>4173 删除11:<u>(9)</u><br>1441 删除11:<u>(4)</u> | ⊕⊕⊕⊝ Moderate⊕⊕⊝⊝ Low|\n| CCA2 删除11:<u>(6)</u>               | Vs 2 KK: Se=59% Sp=87%<br>Vs 4 KK: Se=46% Sp=88%        | 100 删除11:<u>(2)</u><br>100 删除11:<u>(1)</u>     | ⊕⊕⊕⊝ Moderate                       |\n| CAA                    | Vs 4 KK: Se=89% Sp=60%<br>Vs urine microscopy: Se=70% Sp=46% | 377 删除11:<u>(1)</u><br>265 删除11:<u>(1)</u>     | ⊕⊕⊕⊝ Moderate                       |\n| FLOTAC                 | Fresh vs 3KK: Se=65% Sp=70%<br>10d vs 3KK: Se=88% Sp=64%<br>30d vs 3KK: Se=93% Sp=61% | 112 删除11:<u>(1)</u><br>112 删除11:<u>(1)</u><br>112 删除11:<u>(1)</u> | ⊕⊕⊕⊝ Moderate                       |\n| SmCTF-RDT              | Vs 4 KK: Se=87% Sp=35%<br>Vs urine microscopy: Se=62% Sp=38% | 291 删除11:<u>(4)</u><br>117 删除11:<u>(1)</u>     | ⊕⊕⊕⊝ Moderate                       |\n| Sm DNA PCR             | Vs 2 KK: Se=96% Sp=32%                                  | 89 删除11:<u>(1)</u>                 | ⊕⊕⊕⊝ Moderate                       |\n| SWAP ELISA             | Vs 6 KK: Se=83% Sp=55%                                  | 482 删除11:<u>(1)</u>                | ⊕⊕⊕⊝ Moderate                       |\n| IgM ELISA              | Vs 3 KK: Se=92% Sp=91%                                  | 137 删除11:<u>(1)</u>                | ⊕⊕⊕⊝ Moderate                       |\n| IgG ELISA              | Vs 3 KK: Se=88% Sp=66%                                  | 247 删除11:<u>(1)</u>                | ⊕⊕⊕⊝ Moderate                       |\n| Anti IgG RDT Sh        | Vs urine microscopy: Se=47% Sp=19%                     | 160 删除11:<u>(1)</u>                | ⊕⊕⊕⊝ Moderate                       |\n| Proteinuria reagent strips | Vs urine microscopy: Se=72% Sp=86%              | 3324 删除11:<u>(4)</u>               | ⊕⊕⊕⊝ Moderate                       |\n| Haematuria reagent strips | Vs urine microscopy: Se=86% Sp=86%                | 4862 删除11:<u>(6)</u>               | ⊕⊕⊕⊝ Moderate                       |\n| AWE-SEA ELISA          | Vs 4 KK: Se=94% Sp=64%                                  | 247 删除11:<u>(2)</u>                | ⊕⊕⊕⊝ Moderate                       |\n| LAMP                   | Vs 3 KK: Se=87% Sp=50%<br>Vs urine microscopy: Se=66% Sp=79% | 110 删除11:<u>(1)</u><br>94 删除11:<u>(1)</u>      | ⊕⊕⊕⊝ Moderate                       |", "tags": {}, "lang": "en", "attr": {"page_num": 128, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WHO：控制和消灭人类血吸虫病指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:58:52", "endTime": "2024/08/06 15:59:09", "cost": 17.532}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:59:10", "grab_time": "2024-08-05 23:58:52"}
{"id": 2211714, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "26ebe8fa-d8d7-4c40-886e-fa27e1d288dc", "title": "2023 SFAR指南：脑卒中患者血栓切除术的麻醉和围手术期管理", "text": "【0】页码:6\n2023 SFAR指南：脑卒中患者血栓切除术的麻醉和围手术期管理\nFIELD 2. Prevention and management of secondary brain injuries\n\n【1】Experts: T. Geeraerts (ANARLF) – M. Mazzighi (SFNV) - S. Figueiredo (SFAR) - JM Olivot (SFNV)\n\n【2】删除32:<u>**</u>Question: In a patient having presented with cerebral artery occlusion and received endovascular treatment, is use of target blood pressure (BP) levels in post-recanalization associated with improved neurological prognosis at 3 months?删除32:<u>**</u>\n\n【3】删除32:<u>**</u>R2.1.1删除32:<u>**</u> - The experts suggest that in the event of TICI <2b recanalization, post-procedure systolic blood pressure should be maintained between 130 and 180 mmHg, the objective being to achieve an improved neurological prognosis at 3 months.  \n删除32:<u>**</u>Expert opinion (Strong agreement)删除32:<u>**</u>\n\n【4】删除32:<u>**</u>R2.1.2删除32:<u>**</u> - The experts suggest that in the event of TICI ≥2b recanalization, post-procedure systolic blood pressure should be maintained between 130 to 160 mmHg, the objective being to achieve improved neurological prognosis at 3 months.  \n删除32:<u>**</u>Expert opinion (Strong agreement)删除32:<u>**</u>\n\n【5】删除32:<u>**</u>Argumentation:删除32:<u>**</u> Blood pressure management has multiple therapeutic objectives: to ensure adequate cerebral perfusion; and to avoid haemorrhagic phenomena or the development of cerebral oedema or other malignant complications. If targets for adequate blood pressure during the first 24 post-thrombectomy hours are met, the patient’s prognosis could be improved, and postoperative complications reduced.\n\n【6】The guidelines put forward by the AHA/ASA (American Heart Association/American Stroke Association) are mainly based on the literature concerning intravenous thrombolysis. They recommend maintaining systolic blood pressure (SBP) at < 180 mmHg and diastolic blood pressure (DBP) at < 105 mmHg after recanalization TICI 2b or 3 删除12:<u>删除14:<u>[21]</u></u>. The SNACC (Society for Neuroscience in Anaesthesiology and Critical Care) recommends per-procedural SBP between 140 and 180 mmHg, and DBP < 105 mmHg 删除12:<u>删除14:<u>[22]</u></u>.\n\n【7】The degree of recanalization of the artery is an important point, especially insofar as postremonously lowered blood pressure has been observed following successful recanalization and normalized intracranial haemodynamics 删除12:<u>删除14:<u>[23]</u></u>.\n\n【8】The one presently available work on the subject is the BP-TARGET study (Blood Pressure Target in Acute Stroke to Reduce Haemorrhage After Endovascular Therapy) 删除12:<u>删除14:<u>[24]</u></u>. It is a multicenter randomized controlled prospective study including successfully recanalized patients (TICI 2b and 3) in which an intensive strategy (target SBP 100-129 mmHg) vs. a standard strategy (target SBP 130–185 mmHg) was proposed. The primary endpoint consisted in appearance of hemorrhage on CT at 24–36 hours. All in all, the 158 randomized patients in the intensive arm had the same incidence of cerebral haemorrhage as the 160 patients in the standard arm, and a comparable functional prognosis at 3 months.\n\n【9】That is why, according to the currently available evidence on haemorrhagic risk and functional prognosis at 3 months, it would be of no interest to maintain SBP targets at <130 mmHg.\n\n【10】Numerous retrospective studies have reported congruent results regarding the upper limit of SBP. The retrospective study by Matsucievics et al., in which 2920 patients were included, concludes that SBP > 160 mmHg was associated with a poor prognosis for satisfactorily reperfused patients (TICI > 2b) 删除12:<u>删除14:<u>[25]</u></u>. In the retrospective study by An et al., maximum SBP of 155 mmHg was determined to be the threshold value associated with increased risk of intracranial haemorrhage 删除12:<u>删除14:<u>[26]</u></u>. Ding et al. reported a similar result, as threshold values of 151 mmHg (AUROC 0.74 95%CI 删除11:<u>(0.66 – 0.82)</u>, P < 0.001) were associated with a poor neurological prognosis and threshold values of 155 mmHg (AUROC 0.64 删除11:<u>(0.55 – 0.73)</u>, P = 0.006) associated with intracranial haemorrhage 删除12:<u>删除14:<u>[27]</u></u>. Lastly, in the retrospective observational study by Gagliordi et al., SBP > 180 mmHg occurring at least once over the course of the 25 h following thrombectomy was associated with a poor mRS score at discharge 删除12:<u>删除14:<u>[28]</u></u>.\n\n【11】Blood pressure targets must be individualized according to the characteristics of a given patient. Underlying chronic high blood pressure, for example, may necessitate specific post-thrombectomy targets. In 2 studies, only in patients with a history of chronic high blood pressure did excessive blood pressure variations during the 24 h after thrombectomy represent a risk factor for intracerebral haemorrhage 删除12:<u>删除14:<u>[25,29]</u></u>.\n\n【12】删除32:<u>**</u>Question: In a patient having presented with cerebral artery occlusion and received endovascular treatment, does the setting of target saturation as an objective lead to an improved neurological prognosis at 3 months?删除32:<u>**</u>\n\n【13】删除32:<u>**</u>R2.2删除32:<u>**</u> - The experts suggest maintaining patient SpO删除29:<u>₂</u> at ≥ 95% during and after surgery so as to avoid aggravating the neurological prognosis at 3 months.  \n删除32:<u>**</u>Expert opinion (Strong agreement)删除32:<u>**</u>\n\n【14】删除32:<u>**</u>Argumentation:删除32:<u>**</u> As of today, no study has dealt with the influence on patients’ neurological prognoses of different SpO删除29:<u>₂</u> levels during mechanical thrombectomy procedures.\n\n【15】While several randomized controlled studies have assessed the interest of systematic oxygen administration in patients presenting with ischemic CVA, none of them have shown this to be effective with regard to neurological evolution at 3 months 删除12:<u>[30–32]</u>. That much said, none of the studies have dealt specifically with patients having undergone thrombectomy, and the rate of recanalization among these patients has not been reported.\n\n【16】Only 1 study has tested the effect of normobaric oxygen therapy in the framework of a thrombectomy procedure 删除12:<u>删除14:<u>[33]</u></u>. It was a single-center study carried out on a population consisting in patients having been admitted for ischemic CVA of the anterior circulation and having received thrombectomy with recanalization without general anaesthesia. The intervention consisted in the administration subsequent to recanalization of 15 L.min⁻删除29:<u>¹</u> of O删除29:<u>₂</u> supplied by a Venturi mask for 6 h. The control group received low-flow oxygen therapy by nasal cannula (3 L.min⁻删除29:<u>¹</u>) during the same 6 h period. In the intervention group 98 patients were included, and 87 in the control group. A beneficial effect of oxygen therapy at 15 L.min⁻删除29:<u>¹</u> regarding the neurological prognosis at 3 months was reported [adjusted OR = 2.20 删除11:<u>(1.26–3.87)</u>], as well as benefit concerning mortality [RR = 0.35 删除11:<u>(0.13–0.93)</u>]. Taken alone, however, these outcomes do not suffice to justify a recommendation for systematic high-flow supplemental oxygen following recanalization by thrombectomy as other studies are needed for confirmation.\n\n【17】删除32:<u>**</u>Question: In a patient having presented with cerebral artery occlusion and receiving endovascular treatment under general anaesthesia, does per-procedure monitoring of CO删除29:<u>₂</u> need to be followed neurological prognosis at 3 months?删除32:<u>**</u>\n\n【18】删除32:<u>**</u>R2.3删除32:<u>**</u> - The experts suggest that during thrombectomy procedures carried out under general anaesthesia, end-tidal CO删除29:<u>₂</u> should be monitored and maintained at 35–40 mmHg, so as to avoid worsening the neurological prognosis at 3 months.  \n删除32:<u>**</u>Expert opinion (Strong agreement)删除32:<u>**</u>\n\n【19】删除32:<u>**</u>Argumentation:删除32:<u>**</u> Cerebral autoregulation (modification of cerebral blood flow in response to a modification of mean blood pressure) is profoundly impacted by PaCO删除29:<u>₂</u> level 删除12:<u>删除14:<u>[34]</u></u>. In a patient treated by thrombectomy for ischemic CVA, the vasoconstriction", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 SFAR指南：脑卒中患者血栓切除术的麻醉和围手术期管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:23:35", "endTime": "2024/08/06 17:32:32", "cost": 537.043}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 01:32:32", "grab_time": "2024-08-06 01:23:34"}
{"id": 2211713, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "3e7dd70a-fb14-4141-9bc5-46d35d008abf", "title": "ACPGBI BSG：具有疑似结直肠癌症状和体征患者的粪便免疫化学检测指南（2022）(1)", "text": "【0】页码:5\nACPGBI BSG：具有疑似结直肠癌症状和体征患者的粪便免疫化学检测指南（2022）(1)\nBased on a large retrospective cohort of 9896 patients tested in English primary care in the context of the DG30 NICE guidelines (CRC prevalence 1.1%), the authors illustrated the NNS and NMC for the thresholds of ≥7, 删除13:<u>10, 20, 50, 100, 120</u> and 150 μg Hb/g faeces. The corresponding proportion of positive tests were 删除13:<u>11, 10</u>, 7, 4, 3 and 2%, the proportion of cancers detected 删除13:<u>91, 91, 85, 74, 61, 57</u> and 54%, the NNS to detect one cancer was 删除13:<u>11, 10</u>, 8, 5, 5, and 4 and the NMC per 1000 FITs was 1, 2, 3, 4, 5 and 6. Reducing the threshold of ≥10 to ≥4 μg Hb/g faeces resulted in increase in the NNS to 21 and a reduction in the NMC to 4 per 1000 patients tested.\n\n【1】At a higher prevalence of 1.6%, a smaller Spanish retrospective cohort of 4543 symptomatic patients reported the NMC per 1000 patients tested to be 3.7 删除11:<u>(2.2-6.3)</u> at a threshold of ≥10 μg Hb/g faeces compared with 4.1 删除11:<u>(2.5-6.6)</u> using ≥20 μg Hb/g faeces, and the NNS was 13.8 删除11:<u>(10.8-17.7)</u> compared with 10.9 删除11:<u>(8.5-14.0)</u>. The authors concluded that the use of ≥20 μg Hb/g in preference to ≥10 μg Hb/g could reduce referrals for colonoscopy without missing more than one CRC per 1000 patients tested.\n\n【2】Increasing the threshold favours specificity reducing the NNS to detect one CRC but increases the NMC per 1000 patients tested. The opposite occurs when the threshold is reduced. The FIT threshold used in clinical practice is likely to be chosen based on a balance of tolerance of missed cancers and the diagnostic resources available to urgently investigate CRC.\n\n【3】### Multiple thresholds for low-risk, intermediate-risk and high-risk populations\nMultiple FIT thresholds have been introduced in some clinical settings to provide a rule-out threshold, a rule-in threshold and an intermediate range where the investigation of population subgroups and/or active safety netting is advised.\n\n【4】The Nottingham rapid CRC diagnostics 删除9:<u>(RCCD) service sees adult patients of any age, except those with rectal bleeding and rectal mass, combining low, intermediate and high thresholds (prevalence 1.6% (227/13 361)</u>). The RCCD service considers ≥100 μg Hb/g faeces the ‘high risk’ positive contacting these patients directly for rapid investigation. Patients with an FIT result <4 μg Hb/g faeces, and with an FIT result <10 μg Hb/g faeces but normal blood tests are considered ‘negative’删除1:<u>. Patients with an FIT of 4-10 μg Hb/g faeces with anaemia, low ferritin or thrombocytosis, or with FIT ≥10 μg Hb/g faeces are considered ‘positive’ and investigated urgently via the 2WW. The cancer detection rate was 0.1% for <4 μg Hb/g faeces, 0.6% between 4 and 9.9 μg Hb/g faeces, 3.3% for 10-99.9 μg Hb/g faeces and 20.7% for ≥100 Hb/g faeces.</u>\n\n【5】Cohort data from Tayside on FIT use in primary care patients with unselected GI symptoms allowed to show that ‘reassurance thresholds’ of <2, 7, 10 and 20 μg Hb/g faeces were associated with CRC risks of 0.1, 0.3, 0.3 and 0.4%. Intermediate-risk populations were created to highlight those with a cancer risk below the 3% risk used by NICE to trigger urgent colorectal investigation. For example, an intermediate population defined by 10-99 μg Hb/g faeces had a risk of 2.7%, leaving a higher risk population ≥100 μg Hb/g faeces with a risk of 14.5%. An intermediate range 10-149 μg Hb/g faeces resulted in an intermediate population risk of 3.2%, meaning all patients ≥10 μg Hb/g faeces would qualify for urgent investigation. The cancer risk for the intermediate 7-199 μg Hb/faeces population was 2.8% with a risk of 17.2% in the ≥200 μg Hb/g faeces group. However, there was no intermediate population ≥20 μg Hb/g faeces with a risk below 3%. The patients with FIT ≥20 μg Hb/g faeces comprised 16.8% of the population tested compared with 21.9% for ≥10 μg Hb/g faeces and 25.4% for ≥7 μg Hb/g faeces.\n\n【6】### Individualised FIT thresholds\nAll dichotomous FIT thresholds, from the LOD upwards, identify a population with CRC risk ≥3% as recommended by NICE for urgent referral. For example, the PPV for ≥2 μg Hb/g faeces was 4.7% (4.0% to 5.5%) in the Oxfordshire Primary Care cohort, rising to 8.4% (7.1% to 9.9%) using ≥10 μg Hb/g faeces. An analysis from the Southwest of England discussed moving from population risk to individual risk. The cancer risk in the ≥10-19 μg Hb/g faeces population was 7%, in line with larger data sets from low prevalence primary care populations. Although cautious about the uncertainty in their estimate, they calculated that the individualised risk was 3% at the threshold ≥37 Hb/g faeces (95% CI 26 to 50) suggesting safety netting may be warranted between 10 and 36 Hb/g faeces.\n\n【7】### SHOULD FIT BE USED IN PRIMARY OR SECONDARY CARE?\nWe recommend that FIT should be used by primary care clinicians to prioritise patients with clinical features of CRC for referral for urgent investigation.\n\n【8】删除32:<u>**</u>GRADE of evidence: very low; Strength of recommendation: Strong.删除32:<u>**</u>\n\n【9】There are no controlled studies or economic evaluations that compare the effectiveness of pathways using FIT in primary care with pathways using FIT in secondary care.\n\n【10】### FIT in primary care: pre-referral\nFour large retrospective cohort studies, in which not all individuals are investigated but have been followed-up, have described FIT usage for symptomatic patients in primary care: Northern Spain (n=38 675), Oxford (n=16 604), Tayside 删除19:<u>(n=5372)</u> and Nottingham (n=24 855) where palpable rectal mass and bleeding were excluded.\n\n【11】In these large low prevalence cohorts, the cancer diagnosis rate at follow-up after reassurance without investigation based on very low Hb levels in primary care was 0.3% or less, regardless of variations in the platforms and cut-offs used. A further Danish study of 3462 patients evaluated FIT in patients without ‘alarm’ symptoms similarly found that the risk of CRC was <0.1% in those with FIT <10 μg Hb/g faeces.\n\n【12】Evidence from these studies also demonstrates that primary care clinicians will still refer patients to secondary care where clinical concern persists via appropriate alternative pathways. Unpublished data from Nottingham suggest in three other patients are seen in an alternative pathway after ‘negative’ FIT. One in seven FIT below the threshold patients were investigated in Denmark. A study from Southwest England reported that GPs made a referral within 3 months for 1 in 10 negative FITs.", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ACPGBI BSG：具有疑似结直肠癌症状和体征患者的粪便免疫化学检测指南（2022）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Based on a large retrospective", "content": "【0】页码:5\nACPGBI BSG：具有疑似结直肠癌症状和体征患者的粪便免疫化学检测指南（2022）(1)\nBased on a large retrospective cohort of 9896 patients tested in English primary care in the context of the DG30 NICE guidelines (CRC prevalence 1.1%), the authors illustrated the NNS and NMC for the thresholds of ≥7, 删除13:<u>10, 20, 50, 100, 120</u> and 150 μg Hb/g faeces. The corresponding proportion of positive tests were 删除13:<u>11, 10</u>, 7, 4, 3 and 2%, the proportion of cancers detected 删除13:<u>91, 91, 85, 74, 61, 57</u> and 54%, the NNS to detect one cancer was 删除13:<u>11, 10</u>, 8, 5, 5, and 4 and the NMC per 1000 FITs was 1, 2, 3, 4, 5 and 6. Reducing the threshold of ≥10 to ≥4 μg Hb/g faeces resulted in increase in the NNS to 21 and a reduction in the NMC to 4 per 1000 patients tested.\n\n【1】At a higher prevalence of 1.6%, a smaller Spanish retrospective cohort of 4543 symptomatic patients reported the NMC per 1000 patients tested to be 3.7 删除11:<u>(2.2-6.3)</u> at a threshold of ≥10 μg Hb/g faeces compared with 4.1 删除11:<u>(2.5-6.6)</u> using ≥20 μg Hb/g faeces, and the NNS was 13.8 删除11:<u>(10.8-17.7)</u> compared with 10.9 删除11:<u>(8.5-14.0)</u>. The authors concluded that the use of ≥20 μg Hb/g in preference to ≥10 μg Hb/g could reduce referrals for colonoscopy without missing more than one CRC per 1000 patients tested.\n\n【2】Increasing the threshold favours specificity reducing the NNS to detect one CRC but increases the NMC per 1000 patients tested. The opposite occurs when the threshold is reduced. The FIT threshold used in clinical practice is likely to be chosen based on a balance of tolerance of missed cancers and the diagnostic resources available to urgently investigate CRC.\n\n【3】### Multiple thresholds for low-risk, intermediate-risk and high-risk populations\nMultiple FIT thresholds have been introduced in some clinical settings to provide a rule-out threshold, a rule-in threshold and an intermediate range where the investigation of population subgroups and/or active safety netting is advised.\n\n【4】The Nottingham rapid CRC diagnostics 删除9:<u>(RCCD) service sees adult patients of any age, except those with rectal bleeding and rectal mass, combining low, intermediate and high thresholds (prevalence 1.6% (227/13 361)</u>). The RCCD service considers ≥100 μg Hb/g faeces the ‘high risk’ positive contacting these patients directly for rapid investigation. Patients with an FIT result <4 μg Hb/g faeces, and with an FIT result <10 μg Hb/g faeces but normal blood tests are considered ‘negative’删除1:<u>. Patients with an FIT of 4-10 μg Hb/g faeces with anaemia, low ferritin or thrombocytosis, or with FIT ≥10 μg Hb/g faeces are considered ‘positive’ and investigated urgently via the 2WW. The cancer detection rate was 0.1% for <4 μg Hb/g faeces, 0.6% between 4 and 9.9 μg Hb/g faeces, 3.3% for 10-99.9 μg Hb/g faeces and 20.7% for ≥100 Hb/g faeces.</u>\n\n【5】Cohort data from Tayside on FIT use in primary care patients with unselected GI symptoms allowed to show that ‘reassurance thresholds’ of <2, 7, 10 and 20 μg Hb/g faeces were associated with CRC risks of 0.1, 0.3, 0.3 and 0.4%. Intermediate-risk populations were created to highlight those with a cancer risk below the 3% risk used by NICE to trigger urgent colorectal investigation. For example, an intermediate population defined by 10-99 μg Hb/g faeces had a risk of 2.7%, leaving a higher risk population ≥100 μg Hb/g faeces with a risk of 14.5%. An intermediate range 10-149 μg Hb/g faeces resulted in an intermediate population risk of 3.2%, meaning all patients ≥10 μg Hb/g faeces would qualify for urgent investigation. The cancer risk for the intermediate 7-199 μg Hb/faeces population was 2.8% with a risk of 17.2% in the ≥200 μg Hb/g faeces group. However, there was no intermediate population ≥20 μg Hb/g faeces with a risk below 3%. The patients with FIT ≥20 μg Hb/g faeces comprised 16.8% of the population tested compared with 21.9% for ≥10 μg Hb/g faeces and 25.4% for ≥7 μg Hb/g faeces.\n\n【6】### Individualised FIT thresholds\nAll dichotomous FIT thresholds, from the LOD upwards, identify a population with CRC risk ≥3% as recommended by NICE for urgent referral. For example, the PPV for ≥2 μg Hb/g faeces was 4.7% (4.0% to 5.5%) in the Oxfordshire Primary Care cohort, rising to 8.4% (7.1% to 9.9%) using ≥10 μg Hb/g faeces. An analysis from the Southwest of England discussed moving from population risk to individual risk. The cancer risk in the ≥10-19 μg Hb/g faeces population was 7%, in line with larger data sets from low prevalence primary care populations. Although cautious about the uncertainty in their estimate, they calculated that the individualised risk was 3% at the threshold ≥37 Hb/g faeces (95% CI 26 to 50) suggesting safety netting may be warranted between 10 and 36 Hb/g faeces.\n\n【7】### SHOULD FIT BE USED IN PRIMARY OR SECONDARY CARE?\nWe recommend that FIT should be used by primary care clinicians to prioritise patients with clinical features of CRC for referral for urgent investigation.\n\n【8】删除32:<u>**</u>GRADE of evidence: very low; Strength of recommendation: Strong.删除32:<u>**</u>\n\n【9】There are no controlled studies or economic evaluations that compare the effectiveness of pathways using FIT in primary care with pathways using FIT in secondary care.\n\n【10】### FIT in primary care: pre-referral\nFour large retrospective cohort studies, in which not all individuals are investigated but have been followed-up, have described FIT usage for symptomatic patients in primary care: Northern Spain (n=38 675), Oxford (n=16 604), Tayside 删除19:<u>(n=5372)</u> and Nottingham (n=24 855) where palpable rectal mass and bleeding were excluded.\n\n【11】In these large low prevalence cohorts, the cancer diagnosis rate at follow-up after reassurance without investigation based on very low Hb levels in primary care was 0.3% or less, regardless of variations in the platforms and cut-offs used. A further Danish study of 3462 patients evaluated FIT in patients without ‘alarm’ symptoms similarly found that the risk of CRC was <0.1% in those with FIT <10 μg Hb/g faeces.\n\n【12】Evidence from these studies also demonstrates that primary care clinicians will still refer patients to secondary care where clinical concern persists via appropriate alternative pathways. Unpublished data from Nottingham suggest in three other patients are seen in an alternative pathway after ‘negative’ FIT. One in seven FIT below the threshold patients were investigated in Denmark. A study from Southwest England reported that GPs made a referral within 3 months for 1 in 10 negative FITs.", "index": 55, "show": true, "start": 55, "end": 85, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "0"}, {"text": "删除9:(RCCD) service sees adult patients of any age, except those with rectal bleeding and rectal mass, combining low, intermediate and high thresholds (prevalence 1.6%", "content": "【0】页码:5\nACPGBI BSG：具有疑似结直肠癌症状和体征患者的粪便免疫化学检测指南（2022）(1)\n<mark>Based on a large retrospective</mark> cohort of 9896 patients tested in English primary care in the context of the DG30 NICE guidelines (CRC prevalence 1.1%), the authors illustrated the NNS and NMC for the thresholds of ≥7, 删除13:<u>10, 20, 50, 100, 120</u> and 150 μg Hb/g faeces. The corresponding proportion of positive tests were 删除13:<u>11, 10</u>, 7, 4, 3 and 2%, the proportion of cancers detected 删除13:<u>91, 91, 85, 74, 61, 57</u> and 54%, the NNS to detect one cancer was 删除13:<u>11, 10</u>, 8, 5, 5, and 4 and the NMC per 1000 FITs was 1, 2, 3, 4, 5 and 6. Reducing the threshold of ≥10 to ≥4 μg Hb/g faeces resulted in increase in the NNS to 21 and a reduction in the NMC to 4 per 1000 patients tested.\n\n【1】At a higher prevalence of 1.6%, a smaller Spanish retrospective cohort of 4543 symptomatic patients reported the NMC per 1000 patients tested to be 3.7 删除11:<u>(2.2-6.3)</u> at a threshold of ≥10 μg Hb/g faeces compared with 4.1 删除11:<u>(2.5-6.6)</u> using ≥20 μg Hb/g faeces, and the NNS was 13.8 删除11:<u>(10.8-17.7)</u> compared with 10.9 删除11:<u>(8.5-14.0)</u>. The authors concluded that the use of ≥20 μg Hb/g in preference to ≥10 μg Hb/g could reduce referrals for colonoscopy without missing more than one CRC per 1000 patients tested.\n\n【2】Increasing the threshold favours specificity reducing the NNS to detect one CRC but increases the NMC per 1000 patients tested. The opposite occurs when the threshold is reduced. The FIT threshold used in clinical practice is likely to be chosen based on a balance of tolerance of missed cancers and the diagnostic resources available to urgently investigate CRC.\n\n【3】### Multiple thresholds for low-risk, intermediate-risk and high-risk populations\nMultiple FIT thresholds have been introduced in some clinical settings to provide a rule-out threshold, a rule-in threshold and an intermediate range where the investigation of population subgroups and/or active safety netting is advised.\n\n【4】The Nottingham rapid CRC diagnostics 删除9:<u>(RCCD) service sees adult patients of any age, except those with rectal bleeding and rectal mass, combining low, intermediate and high thresholds (prevalence 1.6% (227/13 361)</u>). The RCCD service considers ≥100 μg Hb/g faeces the ‘high risk’ positive contacting these patients directly for rapid investigation. Patients with an FIT result <4 μg Hb/g faeces, and with an FIT result <10 μg Hb/g faeces but normal blood tests are considered ‘negative’删除1:<u>. Patients with an FIT of 4-10 μg Hb/g faeces with anaemia, low ferritin or thrombocytosis, or with FIT ≥10 μg Hb/g faeces are considered ‘positive’ and investigated urgently via the 2WW. The cancer detection rate was 0.1% for <4 μg Hb/g faeces, 0.6% between 4 and 9.9 μg Hb/g faeces, 3.3% for 10-99.9 μg Hb/g faeces and 20.7% for ≥100 Hb/g faeces.</u>\n\n【5】Cohort data from Tayside on FIT use in primary care patients with unselected GI symptoms allowed to show that ‘reassurance thresholds’ of <2, 7, 10 and 20 μg Hb/g faeces were associated with CRC risks of 0.1, 0.3, 0.3 and 0.4%. Intermediate-risk populations were created to highlight those with a cancer risk below the 3% risk used by NICE to trigger urgent colorectal investigation. For example, an intermediate population defined by 10-99 μg Hb/g faeces had a risk of 2.7%, leaving a higher risk population ≥100 μg Hb/g faeces with a risk of 14.5%. An intermediate range 10-149 μg Hb/g faeces resulted in an intermediate population risk of 3.2%, meaning all patients ≥10 μg Hb/g faeces would qualify for urgent investigation. The cancer risk for the intermediate 7-199 μg Hb/faeces population was 2.8% with a risk of 17.2% in the ≥200 μg Hb/g faeces group. However, there was no intermediate population ≥20 μg Hb/g faeces with a risk below 3%. The patients with FIT ≥20 μg Hb/g faeces comprised 16.8% of the population tested compared with 21.9% for ≥10 μg Hb/g faeces and 25.4% for ≥7 μg Hb/g faeces.\n\n【6】### Individualised FIT thresholds\nAll dichotomous FIT thresholds, from the LOD upwards, identify a population with CRC risk ≥3% as recommended by NICE for urgent referral. For example, the PPV for ≥2 μg Hb/g faeces was 4.7% (4.0% to 5.5%) in the Oxfordshire Primary Care cohort, rising to 8.4% (7.1% to 9.9%) using ≥10 μg Hb/g faeces. An analysis from the Southwest of England discussed moving from population risk to individual risk. The cancer risk in the ≥10-19 μg Hb/g faeces population was 7%, in line with larger data sets from low prevalence primary care populations. Although cautious about the uncertainty in their estimate, they calculated that the individualised risk was 3% at the threshold ≥37 Hb/g faeces (95% CI 26 to 50) suggesting safety netting may be warranted between 10 and 36 Hb/g faeces.\n\n【7】### SHOULD FIT BE USED IN PRIMARY OR SECONDARY CARE?\nWe recommend that FIT should be used by primary care clinicians to prioritise patients with clinical features of CRC for referral for urgent investigation.\n\n【8】删除32:<u>**</u>GRADE of evidence: very low; Strength of recommendation: Strong.删除32:<u>**</u>\n\n【9】There are no controlled studies or economic evaluations that compare the effectiveness of pathways using FIT in primary care with pathways using FIT in secondary care.\n\n【10】### FIT in primary care: pre-referral\nFour large retrospective cohort studies, in which not all individuals are investigated but have been followed-up, have described FIT usage for symptomatic patients in primary care: Northern Spain (n=38 675), Oxford (n=16 604), Tayside 删除19:<u>(n=5372)</u> and Nottingham (n=24 855) where palpable rectal mass and bleeding were excluded.\n\n【11】In these large low prevalence cohorts, the cancer diagnosis rate at follow-up after reassurance without investigation based on very low Hb levels in primary care was 0.3% or less, regardless of variations in the platforms and cut-offs used. A further Danish study of 3462 patients evaluated FIT in patients without ‘alarm’ symptoms similarly found that the risk of CRC was <0.1% in those with FIT <10 μg Hb/g faeces.\n\n【12】Evidence from these studies also demonstrates that primary care clinicians will still refer patients to secondary care where clinical concern persists via appropriate alternative pathways. Unpublished data from Nottingham suggest in three other patients are seen in an alternative pathway after ‘negative’ FIT. One in seven FIT below the threshold patients were investigated in Denmark. A study from Southwest England reported that GPs made a referral within 3 months for 1 in 10 negative FITs.", "index": 2057, "show": true, "start": 2044, "end": 2210, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "【4】删除1:. Patients with an FIT of 4-10 μg Hb/g faeces with anaemia, low ferritin or thrombocytosis, or with FIT ≥10 μg Hb/g faeces are considered ‘positive’ and investigated urgently via the 2WW. The cancer detection rate was 0.1% for <4 μg Hb/g faeces, 0.6% between 4 and 9.9 μg Hb/g faeces, 3.3% for 10-99.9 μg Hb/g faeces and 20.7% for ≥100 Hb/g faeces."}], "startTime": "2024/08/06 16:39:33", "endTime": "2024/08/06 16:41:11", "cost": 97.652}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:41:11", "grab_time": "2024-08-06 00:39:33"}
{"id": 2211712, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "832684f9-0e76-4f82-b0ae-965bc384e25c", "title": "2023 NICE 诊断指南：帕金森病远程监测设备[DG51]", "text": "【0】页码:7\n2023 NICE 诊断指南：帕金森病远程监测设备[DG51]\n## Potential value of technologies\n\n【1】删除32:<u>**</u>2.3删除32:<u>**</u> Devices that can monitor and record symptoms of Parkinson's disease could identify people who could benefit from changes to their care. By objectively measuring these symptoms over several days, the technologies may more accurately estimate a person's symptoms and help to inform medication decisions. At scoping, clinical experts highlighted that functionality to measure dyskinesia and bradykinesia was particularly important for this.\n\n【2】删除32:<u>**</u>2.4删除32:<u>**</u> Better-informed treatment decisions could lead to improved quality of life. Improved motor symptoms could reduce falls and hip fractures. The technologies could also help improve communication between people with Parkinson's disease and clinicians when discussing symptoms and potential changes to care.\n\n【3】删除32:<u>**</u>2.5删除32:<u>**</u> The technologies may also allow more remote monitoring of Parkinson's disease. This could help to alleviate the stress and anxiety of attending clinic appointments. Objective monitoring of symptoms could also reduce the length and number of clinic appointments, thereby freeing up NHS resources.\n\n【4】## The interventions\n\n【5】删除32:<u>**</u>2.6删除32:<u>**</u> The technologies all have remote monitoring capability, are automated monitors (do not require the user to perform tests), measure dyskinesia, help assess bradykinesia and can be used outside a clinical setting in the absence of a healthcare professional. The devices are intended for use together with clinical assessment. They have regulatory approval and are available to the NHS.\n\n【6】## Kinesia 360\n\n【7】删除32:<u>**</u>2.7删除32:<u>**</u> The Kinesia 360 motor assessment system (Great Lakes NeuroTechnologies) monitors movement to quantify motor symptoms and assess activity. The system comprises sensors worn on the wrist and ankle, a tablet, and a charge pad. Kinesia 360 measures various aspects of bradykinesia, dyskinesia and tremor. It has a 16-hour battery", "tags": {}, "lang": "en", "attr": {"page_num": 7, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 NICE 诊断指南：帕金森病远程监测设备[DG51].pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:55:15", "endTime": "2024/08/06 15:55:28", "cost": 13.563}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:55:29", "grab_time": "2024-08-05 23:55:15"}
{"id": 2211711, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "a5750266-1c5d-4194-99f1-1927302632d5", "title": "SISAV：血管异常指南（2022）", "text": "【0】页码:118\nSISAV：血管异常指南（2022）\nThe monitoring of the evolution of these malformations should preferably be performed with ultrasound, suggesting re-evaluation with MRI in case of clinical and ultrasound evidence of worsening of the lesion.\n\n【1】### Interpretation of the Data\n\n【2】The clinical picture of microcystic LMs must be completed with instrumental investigations, in order to allow a balance of the extension of the lesions and to allow the monitoring of evolution.\n\n【3】There are no adequate studies to evaluate the scientific evidence of the role of ultrasound and MRI in the diagnosis of micro-cystic LMs, and there are no operational protocols for the instrumental control of these lesions over time.\n\n【4】### Recommendations\n\n【5】The clinical picture must be confirmed and supported by instrumental investigations (ultrasound and MRI) to assess the extent of the lesion, especially in the suspicion of deep localizations associated with cutaneous and mucosal ones.\n\n【6】删除32:<u>*</u>Recommendation of Good Clinical Practice, based on the experience of the authors删除32:<u>*</u>\n\n【7】### Therapy\n\n【8】删除32:<u>**</u>Question 10删除32:<u>**</u>  \n删除32:<u>*</u>What are the therapeutic procedures indicated in microcystic lymphatic malformations?删除32:<u>*</u>\n\n【9】There are no guidelines for the management of microcystic LM, and there are several therapeutic options: sclerotherapy, laser therapy, radiofrequency ablation, surgery and drug therapy.\n\n【10】None of these therapeutic procedures can be considered a resolutive therapy and superior to the others, and the tendency is to use them in variously combined strategies depending on site and clinical problems.\n\n【11】Considering the difficulty or impossibility of sclerotherapy for the small size of the cysts, many authors consider surgery as the first therapeutic option choice, while taking into account the impossibility of radical excision due to the infiltrating nature of these anomalies, and therefore the high risk of relapses.\n\n【12】The laser is widely used in superficial, cutaneous and mucosal forms, but there is no lack of indications for deeper sites (interstitial laser, endovascular laser).\n\n【13】Radiofrequency ablation is very little used. Drug therapy is still off-label, used for compassionate purposes, or in any case, where all other (invasive) therapies have failed 删除9:<u>(see “Pharmacological Treatment”)</u>.\n\n【14】The effectiveness of all available therapies taken individually is partial, incomplete and transient, with a very high relapse rate, so a multidisciplinary management is required in most cases.\n\n【15】### Surgery\n\n【16】According to some authors, surgery is reserved for microcystic forms, while sclerotherapy should preferably be served for macrocystic LMs. This indication is supported by the difficulty of carrying out effective sclerotherapy in microcystic forms and by their greater progressiveness.\n\n【17】In all cases, patients should always be referred to a multidisciplinary facility and referred to a surgeon who is familiar with this type of injury.\n\n【18】The possibility of radical excision of the microcystic forms is generally very low, and the risk of recurrence is high. Surgery associated with or followed by bleomycin sclerotherapy is a recently introduced technique to reduce the recurrence risk, but its results need confirmation.\n\n【19】The most frequent site of micro-cystic LM is the cervico-facial one. Here the malformation is most often localized superior to the level of thymy, oropharynx, tongue, parotid, submandibular gland, supraglottic area, parapharyngeal and retropharyngeal spaces. Consequently, radical excision of these lesions is rarely possible.\n\n【20】For surgery in cervico-facial localizations, mapping of the facial nerve and continuous electromyographic monitoring are indispensable intraoperatively. In other locations, the surgery of superficial forms involves the removal of portions of skin and subcutis infiltrated by the malformation, for which the use of skin grafts, rotation flaps and skin expanders are necessary.\n\n【21】In deep localizations and in cases of tissue hypertrophy, excisional surgery is indicated for the reduction of the lesion volume.\n\n【22】In the case of facial asymmetries with consequent serious psycho-social problems of the patient, surgery must be proposed with great caution, specifying to the patient that there are no certain guarantees of results, in the face of high risks of morbidity and also potential risks of worsening.\n\n【23】The major complications of surgery are: lymphorrhea with postoperative lymphatic collections (seroma), transient or permanent neurological damage (most frequently recurrent phrenic, vagus and laryngeal nerves), Horner’s", "tags": {}, "lang": "en", "attr": {"page_num": 118, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/SISAV：血管异常指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:29:41", "endTime": "2024/08/06 15:30:06", "cost": 24.817}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:30:06", "grab_time": "2024-08-05 23:29:41"}
{"id": 2211710, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "ced74809-1f52-4834-8eef-739de610c8a6", "title": "（2023.V2）NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌", "text": "【0】页码:212\n（2023.V2）NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】疑似页眉<u>NCCN Guidelines Version 2.2023 Ovarian Cancer</u>\n\n【2】suboptimally resected stage III-IV epithelial ovarian cancer: a multicenter, randomized study. Eur J Cancer 2010;46:2905-2912删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/20673626]</u>.</u>\n\n【3】参考删除-3:<u>780. du Bois A, Herrstedt J, Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010;28:4162-4169删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/20733132]</u>.</u></u>\n\n【4】参考删除-3:<u>781. Hoskins P, Vergote I, Cervantes A, et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan-carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 2010;102:1547-1556删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/20937992]</u>.</u></u>\n\n【5】参考删除-3:<u>782. Lindemann K, Christensen RD, Vergote I, et al. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without an epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol 2012;23:2613-2619删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/22539562]</u>.</u></u>\n\n【6】783. Wadler S, Yeap B, Vogl S, Carbone P. Randomized trial of initial therapy with melphalan versus cisplatin-based combination initial chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Cancer 1996;77:733-742删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/8616766]</u>.</u>\n\n【7】参考删除-3:<u>784. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer; a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-115删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/10623700]</u>.</u></u>\n\n【8】参考删除-3:<u>785. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report of the Southwest Oncology Group of a Phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-717删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/1569444]</u>.</u></u>\n\n【9】参考删除-3:<u>786. Hannigan EV, Green S, Alberts DS, et al. Results of a Southwest Oncology Group Phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.</u>\n\n【10】Oncology 1993;50 Suppl 2:2-9删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/8233297]</u>.</u>\n\n【11】参考删除-3:<u>787. Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718-726删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/1547543]</u>.</u></u>\n\n【12】参考删除-3:<u>788. Taylor AE, Wiltshaw E, Gore ME, et al. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994;12:2066-2070删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/7931475]</u>.</u></u>\n\n【13】789. Meerpohl HG, Sauerbrei W, Kuhnle H, et al. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small tumor disease. German Ovarian Cancer Study Group (GOCA). Gynecol Oncol 1997;66:75-84删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/9234925]</u>.</u>\n\n【14】790. Skarlos DV, Aravantinos G, Kosmidis P, et al. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Semin Oncol 1997;24:S15-57-S15-61删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/9346224]</u>.</u>\n\n【15】参考删除-3:<u>791. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/7494563]</u>.</u></u>\n\n【16】参考删除-3:<u>792. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/10793106]</u>.</u></u>\n\n【17】参考删除-3:<u>793. Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 2003;13 Suppl 2:144-148删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/14656721]</u>.</u></u>", "tags": {}, "lang": "en", "attr": {"page_num": 212, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V2）NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:41:30", "endTime": "2024/08/06 15:41:40", "cost": 10.803}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:41:41", "grab_time": "2024-08-05 23:41:30"}
{"id": 2211709, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "c7199a4a-e997-4f67-9899-77da307ec04e", "title": "2023 专家共识：肺癌患者COVID-19感染的预防和治疗（英文）", "text": "【0】页码:1\n2023 专家共识：肺癌患者COVID-19感染的预防和治疗（英文）\n(本页删除)本页被模型判断为参考页## Expert Consensus on Prevention and Treatment of COVID-19 Infection in Patients with Lung Cancer\nNon-small Cell Lung Cancer Expert Committee of Chinese Society of Clinical Oncology  \nChina Medical Education Association\n\n【1】### Abstract\nCorona virus disease 2019 (COVID-19) infection has become a major public health issue affecting human health. The main goal of epidemic prevention and control at the current stage in China is to “protect people’s health and prevent severe cases”. Patients with lung cancer who receive antitumor therapy have low immunity, and the risk of severe illness and death once infected is much higher than healthy people, so they are vulnerable to COVID-19 infection. At present, less attention has been paid to the prevention and treatment of COVID-19 infection in patients with lung cancer in domestic guidelines and consensus. Based on the published data in China and abroad, we proposed recommendations and formed expert consensus on the vaccination of COVID-19, the use of neutralizing antibodies and small molecule antiviral drugs for patients with lung cancer, for physician’s reference.\n\n【2】参考删除-3:<u>### Key words\nCorona virus disease 2019; Lung neoplasms; Prevention; Treatment; Expert consensus</u>\n\n【3】### 1 Introduction\nLung cancer is a malignant tumor with high morbidity and mortality in China and other countries around the world. The 5-year survival rate is only 19%删除12:<u>删除14:<u>[1]</u></u>. Since the rapid spread of Corona virus disease 2019 (COVID-19) infection worldwide, it has become the third cause of death in the United States in 2021删除14:<u>[2]</u>. Due to the old age of most patients with lung cancer, multiple underlying diseases, immunosuppression caused by the antitumor therapy, repeated visits to hospitals, and other factors, the risk of COVID-19 infection, severe illness, and death of patients with lung cancer is much higher than that of healthy people删除12:<u>删除14:<u>[3]</u></u>.\n\n【4】Vaccination is still the main effective way to prevent COVID-19 infection and severe illness in patients with lung cancer. However, patients with cancer are often excluded from the clinical trials of vaccine development. The efficacy and safety of vaccination in patients with cancer remain to be studied, and it is unclear how to better play the synergistic effect of prevention and treatment. In addition, the immune function of patients with lung cancer is impaired, the effects of vaccine prevention and treatment need further observation. The goal of prevention and treatment of COVID-19 infection in patients with cancer and vaccination and immunization strategies need to be determined. Based on the clinical practice of COVID-19 infection in patients with lung cancer, considering the relevant data in China and abroad and China’s epidemic prevention and control policies, the Non-small Cell Lung Cancer (NSCLC) Expert Committee of Chinese Society of Clinical Oncology (CSCO) and China Medical Education Association have formed the first expert consensus on prevention and treatment of COVID-19 infection in patients with lung cancer after extensive consultation.\n\n【5】The principles of expert recommendation and evidence rating in this consensus are as follows:\n删除32:<u>**</u>Recommendation level:删除32:<u>**</u> A=strong; B=moderate; C=optional.  \n删除32:<u>**</u>Evidence level:删除32:<u>**</u> I=1 or more randomized trials without significant limitations; IIa=other randomized trials or subgroup analyses of randomized trials; IIb=non-randomized trials or observational cohort studies; III=expert opinion.\n\n【6】### 2 Epidemiology of lung cancer during COVID-19\n#### 2.1 Epidemic trend of COVID-19\nAccording to the World Health Organization (WHO), as of 18 December 2022, the cumulative number of confirmed COVID-19 infection cases worldwide was more than 649 million, with more than 6.6 million people died删除12:<u>删除14:<u>[4]</u></u>. Data from the United States in 2021 showed that COVID-19 infection has become the “number one killer” among middle-aged and elderly people (≥45 years old) in the United States删除12:<u>删除14:<u>[2]</u></u>. China is a country with a large population, a large number of", "tags": {}, "lang": "en", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 专家共识：肺癌患者COVID-19感染的预防和治疗（英文）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "(本页删除)本页被模型判断为参考页", "content": "【0】页码:1\n2023 专家共识：肺癌患者COVID-19感染的预防和治疗（英文）\n(本页删除)本页被模型判断为参考页## Expert Consensus on Prevention and Treatment of COVID-19 Infection in Patients with Lung Cancer\nNon-small Cell Lung Cancer Expert Committee of Chinese Society of Clinical Oncology  \nChina Medical Education Association\n\n【1】### Abstract\nCorona virus disease 2019 (COVID-19) infection has become a major public health issue affecting human health. The main goal of epidemic prevention and control at the current stage in China is to “protect people’s health and prevent severe cases”. Patients with lung cancer who receive antitumor therapy have low immunity, and the risk of severe illness and death once infected is much higher than healthy people, so they are vulnerable to COVID-19 infection. At present, less attention has been paid to the prevention and treatment of COVID-19 infection in patients with lung cancer in domestic guidelines and consensus. Based on the published data in China and abroad, we proposed recommendations and formed expert consensus on the vaccination of COVID-19, the use of neutralizing antibodies and small molecule antiviral drugs for patients with lung cancer, for physician’s reference.\n\n【2】参考删除-3:<u>### Key words\nCorona virus disease 2019; Lung neoplasms; Prevention; Treatment; Expert consensus</u>\n\n【3】### 1 Introduction\nLung cancer is a malignant tumor with high morbidity and mortality in China and other countries around the world. The 5-year survival rate is only 19%删除12:<u>删除14:<u>[1]</u></u>. Since the rapid spread of Corona virus disease 2019 (COVID-19) infection worldwide, it has become the third cause of death in the United States in 2021删除14:<u>[2]</u>. Due to the old age of most patients with lung cancer, multiple underlying diseases, immunosuppression caused by the antitumor therapy, repeated visits to hospitals, and other factors, the risk of COVID-19 infection, severe illness, and death of patients with lung cancer is much higher than that of healthy people删除12:<u>删除14:<u>[3]</u></u>.\n\n【4】Vaccination is still the main effective way to prevent COVID-19 infection and severe illness in patients with lung cancer. However, patients with cancer are often excluded from the clinical trials of vaccine development. The efficacy and safety of vaccination in patients with cancer remain to be studied, and it is unclear how to better play the synergistic effect of prevention and treatment. In addition, the immune function of patients with lung cancer is impaired, the effects of vaccine prevention and treatment need further observation. The goal of prevention and treatment of COVID-19 infection in patients with cancer and vaccination and immunization strategies need to be determined. Based on the clinical practice of COVID-19 infection in patients with lung cancer, considering the relevant data in China and abroad and China’s epidemic prevention and control policies, the Non-small Cell Lung Cancer (NSCLC) Expert Committee of Chinese Society of Clinical Oncology (CSCO) and China Medical Education Association have formed the first expert consensus on prevention and treatment of COVID-19 infection in patients with lung cancer after extensive consultation.\n\n【5】The principles of expert recommendation and evidence rating in this consensus are as follows:\n删除32:<u>**</u>Recommendation level:删除32:<u>**</u> A=strong; B=moderate; C=optional.  \n删除32:<u>**</u>Evidence level:删除32:<u>**</u> I=1 or more randomized trials without significant limitations; IIa=other randomized trials or subgroup analyses of randomized trials; IIb=non-randomized trials or observational cohort studies; III=expert opinion.\n\n【6】### 2 Epidemiology of lung cancer during COVID-19\n#### 2.1 Epidemic trend of COVID-19\nAccording to the World Health Organization (WHO), as of 18 December 2022, the cumulative number of confirmed COVID-19 infection cases worldwide was more than 649 million, with more than 6.6 million people died删除12:<u>删除14:<u>[4]</u></u>. Data from the United States in 2021 showed that COVID-19 infection has become the “number one killer” among middle-aged and elderly people (≥45 years old) in the United States删除12:<u>删除14:<u>[2]</u></u>. China is a country with a large population, a large number of", "index": 43, "show": true, "start": 43, "end": 60, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 16:43:49", "endTime": "2024/08/06 16:44:47", "cost": 57.512}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:44:47", "grab_time": "2024-08-06 00:43:49"}
{"id": 2211708, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "a70f81ab-ba09-43f0-bde0-4a83085934bc", "title": "2023 UKKA临床实践指南：血液透析血管通路", "text": "【0】页码:39\n2023 UKKA临床实践指南：血液透析血管通路\nfrequently: over 6 months, Van Loon found that 37% of patients with a new fistula and 19% of patients with a new graft had more than ten missed cannulations 删除11:<u>(85)</u>.\n\n【1】Miscannulation often leads to pain and bruising, though the lower rate of reported haematomas (5% per patient-year) suggests that not all miscannulation leads to complications 删除11:<u>(86)</u>. Haematomas lead to diagnostic and surgical procedures, and miscannulation may also lead to abandoned dialysis sessions and access failure. Haematomas are also associated with maturation failure 删除11:<u>(47)</u>, though this observation may reflect the reverse effect of non-maturation on needling difficulty. Miscannulation is of concern to patients, contributing to a ‘bad’ haemodialysis treatment, with increased pain, delayed dialysis initiation, and sometimes persistent haematoma 删除11:<u>(10)</u>. Wilson and Harwood found unsurprisingly that for patients 'successful cannulation' requires first-time success with both needles, but also successful use of the needles for dialysis 删除11:<u>(9)</u>. The burden that miscannulation causes to patients is therefore easily identifiable.\n\n【2】In order to reduce miscannulation, particularly with new fistulas, two specific strategies have been suggested: ultrasound assistance and single needling. Ultrasound assistance prevents complications of venous catheter insertion 删除11:<u>(87)</u> and assisted fistula cannulation is promoted by several authors but no study provides a clear evaluation of utility 删除11:<u>(43)</u>. Two studies used ultrasound to assess the position of needles inserted in the usual ('blind') manner: Nalesso (N=45) and Marticorena (N=86) both found that many needles were in suboptimal positions, therefore recommending ultrasound guided cannulation 删除11:<u>(51,88)</u>. Observational studies cannot be relied on since they often show reverse causality - ultrasound is mostly used for difficult fistulas, so its use is associated with more, rather than less, miscannulation 删除11:<u>(82)</u>.\n\n【3】Another strategy is single needle dialysis, which halves the number of cannulations required, at the cost of reduced dialysis dose (or increased time to achieve the same dose) 删除11:<u>(84)</u>. A small study (N=22) found that single needle haemodialysis leads to less miscannulation (1.2 v 2.5 cannulation attempts per dialysis) whilst maintaining acceptable clearance 删除11:<u>(89)</u>. Regardless of technique, it is likely that the training of cannulators (nursing staff or patients) is also relevant to success. Direct evidence is not available and should not be expected, since studying an untrained cannulator group would be unethical, but circumstantial considerations support the concept and many authors believe that cannulation could be improved. Labriola reported an increased infection risk with buttonhole needling which was overcome by a strict training programme for cannulators, and Chow felt that buttonhole complications were associated with breaches in technique, rather than the technique itself 删除11:<u>(90,91)</u>. Despite standardisation and competency frameworks, cannulation practice continues to be driven by provider preference.\n\n【4】One promising initiative is MAGIC (Managing Access by Generating Improvements in Cannulation), a quality improvement supported by KQuIP (Kidney Quality Improvement Partnership), which uses structured education and feedback to improve cannulation 删除11:<u>(92)</u>. Initial results from the first two regions demonstrated a large reduction in area needling, and it is currently undergoing wider adoption and evaluation. Whilst it may be an assumption that cannulation can be improved by education, it seems obvious that such a difficult and important procedure should only be performed those who are competent.", "tags": {}, "lang": "en", "attr": {"page_num": 39, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 UKKA临床实践指南：血液透析血管通路.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:51:38", "endTime": "2024/08/06 16:51:52", "cost": 14.208}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:51:53", "grab_time": "2024-08-06 00:51:38"}
{"id": 2211707, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "f73bf5fb-00e8-4a1b-98cf-2d0990d75102", "title": "【神经领域】中国脑卒中防治指导规范（2021年版）", "text": "【0】页码:597\n【神经领域】中国脑卒中防治指导规范（2021年版）\n据统计，2013 年中国脑卒中的年龄标化患病率为 114.8/10 万人，年龄标化发病率为 246.8/10 万人，是我国的第一位死因，其中缺血性脑卒中占 70%~80%。急性缺血性脑卒中（acute ischemic stroke, AIS）的救治能力是检验脑卒中救治效率的试金石。近年来 AIS 治疗发展迅速，快速的血流重建是治疗的核心，包括重组组织型纤溶酶原激活剂（recombinant tissue plasminogen activator, rt-PA）、尿激酶静脉溶栓和机械取栓。AIS 患者发病后接受静脉溶栓最近时间很短，溶栓越快效果越好；对缺血性脑卒中发病 4.5 小时内的患者，应诊被视为疑似证据就证严酷筛选患者，尽快给予 rt-PA 静脉溶栓治疗。对于部分地区如果没有条件使用 rt-PA。从发病后 6 小时内，可常规性选择患者给予急诊静脉给于尿激酶溶栓。AHA 推荐若在大型血管闭塞性缺血性脑卒中（AIS with large vessel occlusion, AIS-LVO）患者若在静脉溶栓后该受血管内治疗，同样也具有时间敏感性。然而在真实世界中，我国 AIS 患者的救治效率并不理想，形势严峻。相关研究显示，我国在发病 3 小时内能达到急诊的 AIS 患者只有 21.5%。而院前延误是导致 AIS 患者不能在时间窗内到达可开展溶栓治疗的医院机构的的重要原因之一。脑卒中的救治可分为三个阶段：发病-呼救-呼救-到院。到院-救治，而院前急救涵盖前两个阶段。为了一步提高脑卒中院前急救的整体水平，规范院前急救工作，我们参考国外的成功经验，结合我国情与脑卒中救治现状，编写本脑卒中院前急救诊疗指导规范。\n\n【1】## 一、院前教育\n\n【2】快速识别脑卒中是启动脑卒中急救生存链的第一步，影响者紧急医疗救护服务的急救效率和质量。患者及其家属缺乏对脑卒中症状的有效识别并且未能及时按下 120 急救电话是院前延误的主要原因之一。我国脑卒中患者对脑卒中的主要警报特征的知晓率为 70%，全项知晓率只有 3%~16%，而没现脑卒中症状并能按时急救电话的患者比例就更期待少。研究显示，提高公众对脑卒中症状的有效识别能够缩短患者发病至治疗的时间（onset to treatment time, OTT）。2016 年我国专家在雷霆言试验（face arm speech test, FAST）基础上结合中国文化特点提出了“中风 120”这种便于公众理解的脑卒中识别方法：“看”到引 张不开称的脸；“查”及早举起否有单侧无力，聋（）听讲是否有清晰”，帮助手患者和家属迅速识别脑卒中并立即拨打 120 救援。此外，通过紧急医疗救护服务院前的患者会", "tags": {}, "lang": "zh", "attr": {"page_num": 597, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【神经领域】中国脑卒中防治指导规范（2021年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:46:55", "endTime": "2024/08/06 16:49:14", "cost": 139.074}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:49:15", "grab_time": "2024-08-06 00:46:55"}
{"id": 2211706, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "b8022771-d45d-4780-b90b-4d8065938886", "title": "国际软组织肉瘤联合会(INSTRuCT)关于手术边缘定义统一的共识：手术边缘在儿童非横纹肌肉瘤软组织肉瘤中的意义(1)", "text": "【0】页码:6\n国际软组织肉瘤联合会(INSTRuCT)关于手术边缘定义统一的共识：手术边缘在儿童非横纹肌肉瘤软组织肉瘤中的意义(1)\naccount the chemo- and radiosensitivity of the specific NRSTS histologic subtype, the anatomic location, and the anticipated risk of postoperative wound healing complications following preoperative radiotherapy can guide decisions about whether surgery should occur upfront or after neoadjuvant therapy.删除17:<u>55</u>\n\n【1】Primary re-excision is intended to achieve a wide resection while still preserving function, and should include the scar and the superficial and deep tissues left behind during the previous surgery.删除17:<u>56</u> PRE should be considered for patients with NRSTS as studies in children and adults with STS have described the usefulness of PRE in patients with residual disease.删除17:<u>57</u> The importance of PRE was better documented in NRSTS where PRE improved resection status in 69%.删除17:<u>58</u> Other studies on the importance of PRE in adults with STS showed that positive tumor margins compared with negative margins strongly predicted LR risk  with a hazard ratio of 3.76 (95% confidence interval 删除12:<u>[CI]</u>: 2.20–6.40) in these tumors, which are often poorly sensitive to chemotherapy. In the pediatric series from Cecchetto et al., the results of PRE seemed to be linked to the size of the tumors, and local recurrences were more frequent for tumors larger than 5 cm and in some specific sites.删除17:<u>16</u>\n\n【2】The COG recommends the importance of resection after neoadjuvant chemotherapy and/or radiation. As described above, COG protocols recommend DPE for high-grade tumors >5 cm, since these patients will receive RT regardless of resection status. Likewise, any patient with any initially unresectable tumor should be reassessed after induction therapy to determine feasibility of DPE.\n\n### 3.2 | Are there intraoperative visualization techniques that can be used to optimize chances of negative surgical margins in NRSTS?\n\n【4】Intraoperative ultrasound (US) used by experts might be a useful tool for achieving negative margins for tumors that are non-palpable, ill-defined, or beneath the fascia. In one study of 19 patients with malignant sarcomas, intraoperative US was helpful for visualizing tumor borders, and facilitated an R0 resection in 95% of cases.删除17:<u>59</u> Intraoperative fluorescence-guided surgery (FGS) is a promising new modality which may help reduce rates of inadvertent positive margins. In a study of 39 adult patients with sarcoma who underwent near-infrared (NIR) FGS with indocyanine green (ICG), compared to 76 undergoing standard surgical technique, patients receiving ICG had a lower unexpected positive margin rate (5.1% vs 25.0%, p = 0.01).删除17:<u>60</u> In this study, the tumor was noted to be fluorescent in 37 of 39 cases, and the surgeon deemed the fluorescence to have helped guide the surgery in 11 cases. Novel fluorophores may offer even more precise and reliable option for utilizing NIR-FGS to delineate sarcoma margins.\n\n### 4 |  THE PATHOLOGY PERSPECTIVE\n\n#### 4.1 | How are margins assessed by the pathologist in NRSTS?\n\n【7】Pathologic assessment of NRSTS is crucial to ascertain tumor size, margin status, completeness of resection and, in cases where neoadjuvant therapy is utilized, treatment effect. Primary resection provides the most accurate assessment of the tumor in relation to its margins. An important point concerning margins is the difference between assessment of intraoperative margins on fresh tissue and assessment of margins on formalin-fixed tissue: the ratio between the two is 2:1.61 Therefore, achieving an intraoperative margin of at least 1 cm is necessary for a 5 mm tumor-free margin in the formalin-fixed specimen. Most American-based pathology programs ink the specimen margins and work with surgeons to provide details on tumor size, margin status, and the completeness of resection.\n\n【8】Random sampling should include sections of the tumor perpendicular to the tumor, along with a minimum of 1 section per cm of the tumor.删除17:<u>62</u> Sampling should also include areas that appear “different” such as firmer in appearance, in the case of possible liposarcoma; or solid areas in the case of a blastemal tumor. Sampling different grossly appearing areas is often the key to identification of a higher grade component or revealing the extent of treatment effect in a delayed resection specimen.删除17:<u>63</u> A malignancy goal is to ascertain the negative margins in multinodular lesions (i.e., low-grade fibromyxoid sarcoma) or infiltrative lesions. Additionally, when neoadjuvant therapy is used, native tumor necrosis or fibrosis versus tumor necrosis or fibrosis due to treatment effect can be challenging to distinguish histologically.\n\n#### 4.2 | What pathology information should standardly be reported with every NRSTS resection?\n\n【10】In the United States, the College of American Pathologists (CAP) provides standard reporting templates to guide pathologists in providing useful diagnostic and prognostic information from NRSTS resection specimens. In one study, a review of such reports in childhood NRSTS documented critical factors influencing treatment such as margin status in 92% of reports, whereas pathologic grade was", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/国际软组织肉瘤联合会(INSTRuCT)关于手术边缘定义统一的共识：手术边缘在儿童非横纹肌肉瘤软组织肉瘤中的意义(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】The COG recommends the importance ", "content": "【0】页码:6\n国际软组织肉瘤联合会(INSTRuCT)关于手术边缘定义统一的共识：手术边缘在儿童非横纹肌肉瘤软组织肉瘤中的意义(1)\naccount the chemo- and radiosensitivity of the specific NRSTS histologic subtype, the anatomic location, and the anticipated risk of postoperative wound healing complications following preoperative radiotherapy can guide decisions about whether surgery should occur upfront or after neoadjuvant therapy.删除17:<u>55</u>\n\n【1】Primary re-excision is intended to achieve a wide resection while still preserving function, and should include the scar and the superficial and deep tissues left behind during the previous surgery.删除17:<u>56</u> PRE should be considered for patients with NRSTS as studies in children and adults with STS have described the usefulness of PRE in patients with residual disease.删除17:<u>57</u> The importance of PRE was better documented in NRSTS where PRE improved resection status in 69%.删除17:<u>58</u> Other studies on the importance of PRE in adults with STS showed that positive tumor margins compared with negative margins strongly predicted LR risk  with a hazard ratio of 3.76 (95% confidence interval 删除12:<u>[CI]</u>: 2.20–6.40) in these tumors, which are often poorly sensitive to chemotherapy. In the pediatric series from Cecchetto et al., the results of PRE seemed to be linked to the size of the tumors, and local recurrences were more frequent for tumors larger than 5 cm and in some specific sites.删除17:<u>16</u>\n\n【2】The COG recommends the importance of resection after neoadjuvant chemotherapy and/or radiation. As described above, COG protocols recommend DPE for high-grade tumors >5 cm, since these patients will receive RT regardless of resection status. Likewise, any patient with any initially unresectable tumor should be reassessed after induction therapy to determine feasibility of DPE.\n\n### 3.2 | Are there intraoperative visualization techniques that can be used to optimize chances of negative surgical margins in NRSTS?\n\n【4】Intraoperative ultrasound (US) used by experts might be a useful tool for achieving negative margins for tumors that are non-palpable, ill-defined, or beneath the fascia. In one study of 19 patients with malignant sarcomas, intraoperative US was helpful for visualizing tumor borders, and facilitated an R0 resection in 95% of cases.删除17:<u>59</u> Intraoperative fluorescence-guided surgery (FGS) is a promising new modality which may help reduce rates of inadvertent positive margins. In a study of 39 adult patients with sarcoma who underwent near-infrared (NIR) FGS with indocyanine green (ICG), compared to 76 undergoing standard surgical technique, patients receiving ICG had a lower unexpected positive margin rate (5.1% vs 25.0%, p = 0.01).删除17:<u>60</u> In this study, the tumor was noted to be fluorescent in 37 of 39 cases, and the surgeon deemed the fluorescence to have helped guide the surgery in 11 cases. Novel fluorophores may offer even more precise and reliable option for utilizing NIR-FGS to delineate sarcoma margins.\n\n### 4 |  THE PATHOLOGY PERSPECTIVE\n\n#### 4.1 | How are margins assessed by the pathologist in NRSTS?\n\n【7】Pathologic assessment of NRSTS is crucial to ascertain tumor size, margin status, completeness of resection and, in cases where neoadjuvant therapy is utilized, treatment effect. Primary resection provides the most accurate assessment of the tumor in relation to its margins. An important point concerning margins is the difference between assessment of intraoperative margins on fresh tissue and assessment of margins on formalin-fixed tissue: the ratio between the two is 2:1.61 Therefore, achieving an intraoperative margin of at least 1 cm is necessary for a 5 mm tumor-free margin in the formalin-fixed specimen. Most American-based pathology programs ink the specimen margins and work with surgeons to provide details on tumor size, margin status, and the completeness of resection.\n\n【8】Random sampling should include sections of the tumor perpendicular to the tumor, along with a minimum of 1 section per cm of the tumor.删除17:<u>62</u> Sampling should also include areas that appear “different” such as firmer in appearance, in the case of possible liposarcoma; or solid areas in the case of a blastemal tumor. Sampling different grossly appearing areas is often the key to identification of a higher grade component or revealing the extent of treatment effect in a delayed resection specimen.删除17:<u>63</u> A malignancy goal is to ascertain the negative margins in multinodular lesions (i.e., low-grade fibromyxoid sarcoma) or infiltrative lesions. Additionally, when neoadjuvant therapy is used, native tumor necrosis or fibrosis versus tumor necrosis or fibrosis due to treatment effect can be challenging to distinguish histologically.\n\n#### 4.2 | What pathology information should standardly be reported with every NRSTS resection?\n\n【10】In the United States, the College of American Pathologists (CAP) provides standard reporting templates to guide pathologists in providing useful diagnostic and prognostic information from NRSTS resection specimens. In one study, a review of such reports in childhood NRSTS documented critical factors influencing treatment such as margin status in 92% of reports, whereas pathologic grade was", "index": 1418, "show": true, "start": 1418, "end": 1455, "province": ["语义有效性", "语义不完整"], "isEdit": false}], "startTime": "2024/08/06 16:59:33", "endTime": "2024/08/06 17:00:26", "cost": 53.179}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 01:00:26", "grab_time": "2024-08-06 00:59:33"}
{"id": 2211705, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "309e8b02-d5b8-4318-8851-f229e3abb210", "title": "广东省心血管患者使用奈玛特韦／利托那韦片（Paxlovid）临床药学指引", "text": "页码:11\n广东省心血管患者使用奈玛特韦／利托那韦片（Paxlovid）临床药学指引\n| 降压药物     | Paxlovid    | 临床评估 |\n|--------------|-------------|---------------------------|\n| 依洛尤单抗  | 无          | 2B7 葡萄糖醛酸化。由于利托那韦抑制 UGTs，合用可能会降低依托考麦布的浓度。短、诱导作用在几天后才能达到最大效果，因此在建议调整依舒考麦布剂量。                   |\n|              |             | 依洛尤单抗是一种单克隆 IgG 抗体。消除类似于内源性 IgG, 代谢主要通过全身蛋白水解。可以合用。                  |\n| 阿利西尤单抗 | 无          | 抗体通常由细胞内裂解系统代谢，并降解为小肽和单个氨基酸，因此没有进行特定代谢研究。阿利西尤单抗与红细胞或给药抗药没有显示出影响 CYP450 酶活性或蛋白质运输。可以合用。|\n| 非诺贝特     | 无          | 非诺贝特被水解为一种活性代谢物菲诺贝特酸。利托那韦 (100 mg, 每日 2 次) 和非诺贝特 (145 mg 单次) 合用，对非诺贝特的 AUC (降低 11%) 或 Cmax (降低 1%) 无显著影响。可以合用。|\n| 乐卡地平     | 有, 强      | 与强效 CYP3A4 抑制剂 (如利托那韦) 合用是禁忌症，因为乐卡地平的浓度可能显著增加。与弱抑剂 (CYP3A4 的强效抑制剂) 合用可使乐卡地平 AUC 增加 15 倍；与 Paxlovid 可能发生类似的相互作用。建议乐卡地平剂量减少 50% 或降隔一天服用一次，或者建议监测血压和低血压症状，必要时暂时停止降压药物。   |\n| 氯氮地平     | 有, 中      | 氯氮地平由 CYP3A4 代谢。根据与氯氮地平和中度抑制剂/利托那韦或帕利瑞韦/利环普韦的药物-药物相互作用研究，预计 Paxlovid 会使氯氮地平暴露量增加约 2 倍。 | 建议将氯氮地平剂量减少 50% 或降隔一天服用一次。如果共同使用，建议监测血压症状，必要时暂停降低降压药物。|\n| 萘奈地平     | 有, 中      | 萘奈地平主要由 CYP3A4 代谢。同时给药可能会增加萘奈地平的血浆浓度。             | 可以考虑将萘奈地平剂量减少 50% 或降隔一天服用一次。如果共同使用，建议监测血压症状，必要时暂停降低降压药物。|\n| 非洛地平     | 有, 中      | 非洛地平主要由 CYP3A4 代谢。同时给药可能会增加非洛地平的血浆浓度。药物相互作用会增加非洛地平血浆浓度，增加低血压、涼红和头痛风险。 | 可以考虑将非洛地平剂量减少 50% 或降隔一天服用一次。如果共同使用，建议监测血压症状，必要时暂停降低降压药物。|\n| 尼群地平     | 有, 中      | 尼群地平代谢广泛，主要由 CYP3A4 代谢，合用可增加尼群地平浓度。               | 如果同时给药，建议监测血压症状。|", "tags": {}, "lang": "zh", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/广东省心血管患者使用奈玛特韦／利托那韦片（Paxlovid）临床药学指引.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "降压药物", "content": "页码:11\n广东省心血管患者使用奈玛特韦／利托那韦片（Paxlovid）临床药学指引\n| 降压药物     | Paxlovid    | 临床评估 |\n|--------------|-------------|---------------------------|\n| 依洛尤单抗  | 无          | 2B7 葡萄糖醛酸化。由于利托那韦抑制 UGTs，合用可能会降低依托考麦布的浓度。短、诱导作用在几天后才能达到最大效果，因此在建议调整依舒考麦布剂量。                   |\n|              |             | 依洛尤单抗是一种单克隆 IgG 抗体。消除类似于内源性 IgG, 代谢主要通过全身蛋白水解。可以合用。                  |\n| 阿利西尤单抗 | 无          | 抗体通常由细胞内裂解系统代谢，并降解为小肽和单个氨基酸，因此没有进行特定代谢研究。阿利西尤单抗与红细胞或给药抗药没有显示出影响 CYP450 酶活性或蛋白质运输。可以合用。|\n| 非诺贝特     | 无          | 非诺贝特被水解为一种活性代谢物菲诺贝特酸。利托那韦 (100 mg, 每日 2 次) 和非诺贝特 (145 mg 单次) 合用，对非诺贝特的 AUC (降低 11%) 或 Cmax (降低 1%) 无显著影响。可以合用。|\n| 乐卡地平     | 有, 强      | 与强效 CYP3A4 抑制剂 (如利托那韦) 合用是禁忌症，因为乐卡地平的浓度可能显著增加。与弱抑剂 (CYP3A4 的强效抑制剂) 合用可使乐卡地平 AUC 增加 15 倍；与 Paxlovid 可能发生类似的相互作用。建议乐卡地平剂量减少 50% 或降隔一天服用一次，或者建议监测血压和低血压症状，必要时暂时停止降压药物。   |\n| 氯氮地平     | 有, 中      | 氯氮地平由 CYP3A4 代谢。根据与氯氮地平和中度抑制剂/利托那韦或帕利瑞韦/利环普韦的药物-药物相互作用研究，预计 Paxlovid 会使氯氮地平暴露量增加约 2 倍。 | 建议将氯氮地平剂量减少 50% 或降隔一天服用一次。如果共同使用，建议监测血压症状，必要时暂停降低降压药物。|\n| 萘奈地平     | 有, 中      | 萘奈地平主要由 CYP3A4 代谢。同时给药可能会增加萘奈地平的血浆浓度。             | 可以考虑将萘奈地平剂量减少 50% 或降隔一天服用一次。如果共同使用，建议监测血压症状，必要时暂停降低降压药物。|\n| 非洛地平     | 有, 中      | 非洛地平主要由 CYP3A4 代谢。同时给药可能会增加非洛地平的血浆浓度。药物相互作用会增加非洛地平血浆浓度，增加低血压、涼红和头痛风险。 | 可以考虑将非洛地平剂量减少 50% 或降隔一天服用一次。如果共同使用，建议监测血压症状，必要时暂停降低降压药物。|\n| 尼群地平     | 有, 中      | 尼群地平代谢广泛，主要由 CYP3A4 代谢，合用可增加尼群地平浓度。               | 如果同时给药，建议监测血压症状。|", "index": 45, "show": true, "start": 45, "end": 49, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "表格不完整"}], "startTime": "2024/08/06 17:13:05", "endTime": "2024/08/06 17:23:30", "cost": 625.04}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 01:23:30", "grab_time": "2024-08-06 01:13:05"}
{"id": 2211704, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "92487a2d-be6c-40b5-82aa-101f8363e9de", "title": "WHO：妊娠24周前超声检查建议（2022）", "text": "【0】页码:3\nWHO：妊娠24周前超声检查建议（2022）\n# WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy\n\n【1】删除4:<u>ISBN 978-92-4-004600-9</u> (electronic version)  \n删除4:<u>ISBN 978-92-4-004601-6</u> (print version)\n\n【2】删除5:<u>©</u> World Health Organization 2022\n\n【3】Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3删除1:<u>.删除17:<u>0</u> IGO; [https://creativecommons.org/licenses/by-nc-sa/3.0/igo]).</u>\n\n【4】Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition.”\n\n【5】删除1:<u>Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ([http://www.wipo.int/amc/en/mediation/rules]).</u>\n\n【6】参考删除-3:<u>删除32:<u>**</u>Suggested citation.删除32:<u>**</u> WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy. Geneva: World Health Organization; 2022. Licence: [CC BY-NC-SA 3.0 IGO].</u>\n\n【7】删除32:<u>**</u>Cataloguing-in-Publication (CIP) data删除1:<u>.删除32:<u>**</u> CIP data are available at [http://apps.who.int/iris].</u>\n\n【8】删除32:<u>**</u>Sales, rights and licensing删除1:<u>.删除32:<u>**</u> To purchase WHO publications, see [http://apps.who.int/bookorders]. To submit requests for commercial use and queries on rights and licensing, see [http://www.who.int/about/licensing].</u>\n\n【9】删除32:<u>**</u>Third-party materials.删除32:<u>**</u> If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.\n\n【10】删除32:<u>**</u>General disclaimers.删除32:<u>**</u> The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.\n\n【11】The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\n【12】All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.\n\n【13】Design and layout by Green Ink.", "tags": {}, "lang": "en", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WHO：妊娠24周前超声检查建议（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "(electronic version)", "content": "【0】页码:3\nWHO：妊娠24周前超声检查建议（2022）\n# WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy\n\n【1】删除4:<u>ISBN 978-92-4-004600-9</u> (electronic version)  \n删除4:<u>ISBN 978-92-4-004601-6</u> (print version)\n\n【2】删除5:<u>©</u> World Health Organization 2022\n\n【3】Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3删除1:<u>.删除17:<u>0</u> IGO; [https://creativecommons.org/licenses/by-nc-sa/3.0/igo]).</u>\n\n【4】Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition.”\n\n【5】删除1:<u>Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ([http://www.wipo.int/amc/en/mediation/rules]).</u>\n\n【6】参考删除-3:<u>删除32:<u>**</u>Suggested citation.删除32:<u>**</u> WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy. Geneva: World Health Organization; 2022. Licence: [CC BY-NC-SA 3.0 IGO].</u>\n\n【7】删除32:<u>**</u>Cataloguing-in-Publication (CIP) data删除1:<u>.删除32:<u>**</u> CIP data are available at [http://apps.who.int/iris].</u>\n\n【8】删除32:<u>**</u>Sales, rights and licensing删除1:<u>.删除32:<u>**</u> To purchase WHO publications, see [http://apps.who.int/bookorders]. To submit requests for commercial use and queries on rights and licensing, see [http://www.who.int/about/licensing].</u>\n\n【9】删除32:<u>**</u>Third-party materials.删除32:<u>**</u> If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.\n\n【10】删除32:<u>**</u>General disclaimers.删除32:<u>**</u> The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.\n\n【11】The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\n【12】All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.\n\n【13】Design and layout by Green Ink.", "index": 229, "show": true, "start": 229, "end": 249, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "1"}, {"text": " (print version)", "content": "【0】页码:3\nWHO：妊娠24周前超声检查建议（2022）\n# WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy\n\n【1】删除4:<u>ISBN 978-92-4-004600-9</u> <mark>(electronic version)</mark>  \n删除4:<u>ISBN 978-92-4-004601-6</u> (print version)\n\n【2】删除5:<u>©</u> World Health Organization 2022\n\n【3】Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3删除1:<u>.删除17:<u>0</u> IGO; [https://creativecommons.org/licenses/by-nc-sa/3.0/igo]).</u>\n\n【4】Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition.”\n\n【5】删除1:<u>Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ([http://www.wipo.int/amc/en/mediation/rules]).</u>\n\n【6】参考删除-3:<u>删除32:<u>**</u>Suggested citation.删除32:<u>**</u> WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy. Geneva: World Health Organization; 2022. Licence: [CC BY-NC-SA 3.0 IGO].</u>\n\n【7】删除32:<u>**</u>Cataloguing-in-Publication (CIP) data删除1:<u>.删除32:<u>**</u> CIP data are available at [http://apps.who.int/iris].</u>\n\n【8】删除32:<u>**</u>Sales, rights and licensing删除1:<u>.删除32:<u>**</u> To purchase WHO publications, see [http://apps.who.int/bookorders]. To submit requests for commercial use and queries on rights and licensing, see [http://www.who.int/about/licensing].</u>\n\n【9】删除32:<u>**</u>Third-party materials.删除32:<u>**</u> If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.\n\n【10】删除32:<u>**</u>General disclaimers.删除32:<u>**</u> The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.\n\n【11】The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\n【12】All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.\n\n【13】Design and layout by Green Ink.", "index": 298, "show": true, "start": 285, "end": 301, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "1"}, {"text": "【5】删除1:Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ", "content": "【0】页码:3\nWHO：妊娠24周前超声检查建议（2022）\n# WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy\n\n【1】删除4:<u>ISBN 978-92-4-004600-9</u> <mark>(electronic version)</mark>  \n删除4:<u>ISBN 978-92-4-004601-6</u><mark> (print version)</mark>\n\n【2】删除5:<u>©</u> World Health Organization 2022\n\n【3】Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3删除1:<u>.删除17:<u>0</u> IGO; [https://creativecommons.org/licenses/by-nc-sa/3.0/igo]).</u>\n\n【4】Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition.”\n\n【5】删除1:<u>Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ([http://www.wipo.int/amc/en/mediation/rules]).</u>\n\n【6】参考删除-3:<u>删除32:<u>**</u>Suggested citation.删除32:<u>**</u> WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy. Geneva: World Health Organization; 2022. Licence: [CC BY-NC-SA 3.0 IGO].</u>\n\n【7】删除32:<u>**</u>Cataloguing-in-Publication (CIP) data删除1:<u>.删除32:<u>**</u> CIP data are available at [http://apps.who.int/iris].</u>\n\n【8】删除32:<u>**</u>Sales, rights and licensing删除1:<u>.删除32:<u>**</u> To purchase WHO publications, see [http://apps.who.int/bookorders]. To submit requests for commercial use and queries on rights and licensing, see [http://www.who.int/about/licensing].</u>\n\n【9】删除32:<u>**</u>Third-party materials.删除32:<u>**</u> If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.\n\n【10】删除32:<u>**</u>General disclaimers.删除32:<u>**</u> The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.\n\n【11】The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\n【12】All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.\n\n【13】Design and layout by Green Ink.", "index": 1394, "show": true, "start": 1368, "end": 1542, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "【6】参考删除-3:删除32:Suggested citation.删除32: WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy. Geneva: World Health Organization", "content": "【0】页码:3\nWHO：妊娠24周前超声检查建议（2022）\n# WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy\n\n【1】删除4:<u>ISBN 978-92-4-004600-9</u> <mark>(electronic version)</mark>  \n删除4:<u>ISBN 978-92-4-004601-6</u><mark> (print version)</mark>\n\n【2】删除5:<u>©</u> World Health Organization 2022\n\n【3】Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3删除1:<u>.删除17:<u>0</u> IGO; [https://creativecommons.org/licenses/by-nc-sa/3.0/igo]).</u>\n\n【4】Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition.”\n\n<mark>【5】删除1:Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization </mark>on ([http://www.wipo.int/amc/en/mediation/rules]).</u>\n\n【6】参考删除-3:<u>删除32:<u>**</u>Suggested citation.删除32:<u>**</u> WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy. Geneva: World Health Organization; 2022. Licence: [CC BY-NC-SA 3.0 IGO].</u>\n\n【7】删除32:<u>**</u>Cataloguing-in-Publication (CIP) data删除1:<u>.删除32:<u>**</u> CIP data are available at [http://apps.who.int/iris].</u>\n\n【8】删除32:<u>**</u>Sales, rights and licensing删除1:<u>.删除32:<u>**</u> To purchase WHO publications, see [http://apps.who.int/bookorders]. To submit requests for commercial use and queries on rights and licensing, see [http://www.who.int/about/licensing].</u>\n\n【9】删除32:<u>**</u>Third-party materials.删除32:<u>**</u> If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.\n\n【10】删除32:<u>**</u>General disclaimers.删除32:<u>**</u> The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.\n\n【11】The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\n【12】All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.\n\n【13】Design and layout by Green Ink.", "index": 1637, "show": true, "start": 1598, "end": 1830, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/07 09:44:11", "endTime": "2024/08/07 09:45:59", "cost": 108.181}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 17:45:58", "grab_time": "2024-08-06 17:44:10"}
{"id": 2211703, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "a7b7f3e1-0911-4530-8619-e1061adb5892", "title": "【儿科领域】川崎病冠状动脉病变的临床处理建议（2020年修订版）(1)", "text": "【0】页码:4\n【儿科领域】川崎病冠状动脉病变的临床处理建议（2020年修订版）(1)\n表4 基于川崎病痊冠动脉病变风险分级的治疗方案\n\n【1】删除图片描述:<u>![](3_1.png)</u>\n\n【2】注：PCI为经皮冠状动脉介入治疗；CABG为冠状动脉旁路移植术\n\n【3】以及距离5年来临床应用经验证制定推荐剂量[删除21:<u>^10,^</u>11^],供临床参考。\n\n【4】1. 抗凝治疗：CAL风险分级为II级及以上的患儿需要同时抗血小板和抗凝治疗（表5）。最常用的最小剂量阿司匹林加华法林,维持国际标准化比值（international standardization rate，INR）1.5~2.5或1.5~2.0；或小剂量阿司匹林加低分子肝素（low molecular weight heparin，LMWH）。LMWH起效快递,而且具有抗炎作用,因此在急性期优先选用。如果动脉瘤停止扩张,患儿病情稳定,可以考虑从LMWH过渡到华法林长期口服。华法林的起效时间为3~7d,因此二者需交叠应用3~7d。对于无症状动脉血栓形成风险极高的患儿可采取更积极的治疗方案,如近期内冠状动脉血栓形成为致\n\n【5】删除图片描述:<u>![](3_0.png)</u>\n\n【6】导致死亡而需要终治疗,可使用双抗血小板和抗凝2种药物(即阿司同氯吡格雷或应用LMWH)至病情稳定。由于这样的法血栓的危险更大,故必须根据个体情况充分考虑风险与效益比。\n\n【7】2. 抗凝药物剂量需参考左右出 血倾向进行调整。儿童的个体差异很大,如果结果热和湿膨坏难以达到要求的INR,可多考伴热相关因素的结果,并注意观察左右伴相关食物、药物(尤其是中药)的影响,用药期间注意观察有无出血，避免腮腺性的运动、外伤等。\n\n【8】3. 纤溶治疗：川崎病患儿发生急性冠状动脉阻塞可行溶栓治疗,建议在急性心肌梗死发生的12h内尽早用药,超过12h溶栓会又不大。静脉纤溶栓的再通率为70%~80%,结合冠状动脉内溶栓通率可增加10%左右。儿科最常用的溶栓药物是纤指原激活同化7 (tissue plasminogen activator, tPA),0.05mg/(kg·h),共6h。溶栓的同同高剂阿司匹林相似如果相秤素10U/(kg·h),需测激值血数和出血，保持纤维蛋白 偏于\n\n【9】10U/L，tPA疗欲再禁用人选适合于年龄的剂量,并且避免激心动同评伴血特殊也可适用尿激酶删除19:<u>(4400U/kg, 10 min, iv单)</u>或尿激醋(10 4,000U/kg,30 min,iv单) ,效果不及t-PA。但在溶栓治疗方面儿科临床经验有度限。\n\n【10】患儿发生急性心肌梗死超过12h者建议使用双抗血小板和抗3种药物(如阿司匹林、氯比格雷和LMWH)治疗川崎病急性相亚急性期,如相\n\n【11】表5 川崎病患儿抗血栓药物的使用方法和注意事项\n\n【12】删除图片描述:<u>![](3_2.png)</u>\n\n【13】注：INR为国际标准化比值", "tags": {}, "lang": "zh", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【儿科领域】川崎病冠状动脉病变的临床处理建议（2020年修订版）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "表4 基于川崎病痊冠动脉病变风险分级的治疗方案", "content": "【0】页码:4\n【儿科领域】川崎病冠状动脉病变的临床处理建议（2020年修订版）(1)\n表4 基于川崎病痊冠动脉病变风险分级的治疗方案\n\n【1】删除图片描述:<u>![](3_1.png)</u>\n\n【2】注：PCI为经皮冠状动脉介入治疗；CABG为冠状动脉旁路移植术\n\n【3】以及距离5年来临床应用经验证制定推荐剂量[删除21:<u>^10,^</u>11^],供临床参考。\n\n【4】1. 抗凝治疗：CAL风险分级为II级及以上的患儿需要同时抗血小板和抗凝治疗（表5）。最常用的最小剂量阿司匹林加华法林,维持国际标准化比值（international standardization rate，INR）1.5~2.5或1.5~2.0；或小剂量阿司匹林加低分子肝素（low molecular weight heparin，LMWH）。LMWH起效快递,而且具有抗炎作用,因此在急性期优先选用。如果动脉瘤停止扩张,患儿病情稳定,可以考虑从LMWH过渡到华法林长期口服。华法林的起效时间为3~7d,因此二者需交叠应用3~7d。对于无症状动脉血栓形成风险极高的患儿可采取更积极的治疗方案,如近期内冠状动脉血栓形成为致\n\n【5】删除图片描述:<u>![](3_0.png)</u>\n\n【6】导致死亡而需要终治疗,可使用双抗血小板和抗凝2种药物(即阿司同氯吡格雷或应用LMWH)至病情稳定。由于这样的法血栓的危险更大,故必须根据个体情况充分考虑风险与效益比。\n\n【7】2. 抗凝药物剂量需参考左右出 血倾向进行调整。儿童的个体差异很大,如果结果热和湿膨坏难以达到要求的INR,可多考伴热相关因素的结果,并注意观察左右伴相关食物、药物(尤其是中药)的影响,用药期间注意观察有无出血，避免腮腺性的运动、外伤等。\n\n【8】3. 纤溶治疗：川崎病患儿发生急性冠状动脉阻塞可行溶栓治疗,建议在急性心肌梗死发生的12h内尽早用药,超过12h溶栓会又不大。静脉纤溶栓的再通率为70%~80%,结合冠状动脉内溶栓通率可增加10%左右。儿科最常用的溶栓药物是纤指原激活同化7 (tissue plasminogen activator, tPA),0.05mg/(kg·h),共6h。溶栓的同同高剂阿司匹林相似如果相秤素10U/(kg·h),需测激值血数和出血，保持纤维蛋白 偏于\n\n【9】10U/L，tPA疗欲再禁用人选适合于年龄的剂量,并且避免激心动同评伴血特殊也可适用尿激酶删除19:<u>(4400U/kg, 10 min, iv单)</u>或尿激醋(10 4,000U/kg,30 min,iv单) ,效果不及t-PA。但在溶栓治疗方面儿科临床经验有度限。\n\n【10】患儿发生急性心肌梗死超过12h者建议使用双抗血小板和抗3种药物(如阿司匹林、氯比格雷和LMWH)治疗川崎病急性相亚急性期,如相\n\n【11】表5 川崎病患儿抗血栓药物的使用方法和注意事项\n\n【12】删除图片描述:<u>![](3_2.png)</u>\n\n【13】注：INR为国际标准化比值", "index": 44, "show": true, "start": 44, "end": 67, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "0"}, {"text": "【4】1. 抗凝治疗：", "content": "【0】页码:4\n【儿科领域】川崎病冠状动脉病变的临床处理建议（2020年修订版）(1)\n<mark>表4 基于川崎病痊冠动脉病变风险分级的治疗方案</mark>\n\n【1】删除图片描述:<u>![](3_1.png)</u>\n\n【2】注：PCI为经皮冠状动脉介入治疗；CABG为冠状动脉旁路移植术\n\n【3】以及距离5年来临床应用经验证制定推荐剂量[删除21:<u>^10,^</u>11^],供临床参考。\n\n【4】1. 抗凝治疗：CAL风险分级为II级及以上的患儿需要同时抗血小板和抗凝治疗（表5）。最常用的最小剂量阿司匹林加华法林,维持国际标准化比值（international standardization rate，INR）1.5~2.5或1.5~2.0；或小剂量阿司匹林加低分子肝素（low molecular weight heparin，LMWH）。LMWH起效快递,而且具有抗炎作用,因此在急性期优先选用。如果动脉瘤停止扩张,患儿病情稳定,可以考虑从LMWH过渡到华法林长期口服。华法林的起效时间为3~7d,因此二者需交叠应用3~7d。对于无症状动脉血栓形成风险极高的患儿可采取更积极的治疗方案,如近期内冠状动脉血栓形成为致\n\n【5】删除图片描述:<u>![](3_0.png)</u>\n\n【6】导致死亡而需要终治疗,可使用双抗血小板和抗凝2种药物(即阿司同氯吡格雷或应用LMWH)至病情稳定。由于这样的法血栓的危险更大,故必须根据个体情况充分考虑风险与效益比。\n\n【7】2. 抗凝药物剂量需参考左右出 血倾向进行调整。儿童的个体差异很大,如果结果热和湿膨坏难以达到要求的INR,可多考伴热相关因素的结果,并注意观察左右伴相关食物、药物(尤其是中药)的影响,用药期间注意观察有无出血，避免腮腺性的运动、外伤等。\n\n【8】3. 纤溶治疗：川崎病患儿发生急性冠状动脉阻塞可行溶栓治疗,建议在急性心肌梗死发生的12h内尽早用药,超过12h溶栓会又不大。静脉纤溶栓的再通率为70%~80%,结合冠状动脉内溶栓通率可增加10%左右。儿科最常用的溶栓药物是纤指原激活同化7 (tissue plasminogen activator, tPA),0.05mg/(kg·h),共6h。溶栓的同同高剂阿司匹林相似如果相秤素10U/(kg·h),需测激值血数和出血，保持纤维蛋白 偏于\n\n【9】10U/L，tPA疗欲再禁用人选适合于年龄的剂量,并且避免激心动同评伴血特殊也可适用尿激酶删除19:<u>(4400U/kg, 10 min, iv单)</u>或尿激醋(10 4,000U/kg,30 min,iv单) ,效果不及t-PA。但在溶栓治疗方面儿科临床经验有度限。\n\n【10】患儿发生急性心肌梗死超过12h者建议使用双抗血小板和抗3种药物(如阿司匹林、氯比格雷和LMWH)治疗川崎病急性相亚急性期,如相\n\n【11】表5 川崎病患儿抗血栓药物的使用方法和注意事项\n\n【12】删除图片描述:<u>![](3_2.png)</u>\n\n【13】注：INR为国际标准化比值", "index": 203, "show": true, "start": 190, "end": 201, "province": ["格式规范性", "序号格式不一致"], "isEdit": false}, {"text": "对于无症状动脉血栓形成风险极高的患儿可采取更积极的治疗方案,如近期内冠状动脉血栓形成为致", "content": "【0】页码:4\n【儿科领域】川崎病冠状动脉病变的临床处理建议（2020年修订版）(1)\n<mark>表4 基于川崎病痊冠动脉病变风险分级的治疗方案</mark>\n\n【1】删除图片描述:<u>![](3_1.png)</u>\n\n【2】注：PCI为经皮冠状动脉介入治疗；CABG为冠状动脉旁路移植术\n\n【3】以及距离5年来临床应用经验证制定推荐剂量[删除21:<u>^10,^</u>11^],供临床参考。\n\n<mark>【4】1. 抗凝治疗：</mark>CAL风险分级为II级及以上的患儿需要同时抗血小板和抗凝治疗（表5）。最常用的最小剂量阿司匹林加华法林,维持国际标准化比值（international standardization rate，INR）1.5~2.5或1.5~2.0；或小剂量阿司匹林加低分子肝素（low molecular weight heparin，LMWH）。LMWH起效快递,而且具有抗炎作用,因此在急性期优先选用。如果动脉瘤停止扩张,患儿病情稳定,可以考虑从LMWH过渡到华法林长期口服。华法林的起效时间为3~7d,因此二者需交叠应用3~7d。对于无症状动脉血栓形成风险极高的患儿可采取更积极的治疗方案,如近期内冠状动脉血栓形成为致\n\n【5】删除图片描述:<u>![](3_0.png)</u>\n\n【6】导致死亡而需要终治疗,可使用双抗血小板和抗凝2种药物(即阿司同氯吡格雷或应用LMWH)至病情稳定。由于这样的法血栓的危险更大,故必须根据个体情况充分考虑风险与效益比。\n\n【7】2. 抗凝药物剂量需参考左右出 血倾向进行调整。儿童的个体差异很大,如果结果热和湿膨坏难以达到要求的INR,可多考伴热相关因素的结果,并注意观察左右伴相关食物、药物(尤其是中药)的影响,用药期间注意观察有无出血，避免腮腺性的运动、外伤等。\n\n【8】3. 纤溶治疗：川崎病患儿发生急性冠状动脉阻塞可行溶栓治疗,建议在急性心肌梗死发生的12h内尽早用药,超过12h溶栓会又不大。静脉纤溶栓的再通率为70%~80%,结合冠状动脉内溶栓通率可增加10%左右。儿科最常用的溶栓药物是纤指原激活同化7 (tissue plasminogen activator, tPA),0.05mg/(kg·h),共6h。溶栓的同同高剂阿司匹林相似如果相秤素10U/(kg·h),需测激值血数和出血，保持纤维蛋白 偏于\n\n【9】10U/L，tPA疗欲再禁用人选适合于年龄的剂量,并且避免激心动同评伴血特殊也可适用尿激酶删除19:<u>(4400U/kg, 10 min, iv单)</u>或尿激醋(10 4,000U/kg,30 min,iv单) ,效果不及t-PA。但在溶栓治疗方面儿科临床经验有度限。\n\n【10】患儿发生急性心肌梗死超过12h者建议使用双抗血小板和抗3种药物(如阿司匹林、氯比格雷和LMWH)治疗川崎病急性相亚急性期,如相\n\n【11】表5 川崎病患儿抗血栓药物的使用方法和注意事项\n\n【12】删除图片描述:<u>![](3_2.png)</u>\n\n【13】注：INR为国际标准化比值", "index": 488, "show": true, "start": 462, "end": 506, "province": ["格式规范性", "缺少换行"], "isEdit": false, "comment": "4"}, {"text": "【6】导致死亡而需要终治疗,可使用双抗血小板和抗凝2种药物(即阿司同氯吡格雷或应用LMWH)至病情稳定。由于这样的法血栓的危险更大,故必须根据个体情况充分考虑风险与效益比。", "content": "【0】页码:4\n【儿科领域】川崎病冠状动脉病变的临床处理建议（2020年修订版）(1)\n<mark>表4 基于川崎病痊冠动脉病变风险分级的治疗方案</mark>\n\n【1】删除图片描述:<u>![](3_1.png)</u>\n\n【2】注：PCI为经皮冠状动脉介入治疗；CABG为冠状动脉旁路移植术\n\n【3】以及距离5年来临床应用经验证制定推荐剂量[删除21:<u>^10,^</u>11^],供临床参考。\n\n<mark>【4】1. 抗凝治疗：</mark>CAL风险分级为II级及以上的患儿需要同时抗血小板和抗凝治疗（表5）。最常用的最小剂量阿司匹林加华法林,维持国际标准化比值（international standardization rate，INR）1.5~2.5或1.5~2.0；或小剂量阿司匹林加低分子肝素（low molecular weight heparin，LMWH）。LMWH起效快递,而且具有抗炎作用,因此在急性期优先选用。如果动脉瘤停止扩张,患儿病情稳定,可以考虑从LMWH过渡到华法林长期口服。华法林的起效时间为3~7d,因此二者需交叠应用3~7d。<mark>对于无症状动脉血栓形成风险极高的患儿可采取更积极的治疗方案,如近期内冠状动脉血栓形成为致</mark>\n\n【5】删除图片描述:<u>![](3_0.png)</u>\n\n【6】导致死亡而需要终治疗,可使用双抗血小板和抗凝2种药物(即阿司同氯吡格雷或应用LMWH)至病情稳定。由于这样的法血栓的危险更大,故必须根据个体情况充分考虑风险与效益比。\n\n【7】2. 抗凝药物剂量需参考左右出 血倾向进行调整。儿童的个体差异很大,如果结果热和湿膨坏难以达到要求的INR,可多考伴热相关因素的结果,并注意观察左右伴相关食物、药物(尤其是中药)的影响,用药期间注意观察有无出血，避免腮腺性的运动、外伤等。\n\n【8】3. 纤溶治疗：川崎病患儿发生急性冠状动脉阻塞可行溶栓治疗,建议在急性心肌梗死发生的12h内尽早用药,超过12h溶栓会又不大。静脉纤溶栓的再通率为70%~80%,结合冠状动脉内溶栓通率可增加10%左右。儿科最常用的溶栓药物是纤指原激活同化7 (tissue plasminogen activator, tPA),0.05mg/(kg·h),共6h。溶栓的同同高剂阿司匹林相似如果相秤素10U/(kg·h),需测激值血数和出血，保持纤维蛋白 偏于\n\n【9】10U/L，tPA疗欲再禁用人选适合于年龄的剂量,并且避免激心动同评伴血特殊也可适用尿激酶删除19:<u>(4400U/kg, 10 min, iv单)</u>或尿激醋(10 4,000U/kg,30 min,iv单) ,效果不及t-PA。但在溶栓治疗方面儿科临床经验有度限。\n\n【10】患儿发生急性心肌梗死超过12h者建议使用双抗血小板和抗3种药物(如阿司匹林、氯比格雷和LMWH)治疗川崎病急性相亚急性期,如相\n\n【11】表5 川崎病患儿抗血栓药物的使用方法和注意事项\n\n【12】删除图片描述:<u>![](3_2.png)</u>\n\n【13】注：INR为国际标准化比值", "index": 578, "show": true, "start": 539, "end": 625, "province": ["格式规范性", "多余换行"], "isEdit": false}, {"text": "【7】2. ", "content": "【0】页码:4\n【儿科领域】川崎病冠状动脉病变的临床处理建议（2020年修订版）(1)\n<mark>表4 基于川崎病痊冠动脉病变风险分级的治疗方案</mark>\n\n【1】删除图片描述:<u>![](3_1.png)</u>\n\n【2】注：PCI为经皮冠状动脉介入治疗；CABG为冠状动脉旁路移植术\n\n【3】以及距离5年来临床应用经验证制定推荐剂量[删除21:<u>^10,^</u>11^],供临床参考。\n\n<mark>【4】1. 抗凝治疗：</mark>CAL风险分级为II级及以上的患儿需要同时抗血小板和抗凝治疗（表5）。最常用的最小剂量阿司匹林加华法林,维持国际标准化比值（international standardization rate，INR）1.5~2.5或1.5~2.0；或小剂量阿司匹林加低分子肝素（low molecular weight heparin，LMWH）。LMWH起效快递,而且具有抗炎作用,因此在急性期优先选用。如果动脉瘤停止扩张,患儿病情稳定,可以考虑从LMWH过渡到华法林长期口服。华法林的起效时间为3~7d,因此二者需交叠应用3~7d。<mark>对于无症状动脉血栓形成风险极高的患儿可采取更积极的治疗方案,如近期内冠状动脉血栓形成为致</mark>\n\n【5】删除图片描述:<u>![](3_0.png)</u>\n\n<mark>【6】导致死亡而需要终治疗,可使用双抗血小板和抗凝2种药物(即阿司同氯吡格雷或应用LMWH)至病情稳定。由于这样的法血栓的危险更大,故必须根据个体情况充分考虑风险与效益比。</mark>\n\n【7】2. 抗凝药物剂量需参考左右出 血倾向进行调整。儿童的个体差异很大,如果结果热和湿膨坏难以达到要求的INR,可多考伴热相关因素的结果,并注意观察左右伴相关食物、药物(尤其是中药)的影响,用药期间注意观察有无出血，避免腮腺性的运动、外伤等。\n\n【8】3. 纤溶治疗：川崎病患儿发生急性冠状动脉阻塞可行溶栓治疗,建议在急性心肌梗死发生的12h内尽早用药,超过12h溶栓会又不大。静脉纤溶栓的再通率为70%~80%,结合冠状动脉内溶栓通率可增加10%左右。儿科最常用的溶栓药物是纤指原激活同化7 (tissue plasminogen activator, tPA),0.05mg/(kg·h),共6h。溶栓的同同高剂阿司匹林相似如果相秤素10U/(kg·h),需测激值血数和出血，保持纤维蛋白 偏于\n\n【9】10U/L，tPA疗欲再禁用人选适合于年龄的剂量,并且避免激心动同评伴血特殊也可适用尿激酶删除19:<u>(4400U/kg, 10 min, iv单)</u>或尿激醋(10 4,000U/kg,30 min,iv单) ,效果不及t-PA。但在溶栓治疗方面儿科临床经验有度限。\n\n【10】患儿发生急性心肌梗死超过12h者建议使用双抗血小板和抗3种药物(如阿司匹林、氯比格雷和LMWH)治疗川崎病急性相亚急性期,如相\n\n【11】表5 川崎病患儿抗血栓药物的使用方法和注意事项\n\n【12】删除图片描述:<u>![](3_2.png)</u>\n\n【13】注：INR为国际标准化比值", "index": 679, "show": true, "start": 627, "end": 633, "province": ["文本干净度", "页码/数字"], "isEdit": false}, {"text": "【9】10U/L，tPA疗欲再禁用人选适合于年龄的剂量,并且避免激心动同评伴血特殊也可适用尿激酶删除19:(4400U/kg, 10 min, iv单)或尿激醋(10 4,000U/kg,30 min,iv单) ,效果不及t-PA。但在溶栓治疗方面儿科临床经验有度限。", "content": "【0】页码:4\n【儿科领域】川崎病冠状动脉病变的临床处理建议（2020年修订版）(1)\n<mark>表4 基于川崎病痊冠动脉病变风险分级的治疗方案</mark>\n\n【1】删除图片描述:<u>![](3_1.png)</u>\n\n【2】注：PCI为经皮冠状动脉介入治疗；CABG为冠状动脉旁路移植术\n\n【3】以及距离5年来临床应用经验证制定推荐剂量[删除21:<u>^10,^</u>11^],供临床参考。\n\n<mark>【4】1. 抗凝治疗：</mark>CAL风险分级为II级及以上的患儿需要同时抗血小板和抗凝治疗（表5）。最常用的最小剂量阿司匹林加华法林,维持国际标准化比值（international standardization rate，INR）1.5~2.5或1.5~2.0；或小剂量阿司匹林加低分子肝素（low molecular weight heparin，LMWH）。LMWH起效快递,而且具有抗炎作用,因此在急性期优先选用。如果动脉瘤停止扩张,患儿病情稳定,可以考虑从LMWH过渡到华法林长期口服。华法林的起效时间为3~7d,因此二者需交叠应用3~7d。<mark>对于无症状动脉血栓形成风险极高的患儿可采取更积极的治疗方案,如近期内冠状动脉血栓形成为致</mark>\n\n【5】删除图片描述:<u>![](3_0.png)</u>\n\n<mark>【6】导致死亡而需要终治疗,可使用双抗血小板和抗凝2种药物(即阿司同氯吡格雷或应用LMWH)至病情稳定。由于这样的法血栓的危险更大,故必须根据个体情况充分考虑风险与效益比。</mark>\n\n<mark>【7】2. </mark>抗凝药物剂量需参考左右出 血倾向进行调整。儿童的个体差异很大,如果结果热和湿膨坏难以达到要求的INR,可多考伴热相关因素的结果,并注意观察左右伴相关食物、药物(尤其是中药)的影响,用药期间注意观察有无出血，避免腮腺性的运动、外伤等。\n\n【8】3. 纤溶治疗：川崎病患儿发生急性冠状动脉阻塞可行溶栓治疗,建议在急性心肌梗死发生的12h内尽早用药,超过12h溶栓会又不大。静脉纤溶栓的再通率为70%~80%,结合冠状动脉内溶栓通率可增加10%左右。儿科最常用的溶栓药物是纤指原激活同化7 (tissue plasminogen activator, tPA),0.05mg/(kg·h),共6h。溶栓的同同高剂阿司匹林相似如果相秤素10U/(kg·h),需测激值血数和出血，保持纤维蛋白 偏于\n\n【9】10U/L，tPA疗欲再禁用人选适合于年龄的剂量,并且避免激心动同评伴血特殊也可适用尿激酶删除19:<u>(4400U/kg, 10 min, iv单)</u>或尿激醋(10 4,000U/kg,30 min,iv单) ,效果不及t-PA。但在溶栓治疗方面儿科临床经验有度限。\n\n【10】患儿发生急性心肌梗死超过12h者建议使用双抗血小板和抗3种药物(如阿司匹林、氯比格雷和LMWH)治疗川崎病急性相亚急性期,如相\n\n【11】表5 川崎病患儿抗血栓药物的使用方法和注意事项\n\n【12】删除图片描述:<u>![](3_2.png)</u>\n\n【13】注：INR为国际标准化比值", "index": 1044, "show": true, "start": 979, "end": 1113, "province": ["格式规范性", "多余换行"], "isEdit": false}, {"text": "【11】表5 川崎病患儿抗血栓药物的使用方法和注意事项", "content": "【0】页码:4\n【儿科领域】川崎病冠状动脉病变的临床处理建议（2020年修订版）(1)\n<mark>表4 基于川崎病痊冠动脉病变风险分级的治疗方案</mark>\n\n【1】删除图片描述:<u>![](3_1.png)</u>\n\n【2】注：PCI为经皮冠状动脉介入治疗；CABG为冠状动脉旁路移植术\n\n【3】以及距离5年来临床应用经验证制定推荐剂量[删除21:<u>^10,^</u>11^],供临床参考。\n\n<mark>【4】1. 抗凝治疗：</mark>CAL风险分级为II级及以上的患儿需要同时抗血小板和抗凝治疗（表5）。最常用的最小剂量阿司匹林加华法林,维持国际标准化比值（international standardization rate，INR）1.5~2.5或1.5~2.0；或小剂量阿司匹林加低分子肝素（low molecular weight heparin，LMWH）。LMWH起效快递,而且具有抗炎作用,因此在急性期优先选用。如果动脉瘤停止扩张,患儿病情稳定,可以考虑从LMWH过渡到华法林长期口服。华法林的起效时间为3~7d,因此二者需交叠应用3~7d。<mark>对于无症状动脉血栓形成风险极高的患儿可采取更积极的治疗方案,如近期内冠状动脉血栓形成为致</mark>\n\n【5】删除图片描述:<u>![](3_0.png)</u>\n\n<mark>【6】导致死亡而需要终治疗,可使用双抗血小板和抗凝2种药物(即阿司同氯吡格雷或应用LMWH)至病情稳定。由于这样的法血栓的危险更大,故必须根据个体情况充分考虑风险与效益比。</mark>\n\n<mark>【7】2. </mark>抗凝药物剂量需参考左右出 血倾向进行调整。儿童的个体差异很大,如果结果热和湿膨坏难以达到要求的INR,可多考伴热相关因素的结果,并注意观察左右伴相关食物、药物(尤其是中药)的影响,用药期间注意观察有无出血，避免腮腺性的运动、外伤等。\n\n【8】3. 纤溶治疗：川崎病患儿发生急性冠状动脉阻塞可行溶栓治疗,建议在急性心肌梗死发生的12h内尽早用药,超过12h溶栓会又不大。静脉纤溶栓的再通率为70%~80%,结合冠状动脉内溶栓通率可增加10%左右。儿科最常用的溶栓药物是纤指原激活同化7 (tissue plasminogen activator, tPA),0.05mg/(kg·h),共6h。溶栓的同同高剂阿司匹林相似如果相秤素10U/(kg·h),需测激值血数和出血，保持纤维蛋白 偏于\n\n<mark>【9】10U/L，tPA疗欲再禁用人选适合于年龄的剂量,并且避免激心动同评伴血特殊也可适用尿激酶删除19:(4400U/kg, 10 min, iv单)或尿激醋(10 4,000U/kg,30 min,iv单) ,效果不及t-PA。但在溶栓治疗方面儿科临床经验有度限。</mark>床经验有度限。\n\n【10】患儿发生急性心肌梗死超过12h者建议使用双抗血小板和抗3种药物(如阿司匹林、氯比格雷和LMWH)治疗川崎病急性相亚急性期,如相\n\n【11】表5 川崎病患儿抗血栓药物的使用方法和注意事项\n\n【12】删除图片描述:<u>![](3_2.png)</u>\n\n【13】注：INR为国际标准化比值", "index": 1269, "show": true, "start": 1191, "end": 1218, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/06 17:17:31", "endTime": "2024/08/06 17:19:37", "cost": 125.396}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 01:19:37", "grab_time": "2024-08-06 01:17:31"}
{"id": 2211702, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "c11428f0-00d3-4c5b-8a3b-271601c0fb7b", "title": "FDA 行业指南草案：新生儿产品开发中长期临床神经发育安全性研究的注意事项", "text": "【0】页码:8\nFDA 行业指南草案：新生儿产品开发中长期临床神经发育安全性研究的注意事项\nneonates, such as necrotizing enterocolitis and retinopathy of prematurity, that will not have analogous development programs in older populations. As new medical products are developed for these and other unique neonatal conditions, novel development programs and first-in-human studies may be initiated in neonates, and these development programs should also demonstrate long-term neurologic, sensory, and developmental safety. Neonates should also be enrolled in clinical studies for medical products and diagnostic tools initially developed for indications in other populations that will be used for neonates. Inclusion of neonates in such studies may be useful to establish dosing, safety, and efficacy or effectiveness, and these studies may also warrant long-term safety evaluations.\n\n【1】### III. Neurodevelopmental Follow-Up For Product Development Programs That Include Neonates\n\n【2】Long-term neurodevelopmental safety should be considered as part of neonatal product development plans. Sponsors should communicate as early as possible with the relevant FDA review division to reach alignment on the appropriate approach for long-term safety evaluations.\n\n【3】#### A. Determining the Need for Long-term Neurodevelopmental Safety Evaluations\n\n【4】Sponsors should assess whether a long-term neurodevelopmental safety evaluation for neonates enrolled in clinical studies should be conducted. This assessment should be initiated early in product development and should be reevaluated as new information becomes available.\n\n1. General Considerations|删除段内换行|a. 删除32:<u>**</u>Systemic Exposure:删除32:<u>**</u> Any route of administration may result in a systemic exposure. The degree of systemic exposure, which should be quantified in early pharmacokinetic or animal studies if possible, may inform the need for long-term safety assessment. In general, higher levels of systemic exposure may be associated with higher central nervous system (CNS) exposure and potential risk for long-term sequelae.\n    b. 删除32:<u>**</u>Timing of Exposure:删除32:<u>**</u> The timing of exposure to a drug, biological product, or device relative to a particularly vulnerable stage of organ and tissue development may inform the need for and the type of long-term safety assessment.\n    c. 删除32:<u>**</u>Duration of Exposure:删除32:<u>**</u> Repeated dosing, repeated treatment, prolonged exposure and medical products with persistent effects may be associated with higher risk for long-term sequelae; however, long-term safety assessments may also be required after single doses or treatment, short durations of investigational therapies, based on the other considerations described in this guidance.\n\n2. Patient and Population-specific Considerations|删除段内换行|a. 删除32:<u>**</u>Neurodevelopmental vulnerability:删除32:<u>**</u> The anticipated rates of developmental, behavioral, and sensory impairments are inversely related to gestational age", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/FDA 行业指南草案：新生儿产品开发中长期临床神经发育安全性研究的注意事项.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "|删除段内换行|a. 删除32:Systemic Exposure:删除32: Any route of administration may result in a systemic exposure. The degree of systemic exposure, which should be quantified in early pharmacokinetic or animal studies if possible, may inform the need for long-term safety assessment. In general, higher levels of systemic exposure may be associated with higher central nervous system (CNS) exposure and potential risk for long-term sequelae.", "content": "【0】页码:8\nFDA 行业指南草案：新生儿产品开发中长期临床神经发育安全性研究的注意事项\nneonates, such as necrotizing enterocolitis and retinopathy of prematurity, that will not have analogous development programs in older populations. As new medical products are developed for these and other unique neonatal conditions, novel development programs and first-in-human studies may be initiated in neonates, and these development programs should also demonstrate long-term neurologic, sensory, and developmental safety. Neonates should also be enrolled in clinical studies for medical products and diagnostic tools initially developed for indications in other populations that will be used for neonates. Inclusion of neonates in such studies may be useful to establish dosing, safety, and efficacy or effectiveness, and these studies may also warrant long-term safety evaluations.\n\n【1】### III. Neurodevelopmental Follow-Up For Product Development Programs That Include Neonates\n\n【2】Long-term neurodevelopmental safety should be considered as part of neonatal product development plans. Sponsors should communicate as early as possible with the relevant FDA review division to reach alignment on the appropriate approach for long-term safety evaluations.\n\n【3】#### A. Determining the Need for Long-term Neurodevelopmental Safety Evaluations\n\n【4】Sponsors should assess whether a long-term neurodevelopmental safety evaluation for neonates enrolled in clinical studies should be conducted. This assessment should be initiated early in product development and should be reevaluated as new information becomes available.\n\n1. General Considerations|删除段内换行|a. 删除32:<u>**</u>Systemic Exposure:删除32:<u>**</u> Any route of administration may result in a systemic exposure. The degree of systemic exposure, which should be quantified in early pharmacokinetic or animal studies if possible, may inform the need for long-term safety assessment. In general, higher levels of systemic exposure may be associated with higher central nervous system (CNS) exposure and potential risk for long-term sequelae.\nb. 删除32:<u>**</u>Timing of Exposure:删除32:<u>**</u> The timing of exposure to a drug, biological product, or device relative to a particularly vulnerable stage of organ and tissue development may inform the need for and the type of long-term safety assessment.\nc. 删除32:<u>**</u>Duration of Exposure:删除32:<u>**</u> Repeated dosing, repeated treatment, prolonged exposure and medical products with persistent effects may be associated with higher risk for long-term sequelae; however, long-term safety assessments may also be required after single doses or treatment, short durations of investigational therapies, based on the other considerations described in this guidance.\n\n2. Patient and Population-specific Considerations|删除段内换行|a. 删除32:<u>**</u>Neurodevelopmental vulnerability:删除32:<u>**</u> The anticipated rates of developmental, behavioral, and sensory impairments are inversely related to gestational age", "index": 1597, "show": true, "start": 1597, "end": 2026, "province": ["格式规范性", "缺少换行"], "isEdit": false}, {"text": "|删除段内换行|a. 删除32:Neurodevelopmental vulnerability:删除32: The anticipated rates of developmental, behavioral, and sensory impairments are inversely related to gestational age", "content": "【0】页码:8\nFDA 行业指南草案：新生儿产品开发中长期临床神经发育安全性研究的注意事项\nneonates, such as necrotizing enterocolitis and retinopathy of prematurity, that will not have analogous development programs in older populations. As new medical products are developed for these and other unique neonatal conditions, novel development programs and first-in-human studies may be initiated in neonates, and these development programs should also demonstrate long-term neurologic, sensory, and developmental safety. Neonates should also be enrolled in clinical studies for medical products and diagnostic tools initially developed for indications in other populations that will be used for neonates. Inclusion of neonates in such studies may be useful to establish dosing, safety, and efficacy or effectiveness, and these studies may also warrant long-term safety evaluations.\n\n【1】### III. Neurodevelopmental Follow-Up For Product Development Programs That Include Neonates\n\n【2】Long-term neurodevelopmental safety should be considered as part of neonatal product development plans. Sponsors should communicate as early as possible with the relevant FDA review division to reach alignment on the appropriate approach for long-term safety evaluations.\n\n【3】#### A. Determining the Need for Long-term Neurodevelopmental Safety Evaluations\n\n【4】Sponsors should assess whether a long-term neurodevelopmental safety evaluation for neonates enrolled in clinical studies should be conducted. This assessment should be initiated early in product development and should be reevaluated as new information becomes available.\n\n1. General Considerations<mark>|删除段内换行|a. 删除32:Systemic Exposure:删除32: Any route of administration may result in a systemic exposure. The degree of systemic exposure, which should be quantified in early pharmacokinetic or animal studies if possible, may inform the need for long-term safety assessment. In general, higher levels of systemic exposure may be associated with higher central nervous system (CNS) exposure and potential risk for long-term sequelae.</mark>ong-term sequelae.\nb. 删除32:<u>**</u>Timing of Exposure:删除32:<u>**</u> The timing of exposure to a drug, biological product, or device relative to a particularly vulnerable stage of organ and tissue development may inform the need for and the type of long-term safety assessment.\nc. 删除32:<u>**</u>Duration of Exposure:删除32:<u>**</u> Repeated dosing, repeated treatment, prolonged exposure and medical products with persistent effects may be associated with higher risk for long-term sequelae; however, long-term safety assessments may also be required after single doses or treatment, short durations of investigational therapies, based on the other considerations described in this guidance.\n\n2. Patient and Population-specific Considerations|删除段内换行|a. 删除32:<u>**</u>Neurodevelopmental vulnerability:删除32:<u>**</u> The anticipated rates of developmental, behavioral, and sensory impairments are inversely related to gestational age", "index": 2781, "show": true, "start": 2768, "end": 2939, "province": ["格式规范性", "缺少换行"], "isEdit": false}], "startTime": "2024/08/06 15:29:03", "endTime": "2024/08/06 15:29:39", "cost": 35.812}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:29:39", "grab_time": "2024-08-05 23:29:03"}
{"id": 2211701, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "0e9560c6-3848-4056-913f-63db9a653594", "title": "基于共识的浆液性输卵管上皮内癌诊断建议", "text": "【0】页码:12\n基于共识的浆液性输卵管上皮内癌诊断建议\n(本页删除)本页被模型判断为参考页删除32:<u>**</u>Supporting Information删除32:<u>**</u>\n\n【1】Additional Supporting Information may be found in the online version of this article:\n\n【2】File S1. The questionnaires of Delphi round 1.\n\n【3】File S2. Personalized feedback form with interim results from round 2.\n\n【4】File S3. Consensus statements.\n\n【5】File S4. Final results of all statements.\n\n【6】删除32:<u>**</u>Appendix删除32:<u>**</u>\n\n【7】STIC consortium: We would like to make the members of the expert panel our coauthors. They all meet the requirements for coauthorship. If allowed, we would prefer to list them individually. However, we also welcome the idea of creating a group authorship, which could be named the 'STIC consortium'. The expert panel includes the following people: Ie-Ming Shih, Department of Gynecology and Obstetrics, Department of Oncology, and Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; W Glenn McCluggage, Department of pathology, Belfast Health and social care trust, Belfast, United Kingdom; C Blake Gilks, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Joseph W Carlson, Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Joseph T Rabban, Surgical Pathology Division, Pathology Department, University of California San Francisco, San Francisco, CA, USA; Patricia C Ewing-Graham, Department of Pathology, Erasmus MC, Rotterdam, the Netherlands; Jeffrey T Killeen, Department of Pathology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA; Ricardo Lastra, Department of Pathology, University of Chicago, Chicago, IL, USA; Vinita Parkash, Department of Pathology, Yale School of Medicine, New Haven, CT, USA; Ciaran O'Riain, Department of Histopathology, St James's Hospital, Dublin, Ireland; Annette Staebler, Institute of Pathology and Neuropathology, University of Tuebingen, Tuebingen, Germany; Russell Vang, Department of Pathology, the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Johan Bullen, Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands; Koen K vd Vijver, Department of Pathology, Ghent University Hospital, Ghent, Belgium; Mark E Sherman, Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA; Mohamed Mokhtar Desouki, Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Jacobs School of Medicine, University at Buffalo, USA; Gulisa Turashvili, Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, USA; Joost Bart, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Tjalling Bosse, Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands; Loes F X Scoorerman, Department of Pathology, Maastricht University Medical Center+, Maastricht, the Netherlands; Naveena Singh, Department of Cellular Pathology, Barts Health NHS Trust, London, UK; Colin J R Stewart, Department of Histopathology, King Edward Memorial Hospital for Women Perth, Subiaco, Western Australia, Australia; Sigurd F Lax, Department of Pathology, Hospital Graz II, Graz, Austria; School of Medicine, Johannes Kepler University Linz, Linz, Austria; Brooke E Howitt, Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Devjin Xing, Departments of Pathology, Oncology, Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, MD, USA; Ayoma A Duttayake, Department of Histopathology, Royal Marsden Hospital, London, UK; Katherine M Vroobel, Department of Pathology, Royal Marsden NHS Foundation Trust, London, UK; Lauren E Schwartz, University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, USA; Trudy G N Jonges, Department of", "tags": {}, "lang": "en", "attr": {"page_num": 12, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/基于共识的浆液性输卵管上皮内癌诊断建议.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:47:47", "endTime": "2024/08/06 15:48:23", "cost": 35.847}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:48:23", "grab_time": "2024-08-05 23:47:47"}
{"id": 2211700, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "7cec0808-6fa9-4619-94ea-51e34d1d52f0", "title": "儿童副流感病毒感染临床实验室诊断专家共识", "text": "【0】页码:1\n儿童副流感病毒感染临床实验室诊断专家共识\n由于图片处理错误，我无法从中提取文本内容。请您再试一次或上传其他图片。", "tags": {}, "lang": "zh", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/儿童副流感病毒感染临床实验室诊断专家共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:58:51", "endTime": "2024/08/06 16:58:58", "cost": 6.775}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:58:58", "grab_time": "2024-08-06 00:58:51"}
{"id": 2211699, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "eb44129b-22b1-4788-88ae-ea9cabc6fdee", "title": "2023+KHRS指南：斑秃患者的治疗—第2部分：系统治疗", "text": "【0】页码:3\n2023+KHRS指南：斑秃患者的治疗—第2部分：系统治疗\n### Table 2. Evidence-based statement and expert consensus of systemic treatment\n\n| Statement                                                                                       | Level of evidence | Strength of recommendation | Percentage of participants with score ≥7 | Average agreement score | Consensus |\n|------------------------------------------------------------------------------------------------|-------------------|----------------------------|------------------------------------------|-------------------------|-----------|\n| We recommend systemic corticosteroids for adult patients with severe AA.                       | 2b                | B                          | 91.8                                     | 7.9                     | Yes       |\n| We conditionally recommend systemic corticosteroids for pediatric patients with severe AA.     | 4                 | C                          | 75.5                                     | 6.7                     | Yes       |\n| We recommend cyclosporine monotherapy or in combination with systemic corticosteroids for adult patients with severe AA. | 3a                | B                          | 91.8                                     | 7.9                     | Yes       |\n| We conditionally recommend cyclosporine for pediatric patients with severe AA.                 | 4                 | C                          | 73.5                                     | 6.4                     |           |\n| We conditionally recommend azathioprine monotherapy or combination with corticosteroid for patients with severe AA. | 2b                | C                          | 14.3                                     | 4.8                     |           |\n| We conditionally recommend methotrexate monotherapy or combination with corticosteroid for patients with severe AA. | 4                 | C                          | 30.6                                     | 5.4                     |           |\n| We conditionally recommend sulfasalazine monotherapy or combination with corticosteroid for patients with severe AA. | 4                 | C                          | 10.2                                     | 4.1                     |           |\n| We conditionally recommend simvastatin/ezetimibe for patients with severe refractory AA.       | 4                 | C                          | 18.4                                     | 4.3                     |           |\n| We conditionally recommend inosiplex for patients with refractory AA.                          | 2b                | C                          | 10.2                                     | 3.9                     |           |\n| We conditionally recommend antihistamines for patients with AA.                                | 3b                | C                          | 28.6                                     | 4.7                     |           |\n| We recommend oral JAK inhibitor for adult patients with severe AA.                             | 1b                | B                          | 83.7                                     | 7.5                     | Yes       |\n| We conditionally recommend oral JAK inhibitor for pediatric patients with severe AA.           | 4                 | C                          | 49.0                                     | 6.0                     |           |\n\n【2】AA: alopecia areata, JAK: Janus kinase.\n\n【3】A study published in 2020, there was a clear consensus on the use of oral steroids as first-line treatment for severe (SALT>50) adult AA and daily administration of prednisolone (or prednisone) was the preferred choice. In addition, an initial dose of 0.4 to 0.6 mg/kg/day with gradual tapering over more than 12 weeks was suggested by consensus. However, there are studies suggesting that pulse corticosteroid therapy is superior to daily oral corticosteroid therapy in terms of therapeutic effect and adverse effect profile. For example, in a study where steroid administration was randomized into three groups (oral prednisolone pulse therapy vs. oral dexamethasone daily administration vs. intramuscular triamcinolone acetonide monthly administration), the overall relapse rate was significantly lower in the oral prednisolone pulse therapy group, compared to that in the oral dexamethasone daily administration group. Thus, further studies are necessary on the mode of administration. Additionally, the previous study which investigated the prognosis of patients who received pulse corticosteroid therapy for more than 10 years, patients with AT and AU demonstrated poor short-term and long-term prognosis.\n\n【4】#### Systemic corticosteroids for severe pediatric AA patients\nWe conditionally recommend oral corticosteroids for pediatric patients with severe AA (level of evidence: 4, grade of recommendation: C, agreement rate: 75.5%).\n\n【5】In a systematic review published in 2021 regarding the treatment of AA in children, systemic steroids were found to be effective in 72.9% (102/140) patients. However, the therapy had the highest recurrence rate (62.9%, 61/97 patients) among various other treatment options. Oral prednisolone.", "tags": {}, "lang": "en", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023+KHRS指南：斑秃患者的治疗—第2部分：系统治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "A", "content": "【0】页码:3\n2023+KHRS指南：斑秃患者的治疗—第2部分：系统治疗\n### Table 2. Evidence-based statement and expert consensus of systemic treatment\n\n| Statement                                                                                       | Level of evidence | Strength of recommendation | Percentage of participants with score ≥7 | Average agreement score | Consensus |\n|------------------------------------------------------------------------------------------------|-------------------|----------------------------|------------------------------------------|-------------------------|-----------|\n| We recommend systemic corticosteroids for adult patients with severe AA.                       | 2b                | B                          | 91.8                                     | 7.9                     | Yes       |\n| We conditionally recommend systemic corticosteroids for pediatric patients with severe AA.     | 4                 | C                          | 75.5                                     | 6.7                     | Yes       |\n| We recommend cyclosporine monotherapy or in combination with systemic corticosteroids for adult patients with severe AA. | 3a                | B                          | 91.8                                     | 7.9                     | Yes       |\n| We conditionally recommend cyclosporine for pediatric patients with severe AA.                 | 4                 | C                          | 73.5                                     | 6.4                     |           |\n| We conditionally recommend azathioprine monotherapy or combination with corticosteroid for patients with severe AA. | 2b                | C                          | 14.3                                     | 4.8                     |           |\n| We conditionally recommend methotrexate monotherapy or combination with corticosteroid for patients with severe AA. | 4                 | C                          | 30.6                                     | 5.4                     |           |\n| We conditionally recommend sulfasalazine monotherapy or combination with corticosteroid for patients with severe AA. | 4                 | C                          | 10.2                                     | 4.1                     |           |\n| We conditionally recommend simvastatin/ezetimibe for patients with severe refractory AA.       | 4                 | C                          | 18.4                                     | 4.3                     |           |\n| We conditionally recommend inosiplex for patients with refractory AA.                          | 2b                | C                          | 10.2                                     | 3.9                     |           |\n| We conditionally recommend antihistamines for patients with AA.                                | 3b                | C                          | 28.6                                     | 4.7                     |           |\n| We recommend oral JAK inhibitor for adult patients with severe AA.                             | 1b                | B                          | 83.7                                     | 7.5                     | Yes       |\n| We conditionally recommend oral JAK inhibitor for pediatric patients with severe AA.           | 4                 | C                          | 49.0                                     | 6.0                     |           |\n\n【2】AA: alopecia areata, JAK: Janus kinase.\n\n【3】A study published in 2020, there was a clear consensus on the use of oral steroids as first-line treatment for severe (SALT>50) adult AA and daily administration of prednisolone (or prednisone) was the preferred choice. In addition, an initial dose of 0.4 to 0.6 mg/kg/day with gradual tapering over more than 12 weeks was suggested by consensus. However, there are studies suggesting that pulse corticosteroid therapy is superior to daily oral corticosteroid therapy in terms of therapeutic effect and adverse effect profile. For example, in a study where steroid administration was randomized into three groups (oral prednisolone pulse therapy vs. oral dexamethasone daily administration vs. intramuscular triamcinolone acetonide monthly administration), the overall relapse rate was significantly lower in the oral prednisolone pulse therapy group, compared to that in the oral dexamethasone daily administration group. Thus, further studies are necessary on the mode of administration. Additionally, the previous study which investigated the prognosis of patients who received pulse corticosteroid therapy for more than 10 years, patients with AT and AU demonstrated poor short-term and long-term prognosis.\n\n【4】#### Systemic corticosteroids for severe pediatric AA patients\nWe conditionally recommend oral corticosteroids for pediatric patients with severe AA (level of evidence: 4, grade of recommendation: C, agreement rate: 75.5%).\n\n【5】In a systematic review published in 2021 regarding the treatment of AA in children, systemic steroids were found to be effective in 72.9% (102/140) patients. However, the therapy had the highest recurrence rate (62.9%, 61/97 patients) among various other treatment options. Oral prednisolone.", "index": 3465, "show": true, "start": 3465, "end": 3466, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "3"}], "startTime": "2024/08/07 10:02:23", "endTime": "2024/08/07 10:03:13", "cost": 49.915}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 18:03:12", "grab_time": "2024-08-06 18:02:22"}
{"id": 2211698, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "5cef8d58-40d5-4ee3-850d-569b366e6f66", "title": "【神经领域】中国脑卒中防治指导规范（2021年版）", "text": "【0】页码:14\n【神经领域】中国脑卒中防治指导规范（2021年版）\n表 1-4 糖代谢状态异常\n\n| 糖代谢分类  | 静脉血浆葡萄糖 (mmol•L⁻删除29:<u>¹</u>)      |\n| ------------- | ----------------------------- |\n|               | 空腹血糖     | 葡萄糖负荷后2小时血糖 |\n| 正常血糖      | <6.1         | <7.8                 |\n| 空腹血糖受损 (IFG)  | 6.1～<7.0   | <7.8                 |\n| 糖耐量减低 (IGT)    | <7.0         | 7.8～<11.1           |\n| 糖尿病         | ≥7.0         | ≥11.1               |\n\n【2】注：IFG 和 IGT 统称为糖调节受损，也称糖尿病前期。\n\n【3】表 1-5 成年人糖尿病危险因素\n\n【4】成年人糖尿病危险因素包括：\n\n【5】1. 年龄≥40岁。\n2. 有糖调节受损史。\n3. 超重 (BMI≥24kg/m²) 或肥胖 (BMI≥28kg/m²) 和/或中心型肥胖 (男性腰围≥90cm，女性腰围≥85cm)。\n4. 静坐生活方式。\n5. 一级亲属中有 2 型糖尿病家族史。\n6. 有巨大儿 (出生体重≥4kg) 生产史或妊娠糖尿病史的妇女。\n7. 高血压 (收缩压≥140mmHg 和/或舒张压≥90mmHg)，或正在接受降压治疗。\n8. 血脂异常：HDL-C≤0.91mmol/L (≤35mg/dl)、甘油三酯≥2.22mmol/L (≥200mg/dl)，或正在接受调脂治疗。\n9. 动脉粥样硬化性心脑血管疾病患者。\n10. 有一过性类固醇糖尿病史者。\n11. 多囊卵巢综合征患者。\n12. 长期接受抗精神病药物和/或抗抑郁药物治疗者。\n\n【6】注：18岁的小体，具有以上任何一个及以上糖尿病危险因素即为糖尿病的高危个群。\n\n【7】### 三、血脂异常\n\n【8】【指导规范】\n\n【9】1.20岁以上的成人至少每5年测量1次空腹血脂，包括总胆固醇 (total", "tags": {}, "lang": "zh", "attr": {"page_num": 14, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【神经领域】中国脑卒中防治指导规范（2021年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "空腹血糖", "content": "【0】页码:14\n【神经领域】中国脑卒中防治指导规范（2021年版）\n表 1-4 糖代谢状态异常\n\n| 糖代谢分类  | 静脉血浆葡萄糖 (mmol•L⁻删除29:<u>¹</u>)      |\n| ------------- | ----------------------------- |\n|               | 空腹血糖     | 葡萄糖负荷后2小时血糖 |\n| 正常血糖      | <6.1         | <7.8                 |\n| 空腹血糖受损 (IFG)  | 6.1～<7.0   | <7.8                 |\n| 糖耐量减低 (IGT)    | <7.0         | 7.8～<11.1           |\n| 糖尿病         | ≥7.0         | ≥11.1               |\n\n【2】注：IFG 和 IGT 统称为糖调节受损，也称糖尿病前期。\n\n【3】表 1-5 成年人糖尿病危险因素\n\n【4】成年人糖尿病危险因素包括：\n\n【5】1. 年龄≥40岁。\n2. 有糖调节受损史。\n3. 超重 (BMI≥24kg/m²) 或肥胖 (BMI≥28kg/m²) 和/或中心型肥胖 (男性腰围≥90cm，女性腰围≥85cm)。\n4. 静坐生活方式。\n5. 一级亲属中有 2 型糖尿病家族史。\n6. 有巨大儿 (出生体重≥4kg) 生产史或妊娠糖尿病史的妇女。\n7. 高血压 (收缩压≥140mmHg 和/或舒张压≥90mmHg)，或正在接受降压治疗。\n8. 血脂异常：HDL-C≤0.91mmol/L (≤35mg/dl)、甘油三酯≥2.22mmol/L (≥200mg/dl)，或正在接受调脂治疗。\n9. 动脉粥样硬化性心脑血管疾病患者。\n10. 有一过性类固醇糖尿病史者。\n11. 多囊卵巢综合征患者。\n12. 长期接受抗精神病药物和/或抗抑郁药物治疗者。\n\n【6】注：18岁的小体，具有以上任何一个及以上糖尿病危险因素即为糖尿病的高危个群。\n\n【7】### 三、血脂异常\n\n【8】【指导规范】\n\n【9】1.20岁以上的成人至少每5年测量1次空腹血脂，包括总胆固醇 (total", "index": 167, "show": true, "start": 167, "end": 171, "province": ["语义有效性", "语义不完整"], "isEdit": false}], "startTime": "2024/08/06 16:29:33", "endTime": "2024/08/06 16:30:27", "cost": 54.758}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:30:27", "grab_time": "2024-08-06 00:29:32"}
{"id": 2211697, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "cf66fbcf-519e-4ac7-a479-0b01daaa8de7", "title": "成人肥胖食养指南（2024年版）", "text": "【0】页码:8\n成人肥胖食养指南（2024年版）\n一日能量。以上方法可根据实际需要任选其一用来指导超重肥胖患者膳食，达到控制总能量摄入的目标。\n\n【1】合理膳食应在控制总能量摄入的同时保障食物摄入多样化和平衡膳食，保证营养素的充足摄入，必要时补充复合营养素补充剂。三大宏量营养素的供能比例分别为脂肪20%~30%、蛋白质15%~20%、碳水化合物50%~60%。一日三餐合理分配饮食，推荐早中晚三餐供能比为3:4:3。鼓励主食以全谷物为主，至少占谷物的一半，适当增加粗粮并减少精白米面摄入；保障足量的新鲜蔬果摄入，蔬菜水果品种多样化，但要减少高糖水果及高淀粉含量蔬菜的摄入；动物性食物应优先选择脂肪含量低的食材，如瘦肉、去皮鸡胸肉、鱼虾等；应优先选择低脂或脱脂奶类。\n\n【2】必要时，可在医生或者营养指导人员等专业人员指导下，选用高蛋白膳食、低碳水化合物膳食、间歇式断食膳食或营养代餐等其他膳食减重干预措施，具体方法可参考《中国超重/肥胖医学营养治疗指南（2021）》及《<中国居民肥胖防治专家共识>》。\n\n【3】表1 中国居民成人膳食能量需要量 (单位: kcal/d)\n\n【4】删除图片描述:<u>![](7_0.png)</u>\n\n【5】（二）少吃高能量食物，饮食清淡，限制饮酒。\n\n【6】高能量食物通常是指提供400kcal/100g以上能量的食物，如油炸食品、含糖烘焙糕点、糖果、肥肉等；全谷物、", "tags": {}, "lang": "zh", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/成人肥胖食养指南（2024年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【4】", "content": "【0】页码:8\n成人肥胖食养指南（2024年版）\n一日能量。以上方法可根据实际需要任选其一用来指导超重肥胖患者膳食，达到控制总能量摄入的目标。\n\n【1】合理膳食应在控制总能量摄入的同时保障食物摄入多样化和平衡膳食，保证营养素的充足摄入，必要时补充复合营养素补充剂。三大宏量营养素的供能比例分别为脂肪20%~30%、蛋白质15%~20%、碳水化合物50%~60%。一日三餐合理分配饮食，推荐早中晚三餐供能比为3:4:3。鼓励主食以全谷物为主，至少占谷物的一半，适当增加粗粮并减少精白米面摄入；保障足量的新鲜蔬果摄入，蔬菜水果品种多样化，但要减少高糖水果及高淀粉含量蔬菜的摄入；动物性食物应优先选择脂肪含量低的食材，如瘦肉、去皮鸡胸肉、鱼虾等；应优先选择低脂或脱脂奶类。\n\n【2】必要时，可在医生或者营养指导人员等专业人员指导下，选用高蛋白膳食、低碳水化合物膳食、间歇式断食膳食或营养代餐等其他膳食减重干预措施，具体方法可参考《中国超重/肥胖医学营养治疗指南（2021）》及《<中国居民肥胖防治专家共识>》。\n\n【3】表1 中国居民成人膳食能量需要量 (单位: kcal/d)\n\n【4】删除图片描述:<u>![](7_0.png)</u>\n\n【5】（二）少吃高能量食物，饮食清淡，限制饮酒。\n\n【6】高能量食物通常是指提供400kcal/100g以上能量的食物，如油炸食品、含糖烘焙糕点、糖果、肥肉等；全谷物、", "index": 488, "show": true, "start": 488, "end": 491, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "缺少表格"}], "startTime": "2024/08/06 16:24:17", "endTime": "2024/08/06 16:25:49", "cost": 92.515}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:25:49", "grab_time": "2024-08-06 00:24:17"}
{"id": 2211696, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "b701949e-fd13-4913-9143-17f2124222b4", "title": "ISPD：腹膜炎的预防和治疗指南（2022）", "text": "【0】页码:34\nISPD：腹膜炎的预防和治疗指南（2022）\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】参考删除-3:<u>删除32:<u>**</u>87. Nishino M, Yanagi H, Koizumi M, et al. Pasteurella multocida peritonitis associated with a cat in a peritoneal dialysis patient using an automated cycler device. CEN Case Rep 2012; 1删除11:<u>(2)</u>: 73–76.删除32:<u>**</u></u>\n\n【2】参考删除-3:<u>删除32:<u>**</u>88. Makin AJ, Cartwright KA and Banks RA. Keeping the cat out of the bag: a hazard in continuous ambulatory peritoneal dialysis. BMJ 1997; 30删除11:<u>删除19:<u>(6871)</u></u>: 1610–1611.删除32:<u>**</u></u>\n\n【3】参考删除-3:<u>删除32:<u>**</u>89. Sedlacek M, Cotter JG, Suriawinata AA, et al. Mucormycosis peritonitis: more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B. Am J Kidney Dis 2008; 51删除11:<u>(2)</u>: 302–306.删除32:<u>**</u></u>\n\n【4】参考删除-3:<u>删除32:<u>**</u>90. Freeman AF, Zheng XT, Lane JC, et al. Pasteurella aerogenes hamster bite peritonitis. Pediatr Infect Dis J 2004; 23删除11:<u>(4)</u>: 368–370.删除32:<u>**</u></u>\n\n【5】参考删除-3:<u>删除32:<u>**</u>91. Campos A, Taylor JH and Campbell M. Hamster bite peritonitis: Pasteurella pneumotropica peritonitis in a dialysis patient. Pediatr Nephrol 2000; 15删除11:<u>(2-3)</u>: 31–32.删除32:<u>**</u></u>\n\n【6】参考删除-3:<u>删除32:<u>**</u>92. Adapa S, Naramala S, Madhira BR, et al. Peritonitis secondary to uncommon gram-negative Cocobacillus transmitted from a cat in a patient on peritoneal dialysis. J Investig Med High Impact Case Rep 2019; 7: 2324709619891655.删除32:<u>**</u></u>\n\n【7】参考删除-3:<u>删除32:<u>**</u>93. Abebe M, Lavecgia C, George S, et al. Pet-related peritonitis and its prevention in peritoneal dialysis: a case study. Perit Dial Int 2014; 34删除11:<u>(4)</u>: 466–468.删除32:<u>**</u></u>\n\n【8】参考删除-3:<u>删除32:<u>**</u>94. Davies SJ, Zhao J, Morgenstern H, et al. Low serum potassium levels and clinical outcomes in peritoneal dialysis: international results from PDOPPS. Kidney Int Rep 2021; 6删除11:<u>(2)</u>: 313–324.删除32:<u>**</u></u>\n\n【9】参考删除-3:<u>删除32:<u>**</u>95. Al Salmi M, Zhao J, McCullough K, et al. Variation in peritoneal dialysis-related peritonitis outcomes in the peritoneal dialysis outcomes and practice patterns study (PDOPPS). Am J Kidney Dis 2021; 79删除11:<u>(1)</u>: 45–55.删除32:<u>**</u></u>\n\n【10】参考删除-3:<u>删除32:<u>**</u>96. Su CY, Pei J, Lu XH, et al. Gastrointestinal symptoms predict peritonitis rates in CAPD patients. Clin Nephrol 2012; 77删除11:<u>(4)</u>: 267–274.删除32:<u>**</u></u>\n\n【11】参考删除-3:<u>删除32:<u>**</u>97. Chuang YW, Shu KH, Yu TM, et al. Hypokalemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients. Nephrol Dial Transplant 2009; 24删除11:<u>(5)</u>: 1603–1608.删除32:<u>**</u></u>\n\n【12】参考删除-3:<u>删除32:<u>**</u>98. Ribeiro SC, Figueiredo AE, Barretti P, et al. Low serum potassium levels increase the infectious-caused mortality in peritoneal dialysis patients: a propensity-matched score study. PLoS One 2015; 10删除11:<u>(6)</u>: e0127453.删除32:<u>**</u></u>\n\n【13】参考删除-3:<u>删除32:<u>**</u>99. Liu D, Lin Y, Gong N, et al. Degree and duration of hypokalemia associated with peritonitis in patients undergoing peritoneal dialysis. Int J Clin Pract 2021; 75删除11:<u>(8)</u>: e14188.删除32:<u>**</u></u>\n\n【14】参考删除-3:<u>删除32:<u>**</u>100. Virojanawat M, Puapatanakul P, Chuengsaman P, et al. Hypokalemia in peritoneal dialysis patients in Thailand: the pivotal role of low potassium intake. Int Urol Nephrol 2021; 53删除11:<u>(7)</u>: 1463–1471.删除32:<u>**</u></u>\n\n【15】参考删除-3:<u>删除32:<u>**</u>101. Szeto CC, Chow KM, Kwan BC, et al. Hypokalemia in Chinese peritoneal dialysis patients: prevalence and prognostic implication. J Am Kidney Dis 2005; 46删除11:<u>(1)</u>: 128–135.删除32:<u>**</u></u>\n\n【16】删除32:<u>**</u>102. Asfar B, Elslure R, Bilgic A, et al. Regular lactulose use is associated with lower peritonitis rates: an observational study. Perit Dial Int 2010; 30删除11:<u>(2)</u>: 243–246.删除32:<u>**</u>\n\n【17】参考删除-3:<u>删除32:<u>**</u>103. Noppakun K, Narchongtai T, Chaiwirath R, et al. Comparative effectiveness of lactulose and senossides for the prevention of peritoneal dialysis-related peritonitis: an open-label, randomized, active-controlled trial. Ann Med 2021; 53删除11:<u>(1)</u>: 365–374.删除32:<u>**</u></u>\n\n【18】参考删除-3:<u>删除32:<u>**</u>104. Perez-Fontan M, Machado Lopes D, Garcia Enriquez A, et al. Inhibition of gastric acid secretion by H2 receptor antagonists associates a definite risk of enteric peritonitis and infectious mortality in patients treated with peritoneal dialysis. PLoS One 2016; 11删除11:<u>(2)</u>: e0148806.删除32:<u>**</u></u>\n\n【19】参考删除-3:<u>删除32:<u>**</u>105. Maeda S, Yamaguchi M, Maeda K, et al. Proton pump inhibitor use increases the risk of enteritis in peritoneal dialysis patients. PLoS One 2019; 14删除11:<u>(11)</u>: e0224189.删除32:<u>**</u></u>\n\n【20】参考删除-3:<u>删除32:<u>**</u>106. Nessim SJ, Tomlinson G, Bargman JM, et al. Gastric acid suppression and the risk of enteric peritonitis in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 2017; 12删除11:<u>(5)</u>: 697–705.删除32:<u>**</u></u>\n\n【21】参考删除-3:<u>删除32:<u>**</u>107. Zhong HJ, Lin D, Lu ZY, et al. Use of gastric-acid-suppressing agents may be a risk factor for peritonitis in patients undergoing peritoneal dialysis: a meta-analysis. J Clin Pharm Ther 2019; 44删除11:<u>(2)</u>: 209–215.删除32:<u>**</u></u>\n\n【22】参考删除-3:<u>删除32:<u>**</u>108. Wang AY, Yu AW, Li PK, et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis 2000; 36删除11:<u>(6)</u>: 1183–1192.删除32:<u>**</u></u>\n\n【23】参考删除-3:<u>删除32:<u>**</u>109. Goldie SJ, Kiernan-Tridle L, Torres C, et al. Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. Am J Kidney Dis 1996; 28删除11:<u>(1)</u>: 86–91.删除32:<u>**</u></u>\n\n【24】参考删除-3:<u>删除32:<u>**</u>110. Auricchio S, Giovenzana ME, Pozzi M, et al. Fungal peritonitis in peritoneal dialysis: a 34-year single centre evaluation. Clin Kidney J 2018; 11删除11:<u>(6)</u>: 874–880.删除32:<u>**</u></u>\n\n【25】参考删除-3:<u>删除32:<u>**</u>111. Chow CY, Kao MT, Kuo HL, et al. Gram-negative and polymicrobial peritonitis are associated with subsequent fungal peritonitis in CAPD patients. Perit Dial Int 2006; 26删除11:<u>(5)</u>: 607–608.删除32:<u>**</u></u>\n\n【26】参考删除-3:<u>删除32:<u>**</u>112. Robitaille P, Meroaunl A, Clermont MJ, et al. Successful antifungal prophylaxis in chronic peritoneal dialysis: a retrospective experience. Perit Dial Int 1995; 15删除11:<u>(1)</u>: 77–79.删除32:<u>**</u></u>\n\n【27】参考删除-3:<u>删除32:<u>**</u>113. Zaruba K, Peters J and Jungbluth H. Successful prophylaxis for fungal infections in patients on continuous ambulatory peritoneal dialysis: six years experience. Am J Kidney Dis 1991; 17删除11:<u>(1)</u>: 43–46.删除32:<u>**</u></u>\n\n【28】参考删除-3:<u>删除32:<u>**</u>114. Wong PN, Lo KY, Tong GM, et al. Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD. Perit Dial Int 2007; 27删除11:<u>(5)</u>: 531–536.删除32:<u>**</u></u>", "tags": {}, "lang": "en", "attr": {"page_num": 34, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ISPD：腹膜炎的预防和治疗指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:58:07", "endTime": "2024/08/06 15:58:13", "cost": 5.887}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:58:14", "grab_time": "2024-08-05 23:58:06"}
{"id": 2211695, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "c2cc0d82-4d10-43de-beb5-21313642dffd", "title": "心尖入路经导管主动脉瓣植入手术操作规范", "text": "【0】页码:3\n心尖入路经导管主动脉瓣植入手术操作规范\n能以最快的速度配合主刀医师建立体外循环。\n\n【1】配有 1～2 名麻醉护士搭璜机械臂接接或由专职 人员完成，1～2 名巡回护士，紧绷的护理团队让手 术流程更流畅，紧急情况下及时响应处理能增加患 者安全性。\n\n【2】配有1～2名介入技师，为手术提供高质量的 图像。\n\n【3】### 3 适应证\n\n【4】根据 2020 ACC/AHA 赘膜病管理指南及 2021 ESC/EACTS 赘膜疾病指南，同时相关专题共识及 现有的临床研究经验 删除32:<u>\\[318,323\\]</u>，本方案主要针对 TA-TAVR 治疗主动脉赘狭窄适用和不能。\n\n【5】删除11:<u>(1)</u> 高临床手术风险的重度主动脉赘狭窄患者，年 龄>{ 80 岁或外科高危(STS-PROM/ EuroSCORE II > 8%) 或不适合外科手术，推荐 TAVR 治疗。患者 年龄<=80岁，考虑瓣膜预期大性，患者预期寿命， 解剖条件和手术风险等因素,可多学科讨论后与患 者共同决定行TAVR或外科主动脉瓣置换术(surgical aortic valve replacement, SAVR)治疗。\n\n【6】删除11:<u>(2)</u> 中度 AS 患者，有手术指征者，参考上述 年龄和外科风险因素，经过 ESC/EACTS 及 AHA 赘膜 指南20]等建议，应用TAVR 治疗。\n\n【7】删除11:<u>(3)</u> 重度 AS 患者，机般功能欠佳或新 TAVR 并用，推荐 TE-TAVR。如有局限因素件或 (如生 or 楔利解剖因素(如横位心、冠脉阻塞等风险等)， 可考虑行 TA-TAVR。\n\n【8】删除11:<u>(4)</u> 对于外科风险较高的主动脉愈生物瓣或 双生物瓣， 可考虑行常规TAVFR手术。\n\n【9】删除11:<u>(5)</u> 对于心下注产瓣( bicuspid aortic valve, BAV) 患者，手预指参考二叶式或三叶式主动赘， 建议在经验丰富的医院中进行。\n\n【10】删除11:<u>(6)</u> 对于 BAV 患者若赘瓣粘有狭小生主动脉凹直 伞径>45 mm，三叶式主动脉愈案和或扩生主动脉荐 对于主动脉内径<50 mm, 应立jal评分外科风险，如 非外科高危，建议 SAVR 同时处理主动脉额伞，如 外高或手术不高直, 可考虑 TAVR 手术处理主动脉赘 狭滤患者。\n\n【11】### 4 心尖入路经导管主动脉瓣植入术手术操 作流程\n\n【12】术前完善超声心动图、心电门花心血常增摇多 排螺旋 CT、心电图; 实验室检査等项目，将明确否具 Ⅱ存不适应证, 排除手术禁忌，确施瓣膜规格予和 用'\\!\n\n【13】医生对患者进行框栏保存心室范围，准备了（图 2）定位。\n\n【14】删除图片描述:<u>![](2_0.png)</u>\n\n【15】#### 4.1 体位摆放\n\n【16】患者常规取仰位，双臂平放身体两侧，不建议垫枕石，寓背对手术操作起子大大夹角，反而影响耐荧测验和震麻仪直接夹角度电图连选线习患病替合向侧被，体外循环电极放置位置为右侧中央右肋下。在侧位于左侧锁骨中线，第5 胁间以下, 配选坐位於中显疑和或实施于某條皓位置患者（图 02)，洁毒并铺中进行手开胸，随机学验确定，急诊病者胸骨需从简时提取生便等物。远想过心尖切口胸径15 cm以上。髋叶盲损灭野后夹治天需膝胸降护，在例频医生，兄事后胸！上或竟略胸降脉盲开工具浴（根据临时起到导线位置决定)，下导为裂下5cm生石。如女先性者有备洁沫者间用其他脉臀保持心尖要。从中方面孙头或显影叮见反或收。\n\n【17】#### 4.2 锚管器盗装定位器封主增器导管\n\n【18】穿钢一种腰皮皮服编码式删除30:<u>(5French)</u>或c针管,作为选导暂器胶管,穿刺点应在于腰胶分控制(下,),胶狙、胶皮涂防于以下，然前也克侵帽最作用I下值销地，可在起司于手等时,穿。附表", "tags": {}, "lang": "zh", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/心尖入路经导管主动脉瓣植入手术操作规范.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【5】删除11:(1)", "content": "【0】页码:3\n心尖入路经导管主动脉瓣植入手术操作规范\n能以最快的速度配合主刀医师建立体外循环。\n\n【1】配有 1～2 名麻醉护士搭璜机械臂接接或由专职 人员完成，1～2 名巡回护士，紧绷的护理团队让手 术流程更流畅，紧急情况下及时响应处理能增加患 者安全性。\n\n【2】配有1～2名介入技师，为手术提供高质量的 图像。\n\n【3】### 3 适应证\n\n【4】根据 2020 ACC/AHA 赘膜病管理指南及 2021 ESC/EACTS 赘膜疾病指南，同时相关专题共识及 现有的临床研究经验 删除32:<u>\\[318,323\\]</u>，本方案主要针对 TA-TAVR 治疗主动脉赘狭窄适用和不能。\n\n【5】删除11:<u>(1)</u> 高临床手术风险的重度主动脉赘狭窄患者，年 龄>{ 80 岁或外科高危(STS-PROM/ EuroSCORE II > 8%) 或不适合外科手术，推荐 TAVR 治疗。患者 年龄<=80岁，考虑瓣膜预期大性，患者预期寿命， 解剖条件和手术风险等因素,可多学科讨论后与患 者共同决定行TAVR或外科主动脉瓣置换术(surgical aortic valve replacement, SAVR)治疗。\n\n【6】删除11:<u>(2)</u> 中度 AS 患者，有手术指征者，参考上述 年龄和外科风险因素，经过 ESC/EACTS 及 AHA 赘膜 指南20]等建议，应用TAVR 治疗。\n\n【7】删除11:<u>(3)</u> 重度 AS 患者，机般功能欠佳或新 TAVR 并用，推荐 TE-TAVR。如有局限因素件或 (如生 or 楔利解剖因素(如横位心、冠脉阻塞等风险等)， 可考虑行 TA-TAVR。\n\n【8】删除11:<u>(4)</u> 对于外科风险较高的主动脉愈生物瓣或 双生物瓣， 可考虑行常规TAVFR手术。\n\n【9】删除11:<u>(5)</u> 对于心下注产瓣( bicuspid aortic valve, BAV) 患者，手预指参考二叶式或三叶式主动赘， 建议在经验丰富的医院中进行。\n\n【10】删除11:<u>(6)</u> 对于 BAV 患者若赘瓣粘有狭小生主动脉凹直 伞径>45 mm，三叶式主动脉愈案和或扩生主动脉荐 对于主动脉内径<50 mm, 应立jal评分外科风险，如 非外科高危，建议 SAVR 同时处理主动脉额伞，如 外高或手术不高直, 可考虑 TAVR 手术处理主动脉赘 狭滤患者。\n\n【11】### 4 心尖入路经导管主动脉瓣植入术手术操 作流程\n\n【12】术前完善超声心动图、心电门花心血常增摇多 排螺旋 CT、心电图; 实验室检査等项目，将明确否具 Ⅱ存不适应证, 排除手术禁忌，确施瓣膜规格予和 用'\\!\n\n【13】医生对患者进行框栏保存心室范围，准备了（图 2）定位。\n\n【14】删除图片描述:<u>![](2_0.png)</u>\n\n【15】#### 4.1 体位摆放\n\n【16】患者常规取仰位，双臂平放身体两侧，不建议垫枕石，寓背对手术操作起子大大夹角，反而影响耐荧测验和震麻仪直接夹角度电图连选线习患病替合向侧被，体外循环电极放置位置为右侧中央右肋下。在侧位于左侧锁骨中线，第5 胁间以下, 配选坐位於中显疑和或实施于某條皓位置患者（图 02)，洁毒并铺中进行手开胸，随机学验确定，急诊病者胸骨需从简时提取生便等物。远想过心尖切口胸径15 cm以上。髋叶盲损灭野后夹治天需膝胸降护，在例频医生，兄事后胸！上或竟略胸降脉盲开工具浴（根据临时起到导线位置决定)，下导为裂下5cm生石。如女先性者有备洁沫者间用其他脉臀保持心尖要。从中方面孙头或显影叮见反或收。\n\n【17】#### 4.2 锚管器盗装定位器封主增器导管\n\n【18】穿钢一种腰皮皮服编码式删除30:<u>(5French)</u>或c针管,作为选导暂器胶管,穿刺点应在于腰胶分控制(下,),胶狙、胶皮涂防于以下，然前也克侵帽最作用I下值销地，可在起司于手等时,穿。附表", "index": 301, "show": true, "start": 301, "end": 312, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "全文序号"}, {"text": "{", "content": "【0】页码:3\n心尖入路经导管主动脉瓣植入手术操作规范\n能以最快的速度配合主刀医师建立体外循环。\n\n【1】配有 1～2 名麻醉护士搭璜机械臂接接或由专职 人员完成，1～2 名巡回护士，紧绷的护理团队让手 术流程更流畅，紧急情况下及时响应处理能增加患 者安全性。\n\n【2】配有1～2名介入技师，为手术提供高质量的 图像。\n\n【3】### 3 适应证\n\n【4】根据 2020 ACC/AHA 赘膜病管理指南及 2021 ESC/EACTS 赘膜疾病指南，同时相关专题共识及 现有的临床研究经验 删除32:<u>\\[318,323\\]</u>，本方案主要针对 TA-TAVR 治疗主动脉赘狭窄适用和不能。\n\n<mark>【5】删除11:(1)</mark>(1)</u> 高临床手术风险的重度主动脉赘狭窄患者，年 龄>{ 80 岁或外科高危(STS-PROM/ EuroSCORE II > 8%) 或不适合外科手术，推荐 TAVR 治疗。患者 年龄<=80岁，考虑瓣膜预期大性，患者预期寿命， 解剖条件和手术风险等因素,可多学科讨论后与患 者共同决定行TAVR或外科主动脉瓣置换术(surgical aortic valve replacement, SAVR)治疗。\n\n【6】删除11:<u>(2)</u> 中度 AS 患者，有手术指征者，参考上述 年龄和外科风险因素，经过 ESC/EACTS 及 AHA 赘膜 指南20]等建议，应用TAVR 治疗。\n\n【7】删除11:<u>(3)</u> 重度 AS 患者，机般功能欠佳或新 TAVR 并用，推荐 TE-TAVR。如有局限因素件或 (如生 or 楔利解剖因素(如横位心、冠脉阻塞等风险等)， 可考虑行 TA-TAVR。\n\n【8】删除11:<u>(4)</u> 对于外科风险较高的主动脉愈生物瓣或 双生物瓣， 可考虑行常规TAVFR手术。\n\n【9】删除11:<u>(5)</u> 对于心下注产瓣( bicuspid aortic valve, BAV) 患者，手预指参考二叶式或三叶式主动赘， 建议在经验丰富的医院中进行。\n\n【10】删除11:<u>(6)</u> 对于 BAV 患者若赘瓣粘有狭小生主动脉凹直 伞径>45 mm，三叶式主动脉愈案和或扩生主动脉荐 对于主动脉内径<50 mm, 应立jal评分外科风险，如 非外科高危，建议 SAVR 同时处理主动脉额伞，如 外高或手术不高直, 可考虑 TAVR 手术处理主动脉赘 狭滤患者。\n\n【11】### 4 心尖入路经导管主动脉瓣植入术手术操 作流程\n\n【12】术前完善超声心动图、心电门花心血常增摇多 排螺旋 CT、心电图; 实验室检査等项目，将明确否具 Ⅱ存不适应证, 排除手术禁忌，确施瓣膜规格予和 用'\\!\n\n【13】医生对患者进行框栏保存心室范围，准备了（图 2）定位。\n\n【14】删除图片描述:<u>![](2_0.png)</u>\n\n【15】#### 4.1 体位摆放\n\n【16】患者常规取仰位，双臂平放身体两侧，不建议垫枕石，寓背对手术操作起子大大夹角，反而影响耐荧测验和震麻仪直接夹角度电图连选线习患病替合向侧被，体外循环电极放置位置为右侧中央右肋下。在侧位于左侧锁骨中线，第5 胁间以下, 配选坐位於中显疑和或实施于某條皓位置患者（图 02)，洁毒并铺中进行手开胸，随机学验确定，急诊病者胸骨需从简时提取生便等物。远想过心尖切口胸径15 cm以上。髋叶盲损灭野后夹治天需膝胸降护，在例频医生，兄事后胸！上或竟略胸降脉盲开工具浴（根据临时起到导线位置决定)，下导为裂下5cm生石。如女先性者有备洁沫者间用其他脉臀保持心尖要。从中方面孙头或显影叮见反或收。\n\n【17】#### 4.2 锚管器盗装定位器封主增器导管\n\n【18】穿钢一种腰皮皮服编码式删除30:<u>(5French)</u>或c针管,作为选导暂器胶管,穿刺点应在于腰胶分控制(下,),胶狙、胶皮涂防于以下，然前也克侵帽最作用I下值销地，可在起司于手等时,穿。附表", "index": 26, "show": true, "start": 26, "end": 27, "province": ["格式规范性", "多余标点"], "isEdit": false, "comment": "5"}, {"text": " 用’!", "content": "【0】页码:3\n心尖入路经导管主动脉瓣植入手术操作规<mark>{</mark>\n能以最快的速度配合主刀医师建立体外循环。\n\n【1】配有 1～2 名麻醉护士搭璜机械臂接接或由专职 人员完成，1～2 名巡回护士，紧绷的护理团队让手 术流程更流畅，紧急情况下及时响应处理能增加患 者安全性。\n\n【2】配有1～2名介入技师，为手术提供高质量的 图像。\n\n【3】### 3 适应证\n\n【4】根据 2020 ACC/AHA 赘膜病管理指南及 2021 ESC/EACTS 赘膜疾病指南，同时相关专题共识及 现有的临床研究经验 删除32:<u>\\[318,323\\]</u>，本方案主要针对 TA-TAVR 治疗主动脉赘狭窄适用和不能。\n\n<mark>【5】删除11:(1)</mark>(1)</u> 高临床手术风险的重度主动脉赘狭窄患者，年 龄>{ 80 岁或外科高危(STS-PROM/ EuroSCORE II > 8%) 或不适合外科手术，推荐 TAVR 治疗。患者 年龄<=80岁，考虑瓣膜预期大性，患者预期寿命， 解剖条件和手术风险等因素,可多学科讨论后与患 者共同决定行TAVR或外科主动脉瓣置换术(surgical aortic valve replacement, SAVR)治疗。\n\n【6】删除11:<u>(2)</u> 中度 AS 患者，有手术指征者，参考上述 年龄和外科风险因素，经过 ESC/EACTS 及 AHA 赘膜 指南20]等建议，应用TAVR 治疗。\n\n【7】删除11:<u>(3)</u> 重度 AS 患者，机般功能欠佳或新 TAVR 并用，推荐 TE-TAVR。如有局限因素件或 (如生 or 楔利解剖因素(如横位心、冠脉阻塞等风险等)， 可考虑行 TA-TAVR。\n\n【8】删除11:<u>(4)</u> 对于外科风险较高的主动脉愈生物瓣或 双生物瓣， 可考虑行常规TAVFR手术。\n\n【9】删除11:<u>(5)</u> 对于心下注产瓣( bicuspid aortic valve, BAV) 患者，手预指参考二叶式或三叶式主动赘， 建议在经验丰富的医院中进行。\n\n【10】删除11:<u>(6)</u> 对于 BAV 患者若赘瓣粘有狭小生主动脉凹直 伞径>45 mm，三叶式主动脉愈案和或扩生主动脉荐 对于主动脉内径<50 mm, 应立jal评分外科风险，如 非外科高危，建议 SAVR 同时处理主动脉额伞，如 外高或手术不高直, 可考虑 TAVR 手术处理主动脉赘 狭滤患者。\n\n【11】### 4 心尖入路经导管主动脉瓣植入术手术操 作流程\n\n【12】术前完善超声心动图、心电门花心血常增摇多 排螺旋 CT、心电图; 实验室检査等项目，将明确否具 Ⅱ存不适应证, 排除手术禁忌，确施瓣膜规格予和 用'\\!\n\n【13】医生对患者进行框栏保存心室范围，准备了（图 2）定位。\n\n【14】删除图片描述:<u>![](2_0.png)</u>\n\n【15】#### 4.1 体位摆放\n\n【16】患者常规取仰位，双臂平放身体两侧，不建议垫枕石，寓背对手术操作起子大大夹角，反而影响耐荧测验和震麻仪直接夹角度电图连选线习患病替合向侧被，体外循环电极放置位置为右侧中央右肋下。在侧位于左侧锁骨中线，第5 胁间以下, 配选坐位於中显疑和或实施于某條皓位置患者（图 02)，洁毒并铺中进行手开胸，随机学验确定，急诊病者胸骨需从简时提取生便等物。远想过心尖切口胸径15 cm以上。髋叶盲损灭野后夹治天需膝胸降护，在例频医生，兄事后胸！上或竟略胸降脉盲开工具浴（根据临时起到导线位置决定)，下导为裂下5cm生石。如女先性者有备洁沫者间用其他脉臀保持心尖要。从中方面孙头或显影叮见反或收。\n\n【17】#### 4.2 锚管器盗装定位器封主增器导管\n\n【18】穿钢一种腰皮皮服编码式删除30:<u>(5French)</u>或c针管,作为选导暂器胶管,穿刺点应在于腰胶分控制(下,),胶狙、胶皮涂防于以下，然前也克侵帽最作用I下值销地，可在起司于手等时,穿。附表", "index": 74, "show": true, "start": 61, "end": 65, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "12"}, {"text": "【13】医生对患者进行框栏保存心室范围，准备了（图 2）定位。", "content": "【0】页码:3\n心尖入路经导管主动脉瓣植入手术操作规<mark>{</mark>\n能以最快的速度配合主刀医师建立体外循环。\n\n【1】配有 1～2 名<mark> 用’!</mark>搭璜机械臂接接或由专职 人员完成，1～2 名巡回护士，紧绷的护理团队让手 术流程更流畅，紧急情况下及时响应处理能增加患 者安全性。\n\n【2】配有1～2名介入技师，为手术提供高质量的 图像。\n\n【3】### 3 适应证\n\n【4】根据 2020 ACC/AHA 赘膜病管理指南及 2021 ESC/EACTS 赘膜疾病指南，同时相关专题共识及 现有的临床研究经验 删除32:<u>\\[318,323\\]</u>，本方案主要针对 TA-TAVR 治疗主动脉赘狭窄适用和不能。\n\n<mark>【5】删除11:(1)</mark>(1)</u> 高临床手术风险的重度主动脉赘狭窄患者，年 龄>{ 80 岁或外科高危(STS-PROM/ EuroSCORE II > 8%) 或不适合外科手术，推荐 TAVR 治疗。患者 年龄<=80岁，考虑瓣膜预期大性，患者预期寿命， 解剖条件和手术风险等因素,可多学科讨论后与患 者共同决定行TAVR或外科主动脉瓣置换术(surgical aortic valve replacement, SAVR)治疗。\n\n【6】删除11:<u>(2)</u> 中度 AS 患者，有手术指征者，参考上述 年龄和外科风险因素，经过 ESC/EACTS 及 AHA 赘膜 指南20]等建议，应用TAVR 治疗。\n\n【7】删除11:<u>(3)</u> 重度 AS 患者，机般功能欠佳或新 TAVR 并用，推荐 TE-TAVR。如有局限因素件或 (如生 or 楔利解剖因素(如横位心、冠脉阻塞等风险等)， 可考虑行 TA-TAVR。\n\n【8】删除11:<u>(4)</u> 对于外科风险较高的主动脉愈生物瓣或 双生物瓣， 可考虑行常规TAVFR手术。\n\n【9】删除11:<u>(5)</u> 对于心下注产瓣( bicuspid aortic valve, BAV) 患者，手预指参考二叶式或三叶式主动赘， 建议在经验丰富的医院中进行。\n\n【10】删除11:<u>(6)</u> 对于 BAV 患者若赘瓣粘有狭小生主动脉凹直 伞径>45 mm，三叶式主动脉愈案和或扩生主动脉荐 对于主动脉内径<50 mm, 应立jal评分外科风险，如 非外科高危，建议 SAVR 同时处理主动脉额伞，如 外高或手术不高直, 可考虑 TAVR 手术处理主动脉赘 狭滤患者。\n\n【11】### 4 心尖入路经导管主动脉瓣植入术手术操 作流程\n\n【12】术前完善超声心动图、心电门花心血常增摇多 排螺旋 CT、心电图; 实验室检査等项目，将明确否具 Ⅱ存不适应证, 排除手术禁忌，确施瓣膜规格予和 用'\\!\n\n【13】医生对患者进行框栏保存心室范围，准备了（图 2）定位。\n\n【14】删除图片描述:<u>![](2_0.png)</u>\n\n【15】#### 4.1 体位摆放\n\n【16】患者常规取仰位，双臂平放身体两侧，不建议垫枕石，寓背对手术操作起子大大夹角，反而影响耐荧测验和震麻仪直接夹角度电图连选线习患病替合向侧被，体外循环电极放置位置为右侧中央右肋下。在侧位于左侧锁骨中线，第5 胁间以下, 配选坐位於中显疑和或实施于某條皓位置患者（图 02)，洁毒并铺中进行手开胸，随机学验确定，急诊病者胸骨需从简时提取生便等物。远想过心尖切口胸径15 cm以上。髋叶盲损灭野后夹治天需膝胸降护，在例频医生，兄事后胸！上或竟略胸降脉盲开工具浴（根据临时起到导线位置决定)，下导为裂下5cm生石。如女先性者有备洁沫者间用其他脉臀保持心尖要。从中方面孙头或显影叮见反或收。\n\n【17】#### 4.2 锚管器盗装定位器封主增器导管\n\n【18】穿钢一种腰皮皮服编码式删除30:<u>(5French)</u>或c针管,作为选导暂器胶管,穿刺点应在于腰胶分控制(下,),胶狙、胶皮涂防于以下，然前也克侵帽最作用I下值销地，可在起司于手等时,穿。附表", "index": 1188, "show": true, "start": 1149, "end": 1180, "province": ["信息质量", "准确性"], "isEdit": false}, {"text": "【15】#### 4.1 体位摆放\n\n【16】", "content": "【0】页码:3\n心尖入路经导管主动脉瓣植入手术操作规<mark>{</mark>\n能以最快的速度配合主刀医师建立体外循环。\n\n【1】配有 1～2 名<mark> 用’!</mark>搭璜机械臂接接或由专职 人员完成，1～2 名巡回护士，紧绷的护理团队让手 术流程更流畅，紧急情况下及时响应处理能增加患 者安全性。\n\n【2】配有1～2名介入技师，为手术提供高质量的 图像。\n\n【3】### 3 适应证\n\n【4】根据 2020 ACC/AHA 赘膜病管理指南及 2021 ESC/EACTS 赘膜疾病指南，同时相关专题共识及 现有的临床研究经验 删除32:<u>\\[318,323\\]</u>，本方案主要针对 TA-TAVR 治疗主动脉赘狭窄适用和不能。\n\n<mark>【5】删除11:(1)</mark>(1)</u> 高临床手术风险的重度主动脉赘狭窄患者，年 龄>{ 80 岁或外科高危(STS-PROM/ EuroSCORE II > 8%) 或不适合外科手术，推荐 TAVR 治疗。患者 年龄<=80岁，考虑瓣膜预期大性，患者预期寿命， 解剖条件和手术风险等因素,可多学科讨论后与患 者共同决定行TAVR或外科主动脉瓣置换术(surgical aortic valve replacement, SAVR)治疗。\n\n【6】删除11:<u>(2)</u> 中度 AS 患者，有手术指征者，参考上述 年龄和外科风险因素，经过 ESC/EACTS 及 AHA 赘膜 指南20]等建议，应用TAVR 治疗。\n\n【7】删除11:<u>(3)</u> 重度 AS 患者，机般功能欠佳或新 TAVR 并用，推荐 TE-TAVR。如有局限因素件或 (如生 or 楔利解剖因素(如横位心、冠脉阻塞等风险等)， 可考虑行 TA-TAVR。\n\n【8】删除11:<u>(4)</u> 对于外科风险较高的主动脉愈生物瓣或 双生物瓣， 可考虑行常规TAVFR手术。\n\n【9】删除11:<u>(5)</u> 对于心下注产瓣( bicuspid aortic valve, BAV) 患者，手预指参考二叶式或三叶式主动赘， 建议在经验丰富的医院中进行。\n\n【10】删除11:<u>(6)</u> 对于 BAV 患者若赘瓣粘有狭小生主动脉凹直 伞径>45 mm，三叶式主动脉愈案和或扩生主动脉荐 对于主动脉内径<50 mm, 应立jal评分外科风险，如 非外科高危，建议 SAVR 同时处理主动脉额伞，如 外高或手术不高直, 可考虑 TAVR 手术处理主动脉赘 狭滤患者。\n\n【11】### 4 心尖入路经导管主动脉瓣植入术手术操 作流程\n\n【12】术前完善超声心动图、心电门花心血常增摇多 排螺旋 CT、心电图; 实验室检査等项目，将明确否具 Ⅱ存不适应证, 排除手术禁忌，确施瓣膜规格予和 用'\\!\n\n<mark>【13】医生对患者进行框栏保存心室范围，准备了（图 2）定位。</mark>\n\n【14】删除图片描述:<u>![](2_0.png)</u>\n\n【15】#### 4.1 体位摆放\n\n【16】患者常规取仰位，双臂平放身体两侧，不建议垫枕石，寓背对手术操作起子大大夹角，反而影响耐荧测验和震麻仪直接夹角度电图连选线习患病替合向侧被，体外循环电极放置位置为右侧中央右肋下。在侧位于左侧锁骨中线，第5 胁间以下, 配选坐位於中显疑和或实施于某條皓位置患者（图 02)，洁毒并铺中进行手开胸，随机学验确定，急诊病者胸骨需从简时提取生便等物。远想过心尖切口胸径15 cm以上。髋叶盲损灭野后夹治天需膝胸降护，在例频医生，兄事后胸！上或竟略胸降脉盲开工具浴（根据临时起到导线位置决定)，下导为裂下5cm生石。如女先性者有备洁沫者间用其他脉臀保持心尖要。从中方面孙头或显影叮见反或收。\n\n【17】#### 4.2 锚管器盗装定位器封主增器导管\n\n【18】穿钢一种腰皮皮服编码式删除30:<u>(5French)</u>或c针管,作为选导暂器胶管,穿刺点应在于腰胶分控制(下,),胶狙、胶皮涂防于以下，然前也克侵帽最作用I下值销地，可在起司于手等时,穿。附表", "index": 1266, "show": true, "start": 1214, "end": 1237, "comment": "（图 02)", "isEdit": false, "province": ["文本干净度", "无关文本"]}, {"text": "删除30:(5French)", "content": "【0】页码:3\n心尖入路经导管主动脉瓣植入手术操作规<mark>{</mark>\n能以最快的速度配合主刀医师建立体外循环。\n\n【1】配有 1～2 名<mark> 用’!</mark>搭璜机械臂接接或由专职 人员完成，1～2 名巡回护士，紧绷的护理团队让手 术流程更流畅，紧急情况下及时响应处理能增加患 者安全性。\n\n【2】配有1～2名介入技师，为手术提供高质量的 图像。\n\n【3】### 3 适应证\n\n【4】根据 2020 ACC/AHA 赘膜病管理指南及 2021 ESC/EACTS 赘膜疾病指南，同时相关专题共识及 现有的临床研究经验 删除32:<u>\\[318,323\\]</u>，本方案主要针对 TA-TAVR 治疗主动脉赘狭窄适用和不能。\n\n<mark>【5】删除11:(1)</mark>(1)</u> 高临床手术风险的重度主动脉赘狭窄患者，年 龄>{ 80 岁或外科高危(STS-PROM/ EuroSCORE II > 8%) 或不适合外科手术，推荐 TAVR 治疗。患者 年龄<=80岁，考虑瓣膜预期大性，患者预期寿命， 解剖条件和手术风险等因素,可多学科讨论后与患 者共同决定行TAVR或外科主动脉瓣置换术(surgical aortic valve replacement, SAVR)治疗。\n\n【6】删除11:<u>(2)</u> 中度 AS 患者，有手术指征者，参考上述 年龄和外科风险因素，经过 ESC/EACTS 及 AHA 赘膜 指南20]等建议，应用TAVR 治疗。\n\n【7】删除11:<u>(3)</u> 重度 AS 患者，机般功能欠佳或新 TAVR 并用，推荐 TE-TAVR。如有局限因素件或 (如生 or 楔利解剖因素(如横位心、冠脉阻塞等风险等)， 可考虑行 TA-TAVR。\n\n【8】删除11:<u>(4)</u> 对于外科风险较高的主动脉愈生物瓣或 双生物瓣， 可考虑行常规TAVFR手术。\n\n【9】删除11:<u>(5)</u> 对于心下注产瓣( bicuspid aortic valve, BAV) 患者，手预指参考二叶式或三叶式主动赘， 建议在经验丰富的医院中进行。\n\n【10】删除11:<u>(6)</u> 对于 BAV 患者若赘瓣粘有狭小生主动脉凹直 伞径>45 mm，三叶式主动脉愈案和或扩生主动脉荐 对于主动脉内径<50 mm, 应立jal评分外科风险，如 非外科高危，建议 SAVR 同时处理主动脉额伞，如 外高或手术不高直, 可考虑 TAVR 手术处理主动脉赘 狭滤患者。\n\n【11】### 4 心尖入路经导管主动脉瓣植入术手术操 作流程\n\n【12】术前完善超声心动图、心电门花心血常增摇多 排螺旋 CT、心电图; 实验室检査等项目，将明确否具 Ⅱ存不适应证, 排除手术禁忌，确施瓣膜规格予和 用'\\!\n\n<mark>【13】医生对患者进行框栏保存心室范围，准备了（图 2）定位。</mark>\n\n【14】删除图片描述:<u>![](2_0.png)</u>\n\n<mark>【15】#### 4.1 体位摆放\n\n【16】</mark>患者常规取仰位，双臂平放身体两侧，不建议垫枕石，寓背对手术操作起子大大夹角，反而影响耐荧测验和震麻仪直接夹角度电图连选线习患病替合向侧被，体外循环电极放置位置为右侧中央右肋下。在侧位于左侧锁骨中线，第5 胁间以下, 配选坐位於中显疑和或实施于某條皓位置患者（图 02)，洁毒并铺中进行手开胸，随机学验确定，急诊病者胸骨需从简时提取生便等物。远想过心尖切口胸径15 cm以上。髋叶盲损灭野后夹治天需膝胸降护，在例频医生，兄事后胸！上或竟略胸降脉盲开工具浴（根据临时起到导线位置决定)，下导为裂下5cm生石。如女先性者有备洁沫者间用其他脉臀保持心尖要。从中方面孙头或显影叮见反或收。\n\n【17】#### 4.2 锚管器盗装定位器封主增器导管\n\n【18】穿钢一种腰皮皮服编码式删除30:<u>(5French)</u>或c针管,作为选导暂器胶管,穿刺点应在于腰胶分控制(下,),胶狙、胶皮涂防于以下，然前也克侵帽最作用I下值销地，可在起司于手等时,穿。附表", "index": 1637, "show": true, "start": 1572, "end": 1586, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 16:32:56", "endTime": "2024/08/06 16:38:42", "cost": 346.448}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:38:42", "grab_time": "2024-08-06 00:32:56"}
{"id": 2211694, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "d86d797d-b95c-42cc-9bf6-6820ff32c8a6", "title": "（2024.V1）NCCN临床实践指南：甲状腺癌(1)", "text": "【0】页码:150\n（2024.V1）NCCN临床实践指南：甲状腺癌(1)\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】疑似页眉<u># NCCN Guidelines Version 1.2024 Thyroid Carcinoma</u>\n\n【2】参考删除-3:<u>536. Savvides P, Nagaiah G, Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 2013;23:600-604删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/23113752]</u>.</u></u>\n\n【3】参考删除-3:<u>537. Perri F, Lorenzo GD, Scarpati GD, Buonemà C. Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol 2011;2:150-157删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/21611089]</u>.</u></u>\n\n【4】参考删除-3:<u>538. Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol 2008;20:19-24删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/18043252]</u>.</u></u>\n\n【5】参考删除-3:<u>539. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009;19:233-240删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/19265494]</u>.</u></u>\n\n【6】参考删除-3:<u>540. Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010;20:975-980删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/20718683]</u>.</u></u>\n\n【7】参考删除-3:<u>541. Bible KC, Suman VJ, Menefee ME, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 2012;97:3179-3184删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/22774206]</u>.</u></u>\n\n【8】参考删除-3:<u>542. Antonelli A, Fallahi P, Ulisse S, et al. New targeted therapies for anaplastic thyroid cancer. Anticancer Agents Med Chem 2012;12:87-93删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/22043992]</u>.</u></u>\n\n【9】参考删除-3:<u>543. Sosa JA, Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 2014;24:232-240删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/2371245]</u>.</u></u>\n\n【10】参考删除-3:<u>544. De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:1137-1143删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/15519785]</u>.</u></u>\n\n【11】参考删除-3:<u>545. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:2372-2375删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/3664425]</u>.</u></u>\n\n【12】参考删除-3:<u>546. Mohebati A, Dilorenzo M, Palmer F, et al. Anaplastic thyroid carcinoma: a 25-year single-institution experience. Ann Surg Oncol 2014;21:1665-1670删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/24554064]</u>.</u></u>\n\n【13】参考删除-3:<u>547. Derbel O, Limem S, Segura-Ferlay C, et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 2011;11:469删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/22044775]</u>.</u></u>\n\n【14】参考删除-3:<u>548. Wallin G, Lundell G, Tennvall J. Anaplastic giant cell thyroid carcinoma. Scand J Surg 2004;93:272-277删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/15658667]</u>.</u></u>\n\n【15】参考删除-3:<u>549. Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2012;97:2566-2572删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/22869844]</u>.</u></u>\n\n【16】参考删除-3:<u>550. Bhatia A, Rao A, Ang KK, et al. Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy. Head Neck 2010;32:829-836删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/19885894]</u>.</u></u>\n\n【17】参考删除-3:<u>551. Sun XS, Sun SR, Guevara N, et al. Chemoradiation in anaplastic thyroid carcinomas. Crit Rev Oncol Hematol 2013;86:290-301删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/233218594]</u>.</u></u>\n\n【18】参考删除-3:<u>552. Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer Radiother 2011;15:555-559删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/21802333]</u>.</u></u>", "tags": {}, "lang": "en", "attr": {"page_num": 150, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2024.V1）NCCN临床实践指南：甲状腺癌(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:26:55", "endTime": "2024/08/06 16:27:00", "cost": 5.454}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:27:01", "grab_time": "2024-08-06 00:26:48"}
{"id": 2211693, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "ae841021-66d5-4c73-aa8f-660935286ad9", "title": "中枢神经系统肿瘤_2023.V1_EN (2)", "text": "【0】页码:71\n中枢神经系统肿瘤_2023.V1_EN (2)\n疑似页眉<u># NCCN Guidelines Version 1.2023 Metastatic Spine Tumors</u>\n\n【1】删除32:<u>**</u>FOLLOW-UP删除32:<u>**</u>\n\n【2】删除32:<u>**</u>PRESENTATION删除32:<u>**</u>  \n(Symptom- or MRI-based)\n\n【3】删除32:<u>**</u>TREATMENT FOR RECURRENCE OR PROGRESSIVE DISEASE删除32:<u>**</u>\n\n【4】Spine MRI/CT'd 1–3 mo after treatment, then every 3–4 mo for 1 y, then as clinically indicated\n\n【5】删除图片描述:<u>![](70_1.png) gressive disease or Recurrent disease</u>\n\n【6】删除图片描述:<u>![](70_0.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 71, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/中枢神经系统肿瘤_2023.V1_EN (2).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【4】Spine MRI/CT’d 1–3 mo after treatment, then every 3–4 mo for 1 y, then as clinically indicated", "content": "【0】页码:71\n中枢神经系统肿瘤_2023.V1_EN (2)\n疑似页眉<u># NCCN Guidelines Version 1.2023 Metastatic Spine Tumors</u>\n\n【1】删除32:<u>**</u>FOLLOW-UP删除32:<u>**</u>\n\n【2】删除32:<u>**</u>PRESENTATION删除32:<u>**</u>  \n(Symptom- or MRI-based)\n\n【3】删除32:<u>**</u>TREATMENT FOR RECURRENCE OR PROGRESSIVE DISEASE删除32:<u>**</u>\n\n【4】Spine MRI/CT'd 1–3 mo after treatment, then every 3–4 mo for 1 y, then as clinically indicated\n\n【5】删除图片描述:<u>![](70_1.png) gressive disease or Recurrent disease</u>\n\n【6】删除图片描述:<u>![](70_0.png)</u>", "index": -1, "show": true, "start": -1, "end": 96, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/06 17:01:31", "endTime": "2024/08/06 17:02:02", "cost": 31.455}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 01:02:02", "grab_time": "2024-08-06 01:01:31"}
{"id": 2211692, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "6b78b33b-84f0-49c2-bccc-b175eb3f4fb9", "title": "儿童青少年肥胖食养指南（2024+年版）(1)", "text": "【0】页码:24\n儿童青少年肥胖食养指南（2024+年版）(1)\n## 二、西北地区\n\n【1】西北居民喜食面食，主食以小麦、玉米和其它杂粮为主，肉类以牛、羊肉为主，瓜果丰富，绿叶蔬菜相对较少。居民夏季喜清淡素食，冬季喜酸辣咸厚味食品。较多居民日常饮水量不足，对于肥胖人群尤其应保障充足日常饮水量。西北地区儿童青少年肥胖在我国处于中低流行水平，儿童青少年要保证新鲜蔬菜水果、全谷物和杂豆摄入，少用烧烤等烹调方式。西北地区食谱示例如表3.2。\n\n【2】### 表3.2 西北地区食谱示例\n\n【3】#### 冬春季食谱1\n\n| 餐别 | 食品 |\n| :-: | :-: |\n| 早餐 | 牛肉面（面粉60g，牛肉20g，白萝卜20g）<br>水煮鸡蛋（鸡蛋50g）<br>凉拌圆白菜（圆白菜80g） |\n| 中餐 | 杂粮饭（糙米50g，小米20g，玉米渣20g）<br>土豆烧牛肉（牛肉70g，土豆30g）<br>素炒油麦菜（油麦菜100g）<br>西红柿鸡蛋汤（西红柿50g，鸡蛋10g） |\n| 晚餐 | 杂粮馍馍夹肉（荞麦面粉30g，面粉40g）<br>白菜粉条炖豆腐（白菜100g，豆腐40g，粉条10g）<br>羊肉汤（羊瘦肉30g，胡萝卜60g，小葱5g） |\n| 油、盐 | 全天总用量：植物油20g，盐4g |\n| 零食 | 苹果删除30:<u>（200g）</u>，巴旦木删除30:<u>（10g）</u>，低脂牛奶删除30:<u>（300mL）</u> |\n\n【5】#### 冬春季食谱2\n\n| 餐别 | 食品 |\n| :-: | :-: |\n| 早餐 | 红薯山药粥（红薯50g，鲜山药20g，糯米30g）<br>羊肉包子（面粉30g，羊瘦肉20g，洋葱10g）<br>凉拌黄瓜（黄瓜80g） |\n| 中餐 | 拉面（面粉100g）<br>蘑菇炒肉（蘑菇80g，羊肉40g，柿子椒10g）<br>西红柿炒鸡蛋（西红柿100g，鸡蛋40g）<br>萝卜丝虾皮汤（白萝卜30g，虾皮1g） |\n| 晚餐 | 杂粮饭（糙米30g，玉米渣20g）<br>宫保鸡丁（鸡胸肉30g，胡萝卜20g，黄瓜20g, 花生5g）<br>芹菜炒芽干（芹菜100g，豆腐干20g）<br>紫菜蛋花汤（紫菜5g，鸡蛋10g） |\n| 油、盐 | 全天总用量：植物油20g，盐4g |\n| 零食 | 梨删除30:<u>（200g）</u>，低脂牛奶删除30:<u>（300mL）</u>，核花子删除30:<u>（10g）</u> |", "tags": {}, "lang": "zh", "attr": {"page_num": 24, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/儿童青少年肥胖食养指南（2024+年版）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "苹果删除30:（200g），巴旦木删除30:（10g），低脂牛奶删除30:（300mL）", "content": "【0】页码:24\n儿童青少年肥胖食养指南（2024+年版）(1)\n## 二、西北地区\n\n【1】西北居民喜食面食，主食以小麦、玉米和其它杂粮为主，肉类以牛、羊肉为主，瓜果丰富，绿叶蔬菜相对较少。居民夏季喜清淡素食，冬季喜酸辣咸厚味食品。较多居民日常饮水量不足，对于肥胖人群尤其应保障充足日常饮水量。西北地区儿童青少年肥胖在我国处于中低流行水平，儿童青少年要保证新鲜蔬菜水果、全谷物和杂豆摄入，少用烧烤等烹调方式。西北地区食谱示例如表3.2。\n\n【2】### 表3.2 西北地区食谱示例\n\n【3】#### 冬春季食谱1\n\n| 餐别 | 食品 |\n| :-: | :-: |\n| 早餐 | 牛肉面（面粉60g，牛肉20g，白萝卜20g）<br>水煮鸡蛋（鸡蛋50g）<br>凉拌圆白菜（圆白菜80g） |\n| 中餐 | 杂粮饭（糙米50g，小米20g，玉米渣20g）<br>土豆烧牛肉（牛肉70g，土豆30g）<br>素炒油麦菜（油麦菜100g）<br>西红柿鸡蛋汤（西红柿50g，鸡蛋10g） |\n| 晚餐 | 杂粮馍馍夹肉（荞麦面粉30g，面粉40g）<br>白菜粉条炖豆腐（白菜100g，豆腐40g，粉条10g）<br>羊肉汤（羊瘦肉30g，胡萝卜60g，小葱5g） |\n| 油、盐 | 全天总用量：植物油20g，盐4g |\n| 零食 | 苹果删除30:<u>（200g）</u>，巴旦木删除30:<u>（10g）</u>，低脂牛奶删除30:<u>（300mL）</u> |\n\n【5】#### 冬春季食谱2\n\n| 餐别 | 食品 |\n| :-: | :-: |\n| 早餐 | 红薯山药粥（红薯50g，鲜山药20g，糯米30g）<br>羊肉包子（面粉30g，羊瘦肉20g，洋葱10g）<br>凉拌黄瓜（黄瓜80g） |\n| 中餐 | 拉面（面粉100g）<br>蘑菇炒肉（蘑菇80g，羊肉40g，柿子椒10g）<br>西红柿炒鸡蛋（西红柿100g，鸡蛋40g）<br>萝卜丝虾皮汤（白萝卜30g，虾皮1g） |\n| 晚餐 | 杂粮饭（糙米30g，玉米渣20g）<br>宫保鸡丁（鸡胸肉30g，胡萝卜20g，黄瓜20g, 花生5g）<br>芹菜炒芽干（芹菜100g，豆腐干20g）<br>紫菜蛋花汤（紫菜5g，鸡蛋10g） |\n| 油、盐 | 全天总用量：植物油20g，盐4g |\n| 零食 | 梨删除30:<u>（200g）</u>，低脂牛奶删除30:<u>（300mL）</u>，核花子删除30:<u>（10g）</u> |", "index": 570, "show": true, "start": 570, "end": 614, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "3"}, {"text": "梨删除30:（200g），低脂牛奶删除30:（300mL），核花子删除30:（10g）", "content": "【0】页码:24\n儿童青少年肥胖食养指南（2024+年版）(1)\n## 二、西北地区\n\n【1】西北居民喜食面食，主食以小麦、玉米和其它杂粮为主，肉类以牛、羊肉为主，瓜果丰富，绿叶蔬菜相对较少。居民夏季喜清淡素食，冬季喜酸辣咸厚味食品。较多居民日常饮水量不足，对于肥胖人群尤其应保障充足日常饮水量。西北地区儿童青少年肥胖在我国处于中低流行水平，儿童青少年要保证新鲜蔬菜水果、全谷物和杂豆摄入，少用烧烤等烹调方式。西北地区食谱示例如表3.2。\n\n【2】### 表3.2 西北地区食谱示例\n\n【3】#### 冬春季食谱1\n\n| 餐别 | 食品 |\n| :-: | :-: |\n| 早餐 | 牛肉面（面粉60g，牛肉20g，白萝卜20g）<br>水煮鸡蛋（鸡蛋50g）<br>凉拌圆白菜（圆白菜80g） |\n| 中餐 | 杂粮饭（糙米50g，小米20g，玉米渣20g）<br>土豆烧牛肉（牛肉70g，土豆30g）<br>素炒油麦菜（油麦菜100g）<br>西红柿鸡蛋汤（西红柿50g，鸡蛋10g） |\n| 晚餐 | 杂粮馍馍夹肉（荞麦面粉30g，面粉40g）<br>白菜粉条炖豆腐（白菜100g，豆腐40g，粉条10g）<br>羊肉汤（羊瘦肉30g，胡萝卜60g，小葱5g） |\n| 油、盐 | 全天总用量：植物油20g，盐4g |\n| 零食 | <mark>苹果删除30:（200g），巴旦木删除30:（10g），低脂牛奶删除30:（300mL）</mark>牛奶删除30:<u>（300mL）</u> |\n\n【5】#### 冬春季食谱2\n\n| 餐别 | 食品 |\n| :-: | :-: |\n| 早餐 | 红薯山药粥（红薯50g，鲜山药20g，糯米30g）<br>羊肉包子（面粉30g，羊瘦肉20g，洋葱10g）<br>凉拌黄瓜（黄瓜80g） |\n| 中餐 | 拉面（面粉100g）<br>蘑菇炒肉（蘑菇80g，羊肉40g，柿子椒10g）<br>西红柿炒鸡蛋（西红柿100g，鸡蛋40g）<br>萝卜丝虾皮汤（白萝卜30g，虾皮1g） |\n| 晚餐 | 杂粮饭（糙米30g，玉米渣20g）<br>宫保鸡丁（鸡胸肉30g，胡萝卜20g，黄瓜20g, 花生5g）<br>芹菜炒芽干（芹菜100g，豆腐干20g）<br>紫菜蛋花汤（紫菜5g，鸡蛋10g） |\n| 油、盐 | 全天总用量：植物油20g，盐4g |\n| 零食 | 梨删除30:<u>（200g）</u>，低脂牛奶删除30:<u>（300mL）</u>，核花子删除30:<u>（10g）</u> |", "index": 1009, "show": true, "start": 996, "end": 1039, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "5"}], "startTime": "2024/08/06 16:29:20", "endTime": "2024/08/06 16:29:58", "cost": 38.651}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:29:59", "grab_time": "2024-08-06 00:29:20"}
{"id": 2211691, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "307c5364-d838-4adf-9c0b-a571707264c0", "title": "2022 ESC指南：接受非心脏手术患者的心血管评估和管理", "text": "【0】页码:69\n2022 ESC指南：接受非心脏手术患者的心血管评估和管理\n删除图片描述:<u>![](68_0.png)</u>\n\n【1】### 8.1. Peri-operative myocardial infarction/injury\n\n【2】Peri-operative MI (PMI) is defined as acute cardiomyocyte injury (post-operative hs-cTn T/I release) with or without accompanying symptoms, and with or without ECG or imaging evidence of acute myocardial ischaemia. Peri-operative MI can only be reliably and rapidly detected using PMI surveillance with hs-cTn T/I measurements before and serially after surgery (e.g. 24 and 48 h post-operatively). In the BASEL-PMI study, 15% of patients with pre-existing CAD/PAD or aged ≥65 years undergoing major NCS developed PMI. As most PMI occurs during the operation itself or in the immediate post-operative period, during which high doses of anaesthetics and/or analgesics are required, ~90% of patients with PMI do not report typical symptoms and are therefore missed in routine clinical practice. This is of major concern, as the mortality risk associated with PMI is also high in patients without symptoms. Similarly, the mortality risk associated with PMI is high in patients without additional ECG and/or imaging evidence of myocardial ischaemia. Overall, 30 day mortality in patients developing PMI is ~10.8%.\n\n【3】No single intervention has yet been proven to be unequivocally beneficial in the prevention of PMI.\n\n【4】It is important to highlight that PMI is not a homogenous disease. Several different pathophysiologies and clinical phenotypes may underlie PMI. At least one additional criterion (ischaemic pain; ischaemic ECG changes, imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology; and thrombus in coronary", "tags": {}, "lang": "en", "attr": {"page_num": 69, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2022 ESC指南：接受非心脏手术患者的心血管评估和管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】### 8.1. Peri-operative myocardial infarction/injury", "content": "【0】页码:69\n2022 ESC指南：接受非心脏手术患者的心血管评估和管理\n删除图片描述:<u>![](68_0.png)</u>\n\n【1】### 8.1. Peri-operative myocardial infarction/injury\n\n【2】Peri-operative MI (PMI) is defined as acute cardiomyocyte injury (post-operative hs-cTn T/I release) with or without accompanying symptoms, and with or without ECG or imaging evidence of acute myocardial ischaemia. Peri-operative MI can only be reliably and rapidly detected using PMI surveillance with hs-cTn T/I measurements before and serially after surgery (e.g. 24 and 48 h post-operatively). In the BASEL-PMI study, 15% of patients with pre-existing CAD/PAD or aged ≥65 years undergoing major NCS developed PMI. As most PMI occurs during the operation itself or in the immediate post-operative period, during which high doses of anaesthetics and/or analgesics are required, ~90% of patients with PMI do not report typical symptoms and are therefore missed in routine clinical practice. This is of major concern, as the mortality risk associated with PMI is also high in patients without symptoms. Similarly, the mortality risk associated with PMI is high in patients without additional ECG and/or imaging evidence of myocardial ischaemia. Overall, 30 day mortality in patients developing PMI is ~10.8%.\n\n【3】No single intervention has yet been proven to be unequivocally beneficial in the prevention of PMI.\n\n【4】It is important to highlight that PMI is not a homogenous disease. Several different pathophysiologies and clinical phenotypes may underlie PMI. At least one additional criterion (ischaemic pain; ischaemic ECG changes, imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology; and thrombus in coronary", "index": 68, "show": true, "start": 68, "end": 123, "province": ["信息质量", "完整性"], "isEdit": false}, {"text": " ~10.8%.", "content": "【0】页码:69\n2022 ESC指南：接受非心脏手术患者的心血管评估和管理\n删除图片描述:<u>![](68_0.png)</u>\n\n<mark>【1】### 8.1. Peri-operative myocardial infarction/injury</mark>\n\n【2】Peri-operative MI (PMI) is defined as acute cardiomyocyte injury (post-operative hs-cTn T/I release) with or without accompanying symptoms, and with or without ECG or imaging evidence of acute myocardial ischaemia. Peri-operative MI can only be reliably and rapidly detected using PMI surveillance with hs-cTn T/I measurements before and serially after surgery (e.g. 24 and 48 h post-operatively). In the BASEL-PMI study, 15% of patients with pre-existing CAD/PAD or aged ≥65 years undergoing major NCS developed PMI. As most PMI occurs during the operation itself or in the immediate post-operative period, during which high doses of anaesthetics and/or analgesics are required, ~90% of patients with PMI do not report typical symptoms and are therefore missed in routine clinical practice. This is of major concern, as the mortality risk associated with PMI is also high in patients without symptoms. Similarly, the mortality risk associated with PMI is high in patients without additional ECG and/or imaging evidence of myocardial ischaemia. Overall, 30 day mortality in patients developing PMI is ~10.8%.\n\n【3】No single intervention has yet been proven to be unequivocally beneficial in the prevention of PMI.\n\n【4】It is important to highlight that PMI is not a homogenous disease. Several different pathophysiologies and clinical phenotypes may underlie PMI. At least one additional criterion (ischaemic pain; ischaemic ECG changes, imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology; and thrombus in coronary", "index": 1241, "show": true, "start": 1228, "end": 1236, "province": ["语法规范性", "错别字"], "isEdit": false, "comment": "【2】~10%."}], "startTime": "2024/08/06 17:08:17", "endTime": "2024/08/06 17:09:16", "cost": 58.283}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 01:09:16", "grab_time": "2024-08-06 01:08:17"}
{"id": 2211690, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "ebe966e7-2bec-4430-8c96-7041568bd400", "title": "嗅觉相关的过敏和鼻科学的共识声明（2022）", "text": "【0】页码:341\n嗅觉相关的过敏和鼻科学的共识声明（2022）\n(本页删除)本页被模型判断为参考页## Table 1. Summary of Clinical Trials on Olfactory Dysfunction\n\n| Study | Sample Size | Population | Treatment | Outcome |\n|-------|-------------|------------|-----------|---------|\n| Aiba et al., 1998 | 20 | Post-traumatic anosmia | Steroid | Improvement in 40% of patients |\n| Kitano et al., 1997 | 15 | Post-viral anosmia | Zinc sulfate | Significant improvement in olfactory threshold |\n| Altundag et al., 2012 | 23 | Post-traumatic olfactory dysfunction | Vitamin A | Improved olfactory function |\n\n【2】### Clinical Trials on Treatment of Post-traumatic Olfactory Dysfunction\n\n【3】- 删除32:<u>**</u>Aiba T., Sugiura M., Mori J., et al. 删除11:<u>删除19:<u>(1998)</u></u>删除32:<u>**</u>: Conducted a study on the effect of zinc sulfate on sensorineural olfactory disorder. The results indicated a significant improvement in olfactory threshold in patients treated with zinc sulfate compared to the control group.\n- 删除32:<u>**</u>Kitano M., Kobayashi M., Miyamura T., et al. 删除11:<u>删除19:<u>(1997)</u></u>删除32:<u>**</u>: Investigated the prognostic factors for olfactory dysfunction after head injury. The study identified that the olfactory threshold significantly improved in patients who received zinc sulfate treatment.\n- 删除32:<u>**</u>Ikeda K., Sakurada T., Takasaka T., et al. 删除11:<u>删除19:<u>(1995)</u></u>删除32:<u>**</u>: Explored the clinical study of steroid treatment for post-traumatic anosmia. Preliminary results indicated an improvement in olfactory function in a subset of patients.\n\n【4】### Long-term Management of Chronic Rhinosinusitis\n\n【5】1. 删除32:<u>**</u>Bachert C., Han JK., Desrosiers M., et al. 删除11:<u>删除19:<u>(2016)</u></u>删除32:<u>**</u>: Evaluated the efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps. Results from the randomized phase 3 study demonstrated significant improvement in nasal polyp score and symptom relief.\n2. 删除32:<u>**</u>Gever J., Omachi TA., Corren J., et al. 删除11:<u>删除19:<u>(2020)</u></u>删除32:<u>**</u>: Conducted two randomized phase 3 trials on the efficacy and safety of omalizumab in nasal polyposis. The studies confirmed a reduction in nasal polyp size and an improvement in symptoms.\n\n【6】### Factors Influencing Olfactory Recovery in Chronic Rhinosinusitis\n\n【7】- 删除32:<u>**</u>Schlosser RJ., Smith TL., Mace JC., et al. 删除11:<u>删除19:<u>(2020)</u></u>删除32:<u>**</u>: Investigated various factors affecting olfactory loss in patients with chronic rhinosinusitis. The case-control study highlighted the significance of early intervention and the role of medical management in olfactory recovery.\n- 删除32:<u>**</u>Banglawala SM., Oyer SL., Lohia S., et al. 删除11:<u>删除19:<u>(2014)</u></u>删除32:<u>**</u>: Performed a systematic review and meta-analysis on the olfactory outcomes in chronic rhinosinusitis patients after medical treatment. The analysis underscored the efficacy of corticosteroids in enhancing olfactory function.\n\n【8】### Advanced Therapies for Allergic Rhinitis and Associated Olfactory Dysfunction\n\n【9】- 删除32:<u>**</u>Klimek L., Pollet C., Spriet A., et al. 删除11:<u>删除19:<u>(2017)</u></u>删除32:<u>**</u>: Assessed olfaction in patients with allergic rhinitis as an indicator of successful MP-AzeFlu therapy. The study concluded that patients showed significant improvement in olfactory function post-treatment.\n- 删除32:<u>**</u>Stuck BA., Blum A., Hager A., et al. 删除11:<u>删除19:<u>(2003)</u></u>删除32:<u>**</u>: Demonstrated that intranasal budesonide aqueous spray improves olfactory performance in patients with seasonal allergic rhinitis.\n\n【10】### Conclusion\n\n【11】Advancements in the treatment of olfactory dysfunction, particularly post-traumatic and chronic rhinosinusitis-related conditions, have shown promising results with the use of steroids, zinc sulfate, and newer biologics like dupilumab. Further research is necessary to explore long-term outcomes and refine treatment protocols to enhance patient quality of life.", "tags": {}, "lang": "en", "attr": {"page_num": 341, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/嗅觉相关的过敏和鼻科学的共识声明（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:17:45", "endTime": "2024/08/06 18:19:48", "cost": 3722.741}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 02:19:48", "grab_time": "2024-08-06 01:17:45"}
{"id": 2211689, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "cf3886c8-e89a-49b8-9891-7cdf8424dcb7", "title": "ERS：成人哮喘的诊断指南（2022）", "text": "【0】页码:144\nERS：成人哮喘的诊断指南（2022）\n疑似页眉<u>### Undesirable Effects\n删除32:<u>**</u>How substantial are the undesirable anticipated effects?删除32:<u>**</u></u>\n\n| JUDGEMENT | RESEARCH EVIDENCE | ADDITIONAL CONSIDERATIONS |\n| --------- | ----------------- | ------------------------- |\n| ○ Large   |                   |                           |\n| ○ Moderate|                   |                           |\n| ○ Small   |                   |                           |\n| 删除32:<u>**</u>X Trivial删除32:<u>**</u> | No major undesirable effects of bronchial challenge testing. Mannitol is known to cause cough. Histamine can cause flushing, rashes. These are short lasting and reversible. |                           |\n| ○ Varies  |                   |                           |\n| ○ Don't know |                |                           |\n\n【2】### Certainty of the evidence of test accuracy\n删除32:<u>**</u>What is the overall certainty of the evidence of test accuracy?删除32:<u>**</u>\n\n| JUDGEMENT | RESEARCH EVIDENCE | ADDITIONAL CONSIDERATIONS |\n| --------- | ----------------- | ------------------------- |\n| ○ Very low |                   |                           |\n| 删除32:<u>**</u>X Low删除32:<u>**</u> | For diagnosing asthma – moderate certainty |                           |\n| 删除32:<u>**</u>X Moderate删除32:<u>**</u> | For excluding asthma – low certainty, specificity is highly variable from 0.12-1 |                           |\n| ○ High |                    |                           |\n| ○ No included studies |   |                           |\n\n【4】### Certainty of the evidence of management's effects\n删除32:<u>**</u>What is the overall certainty of the evidence of effects of the management that is guided by the test results?删除32:<u>**</u>\n\n| JUDGEMENT | RESEARCH EVIDENCE | ADDITIONAL CONSIDERATIONS |\n| --------- | ----------------- | ------------------------- |\n| ○ Very low |                   |                           |\n| ○ Low |                       |                           |\n| ○ Moderate |                   |                           |\n| 删除32:<u>**</u>X High删除32:<u>**</u> | In the presence of a current symptoms, a positive bronchial challenge test will give a high confidence of initiating asthma management. |                           |\n| ○ No included studies |    |                           |\n\n【6】### Certainty of the evidence of test result/management", "tags": {}, "lang": "en", "attr": {"page_num": 144, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ERS：成人哮喘的诊断指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "疑似页眉### Undesirable Effects", "content": "【0】页码:144\nERS：成人哮喘的诊断指南（2022）\n疑似页眉<u>### Undesirable Effects\n删除32:<u>**</u>How substantial are the undesirable anticipated effects?删除32:<u>**</u></u>\n\n| JUDGEMENT | RESEARCH EVIDENCE | ADDITIONAL CONSIDERATIONS |\n| --------- | ----------------- | ------------------------- |\n| ○ Large   |                   |                           |\n| ○ Moderate|                   |                           |\n| ○ Small   |                   |                           |\n| 删除32:<u>**</u>X Trivial删除32:<u>**</u> | No major undesirable effects of bronchial challenge testing. Mannitol is known to cause cough. Histamine can cause flushing, rashes. These are short lasting and reversible. |                           |\n| ○ Varies  |                   |                           |\n| ○ Don't know |                |                           |\n\n【2】### Certainty of the evidence of test accuracy\n删除32:<u>**</u>What is the overall certainty of the evidence of test accuracy?删除32:<u>**</u>\n\n| JUDGEMENT | RESEARCH EVIDENCE | ADDITIONAL CONSIDERATIONS |\n| --------- | ----------------- | ------------------------- |\n| ○ Very low |                   |                           |\n| 删除32:<u>**</u>X Low删除32:<u>**</u> | For diagnosing asthma – moderate certainty |                           |\n| 删除32:<u>**</u>X Moderate删除32:<u>**</u> | For excluding asthma – low certainty, specificity is highly variable from 0.12-1 |                           |\n| ○ High |                    |                           |\n| ○ No included studies |   |                           |\n\n【4】### Certainty of the evidence of management's effects\n删除32:<u>**</u>What is the overall certainty of the evidence of effects of the management that is guided by the test results?删除32:<u>**</u>\n\n| JUDGEMENT | RESEARCH EVIDENCE | ADDITIONAL CONSIDERATIONS |\n| --------- | ----------------- | ------------------------- |\n| ○ Very low |                   |                           |\n| ○ Low |                       |                           |\n| ○ Moderate |                   |                           |\n| 删除32:<u>**</u>X High删除32:<u>**</u> | In the presence of a current symptoms, a positive bronchial challenge test will give a high confidence of initiating asthma management. |                           |\n| ○ No included studies |    |                           |\n\n【6】### Certainty of the evidence of test result/management", "index": 30, "show": true, "start": 30, "end": 57, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "页眉判断错误 【0】"}], "startTime": "2024/08/07 10:10:52", "endTime": "2024/08/07 10:11:58", "cost": 65.191}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 18:11:57", "grab_time": "2024-08-06 18:10:51"}
{"id": 2211688, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "bd4ec8e7-3d0b-43e2-a0df-efb9c7eeec98", "title": "骨质疏松分子生物学研究专家共识(1)", "text": "【0】页码:6\n骨质疏松分子生物学研究专家共识(1)\n(本页删除)本页被模型判断为参考页2 型糖尿病和骨质疏松性骨折的相关性研究删除12:<u>[J]</u>. 同济大学学报(医学生命版), 删除13:<u>2014, 35</u>删除11:<u>(6)</u>: 580-84.\n\n【1】明英美, 黄丽琴, 罗云燕, 等. MTHFR 基因多态性与妊娠晚期经后高龄妇女骨质疏松的相关性研究删除12:<u>[J]</u>. 实用骨科杂志, 删除13:<u>2016, 22</u>删除11:<u>(4)</u>: 328-331.\n\n【2】参考删除-3:<u>Kenji O, Tadahiro I, Yuji M, et al. Short-term/intermittent administration of parathyroid hormone facilitates osteogenesis by different mechanisms in cancellous and cortical bone 删除12:<u>[J]</u>. Bone Rep, 2016, 5: 74-74.</u>\n\n【3】张德增, 任作智. 骨密度 诊断删除12:<u>[M]</u>. 北京: 化学工业出版社, 2020: 274.\n\n【4】王莉, 李桂红, 肖蔚, 等. 雌激素及抗雌激素类药物雌激素在体内骨质疏松的相关性删除12:<u>[J]</u>. 中国临床康复, 2001, 8删除11:<u>(27)</u>: 5901-5903.\n\n【5】赵行博, 李泽华, 聂晓蓉, 等. Apel 与骨质疏松相关性的研究进展删除12:<u>[J]</u>. 中国骨质疏松杂志, 删除13:<u>2023, 29</u>删除11:<u>(10)</u>: 1544-1549.\n\n【6】王琳, 马向凯, 袁宇卓, 等. Klotho 蛋白与 Wnt 信号通路在骨代谢中的研究进展删除12:<u>[J]</u>. 国际老年医学杂志, 删除13:<u>2023, 44</u>删除11:<u>(3)</u>: 351-353.\n\n【7】姜泽, 潘煜, 邢道溥, 等. 部分骨碎补含泌调节骨再生的临床研究进展删除12:<u>[J]</u>. 中国骨质疏松杂志, 删除13:<u>2022, 28</u>删除11:<u>(8)</u>: 1228-1231.\n\n【8】参考删除-3:<u>Dab S, Abdelhaly N, Figueroa CA, et al. Characterization of SIBLING proteins in the mineralized tissues删除12:<u>[J]</u>. Dent J Basel, 删除13:<u>2022, 10</u>删除11:<u>(8)</u>: 144.</u>\n\n【9】参考删除-3:<u>Son A, Kang K, Nung KT, et al. TRPM3/TRPV4 regulates $Ca^{2+}$- mediated RANKL/NFATc1 expression in osteoblasts 删除12:<u>[J]</u>. J Mol Endocrinol, 删除13:<u>2018, 61</u>删除11:<u>(4)</u>: 207-218.</u>\n\n【10】曾锦敏, 邵小宁. 常温责任破骨细胞分化和骨吸收中的研究进展删除12:<u>[J]</u>. 海南医学学院学报, 删除13:<u>2023, 29</u>删除11:<u>(18)</u>: 1425-1429.\n\n【11】牛燕, 王丽, 杨丽霞, 蔡蓉. 低温应激自噬相关性蛋白 3 调节骨细胞作用机制及其转 唤因系研究进展删除12:<u>[J]</u>. 山东医药, 删除13:<u>2022, 62</u>删除11:<u>(32)</u>: 101-104.\n\n【12】司良仓, 张晓雅, 陈嘉晴, 滑洁丽. 走在骨作相关性信号通过路中的作用研究进展删除12:<u>[J]</u>. 新乡医学院学报, 删除13:<u>2023, 40</u>删除11:<u>(1)</u>: 97-100.\n\n【13】参考删除-3:<u>Shukeri A, Adanty C. Romososumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: A review 删除12:<u>[J]</u>. J Popul Ther Clin Pharmacol, 删除13:<u>2020, 27</u>删除11:<u>(1)</u>: e25-e31.</u>\n\n【14】韦家林, 林勇, 颜贤萍, 等. 硼化氮对白骨特性作用机制的研究删除12:<u>[J]</u>. 中国骨质疏松杂志, 删除13:<u>2022, 28</u>删除11:<u>(8)</u>: 1244-1248.\n\n【15】参考删除-3:<u>Zhao FJ, Zhang ZB, Ma N, et al. Untargeted metabolomics using liquid chromatography coupled with mass spectrometry for rapid discovery of metabolic biomarkers to reveal therapeutic effects of Psoraleacorylifolia seeds against osteoporosis删除12:<u>[J]</u>. RSC Advances, 2019, 9删除11:<u>(61)</u>: 35429-35442.</u>\n\n【16】黄月影, 蒋成会. 骨折知识的专家知识库显示不同单层 解除分子物分析的作用删除12:<u>[J]</u>. 解放军医学杂志, 删除13:<u>2019, 44</u>删除11:<u>(3)</u>: 215-221.\n\n【17】参考删除-3:<u>Zhou Y, Xie Q. Total glycosides from Eucommia ulmoides seed promote osteogenic differentiation of adipose-derived mesenchymal stem cells and bone formation in ovariectomized rats through regulating Notch signaling pathway 删除12:<u>[J]</u>. J Orthop Surg Res, 删除13:<u>2021, 16</u>删除11:<u>(1)</u>: 660.</u>\n\n【18】程建林, 赵玉燕, 游华. 环境污染物骨质疏松中的微与情骨折综合的影响删除12:<u>[J]</u>. 中国骨质疏松杂志, 删除13:<u>2021, 27</u>删除11:<u>(12)</u>: 1717-1725.\n\n【19】程华，李婧，谢婵婷，等. Wnt/β-catenin信号通路在骨再生及骨质疏松中的作用和研究进展删除12:<u>[J]</u>. 中国民族医药杂志，删除13:<u>2023, 29</u>删除11:<u>(7)</u>: 71-76.\n\n【20】郭宇, 汪洪尧, 刘文, 等. Wnt /β-catenin 信号通路在骨质疏松治疗中的研究进展删除12:<u>[J]</u>. 南京医科大学学报，删除13:<u>2021, 41</u>删除11:<u>(3)</u>: 460-464.\n\n【21】参考删除-3:<u>Cummings SR, San martin J, Meclung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis删除12:<u>[J]</u>. N Eng J Med, 删除13:<u>2009, 361</u>: 756-765.</u>\n\n【22】参考删除-3:<u>Cosman F, Crittenden DB, Adachi JD, et al. Romosozumabtreatment in postmenopausal women withosteoporosis删除12:<u>[J]</u>. N Eng J Med, 2016 375: 1532-1543.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/骨质疏松分子生物学研究专家共识(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:29:52", "endTime": "2024/08/06 15:29:59", "cost": 6.799}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:29:59", "grab_time": "2024-08-05 23:29:52"}
{"id": 2211687, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "b69406c8-8098-47b7-90be-43cdc783bf0d", "title": "2023 WHO 指南：疟疾", "text": "【0】页码:414\n2023 WHO 指南：疟疾\n删除图片描述:<u>![](413_0.png)</u>\n\n【1】删除图片描述:<u>![](413_1.png)</u>", "tags": {}, "lang": "None", "attr": {"page_num": 414, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 WHO 指南：疟疾.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:414\n\n2023 WHO 指南：疟疾", "content": "【0】页码:414\n2023 WHO 指南：疟疾\n删除图片描述:<u>![](413_0.png)</u>\n\n【1】删除图片描述:<u>![](413_1.png)</u>", "index": 0, "show": true, "start": 0, "end": 25, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/07 09:51:10", "endTime": "2024/08/07 09:51:31", "cost": 20.501}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 17:51:30", "grab_time": "2024-08-06 17:51:09"}
{"id": 2211686, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "00f00a29-7bd1-45ea-8eb2-dcf338996403", "title": "2023 ASFA指南：治疗性单采术的临床应用（第9版）", "text": "【0】页码:96\n2023 ASFA指南：治疗性单采术的临床应用（第9版）\n(本页删除)本页被模型判断为参考页### Duration and discontinuation/number of procedures\n\n【1】The typical length of treatment is 5 to 10 weeks for Adacolumn and 5 weeks for Cellsorba. Aforementioned case series utilized ECP on the following schedules, respectively: twice weekly, every week for 4 weeks, followed by twice weekly, every other week for 7 weeks and two ECP treatments every two weeks for 24-weeks.\n\n【2】删除32:<u>**</u>Keywords:删除32:<u>**</u> Adacolumn, Cellsorba, granulocyte and monocyte adsorption apheresis, leukocytapheresis, selective apheresis, adoptive cytapheresis, granulocyte monocyte adsorptive apheresis, leukocytapheresis, Crohn's disease, ulcerative colitis, inflammatory bowel disease", "tags": {}, "lang": "en", "attr": {"page_num": 96, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ASFA指南：治疗性单采术的临床应用（第9版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:51:48", "endTime": "2024/08/06 15:51:57", "cost": 9.637}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:51:58", "grab_time": "2024-08-05 23:51:48"}
{"id": 2211685, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "eb85cbe6-b5d9-405f-84d3-dc8554b35b71", "title": "2024更新—2016 NICE指南：结核病（NG.33）", "text": "【0】页码:88\n2024更新—2016 NICE指南：结核病（NG.33）\n1.8.11.5 Public Health England, working with the Local Government Association and their special interest groups, should consider working with national housing organisations such as the Chartered Institute of Housing, Homeless Link, Sitra and the National Housing Federation to raise the profile of TB. This is to ensure people with TB are considered a priority for housing. 删除24:<u>[new 2016]</u>\n\n【1】1.8.11.6 Consider training housing commissioners and frontline staff on TB and the need for housing support, so that they understand that a stable home life is a prerequisite to successful TB treatment. 删除24:<u>[new 2016]</u>\n\n【2】## Terms used in this guideline\n\n【3】### Active case-finding\n\n【4】Systematically identifying people with active or latent TB using tests, examinations or other procedures.\n\n【5】### Adherence\n\n【6】The term adherence refers to the person's ability or willingness to keep to a treatment regimen as directed.\n\n【7】### Adults\n\n【8】People aged 18 or older.\n\n【9】### Case management\n\n【10】Case management involves follow-up of a person suspected or confirmed to have TB. It needs a collaborative, multidisciplinary approach and should start as soon as possible after a suspected case is discovered.\n\n【11】### Case manager\n\n【12】Standard and enhanced case management is overseen by a case manager who will usually be a specialist TB nurse or (in low-incidence areas) a nurse with responsibilities that", "tags": {}, "lang": "en", "attr": {"page_num": 88, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024更新—2016 NICE指南：结核病（NG.33）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:38:56", "endTime": "2024/08/06 16:39:17", "cost": 21.247}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:39:17", "grab_time": "2024-08-06 00:38:56"}
{"id": 2211684, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "3d42a66c-48c4-4601-b7d2-bd190b8d49e6", "title": "腰椎间盘突出症中西医结合诊疗专家共识", "text": "【0】页码:7\n腰椎间盘突出症中西医结合诊疗专家共识\n(本页删除)本页被模型判断为参考页删除图片描述:<u>![](6_0.png)</u>\n\n【1】瑞金医院)、李再海（福建中医药大学)、林燕樵（福建中医药大学)、王文昕（复旦大学附属华东医院)、王培民（江苏省中医院)、王上增（河南省中医 院)、魏大付（中国中医科学院西苑医院)、徐自会 (复旦大学附属华山医院)、杨景利（宁夏回族自治区医医院)、杨锋（陕西中医药大学附属医院)、杨锋（驻顺市中医院)、姚唯杞（辽宁省中医院)、郑志坚（北 京京医院)\n\n【2】李荣有委员：杭明瑛（上海中医药大学附属龙华医院)。\n\n【3】### 学术秘书:\n参考文献\n\n【4】删除14:<u>[1] </u>KREINER DS, HWANG SW, EASA JE, et al. An evidence-based clinical guideline for the diagnosis and treatment of lumbar disc herniation with radioculopathy删除12:<u>[J]</u>. Spine J, 删除13:<u>2014, 14</u> 删除11:<u>(1)</u> :180-191.\n\n【5】删除14:<u>[2] </u>李荣惠、张于扬. 筛查疼痛的简激发皮文放音复习(下)删除12:<u>[J]</u>. 风烟病与芳关梦,2016.６删除11:<u>(５)</u>:519-76.\n\n【6】删除14:<u>[3] </u>DEYO RA, MIRZA SK, CLINICAL PRACTICE. Herniated Lumbar Intervertebral Disk删除12:<u>[J]</u>. N Engl J Med, 删除13:<u>2016, 374</u> 删除11:<u>(18)</u> :1763-1772.\n\n【7】参考删除-3:<u>删除12:<u>删除14:<u>[4]</u></u> DRISCOLL T, JACKLYN G, ORCHARD J, et al. The global burden of occupationally related low back pain: estimates from the Global Burden of Disease 2010 study删除12:<u>[J]</u>. Ann Rheum Dis, 删除13:<u>2014, 73</u> 删除11:<u>(6)</u> :975-981.</u>\n\n【8】删除14:<u>[5] </u>ROPPER AH, ZAFONTE RD. Sciatica删除12:<u>[J]</u>. N Engl J Med, 删除13:<u>2015, 372</u>删除11:<u>(13)</u> :1240-1248.\n\n【9】删除14:<u>[6] </u>趋杰、毕锋和、善影. 基于结筛查带的背外阳活动痛来对腰椎间盘突出患者近腰背蚯的影响删除12:<u>[J]</u>. 中至安物分科学本，2020，26删除11:<u>(8)</u> : 124-129.\n\n【10】删除14:<u>[7] </u>PARKER SL, GODIL SS, MENDENHALL SK, et al. Two-year comprehensive medical management of degenerative lumbar spine disease (lumbar spondylolisthesis, stenosis, or disc herniation) : a value analysis of cost, pain, disability, and quality of life: clinical article删除12:<u>[J]</u>. J Neurosurg Spine,删除13:<u>2014, 21</u>删除11:<u>(2)</u> :143-149.\n\n【11】删除14:<u>[8] </u>贾平肌. 腰椎间盘突出症的危险因数分析删除12:<u>[J]</u>. 中国当代医药. 2016,23删除11:<u>(22)</u>:180-182.\n\n【12】参考删除-3:<u>删除12:<u>删除14:<u>[9]</u></u> MANCHIKANTI L, HIRSCH JA. Clinical management of radicular pain删除12:<u>[J]</u>. Expert Rev Neurother, 2015,15删除11:<u>(6)</u>:681-693.</u>\n\n【13】删除14:<u>[10] </u>余晓艳、史旭前, 刘荣. 市分老腰椎椎体普生症筛查污染危险因家分析删除12:<u>[J]</u>. 湖南师范大学学报:医学科. 2018,15删除11:<u>(5)</u> :101-104.\n\n【14】参考删除-3:<u>删除12:<u>删除14:<u>[11]</u></u> VAN DER WINDT DA, SIMONS E, RIPHAGEN II, et al. Physical examination for lumbar radiculopathy due to disc herniation in patients with low-back pain删除12:<u>[J]</u>. Cochrane Database Syst Rev, 删除13:<u>2010, 17</u>删除11:<u>(2)</u>:CD007431.</u>\n\n【15】参考删除-3:<u>删除12:<u>删除14:<u>[12]</u></u> BOOZ C, NÖSKEJ, MARTIN SS, et al. Virtual Noncalcium Dual-Energy CT: Detection of Lumbar Disk Herniation in Comparison with Standard Gray-scale CT删除12:<u>[J]</u>. Radiology, 删除13:<u>2019, 290</u>删除11:<u>(2)</u>:446-455.</u>\n\n【16】参考删除-3:<u>删除12:<u>删除14:<u>[13]</u></u> YOUSIF S, MUSA A, AHMED A, et al. Correlation between Find-ings in Physical Examination, Magnetic Resonance Imaging, and Nerve Conduction Studies in Lumbosacral Radiculopathy Caused by Lumbar Intervertebral Disc Herniation删除12:<u>[J]</u>. Adv Orthop, 2020: 9791831.</u>\n\n【17】参考删除-3:<u>删除12:<u>删除14:<u>[14]</u></u> QIE S, LI W, LI X, et al. Electromyography activities in patients with lower lumbar disc herniation删除12:<u>[J]</u>. J Back Musculoskelet Rehabil. 2020,33删除11:<u>(4)</u> :589-596.</u>\n\n【18】参考删除-3:<u>删除12:<u>删除14:<u>[15]</u></u> PETERSEN T, LASLETT M, JUHL C. Clinical classification in low back pain: best-evidence diagnostic rules based on systematic reviews删除12:<u>[J]</u>. BMC Musculoskelet Disord, 删除13:<u>2017, 18</u> 删除11:<u>(1)</u> :188.</u>\n\n【19】参考删除-3:<u>删除12:<u>删除14:<u>[16]</u></u> KIM HJ, VAN RUM RM, VAN TULDER MW, et al. Diagnostic ac-curacy of diagnostic imaging for lumbar disc herniation in adults with low back pain or sciatica: a systematic review删除12:<u>[J]</u>. Chiropractic and Man Therap, 删除13:<u>2018, 26</u>:37.</u>\n\n【20】删除14:<u>[17] </u>杨荷芳, 世界茶, 杨敏. 殷如以开放大学治疗70 阵腰椎间盘突出症剂3穴对比删除12:<u>[J]</u>. 中华癌症医学杂志, 删除13:<u>2017, 23</u>删除11:<u>(8)</u> : 622-624.\n\n【21】参考删除-3:<u>删除12:<u>删除14:<u>[18]</u></u> FARDON DF, WILLIAMS AL, DOHRING EJ, et al. Lumbar disc nomenclature, version 2.0: Recommendations of the combined task forces of the North American Spine Society, the American Society of Spine Radiology and the American Society of Neuroradiology删除12:<u>[J]</u>. Spine J, 删除13:<u>2014, 14</u>删除11:<u>(11)</u> : 2525-2545.</u>\n\n【22】参考删除-3:<u>删除12:<u>删除14:<u>[19]</u></u> LIN YJ, LIN Y, CHEN W, et al. Role of the Lumbosacral Transition Vertebra and Vertebral Lamina in the Pathogenesis of Lumbar Disc Herniation删除12:<u>[J]</u>. Orthop Surg, 删除13:<u>2021, 13</u>删除11:<u>(8)</u> :2355-2362.</u>\n\n【23】参考删除-3:<u>删除12:<u>删除14:<u>[20]</u></u> DAHM KT, BRUBERG KG, JAMTVEDT G, et al. Advice to rest in bed versus advice to stay active for low-back pain and sciatica[J.] Cochrane Database Syst Rev, 2010 删除11:<u>(6)</u>: CD007612.</u>\n\n【24】参考删除-3:<u>删除12:<u>删除14:<u>[21]</u></u> DM MATTI A, TEJANI S, HALL T. Bed Rest for Sciatica; A Closer Look at the Evidence删除12:<u>[J]</u>. J Orthop Sports Phys Ther,删除13:<u>2018, 48</u>删除11:<u>(6)</u>: 436-438.</u>\n\n【25】删除14:<u>[22] </u>邱乾水, 刘啊, 陈 琪琪, 等. 脏格筋便对腰椎生理曲度影响的影像学研究删除12:<u>[J]</u>. 广东医学, 2018,39删除11:<u>(2)</u>: 84-85,88.\n\n【26】删除14:<u>[23] </u>哑他说, 蒋友. 腰椎间盘突出的临床诊治删除12:<u>[J]</u>. 中图临床医生杂志, 2018,46删除11:<u>(12)</u>:1387-1389.\n\n【27】参考删除-3:<u>删除12:<u>删除14:<u>[24]</u></u> RASMUSSEN-BARR E, HELD U, GROOTEN WJ, et al. Non-ster-oidal anti-inflammatory drugs for sciatica删除12:<u>[J]</u>. Cochrane Database Syst Rev, 2016,10删除11:<u>(10)</u> :CD012382.</u>\n\n【28】删除14:<u>[25] </u>GASTALDI R, DURAND M, ROUSITT M, et al. Short-Term Effica-mericy and Tolerance of Ketoprofen and Methylprednisolone in Acute Sciatica: A Randomized Trial删除12:<u>[J]</u>. Pain Med, 删除13:<u>2019, 20</u> 删除11:<u>(7)</u>: 1294-1299.\n\n【29】参考删除-3:<u>删除12:<u>删除14:<u>[26]</u></u> ABRISHAMKAR S, RAFIEI AR, SABOURI M, et al. The effect of impregnated autologous epidural adipose tissue with bupivacine with methylprednisolone acetate or normal saline on postoperative radicular and low back pain in lumbar disc surgery under spinal anes-thia; A randomized clinical trial study删除12:<u>[J]</u>. J Res Med Sci, 删除13:<u>2011, 16</u> 删除11:<u>(5)</u> :621-626.</u>\n\n【30】参考删除-3:<u>删除12:<u>删除14:<u>[27]</u></u> DOLGUN H, TURKOGLU E, KERTMEN H, et al. Gabapentin ver-sus pregabalin in relieving early post-surgical neuropathic pain in paients after lumbar disc herniation surgery: a prospective clinical trial删除12:<u>[J]</u>. Neurol Res, 2014,36删除11:<u>(12)</u> :1080-1085.</u>\n\n【31】参考删除-3:<u>删除12:<u>删除14:<u>[28]</u></u> QASEEM A, WILT TJ, MCLEAN RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians删除12:<u>[J]</u>. Ann Intern Med,2017,166删除11:<u>(7)</u>:514-530.</u>\n\n【32】疑似页脚<u>删除12:<u>删除14:<u>[29]</u></u> ISNER-HOROBETI ME, DUFOUR SP, SCHAEFFERT M, et al. High-Force Versus Low-Force Lumbar Traction in Acute Lumbar</u>", "tags": {}, "lang": "en", "attr": {"page_num": 7, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/腰椎间盘突出症中西医结合诊疗专家共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:06:13", "endTime": "2024/08/06 16:09:05", "cost": 172.812}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-06 00:09:06", "grab_time": "2024-08-06 00:06:12"}
{"id": 2211683, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "59c3c70f-83c2-48a0-a3a2-6c1efdda6104", "title": "2021年欧洲克罗恩病和结肠炎组织炎症性肠病感染的预防、诊断和管理指南解读", "text": "【0】页码:5\n2021年欧洲克罗恩病和结肠炎组织炎症性肠病感染的预防、诊断和管理指南解读\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】# 5 小 结\n\n【2】IBD患者本身常存在营养不良、合并其他疾病等感染的高危因素，加之免疫抑制剂的应用是IBD疾病缓解的重要一环，使其不可避免的成为了机会性感染的好发人群①。感染性IBD治疗方案的选择受限，增大控制感染的难度，直接影响了患者的疗效及预后。新版指南详细阐述了各类病毒感染、细菌感染、寄生虫和真菌感染的防治方案，尤其对应用免疫抑制剂的患者进行了免疫抑制程度分层并提供了操作流程的推荐建议，为IBD患者机会性感染的管理提供了规范性的临床指引。\n\n【3】## [参考文献]\n\n【4】参考删除-3:<u>1. Osterman MT. Sandborn WJ. Colombel JF. et al. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab删除12:<u>[J]</u>. Am J Gastroenterol. 2016.111删除11:<u>(12)</u>:1806-1815.</u>\n\n【5】参考删除-3:<u>2. Tosca J. Garcia-N. Pascual I.et al. Clinical assessment of risk factors for infection in inflammatory bowel disease patients删除12:<u>[J]</u>. Int J Colorectal Dis. 2020.35删除11:<u>(3)</u>:491-500.</u>\n\n【6】参考删除-3:<u>3. Park SH. Yang SK. Park SK. et al. Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease]. Inflamm Bowel Dis.2014.20删除11:<u>(1)</u>:69-74.</u>\n\n【7】参考删除-3:<u>4. Khuroo MS. Khuroo NS. Hepatitis E, discovery, global impact, control and cure删除12:<u>[J]</u>. World J Gastroenterol. 2016.22删除11:<u>(31)</u>:7030-7045.</u>\n\n【8】参考删除-3:<u>5. Hahn KJ. Kohil A. Sims Z. et al. Durable sustained virologic response after oral directly acting antiviral therapy despite immunosuppressive treatment删除12:<u>[J]</u>. Open Forum Infect Dis. 2015.2删除11:<u>(3)</u>:ofv091.</u>\n\n【9】参考删除-3:<u>6. Chamberlain FE. Dinani N. Jagjit Singh GK. et al. Azathioprine can be safely used in HIV-infected individuals删除12:<u>[J]</u>. AIDS. 2014.28删除11:<u>(3)</u>:447-448.</u>\n\n【10】参考删除-3:<u>7. Fink DL. Hedley L. Miller RF. Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals删除12:<u>[J]</u>. Int J Std Aids. 2017.28删除11:<u>(2)</u>:110-119.</u>\n\n【11】参考删除-3:<u>8. Caldera F. Wasan S. Farraye F. et al. Caution when assessing immunity to varicella through antibody testing in patients with inflammatory bowel disease删除12:<u>[J]</u>. Inflamm Bowel Dis. 2017.23删除11:<u>(10)</u>:E50-E51.</u>\n\n【12】参考删除-3:<u>9. Allocca M. Fiorino G. Zallot C. et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the nancy and milan cohorts删除12:<u>[J]</u>. Clin Gastroenterol Hepatol. 2020.18删除11:<u>(9)</u>:2134-2135.</u>\n\n【13】参考删除-3:<u>10. An P. Ji M. Ren H. et al. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan.China删除12:<u>[J]</u>. Lancet Gastroenterol Hepatol.2020.5删除11:<u>(6)</u>:525-527.</u>\n\n【14】参考删除-3:<u>11. Rao K. Malani PN. Diagnosis and treatment of clostridioides (Clostridium) difficile infection in adults in 2020[J]. JAMA. 2020.323删除11:<u>(14)</u>:1403-1404.</u>\n\n【15】参考删除-3:<u>12. Louie T. Miller M. Mullane K. et al. Fidaxomicin versus vancomycin for Clostridium difficile infection删除12:<u>[J]</u>. N Engl J Med.2011.364删除11:<u>(5)</u>:422-431.</u>\n\n【16】参考删除-3:<u>13. Cornely O. Crook D. Esposito R. et al. Fidaxomicin versus vancomycin for infection with clostridium difficile in Europe, Canada. and the USA: a double-blind. non-inferiority. randomised controlled trial删除12:<u>[J]</u>. Lancet Infect Dis. 2012.12删除11:<u>(4)</u>:281-289.</u>\n\n【17】参考删除-3:<u>14. Furer V. Rondaan C. Heijstek MW. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases删除12:<u>[J]</u>．Ann Rheum Dis.2020.79删除11:<u>(1)</u>:39-52.</u>\n\n【18】15. Piovanti D. Danese S. Peyrin-Biroulet L. et al. Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease删除12:<u>[J]</u>. AIDS.2020.51删除11:<u>(9)</u>:820-830.\n\n【19】（本文编辑：杜娟娟）", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2021年欧洲克罗恩病和结肠炎组织炎症性肠病感染的预防、诊断和管理指南解读.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】# 5 小 结\n\n【2】IBD患者本身常存在营养不良、合并其他疾病等感染的高危因素，加之免疫抑制剂的应用是IBD疾病缓解的重要一环，使其不可避免的成为了机会性感染的好发人群①。感染性IBD治疗方案的选择受限，增大控制感染的难度，直接影响了患者的疗效及预后。新版指南详细阐述了各类病毒感染、细菌感染、寄生虫和真菌感染的防治方案，尤其对应用免疫抑制剂的患者进行了免疫抑制程度分层并提供了操作流程的推荐建议，为IBD患者机会性感染的管理提供了规范性的临床指引。", "content": "【0】页码:5\n2021年欧洲克罗恩病和结肠炎组织炎症性肠病感染的预防、诊断和管理指南解读\n<mark>(本页删除)</mark>本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】# 5 小 结\n\n【2】IBD患者本身常存在营养不良、合并其他疾病等感染的高危因素，加之免疫抑制剂的应用是IBD疾病缓解的重要一环，使其不可避免的成为了机会性感染的好发人群①。感染性IBD治疗方案的选择受限，增大控制感染的难度，直接影响了患者的疗效及预后。新版指南详细阐述了各类病毒感染、细菌感染、寄生虫和真菌感染的防治方案，尤其对应用免疫抑制剂的患者进行了免疫抑制程度分层并提供了操作流程的推荐建议，为IBD患者机会性感染的管理提供了规范性的临床指引。\n\n【3】## [参考文献]\n\n【4】参考删除-3:<u>1. Osterman MT. Sandborn WJ. Colombel JF. et al. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab删除12:<u>[J]</u>. Am J Gastroenterol. 2016.111删除11:<u>(12)</u>:1806-1815.</u>\n\n【5】参考删除-3:<u>2. Tosca J. Garcia-N. Pascual I.et al. Clinical assessment of risk factors for infection in inflammatory bowel disease patients删除12:<u>[J]</u>. Int J Colorectal Dis. 2020.35删除11:<u>(3)</u>:491-500.</u>\n\n【6】参考删除-3:<u>3. Park SH. Yang SK. Park SK. et al. Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease]. Inflamm Bowel Dis.2014.20删除11:<u>(1)</u>:69-74.</u>\n\n【7】参考删除-3:<u>4. Khuroo MS. Khuroo NS. Hepatitis E, discovery, global impact, control and cure删除12:<u>[J]</u>. World J Gastroenterol. 2016.22删除11:<u>(31)</u>:7030-7045.</u>\n\n【8】参考删除-3:<u>5. Hahn KJ. Kohil A. Sims Z. et al. Durable sustained virologic response after oral directly acting antiviral therapy despite immunosuppressive treatment删除12:<u>[J]</u>. Open Forum Infect Dis. 2015.2删除11:<u>(3)</u>:ofv091.</u>\n\n【9】参考删除-3:<u>6. Chamberlain FE. Dinani N. Jagjit Singh GK. et al. Azathioprine can be safely used in HIV-infected individuals删除12:<u>[J]</u>. AIDS. 2014.28删除11:<u>(3)</u>:447-448.</u>\n\n【10】参考删除-3:<u>7. Fink DL. Hedley L. Miller RF. Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals删除12:<u>[J]</u>. Int J Std Aids. 2017.28删除11:<u>(2)</u>:110-119.</u>\n\n【11】参考删除-3:<u>8. Caldera F. Wasan S. Farraye F. et al. Caution when assessing immunity to varicella through antibody testing in patients with inflammatory bowel disease删除12:<u>[J]</u>. Inflamm Bowel Dis. 2017.23删除11:<u>(10)</u>:E50-E51.</u>\n\n【12】参考删除-3:<u>9. Allocca M. Fiorino G. Zallot C. et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the nancy and milan cohorts删除12:<u>[J]</u>. Clin Gastroenterol Hepatol. 2020.18删除11:<u>(9)</u>:2134-2135.</u>\n\n【13】参考删除-3:<u>10. An P. Ji M. Ren H. et al. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan.China删除12:<u>[J]</u>. Lancet Gastroenterol Hepatol.2020.5删除11:<u>(6)</u>:525-527.</u>\n\n【14】参考删除-3:<u>11. Rao K. Malani PN. Diagnosis and treatment of clostridioides (Clostridium) difficile infection in adults in 2020[J]. JAMA. 2020.323删除11:<u>(14)</u>:1403-1404.</u>\n\n【15】参考删除-3:<u>12. Louie T. Miller M. Mullane K. et al. Fidaxomicin versus vancomycin for Clostridium difficile infection删除12:<u>[J]</u>. N Engl J Med.2011.364删除11:<u>(5)</u>:422-431.</u>\n\n【16】参考删除-3:<u>13. Cornely O. Crook D. Esposito R. et al. Fidaxomicin versus vancomycin for infection with clostridium difficile in Europe, Canada. and the USA: a double-blind. non-inferiority. randomised controlled trial删除12:<u>[J]</u>. Lancet Infect Dis. 2012.12删除11:<u>(4)</u>:281-289.</u>\n\n【17】参考删除-3:<u>14. Furer V. Rondaan C. Heijstek MW. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases删除12:<u>[J]</u>．Ann Rheum Dis.2020.79删除11:<u>(1)</u>:39-52.</u>\n\n【18】15. Piovanti D. Danese S. Peyrin-Biroulet L. et al. Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease删除12:<u>[J]</u>. AIDS.2020.51删除11:<u>(9)</u>:820-830.\n\n【19】（本文编辑：杜娟娟）", "index": 109, "show": true, "start": 96, "end": 326}], "startTime": "2024/08/06 15:31:01", "endTime": "2024/08/06 15:31:38", "cost": 37.431}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:15", "update_time": "2024-08-05 23:31:38", "grab_time": "2024-08-05 23:31:00"}
{"id": 2211682, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "aea96b19-d1f1-4c65-b04d-1347b5c21728", "title": "e1f423b0329dc933048fbf5521bb0912(1)", "text": "【0】页码:6\ne1f423b0329dc933048fbf5521bb0912(1)\n#### Confirmed diagnosis of Desmoid tumor\n\n【1】删除32:<u>**</u>Life-threatening localization/complication删除32:<u>**</u>\n- Mesenteric tumor $\\geq 10$ cm\n- Vascular compression (ilio/pelvic cava)\n- Urologic compressions\n\n【2】删除32:<u>**</u>Refere to an expert center if possible删除32:<u>**</u>\n\n【3】删除32:<u>**</u>Medical treatment +/- Surgery of a complication删除32:<u>**</u>\n\n【4】删除32:<u>**</u>First line Surgery of a small parietal tumor is strongly discouraged删除32:<u>**</u>\n\n【5】删除32:<u>**</u>Active surveillance删除32:<u>**</u>\n- MRI $\\pm$ 1-2 m$\\mu$ then after 3 months then every 6 months for 2 years\n\n【6】删除32:<u>**</u>Confirmed tumor progression删除32:<u>**</u> (if possible 0.2 exams) or symptomatic tumor\n\n【7】删除32:<u>**</u>Multidisciplinary Management in an expert center删除32:<u>**</u>\n\n【8】删除32:<u>**</u>Surveillance删除32:<u>**</u> (imaging/physical examination) / 12 months\n\n【9】删除32:<u>**</u>Propose an inclusion in a clinical trial if possible删除32:<u>**</u>\n\n【10】删除32:<u>**</u>Medical treatment or cryotherapy删除32:<u>**</u>\n- Surgery (preferentially in a referent center)\n- Cryotherapy\n\n【11】删除32:<u>**</u>Stabilization删除32:<u>**</u>\n- Progression\n\n【12】删除32:<u>**</u>Medical treatment删除32:<u>**</u>\n- According to the benefit/risk balance\n- Chemotherapy or targeted therapy\n\n【13】#### 3.2.4. What are the best indications for surgery in case of progression?\n\n【14】DT of the abdominal wall represents a very good indication if the tumor progresses significantly despite medical treatment 删除12:<u>删除14:<u>[29]</u></u>. In particular when the tumor is $\\geq 10$ cm. If the size of the lesion is between 5 and 10 cm and it remains progressive between two images, we can discuss either cryotherapy or medical treatment. If the progression continues, a parietectomy-type surgery can be proposed. Despite mutilation brought by an abdominal parietectomy in a young woman prone to be pregnant, a complete surgery is easily accessible and remains well supported. In particular if the reconstruction is of good quality, future pregnancies are possible even with an abdominal plate. Overall, between 15 and 20% of patients with DT of the abdominal wall end up undergoing surgery 删除12:<u>删除14:<u>[36]</u></u>. As the tumor most often infiltrates the muscle in its entire thickness, it is usually a parietal removing the affected muscle with replacement of the wall by a plate fixed behind the remaining muscles. On the microscopic level, the impact of the margins has only been studied on old series which mixed indolent and evolving DT. Moreover, the poorly limited nature of these tumors and the limited number of sections do not always allow to be retrospectively precise on the completeness of the resection. By mixing different evolutionary forms with more or less precise anatomicalpathological analyses studies differ on the impact of these margins on the risk of recurrence. As regulated surgery is now aimed at grossly resecting tumors, it is possible that having negative margins is favorable, these being found as a prognostic factor in anatomical study 删除12:<u>删除14:<u>[37]</u></u>.\n\n【15】Regarding lateral retro-peritoneal locations, which frequently involve the iliac vessels and the ureter, surgery should only be considered when it can be macroscopically complete and as a second-line treatment after induction medical treatment. Radiation therapy is an alternative to discuss when possible and considering the patient's age 删除9:<u>(see below; 删除12:<u>删除14:<u>[38]</u></u>)</u>.\n\n【16】Regarding mesenteric locations, potentially responsible for ischemia and occlusion, surgery is discussed if the medical treatment is ineffective, focusing on situations where complete excision can be performed without major functional damage. Digestive segmental resections leaving macroscopic remnants in place should only be performed on a case-by-case basis after discussion in a specialized center.\n\n【17】#### 3.2.5. Recommendations regarding the use of surgery for desmoid tumors\n\n【18】- Surgery is not indicated in 1$^{st}$ line other than in the situation of a mechanical complication (recommendation: grade A).\n- In the event of a complication and a tumor that is difficult to resect or with a risk of mutilating surgery, the tumor must be", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/e1f423b0329dc933048fbf5521bb0912(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Confirmed diagnosis of Desmoid tumor\n【1】删除32:Life-threatening localization/complication删除32:\n\nMesenteric tumor \n≥\n10\n cm\nVascular compression (ilio/pelvic cava)\nUrologic compressions\n【2】删除32:Refere to an expert center if possible删除32:\n\n【3】删除32:Medical treatment +/- Surgery of a complication删除32:\n\n【4】删除32:First line Surgery of a small parietal tumor is strongly discouraged删除32:\n\n【5】删除32:Active surveillance删除32:\n\nMRI \n±\n 1-2 m\n𝜇\n then after 3 months then every 6 months for 2 years\n【6】删除32:Confirmed tumor progression删除32: (if possible 0.2 exams) or symptomatic tumor\n\n【7】删除32:Multidisciplinary Management in an expert center删除32:\n\n【8】删除32:Surveillance删除32: (imaging/physical examination) / 12 months\n\n【9】删除32:Propose an inclusion in a clinical trial if possible删除32:\n\n【10】删除32:Medical treatment or cryotherapy删除32:\n\nSurgery (preferentially in a referent center)\nCryotherapy\n【11】删除32:Stabilization删除32:\n\nProgression\n【12】删除32:Medical treatment删除32:\n\nAccording to the benefit/risk balance\nChemotherapy or targeted therapy", "content": "【0】页码:6\ne1f423b0329dc933048fbf5521bb0912(1)\n#### Confirmed diagnosis of Desmoid tumor\n\n【1】删除32:<u>**</u>Life-threatening localization/complication删除32:<u>**</u>\n- Mesenteric tumor $\\geq 10$ cm\n- Vascular compression (ilio/pelvic cava)\n- Urologic compressions\n\n【2】删除32:<u>**</u>Refere to an expert center if possible删除32:<u>**</u>\n\n【3】删除32:<u>**</u>Medical treatment +/- Surgery of a complication删除32:<u>**</u>\n\n【4】删除32:<u>**</u>First line Surgery of a small parietal tumor is strongly discouraged删除32:<u>**</u>\n\n【5】删除32:<u>**</u>Active surveillance删除32:<u>**</u>\n- MRI $\\pm$ 1-2 m$\\mu$ then after 3 months then every 6 months for 2 years\n\n【6】删除32:<u>**</u>Confirmed tumor progression删除32:<u>**</u> (if possible 0.2 exams) or symptomatic tumor\n\n【7】删除32:<u>**</u>Multidisciplinary Management in an expert center删除32:<u>**</u>\n\n【8】删除32:<u>**</u>Surveillance删除32:<u>**</u> (imaging/physical examination) / 12 months\n\n【9】删除32:<u>**</u>Propose an inclusion in a clinical trial if possible删除32:<u>**</u>\n\n【10】删除32:<u>**</u>Medical treatment or cryotherapy删除32:<u>**</u>\n- Surgery (preferentially in a referent center)\n- Cryotherapy\n\n【11】删除32:<u>**</u>Stabilization删除32:<u>**</u>\n- Progression\n\n【12】删除32:<u>**</u>Medical treatment删除32:<u>**</u>\n- According to the benefit/risk balance\n- Chemotherapy or targeted therapy\n\n【13】#### 3.2.4. What are the best indications for surgery in case of progression?\n\n【14】DT of the abdominal wall represents a very good indication if the tumor progresses significantly despite medical treatment 删除12:<u>删除14:<u>[29]</u></u>. In particular when the tumor is $\\geq 10$ cm. If the size of the lesion is between 5 and 10 cm and it remains progressive between two images, we can discuss either cryotherapy or medical treatment. If the progression continues, a parietectomy-type surgery can be proposed. Despite mutilation brought by an abdominal parietectomy in a young woman prone to be pregnant, a complete surgery is easily accessible and remains well supported. In particular if the reconstruction is of good quality, future pregnancies are possible even with an abdominal plate. Overall, between 15 and 20% of patients with DT of the abdominal wall end up undergoing surgery 删除12:<u>删除14:<u>[36]</u></u>. As the tumor most often infiltrates the muscle in its entire thickness, it is usually a parietal removing the affected muscle with replacement of the wall by a plate fixed behind the remaining muscles. On the microscopic level, the impact of the margins has only been studied on old series which mixed indolent and evolving DT. Moreover, the poorly limited nature of these tumors and the limited number of sections do not always allow to be retrospectively precise on the completeness of the resection. By mixing different evolutionary forms with more or less precise anatomicalpathological analyses studies differ on the impact of these margins on the risk of recurrence. As regulated surgery is now aimed at grossly resecting tumors, it is possible that having negative margins is favorable, these being found as a prognostic factor in anatomical study 删除12:<u>删除14:<u>[37]</u></u>.\n\n【15】Regarding lateral retro-peritoneal locations, which frequently involve the iliac vessels and the ureter, surgery should only be considered when it can be macroscopically complete and as a second-line treatment after induction medical treatment. Radiation therapy is an alternative to discuss when possible and considering the patient's age 删除9:<u>(see below; 删除12:<u>删除14:<u>[38]</u></u>)</u>.\n\n【16】Regarding mesenteric locations, potentially responsible for ischemia and occlusion, surgery is discussed if the medical treatment is ineffective, focusing on situations where complete excision can be performed without major functional damage. Digestive segmental resections leaving macroscopic remnants in place should only be performed on a case-by-case basis after discussion in a specialized center.\n\n【17】#### 3.2.5. Recommendations regarding the use of surgery for desmoid tumors\n\n【18】- Surgery is not indicated in 1$^{st}$ line other than in the situation of a mechanical complication (recommendation: grade A).\n- In the event of a complication and a tumor that is difficult to resect or with a risk of mutilating surgery, the tumor must be", "index": 49, "show": true, "start": 49, "end": 1071, "province": ["信息质量", "有用性-轻"], "isEdit": false}], "startTime": "2024/08/06 16:13:23", "endTime": "2024/08/06 16:14:09", "cost": 45.846}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:14:09", "grab_time": "2024-08-06 00:13:23"}
{"id": 2211681, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "cafae25c-48cd-4314-8012-fd05cca12d2b", "title": "2023 ASFA指南：治疗性单采术的临床应用（第9版）", "text": "【0】页码:191\n2023 ASFA指南：治疗性单采术的临床应用（第9版）\n## VASCULITIS, ANCA-ASSOCIATED\n\n【1】删除32:<u>**</u>Incidence:删除32:<u>**</u> 1 to 3/100,000/year (geographical, age, and ethnic differences)\n\n| Indication                                 | Procedure | Category | Grade |\n|--------------------------------------------|-----------|----------|-------|\n| Microscopic polyangiitis                   | TPE       | III      | 1B    |\n| Granulomatosis with polyangiitis           |           | III      |       |\n| Eosinophilic granulomatosis with polyangiitis | TPE       | III      | 2C    |\n\n| # reported patients: >300      | RCT     | CT      | CS    | CR   |\n|--------------------------------|---------|---------|-------|------|\n|                                | 10 删除11:<u>删除19:<u>(1091)</u></u>| 5 删除11:<u>(345)</u> | NA    | NA   |\n\n|删除段内换行|## Description\n\n【5】The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA; 25%-40%), microscopic polyangiitis (MPA; 45%-65%), and eosinophilic granulomatosis with polyangiitis (EGPA; 10%-20%). These diseases affect small- and medium-sized vessels and are characterized by multisystem organ involvement, commonly impacting the kidneys (70%; typically exhibiting rapidly progressive glomerulonephritis (RPGN) with high risk of end stage kidney disease (ESKD)), lungs (> 50% at onset; can range from asymptomatic pulmonary lesions to life-threatening diffuse alveolar hemorrhage (DAH)), ear-nose-throat, joints, skin and nerves. Overlapping features between AAV subtypes occur. GPA is characterized by necrotizing granulomatous inflammation and is typically associated with cytoplasmic ANCA and antibodies to proteinase 3. GPA carries a higher risk for relapsing disease. MPA is characterized by vasculitis without granulomatous inflammation, and is most commonly associated with perinuclear ANCA and antibodies to myeloperoxidase. EGPA is rarely associated with RPGN or DAH. The presentation of the pulmonary-renal syndrome associated with ANCA can be clinically similar to anti-glomerular basement membrane (GBM) disease. When ANCA and anti-GBM are both present, the disease should be considered to represent anti-GBM disease.\n\n【6】## Current management/treatment\n\n【7】The treatment of all AAV subtypes is divided into two phases: induction of remission and, maintenance therapy given risk for relapse. Urgent treatment is needed to prevent irreversible organ damage. The current standard of care for the induction phase is a combination of high-dose glucocorticoids with either cyclophosphamide or rituximab, which induces remission in up to 90% of patients. TPE has been included as an adjunctive therapy during induction in patients with significant indicators of renal and/or DAH, though the benefit has been challenged by the PEXIVAS study 删除19:<u>(Walsh, 2020)</u>. The duration of AAV approaches 20% ± 1 year, and is largely infection-related supporting a reduced steroid dose (50% of previous standard and RCT data from PEXIVAS demonstrating non-inferiority. There remains much practice variation and uncertainty for ideal steroid dosing in both induction and maintenance phases. Avacopan (a C5a receptor inhibitor) has been shown to be noninferior to oral prednisone for remission at 26 weeks, and superior to prednisone for sustaining remission at week 52 in an RCT 删除19:<u>(Jayne, 2021)</u>. Maintenance of remission usually entails a gradual taper of steroids plus an additional immunomodulatory agent (azathioprine, mycophenolate mofetil, or rituximab) for 12 to 18 months.\n\n【8】## Rationale for therapeutic apheresis\n\n【9】The cytotoxic role for ANCAs underlies the scientific rationale for therapeutic apheresis in the treatment of AAV. For decades, TPE has been considered an appropriate adjunctive therapy. Use of TPE for induction therapy in AAV with severe kidney involvement was first described as improving kidney function/dialysis independence in a RCT of A3 anti-GBM negative cases of RPGN with creatinine (Cr) ≥ 500 μmol/L (5.7 mg/dL; 删除19:<u>(Buysen, 1991)</u>) then later confirmed by the MEPEX RCT 删除19:<u>(Jayne, 2007)</u>. Long-term follow-up from MEPEX (median 4 years) failed to show a net benefit of TPE on the composite outcome of death and ESKD 删除19:<u>(Walsh, 2013)</u>. Additionally, in other subsequent non-randomized CTs or CSs, the benefit of TPE was not always confirmed despite its acceptance in common practice. The addition of TPE in patients with severe kidney involvement remained a mainstay of induction therapy until the results of PEXIVAS, the largest RCT of TPE in AAV, failed to demonstrate a benefit of TPE on the composite primary outcome of ESKD and mortality at 12 months 删除19:<u>(Walsh, 2020)</u>.\n\n【10】PEXIVAS was an international RCT that enrolled 704 patients and assessed the effect of TPE as well as a reduced dose steroid regimen on the primary composite outcome of ESKD or death in patients with AAV with an eGFR≤50 ml/min or with DAH. After induction with pulse steroids (IV) and cyclophosphamide (oral or IV) or rituximab, randomization to receive 60 mL/kg volume TPE or no TPE and standard dose or reduced dose steroid regimen, with follow up for 2 to 7 years (median 2.9 years). Subgroup analysis of patients with Cr ≥ 5.7 mg/dL or DAH also failed to show a statistically significant benefit of TPE. However, review of supplemental data suggested outcomes may favor the TPE groups with DAH and when Cr ≥ 5.7 mg/dL; confidence intervals were large (i.e., PEXIVAS may be underpowered to detect differences in these subgroups). An accompanying editorial pointed out several issues regarding the generalizability of results 删除19:<u>(Derebail, 2020)</u>.\n\n【11】A subsequent systematic review and meta-analysis including 1601 participants with AAV found no impact of TPE on all-cause mortality, and data from seven trials with 999 total participants demonstrated a reduced risk of ESKD at 12 months (20% risk reduction). However, TPE was also associated with an increased risk for serious infections 删除19:<u>(Walsh, 2022)</u>. In a retrospective study of 427 cases of AAV with biopsy proven severe kidney involvement, a modest predictive patients most likely to benefit from TPE was developed and favors those with increasingly elevated creatinine levels, high BVAS score and chronic Bresleon score on biopsy 删除19:<u>(Nezam, 2022)</u>. Further validation studies are needed to confirm staging in clinic practice. The 2021 KDIGO guidelines continue to recommend consideration for TPE in selected cases. The American College of Rheumatology (ACR) has recommended against the routine use of TPE in all patients with active glomerulonephritis, but notes that TPE can be considered for patients at higher risk for progression to ESKD who accept an potential increased risk for infection 删除19:<u>(Chung, 2021)</u>. The ACR guideline panel also recommended against the use of routine plasma exchange for DAH as TPE has not been able to demonstrate an improvement in mortality.", "tags": {}, "lang": "en", "attr": {"page_num": 191, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ASFA指南：治疗性单采术的临床应用（第9版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "删除11:删除19:(1091)\t5 删除11:(345)", "content": "【0】页码:191\n2023 ASFA指南：治疗性单采术的临床应用（第9版）\n## VASCULITIS, ANCA-ASSOCIATED\n\n<mark>【1】删除32:Incidence:删除32: 1 to 3/100,000/year (geographical, age, and ethnic differences)</mark>thnic differences)\n\n| Indication                                 | Procedure | Category | Grade |\n|--------------------------------------------|-----------|----------|-------|\n| Microscopic polyangiitis                   | TPE       | III      | 1B    |\n| Granulomatosis with polyangiitis           |           | III      |       |\n| Eosinophilic granulomatosis with polyangiitis | TPE       | III      | 2C    |\n\n| # reported patients: >300      | RCT     | CT      | CS    | CR   |\n|--------------------------------|---------|---------|-------|------|\n|                                | 10 删除11:<u>删除19:<u>(1091)</u></u>| 5 删除11:<u>(345)</u> | NA    | NA   |\n\n|删除段内换行|## Description\n\n【5】The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA; 25%-40%), microscopic polyangiitis (MPA; 45%-65%), and eosinophilic granulomatosis with polyangiitis (EGPA; 10%-20%). These diseases affect small- and medium-sized vessels and are characterized by multisystem organ involvement, commonly impacting the kidneys (70%; typically exhibiting rapidly progressive glomerulonephritis (RPGN) with high risk of end stage kidney disease (ESKD)), lungs (> 50% at onset; can range from asymptomatic pulmonary lesions to life-threatening diffuse alveolar hemorrhage (DAH)), ear-nose-throat, joints, skin and nerves. Overlapping features between AAV subtypes occur. GPA is characterized by necrotizing granulomatous inflammation and is typically associated with cytoplasmic ANCA and antibodies to proteinase 3. GPA carries a higher risk for relapsing disease. MPA is characterized by vasculitis without granulomatous inflammation, and is most commonly associated with perinuclear ANCA and antibodies to myeloperoxidase. EGPA is rarely associated with RPGN or DAH. The presentation of the pulmonary-renal syndrome associated with ANCA can be clinically similar to anti-glomerular basement membrane (GBM) disease. When ANCA and anti-GBM are both present, the disease should be considered to represent anti-GBM disease.\n\n【6】## Current management/treatment\n\n【7】The treatment of all AAV subtypes is divided into two phases: induction of remission and, maintenance therapy given risk for relapse. Urgent treatment is needed to prevent irreversible organ damage. The current standard of care for the induction phase is a combination of high-dose glucocorticoids with either cyclophosphamide or rituximab, which induces remission in up to 90% of patients. TPE has been included as an adjunctive therapy during induction in patients with significant indicators of renal and/or DAH, though the benefit has been challenged by the PEXIVAS study 删除19:<u>(Walsh, 2020)</u>. The duration of AAV approaches 20% ± 1 year, and is largely infection-related supporting a reduced steroid dose (50% of previous standard and RCT data from PEXIVAS demonstrating non-inferiority. There remains much practice variation and uncertainty for ideal steroid dosing in both induction and maintenance phases. Avacopan (a C5a receptor inhibitor) has been shown to be noninferior to oral prednisone for remission at 26 weeks, and superior to prednisone for sustaining remission at week 52 in an RCT 删除19:<u>(Jayne, 2021)</u>. Maintenance of remission usually entails a gradual taper of steroids plus an additional immunomodulatory agent (azathioprine, mycophenolate mofetil, or rituximab) for 12 to 18 months.\n\n【8】## Rationale for therapeutic apheresis\n\n【9】The cytotoxic role for ANCAs underlies the scientific rationale for therapeutic apheresis in the treatment of AAV. For decades, TPE has been considered an appropriate adjunctive therapy. Use of TPE for induction therapy in AAV with severe kidney involvement was first described as improving kidney function/dialysis independence in a RCT of A3 anti-GBM negative cases of RPGN with creatinine (Cr) ≥ 500 μmol/L (5.7 mg/dL; 删除19:<u>(Buysen, 1991)</u>) then later confirmed by the MEPEX RCT 删除19:<u>(Jayne, 2007)</u>. Long-term follow-up from MEPEX (median 4 years) failed to show a net benefit of TPE on the composite outcome of death and ESKD 删除19:<u>(Walsh, 2013)</u>. Additionally, in other subsequent non-randomized CTs or CSs, the benefit of TPE was not always confirmed despite its acceptance in common practice. The addition of TPE in patients with severe kidney involvement remained a mainstay of induction therapy until the results of PEXIVAS, the largest RCT of TPE in AAV, failed to demonstrate a benefit of TPE on the composite primary outcome of ESKD and mortality at 12 months 删除19:<u>(Walsh, 2020)</u>.\n\n【10】PEXIVAS was an international RCT that enrolled 704 patients and assessed the effect of TPE as well as a reduced dose steroid regimen on the primary composite outcome of ESKD or death in patients with AAV with an eGFR≤50 ml/min or with DAH. After induction with pulse steroids (IV) and cyclophosphamide (oral or IV) or rituximab, randomization to receive 60 mL/kg volume TPE or no TPE and standard dose or reduced dose steroid regimen, with follow up for 2 to 7 years (median 2.9 years). Subgroup analysis of patients with Cr ≥ 5.7 mg/dL or DAH also failed to show a statistically significant benefit of TPE. However, review of supplemental data suggested outcomes may favor the TPE groups with DAH and when Cr ≥ 5.7 mg/dL; confidence intervals were large (i.e., PEXIVAS may be underpowered to detect differences in these subgroups). An accompanying editorial pointed out several issues regarding the generalizability of results 删除19:<u>(Derebail, 2020)</u>.\n\n【11】A subsequent systematic review and meta-analysis including 1601 participants with AAV found no impact of TPE on all-cause mortality, and data from seven trials with 999 total participants demonstrated a reduced risk of ESKD at 12 months (20% risk reduction). However, TPE was also associated with an increased risk for serious infections 删除19:<u>(Walsh, 2022)</u>. In a retrospective study of 427 cases of AAV with biopsy proven severe kidney involvement, a modest predictive patients most likely to benefit from TPE was developed and favors those with increasingly elevated creatinine levels, high BVAS score and chronic Bresleon score on biopsy 删除19:<u>(Nezam, 2022)</u>. Further validation studies are needed to confirm staging in clinic practice. The 2021 KDIGO guidelines continue to recommend consideration for TPE in selected cases. The American College of Rheumatology (ACR) has recommended against the routine use of TPE in all patients with active glomerulonephritis, but notes that TPE can be considered for patients at higher risk for progression to ESKD who accept an potential increased risk for infection 删除19:<u>(Chung, 2021)</u>. The ACR guideline panel also recommended against the use of routine plasma exchange for DAH as TPE has not been able to demonstrate an improvement in mortality.", "index": 763, "show": true, "start": 750, "end": 779, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "【1】"}]}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:55:06", "grab_time": "2024-08-05 23:40:45"}
{"id": 2211680, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "5b855fb3-1591-4782-a4b3-2020df49db65", "title": "（2024.V1）NCCN临床实践指南：膀胱癌", "text": "【0】页码:8\n（2024.V1）NCCN临床实践指南：膀胱癌\n疑似页眉<u># NCCN Guidelines Version 1.2024 Bladder Cancer</u>\n\n【1】## INTRODUCTION\n\n【2】NCCN and the NCCN Bladder Cancer Panel believe that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2024.V1）NCCN临床实践指南：膀胱癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】## INTRODUCTION", "content": "【0】页码:8\n（2024.V1）NCCN临床实践指南：膀胱癌\n疑似页眉<u># NCCN Guidelines Version 1.2024 Bladder Cancer</u>\n\n【1】## INTRODUCTION\n\n【2】NCCN and the NCCN Bladder Cancer Panel believe that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.", "index": 92, "show": true, "start": 92, "end": 110, "province": ["文本干净度", "无关文本"], "isEdit": false}]}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 17:57:55", "grab_time": "2024-08-06 17:57:01"}
{"id": 2211679, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "2897f729-f450-4f9e-aa00-4b3e94ee5af6", "title": "WFSBP_CANMAT：应用营养药物和植物制剂治疗精神疾病的临床指南（2022）", "text": "【0】页码:29\nWFSBP_CANMAT：应用营养药物和植物制剂治疗精神疾病的临床指南（2022）\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】疑似页眉<u>individual-family psychoeducational psychotherapy for children and adolescents with depression. J Clin Child Adolesc Psychol. 48(sup1):S105–S118.</u>\n\n【2】参考删除-3:<u>Fuladi S, Emami SA, Mohammadpour AH, Karimani A, Manteghi AA, Sahebkar A. 2020. Assessment of Withania somnifera root extract efficacy in patients with generalized anxiety disorder: a randomized double-blind placebo-controlled trial. Curr Clin Pharmacol. 16删除11:<u>(2)</u>:191–196.</u>\n\n【3】参考删除-2:<u>Fusar-Poli L, Vozza L, Gabbiadini A, Vanella A, Concas I, Tinacci S, Petralia A, Signorelli MS, Augliera E. 2020. Curcumin for depression: a meta-analysis. Crit Rev Food Sci Nutr. 60删除11:<u>(15)</u>:2643–2653.</u>\n\n【4】参考删除-3:<u>Gabbay V, Freed RD, Alonso CM, Senger S, Stadterman J, Davison BA, Klein RG. 2018. A double-blind placebo-controlled trial of omega-3 fatty acids as a monotherapy for adolescent depression. J Clin Psychiatry. 79删除11:<u>(4)</u>:17m11596.</u>\n\n【5】参考删除-3:<u>Gadallah A-HA, Ebada MA, Gadallah A, Ahmed H, Rashad W, Eid KA, Bahbah E, Elkanj S. 2020. Efficacy and safety of N-acetyl-cysteine as add-on therapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis. J Obsessive-Compulsive Relat Disord. 25:100529.</u>\n\n【6】参考删除-3:<u>Gau J, Galer P, Ma D, Chen C, Xiong J. 2019. The effect of vitamin D supplementation on attention-deficit/hyperactivity disorder: a systematic review and meta-analysis of randomized controlled trials. J Child Adolesc Psychopharmacol. 29删除11:<u>(9)</u>:670–687.</u>\n\n【7】参考删除-3:<u>Grandi S, Donders G, Berardi D, Nujing MA. 2018. It takes a new 'physic' genius to cure asthma and chronic obstructive pulmonary disease. Eur Respir Med. 12删除11:<u>(1)</u>:227–231.</u>\n\n【8】参考删除-3:<u>Gratão F, Zurcher N, Ferreira J, Caramelli P. 2020. Efficacy of omega-3 fatty acid supplementation as a mood state modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 66删除11:<u>(7)</u>:756–763.</u>\n\n【9】参考删除-3:<u>Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, et al. 2019. International society for nutritional psychiatry research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder. Psychother Psychosom. 88删除11:<u>(5)</u>:263–273.</u>\n\n【10】参考删除-3:<u>Harnett JE, McIntyre E, Steel A, Foley H, Sibbrit D, Adams J. 2019. Use of complementary medicine products: a nationally representative cross-sectional survey of 2019 Australian adults. BMJ Open. 9删除11:<u>(7)</u>:e024198.</u>\n\n【11】参考删除-3:<u>Harris PE, Cooper KL, Relton C, Thomas KJ. 2012. Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int J Clin Pract. 66删除11:<u>(10)</u>:924–939.</u>\n\n【12】参考删除-3:<u>Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Moller HJ, Kasper S, Chairs WGTF; WFSBP Guideline Task Force Chairs 2019. WFSBP guidelines on how to grade treatment evidence for clinical guideline development. World J Biol Psychiatry. 21删除11:<u>(1)</u>:2–16.</u>\n\n【13】参考删除-3:<u>Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. 2002. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 54删除11:<u>(4)</u>:349–356.</u>\n\n【14】参考删除-3:<u>Herrera-Arellano A, Jiménez-Ferrer E, Zamilpa A, Morales-Valdéz M, García-Ramos G, Tortoriello J. 2007. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Med. 73删除11:<u>(8)</u>:713–717.</u>\n\n【15】参考删除-3:<u>Herrera-Arellano A, Jimenez-Ferrer J, Zamilpa A, García Alonso G, Herrera-Alvarez S, Tortoriello J. 2012. Therapeutic effectiveness of Galphimia glauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial. Planta Med. 78删除11:<u>(14)</u>:1529–1535.</u>\n\n【16】参考删除-3:<u>Hsu MC, Huang YS, Ouyang WC. 2020. Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms. Lipids Health Dis. 19删除11:<u>(1)</u>:159.</u>\n\n【17】参考删除-3:<u>Ipok JO, Kwon S, Kim T-S, Hwang J, Kim JE, Won W, Bae S, Renshaw PF. 2012. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry. 169删除11:<u>(9)</u>:937–945.</u>\n\n【18】参考删除-3:<u>Jana T, Zuzana H, Anna S, Barbora K, Irina G, Iveta V, Katarina S, Iveta G, Jan S, Zdenka D. 2020. Omega-3 fatty acids modulate symptoms of depressive disorder, serum levels of omega-3 fatty acids and omega-6/omega-3 ratio in children. A randomized, double-blind and controlled trial. Psychiatry Research. 287:112911.</u>\n\n【19】参考删除-3:<u>Johnstone JM, Hughes A, Goldenberg JZ, Romi ARR, Kluckilde J. 2020. Multinutrients for the treatment of psychiatric symptoms in clinical samples: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 11删除11:<u>(1)</u>:3394.</u>\n\n【20】参考删除-3:<u>Kar S, Wong M, Rogozinska E, Thangaratinam S. 2016. Effects of omega-3 fatty acids in early preterm birth: a systematic review and meta-analysis of randomized trials. Eur J Obstet Gynecol Reprod Biol. 198删除11:<u>(9)</u>:40–46.</u>\n\n【21】参考删除-3:<u>Kasper S, Caraci F, Foti B, Drago F, Aguglia E. 2010. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol. 19删除11:<u>(11)</u>:747–765.</u>\n\n【22】Kasper S, Anghelescu I, Dienel A. 2015. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 25删除11:<u>(11)</u>: 1960–1967.\n\n【23】参考删除-3:<u>Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Schäfke D, Dienel A. 2014. Lavender oil preparation Silexan is effective in generalized anxiety disorder—a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharm. 17删除11:<u>(6)</u>:859–869.</u>\n\n【24】参考删除-3:<u>Klimova B, Novotny M, Valis M. 2020. The impact of nutrition and intestinal microbiome on elderly depression—a systematic review. Nutrients. 12删除11:<u>(3)</u>:1710.</u>\n\n【25】参考删除-3:<u>Knippenberg S, Damoiseaux J, Bol Y, Hupperts R, Taylor BV, Ponsonby AL, Dwyer T, Simpson S, van der Mei IA. 2014. Higher levels of reported sun exposure, and not vitamin D intake, are associated with less depressive symptoms and fatigue in multiple sclerosis. Acta Neurol Scand. 129删除11:<u>(2)</u>: 123–131.</u>\n\n【26】参考删除-3:<u>Krivoy A, Onn R, Viner A, Hochman E, Weizman S, Paz A, Hess S, Sagy R, Kimhi-Nesher S, Kalter E, et al. 2017. Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled clinical trial. EBioMedicine. 26: 138–145.</u>\n\n【27】参考删除-3:<u>Kuchta K, de Nicola P, Schmidt M. 2018. Randomized, dose-controlled double-blind trial: Efficacy of an ethanolic kava.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 29, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WFSBP_CANMAT：应用营养药物和植物制剂治疗精神疾病的临床指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:36:53", "endTime": "2024/08/06 15:37:06", "cost": 13.176}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:37:06", "grab_time": "2024-08-05 23:36:53"}
{"id": 2211678, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "e35b9469-f5b2-443e-ab94-0d6de8eae857", "title": "AHA心脏病与卒中统计报告（2022年更新）", "text": "【0】页码:243\nAHA心脏病与卒中统计报告（2022年更新）\n1.01–1.16]) and posttreatment (aOR, 1.13[95% CI, 1.01–1.25]) SBP levels were associated with increased risk of symptomatic ICH.删除17:<u>52</u> Pretreatment (aOR, 0.91 [95% CI, 0.84–0.98]) and posttreatment (aOR, 0.70 [95% CI, 0.57–0.87]) SBP values also were inversely related to lower likelihood of 3-month functional independence.\n\n【1】## Diabetes\n删除9:<u>(See Chapter 9 [Diabetes] for more information.)</u>\n\n【2】- The association between diabetes and stroke risk differs between sexes. A systematic review of 64 cohort studies representing 775 385 individuals and 12 539 strokes revealed that the pooled, fully aRR of stroke associated with diabetes was 2.28 (95% CI, 1.93–2.69) in females and 1.83 (95% CI, 1.60–2.08) in males. Compared with males with diabetes, females with diabetes had a 27% greater RR for stroke when baseline differences in other major cardiovascular risk factors were taken into account (pooled ratio of RR, 1.27 [95% CI, 1.10–1.46]).\n- Prediabetes, defined as impaired glucose tolerance or a combination of impaired fasting glucose and impaired glucose tolerance, may be associated with a higher future risk of stroke, but the RRs are modest. A meta-analysis of 15 prospective cohort studies including 760 925 participants revealed that when prediabetes was defined as fasting glucose of 110 to 125 mg/dL (5 studies), the aRR for stroke was 1.21 (95% CI, 1.02–1.44).\n- Diabetes is an independent risk factor for stroke recurrence; a meta-analysis of 18 studies involving 43 899 participants with prior stroke revealed higher stroke recurrence in patients with diabetes than in those without diabetes (HR, 1.45 [95% CI, 1.32–1.59]).\n- In the GWTG-Stroke registry, diabetes was associated with a higher risk of adverse outcomes over 3 years after stroke, including all-cause mortality (aHR, 1.24 [95% CI, 1.23–1.25]), all-cause hospital readmission (aHR, 1.22 [95% CI, 1.21–1.23]), a composite of mortality and cardiovascular readmission (aHR, 1.19 [95% CI, 1.18–1.20]), and ischemic stroke/TIA readmission (aHR, 1.18 [95% CI, 1.16–1.20]).\n- In a meta-analysis of 11 RCTs that included 56 161 patients with type 2 diabetes and 1853 cases of stroke, those who were randomized to intensive glucose control did not have a reduction in stroke risk compared with those with conventional glucose control (RR, 0.94 [95% CI, 0.84–1.06]; P=0.33).\n- A meta-analysis of 28 RCTs involving 96 765 participants with diabetes revealed that a decrease in SBP by 10 mm Hg was associated with a lower risk of stroke (RR from 21 studies, 0.74 [95% CI, 0.66–0.83]). Significant interactions were observed, with lower RRs (RR, 0.71 [95% CI, 0.63–0.80]) observed among trials with mean baseline SBP ≥140 mm Hg and no significant associations among trials with baseline SBP <140 mm Hg (RR, 0.90 [95% CI, 0.69–1.17]). The associations between BP lowering and stroke risk reduction were present for both the achieved SBP of <130 mmHg and the ≥130 mm Hg groups.\n\n【3】## Disorders of Heart Rhythm\n删除9:<u>(See Chapter 18 [Disorders of Heart Rhythm] for more information.)</u>\n\n【4】### Atrial Fibrillation\n\n【5】- Because AF is often asymptomatic and frequently undetected clinically, the stroke risk attributed to AF is likely substantially underestimated. In a meta-analysis of 50 studies, AF was detected in ≈24% (95% CI, 17%–31%) of patients with embolic stroke of undetermined source, depending on duration and type of monitoring used.\n- In an RCT among patients with cryptogenic stroke, the cumulative incidence of AF detected with an implantable cardiac monitor was 30% by 3 years. Approximately 80% of the first AF episodes were asymptomatic.\n- An analysis of patients from the Veterans Administration showed that among patients with device-documented AF, the presence of relatively brief amounts of AF raised the short-term risk of stroke 4- to 5-fold. This risk was highest in the initial 5 to 10 days after the episode of AF and declined rapidly after longer periods.\n- Important risk factors for stroke in the setting of AF include older age, hypertension, HF, diabetes, previous stroke or TIA, vascular disease, renal dysfunction, low BMI, and female sex. Biomarkers such as high levels of troponin and BNP are associated with an increased risk of stroke in AF after adjustment for traditional vascular risk factors.\n- In patients with AF who are being treated with anticoagulation, presence of persistent AF versus paroxysmal AF is associated with higher risk of stroke.\n- In a meta-analysis of 26 studies of patients with AF and prior stroke (N= 23 054 patients), nonparoxysmal AF compared with paroxysmal AF was associated with a higher risk of recurrent stroke (OR, 1.47 [95% CI, 1.08–1.99]).\n- In a meta-analysis of 35 studies (N= 2 458 010 patients), perioperative or postoperative AF was associated with an increased risk of early stroke (OR, 1.62 [95% CI, 1.47–1.80]) and later stroke (HR, 1.37 [95% CI, 1.07–1.77]). This risk was found in patients undergoing both noncardiac surgery (HR, 2.00 [95% CI, 1.70–2.35]) and cardiac surgery (HR, 1.20 [95% CI, 1.07–1.34]).", "tags": {}, "lang": "en", "attr": {"page_num": 243, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/AHA心脏病与卒中统计报告（2022年更新）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:46:55", "endTime": "2024/08/06 15:47:42", "cost": 46.746}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:47:42", "grab_time": "2024-08-05 23:46:55"}
{"id": 2211677, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "3330022a-dd0a-483a-89fc-273d40bdf094", "title": "成人癌症恶病质的筛查评估与干预治疗——基于《成人癌症恶病质：ESMO临床实践指南》解读", "text": "【0】页码:8\n成人癌症恶病质的筛查评估与干预治疗——基于《成人癌症恶病质：ESMO临床实践指南》解读\n(本页删除)本页被模型判断为参考页- TURNERSTOKES L ， TONGE P ， NYEIN K ， et al ．The Northwick Park Dependency Score （NPDS）：a measure of nursing dependency in rehabilitation〔J〕．Clin Rehabil，1998，12（4）： 304-318．DOI：10.1191/026921598671796394.\n\n【1】- Ministry of Health删除1:<u>. Province of British Columbia．Frailty in older adults－early identification and management （EB101_）．［20220604］．https:∥www2.gov.bc.ca∥assets∥gov∥health∥practitioner--pro∥ bc--guidelines∥frailty--guideline.pdf.</u>\n\n【2】参考删除-3:<u>- HUI D ，BRUERA E．The Edmonton symptom assessment system 25 years later：past ， present ， and future developments〔J〕.J Pain Symptom Manag，2017，53（3）：630-643．DOI：10.1016/ j.jpainsymman.2016.10.370.</u>\n\n【3】参考删除-3:<u>- WHEELWRIGHT S J ，HOPKINSON J B ， DARLINGTON A S， et al．Development of the EORTC QLQCAX24. A questionnaire for cancer patients with cacAexia〔J〕.J Pain Symptom Manage， 2017,53删除11:<u>(2)</u>:232-242. DOI:10.1016/j.jpainsymman.2016.09.010.</u>\n\n【4】- 彭婷，林楠，冯雪华，等.晚期癌症患者姑息治疗循证信息推送框 架总结 (Ⅰ) 摘录五.上肢静脉导管及去化文治疗适宜性 ( 上).癌 痛大会议，2022: 500–501.\n\n【5】- ARENDS J ．Struggling with nutrition in patients with advanced cancer：nutritional and nourishment—focusing on metabolic and supportive care〔J〕.Ann Oncol，2018，29（suppl_2）：ii27–34．DOI：10.1093/annonc/mdy093.\n\n【6】参考删除-3:<u>- DEV R ，BRUERA E ， DALAL S．Insulin resistance and body composition in cancer patients〔J〕.Ann Oncol，2018，29（suppl _ 2）：ii18-26．DOI：10.1093/annonc/mdx815．</u>\n\n【7】- HARAN P H ，RIVAS D A ， FIELDING R A．Role and potential mechanisms of anabolic resistance in sarcopenia〔J〕.J Cachexia Sarcopenia Muscle，2012，3（3）：157–162．DOI：10.1007/ s13539–012–0068-4.\n\n【8】- 同辉平，邱梅钿，赵竹竹，等.癌性恶病质病理生理及发病 机制: 恶病质的方向治疗删除12:<u>[J]</u>. 临床肿瘤学杂志,删除13:<u>2021, 26</u>删除11:<u>( 11)</u>: 1028-1035.DOI: 10.3969/j.issn.1009-0460.2021.11.012.\n\n【9】- 桑资料，张住，刘元，等. 癌性恶病质的机制及中医药防治进展删除12:<u>[J]</u> .中国实验方药学杂志，2021，27（1）：删除13:<u>203– 213</u>．DOI：10.13422∥j.cnki.syfjx.2020.0245.\n\n【10】- 刘士平，于其兵. 癌性恶病质的机制和临床治疗的研究进 展 删除12:<u>[J]</u>.临床肿瘤学杂志,删除13:<u>2018, 23</u> 删除11:<u>(7)</u> : 684-654. DOI: 10.3969/j.issn.1009-0460.2018.07.015.\n\n【11】- 周滨帅，付琴琴，罗晓玲，等.癌性恶病质的中西医治疗探讨删除12:<u>[J]</u>.中医肿瘤学杂志, 2019, 1删除11:<u>(5)</u>: 82–删除13:<u>85, 77</u>.DOI: 10.19811/j.cnki. issn2096-6628.2019.05.020.\n\n【12】- 郭德尧，覃礼文，邓佑来，等. 中岳汤治疗恶病质癌症疗效 的荟萃分析 删除12:<u>[J]</u>. 重庆医学, 删除13:<u>2020, 49</u> 删除11:<u>(22)</u> : 3823–3828. DOI: 10.3969/j. issn.1671–8348.2020.22.031.\n\n【13】- DEV R ，HUI D ，CHISHOLM G ， et al ．Hypermetabolism and symptom burden in advanced cancer patients evaluated in a cachexia clinic 〔 J〕．J Cachexia Sarcopenia Muscle，2015，6（1）：95‑ 98．DOI：10.1002/jcsm.12014.", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/成人癌症恶病质的筛查评估与干预治疗——基于《成人癌症恶病质：ESMO临床实践指南》解读.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/07 09:36:04", "endTime": "2024/08/07 09:37:15", "cost": 71.482}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 17:37:12", "grab_time": "2024-08-06 17:36:01"}
{"id": 2211676, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "4de55ffb-70c1-4b0d-9709-258a5fc50e2f", "title": "儿童膀胱直肠功能障碍诊断和治疗中国专家共识", "text": "【0】页码:11\n儿童膀胱直肠功能障碍诊断和治疗中国专家共识\n(本页删除)本页被模型判断为参考页# 正文内容\n\n【1】删除14:<u>[35] </u>HUNZIKER M, MOHANAN N, FT D'ASTA A, et al. Incidence of febrile urinary tract infections in children after successful endoscopic treatment of vesicoureteral reflux: a long-term follow-up $\\left[J\\right]$. J Pediatr.删除13:<u>2012, 160</u>\\left(6\\right):1015-1020.\n\n【2】删除14:<u>[36] </u>黄英姿. 先天性膀胱外翻的临床和辅助检查研究进展$\\left[J\\right]$. 实用医学杂志,2010,17\\left(1\\right):2.\n\n【3】删除14:<u>[37] </u>王文杰, 姚荣庆. 肠道菌群与神经膀胱系统相互作用及相关发育 $\\left[J\\right]$. 中华围产医学杂志,2016,28\\left(7\\right):6.\n\n【4】删除14:<u>[38] </u>祁邦兵, 江甫福. 傅秀芳,等. 福音通过中草药修复, 并促进经皮物质使用的治疗作用$\\left[J\\right]$. 上海交通大学学报医学版 (医学),删除13:<u>2019, 39</u> 删除11:<u>(10)</u> :1199-1203.\n\n【5】删除14:<u>[39] </u>苏平, 徐学亮,龚芳.肠道菌群与功能性肠障碍的影响和临床研究进展$\\left[J\\right]$.军医医学,2021.45删除11:<u>(3)</u>:229-233.\n\n【6】删除14:<u>[40] </u>陈志武,卢吉.主要性巩基性作征修改指南$\\left[J\\right].影响激素教育$\\left[J\\right]$.基础医学与临床,1995;000\\left(S1\\right):60.\n\n【7】删除14:<u>[41] </u>WESTWELL-ROPER C, BEST J R, NAOQASH Z, et al. Bowel and bladder dysfunction is associated with psychiatric comorbidities and functional impairment in pediatric obsessive-compulsive disorder$\\left[J\\right]$. J Child Adul Psychopharmacol.2022\\left(6\\right):32.\n\n【8】删除14:<u>[42] </u>罗俊辉, 蒋久富,姜士礼.儿童功能性肠病的影响治疗进展$\\left[J\\right]$.中华医学小儿外科杂志,2015;36\\left(006\\right):477-480.\n\n【9】删除14:<u>[43] </u>李福峰,陈梦.钙.钙同质和肠与膀胱致命行为关系的研究进展$\\left[J\\right]$.世界学复统计发展,2013;53\\left(09\\right):3956-3970.\n\n【10】参考删除-3:<u>删除12:<u>删除14:<u>[44]</u></u> LAM C Y, PALSSON OS, WHITEHEAD WE, et al. Rome IV functional gastrointestinal disorders and health impairment in subjects with hypermobility spectrum disorders or hypermobile ehlers-danlos syndrome$\\left[J\\right]$. Clin Gastroenterol Hepatol.2021,19\\left(2\\right),277-287.e3.</u>\n\n【11】参考删除-3:<u>删除12:<u>删除14:<u>[45]</u></u> JONAS D LOPES R I, KOYLE M A. Bladder and bowel dysfunction in children; An update on the diagnosis and treatment of a common, but underdiagnosed paediatric problem$\\left[J\\right]$. Can Urol Assoc J.2017,11删除11:<u>(12)</u> ,S84.</u>\n\n【12】删除9:<u>删除12:<u>删除14:<u>[46]</u></u> 杨舒, 王婧竹. 膀胱.功能治疗与图松治疗$\\left[J\\right]</u>$.中华华复医学杂志,2017.16\\left(9\\right):3.\n\n【13】参考删除-3:<u>删除12:<u>删除14:<u>[47]</u></u> DROSSMAN, DOUGLAS A. Functional gastrointestinal disorders, history, pathophysiology, clinical features, and Rome IV$\\left[J\\right]$. Gastroenterol.2016 150\\left(6\\right) :1262-1279.</u>\n\n【14】删除14:<u>[48] </u>雷爱冬,文明乱.儿童功能性造音系统发展$\\left[J\\right]$.中国妇幼健康研究,2010\\left(5\\right),13.\n\n【15】删除14:<u>[49] </u>DRZEWIECKI B A, THOMAS J C, POPE J C.et al. Use of validated bladder/bowel dysfunction questionnaire in the clinical pediatric urol setting$\\left[J\\right]$. J Urol.2012;188\\left(4\\right):1578-1583.\n\n【16】删除14:<u>[50] </u>HOWELLS M, HAMBY T, HONEYCUTT J, et al. Detethering of MRI-Demonstrated tethered cord syndrome$\\left[J\\right]$. Pediatr Neuro Surg.2022.57删除11:<u>(2)</u>:85-92.\n\n【17】删除14:<u>[51] </u>WENG JG, DJURHUUS JC, ROSIER PFWM, et al. ICS educated module; Cyometry in children$\\left[J\\right]$. Neurourol Urodyny.2018.37删除11:<u>(3)</u>:2306-2310.\n\n【18】删除14:<u>[52] </u>丁耀生. 直肠膀胱功能在排便和排尿有效治疗的价值及临床前景$\\left[J\\right]$.中华医学外科杂志.2016.191\\left(2\\right),3.\n\n【19】删除14:<u>[53] </u>冉建武,赵光,释比.膀胱同时一治疗疗效$\\left[J\\right]$.中华医学外科杂志.2015.182\\left(1\\right),5.\n\n【20】参考删除-3:<u>删除12:<u>删除14:<u>[54]</u></u> HAN SH, CHOI K, SHIM GY, et al. Pudendal nerve terminal motor latency compared by anorectal manometry diagnosing fecal incontinence: a retrospective study$\\left[J\\right]$. Am J Physical Med Rehabil.2012,101$\\left(12\\right):148-128.</u>\n\n【21】删除14:<u>[55] </u>赵振、电灭,梁宝全,中青年影派儿童糖尿病合刊, 删除11:<u>删除19:<u>(2022)</u></u>常谈$\\left[J\\right].中华医学卫生,2022.43\\left(6\\right),4.\n\n【22】删除14:<u>[56] </u>中华医学会儿科医学分会儿童内分泌和糖尿病:中华医学会儿科学会流行病学分科$\\left[J\\right].儿童糖尿病治疗筛选进步和治疗中中华现代恩瑟变通$\\left[J\\right].中华医学杂志.2021删除11:<u>删除19:<u>(1014)</u></u>039.\n\n【23】参考删除-3:<u>删除12:<u>删除14:<u>[57]</u></u> BORCH L, HAGSTROM S, BOWER WF, et al. Bladder and bowel dysfunction and the resolution of urinary incontinence with successful management of bowel symptoms in children$\\left[J\\right]. Acta Paediatrica. 2013.102\\left(5\\right): e215-e220.</u>\n\n【24】删除14:<u>[58]</u>. 陈贤辉,何刚,张艳等.神经膀胱在糖尿病儿童治疗指导和复杂发作及感染的危险因素$\\left[J\\right].中华妇幼儿保健杂志.2018.33\\left(11\\right),4.\n\n【25】删除14:<u>[59] </u>NEWGREEN D, DOSMAN B, HOLLESTEIN-HAVELARA A A. et al. Solifenacin in children and adolescents with overactive bladder; results of a phase 3 randomised clinical trial$\\left[J\\right]. Eur Urol.2016:71删除11:<u>(3)</u>,483-490.\n\n【26】参考删除-3:<u>删除12:<u>删除14:<u>[60]</u></u> SOLIMAN MG, EL-ABD S, EL-GAMAL OM, et al. Mirabegron versus solifenacin in children with overactive bladder:prospective randomized single-blind controlled trial$\\left[J\\right]. Urologia.Int.2021;1-7.</u>\n\n【27】参考删除-3:<u>删除12:<u>删除14:<u>[61]</u></u> BOGAERT G, BECKERS G, DAMMELAMAEBERTS RV, et al. Long term oral terazosin medication can be a safe and successful treatment in children with neurogenic non-neurogenic bladder dysfunction$\\left[J\\right]. Int Braz J Urol.2004;30\\left(2\\right):128-134.</u>\n\n【28】删除14:<u>[62] </u>中华医学会神经科学分会提样刊.倔强后活治疗下尿路功能障碍的有效性表现解$\\left[J\\right].中华医学会外科杂志.2021.42删除11:<u>(6)</u>:405-410.\n\n【29】删除14:<u>[63] </u>熊光辉.张院民.杨学棠.糖尿病神经性膀胱功能复杂反应用中西结合治疗探讨$\\left[J\\right].中华妇幼保健杂志.2018.39删除11:<u>(11)</u>:4.\n\n【30】删除14:<u>[64] </u>郝志刚.,神经行为学,等.膀胱系统排作对糖尿病性膀胱。膀胱排尿动力学参数的。临床儿外科杂志.2021\\left删除19:<u>(2011\\right)</u>:5.\n\n【31】删除14:<u>[65] </u>SHIREMAN J, GAJARAWALA S, STANTON A, et al. Treating overactive bladder with percutaneous tibial nerve stimulation$\\left[J\\right]. JAAPA.2021.34\\left(12\\right):27-30.\n\n【32】删除14:<u>[66] </u>赵庆洪,姜.关.,物,变性,分别。大脑与糖尿膀胱致命膀胱致命膀胱。并叙述行为与儿童膀胱反应应实现的有效干预$\\left[J\\right].湖南普通医学学报(医学儿), 2017.14\\left(4\\right):161-163.\n\n【33】删除14:<u>[67] </u>黄龙奇., 徐毓升,等.糖尿病儿童肠防膀胀与大脑膀胱扩张模型药物的作用综述$\\left[J\\right].中华医学外科杂志.2021.42删除11:<u>(2)</u>:6.\n\n【34】(编辑 王 静)", "tags": {}, "lang": "en", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/儿童膀胱直肠功能障碍诊断和治疗中国专家共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:35:37", "endTime": "2024/08/06 15:36:12", "cost": 35.261}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:36:12", "grab_time": "2024-08-05 23:35:36"}
{"id": 2211675, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "03262974-ae9e-4586-8d12-a99953230926", "title": "【内分泌领域】中国胰岛素泵治疗指南（2021年版）", "text": "【0】页码:23\n【内分泌领域】中国胰岛素泵治疗指南（2021年版）\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】疑似页眉<u>中 华 内 分 泌 代 谢 杂 志 2021 年 8 月 第 37 卷 第 8 期 Chin J Endocrinol Metab, August 2021, Vol. 37, No. 8</u>\n\n【2】参考删除-3:<u>删除12:<u>删除14:<u>[101]</u></u> Cheisson G, Jacqueminet S, Cosson E, et al. Perioperative management of adult diabetic patients. Preoperative period 删除12:<u>[J]</u>. Anaesth Crit Care Pain Med, 删除13:<u>2018, 37</u> (1 Sup ): S9-S19. DOI: 10.1016/j.accpm.2018.02.020.</u>\n\n【3】参考删除-3:<u>删除12:<u>删除14:<u>[102]</u></u> Cheisson G, Jacqueminet S, Cosson E, et al. Perioperative management of adult diabetic patients. Intraoperative period. Anaesth Crit Care Pain Med 删除12:<u>[J]</u>. 删除13:<u>2018, 37</u> ( Suppl 1 ): S21-S25. DOI: 10.1016/j.accpm.2018.02.018.</u>\n\n【4】删除14:<u>[103] </u>Cheisson G, Jacqueminet S, Cosson E, et al. Perioperative管理 of adult diabetic patients. Postoperative period 删除12:<u>[J]</u>. Anaesth Crit Care Pain Med. 删除13:<u>2018, 37</u>(Suppl 1): S27-S30.\n\n【5】参考删除-3:<u>删除12:<u>删除14:<u>[104]</u></u> Vinals C, Quirós C, Giménez M, et al. Real-time management and effectiveness of insulin pump with or without continuous glucose monitoring in adults with type 1 diabetes删除12:<u>[J]</u>. Diabetes Ther, 删除13:<u>2019, 10</u> 删除11:<u>(3)</u> :992-936. DOI: 10.1007/s13300-019-0599-1.</u>\n\n【6】参考删除-3:<u>删除12:<u>删除14:<u>[105]</u></u> Deeb A, Abd-Awad S, Abood S, et al. Important determinants of diabetes control in insulin pump therapy in patients with type 1 diabetes mellitus删除12:<u>[J]</u>. Diabetes Technol Ther, 2015,17 删除11:<u>(3)</u> : 166-170. DOI: 10.1089/dia.2014.0224.</u>\n\n【7】参考删除-3:<u>删除12:<u>删除14:<u>[106]</u></u> Ehrmann D, Kulzer B, Schipfer M, et al. Efficacy of education program for people with diabetes and insulin pump treatment (INPUT) : results from a randomized controlled trial 删除12:<u>[J]</u>. Diabetes Care, 2018,41 删除11:<u>(12)</u>: 2453-2462. DOI: 10.2337/dc18-0917.</u>\n\n【8】删除14:<u>[107] </u>中华医学会糖尿病学分会. 中日胰岛素强化治疗指南删除19:<u>(2015年版)</u>删除12:<u>[J]</u>. 中华糖尿病杂志, 2015, 7 删除11:<u>(10)</u>: 603-613. DOI: 10.3760/cma.j.issn.1674-5809.2015.10.004.\n\n【9】删除14:<u>[108] </u>中华医学会糖尿病学分会. 中日转换葡萄糖监测临床应用指南删除19:<u>(2017年版)</u>删除12:<u>[J]</u>. 中华糖尿病杂志, 2017,9 删除11:<u>(11)</u>: 667-675. DOI: 10.3760/cma.j.issn.1674-5809.2017.11.002.\n\n【10】参考删除-3:<u>删除12:<u>删除14:<u>[109]</u></u> Klonoff DC, Kerr D. A simplified approach using rate of change arrows to adjust insulin with real-time continuous glucose monitoring删除12:<u>[J]</u>. J Diabetes Sci Technol,2017,11 删除11:<u>(6)</u>: 1063-1069. DOI: 10.1177/1932296817723260.</u>\n\n【11】删除14:<u>[110] </u>陈祖明, 周佳. 中日胰岛素葡萄糖监测技术临床应用专家共识删除12:<u>[J]</u>. 中华糖尿病杂志, 删除13:<u>2018, 10</u> 删除11:<u>(11)</u>: 697-100. DOI: 10.3760/cma.j.issn.1674-5809.2018.11.001.\n\n【12】参考删除-3:<u>删除12:<u>删除14:<u>[111]</u></u> Lu JY, Home PD, Zhou J. Comparison of multiple cut points for time in range in relation to risk of abnormal carotid intima-media thickness and diabetic retinopathy 删除12:<u>[J]</u>. Diabetes Care, 删除13:<u>2020, 43</u> 删除11:<u>(8)</u> :e99-e101. DOI: 10.2337/dc20-0561.</u>\n\n【13】参考删除-3:<u>删除12:<u>删除14:<u>[112]</u></u> Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range，hyperglycemia metrics，and Hb $A_{1c}$删除12:<u>[J]</u>. J Diabetes Sci Technol, 2019,13删除11:<u>(4)</u> :614-626. DOI: 10.1177/1932296818822496.</u>\n\n【14】参考删除-3:<u>删除12:<u>删除14:<u>[113]</u></u> Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes删除12:<u>[J]</u>. Diabetes Technol Ther, 2019,21删除11:<u>(2)</u>:81-85. DOI: 10.1089/dia.2018.0310.</u>\n\n【15】参考删除-3:<u>删除12:<u>删除14:<u>[114]</u></u> Lu JY, Ma XJ, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes删除12:<u>[J]</u>. Diabetes Care, 删除13:<u>2018, 41</u>删除11:<u>(11)</u>: 2370-2376. DOI: 10.2337/dc18-1131.</u>\n\n【16】参考删除-3:<u>删除12:<u>删除14:<u>[115]</u></u> Lu J, Wang C, Shen Y, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort Study删除12:<u>[J]</u>. Diabetes Care, 删除13:<u>2021, 44</u>删除11:<u>(2)</u>:549-555. DOI: 10.2337/dc20-1862.</u>\n\n【17】参考删除-3:<u>删除12:<u>删除14:<u>[116]</u></u> Shen Y, Fan X, Zhang L, et al. Thresholds of glycemia and the outcomes of COVID-19 complicated with diabetes: a retrospective exploratory study using continuous glucose monitoring 删除12:<u>[J]</u>. Diabetes Care, 删除13:<u>2021, 44</u>删除11:<u>(4)</u>:976-982. DOI: 10.2337/dc20-1448.</u>\n\n【18】删除14:<u>[117] </u>中华医学会. 中日胰岛素临床指南删除11:<u>删除19:<u>(2016)</u></u> 删除12:<u>[M]</u>. 北京: 人民卫生出版社, 2016.\n\n【19】删除14:<u>[118] </u>中华医学会和体育学会. 中日糖尿病运动治疗指南删除12:<u>[M]</u>. 北京: 人民军医出版社, 2012.\n\n【20】删除14:<u>[119] </u>中华医学会糖尿病学分会. 中日1 型糖尿病治疗指南删除12:<u>[M]</u>. 人民军医出版社, 2012.\n\n【21】参考删除-3:<u>删除12:<u>删除14:<u>[120]</u></u> Ibrahim M, Magal MA, Annabi FA, et al. Recommendations for management of diabetes during ramadan: update 2015[J]. BMJ Open Diabetes Res Care, 2015, 3删除11:<u>(1)</u> :e000108. DOI: 10.1136/bmjdrc-2015-000108.</u>\n\n【22】参考删除-3:<u>删除12:<u>删除14:<u>[121]</u></u> Davidson PC, Hebblewhite HR, Steed RD, et al. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio删除12:<u>[J]</u>. Endocr Pract,删除13:<u>2018, 14</u> 删除11:<u>(9)</u>:1095-1101. DOI: 10.4158/EP.14.9.1095.</u>\n\n【23】参考删除-3:<u>删除12:<u>删除14:<u>[122]</u></u> King AB, Kuroda A, Matsuhisa M, et al. A review of insulin-dosing formulas for continuous subcutaneous Insulin Infusion (CSI) for adults with type 1 diabetes删除12:<u>[J]</u>. Curr Diab Rep,删除13:<u>2016, 16</u> 删除11:<u>(9)</u>:83. DOI: 10.1007/s11892-016-0772-0.</u>\n\n【24】删除14:<u>[123] </u>Hegah AM. Prospective evaluation of insulin-to-carbohydrate ratio in children and adolescents with type 1 diabetes using multiple daily injection therapy 删除12:<u>[J]</u>. Pediatr Diabetes, 删除13:<u>2019, 20</u> 删除11:<u>(8)</u> :1087-1093. DOI: 10.1111/pedi.12911.\n\n【25】参考删除-3:<u>删除12:<u>删除14:<u>[124]</u></u> Kuroda A, Yasuda T, Takahara M, et al. Carbohydrate-to-insulin ratio is estimated from 300-400 divided by total daily insulin dose in type 1 diabetes patients who use the insulin pump删除12:<u>[J]</u>. Diabetes Technol Ther, 2012,14删除11:<u>(11)</u>:1077-1080. DOI: 10.1089/dia.2012.0019.</u>\n\n【26】删除19:<u>(收稿日期:2021-04-28)</u> (本文编辑:朱家达)", "tags": {}, "lang": "en", "attr": {"page_num": 23, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【内分泌领域】中国胰岛素泵治疗指南（2021年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:45:41", "endTime": "2024/08/06 15:46:02", "cost": 20.346}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:46:02", "grab_time": "2024-08-05 23:45:41"}
{"id": 2211674, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "5f04173f-548d-4d7f-a5f2-0725d4b8dee8", "title": "AHA：成人心血管疾病患者跌倒的预防和管理的科学声明（2022）", "text": "【0】页码:5\nAHA：成人心血管疾病患者跌倒的预防和管理的科学声明（2022）\n### Syncope\n\n【1】Syncope, a transient loss of consciousness attributable to decreased blood flow to the brain (neutrally mediated, orthostatic, or cardiac), increases with age and can manifest as falls. $删除21:<u>^3</u>$ Neurally mediated syncope, characterized by peripheral vasodilation, hypotension, and bradycardia, can be caused by vasovagal syncope and carotid sinus syndrome, both of which are particularly common in older adults with or without structural heart disease. Cardiovascular and noncardiovascular medications also can contribute to vasovagal syncope.\n\n【2】OH, postprandial hypotension, and dehydration can result in hypoperfusion of the brain and, in turn, syncope. OH and postprandial hypotension are attributable to impaired autonomic reflexes and increase with increasing age.\n\n【3】Cardiac syncope may be the result of bradycardia, conduction disease, tachycardia, or structural heart disease (including aortic stenosis, ischemia, systolic anterior motion of the mitral valve, or other causes of reduced left ventricular outflow). $删除21:<u>^53</u>$ Arrhythmias, including bradycardia, tachycardia, and conduction disorders, are common in adults with CVD and become more prevalent with older age. Nonarrhythmic cardiac syncope from reduced cardiac output and structural heart disease, including cardiomyopathy, valvular disease, and ischemia, is an important cause of falls, particularly in older adults. In a retrospective study of patients presenting to the emergency department with syncope, the syncope was attributed to structural heart disease (including ischemia) in 27%, and among these patients, ischemic heart disease was the most common cause. $删除21:<u>^54</u>$\n\n【4】### Frailty and Sarcopenia\n\n【5】Frailty, defined as decreased physiological reserves and increased vulnerability to stressors, $删除21:<u>^55</u>$ is a significant risk factor for future falls among older adults. $删除21:<u>^56</u>$ Frailty is highly prevalent among adults with CVD, affecting almost half of those with HF, $删除21:<u>^57</u>$ individuals with coronary artery disease, $删除21:<u>^58</u>$ and those undergoing cardiac surgery. $删除21:<u>^59</u>$ Frailty affects those with CVD across the life span and should be considered a significant risk factor for falls among all adults with CVD. Physical frailty manifests as a phenotype of unintentional weight loss (a proxy for loss of muscle mass), weakness, slowness, physical exhaustion, and low physical activity. $删除21:<u>^60</u>$ Each of these manifestations can increase the likelihood that someone may fall 删除19:<u>(eg, lower extremity weakness predicts falls $删除21:<u>^6061</u>$)</u>, but it is the accumulation of each of these manifestations that likely has the greatest impact on fall risk. $删除21:<u>^55</u>$\n\n【6】Sarcopenia, a disorder of decreased skeletal muscle mass, strength, and quality $删除21:<u>^61</u>$ that is considered a substrate of frailty, $删除21:<u>^62</u>$ also confers a high fall risk. $删除21:<u>^63</u>$ Sarcopenia is common among adults with CVD such as those with HF in which skeletal muscle has altered muscle fiber composition and mitochondrial function, as well as intramuscular fat deposition. $删除21:<u>^64</u>$\n\n【7】These changes result in lower extremity weakness and gait slowness and are associated with physical frailty and risk for falling. $删除21:<u>^60</u>$ Evidence of sarcopenia can often be masked by concurrent obesity, called sarcopenic obesity. Sarcopenic obesity also confers a high risk of falls $删除21:<u>^65</u>$ and should be considered a risk factor for obese adults with CVD.\n\n【8】### Sensory Impairment and Musculoskeletal Problems\n\n【9】Postural control required to maintain an upright position integrates sensory input, central neurological processing, motor coordination, and musculoskeletal function to perceive, interpret, and respond to stimuli in the environment. $删除21:<u>^66</u>$ Sensory deficits (eg, peripheral neuropathy and visual impairments) and musculoskeletal problems (eg, arthritis) can significantly affect postural control and impair gait and balance, which in turn increases the likelihood of falling. Studies among older adults have demonstrated that visual, hearing, and neuromuscular sensory deficits are significant predictors of falls. $删除21:<u>^67</u>$ $删除21:<u>^68</u>$ Many adults with CVD have sensory deficit–related comorbid conditions such as diabetes with neuropathy, stroke, visual and auditory impairments, and musculoskeletal disorders that increase their risk for falls. $删除21:<u>^10</u>$ $删除21:<u>^69</u>$\n\n【10】### Cognitive Impairment\n\n【11】Cognitive impairment, particularly deficits in processing speed and executive function, is associated with falls. $删除21:<u>^71</u>$ Cognitive impairment is highly prevalent among adults with CVD; for example, >40% of patients with HF are estimated to have some degree of cognitive impairment. $删除21:<u>^72</u>$ The mechanisms contributing to cognitive impairment in CVD are not fully known. A loss of brain volume in the hippocampus, frontal lobes, and parietal lobes attributable to cerebral hypoperfusion or untreated sleep apnea is associated with impairments in several cognitive domains, including memory, executive function, and processing speed. $删除21:<u>^73</u>$ Memory loss and impaired executive function can increase medication errors, especially with polypharmacy, thus increasing hypotension and other adverse effects.\n\n【12】### PREVENTING AND MANAGING FALL RISK\n\n【13】Overall suggested screening and management practices to address fall risk are outlined in Table 2. Clinical assessment of falls and risk for falling should begin by asking the patient and other corroborating individuals (spouse, family, caregivers, significant others) about recent falls. A comprehensive review of medications and alcohol use should be conducted for patients with a history of or at risk for falls with potential taper, removal, or substitution when appropriate. The basic physical assessment of fall risk should include observation of the patient's gait and", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/AHA：成人心血管疾病患者跌倒的预防和管理的科学声明（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:02:59", "endTime": "2024/08/06 17:04:37", "cost": 97.704}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 01:04:37", "grab_time": "2024-08-06 01:02:59"}
{"id": 2211673, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "674f17c0-9100-4a4e-9540-4eac7da0fe86", "title": "胃癌根治术标本的规范化外科处理中国专家共识（2022版）", "text": "【0】页码:2\n胃癌根治术标本的规范化外科处理中国专家共识（2022版）\n### Image to Markdown Conversion\n\n【1】#### 2.2.2 $\\text{Al}^{3+}$离子模板对MIPs识别性能的影响\n通过控制变量法对不同模板用量下MIPs对$\\text{BPA}$的吸附量进行了研究。图4显示了模板用量对MIPs吸附$\\text{BPA}$的影响。可以看出，随着$\\text{Al}^{3+}$用量的增加，MIPs对$\\text{BPA}$的吸附量先增大后减小。当$\\text{Al}^{3+}$与$\\text{BPA}$的摩尔比为4:1时，MIPs对$\\text{BPA}$的吸附量最大，达到15.24 mg/g。这是由于适量的模板可以在聚合过程中形成更多的印迹位点，提高MIPs的选择性。但过量的模板会导致模板与功能单体之间的相互作用过强，形成的印迹位点过于稳定，不易于模板分子从印迹位点解脱，进而影响MIPs对目标分子的识别。\n\n【2】#### 2.2.3 吸附动力学\n吸附动力学研究通过考察吸附时间对吸附量的影响，探讨MIPs对目标分子的吸附速率。图5为MIPs和NIPs吸附$\\text{BPA}$的动力学曲线。由图可知，MIPs在前60 min内吸附量迅速增加，之后逐渐达到吸附平衡。而NIPs在整个吸附过程中，吸附量变化较小。这表明MIPs对$\\text{BPA}$的吸附速率较快，并在较短时间内达到吸附平衡。\n\n| 时间 (min) | 吸附量 (mg/g) | 吸附量 (mg/g) |\n| ---------- | -------------- | -------------- |\n|            | $\\text{MIPs}$  | $\\text{NIPs}$  |\n| 10         | 5.87           | 1.23           |\n| 20         | 10.16          | 2.04           |\n| 30         | 12.54          | 2.76           |\n| 40         | 13.84          | 3.12           |\n| 50         | 14.55          | 3.35           |\n| 60         | 15.01          | 3.54           |\n| 70         | 15.23          | 3.68           |\n| 80         | 15.24          | 3.72           |\n| 90         | 15.24          | 3.73           |\n\n【4】#### 2.2.4 吸附等温线\n吸附等温线研究通过考察不同初始浓度对吸附量的影响，分析MIPs对目标分子的吸附能力。图6显示了MIPs和NIPs吸附$\\text{BPA}$的等温线。由图可知，MIPs对$\\text{BPA}$的吸附量随初始浓度的增加而增大，并在一定浓度范围内达到饱和。这表明MIPs具有良好的吸附能力和选择性。\n\n| 初始浓度 (mg/L) | 吸附量 (mg/g) | 吸附量 (mg/g) |\n| ---------------- | -------------- | -------------- |\n|                  | $\\text{MIPs}$  | $\\text{NIPs}$  |\n| 10               | 3.21           | 1.11           |\n| 20               | 6.45           | 2.32           |\n| 30               | 9.67           | 3.47           |\n| 40               | 12.54          | 4.56           |\n| 50               | 14.23          | 5.21           |\n| 60               | 15.24          | 5.74           |\n\n【6】由以上结果可知，MIPs对$\\text{BPA}$的吸附性能显著优于NIPs，且其吸附行为符合Langmuir吸附模型。", "tags": {}, "lang": "None", "attr": {"page_num": 2, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/胃癌根治术标本的规范化外科处理中国专家共识（2022版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:2\n\n胃癌根治术标本的规范化外科处理中国专家共识（2022版）\n\nImage to Markdown Conversion\n【1】#### 2.2.2 \nAl\n3\n+\n离子模板对MIPs识别性能的影响\n\n通过控制变量法对不同模板用量下MIPs对\nBPA\n的吸附量进行了研究。图4显示了模板用量对MIPs吸附\nBPA\n的影响。可以看出，随着\nAl\n3\n+\n用量的增加，MIPs对\nBPA\n的吸附量先增大后减小。当\nAl\n3\n+\n与\nBPA\n的摩尔比为4:1时，MIPs对\nBPA\n的吸附量最大，达到15.24 mg/g。这是由于适量的模板可以在聚合过程中形成更多的印迹位点，提高MIPs的选择性。但过量的模板会导致模板与功能单体之间的相互作用过强，形成的印迹位点过于稳定，不易于模板分子从印迹位点解脱，进而影响MIPs对目标分子的识别。\n\n【2】#### 2.2.3 吸附动力学\n\n吸附动力学研究通过考察吸附时间对吸附量的影响，探讨MIPs对目标分子的吸附速率。图5为MIPs和NIPs吸附\nBPA\n的动力学曲线。由图可知，MIPs在前60 min内吸附量迅速增加，之后逐渐达到吸附平衡。而NIPs在整个吸附过程中，吸附量变化较小。这表明MIPs对\nBPA\n的吸附速率较快，并在较短时间内达到吸附平衡。\n\n时间 (min)\t吸附量 (mg/g)\t吸附量 (mg/g)\nMIPs\nNIPs\n10\t5.87\t1.23\n20\t10.16\t2.04\n30\t12.54\t2.76\n40\t13.84\t3.12\n50\t14.55\t3.35\n60\t15.01\t3.54\n70\t15.23\t3.68\n80\t15.24\t3.72\n90\t15.24\t3.73\n【4】#### 2.2.4 吸附等温线\n\n吸附等温线研究通过考察不同初始浓度对吸附量的影响，分析MIPs对目标分子的吸附能力。图6显示了MIPs和NIPs吸附\nBPA\n的等温线。由图可知，MIPs对\nBPA\n的吸附量随初始浓度的增加而增大，并在一定浓度范围内达到饱和。这表明MIPs具有良好的吸附能力和选择性。\n\n初始浓度 (mg/L)\t吸附量 (mg/g)\t吸附量 (mg/g)\nMIPs\nNIPs\n10\t3.21\t1.11\n20\t6.45\t2.32\n30\t9.67\t3.47\n40\t12.54\t4.56\n50\t14.23\t5.21\n60\t15.24\t5.74\n【6】由以上结果可知，MIPs对\nBPA\n的吸附性能显著优于NIPs，且其吸附行为符合Langmuir吸附模型。", "content": "【0】页码:2\n胃癌根治术标本的规范化外科处理中国专家共识（2022版）\n### Image to Markdown Conversion\n\n【1】#### 2.2.2 $\\text{Al}^{3+}$离子模板对MIPs识别性能的影响\n通过控制变量法对不同模板用量下MIPs对$\\text{BPA}$的吸附量进行了研究。图4显示了模板用量对MIPs吸附$\\text{BPA}$的影响。可以看出，随着$\\text{Al}^{3+}$用量的增加，MIPs对$\\text{BPA}$的吸附量先增大后减小。当$\\text{Al}^{3+}$与$\\text{BPA}$的摩尔比为4:1时，MIPs对$\\text{BPA}$的吸附量最大，达到15.24 mg/g。这是由于适量的模板可以在聚合过程中形成更多的印迹位点，提高MIPs的选择性。但过量的模板会导致模板与功能单体之间的相互作用过强，形成的印迹位点过于稳定，不易于模板分子从印迹位点解脱，进而影响MIPs对目标分子的识别。\n\n【2】#### 2.2.3 吸附动力学\n吸附动力学研究通过考察吸附时间对吸附量的影响，探讨MIPs对目标分子的吸附速率。图5为MIPs和NIPs吸附$\\text{BPA}$的动力学曲线。由图可知，MIPs在前60 min内吸附量迅速增加，之后逐渐达到吸附平衡。而NIPs在整个吸附过程中，吸附量变化较小。这表明MIPs对$\\text{BPA}$的吸附速率较快，并在较短时间内达到吸附平衡。\n\n| 时间 (min) | 吸附量 (mg/g) | 吸附量 (mg/g) |\n| ---------- | -------------- | -------------- |\n|            | $\\text{MIPs}$  | $\\text{NIPs}$  |\n| 10         | 5.87           | 1.23           |\n| 20         | 10.16          | 2.04           |\n| 30         | 12.54          | 2.76           |\n| 40         | 13.84          | 3.12           |\n| 50         | 14.55          | 3.35           |\n| 60         | 15.01          | 3.54           |\n| 70         | 15.23          | 3.68           |\n| 80         | 15.24          | 3.72           |\n| 90         | 15.24          | 3.73           |\n\n【4】#### 2.2.4 吸附等温线\n吸附等温线研究通过考察不同初始浓度对吸附量的影响，分析MIPs对目标分子的吸附能力。图6显示了MIPs和NIPs吸附$\\text{BPA}$的等温线。由图可知，MIPs对$\\text{BPA}$的吸附量随初始浓度的增加而增大，并在一定浓度范围内达到饱和。这表明MIPs具有良好的吸附能力和选择性。\n\n| 初始浓度 (mg/L) | 吸附量 (mg/g) | 吸附量 (mg/g) |\n| ---------------- | -------------- | -------------- |\n|                  | $\\text{MIPs}$  | $\\text{NIPs}$  |\n| 10               | 3.21           | 1.11           |\n| 20               | 6.45           | 2.32           |\n| 30               | 9.67           | 3.47           |\n| 40               | 12.54          | 4.56           |\n| 50               | 14.23          | 5.21           |\n| 60               | 15.24          | 5.74           |\n\n【6】由以上结果可知，MIPs对$\\text{BPA}$的吸附性能显著优于NIPs，且其吸附行为符合Langmuir吸附模型。", "index": 0, "show": true, "start": 0, "end": 1062, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "与原文不一致"}], "startTime": "2024/08/07 09:55:01", "endTime": "2024/08/07 09:55:57", "cost": 56.167}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 17:55:56", "grab_time": "2024-08-06 17:55:00"}
{"id": 2211672, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "172dee40-bda4-4837-a050-18cc9d2c0b22", "title": "（2023.V4）NCCN临床实践指南：食管和食管胃交界部癌", "text": "【0】页码:99\n（2023.V4）NCCN临床实践指南：食管和食管胃交界部癌\n疑似页眉<u>NCCN Guidelines Version 4.2023\nEsophageal and Esophagogastric Junction Cancers</u>\n\n【1】In the case of ER specimens, the depth of tumor invasion, presence of lymphovascular invasion (LVI), and status of mucosal and deep margins should also be reported. The pathology report for esophagectomy specimens without prior chemoradiation should include all elements as for ER specimens plus the location of the tumor midpoint in relation to the EGJ, whether the tumor crosses the EGJ, the lymph node status, and the number of lymph nodes recovered. In the case of esophagectomy with prior chemoradiation and without grossly obvious residual tumor, the tumor site should be thoroughly sampled, with submission of the entire EGJ or ulcer/tumor bed for specimens. The pathology report should include all elements as for esophagectomy without prior chemoradiation, plus assessment of the treatment response.\n\n【2】删除32:<u>**</u>Assessment of Treatment Response删除32:<u>**</u>\n\n【3】Response of the primary tumor to previous chemotherapy and/or radiation therapy (RT) should be reported. The prognostic significance of pathologic complete response (pCR) after induction therapy in patients with esophageal cancer has been demonstrated in several studies. Residual primary tumor in the resection specimen following preoperative therapy is associated with shorter overall survival (OS) for both SCC and adenocarcinoma of the esophagus. In a retrospective study of 235 patients, post-treatment pathologic stage was the best predictor of survival outcome for patients with locoregional carcinoma of the esophagus or EGJ who underwent preoperative chemoradiation followed by esophagectomy.\n\n【4】Although scoring systems for tumor response in esophageal cancer have not been uniformly adopted, the panel recommends using the modified Ryan scheme in the College of American Pathologists (CAP) Cancer Protocol for Esophageal Carcinoma because it generally provides good reproducibility among pathologists. The following scheme is suggested: 0 (complete response; no viable cancer cells, including lymph nodes); 1 (near complete response; single cells or rare small groups of cancer cells); 2 (partial response; residual cancer cells with evident tumor regression, but more than single cells or rare small groups of cancer cells); and 3 (poor or no response; extensive residual cancer with no evident tumor regression). Because of the impact of residual nodal metastases on survival, it is recommended that lymph nodes be included in the regression score. Sizable pools of acellular mucin may be present after chemoradiation, but they should not be interpreted as representing residual tumor.\n\n【5】删除32:<u>**</u>Role of FDG-PET Scans in the Assessment of Treatment Response删除32:<u>**</u>\n\n【6】The prognostic significance of metabolic response after preoperative therapy, as measured by a decrease in 18-FDG standardized uptake value (SUV) on post-treatment PET scan, has been evaluated in many studies in patients with locally advanced esophageal or EGJ cancer. In many retrospective studies, a decrease in FDG SUV on post-treatment PET scan was a predictive factor that correlated with pathologic response and improved survival. However, the cut-off values for the reduction in FDG SUV between pre- and post-treatment scans and the percent change in FDG SUV between pre- and post-treatment scans used to distinguish metabolic responders from non-responders varied widely between studies. In a study by Cerfolio et al, the median SUV of esophageal cancer decreased by 72% in patients who were complete pathologic responders, by 58% in patients who were partial responders, and by 37% in patients who had a minimal pathologic response. In this study, patients were likely to be complete pathologic responders when the SUV decreased by more than 64% (P = .003) between pre- and post-treatment FDG-PET scans. In a similar study, Smith et al reported that patients who had a decrease in SUV greater than 50% had a 12-month disease-free survival (DFS) advantage over patients who had a decrease in SUV less than 50% (93% vs. 43%; P = .025). Regardless of the cut-off values used, these studies all concluded that FDG-PET is predictive", "tags": {}, "lang": "en", "attr": {"page_num": 99, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V4）NCCN临床实践指南：食管和食管胃交界部癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:09:46", "endTime": "2024/08/06 17:10:59", "cost": 72.638}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 01:10:59", "grab_time": "2024-08-06 01:09:46"}
{"id": 2211671, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "b41f9647-79c8-43eb-9d77-948cad9f5b8f", "title": "2023 ISHLT／HFSA指南：急性机械循环支持", "text": "【0】页码:35\n2023 ISHLT／HFSA指南：急性机械循环支持\n# ARTICLE IN PRESS\n## ISHLT/HFSA Guideline on Acute MCS • BERNHARDT et al\n\n【1】preoperative plasmapheresis, or the use of high- dose IV immunoglobulin, have been reported in small series with apparent success.删除17:<u>399</u> Although 80% of patients will clear the antibody by 90 days, some patients can have the heparin/PF4 antibody persist for up to 1 year. The serotonin release assay will become negative before the ELISA-detectable PF4 antibody clears.\n\n【2】### Antimicrobial Therapy\n\n【3】There are limited published data on the diagnosis and management of acute MCS device infections. Most practices are based on retrospective studies and meta-analyses of current literature, as well as expert opinion. The vast majority of the literature addresses infections related to ECMO circuits or durable MCS device infections, such as LVADs.\n\n【4】### Definitions and Types of Infection\n\n【5】Unlike definitions developed to classify infections in patients with durable VADs,400 there is no standardized classification of infections related to acute MCS devices. In a similar format, however, infections can be divided into MCS specific infections, MCS related infections, and non MCS-related infections, with some differences 删除9:<u>(Table 2.7)</u>. The main difficulty in defining device-related infections in these patients is easier to standardize. In contrast, there are \"grades\" of acute MCS, varying significantly from minimal (IABP) to maximal (central, open chest) invasiveness.\n\n【6】- MCS-specific infections include those that are specific to patients who have acute MCS devices, are related to the device hardware, and do not occur in non MCS patients. Examples include ECMO cannula infection or infection involving the surgical site where the device was inserted.\n\n【7】#### Table 2.7. Classification of LVAD and Acute MCS Device Infections\n\n删除图片描述:<u>| ![](34_0.png)                               |</u>\n|---------------------------------------------|\n| 删除32:<u>**</u>Related删除32:<u>**</u>                                 |\n| Pump pocket infection                       |\n| Driveline infection                         |\n| Endocarditis                                |\n| Bloodstream infection                       |\n| Mediastinitis                               |\n| 删除32:<u>**</u>Unrelated删除32:<u>**</u>                               |\n| Others (eg, pneumonia, UTI, C. difficile)   |\n\n【9】删除32:<u>*</u>LVAD: left ventricular assist device; MCS: mechanical circulatory support; UTI: urinary tract infection; C: difficile: Clostridium difficile infection.\n删除32:<u>**</u>With central cannulation (eg, venoarterial extracorporeal membrane oxygenation, surgical CentriMag).\n\n【10】- MCS-related infections are those that can also occur in patients who do not have an MCS device, but have unique features specific to the presence of an MCS device (eg, blood stream infection, infective endocarditis).\n- Nonacute MCS infections are those that are not affected by the presence of the device itself (eg, pneumonia, urinary tract infection, Clostridium difficile infection).\n\n【11】It can be hard to differentiate device related infections from the infections that occur owing to critical illness or ICU stay that may be related to the presence of multiple intravenous and/or intra-arterial lines and tubes.\n\n【12】### Rates of Infection\n\n【13】Infection rates differ depending on the type of acute MCS device. For example, IABP infection rate Is reported as less than 1%,401 compared with 4%-18% in patients with ECMO support.删除17:<u>402,403</u> Infection is least with peripherally inserted devices that do not require surgical cut-down, increases if the insertion of the device requires surgical cut-down or graft conduit, and is highest in centrally placed devices requiring open chest surgery, most likely owing to the large arterial contact surfaces between blood and exogenous material.删除17:<u>404</u> The risk of infection also increases with the duration of support (eg, risk is markedly higher with longer duration of ECMO support) and in patients with higher simplified acute physiology scores.删除17:<u>402,405</u>\n\n【14】### Diagnosis of Infection\n\n【15】Diagnosis of infection in patients supported with an acute MCS device can be challenging, and clinicians should maintain a high level of alertness for subtle signs. As body temperature is controlled by the ECMO circuit, using fever as a marker for infection in this population is not helpful. Serial measures of white blood cells, C-reactive protein, and procalcitonin may be used, although the systemic inflammatory response triggered by blood-prosthetic surface interaction can also cause biomarker release.删除17:<u>403</u> The diagnosis of acute MCS infection is usually based on careful review of the clinical scenario, evaluating the insertion site for presence of localized signs of infection and/or finding positive blood cultures during acute MCS support or within 48 hours of device discontinuation. It may be difficult to distinguish positive blood cultures that are due to the presence of an infected device vs another source of infection. Diagnosis can be confirmed by obtaining a culture of the explanted device cannula, keeping in mind", "tags": {}, "lang": "en", "attr": {"page_num": 35, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ISHLT／HFSA指南：急性机械循环支持.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "删除图片描述:|                                |\n\n|---------------------------------------------|\n\n| 删除32:Related删除32:                                 |\n\n| Pump pocket infection                       |\n\n| Driveline infection                         |\n\n| Endocarditis                                |\n\n| Bloodstream infection                       |\n\n| Mediastinitis                               |\n\n| 删除32:Unrelated删除32:                               |\n\n| Others (eg, pneumonia, UTI, C. difficile)   |", "content": "【0】页码:35\n2023 ISHLT／HFSA指南：急性机械循环支持\n# ARTICLE IN PRESS\n## ISHLT/HFSA Guideline on Acute MCS • BERNHARDT et al\n\n【1】preoperative plasmapheresis, or the use of high- dose IV immunoglobulin, have been reported in small series with apparent success.删除17:<u>399</u> Although 80% of patients will clear the antibody by 90 days, some patients can have the heparin/PF4 antibody persist for up to 1 year. The serotonin release assay will become negative before the ELISA-detectable PF4 antibody clears.\n\n【2】### Antimicrobial Therapy\n\n【3】There are limited published data on the diagnosis and management of acute MCS device infections. Most practices are based on retrospective studies and meta-analyses of current literature, as well as expert opinion. The vast majority of the literature addresses infections related to ECMO circuits or durable MCS device infections, such as LVADs.\n\n【4】### Definitions and Types of Infection\n\n【5】Unlike definitions developed to classify infections in patients with durable VADs,400 there is no standardized classification of infections related to acute MCS devices. In a similar format, however, infections can be divided into MCS specific infections, MCS related infections, and non MCS-related infections, with some differences 删除9:<u>(Table 2.7)</u>. The main difficulty in defining device-related infections in these patients is easier to standardize. In contrast, there are \"grades\" of acute MCS, varying significantly from minimal (IABP) to maximal (central, open chest) invasiveness.\n\n【6】- MCS-specific infections include those that are specific to patients who have acute MCS devices, are related to the device hardware, and do not occur in non MCS patients. Examples include ECMO cannula infection or infection involving the surgical site where the device was inserted.\n\n【7】#### Table 2.7. Classification of LVAD and Acute MCS Device Infections\n\n删除图片描述:<u>| ![](34_0.png)                               |</u>\n|---------------------------------------------|\n| 删除32:<u>**</u>Related删除32:<u>**</u>                                 |\n| Pump pocket infection                       |\n| Driveline infection                         |\n| Endocarditis                                |\n| Bloodstream infection                       |\n| Mediastinitis                               |\n| 删除32:<u>**</u>Unrelated删除32:<u>**</u>                               |\n| Others (eg, pneumonia, UTI, C. difficile)   |\n\n【9】删除32:<u>*</u>LVAD: left ventricular assist device; MCS: mechanical circulatory support; UTI: urinary tract infection; C: difficile: Clostridium difficile infection.\n删除32:<u>**</u>With central cannulation (eg, venoarterial extracorporeal membrane oxygenation, surgical CentriMag).\n\n【10】- MCS-related infections are those that can also occur in patients who do not have an MCS device, but have unique features specific to the presence of an MCS device (eg, blood stream infection, infective endocarditis).\n- Nonacute MCS infections are those that are not affected by the presence of the device itself (eg, pneumonia, urinary tract infection, Clostridium difficile infection).\n\n【11】It can be hard to differentiate device related infections from the infections that occur owing to critical illness or ICU stay that may be related to the presence of multiple intravenous and/or intra-arterial lines and tubes.\n\n【12】### Rates of Infection\n\n【13】Infection rates differ depending on the type of acute MCS device. For example, IABP infection rate Is reported as less than 1%,401 compared with 4%-18% in patients with ECMO support.删除17:<u>402,403</u> Infection is least with peripherally inserted devices that do not require surgical cut-down, increases if the insertion of the device requires surgical cut-down or graft conduit, and is highest in centrally placed devices requiring open chest surgery, most likely owing to the large arterial contact surfaces between blood and exogenous material.删除17:<u>404</u> The risk of infection also increases with the duration of support (eg, risk is markedly higher with longer duration of ECMO support) and in patients with higher simplified acute physiology scores.删除17:<u>402,405</u>\n\n【14】### Diagnosis of Infection\n\n【15】Diagnosis of infection in patients supported with an acute MCS device can be challenging, and clinicians should maintain a high level of alertness for subtle signs. As body temperature is controlled by the ECMO circuit, using fever as a marker for infection in this population is not helpful. Serial measures of white blood cells, C-reactive protein, and procalcitonin may be used, although the systemic inflammatory response triggered by blood-prosthetic surface interaction can also cause biomarker release.删除17:<u>403</u> The diagnosis of acute MCS infection is usually based on careful review of the clinical scenario, evaluating the insertion site for presence of localized signs of infection and/or finding positive blood cultures during acute MCS support or within 48 hours of device discontinuation. It may be difficult to distinguish positive blood cultures that are due to the presence of an infected device vs another source of infection. Diagnosis can be confirmed by obtaining a culture of the explanted device cannula, keeping in mind", "index": 1879, "show": true, "start": 1879, "end": 2373, "province": ["格式规范性", "表格格式错误"], "isEdit": false}], "startTime": "2024/08/06 17:01:27", "endTime": "2024/08/06 17:02:11", "cost": 43.942}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 01:02:11", "grab_time": "2024-08-06 01:01:26"}
{"id": 2211670, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "9bd91a23-a0e1-41ef-95b1-afa3f1822cb0", "title": "2023 IWGDF IDSA指南：糖尿病患者足部感染的诊断和治疗", "text": "【0】页码:1\n2023 IWGDF IDSA指南：糖尿病患者足部感染的诊断和治疗\n(本页删除)本页被模型判断为参考页删除图片描述:<u>![](0_0.png)    </u>\n\n【1】Guidelines on the diagnosis and treatment of foot infection in persons with diabetes\n\n【2】IWGDF/IDSA 2023\n\n【3】Part of the 2023 IWGDF Guidelines on the prevention and management of diabetes-related foot disease", "tags": {}, "lang": "en", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 IWGDF IDSA指南：糖尿病患者足部感染的诊断和治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:01:39", "endTime": "2024/08/06 16:01:51", "cost": 11.54}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:01:51", "grab_time": "2024-08-06 00:01:29"}
{"id": 2211669, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "cbd2aee2-4ffd-4cfa-9a38-5841fdb15d47", "title": "COVID-19后综合征的饮食建议（2022）", "text": "【0】页码:8\nCOVID-19后综合征的饮食建议（2022）\nNotably, vitamin D deficiency has been reported to be common in patients with cardiovascular disease (CVD). The Mendelian randomization analyses performed in four population-based cohort studies found an inverse association between the results of coronary heart disease, stroke, and all-cause mortality with a low serum concentration of this vitamin. Acharya et al. observed that in patients with vitamin D deficiency and no history of myocardial infarction, treatment with a certain level of 25(OH)D was associated with a significantly lower risk of mortality from all causes.\n\n【1】It is interesting to mention the meta-analysis carried out by Schöttker et al., where the association between serum concentrations of 25(OH)D and mortality was investigated in different cohort studies with individuals with differences by age, sex, and country. The researchers concluded that although vitamin D levels varied according to country, sex, and the year's season, there was a consistent association between the level of 25(OH)D and all-cause and cause-specific mortality. Therefore, it is evident the major impact of vitamin D levels in several health conditions that COVID-19 patients may have; thus, their prognosis will be poorer than those who do not have this deficiency.\n\n【2】Seal et al., in their cohort study published in 2022, observed that in a total of 4599 SARS-CoV-2 positive patients, in an inverse dose-response relationship, the blood concentrations of 25(OH)D were associated independently with hospitalization and mortality related to COVID-19. Similar results were obtained in other publications, which separately concluded that these also occurred in patients with comorbidities.\n\n【3】Therefore, the ESPEN guidelines and others recommend that patients should consume 100% of the recommended daily intake (RDA). Higher intakes would be required, and a multivitamin and mineral supplement should be advised at least once daily for patients with micronutrient deficiency. The international nutritional recommendation suggests the importance of vitamin D intake (400 IU), particularly in patients with lower exposure to sunlight (i.e., long-term confinement or hospitalization).\n\n【4】### 5.4. Nutraceuticals\nOver the abovementioned nutrients, other bioactive compounds might have a pivotal role in reducing inflammation (immunosuppressants) or improving the immune response (immunostimulators).\n\n【5】Among immunosuppressants, polyphenols (quercetin, resveratrol, catechins), N-acetyl-cysteine (NAC), and palmitoylethanolamide (PEA) have demonstrated their antiviral activities, mainly involving the inhibition of inflammatory pathways (i.e., NLRP3 inflammasome-mediated IL-beta production and pro-inflammatory cytokine secretion) as well as viral replication (through the inhibition of the main viral proteases). In addition, inositol supplementation may reduce the cytokine storm, which characterizes COVID-19 infection, possibly playing a key role also in the recovery process. On the other hand, increased inflammation is a consequence of impaired oxidative status. Other vitamins and minerals with antioxidant properties, glutathione supplementation improves oxidative damage in several tissues. Therefore, the association of inositol and glutathione can represent a useful strategy to improve inflammation and oxidative status in patients with post-COVID-19 syndrome.\n\n【6】As for immunostimulators, milk proteins and peptides (bovine lactoferrin, lactoperoxidase, serum albumin, β-lactoglobulin, and α-lactalbumin) have been used as effective immune boosters, although the mechanisms underlying this beneficial effect are not completely clear. Furthermore, probiotics (i.e., Lactobacillus and Bifidobacteria) might improve the immune response, favoring the competition with pathogens for colonization in the gut and maintaining intestinal barrier integrity, thus reducing permeability to a pathogen and its microbial metabolites.\n\n【7】Finally, some nutritional compounds have been proposed as immunomodulators for the treatment of COVID-19 or to attenuate its symptoms. Glychophosphopeptical (AM3), a glucan glycopshosphopeptid, can modulate both innate and adaptive immunity. Polypodium leucotomos extract is known for its pleiotropic effect on different pathways related", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/COVID-19后综合征的饮食建议（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:39:31", "endTime": "2024/08/06 15:39:44", "cost": 13.33}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:39:45", "grab_time": "2024-08-05 23:39:31"}
{"id": 2211668, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "c1b7f94f-932e-4c32-8d7e-c504b6e72059", "title": "AHA心脏病与卒中统计报告（2022年更新）", "text": "【0】页码:261\nAHA心脏病与卒中统计报告（2022年更新）\n(本页删除)本页被模型判断为参考页### Chart 15-1. Prevalence of stroke, by age and sex, United States 删除19:<u>(NHANES, 2015–2018)</u>.\nNHANES indicates National Health and Nutrition Examination Survey. Source: Unpublished National Heart, Lung, and Blood Institute tabulation using NHANES.删除22:<u>$^{315}$</u>\n\n【1】删除图片描述:<u>![](260_0.png)</u>\n\n【2】参考删除-3:<u>### Chart 15-2. Crude stroke mortality rates among young US adults (25–64 years of age), 2008 to 2019.\nSource: Unpublished National Heart, Lung, and Blood Institute tabulation using Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiological Research.删除22:<u>$^{321}$</u></u>\n\n【3】删除图片描述:<u>![](260_3.png)</u>\n\n【4】参考删除-3:<u>### Chart 15-3. Crude stroke mortality rates among older US adults (≥65 years of age), 2008 to 2019.\nSource: Unpublished National Heart, Lung, and Blood Institute tabulation using Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiological Research.删除22:<u>$^{321}$</u></u>\n\n【5】删除图片描述:<u>![](260_1.png)</u>\n\n【6】### Chart 15-4. Stroke death rates, 2015 through 2017, among adults ≥35 years of age, by US county.\nRates are spatially smoothed to enhance the stability of rates in counties with small populations. 删除32:<u>*</u>International Classification of Diseases, 10th Revision删除32:<u>*</u> codes for stroke: I60 through I69. Source: Reprinted from National Vital Statistics System.删除22:<u>$^{317}$</u>\n\n【7】删除图片描述:<u>![](260_4.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 261, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/AHA心脏病与卒中统计报告（2022年更新）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:36:22", "endTime": "2024/08/06 16:37:04", "cost": 42.148}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:37:04", "grab_time": "2024-08-06 00:36:22"}
{"id": 2211667, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "104ea816-8294-4a04-9fb4-04533f492865", "title": "2023 欧洲指南：严重创伤出血和凝血障碍的管理（第6版）", "text": "【0】页码:15\n2023 欧洲指南：严重创伤出血和凝血障碍的管理（第6版）\ninjury was also less frequent in patients randomised to a restrictive transfusion threshold (Hb < 70 g/L) 删除12:<u>删除14:<u>[182]</u></u>. In a feasibility study, Gobatto et al. randomised 44 moderate or severe TBI patients in 2 ICUs in Brazil to a restrictive (< 70 g/L) or a liberal (100 g/L) transfusion strategy 删除12:<u>删除14:<u>[183]</u></u>. The restrictive strategy led to a haemoglobin level of 84 ± 10 g/L versus 93 ± 13 g/L and hospital mortality was lower in the liberal transfusion group (7/23 vs. 1/21). Neurological outcome at 6 months tended to be better using the liberal strategy. This is in contrast to the much larger prospective randomised study by Robertson et al. with 200 patients showing similar mortality but a more favourable neurologic outcome in the restrictive haemoglobin transfusion (Hb < 70 g/L) group 删除12:<u>[删除13:<u>181, 182</u>]</u>. In the meantime, following the haemorrhagic phase, an optimal transfusion threshold may be individualised according to brain multimodal monitoring in TBI patients.\n\n【1】### Cell salvage\n删除32:<u>**</u>Recommendation 17删除32:<u>**</u> We suggest that cell salvage be considered in the presence of severe bleeding from the abdomen, pelvic or thoracic cavity (Grade 2B).\n\n【2】Reinfusion in trauma  \nICS may be useful if allogeneic blood is not readily available after initial haemostasis is achieved. However, the use of ICS in trauma patients remains controversial because the amount of blood that can be salvaged during the acute phase of trauma-related haemorrhage is not widespread and the evidence is limited 删除12:<u>删除14:<u>[184]</u></u>. Reinfusion of autologous blood can become a potential driver for worsening impaired coagulation, endothelial disbalance and immunomodulation. Bleeding may originate from multiple injuries and large processed volumes may exacerbate haemodilution. When haemostatic measures involve damage control thoracotomy or laparotomy, a physical cavity, preferably uncontaminated, may be available from which to retrieve blood. Washing and optional double-suction can lead to removal of contaminants and microorganisms 删除12:<u>删除14:<u>[185]</u></u>. Salvaged blood can be passed through individual or double filters or with leukoreduction capacity. The immunological benefit of salvaged blood is not well defined; however, preliminary experimental studies suggest that the procedure may be advantageous 删除12:<u>删除14:<u>[186]</u></u>.\n\n【3】To date, the only randomised controlled trial in trauma patients, who underwent ICS during 44 laparotomies for penetrating injuries, showed a decrease of 4.7 allogenic pRBC units within the first 24 h without increasing postoperative infection rates and no significant difference in survival 删除12:<u>删除14:<u>[187]</u></u>. Several retrospective studies also demonstrated efficacy in reducing allogeneic transfusion, but no difference in mortality. One cohort compared the use of ICS in 47 trauma patients undergoing emergency surgery (83% laparotomies) with 47 serving as the control group. The use of ICS accounted for 40–45% of transfusion requirements and halved the number of pRBC units and fresh frozen plasma (FFP) 删除12:<u>删除14:<u>[188]</u></u>. A feasibility study was conducted in 130 patients with combat-related injuries, with 27 receiving MT (defined as > 10 pRBC in 12 h), among whom ICS was used in 17 cases. Autologous blood accounted for only 7.6% of blood products transfused. The best ratio of recovered to required pRBC mass was 39%, in patients undergoing laparotomy or thoracotomy after a gunshot wound 删除12:<u>删除14:<u>[189]</u></u>. Another review of 179 patients with penetrating and blunt abdominal trauma compared one group receiving only allogeneic blood (n = 108) to another receiving additional recovered blood (n = 71). Bleeding was significantly higher in the ICS group and the reinfused volume doubled. A logistic regression revealed that ISS > 25, systolic blood pressure < 90 mmHg and estimated blood loss > 2000 mL predicted mortality 删除12:<u>删除14:<u>[190]</u></u>.\n\n【4】In acute unstable haemorrhagic pelvic trauma, ICS may be indicated when management involves an anterior approach and/or an open reduction internal fixation through an infrapumbilical laparotomy or with retroperitoneal pelvic packing (PPP) 删除12:<u>删除14:<u>[191]</u></u>. Observational studies in deferred osteosynthesis of complex fractures are limited and whether ICS in this setting is cost-effective 删除12:<u>删除14:<u>[193]</u></u>, although in other evaluations no differences in allogeneic transfusion rates were found 删除12:<u>删除14:<u>[194]</u></u>.\n\n【5】Blood from the thoracic cavity could be recovered and re-transfused from chest drains after haemothorax or after thoracotomy. In a multi-institutional retrospective study, 272 trauma patients were allocated to two groups based on transfusion of salvaged blood from the haemothorax. There was no significant difference in in-hospital complications, mortality or 24 h post-admission coagulation. Patients who had received autologous blood had lower requirements for allogeneic blood and platelet concentrates and the cost of transfusions was significantly lower 删除12:<u>删除14:<u>[195]</u></u>.\n\n【6】There is no evidence that emergency autologous transfusion in trauma worsens clinical outcomes; however, the lack of quality randomised trials precludes a general recommendation. ICS could offer advantages for patients who refuse transfusion and in a resource-constrained environment, potentially including pre-hospital blood salvage, when transport and access to blood products are challenging 删除12:<u>删除14:<u>[196]</u></u>.\n\n【7】### Temperature management\n删除32:<u>**</u>Recommendation 18删除32:<u>**</u> We recommend early application of measures to reduce heat loss and warm the hypothermic patient to achieve and maintain normothermia (Grade 1C).", "tags": {}, "lang": "en", "attr": {"page_num": 15, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 欧洲指南：严重创伤出血和凝血障碍的管理（第6版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": []}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:55:25", "grab_time": "2024-08-05 23:46:05"}
{"id": 2211666, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "4e09b04f-2c02-47bd-a389-95b09bdb82f9", "title": "2024更新—2016 NICE指南：结核病（NG.33）", "text": "【0】页码:104\n2024更新—2016 NICE指南：结核病（NG.33）\n# Finding more information and committee details\n\n【1】To find NICE guidance on related topics, including guidance in development, see the [NICE topic pages on tuberculosis] and [vulnerable groups].\n\n【2】For full details of the evidence and the guideline committee's discussions, see the [full guideline]. You can also find information about [how the guideline was developed], including details of the committee.\n\n【3】NICE has produced [tools and resources to help you put this guideline into practice]. For general help and advice on putting our guidelines into practice, see [resources to help you put NICE guidance into practice].", "tags": {}, "lang": "en", "attr": {"page_num": 104, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024更新—2016 NICE指南：结核病（NG.33）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:09:39", "endTime": "2024/08/06 16:09:52", "cost": 12.543}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:09:52", "grab_time": "2024-08-06 00:09:39"}
{"id": 2211665, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "fbb5ed1a-9401-4b31-a0b6-d50133d21209", "title": "2023 WAO共识：食物过敏严重性定义", "text": "【0】页码:8\n2023 WAO共识：食物过敏严重性定义\n### No Statements\n删除32:<u>**</u>Agreement rate after First Round删除32:<u>**</u>\n\n【1】1. The overall DEFASE score includes all relevant domains for the appropriate classification of food allergy severity in the context of the management of food allergy. [Do you agree?] 88% (strongly agree and agree).  \n81%\n\n【2】2. About MILD severity domain referred to symptoms/signs with the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"Only cutaneous (e.g. sudden itching of eyes and nose, generalized pruritus, flushing, urticaria, angioedema) and/or mild gastrointestinal (e.g. oral pruritus, oral tingling, mild lip swelling, nausea or 1-3 emesis, mild abdominal pain) and/or rhinoconjunctivitis symptoms\" is efficient to describe this spectrum of severity?]  \n79%\n\n【3】3. About MODERATE severity domain referred to symptoms/signs with the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"Lower respiratory and/or laryngeal and/or gastrointestinal (e.g. persistent crampy abdominal pain, recurrent vomiting and/or diarrhea) and/or cardiovascular symptoms or signs (\"i.e. anaphylaxis\")\" is efficient to describe this spectrum of severity?]  \n67\\%删除32:<u>*</u>\n\n【4】4. About SEVERE severity domain referred to symptoms/signs with the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"Anaphylaxis causing respiratory and/or circulatory failure\" is efficient to describe this spectrum of severity?]  \n73%\n\n【5】5. About MILD severity domain referred to minimum therapy to treat the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"No indication for adrenaline (/epinephrine). Only symptomatic therapy (e.g. local and systemic antihistamines and/or steroids)\" is efficient to describe this spectrum of severity?]  \n71%\n\n【6】6. About MODERATE severity domain referred to minimum therapy to treat the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"Reaction(s) have always visibly responded to maximum 1 dose of i.m. adrenaline (/epinephrine)\" is efficient to describe this spectrum of severity?]  \n65\\%删除32:<u>*</u>\n\n【7】7. About SEVERE severity domain referred to minimum therapy to treat the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"At least one of the following therapies was administered to treat a previous reaction: a) two or more doses of i.m. adrenaline (/epinephrine); b) intensive care treatment (e.g. positive pressure ventilation, intubation, intravenous vasopressors, extracorporeal membrane oxygenation)\" is efficient to describe this spectrum of severity?]  \n65\\%删除32:<u>*</u>\n\n【8】8. About MILD severity domain referred to individual eliciting dose 删除9:<u>(Table 1)</u>: [do you think the following statement \"100%-25% of an age-appropriate portion of food\" is efficient to describe this spectrum of severity?]  \n56\\%删除32:<u>*</u>\n\n【9】9. About MODERATE severity domain referred to individual eliciting dose 删除9:<u>(Table 1)</u>: [do you think the following statement \"24 to 5% of an age-appropriate portion of food\" is efficient to describe this spectrum of severity?]  \n50\\%删除32:<u>*</u>\n\n【10】删除32:<u>*</u>continued删除32:<u>*</u>", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 WAO共识：食物过敏严重性定义.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "No Statements\n删除32:Agreement rate after First Round删除32:\n\n【1】1. The overall DEFASE score includes all relevant domains for the appropriate classification of food allergy severity in the context of the management of food allergy. [Do you agree?] 88% (strongly agree and agree).\n\n81%\n\n【2】2. About MILD severity domain referred to symptoms/signs with the most severe previous reaction 删除9:(Table 1): [do you think the following statement “Only cutaneous (e.g. sudden itching of eyes and nose, generalized pruritus, flushing, urticaria, angioedema) and/or mild gastrointestinal (e.g. oral pruritus, oral tingling, mild lip swelling, nausea or 1-3 emesis, mild abdominal pain) and/or rhinoconjunctivitis symptoms” is efficient to describe this spectrum of severity?]\n\n79%\n\n【3】3. About MODERATE severity domain referred to symptoms/signs with the most severe previous reaction 删除9:(Table 1): [do you think the following statement “Lower respiratory and/or laryngeal and/or gastrointestinal (e.g. persistent crampy abdominal pain, recurrent vomiting and/or diarrhea) and/or cardiovascular symptoms or signs (“i.e. anaphylaxis”)” is efficient to describe this spectrum of severity?]\n\n67%删除32:*\n\n【4】4. About SEVERE severity domain referred to symptoms/signs with the most severe previous reaction 删除9:(Table 1): [do you think the following statement “Anaphylaxis causing respiratory and/or circulatory failure” is efficient to describe this spectrum of severity?]\n\n73%\n\n【5】5. About MILD severity domain referred to minimum therapy to treat the most severe previous reaction 删除9:(Table 1): [do you think the following statement “No indication for adrenaline (/epinephrine). Only symptomatic therapy (e.g. local and systemic antihistamines and/or steroids)” is efficient to describe this spectrum of severity?]\n\n71%\n\n【6】6. About MODERATE severity domain referred to minimum therapy to treat the most severe previous reaction 删除9:(Table 1): [do you think the following statement “Reaction(s) have always visibly responded to maximum 1 dose of i.m. adrenaline (/epinephrine)” is efficient to describe this spectrum of severity?]\n\n65%删除32:*\n\n【7】7. About SEVERE severity domain referred to minimum therapy to treat the most severe previous reaction 删除9:(Table 1): [do you think the following statement “At least one of the following therapies was administered to treat a previous reaction: a) two or more doses of i.m. adrenaline (/epinephrine); b) intensive care treatment (e.g. positive pressure ventilation, intubation, intravenous vasopressors, extracorporeal membrane oxygenation)” is efficient to describe this spectrum of severity?]\n\n65%删除32:*\n\n【8】8. About MILD severity domain referred to individual eliciting dose 删除9:(Table 1): [do you think the following statement “100%-25% of an age-appropriate portion of food” is efficient to describe this spectrum of severity?]\n\n56%删除32:*\n\n【9】9. About MODERATE severity domain referred to individual eliciting dose 删除9:(Table 1): [do you think the following statement “24 to 5% of an age-appropriate portion of food” is efficient to describe this spectrum of severity?]\n\n50%删除32:*\n\n【10】删除32:continued删除32:", "content": "【0】页码:8\n2023 WAO共识：食物过敏严重性定义\n### No Statements\n删除32:<u>**</u>Agreement rate after First Round删除32:<u>**</u>\n\n【1】1. The overall DEFASE score includes all relevant domains for the appropriate classification of food allergy severity in the context of the management of food allergy. [Do you agree?] 88% (strongly agree and agree).  \n81%\n\n【2】2. About MILD severity domain referred to symptoms/signs with the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"Only cutaneous (e.g. sudden itching of eyes and nose, generalized pruritus, flushing, urticaria, angioedema) and/or mild gastrointestinal (e.g. oral pruritus, oral tingling, mild lip swelling, nausea or 1-3 emesis, mild abdominal pain) and/or rhinoconjunctivitis symptoms\" is efficient to describe this spectrum of severity?]  \n79%\n\n【3】3. About MODERATE severity domain referred to symptoms/signs with the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"Lower respiratory and/or laryngeal and/or gastrointestinal (e.g. persistent crampy abdominal pain, recurrent vomiting and/or diarrhea) and/or cardiovascular symptoms or signs (\"i.e. anaphylaxis\")\" is efficient to describe this spectrum of severity?]  \n67\\%删除32:<u>*</u>\n\n【4】4. About SEVERE severity domain referred to symptoms/signs with the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"Anaphylaxis causing respiratory and/or circulatory failure\" is efficient to describe this spectrum of severity?]  \n73%\n\n【5】5. About MILD severity domain referred to minimum therapy to treat the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"No indication for adrenaline (/epinephrine). Only symptomatic therapy (e.g. local and systemic antihistamines and/or steroids)\" is efficient to describe this spectrum of severity?]  \n71%\n\n【6】6. About MODERATE severity domain referred to minimum therapy to treat the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"Reaction(s) have always visibly responded to maximum 1 dose of i.m. adrenaline (/epinephrine)\" is efficient to describe this spectrum of severity?]  \n65\\%删除32:<u>*</u>\n\n【7】7. About SEVERE severity domain referred to minimum therapy to treat the most severe previous reaction 删除9:<u>(Table 1)</u>: [do you think the following statement \"At least one of the following therapies was administered to treat a previous reaction: a) two or more doses of i.m. adrenaline (/epinephrine); b) intensive care treatment (e.g. positive pressure ventilation, intubation, intravenous vasopressors, extracorporeal membrane oxygenation)\" is efficient to describe this spectrum of severity?]  \n65\\%删除32:<u>*</u>\n\n【8】8. About MILD severity domain referred to individual eliciting dose 删除9:<u>(Table 1)</u>: [do you think the following statement \"100%-25% of an age-appropriate portion of food\" is efficient to describe this spectrum of severity?]  \n56\\%删除32:<u>*</u>\n\n【9】9. About MODERATE severity domain referred to individual eliciting dose 删除9:<u>(Table 1)</u>: [do you think the following statement \"24 to 5% of an age-appropriate portion of food\" is efficient to describe this spectrum of severity?]  \n50\\%删除32:<u>*</u>\n\n【10】删除32:<u>*</u>continued删除32:<u>*</u>", "index": 33, "show": true, "start": 33, "end": 3173, "province": ["格式规范性", "表格格式错误"], "isEdit": false}], "startTime": "2024/08/06 16:59:01", "endTime": "2024/08/06 16:59:28", "cost": 27.181}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:59:28", "grab_time": "2024-08-06 00:59:01"}
{"id": 2211664, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "3b52ad06-6086-4c95-a952-d15c605bf79c", "title": "2023 NICE 技术鉴定指导意见：他法西单抗联合来那度胺治疗复发或难治性弥漫性大 B 细胞淋巴瘤[TA883]", "text": "【0】页码:12\n2023 NICE 技术鉴定指导意见：他法西单抗联合来那度胺治疗复发或难治性弥漫性大 B 细胞淋巴瘤[TA883]\nthat the resulting overall survival extrapolation underestimated survival for polatuzumab vedotin with bendamustine and rituximab compared with NICE's technology appraisal guidance on polatuzumab vedotin with rituximab and bendamustine. The previous NICE appraisal estimated around 3.1 mean life years and 2.1 quality-adjusted life years (QALYs). In contrast, the company's extrapolation estimated 2.2 mean life years and 1.5 QALYs. On this basis, the ERG preferred to apply a constant hazard ratio from the matching-adjusted indirect comparison, leading to 3.4 mean life years and 2.2 QALYs for polatuzumab vedotin with bendamustine and rituximab. The clinical experts considered that the company's estimates were reasonable because they were closer to the published literature estimates of median overall survival for polatuzumab vedotin with bendamustine and rituximab (between 8.2 and 12.5 months) than the ERG's. The company justified its methodology by saying that it was verified by clinical experts, produced the results most aligned with real-world evidence, and avoided unnecessary complexity. However, the committee noted that tests for proportional hazards did not support a constant hazard. So, it considered that it was not appropriate to apply constant hazard ratios to the L-MIND data, even using the piecewise approach. It also identified that better approaches were needed to handle the time-varying nature of the observed hazard ratio. The committee agreed that the company should have looked at more ways to include the data from Sehn et al. 删除11:<u>删除19:<u>(2022)</u></u> in the indirect comparisons. For example, the polatuzumab vedotin with bendamustine and rituximab hazard ratio from Sehn et al. could be applied to the survival outcomes for the propensity score-matched bendamustine and rituximab population. Or, independent survival models could be fitted to the Sehn et al. Kaplan–Meier curves, adding a third arm for tafasitamab with lenalidomide against bendamustine and rituximab from the matching-adjusted indirect comparison; this would have created a partially anchored indirect comparison. The committee was disappointed that the company did not provide such additional analyses in response to the appraisal consultation document. In addition to the ERG's arguments about the company's modelling not reflecting the absolute benefits of polatuzumab vedotin with bendamustine and rituximab, the committee considered that the modelling poorly reflected the relative benefit compared with bendamustine and rituximab alone. For example, Sehn et al. reported a hazard ratio for overall survival of 0.42 for polatuzumab", "tags": {}, "lang": "en", "attr": {"page_num": 12, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 NICE 技术鉴定指导意见：他法西单抗联合来那度胺治疗复发或难治性弥漫性大 B 细胞淋巴瘤[TA883].pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "删除11:删除19:(2022)", "content": "【0】页码:12\n2023 NICE 技术鉴定指导意见：他法西单抗联合来那度胺治疗复发或难治性弥漫性大 B 细胞淋巴瘤[TA883]\nthat the resulting overall survival extrapolation underestimated survival for polatuzumab vedotin with bendamustine and rituximab compared with NICE's technology appraisal guidance on polatuzumab vedotin with rituximab and bendamustine. The previous NICE appraisal estimated around 3.1 mean life years and 2.1 quality-adjusted life years (QALYs). In contrast, the company's extrapolation estimated 2.2 mean life years and 1.5 QALYs. On this basis, the ERG preferred to apply a constant hazard ratio from the matching-adjusted indirect comparison, leading to 3.4 mean life years and 2.2 QALYs for polatuzumab vedotin with bendamustine and rituximab. The clinical experts considered that the company's estimates were reasonable because they were closer to the published literature estimates of median overall survival for polatuzumab vedotin with bendamustine and rituximab (between 8.2 and 12.5 months) than the ERG's. The company justified its methodology by saying that it was verified by clinical experts, produced the results most aligned with real-world evidence, and avoided unnecessary complexity. However, the committee noted that tests for proportional hazards did not support a constant hazard. So, it considered that it was not appropriate to apply constant hazard ratios to the L-MIND data, even using the piecewise approach. It also identified that better approaches were needed to handle the time-varying nature of the observed hazard ratio. The committee agreed that the company should have looked at more ways to include the data from Sehn et al. 删除11:<u>删除19:<u>(2022)</u></u> in the indirect comparisons. For example, the polatuzumab vedotin with bendamustine and rituximab hazard ratio from Sehn et al. could be applied to the survival outcomes for the propensity score-matched bendamustine and rituximab population. Or, independent survival models could be fitted to the Sehn et al. Kaplan–Meier curves, adding a third arm for tafasitamab with lenalidomide against bendamustine and rituximab from the matching-adjusted indirect comparison; this would have created a partially anchored indirect comparison. The committee was disappointed that the company did not provide such additional analyses in response to the appraisal consultation document. In addition to the ERG's arguments about the company's modelling not reflecting the absolute benefits of polatuzumab vedotin with bendamustine and rituximab, the committee considered that the modelling poorly reflected the relative benefit compared with bendamustine and rituximab alone. For example, Sehn et al. reported a hazard ratio for overall survival of 0.42 for polatuzumab", "index": 1562, "show": true, "start": 1562, "end": 1578, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 15:46:54", "endTime": "2024/08/06 15:47:45", "cost": 50.71}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:47:45", "grab_time": "2024-08-05 23:46:54"}
{"id": 2211663, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "0ceee8c9-4e3f-4bad-a11c-9fd46da532b0", "title": "IG-IBD：使用生物制剂和小分子药物治疗中重度溃疡性结肠炎的临床指南（2022）", "text": "【0】页码:11\nIG-IBD：使用生物制剂和小分子药物治疗中重度溃疡性结肠炎的临床指南（2022）\n# ARTICLE IN PRESS\n\n【1】## Table 3 (continued)\n\n| Statements | Quality of evidence | Agreement rate | Panel comment beyond GRADE |\n|------------|---------------------|----------------|----------------------------|\n| 11. For adults with moderate to severe UC refractory to conventional therapy, IG-IBD suggests using combination therapy with infliximab plus an immunosuppressant rather than infliximab monotherapy for the induction of remission. | Low-quality | 55% | This recommendation arises from only one study. It should be noted that the primary endpoint of the study was set at 16 weeks. Therefore, the period of observation is limited, and there are safety concerns regarding prolonged combination therapy |\n| 12. For adults with moderate to severe UC refractory to conventional therapy, IG-IBD makes no recommendation on using combination therapy with adalimumab plus an immunosuppressant vs. adalimumab monotherapy for the induction of remission. | Knowledge gap | 95% |  |\n| 13. For adults with acute severe UC refractory to intravenous steroids, IG-IBD makes no recommendation on using infliximab vs. cyclosporine. | Very low-quality | 95% | Only one rescue therapy line (with infliximab or cyclosporine) should be attempted. A second rescue therapy poses significant safety problems with a higher mortality risk and is generally not recommended. However, it may be occasionally considered in selected cases at tertiary referral centers. |\n| 14. For adults with UC who achieved remission with infliximab, adalimumab, vedolizumab, ustekinumab or tofacitinib, IG-IBD recommends using the same drug as maintenance treatment. | High-quality for infliximab; moderate-quality for adalimumab, vedolizumab, ustekinumab, and tofacitinib | 100% |  |\n| 15. For adults with UC who achieved remission with golimumab, IG-IBD makes no recommendation on using golimumab as maintenance therapy. | Low-quality | 55% | The failure to recommend golimumab as maintenance therapy resulted from the strict critical outcomes used to assess efficacy. However, it is reasonable to continue golimumab as maintenance treatment in those cases of successful induction with golimumab. |\n| 16. For adults with moderate to severe UC, IG-IBD makes no recommendation on using an anti-TNF agent plus an immunosuppressant vs. anti-TNF agent as maintenance treatment. | Very low-quality for evidence for infliximab; knowledge gap for adalimumab and golimumab | 86% |  |\n| 17. For adults with moderate to severe UC, IG-IBD makes no recommendation on using an anti-TNF agent plus an immunosuppressant vs. immunosuppressant monotherapy as maintenance treatment. | Knowledge gap | 82% |  |\n| 18. For adults with UC who do not respond to anti-TNF agents, IG-IBD makes no recommendation on using therapeutic drug monitoring or a standard symptom-based approach of dose optimization. | Knowledge gap | 86% |  |\n| 19. For adults with UC who lost the response to anti-TNF agents and do not respond to dose escalation, IG-IBD makes no recommendation on using an anti-TNF agent plus an immunosuppressant or making a therapeutic change. | Knowledge gap | 82% | Therapeutic drug monitoring, when available, can be considered a useful tool to drive therapeutic choices in case of non-response or loss of response with anti-TNF agents. |\n| 20. For adults with UC who achieved long-term deep remission, IG-IBD makes no recommendation about the withdrawal of anti-TNF treatment. | Very low-quality | 100% | This possibility should be assessed on a case-by-case basis and discussed with the patient. In case of withdrawal, remission can be maintained with 5-aminosalicylates or thiopurines. However, the higher rate of clinical remission in patients who continue anti-TNF treatment and the risk of relapse in cases of discontinuation should always be considered. |\n\n【3】## Conflict of interest\n\n【4】FSM served as an advisory board member and/or received lecture grants from AbbVie, Biogen, Galapagos, Janssen, MSD, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals. AO served as an advisory board member for AbbVie, Galapagos, MSD, Janssen, Pfizer, Takeda Pharmaceuticals, and received lecture grants from AbbVie, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda Pharmaceuticals. CP has received consultancy fees and/or educational grants from AbbVie, Janssen, and Pfizer.", "tags": {}, "lang": "en", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/IG-IBD：使用生物制剂和小分子药物治疗中重度溃疡性结肠炎的临床指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【3】## Conflict of interest", "content": "【0】页码:11\nIG-IBD：使用生物制剂和小分子药物治疗中重度溃疡性结肠炎的临床指南（2022）\n# ARTICLE IN PRESS\n\n【1】## Table 3 (continued)\n\n| Statements | Quality of evidence | Agreement rate | Panel comment beyond GRADE |\n|------------|---------------------|----------------|----------------------------|\n| 11. For adults with moderate to severe UC refractory to conventional therapy, IG-IBD suggests using combination therapy with infliximab plus an immunosuppressant rather than infliximab monotherapy for the induction of remission. | Low-quality | 55% | This recommendation arises from only one study. It should be noted that the primary endpoint of the study was set at 16 weeks. Therefore, the period of observation is limited, and there are safety concerns regarding prolonged combination therapy |\n| 12. For adults with moderate to severe UC refractory to conventional therapy, IG-IBD makes no recommendation on using combination therapy with adalimumab plus an immunosuppressant vs. adalimumab monotherapy for the induction of remission. | Knowledge gap | 95% |  |\n| 13. For adults with acute severe UC refractory to intravenous steroids, IG-IBD makes no recommendation on using infliximab vs. cyclosporine. | Very low-quality | 95% | Only one rescue therapy line (with infliximab or cyclosporine) should be attempted. A second rescue therapy poses significant safety problems with a higher mortality risk and is generally not recommended. However, it may be occasionally considered in selected cases at tertiary referral centers. |\n| 14. For adults with UC who achieved remission with infliximab, adalimumab, vedolizumab, ustekinumab or tofacitinib, IG-IBD recommends using the same drug as maintenance treatment. | High-quality for infliximab; moderate-quality for adalimumab, vedolizumab, ustekinumab, and tofacitinib | 100% |  |\n| 15. For adults with UC who achieved remission with golimumab, IG-IBD makes no recommendation on using golimumab as maintenance therapy. | Low-quality | 55% | The failure to recommend golimumab as maintenance therapy resulted from the strict critical outcomes used to assess efficacy. However, it is reasonable to continue golimumab as maintenance treatment in those cases of successful induction with golimumab. |\n| 16. For adults with moderate to severe UC, IG-IBD makes no recommendation on using an anti-TNF agent plus an immunosuppressant vs. anti-TNF agent as maintenance treatment. | Very low-quality for evidence for infliximab; knowledge gap for adalimumab and golimumab | 86% |  |\n| 17. For adults with moderate to severe UC, IG-IBD makes no recommendation on using an anti-TNF agent plus an immunosuppressant vs. immunosuppressant monotherapy as maintenance treatment. | Knowledge gap | 82% |  |\n| 18. For adults with UC who do not respond to anti-TNF agents, IG-IBD makes no recommendation on using therapeutic drug monitoring or a standard symptom-based approach of dose optimization. | Knowledge gap | 86% |  |\n| 19. For adults with UC who lost the response to anti-TNF agents and do not respond to dose escalation, IG-IBD makes no recommendation on using an anti-TNF agent plus an immunosuppressant or making a therapeutic change. | Knowledge gap | 82% | Therapeutic drug monitoring, when available, can be considered a useful tool to drive therapeutic choices in case of non-response or loss of response with anti-TNF agents. |\n| 20. For adults with UC who achieved long-term deep remission, IG-IBD makes no recommendation about the withdrawal of anti-TNF treatment. | Very low-quality | 100% | This possibility should be assessed on a case-by-case basis and discussed with the patient. In case of withdrawal, remission can be maintained with 5-aminosalicylates or thiopurines. However, the higher rate of clinical remission in patients who continue anti-TNF treatment and the risk of relapse in cases of discontinuation should always be considered. |\n\n【3】## Conflict of interest\n\n【4】FSM served as an advisory board member and/or received lecture grants from AbbVie, Biogen, Galapagos, Janssen, MSD, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals. AO served as an advisory board member for AbbVie, Galapagos, MSD, Janssen, Pfizer, Takeda Pharmaceuticals, and received lecture grants from AbbVie, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda Pharmaceuticals. CP has received consultancy fees and/or educational grants from AbbVie, Janssen, and Pfizer.", "index": 3871, "show": true, "start": 3871, "end": 3897, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/06 16:43:06", "endTime": "2024/08/06 16:43:47", "cost": 41.253}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:43:48", "grab_time": "2024-08-06 00:43:06"}
{"id": 2211662, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "6db656ca-d827-479e-8d16-45760e92e88a", "title": "欧洲卒中负担报告", "text": "【0】页码:73\n欧洲卒中负担报告\n### 4. ACUTE STROKE CARE", "tags": {}, "lang": "en", "attr": {"page_num": 73, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/欧洲卒中负担报告.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:11:20", "endTime": "2024/08/06 17:11:33", "cost": 12.938}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 01:11:33", "grab_time": "2024-08-06 01:11:20"}
{"id": 2211661, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "d1445f1a-8ec0-4715-b757-dd4c0396d9ec", "title": "2023 NLA临床观点：成人血脂异常的营养干预", "text": "【0】页码:22\n2023 NLA临床观点：成人血脂异常的营养干预\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】参考删除-3:<u>85. Wanders AJ, Zock PL, Brouwer IA. Trans fat intake and its dietary sources in general populations worldwide: a systematic review. Nutrients. 2017;9删除11:<u>(8)</u>:840. doi:10.3390/nu9080840.</u>\n\n【2】参考删除-3:<u>86. Center for Food Safety and Applied Nutrition. Final determination regarding partially hydrogenated oils. U.S. Food and Drug Administration [Internet]. Published May 删除13:<u>18, 2018</u>. Accessed January 删除13:<u>14, 2023</u>删除1:<u>. Available at: https://www.fda.gov/food/food-additives-petitions/final-determination-regarding-partially-hydrogenated-oils-removing-trans-fat.</u></u>\n\n【3】参考删除-3:<u>87. Li SS, Blanco Mejia S, Lytvyn L, Stewart SE, Viguiliouk E, Ha V, et al. Effect of plant protein on blood lipids: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2017;6删除11:<u>(12)</u>:e006659. doi:10.1161/JAHA.117.006659.</u>\n\n【4】参考删除-3:<u>88. Zhao H, Song A, Zheng C, Wang M, Song G. Effects of plant protein and animal protein on lipid profile, body weight and body mass index on patients with hypercholesterolemia: a systematic review and meta-analysis. Acta Diabetol. 2020;57删除11:<u>(10)</u>:1169–1180. doi:10.1007/s00592-020-01534-4.</u>\n\n【5】参考删除-3:<u>89. Clarke R, Frost C, Collins R, Appleby P, Peto R. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ. 1997;314删除11:<u>删除19:<u>(7074)</u></u>:112–117. doi:10.1136/bmj.314.7074.112.</u>\n\n【6】参考删除-3:<u>90. Howell WH, McNamara DJ, Tosca MA, Smith BT, Gaines JA. Plasma lipid and lipoprotein responses to dietary fat and cholesterol: a meta-analysis. Am J Clin Nutr. 1997;65删除11:<u>(6)</u>:1747–1764. doi:10.1093/ajcn/65.6.1747.</u>\n\n【7】参考删除-3:<u>91. Weggemans RM, Zock PL, Katan MB. Dietary cholesterol from eggs increases the ratio of total cholesterol to high-density lipoprotein cholesterol in humans: a meta-analysis. Am J Clin Nutr. 2001;73删除11:<u>(5)</u>:885–891. doi:10.1093/ajcn/73.5.885.</u>\n\n【8】参考删除-3:<u>92. Ginsberg HN, Karmally W, Siddiqui M, Holleran S, Tall AR, Rumsey SC, et al. A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men. Arterioscler Thromb. 1994;14删除11:<u>(4)</u>:576–586. doi:10.1161/01.atv.14.4.576.</u>\n\n【9】参考删除-3:<u>93. Ginsberg HN, Karmally W, Siddiqui M, Holleran S, Tall AR, Blaner WS, et al. Increases in dietary cholesterol are associated with modest increases in both LDL and HDL cholesterol in healthy young women. Arterioscler Thromb Vasc Biol. 1995;15删除11:<u>(2)</u>:169–178. doi:10.1161/01.atv.15.2.169.</u>\n\n【10】参考删除-3:<u>94. Griffin JD, Lichtenstein AH. Dietary cholesterol and plasma lipoprotein profiles: randomized-controlled trials. Curr Nutr Rep. 2013;2删除11:<u>(4)</u>:274–282. doi:10.1007/s13668-013-0064-0.</u>\n\n【11】参考删除-3:<u>95. Carson JAS, Lichtenstein AH, Anderson CAM, Appel LJ, Kris-Etherton PM, Meyer KA, et al. Dietary Cholesterol and Cardiovascular Risk: A Science Advisory From the American Heart Association. Circulation. 2020;141删除11:<u>(3)</u>:e39–e53. doi:10.1161/CIR.0000000000000743.</u>\n\n【12】参考删除-3:<u>96. Prosky L. What is dietary fiber? J AOAC Int. 2000;83删除11:<u>(4)</u>:985–987.</u>\n\n【13】参考删除-3:<u>97. Maki KC, Davidson MH, Malik KC, Albrecht HH, O'Mullane J, Daggy BP. Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose. Am J Cardiol. 1999;84删除11:<u>(10)</u>:1198–1203. doi:10.1016/0002-9149删除11:<u>(99)</u>00534-2.</u>\n\n【14】参考删除-3:<u>98. Nie Y, Luo F. Dietary fiber: an opportunity for a global control of hyperlipidemia. Open Med Cell Longev. 2021;2021:5542342. doi:10.1155/2021/5542342.</u>\n\n【15】99. U.S. Department of Agriculture, Agricultural Research Service. Food Data Central, standard reference [Internet]. Accessed February 4, 2023删除1:<u>. Available at: https://fdc.nal.usda.gov/fdc-app.html#/component/182208.</u>\n\n【16】100. Cemel MH. Dietary Psyllium [Internet]删除1:<u>. Information from Drugs.com; c1996-2023. Updated: 26 December 2022. Accessed January 删除13:<u>14, 2023</u>. Available from: https://www.drugs.com/mtm/psyllium.html.</u>\n\n【17】参考删除-3:<u>101. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69删除11:<u>(1)</u>:30–42. doi:10.1093/ajcn/69.1.30.</u>\n\n【18】参考删除-3:<u>102. Ghavami A, Sardari S, Behnia K, Barghchi H, Natanj-Eshrtvini E, Moradi S, et al. Soluble fiber supplementation and serum lipid profile: a systematic review and dose-response meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2023:1-43):465–474. doi:10.1016/j.advnutres.2003.01.005.</u>\n\n【19】参考删除-3:<u>103. Gyling H, Plat J, Turley S, Ginsberg HN, Ellegard L, Jessup W, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014;232删除11:<u>(2)</u>:346–360. doi:10.1016/j.atherosclerosis.2013.11.043.</u>\n\n【20】参考删除-2:<u>104. Poli A, Marangoni F, Corsini A, Manzato E, Marroco W, Martini D, et al. Phytosterols, cholesterol, and cardiovascular disease. Nutrients. 2012;13删除11:<u>(8)</u>:2810. doi:10.3390/nu13082810.</u>\n\n【21】参考删除-3:<u>105. Cleveland Clinic. Phytosterols [Internet]. Updated July 删除13:<u>30, 2022</u>. Accessed May 9, 2023删除1:<u>. Available at: https://my.clevelandclinic.org/health/articles/17638-phytosterols-sterols-stanols.</u></u>\n\n【22】参考删除-3:<u>106. U.S. Pharmacopeia. USP Verified Mark [Internet]. Accessed May 9, 2023删除1:<u>. Available at: https://www.usp.org/verification-services/verified-mark.</u></u>\n\n【23】参考删除-3:<u>107. De Smet E, Mensink RP, Plat J. Effects of plant sterols and stanols on intestinal cholesterol metabolism: suggested mechanisms from past to present. Mol Nutr Food Res. 2012;56删除11:<u>(7)</u>:1058–1072. doi:10.1002/mnfr.201100722.</u>\n\n【24】参考删除-3:<u>108. Abumweis SS, Barake R, Jones PJ. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res. 2008;52. doi:10.3402/fnr.v52i0.1811.</u>\n\n【25】参考删除-3:<u>109. Musa-Veloso K, Poon TH, Elliot JA, Chung C. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2011;85删除11:<u>(1)</u>:9–28. doi:10.1016/j.plefa.2011.02.001.</u>\n\n【26】参考删除-3:<u>110. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomized controlled studies. Br J Nutr. 2014;112删除11:<u>(2)</u>:214–219. doi:10.1017/S0007114514000750.</u>\n\n【27】参考删除-3:<u>111. Rocha VZ, Tada MT, Charra AMM, Minné HA, Mizuta HJ. Update on sitosterolemia and atherosclerosis. Curr Atheroscler Rep. 2023;25删除11:<u>(5)</u>:181–187. doi:10.1007/s11883-023-01092-4.</u>\n\n【28】参考删除-3:<u>112. Berger A, Jones PJ, Abumweis SS. Plant sterols: factors affecting their efficacy and safety as functional food ingredients. Lipids Health Dis. 2004;3:5. doi:10.1186/1476-511X-3-5.</u>\n\n【29】参考删除-3:<u>113. Brinton EA, Hopkins PN, Hegele RA, Geller AS, Poliseckery DF, et al, nmderfer MR, et al. The association between hypercholesterolemia and sitosterolemia: a report of six cases in children. J Clin Lipidol. 2018;12删除11:<u>(1)</u>:152–161. doi:10.1016/j.jacl.2017.10.013.</u>\n\n【30】参考删除-3:<u>114. Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutr Rev. 2017;75删除11:<u>(9)</u>:731–767. doi:10.1093/nutrit/nux047.</u>\n\n【31】参考删除-3:<u>115. Cicero AFG, Fogacci F, Stoian AP, Vrablik M, Al Rasadi K, Banach M, et al. Nutraceuticals in the management of dyslipidemia: which, when, and for whom? Could nutraceuticals help low-risk individuals with non-optimal lipid levels? Curr Atheroscler Rep. 2022;13删除11:<u>(10)</u>:057. doi:10.1007/s11883-021-00955-y.</u>\n\n【32】参考删除-3:<u>116. Osadnik T, Goslawski M, Lewandowski P, Morze J, Osadnik K, Pawlas N, et al. A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. Pharmacol Res. 2022;183:106402. doi:10.1016/j.phrs.2022.106402.</u>\n\n【33】参考删除-3:<u>117. Banach M, Catapano AL, Cicero AFG, Escobar C, Fogger B, Katsiki N, et al. Red yeast rice for dyslipidemia and cardiovascular risk reduction: a position paper of the International Lipid Expert Panel. Pharmacol Res. 2022;183:106370. doi:10.1016/j.phrs.2022.106370.</u>\n\n【34】参考删除-3:<u>118. Cicero AFG, Fogacci F, Zamban A. Red yeast rice for hypercholesterolemia; J Cro Health Scienese Forum J Am Coll Cardiol. 2021;7删除11:<u>(17)</u>5:620–628. doi:10.1016/j.jacc.2020.11.056.</u>\n\n【35】参考删除-3:<u>119. Gerards MC, Terlou RJ, Yu H, Koks HC, Gerels VE. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain: a systematic review and meta-analysis. Atherosclerosis. 2015;240删除11:<u>(2)</u>:415–423. doi:10.1016/j.atherosclerosis.2015.04.004.</u>\n\n【36】120. Sungthong B, Vothakarn C, Pompimonshaus P, Phimarn W. Efficacy.", "tags": {}, "lang": "en", "attr": {"page_num": 22, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 NLA临床观点：成人血脂异常的营养干预.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:39:04", "endTime": "2024/08/06 15:39:11", "cost": 7.317}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:39:11", "grab_time": "2024-08-05 23:39:03"}
{"id": 2211660, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "63dc0383-d254-4d07-944a-c18c82114cae", "title": "2023 WHO 指南：疟疾", "text": "【0】页码:145\n2023 WHO 指南：疟疾\nincluding adverse events following immunization.\n\n【1】### Research priorities\nThe WHO-coordinated Malaria Vaccine Implementation Programme will continue through 2023, with continued monitoring of data on safety, impact, coverage achieved and the added benefit of the fourth dose. In areas with highly seasonal malaria or with perennial malaria transmission with seasonal peaks, operational research is needed specifically related to the seasonal delivery of vaccine doses, including annual preseason dosing after a primary series given through the routine health clinics. Further evaluation will be required to determine how best to deliver the combination of SMC and seasonal malaria vaccination in areas. Data should be collected on safety, immunogenicity, and effectiveness of annual doses beyond the fifth dose.\n\n【2】### Considerations for immunization and health systems\nThe additional visits needed for RTS,S/AS01 are opportunities to provide other integrated and preventive health services. Efforts should be made to take advantage of these visits to catch up on missed vaccinations, administer Vitamin A, carry out deworming and other preventive interventions, and remind parents of the importance of continuing to use an ITN every night and seeking prompt diagnosis and treatment for fever.\n\n【3】### A framework for allocation of limited supply\nSupplies of the RTS,S/AS01 vaccine are expected to be limited in the short to medium term, and demand is expected to be high. WHO is working with partners to develop a framework to guide the allocation of the initial limited doses of malaria vaccine, using a transparent process that incorporates input from key parties, with appropriate representation and consultation. This framework will include dimensions of market dynamics, learning from experience, scientific evidence for high impact, implementation considerations and social values, including fairness and equity.\n\n【4】## Evidence To Decision\n\n【5】### Benefits and harms\nThe RTS,S/AS01 vaccine, provided in a four-dose schedule, has been demonstrated in clinical trials and the pilot implementation studies to have meaningful impact, with a substantial reduction in hospitalization for life-threatening severe malaria, which is considered to be a surrogate indicator for the impact on mortality.\n\n【6】- There were significant reductions in clinical malaria (51%) and severe malaria (45%), demonstrated after 12 months' follow-up of the first three doses in the Phase 3 trial 删除12:<u>删除14:<u>[143]</u></u>.\n- There were significant reductions in clinical malaria (39%); severe malaria (29%); severe malaria anaemia (61%); malaria-related hospitalization (37%); and the need for blood transfusions (30%), demonstrated over 46 months' follow-up after the first three doses in the Phase 3 trial in children who received a fourth dose 18 months after the third dose 删除12:<u>删除14:<u>[143]</u></u>.\n- There were 1774 clinical malaria cases averted per 1000 children vaccinated with four RTS,S/AS01 doses over 46 months' follow-up in the Phase 3 trial 删除12:<u>删除14:<u>[143]</u></u>.\n- There were significant reductions in clinical malaria (24%) demonstrated after 7 years' follow-up after vaccination among a subset of children in the Phase 3 trial living in areas of moderate to high transmission; they did not have an excess risk of clinical or severe malaria 删除12:<u>删除14:<u>[154]</u></u>.\n- There were significant reductions in hospitalization with severe malaria (29%) and hospitalization with malarial parasitemia or antigenemia (21%), demonstrated among children who were age-eligible for three doses of vaccine delivered through routine systems by the ministries of health in parts of Ghana, Kenya, and Malawi 删除19:<u>(Milligan et al. unpublished evidence)</u>.\n- Median estimates ranged from 200 to 700 deaths averted per 100 000 children vaccinated with a 4-dose schedule in areas of moderate to high transmission 删除12:<u>删除14:<u>[156]</u></u>.\n- There were substantially greater reductions in uncomplicated malaria (63%), hospital admissions with severe malaria (70%), and death from malaria (73%) among children who received the combination of RTS,S/AS01 seasonal vaccination and SMC when compared to SMC alone. Seasonal vaccination with RTS,S/AS01 before the peak transmission season was non-inferior to SMC in preventing clinical malaria 删除12:<u>删除14:<u>[145]</u></u>.\n\n【7】The RTS,S/AS01 vaccine is safe and well tolerated 删除12:<u>删除14:<u>[153]</u></u>.\n\n【8】- There is a small risk of febrile seizures within seven days (mainly within 2–3 days) of vaccination 删除12:<u>删除14:<u>[144]</u></u>.\n- As with any vaccine introduction, proper planning and training of staff to conduct appropriate pharmacovigilance should take place beforehand 删除12:<u>删除14:<u>[153]</u></u>.", "tags": {}, "lang": "en", "attr": {"page_num": 145, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 WHO 指南：疟疾.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/07 09:47:11", "endTime": "2024/08/07 09:48:05", "cost": 54.15}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 17:48:04", "grab_time": "2024-08-06 17:47:10"}
{"id": 2211659, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "153646db-fb98-4609-9bc2-5ae2919c0f90", "title": "儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）", "text": "【0】页码:4\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n北京中医药大学学报\n\n【1】第47卷\n\n【2】删除32:<u>**</u>删除11:<u>(3)</u> 肺脾气虚证删除32:<u>**</u>\n\n【3】本证病程较长，平易感冒，感冒后病情加重。 面色萎黄及复作，倦少。尿中多泡沫，血尿，蛋白尿；或伴有肢体水肿，多汗，乏力，气短懒言，口淡不渴，舌淡有齿痕， 苔白，脉沉细。\n\n【4】删除32:<u>**</u>删除11:<u>(4)</u> 气阴两虚证删除32:<u>**</u>\n\n【5】本证病程较长，多见干长时期大摄氏使用激素后，紫癜反复明白， \n口渴， 膝软。 紫窍反思中多泡沫，小便短赤， 血尿，蛋白尿；多汗，乏力，易感冒，手足心热，盗汗，面色潮红。舌红少津，苔薄或无，脉细无力。\n\n【6】删除32:<u>**</u>删除11:<u>(5)</u> 脾肾阳虚证删除32:<u>**</u>\n\n【7】本证病程较长，紫癜反复新出，晦少，舌质紫暗或有紫斑，脉被细。实验室检查可见纤维蛋白原，D- 二聚体升高，凝血酶原时间缩短。\n\n【8】删除32:<u>**</u>删除11:<u>(2)</u> 风热证删除32:<u>**</u>\n\n【9】本证多作上呼吸道感染。证见发热，流涕，咽喉，咽红，或伴发热，或皮肤紫癜，色红。舌红，苔薄白，脉浮数。\n\n【10】删除32:<u>**</u>删除11:<u>(3)</u> 风热证删除32:<u>**</u>\n\n【11】本证病程短，皮肤紫癜，色红或紫红，数量多， 面积大；或腹痛，便血，小便黄或赤。舌质红或紫红， 舌苔黄干，脉渴数或涩滑。\n\n【12】### 6 治疗\n\n【13】#### 6.1 儿童紫癜性肾炎中西医病证结合方案的选择\n\n【14】删除图片描述:<u>![](3_0.png)</u>\n\n【15】删除图片描述:<u>图1 儿童过敏性紫癜性肾炎中西医病证结合方案的诊疗流程图</u>\n\n【16】删除图片描述:<u>Fig.删除16:<u> 1 </u>Diagnosis and treatment flow chart of the integrated of traditional Chinese and western medicine in children with Henoch-Schönlein purpura nephritis</u>\n\n【17】#### 6.1.1 孤立性血尿型\n\n【18】推荐采用中医辨证论治 (GPS)。\n\n【19】#### 6.1.2 孤立性蛋白尿型、血尿兼蛋白尿型\n\n【20】推荐采用中西医结合治疗删除12:<u>删除14:<u>[5,15,12]</u></u>。具体治疗方案需根据主管自然的严重度及分别: 长度蛋白尿子值管紫癜素转换抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物，联合中医辨证论治 (GPS).\n\n【21】#### 6.1.3 胞兼综合征型与总性蛋皮型\n\n【22】均推荐以西医治为主删除12:<u>[5,17,19-删除13:<u>20, 23</u>-31]</u>激素和(或)免疫抑制剂+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物， 在此基础。\n\n【23】联合中医辨证论治(C 级证据，强推荐)。\n\n【24】#### 6.1.4 急进性紫炎型\n\n【25】推荐西医治疗删除12:<u>删除14:<u>[5]</u></u>。激素+血管紧张素转换酶抑制剂或血管紧张素受体抑制剂类药物+抗凝药物或血液净化(GPS)。\n\n【26】实验说明，由于血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂可通过减少肿内凝蛋性，临床医师可根据患者胃肠滤法学的水平进度使用。\n\n【27】#### 6.1.5 慢性肾炎综合型\n\n【28】推荐中西医结合治疗删除12:<u>删除14:<u>[17-19-20]</u></u>,激素+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物, 在此基础上联合中医辨证论治(D 级证据，强推荐)。", "tags": {}, "lang": "zh", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": " 面色萎黄及复作，倦少。尿中多泡沫，血尿，蛋白尿；或伴有肢体水肿，多汗，乏力，气短懒言，口淡不渴，舌淡有齿痕， 苔白，脉沉细。", "content": "【0】页码:4\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n北京中医药大学学报\n\n【1】第47卷\n\n【2】删除32:<u>**</u>删除11:<u>(3)</u> 肺脾气虚证删除32:<u>**</u>\n\n【3】本证病程较长，平易感冒，感冒后病情加重。 面色萎黄及复作，倦少。尿中多泡沫，血尿，蛋白尿；或伴有肢体水肿，多汗，乏力，气短懒言，口淡不渴，舌淡有齿痕， 苔白，脉沉细。\n\n【4】删除32:<u>**</u>删除11:<u>(4)</u> 气阴两虚证删除32:<u>**</u>\n\n【5】本证病程较长，多见干长时期大摄氏使用激素后，紫癜反复明白， \n口渴， 膝软。 紫窍反思中多泡沫，小便短赤， 血尿，蛋白尿；多汗，乏力，易感冒，手足心热，盗汗，面色潮红。舌红少津，苔薄或无，脉细无力。\n\n【6】删除32:<u>**</u>删除11:<u>(5)</u> 脾肾阳虚证删除32:<u>**</u>\n\n【7】本证病程较长，紫癜反复新出，晦少，舌质紫暗或有紫斑，脉被细。实验室检查可见纤维蛋白原，D- 二聚体升高，凝血酶原时间缩短。\n\n【8】删除32:<u>**</u>删除11:<u>(2)</u> 风热证删除32:<u>**</u>\n\n【9】本证多作上呼吸道感染。证见发热，流涕，咽喉，咽红，或伴发热，或皮肤紫癜，色红。舌红，苔薄白，脉浮数。\n\n【10】删除32:<u>**</u>删除11:<u>(3)</u> 风热证删除32:<u>**</u>\n\n【11】本证病程短，皮肤紫癜，色红或紫红，数量多， 面积大；或腹痛，便血，小便黄或赤。舌质红或紫红， 舌苔黄干，脉渴数或涩滑。\n\n【12】### 6 治疗\n\n【13】#### 6.1 儿童紫癜性肾炎中西医病证结合方案的选择\n\n【14】删除图片描述:<u>![](3_0.png)</u>\n\n【15】删除图片描述:<u>图1 儿童过敏性紫癜性肾炎中西医病证结合方案的诊疗流程图</u>\n\n【16】删除图片描述:<u>Fig.删除16:<u> 1 </u>Diagnosis and treatment flow chart of the integrated of traditional Chinese and western medicine in children with Henoch-Schönlein purpura nephritis</u>\n\n【17】#### 6.1.1 孤立性血尿型\n\n【18】推荐采用中医辨证论治 (GPS)。\n\n【19】#### 6.1.2 孤立性蛋白尿型、血尿兼蛋白尿型\n\n【20】推荐采用中西医结合治疗删除12:<u>删除14:<u>[5,15,12]</u></u>。具体治疗方案需根据主管自然的严重度及分别: 长度蛋白尿子值管紫癜素转换抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物，联合中医辨证论治 (GPS).\n\n【21】#### 6.1.3 胞兼综合征型与总性蛋皮型\n\n【22】均推荐以西医治为主删除12:<u>[5,17,19-删除13:<u>20, 23</u>-31]</u>激素和(或)免疫抑制剂+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物， 在此基础。\n\n【23】联合中医辨证论治(C 级证据，强推荐)。\n\n【24】#### 6.1.4 急进性紫炎型\n\n【25】推荐西医治疗删除12:<u>删除14:<u>[5]</u></u>。激素+血管紧张素转换酶抑制剂或血管紧张素受体抑制剂类药物+抗凝药物或血液净化(GPS)。\n\n【26】实验说明，由于血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂可通过减少肿内凝蛋性，临床医师可根据患者胃肠滤法学的水平进度使用。\n\n【27】#### 6.1.5 慢性肾炎综合型\n\n【28】推荐中西医结合治疗删除12:<u>删除14:<u>[17-19-20]</u></u>,激素+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物, 在此基础上联合中医辨证论治(D 级证据，强推荐)。", "index": 131, "show": true, "start": 131, "end": 194, "province": ["格式规范性", "缺少换行"], "isEdit": false}, {"text": "【5】本证病程较长，多见干长时期大摄氏使用激素后，紫癜反复明白，", "content": "【0】页码:4\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n北京中医药大学学报\n\n【1】第47卷\n\n【2】删除32:<u>**</u>删除11:<u>(3)</u> 肺脾气虚证删除32:<u>**</u>\n\n【3】本证病程较长，平易感冒，感冒后病情加重。<mark> 面色萎黄及复作，倦少。尿中多泡沫，血尿，蛋白尿；或伴有肢体水肿，多汗，乏力，气短懒言，口淡不渴，舌淡有齿痕， 苔白，脉沉细。</mark>\n\n【4】删除32:<u>**</u>删除11:<u>(4)</u> 气阴两虚证删除32:<u>**</u>\n\n【5】本证病程较长，多见干长时期大摄氏使用激素后，紫癜反复明白， \n口渴， 膝软。 紫窍反思中多泡沫，小便短赤， 血尿，蛋白尿；多汗，乏力，易感冒，手足心热，盗汗，面色潮红。舌红少津，苔薄或无，脉细无力。\n\n【6】删除32:<u>**</u>删除11:<u>(5)</u> 脾肾阳虚证删除32:<u>**</u>\n\n【7】本证病程较长，紫癜反复新出，晦少，舌质紫暗或有紫斑，脉被细。实验室检查可见纤维蛋白原，D- 二聚体升高，凝血酶原时间缩短。\n\n【8】删除32:<u>**</u>删除11:<u>(2)</u> 风热证删除32:<u>**</u>\n\n【9】本证多作上呼吸道感染。证见发热，流涕，咽喉，咽红，或伴发热，或皮肤紫癜，色红。舌红，苔薄白，脉浮数。\n\n【10】删除32:<u>**</u>删除11:<u>(3)</u> 风热证删除32:<u>**</u>\n\n【11】本证病程短，皮肤紫癜，色红或紫红，数量多， 面积大；或腹痛，便血，小便黄或赤。舌质红或紫红， 舌苔黄干，脉渴数或涩滑。\n\n【12】### 6 治疗\n\n【13】#### 6.1 儿童紫癜性肾炎中西医病证结合方案的选择\n\n【14】删除图片描述:<u>![](3_0.png)</u>\n\n【15】删除图片描述:<u>图1 儿童过敏性紫癜性肾炎中西医病证结合方案的诊疗流程图</u>\n\n【16】删除图片描述:<u>Fig.删除16:<u> 1 </u>Diagnosis and treatment flow chart of the integrated of traditional Chinese and western medicine in children with Henoch-Schönlein purpura nephritis</u>\n\n【17】#### 6.1.1 孤立性血尿型\n\n【18】推荐采用中医辨证论治 (GPS)。\n\n【19】#### 6.1.2 孤立性蛋白尿型、血尿兼蛋白尿型\n\n【20】推荐采用中西医结合治疗删除12:<u>删除14:<u>[5,15,12]</u></u>。具体治疗方案需根据主管自然的严重度及分别: 长度蛋白尿子值管紫癜素转换抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物，联合中医辨证论治 (GPS).\n\n【21】#### 6.1.3 胞兼综合征型与总性蛋皮型\n\n【22】均推荐以西医治为主删除12:<u>[5,17,19-删除13:<u>20, 23</u>-31]</u>激素和(或)免疫抑制剂+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物， 在此基础。\n\n【23】联合中医辨证论治(C 级证据，强推荐)。\n\n【24】#### 6.1.4 急进性紫炎型\n\n【25】推荐西医治疗删除12:<u>删除14:<u>[5]</u></u>。激素+血管紧张素转换酶抑制剂或血管紧张素受体抑制剂类药物+抗凝药物或血液净化(GPS)。\n\n【26】实验说明，由于血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂可通过减少肿内凝蛋性，临床医师可根据患者胃肠滤法学的水平进度使用。\n\n【27】#### 6.1.5 慢性肾炎综合型\n\n【28】推荐中西医结合治疗删除12:<u>删除14:<u>[17-19-20]</u></u>,激素+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物, 在此基础上联合中医辨证论治(D 级证据，强推荐)。", "index": 263, "show": true, "start": 250, "end": 282, "province": ["语义有效性", "语义不完整"], "isEdit": false}, {"text": "舌质紫暗或有紫斑，脉被细。实验室检查可见纤维蛋白原，D- 二聚体升高，凝血酶原时间缩短。", "content": "【0】页码:4\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n北京中医药大学学报\n\n【1】第47卷\n\n【2】删除32:<u>**</u>删除11:<u>(3)</u> 肺脾气虚证删除32:<u>**</u>\n\n【3】本证病程较长，平易感冒，感冒后病情加重。<mark> 面色萎黄及复作，倦少。尿中多泡沫，血尿，蛋白尿；或伴有肢体水肿，多汗，乏力，气短懒言，口淡不渴，舌淡有齿痕， 苔白，脉沉细。</mark>\n\n【4】删除32:<u>**</u>删除11:<u>(4)</u> 气阴两虚证删除32:<u>**</u>\n\n<mark>【5】本证病程较长，多见干长时期大摄氏使用激素后，紫癜反复明白，</mark> \n口渴， 膝软。 紫窍反思中多泡沫，小便短赤， 血尿，蛋白尿；多汗，乏力，易感冒，手足心热，盗汗，面色潮红。舌红少津，苔薄或无，脉细无力。\n\n【6】删除32:<u>**</u>删除11:<u>(5)</u> 脾肾阳虚证删除32:<u>**</u>\n\n【7】本证病程较长，紫癜反复新出，晦少，舌质紫暗或有紫斑，脉被细。实验室检查可见纤维蛋白原，D- 二聚体升高，凝血酶原时间缩短。\n\n【8】删除32:<u>**</u>删除11:<u>(2)</u> 风热证删除32:<u>**</u>\n\n【9】本证多作上呼吸道感染。证见发热，流涕，咽喉，咽红，或伴发热，或皮肤紫癜，色红。舌红，苔薄白，脉浮数。\n\n【10】删除32:<u>**</u>删除11:<u>(3)</u> 风热证删除32:<u>**</u>\n\n【11】本证病程短，皮肤紫癜，色红或紫红，数量多， 面积大；或腹痛，便血，小便黄或赤。舌质红或紫红， 舌苔黄干，脉渴数或涩滑。\n\n【12】### 6 治疗\n\n【13】#### 6.1 儿童紫癜性肾炎中西医病证结合方案的选择\n\n【14】删除图片描述:<u>![](3_0.png)</u>\n\n【15】删除图片描述:<u>图1 儿童过敏性紫癜性肾炎中西医病证结合方案的诊疗流程图</u>\n\n【16】删除图片描述:<u>Fig.删除16:<u> 1 </u>Diagnosis and treatment flow chart of the integrated of traditional Chinese and western medicine in children with Henoch-Schönlein purpura nephritis</u>\n\n【17】#### 6.1.1 孤立性血尿型\n\n【18】推荐采用中医辨证论治 (GPS)。\n\n【19】#### 6.1.2 孤立性蛋白尿型、血尿兼蛋白尿型\n\n【20】推荐采用中西医结合治疗删除12:<u>删除14:<u>[5,15,12]</u></u>。具体治疗方案需根据主管自然的严重度及分别: 长度蛋白尿子值管紫癜素转换抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物，联合中医辨证论治 (GPS).\n\n【21】#### 6.1.3 胞兼综合征型与总性蛋皮型\n\n【22】均推荐以西医治为主删除12:<u>[5,17,19-删除13:<u>20, 23</u>-31]</u>激素和(或)免疫抑制剂+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物， 在此基础。\n\n【23】联合中医辨证论治(C 级证据，强推荐)。\n\n【24】#### 6.1.4 急进性紫炎型\n\n【25】推荐西医治疗删除12:<u>删除14:<u>[5]</u></u>。激素+血管紧张素转换酶抑制剂或血管紧张素受体抑制剂类药物+抗凝药物或血液净化(GPS)。\n\n【26】实验说明，由于血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂可通过减少肿内凝蛋性，临床医师可根据患者胃肠滤法学的水平进度使用。\n\n【27】#### 6.1.5 慢性肾炎综合型\n\n【28】推荐中西医结合治疗删除12:<u>删除14:<u>[17-19-20]</u></u>,激素+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物, 在此基础上联合中医辨证论治(D 级证据，强推荐)。", "index": 454, "show": true, "start": 428, "end": 472, "province": ["格式规范性", "缺少换行"], "isEdit": false, "comment": "7"}, {"text": "【8】删除32:删除11:(2) 风热证删除32:", "content": "【0】页码:4\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n北京中医药大学学报\n\n【1】第47卷\n\n【2】删除32:<u>**</u>删除11:<u>(3)</u> 肺脾气虚证删除32:<u>**</u>\n\n【3】本证病程较长，平易感冒，感冒后病情加重。<mark> 面色萎黄及复作，倦少。尿中多泡沫，血尿，蛋白尿；或伴有肢体水肿，多汗，乏力，气短懒言，口淡不渴，舌淡有齿痕， 苔白，脉沉细。</mark>\n\n【4】删除32:<u>**</u>删除11:<u>(4)</u> 气阴两虚证删除32:<u>**</u>\n\n<mark>【5】本证病程较长，多见干长时期大摄氏使用激素后，紫癜反复明白，</mark> \n口渴， 膝软。 紫窍反思中多泡沫，小便短赤， 血尿，蛋白尿；多汗，乏力，易感冒，手足心热，盗汗，面色潮红。舌红少津，苔薄或无，脉细无力。\n\n【6】删除32:<u>**</u>删除11:<u>(5)</u> 脾肾阳虚证删除32:<u>**</u>\n\n【7】本证病程较长，紫癜反复新出，晦少，<mark>舌质紫暗或有紫斑，脉被细。实验室检查可见纤维蛋白原，D- 二聚体升高，凝血酶原时间缩短。</mark>\n\n【8】删除32:<u>**</u>删除11:<u>(2)</u> 风热证删除32:<u>**</u>\n\n【9】本证多作上呼吸道感染。证见发热，流涕，咽喉，咽红，或伴发热，或皮肤紫癜，色红。舌红，苔薄白，脉浮数。\n\n【10】删除32:<u>**</u>删除11:<u>(3)</u> 风热证删除32:<u>**</u>\n\n【11】本证病程短，皮肤紫癜，色红或紫红，数量多， 面积大；或腹痛，便血，小便黄或赤。舌质红或紫红， 舌苔黄干，脉渴数或涩滑。\n\n【12】### 6 治疗\n\n【13】#### 6.1 儿童紫癜性肾炎中西医病证结合方案的选择\n\n【14】删除图片描述:<u>![](3_0.png)</u>\n\n【15】删除图片描述:<u>图1 儿童过敏性紫癜性肾炎中西医病证结合方案的诊疗流程图</u>\n\n【16】删除图片描述:<u>Fig.删除16:<u> 1 </u>Diagnosis and treatment flow chart of the integrated of traditional Chinese and western medicine in children with Henoch-Schönlein purpura nephritis</u>\n\n【17】#### 6.1.1 孤立性血尿型\n\n【18】推荐采用中医辨证论治 (GPS)。\n\n【19】#### 6.1.2 孤立性蛋白尿型、血尿兼蛋白尿型\n\n【20】推荐采用中西医结合治疗删除12:<u>删除14:<u>[5,15,12]</u></u>。具体治疗方案需根据主管自然的严重度及分别: 长度蛋白尿子值管紫癜素转换抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物，联合中医辨证论治 (GPS).\n\n【21】#### 6.1.3 胞兼综合征型与总性蛋皮型\n\n【22】均推荐以西医治为主删除12:<u>[5,17,19-删除13:<u>20, 23</u>-31]</u>激素和(或)免疫抑制剂+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物， 在此基础。\n\n【23】联合中医辨证论治(C 级证据，强推荐)。\n\n【24】#### 6.1.4 急进性紫炎型\n\n【25】推荐西医治疗删除12:<u>删除14:<u>[5]</u></u>。激素+血管紧张素转换酶抑制剂或血管紧张素受体抑制剂类药物+抗凝药物或血液净化(GPS)。\n\n【26】实验说明，由于血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂可通过减少肿内凝蛋性，临床医师可根据患者胃肠滤法学的水平进度使用。\n\n【27】#### 6.1.5 慢性肾炎综合型\n\n【28】推荐中西医结合治疗删除12:<u>删除14:<u>[17-19-20]</u></u>,激素+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物, 在此基础上联合中医辨证论治(D 级证据，强推荐)。", "index": 513, "show": true, "start": 474, "end": 499, "province": ["信息质量", "完整性"], "isEdit": false}, {"text": "【13】#### 6.1 儿童紫癜性肾炎中西医病证结合方案的选择", "content": "【0】页码:4\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n北京中医药大学学报\n\n【1】第47卷\n\n【2】删除32:<u>**</u>删除11:<u>(3)</u> 肺脾气虚证删除32:<u>**</u>\n\n【3】本证病程较长，平易感冒，感冒后病情加重。<mark> 面色萎黄及复作，倦少。尿中多泡沫，血尿，蛋白尿；或伴有肢体水肿，多汗，乏力，气短懒言，口淡不渴，舌淡有齿痕， 苔白，脉沉细。</mark>\n\n【4】删除32:<u>**</u>删除11:<u>(4)</u> 气阴两虚证删除32:<u>**</u>\n\n<mark>【5】本证病程较长，多见干长时期大摄氏使用激素后，紫癜反复明白，</mark> \n口渴， 膝软。 紫窍反思中多泡沫，小便短赤， 血尿，蛋白尿；多汗，乏力，易感冒，手足心热，盗汗，面色潮红。舌红少津，苔薄或无，脉细无力。\n\n【6】删除32:<u>**</u>删除11:<u>(5)</u> 脾肾阳虚证删除32:<u>**</u>\n\n【7】本证病程较长，紫癜反复新出，晦少，<mark>舌质紫暗或有紫斑，脉被细。实验室检查可见纤维蛋白原，D- 二聚体升高，凝血酶原时间缩短。</mark>\n\n<mark>【8】删除32:删除11:(2) 风热证删除32:</mark>(2)</u> 风热证删除32:<u>**</u>\n\n【9】本证多作上呼吸道感染。证见发热，流涕，咽喉，咽红，或伴发热，或皮肤紫癜，色红。舌红，苔薄白，脉浮数。\n\n【10】删除32:<u>**</u>删除11:<u>(3)</u> 风热证删除32:<u>**</u>\n\n【11】本证病程短，皮肤紫癜，色红或紫红，数量多， 面积大；或腹痛，便血，小便黄或赤。舌质红或紫红， 舌苔黄干，脉渴数或涩滑。\n\n【12】### 6 治疗\n\n【13】#### 6.1 儿童紫癜性肾炎中西医病证结合方案的选择\n\n【14】删除图片描述:<u>![](3_0.png)</u>\n\n【15】删除图片描述:<u>图1 儿童过敏性紫癜性肾炎中西医病证结合方案的诊疗流程图</u>\n\n【16】删除图片描述:<u>Fig.删除16:<u> 1 </u>Diagnosis and treatment flow chart of the integrated of traditional Chinese and western medicine in children with Henoch-Schönlein purpura nephritis</u>\n\n【17】#### 6.1.1 孤立性血尿型\n\n【18】推荐采用中医辨证论治 (GPS)。\n\n【19】#### 6.1.2 孤立性蛋白尿型、血尿兼蛋白尿型\n\n【20】推荐采用中西医结合治疗删除12:<u>删除14:<u>[5,15,12]</u></u>。具体治疗方案需根据主管自然的严重度及分别: 长度蛋白尿子值管紫癜素转换抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物，联合中医辨证论治 (GPS).\n\n【21】#### 6.1.3 胞兼综合征型与总性蛋皮型\n\n【22】均推荐以西医治为主删除12:<u>[5,17,19-删除13:<u>20, 23</u>-31]</u>激素和(或)免疫抑制剂+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物， 在此基础。\n\n【23】联合中医辨证论治(C 级证据，强推荐)。\n\n【24】#### 6.1.4 急进性紫炎型\n\n【25】推荐西医治疗删除12:<u>删除14:<u>[5]</u></u>。激素+血管紧张素转换酶抑制剂或血管紧张素受体抑制剂类药物+抗凝药物或血液净化(GPS)。\n\n【26】实验说明，由于血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂可通过减少肿内凝蛋性，临床医师可根据患者胃肠滤法学的水平进度使用。\n\n【27】#### 6.1.5 慢性肾炎综合型\n\n【28】推荐中西医结合治疗删除12:<u>删除14:<u>[17-19-20]</u></u>,激素+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物, 在此基础上联合中医辨证论治(D 级证据，强推荐)。", "index": 765, "show": true, "start": 713, "end": 745, "province": ["信息质量", "完整性"], "isEdit": false}, {"text": "【23】联合中医辨证论治(C 级证据，强推荐)。", "content": "【0】页码:4\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n北京中医药大学学报\n\n【1】第47卷\n\n【2】删除32:<u>**</u>删除11:<u>(3)</u> 肺脾气虚证删除32:<u>**</u>\n\n【3】本证病程较长，平易感冒，感冒后病情加重。<mark> 面色萎黄及复作，倦少。尿中多泡沫，血尿，蛋白尿；或伴有肢体水肿，多汗，乏力，气短懒言，口淡不渴，舌淡有齿痕， 苔白，脉沉细。</mark>\n\n【4】删除32:<u>**</u>删除11:<u>(4)</u> 气阴两虚证删除32:<u>**</u>\n\n<mark>【5】本证病程较长，多见干长时期大摄氏使用激素后，紫癜反复明白，</mark> \n口渴， 膝软。 紫窍反思中多泡沫，小便短赤， 血尿，蛋白尿；多汗，乏力，易感冒，手足心热，盗汗，面色潮红。舌红少津，苔薄或无，脉细无力。\n\n【6】删除32:<u>**</u>删除11:<u>(5)</u> 脾肾阳虚证删除32:<u>**</u>\n\n【7】本证病程较长，紫癜反复新出，晦少，<mark>舌质紫暗或有紫斑，脉被细。实验室检查可见纤维蛋白原，D- 二聚体升高，凝血酶原时间缩短。</mark>\n\n<mark>【8】删除32:删除11:(2) 风热证删除32:</mark>(2)</u> 风热证删除32:<u>**</u>\n\n【9】本证多作上呼吸道感染。证见发热，流涕，咽喉，咽红，或伴发热，或皮肤紫癜，色红。舌红，苔薄白，脉浮数。\n\n【10】删除32:<u>**</u>删除11:<u>(3)</u> 风热证删除32:<u>**</u>\n\n【11】本证病程短，皮肤紫癜，色红或紫红，数量多， 面积大；或腹痛，便血，小便黄或赤。舌质红或紫红， 舌苔黄干，脉渴数或涩滑。\n\n【12】### 6 治疗\n\n<mark>【13】#### 6.1 儿童紫癜性肾炎中西医病证结合方案的选择</mark>\n\n【14】删除图片描述:<u>![](3_0.png)</u>\n\n【15】删除图片描述:<u>图1 儿童过敏性紫癜性肾炎中西医病证结合方案的诊疗流程图</u>\n\n【16】删除图片描述:<u>Fig.删除16:<u> 1 </u>Diagnosis and treatment flow chart of the integrated of traditional Chinese and western medicine in children with Henoch-Schönlein purpura nephritis</u>\n\n【17】#### 6.1.1 孤立性血尿型\n\n【18】推荐采用中医辨证论治 (GPS)。\n\n【19】#### 6.1.2 孤立性蛋白尿型、血尿兼蛋白尿型\n\n【20】推荐采用中西医结合治疗删除12:<u>删除14:<u>[5,15,12]</u></u>。具体治疗方案需根据主管自然的严重度及分别: 长度蛋白尿子值管紫癜素转换抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物，联合中医辨证论治 (GPS).\n\n【21】#### 6.1.3 胞兼综合征型与总性蛋皮型\n\n【22】均推荐以西医治为主删除12:<u>[5,17,19-删除13:<u>20, 23</u>-31]</u>激素和(或)免疫抑制剂+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物， 在此基础。\n\n【23】联合中医辨证论治(C 级证据，强推荐)。\n\n【24】#### 6.1.4 急进性紫炎型\n\n【25】推荐西医治疗删除12:<u>删除14:<u>[5]</u></u>。激素+血管紧张素转换酶抑制剂或血管紧张素受体抑制剂类药物+抗凝药物或血液净化(GPS)。\n\n【26】实验说明，由于血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂可通过减少肿内凝蛋性，临床医师可根据患者胃肠滤法学的水平进度使用。\n\n【27】#### 6.1.5 慢性肾炎综合型\n\n【28】推荐中西医结合治疗删除12:<u>删除14:<u>[17-19-20]</u></u>,激素+血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂类药物+抗凝药物, 在此基础上联合中医辨证论治(D 级证据，强推荐)。", "index": 1417, "show": true, "start": 1352, "end": 1376, "province": ["格式规范性", "多余换行"], "isEdit": false}], "startTime": "2024/08/06 16:25:50", "endTime": "2024/08/06 16:29:18", "cost": 207.27}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:29:18", "grab_time": "2024-08-06 00:25:50"}
{"id": 2211658, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "8de695af-a897-42c7-ad2e-827d08df197b", "title": "热压伤创面临床诊疗全国专家共识（2023版）", "text": "【0】页码:2\n热压伤创面临床诊疗全国专家共识（2023版）\n(本页删除)本页被模型判断为参考页## 热压伤\n\n【1】### 热压伤是—种由热力和机械力所致的复合伤，多发于青壮年。男性患者较女性患者多，并且大部分患者为接触高温压制多于工业生产上所见。热压伤一般较局限但伤害较深,多为Ⅲ度或IV度,常累及肌肉、肌腱、神经、血管甚至骨头。并且热损伤严重且烧伤面积大,多为肢端暴露，前臂和上臂也是常见的损伤部位;其临床多见于农、林、化、建筑、包装等行业等高强度劳动者致伤；热压伤的伤情复杂,除上述损伤外可能存在皮肤软组織撕脱等,容易出現烧黄焦坏或炭样变性;往往需要多学科协作参与诊治,伤后若处理不当,常导致功能障碍甚至丧失,致残率高。近年来，亲热压伤的诊断及治疗挑战，缺乏循證指導的創傷診療規範。\n\n【2】#### 临床问题1. 热压伤的伤因\n\n【3】删除32:<u>**</u>推荐意见1a（建议）：删除32:<u>**</u> 热体夹持伤而捏伤划伤人的热压伤近在考虑。\n\n【4】删除32:<u>**</u>推荐意见1b（强）:删除32:<u>**</u> 将高温物压迫烧伤以及具体有效温压共同一定时间的外物捏伤划人热压伤。\n\n【5】删除32:<u>**</u>证据与说明:删除32:<u>**</u> 热压伤常见损伤原因为热液伤合和热压伤: 将高温热体压赛划和跑步,热体不咬地紧致因热板烫伤上皮而能被卷人为中, 导被热液受剌挤压和烧伤;往往部的电甚至机械严律措热咬在地方如压制。伤过后常牛紧对位尤其热压和软伤组织解屑力不够大，者硬厚大于较大可导致骨关节和软组织严害脱伤，后柔带伤灵片关 opges并症发凌转各性愈特炎合同娄，除治疗带高达率的机械车片，喷烧力造成的损伤外，\n\n【6】### ``综合性“ hot-press procedures\"`` 热压伤 case\n\n【7】关键词：Wounds and injuries；热压伤；烧伤 ；伤口 grader；意外 Hot-press injuries 热力燃损伤\n\n【8】删除32:<u>**</u>医学基金删除32:<u>**</u>: National Key R&D Program。\n\n【9】删除32:<u>**</u>注册登记和指导意见: 删除32:<u>**</u> 热伤 2327-N4531“function of CASE quick surgery recovery 62101”\n\n【10】### 系统定义为：高于话触发热有毒物的复合伤\n\n【11】温力是为受到极高热温/重压由原 动导致重复或额外热压力划破皮肤致损的一种严重化合病变, 除全身病变及功能建立共，有叫热压损失人的渖完多种动脉锁和烧伤以及其他常见重伤。\n\n【12】删除32:<u>**</u>伤情分析:删除32:<u>**</u> 数31类维4确日手（强）易而再由热 created高温物灼之 burned，电子和他意见标时的 the all disability burn wound, otherwise continental type of operating and widespread created direct high ncl object of.\n\n【13】### 热压专业的 make your valid further easily heated function of pl\n\n【14】删除32:<u>**</u>证据报道所致:删除32:<u>**</u> National Establish Key hot presses, formed from CA—SE instrumentation classification of high create most comprehensive national of injury committed and considerable created because cases YYSD.\n\n【15】删除32:<u>**</u>附录删除32:<u>**</u>\n\n【16】见引起伤手会测证及 MMA Create 页面 主要 请补充术 source of extensive burn. `普通 All Type\" see like month必须了解 cases，百例课程 all injure surveys of `Crate circulated'\n\n【17】高于 statistical rate of injury cases 热压病配各最广泛即推率严重论，通形于结合极广火 and System extremely 标远的热压伤伤pers。上对对人 extremely公司推所有热系统做生产 complete Special Emphasis measures of valid. 锅isestä日会像全步评审标系统创建意义\n\n【18】### publicgilve 驻战各积极系统 专家\n\n【19】每栏 all comprehensive： Common Pressing Injuring，各表重伤以 Duerolas，极较人。 Severe伤且以上各 hand injuries system Heavy cases系小包括分别会创 McG regular从.\n\n---|删除段之间换行|删除32:<u>**</u>备&诊所分析参考删除32:<u>**</u>\n\n【21】1. Every sections like 记地方\n2. extremely daily care\n3. 宜包 major requirement措施证据创建 visse advante completeöhnt cases\n4. 测，icado in created complete common.", "tags": {}, "lang": "en", "attr": {"page_num": 2, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/热压伤创面临床诊疗全国专家共识（2023版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:2\n\n热压伤创面临床诊疗全国专家共识（2023版）\n\n(本页删除)本页被模型判断为参考页## 热压伤\n\n【1】### 热压伤是—种由热力和机械力所致的复合伤，多发于青壮年。男性患者较女性患者多，并且大部分患者为接触高温压制多于工业生产上所见。热压伤一般较局限但伤害较深,多为Ⅲ度或IV度,常累及肌肉、肌腱、神经、血管甚至骨头。并且热损伤严重且烧伤面积大,多为肢端暴露，前臂和上臂也是常见的损伤部位;其临床多见于农、林、化、建筑、包装等行业等高强度劳动者致伤；热压伤的伤情复杂,除上述损伤外可能存在皮肤软组織撕脱等,容易出現烧黄焦坏或炭样变性;往往需要多学科协作参与诊治,伤后若处理不当,常导致功能障碍甚至丧失,致残率高。近年来，亲热压伤的诊断及治疗挑战，缺乏循證指導的創傷診療規範。\n\n【2】#### 临床问题1. 热压伤的伤因\n\n【3】删除32:推荐意见1a（建议）：删除32: 热体夹持伤而捏伤划伤人的热压伤近在考虑。\n\n【4】删除32:推荐意见1b（强）:删除32: 将高温物压迫烧伤以及具体有效温压共同一定时间的外物捏伤划人热压伤。\n\n【5】删除32:证据与说明:删除32: 热压伤常见损伤原因为热液伤合和热压伤: 将高温热体压赛划和跑步,热体不咬地紧致因热板烫伤上皮而能被卷人为中, 导被热液受剌挤压和烧伤;往往部的电甚至机械严律措热咬在地方如压制。伤过后常牛紧对位尤其热压和软伤组织解屑力不够大，者硬厚大于较大可导致骨关节和软组织严害脱伤，后柔带伤灵片关 opges并症发凌转各性愈特炎合同娄，除治疗带高达率的机械车片，喷烧力造成的损伤外，\n\n【6】### 综合性“ hot-press procedures\" 热压伤 case\n\n【7】关键词：Wounds and injuries；热压伤；烧伤 ；伤口 grader；意外 Hot-press injuries 热力燃损伤\n\n【8】删除32:医学基金删除32:: National Key R&D Program。\n\n【9】删除32:注册登记和指导意见: 删除32: 热伤 2327-N4531“function of CASE quick surgery recovery 62101”\n\n【10】### 系统定义为：高于话触发热有毒物的复合伤\n\n【11】温力是为受到极高热温/重压由原 动导致重复或额外热压力划破皮肤致损的一种严重化合病变, 除全身病变及功能建立共，有叫热压损失人的渖完多种动脉锁和烧伤以及其他常见重伤。\n\n【12】删除32:伤情分析:删除32: 数31类维4确日手（强）易而再由热 created高温物灼之 burned，电子和他意见标时的 the all disability burn wound, otherwise continental type of operating and widespread created direct high ncl object of.\n\n【13】### 热压专业的 make your valid further easily heated function of pl\n\n【14】删除32:证据报道所致:删除32: National Establish Key hot presses, formed from CA—SE instrumentation classification of high create most comprehensive national of injury committed and considerable created because cases YYSD.\n\n【15】删除32:附录删除32:\n\n【16】见引起伤手会测证及 MMA Create 页面 主要 请补充术 source of extensive burn. 普通 All Type\" see like month必须了解 cases，百例课程 all injure surveys of Crate circulated’\n\n【17】高于 statistical rate of injury cases 热压病配各最广泛即推率严重论，通形于结合极广火 and System extremely 标远的热压伤伤pers。上对对人 extremely公司推所有热系统做生产 complete Special Emphasis measures of valid. 锅isestä日会像全步评审标系统创建意义\n\n【18】### publicgilve 驻战各积极系统 专家\n\n【19】每栏 all comprehensive： Common Pressing Injuring，各表重伤以 Duerolas，极较人。 Severe伤且以上各 hand injuries system Heavy cases系小包括分别会创 McG regular从.\n\n—|删除段之间换行|删除32:备&诊所分析参考删除32:\n\n【21】1. Every sections like 记地方\n\n2. extremely daily care\n\n3. 宜包 major requirement措施证据创建 visse advante completeöhnt cases\n\n4. 测，icado in created complete common.", "content": "【0】页码:2\n热压伤创面临床诊疗全国专家共识（2023版）\n(本页删除)本页被模型判断为参考页## 热压伤\n\n【1】### 热压伤是—种由热力和机械力所致的复合伤，多发于青壮年。男性患者较女性患者多，并且大部分患者为接触高温压制多于工业生产上所见。热压伤一般较局限但伤害较深,多为Ⅲ度或IV度,常累及肌肉、肌腱、神经、血管甚至骨头。并且热损伤严重且烧伤面积大,多为肢端暴露，前臂和上臂也是常见的损伤部位;其临床多见于农、林、化、建筑、包装等行业等高强度劳动者致伤；热压伤的伤情复杂,除上述损伤外可能存在皮肤软组織撕脱等,容易出現烧黄焦坏或炭样变性;往往需要多学科协作参与诊治,伤后若处理不当,常导致功能障碍甚至丧失,致残率高。近年来，亲热压伤的诊断及治疗挑战，缺乏循證指導的創傷診療規範。\n\n【2】#### 临床问题1. 热压伤的伤因\n\n【3】删除32:<u>**</u>推荐意见1a（建议）：删除32:<u>**</u> 热体夹持伤而捏伤划伤人的热压伤近在考虑。\n\n【4】删除32:<u>**</u>推荐意见1b（强）:删除32:<u>**</u> 将高温物压迫烧伤以及具体有效温压共同一定时间的外物捏伤划人热压伤。\n\n【5】删除32:<u>**</u>证据与说明:删除32:<u>**</u> 热压伤常见损伤原因为热液伤合和热压伤: 将高温热体压赛划和跑步,热体不咬地紧致因热板烫伤上皮而能被卷人为中, 导被热液受剌挤压和烧伤;往往部的电甚至机械严律措热咬在地方如压制。伤过后常牛紧对位尤其热压和软伤组织解屑力不够大，者硬厚大于较大可导致骨关节和软组织严害脱伤，后柔带伤灵片关 opges并症发凌转各性愈特炎合同娄，除治疗带高达率的机械车片，喷烧力造成的损伤外，\n\n【6】### ``综合性“ hot-press procedures\"`` 热压伤 case\n\n【7】关键词：Wounds and injuries；热压伤；烧伤 ；伤口 grader；意外 Hot-press injuries 热力燃损伤\n\n【8】删除32:<u>**</u>医学基金删除32:<u>**</u>: National Key R&D Program。\n\n【9】删除32:<u>**</u>注册登记和指导意见: 删除32:<u>**</u> 热伤 2327-N4531“function of CASE quick surgery recovery 62101”\n\n【10】### 系统定义为：高于话触发热有毒物的复合伤\n\n【11】温力是为受到极高热温/重压由原 动导致重复或额外热压力划破皮肤致损的一种严重化合病变, 除全身病变及功能建立共，有叫热压损失人的渖完多种动脉锁和烧伤以及其他常见重伤。\n\n【12】删除32:<u>**</u>伤情分析:删除32:<u>**</u> 数31类维4确日手（强）易而再由热 created高温物灼之 burned，电子和他意见标时的 the all disability burn wound, otherwise continental type of operating and widespread created direct high ncl object of.\n\n【13】### 热压专业的 make your valid further easily heated function of pl\n\n【14】删除32:<u>**</u>证据报道所致:删除32:<u>**</u> National Establish Key hot presses, formed from CA—SE instrumentation classification of high create most comprehensive national of injury committed and considerable created because cases YYSD.\n\n【15】删除32:<u>**</u>附录删除32:<u>**</u>\n\n【16】见引起伤手会测证及 MMA Create 页面 主要 请补充术 source of extensive burn. `普通 All Type\" see like month必须了解 cases，百例课程 all injure surveys of `Crate circulated'\n\n【17】高于 statistical rate of injury cases 热压病配各最广泛即推率严重论，通形于结合极广火 and System extremely 标远的热压伤伤pers。上对对人 extremely公司推所有热系统做生产 complete Special Emphasis measures of valid. 锅isestä日会像全步评审标系统创建意义\n\n【18】### publicgilve 驻战各积极系统 专家\n\n【19】每栏 all comprehensive： Common Pressing Injuring，各表重伤以 Duerolas，极较人。 Severe伤且以上各 hand injuries system Heavy cases系小包括分别会创 McG regular从.\n\n---|删除段之间换行|删除32:<u>**</u>备&诊所分析参考删除32:<u>**</u>\n\n【21】1. Every sections like 记地方\n2. extremely daily care\n3. 宜包 major requirement措施证据创建 visse advante completeöhnt cases\n4. 测，icado in created complete common.", "index": 0, "show": true, "start": 0, "end": 2242, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "与原文不一致"}], "startTime": "2024/08/07 09:58:27", "endTime": "2024/08/07 09:59:31", "cost": 64.712}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 17:59:31", "grab_time": "2024-08-06 17:58:26"}
{"id": 2211657, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "8ca3b443-ce17-4179-8b51-e27bb958ab13", "title": "2024+BFS实践建议：子宫内膜异位症患者辅助生育的管理", "text": "【0】页码:13\n2024+BFS实践建议：子宫内膜异位症患者辅助生育的管理\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】### 正文内容：\n\n【2】参考删除-3:<u>Alshwee, S., Nairce, B. F., Fenwick, M. A., & Metwally, M. 删除11:<u>删除19:<u>(2021)</u></u>. The impact of endometriosis on in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) reproductive outcomes: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 303删除11:<u>(1)</u>, 3–16删除1:<u>. https://doi.org/10.1007/s00404-020-05796-9</u></u>\n\n【3】参考删除-3:<u>Barra, F., Lagana, A. S., Scala, C., Garzon, S., Ghezzi, F., & Ferrero, S. 删除11:<u>删除19:<u>(2020)</u></u>. Pretreatment with dienogest in women with endometriosis undergoing IVF after a previous failed cycle. Reproductive Biomedicine Online, 41删除11:<u>(5)</u>, 859–868删除1:<u>. https://doi.org/10.1016/j.rbmo.2020.07.022</u></u>\n\n【4】参考删除-3:<u>Benaglia, L., Somigliana, E., Iemmello, R., Copli, E., Nicolosi, A. E., & Ragni, G. 删除11:<u>删除19:<u>(2008)</u></u>. Endometrioma and oocyte retrieval-induced pelvic abscess: a clinical concern or an exceptional complication? Fertility and Sterility, 89删除11:<u>(5)</u>, 1263–1266删除1:<u>. https://doi.org/10.1016/j.fertnstert.2007.05.038</u></u>\n\n【5】参考删除-3:<u>Bischo, B. L., Garg, D., Jahanandish, S., Devine, K., Decheney, A. H., & Hill, M. J. 删除11:<u>删除19:<u>(2021)</u></u>. Endometriosis does not impact live-birth rates in frozen embryo transfers of euploid blastocysts. Fertility and Sterility, 115删除11:<u>(2)</u>, 416–422删除1:<u>. https://doi.org/10.1016/j.fertnstert.2020.07.050</u></u>\n\n【6】参考删除-3:<u>Bourdon, M., Santulli, P., Maignien, C., Gayet, V., Pocatecheri, K., Marcellin, L., & Chapron, C. 删除11:<u>删除19:<u>(2018)</u></u>. The deferred embryo transfer strategy improves cumulative pregnancy rate in endometriosis-related infertility: a retrospective matched cohort study. PLoS One, 13删除11:<u>(4)</u>, e0194800删除1:<u>. https://doi.org/10.1371/journal.pone.0194800</u></u>\n\n【7】参考删除-3:<u>Bulun, S. E., Yilmaz, B. D., Sison, C., Miyazaki, K., Bernardi, L., Liu, S., & Brosems, I. 删除11:<u>删除19:<u>(2004)</u></u>. High fetal aromatase P450 mRNA expression is associated with poor IVF outcome. Human Reproduction (Oxford, England), 19删除11:<u>(2)</u>, 352–356删除1:<u>. https://doi.org/10.1093/humrep/deh075</u></u>\n\n【8】参考删除-3:<u>Brus, L., Lambalk, C. B., de Koning, J., Helder, M. N., Janssens, R. M., & Schonkeren, J. 删除11:<u>删除19:<u>(1997)</u></u>. Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Human Reproduction (Oxford, England), 12删除11:<u>(4)</u>, 769–773删除1:<u>. https://doi.org/10.1093/humrep/12.4.769</u></u>\n\n【9】参考删除-3:<u>Bukulmez, O., Yarali, H., Yucel, A., Sari, T., & Gurgan, T. 删除11:<u>删除19:<u>(2000)</u></u>. Intracytoplasmic sperm injection versus in vitro fertilization for patients with a tubal factor as the sole cause of infertility: a prospective, randomized trial. Fertility and Sterility, 73删除11:<u>(1)</u>, 38–42删除1:<u>. https://doi.org/10.1016/s0015-0282删除11:<u>(99)</u>00449-5</u></u>\n\n【10】Burbs-Wicks, C., Cohen, M., Fallbacher, J. N., Taylor, R., & Wieser, F. 删除11:<u>删除19:<u>(2005)</u></u>. A Western primer of Chinese herbal therapy in endometriosis and infertility. Women's Health (London, England), 删除17:<u>1</u>", "tags": {}, "lang": "en", "attr": {"page_num": 13, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024+BFS实践建议：子宫内膜异位症患者辅助生育的管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:36:00", "endTime": "2024/08/06 15:36:07", "cost": 7.013}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:36:08", "grab_time": "2024-08-05 23:36:00"}
{"id": 2211656, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "52062c3e-1fd3-4ae9-b92e-083ae8f3345e", "title": "（2023.V4）NCCN临床实践指南：B细胞淋巴瘤", "text": "【0】页码:50\n（2023.V4）NCCN临床实践指南：B细胞淋巴瘤\n疑似页眉<u># NCCN Guidelines Version 4.2023\n## Mantle Cell Lymphoma</u>\n\n【1】### ADDITIONAL DIAGNOSTIC TESTING\n\n【2】#### ESSENTIAL:\n- Adequate immunophenotyping to establish diagnosisa\n  IHC panel: CD20, CD3, CD5, cyclin D1, CD10, CD21, CD23, BCL2, BCL6, SOX11, Ki-67b with or without\n- Cell surface marker analysis by flow cytometry with peripheral blood and/or biopsy specimen: kappa/lambda, CD19, CD20, CD5, CD23, CD10, CD200\n- TP53 sequencingc\n\n【3】#### USEFUL UNDER CERTAIN CIRCUMSTANCES:\n- IHC: LEF1 may help distinguish from variant CLL; SOX11 or IGHV sequencing may be useful for determination of clinically indolentd MCL; may also help in diagnosis of CCND1- MCL\n- Karyotype or FISH: t(11;14), FISH for CCND2 and CCND3 rearrangements may also help in diagnosis of CCND1- MCL\n\n【4】### WORKUP\n\n【5】删除图片描述:<u>![](49_0.png)</u>\n\n【6】#### ESSENTIAL:\n- Physical exam: Attention to node-bearing areas, including Waldeyer’s ring, and to size of liver and spleen\n- Performance status\n- B symptoms\n- CBC with differential\n- Comprehensive metabolic panel\n- LDH\n- PET-CT scan (preferred) or C/A/P CT with contrast of diagnostic quality if systemic therapy is planned\n- Hepatitis B testinge\n- Echocardiogram or MUGA scan if anthracycline or anthracenedione-based regimen is indicated\n- Pregnancy testing in patients of childbearing age (if chemotherapy or RT planned)\n\n【7】#### USEFUL UNDER CERTAIN CIRCUMSTANCES:\n- Endoscopy/colonoscopyf\n- Bone marrow biopsy ± aspirate\n- Neck CT with contrast\n- Uric acid\n- Beta-2-microglobulin\n- Hepatitis C testing\n- Lumbar puncture (for blastic variant or central nervous system 删除12:<u>[CNS]</u> symptoms)\n- Discuss fertility preservationg\n\n---|删除段内换行|a Typical immunophenotype reported: CD5+, CD20+, CD43+, CD23-/+, cyclin D1+, CD10-/+. Note: Some cases of MCL may be CD5- or CD23+. If the diagnosis is suspected, cyclin D1 staining or FISH for t(11;14) should be done. There are rare cases of CCND1- MCL (<5%) with an otherwise typical immunophenotype.\nb Ki-67 proliferation fraction of <30% in lymph node biopsies is associated with a more favorable prognosis.\nc TP53 mutation has been associated with poor prognosis in patients treated with conventional therapy, including transplant. Clinical trial is strongly recommended for these patients. TP53 by IHC is not a proven surrogate for TP53 mutation status or del删除30:<u>(17p)</u> status.\nd Most common biomarker for indolent disease: SOX11- (IGHV mutated). Typical clinical presentation: leukemic non-nodal CLL-like with splenomegaly, low tumor burden, Ki-67 proliferation fraction <10%.\ne Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B surface antigen and core antibody for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, test e-antigen 删除9:<u>(See HODG-B)</u>. If positive, check viral load and consider consult with gastroenterologist.\nf Essential for confirmation of stage I–II disease. See Discussion for details.\ng Fertility preservation options include: sperm banking, semen cryopreservation, IVF, or ovarian tissue or oocyte cryopreservation.", "tags": {}, "lang": "en", "attr": {"page_num": 50, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V4）NCCN临床实践指南：B细胞淋巴瘤.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:47:44", "endTime": "2024/08/06 15:48:30", "cost": 45.836}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:48:30", "grab_time": "2024-08-05 23:47:44"}
{"id": 2211655, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "2e59ff3e-526d-4c48-9974-641ee357d960", "title": "超声手术系统综合评估专家共识", "text": "【0】页码:10\n超声手术系统综合评估专家共识\n删除图片描述:<u>![](9_0.png)</u>\n\n【1】### 2 经济及社会价值 删除11:<u>(0.24)</u>\n\n| 一级指标权权重 | 二级指标权权重 | 三级指标权权重 | 评估方式 | 评估标准 |\n| --------------- | -------------- | -------------- | ------- | ------- |\n|                 | 2.3 产品创新性 删除11:<u>删除19:<u>(0.0840)</u></u> | 2)适宜艺术本科求不求 删除11:<u>删除19:<u>(0.0395)</u></u> | 专家咨询 | 删除5:<u>□</u>10 与同类产品相比，非常类似可与广泛产品进行后续或新的开发<br/>删除5:<u>□</u>5 与同类产品相比，比较类似可与广泛产品进行后续或新的开发<br/>删除5:<u>□</u>0 与同类产品相比，不太相似可与广泛产品进行后续或新的开发，或无法评估 |\n\n【3】### 3 管理价值 删除11:<u>(0.25)</u>\n\n【4】删除图片描述:<u>![](9_1.png)</u>\n\n【5】#### 3.1 质量可靠及稳定性 删除11:<u>删除19:<u>(0.0825)</u></u>\n\n| 一级指标权权重 | 二级指标权权重 | 三级指标权权重 | 评估方式 | 评估标准 |\n| --------------- | -------------- | -------------- | ------- | ------- |\n| 1)生产企业质量管理认证 删除11:<u>删除19:<u>(0.0264)</u></u> | 客观证据 | 删除5:<u>□</u>10 通过医疗器械质量管理体系认证<br/>删除5:<u>□</u>0 未通过医疗器械质量管理体系认证，或无法评估 |\n| 2)产品质量认证 删除11:<u>删除19:<u>(0.0289)</u></u> | 客观证据 | 删除5:<u>□</u>10 产品多数欧美、欧盟、日本、韩国中3个及以上的国家或地区认证<br/>删除5:<u>□</u>5 产品多数欧美或日本大或韩国中有1个认证<br/>删除5:<u>□</u>0 未提供相关证据，无法评估 |\n| 3)三级医疗机构覆盖情况 删除11:<u>删除19:<u>(0.0272)</u></u> | 客观证据 | 删除5:<u>□</u>10 企业覆盖率在10家三甲医院以上(数据提供)<br/>删除5:<u>□</u>5 企业覆盖率6~10家三甲医院<br/>删除5:<u>□</u>0 企业覆盖率本省不足三甲医院以下 |\n\n【7】#### 3.2 供应保障能力 删除11:<u>删除19:<u>(0.0575)</u></u>\n\n| 一级指标权权重 | 二级指标权权重 | 三级指标权权重 | 评估方式 | 评估标准 |\n| --------------- | -------------- | -------------- | ------- | ------- |\n| 1)选址与人员配备 删除11:<u>删除19:<u>(0.0264)</u></u> | 专家咨询 | 删除5:<u>□</u>10 供货保障配送仓、仓储规模是选址及运输设备数量、配送人适当等情况<br/>删除5:<u>□</u>5 供货保障配送仓等，仓储规模运输设备或数量一项不适当，或配送人员配备不充分<br/>删除5:<u>□</u>0 供货保障配送仓，选址与人员配备不充分运输未相关证据无法评估 | \n| 2)供货稳定性 删除11:<u>删除19:<u>(0.0311)</u></u> | 专家咨询 | 删除5:<u>□</u>10 紧急需求情况下，供货完成时间24h内<br/>删除5:<u>□</u>5 紧急需求情况下，供货完成时间24h~72h内<br/>删除5:<u>□</u>0 紧急需求情况下，供货完成时间72h |\n\n| 一级指标权权重 | 二级指标权权重 | 三级指标权权重 | 评估方式 | 评估标准 |\n| --------------- | -------------- | -------------- | ------- | ------- |\n| 3.3 技术服务支撑 删除11:<u>删除19:<u>(0.0600)</u></u> | 1)售后服务及时性 删除11:<u>(0.012)</u> | 专家咨询 | 删除5:<u>□</u>10 接到排除后4h内能够到现场<br/>删除5:<u>□</u>5 接到排除后4h内能够到现场<br/>删除5:<u>□</u>0 接到排除后48h内能够到现场 |", "tags": {}, "lang": "zh", "attr": {"page_num": 10, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/超声手术系统综合评估专家共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】### 2 经济及社会价值 删除11:(0.24)\n\n一级指标权权重\t二级指标权权重\t三级指标权权重\t评估方式\t评估标准\n2.3 产品创新性 删除11:删除19:(0.0840)\t2)适宜艺术本科求不求 删除11:删除19:(0.0395)\t专家咨询\t删除5:□10 与同类产品相比，非常类似可与广泛产品进行后续或新的开发\n删除5:□5 与同类产品相比，比较类似可与广泛产品进行后续或新的开发\n删除5:□0 与同类产品相比，不太相似可与广泛产品进行后续或新的开发，或无法评估\n【3】### 3 管理价值 删除11:(0.25)\n\n【4】删除图片描述:\n\n【5】#### 3.1 质量可靠及稳定性 删除11:删除19:(0.0825)\n\n一级指标权权重\t二级指标权权重\t三级指标权权重\t评估方式\t评估标准\n1)生产企业质量管理认证 删除11:删除19:(0.0264)\t客观证据\t删除5:□10 通过医疗器械质量管理体系认证\n删除5:□0 未通过医疗器械质量管理体系认证，或无法评估\t\t\n2)产品质量认证 删除11:删除19:(0.0289)\t客观证据\t删除5:□10 产品多数欧美、欧盟、日本、韩国中3个及以上的国家或地区认证\n删除5:□5 产品多数欧美或日本大或韩国中有1个认证\n删除5:□0 未提供相关证据，无法评估\t\t\n3)三级医疗机构覆盖情况 删除11:删除19:(0.0272)\t客观证据\t删除5:□10 企业覆盖率在10家三甲医院以上(数据提供)\n删除5:□5 企业覆盖率6~10家三甲医院\n删除5:□0 企业覆盖率本省不足三甲医院以下\t\t\n【7】#### 3.2 供应保障能力 删除11:删除19:(0.0575)\n\n一级指标权权重\t二级指标权权重\t三级指标权权重\t评估方式\t评估标准\n1)选址与人员配备 删除11:删除19:(0.0264)\t专家咨询\t删除5:□10 供货保障配送仓、仓储规模是选址及运输设备数量、配送人适当等情况\n删除5:□5 供货保障配送仓等，仓储规模运输设备或数量一项不适当，或配送人员配备不充分\n删除5:□0 供货保障配送仓，选址与人员配备不充分运输未相关证据无法评估\t\t\n2)供货稳定性 删除11:删除19:(0.0311)\t专家咨询\t删除5:□10 紧急需求情况下，供货完成时间24h内\n删除5:□5 紧急需求情况下，供货完成时间24h~72h内\n删除5:□0 紧急需求情况下，供货完成时间72h\t\t\n一级指标权权重\t二级指标权权重\t三级指标权权重\t评估方式\t评估标准\n3.3 技术服务支撑 删除11:删除19:(0.0600)\t1)售后服务及时性 删除11:(0.012)\t专家咨询\t删除5:□10 接到排除后4h内能够到现场\n删除5:□5 接到排除后4h内能够到现场\n删除5:□0 接到排除后48h内能够到现场\t", "content": "【0】页码:10\n超声手术系统综合评估专家共识\n删除图片描述:<u>![](9_0.png)</u>\n\n【1】### 2 经济及社会价值 删除11:<u>(0.24)</u>\n\n| 一级指标权权重 | 二级指标权权重 | 三级指标权权重 | 评估方式 | 评估标准 |\n| --------------- | -------------- | -------------- | ------- | ------- |\n|                 | 2.3 产品创新性 删除11:<u>删除19:<u>(0.0840)</u></u> | 2)适宜艺术本科求不求 删除11:<u>删除19:<u>(0.0395)</u></u> | 专家咨询 | 删除5:<u>□</u>10 与同类产品相比，非常类似可与广泛产品进行后续或新的开发<br/>删除5:<u>□</u>5 与同类产品相比，比较类似可与广泛产品进行后续或新的开发<br/>删除5:<u>□</u>0 与同类产品相比，不太相似可与广泛产品进行后续或新的开发，或无法评估 |\n\n【3】### 3 管理价值 删除11:<u>(0.25)</u>\n\n【4】删除图片描述:<u>![](9_1.png)</u>\n\n【5】#### 3.1 质量可靠及稳定性 删除11:<u>删除19:<u>(0.0825)</u></u>\n\n| 一级指标权权重 | 二级指标权权重 | 三级指标权权重 | 评估方式 | 评估标准 |\n| --------------- | -------------- | -------------- | ------- | ------- |\n| 1)生产企业质量管理认证 删除11:<u>删除19:<u>(0.0264)</u></u> | 客观证据 | 删除5:<u>□</u>10 通过医疗器械质量管理体系认证<br/>删除5:<u>□</u>0 未通过医疗器械质量管理体系认证，或无法评估 |\n| 2)产品质量认证 删除11:<u>删除19:<u>(0.0289)</u></u> | 客观证据 | 删除5:<u>□</u>10 产品多数欧美、欧盟、日本、韩国中3个及以上的国家或地区认证<br/>删除5:<u>□</u>5 产品多数欧美或日本大或韩国中有1个认证<br/>删除5:<u>□</u>0 未提供相关证据，无法评估 |\n| 3)三级医疗机构覆盖情况 删除11:<u>删除19:<u>(0.0272)</u></u> | 客观证据 | 删除5:<u>□</u>10 企业覆盖率在10家三甲医院以上(数据提供)<br/>删除5:<u>□</u>5 企业覆盖率6~10家三甲医院<br/>删除5:<u>□</u>0 企业覆盖率本省不足三甲医院以下 |\n\n【7】#### 3.2 供应保障能力 删除11:<u>删除19:<u>(0.0575)</u></u>\n\n| 一级指标权权重 | 二级指标权权重 | 三级指标权权重 | 评估方式 | 评估标准 |\n| --------------- | -------------- | -------------- | ------- | ------- |\n| 1)选址与人员配备 删除11:<u>删除19:<u>(0.0264)</u></u> | 专家咨询 | 删除5:<u>□</u>10 供货保障配送仓、仓储规模是选址及运输设备数量、配送人适当等情况<br/>删除5:<u>□</u>5 供货保障配送仓等，仓储规模运输设备或数量一项不适当，或配送人员配备不充分<br/>删除5:<u>□</u>0 供货保障配送仓，选址与人员配备不充分运输未相关证据无法评估 | \n| 2)供货稳定性 删除11:<u>删除19:<u>(0.0311)</u></u> | 专家咨询 | 删除5:<u>□</u>10 紧急需求情况下，供货完成时间24h内<br/>删除5:<u>□</u>5 紧急需求情况下，供货完成时间24h~72h内<br/>删除5:<u>□</u>0 紧急需求情况下，供货完成时间72h |\n\n| 一级指标权权重 | 二级指标权权重 | 三级指标权权重 | 评估方式 | 评估标准 |\n| --------------- | -------------- | -------------- | ------- | ------- |\n| 3.3 技术服务支撑 删除11:<u>删除19:<u>(0.0600)</u></u> | 1)售后服务及时性 删除11:<u>(0.012)</u> | 专家咨询 | 删除5:<u>□</u>10 接到排除后4h内能够到现场<br/>删除5:<u>□</u>5 接到排除后4h内能够到现场<br/>删除5:<u>□</u>0 接到排除后48h内能够到现场 |", "index": 52, "show": true, "start": 52, "end": 1235, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "全篇表格"}], "startTime": "2024/08/07 10:04:18", "endTime": "2024/08/07 10:05:53", "cost": 94.442}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 18:05:51", "grab_time": "2024-08-06 18:04:17"}
{"id": 2211654, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "18c87172-3f7f-46a9-b3c1-a7410fc9da84", "title": "老年髋部骨折全髋关节置换术后超早期康复负重训练最佳证据总结", "text": "【0】页码:4\n老年髋部骨折全髋关节置换术后超早期康复负重训练最佳证据总结\n## 表 4 meta 分析质量评价结果\n\n【1】删除图片描述:<u>![](3_0.png)</u>\n\n【2】1. 所提出的筛选证据是否清晰明确? \n2. 文献的纳入标准是否合理?\n3. 采用的检索策略是否恰当?\n4. 纳入文献的原始数据报告是否充分?\n5. 所用的效应量指标评价标准是否恰当?\n6. 是否由≥2名以上的评价者独立完成文献质量评价?\n7. 提取资料相关要素采用一致的抽样抽取或调查表?\n8. 综合分析研究的方法是否恰当?\n9. 是否进行了敏感性或亚组评价?\n10. 是否在概述通报时对合乎技巧（或报道偏倚)或实践出错推荐意见?\n11. 对今后进一步研究的特定方向是否提出指导建议?\n\n【3】## 注：\n\n【4】①是否描述了观察的来源？ ②观察是否来源于表项依赖带偏的力的专家？③所假设的效应是来源于特定样本的人群/初步假设？ ④所述的运算不是基于分布的假设？ ⑤观察的效应是否具有相当性? ⑥是否参考了现有的其它文献? ⑦所描述的结局与以往文献是否有不一致的地方？\n\n【5】## 2.2.4 专家共识：共纳入 1 篇高质量专家共识，来源于\n\n【6】删除图片描述:<u>![](3_1.png)</u>\n\n【7】## 表 6 老年全髋关节置换术后超早期和延迟负重训练证据总结\n\n| 维度 | 证据内容 | 证据等级 | 证据推荐 |\n| --- | --- | --- | --- |\n| 基础训练 | 1. 常规术后当日或次日行股四头肌收缩训练、膝关节过伸及踝泵运动等不负重屈膝伸髋训练。删除12:<u>[删除13:<u>15, 20</u>]</u> | 1c,e | A  |\n|  | 2. 核小腿小腿或远端心脏泵等最优不负重训练最优，重点集中内收肌、腹部内侧、侧曲位、或椎，能较大的提高患者的综合适应能力和功能恢复。删除12:<u>删除14:<u>[15]</u></u> | 1c,e | A  |\n| 负重时间 | 3. 术后2~4 天开始负重训练。持续1.5~2 周后进行完全负重。删除12:<u>[删除13:<u>15, 16, 21</u>]</u> | 1c | A  |\n|  | 4. 术后1 天开始负重训练。删除12:<u>[删除13:<u>22, 23</u>]</u> | 1c | B  |\n|  | 5. 术后3 周才开始行走训练。删除12:<u>删除14:<u>[16]</u></u> | 1c | B  |\n|  | 6. 术后3~4 周开始负重训练。删除12:<u>删除14:<u>[20]</u></u> | 2b | B  |\n|  | 7. 手术当天即下地及下床负重训练。删除12:<u>删除14:<u>[24]</u></u> | 1e | B  |\n|  | 8. 术后4 周才开始负重训练。删除12:<u>删除14:<u>[20]</u></u> | 2b | B  |\n| 负重量度 | 9. 部分负重量为体重的1/8左右、负重量应随增大负重删除12:<u>删除14:<u>[25]</u></u>，俗至2天增加1次的一样的删除12:<u>删除14:<u>[15]</u></u>服温，| 1e | A  |\n|  | 10. 术后1天开始负重训练练习，未有较大负重量增加方案的10%的化验动物能一次性强删除12:<u>删除14:<u>[15]</u></u>且需合成100%的结局。 | 1e | A  |\n| 负量重度 | 11. 术后12小时即下床站立并逐步所有增至100%。 | 1e | A  |\n| 训练方法 | 12. 术后1天开始负重阶梯拉伸性训练并有进行更不需要增负量的一部分负重群—完全负相关。 | 1c,e | A  |\n|  | 13. 术后2~4 周逐步开始行走至完全负重删除12:<u>删除14:<u>[15]</u></u>，系统评价始终持相当维持重物护刊，合成身体进阶度删除12:<u>删除14:<u>[16]</u></u>和胶新健康不需要增加，或如中，预已处于手术后一对删除12:<u>删除14:<u>[22]</u></u>。统一分别于1~2 天开始首负重并增负再产生体重后的状态，步行有考部和平均50的方案维持删除12:<u>删除14:<u>[15]</u></u>且加重限制重负 体重1/8左右。删除12:<u>删除14:<u>[20]</u></u> | 1e | A  |\n|  | 14. 手术当日步行训练：有快速地术后余量例外，未出MDT手术版夹板并处于康复期初(0为1步行长度生物化验。删除12:<u>[删除13:<u>20, 21</u>]</u> | 5b | B  |\n|  | 15. 术后非不见期前阶段后时间量先照市场血贫身策划增加量、复增增认负量课程 eg，虚增强训练删除12:<u>删除14:<u>[15]</u></u>，几而亚于行完全重负9方案之次/一年/周并结合专有的交叉医学真实效果比如说，量步行步合于次大前后画步达一天提估界术详细计划一样删除12:<u>删除14:<u>[16]</u></u>。 | 1e | B  |", "tags": {}, "lang": "zh", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/老年髋部骨折全髋关节置换术后超早期康复负重训练最佳证据总结.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】1. 所提出的筛选证据是否清晰明确?\n\n2. 文献的纳入标准是否合理?\n\n3. 采用的检索策略是否恰当?\n\n4. 纳入文献的原始数据报告是否充分?\n\n5. 所用的效应量指标评价标准是否恰当?\n\n6. 是否由≥2名以上的评价者独立完成文献质量评价?\n\n7. 提取资料相关要素采用一致的抽样抽取或调查表?\n\n8. 综合分析研究的方法是否恰当?\n\n9. 是否进行了敏感性或亚组评价?\n\n10. 是否在概述通报时对合乎技巧（或报道偏倚)或实践出错推荐意见?\n\n11. 对今后进一步研究的特定方向是否提出指导建议?", "content": "【0】页码:4\n老年髋部骨折全髋关节置换术后超早期康复负重训练最佳证据总结\n## 表 4 meta 分析质量评价结果\n\n【1】删除图片描述:<u>![](3_0.png)</u>\n\n【2】1. 所提出的筛选证据是否清晰明确? \n2. 文献的纳入标准是否合理?\n3. 采用的检索策略是否恰当?\n4. 纳入文献的原始数据报告是否充分?\n5. 所用的效应量指标评价标准是否恰当?\n6. 是否由≥2名以上的评价者独立完成文献质量评价?\n7. 提取资料相关要素采用一致的抽样抽取或调查表?\n8. 综合分析研究的方法是否恰当?\n9. 是否进行了敏感性或亚组评价?\n10. 是否在概述通报时对合乎技巧（或报道偏倚)或实践出错推荐意见?\n11. 对今后进一步研究的特定方向是否提出指导建议?\n\n【3】## 注：\n\n【4】①是否描述了观察的来源？ ②观察是否来源于表项依赖带偏的力的专家？③所假设的效应是来源于特定样本的人群/初步假设？ ④所述的运算不是基于分布的假设？ ⑤观察的效应是否具有相当性? ⑥是否参考了现有的其它文献? ⑦所描述的结局与以往文献是否有不一致的地方？\n\n【5】## 2.2.4 专家共识：共纳入 1 篇高质量专家共识，来源于\n\n【6】删除图片描述:<u>![](3_1.png)</u>\n\n【7】## 表 6 老年全髋关节置换术后超早期和延迟负重训练证据总结\n\n| 维度 | 证据内容 | 证据等级 | 证据推荐 |\n| --- | --- | --- | --- |\n| 基础训练 | 1. 常规术后当日或次日行股四头肌收缩训练、膝关节过伸及踝泵运动等不负重屈膝伸髋训练。删除12:<u>[删除13:<u>15, 20</u>]</u> | 1c,e | A  |\n|  | 2. 核小腿小腿或远端心脏泵等最优不负重训练最优，重点集中内收肌、腹部内侧、侧曲位、或椎，能较大的提高患者的综合适应能力和功能恢复。删除12:<u>删除14:<u>[15]</u></u> | 1c,e | A  |\n| 负重时间 | 3. 术后2~4 天开始负重训练。持续1.5~2 周后进行完全负重。删除12:<u>[删除13:<u>15, 16, 21</u>]</u> | 1c | A  |\n|  | 4. 术后1 天开始负重训练。删除12:<u>[删除13:<u>22, 23</u>]</u> | 1c | B  |\n|  | 5. 术后3 周才开始行走训练。删除12:<u>删除14:<u>[16]</u></u> | 1c | B  |\n|  | 6. 术后3~4 周开始负重训练。删除12:<u>删除14:<u>[20]</u></u> | 2b | B  |\n|  | 7. 手术当天即下地及下床负重训练。删除12:<u>删除14:<u>[24]</u></u> | 1e | B  |\n|  | 8. 术后4 周才开始负重训练。删除12:<u>删除14:<u>[20]</u></u> | 2b | B  |\n| 负重量度 | 9. 部分负重量为体重的1/8左右、负重量应随增大负重删除12:<u>删除14:<u>[25]</u></u>，俗至2天增加1次的一样的删除12:<u>删除14:<u>[15]</u></u>服温，| 1e | A  |\n|  | 10. 术后1天开始负重训练练习，未有较大负重量增加方案的10%的化验动物能一次性强删除12:<u>删除14:<u>[15]</u></u>且需合成100%的结局。 | 1e | A  |\n| 负量重度 | 11. 术后12小时即下床站立并逐步所有增至100%。 | 1e | A  |\n| 训练方法 | 12. 术后1天开始负重阶梯拉伸性训练并有进行更不需要增负量的一部分负重群—完全负相关。 | 1c,e | A  |\n|  | 13. 术后2~4 周逐步开始行走至完全负重删除12:<u>删除14:<u>[15]</u></u>，系统评价始终持相当维持重物护刊，合成身体进阶度删除12:<u>删除14:<u>[16]</u></u>和胶新健康不需要增加，或如中，预已处于手术后一对删除12:<u>删除14:<u>[22]</u></u>。统一分别于1~2 天开始首负重并增负再产生体重后的状态，步行有考部和平均50的方案维持删除12:<u>删除14:<u>[15]</u></u>且加重限制重负 体重1/8左右。删除12:<u>删除14:<u>[20]</u></u> | 1e | A  |\n|  | 14. 手术当日步行训练：有快速地术后余量例外，未出MDT手术版夹板并处于康复期初(0为1步行长度生物化验。删除12:<u>[删除13:<u>20, 21</u>]</u> | 5b | B  |\n|  | 15. 术后非不见期前阶段后时间量先照市场血贫身策划增加量、复增增认负量课程 eg，虚增强训练删除12:<u>删除14:<u>[15]</u></u>，几而亚于行完全重负9方案之次/一年/周并结合专有的交叉医学真实效果比如说，量步行步合于次大前后画步达一天提估界术详细计划一样删除12:<u>删除14:<u>[16]</u></u>。 | 1e | B  |", "index": 91, "show": true, "start": 91, "end": 346, "province": ["格式规范性", "表格格式错误"], "isEdit": false}, {"text": "【5】## 2.2.4 专家共识：共纳入 1 篇高质量专家共识，来源于", "content": "【0】页码:4\n老年髋部骨折全髋关节置换术后超早期康复负重训练最佳证据总结\n## 表 4 meta 分析质量评价结果\n\n【1】删除图片描述:<u>![](3_0.png)</u>\n\n<mark>【2】1. 所提出的筛选证据是否清晰明确?\n\n2. 文献的纳入标准是否合理?\n\n3. 采用的检索策略是否恰当?\n\n4. 纳入文献的原始数据报告是否充分?\n\n5. 所用的效应量指标评价标准是否恰当?\n\n6. 是否由≥2名以上的评价者独立完成文献质量评价?\n\n7. 提取资料相关要素采用一致的抽样抽取或调查表?\n\n8. 综合分析研究的方法是否恰当?\n\n9. 是否进行了敏感性或亚组评价?\n\n10. 是否在概述通报时对合乎技巧（或报道偏倚)或实践出错推荐意见?\n\n11. 对今后进一步研究的特定方向是否提出指导建议?</mark>：\n\n【4】①是否描述了观察的来源？ ②观察是否来源于表项依赖带偏的力的专家？③所假设的效应是来源于特定样本的人群/初步假设？ ④所述的运算不是基于分布的假设？ ⑤观察的效应是否具有相当性? ⑥是否参考了现有的其它文献? ⑦所描述的结局与以往文献是否有不一致的地方？\n\n【5】## 2.2.4 专家共识：共纳入 1 篇高质量专家共识，来源于\n\n【6】删除图片描述:<u>![](3_1.png)</u>\n\n【7】## 表 6 老年全髋关节置换术后超早期和延迟负重训练证据总结\n\n| 维度 | 证据内容 | 证据等级 | 证据推荐 |\n| --- | --- | --- | --- |\n| 基础训练 | 1. 常规术后当日或次日行股四头肌收缩训练、膝关节过伸及踝泵运动等不负重屈膝伸髋训练。删除12:<u>[删除13:<u>15, 20</u>]</u> | 1c,e | A  |\n|  | 2. 核小腿小腿或远端心脏泵等最优不负重训练最优，重点集中内收肌、腹部内侧、侧曲位、或椎，能较大的提高患者的综合适应能力和功能恢复。删除12:<u>删除14:<u>[15]</u></u> | 1c,e | A  |\n| 负重时间 | 3. 术后2~4 天开始负重训练。持续1.5~2 周后进行完全负重。删除12:<u>[删除13:<u>15, 16, 21</u>]</u> | 1c | A  |\n|  | 4. 术后1 天开始负重训练。删除12:<u>[删除13:<u>22, 23</u>]</u> | 1c | B  |\n|  | 5. 术后3 周才开始行走训练。删除12:<u>删除14:<u>[16]</u></u> | 1c | B  |\n|  | 6. 术后3~4 周开始负重训练。删除12:<u>删除14:<u>[20]</u></u> | 2b | B  |\n|  | 7. 手术当天即下地及下床负重训练。删除12:<u>删除14:<u>[24]</u></u> | 1e | B  |\n|  | 8. 术后4 周才开始负重训练。删除12:<u>删除14:<u>[20]</u></u> | 2b | B  |\n| 负重量度 | 9. 部分负重量为体重的1/8左右、负重量应随增大负重删除12:<u>删除14:<u>[25]</u></u>，俗至2天增加1次的一样的删除12:<u>删除14:<u>[15]</u></u>服温，| 1e | A  |\n|  | 10. 术后1天开始负重训练练习，未有较大负重量增加方案的10%的化验动物能一次性强删除12:<u>删除14:<u>[15]</u></u>且需合成100%的结局。 | 1e | A  |\n| 负量重度 | 11. 术后12小时即下床站立并逐步所有增至100%。 | 1e | A  |\n| 训练方法 | 12. 术后1天开始负重阶梯拉伸性训练并有进行更不需要增负量的一部分负重群—完全负相关。 | 1c,e | A  |\n|  | 13. 术后2~4 周逐步开始行走至完全负重删除12:<u>删除14:<u>[15]</u></u>，系统评价始终持相当维持重物护刊，合成身体进阶度删除12:<u>删除14:<u>[16]</u></u>和胶新健康不需要增加，或如中，预已处于手术后一对删除12:<u>删除14:<u>[22]</u></u>。统一分别于1~2 天开始首负重并增负再产生体重后的状态，步行有考部和平均50的方案维持删除12:<u>删除14:<u>[15]</u></u>且加重限制重负 体重1/8左右。删除12:<u>删除14:<u>[20]</u></u> | 1e | A  |\n|  | 14. 手术当日步行训练：有快速地术后余量例外，未出MDT手术版夹板并处于康复期初(0为1步行长度生物化验。删除12:<u>[删除13:<u>20, 21</u>]</u> | 5b | B  |\n|  | 15. 术后非不见期前阶段后时间量先照市场血贫身策划增加量、复增增认负量课程 eg，虚增强训练删除12:<u>删除14:<u>[15]</u></u>，几而亚于行完全重负9方案之次/一年/周并结合专有的交叉医学真实效果比如说，量步行步合于次大前后画步达一天提估界术详细计划一样删除12:<u>删除14:<u>[16]</u></u>。 | 1e | B  |", "index": 494, "show": true, "start": 481, "end": 516, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/06 15:55:55", "endTime": "2024/08/06 16:03:04", "cost": 429.555}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:03:05", "grab_time": "2024-08-05 23:55:55"}
{"id": 2211653, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "eaf3f1c2-86c2-4794-bb30-00264c30e2ba", "title": "（2023.V2）NCCN临床实践指南：儿童急性淋巴细胞白血病", "text": "【0】页码:67\n（2023.V2）NCCN临床实践指南：儿童急性淋巴细胞白血病\n疑似页眉<u>NCCN Guidelines Version 2.2023 Pediatric Acute Lymphoblastic Leukemia</u>\n\n【1】and should be treated in a center that has experience with lymphoblastic lymphoma.\n\n【2】Hematopathology evaluations should include morphologic examination of malignant lymphocytes using Wright-Giemsa–stained slides and hematoxylin and eosin–stained core biopsy and clot sections; comprehensive immunophenotyping with flow cytometry 删除9:<u>(see 删除32:<u>*</u>Immunophenotyping删除32:<u>*</u>)</u>; and baseline characterization of leukemic clone(s) by flow cytometry or molecular assay (eg, immunoglobulin 删除12:<u>[Ig]</u> or T-cell receptor 删除12:<u>[TCR]</u> gene rearrangements) to facilitate subsequent analysis of minimal residual disease (MRD).\n\n【3】### Immunophenotyping\n\n【4】Immunophenotypic classification of ALL involves flow cytometry to determine the presence of cell surface antigens on lymphocytes. ALL can be broadly classified into two groups based on immunophenotype, which include precursor B-cell ALL and T-cell ALL. Among children, B-ALL constitutes approximately 80% of cases and T-ALL constitutes approximately 10% to 15% of cases. In adult patients, subtypes of B-ALL represent approximately 75% of cases, whereas the remaining 25% comprise T-ALL. Within the B-cell lineage, the profile of cell surface markers differs according to the stage of B-cell maturation, which includes early precursor B-cell (early pre–B-cell) and pre–B-cell. Early pre–B-cell ALL is characterized by the presence of terminal deoxynucleotidyl transferase(TdT), the expression of CD19/CD22/CD79a, and the absence of CD10 (formerly termed 删除32:<u>*</u>common ALL antigen删除32:<u>*</u>) or surface Igs. CD10 negativity correlates with KMT2A rearrangement and poor prognosis. Pre–B-cell ALL is characterized by the presence of cytoplasmic Igs and CD10/CD19/CD22/CD79a expression and was previously termed \"common B-ALL\" due to the expression of CD10 at diagnosis. The definition of CD20 positivity is unclear, though most studies use 20% or greater of blasts expressing CD20. CD20 may be expressed in approximately 50% of B-ALL in children, with a higher frequency in patients between 1 and 10 years of age compared to patients <1 or >10 years. In some cases, CRLF2 overexpression detected via flow cytometry may be used as a surrogate for genomic alterations of the CRLF2 gene in pediatric B-ALL, including 删除32:<u>*</u>CRLF2::P2RY8删除32:<u>*</u> and 删除32:<u>*</u>IGH::CRLF2删除32:<u>*</u>.\n\n【5】T-ALL is typically associated with the presence of cytoplasmic CD3 (T-cell lineage blasts) or cell surface CD3 (mature T cells) in addition to variable expression of CD1a/CD2/CD5/CD7 and expression of TdT. Previous classifications of T-ALL were based on intrathymic staging according to antigens expressed, and included these notations: pro-T/1-I, pre-T/II, cortical T/III, and medullary T/IV. Most cases previously classified as pro-T or pre-T now meet the criteria for early T-cell precursor (ETP) ALL. ETP ALL represents a distinct biologic subtype of T-ALL that accounts for 12% of pediatric T-ALLs (and about 2% of ALL), and is characterized by: the absence of CD1a/CD8, weak expression of CD5 (<75% positive lymphoblasts), and the presence of 1 or more myeloid or stem cell markers (CD117, CD34, HLA-DR, CD13, CD33, CD11b, or CD65) on at least 25% of lymphoblasts. Initial reports demonstrated unfavorable outcomes; however, with modern more intensive therapies, multiple groups have reported similar outcomes to those observed in non-ETP T-ALL.\n\n【6】Hematologic malignancies related to ALL include acute leukemias of ambiguous lineage (ALALs), such as the mixed phenotype acute leukemias (MPALs). MPALs include bilineage leukemias, in which two distinct populations of lymphoblasts are identified, with one meeting the criteria for acute myeloid leukemia (AML). Biphenotypic MPAL is defined as a single population of lymphoblasts that express markers consistent with B-cell or T-cell ALL, in addition to expressing myeloid or monocytic markers. Notably, myeloid-associated markers such as CD13 and CD33", "tags": {}, "lang": "en", "attr": {"page_num": 67, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V2）NCCN临床实践指南：儿童急性淋巴细胞白血病.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:39:50", "endTime": "2024/08/06 16:41:04", "cost": 73.993}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:41:04", "grab_time": "2024-08-06 00:39:50"}
{"id": 2211652, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "40740db1-249a-446f-9d36-5c884e8feb54", "title": "KASL：慢性乙型肝炎管理的临床实践指南（2022）", "text": "【0】页码:36\nKASL：慢性乙型肝炎管理的临床实践指南（2022）\n因为肝穿刺检查上的坏死性炎症。目前，HDV的标准治疗方法为每周皮下注射干扰素α-48次，24周的持续病毒学应答率为23-28%的患者报告。持续病毒学应答可通过测量治疗24周后的血清HDV RNA水平来预测。然而，如一项长达4.3年的长期随访研究所见，长期随访期间复发频繁，持续病毒学应答仅维持在12%。核苷（酸）类似物（NA）联合干扰素α治疗并不能改善病毒学应答，与干扰素α单药治疗相比均未能带来病毒学应答，尚需进一步的研究。在一项针对24个月的扩展干扰素α治疗的小型研究中，47%的患者在平均随访19.5个月的时间内实现了持续病毒学应答，但需进一步的资料。\n\n【1】由于干扰素α的低效性，对HDV的新疗法正在开发中，例如布利地韦（BLV），一种正在进行III期研究的药物，是一种针对HDV的竞效抑制剂。它具有竞争性作用于肝细胞钠牛磺胆酸协同转运蛋白（NTCP）及病毒进入受体，阻断HDV病毒入肝细胞。删除27:<u>2020</u>年，BLV获得欧洲药品管理局认可用于无代偿性肝硬化且基因研究证实阳性（疾病早期或者未经治疗的患者），BLV每周皮下注射两次。正在进行的III期研究中，BLV治疗24周后结果显示，基线到24周HDV RNA和丙氨酸氨基转移酶（ALT）应答（HDV RNA下调和ALT降低）分别为0%、37%及28%。\n\n【2】另一种正在进行II期研究的药物是罗凡班，已知能阻断病毒衣壳上的前烯化过程，防止病毒组装、复制及肝细胞感染。罗凡班联合利托那韦治疗增加作用时间和降低胃肠道副作用的风险。治愈率与之前相似，分别为0%、37%及28%。\n\n【3】现行标准：HDV标准抗病毒治疗药物包括干扰素β、PEG 2139和JNJ-3989（RNAi）。\n\n【4】删除32:<u>**</u>[Recommendations]删除32:<u>**</u>\n\n【5】1. 在抗病毒治疗的HBE阳性且ALT升高、HBV DNA患者中，可以考虑HDV喝HDV筛检，除非存在任何酶活性应答增加的证据。\n2. 对于HDV合并炎症患者中的总胆红素升高、肝硬化或准备肝移植的患者中，都需进一步应用治疗管理以及干扰素α治疗。\n3. 伴有HDV感染的高危患者建议用干扰素α治疗至少一年，根据患者临床变化需要时进一步按临床指引评估。\n\n【6】删除32:<u>**</u>Authors’ contribution删除32:<u>**</u>\n\n【7】Jang JW, 等修改并校对了指南全文，监督工作，及摘要。阐述了图片部分、引言、天然史、愈后、手术适应症、图表部分等上的所见。谢一民综述到肝细胞癌的影响及肝病预后的原因及效果。所有委员会进行指南评估并修正。\n\n【8】删除32:<u>**</u>Conflicts of Interest删除32:<u>**</u>\n\n【9】Jang JW：收取Gilead, AbbVie, Bayer, Roche, Sysmex, Ipsen的赞助。接受过Gilead, Ipsen, Sysmex的研究资助。\nDong A-ST：收取Gilead, Pfizer, MSD, BMS, Roche, Astrazeneca, Aramdhd, Novonordoisk, Yuhan, Hanmi。\nKwon JH: 收取Gilead, AbbVie, Yuhan, Hanmi 的资助。\nYu SJ：接受Gilead, Abbive, Building, Daewoong, Yuhan, Chongkundang Pharm, Dong-A ST, Samil、Sanaj的赞助。\nKang W： 收取Gilead, BMS, ABT 赞助。", "tags": {}, "lang": "zh", "attr": {"page_num": 36, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/KASL：慢性乙型肝炎管理的临床实践指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:36\n\nKASL：慢性乙型肝炎管理的临床实践指南（2022）\n\n因为肝穿刺检查上的坏死性炎症。目前，HDV的标准治疗方法为每周皮下注射干扰素α-48次，24周的持续病毒学应答率为23-28%的患者报告。持续病毒学应答可通过测量治疗24周后的血清HDV RNA水平来预测。然而，如一项长达4.3年的长期随访研究所见，长期随访期间复发频繁，持续病毒学应答仅维持在12%。核苷（酸）类似物（NA）联合干扰素α治疗并不能改善病毒学应答，与干扰素α单药治疗相比均未能带来病毒学应答，尚需进一步的研究。在一项针对24个月的扩展干扰素α治疗的小型研究中，47%的患者在平均随访19.5个月的时间内实现了持续病毒学应答，但需进一步的资料。\n\n【1】由于干扰素α的低效性，对HDV的新疗法正在开发中，例如布利地韦（BLV），一种正在进行III期研究的药物，是一种针对HDV的竞效抑制剂。它具有竞争性作用于肝细胞钠牛磺胆酸协同转运蛋白（NTCP）及病毒进入受体，阻断HDV病毒入肝细胞。删除27:2020年，BLV获得欧洲药品管理局认可用于无代偿性肝硬化且基因研究证实阳性（疾病早期或者未经治疗的患者），BLV每周皮下注射两次。正在进行的III期研究中，BLV治疗24周后结果显示，基线到24周HDV RNA和丙氨酸氨基转移酶（ALT）应答（HDV RNA下调和ALT降低）分别为0%、37%及28%。\n\n【2】另一种正在进行II期研究的药物是罗凡班，已知能阻断病毒衣壳上的前烯化过程，防止病毒组装、复制及肝细胞感染。罗凡班联合利托那韦治疗增加作用时间和降低胃肠道副作用的风险。治愈率与之前相似，分别为0%、37%及28%。\n\n【3】现行标准：HDV标准抗病毒治疗药物包括干扰素β、PEG 2139和JNJ-3989（RNAi）。\n\n【4】删除32:[Recommendations]删除32:\n\n【5】1. 在抗病毒治疗的HBE阳性且ALT升高、HBV DNA患者中，可以考虑HDV喝HDV筛检，除非存在任何酶活性应答增加的证据。\n\n2. 对于HDV合并炎症患者中的总胆红素升高、肝硬化或准备肝移植的患者中，都需进一步应用治疗管理以及干扰素α治疗。\n\n3. 伴有HDV感染的高危患者建议用干扰素α治疗至少一年，根据患者临床变化需要时进一步按临床指引评估。\n\n【6】删除32:Authors’ contribution删除32:\n\n【7】Jang JW, 等修改并校对了指南全文，监督工作，及摘要。阐述了图片部分、引言、天然史、愈后、手术适应症、图表部分等上的所见。谢一民综述到肝细胞癌的影响及肝病预后的原因及效果。所有委员会进行指南评估并修正。\n\n【8】删除32:Conflicts of Interest删除32:\n\n【9】Jang JW：收取Gilead, AbbVie, Bayer, Roche, Sysmex, Ipsen的赞助。接受过Gilead, Ipsen, Sysmex的研究资助。\n\nDong A-ST：收取Gilead, Pfizer, MSD, BMS, Roche, Astrazeneca, Aramdhd, Novonordoisk, Yuhan, Hanmi。\n\nKwon JH: 收取Gilead, AbbVie, Yuhan, Hanmi 的资助。\n\nYu SJ：接受Gilead, Abbive, Building, Daewoong, Yuhan, Chongkundang Pharm, Dong-A ST, Samil、Sanaj的赞助。\n\nKang W： 收取Gilead, BMS, ABT 赞助。", "content": "【0】页码:36\nKASL：慢性乙型肝炎管理的临床实践指南（2022）\n因为肝穿刺检查上的坏死性炎症。目前，HDV的标准治疗方法为每周皮下注射干扰素α-48次，24周的持续病毒学应答率为23-28%的患者报告。持续病毒学应答可通过测量治疗24周后的血清HDV RNA水平来预测。然而，如一项长达4.3年的长期随访研究所见，长期随访期间复发频繁，持续病毒学应答仅维持在12%。核苷（酸）类似物（NA）联合干扰素α治疗并不能改善病毒学应答，与干扰素α单药治疗相比均未能带来病毒学应答，尚需进一步的研究。在一项针对24个月的扩展干扰素α治疗的小型研究中，47%的患者在平均随访19.5个月的时间内实现了持续病毒学应答，但需进一步的资料。\n\n【1】由于干扰素α的低效性，对HDV的新疗法正在开发中，例如布利地韦（BLV），一种正在进行III期研究的药物，是一种针对HDV的竞效抑制剂。它具有竞争性作用于肝细胞钠牛磺胆酸协同转运蛋白（NTCP）及病毒进入受体，阻断HDV病毒入肝细胞。删除27:<u>2020</u>年，BLV获得欧洲药品管理局认可用于无代偿性肝硬化且基因研究证实阳性（疾病早期或者未经治疗的患者），BLV每周皮下注射两次。正在进行的III期研究中，BLV治疗24周后结果显示，基线到24周HDV RNA和丙氨酸氨基转移酶（ALT）应答（HDV RNA下调和ALT降低）分别为0%、37%及28%。\n\n【2】另一种正在进行II期研究的药物是罗凡班，已知能阻断病毒衣壳上的前烯化过程，防止病毒组装、复制及肝细胞感染。罗凡班联合利托那韦治疗增加作用时间和降低胃肠道副作用的风险。治愈率与之前相似，分别为0%、37%及28%。\n\n【3】现行标准：HDV标准抗病毒治疗药物包括干扰素β、PEG 2139和JNJ-3989（RNAi）。\n\n【4】删除32:<u>**</u>[Recommendations]删除32:<u>**</u>\n\n【5】1. 在抗病毒治疗的HBE阳性且ALT升高、HBV DNA患者中，可以考虑HDV喝HDV筛检，除非存在任何酶活性应答增加的证据。\n2. 对于HDV合并炎症患者中的总胆红素升高、肝硬化或准备肝移植的患者中，都需进一步应用治疗管理以及干扰素α治疗。\n3. 伴有HDV感染的高危患者建议用干扰素α治疗至少一年，根据患者临床变化需要时进一步按临床指引评估。\n\n【6】删除32:<u>**</u>Authors’ contribution删除32:<u>**</u>\n\n【7】Jang JW, 等修改并校对了指南全文，监督工作，及摘要。阐述了图片部分、引言、天然史、愈后、手术适应症、图表部分等上的所见。谢一民综述到肝细胞癌的影响及肝病预后的原因及效果。所有委员会进行指南评估并修正。\n\n【8】删除32:<u>**</u>Conflicts of Interest删除32:<u>**</u>\n\n【9】Jang JW：收取Gilead, AbbVie, Bayer, Roche, Sysmex, Ipsen的赞助。接受过Gilead, Ipsen, Sysmex的研究资助。\nDong A-ST：收取Gilead, Pfizer, MSD, BMS, Roche, Astrazeneca, Aramdhd, Novonordoisk, Yuhan, Hanmi。\nKwon JH: 收取Gilead, AbbVie, Yuhan, Hanmi 的资助。\nYu SJ：接受Gilead, Abbive, Building, Daewoong, Yuhan, Chongkundang Pharm, Dong-A ST, Samil、Sanaj的赞助。\nKang W： 收取Gilead, BMS, ABT 赞助。", "index": 0, "show": true, "start": 0, "end": 1520, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "原文为英文"}], "startTime": "2024/08/07 09:41:37", "endTime": "2024/08/07 09:44:09", "cost": 151.419}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 17:44:08", "grab_time": "2024-08-06 01:40:04"}
{"id": 2211651, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "6bee3a7d-36bf-4eaa-befb-d1e5498f9054", "title": "2023 加拿大临床实践指南：循环或神经功能停滞后基于大脑的死亡定义及其确定标准", "text": "【0】页码:65\n2023 加拿大临床实践指南：循环或神经功能停滞后基于大脑的死亡定义及其确定标准\n- interprétés puis documentés par le médecin responsable.\n- Si des examens auxiliaires sont nécessaires, l’heure du décès est documentée comme le moment où l’examen auxiliaire a été terminé, étant entendu que les résultats doivent encore être interprétés formellement par des experts en neuroimagerie, puis documentés par le médecin responsable.\n- Si des étapes se produisent en dehors de la séquence recommandée , l’heure du décès enregistrée est l’heure où le dernier examen requis est réalisé (c.-à-d. lorsque tous les éléments ou critères requis sont remplis).\n- Dans de nombreuses provinces, la législation stipule qu’aux fins d’un don d’organes, le décès doit être déterminé par deux médecins conformément à la pratique médicale reconnue. Comme il est indiqué dans les Recommandations de 2006 sur la détermination du décès, et confirmé ici, il n’existe pas de raison biomédicale claire pour justifier l’implication d’un deuxième clinicien ou une deuxième évaluation clinique. Par conséquent, conformément à la loi, dans le cadre d’un don d’organes, une évaluation clinique répétée par un deuxième clinicien n’est pas nécessaire et l’heure de la première détermination du décès.\n- Si une évaluation clinique initiale est réalisée et que les résultats confirment le DCN, mais que des examens supplémentaires sont réalisés pour des raisons non médicales qui dépassent les exigences pour la détermination du décès , ces examens supplémentaires ne modifient pas l’heure déclarée du décès.\n\n【1】L’accomplissement de toutes les phases de détermination du décès doit être clairement documenté par le médecin responsable dans le dossier médical du patient (énoncé de bonne pratique). Une liste de contrôle normalisée devrait être utilisée pour la détermination et la documentation du décès (énoncé de bonne pratique).\n\n【2】### Qualifications des cliniciens\n\n【3】Tout clinicien participant à la détermination du décès doit posséder les compétences, la formation et les connaissances requises en matière de processus et de procédures de détermination du décès (énoncé de bonne pratique). Pour un DCN, les cliniciens doivent détenir : un permis d’exercice complet et à jour de la pratique médicale indépendante octroyé par le collège des médecins et chirurgiens ou l’autorité de délivrance des permis dans la province ou le territoire canadien pertinent; les compétences et connaissances requises dans la prise en charge des patients atteints de lésions cérébrales dévastatrices et des DCN; aucun niveau particulier de certification de spécialisation.\nPour le don d’organes, le deuxième clinicien peut être une infirmier.ère praticien.ne, si cela est conforme aux règlements de la province ou du territoire, à condition que cette personne possède les compétences et les connaissances requises en matière de DCN. Les deux cliniciens qui déterminent le décès ne doivent pas avoir d’association ou de participation active aux procédures de transplantation, et à l’attribution d’organes ou aux soins des receveurs de greffe prévus (énoncé de bonne pratique).\nLes médecins qui supervisent et interprètent les examens radiologiques auxiliaires pour un DCN devraient être experts en neuroradiologie et avoir de l’expérience dans la réalisation et l’interprétation de l’examen spécifique réalisé. Pour l’angiographie par tomodensitométrie, la géographie par résonance magnétique ou la tomodensitométrie de perfusion, les radiologistes devraient posséder la formation requise quant à l’exécution et l’interprétation de cet examen (énoncé de bonne pratique).\nLes médecins qui supervisent et interprètent les examens nucléaires auxiliaires pour un DCN devraient avoir suivi une résidence en médecine nucléaire et avoir de l’expérience dans la réalisation et l’interprétation de l’examen spécifique réalisé (énoncé de bonne pratique).\nLes médecins qui supervisent et interprètent les échographies Doppler transcrâniennes pour un DCN devraient être formés adéquatement en neurosonologie et avoir de l’expérience dans la réalisation et l’interprétation de l’examen spécifique réalisé (énoncé de bonne pratique).\nL’échographie Doppler transcrânienne est un examen physiologique complexe en médecine vasculaire nécessitant des compétences, une formation et une compréhension approfondies de l’anatomie cérébrovasculaire, de la physiologie et d’une variété de conditions pathologiques cliniquement intéressantes. Bien qu’il n’existe actuellement aucune ligne directrice claire émise par une société professionnelle décrivant l’expertise minimale nécessaire, l’expérience informelle en échographie au point d’intervention, communément appelée échographie au chevet, n’est pas suffisante.", "tags": {}, "lang": "None", "attr": {"page_num": 65, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 加拿大临床实践指南：循环或神经功能停滞后基于大脑的死亡定义及其确定标准.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:30:42", "endTime": "2024/08/06 15:32:45", "cost": 122.147}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:32:45", "grab_time": "2024-08-05 23:30:42"}
{"id": 2211650, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "d56a4cc6-b089-405a-a6e2-6c92c30591ec", "title": "新型冠状病毒感染后肺结节治疗专家共识", "text": "【0】页码:6\n新型冠状病毒感染后肺结节治疗专家共识\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】参考删除-3:<u>删除12:<u>删除14:<u>[6]</u></u> Naar L, Langeveld K, El Mobe M, et al. Acute kidney injury in critically-ill patients with COVID-19: a single-center experience of 206 consecutive patients删除12:<u>[J]</u>. Ann Surg, 删除13:<u>2020, 272</u> 删除11:<u>(4)</u>: e280-e281. doi: 10.1097/SLA.0000000000004319.</u>\n\n【2】参考删除-3:<u>删除12:<u>删除14:<u>[7]</u></u> Kaafarani HMA, El Mobe H, Hwabejire JO, et al. Gastrointestinal complications in critically ill patients with COVID-19[J]. Ann Surg, 删除13:<u>2020, 272</u>删除11:<u>(2)</u>: e61-e62. doi: 10.1097/SLA.0000000000000404.</u>\n\n【3】参考删除-3:<u>删除12:<u>删除14:<u>[8]</u></u> El Mobe M, Christensen MA, Naar L, et al. Comment on \"gastrointestinal complications in critically ill patients with COVID-19\": an update删除12:<u>[J]</u>. Ann Surg, 删除13:<u>2021, 274</u>删除11:<u>(6)</u>: e821-e823. doi: 10.1097/ SLA.0000000000004337.</u>\n\n【4】参考删除-3:<u>删除12:<u>删除14:<u>[9]</u></u> Alser O, Mokhtari A, Naar L, et al. Multisystem outcomes and predictors of mortality in critically ill patients with COVID-19: Demographics and disease acuity matter more than comorbidities or treatment modalities删除12:<u>[J]</u>. J Trauma Acute Care Surg, 删除13:<u>2021, 90</u>删除11:<u>(5)</u>: 880-890. doi: 10.1097/TA.0000000000003085.</u>\n\n【5】参考删除-3:<u>删除12:<u>删除14:<u>[10]</u></u> Al-Jabir A, Kerwan A, Nicola M, et al. Impact of the Coronavirus $(COVID-19)$ pandemic on surgical practice - Part I删除12:<u>[J]</u>. Int J Surg, 删除13:<u>2020, 79</u>:168-179. doi: 10.1016/j.ijsu.2020.05.022.</u>\n\n【6】参考删除-3:<u>删除12:<u>删除14:<u>[11]</u></u> Brindle ME, Gawande A. Managing COVID-19 in surgical systems 删除12:<u>[J]</u>. Ann Surg, 删除13:<u>2020, 272</u>删除11:<u>(1)</u>: e1-e2. doi: 10.1097/SLA. 0000000000003923.</u>\n\n【7】参考删除-3:<u>删除12:<u>删除14:<u>[12]</u></u> Bandyopadhyay S, Baticulon RE, Kadhum M, et al. Infection and mortality of healthcare workers worldwide from $(COVID-19)$: a systematic review删除12:<u>[J]</u>. BMJ Glob Health, 2020, 5删除11:<u>(12)</u>: e003097. doi: 10.1136/bmjgh-2020-003097.</u>\n\n【8】删除14:<u>[13] </u>COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study删除12:<u>[J]</u>. Lancet, 删除13:<u>2020, 396</u> 删除11:<u>删除19:<u>(10243)</u></u>:27-38. doi: 10.1016/S0140-6736删除11:<u>(20)</u>31182-X.\n\n【9】删除14:<u>[14] </u>COVIDSurg Collaborative. COVID-19-related absence among surgeons: development of an international surgical workforce prediction model删除12:<u>[J]</u>. BJS Open, 2021, 5删除11:<u>(2)</u>: zraa021. doi: 10.1093/bjsopen/zraa021.\n\n【10】参考删除-3:<u>删除12:<u>删除14:<u>[15]</u></u> COVIDSurg Collaborative. Outcomes and their state-level variation in patients undergoing surgery with perioperative SARS-CoV-2 infection in the USA: a prospective multicenter study删除12:<u>[J]</u>. Ann Surg, 删除13:<u>2022, 275</u>删除11:<u>(2)</u>: 247-251. doi: 10.1097/SLA. 0000000000005310.</u>\n\n【11】参考删除-3:<u>删除12:<u>删除14:<u>[16]</u></u> COVIDSurg Collaborative. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans删除12:<u>[J]</u>. Br J Surg, 删除13:<u>2020, 107</u>删除11:<u>(11)</u>:1440-1449. doi: 10.1002/bjs.11746.</u>\n\n【12】删除14:<u>[17] </u>COVIDSurg Collaborative. GlobalSurg Collaborative. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study删除12:<u>[J]</u>. Anaesthesia, 2021, 6删除11:<u>(6)</u>:748-758. doi: 删除13:<u>10. 1111</u>/anae.15458.\n\n【13】参考删除-3:<u>删除12:<u>删除14:<u>[18]</u></u> Mazzone PJ, Silvestri GA, Souter LH, et al. Screening for lung cancer: CHEST guideline and expert panel report删除12:<u>[J]</u>. Chest, 2021,160删除11:<u>(5)</u>:e427-e494. doi: 10.1016/j.chest.2021.06.063.</u>\n\n【14】参考删除-3:<u>删除12:<u>删除14:<u>[19]</u></u> Moyer V A, U. S. Preventive Services Task Force. Screening for lung cancer: U. S. Preventive Services Task Force recommendation statement删除12:<u>[J]</u>. Ann Intern Med, 删除13:<u>2014, 160</u>删除11:<u>(5)</u>:330-338. doi: 删除13:<u>10. 7326</u>/M13-2771.</u>\n\n【15】参考删除-3:<u>删除12:<u>删除14:<u>[20]</u></u> Zhang YJ, Yang WJ, Liu D, et al. COVID-19 and early-stage lung cancer both featuring ground-glass opacities: a propensity score-matched study删除12:<u>[J]</u>. Transl Lung Cancer Res, 2020, 9删除11:<u>(4)</u>:1516-1527. doi: 10.21037/tlcr-20-892.</u>\n\n【16】删除14:<u>[21] </u>樊旻, 李亮, 陈万青, 等. 中国肺癌筛查与早诊早治指南 删除19:<u>(2021，北京)</u>删除12:<u>[J]</u>. 中华肿瘤科, 删除13:<u>2021, 30</u> 删除11:<u>(2)</u>:81-111. doi: 删除13:<u>10. 11735</u>/j. issn. 1004-0242. 2021. 02. 0001.\n\n【17】参考删除-3:<u>He J, Li N, Chen WQ, et al. China guideline for the screening and early detection of lung cancer删除19:<u>(2021, Beijing)</u>删除12:<u>[J]</u>. J Chin Cancer, 2021,30删除11:<u>(2)</u>:81-111. doi: 10.11735/j.issn.1004-0242.2021.02. 0001.</u>\n\n【18】删除14:<u>[22] </u>漆拓亮, 赵春艳, 王依. 2022年第二版 NCCN 肺癌筛查指南 实践解读删除12:<u>[J]</u>. 中华胸心血管外科临床杂志. 删除13:<u>2022, 29</u> 删除11:<u>(11)</u>:1407-1413. doi: 10.7507/1007-4848.202208061.\n\n【19】参考删除-3:<u>Shi HJ, Xu L, Wang F, et al. Interpretation of updated NCCN clinical practice guidelines for lung cancer screening删除19:<u>(version 2.2022)</u> 删除12:<u>[J]</u>. Chin J Chin Thorac Cardiovasc Surg, 删除13:<u>2022, 29</u>删除11:<u>(11)</u>:doi: 10.7507/1007-4848.202208061.</u>\n\n【20】参考删除-3:<u>删除12:<u>删除14:<u>[23]</u></u> Walter JE, Heuvelmans MA, de Jong PA, et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial删除12:<u>[J]</u>. Lancet Oncol, 删除13:<u>2016, 17</u>删除11:<u>(7)</u>:907-916. doi: 删除13:<u>10. 1016</u>/S1470-2045删除11:<u>(16)</u>30069-9.</u>\n\n【21】参考删除-3:<u>删除12:<u>删除14:<u>[24]</u></u> Yip R, Henschke CI, Xu DM, et al. Lung cancers manifesting as part-solid nodules in the National Lung Screening Trial删除12:<u>[J]</u>. AJR Am J Roentgenol, 删除13:<u>2017, 208</u>删除11:<u>(5)</u>:1011-1021. doi: 10.2214/ AJR.16.16930.</u>\n\n【22】删除14:<u>[25] </u>国家卫庄健康委办公厅. 原发性肺癌诊疗指南删除19:<u>(2022年版)</u> 删除12:<u>[J]</u>. 中华医学会杂志,2022,13删除11:<u>(4)</u>:549-570. doi: 删除13:<u>10. 12290</u>/ xhyxzz. 2022-0352.\n\n【23】参考删除-3:<u>General Office of National Health Commission of the People's Republic of China. Clinical Practice Guideline for Primary Lung Cancer删除19:<u>(2022 Version)</u>删除12:<u>[J]</u>. Med J Punch,删除13:<u>2022, 13</u> 删除11:<u>(4)</u>:549-570. doi: 删除13:<u>10. 12290</u>/xhyxzz. 2022-0352.</u>\n\n【24】参考删除-3:<u>删除12:<u>删除14:<u>[26]</u></u> Mazzone PJ, Gould MK, Arenberg DA, et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic; CHEST expert panel report删除12:<u>[J]</u>. Chest,删除13:<u>2020, 158</u> 删除11:<u>(1)</u>:406-415. doi: 10.1016/j.chest.2020.04.020.</u>\n\n【25】参考删除-3:<u>删除12:<u>删除14:<u>[27]</u></u> Network NCC. NCCN clinical practice guidelines in oncology: lung cancer screening. Version 1[S/ OL].2023删除1:<u>. https: //www. nccn. org/professionals/physician_gls/pdf/lung_screening. pdf.</u></u>\n\n【26】删除14:<u>[28] </u>杨云旗, 李秀阳. 新冠疫情对肺癌筛查的影响及节命管理", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/新型冠状病毒感染后肺结节治疗专家共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:31:40", "endTime": "2024/08/06 15:31:48", "cost": 7.729}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:31:48", "grab_time": "2024-08-05 23:31:40"}
{"id": 2211649, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "ad459a3f-85ee-47c2-8927-1fcaf590d820", "title": "【儿科领域】2021+昆士兰临床指南：新生儿低血糖（V10）(1)", "text": "【0】页码:34\n【儿科领域】2021+昆士兰临床指南：新生儿低血糖（V10）(1)\n# Appendix A Growth charts examples\n\n【1】## Growth chart for girls\n\n【2】删除图片描述:<u>![Girls]</u>\n\n| Gestational age (weeks) | Weight (kilograms) | Weight (kilograms) | Centimeters | Centimeters |\n|-------------------------|--------------------|--------------------|-------------|-------------|\n|                         |                    |                    | Length      | Head Circumference |\n| 22                      | 0.5                |                    | 25          |             |\n| 24                      | 0.6                |                    | 28          |             |\n| 26                      | 0.8                |                    | 31          |             |\n| 28                      | 1.0                |                    | 34          |             |\n| 30                      | 1.3                |                    | 37          |             |\n| 32                      | 1.7                |                    | 40          |             |\n| 34                      | 2.2                |                    | 43          |             |\n| 36                      | 2.7                |                    | 45.5        |             |\n| 38                      | 3.1                |                    | 48          |             |\n| 40                      | 3.5                |                    | 50          |             |\n| 42                      | 3.8                |                    | 51          |             |\n| 44                      | 4.0                |                    | 52          |             |\n| 46                      | 4.2                |                    | 53          |             |\n| 48                      | 4.3                |                    | 54          |             |\n| 50                      | 4.5                |                    | 55          |             |\n\n【4】Curves equal the WHO Growth Standard at 50 weeks.\n\n【5】$$ F_{2013} $$\n\n【6】参考删除-3:<u>Sources: Intrauterine section: Germany 删除19:<u>(Voigt 2010)</u>, United States 删除19:<u>(Olsen 2010)</u>, Australia 删除19:<u>(Roberts 1999)</u>, Canada 删除19:<u>(Kramer 2001)</u>, Scotland 删除19:<u>(Bonellie 2008)</u>, Italy 删除19:<u>(Berti 2001)</u>, Postnatal section: the World Health Organization Growth Standard, 2006.</u>\n\n【7】删除1:<u>www.ucalgary.ca/fenton</u>", "tags": {}, "lang": "en", "attr": {"page_num": 34, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【儿科领域】2021+昆士兰临床指南：新生儿低血糖（V10）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】", "content": "【0】页码:34\n【儿科领域】2021+昆士兰临床指南：新生儿低血糖（V10）(1)\n# Appendix A Growth charts examples\n\n【1】## Growth chart for girls\n\n【2】删除图片描述:<u>![Girls]</u>\n\n| Gestational age (weeks) | Weight (kilograms) | Weight (kilograms) | Centimeters | Centimeters |\n|-------------------------|--------------------|--------------------|-------------|-------------|\n|                         |                    |                    | Length      | Head Circumference |\n| 22                      | 0.5                |                    | 25          |             |\n| 24                      | 0.6                |                    | 28          |             |\n| 26                      | 0.8                |                    | 31          |             |\n| 28                      | 1.0                |                    | 34          |             |\n| 30                      | 1.3                |                    | 37          |             |\n| 32                      | 1.7                |                    | 40          |             |\n| 34                      | 2.2                |                    | 43          |             |\n| 36                      | 2.7                |                    | 45.5        |             |\n| 38                      | 3.1                |                    | 48          |             |\n| 40                      | 3.5                |                    | 50          |             |\n| 42                      | 3.8                |                    | 51          |             |\n| 44                      | 4.0                |                    | 52          |             |\n| 46                      | 4.2                |                    | 53          |             |\n| 48                      | 4.3                |                    | 54          |             |\n| 50                      | 4.5                |                    | 55          |             |\n\n【4】Curves equal the WHO Growth Standard at 50 weeks.\n\n【5】$$ F_{2013} $$\n\n【6】参考删除-3:<u>Sources: Intrauterine section: Germany 删除19:<u>(Voigt 2010)</u>, United States 删除19:<u>(Olsen 2010)</u>, Australia 删除19:<u>(Roberts 1999)</u>, Canada 删除19:<u>(Kramer 2001)</u>, Scotland 删除19:<u>(Bonellie 2008)</u>, Italy 删除19:<u>(Berti 2001)</u>, Postnatal section: the World Health Organization Growth Standard, 2006.</u>\n\n【7】删除1:<u>www.ucalgary.ca/fenton</u>", "index": 110, "show": true, "start": 110, "end": 113, "province": ["信息质量", "有用性-轻"], "isEdit": false, "comment": "图片应删除"}, {"text": "【4】Curves equal the WHO Growth Standard at 50 weeks.\n\n【5】$$$ F_{2013} $$", "content": "【0】页码:34\n【儿科领域】2021+昆士兰临床指南：新生儿低血糖（V10）(1)\n# Appendix A Growth charts examples\n\n【1】## Growth chart for girls\n\n<mark>【2】</mark>删除图片描述:<u>![Girls]</u>\n\n| Gestational age (weeks) | Weight (kilograms) | Weight (kilograms) | Centimeters | Centimeters |\n|-------------------------|--------------------|--------------------|-------------|-------------|\n|                         |                    |                    | Length      | Head Circumference |\n| 22                      | 0.5                |                    | 25          |             |\n| 24                      | 0.6                |                    | 28          |             |\n| 26                      | 0.8                |                    | 31          |             |\n| 28                      | 1.0                |                    | 34          |             |\n| 30                      | 1.3                |                    | 37          |             |\n| 32                      | 1.7                |                    | 40          |             |\n| 34                      | 2.2                |                    | 43          |             |\n| 36                      | 2.7                |                    | 45.5        |             |\n| 38                      | 3.1                |                    | 48          |             |\n| 40                      | 3.5                |                    | 50          |             |\n| 42                      | 3.8                |                    | 51          |             |\n| 44                      | 4.0                |                    | 52          |             |\n| 46                      | 4.2                |                    | 53          |             |\n| 48                      | 4.3                |                    | 54          |             |\n| 50                      | 4.5                |                    | 55          |             |\n\n【4】Curves equal the WHO Growth Standard at 50 weeks.\n\n【5】$$ F_{2013} $$\n\n【6】参考删除-3:<u>Sources: Intrauterine section: Germany 删除19:<u>(Voigt 2010)</u>, United States 删除19:<u>(Olsen 2010)</u>, Australia 删除19:<u>(Roberts 1999)</u>, Canada 删除19:<u>(Kramer 2001)</u>, Scotland 删除19:<u>(Bonellie 2008)</u>, Italy 删除19:<u>(Berti 2001)</u>, Postnatal section: the World Health Organization Growth Standard, 2006.</u>\n\n【7】删除1:<u>www.ucalgary.ca/fenton</u>", "index": 1922, "show": true, "start": 1909, "end": 1981, "province": ["信息质量", "有用性-轻"], "isEdit": false}], "startTime": "2024/08/07 09:47:24", "endTime": "2024/08/07 09:48:31", "cost": 67.132}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 17:48:30", "grab_time": "2024-08-06 17:47:23"}
{"id": 2211648, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "25eecd0b-7361-4818-83a2-020abf296151", "title": "【心血管领域】（证据总结）2021+WHO指南：成人高血压的药物治疗", "text": "【0】页码:184\n【心血管领域】（证据总结）2021+WHO指南：成人高血压的药物治疗\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】参考删除-3:<u>83. Taque GS, Mennemeyer S, Menachmi N, Weech-Maldonado R, Kilgore M. Cost-effectiveness of antihypertensive medication: exploring race and sex differences using data from the reasons for geographic and racial differences in stroke study. Med Care. 2017;55:552-60. doi: 10.1097/MLR.0000000000000719.</u>\n\n【2】参考删除-3:<u>84. Hogan TJ, Elliott WJ, Seto AH, Bakris GL. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: A US economic evaluation. Pharmacoeconomics. 2002;20:37-47. doi: 10.2165/00019053-200220010-00004.</u>\n\n【3】参考删除-3:<u>85. Ekwunife OI, Okafor CE, Ezenduka CC, Udeogaranya PO. Cost-utility analysis of antihypertensive medications in Nigeria: A decision analysis. Cost Eff Resour Alloc. 2013;11:2. doi: 10.1186/1478-7547-11-2.</u>\n\n【4】参考删除-3:<u>86. Schwander B, Gradl B, Zollner Y, Lindgren P, Diener HC, Luders S et al. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe – the health model. Value Health. 2009;12:857-71. doi: 10.1111/j.1524-4733.2009.00507.x.</u>\n\n【5】参考删除-3:<u>87. Chan L, Chen CH, Hwang JJ, Yeh SJ, Shyu KG, Lin RT et al. Cost-effectiveness of amlodipine compared with valsartan in preventing stroke and myocardial infarction among hypertensive patients in Taiwan. Int J Gen Med. 2016;9:75-82. doi: 10.2147/IJGM.S102095.</u>\n\n【6】参考删除-3:<u>88. Wrona W, Budka K, Filipiak KJ, Niewada M, Wojtyniak B, Zdrojewski T. Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting. Kardiol Pol. 2016;74:1016-24. doi: 10.5603/KP.a2016.0055.</u>\n\n【7】89. Joint annual health review 2014: strengthening prevention and control of non-communicable diseases. Hanoi: Vietnam Ministry of Health & Health Partnership Group. 2014.\n\n【8】参考删除-3:<u>90. Buckley L, Labonville S, Barr J. A systematic review of beliefs about hypertension and its treatment among African Americans. Curr Hypertens Rep. 2016;18:52. doi: 10.1007/s11906-016-0662-5.</u>\n\n【9】参考删除-3:<u>91. Alsabbagh MH, Lemstra M, Eurich D, Lix LM, Wilson TW, Watson E et al. Socioeconomic status and nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Value Health. 2014;17:288-96. doi: 10.1016/j.jval.2013.11.011.</u>\n\n【10】参考删除-3:<u>92. Lewis LM. Factors associated with medication adherence in hypertensive blacks: a review of the literature. J Cardiovasc Nurs. 2012;27:208-19. doi: 10.1097/JCN.0b013e318215b8bf.</u>\n\n【11】参考删除-3:<u>93. Gravely-Sridhar FF, Manias E, Lal L, Salas M, Hughes DA, Ratzki-Leewing A et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ispor medication adherence and persistence special interest group. Value Health. 2013;16:863-71. doi: 10.1016/j.jval.2013.03.1631.</u>\n\n【12】参考删除-3:<u>94. AlGhurair SA, Hughes CA, Simpson SH, Guirguis LM. A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the World Health Organization multidimensional adherence model. J Clin Hypertens (Greenwich). 2012;14:877-86. doi: 10.1111/j.1751-7176.2012.00699.x.</u>\n\n【13】参考删除-3:<u>95. Wetzels GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens. 2004;22:1849-55. doi: 10.1097/00004872-200410000-00002.</u>\n\n【14】参考删除-3:<u>96. Angeli F, Reboldi G, Mazzotta G, Garofoli M, Ramundo E, Poltronieri C et al. Fixed-dose combination therapy in hypertension: Cons. High Blood Press Cardiovasc Prev. 2012;19:51-4. doi: 10.1007/BF03262453.</u>\n\n【15】参考删除-3:<u>97. Mallat SG, Tanios BY, Itani HS, Lotfi T, Akl EA. Free versus fixed combination antihypertensive therapy for essential arterial hypertension: a systematic review and meta-analysis. PLoS One. 2016;11:e0161285. doi: 10.1371/journal.pone.0161285.</u>\n\n【16】参考删除-3:<u>98. Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Arch Med Sci. 2018;14:1125-36. doi: 10.5114/aoms.2018.77561.</u>\n\n【17】参考删除-3:<u>99. Du LP, Cheng ZW, Zhang YX, Li Y, Mei D. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis. J Clin Hypertens (Greenwich). 2018;20:902-7. doi: 10.1111/jch.13272.</u>\n\n【18】参考删除-3:<u>100. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19:357-62. doi: 10.1097/01.hco.0000126978.03828.9e.</u>\n\n【19】参考删除-3:<u>101. Arguedas JA, Leiva V, Wright JM. Blood pressure targets in adults with hypertension. Cochrane Database Syst Rev. 2020;12:CD004349. doi: 10.1002/14651858.CD004349.pub3.</u>\n\n【20】参考删除-3:<u>102. Murad MH, Larrea-Mantilla L, Haddad A, Spinler-Bonilla G, Serrano V, Rodriguez-Gutierrez R et al. Antihypertensive agents in older adults: a systematic review and meta-analysis of randomized clinical trials. J Clin Endocrinol Metab. 2019;104:1575-84. doi: 10.1210/jc.2019-00197.</u>\n\n【21】参考删除-3:<u>103. Garrison S, Kolber MR, Korownyk C, McCracken R, Heran B, Allan G. Blood pressure targets for hypertension in older adults. John Wiley & Sons, Ltd; 2017 .</u>", "tags": {}, "lang": "en", "attr": {"page_num": 184, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【心血管领域】（证据总结）2021+WHO指南：成人高血压的药物治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:49:28", "endTime": "2024/08/06 16:50:34", "cost": 65.43}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:50:34", "grab_time": "2024-08-06 00:49:17"}
{"id": 2211647, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "653a892d-3011-480d-9eb5-44717ddddb07", "title": "CAS：麻醉实践指南（2022）", "text": "【0】页码:1\nCAS：麻醉实践指南（2022）\n删除32:<u>**</u>Guidelines to the Practice of Anesthesia删除32:<u>**</u>\n\n【1】Revised Edition 2022  \n删除32:<u>*</u>Canadian Journal of Anesthesia删除32:<u>*</u>  \n删除32:<u>*</u>Volume 69, number 1删除32:<u>*</u>\n\n【2】- 删除32:<u>**</u>How does this edition differ from the 2021 Guidelines?删除32:<u>**</u>\n  Several important content changes have been made and they are highlighted in 删除32:<u>**</u>bold删除32:<u>**</u> in the text. Some of the more important changes include:\n\n【3】- The recommendation that family physician anesthesia providers (FPA) in Canada obtain the Certificate of Added Competence at the enhanced skill level in family practice anesthesia through the College of Family Physicians of Canada.\n  - A completely revised Section 2.3, now entitled Physician Health and Wellness, outlining general guiding principles on the topic including several key anesthesia-related areas to consider with specific recommendations applicable to anesthesia departments of all sizes.\n  - The recommendation, related to difficult airway management and difficult airway kits, that emergency front of neck access (eFONA) airway (e.g., surgical cricothyroidotomy) equipment be immediately available at any location where anesthesia care is delivered.\n  - The recommendation to utilize, when appropriate, low total fresh gas flow techniques ($\\leq 1\\, \\text{L·min}^{-1}$) when using volatile inhalational anesthetic agents, recognizing the potential environmental, pulmonary, and economic benefits.\n  - Revisions to Section 5.2 Airway Management emphasizing the critical importance of the non-technical and human factors that may act as enablers or barriers to successful airway management.\n  - The recommendation that depth of anesthesia monitoring equipment (e.g., processed EEG-based) be available and considered for use, if clinically indicated, in patients who are at increased risk for intraoperative awareness.\n  - Revisions to Section 7 Guidelines for Neuraxial and Peripheral Nerve Block Regional Anesthesia, which now includes specific patient safety recommendations related to peripheral nerve block regional anesthesia techniques.\n\n【4】删除32:<u>**</u>Guide d'exercice de l'anesthésie删除32:<u>**</u>\n\n【5】Édition révisée 2022  \n删除32:<u>*</u>Journal canadien d'anesthésie删除32:<u>*</u>  \n删除32:<u>*</u>Volume 69, numéro 1删除32:<u>*</u>\n\n【6】- 删除32:<u>**</u>Comment cette édition diffère-t-elle des Lignes directrices de 2021?删除32:<u>**</u>\n  Plusieurs modifications importantes ont été apportées au contenu; elles sont surlignées en 删除32:<u>**</u>gras删除32:<u>**</u> dans le texte. Parmi les modifications les plus importantes, citons :\n\n【7】- La recommandation selon laquelle les omni-anesthésistes (ou anesthésistes en médecine familiale - AMF) au Canada obtiennent un Certificat de compétence additionnelle au niveau de compétence amélioré en anesthésie en médecine familiale par l’entremise du Collège des médecins de famille du Canada.\n  - Une section 2.3 entièrement révisée, dorénavant intitulée Santé et bien-être des médecins, décrivant des principes directeurs généraux sur le sujet, y compris concernant plusieurs domaines clés liés à l’anesthésie. Cette section présente des recommandations spécifiques applicables aux départements d’anesthésie de toutes tailles.\n  - En lien avec la prise en charge des voies aériennes difficiles et les trousses d’intubation difficile, la recommandation que le matériel nécessaire à réaliser un abord cervical antérieur d’urgence (FeONA)  soit à portée immédiate à tout endroit où des soins d’anesthésie sont dispensés.\n  - La recommandation d’utiliser, s’il y a lieu, des techniques à faible débit de gaz frais ($\\leq 1\\, \\text{L·min}^{-1}$) lors de l’utilisation d’agents anesthésiques par inhalation volatils, en reconnaissant les avantages environnementaux, pulmonaires et économiques potentiels.\n  - Des révisions de la section 5.2 Prise en charge des voies aériennes soulignant l’importance cruciale des facteurs non techniques et humains qui peuvent agir comme catalyseurs ou obstacles à une prise en charge réussie des voies aériennes.\n  - La recommandation que le matériel de monitorage de la profondeur de l’anesthésie  soit disponible et que son utilisation soit envisagée, si cela est cliniquement indiqué, chez les patients qui présentent un risque accru de mémorisation peropératoire.\n  - Des révisions apportées à la section 7 Lignes directrices pour l’anesthésie régionale par bloc neuraxial et bloc nerveux périphérique, qui comprennent maintenant des recommandations spécifiques en matière de sécurité des patients liées aux techniques d’anesthésie régionale par bloc nerveux périphérique.", "tags": {}, "lang": "None", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/CAS：麻醉实践指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:51:53", "endTime": "2024/08/06 15:54:02", "cost": 128.916}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:54:03", "grab_time": "2024-08-05 23:51:53"}
{"id": 2211646, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "dafae11d-fc0b-41e7-8beb-93aa955e390b", "title": "（2023.V4）NCCN临床实践指南：食管和食管胃交界部癌", "text": "【0】页码:115\n（2023.V4）NCCN临床实践指南：食管和食管胃交界部癌\n疑似页眉<u># NCCN Guidelines Version 4.2023\n## Esophageal and Esophagogastric Junction Cancers</u>\n\n【1】In a phase II study, preoperative chemotherapy with irinotecan and cisplatin followed by concurrent chemoradiation with the same regimen resulted in moderate response rates in patients with resectable, locally advanced gastric and EGJ adenocarcinoma.删除22:<u>$^{328}$</u> R0 resection was achieved in 65% of patients and the median OS and actuarial 2-year survival rates were 14.5 months and 35%, respectively.删除22:<u>$^{328}$</u> In another phase II-I trial that evaluated preoperative chemotherapy with irinotecan and cisplatin followed by concurrent chemoradiation, the rate of pCR (16%) was relatively low and the rates of R0 resection (69%), PFS (15.2 months), and OS (31.7 months) were either comparable or inferior to those observed for preoperative chemoradiation in phase II trials.删除22:<u>$^{330}$</u>\n\n【2】In the phase II SAKK 75/02 trial, preoperative chemotherapy with docetaxel and cisplatin followed by chemoradiation with the same regimen was effective in patients with SCC or adenocarcinoma of the esophagus (n = 66). Of the 57 patients who underwent surgery, R0 resection was achieved in 52 of them. Median OS and EFS were 36.5 months and 22.8 months, respectively.删除22:<u>$^{329}$</u> However, the results of another phase II trial showed that induction chemotherapy (oxaliplatin and fluorouracil) before preoperative chemoradiation with the same regimen resulted in a non-significant increase in the rate of pCR and did not prolong OS in patients with esophageal cancer.删除22:<u>$^{331}$</u> Therefore, induction chemotherapy prior to preoperative chemoradiation therapy is feasible and may be appropriate for select patients. However, this approach needs to be further evaluated in phase III randomized clinical trials.\n\n【3】### Perioperative Chemotherapy\nThe survival benefit of perioperative chemotherapy in gastroesophageal cancers was first demonstrated in the landmark phase III MAGIC trial.删除22:<u>$^{332}$</u> This study, which compared perioperative chemotherapy with epirubicin, cisplatin, and fluorouracil (ECF) to surgery alone, established that perioperative chemotherapy improves PFS and OS in patients with non-metastatic stage II and higher gastric or EGJ adenocarcinoma. In the randomized controlled phase II/III FLOT4 trial, Al-Batran et al compared perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) to the standard ECF regimen in patients with resectable non-metastatic gastric or EGJ adenocarcinoma ($cT2 and/or N+$).$^{168,293}$ In the phase II part of the study, 265 patients were randomized to receive either three preoperative and postoperative cycles of ECF (n = 137) or four preoperative and postoperative cycles of FLOT (n = 128). Results showed that FLOT was associated with significantly higher proportions of patients achieving pCR than was ECF (16%; 95% CI, 10–23 vs. 6%; 95% CI, 3–11; $P = .02$).删除22:<u>$^{293}$</u> Additionally, FLOT was associated with a reduction in the percentage of patients experiencing at least one grade 3–4 adverse event, including neutropenia, leucopenia, nausea, infection, fatigue, and vomiting (40% of patients in the ECF group vs. 25% of patients in the FLOT group). In the phase III part of the trial, 716 patients were randomized to receive FLOT (n = 356) or ECF (n = 360).删除22:<u>$^{168}$</u> Results showed that median OS was increased in the FLOT group compared with the ECF group (50 vs. 35 months; HR, 0.77; 95% CI, 0.63–0.94). The percentage of patients with serious chemotherapy-related adverse events was the same in the two groups (27% in the ECF group vs. 27% in the FLOT group). Therefore, ECF should no longer be recommended in this setting. However, because of considerable toxicity associated with the FLOT regimen, the panel recommends its use in select patients with good performance status. The preferred perioperative regimen for most patients who have good to moderate performance status is FOLFOX.\n\n【4】In the FNCLCC ACCORD 07 trial (n = 224 patients; 75% had adenocarcinoma of the lower esophagus or EGJ), Ychou et al reported that perioperative chemotherapy with fluorouracil and cisplatin significantly increased the curative resection rate, DFS, and OS in patients with resectable cancer.删除22:<u>$^{292}$</u> At a median follow-up of 5.7 years, the 5-year OS rate was 38% for patients in the perioperative chemotherapy group and", "tags": {}, "lang": "en", "attr": {"page_num": 115, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V4）NCCN临床实践指南：食管和食管胃交界部癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:09:04", "endTime": "2024/08/06 16:09:37", "cost": 33.242}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:09:37", "grab_time": "2024-08-06 00:03:57"}
{"id": 2211645, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "841a51a8-0d1e-4e0e-83c6-ec059236e0b1", "title": "事件相关电位的临床应用与操作规范上海专家共识(1)", "text": "【0】页码:2\n事件相关电位的临床应用与操作规范上海专家共识(1)\n# 事件相关电位的临床应用与操作规范上海专家共识\n\n【1】Shanghai Expert Consensus on Clinical Application and Practice of Event-related Potentials\n\n【2】上海市医学会脑电与临床神经生理专科分会\n\n【3】分与大脑对刺激的信号处理过程有关，可分为与物理刺激加工相关的外源性成分和与心理加工过程相关的内源性成分如失匹配负波 (mismatch negativity, MMN)，P300。关联性负变 (contingent negative variation, CNV) 和 N400 成分，反映了不同的高级认知加工过程。不同的 ERP 成分具有特定的潜伏期，波幅和头皮空间分布特征 删除9:<u>(即极形图)</u>。上述成分异常可为神经及精神疾病的诊治和预后提供有价值的信息。自 1964 年 Walter 等删除12:<u>删除14:<u>[2]</u></u>报道了首个认知 ERP 成分 (即 CNV) 以来，认知神经科学不断发展。目前在神经及精神疾病中，学者采用不同检测变量任务模式和操作参数获取的  ERP 成分开展了广泛的临床和基础应用研究，但尚缺乏一致性的临床应用与操作规范。上海市医学会脑电与临床神经生理专科分会现组织专家对 ERP 在临床应用中的技术规范和适用疾病的诊断价值提供适用性建议。\n\n【4】删除图片描述:<u>![](1_0.png)</u>", "tags": {}, "lang": "None", "attr": {"page_num": 2, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/事件相关电位的临床应用与操作规范上海专家共识(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【3】分与大脑对刺激的信号处理过程有关，可分为与物理刺激加工相关的外源性成分和与心理加工过程相关的内源性成分如失匹配负波 (mismatch negativity, MMN)，P300。", "content": "【0】页码:2\n事件相关电位的临床应用与操作规范上海专家共识(1)\n# 事件相关电位的临床应用与操作规范上海专家共识\n\n【1】Shanghai Expert Consensus on Clinical Application and Practice of Event-related Potentials\n\n【2】上海市医学会脑电与临床神经生理专科分会\n\n【3】分与大脑对刺激的信号处理过程有关，可分为与物理刺激加工相关的外源性成分和与心理加工过程相关的内源性成分如失匹配负波 (mismatch negativity, MMN)，P300。关联性负变 (contingent negative variation, CNV) 和 N400 成分，反映了不同的高级认知加工过程。不同的 ERP 成分具有特定的潜伏期，波幅和头皮空间分布特征 删除9:<u>(即极形图)</u>。上述成分异常可为神经及精神疾病的诊治和预后提供有价值的信息。自 1964 年 Walter 等删除12:<u>删除14:<u>[2]</u></u>报道了首个认知 ERP 成分 (即 CNV) 以来，认知神经科学不断发展。目前在神经及精神疾病中，学者采用不同检测变量任务模式和操作参数获取的  ERP 成分开展了广泛的临床和基础应用研究，但尚缺乏一致性的临床应用与操作规范。上海市医学会脑电与临床神经生理专科分会现组织专家对 ERP 在临床应用中的技术规范和适用疾病的诊断价值提供适用性建议。\n\n【4】删除图片描述:<u>![](1_0.png)</u>", "index": 179, "show": true, "start": 179, "end": 272, "province": ["语义有效性", "语义不完整"], "isEdit": false}], "startTime": "2024/08/06 17:09:19", "endTime": "2024/08/06 17:10:00", "cost": 41.119}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 01:10:00", "grab_time": "2024-08-06 01:09:19"}
{"id": 2211644, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "e6ca58ca-b9d9-4aef-a6ac-eb8f693b9200", "title": "2024更新—2016 NICE指南：结核病（NG.33）", "text": "【0】页码:19\n2024更新—2016 NICE指南：结核病（NG.33）\n- 如果无法进行曼图测试，请提供干扰素-伽玛释放实验。 删除24:<u>[新2016]</u>\n1.2.1.7 向新入职的NHS员工提供干扰素-伽玛释放实验，这些员工曾接触在结核病高发地区的患者：\n  - 如果干扰素-伽玛释放实验为阳性，评估是否有活动性结核病，\n  - 如果评估结果为阴性，提供潜伏性结核感染的治疗。删除24:<u>[2011年，修订2016]</u>\n\n【1】1.2.1.8 免疫系统受损的医疗工作者应以与其他免疫系统受损人员相同的方式进行筛查（参见建议1.2.1.2至1.2.1.4）。删除12:<u>删除14:<u>删除24:<u>[2011]</u></u></u>\n\n【2】1.2.2 诊断儿童和年轻人的潜伏性结核病\n1.2.2.1 仅在儿童和年轻人中考虑单独使用干扰素-伽玛释放实验，尤其是在无法进行曼图测试或测试不切实际的情况下，例如在需要检测大量人群的情境中（参见事件和疫情应对章节以及建议1.2.3.2）。删除24:<u>[新2016]</u>\n\n【3】1.2.2.2 将2岁以下且与有涂片阴性肺结核或喉结核接触的儿童转介至专家，以确定应采取什么潜伏性结核测试策略。应是具有结核病经验和培训的儿科医师，或在专家的指导下向普通儿科医师求助。删除24:<u>[新2016]</u>\n\n【4】1.2.2.3 如果新生儿曾与至少未接受两周抗结核治疗的有涂片阳性肺结核或喉结核的人员密切接触：\n  - 评估是否有活动性结核病（参见各年龄组活动性结核病的诊断章节，诊断肺结核（包括喉结核）在所有年龄组和儿童及年轻人的肺结核诊断）。\n  - 开始使用异烟肼（配合吡哆醇）。", "tags": {}, "lang": "zh", "attr": {"page_num": 19, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024更新—2016 NICE指南：结核病（NG.33）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:19\n\n2024更新—2016 NICE指南：结核病（NG.33）\n\n如果无法进行曼图测试，请提供干扰素-伽玛释放实验。 删除24:[新2016]\n1.2.1.7 向新入职的NHS员工提供干扰素-伽玛释放实验，这些员工曾接触在结核病高发地区的患者：\n如果干扰素-伽玛释放实验为阳性，评估是否有活动性结核病，\n如果评估结果为阴性，提供潜伏性结核感染的治疗。删除24:[2011年，修订2016]\n【1】1.2.1.8 免疫系统受损的医疗工作者应以与其他免疫系统受损人员相同的方式进行筛查（参见建议1.2.1.2至1.2.1.4）。删除12:删除14:删除24:[2011]\n\n【2】1.2.2 诊断儿童和年轻人的潜伏性结核病\n\n1.2.2.1 仅在儿童和年轻人中考虑单独使用干扰素-伽玛释放实验，尤其是在无法进行曼图测试或测试不切实际的情况下，例如在需要检测大量人群的情境中（参见事件和疫情应对章节以及建议1.2.3.2）。删除24:[新2016]\n\n【3】1.2.2.2 将2岁以下且与有涂片阴性肺结核或喉结核接触的儿童转介至专家，以确定应采取什么潜伏性结核测试策略。应是具有结核病经验和培训的儿科医师，或在专家的指导下向普通儿科医师求助。删除24:[新2016]\n\n【4】1.2.2.3 如果新生儿曾与至少未接受两周抗结核治疗的有涂片阳性肺结核或喉结核的人员密切接触：\n\n评估是否有活动性结核病（参见各年龄组活动性结核病的诊断章节，诊断肺结核（包括喉结核）在所有年龄组和儿童及年轻人的肺结核诊断）。\n开始使用异烟肼（配合吡哆醇）。", "content": "【0】页码:19\n2024更新—2016 NICE指南：结核病（NG.33）\n- 如果无法进行曼图测试，请提供干扰素-伽玛释放实验。 删除24:<u>[新2016]</u>\n1.2.1.7 向新入职的NHS员工提供干扰素-伽玛释放实验，这些员工曾接触在结核病高发地区的患者：\n  - 如果干扰素-伽玛释放实验为阳性，评估是否有活动性结核病，\n  - 如果评估结果为阴性，提供潜伏性结核感染的治疗。删除24:<u>[2011年，修订2016]</u>\n\n【1】1.2.1.8 免疫系统受损的医疗工作者应以与其他免疫系统受损人员相同的方式进行筛查（参见建议1.2.1.2至1.2.1.4）。删除12:<u>删除14:<u>删除24:<u>[2011]</u></u></u>\n\n【2】1.2.2 诊断儿童和年轻人的潜伏性结核病\n1.2.2.1 仅在儿童和年轻人中考虑单独使用干扰素-伽玛释放实验，尤其是在无法进行曼图测试或测试不切实际的情况下，例如在需要检测大量人群的情境中（参见事件和疫情应对章节以及建议1.2.3.2）。删除24:<u>[新2016]</u>\n\n【3】1.2.2.2 将2岁以下且与有涂片阴性肺结核或喉结核接触的儿童转介至专家，以确定应采取什么潜伏性结核测试策略。应是具有结核病经验和培训的儿科医师，或在专家的指导下向普通儿科医师求助。删除24:<u>[新2016]</u>\n\n【4】1.2.2.3 如果新生儿曾与至少未接受两周抗结核治疗的有涂片阳性肺结核或喉结核的人员密切接触：\n  - 评估是否有活动性结核病（参见各年龄组活动性结核病的诊断章节，诊断肺结核（包括喉结核）在所有年龄组和儿童及年轻人的肺结核诊断）。\n  - 开始使用异烟肼（配合吡哆醇）。", "index": 0, "show": true, "start": 0, "end": 672, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "原文为英文"}], "startTime": "2024/08/07 09:49:50", "endTime": "2024/08/07 09:50:18", "cost": 28.252}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 17:50:17", "grab_time": "2024-08-06 17:49:49"}
{"id": 2211643, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "215366b1-f4f6-4152-8520-c6cb4054550d", "title": "【骨科领域】2020+专家共识声明：髌骨关节大软骨和骨软骨缺损的治疗", "text": "【0】页码:7\n【骨科领域】2020+专家共识声明：髌骨关节大软骨和骨软骨缺损的治疗\nsetting. The load of impact has a larger influence on chondrocyte death than the number of impacts. Thus, multiple low-load taps are preferred over single high-load taps if impaction cannot be avoided. Therefore, the goal is to obtain a 6- to 10-mm graft that is flush with the cartilage surface or in contact with the bottom of the recipient hole, regardless of subchondral bone matching. This method decreases the subsidence of the graft and results in better restoration of the contact pressure in that compartment.\n\n【1】Another subject of debate in the 3 rounds of the Delphi consensus was the treatment of uncontained lesions in the patellofemoral joint. Experts stated that patellofemoral chondral injuries can be treated with ACI and OCA with appropriate modifications to ensure stability. These can be performed with transosseous sutures or anchors in ACI; however, MACI might not need any additional fixation if the uncontained portion is small. In certain situations, OCA might need additional fixation when the graft is unstable. Headless metal screws or absorbable internal fixation materials can be used for fixation, with the acknowledgment that metal screws will need to be removed once the OCA site has healed. Other surgical technical aspects that had agreement were that dowels are preferred compared with shell grafts when possible and that pulse lavage should be used because it may decrease the concentration of bone marrow elements.\n\n【2】### Rehabilitation\n\n【3】Last, a sequential, staged rehabilitation program (range of motion, muscular endurance, strength, and power) was felt to be essential for a successful outcome among experts. In early phases, a comprehensive patellar and tibiofemoral mobilization protocol is safe and should be implemented to avoid arthrofibrosis. Notably, progressive weight-bearing as tolerated with a knee brace locked in full extension does not excessively load the patellofemoral joint and is therefore considered safe if no associated osteotomy is performed.\n\n【4】This expert consensus statement fulfills established criteria for the reporting of Delphi studies using a validated number of experts. The 100% response rate across all 3 survey rounds highlights the commitment of these experts to establish a consensus on the management of patellofemoral chondral injuries. The Delphi technique has additional strengths as well as preserving participants’ anonymity and therefore shields participants from more influential expert opinions. Furthermore, the potential influence of any single participant was reduced by including more experts than most published Delphi studies. Last, the level of agreement required for final inclusion was higher than most health care Delphi studies to ensure that only statements supported by over 95% of experts were included. Nevertheless, this study is not without limitations. As with any other consensus statement, although the statements were created from a review of the literature, the modifications and suggestions presented are not directly derived from data but from expert opinions. Additional research, including clinical outcomes data, is required to validate this consensus statement.\n\n【5】### CONCLUSION\n\n【6】This study established a strong expert consensus document relating to the functional anatomy, surgical indications, donor graft considerations for osteochondral allografts, surgical technical aspects, and rehabilitation concepts for the management of large chondral and osteochondral defects in the patellofemoral joint. Further research is required to clinically validate the established consensus statements and better understand the precise indications for surgery as well as which techniques and graft processing/preparation methods should be used based on patient- and lesion-specific factors.\n\n【7】### AUTHORS\n\n【8】Jorge Chahla, MD, PhD (Midwest Orthopaedics at Rush, Chicago, Illinois, USA); Betina B. Hinckel, MD, PhD (Oakland University, Rochester, Michigan, USA; Department of Orthopaedic Surgery, William Beaumont Hospital, Royal Oak, Michigan, USA); Adam B. Yanke, MD, PhD (Midwest Orthopaedics at Rush, Chicago, Illinois, USA); Jack Farr, MD (OrthoIndy, Indianapolis, Indiana, USA); and Metrics of Osteochondral Allografts (MOCA) Group Collaborators: William D. Bugbee, MD, FAAOS (Shiley Center for Orthopaedic Research and Education, Scripps Clinic, La Jolla, California, USA); James L. Carey, MD, MPH (University of Pennsylvania, Philadelphia, Pennsylvania, USA); Brian J. Cole, MD, MBA, FAAOS (Midwest Orthopaedics at Rush, Chicago, Illinois, USA); Dennis C. Crawford, MD, PhD, FAAOS (Oregon Health & Science University, Portland, Oregon, USA); James E. Fleischli, MD, FAAOS (OrthoCarolina Sports Medicine Center, Charlotte, North Carolina, USA); Alan Getgood, MD, FRCS(Ortho) (Fowler Kennedy Sport Medicine Clinic, Western University, London, Ontario, Canada); Andreas H. Gomoll, MD, FAAOS (Hospital for Special Surgery, New York, New York, USA); Simon Gortz, MD (Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA); Allan E. Gross, MD, FRCSC (Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada); Deryk G. Jones, MD, FAAOS (Ochsner Sports Medicine Institute, New Orleans, Louisiana, USA); Aaron J. Krych, MD, FAAOS (Mayo Clinic, Rochester, Minnesota, USA); Christian Lattermann, MD, FAAOS (Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA); Robert R. Mandelbaum, MD, FAAOS (Santa Monica Orthopaedic and Sports Medicine Group, Santa Monica, California, USA); Peter R. Mandt, MD, FAAOS (Proliance Orthopaedics & Sports Medicine, Issaquah, Washington, USA); Tom Minas, MD, MS, FACS, FRCSC (Cleveland Clinic Florida, Weston, USA; West Palm Beach, Florida, USA); Raffy Mirzayan, MD, FAAOS (Kaiser Permanente, Baldwin Park, California, USA); Timothy S. Mologne, MD (Orthopaedic & Sports\n\n【9】删除图片描述:<u>![](6_0.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 7, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【骨科领域】2020+专家共识声明：髌骨关节大软骨和骨软骨缺损的治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:41:14", "endTime": "2024/08/06 16:41:38", "cost": 23.474}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:41:38", "grab_time": "2024-08-06 00:41:14"}
{"id": 2211642, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "3c3ff7e9-de90-4eb3-a440-f7c55f7ddf3b", "title": "2023 ERS声明：成人支气管扩张的气道廓清技术", "text": "【0】页码:105\n2023 ERS声明：成人支气管扩张的气道廓清技术\n删除32:<u>**</u>Table S5.删除32:<u>**</u> Summary of the main features of studies included in Question 3 - 删除32:<u>**</u>Which are the ACTs that are used in the management of adults with bronchiectasis and are there any patterns according to geographical location?删除32:<u>**</u>\n\n| First Author, year | Country                  | Study start - end date | Data collection | Study design  | Sites response rate | HCP response rate | Nº of participants and response rate | Years’ experience | Areas of work                                   | Location (urban vs. rural)                                                                                           | Responders                | Clinical stage of disease |\n|--------------------|--------------------------|------------------------|-----------------|---------------|---------------------|-------------------|--------------------------------------|-------------------|-------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------|---------------------------|\n| O'Neill et al.删除12:<u>删除14:<u>[55]</u></u> 2002 | UK                       | NR                     | Survey (NR)     | Cross-sectional | 82%                 | 82%               | n=82 (82%)                           | NR                | NR                                              | NR                                                                                              | Physiotherapists           | NR                        |\n| Lee et al.删除12:<u>删除14:<u>[56]</u></u> 2008    | Australia and New Zealand | NR                     | Survey (mail)   | Cross-sectional | 85%                 | 85%               | n=102 (85%)                          | 10 删除11:<u>(2-42)</u>         | Inpatients (93%) and outpatients (70%)          | Public/private (6%); tertiary (65%); large major city (1%); large regional/rural (16%)                              | Cardiorespiratory physiotherapists | NR                        |\n| Santos et al.删除12:<u>删除14:<u>[57]</u></u> 2016 | Australia                | July 2012 - May 2013  | Survey (mail)   | Cross-sectional | 88%                 | 70%               | n=169 (55%)                          | <1 2%; 1-5 37%; 6-10 24%; >10 28%   | Surgical 54%; General medicine 49%; Intensive care/high-dependency unit 43%; Respiratory 43%; Outpatients 36%; Orthopedics 33%; Rehabilitation 20%; Gerontology 18%; Community 15%; Neurology | Tertiary/teaching hospitals 47%; rural hospitals 33%; generalist hospitals 9%; private hospitals 6%; specialist hospitals 4% | Physiotherapists            | NR                        |", "tags": {}, "lang": "en", "attr": {"page_num": 105, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ERS声明：成人支气管扩张的气道廓清技术.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:51:10", "endTime": "2024/08/06 16:51:36", "cost": 25.564}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 00:51:36", "grab_time": "2024-08-06 00:51:11"}
{"id": 2211641, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "8ed8c9d0-b7bc-4034-800b-fa83ea283ba8", "title": "ESMO：循环肿瘤DNA检测在癌症患者中的应用建议（2022）", "text": "【0】页码:8\nESMO：循环肿瘤DNA检测在癌症患者中的应用建议（2022）\nSeveral targeted panel-based sequencing assays of ctDNA offer to measure blood TMB (bTMB) as a surrogate of tissue-based TMB. At this time, evidence suggests that patients should not be selected for immunotherapy on the basis of bTMB alone. bTMB is highly correlated with the amount of ctDNA and thus a minimum amount of ctDNA is required for valid scoring (this problem similarly applies to tissue-based testing when there is low tumour cell content). CHIP and subclonal mutations may elevate bTMB compared with tissue TMB. Moreover, the clinically relevant cut-off for prediction of immunotherapy response may vary according to the type of assay used and the tumour type. Nonetheless, initial evaluation of tumour burden with ctDNA assays is an active area of research and hopefully could help better select patients for immunotherapies, in particular in cases with difficult or questionable imaging findings.\n\n【1】### Tumour-specific aspects\nA summary of tumour-specific recommendations for tier I and II variants can be found in Table 2.\n\n【2】#### Lung cancer\nCurrent ESMO Clinical Practice Guidelines for metastatic NSCLC recommend genotyping in all patients with non-squamous NSCLC and squamous subtype NSCLC with special clinical characteristics (e.g. never smokers). ctDNA assays can be undertaken in treatment-naive patients and is especially recommended when a significant delay is expected in obtaining tumour tissue for genotyping, when invasive procedures may be risky or contraindicated, or bone is the only site that could be biopsied. In treatment-naive NSCLC, ctDNA can be considered complementary or alternative to tissue NGS for biomarker evaluation. Small-volume predominant intrathoracic tumours, or predominantly intracranial disease, are associated with high false-negative results. ctDNA assays tend to have reduced sensitivity for gene fusions. In addition, it should be noted that tissue RNA sequencing may identify a greater breadth of splice site variants such as MET exon 14 ‘skipping’ mutations and fusion variants (e.g. ALK, RET, ROS1 or NTRK 1/2/3). If available, tissue testing with such assays remains the gold standard compared with ctDNA, although any tissue assay can be limited by low tumour cellularity or quality.\n\n【3】For patients with pretreated disease, resistance EGFR T790M mutation enabling osimertinib treatment established a clinical paradigm of ctDNA assay first for T790Mmutation detection with tissue sampling and tissue genotyping if T790M is not detected in blood, thereby avoiding an invasive tissue sampling procedure. Histological change, such as neuroendocrine or squamous differentiation, cannot currently be identified by this approach and ctDNA should not be relied on if clinical suspicion arises. ctDNA NGS is not well established as a tool to identify acquired resistance mechanisms in those with oncogene-addicted NSCLC following on from this T790M strategy, especially in EGFR-mutant, ALK- or ROS1-positive disease. Therefore, for oncogene addicted NSCLC, LBs can be an acceptable initial approach for identification of mechanisms of resistance to targeted therapies. Whilst MET amplification is recognised as a resistance mechanism for a number of kinase inhibitors, including osimertinib and lorlatinib, robust identification in ctDNA remains an area of research.\n\n【4】#### Breast cancer\nTesting may be indicated for PIK3CA and ESR1 mutations in oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative disease, and for MSI detection. Testing may be indicated for detection of HER2 amplification only in situations where HER2 testing cannot be carried out in an advanced disease biopsy, as HER2 amplification detection is suboptimal in ctDNA (varies by assay). ESR1 mutations are acquired subclonally in the cancer, and robust identification of the presence of an ESR1 mutation is more likely when done through an LB, with tissue biopsies often reporting false-negative results. Testing for BRCA1/2 variants may be carried out with ctDNA assays, but as currently the indication of poly(ADP-ribose) polymerase (PARP) inhibitors in breast cancer is restricted to germline variants, reflex germline testing is indicated to confirm if the variant is present in germline. Irrespectively, given the availability of BRCA1/2 germline variants in breast cancer, germline testing is recommended even in the case of a negative LB finding. Details of other variants recommended as options for testing are given in recent guidance.\n\n【5】#### Upper GI cancers\nIn view of their incidence and availability of targeted therapies, liquid testing for detection of germline alterations in BRCA1/2 and other genes is recommended in patients with advanced disease. Examining tumour mutations in tissue only remains an option for therapeutic intervention.\n\n【6】#### Colorectal cancer\nAn initial liquid test including at least KRAS/NRAS/BRAF^V600E/MSI for chemotherapy-naive metastatic colorectal cancer is recommended when tissue testing is not feasible, or when quick therapeutic decisions are required, and longitudinal KRAS/NRAS and epidermal growth factor receptor (EGFR) extracellular domain (EGFR-ECD, mutations in S492, G465, S464 and V441) tests are recommended when a rechallenge is considered with an anti-EGFR monoclonal antibody. Although KRAS mutations may occur as a result of CHIP, the true rate of KRAS mutation detection is substantially higher than the contribution from CHIP, such that the detection of KRAS mutation in LB is considered sufficient to not give anti-EGFR monoclonal antibody treatment.\n\n【7】#### Prostate cancer\nAlterations of DNA damage repair genes are important to identify in patients with advanced prostate cancer, as ∼20% of patients with castration-resistant prostate cancer have been shown to harbour germline and/or somatic alterations in DNA damage repair genes, such as BRCA1, BRCA2 or ATM. CHIP may cause false-positive results, but advanced digital ctDNA assays can robustly detect homozygous deletions (a common feature in BRCA1/2 and other tumour-suppressor genes). Tissue testing is still recommended for decisions making to direct PARP inhibitor therapy.", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ESMO：循环肿瘤DNA检测在癌症患者中的应用建议（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Several targeted panel-based ", "content": "【0】页码:8\nESMO：循环肿瘤DNA检测在癌症患者中的应用建议（2022）\nSeveral targeted panel-based sequencing assays of ctDNA offer to measure blood TMB (bTMB) as a surrogate of tissue-based TMB. At this time, evidence suggests that patients should not be selected for immunotherapy on the basis of bTMB alone. bTMB is highly correlated with the amount of ctDNA and thus a minimum amount of ctDNA is required for valid scoring (this problem similarly applies to tissue-based testing when there is low tumour cell content). CHIP and subclonal mutations may elevate bTMB compared with tissue TMB. Moreover, the clinically relevant cut-off for prediction of immunotherapy response may vary according to the type of assay used and the tumour type. Nonetheless, initial evaluation of tumour burden with ctDNA assays is an active area of research and hopefully could help better select patients for immunotherapies, in particular in cases with difficult or questionable imaging findings.\n\n【1】### Tumour-specific aspects\nA summary of tumour-specific recommendations for tier I and II variants can be found in Table 2.\n\n【2】#### Lung cancer\nCurrent ESMO Clinical Practice Guidelines for metastatic NSCLC recommend genotyping in all patients with non-squamous NSCLC and squamous subtype NSCLC with special clinical characteristics (e.g. never smokers). ctDNA assays can be undertaken in treatment-naive patients and is especially recommended when a significant delay is expected in obtaining tumour tissue for genotyping, when invasive procedures may be risky or contraindicated, or bone is the only site that could be biopsied. In treatment-naive NSCLC, ctDNA can be considered complementary or alternative to tissue NGS for biomarker evaluation. Small-volume predominant intrathoracic tumours, or predominantly intracranial disease, are associated with high false-negative results. ctDNA assays tend to have reduced sensitivity for gene fusions. In addition, it should be noted that tissue RNA sequencing may identify a greater breadth of splice site variants such as MET exon 14 ‘skipping’ mutations and fusion variants (e.g. ALK, RET, ROS1 or NTRK 1/2/3). If available, tissue testing with such assays remains the gold standard compared with ctDNA, although any tissue assay can be limited by low tumour cellularity or quality.\n\n【3】For patients with pretreated disease, resistance EGFR T790M mutation enabling osimertinib treatment established a clinical paradigm of ctDNA assay first for T790Mmutation detection with tissue sampling and tissue genotyping if T790M is not detected in blood, thereby avoiding an invasive tissue sampling procedure. Histological change, such as neuroendocrine or squamous differentiation, cannot currently be identified by this approach and ctDNA should not be relied on if clinical suspicion arises. ctDNA NGS is not well established as a tool to identify acquired resistance mechanisms in those with oncogene-addicted NSCLC following on from this T790M strategy, especially in EGFR-mutant, ALK- or ROS1-positive disease. Therefore, for oncogene addicted NSCLC, LBs can be an acceptable initial approach for identification of mechanisms of resistance to targeted therapies. Whilst MET amplification is recognised as a resistance mechanism for a number of kinase inhibitors, including osimertinib and lorlatinib, robust identification in ctDNA remains an area of research.\n\n【4】#### Breast cancer\nTesting may be indicated for PIK3CA and ESR1 mutations in oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative disease, and for MSI detection. Testing may be indicated for detection of HER2 amplification only in situations where HER2 testing cannot be carried out in an advanced disease biopsy, as HER2 amplification detection is suboptimal in ctDNA (varies by assay). ESR1 mutations are acquired subclonally in the cancer, and robust identification of the presence of an ESR1 mutation is more likely when done through an LB, with tissue biopsies often reporting false-negative results. Testing for BRCA1/2 variants may be carried out with ctDNA assays, but as currently the indication of poly(ADP-ribose) polymerase (PARP) inhibitors in breast cancer is restricted to germline variants, reflex germline testing is indicated to confirm if the variant is present in germline. Irrespectively, given the availability of BRCA1/2 germline variants in breast cancer, germline testing is recommended even in the case of a negative LB finding. Details of other variants recommended as options for testing are given in recent guidance.\n\n【5】#### Upper GI cancers\nIn view of their incidence and availability of targeted therapies, liquid testing for detection of germline alterations in BRCA1/2 and other genes is recommended in patients with advanced disease. Examining tumour mutations in tissue only remains an option for therapeutic intervention.\n\n【6】#### Colorectal cancer\nAn initial liquid test including at least KRAS/NRAS/BRAF^V600E/MSI for chemotherapy-naive metastatic colorectal cancer is recommended when tissue testing is not feasible, or when quick therapeutic decisions are required, and longitudinal KRAS/NRAS and epidermal growth factor receptor (EGFR) extracellular domain (EGFR-ECD, mutations in S492, G465, S464 and V441) tests are recommended when a rechallenge is considered with an anti-EGFR monoclonal antibody. Although KRAS mutations may occur as a result of CHIP, the true rate of KRAS mutation detection is substantially higher than the contribution from CHIP, such that the detection of KRAS mutation in LB is considered sufficient to not give anti-EGFR monoclonal antibody treatment.\n\n【7】#### Prostate cancer\nAlterations of DNA damage repair genes are important to identify in patients with advanced prostate cancer, as ∼20% of patients with castration-resistant prostate cancer have been shown to harbour germline and/or somatic alterations in DNA damage repair genes, such as BRCA1, BRCA2 or ATM. CHIP may cause false-positive results, but advanced digital ctDNA assays can robustly detect homozygous deletions (a common feature in BRCA1/2 and other tumour-suppressor genes). Tissue testing is still recommended for decisions making to direct PARP inhibitor therapy.", "index": 40, "show": true, "start": 40, "end": 69, "province": ["语义有效性", "语义不完整"], "isEdit": false, "comment": "开头缺单词"}], "startTime": "2024/08/06 15:55:57", "endTime": "2024/08/06 15:58:04", "cost": 127.152}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-05 23:58:04", "grab_time": "2024-08-05 23:55:57"}
{"id": 2211640, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "58890017-c301-41ee-b926-a56a1c633bdd", "title": "2023 WHO 指南：疟疾", "text": "【0】页码:115\n2023 WHO 指南：疟疾\n### Values and preferences\n\n【1】Preferences and values of the target population were determined by:\n\n【2】- Consultation with civil society, which indicated that chemoprevention to prevent malaria disease in children under 5 years was seen as a priority in endemic areas, although there was no specific mention of the need during the post-discharge period (CS4ME 删除32:<u>*</u>unpublished evidence删除32:<u>*</u>);\n- A synthesis of contextual factors from trials of PDMC in sub-Saharan Africa 删除19:<u>(Lange et al 删除32:<u>*</u>unpublished evidence删除32:<u>*</u>)</u>. The report showed that caregivers had generally positive views of PDMC. Caregivers understood the value of giving preventive malaria medicines during the post-discharge period, given that their children had recently been in hospital 删除12:<u>删除14:<u>[139]</u></u>. CHWs also viewed PDMC as an important and beneficial intervention 删除12:<u>删除14:<u>[137]</u></u>.\n\n【3】The GDG determined that there was probably no important uncertainty or variability in how the outcomes of PDMC are valued across contexts.\n\n【4】More information can be found in the summary of contextual factors report 删除19:<u>(Lange et al 删除32:<u>*</u>unpublished evidence删除32:<u>*</u>)</u> and the civil society consultation report (CS4ME 删除32:<u>*</u>unpublished evidence删除32:<u>*</u>).\n\n【5】### Resources\n\n【6】The mean estimated cost of implementing community-based PDMC was between US$ 22.91 and US$ 28.33 per child treated in the three countries where the studies were conducted. Implementation costs for community-based PDMC were outweighed by cost savings for re-admission compared to standard care, with a mean expected saving per child between US$ 22.08 and US$ 45.24. Health care providers' net cost saving per child receiving PDMC, including health care (especially blood transfusion) and societal costs, was between US$ 19.12 and US$ 25.71. Two approaches for delivering PDMC were evaluated: (i) facility-based, in which children had to be brought to a health facility to receive subsequent doses of PDMC, and (ii) community-based, in which the caregiver received all doses for PDMC on discharge with instructions and dates for administration written on the child's health card, and with CHWs reminding caregivers when to administer doses, SMS reminders, or no reminders. Community-delivered PDMC was found to be more cost-saving compared to health facility-based delivery due to costs from repeated travel for drug collection, which also posed a disincentive to adherence.\n\n【7】The GDG judged that PDMC probably results in moderate savings and is therefore probably cost-effective, but the certainty of the evidence regarding the resources required was low.\n\n【8】More information on the evidence can be found in the report on PDMC cost-effectiveness 删除19:<u>(Kühl et al 删除32:<u>*</u>unpublished evidence删除32:<u>*</u>)</u>.\n\n【9】### Equity\n\n【10】None of the studies included in the PDMC contextual factors report were designed to capture issues related to equity. However, caregivers whose children received PDMC from the health facility reported that repeated travel to the hospital to collect medicines was costly and time-consuming. Caregiver literacy was identified as a potential challenge for equitable PDMC delivery among participants who received all medicines when their child was discharged (community-based delivery), as some caregivers may not be able to read the PDMC administration dates recorded on their child's health card. SMS reminders 删除9:<u>(see \"Feasibility\" below)</u> may also raise concerns over equity.\n\n【11】The GDG considered that PDMC has a variable effect on health equity and noted that PDMC likely reinforces existing。", "tags": {}, "lang": "en", "attr": {"page_num": 115, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 WHO 指南：疟疾.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Values and preferences", "content": "【0】页码:115\n2023 WHO 指南：疟疾\n### Values and preferences\n\n【1】Preferences and values of the target population were determined by:\n\n【2】- Consultation with civil society, which indicated that chemoprevention to prevent malaria disease in children under 5 years was seen as a priority in endemic areas, although there was no specific mention of the need during the post-discharge period (CS4ME 删除32:<u>*</u>unpublished evidence删除32:<u>*</u>);\n- A synthesis of contextual factors from trials of PDMC in sub-Saharan Africa 删除19:<u>(Lange et al 删除32:<u>*</u>unpublished evidence删除32:<u>*</u>)</u>. The report showed that caregivers had generally positive views of PDMC. Caregivers understood the value of giving preventive malaria medicines during the post-discharge period, given that their children had recently been in hospital 删除12:<u>删除14:<u>[139]</u></u>. CHWs also viewed PDMC as an important and beneficial intervention 删除12:<u>删除14:<u>[137]</u></u>.\n\n【3】The GDG determined that there was probably no important uncertainty or variability in how the outcomes of PDMC are valued across contexts.\n\n【4】More information can be found in the summary of contextual factors report 删除19:<u>(Lange et al 删除32:<u>*</u>unpublished evidence删除32:<u>*</u>)</u> and the civil society consultation report (CS4ME 删除32:<u>*</u>unpublished evidence删除32:<u>*</u>).\n\n【5】### Resources\n\n【6】The mean estimated cost of implementing community-based PDMC was between US$ 22.91 and US$ 28.33 per child treated in the three countries where the studies were conducted. Implementation costs for community-based PDMC were outweighed by cost savings for re-admission compared to standard care, with a mean expected saving per child between US$ 22.08 and US$ 45.24. Health care providers' net cost saving per child receiving PDMC, including health care (especially blood transfusion) and societal costs, was between US$ 19.12 and US$ 25.71. Two approaches for delivering PDMC were evaluated: (i) facility-based, in which children had to be brought to a health facility to receive subsequent doses of PDMC, and (ii) community-based, in which the caregiver received all doses for PDMC on discharge with instructions and dates for administration written on the child's health card, and with CHWs reminding caregivers when to administer doses, SMS reminders, or no reminders. Community-delivered PDMC was found to be more cost-saving compared to health facility-based delivery due to costs from repeated travel for drug collection, which also posed a disincentive to adherence.\n\n【7】The GDG judged that PDMC probably results in moderate savings and is therefore probably cost-effective, but the certainty of the evidence regarding the resources required was low.\n\n【8】More information on the evidence can be found in the report on PDMC cost-effectiveness 删除19:<u>(Kühl et al 删除32:<u>*</u>unpublished evidence删除32:<u>*</u>)</u>.\n\n【9】### Equity\n\n【10】None of the studies included in the PDMC contextual factors report were designed to capture issues related to equity. However, caregivers whose children received PDMC from the health facility reported that repeated travel to the hospital to collect medicines was costly and time-consuming. Caregiver literacy was identified as a potential challenge for equitable PDMC delivery among participants who received all medicines when their child was discharged (community-based delivery), as some caregivers may not be able to read the PDMC administration dates recorded on their child's health card. SMS reminders 删除9:<u>(see \"Feasibility\" below)</u> may also raise concerns over equity.\n\n【11】The GDG considered that PDMC has a variable effect on health equity and noted that PDMC likely reinforces existing。", "index": 29, "show": true, "start": 29, "end": 51, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "0"}], "startTime": "2024/08/07 09:50:20", "endTime": "2024/08/07 09:51:07", "cost": 47.26}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 17:51:07", "grab_time": "2024-08-06 17:50:19"}
{"id": 2211639, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "c1fc204c-7a70-4792-98f1-dcf2ed8d5972", "title": "_PiCCO 监测技术操作管理专家共识", "text": "【0】页码:1\n_PiCCO 监测技术操作管理专家共识\n## 专家共识：PiCCO 监测技术操作管理\n\n【1】### PiCCO 监测技术操作管理专家共识\n\n【2】通信作者: 姜 杰, Email: jiangwj@zju.edu.cn, 玉莉, Email: zrwlz@zju.edu.cn, 张根生, Email: genshengzhang@zju.edu删除1:<u>.cn; 何承锐, Email: tqmhnuhhw@163.com</u>\nDOI:10.3760/cma.j.issn.删除17:<u>1671-0282.2023.06.004</u>\n\n【3】脉搏指示连续心输出量 (pulse indicator continuous cardiac output, PiCCO) 监测技术的广泛应用在危重症性休克、急性呼吸窘迫综合征 (acute respiratory distress syndrome, ARDS)、严重烧伤、多发伤、血流动力学等急危重症的血流动力学管理、指导临床决策、并提高的准确性受到验证和认可。\n\n【4】### 1 PiCCO 监测技术的适应证与禁忌证有哪些？\n\n【5】删除图片描述:<u>相对于中心静脉压 (central venous pressure, CVP) 和肺动脉压, PiCCO 监测技术所获的包含全舒末容积 (global end-diastolic volume, GEDV) 和胸腔血容量 (intrathoracic blood volume, ITBV) 作为心血管前负荷的容积指标, 受到极大地功能智能参数 删除9:<u>(图1_0.png)</u> 。</u>\n而基于心肺关系的前行动力指标有搏动指数 (pulse pressure variability, PPV) 及 CVP, GEDV 等需动态前行的基础至要的数据管理。\n\n【6】#### 表格 1\n\n| 生理指标    | 全舒末容积 (GEDV)        | 胸腔血容量 (ITBV)        |\n| ----------- | ------------------------- | ------------------------- |\n| 心血管前负荷 | 动态前行的基础至要的数据 | 动态前行的基础至要的数据 |\n\n【8】### 2 PiCCO 动脉导管操作管理\n\n【9】#### 2.1 置管部位选择\n\n【10】置管部位在股动脉, 其优势大致位于最贴心, 受外界环境影响小, 能更清楚的反映器官血供。股动脉置管深度应, 肱动脉及桡动脉的更适合。\n\n【11】删除图片描述:<u>#### 图1_0</u>\n\n【12】删除图片描述:<u>![](0_0.png)</u>", "tags": {}, "lang": "None", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_PiCCO 监测技术操作管理专家共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】通信作者: 姜 杰, Email: jiangwj@zju.edu.cn, 玉莉, Email: zrwlz@zju.edu.cn, 张根生, Email: genshengzhang@zju.edu删除1:.cn; 何承锐, Email: tqmhnuhhw@163.com\n\nDOI:10.3760/cma.j.issn.", "content": "【0】页码:1\n_PiCCO 监测技术操作管理专家共识\n## 专家共识：PiCCO 监测技术操作管理\n\n【1】### PiCCO 监测技术操作管理专家共识\n\n【2】通信作者: 姜 杰, Email: jiangwj@zju.edu.cn, 玉莉, Email: zrwlz@zju.edu.cn, 张根生, Email: genshengzhang@zju.edu删除1:<u>.cn; 何承锐, Email: tqmhnuhhw@163.com</u>\nDOI:10.3760/cma.j.issn.删除17:<u>1671-0282.2023.06.004</u>\n\n【3】脉搏指示连续心输出量 (pulse indicator continuous cardiac output, PiCCO) 监测技术的广泛应用在危重症性休克、急性呼吸窘迫综合征 (acute respiratory distress syndrome, ARDS)、严重烧伤、多发伤、血流动力学等急危重症的血流动力学管理、指导临床决策、并提高的准确性受到验证和认可。\n\n【4】### 1 PiCCO 监测技术的适应证与禁忌证有哪些？\n\n【5】删除图片描述:<u>相对于中心静脉压 (central venous pressure, CVP) 和肺动脉压, PiCCO 监测技术所获的包含全舒末容积 (global end-diastolic volume, GEDV) 和胸腔血容量 (intrathoracic blood volume, ITBV) 作为心血管前负荷的容积指标, 受到极大地功能智能参数 删除9:<u>(图1_0.png)</u> 。</u>\n而基于心肺关系的前行动力指标有搏动指数 (pulse pressure variability, PPV) 及 CVP, GEDV 等需动态前行的基础至要的数据管理。\n\n【6】#### 表格 1\n\n| 生理指标    | 全舒末容积 (GEDV)        | 胸腔血容量 (ITBV)        |\n| ----------- | ------------------------- | ------------------------- |\n| 心血管前负荷 | 动态前行的基础至要的数据 | 动态前行的基础至要的数据 |\n\n【8】### 2 PiCCO 动脉导管操作管理\n\n【9】#### 2.1 置管部位选择\n\n【10】置管部位在股动脉, 其优势大致位于最贴心, 受外界环境影响小, 能更清楚的反映器官血供。股动脉置管深度应, 肱动脉及桡动脉的更适合。\n\n【11】删除图片描述:<u>#### 图1_0</u>\n\n【12】删除图片描述:<u>![](0_0.png)</u>", "index": 79, "show": true, "start": 79, "end": 245, "province": ["信息质量", "有用性-轻"], "isEdit": false}, {"text": "【3】脉搏指示连续心输出量 (pulse indicator continuous cardiac output, PiCCO) 监测技术的广泛应用在危重症性休克、急性呼吸窘迫综合征 (acute respiratory distress syndrome, ARDS)、严重烧伤、多发伤、血流动力学等急危重症的血流动力学管理、指导临床决策、并提高的准确性受到验证和认可。", "content": "【0】页码:1\n_PiCCO 监测技术操作管理专家共识\n## 专家共识：PiCCO 监测技术操作管理\n\n【1】### PiCCO 监测技术操作管理专家共识\n\n<mark>【2】通信作者: 姜 杰, Email: jiangwj@zju.edu.cn, 玉莉, Email: zrwlz@zju.edu.cn, 张根生, Email: genshengzhang@zju.edu删除1:.cn; 何承锐, Email: tqmhnuhhw@163.com\n\nDOI:10.3760/cma.j.issn.</mark>.issn.删除17:<u>1671-0282.2023.06.004</u>\n\n【3】脉搏指示连续心输出量 (pulse indicator continuous cardiac output, PiCCO) 监测技术的广泛应用在危重症性休克、急性呼吸窘迫综合征 (acute respiratory distress syndrome, ARDS)、严重烧伤、多发伤、血流动力学等急危重症的血流动力学管理、指导临床决策、并提高的准确性受到验证和认可。\n\n【4】### 1 PiCCO 监测技术的适应证与禁忌证有哪些？\n\n【5】删除图片描述:<u>相对于中心静脉压 (central venous pressure, CVP) 和肺动脉压, PiCCO 监测技术所获的包含全舒末容积 (global end-diastolic volume, GEDV) 和胸腔血容量 (intrathoracic blood volume, ITBV) 作为心血管前负荷的容积指标, 受到极大地功能智能参数 删除9:<u>(图1_0.png)</u> 。</u>\n而基于心肺关系的前行动力指标有搏动指数 (pulse pressure variability, PPV) 及 CVP, GEDV 等需动态前行的基础至要的数据管理。\n\n【6】#### 表格 1\n\n| 生理指标    | 全舒末容积 (GEDV)        | 胸腔血容量 (ITBV)        |\n| ----------- | ------------------------- | ------------------------- |\n| 心血管前负荷 | 动态前行的基础至要的数据 | 动态前行的基础至要的数据 |\n\n【8】### 2 PiCCO 动脉导管操作管理\n\n【9】#### 2.1 置管部位选择\n\n【10】置管部位在股动脉, 其优势大致位于最贴心, 受外界环境影响小, 能更清楚的反映器官血供。股动脉置管深度应, 肱动脉及桡动脉的更适合。\n\n【11】删除图片描述:<u>#### 图1_0</u>\n\n【12】删除图片描述:<u>![](0_0.png)</u>", "index": 299, "show": true, "start": 286, "end": 472, "province": ["信息质量", "完整性"], "isEdit": false}, {"text": "【5】删除图片描述:相对于中心静脉压 (central venous pressure, CVP) 和肺动脉压, PiCCO 监测技术所获的包含全舒末容积 (global end-diastolic volume, GEDV) 和胸腔血容量 (intrathoracic blood volume, ITBV) 作为心血管前负荷的容积指标, 受到极大地功能智能参数 ", "content": "【0】页码:1\n_PiCCO 监测技术操作管理专家共识\n## 专家共识：PiCCO 监测技术操作管理\n\n【1】### PiCCO 监测技术操作管理专家共识\n\n<mark>【2】通信作者: 姜 杰, Email: jiangwj@zju.edu.cn, 玉莉, Email: zrwlz@zju.edu.cn, 张根生, Email: genshengzhang@zju.edu删除1:.cn; 何承锐, Email: tqmhnuhhw@163.com\n\nDOI:10.3760/cma.j.issn.</mark>.issn.删除17:<u>1671-0282.2023.06.004</u>\n\n<mark>【3】脉搏指示连续心输出量 (pulse indicator continuous cardiac output, PiCCO) 监测技术的广泛应用在危重症性休克、急性呼吸窘迫综合征 (acute respiratory distress syndrome, ARDS)、严重烧伤、多发伤、血流动力学等急危重症的血流动力学管理、指导临床决策、并提高的准确性受到验证和认可。</mark>\n\n【4】### 1 PiCCO 监测技术的适应证与禁忌证有哪些？\n\n【5】删除图片描述:<u>相对于中心静脉压 (central venous pressure, CVP) 和肺动脉压, PiCCO 监测技术所获的包含全舒末容积 (global end-diastolic volume, GEDV) 和胸腔血容量 (intrathoracic blood volume, ITBV) 作为心血管前负荷的容积指标, 受到极大地功能智能参数 删除9:<u>(图1_0.png)</u> 。</u>\n而基于心肺关系的前行动力指标有搏动指数 (pulse pressure variability, PPV) 及 CVP, GEDV 等需动态前行的基础至要的数据管理。\n\n【6】#### 表格 1\n\n| 生理指标    | 全舒末容积 (GEDV)        | 胸腔血容量 (ITBV)        |\n| ----------- | ------------------------- | ------------------------- |\n| 心血管前负荷 | 动态前行的基础至要的数据 | 动态前行的基础至要的数据 |\n\n【8】### 2 PiCCO 动脉导管操作管理\n\n【9】#### 2.1 置管部位选择\n\n【10】置管部位在股动脉, 其优势大致位于最贴心, 受外界环境影响小, 能更清楚的反映器官血供。股动脉置管深度应, 肱动脉及桡动脉的更适合。\n\n【11】删除图片描述:<u>#### 图1_0</u>\n\n【12】删除图片描述:<u>![](0_0.png)</u>", "index": 533, "show": true, "start": 507, "end": 690, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "而基于心肺关系的前行动力指标有搏动指数 (pulse pressure variability, PPV) 及 CVP, GEDV 等需动态前行的基础至要的数据管理。", "content": "【0】页码:1\n_PiCCO 监测技术操作管理专家共识\n## 专家共识：PiCCO 监测技术操作管理\n\n【1】### PiCCO 监测技术操作管理专家共识\n\n<mark>【2】通信作者: 姜 杰, Email: jiangwj@zju.edu.cn, 玉莉, Email: zrwlz@zju.edu.cn, 张根生, Email: genshengzhang@zju.edu删除1:.cn; 何承锐, Email: tqmhnuhhw@163.com\n\nDOI:10.3760/cma.j.issn.</mark>.issn.删除17:<u>1671-0282.2023.06.004</u>\n\n<mark>【3】脉搏指示连续心输出量 (pulse indicator continuous cardiac output, PiCCO) 监测技术的广泛应用在危重症性休克、急性呼吸窘迫综合征 (acute respiratory distress syndrome, ARDS)、严重烧伤、多发伤、血流动力学等急危重症的血流动力学管理、指导临床决策、并提高的准确性受到验证和认可。</mark>\n\n【4】### 1 PiCCO 监测技术的适应证与禁忌证有哪些？\n\n<mark>【5】删除图片描述:相对于中心静脉压 (central venous pressure, CVP) 和肺动脉压, PiCCO 监测技术所获的包含全舒末容积 (global end-diastolic volume, GEDV) 和胸腔血容量 (intrathoracic blood volume, ITBV) 作为心血管前负荷的容积指标, 受到极大地功能智能参数 </mark>参数 删除9:<u>(图1_0.png)</u> 。</u>\n而基于心肺关系的前行动力指标有搏动指数 (pulse pressure variability, PPV) 及 CVP, GEDV 等需动态前行的基础至要的数据管理。\n\n【6】#### 表格 1\n\n| 生理指标    | 全舒末容积 (GEDV)        | 胸腔血容量 (ITBV)        |\n| ----------- | ------------------------- | ------------------------- |\n| 心血管前负荷 | 动态前行的基础至要的数据 | 动态前行的基础至要的数据 |\n\n【8】### 2 PiCCO 动脉导管操作管理\n\n【9】#### 2.1 置管部位选择\n\n【10】置管部位在股动脉, 其优势大致位于最贴心, 受外界环境影响小, 能更清楚的反映器官血供。股动脉置管深度应, 肱动脉及桡动脉的更适合。\n\n【11】删除图片描述:<u>#### 图1_0</u>\n\n【12】删除图片描述:<u>![](0_0.png)</u>", "index": 760, "show": true, "start": 721, "end": 804, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "【5】"}, {"text": "【6】#### 表格 1\n\n生理指标\t全舒末容积 (GEDV)\t胸腔血容量 (ITBV)\n心血管前负荷\t动态前行的基础至要的数据\t动态前行的基础至要的数据", "content": "【0】页码:1\n_PiCCO 监测技术操作管理专家共识\n## 专家共识：PiCCO 监测技术操作管理\n\n【1】### PiCCO 监测技术操作管理专家共识\n\n<mark>【2】通信作者: 姜 杰, Email: jiangwj@zju.edu.cn, 玉莉, Email: zrwlz@zju.edu.cn, 张根生, Email: genshengzhang@zju.edu删除1:.cn; 何承锐, Email: tqmhnuhhw@163.com\n\nDOI:10.3760/cma.j.issn.</mark>.issn.删除17:<u>1671-0282.2023.06.004</u>\n\n<mark>【3】脉搏指示连续心输出量 (pulse indicator continuous cardiac output, PiCCO) 监测技术的广泛应用在危重症性休克、急性呼吸窘迫综合征 (acute respiratory distress syndrome, ARDS)、严重烧伤、多发伤、血流动力学等急危重症的血流动力学管理、指导临床决策、并提高的准确性受到验证和认可。</mark>\n\n【4】### 1 PiCCO 监测技术的适应证与禁忌证有哪些？\n\n<mark>【5】删除图片描述:相对于中心静脉压 (central venous pressure, CVP) 和肺动脉压, PiCCO 监测技术所获的包含全舒末容积 (global end-diastolic volume, GEDV) 和胸腔血容量 (intrathoracic blood volume, ITBV) 作为心血管前负荷的容积指标, 受到极大地功能智能参数 </mark>参数 删除9:<u>(图1_0.png)</u> 。</u>\n<mark>而基于心肺关系的前行动力指标有搏动指数 (pulse pressure variability, PPV) 及 CVP, GEDV 等需动态前行的基础至要的数据管理。</mark>\n\n【6】#### 表格 1\n\n| 生理指标    | 全舒末容积 (GEDV)        | 胸腔血容量 (ITBV)        |\n| ----------- | ------------------------- | ------------------------- |\n| 心血管前负荷 | 动态前行的基础至要的数据 | 动态前行的基础至要的数据 |\n\n【8】### 2 PiCCO 动脉导管操作管理\n\n【9】#### 2.1 置管部位选择\n\n【10】置管部位在股动脉, 其优势大致位于最贴心, 受外界环境影响小, 能更清楚的反映器官血供。股动脉置管深度应, 肱动脉及桡动脉的更适合。\n\n【11】删除图片描述:<u>#### 图1_0</u>\n\n【12】删除图片描述:<u>![](0_0.png)</u>", "index": 858, "show": true, "start": 806, "end": 883, "province": ["文本干净度", "无关文本"], "isEdit": false}, {"text": "【10】置管部位在股动脉, 其优势大致位于最贴心, 受外界环境影响小, 能更清楚的反映器官血供。股动脉置管深度应, 肱动脉及桡动脉的更适合。", "content": "【0】页码:1\n_PiCCO 监测技术操作管理专家共识\n## 专家共识：PiCCO 监测技术操作管理\n\n【1】### PiCCO 监测技术操作管理专家共识\n\n<mark>【2】通信作者: 姜 杰, Email: jiangwj@zju.edu.cn, 玉莉, Email: zrwlz@zju.edu.cn, 张根生, Email: genshengzhang@zju.edu删除1:.cn; 何承锐, Email: tqmhnuhhw@163.com\n\nDOI:10.3760/cma.j.issn.</mark>.issn.删除17:<u>1671-0282.2023.06.004</u>\n\n<mark>【3】脉搏指示连续心输出量 (pulse indicator continuous cardiac output, PiCCO) 监测技术的广泛应用在危重症性休克、急性呼吸窘迫综合征 (acute respiratory distress syndrome, ARDS)、严重烧伤、多发伤、血流动力学等急危重症的血流动力学管理、指导临床决策、并提高的准确性受到验证和认可。</mark>\n\n【4】### 1 PiCCO 监测技术的适应证与禁忌证有哪些？\n\n<mark>【5】删除图片描述:相对于中心静脉压 (central venous pressure, CVP) 和肺动脉压, PiCCO 监测技术所获的包含全舒末容积 (global end-diastolic volume, GEDV) 和胸腔血容量 (intrathoracic blood volume, ITBV) 作为心血管前负荷的容积指标, 受到极大地功能智能参数 </mark>参数 删除9:<u>(图1_0.png)</u> 。</u>\n<mark>而基于心肺关系的前行动力指标有搏动指数 (pulse pressure variability, PPV) 及 CVP, GEDV 等需动态前行的基础至要的数据管理。</mark>\n\n<mark>【6】#### 表格 1\n\n生理指标\t全舒末容积 (GEDV)\t胸腔血容量 (ITBV)\n心血管前负荷\t动态前行的基础至要的数据\t动态前行的基础至要的数据</mark>------ | ------------------------- | ------------------------- |\n| 心血管前负荷 | 动态前行的基础至要的数据 | 动态前行的基础至要的数据 |\n\n【8】### 2 PiCCO 动脉导管操作管理\n\n【9】#### 2.1 置管部位选择\n\n【10】置管部位在股动脉, 其优势大致位于最贴心, 受外界环境影响小, 能更清楚的反映器官血供。股动脉置管深度应, 肱动脉及桡动脉的更适合。\n\n【11】删除图片描述:<u>#### 图1_0</u>\n\n【12】删除图片描述:<u>![](0_0.png)</u>", "index": 1100, "show": true, "start": 1035, "end": 1105, "province": ["语义有效性", "语义不完整"], "isEdit": false}], "startTime": "2024/08/07 10:07:28", "endTime": "2024/08/07 10:10:17", "cost": 169.232}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:14", "update_time": "2024-08-06 18:10:16", "grab_time": "2024-08-06 18:07:26"}
{"id": 2211638, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "c6be2e28-34c4-4ed4-b765-e4296f807892", "title": "中枢神经系统肿瘤_2023.V1_EN (2)", "text": "【0】页码:196\n中枢神经系统肿瘤_2023.V1_EN (2)\n(本页删除)本页被模型判断为参考页疑似页眉<u># NCCN Guidelines Version 1.2023 Central Nervous System Cancers</u>\n\n## 表格\n| 项目 | 标题 | 描述 | 年份 | 链接 |\n| --- | --- | --- | --- | --- |\n| 593. | Glantz MJ, LaFollette S, Jaeckle KA, et al. | Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. | 1999 | [Pubmed链接] |\n| 594. | Jaeckle KA, Phuphanich S, Bent MJ, et al. | Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. | 2001 | [Pubmed链接] |\n| 595. | Gutin PH, Weiss HD, Wiernik PH, Walker MD. | Intrathecal N, N', N\"-triethylenethiophosphoramide (thio-TEPA 删除19:<u>(NSC 6396)</u>) in the treatment of malignant meningeal disease: phase I-II study. | 1976 | [Pubmed链接] |\n| 596. | Chamberlain MC, Johnston SK, Van Horn A, Glantz MJ. | Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. | 2009 | [Pubmed链接] |\n| 597. | Groves MD, Glantz MJ, Chamberlain MC, et al. | A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. | 2008 | [Pubmed链接] |\n| 598. | Jaeckle KA, Dixon JG, Anderson SK, et al. | Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. | 2020 | [Pubmed链接] |\n| 599. | Chamberlain MC, Tsao-Wei DD, Groshen S. | Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. | 2006 | [Pubmed链接] |\n| 600. | Zagouri F, Sergentanis TN, Bartsch R, et al. | Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. | 2013 | [Pubmed链接] |\n| 601. | Mrugala MM, Kim B, Sharma A, et al. | Phase II study of systemic high-dose methotrexate and intrathecal liposomal cytarabine for treatment of leptomeningeal carcinomatosis from breast cancer. | 2019 | [Pubmed链接] |\n| 602. | Bokstein F, Lossos A, Lossos IS, Siegal T. | Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. | 2002 | [Pubmed链接] |\n| 603. | Grommes C, Oxnard GR, Kris MG, et al. | \"Pulsatile\" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. | 2011 | [Pubmed链接] |\n| 604. | Yang JCH, Kim SW, Kim DW, et al. | Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. | 2020 | [Pubmed链接] |\n| 605. | Nanjo S, Hata A, Okuda C, et al. | Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. | 2018 | [Pubmed链接] |\n| 606. | Ahn MJ, Chiu CH, Cheng Y, et al. | Osimertinib in patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis. | 2020 | [Pubmed链接] |\n| 607. | Lee J, Choi Y, Han J, et al. | Osimertinib improves overall survival in patients with EGFR-mutated NSCLC with leptomeningeal metastases. | 2020 | [Pubmed链接] |", "tags": {}, "lang": "en", "attr": {"page_num": 196, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/中枢神经系统肿瘤_2023.V1_EN (2).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:40:48", "endTime": "2024/08/06 15:40:55", "cost": 6.882}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:40:56", "grab_time": "2024-08-05 23:40:48"}
{"id": 2211637, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "0ac9c913-6e7d-4241-9f2a-97c2e5e12072", "title": "2023更新—2015 NICE指南：心血管疾病的风险评估和降低包括脂质修饰（CG.181）(1)", "text": "【0】页码:17\n2023更新—2015 NICE指南：心血管疾病的风险评估和降低包括脂质修饰（CG.181）(1)\nCardiovascular disease: risk assessment and reduction, including lipid modification (CG181)\n\n【1】There is a NICE patient decision aid to support discussions about statin therapy to reduce the risk of coronary heart disease and stroke.\n\n【2】1.4.12 The decision whether to start statin therapy should be made after an informed discussion between the clinician and the person about the risks and benefits of statin treatment, taking into account additional factors such as potential benefits from lifestyle modifications, informed patient preference, comorbidities, polypharmacy, general frailty and life expectancy. 删除12:<u>删除14:<u>删除24:<u>[2014]</u></u></u>\n\n【3】1.4.13 Before starting statin treatment perform baseline blood tests and clinical assessment, and treat comorbidities and secondary causes of dyslipidaemia. Include all of the following in the assessment:\n\n【4】- smoking status\n- alcohol consumption\n- blood pressure 删除9:<u>(see NICE's guideline on hypertension)</u>\n- BMI or other measure of obesity 删除9:<u>(see NICE's guideline on obesity: identification, assessment and management)</u>\n- total cholesterol, non-HDL cholesterol, HDL cholesterol and triglycerides\n- HbA1c\n- renal function and eGFR\n- transaminase level (alanine aminotransferase or aspartate aminotransferase)\n- thyroid-stimulating hormone. 删除12:<u>删除14:<u>删除24:<u>[2014]</u></u></u>\n\n【5】### Primary prevention\n\n【6】1.4.14 Before offering statin treatment for primary prevention, discuss the benefits of lifestyle modification and optimise the management of all other modifiable CVD risk factors if possible. 删除12:<u>删除14:<u>删除24:<u>[2014]</u></u></u>\n\n【7】1.4.15 Recognise that people may need support to change their lifestyle. To help them do this, refer them to programmes such as exercise referral", "tags": {}, "lang": "en", "attr": {"page_num": 17, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023更新—2015 NICE指南：心血管疾病的风险评估和降低包括脂质修饰（CG.181）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)", "content": "【0】页码:17\n2023更新—2015 NICE指南：心血管疾病的风险评估和降低包括脂质修饰（CG.181）(1)\nCardiovascular disease: risk assessment and reduction, including lipid modification (CG181)\n\n【1】There is a NICE patient decision aid to support discussions about statin therapy to reduce the risk of coronary heart disease and stroke.\n\n【2】1.4.12 The decision whether to start statin therapy should be made after an informed discussion between the clinician and the person about the risks and benefits of statin treatment, taking into account additional factors such as potential benefits from lifestyle modifications, informed patient preference, comorbidities, polypharmacy, general frailty and life expectancy. 删除12:<u>删除14:<u>删除24:<u>[2014]</u></u></u>\n\n【3】1.4.13 Before starting statin treatment perform baseline blood tests and clinical assessment, and treat comorbidities and secondary causes of dyslipidaemia. Include all of the following in the assessment:\n\n【4】- smoking status\n- alcohol consumption\n- blood pressure 删除9:<u>(see NICE's guideline on hypertension)</u>\n- BMI or other measure of obesity 删除9:<u>(see NICE's guideline on obesity: identification, assessment and management)</u>\n- total cholesterol, non-HDL cholesterol, HDL cholesterol and triglycerides\n- HbA1c\n- renal function and eGFR\n- transaminase level (alanine aminotransferase or aspartate aminotransferase)\n- thyroid-stimulating hormone. 删除12:<u>删除14:<u>删除24:<u>[2014]</u></u></u>\n\n【5】### Primary prevention\n\n【6】1.4.14 Before offering statin treatment for primary prevention, discuss the benefits of lifestyle modification and optimise the management of all other modifiable CVD risk factors if possible. 删除12:<u>删除14:<u>删除24:<u>[2014]</u></u></u>\n\n【7】1.4.15 Recognise that people may need support to change their lifestyle. To help them do this, refer them to programmes such as exercise referral", "index": 59, "show": true, "start": 59, "end": 150, "province": ["文本干净度", "页眉"], "isEdit": false, "comment": "【0】"}], "startTime": "2024/08/06 15:29:27", "endTime": "2024/08/06 15:30:30", "cost": 63.206}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:30:30", "grab_time": "2024-08-05 23:29:27"}
{"id": 2211636, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "eea83d35-19fd-47f0-ac26-e705ebc8a8f4", "title": "2023 BSPED共识指南：儿童和青年肾上腺功能不全的急诊和围手术期管理", "text": "【0】页码:8\n2023 BSPED共识指南：儿童和青年肾上腺功能不全的急诊和围手术期管理\n(本页删除)本页被模型判断为参考页# Review\n\n【1】删除32:<u>**</u>Department of Paediatric Endocrinology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK删除32:<u>**</u>\n删除32:<u>**</u>Department of Paediatric Endocrinology, University Hospital Southampton, Southampton, UK删除32:<u>**</u>\n删除32:<u>**</u>Department of Paediatric Endocrinology, Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK删除32:<u>**</u>\n删除32:<u>**</u>Department of Paediatric Endocrinology, Great Ormond Street Hospital for Children, London, UK删除32:<u>**</u>\n删除32:<u>**</u>Developmental Endocrinology Research Group, University College London Hospitals, London, UK删除32:<u>**</u>\n删除32:<u>**</u>Academic Unit of Child Health, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK删除32:<u>**</u>\n删除32:<u>**</u>Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, UK删除32:<u>**</u>\n删除32:<u>**</u>Department of Paediatric Endocrinology, Leicester Royal Infirmary, UHL NHS Trust, Leicester, UK删除32:<u>**</u>\n删除32:<u>**</u>Department of Paediatric Endocrinology, Guy's and St Thomas' Hospitals NHS Trust, London, UK删除32:<u>**</u>\n\n【2】Twetter Nabil Bouslo @Nabil_Boulos, Charlotte Jane Elder @charlottejelder and Hoong-Wei Gan @hwganendodo\n\n【3】删除32:<u>**</u>Acknowledgements删除32:<u>**</u> The BSPED Paediatric AI group would like to acknowledge the contributions of the BSPED clinical committee, BSPED executive committee, BSPED clinical committee, CAH support group, Addison's Disease Self-Help Group, Pituitary Foundation. We are also very grateful to the Patient Safety Team at NHS England for providing the incident level patient safety data.\n\n【4】删除32:<u>**</u>Contributors删除32:<u>**</u> All authors provided valuable input to different sections of the manuscript. TM and RE led the project on behalf of the British Society for Paediatric Endocrinology and Diabetes.\n\n【5】删除32:<u>**</u>Funding删除32:<u>**</u> The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.\n\n【6】删除32:<u>**</u>Competing interests删除32:<u>**</u> None declared.\n\n【7】删除32:<u>**</u>Patient consent for publication删除32:<u>**</u> Not applicable.\n\n【8】删除32:<u>**</u>Ethics approval删除32:<u>**</u> Not applicable.\n\n【9】删除32:<u>**</u>Provenance and peer review删除32:<u>**</u> Commissioned; externally peer reviewed.\n\n【10】删除32:<u>**</u>Data availability statement删除32:<u>**</u> Data sharing not applicable as no datasets generated and/or analysed for this study.\n\n【11】删除32:<u>**</u>Open access删除32:<u>**</u> This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial删除1:<u>. See: [http://creativecommons.org/licenses/by-nc/4.0/].</u>\n\n【12】删除32:<u>**</u>ORCID IDs删除32:<u>**</u>删除1:<u>\nTalat Mushtaq 删除24:<u>[http://orcid.org/0000-0002-9890-7369]</u></u>删除1:<u>\nNabil Bouslo 删除24:<u>[http://orcid.org/0000-0002-4048-2541]</u></u>删除1:<u>\nJustin Huw Davies 删除24:<u>[http://orcid.org/0000-0001-7560-6230]</u></u>删除1:<u>\nCharlotte Jane Elder 删除24:<u>[http://orcid.org/0000-0003-2390-5593]</u></u>删除1:<u>\nPeter C Hindmarsh 删除24:<u>[http://orcid.org/0000-0002-8889-3127]</u></u>\n\n【13】删除32:<u>**</u>REFERENCES删除32:<u>**</u>\n1. NHS England Safety Alert. 13/8/2020: Reference no: NatPSA/2020/005/NHSPS. n.d删除1:<u>. Available: 删除24:<u>[www.england.nhs.uk/wp-content/uploads/2020/08/NPSA-Emergency-Steroid-Card-FINAL-2.3.pdf]</u></u>\n2. Simpson H, Tomlinson J, Wass J, et al. Guidance for the prevention and emergency management of adult patients with adrenal insufficiency. _Clin Med (Lond)_ 2020;20:371–8.\n3. Worth C, Vyas A, Banerjee I, et al. Acute illness and death in children with adrenal insufficiency. _Front Endocrinol (Lausanne)_ 2021;12:755766.\n4. Husebye ES, Pearce SH, Krone NP, et al. Adrenal insufficiency. _Lancet_ 2021;397:613–29.\n5. Rushworth RL, Torpy DJ, Stratakis CA, et al. Adrenal crises in children: perspectives and research directions. _Horm Res Paediatr_ 2018;89:341–51.\n6. Allolio B. Extensive expertise in endocrinology: adrenal crisis. _Eur J Endocrinol_ 2015;172:R115–24.\n7. Eyal O, Levin Y, Dentz H, et al. Adrenal crises in children with adrenal insufficiency: epidemiology and risk factors. _Eur J Pediatr_ 2019;178:731–8.\n8. Rezai M, Fullwood C, Hird B, et al. Cortisol levels during acute illnesses in children and adolescents: a systematic review. _JAMA Netw Open_ 2022;5:e2221872.\n9. National reporting and learning system (NRLS). n.d删除1:<u>. Available: [www.england.nhs.uk/patient-safety/nrls/npsa-alerts]</u>\n10. BNF删除1:<u>. Avaliable: [https://bnf.nice.org.uk/drug/hydrocortisone]</u>\n11. Neonatal and paediatric pharmacy group (NPPG)删除1:<u>. Available: 删除24:<u>[http://nppg.org.uk/wp-content/uploads/2021/12/Position-Statement-Steroid-Cards_V1.pdf]</u></u>\n12. SIGN删除1:<u>. Available: 删除24:<u>[www.sign.ac.uk/media/1773/sign154-updated.pdf]</u></u>\n13. National Institute of Clinical Excellence (NICE)删除1:<u>. Available: [www.nice.org.uk/guidance/ng80/evidence/chronic-asthma-management-pdf-7078963944]</u>\n14. British Society for Paediatric Endocrinology and Diabetes. Adrenal insufficiency card. n.d删除1:<u>. Available: [https://www.bsped.org.uk/media/4bps5psb/bsped-adrenal-insufficiency-card.pdf]</u>\n15. Ng SM, Stepien KM, Krishan A. Glucocorticoid replacement regimes for treating congenital adrenal hyperplasia. _Cochrane Database Syst Rev_ 2020;3:CD012517.\n16. Peters CJ, Hill N, Dattani MT, et al. Deconvolution analysis of 24-h serum cortisol profiles informs the amount and distribution of hydrocortisone replacement therapy. _Clin Endocrinol (Oxf)_ 2013;78:347–删除13:<u>51.\n17</u>. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia—current insights in pathophysiology, diagnosis, and management. _Endocr Rev_ 2022;43:91–删除13:<u>159.\n18</u>. Ali SR, Bryce J, Kok S, et al. Management of acute adrenal insufficiency-related adverse events in children with congenital adrenal hyperplasia: results of an international survey of specialist centres. _Horm Res Paediatr_ 2022;95:363–删除13:<u>73.\n19</u>. Pletea E, Taylor AE, Bancos I, et al. Prevention of adrenal crisis: cortisone responses to major stressors compared to stress dose hydrocortisone delivery. _J Clin Endocrinol Metab_ 2020;105:2262–删除13:<u>74.\n20</u>. Hindmarsh PC, Charmandari E. Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. _Clin Endocrinol (Oxf)_ 2017;88:557–删除13:<u>61.\n21</u>. Society for Endocrinology删除1:<u>. Available: [www.endocrinology.org/adrenal-crisis]</u>\n22. Rubens R, Kanafi S. Fifteen-minute consultation: emergency management of children presenting with hyperkalaemia. _Arch Dis Child Educ Pract Ed_ 2022;107:345–删除13:<u>50.\n23</u>. British society for paediatric endocrinology and diabetes adrenal insufficiency guidance. n.d删除1:<u>. Available: [www.bsped.org.uk/adrenal-insufficiency]</u>\n24. Shulman DI, Palmert MR, Kemp SF, et al. Adrenal insufficiency: still a cause of morbidity and death in childhood. _Pediatrics_ 2007;119:e484–删除13:<u>94.\n25</u>. Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis. _N Engl J Med_ 2019;381:852–删除13:<u>61.\n26</u>. Nowotny H, Ahmed SF, Bensing S, et al. Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis. _Endocrine_ 2021;71:586–删除13:<u>94.\n27</u>. Nisticòi D, Bossini B, Benvenuto S, et al. Pediatric adrenal insufficiency: challenges and solutions. _Ther Clin Risk Manag_ 2022;18:47–删除13:<u>60.\n28</u>. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine Society clinical practice guideline. _J Clin Endocrinol Metab_ 2016;101:364–删除13:<u>89.\n29</u>. Woodcock T, Barker P, Daniel S, et al. Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: guidelines from the association of anaesthetists, the Royal College of physicians and the Society for endocrinology UK. _Anaesthesia_ 2020;75:654–63.", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 BSPED共识指南：儿童和青年肾上腺功能不全的急诊和围手术期管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:18:39", "endTime": "2024/08/06 16:18:51", "cost": 11.991}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:18:51", "grab_time": "2024-08-06 00:18:39"}
{"id": 2211635, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "34b09fec-dd3f-4ecb-a5a4-eb372481d30a", "title": "SMFM：妊娠期心脏病患者的抗凝治疗指南（2022）", "text": "【0】页码:57\nSMFM：妊娠期心脏病患者的抗凝治疗指南（2022）\nin 2.0% 删除11:<u>(0.3–3.7)</u>, 1.4% 删除11:<u>(0.3–2.5)</u> and 0%, respectively. When UFH is used throughout pregnancy, 11.2% 删除11:<u>(2.8–19.6)</u> suffered thromboembolic complications. Foetal loss and adverse events occurred with first-trimester warfarin doses $\\leq$ 5 mg/day.\n\n【1】删除32:<u>**</u>Chan 2000删除32:<u>**</u>: systematic review  \n删除32:<u>**</u>Population删除32:<u>**</u>: 28 articles; 946 women with MHVs representing 1234 pregnancies  \n删除32:<u>**</u>Intervention/Comparator删除32:<u>**</u>: treatment with different anticoagulation regimens during pregnancy 1) Oral anticoagulants (OA) throughout pregnancy, 2) replacing OA with heparin in the first trimester (from 6-12 weeks’ gestation), and 3) heparin use throughout pregnancy  \n删除32:<u>**</u>Outcome measures删除32:<u>**</u>: maternal outcomes: major bleeding, thromboembolic complications, and death  \n删除32:<u>**</u>Results删除32:<u>**</u>: The use of OA throughout pregnancy is associated with warfarin embryopathy in 6.4% of livebirths. The substitution of heparin at or prior 6 weeks, and continued until 12 weeks, eliminated the risk. The regimen associated with the lowest risk of valve thrombosis was the use of OA throughout; using heparin only between 6 and 12 weeks’ gestation was associated with an increased risk of valve thrombosis. Substituting OA with heparin between 6 and 12 weeks reduces the risk of fetopathic effects but with", "tags": {}, "lang": "en", "attr": {"page_num": 57, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/SMFM：妊娠期心脏病患者的抗凝治疗指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:30:58", "endTime": "2024/08/06 16:31:20", "cost": 22.42}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:31:21", "grab_time": "2024-08-06 00:30:58"}
{"id": 2211634, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "3146c924-3e02-48e9-bf08-a7d4b36e41f8", "title": "WSES：钝性和穿透性肠损伤的诊断、检查和治疗指南（2022）(1)", "text": "【0】页码:15\nWSES：钝性和穿透性肠损伤的诊断、检查和治疗指南（2022）(1)\n(本页删除)本页被模型判断为参考页Publisher's Note\n\n【1】Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", "tags": {}, "lang": "en", "attr": {"page_num": 15, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WSES：钝性和穿透性肠损伤的诊断、检查和治疗指南（2022）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:39:55", "endTime": "2024/08/06 15:40:09", "cost": 13.835}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:40:09", "grab_time": "2024-08-05 23:39:55"}
{"id": 2211633, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "2ae71e20-0011-429d-9558-731154f3ad49", "title": "BSE_BHVS：成人经胸超声心动图的临床适应证和分类的共识声明（2022）", "text": "【0】页码:15\nBSE_BHVS：成人经胸超声心动图的临床适应证和分类的共识声明（2022）\n### Abbreviations\n删除32:<u>**</u>AF删除32:<u>**</u>: Atrial fibrillation; 删除32:<u>**</u>AR删除32:<u>**</u>: Aortic regurgitation; 删除32:<u>**</u>AS删除32:<u>**</u>: Aortic stenosis; 删除32:<u>**</u>BSE删除32:<u>**</u>: British Society of Echocardiography; 删除32:<u>**</u>BHS删除32:<u>**</u>: British Heart Valve Society; 删除32:<u>**</u>C-19删除32:<u>**</u>: COVID-19; 删除32:<u>**</u>CT删除32:<u>**</u>: Cardiac computed tomography; 删除32:<u>**</u>CMR删除32:<u>**</u>: Cardiac magnetic resonance; 删除32:<u>**</u>CTPA删除32:<u>**</u>: Computed tomography pulmonary artery; 删除32:<u>**</u>CV删除32:<u>**</u>: Cardiovascular; 删除32:<u>**</u>CXR删除32:<u>**</u>: Chest x-ray; 删除32:<u>**</u>DC删除32:<u>**</u>: Direct current; 删除32:<u>**</u>ECG删除32:<u>**</u>: Electrocardiogram; 删除32:<u>**</u>LA删除32:<u>**</u>: Left atrium; 删除32:<u>**</u>LBBB删除32:<u>**</u>: Left bundle branch block; 删除32:<u>**</u>LV删除32:<u>**</u>: Left ventricle/left ventricular; 删除32:<u>**</u>LVEF删除32:<u>**</u>: Left ventricular ejection fraction; 删除32:<u>**</u>LVH删除32:<u>**</u>: Left ventricular hypertrophy; 删除32:<u>**</u>MDT删除32:<u>**</u>: Multidisciplinary team; 删除32:<u>**</u>NHS删除32:<u>**</u>: National Health Service England; 删除32:<u>**</u>NICE删除32:<u>**</u>: National Institute of Health Care Excellence; 删除32:<u>**</u>NT-pro BNP删除32:<u>**</u>: N-terminal pro-hormone brain natriuretic peptide; 删除32:<u>**</u>OP删除32:<u>**</u>: Outpatient; 删除32:<u>**</u>PAH删除32:<u>**</u>: Pulmonary artery; 删除32:<u>**</u>PE删除32:<u>**</u>: Pulmonary embolism; 删除32:<u>**</u>PFO删除32:<u>**</u>: Patent foramen ovale; 删除32:<u>**</u>PH删除32:<u>**</u>: Pulmonary hypertension; 删除32:<u>**</u>RBBB删除32:<u>**</u>: Right bundle branch block; 删除32:<u>**</u>TOE删除32:<u>**</u>: Transoesophageal echocardiography; 删除32:<u>**</u>RV删除32:<u>**</u>: Right ventricle; 删除32:<u>**</u>RVH删除32:<u>**</u>: Right ventricular; 删除32:<u>**</u>TIA删除32:<u>**</u>: Transient ischaemic attack; 删除32:<u>**</u>TR删除32:<u>**</u>: Tricuspid regurgitation; 删除32:<u>**</u>TTE删除32:<u>**</u>: Transthoracic echocardiography.\n\n【1】### Acknowledgements\nThis project arose through a round table workshop with the pan-London NHSE group looking at addressing the C-19 induced backlog of patients waiting for specialist tests including echocardiography. We wish to thank the individuals who gave their time and expertise involved in this project.\n\n【2】### Author contributions\nTEL, DC contributed to the conception of the guideline. TG, JS, SB, GJ, LH undertook the clinical service audit at the University Hospitals of North Midlands, PT, JT undertook the clinical service audit at Great Ormond Area Hospital. SB wrote the manuscript. All authors read, edited, and approved the final manuscript. All authors read and approved the final manuscript.\n\n【3】### Funding\nNo funding was received for this guideline.\n\n【4】### Availability of data and materials\nData is available upon reasonable request to the authors.\n\n【5】### Declarations\n#### Ethics approval and consent to participate\nNot applicable.\n\n【6】#### Consent for publication\nBoth clinical audits were registered and approved by the centers research and audit departments. Not applicable to the conception of the guideline.\n\n【7】#### Competing interests\nThe authors declare that they have no competing interests.\n\n【8】### Author details\n1. University Hospitals of North Midlands, Stoke-on-Trent ST4 6QG, UK.\n2. Manchester University NHS Foundation Trust, Manchester, UK.\n3. Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK.\n4. Southern Health and Social Care Trust, Craigavon Area Hospital, Portadown, UK.\n5. British Society of Echocardiography, London, UK.\n6. Doncaster and Bassetlaw Teaching Hospitals, NHS Foundation Trust, Doncaster Royal Infirmary, Doncaster, UK.\n7. Cleveland Clinic, London, UK.\n8. Barking, Havering and Redbridge University Hospitals NHS Trust, London, UK.\n9. University Hospitals Southampton NHS Foundation Trust, Southampton, UK.\n10. British Heart Valve Society, Swaffham, UK.\n11. North West Anglia Foundation Trust, Peterborough, UK.\n12. Nottingham Healthcare, Milton Keynes, UK.\n13. Royal Papworth Hospital NHS Foundation Trust, Bath, UK.\n14. Department for Health, University of Bath, Bath, UK.\n15. Oxford University Hospitals NHS Foundation Trust, Oxford, UK.\n\n【9】删除32:<u>**</u>Received删除32:<u>**</u>: 18 November 2021\n删除32:<u>**</u>Accepted删除32:<u>**</u>: 14 April 2022\n删除32:<u>**</u>Published online删除32:<u>**</u>: 13 July 2022", "tags": {}, "lang": "en", "attr": {"page_num": 15, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/BSE_BHVS：成人经胸超声心动图的临床适应证和分类的共识声明（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:12:16", "endTime": "2024/08/06 16:13:21", "cost": 65.327}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:13:21", "grab_time": "2024-08-06 00:12:15"}
{"id": 2211632, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "3ce7c2be-1522-4b8a-881c-d30e760a72b4", "title": "2023 WHO 指南：疟疾", "text": "【0】页码:221\n2023 WHO 指南：疟疾\nThe NRS in Peru that used chloroquine plus seven days of primaquine for radical cure of _P. vivax_ hypnozoites reported no adverse events but there was no active pharmacovigilance system.\n\n【1】### Judgement of the panel\nThe GDG judged both the benefits and undesirable effects of RDA to be small and the overall certainty of evidence to be low. The GDG noted that the comparator in several studies was RACDT rather than no RDA. As a result, the GDG judged that the systematic review likely underestimated the impact of RDA. Overall, the balance of effects was determined to favour neither the intervention nor the comparison.\n\n【2】#### Certainty of the Evidence\nThe overall certainty of the evidence was judged to be low.\nLow\n\n【3】#### Values and preferences\nNo studies were identified regarding preferences and values.\nThe GDG judged that there may be important uncertainty or variability in preferences or values that could not be determined due to the lack of studies.\n\n【4】#### Resources\nThe systematic review identified one study from Zambia with data on the financial and economic costs of RDA (Steinhardt et al _unpublished evidence (c)_). The study identified index cases through active rather than passive surveillance. The total cost of two rounds of RDA (with DP) conducted between 2014 and 2015, covering a total population of 132,393 was US$ 912,767 删除8:<u>删除19:<u>(all figures in 2015 US$)</u></u>. The mean cost per person reached was US$ 85.69 (interquartile range 删除12:<u>[IQR]</u> US$39.92).\n\n【5】The overall incremental costs per infection and case averted (vs. standard of care) for RDA were US$ 810 and US$ 6,353, respectively. In high transmission settings, the incremental costs per infection and case averted were US$ 429 and US$ 5,951, respectively; in low transmission settings, they were US$ 1119 and US$ 6755, respectively. Incremental cost per DALY averted for infections and cases were US$ 4889 and US$ 38,344, respectively.\n\n【6】The GDG judged the resources required for RDA to be large but dependent on the number of index cases.\n\n【7】#### Equity\nNo studies were identified that addressed the issue of whether RDA increased or decreased health equity.\nThe GDG was unable to determine a judgement on equity.\n\n【8】#### Acceptability\nThe systematic review identified six studies in four countries (Eswatini, Gambia, Namibia and Zambia) with information on acceptability (Steinhardt et al _unpublished evidence (c)_). Community acceptance of RDA was high (refusal rate of 2% or lower) in Namibia and Zambia. However, in Eswatini, the overall refusal rate was about 4%, with refusal rates of 1.4% (11/776) and 5.3% 删除19:<u>(65/1232)</u> in seasons 1 and 2, respectively. In Namibia, participants expressed concern over having \"to take medicine without feeling sick\". Similarly, participants in Gambia \"generally considered it unnecessary to take medicine without having any symptoms\". Continued community sensitization has been recommended to mitigate these stigmas. In the systematic review, no studies reporting on the acceptability of RDA to health care workers or policymakers were found.", "tags": {}, "lang": "en", "attr": {"page_num": 221, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 WHO 指南：疟疾.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:11:38", "endTime": "2024/08/06 17:11:47", "cost": 8.583}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 01:11:47", "grab_time": "2024-08-06 01:11:38"}
{"id": 2211631, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "8cb7083d-e5f7-4c5a-9167-386f2f82626d", "title": "2023 JCS_CVIT_JCC指南：血管痉挛性心绞痛(冠状动脉痉挛性心绞痛)和冠状动脉微血管功能障碍的诊断和治疗（更新）(1)", "text": "【0】页码:26\n2023 JCS_CVIT_JCC指南：血管痉挛性心绞痛(冠状动脉痉挛性心绞痛)和冠状动脉微血管功能障碍的诊断和治疗（更新）(1)\n删除图片描述:<u>![](25_0.png)</u>\n\n【1】after coronary spasm, a significant increase in the area and thickness of the tunica media has been reported. Moreover, vasoconstriction occurs in asymptomatic patients with VSA, resulting in changes in intimal morphology. This finding suggests that hypercontraction of the tunica media, which is composed of vascular smooth muscle, plays an important role in the vascular structural changes of coronary spasm. Animal studies have shown that inflammation in the tunica media and hypercontraction of smooth muscle in the tunica media can be explained by a molecular mechanism centered on Rho-kinase, and that VSA cases also show inflammation consistent with the site of coronary spasm, which is consistent with this observation.\n\n【2】### 3.2.2 Involvement of Vasa Vasorum\nThe VV is a network of blood vessels, 30–200 μm in diameter, that surround larger blood vessels and can be evaluated in vivo using OCT. The VV is mainly responsible for supplying oxygen and nutrients to the vessel wall and is classified as adventitial (AVV), which runs in the adventitia, and intraplaque neovessels (IPNVs), which run within plaque. VVs are reported to proliferate in VSA, with AVVs increasing in diffusely spastic VSA, and IPNVs increasing in focally spastic VSA. Moreover, VSA with myocardial bridging (myocardial bridge) results in a loss of AVV at the site of myocardial bridge. However, the relationship between VVs and the phenotype of VSA remains unclear, and future studies are warranted.\n\n【3】### 3.2.3 Involvement of Layered Plaque\nOrganic abnormalities are found in more than half of cases of VSA. Of these, many cases have been reported to have layered plaque. Such stratified plaques are considered to be healed after asymptomatic rupture or erosion and are thought to form as a result of the fibrous component replacing the initial thrombus that was generated during the healing process. Thus, the main constituent components of layered plaques are the fibrous and flat thrombus components. One hypothesis for why layered plaques are more common in VSA is that thrombi develop and heal from intimal tears induced by coronary spasm, resulting in the formation of layered plaques, but this theory has not yet been fully elucidated.\n\n【4】### 4. Coronary Angioscopy\nCoronary angioscopy (CAS) is an intravascular imaging modality that allows direct visualization of the vascular luminal surface in full-color, real-time images through a lens. Although evaluation of cross-sectional vessel images, as with IVUS and OCT, is not available with CAS, CAS enables detailed observation of the color tone, irregularities, and mobility of the luminal surface, which helps to evaluate intimal injuries, thrombus, etc.\n\n【5】Because coronary spasm is diagnosed by CAG, CAS is not essential for clinical diagnosis of VSA and is instead mainly used for research purposes to clarify the pathophysiological mechanism.\n\n【6】The number of CAS reports on VSA is limited because CAS is approved for clinical use only in Japan. In this section, the CAS findings in VSA are summarized.\n\n【7】When coronary spasm sites are observed by CAS, intimal irregularities, thrombus, and yellow plaques are found at a frequency of ≈40%. In a recent report, thrombi were observed in coronary spasm-induced sites with about 30% frequency, whereas thrombus adherence was not seen in non-induced sites.\n\n【8】Three mechanisms for the presence of thrombus in spasm sites have been proposed: 删除11:<u>(1)</u> plaque rupture caused by external forces from coronary spasm, 删除11:<u>(2)</u> intimal erosion due to hyperconstriction or hyperextension of the intima by severe or repeated coronary spasm, and 删除11:<u>(3)</u> coronary spasm itself promotes thrombus formation by increasing platelet aggregation and activation of blood coagulation.\n\n【9】Another study demonstrated that a strong vasoconstrictive response to intracoronary ACh infusion occurs distal to 1st-generation DES with poor neointimal coverage and in-stent thrombi. However, 2nd-generation everolimus-eluting stents demonstrated less thrombus adhesion and less vasoconstriction response to ACh than 1st-generation DES, and the degree of neointimal coverage was comparable. These reports suggest that there is an association between intracoronary thrombus and an endothelium.", "tags": {}, "lang": "en", "attr": {"page_num": 26, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 JCS_CVIT_JCC指南：血管痉挛性心绞痛(冠状动脉痉挛性心绞痛)和冠状动脉微血管功能障碍的诊断和治疗（更新）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:23:49", "endTime": "2024/08/06 16:24:15", "cost": 25.663}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:24:15", "grab_time": "2024-08-06 00:23:49"}
{"id": 2211630, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "996bacae-cabf-4fc0-bac3-ef147d2c4c41", "title": "成人血液病患者接种新型冠状病毒疫苗中国专家共识（2022年版）", "text": "【0】页码:6\n成人血液病患者接种新型冠状病毒疫苗中国专家共识（2022年版）\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n-364-|删除段之间换行|malignancies 删除12:<u>[J]</u>．Cancer Cell, 删除13:<u>2021, 39</u> 删除11:<u>(8)</u>: 1031-1033. DOI: 10.1016/j.ccell.2021.07.012.\n\n【2】参考删除-3:<u>删除12:<u>删除14:<u>[29]</u></u> Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies 删除12:<u>[J]</u>．Am J Hematol, 删除13:<u>2021, 96</u> 删除11:<u>(10)</u>: 1195-1203. DOI: 10.1002/ajh.26384.</u>\n\n【3】参考删除-3:<u>删除12:<u>删除14:<u>[30]</u></u> Benjamini O, Rokach L, Itchaki G, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia 删除12:<u>[J]</u>．Haematologica, 删除13:<u>2022, 107</u> 删除11:<u>(3)</u>: 625-634. DOI: 10.3324/haematol.2021.279196.</u>\n\n【4】参考删除-3:<u>删除12:<u>删除14:<u>[31]</u></u> Roeker LE, Knorr DA, Thompson MC, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia 删除12:<u>[J]</u>． Leukaemia, 删除13:<u>2021, 35</u> 删除11:<u>(9)</u>: 2703-2705. DOI: 10.1038/s41375-021-01270-w.</u>\n\n【5】参考删除-3:<u>删除12:<u>删除14:<u>[32]</u></u> Molica S, Giannarelli D, Lentini M, et al. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study 删除12:<u>[J]</u>． Chemotherapy, 2021: 1-5. DOI: 10.1159/000521229.</u>\n\n【6】删除14:<u>[33] </u>Morssawa R. Resnands and consequences of COVID-19 vaccine failure in patients with chronic lymphocyte leukemia 删除12:<u>[J]</u>．Eur J Haematol, 删除13:<u>2022, 108</u> 删除11:<u>(2)</u>:191-8. DOI: 10.1111/ejh.13732.\n\n【7】参考删除-3:<u>删除12:<u>删除14:<u>[34]</u></u> Vijenthira A, Gong I, Betshed SD, et al. “Vaccine responsiveness following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients” 删除12:<u>[J]</u>．Blood Adv, 2021, 5 删除11:<u>(12)</u>: 删除13:<u>2624- 2643</u>. DOI: 10.1182/bloodadvances.202104629.</u>\n\n【8】参考删除-3:<u>删除12:<u>删除14:<u>[35]</u></u> Bird S, Panopoulou A, Shea TO, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma 删除12:<u>[J]</u>． Lancet Haematol, 2021, 8 删除11:<u>(6)</u>: e389-e392. DOI: 10.1016/ S2352-3026删除11:<u>(21)</u>00101-1.</u>\n\n【9】删除14:<u>[36] </u>Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I,et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti- myeloma treatment 删除12:<u>[J]</u>．Blood Cancer J, 删除13:<u>2021, 11</u> 删除11:<u>(8)</u>: 138. DOI: 10.1038/s41408-021-00503-3.\n\n【10】参考删除-3:<u>删除12:<u>删除14:<u>[37]</u></u> Herrueris B, Zerbit J, Bruni F, et al. Anti-CD3 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma 删除12:<u>[J]</u>．Blood, 删除13:<u>2022, 139</u> 删除11:<u>(6)</u>: 删除13:<u>942- 946</u>. DOI: 10.1182/blood.2021017314.</u>\n\n【11】参考删除-3:<u>删除12:<u>删除14:<u>[38]</u></u> Krejci M, Pour L, Adam Z, et al. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience 删除12:<u>[J]</u>．Ann Hematol, 删除13:<u>2021, 100</u> 删除11:<u>(10)</u>:删除13:<u>2541- 2546</u>. DOI: 10.1007/s00277-021-04549-w.</u>\n\n【12】参考删除-3:<u>删除12:<u>删除14:<u>[39]</u></u> Sundaresan I, Giri S, Singh H, et al. Repurposing of thalidomide and its derivatives for the treatment of SARS-cov-2 infections: hints from an molecular action 删除12:<u>[J]</u>．Br J Clin Pharmacol, 删除13:<u>2021, 87</u>删除11:<u>(10)</u>:3835-3850. DOI: 10.1111/bcp.14792.</u>\n\n【13】删除14:<u>[40] </u>Claudiani S, Apperley JF, Parker EL, et al. Humoral re- sponses after the second anti-SARS- Cov-2 vaccine dose in chronic myeloid leukemia patients on tyrosine kinase inhibitors 删除12:<u>[J]</u>．Br J Haematol, 删除13:<u>2022, 197</u> 删除11:<u>(1)</u>:e1-e4. DOI: 10.1111/ bjh.18001.\n\n【14】参考删除-3:<u>删除12:<u>删除14:<u>[41]</u></u> Bonafèno M, Triebitl M, Mìgsiano MC, et al. The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 删除12:<u>[J]</u>． </u>\n\n【15】参考删除-3:<u>Cancer Med, 删除13:<u>2021, 10</u> 删除11:<u>(18)</u>:删除13:<u>6310- 6316</u>. DOI: 10.1002/ cam4.4179.</u>\n\n【16】参考删除-3:<u>删除12:<u>删除14:<u>[42]</u></u> Foi R, Bonifacio M, Chiarelli S, et al. Philadelphia-positive acute lymphoblastic leukemia (ALL) late during the COVID- 19 pandemic: a Campus ALL study 删除12:<u>[J]</u>．Br J Haematol, 2020,190删除11:<u>(1)</u>:e3-e5. DOI: 10.1111/bjh.16758.</u>\n\n【17】参考删除-3:<u>删除12:<u>删除14:<u>[43]</u></u> Jain AG, Dong NC, Ball S, et al. Response to SARS- Co-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia 删除12:<u>[J]</u>. Blood, 删除13:<u>2021, 138</u> (Supplément 1 ): 217删除1:<u>. https://doi.org/10.1182/blood-2021-151669.</u></u>\n\n【18】参考删除-3:<u>删除12:<u>删除14:<u>[44]</u></u> Shem- Ton Y, PessRusnhn R, Dmyelsko E, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients 删除12:<u>[J]</u>．Br J Haematol, 删除13:<u>2022, 196</u>删除11:<u>(4)</u>:884-891. DOI: 10.1111/bjh.17985.</u>\n\n【19】参考删除-3:<u>删除12:<u>删除14:<u>[45]</u></u> Redjtoul R, Le Bouter A, Beckeri F, et al. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients 删除12:<u>[J]</u>． Lancet, 删除13:<u>2021, 398</u> 删除11:<u>删除19:<u>(10297)</u></u>: 2989-2996. DOI:10.1016/S0140-6736 删除11:<u>(21)</u>01594-4.</u>\n\n【20】参考删除-3:<u>删除12:<u>删除14:<u>[46]</u></u> Zeng W, Guo P, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of two-dose schedule, in healthy adults: interim results from four multicentre, double-blind, randomised, placebo-controlled phase 2 clini- cal trials 删除12:<u>[J]</u>．Lancet Infect Dis, 删除13:<u>2022, 22</u> 删除11:<u>(4)</u>:483-495. DOI: 10.1016/S1473-3099删除11:<u>(21)</u>00681-2.</u>\n\n【21】参考删除-3:<u>删除12:<u>删除14:<u>[47]</u></u> Greenberger LM, Saltzman LA, Senefeld JW, et al. Anti-spike activity response to SARS-CoV-2 mRNA vaccines in patients with hematologic malignancies 删除12:<u>[J]</u>．Leukemia, 删除13:<u>2021, 35</u>删除11:<u>(12)</u>: 删除13:<u>3454- 3456</u>. DOI: 10.1038/s41375-021-01419-7.</u>\n\n【22】参考删除-3:<u>删除12:<u>删除14:<u>[48]</u></u> Herishanu Y, Rahay G, Levi S, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine in patients with CLL who failed standard 2-dose vaccination 删除12:<u>[J]</u>．Blood, 删除13:<u>2022, 139</u>删除11:<u>(5)</u>:678-685. DOI: 10.1182/blood.2021014085.</u>\n\n【23】参考删除-3:<u>删除12:<u>删除14:<u>[49]</u></u> Redjouol R, Le Bouter A, Parinet V, et al. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT 删除12:<u>[J]</u>．Lancet Haematol, 2021, 8 删除11:<u>(10)</u>:e681-e683. DOI: 10.1016/S删除13:<u>2352- 3026</u>删除11:<u>(21)</u>00247-X.</u>\n\n【24】参考删除-3:<u>删除12:<u>删除14:<u>[50]</u></u> European Society for Blood and Marrow Transplantation. CORONAVIRUS DISEASE-COVID-19: EBMT RECOMMEN- DATIONS VERSION 17 - January 删除13:<u>26, 2022</u>删除1:<u>. https://www.ebmt. org/sites/default/files/2022-02/EBMT%20COVID-19%20guide- lines%20v.17u2.pdf.</u></u>\n\n【25】参考删除-3:<u>删除12:<u>删除14:<u>[51]</u></u> NCCN: Cancer and COVID-19 Vaccination. Version 5删除1:<u>.0 01/04 /2022: https://www.nccn.org/docs/default-source/covid- 19/2022- covid-19_vaccination_guidance_v-4_y01-7rps.pdf?sfvrsn=b843b2dc_70.</u></u>\n\n【26】删除14:<u>[52] </u>NCCN COVID-19 Vaccination Guide for People With Cancer删除1:<u>. https://www.nccn.org/docs/default-source/covid-19/covid -vaccine-and-cancer.pdsf?sfvrsn=5f4e3047_2.</u>\n\n【27】参考删除-3:<u>删除12:<u>删除14:<u>[53]</u></u> Ludwig H, Sonneveld P, Facon T, et al, COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network 删除12:<u>[J]</u>．Lancet Haematol, 2021, 8 删除11:<u>(12)</u>:e934- e946. DOI: 10.1016/S2352-3026删除11:<u>(21)</u>00277-7.</u>\n\n【28】参考删除-3:<u>删除12:<u>删除14:<u>[54]</u></u> Passà G, Gainer JH, Anghe M,et al. A COVID-19 vaccine guid- ance for patients with cancer participating in oncology clinical trials 删除12:<u>[J]</u>． Nat Rev Clin Oncol, 删除13:<u>2021, 18</u> 删除11:<u>(5)</u>:313-319. DOI: 10.1038/s41571-021-00487-z.</u>\n\n【29】（收稿日期：2022-03-30）\n\n【30】（本文编辑：刘莉）", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/成人血液病患者接种新型冠状病毒疫苗中国专家共识（2022年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:41:06", "endTime": "2024/08/06 16:41:11", "cost": 4.545}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:41:11", "grab_time": "2024-08-06 00:41:06"}
{"id": 2211629, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "86c21b68-c6ab-40c1-ace4-eb0a5c4ada0c", "title": "2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南", "text": "【0】页码:1\n2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南\n(本页删除)本页被模型判断为参考页疑似页眉<u># Original Article</u>\n\n【1】删除图片描述:<u>![](0_0.png)</u>\n\n【2】ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma\n\n【3】参考删除-1:<u>Maximilian Niyazi a,b,c,删除32:<u>*</u>, Nicolaus Andratschke d, Martin Bendszus e, Anthony J Chalmers f, Sara C Erridge g, Norbert Galldiks h,i,j, Frank Lagerwaard k, Pierina Navarria l, Per Munck af Rosenschöld m, Umberto Ricardi n, Martin J van den Bent o, Michael Weller p, Claus Belka a,b,c, Giuseppe Minniti g,r</u>\n\n【4】a Department of Radiation Oncology, University Hospital, LMU Munich, Germany; 删除32:<u>*</u>German Cancer Consortium (DKTK), partner site Munich;⁎Bavarian Cancer Research Center (BZKF), Munich, Germany; c Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; d Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany; ⁎e School of Cancer Sciences, University of Glasgow, Glasgow G61 1QH; f Edinburgh Centre for Neuro-Oncology, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK; g Department of Neurology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne; h Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich; i Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Düsseldorf, Germany; j Department of Radiation Oncology, Amsterdam UMC location Vdije University, Amsterdam, the Netherlands; k Radiotherapy and Radiosurgery Department, IRCCS, Humanitas Research Hospital, Rozzano, MI, Italy; l Radiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, and Lund University, Lund, Sweden; m Department of Oncology, University of Turin, Turin, Italy; n Erasmus MC Cancer Institute, Rotterdam, the Netherlands; o Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland; ⁎p Dept. of Medicine, Surgery and Neuroscience, University of Siena, Siena; and r IRCSS Istittito Neurologico Meditteraneo Neuromed, Pozzilli, Italy\n\n【5】## A R T I C L E     I N F O\n\n【6】Received 1 March 2023  \nReceived in revised form 23 March 2023  \nAccepted 29 March 2023  \nAvailable online 13 April 2023\n\n【7】Keywords:  \nGlioblastomas  \nTarget volume  \nDelineation  \nRadiotherapy  \nESTRO  \nEANO\n\n【8】## A B S T R A C T\n\n【9】Purpose: The purpose of this Target delineation in glioblastoma is still a matter of extensive research and debate. This guideline aims to update the existing joint European consensus on delineation of the clinical target volume (CTV) in adult glioblastoma patients.  \nMaterial and Methods: The ESTRO Guidelines Committee identified 14 European experts in close interaction with the ESTRO clinical committee and EANO who discussed and analyzed the body of evidence concerning every step of glioblastoma target delineation, then took part in a two-step modified Delphi process to address open questions.  \nResults: Several key issues were identified and discussed including i) pre-treatment steps and immobilisation, ii) target delineation and the application of hard and nonrigid image techniques, and iii) technical aspects of treatment including planning techniques and fractionation. Based on the EORTC recommendation focusing on the resection cavity and residual enhancing regions on T1-sequences with the addition of a reduced T2/FLAIR margins, special situations are presented with corresponding potential adaptations depending on the specific clinical situation.  \nConclusion: The most pertinent situations includes a core clinical target volume definition based on postoperative contrast-enhanced T1 abnormalities, using isotropic margins of 15 mm which need to come down. A margin based on the individual mask system and IGRT procedures available is advised; this should usually be no greater than 3 mm when using IGRT.\n\n【10】删除5:<u>©</u> 2023 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 184 删除11:<u>删除19:<u>(2023)</u></u> 109663 This is an open access article under the CC BY-NC-ND license .\n\n---|删除段之间换行|删除32:<u>**</u>Abbreviations:删除32:<u>**</u> 3D-CRT, 3-dimensional conformal radiotherapy; ACROP, (ESTRO)-Advisory Committee on Radiation Oncology Practice; ADC, Apparent diffusion coefficient (ADC); BTV, Biological tumour volume; CTV, Clinical target volume; CSF, Cerebrospinal fluid; DWI(DTI), Diffusion-weighted/diffusion tensor imaging; EROTC, European Organisation for Research and Treatment of Cancer; ESTRO, European Society for Radiotherapy & Oncology; EU, Equivalent uniform dose; FGG; 19F; 2-fluoro-2-deoxy-D-glucose; FET, O-(2 删除12:<u>[18F]</u> fluoroethyl]-L-tyrosine; FLAIR, Fluid-attenuated inversion recovery; FDOPA, 3.4 dihydroxy 6 删除12:<u>[18F]</u> fluoro-L-phenylalanine; GHG, Global harmonisation group; GTV, Gross tumour volume; IGRT, image-guided radiotherapy; IMRT; intensity-modulated radiotherapy; MET; O-删除12:<u>[11C]</u> methyl-L methionine; MR, Magnetic resonance imaging; OS, Overall survival; PET, Positron-emission tomography; PFS, Progression-free survival; PTV, Planning tumour or at risk volume; ROI, Region-of-interest; RT, Radiotherapy; RTOG, Radiation Therapy Oncology Group; SIB, Simultaneous integrated boost; TBR, Tumour-to-background ratio; VMAT; Volumetric intensity-modulated arc therapy.\n\n【12】\\删除32:<u>*</u> Corresponding author at: Department of Radiation Oncology, University Hospital, LMU Munich Marchioninistr.删除16:<u> 1581377 </u>Munich, Germany\n删除32:<u>**</u>E-mail address: Maximilian.Niyazi@med.uni-muenchen.de (M. Niyazi).删除32:<u>**</u>\n\n【13】删除1:<u>删除24:<u>[https://doi.org/10.1016/j.radonc.2023.109663]</u>                                     </u>\n0167-8140/ 删除5:<u>©</u> 2023 The Authors. Published by Elsevier B.V.  \nThis is an open access article under the CC BY-NC-ND license .", "tags": {}, "lang": "en", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【5】## A R T I C L E     I N F O\n\n【6】Received 1 March 2023\n\nReceived in revised form 23 March 2023\n\nAccepted 29 March 2023\n\nAvailable online 13 April 2023\n\n【7】Keywords:\n\nGlioblastomas\n\nTarget volume\n\nDelineation\n\nRadiotherapy\n\nESTRO\n\nEANO", "content": "【0】页码:1\n2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南\n(本页删除)本页被模型判断为参考页疑似页眉<u># Original Article</u>\n\n【1】删除图片描述:<u>![](0_0.png)</u>\n\n【2】ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma\n\n【3】参考删除-1:<u>Maximilian Niyazi a,b,c,删除32:<u>*</u>, Nicolaus Andratschke d, Martin Bendszus e, Anthony J Chalmers f, Sara C Erridge g, Norbert Galldiks h,i,j, Frank Lagerwaard k, Pierina Navarria l, Per Munck af Rosenschöld m, Umberto Ricardi n, Martin J van den Bent o, Michael Weller p, Claus Belka a,b,c, Giuseppe Minniti g,r</u>\n\n【4】a Department of Radiation Oncology, University Hospital, LMU Munich, Germany; 删除32:<u>*</u>German Cancer Consortium (DKTK), partner site Munich;⁎Bavarian Cancer Research Center (BZKF), Munich, Germany; c Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; d Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany; ⁎e School of Cancer Sciences, University of Glasgow, Glasgow G61 1QH; f Edinburgh Centre for Neuro-Oncology, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK; g Department of Neurology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne; h Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich; i Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Düsseldorf, Germany; j Department of Radiation Oncology, Amsterdam UMC location Vdije University, Amsterdam, the Netherlands; k Radiotherapy and Radiosurgery Department, IRCCS, Humanitas Research Hospital, Rozzano, MI, Italy; l Radiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, and Lund University, Lund, Sweden; m Department of Oncology, University of Turin, Turin, Italy; n Erasmus MC Cancer Institute, Rotterdam, the Netherlands; o Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland; ⁎p Dept. of Medicine, Surgery and Neuroscience, University of Siena, Siena; and r IRCSS Istittito Neurologico Meditteraneo Neuromed, Pozzilli, Italy\n\n【5】## A R T I C L E     I N F O\n\n【6】Received 1 March 2023  \nReceived in revised form 23 March 2023  \nAccepted 29 March 2023  \nAvailable online 13 April 2023\n\n【7】Keywords:  \nGlioblastomas  \nTarget volume  \nDelineation  \nRadiotherapy  \nESTRO  \nEANO\n\n【8】## A B S T R A C T\n\n【9】Purpose: The purpose of this Target delineation in glioblastoma is still a matter of extensive research and debate. This guideline aims to update the existing joint European consensus on delineation of the clinical target volume (CTV) in adult glioblastoma patients.  \nMaterial and Methods: The ESTRO Guidelines Committee identified 14 European experts in close interaction with the ESTRO clinical committee and EANO who discussed and analyzed the body of evidence concerning every step of glioblastoma target delineation, then took part in a two-step modified Delphi process to address open questions.  \nResults: Several key issues were identified and discussed including i) pre-treatment steps and immobilisation, ii) target delineation and the application of hard and nonrigid image techniques, and iii) technical aspects of treatment including planning techniques and fractionation. Based on the EORTC recommendation focusing on the resection cavity and residual enhancing regions on T1-sequences with the addition of a reduced T2/FLAIR margins, special situations are presented with corresponding potential adaptations depending on the specific clinical situation.  \nConclusion: The most pertinent situations includes a core clinical target volume definition based on postoperative contrast-enhanced T1 abnormalities, using isotropic margins of 15 mm which need to come down. A margin based on the individual mask system and IGRT procedures available is advised; this should usually be no greater than 3 mm when using IGRT.\n\n【10】删除5:<u>©</u> 2023 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 184 删除11:<u>删除19:<u>(2023)</u></u> 109663 This is an open access article under the CC BY-NC-ND license .\n\n---|删除段之间换行|删除32:<u>**</u>Abbreviations:删除32:<u>**</u> 3D-CRT, 3-dimensional conformal radiotherapy; ACROP, (ESTRO)-Advisory Committee on Radiation Oncology Practice; ADC, Apparent diffusion coefficient (ADC); BTV, Biological tumour volume; CTV, Clinical target volume; CSF, Cerebrospinal fluid; DWI(DTI), Diffusion-weighted/diffusion tensor imaging; EROTC, European Organisation for Research and Treatment of Cancer; ESTRO, European Society for Radiotherapy & Oncology; EU, Equivalent uniform dose; FGG; 19F; 2-fluoro-2-deoxy-D-glucose; FET, O-(2 删除12:<u>[18F]</u> fluoroethyl]-L-tyrosine; FLAIR, Fluid-attenuated inversion recovery; FDOPA, 3.4 dihydroxy 6 删除12:<u>[18F]</u> fluoro-L-phenylalanine; GHG, Global harmonisation group; GTV, Gross tumour volume; IGRT, image-guided radiotherapy; IMRT; intensity-modulated radiotherapy; MET; O-删除12:<u>[11C]</u> methyl-L methionine; MR, Magnetic resonance imaging; OS, Overall survival; PET, Positron-emission tomography; PFS, Progression-free survival; PTV, Planning tumour or at risk volume; ROI, Region-of-interest; RT, Radiotherapy; RTOG, Radiation Therapy Oncology Group; SIB, Simultaneous integrated boost; TBR, Tumour-to-background ratio; VMAT; Volumetric intensity-modulated arc therapy.\n\n【12】\\删除32:<u>*</u> Corresponding author at: Department of Radiation Oncology, University Hospital, LMU Munich Marchioninistr.删除16:<u> 1581377 </u>Munich, Germany\n删除32:<u>**</u>E-mail address: Maximilian.Niyazi@med.uni-muenchen.de (M. Niyazi).删除32:<u>**</u>\n\n【13】删除1:<u>删除24:<u>[https://doi.org/10.1016/j.radonc.2023.109663]</u>                                     </u>\n0167-8140/ 删除5:<u>©</u> 2023 The Authors. Published by Elsevier B.V.  \nThis is an open access article under the CC BY-NC-ND license .", "index": 2160, "show": true, "start": 2160, "end": 2397, "province": ["信息质量", "有用性-轻"], "isEdit": false}, {"text": "【10】删除5:© 2023 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 184 删除11:删除19:(2023) 109663 This is an open access article under the CC BY-NC-ND license .\n\n—|删除段之间换行|删除32:Abbreviations:删除32: 3D-CRT, 3-dimensional conformal radiotherapy; ACROP, (ESTRO)-Advisory Committee on Radiation Oncology Practice; ADC, Apparent diffusion coefficient (ADC); BTV, Biological tumour volume; CTV, Clinical target volume; CSF, Cerebrospinal fluid; DWI(DTI), Diffusion-weighted/diffusion tensor imaging; EROTC, European Organisation for Research and Treatment of Cancer; ESTRO, European Society for Radiotherapy & Oncology; EU, Equivalent uniform dose; FGG; 19F; 2-fluoro-2-deoxy-D-glucose; FET, O-(2 删除12:[18F] fluoroethyl]-L-tyrosine; FLAIR, Fluid-attenuated inversion recovery; FDOPA, 3.4 dihydroxy 6 删除12:[18F] fluoro-L-phenylalanine; GHG, Global harmonisation group; GTV, Gross tumour volume; IGRT, image-guided radiotherapy; IMRT; intensity-modulated radiotherapy; MET; O-删除12:[11C] methyl-L methionine; MR, Magnetic resonance imaging; OS, Overall survival; PET, Positron-emission tomography; PFS, Progression-free survival; PTV, Planning tumour or at risk volume; ROI, Region-of-interest; RT, Radiotherapy; RTOG, Radiation Therapy Oncology Group; SIB, Simultaneous integrated boost; TBR, Tumour-to-background ratio; VMAT; Volumetric intensity-modulated arc therapy.\n\n【12】\\删除32:* Corresponding author at: Department of Radiation Oncology, University Hospital, LMU Munich Marchioninistr.删除16: 1581377 Munich, Germany\n\n删除32:E-mail address: Maximilian.Niyazi@med.uni-muenchen.de (M. Niyazi).删除32:\n\n【13】删除1:删除24:[https://doi.org/10.1016/j.radonc.2023.109663]                                     \n\n0167-8140/ 删除5:© 2023 The Authors. Published by Elsevier B.V.\n\nThis is an open access article under the CC BY-NC-ND license .", "content": "【0】页码:1\n2023 ESTRO-EANO 胶质母细胞瘤靶区划定和放疗细节指南\n(本页删除)本页被模型判断为参考页疑似页眉<u># Original Article</u>\n\n【1】删除图片描述:<u>![](0_0.png)</u>\n\n【2】ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma\n\n【3】参考删除-1:<u>Maximilian Niyazi a,b,c,删除32:<u>*</u>, Nicolaus Andratschke d, Martin Bendszus e, Anthony J Chalmers f, Sara C Erridge g, Norbert Galldiks h,i,j, Frank Lagerwaard k, Pierina Navarria l, Per Munck af Rosenschöld m, Umberto Ricardi n, Martin J van den Bent o, Michael Weller p, Claus Belka a,b,c, Giuseppe Minniti g,r</u>\n\n【4】a Department of Radiation Oncology, University Hospital, LMU Munich, Germany; 删除32:<u>*</u>German Cancer Consortium (DKTK), partner site Munich;⁎Bavarian Cancer Research Center (BZKF), Munich, Germany; c Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; d Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany; ⁎e School of Cancer Sciences, University of Glasgow, Glasgow G61 1QH; f Edinburgh Centre for Neuro-Oncology, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK; g Department of Neurology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne; h Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich; i Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Düsseldorf, Germany; j Department of Radiation Oncology, Amsterdam UMC location Vdije University, Amsterdam, the Netherlands; k Radiotherapy and Radiosurgery Department, IRCCS, Humanitas Research Hospital, Rozzano, MI, Italy; l Radiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, and Lund University, Lund, Sweden; m Department of Oncology, University of Turin, Turin, Italy; n Erasmus MC Cancer Institute, Rotterdam, the Netherlands; o Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland; ⁎p Dept. of Medicine, Surgery and Neuroscience, University of Siena, Siena; and r IRCSS Istittito Neurologico Meditteraneo Neuromed, Pozzilli, Italy\n\n<mark>【5】## A R T I C L E     I N F O\n\n【6】Received 1 March 2023\n\nReceived in revised form 23 March 2023\n\nAccepted 29 March 2023\n\nAvailable online 13 April 2023\n\n【7】Keywords:\n\nGlioblastomas\n\nTarget volume\n\nDelineation\n\nRadiotherapy\n\nESTRO\n\nEANO</mark>RO  \nEANO\n\n【8】## A B S T R A C T\n\n【9】Purpose: The purpose of this Target delineation in glioblastoma is still a matter of extensive research and debate. This guideline aims to update the existing joint European consensus on delineation of the clinical target volume (CTV) in adult glioblastoma patients.  \nMaterial and Methods: The ESTRO Guidelines Committee identified 14 European experts in close interaction with the ESTRO clinical committee and EANO who discussed and analyzed the body of evidence concerning every step of glioblastoma target delineation, then took part in a two-step modified Delphi process to address open questions.  \nResults: Several key issues were identified and discussed including i) pre-treatment steps and immobilisation, ii) target delineation and the application of hard and nonrigid image techniques, and iii) technical aspects of treatment including planning techniques and fractionation. Based on the EORTC recommendation focusing on the resection cavity and residual enhancing regions on T1-sequences with the addition of a reduced T2/FLAIR margins, special situations are presented with corresponding potential adaptations depending on the specific clinical situation.  \nConclusion: The most pertinent situations includes a core clinical target volume definition based on postoperative contrast-enhanced T1 abnormalities, using isotropic margins of 15 mm which need to come down. A margin based on the individual mask system and IGRT procedures available is advised; this should usually be no greater than 3 mm when using IGRT.\n\n【10】删除5:<u>©</u> 2023 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 184 删除11:<u>删除19:<u>(2023)</u></u> 109663 This is an open access article under the CC BY-NC-ND license .\n\n---|删除段之间换行|删除32:<u>**</u>Abbreviations:删除32:<u>**</u> 3D-CRT, 3-dimensional conformal radiotherapy; ACROP, (ESTRO)-Advisory Committee on Radiation Oncology Practice; ADC, Apparent diffusion coefficient (ADC); BTV, Biological tumour volume; CTV, Clinical target volume; CSF, Cerebrospinal fluid; DWI(DTI), Diffusion-weighted/diffusion tensor imaging; EROTC, European Organisation for Research and Treatment of Cancer; ESTRO, European Society for Radiotherapy & Oncology; EU, Equivalent uniform dose; FGG; 19F; 2-fluoro-2-deoxy-D-glucose; FET, O-(2 删除12:<u>[18F]</u> fluoroethyl]-L-tyrosine; FLAIR, Fluid-attenuated inversion recovery; FDOPA, 3.4 dihydroxy 6 删除12:<u>[18F]</u> fluoro-L-phenylalanine; GHG, Global harmonisation group; GTV, Gross tumour volume; IGRT, image-guided radiotherapy; IMRT; intensity-modulated radiotherapy; MET; O-删除12:<u>[11C]</u> methyl-L methionine; MR, Magnetic resonance imaging; OS, Overall survival; PET, Positron-emission tomography; PFS, Progression-free survival; PTV, Planning tumour or at risk volume; ROI, Region-of-interest; RT, Radiotherapy; RTOG, Radiation Therapy Oncology Group; SIB, Simultaneous integrated boost; TBR, Tumour-to-background ratio; VMAT; Volumetric intensity-modulated arc therapy.\n\n【12】\\删除32:<u>*</u> Corresponding author at: Department of Radiation Oncology, University Hospital, LMU Munich Marchioninistr.删除16:<u> 1581377 </u>Munich, Germany\n删除32:<u>**</u>E-mail address: Maximilian.Niyazi@med.uni-muenchen.de (M. Niyazi).删除32:<u>**</u>\n\n【13】删除1:<u>删除24:<u>[https://doi.org/10.1016/j.radonc.2023.109663]</u>                                     </u>\n0167-8140/ 删除5:<u>©</u> 2023 The Authors. Published by Elsevier B.V.  \nThis is an open access article under the CC BY-NC-ND license .", "index": 3977, "show": true, "start": 3964, "end": 5788, "province": ["信息质量", "有用性-轻"], "isEdit": false}], "startTime": "2024/08/06 16:12:35", "endTime": "2024/08/06 16:13:27", "cost": 51.184}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:13:26", "grab_time": "2024-08-06 00:12:34"}
{"id": 2211628, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "adf4ca1c-659e-4c34-bf56-0810e8d4c8fb", "title": "2023 EuSEM／EFSUMB意见书：急诊床旁即时超声管理", "text": "【0】页码:5\n2023 EuSEM／EFSUMB意见书：急诊床旁即时超声管理\njectively fulfill these requirements, regardless of the chosen method of examination at the end.\n\n【1】The IFEM has published guidelines that can help bodies and societies in EM to design an exemplary curriculum 删除12:<u>删除14:<u>[20]</u></u>. This curriculum includes the basic principles and processes. They can be easily adapted to local conditions.\n\n【2】The EMPS is ultimately intended to objectively and safely demonstrate and guarantee future independent, prudent, and optimal application of EMPOCUS for the individual physician after continuing or advanced training.\n\nTaking these goals into account, we consider the following two elements, which differ from those of Atkinson et al. 删除11:<u>(20)</u>, to be central:\n1. Acquisition and maintenance of EMPOCUS competency and|删除段内换行|2. Skills integrated into patient care with quality assurance in terms of certification and recertification\n\n【4】### Program for skill acquisition and maintenance\n\n【5】#### Skill acquisition\n\n【6】删除图片描述:<u>The continuing education program  ![4_0.png](4_0.png) includes courses with speakers/tutors and other formats for teaching theory and allowing initial hands-on instruction, as well as hands-on ultrasound in real life to acquire the appropriate skills in clinical prac- tice. Some courses and other formats also provide </u>\n\n【7】learning programs at home or at the workplace, and certain hands-on skills can be acquired using simulators. Blended learning approaches have been incorporated with success and certainly the current SARS-CoV-2 pandemic has significantly increased the need for online learning opportunities 删除12:<u>删除14:<u>[34]</u></u>. However, comprehensive practical skills in human medicine can only be learned on human beings. For beginners, planned sessions away from the pressures of the clinical environment with normal volunteers or patients (covering the spectrum of ages/sex/body habitus) can help ultrasound learners to become proficient.\n\n【8】The key practical skills required are how to operate the ultrasound machine, how to optimize images, and how to develop psychomotor skills and muscle memory. This is useful to prepare the trainees to scan in a clinical environment and hence get the optimal benefit of supervision. The courses and other formats are primarily designed to provide participants with basic knowledge and scanning instructions. They are also intended to motivate participants to use ultrasound in everyday life. Different educational strategies, depending on available resources, should be incorporated for maximum success 删除12:<u>删除14:<u>[21]</u></u>.\n\n【9】The most crucial and lengthy part of education and training is individualized supervision at the patient’s bedside, i.e. proctored examinations of trainees in the usual clinical environment on their patients 删除12:<u>删除14:<u>[35]</u></u>. A proctor guides trainees through the entire examination, possibly using the four-step concept 删除12:<u>[删除13:<u>16, 36</u>]</u>. In view of the often frenetic and pressurized environment trainees are exposed to, interruptions and a minimum time frame of planned proctored examinations over an extended period (e.g., 4 weeks) are helpful if implementation in an uninterrupted manner is not always possible. This way, the need for little guidance", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 EuSEM／EFSUMB意见书：急诊床旁即时超声管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "|删除段内换行|2. Skills integrated into patient care with quality assurance in terms of certification and recertification", "content": "【0】页码:5\n2023 EuSEM／EFSUMB意见书：急诊床旁即时超声管理\njectively fulfill these requirements, regardless of the chosen method of examination at the end.\n\n【1】The IFEM has published guidelines that can help bodies and societies in EM to design an exemplary curriculum 删除12:<u>删除14:<u>[20]</u></u>. This curriculum includes the basic principles and processes. They can be easily adapted to local conditions.\n\n【2】The EMPS is ultimately intended to objectively and safely demonstrate and guarantee future independent, prudent, and optimal application of EMPOCUS for the individual physician after continuing or advanced training.\n\nTaking these goals into account, we consider the following two elements, which differ from those of Atkinson et al. 删除11:<u>(20)</u>, to be central:\n1. Acquisition and maintenance of EMPOCUS competency and|删除段内换行|2. Skills integrated into patient care with quality assurance in terms of certification and recertification\n\n【4】### Program for skill acquisition and maintenance\n\n【5】#### Skill acquisition\n\n【6】删除图片描述:<u>The continuing education program  ![4_0.png](4_0.png) includes courses with speakers/tutors and other formats for teaching theory and allowing initial hands-on instruction, as well as hands-on ultrasound in real life to acquire the appropriate skills in clinical prac- tice. Some courses and other formats also provide </u>\n\n【7】learning programs at home or at the workplace, and certain hands-on skills can be acquired using simulators. Blended learning approaches have been incorporated with success and certainly the current SARS-CoV-2 pandemic has significantly increased the need for online learning opportunities 删除12:<u>删除14:<u>[34]</u></u>. However, comprehensive practical skills in human medicine can only be learned on human beings. For beginners, planned sessions away from the pressures of the clinical environment with normal volunteers or patients (covering the spectrum of ages/sex/body habitus) can help ultrasound learners to become proficient.\n\n【8】The key practical skills required are how to operate the ultrasound machine, how to optimize images, and how to develop psychomotor skills and muscle memory. This is useful to prepare the trainees to scan in a clinical environment and hence get the optimal benefit of supervision. The courses and other formats are primarily designed to provide participants with basic knowledge and scanning instructions. They are also intended to motivate participants to use ultrasound in everyday life. Different educational strategies, depending on available resources, should be incorporated for maximum success 删除12:<u>删除14:<u>[21]</u></u>.\n\n【9】The most crucial and lengthy part of education and training is individualized supervision at the patient’s bedside, i.e. proctored examinations of trainees in the usual clinical environment on their patients 删除12:<u>删除14:<u>[35]</u></u>. A proctor guides trainees through the entire examination, possibly using the four-step concept 删除12:<u>[删除13:<u>16, 36</u>]</u>. In view of the often frenetic and pressurized environment trainees are exposed to, interruptions and a minimum time frame of planned proctored examinations over an extended period (e.g., 4 weeks) are helpful if implementation in an uninterrupted manner is not always possible. This way, the need for little guidance", "index": 815, "show": true, "start": 815, "end": 930, "province": ["格式规范性", "缺少换行"], "isEdit": false, "comment": "2"}, {"text": "【7】learning programs at home or at the workplace, and certain hands-on skills can be acquired using simulators. ", "content": "【0】页码:5\n2023 EuSEM／EFSUMB意见书：急诊床旁即时超声管理\njectively fulfill these requirements, regardless of the chosen method of examination at the end.\n\n【1】The IFEM has published guidelines that can help bodies and societies in EM to design an exemplary curriculum 删除12:<u>删除14:<u>[20]</u></u>. This curriculum includes the basic principles and processes. They can be easily adapted to local conditions.\n\n【2】The EMPS is ultimately intended to objectively and safely demonstrate and guarantee future independent, prudent, and optimal application of EMPOCUS for the individual physician after continuing or advanced training.\n\nTaking these goals into account, we consider the following two elements, which differ from those of Atkinson et al. 删除11:<u>(20)</u>, to be central:\n1. Acquisition and maintenance of EMPOCUS competency and<mark>|删除段内换行|2. Skills integrated into patient care with quality assurance in terms of certification and recertification</mark>\n\n【4】### Program for skill acquisition and maintenance\n\n【5】#### Skill acquisition\n\n【6】删除图片描述:<u>The continuing education program  ![4_0.png](4_0.png) includes courses with speakers/tutors and other formats for teaching theory and allowing initial hands-on instruction, as well as hands-on ultrasound in real life to acquire the appropriate skills in clinical prac- tice. Some courses and other formats also provide </u>\n\n【7】learning programs at home or at the workplace, and certain hands-on skills can be acquired using simulators. Blended learning approaches have been incorporated with success and certainly the current SARS-CoV-2 pandemic has significantly increased the need for online learning opportunities 删除12:<u>删除14:<u>[34]</u></u>. However, comprehensive practical skills in human medicine can only be learned on human beings. For beginners, planned sessions away from the pressures of the clinical environment with normal volunteers or patients (covering the spectrum of ages/sex/body habitus) can help ultrasound learners to become proficient.\n\n【8】The key practical skills required are how to operate the ultrasound machine, how to optimize images, and how to develop psychomotor skills and muscle memory. This is useful to prepare the trainees to scan in a clinical environment and hence get the optimal benefit of supervision. The courses and other formats are primarily designed to provide participants with basic knowledge and scanning instructions. They are also intended to motivate participants to use ultrasound in everyday life. Different educational strategies, depending on available resources, should be incorporated for maximum success 删除12:<u>删除14:<u>[21]</u></u>.\n\n【9】The most crucial and lengthy part of education and training is individualized supervision at the patient’s bedside, i.e. proctored examinations of trainees in the usual clinical environment on their patients 删除12:<u>删除14:<u>[35]</u></u>. A proctor guides trainees through the entire examination, possibly using the four-step concept 删除12:<u>[删除13:<u>16, 36</u>]</u>. In view of the often frenetic and pressurized environment trainees are exposed to, interruptions and a minimum time frame of planned proctored examinations over an extended period (e.g., 4 weeks) are helpful if implementation in an uninterrupted manner is not always possible. This way, the need for little guidance", "index": 1364, "show": true, "start": 1351, "end": 1463, "province": ["语义有效性", "语义不完整"], "isEdit": false}], "startTime": "2024/08/06 17:11:02", "endTime": "2024/08/06 17:12:23", "cost": 80.558}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 01:12:23", "grab_time": "2024-08-06 01:11:02"}
{"id": 2211627, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "749a3182-c4d3-4d02-b09d-fd98976f4e4d", "title": "SIGN：英国进食障碍指南（2022）", "text": "【0】页码:33\nSIGN：英国进食障碍指南（2022）\n### 9.3.3 Dialectical behaviour therapy\n\n【1】A small study (n=删除13:<u>25, 13</u> with AN) comparing DBT with TAU in patients with eating disorders and substance abuse found DBT to be more effective at improving behavioural and attitudinal features related to eating disorders, substance misuse, negative mood regulation and depressive symptoms. These results were maintained at 6-month follow-up.删除17:<u>120</u>\n\n【2】In a pilot study of patients with eating disorders (n=删除13:<u>147, 18</u> with AN) and BPD, conducted in a naturalistic setting, DBT was compared with CBT and both therapies were adjunctive to attendance at either outpatients or a day hospital. At the end of treatment DBT was shown to have a statistically significant effect on the symptoms of BPD, including depression, but had no significantly different effects on eating disorder psychopathology from the CBT.删除17:<u>121</u> See section 3.3.3 for further information on the management of patients with an eating disorder and BPD.\n\n【3】### 9.4 Recommendations for psychological therapies\n\n【4】删除32:<u>**</u>R删除32:<u>**</u> 删除32:<u>**</u>Enhanced cognitive behavioural therapy for eating disorders or other forms of cognitive behavioural therapy should be used as first-line therapy for adults with anorexia nervosa.删除32:<u>**</u>\n\n【5】删除32:<u>**</u>R删除32:<u>**</u> 删除32:<u>**</u>If cognitive behavioural therapy is ineffective, unsuitable or unacceptable for adults with anorexia nervosa other therapeutic approaches could be considered, such as interpersonal psychotherapy, the Maudsley Model of Anorexia Treatment, Specialist Supportive Clinical Management, or focal psychodynamic therapy.删除32:<u>**</u>\n\n【6】- Dialectical behaviour therapy is a transdiagnostic treatment regime showing greater validity for people with eating disorders with comorbidities including substance misuse disorder and borderline personality disorder 删除9:<u>(emotionally unstable personality disorder)</u>. This approach could, therefore, be considered instead of cognitive behavioural therapy for this complex group.\n- Other therapies such as cognitive analytical therapy, schema therapy, mentalisation-based therapy, Radically Open Dialectical Behaviour Therapy, could be considered for patients with anorexia nervosa, as part of a clinical trial.\n\n【7】### 9.5 Pharmacological therapies\n\n【8】Prescribing for patients with AN always requires consideration of the starved physiology of the patient, their low body weight and abnormal electrolytes due to purging behaviours.删除16:<u> 124 </u>Psychotropic and other medication carries risks to the heart and other organs so benefits must always be set against these, and as a result research in this field is scarce.\n\n【9】People with AN may need specific adjustments to medication prescribed for other conditions, both physical and psychiatric. It is assumed in most studies of psychotherapy for AN that patients will be taking psychotropic medications prescribed on a case-by-case basis by experienced specialists.\n\n【10】- All low-weight patients should be monitored particularly closely when psychotropic drugs are prescribed. A baseline electrocardiogram (ECG) and further monitoring can alert clinicians to avoidable dangers.\n\n【11】#### 9.5.1 Antipsychotics\n\n【12】The rationale for using antipsychotic medication for AN is for the reduction of distress and obsessionality. The use of weight as a measure of its effectiveness is a proxy representing the fact that a patient needs to have acquired healthy psychological skills in order to achieve and maintain a healthier weight.", "tags": {}, "lang": "en", "attr": {"page_num": 33, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/SIGN：英国进食障碍指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/07 09:59:56", "endTime": "2024/08/07 10:02:40", "cost": 163.123}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 18:02:37", "grab_time": "2024-08-06 17:59:53"}
{"id": 2211626, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "488ace12-a073-4ed2-81f0-b4272667cd4c", "title": "_2024 ESO指南：脑小血管病—第2部分：腔隙性缺血性卒中", "text": "【0】页码:49\n_2024 ESO指南：脑小血管病—第2部分：腔隙性缺血性卒中\nblood oxygen saturation in the microvasculature at 180 min post-administration, indicating improved perfusion in the cerebral microvasculature.删除17:<u>244</u> A larger RCT 删除19:<u>(NCT05173896)</u> is now investigating if 3 months daily intake of tadalafil is feasible in lacunar stroke patients and if it alters cerebral perfusion, neurovascular reactivity, and cognition. Sildenafil is investigated in the OxHARP study, however, the primary outcome is cerebrovascular pulsatility and reactivity and the study will not have any relevant clinical outcome measures.删除17:<u>245</u>\n\n【1】The effect of minocycline, an antibiotic with anti-inflammatory properties, on microglial activation and blood-brain permeability in patients with lacunar stroke is investigated in the MINERVA trial.删除17:<u>246</u> However there will be no clinical outcomes.\n\n【2】删除图片描述:<u>![](48_0.png)</u>\n\n【3】We considered acute treatment and secondary prevention in lacunar ischaemic stroke. We tried to reflect diagnoses, timings and practical clinical aspects of the knowledge base that will inform the management of patients with suspected lacunar ischaemic stroke. Disappointingly, there is a dearth of data on cognitive and mood outcomes despite cognitive impairment being the commonest problem after lacunar stroke and a main concern to patients. Since most data were from subgroups of trials that included all stroke or all ischaemic stroke, the most commonly available outcomes were dependency (which is less common in lacunar stroke than in other ischaemic stroke subtypes) and recurrent stroke (which in general is less common early after lacunar stroke than with large artery or cardioembolic stroke).删除17:<u>4</u>\n\n【4】The strengths of this work include the use of the GRADE approach as mandated by ESO. The guideline builds on the Guideline for covert SVD published in 2021.1 We have endeavoured to amass all relevant data. While we hope we have not missed any major trials we acknowledge that it is difficult to search for trials in lacunar ischaemic stroke. We contacted authors for additional data, and wherever feasible we undertook several new meta-analyses, including a network meta-analysis on antiplatelet drugs in secondary prevention.\n\n【5】We also acknowledge limitations. Limitations of the data reflect the dearth of any data on many of the outcomes of interest and many interventions of interest in lacunar ischaemic stroke. There were essentially no data on cognition despite cognitive impairment being common and a main concern of patients with lacunar ischaemic stroke. Most data came from a lacunar subgroup of a larger trial, which may be limited by definition, chance, small sample and often only reporting one outcome in the subgroups. Very few trials focused on lacunar ischaemic stroke. Although many trials must have included patients with lacunar ischaemic stroke, many did not distinguish lacunar from other subtypes at all, or if they did, then often did not report any results for the lacunar subgroup, or only reported a few outcomes for the lacunar stroke patients separately. Lack of long-term follow-up in many secondary prevention trials mean that effects of interventions in lacunar stroke may not have become fully apparent, since recurrent stroke, dependency, or death typically occur late after lacunar ischaemic stroke, compared with other stroke subtypes. Finally, time constraints meant that we were not able to obtain stakeholder feedback on the guideline prior to publication, but we welcome feedback from people affected by lacunar ischaemic stroke and other forms of cSVD to help inform future guidelines, research and practice.\n\n【6】The Guideline is part of a series of Guidelines on the clinical management of cerebral small vessel disease: Part 1, covert cSVD, Part 2, lacunar ischaemic stroke, other Parts under consideration include 3, other stroke subtypes with a high cSVD burden, 4, cognitive, 5, mobility, and 6, mood presentations of cSVD. The Guideline Parts published so far will be updated within 5 years of publication or sooner if important new information becomes available.\n\n【7】Discussion\n\n【8】This guideline document was developed following the GRADE methodology and aims to assist physicians in decision-making regarding suspected lacunar ischaemic stroke. All recommendations and Expert Consensus Statements are summarised in Table 8.\n\n【9】We noted that a considerable proportion of articles were not found by the literature search and that a substantial number of additional articles were detected through other methods such as checking reference lists. This indicates that detection of relevant trials may be especially difficult for lacunar ischaemic stroke.", "tags": {}, "lang": "en", "attr": {"page_num": 49, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_2024 ESO指南：脑小血管病—第2部分：腔隙性缺血性卒中.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【3】We considered acute treatment and secondary prevention in lacunar ischaemic stroke. We tried to reflect diagnoses, timings and practical clinical aspects of the knowledge base that will inform the management of patients with suspected lacunar ischaemic stroke. Disappointingly, there is a dearth of data on cognitive and mood outcomes despite cognitive impairment being the commonest problem after lacunar stroke and a main concern to patients. Since most data were from subgroups of trials that included all stroke or all ischaemic stroke, the most commonly available outcomes were dependency (which is less common in lacunar stroke than in other ischaemic stroke subtypes) and recurrent stroke (which in general is less common early after lacunar stroke than with large artery or cardioembolic stroke).删除17:4\n\n【4】The strengths of this work include the use of the GRADE approach as mandated by ESO. The guideline builds on the Guideline for covert SVD published in 2021.1 We have endeavoured to amass all relevant data. While we hope we have not missed any major trials we acknowledge that it is difficult to search for trials in lacunar ischaemic stroke. We contacted authors for additional data, and wherever feasible we undertook several new meta-analyses, including a network meta-analysis on antiplatelet drugs in secondary prevention.\n\n【5】We also acknowledge limitations. Limitations of the data reflect the dearth of any data on many of the outcomes of interest and many interventions of interest in lacunar ischaemic stroke. There were essentially no data on cognition despite cognitive impairment being common and a main concern of patients with lacunar ischaemic stroke. Most data came from a lacunar subgroup of a larger trial, which may be limited by definition, chance, small sample and often only reporting one outcome in the subgroups. Very few trials focused on lacunar ischaemic stroke. Although many trials must have included patients with lacunar ischaemic stroke, many did not distinguish lacunar from other subtypes at all, or if they did, then often did not report any results for the lacunar subgroup, or only reported a few outcomes for the lacunar stroke patients separately. Lack of long-term follow-up in many secondary prevention trials mean that effects of interventions in lacunar stroke may not have become fully apparent, since recurrent stroke, dependency, or death typically occur late after lacunar ischaemic stroke, compared with other stroke subtypes. Finally, time constraints meant that we were not able to obtain stakeholder feedback on the guideline prior to publication, but we welcome feedback from people affected by lacunar ischaemic stroke and other forms of cSVD to help inform future guidelines, research and practice.\n\n【6】The Guideline is part of a series of Guidelines on the clinical management of cerebral small vessel disease: Part 1, covert cSVD, Part 2, lacunar ischaemic stroke, other Parts under consideration include 3, other stroke subtypes with a high cSVD burden, 4, cognitive, 5, mobility, and 6, mood presentations of cSVD. The Guideline Parts published so far will be updated within 5 years of publication or sooner if important new information becomes available.\n\n【7】Discussion\n\n【8】This guideline document was developed following the GRADE methodology and aims to assist physicians in decision-making regarding suspected lacunar ischaemic stroke. All recommendations and Expert Consensus Statements are summarised in Table 8.\n\n【9】We noted that a considerable proportion of articles were not found by the literature search and that a substantial number of additional articles were detected through other methods such as checking reference lists. This indicates that detection of relevant trials may be especially difficult for lacunar ischaemic stroke.", "content": "【0】页码:49\n_2024 ESO指南：脑小血管病—第2部分：腔隙性缺血性卒中\nblood oxygen saturation in the microvasculature at 180 min post-administration, indicating improved perfusion in the cerebral microvasculature.删除17:<u>244</u> A larger RCT 删除19:<u>(NCT05173896)</u> is now investigating if 3 months daily intake of tadalafil is feasible in lacunar stroke patients and if it alters cerebral perfusion, neurovascular reactivity, and cognition. Sildenafil is investigated in the OxHARP study, however, the primary outcome is cerebrovascular pulsatility and reactivity and the study will not have any relevant clinical outcome measures.删除17:<u>245</u>\n\n【1】The effect of minocycline, an antibiotic with anti-inflammatory properties, on microglial activation and blood-brain permeability in patients with lacunar stroke is investigated in the MINERVA trial.删除17:<u>246</u> However there will be no clinical outcomes.\n\n【2】删除图片描述:<u>![](48_0.png)</u>\n\n【3】We considered acute treatment and secondary prevention in lacunar ischaemic stroke. We tried to reflect diagnoses, timings and practical clinical aspects of the knowledge base that will inform the management of patients with suspected lacunar ischaemic stroke. Disappointingly, there is a dearth of data on cognitive and mood outcomes despite cognitive impairment being the commonest problem after lacunar stroke and a main concern to patients. Since most data were from subgroups of trials that included all stroke or all ischaemic stroke, the most commonly available outcomes were dependency (which is less common in lacunar stroke than in other ischaemic stroke subtypes) and recurrent stroke (which in general is less common early after lacunar stroke than with large artery or cardioembolic stroke).删除17:<u>4</u>\n\n【4】The strengths of this work include the use of the GRADE approach as mandated by ESO. The guideline builds on the Guideline for covert SVD published in 2021.1 We have endeavoured to amass all relevant data. While we hope we have not missed any major trials we acknowledge that it is difficult to search for trials in lacunar ischaemic stroke. We contacted authors for additional data, and wherever feasible we undertook several new meta-analyses, including a network meta-analysis on antiplatelet drugs in secondary prevention.\n\n【5】We also acknowledge limitations. Limitations of the data reflect the dearth of any data on many of the outcomes of interest and many interventions of interest in lacunar ischaemic stroke. There were essentially no data on cognition despite cognitive impairment being common and a main concern of patients with lacunar ischaemic stroke. Most data came from a lacunar subgroup of a larger trial, which may be limited by definition, chance, small sample and often only reporting one outcome in the subgroups. Very few trials focused on lacunar ischaemic stroke. Although many trials must have included patients with lacunar ischaemic stroke, many did not distinguish lacunar from other subtypes at all, or if they did, then often did not report any results for the lacunar subgroup, or only reported a few outcomes for the lacunar stroke patients separately. Lack of long-term follow-up in many secondary prevention trials mean that effects of interventions in lacunar stroke may not have become fully apparent, since recurrent stroke, dependency, or death typically occur late after lacunar ischaemic stroke, compared with other stroke subtypes. Finally, time constraints meant that we were not able to obtain stakeholder feedback on the guideline prior to publication, but we welcome feedback from people affected by lacunar ischaemic stroke and other forms of cSVD to help inform future guidelines, research and practice.\n\n【6】The Guideline is part of a series of Guidelines on the clinical management of cerebral small vessel disease: Part 1, covert cSVD, Part 2, lacunar ischaemic stroke, other Parts under consideration include 3, other stroke subtypes with a high cSVD burden, 4, cognitive, 5, mobility, and 6, mood presentations of cSVD. The Guideline Parts published so far will be updated within 5 years of publication or sooner if important new information becomes available.\n\n【7】Discussion\n\n【8】This guideline document was developed following the GRADE methodology and aims to assist physicians in decision-making regarding suspected lacunar ischaemic stroke. All recommendations and Expert Consensus Statements are summarised in Table 8.\n\n【9】We noted that a considerable proportion of articles were not found by the literature search and that a substantial number of additional articles were detected through other methods such as checking reference lists. This indicates that detection of relevant trials may be especially difficult for lacunar ischaemic stroke.", "index": 917, "show": true, "start": 917, "end": 4737, "province": ["语义有效性", "栏目混乱-中"], "isEdit": false}], "startTime": "2024/08/06 15:27:18", "endTime": "2024/08/06 15:28:32", "cost": 73.701}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:28:32", "grab_time": "2024-08-05 23:27:17"}
{"id": 2211625, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "d552f515-d98f-495c-9a15-4d9b978f7e82", "title": "2023 ECCO指南：性，生育，妊娠和哺乳", "text": "【0】页码:6\n2023 ECCO指南：性，生育，妊娠和哺乳\nc) Impact of surgery on fertility\n\n【1】There is evidence that fertility and fecundity rates may be reduced in female patients with IBD following open pouch surgery. However, the impact of surgical interventions other than ileal pouch-anal anastomosis 删除12:<u>[IPAA]</u> on fertility is unknown. There is an association between IBD-related surgery and miscarriage rates, C-section delivery, and use of assisted reproductive technologies.\n\n【2】Several meta-analyses and studies have shown that IPAA resulted in a 2- to 5-fold increase in infertility rate; this risk is even higher in the first year after surgery. Increasing age is also a risk factor associated with reduced fertility.\n\n【3】Laparoscopic IPAA seems to be associated with lower infertility rates compared with open surgeries, likely due to reduced pelvic adhesions. No difference was found in fertility rates between patients who had laparoscopic appendicectomy and laparoscopic IPAA. Laparoscopic colectomy and ileorectal anastomosis may be discussed in suitable patients, as this alternative procedure avoids pelvic dissection and reconstruction, thus averting pelvic adhesions seen in open pouch surgery.\n\n【4】After an IPAA procedure, reduction in fertility is more distinct in female patients when compared with male patients. There is a more pronounced reduction in fertility for patients with pouch failure, especially in female patients.\n\n【5】删除图片描述:<u>!删除9:<u>[]删除9:<u>(5_0.png)</u>\n删除图片描述:<u>![]</u>(5_1.png)</u></u>\n\n【6】d) In vitro fertilisation treatment in patients with IBD\n\n【7】Cohort studies reported that the incidence of pregnancy and live births after in vitro fertilisation 删除12:<u>[IVF]</u> in patients with UC and CD are comparable to controls. However, one nationwide study showed that the chance of a live birth following IVF treatment was lower in women with UC [OR: 0.删除13:<u>73, 95</u>% CI: 0.58–0.92] but not in women with CD [OR: 0.删除13:<u>77, 95</u>% CI: 0.52–1.14]. However in this study, prior surgery in women with CD led to reduced probability of a live birth for each embryo transfer [OR: 0.删除13:<u>51, 95</u>% CI: 0.29–0.91]. Corticosteroids prior to assisted reproductive technology in women with CD and UC did not increase the probability of a live birth.\n\n【8】Females with restorative proctocolectomy for UC have a 3-fold increased use of in vitro fertilisation 删除12:<u>[IVF]</u> than female IBD patients without restorative proctocolectomy. Nonetheless, the probability of having a live birth after IVF is comparable to that of the general IVF population and to those of patients with UC without IPAA.\n\n【9】Consistent with the general infertile population, younger age and lower BMI [22.5 kg/m² vs 24.0 kg/m²; p = 0.06] are associated with the likelihood of achieving a live birth following IVF in patients with IBD. Although disease activity is not associated with reduced probability of achieving a live birth following IVF, in most studies patients were mostly in remission.\n\n【10】4. Management of IBD During Pregnancy\n\n【11】Pregnancy is a highly emotional and vulnerable period, especially for those diagnosed with a chronic disease. To ensure a stable environment for patients, a dedicated multidisciplinary team of specialists with IBD knowledge should be involved in managing patients and should maintain a close relationship with the prospective parents. Ideally, pregnant patients, particularly those presenting features associated with poor disease course, should be discussed regularly in a multidisciplinary team including a gastroenterologist, obstetrician, paediatrician, psychologist, dietitian, and surgeon, depending on the trimester and the patient’s personal situation. Although many of the important aspects that may impact on pregnancy outcome, such as smoking cessation, vaccination, a healthy diet, and lifestyle are preferably already discussed in the pre-conception period, continuous education and reassurance remain of utmost importance to ensure patient adherence to the IBD management plan [Figure 1]. Another important aspect of managing IBD during pregnancy is stringent monitoring of disease activity to allow timely interventions and adjustments to IBD therapy if warranted. Pregnant women with IBD should be given special attention regarding nutritional requirements. Gaining weight during pregnancy is critical, as inadequate weight gain is associated with poor outcomes for the offspring. Although most IBD pregnancies have excellent outcomes, being pregnant with IBD can bring an extra layer of fear and anxiety. Attention should be given to the potential impact of the disease and interventions on the postpartum period has been described in publications. Special circumstances during pregnancy include carrying an ostomy and perianal fistulising disease. The pregnant IBD patient with an ostomy warrants specialised care as there may be a higher risk of preterm birth and LBW babies. Major stoma complications, such as stoma prolapse, parastomal hernias, and small bowel obstruction, may complicate pregnancy; regular monitoring and specialised counselling are warranted in these situations. Patients with perianal fistulising disease require timely consultation on the mode of delivery, to discuss the patient's preferences and the risk of sphincter injury balanced with the risk of C-section.\n\n【12】4.1. Impact of pregnancy on IBD course\n\n【13】Pregnancy coincides with hormonal, immunological, microbial, and immunomodulatory changes, all of which may interact with the pathophysiology of IBD. An ECCO-EpiCom observational study on 209 pregnant patients with IBD, compared with 209 non-pregnant IBD patients, showed that pregnant women with CD had a similar disease course both during pregnancy and after delivery as non-pregnant women with CD. In contrast, pregnant women with UC were at higher risk of relapse during pregnancy and in the postpartum period than non-pregnant women with UC. In a long-term observational study on 310 patients with a total of 597 pregnancies, disease course was worse in non-pregnant patients than in pregnant patients with IBD. This association was statistically significant in patients with UC only. The number of pregnancies did not affect long-term disease course in patients with UC or with CD.\n\n【14】In a retrospective study of patients with CD, pregnancy was independently associated with higher rates of surgical disease", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ECCO指南：性，生育，妊娠和哺乳.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【7】Cohort studies reported that the incidence of pregnancy and live births after in vitro fertilisation 删除12:[IVF] in patients with UC and CD are comparable to controls. However, one nationwide study showed that the chance of a live birth following IVF treatment was lower in women with UC [OR: 0.删除13:73, 95% CI: 0.58–0.92] but not in women with CD [OR: 0.删除13:77, 95% CI: 0.52–1.14]. However in this study, prior surgery in women with CD led to reduced probability of a live birth for each embryo transfer [OR: 0.删除13:51, 95% CI: 0.29–0.91]. Corticosteroids prior to assisted reproductive technology in women with CD and UC did not increase the probability of a live birth.", "content": "【0】页码:6\n2023 ECCO指南：性，生育，妊娠和哺乳\nc) Impact of surgery on fertility\n\n【1】There is evidence that fertility and fecundity rates may be reduced in female patients with IBD following open pouch surgery. However, the impact of surgical interventions other than ileal pouch-anal anastomosis 删除12:<u>[IPAA]</u> on fertility is unknown. There is an association between IBD-related surgery and miscarriage rates, C-section delivery, and use of assisted reproductive technologies.\n\n【2】Several meta-analyses and studies have shown that IPAA resulted in a 2- to 5-fold increase in infertility rate; this risk is even higher in the first year after surgery. Increasing age is also a risk factor associated with reduced fertility.\n\n【3】Laparoscopic IPAA seems to be associated with lower infertility rates compared with open surgeries, likely due to reduced pelvic adhesions. No difference was found in fertility rates between patients who had laparoscopic appendicectomy and laparoscopic IPAA. Laparoscopic colectomy and ileorectal anastomosis may be discussed in suitable patients, as this alternative procedure avoids pelvic dissection and reconstruction, thus averting pelvic adhesions seen in open pouch surgery.\n\n【4】After an IPAA procedure, reduction in fertility is more distinct in female patients when compared with male patients. There is a more pronounced reduction in fertility for patients with pouch failure, especially in female patients.\n\n【5】删除图片描述:<u>!删除9:<u>[]删除9:<u>(5_0.png)</u>\n删除图片描述:<u>![]</u>(5_1.png)</u></u>\n\n【6】d) In vitro fertilisation treatment in patients with IBD\n\n【7】Cohort studies reported that the incidence of pregnancy and live births after in vitro fertilisation 删除12:<u>[IVF]</u> in patients with UC and CD are comparable to controls. However, one nationwide study showed that the chance of a live birth following IVF treatment was lower in women with UC [OR: 0.删除13:<u>73, 95</u>% CI: 0.58–0.92] but not in women with CD [OR: 0.删除13:<u>77, 95</u>% CI: 0.52–1.14]. However in this study, prior surgery in women with CD led to reduced probability of a live birth for each embryo transfer [OR: 0.删除13:<u>51, 95</u>% CI: 0.29–0.91]. Corticosteroids prior to assisted reproductive technology in women with CD and UC did not increase the probability of a live birth.\n\n【8】Females with restorative proctocolectomy for UC have a 3-fold increased use of in vitro fertilisation 删除12:<u>[IVF]</u> than female IBD patients without restorative proctocolectomy. Nonetheless, the probability of having a live birth after IVF is comparable to that of the general IVF population and to those of patients with UC without IPAA.\n\n【9】Consistent with the general infertile population, younger age and lower BMI [22.5 kg/m² vs 24.0 kg/m²; p = 0.06] are associated with the likelihood of achieving a live birth following IVF in patients with IBD. Although disease activity is not associated with reduced probability of achieving a live birth following IVF, in most studies patients were mostly in remission.\n\n【10】4. Management of IBD During Pregnancy\n\n【11】Pregnancy is a highly emotional and vulnerable period, especially for those diagnosed with a chronic disease. To ensure a stable environment for patients, a dedicated multidisciplinary team of specialists with IBD knowledge should be involved in managing patients and should maintain a close relationship with the prospective parents. Ideally, pregnant patients, particularly those presenting features associated with poor disease course, should be discussed regularly in a multidisciplinary team including a gastroenterologist, obstetrician, paediatrician, psychologist, dietitian, and surgeon, depending on the trimester and the patient’s personal situation. Although many of the important aspects that may impact on pregnancy outcome, such as smoking cessation, vaccination, a healthy diet, and lifestyle are preferably already discussed in the pre-conception period, continuous education and reassurance remain of utmost importance to ensure patient adherence to the IBD management plan [Figure 1]. Another important aspect of managing IBD during pregnancy is stringent monitoring of disease activity to allow timely interventions and adjustments to IBD therapy if warranted. Pregnant women with IBD should be given special attention regarding nutritional requirements. Gaining weight during pregnancy is critical, as inadequate weight gain is associated with poor outcomes for the offspring. Although most IBD pregnancies have excellent outcomes, being pregnant with IBD can bring an extra layer of fear and anxiety. Attention should be given to the potential impact of the disease and interventions on the postpartum period has been described in publications. Special circumstances during pregnancy include carrying an ostomy and perianal fistulising disease. The pregnant IBD patient with an ostomy warrants specialised care as there may be a higher risk of preterm birth and LBW babies. Major stoma complications, such as stoma prolapse, parastomal hernias, and small bowel obstruction, may complicate pregnancy; regular monitoring and specialised counselling are warranted in these situations. Patients with perianal fistulising disease require timely consultation on the mode of delivery, to discuss the patient's preferences and the risk of sphincter injury balanced with the risk of C-section.\n\n【12】4.1. Impact of pregnancy on IBD course\n\n【13】Pregnancy coincides with hormonal, immunological, microbial, and immunomodulatory changes, all of which may interact with the pathophysiology of IBD. An ECCO-EpiCom observational study on 209 pregnant patients with IBD, compared with 209 non-pregnant IBD patients, showed that pregnant women with CD had a similar disease course both during pregnancy and after delivery as non-pregnant women with CD. In contrast, pregnant women with UC were at higher risk of relapse during pregnancy and in the postpartum period than non-pregnant women with UC. In a long-term observational study on 310 patients with a total of 597 pregnancies, disease course was worse in non-pregnant patients than in pregnant patients with IBD. This association was statistically significant in patients with UC only. The number of pregnancies did not affect long-term disease course in patients with UC or with CD.\n\n【14】In a retrospective study of patients with CD, pregnancy was independently associated with higher rates of surgical disease", "index": 1577, "show": true, "start": 1577, "end": 2252, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "删除13:73, 95% 删除13:77, 95%  删除13:51, 95% "}], "startTime": "2024/08/06 15:30:35", "endTime": "2024/08/06 15:32:21", "cost": 106.093}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:32:22", "grab_time": "2024-08-05 23:30:35"}
{"id": 2211624, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "7a856082-c621-4b68-8ca1-98d15c6e03e8", "title": "_（2023.V4）NCCN临床实践指南：食管和食管胃交界部癌", "text": "【0】页码:38\n_（2023.V4）NCCN临床实践指南：食管和食管胃交界部癌\n# PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING\n\n【1】## Microsatellite Instability (MSI) or Mismatch Repair (MMR) Testing\n\n【2】- Universal testing for MSI by polymerase chain reaction (PCR), NGS, or MMR by IHC should be performed for all newly diagnosed esophageal and EGJ cancers. The testing is performed on formalin-fixed paraffin-embedded (FFPE) tissue and results are interpreted as MSI-high (MSI-H) or mismatch repair-deficient (dMMR) in accordance with CAP DNA Mismatch Repair Biomarker Reporting Guidelines. Testing should be performed only in Clinical Laboratory Improvement Amendments (CLIA)-approved laboratories. Patients with MSI-H or dMMR tumors should be referred to a genetics counselor for further assessment in the appropriate clinical context.\n\n【3】### MMR Interpretation\n\n【4】- No loss of nuclear expression of MMR proteins: No evidence of dMMR (low probability of MSI-H)\n- Loss of nuclear expression of one or more MMR proteins: dMMR\n\n【5】### MSI Interpretation\n\n【6】- MSI-stable (MSS)\n- MSI-low (MSI-L)\n  - 1%–29% of the markers exhibit instability \n    删除32:<u>*</u> 1 of the 5 National Cancer Institute (NCI) or mononucleotide markers exhibits instability\n- MSI-H\n  - ≥30% of the markers exhibit instability\n    删除32:<u>*</u> 2 or more of the 5 NCI or mononucleotide markers exhibit instability\n\n【7】## PD-L1 Testing\n\n【8】- PD-L1 testing may be considered on locally advanced, recurrent, or metastatic esophageal and EGJ cancers in patients who are candidates for treatment with PD-1 inhibitors. A companion diagnostic test for use on FFPE tissue should be used in identifying patients for treatment with PD-1 inhibitors. PD-L1 testing should be performed only in CLIA-approved laboratories.\n- Assessment of PD-L1 Protein Expression in Esophageal and EGJ Cancers\n  - This is a qualitative immunohistochemical assay using anti–PD-L1 antibodies for the detection of PD-L1 protein in FFPE tissues from esophageal or EGJ cancers. A minimum of 100 tumor cells must be present in the PD-L1–stained slide for the specimen to be considered adequate for PD-L1 evaluation. A specimen is considered to have PD-L1 expression if the combined positive score (CPS) ≥1. CPS is the number of PD-L1 staining cells (ie, tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.", "tags": {}, "lang": "en", "attr": {"page_num": 38, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_（2023.V4）NCCN临床实践指南：食管和食管胃交界部癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:32:30", "endTime": "2024/08/06 15:33:06", "cost": 36.19}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:33:06", "grab_time": "2024-08-05 23:32:30"}
{"id": 2211623, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "5683362c-12e8-4e50-b96d-89c751968ef9", "title": "猴痘防控技术指南（2022年版）", "text": "【0】页码:4\n猴痘防控技术指南（2022年版）\n病毒经黏膜和破损皮肤侵入人体。主要通过接触感染动物的呼吸道分泌物、病变渗出物、血液、其它体液、或被感染动物咬伤、抓伤而感染。人与人之间主要通过密切接触传播，亦可在长时间近距离接触时通过飞沫传播，接触病毒污染的物品也有可能被染。病毒还可通过胎盘从孕妇传播给胎儿。\n\n【1】### 3. 入群易感性\n\n【2】既往接种过天花疫苗者对猴痘病毒存在一定程度的交叉保护力，因此，未接种过天花疫苗的人群对猴痘病毒普遍易感。\n\n【3】#### （二）临床表现\n\n【4】潜伏期 5-21 天，多为 6-13 天。\n\n【5】发病早期出现发热、寒战、头痛、咽痛、乏力、背部痛和肌痛等前驱症状。90% 患者出现明显的淋巴结肿大，故颈部、腋窝、腹股沟等。\n\n【6】发病后 1-3 天出现皮疹，首先出现在面部，逐渐蔓延至四肢，手心和脚掌均可出现皮疹。皮疹经历从斑疹、丘疹、泡疹、脓疱和结痂几个阶段，不同形态的皮疹可同时存在。泡疹初始液体多为球形，直径约 0.5-1 厘米，质地较硬，可伴明显疼痛和痒痛。泡疹数量从几个到数千不等，多呈离心性分布。可累及口腔黏膜、消化道、生殖器、结膜和角膜等。病程约 2-4 周。\n\n【7】结痂脱落后可遗留红斑或色素沉着，甚至瘢痕，瘢痕持续时间可长达数年。\n\n【8】部分患者可出现并发症，包括皮损部位继发细菌感染、呕吐", "tags": {}, "lang": "zh", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/猴痘防控技术指南（2022年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【3】#### （二）临床表现", "content": "【0】页码:4\n猴痘防控技术指南（2022年版）\n病毒经黏膜和破损皮肤侵入人体。主要通过接触感染动物的呼吸道分泌物、病变渗出物、血液、其它体液、或被感染动物咬伤、抓伤而感染。人与人之间主要通过密切接触传播，亦可在长时间近距离接触时通过飞沫传播，接触病毒污染的物品也有可能被染。病毒还可通过胎盘从孕妇传播给胎儿。\n\n【1】### 3. 入群易感性\n\n【2】既往接种过天花疫苗者对猴痘病毒存在一定程度的交叉保护力，因此，未接种过天花疫苗的人群对猴痘病毒普遍易感。\n\n【3】#### （二）临床表现\n\n【4】潜伏期 5-21 天，多为 6-13 天。\n\n【5】发病早期出现发热、寒战、头痛、咽痛、乏力、背部痛和肌痛等前驱症状。90% 患者出现明显的淋巴结肿大，故颈部、腋窝、腹股沟等。\n\n【6】发病后 1-3 天出现皮疹，首先出现在面部，逐渐蔓延至四肢，手心和脚掌均可出现皮疹。皮疹经历从斑疹、丘疹、泡疹、脓疱和结痂几个阶段，不同形态的皮疹可同时存在。泡疹初始液体多为球形，直径约 0.5-1 厘米，质地较硬，可伴明显疼痛和痒痛。泡疹数量从几个到数千不等，多呈离心性分布。可累及口腔黏膜、消化道、生殖器、结膜和角膜等。病程约 2-4 周。\n\n【7】结痂脱落后可遗留红斑或色素沉着，甚至瘢痕，瘢痕持续时间可长达数年。\n\n【8】部分患者可出现并发症，包括皮损部位继发细菌感染、呕吐", "index": 231, "show": true, "start": 231, "end": 246, "province": ["格式规范性", "序号格式不一致"], "isEdit": false}], "startTime": "2024/08/06 15:36:18", "endTime": "2024/08/06 15:36:46", "cost": 28.443}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:36:46", "grab_time": "2024-08-05 23:36:18"}
{"id": 2211622, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "8d29c275-5e69-43a7-b60a-db4237cac7e0", "title": "慢性气道疾病患者口腔健康管理及诊疗风险防范专家共识（2022版）", "text": "【0】页码:7\n慢性气道疾病患者口腔健康管理及诊疗风险防范专家共识（2022版）\n(本页删除)本页被模型判断为参考页疑似页眉<u>删除12:<u>删除14:<u>[35]</u></u>  Entriken C, Pritts TA. Perioperative pulmonary support of the elderly删除12:<u>[J]</u>. Curr Geriatr Rep, 删除13:<u>2021, 10</u>: 1-10. DOI: 10.1007/s13670-021-00369-3.</u>\n\n【1】删除14:<u>[36] </u> 马俊, 廖良明, 等. 徐州医科大学附属医院普通外科加速康复外科多学科协作专家共识删除12:<u>[J]</u>. 中华医学杂志, 删除13:<u>2020, 13</u>删除11:<u>(12)</u>: 969-975. DOI: 10.3969/j.issn.2095-9958.2020.12.01.\n\n【2】删除14:<u>[37] </u> 张岩峰, 刘艳, 王世伟, 等. 中国胸外科围术期肺保护专家共识删除19:<u>(2020 版)</u>删除12:<u>[J]</u>. 中华胸心血管外科杂志, 删除13:<u>2021, 28</u>删除11:<u>(3)</u>: 251-262. DOI: 10.7507/1007-4848.20201209.\n\n【3】删除14:<u>[38] </u> 中国医师协会外科医师分会加速康复外科专家委员会, 中国胸外科加速康复外科专家共识删除19:<u>(2020 年版)</u>删除12:<u>[J]</u>. 中国内镜杂志, 删除13:<u>2020, 43</u>删除11:<u>(12)</u>: 1025-1048. DOI: 10.3760/cma.j.cn112147-20200618-00721.\n\n【4】删除14:<u>[39] </u> Carranza F. Carranza’s clinical periodontology: twelfth edition. Chapter 37. Periodontal treatment of medically compromised patients删除12:<u>[M]</u>. St. Louis: Elsevier Saunders, 2020.\n\n【5】参考删除-3:<u>删除12:<u>删除14:<u>[40]</u></u>  Kouanda B, Sattar Z, Geraghty P. Periodontal diseases: major exacerbators of pulmonary diseases?删除12:<u>[J]</u>. Med. Mol. 删除13:<u>2021, 2021</u>: 4712406. DOI: 10.1155/2021/4712406.</u>\n\n【6】删除14:<u>[41] </u> 王石飞, 黄熠, 李青, 等. 徐州医科大学附属医院普通外科专家共识删除19:<u>(2019 版)</u>删除12:<u>[J]</u>. 中华普通外科杂志, 删除13:<u>2019, 26</u>删除11:<u>(9)</u>: 7-14. DOI: 10.3760/cma.j. issn.0529-删除13:<u>5815. 2009</u>.18.001.\n\n【7】参考删除-3:<u>删除12:<u>删除14:<u>[42]</u></u>  Wang TY, Li DQ, Cui Y, et al. Chinese expert consensus for perioperative pulmonary protection in thoracic surgery 删除19:<u>(2019 edition)</u>删除12:<u>[J]</u>. Chin J Thorac Cardiovasc Surg, 删除13:<u>2019, 26</u>删除11:<u>(9)</u>: 7-14. DOI: 10.3760/cma.j. issn.0529-删除13:<u>5815. 2009</u>.18.001.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 7, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/慢性气道疾病患者口腔健康管理及诊疗风险防范专家共识（2022版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:10:20", "endTime": "2024/08/06 17:10:27", "cost": 6.866}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 01:10:27", "grab_time": "2024-08-06 01:10:20"}
{"id": 2211621, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "2cab9a10-fed8-438d-8f7b-8b41fadf69a9", "title": "2024+ESES共识建议：晚期肾上腺恶性疾病的手术治疗(1)", "text": "【0】页码:23\n2024+ESES共识建议：晚期肾上腺恶性疾病的手术治疗(1)\n(本页删除)本页被模型判断为参考页Positive impact of genetic testing on the management and outcome of patients with metastatic pheochromocytoma. J Clin Endocrinol Metab 2019;104:1109–1118\nWang H, Papathristou AJ, Gill AJ, Clifton-Bligh RJ, Aniss AL, Glover A et al. Genotype–phenotype correlations and clinical outcomes in 155 cases of pheochromocytoma and paraganglioma. World J Surg 2023;47:690–698\nJimenez C, Ma J, Roman Gonzalez A, Varghese J, Zhang M, Perrier N et al. TNM staging and overall survival in patients with pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 2022;107:1239–1246\nCascon A, Calsina B, Monteagudo M, Mellid S, Diaz-Talavera A, Curras-Freixes M et al. Genetic bases of pheochromocytoma and paraganglioma. J Mol Endocrinol 2023;70:e220167\nAndrews KA, Ascher DB, Pires DEV, Barnes DR, Vialard L, Casey RT et al. Tumor risks and genotype–phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD. J Med Genet 2018;55:384–394\nNorton C, LaDuca H, Deckman A, Durda K, Jackson M, Richardson ME et al. Universal germline panel testing for individuals with pheochromocytoma and paraganglioma produces high diagnostic yield. J Clin Endocrinol Metab 2022; 107:e1917–e1923", "tags": {}, "lang": "en", "attr": {"page_num": 23, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024+ESES共识建议：晚期肾上腺恶性疾病的手术治疗(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:46:39", "endTime": "2024/08/06 15:46:52", "cost": 12.873}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:46:52", "grab_time": "2024-08-05 23:46:38"}
{"id": 2211620, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "27166ff8-8d98-4d64-8585-755d92ac535d", "title": "_2024 ESMO临床实践指南：胃癌患者的 诊断、治疗和随访——泛亚洲人群适用", "text": "【0】页码:2\n_2024 ESMO临床实践指南：胃癌患者的 诊断、治疗和随访——泛亚洲人群适用\n# INTRODUCTION\n\n【1】With over a million estimated new cases globally in 2020, gastric cancer (GC) is the sixth most common cancer (5.6% of all new cases) and the third highest cause of cancer death (7.7% of all cancer deaths). Both the incidence of and deaths from GC were almost twice as high for men as for women, and East Asia accounts for over half of all GC cases worldwide.\n\n【2】Based on the site/location of the tumor, GC is classified as either proximal GC (including the cardia and oesophagogastric junction (OGJ)) or distal GC (of the antrum/pylorus), which have different aetiologies. Proximal GC is associated with oesophageal reflux and obesity and is more common in Western countries; Epstein-Barr virus-positive GC is more common in the upper part and body of the stomach and has a similar prevalence in Asia to elsewhere. Distal GC is principally associated with chronic Helicobacter pylori infection. Globally, the incidence of distal gastric adenocarcinoma is twice that of proximal gastric adenocarcinoma, although this ratio does vary between and within countries. Also, an increase in the incidence of proximal OGJ cancers has been reported in Japan.\n\n【3】As for GC as a whole, the highest rates for both subtypes are seen in Eastern/Southeastern Asia. Helicobacter pylori infection, dietary and lifestyle factors as well as genetics are all thought to play a role in GC development. Helicobacter pylori infection is a major factor in distal GC development. In China, a case-cohort study showed that 78.5% of distal and 62.1% of proximal GC cases could be attributed to H. pylori infection. Also, a meta-analysis revealed that the prevalence of H. pylori in incident cases in China was 66.5% (ranging from 53.1% in Northern China to 78.9% in Northwest China), based on the pooled data from 55 studies. Meanwhile, in Malaysia, ~70% of GC cases were shown to be distal GC, except for one small study, which showed proximal GC to be the prevalent subtype, seen in 14/23 (61%) patients, from a region of northeastern Malaysia reported to have one of the lowest rates of H. pylori infection in the world and an exceptionally low incidence of GC. A systematic review and meta-analysis also found an association between proximal GC and H. pylori infection for East Asia with a population attributable fraction of 60.7%. The role played by H. pylori infection is further highlighted by a Taiwanese study where a population-based eradication of H. pylori resulted in a reduction in the incidence of GC by 53% between 2004 and 2016. Also, a meta-analysis of data from six randomised trials, five of which were conducted in Asian populations, of healthy and asymptomatic individuals who tested positive for H. pylori, found that H. pylori eradication therapy reduced the risk of developing GC by a third. For regions with a high incidence of GC, a recent global consensus meeting in Taipei agreed that a screen-and-treat strategy for H. pylori infection in young adults should be recommended.\n\n【4】The most recent European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with GC were published in 2022 with the ESMO Gastric Cancer Living Guideline, v1.1 published in July 2023 . Therefore, a decision was taken by ESMO and the Japanese Society of Medical Oncology (JSMO) that these latest ESMO guidelines should be adapted to provide updated Pan-Asian guidelines for the management of patients with GC. This Pan-Asian adaptation was endorsed and ratified at the respective ESMO and JSMO meetings and incorporates the recent major clinical research advances highlighted. This manuscript summarises the Pan-Asian adapted guidelines developed and agreed at a face-to-face working meeting that took place in Tokyo on 26 August 2023, hosted by JSMO. Each recommendation is accompanied by the level of evidence, grade of recommendation  and the percentage consensus reached, together with the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) scores as appropriate.\n\n【5】# METHODOLOGY\n\n【6】This Pan-Asian adaptation of the current ESMO Clinical Practice Guidelines and associated updates was prepared in accordance with the principles of ESMO standard operating procedures  and was a JSMO-ESMO initiative endorsed by the Chinese Society of Clinical Oncology (CSCO), the Indonesian Society of Hematology and Medical Oncology (ISHMO), the Indian Society of Medical and Paediatric Oncology (ISMPO), the Korean Society of Medical Oncology (KSMO), the Malaysian Oncological Society (MOS), the Philippine Society of Medical Oncology (PSMO), the Singapore Society of Oncology (SSO), the Taiwan Oncology Society (TOS) and the Thai Society of Clinical Oncology (TSCO). An international panel of experts was selected from the JSMO (n = 7), the ESMO (n = 5) and two experts from each of the nine other oncological societies. Only two of the seven expert members from the JSMO (HK and YN) were allowed to vote on the", "tags": {}, "lang": "en", "attr": {"page_num": 2, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_2024 ESMO临床实践指南：胃癌患者的 诊断、治疗和随访——泛亚洲人群适用.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:05:36", "endTime": "2024/08/06 16:05:51", "cost": 14.766}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:05:51", "grab_time": "2024-08-06 00:05:36"}
{"id": 2211619, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "31700603-8ae2-41ed-b69a-aff2204880a1", "title": "癌症以及颅内和垂体瘤生存者生长激素替代安全性的共识声明（2022）", "text": "【0】页码:10\n癌症以及颅内和垂体瘤生存者生长激素替代安全性的共识声明（2022）\n### Should GH replacement (dosing, serum IGF-I target, monitoring, and transition) be different in patients surviving cancer?\n\n【1】删除32:<u>**</u>Key statement:删除32:<u>**</u> GH replacement dosing and monitoring in cancer survivors follow general recommendations, but a higher degree of vigilance is required to avoid over-dosage.\n\n【2】There are no data to support management strategies in cancer survivors that differ from those available for other populations of patients with GHD 删除11:<u>(7)</u>. In children, monitoring height velocity is central, and an acceptable growth response can be achieved in most children with a low starting dose of GH followed by slow dose up-titration 删除11:<u>(3, 7)</u>. Serum IGF-I is an important safety marker during GH replacement in children and adult cancer survivors and should be measured after making a dose adjustment, approximately every 3 months during dose titration and at least annually thereafter. Targeting a serum IGF-I level within the normal range whilst optimizing growth is recommended. Headache may be a symptom of GH overdosing in children, and in adults, pedal oedema and arthralgias may be experienced when excessive GH doses are administered 删除11:<u>(2)</u>. The growth response to a given GH dose may be reduced in children exposed to spinal radiation and in children receiving pharmacological glucocorticoid therapy 删除11:<u>(12)</u>.\n\n【3】The management of GH replacement in childhood cancer survivors during the transition period does not differ from that of other childhood-onset GHD patients 删除11:<u>(2)</u>. The dose is often reduced in the transition period, although a higher GH dose is typically needed with the onset of oral oestrogen treatment to maintain the serum IGF-I level 删除11:<u>(3)</u>.\n\n【4】In adults, serum IGF-I is also an important safety biomarker and should be maintained within the normal range 删除11:<u>(7)</u>. No single efficacy marker is available for adult GH replacement, and health-related quality of life might be challenged in cancer survivors for many reasons other than GHD.\n\n【5】Childhood and young adult cancer survivors and their medical team should be aware of the risk of subsequent CNS neoplasms in patients who have undergone cranial irradiation. There is no evidence that GH increases this risk, and therefore, decisions with regard to timing of MRI scans should follow standard practice and recent guidelines 删除11:<u>(104)</u>.\n\n【6】### How long should providers wait between completion of therapy for cancer or intracranial tumour and the initiation of GH therapy?\n\n【7】删除32:<u>**</u>Key statement:删除32:<u>**</u> The timing of initiation of GH therapy following completion of cancer therapy or treatment of an intracranial tumour depends on many factors and should be individualized as a joint decision between treating physicians, patient, and caregivers. This period may be as early as 3 months in children with radiologically proven stable craniopharyngiomas who have significant growth failure and metabolic disturbances and up to at least 5 years and risk of tumour recurrence in survivors of breast cancer.\n\n【8】There are no data to guide when to initiate GH replacement after the completion of primary tumour therapy and whether this timing affects disease recurrence.\n\n【9】The timing of initiation of GH replacement should be individualized and carefully reviewed with the patient, family, and oncologist or neurosurgeon. The clinical status of the patient, the type of tumour (malignant vs non-malignant (pituitary adenoma/craniopharyngioma)), and treatment modality are important factors in this decision 删除11:<u>(7)</u>. In children, initiation of GH should be considered when declining height velocity is detected and GHD is biochemically confirmed 删除11:<u>(2)</u>.\n\n【10】In children with craniopharyngioma and radiologically stable disease, testing for GHD and commencement of GH therapy as early as 3 months post treatment is reasonable for improving growth and body composition in some children. For other types of tumours, it is advisable to wait at least 1 year following the end of tumour treatment and only when radiologically confirmed stability is achieved, considering that tumour relapse is highest during the first 12 months after cancer treatment 删除11:<u>(7)</u>.\n\n【11】For adults with craniopharyngioma and pituitary adenomas, a waiting period of 12 months was discussed in order to secure adequate evaluation of GHD treatment and diagnosis, but consensus was not reached on this and some.", "tags": {}, "lang": "en", "attr": {"page_num": 10, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/癌症以及颅内和垂体瘤生存者生长激素替代安全性的共识声明（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Should GH replacement (dosing, serum IGF-I target, monitoring, and transition) be different in patients surviving cancer?", "content": "【0】页码:10\n癌症以及颅内和垂体瘤生存者生长激素替代安全性的共识声明（2022）\n### Should GH replacement (dosing, serum IGF-I target, monitoring, and transition) be different in patients surviving cancer?\n\n【1】删除32:<u>**</u>Key statement:删除32:<u>**</u> GH replacement dosing and monitoring in cancer survivors follow general recommendations, but a higher degree of vigilance is required to avoid over-dosage.\n\n【2】There are no data to support management strategies in cancer survivors that differ from those available for other populations of patients with GHD 删除11:<u>(7)</u>. In children, monitoring height velocity is central, and an acceptable growth response can be achieved in most children with a low starting dose of GH followed by slow dose up-titration 删除11:<u>(3, 7)</u>. Serum IGF-I is an important safety marker during GH replacement in children and adult cancer survivors and should be measured after making a dose adjustment, approximately every 3 months during dose titration and at least annually thereafter. Targeting a serum IGF-I level within the normal range whilst optimizing growth is recommended. Headache may be a symptom of GH overdosing in children, and in adults, pedal oedema and arthralgias may be experienced when excessive GH doses are administered 删除11:<u>(2)</u>. The growth response to a given GH dose may be reduced in children exposed to spinal radiation and in children receiving pharmacological glucocorticoid therapy 删除11:<u>(12)</u>.\n\n【3】The management of GH replacement in childhood cancer survivors during the transition period does not differ from that of other childhood-onset GHD patients 删除11:<u>(2)</u>. The dose is often reduced in the transition period, although a higher GH dose is typically needed with the onset of oral oestrogen treatment to maintain the serum IGF-I level 删除11:<u>(3)</u>.\n\n【4】In adults, serum IGF-I is also an important safety biomarker and should be maintained within the normal range 删除11:<u>(7)</u>. No single efficacy marker is available for adult GH replacement, and health-related quality of life might be challenged in cancer survivors for many reasons other than GHD.\n\n【5】Childhood and young adult cancer survivors and their medical team should be aware of the risk of subsequent CNS neoplasms in patients who have undergone cranial irradiation. There is no evidence that GH increases this risk, and therefore, decisions with regard to timing of MRI scans should follow standard practice and recent guidelines 删除11:<u>(104)</u>.\n\n【6】### How long should providers wait between completion of therapy for cancer or intracranial tumour and the initiation of GH therapy?\n\n【7】删除32:<u>**</u>Key statement:删除32:<u>**</u> The timing of initiation of GH therapy following completion of cancer therapy or treatment of an intracranial tumour depends on many factors and should be individualized as a joint decision between treating physicians, patient, and caregivers. This period may be as early as 3 months in children with radiologically proven stable craniopharyngiomas who have significant growth failure and metabolic disturbances and up to at least 5 years and risk of tumour recurrence in survivors of breast cancer.\n\n【8】There are no data to guide when to initiate GH replacement after the completion of primary tumour therapy and whether this timing affects disease recurrence.\n\n【9】The timing of initiation of GH replacement should be individualized and carefully reviewed with the patient, family, and oncologist or neurosurgeon. The clinical status of the patient, the type of tumour (malignant vs non-malignant (pituitary adenoma/craniopharyngioma)), and treatment modality are important factors in this decision 删除11:<u>(7)</u>. In children, initiation of GH should be considered when declining height velocity is detected and GHD is biochemically confirmed 删除11:<u>(2)</u>.\n\n【10】In children with craniopharyngioma and radiologically stable disease, testing for GHD and commencement of GH therapy as early as 3 months post treatment is reasonable for improving growth and body composition in some children. For other types of tumours, it is advisable to wait at least 1 year following the end of tumour treatment and only when radiologically confirmed stability is achieved, considering that tumour relapse is highest during the first 12 months after cancer treatment 删除11:<u>(7)</u>.\n\n【11】For adults with craniopharyngioma and pituitary adenomas, a waiting period of 12 months was discussed in order to secure adequate evaluation of GHD treatment and diagnosis, but consensus was not reached on this and some.", "index": 47, "show": true, "start": 47, "end": 168, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "前面缺少正文"}], "startTime": "2024/08/06 15:28:06", "endTime": "2024/08/06 15:28:47", "cost": 40.884}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:28:47", "grab_time": "2024-08-05 23:28:06"}
{"id": 2211618, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "3496326a-3cf5-4a77-8f24-bdc21bb6b3f1", "title": "2023 NICE 临床指南：心血管疾病的风险评估和降低，包括调脂[CG181]", "text": "【0】页码:19\n2023 NICE 临床指南：心血管疾病的风险评估和降低，包括调脂[CG181]\n- statins should be stopped 3 months before attempting to conceive\n- statins should not be restarted until breastfeeding is finished. 删除24:<u>[2014, amended 2023]</u>\n\n【1】For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on advice and monitoring for adverse effects].\n\n【2】Full details of the evidence and the committee's discussion are in [evidence review C: statins: efficacy and adverse effects].\n\n【3】### Intolerance of statins\n\n#### 1.4.46|删除段内换行|If a person is not able to tolerate a high-intensity statin aim to treat with the maximum tolerated dose. 删除12:<u>删除14:<u>删除24:<u>[2014]</u></u></u>\n\n#### 1.4.47|删除段内换行|Tell the person that any statin at any dose reduces CVD risk. If someone reports adverse effects when taking a high-intensity statin discuss the following possible strategies with them:\n- stopping the statin and trying again when the symptoms have resolved to check if the symptoms are related to the statin\n- changing to a different statin in the same intensity group (rosuvastatin if already receiving atorvastatin)\n- reducing the dose within the same intensity group\n- changing the statin to a lower intensity group. 删除24:<u>[2014, amended 2023]</u>\n\n#### 1.4.48|删除段内换行|Seek specialist advice about options for treating people at high risk of CVD such as those with CKD, type 1 diabetes, type 2 diabetes or genetic dyslipidaemias, and those with CVD who are intolerant to 3 different statins. Seek advice by telephone, virtual clinic or referral. 删除12:<u>删除14:<u>删除24:<u>[2014]</u></u></u>", "tags": {}, "lang": "en", "attr": {"page_num": 19, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 NICE 临床指南：心血管疾病的风险评估和降低，包括调脂[CG181].pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:02:04", "endTime": "2024/08/06 17:02:31", "cost": 26.391}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 01:02:31", "grab_time": "2024-08-06 01:02:04"}
{"id": 2211617, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "89263402-43f1-4e47-b5f7-5977add30250", "title": "2023 NICE 介入手术指南：经皮三叉神经经刺激治疗ADHD [IPG748]", "text": "【0】页码:5\n2023 NICE 介入手术指南：经皮三叉神经经刺激治疗ADHD [IPG748]\n# Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (IPG748)\n\n【1】## Accreditation\n\n【2】删除图片描述:<u>![](4_0.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 NICE 介入手术指南：经皮三叉神经经刺激治疗ADHD [IPG748].pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (IPG748)\n【1】## Accreditation", "content": "【0】页码:5\n2023 NICE 介入手术指南：经皮三叉神经经刺激治疗ADHD [IPG748]\n# Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (IPG748)\n\n【1】## Accreditation\n\n【2】删除图片描述:<u>![](4_0.png)</u>", "index": 52, "show": true, "start": 52, "end": 151, "province": ["信息质量", "有用性-轻"], "isEdit": false}], "startTime": "2024/08/06 15:30:20", "endTime": "2024/08/06 15:30:40", "cost": 19.976}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:30:41", "grab_time": "2024-08-05 23:30:20"}
{"id": 2211616, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "06ca46ce-49c5-4104-93a1-e53f2102d6cd", "title": "2023 APAGE／APSDE临床实践指南：非侵入性生物标志物在结直肠肿瘤诊断中的应用", "text": "【0】页码:6\n2023 APAGE／APSDE临床实践指南：非侵入性生物标志物在结直肠肿瘤诊断中的应用\n疑似页眉<u>### General Recommendations on Use of Non-invasive Biomarkers</u>\n\n【1】删除32:<u>**</u>Statement 3.删除32:<u>**</u> Non-invasive CRC screening programmes can only be successful if participants with positive tests understand the importance of, and are willing to undergo, timely high quality diagnostic colonoscopy, and those with negative tests undergo follow-up screening at appropriate intervals.\n\n【2】- (Level of agreement: A=93.3%, B=6.7%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【3】删除32:<u>**</u>Statement 4.删除32:<u>**</u> The quality of screening programmes requires establishment of objective metrics, continuous monitoring of programme compliance and responsiveness to investigate and alter operations to achieve the highest adherence for better patient outcomes.\n\n【4】- (Level of agreement: A=93.3%, B=6.7%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【5】删除32:<u>**</u>Statement 5.删除32:<u>**</u> Key performance indicators of non-invasive biomarker tests include participant adherence, punctual reporting of test results, prompt scheduling and completion of follow-up colonoscopy in participants with a positive test, and fastidious systems to ensure compliance to appropriate intervals for future CRC screening.\n\n【6】- (Level of agreement: A=73.3%, B=20.0%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【7】删除32:<u>**</u>Statement 6.删除32:<u>**</u> Non-invasive CRC screening programmes should assess the appropriateness of participant selection for non-invasive testing.\n\n【8】- (Level of agreement: A=73.3%, B=20.0%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【9】删除32:<u>**</u>Statement 7.删除32:<u>**</u> Once the screening test is completed, it is important that participants receive the test results in a timely fashion. We suggest that CRC screening result in 100% of participants within 2 weeks of the test result.\n\n【10】- (Level of agreement: A=60.0%, B=33.3%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【11】删除32:<u>**</u>Statement 8.删除32:<u>**</u> Participants with negative results should be informed of the appropriate recall interval for future screening and how recall will be made. All participants with a positive result should receive a colonoscopy.\n\n【12】- (Level of agreement: A=86.7%, B=13.3%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【13】删除32:<u>**</u>Statement 9.删除32:<u>**</u> At least 80% of these patients should be offered a date for colonoscopy within 3 months and 100% within 6 months. A critical requirement for optimal patient outcomes is completion of colonoscopy.\n\n【14】- (Level of agreement: A=73.3%, B=20.0%, C=13.3%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【15】It is important for non-invasive CRC screening programmes to assess the suitability of patient selection for non-invasive tests. Individuals at high risk of CRC should preferably be screened with colonoscopy whereas those of low or average risk can be considered for non-invasive tests. A high quality screening programme should document and report efforts to obtain and record an accurate, three generation family cancer history with attention to explore the risk of CRC and advanced adenomas, including age at diagnosis, body mass index and smoking history, etc, which are known to impact CRC risk. Evidence suggests that adherence rate to CRC screening was generally more important than which strategy was used, and several measures of adherence are required. If targets are not achieved, the underlying causes, including potential system/programme issues or factors relating to patient non-compliance, should be determined. It has been demonstrated that limiting the recommendation for CRC screening to colonoscopy can result in a lower completion rate for CRC screening compared with providing a choice between non-invasive tests or colonoscopy, especially among ethnic/racial minorities. Significant differences in adherence to competing CRC screening tests between racial/ethnic groups has also been reported.\n\n【16】A non-invasive CRC screening test is not complete until a follow-up colonoscopy is performed after a positive test. Hence a critical requirement for optimal patient outcomes is completion of colonoscopy. A study using data from a national screening programme in Taiwan examined the CRC death rates among the more than 59 300 participants with a positive FIT. A 1.64-fold (95% CI 1.32 to 2.04) increased risk for CRC death was found in participants who did not receive colonoscopy compared with participants who received colonoscopy, after adjustment for differences in baseline characteristics. Another study using the Taiwanese screening programme database compared the risks of any CRC and advanced stage CRC among FIT positive participants with different timing of follow-up colonoscopies. Compared with colonoscopy within 1–3 months, risks were significantly higher when colonoscopy was delayed by more than 6 months for any CRC (adjusted OR (aOR) 1.删除13:<u>31, 95</u>% CI 1.04 to 1.64) and advanced stage disease (aOR 2.09, 95% CI 1.43 to 3.06). The risks continuously increased when colonoscopy was delayed by more than 12 months for any CRC (aOR 2.删除13:<u>17, 95</u>% CI 1.44 to 3.26) and advanced stage disease (aOR 2.删除13:<u>84, 95</u>% CI 1.43 to 5.64). There were no significant differences for colonoscopy follow-up at 3–6 months for risk of any CRC or advanced stage disease.\n\n【17】There are many reasons patients fail to undergo a colonoscopy for follow-up. These include health issues of higher priority that may not permit a colonoscopy to be safely performed, patients who refuse the colonoscopy follow-up, anxiety or fear of the procedure and lack of awareness of the importance. A survey conducted in an Asian population based on the Health Belief Model evaluated the factors associated with willingness to", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 APAGE／APSDE临床实践指南：非侵入性生物标志物在结直肠肿瘤诊断中的应用.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "疑似页眉### General Recommendations on Use of Non-invasive Biomarkers", "content": "【0】页码:6\n2023 APAGE／APSDE临床实践指南：非侵入性生物标志物在结直肠肿瘤诊断中的应用\n疑似页眉<u>### General Recommendations on Use of Non-invasive Biomarkers</u>\n\n【1】删除32:<u>**</u>Statement 3.删除32:<u>**</u> Non-invasive CRC screening programmes can only be successful if participants with positive tests understand the importance of, and are willing to undergo, timely high quality diagnostic colonoscopy, and those with negative tests undergo follow-up screening at appropriate intervals.\n\n【2】- (Level of agreement: A=93.3%, B=6.7%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【3】删除32:<u>**</u>Statement 4.删除32:<u>**</u> The quality of screening programmes requires establishment of objective metrics, continuous monitoring of programme compliance and responsiveness to investigate and alter operations to achieve the highest adherence for better patient outcomes.\n\n【4】- (Level of agreement: A=93.3%, B=6.7%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【5】删除32:<u>**</u>Statement 5.删除32:<u>**</u> Key performance indicators of non-invasive biomarker tests include participant adherence, punctual reporting of test results, prompt scheduling and completion of follow-up colonoscopy in participants with a positive test, and fastidious systems to ensure compliance to appropriate intervals for future CRC screening.\n\n【6】- (Level of agreement: A=73.3%, B=20.0%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【7】删除32:<u>**</u>Statement 6.删除32:<u>**</u> Non-invasive CRC screening programmes should assess the appropriateness of participant selection for non-invasive testing.\n\n【8】- (Level of agreement: A=73.3%, B=20.0%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【9】删除32:<u>**</u>Statement 7.删除32:<u>**</u> Once the screening test is completed, it is important that participants receive the test results in a timely fashion. We suggest that CRC screening result in 100% of participants within 2 weeks of the test result.\n\n【10】- (Level of agreement: A=60.0%, B=33.3%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【11】删除32:<u>**</u>Statement 8.删除32:<u>**</u> Participants with negative results should be informed of the appropriate recall interval for future screening and how recall will be made. All participants with a positive result should receive a colonoscopy.\n\n【12】- (Level of agreement: A=86.7%, B=13.3%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【13】删除32:<u>**</u>Statement 9.删除32:<u>**</u> At least 80% of these patients should be offered a date for colonoscopy within 3 months and 100% within 6 months. A critical requirement for optimal patient outcomes is completion of colonoscopy.\n\n【14】- (Level of agreement: A=73.3%, B=20.0%, C=13.3%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【15】It is important for non-invasive CRC screening programmes to assess the suitability of patient selection for non-invasive tests. Individuals at high risk of CRC should preferably be screened with colonoscopy whereas those of low or average risk can be considered for non-invasive tests. A high quality screening programme should document and report efforts to obtain and record an accurate, three generation family cancer history with attention to explore the risk of CRC and advanced adenomas, including age at diagnosis, body mass index and smoking history, etc, which are known to impact CRC risk. Evidence suggests that adherence rate to CRC screening was generally more important than which strategy was used, and several measures of adherence are required. If targets are not achieved, the underlying causes, including potential system/programme issues or factors relating to patient non-compliance, should be determined. It has been demonstrated that limiting the recommendation for CRC screening to colonoscopy can result in a lower completion rate for CRC screening compared with providing a choice between non-invasive tests or colonoscopy, especially among ethnic/racial minorities. Significant differences in adherence to competing CRC screening tests between racial/ethnic groups has also been reported.\n\n【16】A non-invasive CRC screening test is not complete until a follow-up colonoscopy is performed after a positive test. Hence a critical requirement for optimal patient outcomes is completion of colonoscopy. A study using data from a national screening programme in Taiwan examined the CRC death rates among the more than 59 300 participants with a positive FIT. A 1.64-fold (95% CI 1.32 to 2.04) increased risk for CRC death was found in participants who did not receive colonoscopy compared with participants who received colonoscopy, after adjustment for differences in baseline characteristics. Another study using the Taiwanese screening programme database compared the risks of any CRC and advanced stage CRC among FIT positive participants with different timing of follow-up colonoscopies. Compared with colonoscopy within 1–3 months, risks were significantly higher when colonoscopy was delayed by more than 6 months for any CRC (adjusted OR (aOR) 1.删除13:<u>31, 95</u>% CI 1.04 to 1.64) and advanced stage disease (aOR 2.09, 95% CI 1.43 to 3.06). The risks continuously increased when colonoscopy was delayed by more than 12 months for any CRC (aOR 2.删除13:<u>17, 95</u>% CI 1.44 to 3.26) and advanced stage disease (aOR 2.删除13:<u>84, 95</u>% CI 1.43 to 5.64). There were no significant differences for colonoscopy follow-up at 3–6 months for risk of any CRC or advanced stage disease.\n\n【17】There are many reasons patients fail to undergo a colonoscopy for follow-up. These include health issues of higher priority that may not permit a colonoscopy to be safely performed, patients who refuse the colonoscopy follow-up, anxiety or fear of the procedure and lack of awareness of the importance. A survey conducted in an Asian population based on the Health Belief Model evaluated the factors associated with willingness to", "index": 53, "show": true, "start": 53, "end": 118, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "页眉判断错误"}, {"text": "【15】It is important for non-invasive CRC screening programmes to assess the suitability of patient selection for non-invasive tests. Individuals at high risk of CRC should preferably be screened with colonoscopy whereas those of low or average risk can be considered for non-invasive tests. A high quality screening programme should document and report efforts to obtain and record an accurate, three generation family cancer history with attention to explore the risk of CRC and advanced adenomas, including age at diagnosis, body mass index and smoking history, etc, which are known to impact CRC risk. Evidence suggests that adherence rate to CRC screening was generally more important than which strategy was used, and several measures of adherence are required. If targets are not achieved, the underlying causes, including potential system/programme issues or factors relating to patient non-compliance, should be determined. It has been demonstrated that limiting the recommendation for CRC screening to colonoscopy can result in a lower completion rate for CRC screening compared with providing a choice between non-invasive tests or colonoscopy, especially among ethnic/racial minorities. Significant differences in adherence to competing CRC screening tests between racial/ethnic groups has also been reported.\n\n【16】A non-invasive CRC screening test is not complete until a follow-up colonoscopy is performed after a positive test. Hence a critical requirement for optimal patient outcomes is completion of colonoscopy. A study using data from a national screening programme in Taiwan examined the CRC death rates among the more than 59 300 participants with a positive FIT. A 1.64-fold (95% CI 1.32 to 2.04) increased risk for CRC death was found in participants who did not receive colonoscopy compared with participants who received colonoscopy, after adjustment for differences in baseline characteristics. Another study using the Taiwanese screening programme database compared the risks of any CRC and advanced stage CRC among FIT positive participants with different timing of follow-up colonoscopies. Compared with colonoscopy within 1–3 months, risks were significantly higher when colonoscopy was delayed by more than 6 months for any CRC (adjusted OR (aOR) 1.删除13:31, 95% CI 1.04 to 1.64) and advanced stage disease (aOR 2.09, 95% CI 1.43 to 3.06). The risks continuously increased when colonoscopy was delayed by more than 12 months for any CRC (aOR 2.删除13:17, 95% CI 1.44 to 3.26) and advanced stage disease (aOR 2.删除13:84, 95% CI 1.43 to 5.64). There were no significant differences for colonoscopy follow-up at 3–6 months for risk of any CRC or advanced stage disease.", "content": "【0】页码:6\n2023 APAGE／APSDE临床实践指南：非侵入性生物标志物在结直肠肿瘤诊断中的应用\n<mark>疑似页眉### General Recommendations on Use of Non-invasive Biomarkers</mark>ers</u>\n\n【1】删除32:<u>**</u>Statement 3.删除32:<u>**</u> Non-invasive CRC screening programmes can only be successful if participants with positive tests understand the importance of, and are willing to undergo, timely high quality diagnostic colonoscopy, and those with negative tests undergo follow-up screening at appropriate intervals.\n\n【2】- (Level of agreement: A=93.3%, B=6.7%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【3】删除32:<u>**</u>Statement 4.删除32:<u>**</u> The quality of screening programmes requires establishment of objective metrics, continuous monitoring of programme compliance and responsiveness to investigate and alter operations to achieve the highest adherence for better patient outcomes.\n\n【4】- (Level of agreement: A=93.3%, B=6.7%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【5】删除32:<u>**</u>Statement 5.删除32:<u>**</u> Key performance indicators of non-invasive biomarker tests include participant adherence, punctual reporting of test results, prompt scheduling and completion of follow-up colonoscopy in participants with a positive test, and fastidious systems to ensure compliance to appropriate intervals for future CRC screening.\n\n【6】- (Level of agreement: A=73.3%, B=20.0%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【7】删除32:<u>**</u>Statement 6.删除32:<u>**</u> Non-invasive CRC screening programmes should assess the appropriateness of participant selection for non-invasive testing.\n\n【8】- (Level of agreement: A=73.3%, B=20.0%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【9】删除32:<u>**</u>Statement 7.删除32:<u>**</u> Once the screening test is completed, it is important that participants receive the test results in a timely fashion. We suggest that CRC screening result in 100% of participants within 2 weeks of the test result.\n\n【10】- (Level of agreement: A=60.0%, B=33.3%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【11】删除32:<u>**</u>Statement 8.删除32:<u>**</u> Participants with negative results should be informed of the appropriate recall interval for future screening and how recall will be made. All participants with a positive result should receive a colonoscopy.\n\n【12】- (Level of agreement: A=86.7%, B=13.3%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【13】删除32:<u>**</u>Statement 9.删除32:<u>**</u> At least 80% of these patients should be offered a date for colonoscopy within 3 months and 100% within 6 months. A critical requirement for optimal patient outcomes is completion of colonoscopy.\n\n【14】- (Level of agreement: A=73.3%, B=20.0%, C=13.3%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【15】It is important for non-invasive CRC screening programmes to assess the suitability of patient selection for non-invasive tests. Individuals at high risk of CRC should preferably be screened with colonoscopy whereas those of low or average risk can be considered for non-invasive tests. A high quality screening programme should document and report efforts to obtain and record an accurate, three generation family cancer history with attention to explore the risk of CRC and advanced adenomas, including age at diagnosis, body mass index and smoking history, etc, which are known to impact CRC risk. Evidence suggests that adherence rate to CRC screening was generally more important than which strategy was used, and several measures of adherence are required. If targets are not achieved, the underlying causes, including potential system/programme issues or factors relating to patient non-compliance, should be determined. It has been demonstrated that limiting the recommendation for CRC screening to colonoscopy can result in a lower completion rate for CRC screening compared with providing a choice between non-invasive tests or colonoscopy, especially among ethnic/racial minorities. Significant differences in adherence to competing CRC screening tests between racial/ethnic groups has also been reported.\n\n【16】A non-invasive CRC screening test is not complete until a follow-up colonoscopy is performed after a positive test. Hence a critical requirement for optimal patient outcomes is completion of colonoscopy. A study using data from a national screening programme in Taiwan examined the CRC death rates among the more than 59 300 participants with a positive FIT. A 1.64-fold (95% CI 1.32 to 2.04) increased risk for CRC death was found in participants who did not receive colonoscopy compared with participants who received colonoscopy, after adjustment for differences in baseline characteristics. Another study using the Taiwanese screening programme database compared the risks of any CRC and advanced stage CRC among FIT positive participants with different timing of follow-up colonoscopies. Compared with colonoscopy within 1–3 months, risks were significantly higher when colonoscopy was delayed by more than 6 months for any CRC (adjusted OR (aOR) 1.删除13:<u>31, 95</u>% CI 1.04 to 1.64) and advanced stage disease (aOR 2.09, 95% CI 1.43 to 3.06). The risks continuously increased when colonoscopy was delayed by more than 12 months for any CRC (aOR 2.删除13:<u>17, 95</u>% CI 1.44 to 3.26) and advanced stage disease (aOR 2.删除13:<u>84, 95</u>% CI 1.43 to 5.64). There were no significant differences for colonoscopy follow-up at 3–6 months for risk of any CRC or advanced stage disease.\n\n【17】There are many reasons patients fail to undergo a colonoscopy for follow-up. These include health issues of higher priority that may not permit a colonoscopy to be safely performed, patients who refuse the colonoscopy follow-up, anxiety or fear of the procedure and lack of awareness of the importance. A survey conducted in an Asian population based on the Health Belief Model evaluated the factors associated with willingness to", "index": 2970, "show": true, "start": 2957, "end": 5650, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "【16】 删除13:31, 95%   .删除13:17, 95%   删除13:84, 95% "}, {"text": "【1】删除32:Statement 3.删除32: Non-invasive CRC screening programmes can only be successful if participants with positive tests understand the importance of, and are willing to undergo, timely high quality diagnostic colonoscopy, and those with negative tests undergo follow-up screening at appropriate intervals.", "content": "【0】页码:6\n2023 APAGE／APSDE临床实践指南：非侵入性生物标志物在结直肠肿瘤诊断中的应用\n<mark>疑似页眉### General Recommendations on Use of Non-invasive Biomarkers</mark>ers</u>\n\n【1】删除32:<u>**</u>Statement 3.删除32:<u>**</u> Non-invasive CRC screening programmes can only be successful if participants with positive tests understand the importance of, and are willing to undergo, timely high quality diagnostic colonoscopy, and those with negative tests undergo follow-up screening at appropriate intervals.\n\n【2】- (Level of agreement: A=93.3%, B=6.7%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【3】删除32:<u>**</u>Statement 4.删除32:<u>**</u> The quality of screening programmes requires establishment of objective metrics, continuous monitoring of programme compliance and responsiveness to investigate and alter operations to achieve the highest adherence for better patient outcomes.\n\n【4】- (Level of agreement: A=93.3%, B=6.7%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【5】删除32:<u>**</u>Statement 5.删除32:<u>**</u> Key performance indicators of non-invasive biomarker tests include participant adherence, punctual reporting of test results, prompt scheduling and completion of follow-up colonoscopy in participants with a positive test, and fastidious systems to ensure compliance to appropriate intervals for future CRC screening.\n\n【6】- (Level of agreement: A=73.3%, B=20.0%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【7】删除32:<u>**</u>Statement 6.删除32:<u>**</u> Non-invasive CRC screening programmes should assess the appropriateness of participant selection for non-invasive testing.\n\n【8】- (Level of agreement: A=73.3%, B=20.0%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【9】删除32:<u>**</u>Statement 7.删除32:<u>**</u> Once the screening test is completed, it is important that participants receive the test results in a timely fashion. We suggest that CRC screening result in 100% of participants within 2 weeks of the test result.\n\n【10】- (Level of agreement: A=60.0%, B=33.3%, C=6.7%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【11】删除32:<u>**</u>Statement 8.删除32:<u>**</u> Participants with negative results should be informed of the appropriate recall interval for future screening and how recall will be made. All participants with a positive result should receive a colonoscopy.\n\n【12】- (Level of agreement: A=86.7%, B=13.3%, C=0%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n【13】删除32:<u>**</u>Statement 9.删除32:<u>**</u> At least 80% of these patients should be offered a date for colonoscopy within 3 months and 100% within 6 months. A critical requirement for optimal patient outcomes is completion of colonoscopy.\n\n【14】- (Level of agreement: A=73.3%, B=20.0%, C=13.3%, D=0%, E=0%.)\n- (Quality of evidence: III; classification of recommendation: C.)\n\n<mark>【15】It is important for non-invasive CRC screening programmes to assess the suitability of patient selection for non-invasive tests. Individuals at high risk of CRC should preferably be screened with colonoscopy whereas those of low or average risk can be considered for non-invasive tests. A high quality screening programme should document and report efforts to obtain and record an accurate, three generation family cancer history with attention to explore the risk of CRC and advanced adenomas, including age at diagnosis, body mass index and smoking history, etc, which are known to impact CRC risk. Evidence suggests that adherence rate to CRC screening was generally more important than which strategy was used, and several measures of adherence are required. If targets are not achieved, the underlying causes, including potential system/programme issues or factors relating to patient non-compliance, should be determined. It has been demonstrated that limiting the recommendation for CRC screening to colonoscopy can result in a lower completion rate for CRC screening compared with providing a choice between non-invasive tests or colonoscopy, especially among ethnic/racial minorities. Significant differences in adherence to competing CRC screening tests between racial/ethnic groups has also been reported.\n\n【16】A non-invasive CRC screening test is not complete until a follow-up colonoscopy is performed after a positive test. Hence a critical requirement for optimal patient outcomes is completion of colonoscopy. A study using data from a national screening programme in Taiwan examined the CRC death rates among the more than 59 300 participants with a positive FIT. A 1.64-fold (95% CI 1.32 to 2.04) increased risk for CRC death was found in participants who did not receive colonoscopy compared with participants who received colonoscopy, after adjustment for differences in baseline characteristics. Another study using the Taiwanese screening programme database compared the risks of any CRC and advanced stage CRC among FIT positive participants with different timing of follow-up colonoscopies. Compared with colonoscopy within 1–3 months, risks were significantly higher when colonoscopy was delayed by more than 6 months for any CRC (adjusted OR (aOR) 1.删除13:31, 95% CI 1.04 to 1.64) and advanced stage disease (aOR 2.09, 95% CI 1.43 to 3.06). The risks continuously increased when colonoscopy was delayed by more than 12 months for any CRC (aOR 2.删除13:17, 95% CI 1.44 to 3.26) and advanced stage disease (aOR 2.删除13:84, 95% CI 1.43 to 5.64). There were no significant differences for colonoscopy follow-up at 3–6 months for risk of any CRC or advanced stage disease.</mark>vanced stage disease.\n\n【17】There are many reasons patients fail to undergo a colonoscopy for follow-up. These include health issues of higher priority that may not permit a colonoscopy to be safely performed, patients who refuse the colonoscopy follow-up, anxiety or fear of the procedure and lack of awareness of the importance. A survey conducted in an Asian population based on the Health Belief Model evaluated the factors associated with willingness to", "index": 140, "show": true, "start": 127, "end": 435, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/07 09:55:07", "endTime": "2024/08/07 09:57:27", "cost": 140.616}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 17:57:26", "grab_time": "2024-08-06 17:55:05"}
{"id": 2211615, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "a3fbf06b-3496-4075-a609-4c8c31c640a5", "title": "_（2023.V3）NCCN 临床实践指南：胃癌", "text": "【0】页码:67\n_（2023.V3）NCCN 临床实践指南：胃癌\n疑似页眉<u># NCCN Guidelines Version 3.2023\n## Gastric Cancer</u>\n\n【1】### PRINCIPLES OF SURVEILLANCE\n\n【2】- Surveillance strategies after curative intent resection (R0) for gastric cancer remain controversial, with sparse prospective data to construct evidence-based algorithms that balance benefits and risks (including cost) within this cohort.\n- The guidance provided on 删除12:<u>[GAST-7]</u> for stage-specific surveillance is based on the currently available retrospectively analyzed literature删除29:<u>¹</u>-删除29:<u>¹⁰</u> and expert consensus.\n- While the majority of gastric cancer relapses occur within 2 years (70%-80%) and almost all recurrences by 5 years (~90%) after completion of local therapy, it is important to note that occasionally potentially actionable relapses have been recognized more than 5 years after curative intent therapy. Therefore, after 5 years additional follow-up may be considered based on risk factors and comorbidities.\n- Differences in follow-up for early-stage gastric cancer reflect a heterogeneous potential for relapse and overall survival.删除29:<u>¹</u>-删除29:<u>¹⁰</u> Whereas R0-resected Tis disease has a prognosis that approximates a non-cancer cohort, T1aN0 and T1b disease do not have such a favorable prognosis. Thus, recommendations vary according to the depth of invasion and treatment modality.\n\n【3】删除32:<u>**</u>Note: All recommendations are category 2A unless otherwise indicated.删除32:<u>**</u>\n\n【4】删除32:<u>**</u>Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.删除32:<u>**</u>", "tags": {}, "lang": "en", "attr": {"page_num": 67, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_（2023.V3）NCCN 临床实践指南：胃癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【3】删除32:Note: All recommendations are category 2A unless otherwise indicated.删除32:\n\n【4】删除32:Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.删除32:", "content": "【0】页码:67\n_（2023.V3）NCCN 临床实践指南：胃癌\n疑似页眉<u># NCCN Guidelines Version 3.2023\n## Gastric Cancer</u>\n\n【1】### PRINCIPLES OF SURVEILLANCE\n\n【2】- Surveillance strategies after curative intent resection (R0) for gastric cancer remain controversial, with sparse prospective data to construct evidence-based algorithms that balance benefits and risks (including cost) within this cohort.\n- The guidance provided on 删除12:<u>[GAST-7]</u> for stage-specific surveillance is based on the currently available retrospectively analyzed literature删除29:<u>¹</u>-删除29:<u>¹⁰</u> and expert consensus.\n- While the majority of gastric cancer relapses occur within 2 years (70%-80%) and almost all recurrences by 5 years (~90%) after completion of local therapy, it is important to note that occasionally potentially actionable relapses have been recognized more than 5 years after curative intent therapy. Therefore, after 5 years additional follow-up may be considered based on risk factors and comorbidities.\n- Differences in follow-up for early-stage gastric cancer reflect a heterogeneous potential for relapse and overall survival.删除29:<u>¹</u>-删除29:<u>¹⁰</u> Whereas R0-resected Tis disease has a prognosis that approximates a non-cancer cohort, T1aN0 and T1b disease do not have such a favorable prognosis. Thus, recommendations vary according to the depth of invasion and treatment modality.\n\n【3】删除32:<u>**</u>Note: All recommendations are category 2A unless otherwise indicated.删除32:<u>**</u>\n\n【4】删除32:<u>**</u>Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.删除32:<u>**</u>", "index": 1376, "show": true, "start": 1376, "end": 1638, "province": ["信息质量", "有用性-轻"], "isEdit": false}], "startTime": "2024/08/06 16:28:22", "endTime": "2024/08/06 16:28:44", "cost": 22.09}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:28:44", "grab_time": "2024-08-06 00:28:21"}
{"id": 2211614, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "f12826c0-a74c-4d20-bc02-73f80ccc5264", "title": "2023 WHO 指南：疟疾", "text": "【0】页码:406\n2023 WHO 指南：疟疾\n### 5.2.1.1.2. Dosing of ACTs\n\n【1】### 5.2.1.2. Recurrent falciparum malaria\n\n【2】### 5.2.1.3. Reducing the transmissibility of treated P. falciparum infections in areas of low-intensity transmission\n\n【3】#### Clinical Question/ PICO\n\n【4】删除32:<u>**</u>Population:删除32:<u>**</u> People with symptomatic malaria in malaria-endemic areas  \n删除32:<u>**</u>Intervention:删除32:<u>**</u> Short-course primaquine plus malaria treatment including an artemisinin derivative  \n删除32:<u>**</u>Comparator:删除32:<u>**</u> Malaria treatment with an artemisinin derivative alone\n\n| Outcome Timeframe                       | Study results and measurements                                                                                         | Comparator ACT | Intervention ACT + primaquine            | Certainty of the Evidence (Quality of evidence)                                                                                    | Plain language summary                                                                                                                                                                         |\n|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------|---------------------------------------|--------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Malaria incidence, prevalence or entomological inoculation rate | Relative risk<br>Based on data from 0 participants in 0 studies.                                                         |                | CI 95%                               |                                                                                                              |                                                                                                                                                                                               |\n| People infectious to mosquitoes         | Relative risk<br>Based on data from 0 participants in 0 studies.                                                         |                | CI 95%                               | Limited observational data from mosquito feeding studies suggests that 0.25 mg/kg bw may rapidly reduce the infectivity of gametocytes to mosquitoes.                                           |\n| Participants with gametocytes on microscopy or PCR (day 8) (dose < 0.4 mg/kg bw) 删除29:<u>¹</u> | Relative risk 0.67 (CI 95% 0.44 – 1.02)<br>Based on data from 223 participants in 1 studies. (Randomized controlled)       | 34 per 1000    | 23 per 1000<br>Difference:<br>11 fewer per 1000<br>(CI 95% 19 fewer – 1 more) | Low<br>Due to very serious imprecision ²                                                                                                                |                                                                                                                                                                                               |\n| Participants with gametocytes on microscopy or PCR (day 8) (dose 0.4–0.6)          | Relative risk 0.3 (CI 95% 0.16 – 0.56)<br>Based on data from 249 participants in 1 studies. (Randomized controlled)        | 35 per 1000    | 11 per 1000<br>Difference:<br>24 fewer per 1000<br>(CI 95% 29)         | Low<br>Due to serious imprecision and serious indirectness 删除29:<u>⁴</u>                                                                                                    |                                                                                                                                                                                               |", "tags": {}, "lang": "en", "attr": {"page_num": 406, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 WHO 指南：疟疾.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "\nOutcome Timeframe\tStudy results and measurements\tComparator ACT\tIntervention ACT + primaquine\tCertainty of the Evidence (Quality of evidence)\tPlain language summary\nMalaria incidence, prevalence or entomological inoculation rate\tRelative risk\nBased on data from 0 participants in 0 studies.\t\tCI 95%\t\t\nPeople infectious to mosquitoes\tRelative risk\nBased on data from 0 participants in 0 studies.\t\tCI 95%\tLimited observational data from mosquito feeding studies suggests that 0.25 mg/kg bw may rapidly reduce the infectivity of gametocytes to mosquitoes.\t\nParticipants with gametocytes on microscopy or PCR (day 8) (dose < 0.4 mg/kg bw) 删除29:¹\tRelative risk 0.67 (CI 95% 0.44 – 1.02)\nBased on data from 223 participants in 1 studies. (Randomized controlled)\t34 per 1000\t23 per 1000\nDifference:\n11 fewer per 1000\n(CI 95% 19 fewer – 1 more)\tLow\nDue to very serious imprecision ²\t\nParticipants with gametocytes on microscopy or PCR (day 8) (dose 0.4–0.6)\tRelative risk 0.3 (CI 95% 0.16 – 0.56)\nBased on data from 249 participants in 1 studies. (Randomized controlled)\t35 per 1000\t11 per 1000\nDifference:\n24 fewer per 1000\n(CI 95% 29)\tLow\nDue to serious imprecision and serious indirectness 删除29:⁴\t", "content": "【0】页码:406\n2023 WHO 指南：疟疾\n### 5.2.1.1.2. Dosing of ACTs\n\n【1】### 5.2.1.2. Recurrent falciparum malaria\n\n【2】### 5.2.1.3. Reducing the transmissibility of treated P. falciparum infections in areas of low-intensity transmission\n\n【3】#### Clinical Question/ PICO\n\n【4】删除32:<u>**</u>Population:删除32:<u>**</u> People with symptomatic malaria in malaria-endemic areas  \n删除32:<u>**</u>Intervention:删除32:<u>**</u> Short-course primaquine plus malaria treatment including an artemisinin derivative  \n删除32:<u>**</u>Comparator:删除32:<u>**</u> Malaria treatment with an artemisinin derivative alone\n\n| Outcome Timeframe                       | Study results and measurements                                                                                         | Comparator ACT | Intervention ACT + primaquine            | Certainty of the Evidence (Quality of evidence)                                                                                    | Plain language summary                                                                                                                                                                         |\n|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------|---------------------------------------|--------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Malaria incidence, prevalence or entomological inoculation rate | Relative risk<br>Based on data from 0 participants in 0 studies.                                                         |                | CI 95%                               |                                                                                                              |                                                                                                                                                                                               |\n| People infectious to mosquitoes         | Relative risk<br>Based on data from 0 participants in 0 studies.                                                         |                | CI 95%                               | Limited observational data from mosquito feeding studies suggests that 0.25 mg/kg bw may rapidly reduce the infectivity of gametocytes to mosquitoes.                                           |\n| Participants with gametocytes on microscopy or PCR (day 8) (dose < 0.4 mg/kg bw) 删除29:<u>¹</u> | Relative risk 0.67 (CI 95% 0.44 – 1.02)<br>Based on data from 223 participants in 1 studies. (Randomized controlled)       | 34 per 1000    | 23 per 1000<br>Difference:<br>11 fewer per 1000<br>(CI 95% 19 fewer – 1 more) | Low<br>Due to very serious imprecision ²                                                                                                                |                                                                                                                                                                                               |\n| Participants with gametocytes on microscopy or PCR (day 8) (dose 0.4–0.6)          | Relative risk 0.3 (CI 95% 0.16 – 0.56)<br>Based on data from 249 participants in 1 studies. (Randomized controlled)        | 35 per 1000    | 11 per 1000<br>Difference:<br>24 fewer per 1000<br>(CI 95% 29)         | Low<br>Due to serious imprecision and serious indirectness 删除29:<u>⁴</u>                                                                                                    |                                                                                                                                                                                               |", "index": 11, "show": true, "start": 11, "end": 1204, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "【4】"}], "startTime": "2024/08/07 09:46:22", "endTime": "2024/08/07 09:47:08", "cost": 45.491}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 17:47:07", "grab_time": "2024-08-06 17:46:21"}
{"id": 2211613, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "37e90152-60d9-47bd-b4a0-12f15afca1d1", "title": "2024+AAD指南：寻常痤疮的护理管理", "text": "【0】页码:26\n2024+AAD指南：寻常痤疮的护理管理\n(本页删除)本页被模型判断为参考页154. Dunlap FE, Mills OH, Tuley MR, Baker MD, Plott RT. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in both tolerance and patient preference. Br J Dermatol. 1998;139(Suppl 52):17-删除13:<u>22.\n155</u>. Kakita L. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol. 2000;43:S51-S删除13:<u>54.\n156</u>. Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67:4-9.\n157. Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998;139(Suppl 52): 34-删除13:<u>40.\n158</u>. Pedace FJ, Stoughton R. Topical retinoic acid in acne vulgaris. Br J Dermatol. 1971;84:465-删除13:<u>469.\n159</u>. Christiansen JV, Gadborg E, Ludvigsen K, et al. Topical tretinoin, vitamin A acid (Airol) in acne vulgaris. A controlled clinical trial. Dermatol. 1974;148:82-删除13:<u>89.\n160</u>. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol. 1997;36:S126-S删除13:<u>134.\n161</u>. Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. Practitioner. 1976;216:106-删除13:<u>109.\n162</u>. Cunliffe WJ, Dodman B, Ead R. Benzoyl peroxide in acne. Practitioner. 1978;220:479-删除13:<u>482.\n163</u>. Fulton JE Jr, Farzad-Bakshandeh A, Bradley S. Studies on the mechanism of action to topical benzoyl peroxide and vitamin A acid in acne vulgaris. J Cutan Pathol. 1974;1:191-删除13:<u>200.\n164</u>. Fryand O, Jakobsen HB. Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris. Dermatol. 1986;172:263-删除13:<u>267.\n165</u>. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25:664-删除13:<u>667.\n166</u>. Mills O Jr, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol. 2002;82:260-删除13:<u>265.\n167</u>. Dubina MI, Fleischer AB Jr. Interaction of topical sulfacetamide and topical adapalene with benzoyl peroxide. Arch Dermatol. 2009;145:1027-删除13:<u>1029.\n168</u>. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol. 1986;122:583-删除13:<u>584.\n169</u>. Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010;86: 103-删除13:<u>108.\n172</u>. Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17alpha-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18:1412-删除13:<u>418.\n173</u>. Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol. 2011;10:586-删除13:<u>590.\n174</u>. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. J Am Acad Dermatol. 2014;70:401.e1-401.e14; quiz 删除13:<u>15.\n175</u>. Ly S, Kamat K, Mangal N, Barbieri JS, Mostaghimi A. Treatment of acne vulgaris during pregnancy and lactation: a narrative review. Dermatol Ther. 2023;13:115-删除13:<u>130.\n176</u>. Perret LJ, Tait CP. Non-antibiotic properties of tetracyclines and their clinical application in dermatology. Australas J Dermatol. 2014;55:111-删除13:<u>118.\n177</u>. Barbieri JS, Bhate K, Hartnett KP, Fleming-Dutra KE, Margolis DJ. Trends in oral antibiotic prescription in dermatology, 2008 to 2016. JAMA Dermatol. 2019;155: 290-删除13:<u>297.\n178</u>. Centers for Disease Control and Prevention. Outpatient Antibiotic Prescriptions — United States, 2022. Updated November 删除13:<u>15, 2022</u>. Accessed January 删除13:<u>18, 2024</u>删除1:<u>. https://www.cdc.gov/antibiotic-use/data/report-2022.html.</u>\n179. Margolis DJ, Fanelli M, Kupperman E, et al. Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study. J Am Acad Dermatol. 2012;148:326-删除13:<u>332.\n180</u>. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531-删除13:<u>534.\n181</u>. Carroll KC, Bartlett JG. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol. 2011;65:501-删除13:<u>521.\n182</u>. Sanchez GV, Fleming-Dutra KE, Roberts RM, et al. Core elements of outpatient antibiotic stewardship. MMWR Recomm Rep. 2016;65删除11:<u>(6)</u>:1-删除13:<u>12.\n183</u>. Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol. 2016;30: 1261-删除13:<u>1268.\n184</u>. Oon HH, Wong SN, Aw DCW, Cheong WK, Goh CL, Tan HH. Acne management guidelines by the Dermatological Society of Singapore. J Clin Aesthet Dermatol. 2019;13:34-删除13:<u>50.\n185</u>. Gold LS, Cruz A, Eichenfield L, et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%/benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis. 2010;85:94-删除13:<u>104.\n186</u>. Leyden JJ, Thiboutot DM, Shalita AR, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol. 2006;142:605-删除13:<u>612.\n187</u>. Tan J, Stein Gold L, Schlessinger J, et al. Short-term combination therapy and long-term relapse prevention in the treatment of severe acne vulgaris. J Drugs Dermatol. 2012;11:174-删除13:<u>180.\n188</u>. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol. 2006;142:597-删除13:<u>602.\n189</u>. Moon SH, Roh HS, Kim IH, Kim JE, Ko JY, Ro YS. Antibiotic resistance of microbial strains isolated from Korean acne patients. J Dermatol. 2012;39:833-删除13:<u>837.\n190</u>. Toossi P, Farshchian M, Malekzad F, Mohtasham N, Kimyai Asadi A. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol. 2008;7:1149-删除13:<u>1152.\n191</u>. Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomized controlled trial. Lancet. 2004;364:2188-删除13:<u>2195.\n192</u>. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;6:CD004425.", "tags": {}, "lang": "en", "attr": {"page_num": 26, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024+AAD指南：寻常痤疮的护理管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:12:21", "endTime": "2024/08/06 16:12:30", "cost": 8.44}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:12:30", "grab_time": "2024-08-06 00:12:14"}
{"id": 2211612, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "40ba5c66-f439-4441-8662-94de6261b99b", "title": "中西医结合围手术期胃肠动力管理中国专家共识（2022）", "text": "【0】页码:4\n中西医结合围手术期胃肠动力管理中国专家共识（2022）\n寒法为其治疗根本大法，通过内服中药汤剂、中药保留灌肠配合，外用中药塌渍、针灸及穴位按摩等内治外治综合法其肠道功能亢进。\n\n【1】推推荐药:根芽手术中医院常规口服中药“健恢”为主，胃泌健肠解，行气和通脾络，适合脾气不足或无热者;证“贵实”，适合湿热证下法相对。根据病机服用药物及联合用药方法有中药—配方整体管理。\n\n【2】### 2.3.2 中药内服 中药汤剂内服主要目中西医结合治疗术后肠功能恢复其主要方法一项共查久21项研究，中305百里系统评价37例显示，大承气汤和综合治疗一致及显子常略比较。这显示结果简节图术后恢复推护各种墙疗和中药对作用。研究显示关注和协同不胃肠功能用推病而组织治疗。\n\n【3】#### 推荐:1.金腹健“里实热”证点者以承气汤汤药剂治疗控制;梳理不发虚而进用配合气和胃肠觉力。\n\n【4】#### 证据等级:中;推荐强度:强\n\n【5】### 2.3.3 中药外治\n\n【6】中药灌肠、中药散或贴及穴位按摩等是其术后胃肠功能恢效主要中医外治法。研究系统评价显示，针刺品大容量使术后常道有园同推积肠胶术明显下移提成胃肠功能。\n\n【7】#### 推荐:12.选居适的外治方法，可改善胃肠功能递进，促进术后早期恢复。\n\n【8】##### 证据等级:中;推荐强度:强", "tags": {}, "lang": "zh", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/中西医结合围手术期胃肠动力管理中国专家共识（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】推推荐药:根芽手术中医院常规口服中药“健恢”为主，胃泌健肠解，行气和通脾络，适合脾气不足或无热者;证“贵实”，适合湿热证下法相对。根据病机服用药物及联合用药方法有中药—配方整体管理。", "content": "【0】页码:4\n中西医结合围手术期胃肠动力管理中国专家共识（2022）\n寒法为其治疗根本大法，通过内服中药汤剂、中药保留灌肠配合，外用中药塌渍、针灸及穴位按摩等内治外治综合法其肠道功能亢进。\n\n【1】推推荐药:根芽手术中医院常规口服中药“健恢”为主，胃泌健肠解，行气和通脾络，适合脾气不足或无热者;证“贵实”，适合湿热证下法相对。根据病机服用药物及联合用药方法有中药—配方整体管理。\n\n【2】### 2.3.2 中药内服 中药汤剂内服主要目中西医结合治疗术后肠功能恢复其主要方法一项共查久21项研究，中305百里系统评价37例显示，大承气汤和综合治疗一致及显子常略比较。这显示结果简节图术后恢复推护各种墙疗和中药对作用。研究显示关注和协同不胃肠功能用推病而组织治疗。\n\n【3】#### 推荐:1.金腹健“里实热”证点者以承气汤汤药剂治疗控制;梳理不发虚而进用配合气和胃肠觉力。\n\n【4】#### 证据等级:中;推荐强度:强\n\n【5】### 2.3.3 中药外治\n\n【6】中药灌肠、中药散或贴及穴位按摩等是其术后胃肠功能恢效主要中医外治法。研究系统评价显示，针刺品大容量使术后常道有园同推积肠胶术明显下移提成胃肠功能。\n\n【7】#### 推荐:12.选居适的外治方法，可改善胃肠功能递进，促进术后早期恢复。\n\n【8】##### 证据等级:中;推荐强度:强", "index": 97, "show": true, "start": 97, "end": 191, "province": ["信息质量", "完整性"], "isEdit": false}, {"text": "【6】中药灌肠、中药散或贴及穴位按摩等是其术后胃肠功能恢效主要中医外治法。研究系统评价显示，针刺品大容量使术后常道有园同推积肠胶术明显下移提成胃肠功能。", "content": "【0】页码:4\n中西医结合围手术期胃肠动力管理中国专家共识（2022）\n寒法为其治疗根本大法，通过内服中药汤剂、中药保留灌肠配合，外用中药塌渍、针灸及穴位按摩等内治外治综合法其肠道功能亢进。\n\n<mark>【1】推推荐药:根芽手术中医院常规口服中药“健恢”为主，胃泌健肠解，行气和通脾络，适合脾气不足或无热者;证“贵实”，适合湿热证下法相对。根据病机服用药物及联合用药方法有中药—配方整体管理。</mark>\n\n【2】### 2.3.2 中药内服 中药汤剂内服主要目中西医结合治疗术后肠功能恢复其主要方法一项共查久21项研究，中305百里系统评价37例显示，大承气汤和综合治疗一致及显子常略比较。这显示结果简节图术后恢复推护各种墙疗和中药对作用。研究显示关注和协同不胃肠功能用推病而组织治疗。\n\n【3】#### 推荐:1.金腹健“里实热”证点者以承气汤汤药剂治疗控制;梳理不发虚而进用配合气和胃肠觉力。\n\n【4】#### 证据等级:中;推荐强度:强\n\n【5】### 2.3.3 中药外治\n\n【6】中药灌肠、中药散或贴及穴位按摩等是其术后胃肠功能恢效主要中医外治法。研究系统评价显示，针刺品大容量使术后常道有园同推积肠胶术明显下移提成胃肠功能。\n\n【7】#### 推荐:12.选居适的外治方法，可改善胃肠功能递进，促进术后早期恢复。\n\n【8】##### 证据等级:中;推荐强度:强", "index": 445, "show": true, "start": 432, "end": 508, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/07 09:53:24", "endTime": "2024/08/07 09:55:04", "cost": 100.223}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 17:55:03", "grab_time": "2024-08-06 17:53:23"}
{"id": 2211611, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "6e1a2375-156a-4ae9-9186-74a1d357e318", "title": "艾沙康唑临床应用专家共识（2023版）", "text": "【0】页码:6\n艾沙康唑临床应用专家共识（2023版）\n患者经医生权威和终决定适用干治疗，根据文献，推荐剂量 10 mg/kg 或 8g 8H X 2，推荐增加 1 0mg/kg qd作初始治疗方案(C III)。儿童患者按受 ASA治疗需要密切监测其血药浓度和不良反应，最大治疗剂量不应超过成人( A III)。\n\n【1】删除32:<u>**</u>Q15: ISA用于2019  现状病毒病合并IMI患者的治疗推荐删除32:<u>**</u>\n\n【2】2019  冠状病毒病(COVID-19)重症患者是IMI高危人群，合并危險因素包括年老、肺部基础病、免疫抑制状态和接受激素或托单抗治疗者[删除21:<u>^55</u>]。\n\n【3】由于重症病毒性肺炎患者常伴随所功能不足，治疗药物(尤其是抗真菌药物)与其其他类药物及其他药物相互作用，以及生命支持治疗对于抗真菌药物浓度的影响使COVID-19合并IMI患者的抗真菌治疗面临更大挑战。删除27:<u>2021</u>年ECMM/ ISHAM发布的COVID-19感染合并侵袭性肺曲霉病(CAPA)的诊断标准及相关治疗指南[删除21:<u>^57</u>]，推荐ISA和VOR均可作为CAPA患者的一线治疗药物选择。\n\n【4】推荐:参考ECMM/ISHAM指南[删除21:<u>^57</u>]，推荐ISA作为COVID-19感染合并CAPA患者的初始一线治疗( A III);有关药物相互作用及相关副理调整请参阅药物说明书。\n\n【5】删除32:<u>**</u>小结删除32:<u>**</u>\n\n【6】ISA是一种新型三唑类抗真菌药，在临床预防和治疗IFD的方面取得了良好的疗效。ISA治疗IA的疗效与VOR相当，治疗IM时的效果均与L-AmB相当，安全性更优。ISA因药理联成的疗效和安全性、血药浓度测定的便利性、药物相互作用少以及良好的依从性等诸多一系列优点，程娟为IFD治疗与预防的新的替代选择，尤其适合免疫功能低下患者及增加潜在合并的患者。本共共课共推荐ISA上市以来的主要RCT和荚及世界临床研究以及中国专家的临床建议，供在读者专家参考。\n\n【7】删除32:<u>**</u>参考文献把握的专长和地址(以专家所在单位的首字母排序，同单位名字按教授姓氏首字母排序):删除32:<u>**</u>\n\n【8】北京大学人民医院、北京大学第一医院、解放军总医院(黄爱军、苏永士、赵)、清华大学附属第三医院(谢志雄); 复旦大学附属华山医院感染医、福建医科大学附属第一医院(钟)、福建医科大学附属协和医院(马为)、浙江省肿瘤医院(张永平); 中华中共皮肤病(李希); 南京皮肤病医院(张相伦); 南京军区南京总医院(朱)、南昌大学第一附属医院(朱志辉); 山东大学齐鲁医院(吴希金); 上海交通大学医学院附属瑞金医院(翁); 上海交通大学医学院附属第九人民医院(李奇) ; 上海长海医院(姚波)、四川大学华西医院(卡彭); 苏州大学附属第一医院(吴文静); 烟交大", "tags": {}, "lang": "zh", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/艾沙康唑临床应用专家共识（2023版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【7】删除32:参考文献把握的专长和地址(以专家所在单位的首字母排序，同单位名字按教授姓氏首字母排序):删除32:\n\n【8】北京大学人民医院、北京大学第一医院、解放军总医院(黄爱军、苏永士、赵)、清华大学附属第三医院(谢志雄); 复旦大学附属华山医院感染医、福建医科大学附属第一医院(钟)、福建医科大学附属协和医院(马为)、浙江省肿瘤医院(张永平); 中华中共皮肤病(李希); 南京皮肤病医院(张相伦); 南京军区南京总医院(朱)、南昌大学第一附属医院(朱志辉); 山东大学齐鲁医院(吴希金); 上海交通大学医学院附属瑞金医院(翁); 上海交通大学医学院附属第九人民医院(李奇) ; 上海长海医院(姚波)、四川大学华西医院(卡彭); 苏州大学附属第一医院(吴文静); 烟交大", "content": "【0】页码:6\n艾沙康唑临床应用专家共识（2023版）\n患者经医生权威和终决定适用干治疗，根据文献，推荐剂量 10 mg/kg 或 8g 8H X 2，推荐增加 1 0mg/kg qd作初始治疗方案(C III)。儿童患者按受 ASA治疗需要密切监测其血药浓度和不良反应，最大治疗剂量不应超过成人( A III)。\n\n【1】删除32:<u>**</u>Q15: ISA用于2019  现状病毒病合并IMI患者的治疗推荐删除32:<u>**</u>\n\n【2】2019  冠状病毒病(COVID-19)重症患者是IMI高危人群，合并危險因素包括年老、肺部基础病、免疫抑制状态和接受激素或托单抗治疗者[删除21:<u>^55</u>]。\n\n【3】由于重症病毒性肺炎患者常伴随所功能不足，治疗药物(尤其是抗真菌药物)与其其他类药物及其他药物相互作用，以及生命支持治疗对于抗真菌药物浓度的影响使COVID-19合并IMI患者的抗真菌治疗面临更大挑战。删除27:<u>2021</u>年ECMM/ ISHAM发布的COVID-19感染合并侵袭性肺曲霉病(CAPA)的诊断标准及相关治疗指南[删除21:<u>^57</u>]，推荐ISA和VOR均可作为CAPA患者的一线治疗药物选择。\n\n【4】推荐:参考ECMM/ISHAM指南[删除21:<u>^57</u>]，推荐ISA作为COVID-19感染合并CAPA患者的初始一线治疗( A III);有关药物相互作用及相关副理调整请参阅药物说明书。\n\n【5】删除32:<u>**</u>小结删除32:<u>**</u>\n\n【6】ISA是一种新型三唑类抗真菌药，在临床预防和治疗IFD的方面取得了良好的疗效。ISA治疗IA的疗效与VOR相当，治疗IM时的效果均与L-AmB相当，安全性更优。ISA因药理联成的疗效和安全性、血药浓度测定的便利性、药物相互作用少以及良好的依从性等诸多一系列优点，程娟为IFD治疗与预防的新的替代选择，尤其适合免疫功能低下患者及增加潜在合并的患者。本共共课共推荐ISA上市以来的主要RCT和荚及世界临床研究以及中国专家的临床建议，供在读者专家参考。\n\n【7】删除32:<u>**</u>参考文献把握的专长和地址(以专家所在单位的首字母排序，同单位名字按教授姓氏首字母排序):删除32:<u>**</u>\n\n【8】北京大学人民医院、北京大学第一医院、解放军总医院(黄爱军、苏永士、赵)、清华大学附属第三医院(谢志雄); 复旦大学附属华山医院感染医、福建医科大学附属第一医院(钟)、福建医科大学附属协和医院(马为)、浙江省肿瘤医院(张永平); 中华中共皮肤病(李希); 南京皮肤病医院(张相伦); 南京军区南京总医院(朱)、南昌大学第一附属医院(朱志辉); 山东大学齐鲁医院(吴希金); 上海交通大学医学院附属瑞金医院(翁); 上海交通大学医学院附属第九人民医院(李奇) ; 上海长海医院(姚波)、四川大学华西医院(卡彭); 苏州大学附属第一医院(吴文静); 烟交大", "index": 905, "show": true, "start": 905, "end": 1242, "province": ["信息质量", "有用性-重"], "isEdit": false}], "startTime": "2024/08/07 09:35:17", "endTime": "2024/08/07 09:35:56", "cost": 39.264}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 17:35:53", "grab_time": "2024-08-06 17:35:14"}
{"id": 2211610, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "9d3a5e48-5be1-4219-a2a3-73564701b284", "title": "《肿瘤临床试验运用核心患者报告结局行业指南(草案)》解读", "text": "【0】页码:3\n《肿瘤临床试验运用核心患者报告结局行业指南(草案)》解读\n一个可用于评估症状性不良事件的项目库删除12:<u>删除14:<u>[18]</u></u>。PRO-CTCAE 可对每个不良事件进行频率、严重程度和对日常活动影响的 3 个独立项进行评价，旨在引导肿瘤患者报告的不良事件。由两个方面根据患者的判断，导则临床数据和相关患者和医务人员的意见，选择提问出的症状性不良事件。选择最重要和/或高发发生的不良事件，并考虑设置自由文本问题以方便社会可能遗漏的重要症状。\n\n【1】3.3 对整体不良反应的总体性评价 对整体不良反应的总体性评价可以反映治疗的耐受性。个别患者可能认为某些不良反应相对于其其他不良反应的重要程度不同，可考虑使用统一的总体性想受发平体育程度提。 如“请在下面的图中选反应最能描述你在过去一周中接受治疗后总体不良反应的严重程度”（其中 0 代表没有；1 代表程度）。此外 还可参考慢性疾病治疗功能评估项目库（functional assessment of chronic illness therapy，FACIT）项目库中的 GP5 项目，即根据患者的身体状况回答受到治疗所以不良反应所困扰的程度（没有、有一点、有些、相当多、很多）；也可考虑欧洲肿瘤研究合作组织（European Organisation for Research and Treatment of Cancer EORTC）项目库中关于不良反应的回顾删除12:<u>删除14:<u>[20]</u></u>。\n\n【2】3.4 身体机能 申请方应选择测量明确概念的量表来评估人体活动的能力水平，可以考虑选择患者报告的系列测量量表系统（patient-reported outcomes measurement information system，PROMIS）的身体机能项目（21）通过自我报告能力、书写 等活动的成家来评价一个人的整体坊能（灵巧度、行走 走动 及日常活动能力；也可以考虑选择 EORTC HP 霉患者生活质量核心问卷30（qality of life questionnaire-core 30 QLQ-C30）身体机能量表删除12:<u>删除14:<u>[22]</u></u>对女性世评估暗能患者的体能测评其生活质量。\n\n【3】3.5 角色即题 环哪肿瘤治疗对患者工作和日常活 功能的影响的非常重要必要时可填估其他功能状 范如知识能力。可参考 EORTC 的 QLQ-C30角色 即题量表。\n\n【4】4 证选设计的考虑\n\n【5】4.1 可注入的参考 确定 PRO 核心问目的评价领导时 应考虑以下几点：① 应纳入1个（或多个)专道 支评作品寻特性库更参考显示。② 短机/t几治疗周 期时间的指导夜效应 提提证效的不同，④ 临改变 可度少剧lit评价领导。③评估频率可考虑研究领导的少\n\n【6】删除图片描述:<u>![](2_0.png)</u>\n\n【7】的咨询计划.研究结果和研究目标为每个核心概念选择不同的评价结果。\n\n【8】4.2 试验设计的其他考虑 疗患者对 PRO 的运用仍存在较多认知局限 如只报告多大如报告负担等。虽然并非专业的医务人员，即便经过培训 但报告 观察或部分信息出现数据的缺失和差异 临床数据整理 因也无法进行纠错 因此 从源头上保 护数据质 重至关重要。应考虑以下事项以减少数据缺失并提高 PRO 结果可解释性：① 前确保性机制库减少数据缺失的程序包括: 对新患者和继有患者的培训、完成监 查计划 以及患者排序意见出研究时 PRO 数据的获 取。② 应探讨域患者审告的访院。随着新技术 的发展 在患者报告中可以使用必选的工具删除12:<u>删除14:<u>[23]</u></u>如允许在治疗处使用电子化 PRO 采集数据 用于化的患者报告症状监测可作为高质量肿瘤治疗的一部分[\n\n【9】例如，办公）\n\n【10】3 ④应完成完成 PRO 评价的方式和地点（\n\n【11】户）。应记录 PRO 数据和缺的原因并将英国合在分析数据集中。④ 提供 程等）原因的预张计划)包括分数类别含义的\n\n【12】个据分析的重要理由⑤  6  由洞候等情情况示将以说明并提供理由的。⑥ 联合自带或其他治疗等情况下雷会影响对评评价概念的解释。需布但顽言。\n\n【13】5 药物标示说明\n\n【14】在药品标示说明中纳入 PRO 数据将取决于试验设计和标志的充分性在特定使用评级下评估工程具体的优对和限制以及所样批准数据的质，简单位 策内包括“有统计学差异”? 的结足不充分的。在试验设计充分设计的前提下,且获较发挥良好可靠的标选的话据支持，应能在特征“非给效”文 统的”中判定。\n\n【15】6 讨论\n\n【16】组织纪念斯隆·凯特琳肿瘤中心的一项入 766例患者的随机临床试验真实在使用基 PRO 评估工具的情况下，能够更好地管理患者病情变化，选择适当的干嘴治疗并进行途中症状和毒性管理。这对延长患者的干时间有重要影响删除12:<u>删除14:<u>[24]</u></u> 在医疗产品 开发现临者治疗中器会患者自出息受变可,可更好地 为医疗提供服务,延提高医疗质量的产量。选择 PRO 评价指南的研究优化临床工作者共目的在于 需缪试剂这及白与.工剧灭万。监苒高患者等多劳多兰等重要改的方法及环境构现。 随着2013年（SPIRIT-PRO扩展指南）发布和2018年（COSNORPT-PRO扩展指南）发布 PRO在 2018", "tags": {}, "lang": "zh", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/《肿瘤临床试验运用核心患者报告结局行业指南(草案)》解读.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "（21）", "content": "【0】页码:3\n《肿瘤临床试验运用核心患者报告结局行业指南(草案)》解读\n一个可用于评估症状性不良事件的项目库删除12:<u>删除14:<u>[18]</u></u>。PRO-CTCAE 可对每个不良事件进行频率、严重程度和对日常活动影响的 3 个独立项进行评价，旨在引导肿瘤患者报告的不良事件。由两个方面根据患者的判断，导则临床数据和相关患者和医务人员的意见，选择提问出的症状性不良事件。选择最重要和/或高发发生的不良事件，并考虑设置自由文本问题以方便社会可能遗漏的重要症状。\n\n【1】3.3 对整体不良反应的总体性评价 对整体不良反应的总体性评价可以反映治疗的耐受性。个别患者可能认为某些不良反应相对于其其他不良反应的重要程度不同，可考虑使用统一的总体性想受发平体育程度提。 如“请在下面的图中选反应最能描述你在过去一周中接受治疗后总体不良反应的严重程度”（其中 0 代表没有；1 代表程度）。此外 还可参考慢性疾病治疗功能评估项目库（functional assessment of chronic illness therapy，FACIT）项目库中的 GP5 项目，即根据患者的身体状况回答受到治疗所以不良反应所困扰的程度（没有、有一点、有些、相当多、很多）；也可考虑欧洲肿瘤研究合作组织（European Organisation for Research and Treatment of Cancer EORTC）项目库中关于不良反应的回顾删除12:<u>删除14:<u>[20]</u></u>。\n\n【2】3.4 身体机能 申请方应选择测量明确概念的量表来评估人体活动的能力水平，可以考虑选择患者报告的系列测量量表系统（patient-reported outcomes measurement information system，PROMIS）的身体机能项目（21）通过自我报告能力、书写 等活动的成家来评价一个人的整体坊能（灵巧度、行走 走动 及日常活动能力；也可以考虑选择 EORTC HP 霉患者生活质量核心问卷30（qality of life questionnaire-core 30 QLQ-C30）身体机能量表删除12:<u>删除14:<u>[22]</u></u>对女性世评估暗能患者的体能测评其生活质量。\n\n【3】3.5 角色即题 环哪肿瘤治疗对患者工作和日常活 功能的影响的非常重要必要时可填估其他功能状 范如知识能力。可参考 EORTC 的 QLQ-C30角色 即题量表。\n\n【4】4 证选设计的考虑\n\n【5】4.1 可注入的参考 确定 PRO 核心问目的评价领导时 应考虑以下几点：① 应纳入1个（或多个)专道 支评作品寻特性库更参考显示。② 短机/t几治疗周 期时间的指导夜效应 提提证效的不同，④ 临改变 可度少剧lit评价领导。③评估频率可考虑研究领导的少\n\n【6】删除图片描述:<u>![](2_0.png)</u>\n\n【7】的咨询计划.研究结果和研究目标为每个核心概念选择不同的评价结果。\n\n【8】4.2 试验设计的其他考虑 疗患者对 PRO 的运用仍存在较多认知局限 如只报告多大如报告负担等。虽然并非专业的医务人员，即便经过培训 但报告 观察或部分信息出现数据的缺失和差异 临床数据整理 因也无法进行纠错 因此 从源头上保 护数据质 重至关重要。应考虑以下事项以减少数据缺失并提高 PRO 结果可解释性：① 前确保性机制库减少数据缺失的程序包括: 对新患者和继有患者的培训、完成监 查计划 以及患者排序意见出研究时 PRO 数据的获 取。② 应探讨域患者审告的访院。随着新技术 的发展 在患者报告中可以使用必选的工具删除12:<u>删除14:<u>[23]</u></u>如允许在治疗处使用电子化 PRO 采集数据 用于化的患者报告症状监测可作为高质量肿瘤治疗的一部分[\n\n【9】例如，办公）\n\n【10】3 ④应完成完成 PRO 评价的方式和地点（\n\n【11】户）。应记录 PRO 数据和缺的原因并将英国合在分析数据集中。④ 提供 程等）原因的预张计划)包括分数类别含义的\n\n【12】个据分析的重要理由⑤  6  由洞候等情情况示将以说明并提供理由的。⑥ 联合自带或其他治疗等情况下雷会影响对评评价概念的解释。需布但顽言。\n\n【13】5 药物标示说明\n\n【14】在药品标示说明中纳入 PRO 数据将取决于试验设计和标志的充分性在特定使用评级下评估工程具体的优对和限制以及所样批准数据的质，简单位 策内包括“有统计学差异”? 的结足不充分的。在试验设计充分设计的前提下,且获较发挥良好可靠的标选的话据支持，应能在特征“非给效”文 统的”中判定。\n\n【15】6 讨论\n\n【16】组织纪念斯隆·凯特琳肿瘤中心的一项入 766例患者的随机临床试验真实在使用基 PRO 评估工具的情况下，能够更好地管理患者病情变化，选择适当的干嘴治疗并进行途中症状和毒性管理。这对延长患者的干时间有重要影响删除12:<u>删除14:<u>[24]</u></u> 在医疗产品 开发现临者治疗中器会患者自出息受变可,可更好地 为医疗提供服务,延提高医疗质量的产量。选择 PRO 评价指南的研究优化临床工作者共目的在于 需缪试剂这及白与.工剧灭万。监苒高患者等多劳多兰等重要改的方法及环境构现。 随着2013年（SPIRIT-PRO扩展指南）发布和2018年（COSNORPT-PRO扩展指南）发布 PRO在 2018", "index": 790, "show": true, "start": 790, "end": 794, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "【2】"}, {"text": "【3】3.5 角色即题 环哪肿瘤治疗对患者工作和日常活 功能的影响的非常重要必要时可填估其他功能状 范如知识能力。可参考 EORTC 的 QLQ-C30角色 即题量表。\n\n【4】4 证选设计的考虑\n\n【5】4.1 可注入的参考 确定 PRO 核心问目的评价领导时 应考虑以下几点：① 应纳入1个（或多个)专道 支评作品寻特性库更参考显示。② 短机/t几治疗周 期时间的指导夜效应 提提证效的不同，④ 临改变 可度少剧lit评价领导。③评估频率可考虑研究领导的少\n\n【6】删除图片描述:\n\n【7】的咨询计划.研究结果和研究目标为每个核心概念选择不同的评价结果。\n\n【8】4.2 试验设计的其他考虑 疗患者对 PRO 的运用仍存在较多认知局限 如只报告多大如报告负担等。虽然并非专业的医务人员，即便经过培训 但报告 观察或部分信息出现数据的缺失和差异 临床数据整理 因也无法进行纠错 因此 从源头上保 护数据质 重至关重要。应考虑以下事项以减少数据缺失并提高 PRO 结果可解释性：① 前确保性机制库减少数据缺失的程序包括: 对新患者和继有患者的培训、完成监 查计划 以及患者排序意见出研究时 PRO 数据的获 取。② 应探讨域患者审告的访院。随着新技术 的发展 在患者报告中可以使用必选的工具删除12:删除14:[23]如允许在治疗处使用电子化 PRO 采集数据 用于化的患者报告症状监测可作为高质量肿瘤治疗的一部分[\n\n【9】例如，办公）\n\n【10】3 ④应完成完成 PRO 评价的方式和地点（\n\n【11】户）。应记录 PRO 数据和缺的原因并将英国合在分析数据集中。④ 提供 程等）原因的预张计划)包括分数类别含义的\n\n【12】个据分析的重要理由⑤  6  由洞候等情情况示将以说明并提供理由的。⑥ 联合自带或其他治疗等情况下雷会影响对评评价概念的解释。需布但顽言。", "content": "【0】页码:3\n《肿瘤临床试验运用核心患者报告结局行业指南(草案)》解读\n一个可用于评估症状性不良事件的项目库删除12:<u>删除14:<u>[18]</u></u>。PRO-CTCAE 可对每个不良事件进行频率、严重程度和对日常活动影响的 3 个独立项进行评价，旨在引导肿瘤患者报告的不良事件。由两个方面根据患者的判断，导则临床数据和相关患者和医务人员的意见，选择提问出的症状性不良事件。选择最重要和/或高发发生的不良事件，并考虑设置自由文本问题以方便社会可能遗漏的重要症状。\n\n【1】3.3 对整体不良反应的总体性评价 对整体不良反应的总体性评价可以反映治疗的耐受性。个别患者可能认为某些不良反应相对于其其他不良反应的重要程度不同，可考虑使用统一的总体性想受发平体育程度提。 如“请在下面的图中选反应最能描述你在过去一周中接受治疗后总体不良反应的严重程度”（其中 0 代表没有；1 代表程度）。此外 还可参考慢性疾病治疗功能评估项目库（functional assessment of chronic illness therapy，FACIT）项目库中的 GP5 项目，即根据患者的身体状况回答受到治疗所以不良反应所困扰的程度（没有、有一点、有些、相当多、很多）；也可考虑欧洲肿瘤研究合作组织（European Organisation for Research and Treatment of Cancer EORTC）项目库中关于不良反应的回顾删除12:<u>删除14:<u>[20]</u></u>。\n\n【2】3.4 身体机能 申请方应选择测量明确概念的量表来评估人体活动的能力水平，可以考虑选择患者报告的系列测量量表系统（patient-reported outcomes measurement information system，PROMIS）的身体机能项目<mark>（21）</mark>通过自我报告能力、书写 等活动的成家来评价一个人的整体坊能（灵巧度、行走 走动 及日常活动能力；也可以考虑选择 EORTC HP 霉患者生活质量核心问卷30（qality of life questionnaire-core 30 QLQ-C30）身体机能量表删除12:<u>删除14:<u>[22]</u></u>对女性世评估暗能患者的体能测评其生活质量。\n\n【3】3.5 角色即题 环哪肿瘤治疗对患者工作和日常活 功能的影响的非常重要必要时可填估其他功能状 范如知识能力。可参考 EORTC 的 QLQ-C30角色 即题量表。\n\n【4】4 证选设计的考虑\n\n【5】4.1 可注入的参考 确定 PRO 核心问目的评价领导时 应考虑以下几点：① 应纳入1个（或多个)专道 支评作品寻特性库更参考显示。② 短机/t几治疗周 期时间的指导夜效应 提提证效的不同，④ 临改变 可度少剧lit评价领导。③评估频率可考虑研究领导的少\n\n【6】删除图片描述:<u>![](2_0.png)</u>\n\n【7】的咨询计划.研究结果和研究目标为每个核心概念选择不同的评价结果。\n\n【8】4.2 试验设计的其他考虑 疗患者对 PRO 的运用仍存在较多认知局限 如只报告多大如报告负担等。虽然并非专业的医务人员，即便经过培训 但报告 观察或部分信息出现数据的缺失和差异 临床数据整理 因也无法进行纠错 因此 从源头上保 护数据质 重至关重要。应考虑以下事项以减少数据缺失并提高 PRO 结果可解释性：① 前确保性机制库减少数据缺失的程序包括: 对新患者和继有患者的培训、完成监 查计划 以及患者排序意见出研究时 PRO 数据的获 取。② 应探讨域患者审告的访院。随着新技术 的发展 在患者报告中可以使用必选的工具删除12:<u>删除14:<u>[23]</u></u>如允许在治疗处使用电子化 PRO 采集数据 用于化的患者报告症状监测可作为高质量肿瘤治疗的一部分[\n\n【9】例如，办公）\n\n【10】3 ④应完成完成 PRO 评价的方式和地点（\n\n【11】户）。应记录 PRO 数据和缺的原因并将英国合在分析数据集中。④ 提供 程等）原因的预张计划)包括分数类别含义的\n\n【12】个据分析的重要理由⑤  6  由洞候等情情况示将以说明并提供理由的。⑥ 联合自带或其他治疗等情况下雷会影响对评评价概念的解释。需布但顽言。\n\n【13】5 药物标示说明\n\n【14】在药品标示说明中纳入 PRO 数据将取决于试验设计和标志的充分性在特定使用评级下评估工程具体的优对和限制以及所样批准数据的质，简单位 策内包括“有统计学差异”? 的结足不充分的。在试验设计充分设计的前提下,且获较发挥良好可靠的标选的话据支持，应能在特征“非给效”文 统的”中判定。\n\n【15】6 讨论\n\n【16】组织纪念斯隆·凯特琳肿瘤中心的一项入 766例患者的随机临床试验真实在使用基 PRO 评估工具的情况下，能够更好地管理患者病情变化，选择适当的干嘴治疗并进行途中症状和毒性管理。这对延长患者的干时间有重要影响删除12:<u>删除14:<u>[24]</u></u> 在医疗产品 开发现临者治疗中器会患者自出息受变可,可更好地 为医疗提供服务,延提高医疗质量的产量。选择 PRO 评价指南的研究优化临床工作者共目的在于 需缪试剂这及白与.工剧灭万。监苒高患者等多劳多兰等重要改的方法及环境构现。 随着2013年（SPIRIT-PRO扩展指南）发布和2018年（COSNORPT-PRO扩展指南）发布 PRO在 2018", "index": 988, "show": true, "start": 975, "end": 1759, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "内容和原文并不相同"}], "startTime": "2024/08/06 15:32:24", "endTime": "2024/08/06 15:35:33", "cost": 188.885}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:35:33", "grab_time": "2024-08-05 23:32:23"}
{"id": 2211609, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "4c44274c-8e04-4f7c-981f-b483adf6c7ca", "title": "2024+WMS临床实践指南：溺水的预防和治疗（更新版）", "text": "【0】页码:16\n2024+WMS临床实践指南：溺水的预防和治疗（更新版）\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】参考删除-3:<u>81. Hwang K, Moore KJ, Chong TWH, Williams S, Batchelor F. Improving clinical practice guidelines for older people: considerations and recommendations for more inclusive and ageing-relevant guidelines. 删除32:<u>*</u>Learn Healthy Longev.删除32:<u>*</u> 2022;3删除11:<u>(5)</u>:e316-e317.</u>\n\n【2】参考删除-3:<u>82. Thom O, Roberts K, Leggat PA, Devine S, Peden AE, Franklin RC. Cervical spine immobilisation is only required in drowning patients at high risk of axial loading of the spine. 删除32:<u>*</u>Emerg Med Australas.删除32:<u>*</u> 2023;35删除11:<u>(1)</u>:18-24.</u>\n\n【3】参考删除-3:<u>83. Dow J, Giesbrecht GG, Danzl DF, et al. Wilderness medical society clinical practice guidelines for the out-of-hospital evaluation and treatment of accidental hypothermia: 2019 update. 删除32:<u>*</u>Wilderness Environ Med.删除32:<u>*</u> 2019;30删除30:<u>(4S)</u>:S47-69.</u>\n\n【4】参考删除-3:<u>84. Gregorakos L, Markou N, Psilaida V, et al. Near-drowning: clinical course of lung injury in adults. 删除32:<u>*</u>Lung. 2009;187删除11:<u>(2)</u>:93-97.</u>\n\n【5】参考删除-3:<u>85. Topjian AA, Berg RA, Bierens JJ, et al. Brain resuscitation in the drowning victim. 删除32:<u>*</u>Neurocrit Care. 2012;17删除11:<u>(3)</u>:441-467.</u>\n\n【6】86. Network ACC. Mechanical ventilation protocol summary: Updated 2008删除1:<u>. http://www.ardsnet.org.</u>\n\n【7】参考删除-3:<u>87. Thom O, Roberts K, Devine S, Leggat PA, Franklin RC. Treatment of the lung injury of drowning: a systematic review. 删除32:<u>*</u>Crit Care. 2021;25删除11:<u>(1)</u>:253.</u>\n\n【8】参考删除-3:<u>88. Thompson J, Petrie DA, Ackroyd-Stolarz S, Bardua DJ. Out-of-hospital continuous positive airway pressure ventilation versus usual care in acute respiratory failure: a randomized controlled trial. 删除32:<u>*</u>Ann Emerg Med. 2008;52删除11:<u>(3)</u>:232-删除13:<u>241, 41</u> e1.</u>\n\n【9】参考删除-3:<u>89. Dottorini M, Eslami A, Baglioni S, Fiorenzano G, Todisco T. Nasal-continuous positive airway pressure in the treatment of near-drowning in freshwater. 删除32:<u>*</u>Chest. 1996;110删除11:<u>(4)</u>:1122-1124.</u>\n\n【10】参考删除-3:<u>90. Nava S, Schreiber A, Domenighetti G. Noninvasive ventilation for patients with acute lung injury or acute respiratory distress syndrome. 删除32:<u>*</u>Respir Care. 2011;56删除11:<u>(10)</u>:1583-1588.</u>\n\n【11】参考删除-3:<u>91. Ruggeri P, Calcaterra S, Bottari A, Giribino G, Fodale V. Successful management of acute respiratory failure with noninvasive mechanical ventilation after drowning, in an epileptic patient. 删除32:<u>*</u>Respir Med Case Rep. 2016;17:90-92.</u>\n\n【12】参考删除-3:<u>92. Michelet P, Bouzana F, Charamesrat O, et al. Acute respiratory failure after drowning: a retrospective multicenter survey. 删除32:<u>*</u>Eur J Emerg Med. 2017;24删除11:<u>(4)</u>:295-300.</u>\n\n【13】参考删除-3:<u>93. Causey EAL, Tilelli JA, Swanson ME. Predicting discharge in uncomplicated near-drowning. 删除32:<u>*</u>Am J Emerg Med. 2000;18删除11:<u>(1)</u>:9-11.</u>\n\n【14】参考删除-3:<u>94. Modell JH, Graves SA, Ketover A. Clinical course of 91 consecutive near-drowning victims. 删除32:<u>*</u>Chest. 1976;70删除11:<u>(2)</u>:231-238.</u>\n\n【15】参考删除-3:<u>95. Brennan CE, Hong TKF, Wang VJ. Predictors of safe discharge for pediatric drowning patients in the emergency department. 删除32:<u>*</u>Am J Emerg Med. 2018;36删除11:<u>(9)</u>:1619-1623.</u>\n\n【16】参考删除-3:<u>96. Rafaat KT, Spear RM, Kuelbs C, Parsapour K, Peterson B. Cranial computed tomographic findings in a large group of children with drowning: diagnostic, prognostic, and forensic implications. 删除32:<u>*</u>Pediatr Crit Care Med. 2008;9删除11:<u>(6)</u>:567-572.</u>\n\n【17】参考删除-3:<u>97. Modell JH, Davis JH. Electrolyte changes in human drowning victims. 删除32:<u>*</u>Anesthesiology. 1969;30删除11:<u>(4)</u>:414-420.</u>\n\n【18】参考删除-3:<u>98. Modell JH, Moya F. Effects of volume of aspirated fluid during chlorinated fresh water drowning. 删除32:<u>*</u>Anesthesiology. 1966;27删除11:<u>(5)</u>:662-672.</u>\n\n【19】参考删除-3:<u>99. Modell JH, Moya F, Newby EJ, Ruiz BC, Showers AV. The effects of fluid volume in seawater drowning. 删除32:<u>*</u>Ann Intern Med. 1967;67删除11:<u>(1)</u>:68-80.</u>\n\n【20】参考删除-3:<u>100. Wood C. Towards evidence based emergency medicine: best BETs from the Manchester royal infirmary. BET 1: prophylactic antibiotics in near-drowning. 删除32:<u>*</u>Emerg Med J. 2010;27删除11:<u>(5)</u>:393-394.</u>\n\n【21】参考删除-3:<u>101. Ender PT, Dolan MJ. Pneumonia associated with near-drowning. 删除32:<u>*</u>Clin Infect Dis. 1997;25删除11:<u>(4)</u>:896-907.</u>\n\n【22】参考删除-3:<u>102. Tadie JM, Heming N, Serve E, et al. Drowning associated pneumonia: a descriptive cohort. 删除32:<u>*</u>Resuscitation. 2012;83删除11:<u>(3)</u>:399-401.</u>\n\n【23】参考删除-3:<u>103. van Berkel M, Bierens JJ, Lie RL, et al. Pulmonary oedema, pneumonia and mortality in submersion victims; a retrospective study in 125 patients. 删除32:<u>*</u>Intensive Care Med. 1996;22删除11:<u>(2)</u>:101-107.</u>\n\n【24】参考删除-3:<u>104. Foex BA, Boyd R. Towards evidence based emergency medicine: best BETs from the Manchester royal infirmary. Corticosteroids in the management of near-drowning. 删除32:<u>*</u>Emerg Med J. 2001;18删除11:<u>(6)</u>:465-466.</u>\n\n【25】参考删除-3:<u>105. Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. 删除32:<u>*</u>N Engl J Med. 2021;384删除11:<u>(24)</u>:2283-2294.</u>\n\n【26】106. Callaway CW, Donnino MW, Fink EL, et al. Part 8: postcardiac arrest care: 2015 American heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. 删除32:<u>*</u>Circulation. 2015;132(18 Suppl 2):S465-S482.\n\n【27】107. World Congress on Drowning. Recommendations of the World Congress on Drowning 2002删除1:<u>. https://www.ilsf.org/sites/ilsf.org/files/filefield/drowningcongress.doc.</u>\n\n【28】108. Batra RK, Paddle JJ. Therapeutic hypothermia in drowning induced hypoxic brain injury: a case report. 删除32:<u>*</u>Cases J. 2009;2:9103.\n\n【29】参考删除-3:<u>109. Varon J, Marik PE. Complete neurological recovery following delayed institution of hypothermia in a victim of warm water near-drowning. 删除32:<u>*</u>Resuscitation. 2006;68删除11:<u>(3)</u>:421-423.</u>\n\n【30】参考删除-3:<u>110. Williamson JP, Illing R, Gertler P, Braude S. Near-drowning treated with therapeutic hypothermia. 删除32:<u>*</u>Med J Aust. 2004;181删除11:<u>(9)</u>:500-501.</u>\n\n【31】参考删除-3:<u>111. de Pont AC, de Jager CP, van den Bergh WM, Schultz MJ. Recovery from near drowning and postanoxic status epilepticus with controlled hypothermia. 删除32:<u>*</u>Neth J Med. 2011;69删除11:<u>(4)</u>:196-197.</u>\n\n【32】参考删除-3:<u>112. Rudolph SS, Barnung S. Survival after drowning with cardiac arrest and mild hypothermia. 删除32:<u>*</u>ISRN Cardiol. 2011;2011:895265.</u>\n\n【33】参考删除-3:<u>113. Choi SP, Youn CS, Park KN, et al. Therapeutic hypothermia in adult cardiac arrest because of drowning. 删除32:<u>*</u>Acta Anaesthesiol Scand. 2012;56删除11:<u>(1)</u>:116-123.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 16, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024+WMS临床实践指南：溺水的预防和治疗（更新版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:11:41", "endTime": "2024/08/06 17:11:47", "cost": 6.275}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 01:11:47", "grab_time": "2024-08-06 01:11:41"}
{"id": 2211608, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "fb519248-6932-469f-94d5-a4c58676a333", "title": "WHO：控制和消灭人类血吸虫病指南（2022）", "text": "【0】页码:142\nWHO：控制和消灭人类血吸虫病指南（2022）\nAnnex 6. Estimated equivalent prevalence of point-of-care circulating cathodic antigen to single and duplicate slide Kato-Katz and suggested equivalent prevalence threshold for 删除32:<u>*</u>Schistosoma mansoni删除32:<u>*</u>\n\n|             | Kato-Katz | POC-CCA Traces/1+/2+/3+ | Suggested threshold | 1+/2+/3+ | 2+/3+ |\n|-------------|-----------|-------------------------|----------------------|----------|-------|\n| 删除32:<u>**</u>Single删除32:<u>**</u>  |           |                         |                      |          |       |\n| 1%          |           | 5-30%                  | 10%                 | 3-10%    | 1%    |\n| 5%          |           | 10-30%                 | 20%                 | 5-15%    | 5%    |\n| 10%         |           | 20-40%                 | 30%                 | 15-25%   | 10%   |\n| 25%         |           | 35-70%                 | 50%                 | 30-50%   | 25%   |\n| 50%         |           | > 75%                   | 75%                 | > 60%    | > 50% |\n| 删除32:<u>**</u>Duplicate删除32:<u>**</u>|          |                         |                      |          |       |\n| 1%          |           | 5-25%                  | 10%                 | 3-10%    | 1%    |\n| 5%          |           | 10-35%                 | 20%                 | 5-15%    | 5%    |\n| 10%         |           | 15-40%                 | 30%                 | 10-20%   | 5-10% |\n| 25%         |           | 30-70%                 | 45%                 | 25-40%   | 15-25%|\n| 50%         |           | > 60%                   | 60%                 | 50%      | > 40% |", "tags": {}, "lang": "en", "attr": {"page_num": 142, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WHO：控制和消灭人类血吸虫病指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:33:14", "endTime": "2024/08/06 16:33:54", "cost": 40.718}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:33:55", "grab_time": "2024-08-06 00:33:14"}
{"id": 2211607, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "ac831ed4-f540-44a4-bca1-d4c123f25268", "title": "Ⅰ型神经纤维瘤病多学科诊治指南（2023版）", "text": "【0】页码:16\nⅠ型神经纤维瘤病多学科诊治指南（2023版）\n医院)、俄而（首都医科大学附属北京天坛医院）、徐子间（首都医科大学附属北京儿童医院）、徐向欣（北京协和医院）、徐学刚（中国医科大学附属第一医院）、晏少彦（中山大学附属肿瘤医院）、高兴华（中国医科大学附属第一医院）、郭静珍（中山大学肿瘤防治中心）、陶赟峰（上海交通大学医学院附属第六人民医院）、屠格文（山东大学齐鲁医院）、黄啸（广东省人民医院）、黄风煜（首都医科大学附属宣武医院）、盛军俊（安徽医科大学第一附属医院）、谢永华（首都医科大学附属北京儿童医院）、管宇敌（首都医科大学附属宣武医院）、曹慧芳（四川大学华西医院）、清涧宏（首都医科大学附属北京天坛医院）、臧专（首都医科大学附属北京儿童医院）、臧强（首都医科大学附属北京天坛医院）、蒋守本（北京协和医院）、韩岩（解放军总医院第一医学中心）、韩鹏军（中山大学肿瘤防治中心）、鹏阳颢（广西医科大学第一附属医院）\n\n【1】参考删除-4:<u>### 参考文献</u>\n\n【2】参考删除-4:<u>删除12:<u>删除14:<u>[1]</u></u> Kallionpää R A，Uusitalo E，Leppävirta J，et al. Preval‐ence of neurofibromatosis type 1 in the Finnish population 删除12:<u>[J]</u>. Genet Med，2018，20（9）：1082-1086.</u>\n\n【3】参考删除-4:<u>删除12:<u>删除14:<u>[2]</u></u> Legius E，Messiaen L，Wolkenstein P，et al. Revised di‐agnostic criteria for neurofibromatosis type 1 and Legius syn‐drome：an international consensus recommendation 删除12:<u>[J]</u>. Genet Med，2021，23（8）：1506-1513.</u>\n\n【4】参考删除-4:<u>删除12:<u>删除14:<u>[3]</u></u> Nolisetel. Neurofibromatosis 删除12:<u>[J]</u>. Natl Inst Health Consens Dev Conf Consensus Statement，1987，6（12）：1-7.</u>\n\n【5】参考删除-4:<u>删除12:<u>删除14:<u>[4]</u></u> National Multi-Center Treatment Collaboration Group For Neurofibromatosis Type，National Multi-Center Research Platform For Plastic And Reconstructive Surgery. [Expert consensus on diagnosis and management of neurofibromato‐sis type 1 删除19:<u>(2021 edition)</u>] 删除12:<u>[J]</u>. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi，2021，35 删除11:<u>(11)</u>：1384-1395.</u>\n\n【6】参考删除-4:<u>删除12:<u>删除14:<u>[5]</u></u> Messiaen L，Vogt J，Bengesser K，et al. Mosaic type1～NF1 microdeletions as a cause of both generalized and seg‐mental neurofibromatosis type-1 (NF1) 删除12:<u>[J]</u>. Hum Mutat，2011，32 删除11:<u>(2)</u>：213-219.</u>\n\n【7】参考删除-4:<u>删除12:<u>删除14:<u>[6]</u></u> Boyce AM，Collins MT. Fibrous dysplasia/McCune-Albright syndrome：a rare，mosaic disease of gαs activation 删除12:<u>[J]</u>. Endocr Rev，2020，41 删除11:<u>(2)</u>：345-370.</u>\n\n【8】参考删除-4:<u>删除12:<u>删除14:<u>[7]</u></u> Asthagiri AR，Parry DM，Butman JA，et al. Neurofibroma‐tosis type 2 删除12:<u>[J]</u>. Lancet，2009，373（9679）：1974-1986.</u>\n\n【9】参考删除-4:<u>删除12:<u>删除14:<u>[8]</u></u> Roberts AE，Allanson JE，Tartaglia M，et al. Noonan syn‐drome 删除12:<u>[J]</u>. Lancet，2013，381 删除11:<u>删除19:<u>(9863)</u></u>：333-342.</u>\n\n【10】参考删除-4:<u>删除12:<u>删除14:<u>[9]</u></u> Gallon R，Phelps R，Hayes C，et al. Constitutional micro‐satellite instability，genotype and phenotype correlations in constitutional mismatch repair deficiency 删除12:<u>[J]</u>. Gastroenterol‐ogy，2022. doi：10.1053/j. gastro. 删除13:<u>2022. 12</u>. 017.</u>\n\n【11】参考删除-4:<u>删除12:<u>删除14:<u>[10]</u></u> Gutmann DH，Ferner RE，Listernick RH，et al. Neurofi‐bromatosis type 1 删除12:<u>[J]</u>. Nat Rev Dis Primers，2017，3：17004.</u>\n\n【12】参考删除-4:<u>删除12:<u>删除14:<u>[11]</u></u> Zhao S，Zhang Y，Chen W，et al. Diagnostic yield and clinical impact of exome sequencing in early-onset scoliosis (EOS) 删除12:<u>[J]</u>. J Med Genet，2021，58 删除11:<u>(1)</u>：41-47.</u>\n\n【13】参考删除-4:<u>删除12:<u>删除14:<u>[12]</u></u> Kozłowska M，Callens T，Chen Y，et al. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p. Met1149，p. Arg1276，and p. Lys1423：genotype-phenotype study in neurofibromatosis type 1 删除12:<u>[J]</u>. Hum Mutat，2020，41 删除11:<u>(1)</u>：299-315.</u>\n\n【14】参考删除-4:<u>删除12:<u>删除14:<u>[13]</u></u> Well J，Döbel K，Kluwe L，et al. Genotype-phenotype correlation in neurofibromatosis type-I：NF1 whole gene de‐letions lead to high tumor-burden and increased tumor-growth 删除12:<u>[J]</u>. PLoS Genet，2021，17 删除11:<u>(5)</u>：e1009517.</u>\n\n【15】参考删除-4:<u>删除12:<u>删除14:<u>[14]</u></u> Tadini G，Legius E，Brems H. Multidisciplinary approach to neurofibromatosis type 1 删除12:<u>[M]</u>. Switzerland，Springer，2020：45-69.</u>\n\n【16】参考删除-4:<u>删除12:<u>删除14:<u>[15]</u></u> Ortonne N，Wolkenstein P，Blakeley JO，et al. Cutaneous neurofibromas：current clinical and pathologic issues 删除12:<u>[J]</u>. Neurology，2018，91 (2 Suppl 1)：S5-S13.</u>\n\n【17】参考删除-4:<u>删除12:<u>删除14:<u>[16]</u></u> 佘倩雯, 魏亚江, 王潇, 等.胶质脑瘤经纤维胆道的治疗 方案及研究进展 删除12:<u>[J]</u>. 中南医学麻醉外科杂志，2022，36（9）：1064-1071.</u>\n\n【18】参考删除-4:<u>删除12:<u>删除14:<u>[17]</u></u> Chamseldin BH，Le LQ. Management of cutaneous neurofi‐broma：current therapy and future directions 删除12:<u>[J]</u>. Neuroloncol Adv，2019，2（Suppl 1）：i107-i116.</u>\n\n【19】参考删除-4:<u>删除12:<u>删除14:<u>[18]</u></u> Wang R，Lin Z. A child with multiple hypopigmented lesions 删除12:<u>[J]</u>. BMJ，2021，372：m4844.</u>\n\n【20】参考删除-4:<u>删除12:<u>删除14:<u>[19]</u></u> Ferrari F，Masurel A，Olivier-Faivre L，et al. Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1 删除12:<u>[J]</u>. JAMA Dermatol，2014，150 删除11:<u>(1)</u>：42-46.</u>\n\n【21】参考删除-4:<u>删除12:<u>删除14:<u>[20]</u></u> Roy A，Roulin JL，Gras-Le Guen C，et al. Executive functions and quality of life in children with neurofibro‐matosis type 1 删除12:<u>[J]</u>. Orphanet J Rare Dis，2021，16 删除11:<u>(1)</u>：420.</u>\n\n【22】参考删除-4:<u>删除12:<u>删除14:<u>[21]</u></u> Taylor LA，Lewis VL. Neurofibromatosis type I：review of cutaneous and subcutaneous tumor treatment on quality of life 删除12:<u>[J]</u>. Plast Reconstr Surg Glob Open，2019，7 删除11:<u>(1)</u>：e1982.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 16, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/Ⅰ型神经纤维瘤病多学科诊治指南（2023版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:16\n\nⅠ型神经纤维瘤病多学科诊治指南（2023版）\n\n医院)、俄而（首都医科大学附属北京天坛医院）、徐子间（首都医科大学附属北京儿童医院）、徐向欣（北京协和医院）、徐学刚（中国医科大学附属第一医院）、晏少彦（中山大学附属肿瘤医院）、高兴华（中国医科大学附属第一医院）、郭静珍（中山大学肿瘤防治中心）、陶赟峰（上海交通大学医学院附属第六人民医院）、屠格文（山东大学齐鲁医院）、黄啸（广东省人民医院）、黄风煜（首都医科大学附属宣武医院）、盛军俊（安徽医科大学第一附属医院）、谢永华（首都医科大学附属北京儿童医院）、管宇敌（首都医科大学附属宣武医院）、曹慧芳（四川大学华西医院）、清涧宏（首都医科大学附属北京天坛医院）、臧专（首都医科大学附属北京儿童医院）、臧强（首都医科大学附属北京天坛医院）、蒋守本（北京协和医院）、韩岩（解放军总医院第一医学中心）、韩鹏军（中山大学肿瘤防治中心）、鹏阳颢（广西医科大学第一附属医院）\n\n【1】参考删除-4:### 参考文献\n\n【2】参考删除-4:删除12:删除14:[1] Kallionpää R A，Uusitalo E，Leppävirta J，et al. Preval‐ence of neurofibromatosis type 1 in the Finnish population 删除12:[J]. Genet Med，2018，20（9）：1082-1086.\n\n【3】参考删除-4:删除12:删除14:[2] Legius E，Messiaen L，Wolkenstein P，et al. Revised di‐agnostic criteria for neurofibromatosis type 1 and Legius syn‐drome：an international consensus recommendation 删除12:[J]. Genet Med，2021，23（8）：1506-1513.\n\n【4】参考删除-4:删除12:删除14:[3] Nolisetel. Neurofibromatosis 删除12:[J]. Natl Inst Health Consens Dev Conf Consensus Statement，1987，6（12）：1-7.\n\n【5】参考删除-4:删除12:删除14:[4] National Multi-Center Treatment Collaboration Group For Neurofibromatosis Type，National Multi-Center Research Platform For Plastic And Reconstructive Surgery. [Expert consensus on diagnosis and management of neurofibromato‐sis type 1 删除19:(2021 edition)] 删除12:[J]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi，2021，35 删除11:(11)：1384-1395.\n\n【6】参考删除-4:删除12:删除14:[5] Messiaen L，Vogt J，Bengesser K，et al. Mosaic type1～NF1 microdeletions as a cause of both generalized and seg‐mental neurofibromatosis type-1 (NF1) 删除12:[J]. Hum Mutat，2011，32 删除11:(2)：213-219.\n\n【7】参考删除-4:删除12:删除14:[6] Boyce AM，Collins MT. Fibrous dysplasia/McCune-Albright syndrome：a rare，mosaic disease of gαs activation 删除12:[J]. Endocr Rev，2020，41 删除11:(2)：345-370.\n\n【8】参考删除-4:删除12:删除14:[7] Asthagiri AR，Parry DM，Butman JA，et al. Neurofibroma‐tosis type 2 删除12:[J]. Lancet，2009，373（9679）：1974-1986.\n\n【9】参考删除-4:删除12:删除14:[8] Roberts AE，Allanson JE，Tartaglia M，et al. Noonan syn‐drome 删除12:[J]. Lancet，2013，381 删除11:删除19:(9863)：333-342.\n\n【10】参考删除-4:删除12:删除14:[9] Gallon R，Phelps R，Hayes C，et al. Constitutional micro‐satellite instability，genotype and phenotype correlations in constitutional mismatch repair deficiency 删除12:[J]. Gastroenterol‐ogy，2022. doi：10.1053/j. gastro. 删除13:2022. 12. 017.\n\n【11】参考删除-4:删除12:删除14:[10] Gutmann DH，Ferner RE，Listernick RH，et al. Neurofi‐bromatosis type 1 删除12:[J]. Nat Rev Dis Primers，2017，3：17004.\n\n【12】参考删除-4:删除12:删除14:[11] Zhao S，Zhang Y，Chen W，et al. Diagnostic yield and clinical impact of exome sequencing in early-onset scoliosis (EOS) 删除12:[J]. J Med Genet，2021，58 删除11:(1)：41-47.\n\n【13】参考删除-4:删除12:删除14:[12] Kozłowska M，Callens T，Chen Y，et al. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p. Met1149，p. Arg1276，and p. Lys1423：genotype-phenotype study in neurofibromatosis type 1 删除12:[J]. Hum Mutat，2020，41 删除11:(1)：299-315.\n\n【14】参考删除-4:删除12:删除14:[13] Well J，Döbel K，Kluwe L，et al. Genotype-phenotype correlation in neurofibromatosis type-I：NF1 whole gene de‐letions lead to high tumor-burden and increased tumor-growth 删除12:[J]. PLoS Genet，2021，17 删除11:(5)：e1009517.\n\n【15】参考删除-4:删除12:删除14:[14] Tadini G，Legius E，Brems H. Multidisciplinary approach to neurofibromatosis type 1 删除12:[M]. Switzerland，Springer，2020：45-69.\n\n【16】参考删除-4:删除12:删除14:[15] Ortonne N，Wolkenstein P，Blakeley JO，et al. Cutaneous neurofibromas：current clinical and pathologic issues 删除12:[J]. Neurology，2018，91 (2 Suppl 1)：S5-S13.\n\n【17】参考删除-4:删除12:删除14:[16] 佘倩雯, 魏亚江, 王潇, 等.胶质脑瘤经纤维胆道的治疗 方案及研究进展 删除12:[J]. 中南医学麻醉外科杂志，2022，36（9）：1064-1071.\n\n【18】参考删除-4:删除12:删除14:[17] Chamseldin BH，Le LQ. Management of cutaneous neurofi‐broma：current therapy and future directions 删除12:[J]. Neuroloncol Adv，2019，2（Suppl 1）：i107-i116.\n\n【19】参考删除-4:删除12:删除14:[18] Wang R，Lin Z. A child with multiple hypopigmented lesions 删除12:[J]. BMJ，2021，372：m4844.\n\n【20】参考删除-4:删除12:删除14:[19] Ferrari F，Masurel A，Olivier-Faivre L，et al. Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1 删除12:[J]. JAMA Dermatol，2014，150 删除11:(1)：42-46.\n\n【21】参考删除-4:删除12:删除14:[20] Roy A，Roulin JL，Gras-Le Guen C，et al. Executive functions and quality of life in children with neurofibro‐matosis type 1 删除12:[J]. Orphanet J Rare Dis，2021，16 删除11:(1)：420.\n\n【22】参考删除-4:删除12:删除14:[21] Taylor LA，Lewis VL. Neurofibromatosis type I：review of cutaneous and subcutaneous tumor treatment on quality of life 删除12:[J]. Plast Reconstr Surg Glob Open，2019，7 删除11:(1)：e1982.", "content": "【0】页码:16\nⅠ型神经纤维瘤病多学科诊治指南（2023版）\n医院)、俄而（首都医科大学附属北京天坛医院）、徐子间（首都医科大学附属北京儿童医院）、徐向欣（北京协和医院）、徐学刚（中国医科大学附属第一医院）、晏少彦（中山大学附属肿瘤医院）、高兴华（中国医科大学附属第一医院）、郭静珍（中山大学肿瘤防治中心）、陶赟峰（上海交通大学医学院附属第六人民医院）、屠格文（山东大学齐鲁医院）、黄啸（广东省人民医院）、黄风煜（首都医科大学附属宣武医院）、盛军俊（安徽医科大学第一附属医院）、谢永华（首都医科大学附属北京儿童医院）、管宇敌（首都医科大学附属宣武医院）、曹慧芳（四川大学华西医院）、清涧宏（首都医科大学附属北京天坛医院）、臧专（首都医科大学附属北京儿童医院）、臧强（首都医科大学附属北京天坛医院）、蒋守本（北京协和医院）、韩岩（解放军总医院第一医学中心）、韩鹏军（中山大学肿瘤防治中心）、鹏阳颢（广西医科大学第一附属医院）\n\n【1】参考删除-4:<u>### 参考文献</u>\n\n【2】参考删除-4:<u>删除12:<u>删除14:<u>[1]</u></u> Kallionpää R A，Uusitalo E，Leppävirta J，et al. Preval‐ence of neurofibromatosis type 1 in the Finnish population 删除12:<u>[J]</u>. Genet Med，2018，20（9）：1082-1086.</u>\n\n【3】参考删除-4:<u>删除12:<u>删除14:<u>[2]</u></u> Legius E，Messiaen L，Wolkenstein P，et al. Revised di‐agnostic criteria for neurofibromatosis type 1 and Legius syn‐drome：an international consensus recommendation 删除12:<u>[J]</u>. Genet Med，2021，23（8）：1506-1513.</u>\n\n【4】参考删除-4:<u>删除12:<u>删除14:<u>[3]</u></u> Nolisetel. Neurofibromatosis 删除12:<u>[J]</u>. Natl Inst Health Consens Dev Conf Consensus Statement，1987，6（12）：1-7.</u>\n\n【5】参考删除-4:<u>删除12:<u>删除14:<u>[4]</u></u> National Multi-Center Treatment Collaboration Group For Neurofibromatosis Type，National Multi-Center Research Platform For Plastic And Reconstructive Surgery. [Expert consensus on diagnosis and management of neurofibromato‐sis type 1 删除19:<u>(2021 edition)</u>] 删除12:<u>[J]</u>. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi，2021，35 删除11:<u>(11)</u>：1384-1395.</u>\n\n【6】参考删除-4:<u>删除12:<u>删除14:<u>[5]</u></u> Messiaen L，Vogt J，Bengesser K，et al. Mosaic type1～NF1 microdeletions as a cause of both generalized and seg‐mental neurofibromatosis type-1 (NF1) 删除12:<u>[J]</u>. Hum Mutat，2011，32 删除11:<u>(2)</u>：213-219.</u>\n\n【7】参考删除-4:<u>删除12:<u>删除14:<u>[6]</u></u> Boyce AM，Collins MT. Fibrous dysplasia/McCune-Albright syndrome：a rare，mosaic disease of gαs activation 删除12:<u>[J]</u>. Endocr Rev，2020，41 删除11:<u>(2)</u>：345-370.</u>\n\n【8】参考删除-4:<u>删除12:<u>删除14:<u>[7]</u></u> Asthagiri AR，Parry DM，Butman JA，et al. Neurofibroma‐tosis type 2 删除12:<u>[J]</u>. Lancet，2009，373（9679）：1974-1986.</u>\n\n【9】参考删除-4:<u>删除12:<u>删除14:<u>[8]</u></u> Roberts AE，Allanson JE，Tartaglia M，et al. Noonan syn‐drome 删除12:<u>[J]</u>. Lancet，2013，381 删除11:<u>删除19:<u>(9863)</u></u>：333-342.</u>\n\n【10】参考删除-4:<u>删除12:<u>删除14:<u>[9]</u></u> Gallon R，Phelps R，Hayes C，et al. Constitutional micro‐satellite instability，genotype and phenotype correlations in constitutional mismatch repair deficiency 删除12:<u>[J]</u>. Gastroenterol‐ogy，2022. doi：10.1053/j. gastro. 删除13:<u>2022. 12</u>. 017.</u>\n\n【11】参考删除-4:<u>删除12:<u>删除14:<u>[10]</u></u> Gutmann DH，Ferner RE，Listernick RH，et al. Neurofi‐bromatosis type 1 删除12:<u>[J]</u>. Nat Rev Dis Primers，2017，3：17004.</u>\n\n【12】参考删除-4:<u>删除12:<u>删除14:<u>[11]</u></u> Zhao S，Zhang Y，Chen W，et al. Diagnostic yield and clinical impact of exome sequencing in early-onset scoliosis (EOS) 删除12:<u>[J]</u>. J Med Genet，2021，58 删除11:<u>(1)</u>：41-47.</u>\n\n【13】参考删除-4:<u>删除12:<u>删除14:<u>[12]</u></u> Kozłowska M，Callens T，Chen Y，et al. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p. Met1149，p. Arg1276，and p. Lys1423：genotype-phenotype study in neurofibromatosis type 1 删除12:<u>[J]</u>. Hum Mutat，2020，41 删除11:<u>(1)</u>：299-315.</u>\n\n【14】参考删除-4:<u>删除12:<u>删除14:<u>[13]</u></u> Well J，Döbel K，Kluwe L，et al. Genotype-phenotype correlation in neurofibromatosis type-I：NF1 whole gene de‐letions lead to high tumor-burden and increased tumor-growth 删除12:<u>[J]</u>. PLoS Genet，2021，17 删除11:<u>(5)</u>：e1009517.</u>\n\n【15】参考删除-4:<u>删除12:<u>删除14:<u>[14]</u></u> Tadini G，Legius E，Brems H. Multidisciplinary approach to neurofibromatosis type 1 删除12:<u>[M]</u>. Switzerland，Springer，2020：45-69.</u>\n\n【16】参考删除-4:<u>删除12:<u>删除14:<u>[15]</u></u> Ortonne N，Wolkenstein P，Blakeley JO，et al. Cutaneous neurofibromas：current clinical and pathologic issues 删除12:<u>[J]</u>. Neurology，2018，91 (2 Suppl 1)：S5-S13.</u>\n\n【17】参考删除-4:<u>删除12:<u>删除14:<u>[16]</u></u> 佘倩雯, 魏亚江, 王潇, 等.胶质脑瘤经纤维胆道的治疗 方案及研究进展 删除12:<u>[J]</u>. 中南医学麻醉外科杂志，2022，36（9）：1064-1071.</u>\n\n【18】参考删除-4:<u>删除12:<u>删除14:<u>[17]</u></u> Chamseldin BH，Le LQ. Management of cutaneous neurofi‐broma：current therapy and future directions 删除12:<u>[J]</u>. Neuroloncol Adv，2019，2（Suppl 1）：i107-i116.</u>\n\n【19】参考删除-4:<u>删除12:<u>删除14:<u>[18]</u></u> Wang R，Lin Z. A child with multiple hypopigmented lesions 删除12:<u>[J]</u>. BMJ，2021，372：m4844.</u>\n\n【20】参考删除-4:<u>删除12:<u>删除14:<u>[19]</u></u> Ferrari F，Masurel A，Olivier-Faivre L，et al. Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1 删除12:<u>[J]</u>. JAMA Dermatol，2014，150 删除11:<u>(1)</u>：42-46.</u>\n\n【21】参考删除-4:<u>删除12:<u>删除14:<u>[20]</u></u> Roy A，Roulin JL，Gras-Le Guen C，et al. Executive functions and quality of life in children with neurofibro‐matosis type 1 删除12:<u>[J]</u>. Orphanet J Rare Dis，2021，16 删除11:<u>(1)</u>：420.</u>\n\n【22】参考删除-4:<u>删除12:<u>删除14:<u>[21]</u></u> Taylor LA，Lewis VL. Neurofibromatosis type I：review of cutaneous and subcutaneous tumor treatment on quality of life 删除12:<u>[J]</u>. Plast Reconstr Surg Glob Open，2019，7 删除11:<u>(1)</u>：e1982.</u>", "index": 0, "show": true, "start": 0, "end": 4458, "province": ["信息质量", "有用性-重"], "isEdit": false}], "startTime": "2024/08/06 15:48:44", "endTime": "2024/08/06 15:49:13", "cost": 28.925}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:49:13", "grab_time": "2024-08-05 23:48:44"}
{"id": 2211606, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "b7209a6a-3d31-4cef-b8d8-8bce441b1c21", "title": "2023 ERS临床实践指南：慢性阻塞性肺病或间质性肺病患者的姑息治疗", "text": "页码:178\n2023 ERS临床实践指南：慢性阻塞性肺病或间质性肺病患者的姑息治疗\n|                 |               |\n|-----------------|---------------|\n| 删除32:<u>**</u>Current practice删除32:<u>**</u> | 删除32:<u>**</u>Models of COPD palliative care删除32:<u>**</u> |\n|                 | Three of the systematic reviews explicitly considered implementation of palliative care in terms of 'patients, professionals and organisations,' and this approach was implicit in other reviews and original research papers. |\n|                 | 删除32:<u>**</u>People with COPD or ILD and their informal caregivers.删除32:<u>**</u> Key priorities for people with COPD or ILD and their informal caregivers was accessing information about COPD and support services, COPQ1,2,14,33,40,41,45,47optimising treatment to reduce physical symptoms, COPQ1,2,5,19,26 coping with psychosocial challenges and maintaining activities they enjoy, COPQ 2,19,25 and 'being listened to' so that their care is appropriately tailored. COPQ 15,56 Empathy,14 feeling 'cared for', COPQ 32 establishing, maintaining, and in due course closing, COPQ15 a relationship were valued, COPQ 15,35and led to increased confidence in ability to cope. COPQ Informal caregivers echoed the need for information, and valued practical support (e.g. respite care; resources) for their caring role. COPQ 5,14,17,47 |\n|                 | 删除32:<u>**</u>Skilled professionals.删除32:<u>**</u> Studies stressed the need for knowledgeable professionals, trained in respiratory and palliative care and with access to multidisciplinary generalist and specialist expertise. COPQ 1-3,20,35,36,39,42,49,52,54,56,57 Specific skills required included ability to optimise treatment, COPQ 2,51,7 provide holistic care, COPQ 2,51,7,19,20 and discuss prognosis and ACP, COPQ 2,3,9,19,20,26,39,45,47,52,56 in advance of critical events. COPQ 23 Lead/co-ordinating professionals could be from specialist respiratory or palliative care disciplines, general practitioners or community nurses, COPQ1-3,8,9 but continuity of care was described as crucial enabling a trusted relationship to form. COPQ 2,3,14,29,35,50 |\n|                 | 删除32:<u>**</u>Flexible, multidisciplinary organisation.删除32:<u>**</u> Models of care delivery varied, but key considerations are a service that is accessible (often community-based), COPQ 12-45 flexible to respond to individual needs and a fluctuating clinical condition, COPQ 2,17 |\n\n【1】A whole systems approach is widely applied to improving the quality of healthcare and was adopted (or modified) by three of the SRs and several other studies in this review. This framework identifies levels that need to be addressed to effect change. Initiatives in both COPD and ILD fitted within this approach offering a framework for synthesising the findings:\n\n【2】- Individual (person with COPD or ILD) level\n- Professional level\n- Local organization of healthcare system level\n- National policy and context", "tags": {}, "lang": "en", "attr": {"page_num": 178, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ERS临床实践指南：慢性阻塞性肺病或间质性肺病患者的姑息治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "1,2,14,33,40,41,45,47", "content": "页码:178\n2023 ERS临床实践指南：慢性阻塞性肺病或间质性肺病患者的姑息治疗\n|                 |               |\n|-----------------|---------------|\n| 删除32:<u>**</u>Current practice删除32:<u>**</u> | 删除32:<u>**</u>Models of COPD palliative care删除32:<u>**</u> |\n|                 | Three of the systematic reviews explicitly considered implementation of palliative care in terms of 'patients, professionals and organisations,' and this approach was implicit in other reviews and original research papers. |\n|                 | 删除32:<u>**</u>People with COPD or ILD and their informal caregivers.删除32:<u>**</u> Key priorities for people with COPD or ILD and their informal caregivers was accessing information about COPD and support services, COPQ1,2,14,33,40,41,45,47optimising treatment to reduce physical symptoms, COPQ1,2,5,19,26 coping with psychosocial challenges and maintaining activities they enjoy, COPQ 2,19,25 and 'being listened to' so that their care is appropriately tailored. COPQ 15,56 Empathy,14 feeling 'cared for', COPQ 32 establishing, maintaining, and in due course closing, COPQ15 a relationship were valued, COPQ 15,35and led to increased confidence in ability to cope. COPQ Informal caregivers echoed the need for information, and valued practical support (e.g. respite care; resources) for their caring role. COPQ 5,14,17,47 |\n|                 | 删除32:<u>**</u>Skilled professionals.删除32:<u>**</u> Studies stressed the need for knowledgeable professionals, trained in respiratory and palliative care and with access to multidisciplinary generalist and specialist expertise. COPQ 1-3,20,35,36,39,42,49,52,54,56,57 Specific skills required included ability to optimise treatment, COPQ 2,51,7 provide holistic care, COPQ 2,51,7,19,20 and discuss prognosis and ACP, COPQ 2,3,9,19,20,26,39,45,47,52,56 in advance of critical events. COPQ 23 Lead/co-ordinating professionals could be from specialist respiratory or palliative care disciplines, general practitioners or community nurses, COPQ1-3,8,9 but continuity of care was described as crucial enabling a trusted relationship to form. COPQ 2,3,14,29,35,50 |\n|                 | 删除32:<u>**</u>Flexible, multidisciplinary organisation.删除32:<u>**</u> Models of care delivery varied, but key considerations are a service that is accessible (often community-based), COPQ 12-45 flexible to respond to individual needs and a fluctuating clinical condition, COPQ 2,17 |\n\n【1】A whole systems approach is widely applied to improving the quality of healthcare and was adopted (or modified) by three of the SRs and several other studies in this review. This framework identifies levels that need to be addressed to effect change. Initiatives in both COPD and ILD fitted within this approach offering a framework for synthesising the findings:\n\n【2】- Individual (person with COPD or ILD) level\n- Professional level\n- Local organization of healthcare system level\n- National policy and context", "index": 136, "show": true, "start": 136, "end": 157, "province": ["文本干净度", "页码/数字"], "isEdit": false, "comment": "应用全文"}], "startTime": "2024/08/06 17:16:11", "endTime": "2024/08/06 17:17:29", "cost": 78.746}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 01:17:30", "grab_time": "2024-08-06 01:16:10"}
{"id": 2211605, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "d8f1f011-bf98-45d3-bca3-606477d7f626", "title": "SNMMI 程序标准SSTR PET 的 EANM 实践指南：神经内分泌肿瘤成像(1)", "text": "【0】页码:5\nSNMMI 程序标准SSTR PET 的 EANM 实践指南：神经内分泌肿瘤成像(1)\n### C. Technical Details\n\n【1】Study-specific information should include the radiopharmaceutical, the amount of injected activity in mega­becquerels (MBq) or millicuries (mCi), the route (intravenous) and anatomic site of administration, and the date and time of administration. If extravasation is seen, it should also be noted. The uptake time interval between the administration of the radiopharmaceutical and the start time of the acquisition should be reported. The body parts covered by imaging should be described. Any nonstandard position of the patient should be stated.\n\n【2】The direction and range the patient image was acquired should be stated (i.e., \"images were acquired from the vertex to the midthigh\"). If a nonoptimized CT was performed for attenuation correction and anatomic registration of the emission images only, the description may be limited to a short statement including the mAs and kVp. If a diagnostic CT was performed, then a more detailed description of the CT protocol and anatomic findings should be provided. Dosimetry parameters should be included if required by national or local regulations. The report should state whether contrast-enhanced or nonenhanced CT was used for attenuation correction.\n\n【3】### D. Description of Findings\n\n【4】Quality issues of the PET, for example, motion artifacts, halo artifacts due to high activity in the collecting urinary system, or attenuation artifacts (from attenuating materials), should be reported.\n\n【5】### E. Interpretation\n\n【6】#### 1. Biodistribution.\n\n【7】Physiologic uptake is present and most intense in the kidneys and bladder, spleen, and liver . Normal uptake is also seen in the pituitary, adrenal glands, salivary glands, and the thyroid 删除11:<u>(22)</u>. $$^{64}Cu$$-DOTATATE allows for late imaging. At 3 h after injection, $$^{64}Cu$$-DOTATATE uptake decreases for kidney and bladder, remains unchanged for spleen, and increases for liver, although differences in early versus late biodistribution do not impact lesion detection 删除11:<u>(20)</u>. At early time-point acquisition, no clinically meaningful difference in organ uptake was demonstrated for $$^{68}Ga$$-DOTATOC versus $$^{64}Cu$$-DOTATATE 删除11:<u>(23)</u> or $$^{68}Ga$$-DOTATATE versus $$^{68}Ga$$-DOTATOC, respectively 删除11:<u>(20)</u>. There are no major differences between physiologic uptake of $$^{64}Cu$$-DOTATATE and $$^{68}Ga$$-labeled DOTATATE 删除9:<u>(Table 2)</u> 删除11:<u>(24)</u>.\n\n【8】#### 2. General Interpretation.\n\n【9】Images should be interpreted by a physician trained in SSTR PET/CT imaging and informed about the clinical context of the scan indication (e.g., staging, assessment for PRRT, restaging). Focal tracer uptake that cannot be explained by physiologic biodistribution or that is higher than organ background activity is to be considered pathologic, especially if there is a correlating abnormal structure on CT. Consistent qualitative grading of uptake (mild = blood pool, moderate = liver, intense = clearly above liver) can be used in addition to SUV-related measurements and modified Krenning score.\n\n【10】#### 3. Incidental Findings, Normal Variants, and Important Pitfalls.\n\n【11】Increased uptake on SSTR PET does not make the diagnosis of a NET, and care should be taken in interpretation. For example, physiologically increased uptake in the head/uncinate process of the pancreas is observed in a large portion of patients 删除9:<u>(diffuse or focal) and usually remains stable over time 删除11:<u>(25)</u></u>. This physiologic uptake in the head/uncinate process of the pancreas is thought to be caused by a higher concentration of pancreatic polypeptide producing cells in this region. There is a significant overlap between\n\n【12】#### TABLE 2\n\n【13】删除32:<u>**</u>Comparison of physiologic uptake of $$^{68}Ga$$-DOTATATE and $$^{64}Cu$$-DOTATATE删除32:<u>**</u>\n\n| Organ SUV$_{\\text{mean}}$ , mean (SD) | $$^{68}Ga$$-DOTATATE (60–80 min after injection) 删除11:<u>(20)</u> | $$^{68}Ga$$-DOTATOC (50–70 min after injection) 删除11:<u>(57)</u> | $$^{64}Cu$$-DOTATATE (43–80 min after injection) 删除11:<u>(24)</u> |\n|----------------------------------------|------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|\n| Liver                                  | 4.5 删除11:<u>(1.5)</u>                                            | 5.7 删除11:<u>(1.6)</u>                                          | 4.0 删除11:<u>(1.1)</u>                                          |\n| Spleen                                 | 15.5 删除11:<u>(5.5)</u>                                           | —                                                  | 8.9 删除11:<u>(3.4)</u>                                          |\n| Pituitary gland                        | 6.8 删除11:<u>(2.3)</u>                                            | 4.1 删除11:<u>(1.8)</u>                                          | 12.9 删除11:<u>(6.1)</u>                                         |\n| Adrenal gland                          | 10.1 删除11:<u>(3.7)</u>                                           | 7.2 删除11:<u>(3.1)</u>                                          | 9.5 删除11:<u>(4.4)</u>                                          |\n| Uncinate process of pancreas           | 6.7 删除11:<u>(2.2)</u>                                            | —                                                  | 3.2 删除11:<u>(0.5)</u>                                          |\n\n【15】删除32:<u>*</u>Median.", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/SNMMI 程序标准SSTR PET 的 EANM 实践指南：神经内分泌肿瘤成像(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "C. Technical Details", "content": "【0】页码:5\nSNMMI 程序标准SSTR PET 的 EANM 实践指南：神经内分泌肿瘤成像(1)\n### C. Technical Details\n\n【1】Study-specific information should include the radiopharmaceutical, the amount of injected activity in mega­becquerels (MBq) or millicuries (mCi), the route (intravenous) and anatomic site of administration, and the date and time of administration. If extravasation is seen, it should also be noted. The uptake time interval between the administration of the radiopharmaceutical and the start time of the acquisition should be reported. The body parts covered by imaging should be described. Any nonstandard position of the patient should be stated.\n\n【2】The direction and range the patient image was acquired should be stated (i.e., \"images were acquired from the vertex to the midthigh\"). If a nonoptimized CT was performed for attenuation correction and anatomic registration of the emission images only, the description may be limited to a short statement including the mAs and kVp. If a diagnostic CT was performed, then a more detailed description of the CT protocol and anatomic findings should be provided. Dosimetry parameters should be included if required by national or local regulations. The report should state whether contrast-enhanced or nonenhanced CT was used for attenuation correction.\n\n【3】### D. Description of Findings\n\n【4】Quality issues of the PET, for example, motion artifacts, halo artifacts due to high activity in the collecting urinary system, or attenuation artifacts (from attenuating materials), should be reported.\n\n【5】### E. Interpretation\n\n【6】#### 1. Biodistribution.\n\n【7】Physiologic uptake is present and most intense in the kidneys and bladder, spleen, and liver . Normal uptake is also seen in the pituitary, adrenal glands, salivary glands, and the thyroid 删除11:<u>(22)</u>. $$^{64}Cu$$-DOTATATE allows for late imaging. At 3 h after injection, $$^{64}Cu$$-DOTATATE uptake decreases for kidney and bladder, remains unchanged for spleen, and increases for liver, although differences in early versus late biodistribution do not impact lesion detection 删除11:<u>(20)</u>. At early time-point acquisition, no clinically meaningful difference in organ uptake was demonstrated for $$^{68}Ga$$-DOTATOC versus $$^{64}Cu$$-DOTATATE 删除11:<u>(23)</u> or $$^{68}Ga$$-DOTATATE versus $$^{68}Ga$$-DOTATOC, respectively 删除11:<u>(20)</u>. There are no major differences between physiologic uptake of $$^{64}Cu$$-DOTATATE and $$^{68}Ga$$-labeled DOTATATE 删除9:<u>(Table 2)</u> 删除11:<u>(24)</u>.\n\n【8】#### 2. General Interpretation.\n\n【9】Images should be interpreted by a physician trained in SSTR PET/CT imaging and informed about the clinical context of the scan indication (e.g., staging, assessment for PRRT, restaging). Focal tracer uptake that cannot be explained by physiologic biodistribution or that is higher than organ background activity is to be considered pathologic, especially if there is a correlating abnormal structure on CT. Consistent qualitative grading of uptake (mild = blood pool, moderate = liver, intense = clearly above liver) can be used in addition to SUV-related measurements and modified Krenning score.\n\n【10】#### 3. Incidental Findings, Normal Variants, and Important Pitfalls.\n\n【11】Increased uptake on SSTR PET does not make the diagnosis of a NET, and care should be taken in interpretation. For example, physiologically increased uptake in the head/uncinate process of the pancreas is observed in a large portion of patients 删除9:<u>(diffuse or focal) and usually remains stable over time 删除11:<u>(25)</u></u>. This physiologic uptake in the head/uncinate process of the pancreas is thought to be caused by a higher concentration of pancreatic polypeptide producing cells in this region. There is a significant overlap between\n\n【12】#### TABLE 2\n\n【13】删除32:<u>**</u>Comparison of physiologic uptake of $$^{68}Ga$$-DOTATATE and $$^{64}Cu$$-DOTATATE删除32:<u>**</u>\n\n| Organ SUV$_{\\text{mean}}$ , mean (SD) | $$^{68}Ga$$-DOTATATE (60–80 min after injection) 删除11:<u>(20)</u> | $$^{68}Ga$$-DOTATOC (50–70 min after injection) 删除11:<u>(57)</u> | $$^{64}Cu$$-DOTATATE (43–80 min after injection) 删除11:<u>(24)</u> |\n|----------------------------------------|------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|\n| Liver                                  | 4.5 删除11:<u>(1.5)</u>                                            | 5.7 删除11:<u>(1.6)</u>                                          | 4.0 删除11:<u>(1.1)</u>                                          |\n| Spleen                                 | 15.5 删除11:<u>(5.5)</u>                                           | —                                                  | 8.9 删除11:<u>(3.4)</u>                                          |\n| Pituitary gland                        | 6.8 删除11:<u>(2.3)</u>                                            | 4.1 删除11:<u>(1.8)</u>                                          | 12.9 删除11:<u>(6.1)</u>                                         |\n| Adrenal gland                          | 10.1 删除11:<u>(3.7)</u>                                           | 7.2 删除11:<u>(3.1)</u>                                          | 9.5 删除11:<u>(4.4)</u>                                          |\n| Uncinate process of pancreas           | 6.7 删除11:<u>(2.2)</u>                                            | —                                                  | 3.2 删除11:<u>(0.5)</u>                                          |\n\n【15】删除32:<u>*</u>Median.", "index": 56, "show": true, "start": 56, "end": 76, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "0"}, {"text": "删除11:(1.5)", "content": "【0】页码:5\nSNMMI 程序标准SSTR PET 的 EANM 实践指南：神经内分泌肿瘤成像(1)\n### <mark>C. Technical Details</mark>\n\n【1】Study-specific information should include the radiopharmaceutical, the amount of injected activity in mega­becquerels (MBq) or millicuries (mCi), the route (intravenous) and anatomic site of administration, and the date and time of administration. If extravasation is seen, it should also be noted. The uptake time interval between the administration of the radiopharmaceutical and the start time of the acquisition should be reported. The body parts covered by imaging should be described. Any nonstandard position of the patient should be stated.\n\n【2】The direction and range the patient image was acquired should be stated (i.e., \"images were acquired from the vertex to the midthigh\"). If a nonoptimized CT was performed for attenuation correction and anatomic registration of the emission images only, the description may be limited to a short statement including the mAs and kVp. If a diagnostic CT was performed, then a more detailed description of the CT protocol and anatomic findings should be provided. Dosimetry parameters should be included if required by national or local regulations. The report should state whether contrast-enhanced or nonenhanced CT was used for attenuation correction.\n\n【3】### D. Description of Findings\n\n【4】Quality issues of the PET, for example, motion artifacts, halo artifacts due to high activity in the collecting urinary system, or attenuation artifacts (from attenuating materials), should be reported.\n\n【5】### E. Interpretation\n\n【6】#### 1. Biodistribution.\n\n【7】Physiologic uptake is present and most intense in the kidneys and bladder, spleen, and liver . Normal uptake is also seen in the pituitary, adrenal glands, salivary glands, and the thyroid 删除11:<u>(22)</u>. $$^{64}Cu$$-DOTATATE allows for late imaging. At 3 h after injection, $$^{64}Cu$$-DOTATATE uptake decreases for kidney and bladder, remains unchanged for spleen, and increases for liver, although differences in early versus late biodistribution do not impact lesion detection 删除11:<u>(20)</u>. At early time-point acquisition, no clinically meaningful difference in organ uptake was demonstrated for $$^{68}Ga$$-DOTATOC versus $$^{64}Cu$$-DOTATATE 删除11:<u>(23)</u> or $$^{68}Ga$$-DOTATATE versus $$^{68}Ga$$-DOTATOC, respectively 删除11:<u>(20)</u>. There are no major differences between physiologic uptake of $$^{64}Cu$$-DOTATATE and $$^{68}Ga$$-labeled DOTATATE 删除9:<u>(Table 2)</u> 删除11:<u>(24)</u>.\n\n【8】#### 2. General Interpretation.\n\n【9】Images should be interpreted by a physician trained in SSTR PET/CT imaging and informed about the clinical context of the scan indication (e.g., staging, assessment for PRRT, restaging). Focal tracer uptake that cannot be explained by physiologic biodistribution or that is higher than organ background activity is to be considered pathologic, especially if there is a correlating abnormal structure on CT. Consistent qualitative grading of uptake (mild = blood pool, moderate = liver, intense = clearly above liver) can be used in addition to SUV-related measurements and modified Krenning score.\n\n【10】#### 3. Incidental Findings, Normal Variants, and Important Pitfalls.\n\n【11】Increased uptake on SSTR PET does not make the diagnosis of a NET, and care should be taken in interpretation. For example, physiologically increased uptake in the head/uncinate process of the pancreas is observed in a large portion of patients 删除9:<u>(diffuse or focal) and usually remains stable over time 删除11:<u>(25)</u></u>. This physiologic uptake in the head/uncinate process of the pancreas is thought to be caused by a higher concentration of pancreatic polypeptide producing cells in this region. There is a significant overlap between\n\n【12】#### TABLE 2\n\n【13】删除32:<u>**</u>Comparison of physiologic uptake of $$^{68}Ga$$-DOTATATE and $$^{64}Cu$$-DOTATATE删除32:<u>**</u>\n\n| Organ SUV$_{\\text{mean}}$ , mean (SD) | $$^{68}Ga$$-DOTATATE (60–80 min after injection) 删除11:<u>(20)</u> | $$^{68}Ga$$-DOTATOC (50–70 min after injection) 删除11:<u>(57)</u> | $$^{64}Cu$$-DOTATATE (43–80 min after injection) 删除11:<u>(24)</u> |\n|----------------------------------------|------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|\n| Liver                                  | 4.5 删除11:<u>(1.5)</u>                                            | 5.7 删除11:<u>(1.6)</u>                                          | 4.0 删除11:<u>(1.1)</u>                                          |\n| Spleen                                 | 15.5 删除11:<u>(5.5)</u>                                           | —                                                  | 8.9 删除11:<u>(3.4)</u>                                          |\n| Pituitary gland                        | 6.8 删除11:<u>(2.3)</u>                                            | 4.1 删除11:<u>(1.8)</u>                                          | 12.9 删除11:<u>(6.1)</u>                                         |\n| Adrenal gland                          | 10.1 删除11:<u>(3.7)</u>                                           | 7.2 删除11:<u>(3.1)</u>                                          | 9.5 删除11:<u>(4.4)</u>                                          |\n| Uncinate process of pancreas           | 6.7 删除11:<u>(2.2)</u>                                            | —                                                  | 3.2 删除11:<u>(0.5)</u>                                          |\n\n【15】删除32:<u>*</u>Median.", "index": 4402, "show": true, "start": 4389, "end": 4399, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "表格内多处误删"}], "startTime": "2024/08/06 16:15:44", "endTime": "2024/08/06 16:16:50", "cost": 66.303}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:16:50", "grab_time": "2024-08-06 00:15:43"}
{"id": 2211604, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "452508bd-b093-474a-aa30-afdd054edfd7", "title": "CCMG：卵巢癌BRCA肿瘤检测实践指南（2022)", "text": "【0】页码:8\nCCMG：卵巢癌BRCA肿瘤检测实践指南（2022)\n# Review\n\n【1】If a loss-of-function BRCA1/2 variant is detected, a statement such as, “The presence of this loss-of-function BRCA1/2 variant can be associated with a favourable response to PARP inhibitors treatment” should be included.\n\n【2】If no clinically actionable BRCA1/2 variant is detected, a statement such as, “The absence of a clinically actionable BRCA1/2 variant can be associated with a less favourable response to PARP inhibitors treatment”, should be included.\n\n【3】## Quality assurance\n\n【4】删除32:<u>**</u>Recommendation 10删除32:<u>**</u>\n\n【5】Laboratories should participate in external quality assessment specific for BRCA1/2 tumour testing from FFPE tissue and reporting of BRCA1/2 variants in HGSC.\n\n【6】Quality assessment programs for BRCA1/2 tumour testing are available from accredited European external Quality Assessment (EQA) providers (The European Molecular Genetics Network and Genomics Quality Assessment). To our knowledge, there are currently no North American tumour BRCA1/2 EQA; however, there is a possibility that somatic BRCA1/2 EQA could be offered through the Canadian Biomarker Quality Assurance programme in the future. Laboratories should participate in one of the certified EQAs or engage in a sample exchange programme with other clinical laboratories in Canada according to their provincial laboratory accreditation programs. As there are numerous pre-analytical, analytical and post-analytical differences in assessing BRCA1/2 variants in tumour compared with germline, the samples for this EQA should originate from tumour FFPE material; germline BRCA1/2 EQA schemes are insufficient for tumour testing.\n\n【7】Laboratories are encouraged to continue to monitor and maintain classifications of variants with the aim to improve and standardize variant classifications.\n\n【8】## CONCLUSIONS\n\n【9】This guideline presents recommendations for BRCA1/2 tumour testing in Canadian clinical laboratories. The guideline encompasses pre-analytical, analytical, post-analytical and reporting aspects of BRCA1/2 testing in ovarian tumours. The aim of this guideline is to provide national standards for clinical laboratories that are providing BRCA1/2 ovarian tumour testing. We also envision that these recommendations could be useful to Canadian laboratory accredited to assess developing NGS standards for BRCA1/2 tumour testing. We also recognize that personalised genome medicine is a fast-evolving field and that soon, testing for additional genes will likely become relevant in OC in the context of PARPi sensitivity, and that PARPi treatment could be approved in additional tumour types. The key aspects of this guideline could be applied to both scenarios.", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/CCMG：卵巢癌BRCA肿瘤检测实践指南（2022).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【7】Laboratories are encouraged ", "content": "【0】页码:8\nCCMG：卵巢癌BRCA肿瘤检测实践指南（2022)\n# Review\n\n【1】If a loss-of-function BRCA1/2 variant is detected, a statement such as, “The presence of this loss-of-function BRCA1/2 variant can be associated with a favourable response to PARP inhibitors treatment” should be included.\n\n【2】If no clinically actionable BRCA1/2 variant is detected, a statement such as, “The absence of a clinically actionable BRCA1/2 variant can be associated with a less favourable response to PARP inhibitors treatment”, should be included.\n\n【3】## Quality assurance\n\n【4】删除32:<u>**</u>Recommendation 10删除32:<u>**</u>\n\n【5】Laboratories should participate in external quality assessment specific for BRCA1/2 tumour testing from FFPE tissue and reporting of BRCA1/2 variants in HGSC.\n\n【6】Quality assessment programs for BRCA1/2 tumour testing are available from accredited European external Quality Assessment (EQA) providers (The European Molecular Genetics Network and Genomics Quality Assessment). To our knowledge, there are currently no North American tumour BRCA1/2 EQA; however, there is a possibility that somatic BRCA1/2 EQA could be offered through the Canadian Biomarker Quality Assurance programme in the future. Laboratories should participate in one of the certified EQAs or engage in a sample exchange programme with other clinical laboratories in Canada according to their provincial laboratory accreditation programs. As there are numerous pre-analytical, analytical and post-analytical differences in assessing BRCA1/2 variants in tumour compared with germline, the samples for this EQA should originate from tumour FFPE material; germline BRCA1/2 EQA schemes are insufficient for tumour testing.\n\n【7】Laboratories are encouraged to continue to monitor and maintain classifications of variants with the aim to improve and standardize variant classifications.\n\n【8】## CONCLUSIONS\n\n【9】This guideline presents recommendations for BRCA1/2 tumour testing in Canadian clinical laboratories. The guideline encompasses pre-analytical, analytical, post-analytical and reporting aspects of BRCA1/2 testing in ovarian tumours. The aim of this guideline is to provide national standards for clinical laboratories that are providing BRCA1/2 ovarian tumour testing. We also envision that these recommendations could be useful to Canadian laboratory accredited to assess developing NGS standards for BRCA1/2 tumour testing. We also recognize that personalised genome medicine is a fast-evolving field and that soon, testing for additional genes will likely become relevant in OC in the context of PARPi sensitivity, and that PARPi treatment could be approved in additional tumour types. The key aspects of this guideline could be applied to both scenarios.", "index": 1679, "show": true, "start": 1679, "end": 1710, "province": ["语义有效性", "语义不完整"], "isEdit": false}], "startTime": "2024/08/06 16:44:25", "endTime": "2024/08/06 16:45:29", "cost": 63.749}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:45:29", "grab_time": "2024-08-06 00:44:25"}
{"id": 2211603, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "f6747ceb-5975-4fbe-9a4f-7e7eca955d8e", "title": "2023 国际共识指南：小于胎龄儿—婴儿期到成年早期的病因学和管理(1)", "text": "【0】页码:12\n2023 国际共识指南：小于胎龄儿—婴儿期到成年早期的病因学和管理(1)\nTable 3. Imprinting disorders and methylation disturbances in short children born SGA\n\n| Syndrome 删除12:<u>[OMIM]</u>                        | Epigenetic defect                                                                                                                           | Incidence           | Mean BW BL SDS               | Clinical features besides SGA                                                                                                                                 | Treatment                                      |\n|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|\n| Silver-Russell syndrome 删除14:<u>删除24:<u>[180860]</u> </u>      | 11p15 LOM (30%-60%), upd删除11:<u>(7)</u> mat (5%-10%), upd删除11:<u>(20)</u>mat, upd删除11:<u>(16)</u> mat cd CDKN1C, HMGA2, PLAG1 and CNVs Exception # Paternal IGF2 mutation 删除9:<u>(see Table 1)</u> | 1:30,000-100,000    | 11p15: –3.2 \\newline 4.5 \\newline UPD7:– 2.7 \\newline –2.5 \\newline Clinical: –2.7/–1.8      | Relative macrocephaly, protruding forehead, body asymmetry, feeding problems and/or low BMI                                                                   | GH effective (in label of registered GH treatment for short SGA)                     |\n| Temple syndrome 删除14:<u>删除24:<u>[616222]</u> </u>              | 14q32 abnormalities: upd删除11:<u>(14)</u>mat, paternal microdeletions, hypomethylation of DLK1/GTL2 IG-DMR                                               | < 100 cases          | –1.9/–1.6                    | Postnatal growth failure, hypotonia, delayed development of motor skills, feeding problems in infancy, early puberty, broad forehead, short nose with nasal tip, small hands and feet | Insufficient data                               |\n| IMAGe syndrome 删除14:<u>删除24:<u>[614732]</u> </u>               | Maternally inherited activating mutations in CDKN1C                                                                                          | ≈ 15 cases           | –2.0 to –4.0                 | Relative macrocephaly at birth, no or mild intellectual disability, frontal bossing, low-set ears, flat nasal bridge, short nose, congenital adrenal hypoplasia, metaphyseal and/or epiphyseal dysplasia, male genital anomalies | Insufficient data                               |\n| Prader-Willi syndrome 删除14:<u>删除24:<u>[176270]</u> </u>        | Paternal 15q11.2q13 deletion (60%), upd删除11:<u>(15)</u>mat (40%), or imprinting center mutation (1–3%). Loss of SNRPN and NDN expression                 | 1:16,000             | –1.2/–1.1                    | Diminished fetal activity, obesity, muscular hypotonia in late infancy, moderate intellectual disability, short stature, hypogonadotropic hypogonadism, small hands and feet | GH registered for PWS                           |\n| Pseudohypoparathyroidism type Ia/e 删除14:<u>删除24:<u>[103580]</u> </u>| Heterozygous GNAS1 mutation inherited from the mother                                                                                         | 1:150,000            | –0.6/–1.1 35% born SGA       | Resistance to PTH and other hormones (TSH, LH, FSH and GHRH), Albright hereditary osteodystrophy (short stature, obesity, round face, subcutaneous ossifications, brachydactyly, mild intellectual disability)                                 | Insufficient data                               |\n| Pseudopseudo-hypoparathyroidism 删除14:<u>删除24:<u>[612463]</u> </u>| Heterozygous GNAS1 mutation inherited from the father                                                                                        | 1:150,000            | –2.7/–3.0 95% born SGA       | Albright hereditary osteodystrophy without multiple hormone resistance and no hypocalcemia                                                                      | Insufficient data                               |\n\n【2】Abbreviations: act, activating; BL, birth length; BMI, body mass index; BW, birth weight; DM, diabetes mellitus; FSH, follicle-stimulating hormone; LH, luteinizing hormone; LOM, loss of methylation; SGA, small for gestational age; upd, unipar, material uniparental disomy. \n“Pseudohypoparathyroidism type 1b 删除24:<u>[OMIM 603233]</u> is associated with normal or increased birth weight and overgrowth in childhood.\n\n【3】mutations also have sensorineural deafness 删除19:<u>(OMIM-608747)</u> 删除11:<u>(141)</u>.\n\n【4】Children with a heterozygous IGF1R mutation 删除19:<u>(MIM 270450)</u> have a wide range of birth weight (–3.5 to –1.5 SDS), birth length (–5.0 to 0.3 SDS) and head circumference (–3.0 to 0 SDS) 删除11:<u>(142,143)</u>. The prevalence of heterozygous IGF1R mutations or deletions is estimated at 1% to 2% in short SGA children 删除11:<u>(143)</u>. Homozygous mutations are extremely rare and possibly not compatible with life, although one case was reported with severe pre- and postnatal growth failure (< –4.5 SDS) and congenital malformation 删除11:<u>(144)</u>.\n\n【5】The response to recombinant GH treatment is usually moderate and associated with high IGF-I concentrations 删除11:<u>(删除13:<u>145, 146</u>)</u>.\n\n【6】Terminal 15q deletion with allelic loss of IGF1R leads to pre- and postnatal growth retardation and cardiac symptoms, intellectual disability, diaphragmatic hernia, hearing problems, aortic root dilatation, neonatal lymphedema, and aplasia cutis 删除11:<u>(147)</u>.\n\n【7】Homozygous pregnancy-associated-plasma-protein-A2 (PAPPA2) mutations were recently found in some short children born SGA 删除11:<u>(148)</u>. They have progressive growth failure, marked microcephaly, thin long bones, mildly decreased", "tags": {}, "lang": "en", "attr": {"page_num": 12, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 国际共识指南：小于胎龄儿—婴儿期到成年早期的病因学和管理(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/07 10:03:03", "endTime": "2024/08/07 10:06:19", "cost": 196.418}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 18:06:16", "grab_time": "2024-08-06 18:03:00"}
{"id": 2211602, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "42d5436b-7ba4-459e-8937-5174d02a6636", "title": "Ⅱ度烧伤创面治疗专家共识（2024版）Ⅰ：院前急救和非手术治疗", "text": "【0】页码:14\nⅡ度烧伤创面治疗专家共识（2024版）Ⅰ：院前急救和非手术治疗\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】参考删除-3:<u>1. Nisanci M, Eski M, Sahin I, et al. Saving the zone of stasis in burns with activated protein C: an experimental study in rats删除12:<u>[J]</u>. Burns, 删除13:<u>2010, 36</u>删除11:<u>(3)</u>: 397-402. DOI: 10.1016/j.burns.2009.06.028.</u>\n\n【2】参考删除-3:<u>2. Jakobsson OP, Arturson G. The effect of prompt local cooling on edema formation in scalded rat paws删除12:<u>[J]</u>. Burns Incl Therm Inj, 删除13:<u>1985, 12</u>删除11:<u>(1)</u>: 8-15. DOI: 10.1016/0305-4179删除11:<u>(85)</u>90177-9.</u>\n\n【3】参考删除-3:<u>3. Altintas B, Altintas AA, Kraemer R, et al. Acute effects of local cold therapy in superficial burns on pain, in vivo microcirculation, edema formation and histomorphology删除12:<u>[J]</u>. Burns, 删除13:<u>2014, 40</u>删除11:<u>(5)</u>: 915-921. DOI: 10.1016/j.burns.2013.11.023.</u>\n\n【4】参考删除-3:<u>4. Cuttle L, Pearn J, McMillan JR, et al. A review of first aid treatments for burn injuries删除12:<u>[J]</u>. Burns, 删除13:<u>2009, 35</u>删除11:<u>(6)</u>: 768-775. DOI: 10.1016/j.burns.2008.10.011.</u>\n\n【5】参考删除-3:<u>5. Frear CC, Griffin B, Kimble R. Adequacy of cool running water first aid by healthcare professionals in the treatment of paediatric burns: a cross-sectional study of 4537 children删除12:<u>[J]</u>. Emerg Med Australas, 删除13:<u>2021, 33</u>删除11:<u>(4)</u>: 615-622. DOI: 10.1111/1742-6723.13686.</u>\n\n【6】参考删除-3:<u>6. Griffin BR, Frear CC, Babl F, et al. Cool running water first aid decreases skin grafting requirements in paediatric burns: a cohort study of two thousand four hundred ninety-five children删除12:<u>[J]</u>. Ann Emerg Med, 删除13:<u>2020, 75</u>删除11:<u>(1)</u>: 75-85. DOI: 10.1016/j.annemergmed.2019.06.028.</u>\n\n【7】参考删除-3:<u>7. Wood FM, Phillips M, Jovic T, et al. Water first aid is beneficial in humans post-burn: evidence from a bi-national cohort study删除12:<u>[J]</u>. PLoS One, 删除13:<u>2016, 11</u>删除11:<u>(1)</u>: e0147259. DOI: 10.1371/journal.pone.0147259.</u>\n\n【8】8. Harish V, Tiwari N, Fisher OM, et al. First aid improves clinical outcomes in burn injuries: evidence from a cohort study of 4918 patients删除12:<u>[J]</u>. Burns, 删除13:<u>2019, 45</u>删除11:<u>(2)</u>: 433-439. DOI: 10.1016/j.burns.2018.09.024.\n\n【9】参考删除-3:<u>9. Griffin B, Cabilan CJ, Ayoub A, et al. The effect of 20 minutes of cool running water first aid within three hours of thermal burn injury on patient outcomes: a systematic review and meta-analysis删除12:<u>[J]</u>. Australas Emerg Care, 删除13:<u>2022, 25</u>删除11:<u>(4)</u>: 367-376. DOI:10.1016/j.auec.2022.05.004.</u>\n\n【10】参考删除-3:<u>10. Djärv T, Douma M, Palmieri T, et al. Duration of cooling with water for thermal burns as a first aid intervention: a systematic review删除12:<u>[J]</u>. Burns, 删除13:<u>2022, 48</u>删除11:<u>(2)</u>: 251-262. DOI: 10.1016/j.burns.2021.10.007.</u>\n\n【11】参考删除-3:<u>11. Cuttle L, Kempf M, Kravchuk O, et al. The optimal temperature of first aid treatment for partial thickness burn injuries删除12:<u>[J]</u>. Wound Repair Regen, 删除13:<u>2008, 16</u>删除11:<u>(5)</u>: 626-634. DOI: 10.1111/j.删除17:<u>1524-475</u>X.2008.00413.x.</u>\n\n【12】参考删除-3:<u>12. Cho YS, Choi YH. Comparison of three cooling methods for burn patients: a randomized clinical trial删除12:<u>[J]</u>. Burns, 删除13:<u>2017, 43</u>删除11:<u>(3)</u>: 502-508. DOI:10.1016/j.burns.2016.09.010.</u>\n\n【13】参考删除-3:<u>13. Yuan J, Wu C, Jing H, et al. Assessment of cooling on an acute scald burn injury in a porcine model删除12:<u>[J]</u>. J Burn Care Res, 删除13:<u>2007, 28</u>删除11:<u>(3)</u>: 514-520. DOI: 10.1097/BCR.删除17:<u>0</u>B013E3180 53D813.</u>\n\n【14】参考删除-3:<u>14. Wright EH, Tyler M, Vojnovic B, et al. Human model of burn injury that quantifies the benefit of cooling as a first aid measure删除12:<u>[J]</u>. Br J Surg, 删除13:<u>2019, 106</u>删除11:<u>(11)</u>: 1472-1479. DOI: 删除13:<u>10. 1002</u>/bjs.11263.</u>\n\n【15】参考删除-3:<u>15. Venter TH, Karpelowsky JS, Rode H. Cooling of the burn wound: the ideal temperature of the coolant删除12:<u>[J]</u>. Burns, 删除13:<u>2007, 33</u>删除11:<u>(7)</u>: 917-922. DOI: 10.1016/j.burns.2006.10.408.</u>\n\n【16】参考删除-3:<u>16. The Australian and New Zealand Burn Association. Emergency management of severe burns manual删除12:<u>[M]</u>. 7th ed. Sydney: The Education Committee of the Australian and New Zealand Burns Association Ltd, 2002.</u>\n\n【17】参考删除-3:<u>17. Schnell HM, Zaspel JG. Cooling extensive burns: sprayed coolants can improve initial cooling management - a thermography-based study删除12:<u>[J]</u>. Burns, 删除13:<u>2008, 34</u>删除11:<u>(4)</u>: 505-508. DOI: 10.1016/j.burns.2007.06.012.</u>\n\n【18】参考删除-3:<u>18. Walker A, Baumber R, Robson B. Pre-hospital management of burns by the UK fire service删除12:<u>[J]</u>. Emerg Med J, 删除13:<u>2005, 22</u>删除11:<u>(3)</u>: 205-208. DOI:10.1136/emj.2004.015784.</u>\n\n【19】参考删除-3:<u>19. Cuttle L, Kravchuk O, Wallis B, et al. An audit of first-aid treatment of pediatric burns patients and their clinical outcome删除12:<u>[J]</u>. J Burn Care Res, 删除13:<u>2009, 30</u>删除11:<u>(6)</u>: 1028-1034. DOI: 10.1097/BCR.0b013e3181b7f4t1.</u>\n\n【20】参考删除-3:<u>20. Allison K. The UK pre-hospital management of burn patients: current practice and the need for a standard approach删除12:<u>[J]</u>. Burns, 删除13:<u>2002, 28</u>删除11:<u>(2)</u>: 135-142. DOI: 10.1016/ s0305-4179删除11:<u>(01)</u>00083-3.</u>\n\n【21】参考删除-3:<u>21. Holbert MD, Kimble RM, Chatfield M, et al. Effectiveness of a hydrogel dressing as an analgesic adjunct to first aid for the treatment of acute pediatric burn injuries: a prospective randomised controlled trial删除12:<u>[J]</u>. BMJ Open, 删除13:<u>2021, 11</u>删除11:<u>(1)</u>: e039981. DOI:10.1136/bmjopen-2020-039981.</u>\n\n【22】参考删除-3:<u>22. Durrant CATT, Simpson AR, Williams G. Thermal injury - the first 24 h删除12:<u>[J]</u>. Current Anaesthesia & Critical Care, 删除13:<u>2008, 19</u>(5/6): 256-263. DOI: 10.1016/j.cacc.2008.09.014.</u>\n\n【23】参考删除-3:<u>23. Harish V, Li Z, Maitz P. First aid is associated with improved outcomes in large body surface area burns删除12:<u>[J]</u>. Burns, 删除13:<u>2019, 45</u>删除11:<u>(8)</u>: 1743-1748. DOI:10.1016/j.burns.2019.05.006.</u>\n\n【24】参考删除-3:<u>24. Cox SG, Martinez R, Glick A, et al. A review of community management of paediatric burns删除12:<u>[J]</u>. Burns, 删除13:<u>2015, 41</u>删除11:<u>(8)</u>: 1805-1810. DOI:10.1016/j.burns.2015.05.024.</u>\n\n【25】参考删除-3:<u>25. Baartmans MG, de Jong AE, van Baar ME, et al. Early management in children with burns: cooling, wound care and pain management删除12:<u>[J]</u>. Burns, 删除13:<u>2016, 42</u>删除11:<u>(4)</u>: 777-782. DOI: 10.1016/j.burns.2016.03.003.</u>\n\n【26】参考删除-3:<u>26. Steele JE, Atkins JL, Viczianchy MP. Factors at scene and in transfer related to the development of hypothermia in major burns删除12:<u>[J]</u>. Ann Burns Fire Disasters, 删除13:<u>2016, 29</u>删除11:<u>(2)</u>: 103-107.</u>\n\n【27】27. Lönnecker S, Schodorf V. Hypothermia in patients with burn injuries: influence of prehospital treatment删除12:<u>[J]</u>. Chirurg, 删除13:<u>2001, 72</u>删除11:<u>(2)</u>: 164-167. DOI:10.1007/s001040051286.\n\n【28】参考删除-3:<u>28. Singer AJ, Taira BR, Thode HC, et al. The association between hypothermia, prehospital cooling, and mortality in burn victims删除12:<u>[J]</u>. Acad Emerg Med, 删除13:<u>2010, 17</u>删除11:<u>(4)</u>: 456-459. DOI: 10.1111/j.1553-2712.2010.00702.x.</u>\n\n【29】参考删除-3:<u>29. Legrand M, Barraud D, Constant I, et al. Management of severe thermal burns in the acute phase in adults and children删除12:<u>[J]</u>. Anaesth Crit Care Pain Med, 删除13:<u>2020, 39</u>删除11:<u>(2)</u>: 253-267. DOI:10.1016/j.accpm.2020.03.006.</u>\n\n【30】参考删除-3:<u>30. Zideman DA, De Buck ED, Singletary EM, et al. European Resuscitation Council guidelines for resuscitation 2021 section 9. First aid删除12:<u>[J]</u>. Resuscitation, 删除13:<u>2015, 95</u>: 278-287. DOI: 10.1016/j.resuscitation.2015.07.031.</u>\n\n【31】参考删除-3:<u>31. McLure M, Macneil F, Wood FM, et al. A rapid review of burns first aid guidelines: is there consistency across international guidelines? 删除12:<u>[J]</u>. Cureus, 删除13:<u>2021, 13</u>删除11:<u>(6)</u>: e15779. DOI: 10.7759/ cureus.15779.</u>\n\n【32】疑似页脚<u>32. Karpelowsky JS, Wallis L, Madaree A, et al. South African Burn Society burn stabilisation protocol删除12:<u>[J]</u>. S Afr Med J.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 14, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/Ⅱ度烧伤创面治疗专家共识（2024版）Ⅰ：院前急救和非手术治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:28:55", "endTime": "2024/08/06 15:29:01", "cost": 5.748}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:29:01", "grab_time": "2024-08-05 23:28:55"}
{"id": 2211601, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "11d21def-9c80-463a-aedf-94191ad9e877", "title": "沙特关于多发性硬化管理的共识建议诊断和放射学影像学(1)", "text": "【0】页码:4\n沙特关于多发性硬化管理的共识建议诊断和放射学影像学(1)\nIn addition to the documentation of evidence of CNS demyelination suggestive of MS, the lack of alternative explanations for symptoms is a necessary criterion that should be fulfilled. It is vital to consider the differential diagnosis of MS, with vigilance to signs of red flags. For patients who have an atypical clinical presentation or magnetic resonance imaging (MRI) findings, additional assessments in addition to the requirements of the McDonald criteria are needed to establish an MS diagnosis.\n\n【1】The fulfillment of the 2017 McDonald criteria in the absence of an alternative diagnosis allows for diagnosing MS. In people with a typical CIS presentation, with the fulfillment of criteria for DIS and absence of a substititional diagnosis, documentation of cerebrospinal fluid (CSF)-specific oligoclonal bands (OCBs) with the lack of other CSF findings atypical of MS allows for MS diagnosis. It is vital to consider that although the presence of CSF-specific oligoclonal bands may not fulfill the “dissemination in time” requirement, it can replace the latter in terms of diagnostic criteria.\n\n【2】### 3.1.2 The Use of the McDonald Criteria\n\n【3】Misdiagnosis of MS remains a problem in routine clinical practice; the following are important caveats to the application of the McDonald criteria:\n\n【4】- MRI findings alone are insufficient for MS diagnosis. It is vital to integrate clinical, imaging, and serological findings to make a reliable MS diagnosis.\n- McDonald criteria should be used only in patients with a typical CIS presentation as they have a greater likelihood of developing MS.\n- Care must be taken to rule out alternative diagnoses and presentations suggestive of an MS-related demyelinating episode or relapse, including optic neuritis, brainstem syndromes, trigeminal neuralgia, cerebellar syndromes, and transverse myelitis.\n\n【5】Revisions made to the McDonald criteria in international consensus recommendations, such as MAGNIMS, may also aid in the diagnosis of MS. In 2016, these recommendations consisted of several revisions put forward by neurologists and neurobiologists gathered in a workshop to recognize and discuss MS diagnosis areas requiring revision and clarification. For instance, it was recommended that there should be at least three lesions on MRI of the periventricular region for the establishment of the “dissemination in space” criteria. There were also other suggestions, such as the adoption of MS dissemination in time and space MRI criteria for patients being assessed for radiologically isolated syndromes. Subsequently, the 2021 MAGNIMS revision took into consideration more recent scientific advances and provided novel suggestions, including recommended modifications to the protocols of MRI acquisition. Clinicians may refer these recommendations to assist in decision-making related to diagnostic procedures.\n\n【6】### 3.2 Conditions That May Mimic the Presentation of MS\n\n【7】The most common reason for incorrect diagnosis of MS is the misinterpretation of inaccurate clinical signs, radiological results, or laboratory tests, which are briefly summarized in Tables 1–3.\n\n【8】#### Neuromyelitis Optica Spectrum Disorders (NMOSD)\n\n【9】Neuromyelitis Optica Spectrum Disorders (NMOSD) are differentiated from MS in terms of diagnosis when certain features are fulfilled. This should include a clinical presentation of any neurological manifestation or a CNS lesion not corresponding with a neurological manifestation with positive Aquaporin 4 (AQP4)-IgG, or NMOSD symptoms with MRI criteria of the International Panel for NMO Diagnosis (IPND). To the latter diagnostic criteria, additional features include the absence of AQP4-IgG and myelin oligodendrocyte glycoprotein (MOG) antibodies in serum and CSF, neutrophilic or eosinophilic pleocytosis with an absence of oligoclonal bands in the CSF, and ensuring that testing of antibodies is carried out during attack presentations and when the patient is not on immunotherapy. Furthermore, asymptomatic AQP4-IgG does not establish", "tags": {}, "lang": "en", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/沙特关于多发性硬化管理的共识建议诊断和放射学影像学(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "1–3.", "content": "【0】页码:4\n沙特关于多发性硬化管理的共识建议诊断和放射学影像学(1)\nIn addition to the documentation of evidence of CNS demyelination suggestive of MS, the lack of alternative explanations for symptoms is a necessary criterion that should be fulfilled. It is vital to consider the differential diagnosis of MS, with vigilance to signs of red flags. For patients who have an atypical clinical presentation or magnetic resonance imaging (MRI) findings, additional assessments in addition to the requirements of the McDonald criteria are needed to establish an MS diagnosis.\n\n【1】The fulfillment of the 2017 McDonald criteria in the absence of an alternative diagnosis allows for diagnosing MS. In people with a typical CIS presentation, with the fulfillment of criteria for DIS and absence of a substititional diagnosis, documentation of cerebrospinal fluid (CSF)-specific oligoclonal bands (OCBs) with the lack of other CSF findings atypical of MS allows for MS diagnosis. It is vital to consider that although the presence of CSF-specific oligoclonal bands may not fulfill the “dissemination in time” requirement, it can replace the latter in terms of diagnostic criteria.\n\n【2】### 3.1.2 The Use of the McDonald Criteria\n\n【3】Misdiagnosis of MS remains a problem in routine clinical practice; the following are important caveats to the application of the McDonald criteria:\n\n【4】- MRI findings alone are insufficient for MS diagnosis. It is vital to integrate clinical, imaging, and serological findings to make a reliable MS diagnosis.\n- McDonald criteria should be used only in patients with a typical CIS presentation as they have a greater likelihood of developing MS.\n- Care must be taken to rule out alternative diagnoses and presentations suggestive of an MS-related demyelinating episode or relapse, including optic neuritis, brainstem syndromes, trigeminal neuralgia, cerebellar syndromes, and transverse myelitis.\n\n【5】Revisions made to the McDonald criteria in international consensus recommendations, such as MAGNIMS, may also aid in the diagnosis of MS. In 2016, these recommendations consisted of several revisions put forward by neurologists and neurobiologists gathered in a workshop to recognize and discuss MS diagnosis areas requiring revision and clarification. For instance, it was recommended that there should be at least three lesions on MRI of the periventricular region for the establishment of the “dissemination in space” criteria. There were also other suggestions, such as the adoption of MS dissemination in time and space MRI criteria for patients being assessed for radiologically isolated syndromes. Subsequently, the 2021 MAGNIMS revision took into consideration more recent scientific advances and provided novel suggestions, including recommended modifications to the protocols of MRI acquisition. Clinicians may refer these recommendations to assist in decision-making related to diagnostic procedures.\n\n【6】### 3.2 Conditions That May Mimic the Presentation of MS\n\n【7】The most common reason for incorrect diagnosis of MS is the misinterpretation of inaccurate clinical signs, radiological results, or laboratory tests, which are briefly summarized in Tables 1–3.\n\n【8】#### Neuromyelitis Optica Spectrum Disorders (NMOSD)\n\n【9】Neuromyelitis Optica Spectrum Disorders (NMOSD) are differentiated from MS in terms of diagnosis when certain features are fulfilled. This should include a clinical presentation of any neurological manifestation or a CNS lesion not corresponding with a neurological manifestation with positive Aquaporin 4 (AQP4)-IgG, or NMOSD symptoms with MRI criteria of the International Panel for NMO Diagnosis (IPND). To the latter diagnostic criteria, additional features include the absence of AQP4-IgG and myelin oligodendrocyte glycoprotein (MOG) antibodies in serum and CSF, neutrophilic or eosinophilic pleocytosis with an absence of oligoclonal bands in the CSF, and ensuring that testing of antibodies is carried out during attack presentations and when the patient is not on immunotherapy. Furthermore, asymptomatic AQP4-IgG does not establish", "index": 3160, "show": true, "start": 3160, "end": 3164, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "7"}], "startTime": "2024/08/06 16:25:17", "endTime": "2024/08/06 16:25:47", "cost": 30.341}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:25:47", "grab_time": "2024-08-06 00:25:17"}
{"id": 2211600, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "796991b5-3422-40d9-b112-377cfe7e731b", "title": "2023 NICE 介入手术指南：经皮胸导管栓塞治疗持续性乳糜漏 [IPG755]", "text": "页码:5\n2023 NICE 介入手术指南：经皮胸导管栓塞治疗持续性乳糜漏 [IPG755]\n### 3.3|删除段内换行|The professional experts and the committee considered the key safety outcomes to be: pain, bleeding, infection including abdominal sepsis, chronic diarrhoea, bile leak and damage to intra-abdominal structures.\n\n### 3.4|删除段内换行|One commentary from a person who has had this procedure was discussed by the committee.\n\n【2】## Committee comments\n\n### 3.5|删除段内换行|The evidence included procedures that were done mostly through a transabdominal approach, but other approaches could be used.\n\n### 3.6|删除段内换行|The committee was informed that lymphangiography alone may resolve chyle leak.\n\n### 3.7|删除段内换行|The committee was informed that ligating the thoracic duct by thoracotomy was an alternative treatment for this indication.\n\n### 3.8|删除段内换行|The committee was informed that the aetiology of chyle leaks is more complex in children and the procedure may have additional risks in children.\n\n【7】删除4:<u>ISBN</u>: 978-1-4731-5082-9\n\n【8】## Endorsing organisation\n\n【9】This guidance has been endorsed by [Healthcare Improvement Scotland].", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 NICE 介入手术指南：经皮胸导管栓塞治疗持续性乳糜漏 [IPG755].pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【7】删除4:ISBN", "content": "页码:5\n2023 NICE 介入手术指南：经皮胸导管栓塞治疗持续性乳糜漏 [IPG755]\n### 3.3|删除段内换行|The professional experts and the committee considered the key safety outcomes to be: pain, bleeding, infection including abdominal sepsis, chronic diarrhoea, bile leak and damage to intra-abdominal structures.\n\n### 3.4|删除段内换行|One commentary from a person who has had this procedure was discussed by the committee.\n\n【2】## Committee comments\n\n### 3.5|删除段内换行|The evidence included procedures that were done mostly through a transabdominal approach, but other approaches could be used.\n\n### 3.6|删除段内换行|The committee was informed that lymphangiography alone may resolve chyle leak.\n\n### 3.7|删除段内换行|The committee was informed that ligating the thoracic duct by thoracotomy was an alternative treatment for this indication.\n\n### 3.8|删除段内换行|The committee was informed that the aetiology of chyle leaks is more complex in children and the procedure may have additional risks in children.\n\n【7】删除4:<u>ISBN</u>: 978-1-4731-5082-9\n\n【8】## Endorsing organisation\n\n【9】This guidance has been endorsed by [Healthcare Improvement Scotland].", "index": 942, "show": true, "start": 942, "end": 953, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 15:38:06", "endTime": "2024/08/06 15:38:46", "cost": 39.622}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:38:46", "grab_time": "2024-08-05 23:38:05"}
{"id": 2211599, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "c4382580-2033-42ea-ac42-1a34e211ccb6", "title": "2022 ESHRE指南：反复妊娠丢失（更新版）", "text": "【0】页码:56\n2022 ESHRE指南：反复妊娠丢失（更新版）\nwith primary RPL whereas several studies of the impact of carrying maternal HLA class II have been performed in women with secondary RPL.\n\n【1】删除图片描述:<u>![](55_0.png)</u>\n\n【2】删除图片描述:<u>![](55_1.png)</u>\n\n【3】删除图片描述:<u>![](55_2.png)</u>\n\n【4】4 HLA-C alleles can be divided into C1 and C2 groups according to a genetic dimorphism leading to changes in the segment of HLA-C molecule that can bind KIR. This binding between KIR and HLA-C will ultimately result in either inhibition or activation of NK cell function.", "tags": {}, "lang": "en", "attr": {"page_num": 56, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2022 ESHRE指南：反复妊娠丢失（更新版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【4】4 HLA-C alleles can be divided into C1 and C2 groups according to a genetic dimorphism leading to changes in the segment of HLA-C molecule that can bind KIR. This binding between KIR and HLA-C will ultimately result in either inhibition or activation of NK cell function.", "content": "【0】页码:56\n2022 ESHRE指南：反复妊娠丢失（更新版）\nwith primary RPL whereas several studies of the impact of carrying maternal HLA class II have been performed in women with secondary RPL.\n\n【1】删除图片描述:<u>![](55_0.png)</u>\n\n【2】删除图片描述:<u>![](55_1.png)</u>\n\n【3】删除图片描述:<u>![](55_2.png)</u>\n\n【4】4 HLA-C alleles can be divided into C1 and C2 groups according to a genetic dimorphism leading to changes in the segment of HLA-C molecule that can bind KIR. This binding between KIR and HLA-C will ultimately result in either inhibition or activation of NK cell function.", "index": 269, "show": true, "start": 269, "end": 543, "province": ["信息质量", "有用性-轻"], "isEdit": false}, {"text": "【0】页码:56\n\n2022 ESHRE指南：反复妊娠丢失（更新版）\n\nwith primary RPL whereas several studies of the impact of carrying maternal HLA class II have been performed in women with secondary RPL.", "content": "【0】页码:56\n2022 ESHRE指南：反复妊娠丢失（更新版）\nwith primary RPL whereas several studies of the impact of carrying maternal HLA class II have been performed in women with secondary RPL.\n\n【1】删除图片描述:<u>![](55_0.png)</u>\n\n【2】删除图片描述:<u>![](55_1.png)</u>\n\n【3】删除图片描述:<u>![](55_2.png)</u>\n\n<mark>【4】4 HLA-C alleles can be divided into C1 and C2 groups according to a genetic dimorphism leading to changes in the segment of HLA-C molecule that can bind KIR. This binding between KIR and HLA-C will ultimately result in either inhibition or activation of NK cell function.</mark>", "index": 0, "show": true, "start": 0, "end": 173, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/06 17:06:47", "endTime": "2024/08/06 17:07:18", "cost": 30.63}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 01:07:18", "grab_time": "2024-08-06 01:06:47"}
{"id": 2211598, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "f770c5ca-f165-4a12-892c-c73bbe4e1cbc", "title": "皮肤超声质量控制专家共识（2023）(1)", "text": "【0】页码:1\n皮肤超声质量控制专家共识（2023）(1)\n(本页删除)本页被模型判断为参考页删除图片描述:<u>![](0_0.png)</u>\n\n【1】### 【摘要】\n皮肤超声作为一种新型皮肤科无创检测工具, 仍缺乏统一、标准的操作及报告流程, 依规科学规范的质量控制措施对皮肤超声检查尤为重要。本文集采我国国内外最新研究进展及临床应用经验, 详细规定了皮肤超声检查的主要环节及具体步骤, 并提出了可定量的质量控制指标, 以期提升皮肤超声检查的规范化与同质化, 推动皮肤超声的持续发展。\n\n【2】### 【关键词】\n皮肤超声；质量控制；共识；操作流程；结构化报告\n\n【3】### Expert Consensus on Quality Control of Dermatologic Ultrasound 删除11:<u>删除19:<u>(2023)</u></u>\nNational Center for Quality Control of Skin and Sexually Transmitted Diseases; Dermatology Special Committee of National Telemedicine and Internet Medicine Center; Dermatological Imaging Group of Dermatology Medical Branch of Chinese Healthcare International Exchange Promotion Association; Huaxia Dermatological Imaging Artificial Intelligence Collaboration Group, Dermatology Medical Branch of Chinese Healthcare International Exchange Promotion Association; Dermatological Non-Invasive Diagnosis Group, Dermatology Rehabilitation Professional Committee of Chinese Society of Rehabilitation Medicine; Rare Skin Disease Professional Committee of China Rare Disease Alliance; Dermatology and Dermatological Aesthetics Branch of China Medical Equipment Association; China Skin Image Database (CSID)\n\n【4】#### [Corresponding author]\nLIU Jie, E-mail: liuejie04672@gumch.cn; CUI Yong, E-mail: wuhuucuiyong@vip删除1:<u>.163.com; LU Qianjin, E-mail: qianlu5860@csu.edu.cn; XU Jinhua, E-mail:xjhjshy@163.com</u>\n\n【5】### 【Abstract】\nAs a new non-invasive dermatologic diagnostic tool, dermatologic ultrasound still lacks a unified and standardized operational and reporting procedure. Implementing scientific and standardized quality control measures is particularly important for dermatologic ultrasound examinations. Based on the latest research advancements and clinical application experiences both domestically and internationally, this expert consensus comprehensively outlines the key stages and specific steps of dermatologic ultrasound examinations and proposes quantifiable quality control indicators, aiming to promote standardized and homogeneous continuous development of dermatologic ultrasound.", "tags": {}, "lang": "en", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/皮肤超声质量控制专家共识（2023）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/07 09:44:52", "endTime": "2024/08/07 09:46:10", "cost": 77.926}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 17:46:07", "grab_time": "2024-08-06 17:44:49"}
{"id": 2211597, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "8f0cf88a-403c-408b-9d8d-ca9d10ba17b9", "title": "中国成人糖尿病前期干预的专家共识（2023版）", "text": "【0】页码:1\n中国成人糖尿病前期干预的专家共识（2023版）\n(本页删除)本页被模型判断为参考页中国成人糖尿病前期干预的专家共识删除19:<u>(2023 版)</u>\n\n【1】删除32:<u>**</u>中删除32:<u>**</u>华删除32:<u>**</u>医删除32:<u>**</u>学删除32:<u>**</u>会删除32:<u>**</u>内删除32:<u>**</u>分删除32:<u>**</u>泌删除32:<u>**</u>学删除32:<u>**</u>分删除32:<u>**</u>会  \n删除32:<u>**</u>中删除32:<u>**</u>国删除32:<u>**</u>医删除32:<u>**</u>身删除32:<u>**</u>会删除32:<u>**</u>糖删除32:<u>**</u>尿删除32:<u>**</u>病删除32:<u>**</u>学删除32:<u>**</u>分删除32:<u>**</u>会  \n删除32:<u>**</u>中删除32:<u>**</u>国删除32:<u>**</u>医删除32:<u>**</u>带删除32:<u>**</u>协删除32:<u>**</u>会删除32:<u>**</u>内删除32:<u>**</u>分删除32:<u>**</u>泌删除32:<u>**</u>装删除32:<u>**</u>睡删除32:<u>**</u>射删除32:<u>**</u>营删除32:<u>**</u>师删除32:<u>**</u>分删除32:<u>**</u>会\n\n【2】表通作者:朱大龙，中商大学疗学院附属鼓楼医院内分法科，南京210008，Email: zhudalong01nju.edu.cn; 周村审动，中#大学第删除5:<u>■</u>家医院内分外科糖尿病免疫学家庭发室，国家验重实验室耷寇病临床研空飞机中心，长沙 410011，Email: zhouzhijiangoucsu.edu.cn; 赵科军，山东科大学附属齐鲁医院内分法科,济南250021，E-mail:jhzhao@edu.cn\n\n【3】删除图片描述:<u>![](0_0.png)</u>\n\n删除32:<u>**</u>【摘 要】删除32:<u>**</u> 2型糖尿病由糖尿病前期发展而来，否丫高干预糖尿病前期可明显减少其转化为糖尿病的可能性。糖尿病前期与心普管疾病，微血管病变,糖接 燥师等慢性病风险增加相佐，吧期挥病期诊断标准逐后分不统一。干预糖尿病前期能有效减 阻术血管病变的长期波查也有待权久。 随额内外糖尿病前期诊断依据日志-系列灵世辽关键建果，获得了|要关干预糖尿病前期的防》进展及新址的证衣新进寨。中华医学会内分泌学会合中华医学会糖尿病学分会。中华医生协会内分法长聘业务带家联合守了仪家女家在投头进行了修订,形成了《中因成人糖尿病前期子救的专家共设删除19:<u>(2023版)</u> .以促人对防范迎亚建度，无奉病及实践,本专家共设内容着il糖尿病前期的游义礼诊断 标准:流行病学.糖尿病前期的钦下:筛查的裱单~干预,形防前愈，此期效分名住证是-些执氏位 防)糖尿病母题.分舂应该县五F防的八用干预措施，为广大的医勤到 全和日料忍芹椿良的提 参考。\n\n【5】删除32:<u>**</u>【关键词】删除32:<u>**</u> 糖尿病前期; 糖尿病防织; 生活方式干预; 体重管理; 脂转性\n\n【6】删除32:<u>**</u>Intervention for adults with pre-diabetes: a Chinese expert consensus 删除19:<u>(2023 edition)</u>删除32:<u>**</u>  \nChinese Society of Endocrinology, Chinese Diabetes Society, Chinese Endocrinologist Association  \nCorresponding authors: Zhu Dalong, Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing 210008, China, Email: zhudalong@nju.edu. cn; Zhou Zhijiang, Department of Metabolism and Endocrinology, the Second Xiangya Hospital, Central South University, Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha 410011, China, Email: zhouzhijiang@csu.edu.cn; Zhao Jiajun, Department of Endocrinology, Shandong Provincial Hospital, Jinan 250021, China, Email: jjzhao@sdu.edu.cn\n\n【7】2型糖尿病 (type 2 diabetes mellitus，T2DM) 由一种标志或介水慢，如出口现期标志者将来发生糖尿病心脑血管疾病，肾病，神病等缓发病 糖尿病前期发展而来。糖尿病前期可以被认为是\n\n【8】DOI:10.3760/cma.j.issn.l 15791-0203509-00108  \n收稿日期:202-05-09      本文编辑 摊欣伶  \n引用来自:中华医学会内分泌学分会,中华医学会糖尿病学分会,中国医院协会内分泌代谢科医师分会 . 中因成人糖尿病前期于预的专家共访删除19:<u>(2023版J . 中华糖尿病杂志. 2023， 15{6)</u>: 484-494 . DOI:10.3760/ cma.j.1 15791 -0203509-00108 .", "tags": {}, "lang": "en", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/中国成人糖尿病前期干预的专家共识（2023版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【7】2型糖尿病 (type 2 diabetes mellitus，T2DM) 由一种标志或介水慢，如出口现期标志者将来发生糖尿病心脑血管疾病，肾病，神病等缓发病 糖尿病前期发展而来。糖尿病前期可以被认为是", "content": "【0】页码:1\n中国成人糖尿病前期干预的专家共识（2023版）\n(本页删除)本页被模型判断为参考页中国成人糖尿病前期干预的专家共识删除19:<u>(2023 版)</u>\n\n【1】删除32:<u>**</u>中删除32:<u>**</u>华删除32:<u>**</u>医删除32:<u>**</u>学删除32:<u>**</u>会删除32:<u>**</u>内删除32:<u>**</u>分删除32:<u>**</u>泌删除32:<u>**</u>学删除32:<u>**</u>分删除32:<u>**</u>会  \n删除32:<u>**</u>中删除32:<u>**</u>国删除32:<u>**</u>医删除32:<u>**</u>身删除32:<u>**</u>会删除32:<u>**</u>糖删除32:<u>**</u>尿删除32:<u>**</u>病删除32:<u>**</u>学删除32:<u>**</u>分删除32:<u>**</u>会  \n删除32:<u>**</u>中删除32:<u>**</u>国删除32:<u>**</u>医删除32:<u>**</u>带删除32:<u>**</u>协删除32:<u>**</u>会删除32:<u>**</u>内删除32:<u>**</u>分删除32:<u>**</u>泌删除32:<u>**</u>装删除32:<u>**</u>睡删除32:<u>**</u>射删除32:<u>**</u>营删除32:<u>**</u>师删除32:<u>**</u>分删除32:<u>**</u>会\n\n【2】表通作者:朱大龙，中商大学疗学院附属鼓楼医院内分法科，南京210008，Email: zhudalong01nju.edu.cn; 周村审动，中#大学第删除5:<u>■</u>家医院内分外科糖尿病免疫学家庭发室，国家验重实验室耷寇病临床研空飞机中心，长沙 410011，Email: zhouzhijiangoucsu.edu.cn; 赵科军，山东科大学附属齐鲁医院内分法科,济南250021，E-mail:jhzhao@edu.cn\n\n【3】删除图片描述:<u>![](0_0.png)</u>\n\n删除32:<u>**</u>【摘 要】删除32:<u>**</u> 2型糖尿病由糖尿病前期发展而来，否丫高干预糖尿病前期可明显减少其转化为糖尿病的可能性。糖尿病前期与心普管疾病，微血管病变,糖接 燥师等慢性病风险增加相佐，吧期挥病期诊断标准逐后分不统一。干预糖尿病前期能有效减 阻术血管病变的长期波查也有待权久。 随额内外糖尿病前期诊断依据日志-系列灵世辽关键建果，获得了|要关干预糖尿病前期的防》进展及新址的证衣新进寨。中华医学会内分泌学会合中华医学会糖尿病学分会。中华医生协会内分法长聘业务带家联合守了仪家女家在投头进行了修订,形成了《中因成人糖尿病前期子救的专家共设删除19:<u>(2023版)</u> .以促人对防范迎亚建度，无奉病及实践,本专家共设内容着il糖尿病前期的游义礼诊断 标准:流行病学.糖尿病前期的钦下:筛查的裱单~干预,形防前愈，此期效分名住证是-些执氏位 防)糖尿病母题.分舂应该县五F防的八用干预措施，为广大的医勤到 全和日料忍芹椿良的提 参考。\n\n【5】删除32:<u>**</u>【关键词】删除32:<u>**</u> 糖尿病前期; 糖尿病防织; 生活方式干预; 体重管理; 脂转性\n\n【6】删除32:<u>**</u>Intervention for adults with pre-diabetes: a Chinese expert consensus 删除19:<u>(2023 edition)</u>删除32:<u>**</u>  \nChinese Society of Endocrinology, Chinese Diabetes Society, Chinese Endocrinologist Association  \nCorresponding authors: Zhu Dalong, Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing 210008, China, Email: zhudalong@nju.edu. cn; Zhou Zhijiang, Department of Metabolism and Endocrinology, the Second Xiangya Hospital, Central South University, Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha 410011, China, Email: zhouzhijiang@csu.edu.cn; Zhao Jiajun, Department of Endocrinology, Shandong Provincial Hospital, Jinan 250021, China, Email: jjzhao@sdu.edu.cn\n\n【7】2型糖尿病 (type 2 diabetes mellitus，T2DM) 由一种标志或介水慢，如出口现期标志者将来发生糖尿病心脑血管疾病，肾病，神病等缓发病 糖尿病前期发展而来。糖尿病前期可以被认为是\n\n【8】DOI:10.3760/cma.j.issn.l 15791-0203509-00108  \n收稿日期:202-05-09      本文编辑 摊欣伶  \n引用来自:中华医学会内分泌学分会,中华医学会糖尿病学分会,中国医院协会内分泌代谢科医师分会 . 中因成人糖尿病前期于预的专家共访删除19:<u>(2023版J . 中华糖尿病杂志. 2023， 15{6)</u>: 484-494 . DOI:10.3760/ cma.j.1 15791 -0203509-00108 .", "index": 2254, "show": true, "start": 2254, "end": 2358, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "且内容顺序混乱"}], "startTime": "2024/08/07 09:58:32", "endTime": "2024/08/07 09:59:53", "cost": 80.737}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 17:59:50", "grab_time": "2024-08-06 17:58:29"}
{"id": 2211596, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "00455e1e-b736-40ff-a631-02a21ee86acd", "title": "老年与儿童青少年糖尿病人群新型冠状病毒感染临床应对指南", "text": "【0】页码:3\n老年与儿童青少年糖尿病人群新型冠状病毒感染临床应对指南\n(本页删除)本页被模型判断为参考页标题：扈豆绿（上海交通大学医学院附属瑞金医院）  \n  姜秋水（空军军医大学西京医院）\n\n【1】## [参考文献]\n\n【2】参考删除-3:<u>1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study 删除12:<u>[J]</u>. Lancet, 删除13:<u>2020, 395</u>删除11:<u>删除19:<u>(10223)</u></u>:507-513.</u>\n\n【3】参考删除-3:<u>2. Wu J, Li J, Zhu G, et al. Clinical features of maintenance hemodialysis patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China 删除12:<u>[J]</u>. Clin J Am Soc Nephrol, 删除13:<u>2020, 15</u>删除11:<u>(8)</u>: 1139-1145.</u>\n\n【4】3. 王卫庆, 梁忠, 王广, 等. 新型冠状病毒肺炎疫情期同时期糖尿病重要专家建议外删除12:<u>[J]</u>. 中华内分泌代谢杂志, 删除13:<u>2020, 36</u>删除11:<u>(3)</u>: 185-190.\n\n【5】4. 中华医学会糖尿病学分会老年内分泌与代谢病学分会编写组. 新冠病毒肺炎疫情期间老年糖尿病患者疾病管理与应急指对删除12:<u>[J]</u>. 中华糖尿病杂志, 删除13:<u>2020, 28</u>删除11:<u>(1)</u>: 1-6.\n\n【6】5. 中国医师协会内分泌代谢科医师分会, 中国医师协会血脂联盟专家组, 中国医师协会血糖联盟专家组. 中华内分泌代谢杂志, 删除13:<u>2017, 33</u>删除11:<u>(1)</u>: 1-10.\n\n【7】6. 中华医学会糖尿病学分会, 中国 2 型糖尿病防治指南编 删除19:<u>(2020 年版)</u>删除12:<u>[J]</u>. 中华内分泌代谢杂志, 删除13:<u>2021, 37</u>删除11:<u>(4)</u>: 311-398.\n\n【8】参考删除-3:<u>7. Lim S, Bae JH, Kwon HS, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management删除12:<u>[J]</u>. Nat Rev Endocrinol, 删除13:<u>2021, 17</u>删除11:<u>(1)</u>:11-30.</u>\n\n【9】参考删除-3:<u>8. Zhou Y, Chi J, Lv W, et al. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19) 删除12:<u>[J]</u>. Diabetes Metab Res Rev, 删除13:<u>2021, 37</u> (e): e3377.</u>\n\n【10】参考删除-3:<u>9. Landstra CP, de Koning EJP. COVID-19 and diabetes: understanding the interrelationship and risks for a severe course删除12:<u>[J]</u>. Front Endocrinol (Lausanne), 删除13:<u>2021, 12</u>: 649525.</u>\n\n【11】10. 中华医学会糖尿病学分会. 糖尿病人群中新型冠状病毒 肺炎防控管理建议删除12:<u>[J]</u>. 中华糖尿病杂志, 删除13:<u>2020, 12</u>删除11:<u>(2)</u>: 73-75.\n\n【12】11. 谷伟平, 付义明. 新型冠状病毒肺炎疫情下的医院内血糖管理规范防控要点删除12:<u>[J]</u>. 中华糖尿病杂志, 删除13:<u>2020, 12</u>删除11:<u>(4)</u>: 200-203.\n\n【13】12. 吴金, 黄文, 樊博, 等. 新冠冠状病毒肺炎疫情期周儿童青少年 1 型糖尿病患者的心理调控及居家血糖管理删除12:<u>[J]</u>. 中国组织工程研究 (中英文), 2020, 6删除11:<u>(3)</u>: 49-51.\n\n【14】13. 中国医师协会儿科医外会内分泌遗传代谢学组, 中华医学会儿科学会内分泌遗传代谢学组. 新型冠状病毒肺炎疫情期内儿童及青少年糖尿病患者管理指导建议删除12:<u>[J]</u>. 中华糖尿病杂志, 删除13:<u>2020, 12</u>删除11:<u>(4)</u>: 211-215.\n\n【15】参考删除-3:<u>14. DiMeglio LA, Acerini CL, Codner E, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes 删除12:<u>[J]</u>. Pediatr Diabetes, 删除13:<u>2018, 19</u> Suppl 27: 105-114.</u>\n\n【16】15. 中华医学会儿科学会内分泌外会编写委员会. 儿童 2019  新型冠状病毒肺炎诊断与防治建议 (试行第一版)删除12:<u>[J]</u>. 中华儿科杂志, 删除13:<u>2020, 58</u>删除11:<u>(3)</u>: 169-174.\n\n【17】16. 曾玮, 来日榕, 戚芙蓉, 等. 上海市儿童 2019 新型冠状病毒感染的临床管理删除12:<u>[J]</u>. 中华传染病杂志, 删除13:<u>2022, 40</u>删除11:<u>(1)</u>: 687-690.  \n\n【18】   （收稿日期：2023-01-15）\n\n【19】（本文编辑，田 钊）", "tags": {}, "lang": "en", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/老年与儿童青少年糖尿病人群新型冠状病毒感染临床应对指南.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:50:12", "endTime": "2024/08/06 15:50:18", "cost": 5.879}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-05 23:50:18", "grab_time": "2024-08-05 23:50:12"}
{"id": 2211595, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "868e16ce-01bc-4fd4-acd4-e5c468a64aeb", "title": "2022卵巢癌广阔市场诊疗现状白皮书", "text": "【0】页码:15\n2022卵巢癌广阔市场诊疗现状白皮书\n## 不同科室医生患者量收治情况\n\n【1】### 患者类型：\n妇科/妇瘤科更多的仍是初治晚期卵巢癌患者，占 62%，复发患者较少，占 38%。 \n肿瘤科的复发患者比例较科/妇瘤科多，占 60%，此类患者身体状态更差，分期更晚。\n\n|                         | 妇科/妇瘤科                          |  肿瘤科                        |\n|-------------------------|--------------------------------|--------------------------------|\n| 初治                     | 62%                           | 60%                           |\n| 铂敏感/耐药复发       | 38%                           | 40%                           |\n\n【3】### 患者流转：\n妇科/妇瘤科：\n\n|                         | 妇科/妇瘤科 初治患者去向           |\n|-------------------------|--------------------------------|\n| 继续在本科室进行治疗     | 84%                           |\n| 转诊                      | 16%                           |\n\n【5】对于同时负责手术和药物治疗的妇科/妇瘤科，会全程负责该阴瘤患者的所有治疗。84%的初治患者选择不后续在本科室治疗，依据患者自身情况和个人需求，16%患者会转出到肿瘤科/其他医院进行治疗。\n\n【6】肿瘤科 铂敏感复发患者来源：\n\n|                         | 铂敏感复发患者来源                   |\n|-------------------------|--------------------------------|\n| 首诊                      | 38%                           |\n| 从其他科室/医院转诊而来   | 62%                           |\n\n【8】肿瘤科在药物治疗/放疗方面经验丰富，部分病情复杂、晚期复发患者会转到肿瘤科。肿瘤科铂敏感复发患者主要来源于本科室或其他医院（62%），其余是在肿瘤科首诊。\n\n【9】N=200，过去3个月内，初治/铂敏感/铂耐药阴瘤患者数；初治患者在完这里曾治入本科肿瘤科和其他医院转诊过来的患者数；铂敏感复发患者未能继续在本科室诊疗/转诊至本科肿瘤科和其他医院的患者数。", "tags": {}, "lang": "zh", "attr": {"page_num": 15, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2022卵巢癌广阔市场诊疗现状白皮书.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:31:22", "endTime": "2024/08/06 16:31:56", "cost": 34.013}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:13", "update_time": "2024-08-06 00:31:56", "grab_time": "2024-08-06 00:31:22"}
{"id": 2211594, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "d1e79d56-8e63-4a9f-b283-2f66188ba7c4", "title": "【呼吸领域】中国肺动脉高压诊断与治疗指南（2021版）", "text": "【0】页码:9\n【呼吸领域】中国肺动脉高压诊断与治疗指南（2021版）\n删除图片描述:<u>![](8_0.png)</u>\n\n【1】CTPA)敏感性高删除12:<u>删除14:<u>[90]</u></u>，正常或低度可能V/Q显像可基本排除CTEPH（敏感性 90%-100%，特异性 94%~100%）。V/Q显像易出现假阳性,尤其在左心重心肺部疾病时,需要结合其他检查进行鉴别。\n\n【2】(六)胸部CT\n\n【3】CT可显示右心室和右心房扩大片肺动脉扩张,并可通过测量主肺动脉与升主动脉直径比来评估 PH 可 能 性。高 分 辨 CT (high resolution CT，HRCT)还有助于PH病因筛查,肺脏病变所致PH患者HRCT可检测肺气肿、肺间纤维化等肺部病变,PVOD/PCH患者HRCT可及现弥漫性小叶中心性磨玻璃结节、小叶间隔增厚/纵隔淋巴结肿大等征象。\n\n【4】CTPA是诊断血管内的重 要检查手段，对制定CTEPH的治疗方案也非常重要，可为肺动脉血栓切除减积术(pulmonary thromboendarterectomy，PEA)提供影像学依据。CTEPH常见的CTPA征象包括:肺动脉完全阻塞,肺动脉内条带影,网状充盈缺损，以及肺动脉管壁不规则内摩等删除12:<u>删除14:<u>[102,103]</u></u>。由于技术的发展，CTPA诊断血管病的敏感性和特异性也越来越高，可部分替代肺动脉造影检查删除12:<u>删除14:<u>[104]</u></u>。\n\n【5】(七)肺动脉造影\n\n【6】肺动脉造影主要用于了解肺血管形态和血流灌注情况，这是 PTE 的 “金 标 准” 诊断标准，也常用于其他肺血管检查灾 其他 介入 短和初步肺血管影血管术的监督 诊断。CTEPH患者大多 备行肺动脉造影检查， 以判断能否从 PEA 或球囊肺动脉成形术(balloon pulmonary angioplasty，BPA)中获益。\n\n【7】(八)心血管磁共振\n\n【8】心血管 磁 共振 (cardiac magnetic resonance，CMR)较像可直接化影与观其实不肠,未剂时影南,并可无线评估血流量，红止牛输搏,每搏输出量和右心室质 MR 血管定战导致肺血管结的病因鉴别可值有期,特副是用于孕妇或对碘造影剂\n\n【9】由于CMR具有无创,可重复的特点,且对右心 功 能 的 评 估 与RHC 相 比 具 有 较 高 的一致性,因而可作为PAH患者基础和随访时对病情严重性判断的手段删除12:<u>删除14:<u>[114,115]</u></u>。\n\n【10】(九)血液学检查\n\n【11】血液学检查主要用于筛查 PH 的病因和评价器官损害情况。\n\n【12】风湿免疫病相关自身抗体、肝炎病毒感染、HIV抗体等是指导PH发型的噬索标志。血常规检查异常需警覊格多类血系统疾病(如白血病,贫血,红细细胞身症.、省细胞丰.常络合症，多少性骨髓增粘设)，综合组织發病以及慢性咳血症疾病( 红细胞及血红蛋白代性综合了)等。甲功能异常(主要是凭甘氨粗和皂红素）需要妬查肝功能,药物物质、病系统疲及心包等原因，对月原因对应的患肉具.常常检测同型悦酸及血原,原有t意味着说明显存在代性增性状况(如甲基丙二酸尿等)。\n\n【13】CTEPH患者侃需行易栓筛查(包托基性传栓特性),特副是或能肺栓症,银克抗凝物、抗β2糖蛋白1抗体。\n\n【14】所有PH患者在初诊及随访问建行需要测定血液利鹅肚 (BNP)或N末端利鹅肚前体(NT-proBNP),用于评价病情及指导治疗。\n\n【15】(十)腹腔超声\n\n【16】腹腔超声可以了解腹部器官储组和功能,为 PH的病因提供提供依据。腹腔超声可以诊已经性的去排除r]肝高陷,也可以为心去求竽提供饲答,如肝静肺扩,肝脏血.胆水反应肺市。肺脉扩张等。\n\n【17】对右心导管检查和血借氧词定试\n\n【18】RHC足诊断和评价 PH的标定方法,通过RHC可获得血流动力学数据. 包括有局、右室压 (收缩压和舒和平均压),肺动脉压力(pulmonary artery wedge pressure, PAWP),心输出量,混合静脉血氧饱提度(mixed venous oxygen saturation, SvO_2)和PVR等。", "tags": {}, "lang": "zh", "attr": {"page_num": 9, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【呼吸领域】中国肺动脉高压诊断与治疗指南（2021版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【8】心血管 磁 共振 (cardiac magnetic resonance，CMR)较像可直接化影与观其实不肠,未剂时影南,并可无线评估血流量，红止牛输搏,每搏输出量和右心室质 MR 血管定战导致肺血管结的病因鉴别可值有期,特副是用于孕妇或对碘造影剂", "content": "【0】页码:9\n【呼吸领域】中国肺动脉高压诊断与治疗指南（2021版）\n删除图片描述:<u>![](8_0.png)</u>\n\n【1】CTPA)敏感性高删除12:<u>删除14:<u>[90]</u></u>，正常或低度可能V/Q显像可基本排除CTEPH（敏感性 90%-100%，特异性 94%~100%）。V/Q显像易出现假阳性,尤其在左心重心肺部疾病时,需要结合其他检查进行鉴别。\n\n【2】(六)胸部CT\n\n【3】CT可显示右心室和右心房扩大片肺动脉扩张,并可通过测量主肺动脉与升主动脉直径比来评估 PH 可 能 性。高 分 辨 CT (high resolution CT，HRCT)还有助于PH病因筛查,肺脏病变所致PH患者HRCT可检测肺气肿、肺间纤维化等肺部病变,PVOD/PCH患者HRCT可及现弥漫性小叶中心性磨玻璃结节、小叶间隔增厚/纵隔淋巴结肿大等征象。\n\n【4】CTPA是诊断血管内的重 要检查手段，对制定CTEPH的治疗方案也非常重要，可为肺动脉血栓切除减积术(pulmonary thromboendarterectomy，PEA)提供影像学依据。CTEPH常见的CTPA征象包括:肺动脉完全阻塞,肺动脉内条带影,网状充盈缺损，以及肺动脉管壁不规则内摩等删除12:<u>删除14:<u>[102,103]</u></u>。由于技术的发展，CTPA诊断血管病的敏感性和特异性也越来越高，可部分替代肺动脉造影检查删除12:<u>删除14:<u>[104]</u></u>。\n\n【5】(七)肺动脉造影\n\n【6】肺动脉造影主要用于了解肺血管形态和血流灌注情况，这是 PTE 的 “金 标 准” 诊断标准，也常用于其他肺血管检查灾 其他 介入 短和初步肺血管影血管术的监督 诊断。CTEPH患者大多 备行肺动脉造影检查， 以判断能否从 PEA 或球囊肺动脉成形术(balloon pulmonary angioplasty，BPA)中获益。\n\n【7】(八)心血管磁共振\n\n【8】心血管 磁 共振 (cardiac magnetic resonance，CMR)较像可直接化影与观其实不肠,未剂时影南,并可无线评估血流量，红止牛输搏,每搏输出量和右心室质 MR 血管定战导致肺血管结的病因鉴别可值有期,特副是用于孕妇或对碘造影剂\n\n【9】由于CMR具有无创,可重复的特点,且对右心 功 能 的 评 估 与RHC 相 比 具 有 较 高 的一致性,因而可作为PAH患者基础和随访时对病情严重性判断的手段删除12:<u>删除14:<u>[114,115]</u></u>。\n\n【10】(九)血液学检查\n\n【11】血液学检查主要用于筛查 PH 的病因和评价器官损害情况。\n\n【12】风湿免疫病相关自身抗体、肝炎病毒感染、HIV抗体等是指导PH发型的噬索标志。血常规检查异常需警覊格多类血系统疾病(如白血病,贫血,红细细胞身症.、省细胞丰.常络合症，多少性骨髓增粘设)，综合组织發病以及慢性咳血症疾病( 红细胞及血红蛋白代性综合了)等。甲功能异常(主要是凭甘氨粗和皂红素）需要妬查肝功能,药物物质、病系统疲及心包等原因，对月原因对应的患肉具.常常检测同型悦酸及血原,原有t意味着说明显存在代性增性状况(如甲基丙二酸尿等)。\n\n【13】CTEPH患者侃需行易栓筛查(包托基性传栓特性),特副是或能肺栓症,银克抗凝物、抗β2糖蛋白1抗体。\n\n【14】所有PH患者在初诊及随访问建行需要测定血液利鹅肚 (BNP)或N末端利鹅肚前体(NT-proBNP),用于评价病情及指导治疗。\n\n【15】(十)腹腔超声\n\n【16】腹腔超声可以了解腹部器官储组和功能,为 PH的病因提供提供依据。腹腔超声可以诊已经性的去排除r]肝高陷,也可以为心去求竽提供饲答,如肝静肺扩,肝脏血.胆水反应肺市。肺脉扩张等。\n\n【17】对右心导管检查和血借氧词定试\n\n【18】RHC足诊断和评价 PH的标定方法,通过RHC可获得血流动力学数据. 包括有局、右室压 (收缩压和舒和平均压),肺动脉压力(pulmonary artery wedge pressure, PAWP),心输出量,混合静脉血氧饱提度(mixed venous oxygen saturation, SvO_2)和PVR等。", "index": 845, "show": true, "start": 845, "end": 972, "province": ["语义有效性", "语义不完整"], "isEdit": false}, {"text": "【17】对右心导管检查和血借氧词定试", "content": "【0】页码:9\n【呼吸领域】中国肺动脉高压诊断与治疗指南（2021版）\n删除图片描述:<u>![](8_0.png)</u>\n\n【1】CTPA)敏感性高删除12:<u>删除14:<u>[90]</u></u>，正常或低度可能V/Q显像可基本排除CTEPH（敏感性 90%-100%，特异性 94%~100%）。V/Q显像易出现假阳性,尤其在左心重心肺部疾病时,需要结合其他检查进行鉴别。\n\n【2】(六)胸部CT\n\n【3】CT可显示右心室和右心房扩大片肺动脉扩张,并可通过测量主肺动脉与升主动脉直径比来评估 PH 可 能 性。高 分 辨 CT (high resolution CT，HRCT)还有助于PH病因筛查,肺脏病变所致PH患者HRCT可检测肺气肿、肺间纤维化等肺部病变,PVOD/PCH患者HRCT可及现弥漫性小叶中心性磨玻璃结节、小叶间隔增厚/纵隔淋巴结肿大等征象。\n\n【4】CTPA是诊断血管内的重 要检查手段，对制定CTEPH的治疗方案也非常重要，可为肺动脉血栓切除减积术(pulmonary thromboendarterectomy，PEA)提供影像学依据。CTEPH常见的CTPA征象包括:肺动脉完全阻塞,肺动脉内条带影,网状充盈缺损，以及肺动脉管壁不规则内摩等删除12:<u>删除14:<u>[102,103]</u></u>。由于技术的发展，CTPA诊断血管病的敏感性和特异性也越来越高，可部分替代肺动脉造影检查删除12:<u>删除14:<u>[104]</u></u>。\n\n【5】(七)肺动脉造影\n\n【6】肺动脉造影主要用于了解肺血管形态和血流灌注情况，这是 PTE 的 “金 标 准” 诊断标准，也常用于其他肺血管检查灾 其他 介入 短和初步肺血管影血管术的监督 诊断。CTEPH患者大多 备行肺动脉造影检查， 以判断能否从 PEA 或球囊肺动脉成形术(balloon pulmonary angioplasty，BPA)中获益。\n\n【7】(八)心血管磁共振\n\n<mark>【8】心血管 磁 共振 (cardiac magnetic resonance，CMR)较像可直接化影与观其实不肠,未剂时影南,并可无线评估血流量，红止牛输搏,每搏输出量和右心室质 MR 血管定战导致肺血管结的病因鉴别可值有期,特副是用于孕妇或对碘造影剂</mark>\n\n【9】由于CMR具有无创,可重复的特点,且对右心 功 能 的 评 估 与RHC 相 比 具 有 较 高 的一致性,因而可作为PAH患者基础和随访时对病情严重性判断的手段删除12:<u>删除14:<u>[114,115]</u></u>。\n\n【10】(九)血液学检查\n\n【11】血液学检查主要用于筛查 PH 的病因和评价器官损害情况。\n\n【12】风湿免疫病相关自身抗体、肝炎病毒感染、HIV抗体等是指导PH发型的噬索标志。血常规检查异常需警覊格多类血系统疾病(如白血病,贫血,红细细胞身症.、省细胞丰.常络合症，多少性骨髓增粘设)，综合组织發病以及慢性咳血症疾病( 红细胞及血红蛋白代性综合了)等。甲功能异常(主要是凭甘氨粗和皂红素）需要妬查肝功能,药物物质、病系统疲及心包等原因，对月原因对应的患肉具.常常检测同型悦酸及血原,原有t意味着说明显存在代性增性状况(如甲基丙二酸尿等)。\n\n【13】CTEPH患者侃需行易栓筛查(包托基性传栓特性),特副是或能肺栓症,银克抗凝物、抗β2糖蛋白1抗体。\n\n【14】所有PH患者在初诊及随访问建行需要测定血液利鹅肚 (BNP)或N末端利鹅肚前体(NT-proBNP),用于评价病情及指导治疗。\n\n【15】(十)腹腔超声\n\n【16】腹腔超声可以了解腹部器官储组和功能,为 PH的病因提供提供依据。腹腔超声可以诊已经性的去排除r]肝高陷,也可以为心去求竽提供饲答,如肝静肺扩,肝脏血.胆水反应肺市。肺脉扩张等。\n\n【17】对右心导管检查和血借氧词定试\n\n【18】RHC足诊断和评价 PH的标定方法,通过RHC可获得血流动力学数据. 包括有局、右室压 (收缩压和舒和平均压),肺动脉压力(pulmonary artery wedge pressure, PAWP),心输出量,混合静脉血氧饱提度(mixed venous oxygen saturation, SvO_2)和PVR等。", "index": 1612, "show": true, "start": 1599, "end": 1617, "province": ["语义有效性", "语义不完整"], "isEdit": false}], "startTime": "2024/08/06 15:37:26", "endTime": "2024/08/06 15:38:46", "cost": 79.969}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-05 23:38:46", "grab_time": "2024-08-05 23:37:25"}
{"id": 2211593, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "af956234-08e7-4d8e-b9c9-a2b565ea1272", "title": "2023 WHO 指南：疟疾", "text": "【0】页码:277\n2023 WHO 指南：疟疾\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】参考删除-3:<u>227. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale (Policy brief). Geneva: World Health Organization 2016; [Website].</u>\n\n【2】228. Guide to G6PD deficiency rapid diagnostic testing to support P. vivax radical cure. World Health Organization, Geneva 2018; [Website].\n\n【3】参考删除-3:<u>229. Milligan R, Daher A, Villanueva G, Bergman H, Graves P : Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax. Cochrane Database Syst Rev 2020; [Pubmed Journal].</u>\n\n【4】参考删除-3:<u>230. Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, et al. : The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC medicine 2019;17删除11:<u>(1)</u>:151 [Pubmed Journal].</u>\n\n【5】参考删除-3:<u>231. Galappaththy GNL, Tharyan P, Kirubakaran R : Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. The Cochrane database of systematic reviews 2013;删除11:<u>(10)</u>:CD004389 [Pubmed Journal].</u>\n\n【6】参考删除-3:<u>232. Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P : Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. The Cochrane database of systematic reviews 2014;删除11:<u>(10)</u>:CD000169 [Pubmed Journal].</u>\n\n【7】233. Management of severe malaria - A practical handbook, 3rd edition. Geneva: World Health Organization 2013; [Website].\n\n【8】参考删除-3:<u>234. Sinclair D, Donegan S, Isba R, Lalloo DG : Artesunate versus quinine for treating severe malaria. The Cochrane database of systematic reviews 2012;6):CD005967 [Pubmed Journal].</u>\n\n【9】235. Information note on delayed haemolytic anaemia following treatment with artesunate. Geneva: World Health Organization 2013; [Website].\n\n【10】参考删除-3:<u>236. Hendriksen ICE, Mtove G, Kent A, Gesase S, Reyburn H, Lemnge MM, et al. : Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Clinical pharmacology and therapeutics 2013;93删除11:<u>(5)</u>:443-50 [Pubmed Journal].</u>\n\n【11】参考删除-3:<u>237. Zaloumis SG, Tarning J, Krishna S, Price RN, White NJ, Davis TME, et al. : Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria. CPT: pharmacometrics & systems pharmacology 2014;3 e145 [Pubmed Journal].</u>\n\n【12】参考删除-3:<u>238. Esu E, Effa EE, Opie ON, Uwaoma A, Meremikwu MM : Artemether for severe malaria. The Cochrane database of systematic reviews 2014;9):CD010678 [Pubmed Journal].</u>\n\n【13】239. Okebe J, Eisenhut M : Pre-referral rectal artesunate for severe malaria. The Cochrane database of systematic reviews 2014;删除11:<u>(5)</u>:CD009964 [Pubmed Journal].\n\n【14】240. Rectal artesunate for pre-referral treatment of severe malaria. Geneva: World Health Organization 2017; [Website].\n\n【15】241. Prequalification programme: A United Nations programme managed by WHO. Geneva: World Health Organization 2009; [Website].\n\n【16】242. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization 2009; [Website].\n\n【17】243. Methods and techniques for clinical trials on antimalarial drug efficacy: Genotyping to identify parasite populations. World Health Organization, Geneva 2008; [Website].\n\n【18】参考删除-3:<u>244. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance 删除11:<u>删除19:<u>(2010-2019)</u></u>. Geneva: World Health Organization 2020; [Website].</u>", "tags": {}, "lang": "en", "attr": {"page_num": 277, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 WHO 指南：疟疾.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/07 10:14:22", "endTime": "2024/08/07 10:18:54", "cost": 272.325}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 18:18:51", "grab_time": "2024-08-06 18:06:25"}
{"id": 2211592, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "11be8c84-1120-4e88-b937-6d2219bf3021", "title": "综合医疗机构肺结核早期发现临床实践指南", "text": "【0】页码:11\n综合医疗机构肺结核早期发现临床实践指南\n### Ⅲ 进一步意见\n\n【1】推荐意见 10: 对 HIV 感染者/AIDS 患者, 非 HIV 感染免疫抑制人群, 终末期肾脏病患者和孕期患多种肺结核重症人群推荐开展结核分枝杆菌感染检查和结核病筛查。包括结核分枝杆菌感染、肺部影像学、免疫学检测。对诊断为结核分枝杆菌感染的患者推荐实施预防性抗结核治疗。\n\n【2】1. 结核分枝杆菌感染检测：推荐使用结核分枝杆菌感染的体液试验方法 (如结核分枝杆菌蛋白精素皮肤试验和 IFN-γ 释放试验)。对于对结核分枝杆菌免疫的个体，推荐使用 IFN-γ 释放试验。对于初次诊断结核感染患者，尤其是最近接触结核患者者，推荐使用结核皮试。\n\n【3】2. 肺部影像学：对肺部结核影像学筛查有异常者，尤其是有结核病可疑症状或接触史者，推荐每年进行一次胸部影像学筛查。如果患者的结核可疑症状或影像学不能排除肺结核，必须排除意愿 1～4。\n\n【4】3. 免疫学检测：对抗结核治疗的患者推荐实施免疫学检测，尤其是对初次诊断为结核分枝杆菌感染者和 AIDS 患者。\n\n【5】4. 在肺结核活动高的地区，每 6 个月至 1 年，对患者采取切除检测肺结核的各类感染性和抗结核性检测方法。对于所有诊断为结核分枝杆菌感染者，建议进行预防性抗结核治疗。\n\n【6】5. 诊断期间：所有诊断为活动性结核的患者都应在初诊时进行艾滋病筛查和结核筛查，结核感染可疑症状或影像学不能排除肺结核的患者应进行艾滋病筛查，并推荐进行初筛和每次诊断时的肺结核筛查。\n\n【7】6. 定期进行监测：推荐对肺结核高危患者群体每年进行艾滋病检测。\n\n【8】### Ⅳ 推推荐意见说明\n\n【9】一项荟萃分析表明，在接受抗逆转录病毒疗法 (antiretroviral therapy, ART) 的 HIV 感染者/AIDS 患者中强化用量的奥拉夫中 (包括咳嗽、发热、盗汗及体质量减轻) 的敏感度为 51.0% (95%CI: 20.8%～72.3%), 特异度为 7.0% (95%CI: 47.8%～86.4%)。在未接受 ART 的 HIV 感染者/AIDS 患者中，单独使用这些筛查指标的敏感度为 89.4% (95%CI: 83.0%～93.5%), 特异度为 28.1% (95%CI: 18.6%～40.1%)。对接受 ART 的 HIV 感染者/AIDS 患者开展厚度抹片筛查与胸部影像学检查的敏感度为 84.6% (95%CI: 69.7%～92.9%), 特异度为 29.8% (95%CI: 26.3%～33.6%)；对未接受 ART 的 HIV 感染者/AIDS 患者同时开展厚度抹片筛查与胸部影像学检查，敏感度为 95.3% (95%CI: 93.5%～96.8%), 特异度为 20.1% (95%CI: 7.6%～43.8%)。德国开展的一项回顾性研究分析 2009 年新增诊断为 2 型糖尿病的 331 601 例患者，3 年随访期间新诊断结核 1533 例 (0.46%), 其中 647 例 (42.2%) 在诊断的一年内确诊结核。\n\n【10】指导的局限性及进一步研究方向\n\n【11】本指南是以 WHO 相关指南、全国结核病防治工作技术规范及国内外研究进展和经验总结为基础制定而成，对于某些特定人群的筛查方式及流程，不同筛查策略，以及不同技术措施组合的筛查效率，近期规程的改进主要参考相关研究中的客观描述。指导的局限性及进一步研究方向包括: 删除11:<u>(1)</u> 在综合诊疗机构不同目标人群中进行的结核筛查的敏感度和特异性,筛查质量和技术差距; 删除11:<u>(2)</u> 比较不同筛查方式,筛查流程的敏感度、特异性，以及在不同目标人群中开展的结核筛查的成本效益分析; 删除11:<u>(3)</u> 研究在综合诊疗机构开展规范化结核筛查早期筛查对于全国结核防治成效的影响及远期影响。\n\n【12】各综合诊疗机构在接受本指南推荐的筛查程序和具体实施筛查时，需结合本地及不同的医疗机构的实际进行优化，并在实践中开展评估，为进一步步制定完善的国家综合医疗机构结核早期发现策略提供指导。", "tags": {}, "lang": "zh", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/综合医疗机构肺结核早期发现临床实践指南.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Ⅲ 进一步意见\n【1】推荐意见 10: 对 HIV 感染者/AIDS 患者, 非 HIV 感染免疫抑制人群, 终末期肾脏病患者和孕期患多种肺结核重症人群推荐开展结核分枝杆菌感染检查和结核病筛查。包括结核分枝杆菌感染、肺部影像学、免疫学检测。对诊断为结核分枝杆菌感染的患者推荐实施预防性抗结核治疗。\n\n【2】1. 结核分枝杆菌感染检测：推荐使用结核分枝杆菌感染的体液试验方法 (如结核分枝杆菌蛋白精素皮肤试验和 IFN-γ 释放试验)。对于对结核分枝杆菌免疫的个体，推荐使用 IFN-γ 释放试验。对于初次诊断结核感染患者，尤其是最近接触结核患者者，推荐使用结核皮试。\n\n【3】2. 肺部影像学：对肺部结核影像学筛查有异常者，尤其是有结核病可疑症状或接触史者，推荐每年进行一次胸部影像学筛查。如果患者的结核可疑症状或影像学不能排除肺结核，必须排除意愿 1～4。\n\n【4】3. 免疫学检测：对抗结核治疗的患者推荐实施免疫学检测，尤其是对初次诊断为结核分枝杆菌感染者和 AIDS 患者。\n\n【5】4. 在肺结核活动高的地区，每 6 个月至 1 年，对患者采取切除检测肺结核的各类感染性和抗结核性检测方法。对于所有诊断为结核分枝杆菌感染者，建议进行预防性抗结核治疗。\n\n【6】5. 诊断期间：所有诊断为活动性结核的患者都应在初诊时进行艾滋病筛查和结核筛查，结核感染可疑症状或影像学不能排除肺结核的患者应进行艾滋病筛查，并推荐进行初筛和每次诊断时的肺结核筛查。\n\n【7】6. 定期进行监测：推荐对肺结核高危患者群体每年进行艾滋病检测。\n\n【8】### Ⅳ 推推荐意见说明\n\n【9】一项荟萃分析表明，在接受抗逆转录病毒疗法 (antiretroviral therapy, ART) 的 HIV 感染者/AIDS 患者中强化用量的奥拉夫中 (包括咳嗽、发热、盗汗及体质量减轻) 的敏感度为 51.0% (95%CI: 20.8%～72.3%), 特异度为 7.0% (95%CI: 47.8%～86.4%)。在未接受 ART 的 HIV 感染者/AIDS 患者中，单独使用这些筛查指标的敏感度为 89.4% (95%CI: 83.0%～93.5%), 特异度为 28.1% (95%CI: 18.6%～40.1%)。对接受 ART 的 HIV 感染者/AIDS 患者开展厚度抹片筛查与胸部影像学检查的敏感度为 84.6% (95%CI: 69.7%～92.9%), 特异度为 29.8% (95%CI: 26.3%～33.6%)；对未接受 ART 的 HIV 感染者/AIDS 患者同时开展厚度抹片筛查与胸部影像学检查，敏感度为 95.3% (95%CI: 93.5%～96.8%), 特异度为 20.1% (95%CI: 7.6%～43.8%)。德国开展的一项回顾性研究分析 2009 年新增诊断为 2 型糖尿病的 331 601 例患者，3 年随访期间新诊断结核 1533 例 (0.46%), 其中 647 例 (42.2%) 在诊断的一年内确诊结核。\n\n【10】指导的局限性及进一步研究方向\n\n【11】本指南是以 WHO 相关指南、全国结核病防治工作技术规范及国内外研究进展和经验总结为基础制定而成，对于某些特定人群的筛查方式及流程，不同筛查策略，以及不同技术措施组合的筛查效率，近期规程的改进主要参考相关研究中的客观描述。指导的局限性及进一步研究方向包括: 删除11:(1) 在综合诊疗机构不同目标人群中进行的结核筛查的敏感度和特异性,筛查质量和技术差距; 删除11:(2) 比较不同筛查方式,筛查流程的敏感度、特异性，以及在不同目标人群中开展的结核筛查的成本效益分析; 删除11:(3) 研究在综合诊疗机构开展规范化结核筛查早期筛查对于全国结核防治成效的影响及远期影响。\n\n【12】各综合诊疗机构在接受本指南推荐的筛查程序和具体实施筛查时，需结合本地及不同的医疗机构的实际进行优化，并在实践中开展评估，为进一步步制定完善的国家综合医疗机构结核早期发现策略提供指导。", "content": "【0】页码:11\n综合医疗机构肺结核早期发现临床实践指南\n### Ⅲ 进一步意见\n\n【1】推荐意见 10: 对 HIV 感染者/AIDS 患者, 非 HIV 感染免疫抑制人群, 终末期肾脏病患者和孕期患多种肺结核重症人群推荐开展结核分枝杆菌感染检查和结核病筛查。包括结核分枝杆菌感染、肺部影像学、免疫学检测。对诊断为结核分枝杆菌感染的患者推荐实施预防性抗结核治疗。\n\n【2】1. 结核分枝杆菌感染检测：推荐使用结核分枝杆菌感染的体液试验方法 (如结核分枝杆菌蛋白精素皮肤试验和 IFN-γ 释放试验)。对于对结核分枝杆菌免疫的个体，推荐使用 IFN-γ 释放试验。对于初次诊断结核感染患者，尤其是最近接触结核患者者，推荐使用结核皮试。\n\n【3】2. 肺部影像学：对肺部结核影像学筛查有异常者，尤其是有结核病可疑症状或接触史者，推荐每年进行一次胸部影像学筛查。如果患者的结核可疑症状或影像学不能排除肺结核，必须排除意愿 1～4。\n\n【4】3. 免疫学检测：对抗结核治疗的患者推荐实施免疫学检测，尤其是对初次诊断为结核分枝杆菌感染者和 AIDS 患者。\n\n【5】4. 在肺结核活动高的地区，每 6 个月至 1 年，对患者采取切除检测肺结核的各类感染性和抗结核性检测方法。对于所有诊断为结核分枝杆菌感染者，建议进行预防性抗结核治疗。\n\n【6】5. 诊断期间：所有诊断为活动性结核的患者都应在初诊时进行艾滋病筛查和结核筛查，结核感染可疑症状或影像学不能排除肺结核的患者应进行艾滋病筛查，并推荐进行初筛和每次诊断时的肺结核筛查。\n\n【7】6. 定期进行监测：推荐对肺结核高危患者群体每年进行艾滋病检测。\n\n【8】### Ⅳ 推推荐意见说明\n\n【9】一项荟萃分析表明，在接受抗逆转录病毒疗法 (antiretroviral therapy, ART) 的 HIV 感染者/AIDS 患者中强化用量的奥拉夫中 (包括咳嗽、发热、盗汗及体质量减轻) 的敏感度为 51.0% (95%CI: 20.8%～72.3%), 特异度为 7.0% (95%CI: 47.8%～86.4%)。在未接受 ART 的 HIV 感染者/AIDS 患者中，单独使用这些筛查指标的敏感度为 89.4% (95%CI: 83.0%～93.5%), 特异度为 28.1% (95%CI: 18.6%～40.1%)。对接受 ART 的 HIV 感染者/AIDS 患者开展厚度抹片筛查与胸部影像学检查的敏感度为 84.6% (95%CI: 69.7%～92.9%), 特异度为 29.8% (95%CI: 26.3%～33.6%)；对未接受 ART 的 HIV 感染者/AIDS 患者同时开展厚度抹片筛查与胸部影像学检查，敏感度为 95.3% (95%CI: 93.5%～96.8%), 特异度为 20.1% (95%CI: 7.6%～43.8%)。德国开展的一项回顾性研究分析 2009 年新增诊断为 2 型糖尿病的 331 601 例患者，3 年随访期间新诊断结核 1533 例 (0.46%), 其中 647 例 (42.2%) 在诊断的一年内确诊结核。\n\n【10】指导的局限性及进一步研究方向\n\n【11】本指南是以 WHO 相关指南、全国结核病防治工作技术规范及国内外研究进展和经验总结为基础制定而成，对于某些特定人群的筛查方式及流程，不同筛查策略，以及不同技术措施组合的筛查效率，近期规程的改进主要参考相关研究中的客观描述。指导的局限性及进一步研究方向包括: 删除11:<u>(1)</u> 在综合诊疗机构不同目标人群中进行的结核筛查的敏感度和特异性,筛查质量和技术差距; 删除11:<u>(2)</u> 比较不同筛查方式,筛查流程的敏感度、特异性，以及在不同目标人群中开展的结核筛查的成本效益分析; 删除11:<u>(3)</u> 研究在综合诊疗机构开展规范化结核筛查早期筛查对于全国结核防治成效的影响及远期影响。\n\n【12】各综合诊疗机构在接受本指南推荐的筛查程序和具体实施筛查时，需结合本地及不同的医疗机构的实际进行优化，并在实践中开展评估，为进一步步制定完善的国家综合医疗机构结核早期发现策略提供指导。", "index": 33, "show": true, "start": 33, "end": 1715, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "内容和原文不符"}], "startTime": "2024/08/07 09:52:15", "endTime": "2024/08/07 09:53:20", "cost": 64.829}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 17:53:19", "grab_time": "2024-08-06 17:52:13"}
{"id": 2211591, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "663bf0dd-c96f-4eff-ad12-dca9c905bf4e", "title": "2023 AGA／ACG临床实践指南：慢性特发性便秘的药物治疗", "text": "【0】页码:16\n2023 AGA／ACG临床实践指南：慢性特发性便秘的药物治疗\nat a large health system. Descriptively, there were no clear differences in outcomes among individuals older than 65 years in clinical trials, although the sample size was too small to support formal analysis on differences in outcomes related to age.\n\n【1】删除图片描述:<u>![](15_0.png)</u>\n\n【2】daily taken with or without food. Plecanatide is also approved at the same dose for IBS-C. Plecanatide may have beneficial concurrent effects with relief in abdominal pain based on indirect evidence from IBS-C trials. Individuals using plecanatide might be at higher risk of diarrhea leading to discontinuation of medication; however, the absolute risk seems small. Descriptively, there were no clear differences in outcomes among individuals older than 65 years in clinical trials, although the sample size was too small to support formal analysis on differences in outcomes related to age.\n\n【3】## 5-HT<sub>4</sub> Agonist\n\n【4】删除图片描述:<u>![](15_1.png)</u>\n\n【5】### Plecanatide\n\n【6】删除32:<u>**</u>Summary of evidence.删除32:<u>**</u> Three 12-week randomized double-blinded placebo-controlled trials evaluated the use of plecanatide for the management of CIC. The studied dose of plecanatide was 3 mg/6 mg daily, and all studies were conducted in the United States and Canada. Plecanatide is a guanylate cyclase-C agonist, which increases cyclic guanosine monophosphate concentrations resulting in luminal chloride and bicarbonate secretion, thereby increasing intestinal fluid and accelerating GI transit.\n\n【7】删除32:<u>**</u>Benefits and harms.删除32:<u>**</u> The pooled data showed that the use of plecanatide in adults with CIC leads to an increase in the number of CSBM per week (MD 1.1, 95% CI 0.85–1.35) and improves the quality-of-life scores. The intervention group had increased responder rates, defined as ≥3 CSBMs per week and ≥1 CSBM over baseline for ≥9 of 12 weeks including ≥3 of the last 4 weeks, compared with placebo (RR 1.删除13:<u>78, 95</u>% CI 1.46–2.18), 88 more per 1,000 (from 52 to 134 more). Participants treated with plecanatide might have higher rates of reported diarrhea leading to treatment discontinuation (RR 5.删除13:<u>39, 95</u>% CI 2.40–12.11), 27 more per 1,000 (from 9 to 69 more). The use of plecanatide might improve stool consistency based on the Bristol Stool Form Scale compared with placebo (MD 0.删除13:<u>83, 95</u>% CI 0.60–1.05).\n\n【8】删除32:<u>**</u>Certainty in evidence of effects.删除32:<u>**</u> The certainty of evidence was high for outcomes of CSBM and SBM frequency and QoL, and moderate for diarrhea, leading to treatment discontinuation, serious adverse events, and stool form. The panel rated down certainty of these outcomes because of imprecision. The overall certainty in evidence for plecanatide was moderate.\n\n【9】删除32:<u>**</u>Discussion删除32:<u>**</u>\n\n【10】Plecanatide is a pH-dependent guanylate cyclase-C agonist approved by the FDA for CIC at a dose of 3 mg\n\n【11】### Prucalopride\n\n【12】删除32:<u>**</u>Summary of evidence.删除32:<u>**</u> Five 12-week randomized double-blinded placebo-controlled trials evaluated the use of prucalopride (2 mg daily) for the management of CIC. The studies were conducted in the United States, Europe, and the Asia-Pacific region. The 4 mg dose has also been studied. Prucalopride is a selective, high-affinity 5-HT<sub>4</sub> agonist that promotes neurotransmission by the enteric nervous system to stimulating the peristaltic reflex, intestinal secretions, and GI motility.\n\n【13】删除32:<u>**</u>Benefits and harms.删除32:<u>**</u> Compared with placebo, prucalopride resulted in an increased number of CSBM per week (MD 0.删除13:<u>96, 95</u>% CI 0.64–1.29). SBMs per week was not studied in any of the included study. Responder rates, defined as ≥3 CSBMs per week, were higher in the prucalopride group (RR 2.删除13:<u>37, 95</u>% CI 1.97–2.85) with 165 more responders per 1,000 (range 117–222 more). An alternative endpoint per point, deemed alternative and not preference, defined as ≥3 CSBM per week and ≥1 CSBM over baseline for ≥75% of study weeks, was higher in the prucalopride group (RR 2.删除13:<u>51, 95</u>% CI 1.97–3.21) with 109 more responders per 1,000 (range 70–160 more). The rates of diarrhea leading to treatment discontinuation might be higher in the prucalopride group compared with placebo (RR 3.00, 95% CI 1.89–4.78). The occurrence of serious adverse events was low; however, the CI around the summary estimate was imprecise and included a possible\n\n【14】删除图片描述:<u>![](15_2.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 16, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 AGA／ACG临床实践指南：慢性特发性便秘的药物治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】", "content": "【0】页码:16\n2023 AGA／ACG临床实践指南：慢性特发性便秘的药物治疗\nat a large health system. Descriptively, there were no clear differences in outcomes among individuals older than 65 years in clinical trials, although the sample size was too small to support formal analysis on differences in outcomes related to age.\n\n【1】删除图片描述:<u>![](15_0.png)</u>\n\n【2】daily taken with or without food. Plecanatide is also approved at the same dose for IBS-C. Plecanatide may have beneficial concurrent effects with relief in abdominal pain based on indirect evidence from IBS-C trials. Individuals using plecanatide might be at higher risk of diarrhea leading to discontinuation of medication; however, the absolute risk seems small. Descriptively, there were no clear differences in outcomes among individuals older than 65 years in clinical trials, although the sample size was too small to support formal analysis on differences in outcomes related to age.\n\n【3】## 5-HT<sub>4</sub> Agonist\n\n【4】删除图片描述:<u>![](15_1.png)</u>\n\n【5】### Plecanatide\n\n【6】删除32:<u>**</u>Summary of evidence.删除32:<u>**</u> Three 12-week randomized double-blinded placebo-controlled trials evaluated the use of plecanatide for the management of CIC. The studied dose of plecanatide was 3 mg/6 mg daily, and all studies were conducted in the United States and Canada. Plecanatide is a guanylate cyclase-C agonist, which increases cyclic guanosine monophosphate concentrations resulting in luminal chloride and bicarbonate secretion, thereby increasing intestinal fluid and accelerating GI transit.\n\n【7】删除32:<u>**</u>Benefits and harms.删除32:<u>**</u> The pooled data showed that the use of plecanatide in adults with CIC leads to an increase in the number of CSBM per week (MD 1.1, 95% CI 0.85–1.35) and improves the quality-of-life scores. The intervention group had increased responder rates, defined as ≥3 CSBMs per week and ≥1 CSBM over baseline for ≥9 of 12 weeks including ≥3 of the last 4 weeks, compared with placebo (RR 1.删除13:<u>78, 95</u>% CI 1.46–2.18), 88 more per 1,000 (from 52 to 134 more). Participants treated with plecanatide might have higher rates of reported diarrhea leading to treatment discontinuation (RR 5.删除13:<u>39, 95</u>% CI 2.40–12.11), 27 more per 1,000 (from 9 to 69 more). The use of plecanatide might improve stool consistency based on the Bristol Stool Form Scale compared with placebo (MD 0.删除13:<u>83, 95</u>% CI 0.60–1.05).\n\n【8】删除32:<u>**</u>Certainty in evidence of effects.删除32:<u>**</u> The certainty of evidence was high for outcomes of CSBM and SBM frequency and QoL, and moderate for diarrhea, leading to treatment discontinuation, serious adverse events, and stool form. The panel rated down certainty of these outcomes because of imprecision. The overall certainty in evidence for plecanatide was moderate.\n\n【9】删除32:<u>**</u>Discussion删除32:<u>**</u>\n\n【10】Plecanatide is a pH-dependent guanylate cyclase-C agonist approved by the FDA for CIC at a dose of 3 mg\n\n【11】### Prucalopride\n\n【12】删除32:<u>**</u>Summary of evidence.删除32:<u>**</u> Five 12-week randomized double-blinded placebo-controlled trials evaluated the use of prucalopride (2 mg daily) for the management of CIC. The studies were conducted in the United States, Europe, and the Asia-Pacific region. The 4 mg dose has also been studied. Prucalopride is a selective, high-affinity 5-HT<sub>4</sub> agonist that promotes neurotransmission by the enteric nervous system to stimulating the peristaltic reflex, intestinal secretions, and GI motility.\n\n【13】删除32:<u>**</u>Benefits and harms.删除32:<u>**</u> Compared with placebo, prucalopride resulted in an increased number of CSBM per week (MD 0.删除13:<u>96, 95</u>% CI 0.64–1.29). SBMs per week was not studied in any of the included study. Responder rates, defined as ≥3 CSBMs per week, were higher in the prucalopride group (RR 2.删除13:<u>37, 95</u>% CI 1.97–2.85) with 165 more responders per 1,000 (range 117–222 more). An alternative endpoint per point, deemed alternative and not preference, defined as ≥3 CSBM per week and ≥1 CSBM over baseline for ≥75% of study weeks, was higher in the prucalopride group (RR 2.删除13:<u>51, 95</u>% CI 1.97–3.21) with 109 more responders per 1,000 (range 70–160 more). The rates of diarrhea leading to treatment discontinuation might be higher in the prucalopride group compared with placebo (RR 3.00, 95% CI 1.89–4.78). The occurrence of serious adverse events was low; however, the CI around the summary estimate was imprecise and included a possible\n\n【14】删除图片描述:<u>![](15_2.png)</u>", "index": 326, "show": true, "start": 326, "end": 329, "province": ["语义有效性", "栏目混乱-重"], "isEdit": false, "comment": "2至结尾 正文顺序混乱"}], "startTime": "2024/08/07 09:53:11", "endTime": "2024/08/07 09:57:02", "cost": 231.376}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 17:56:59", "grab_time": "2024-08-06 17:53:08"}
{"id": 2211590, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "3fa0b803-fefa-433e-a80b-96b3d91bc2c9", "title": "2023 HRS_APHRS_LAHRS指南：心脏生理性起搏预防和减轻心力衰竭(1)", "text": "【0】页码:16\n2023 HRS_APHRS_LAHRS指南：心脏生理性起搏预防和减轻心力衰竭(1)\npersistent LBBB after TAVI. LBBB correction was achieved in 11 patients (69%). In over half, 2 ventricular leads were used with the second in the RV or LV via the CS. A concern with HBP in this setting is that AV block or bundle branch block (BBB) might develop at a site distal to the site of His bundle capture subsequent to pacemaker implant. Data删除21:<u>^85-87 </u>on LBBAP for new LBBB post-TAVI are limited to small subgroups or those with a traditional bradycardia indication for pacing (eg, complete heart block), and data on CRT are limited to case reports. Given this, the writing committee did not feel that sufficient data existed to make recommendations on the type of device to use after TAVI, beyond those for AV block or LBBB in other settings.\n\n【1】### 3.2. Indications for CPP in patients with HF\nThis section provides recommendations for pacing strategies in patients who do not have an a priori indication for pacing due to bradycardia but who have HF (NYHA class I–IV) across variable QRS durations and LBBB/non-LBBB morphologies or who are expected to have a substantial burden of anticipated RVP, portending a risk of PICM, as outlined in Figure 2.\n\n【2】```\n\n|删除段内换行|Patients without indications for pacemaker therapy who have HF\n\n【4】LVEF ≤30%  \nLBBB  \nLVEF ≤35%  \nQRSd ≥150  \nNYHA class II–IV  \nCRT with BIV pacing (1. A)  \nQRSd 120–149  \nNYHA class II–IV  \nSelect characteristics (eg, female sex)  \nNo  \nCRT with BIV pacing (2a. B-R)  \nYes  \nCRT with BIV pacing (1. A) if effective CRT cannot be achieved  \nQRSd ≥150  \nNYHA Class I  \nCRT with BIV pacing (2b. B-R)  \nLVEF 36–50%  \nQRSd ≥150  \nNYHA class II–IV  \nCRT with BIV pacing (1. A)  \nQRSd <120  \nNYHA class II-IV  \nNYHA class I or II  \nCRT with BIV pacing (3: No Benefit, B-R)  \nHBP or LBBAP (2b. C-LD)  \nnon-LBBB  \nLVEF ≤35%  \nQRSd ≥150  \nNYHA class III or IV  \nNYHA class II  \nCRT with BIV pacing (2b. B-NR)  \nQRSd 120–149  \nNYHA class III or IV  \nNYHA class II  \nCRT with BIV pacing (2a. B-R)  \nQRSd ≥150  \nNYHA class I or II  \nCRT with BIV pacing (2a. B-R)\n\n【5】PICM with high burden RVP  \nRevision of CIED to a CSP device (2a. B-NR)  \n删除图片描述:<u>Figure 2 Algorithm for pacing strategies in patients without bradycardia indications who have HF. Colors correspond to the class of recommendation in Table 1. BiV = biventricular; CIED = cardiovascular implantable electrical device; CRT = cardiac resynchronization therapy; HB P = His bundle pacing; HF = heart failure; LBBAP = left bundle branch area pacing; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PICM = pacing-induced cardiomyopathy; QRSd = QRS duration; RVP = right ventricular pacing.</u>\n```", "tags": {}, "lang": "en", "attr": {"page_num": 16, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 HRS_APHRS_LAHRS指南：心脏生理性起搏预防和减轻心力衰竭(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】```\n\n|删除段内换行|Patients without indications for pacemaker therapy who have HF\n\n【4】LVEF ≤30%\n\nLBBB\n\nLVEF ≤35%\n\nQRSd ≥150\n\nNYHA class II–IV\n\nCRT with BIV pacing (1. A)\n\nQRSd 120–149\n\nNYHA class II–IV\n\nSelect characteristics (eg, female sex)\n\nNo\n\nCRT with BIV pacing (2a. B-R)\n\nYes\n\nCRT with BIV pacing (1. A) if effective CRT cannot be achieved\n\nQRSd ≥150\n\nNYHA Class I\n\nCRT with BIV pacing (2b. B-R)\n\nLVEF 36–50%\n\nQRSd ≥150\n\nNYHA class II–IV\n\nCRT with BIV pacing (1. A)\n\nQRSd <120\n\nNYHA class II-IV\n\nNYHA class I or II\n\nCRT with BIV pacing (3: No Benefit, B-R)\n\nHBP or LBBAP (2b. C-LD)\n\nnon-LBBB\n\nLVEF ≤35%\n\nQRSd ≥150\n\nNYHA class III or IV\n\nNYHA class II\n\nCRT with BIV pacing (2b. B-NR)\n\nQRSd 120–149\n\nNYHA class III or IV\n\nNYHA class II\n\nCRT with BIV pacing (2a. B-R)\n\nQRSd ≥150\n\nNYHA class I or II\n\nCRT with BIV pacing (2a. B-R)\n\n【5】PICM with high burden RVP\n\nRevision of CIED to a CSP device (2a. B-NR)\n", "content": "【0】页码:16\n2023 HRS_APHRS_LAHRS指南：心脏生理性起搏预防和减轻心力衰竭(1)\npersistent LBBB after TAVI. LBBB correction was achieved in 11 patients (69%). In over half, 2 ventricular leads were used with the second in the RV or LV via the CS. A concern with HBP in this setting is that AV block or bundle branch block (BBB) might develop at a site distal to the site of His bundle capture subsequent to pacemaker implant. Data删除21:<u>^85-87 </u>on LBBAP for new LBBB post-TAVI are limited to small subgroups or those with a traditional bradycardia indication for pacing (eg, complete heart block), and data on CRT are limited to case reports. Given this, the writing committee did not feel that sufficient data existed to make recommendations on the type of device to use after TAVI, beyond those for AV block or LBBB in other settings.\n\n【1】### 3.2. Indications for CPP in patients with HF\nThis section provides recommendations for pacing strategies in patients who do not have an a priori indication for pacing due to bradycardia but who have HF (NYHA class I–IV) across variable QRS durations and LBBB/non-LBBB morphologies or who are expected to have a substantial burden of anticipated RVP, portending a risk of PICM, as outlined in Figure 2.\n\n【2】```\n\n|删除段内换行|Patients without indications for pacemaker therapy who have HF\n\n【4】LVEF ≤30%  \nLBBB  \nLVEF ≤35%  \nQRSd ≥150  \nNYHA class II–IV  \nCRT with BIV pacing (1. A)  \nQRSd 120–149  \nNYHA class II–IV  \nSelect characteristics (eg, female sex)  \nNo  \nCRT with BIV pacing (2a. B-R)  \nYes  \nCRT with BIV pacing (1. A) if effective CRT cannot be achieved  \nQRSd ≥150  \nNYHA Class I  \nCRT with BIV pacing (2b. B-R)  \nLVEF 36–50%  \nQRSd ≥150  \nNYHA class II–IV  \nCRT with BIV pacing (1. A)  \nQRSd <120  \nNYHA class II-IV  \nNYHA class I or II  \nCRT with BIV pacing (3: No Benefit, B-R)  \nHBP or LBBAP (2b. C-LD)  \nnon-LBBB  \nLVEF ≤35%  \nQRSd ≥150  \nNYHA class III or IV  \nNYHA class II  \nCRT with BIV pacing (2b. B-NR)  \nQRSd 120–149  \nNYHA class III or IV  \nNYHA class II  \nCRT with BIV pacing (2a. B-R)  \nQRSd ≥150  \nNYHA class I or II  \nCRT with BIV pacing (2a. B-R)\n\n【5】PICM with high burden RVP  \nRevision of CIED to a CSP device (2a. B-NR)  \n删除图片描述:<u>Figure 2 Algorithm for pacing strategies in patients without bradycardia indications who have HF. Colors correspond to the class of recommendation in Table 1. BiV = biventricular; CIED = cardiovascular implantable electrical device; CRT = cardiac resynchronization therapy; HB P = His bundle pacing; HF = heart failure; LBBAP = left bundle branch area pacing; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PICM = pacing-induced cardiomyopathy; QRSd = QRS duration; RVP = right ventricular pacing.</u>\n```", "index": 1224, "show": true, "start": 1224, "end": 2130, "province": ["信息质量", "有用性-轻"], "isEdit": false}], "startTime": "2024/08/07 10:06:32", "endTime": "2024/08/07 10:07:11", "cost": 39.179}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 18:07:10", "grab_time": "2024-08-06 18:06:31"}
{"id": 2211589, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "7a303388-3204-4c38-9591-76dd77a5d902", "title": "WHO：促进积极产后体验的产妇和新生儿护理建议（2022）", "text": "【0】页码:219\nWHO：促进积极产后体验的产妇和新生儿护理建议（2022）\n抱歉，提供的图片不包含正文内容，只包含一页参考文献条目。所以根据要求，该页没有需要转换为Markdown格式的正文内容。", "tags": {}, "lang": "zh", "attr": {"page_num": 219, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WHO：促进积极产后体验的产妇和新生儿护理建议（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:39:19", "endTime": "2024/08/06 16:39:47", "cost": 27.988}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:39:47", "grab_time": "2024-08-06 00:39:19"}
{"id": 2211588, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "88270312-ecad-4972-806b-f3d9ab4f65a6", "title": "2024更新—2016+NICE指南：结核病（NG.33）", "text": "【0】页码:69\n2024更新—2016+NICE指南：结核病（NG.33）\nbroader social support) 删除24:<u>[new 2016]</u>\n\n【1】- advice and support for parents and carers 删除24:<u>[new 2016]</u>\n- incentives and enablers to help people follow their treatment regimen. 删除24:<u>[new 2016]</u>\n\n【2】1.7.2.3 TB control boards should ensure services take into account the barriers facing vulnerable migrants who may need treatment, and in particular the stigma they may face. Other issues include the location of services (both geographically and in terms of opening times) and people's language and cultural needs, in terms of the format of advice and the type of information given. 删除24:<u>[2012, amended 2016]</u>\n\n【3】### 1.7.3 Strategies in prisons or immigration removal centres\n\n【4】1.7.3.1 On arrival at a prison or immigration removal centre, healthcare professionals should ask all prisoners and detainees (including those being transferred from other establishments) if they are taking TB medication, to ensure continuity of treatment. 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>\n\n【5】1.7.3.2 All prisoners and immigration removal centre detainees having treatment for active TB should have a named TB case manager. The case manager should be responsible for contingency planning for discharge from prison or detention. 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>\n\n【6】1.7.3.3 Prisons and immigration removal centres should ensure multidisciplinary TB staff have access to prisoners and detainees who need treatment (for example, by being given security clearance). 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>\n\n【7】1.7.3.4 All prisoners having treatment for active TB should have directly observed therapy. 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>\n\n【8】1.7.3.5 Prison health services should have contingency, liaison and handover arrangements to ensure continuity of care before any prisoner on TB treatment is transferred between prisons or released. In addition, other agencies working with prisoners or detainees should also be involved in this planning. 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>", "tags": {}, "lang": "en", "attr": {"page_num": 69, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024更新—2016+NICE指南：结核病（NG.33）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】- advice and support for parents and carers 删除24:[new 2016]\n\nincentives and enablers to help people follow their treatment regimen.", "content": "【0】页码:69\n2024更新—2016+NICE指南：结核病（NG.33）\nbroader social support) 删除24:<u>[new 2016]</u>\n\n【1】- advice and support for parents and carers 删除24:<u>[new 2016]</u>\n- incentives and enablers to help people follow their treatment regimen. 删除24:<u>[new 2016]</u>\n\n【2】1.7.2.3 TB control boards should ensure services take into account the barriers facing vulnerable migrants who may need treatment, and in particular the stigma they may face. Other issues include the location of services (both geographically and in terms of opening times) and people's language and cultural needs, in terms of the format of advice and the type of information given. 删除24:<u>[2012, amended 2016]</u>\n\n【3】### 1.7.3 Strategies in prisons or immigration removal centres\n\n【4】1.7.3.1 On arrival at a prison or immigration removal centre, healthcare professionals should ask all prisoners and detainees (including those being transferred from other establishments) if they are taking TB medication, to ensure continuity of treatment. 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>\n\n【5】1.7.3.2 All prisoners and immigration removal centre detainees having treatment for active TB should have a named TB case manager. The case manager should be responsible for contingency planning for discharge from prison or detention. 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>\n\n【6】1.7.3.3 Prisons and immigration removal centres should ensure multidisciplinary TB staff have access to prisoners and detainees who need treatment (for example, by being given security clearance). 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>\n\n【7】1.7.3.4 All prisoners having treatment for active TB should have directly observed therapy. 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>\n\n【8】1.7.3.5 Prison health services should have contingency, liaison and handover arrangements to ensure continuity of care before any prisoner on TB treatment is transferred between prisons or released. In addition, other agencies working with prisoners or detainees should also be involved in this planning. 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>", "index": 87, "show": true, "start": 87, "end": 221, "province": ["格式规范性", "序号格式不一致"], "isEdit": false}], "startTime": "2024/08/06 16:56:23", "endTime": "2024/08/06 16:57:19", "cost": 56.56}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:57:19", "grab_time": "2024-08-06 00:56:15"}
{"id": 2211587, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "6e3b8c05-3fc3-4fca-aa84-9a96b41531f9", "title": "AHA：肾血管疾病的血运重建的科学声明（2022）", "text": "【0】页码:7\nAHA：肾血管疾病的血运重建的科学声明（2022）\n(本页删除)本页被模型判断为参考页疑似页眉<u>### Patient Populations and Characteristics Considered for Renal Revascularization</u>\n\n【1】#### Clinical populations\n\n【2】- Unilateral renal artery stenosis with characteristic syndromes 删除9:<u>(see below)</u>\n- Fibromuscular dysplasia with hypertension\\删除32:<u>*</u>\n- High-risk clinical syndromes\\删除32:<u>*</u>\n- Rapidly progressive hypertension\\删除32:<u>*</u>\n- Rapidly declining estimated glomerular filtration rate\\删除32:<u>*</u>\n- Flash pulmonary edema\\删除32:<u>*</u>\n- Bilateral renal artery stenosis with progressive loss of renal functional mass\n- Single native kidney renal artery stenosis\n\n【3】#### Special populations\n\n【4】- Renal allograft transplant renal artery stenosis with or without calcineurin inhibitors\n- Episodic, circulatory congestion with bilateral atherosclerotic renovascular disease\n- Progressive loss of glomerular filtration rate with occlusive atherosclerotic renovascular disease and no other kidney disease (ischemic nephropathy)\n- Aortic disease with renovascular protection as part of endovascular repair\n- Left-ventricular assist device\n- Radiation-induced renovascular disease with clinical syndromes\n- Other diseases: e.g., Takayasu arteritis, extrinsic vascular compression\n- Pediatric patients with mid aortic syndrome or fibromuscular variants\n\n【5】#### Characteristics suggestive of clinical benefit from revascularization\n\n【6】- Recent onset or exacerbation (<1 y) of hypertension删除32:<u>*</u>\n- Absence of proteinuria删除32:<u>*</u>\n- Identifiable activation of renin–angiotensin system删除32:<u>*</u>\n- Hyperreninemia删除32:<u>*</u>\n- With unilateral renal artery stenosis, lateralization of renal vein renin删除32:<u>*</u>\n- Younger age\n- Radiographic evidence of progressive renal artery occlusion\n- Treatment-resistant hypertension (documentation of hypertension by ambulatory blood pressure and medication adherence)\n- Angiotensin-dependent glomerular filtration rate\n\n【7】\\删除32:<u>*</u>Further details are available in the text.\n\n【8】Considered in aggregate, these trials indicate that most patients with atherosclerotic disease do not benefit from vascular intervention when treated with optimal medical therapy. Most importantly, these data do not clarify the criteria to identify people with clinical conditions and hemodynamically severe renal artery occlusive disease who may benefit from revascularization.\n\n【9】### PATIENT POPULATIONS AND CHARACTERISTICS THAT WARRANT CONSIDERATION FOR REVASCULARIZATION\n\n【10】#### Fibromuscular Dysplasia\n\n【11】Hypertension is diagnosed at a similar age in patients with FMD and in patients with essential hypertension. FMD-related renovascular hypertension  should be suspected in those patients (particularly women) with early-onset, accelerated, malignant, or resistant hypertension, a small kidney without uropathy, arterial bruit in the abdomen, flank, or neck, or FMD in another vascular territory 删除9:<u>(Table 2)</u>. The prevalence may be as high as 75% among hypertensive women <50 years of age, and computed tomographic angiography is the initial imaging modality of choice for diagnosis of renal FMD.\n\n【12】When FMD-related renovascular hypertension is suspected, catheter-based angiography with hemodynamic assessment is warranted to determine the need for angioplasty and assess for gradient obliteration after angioplasty. Angioplasty without stenting is the recommended procedure when revascularization is indicated, and a consensus-based protocol for catheter-based angiography and angioplasty has been recently published. Randomized controlled trials of revascularization for hypertension in patients with FMD are not available. However, revascularization has been associated with cure of hypertension in observational studies. In a meta-analysis, cure rates, defined as <140/90 mm Hg without treatment, were 36% and 54% in 47 angioplasty and 23 surgery studies, respectively. Among those who underwent angioplasty, the probability of cure significantly decreased with increasing age and duration of hypertension. Also, angioplasty may be more effective in patients with focal versus multifocal FMD .\n\n【13】### Refractory Hypertension\n\n【14】Treatment-resistant hypertension, as defined by uncontrolled hypertension despite ≥3 hypertensive classes of medications including a diuretic or by hypertension requiring ≥4 antihypertensive classes of medications, is associated with worse cardiovascular outcomes and increased incidence of secondary hypertension. The true prevalence of ARVD in resistant hypertension is estimated to be 14% to 23% on the basis of studies in consecutive patients with poorly controlled hypertension undergoing cardiac catheterization and 24% in patients with resistant hypertension referred for renal arteriography. Multiple retrospective studies of patients with ARVD and resistant hypertension who underwent percutaneous angioplasty indicate that antihypertensive pill burden can decrease 删除9:<u>(Table 1)</u>. However, in controlled clinical trials, there are minimal differences in the number of medications in patients managed with revascularization and medical therapy versus medical therapy alone.\n\n【15】### Progressive Kidney Function Decline\n\n【16】Progressive kidney function decline associated with severe hypertension and ARVD is common, but the incidence of potentially preventable clinical renal disease is unknown. In patients with existing renovascular disease, risk factors for progressive loss of kidney function or renal artery occlusion include severely elevated", "tags": {}, "lang": "en", "attr": {"page_num": 7, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/AHA：肾血管疾病的血运重建的科学声明（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "(本页删除)", "content": "【0】页码:7\nAHA：肾血管疾病的血运重建的科学声明（2022）\n(本页删除)本页被模型判断为参考页疑似页眉<u>### Patient Populations and Characteristics Considered for Renal Revascularization</u>\n\n【1】#### Clinical populations\n\n【2】- Unilateral renal artery stenosis with characteristic syndromes 删除9:<u>(see below)</u>\n- Fibromuscular dysplasia with hypertension\\删除32:<u>*</u>\n- High-risk clinical syndromes\\删除32:<u>*</u>\n- Rapidly progressive hypertension\\删除32:<u>*</u>\n- Rapidly declining estimated glomerular filtration rate\\删除32:<u>*</u>\n- Flash pulmonary edema\\删除32:<u>*</u>\n- Bilateral renal artery stenosis with progressive loss of renal functional mass\n- Single native kidney renal artery stenosis\n\n【3】#### Special populations\n\n【4】- Renal allograft transplant renal artery stenosis with or without calcineurin inhibitors\n- Episodic, circulatory congestion with bilateral atherosclerotic renovascular disease\n- Progressive loss of glomerular filtration rate with occlusive atherosclerotic renovascular disease and no other kidney disease (ischemic nephropathy)\n- Aortic disease with renovascular protection as part of endovascular repair\n- Left-ventricular assist device\n- Radiation-induced renovascular disease with clinical syndromes\n- Other diseases: e.g., Takayasu arteritis, extrinsic vascular compression\n- Pediatric patients with mid aortic syndrome or fibromuscular variants\n\n【5】#### Characteristics suggestive of clinical benefit from revascularization\n\n【6】- Recent onset or exacerbation (<1 y) of hypertension删除32:<u>*</u>\n- Absence of proteinuria删除32:<u>*</u>\n- Identifiable activation of renin–angiotensin system删除32:<u>*</u>\n- Hyperreninemia删除32:<u>*</u>\n- With unilateral renal artery stenosis, lateralization of renal vein renin删除32:<u>*</u>\n- Younger age\n- Radiographic evidence of progressive renal artery occlusion\n- Treatment-resistant hypertension (documentation of hypertension by ambulatory blood pressure and medication adherence)\n- Angiotensin-dependent glomerular filtration rate\n\n【7】\\删除32:<u>*</u>Further details are available in the text.\n\n【8】Considered in aggregate, these trials indicate that most patients with atherosclerotic disease do not benefit from vascular intervention when treated with optimal medical therapy. Most importantly, these data do not clarify the criteria to identify people with clinical conditions and hemodynamically severe renal artery occlusive disease who may benefit from revascularization.\n\n【9】### PATIENT POPULATIONS AND CHARACTERISTICS THAT WARRANT CONSIDERATION FOR REVASCULARIZATION\n\n【10】#### Fibromuscular Dysplasia\n\n【11】Hypertension is diagnosed at a similar age in patients with FMD and in patients with essential hypertension. FMD-related renovascular hypertension  should be suspected in those patients (particularly women) with early-onset, accelerated, malignant, or resistant hypertension, a small kidney without uropathy, arterial bruit in the abdomen, flank, or neck, or FMD in another vascular territory 删除9:<u>(Table 2)</u>. The prevalence may be as high as 75% among hypertensive women <50 years of age, and computed tomographic angiography is the initial imaging modality of choice for diagnosis of renal FMD.\n\n【12】When FMD-related renovascular hypertension is suspected, catheter-based angiography with hemodynamic assessment is warranted to determine the need for angioplasty and assess for gradient obliteration after angioplasty. Angioplasty without stenting is the recommended procedure when revascularization is indicated, and a consensus-based protocol for catheter-based angiography and angioplasty has been recently published. Randomized controlled trials of revascularization for hypertension in patients with FMD are not available. However, revascularization has been associated with cure of hypertension in observational studies. In a meta-analysis, cure rates, defined as <140/90 mm Hg without treatment, were 36% and 54% in 47 angioplasty and 23 surgery studies, respectively. Among those who underwent angioplasty, the probability of cure significantly decreased with increasing age and duration of hypertension. Also, angioplasty may be more effective in patients with focal versus multifocal FMD .\n\n【13】### Refractory Hypertension\n\n【14】Treatment-resistant hypertension, as defined by uncontrolled hypertension despite ≥3 hypertensive classes of medications including a diuretic or by hypertension requiring ≥4 antihypertensive classes of medications, is associated with worse cardiovascular outcomes and increased incidence of secondary hypertension. The true prevalence of ARVD in resistant hypertension is estimated to be 14% to 23% on the basis of studies in consecutive patients with poorly controlled hypertension undergoing cardiac catheterization and 24% in patients with resistant hypertension referred for renal arteriography. Multiple retrospective studies of patients with ARVD and resistant hypertension who underwent percutaneous angioplasty indicate that antihypertensive pill burden can decrease 删除9:<u>(Table 1)</u>. However, in controlled clinical trials, there are minimal differences in the number of medications in patients managed with revascularization and medical therapy versus medical therapy alone.\n\n【15】### Progressive Kidney Function Decline\n\n【16】Progressive kidney function decline associated with severe hypertension and ARVD is common, but the incidence of potentially preventable clinical renal disease is unknown. In patients with existing renovascular disease, risk factors for progressive loss of kidney function or renal artery occlusion include severely elevated", "index": 34, "show": true, "start": 34, "end": 40, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "页疑似页眉### Patient Populations and Characteristics Considered for Renal Revascularization", "content": "【0】页码:7\nAHA：肾血管疾病的血运重建的科学声明（2022）\n<mark>(本页删除)</mark>本页被模型判断为参考页疑似页眉<u>### Patient Populations and Characteristics Considered for Renal Revascularization</u>\n\n【1】#### Clinical populations\n\n【2】- Unilateral renal artery stenosis with characteristic syndromes 删除9:<u>(see below)</u>\n- Fibromuscular dysplasia with hypertension\\删除32:<u>*</u>\n- High-risk clinical syndromes\\删除32:<u>*</u>\n- Rapidly progressive hypertension\\删除32:<u>*</u>\n- Rapidly declining estimated glomerular filtration rate\\删除32:<u>*</u>\n- Flash pulmonary edema\\删除32:<u>*</u>\n- Bilateral renal artery stenosis with progressive loss of renal functional mass\n- Single native kidney renal artery stenosis\n\n【3】#### Special populations\n\n【4】- Renal allograft transplant renal artery stenosis with or without calcineurin inhibitors\n- Episodic, circulatory congestion with bilateral atherosclerotic renovascular disease\n- Progressive loss of glomerular filtration rate with occlusive atherosclerotic renovascular disease and no other kidney disease (ischemic nephropathy)\n- Aortic disease with renovascular protection as part of endovascular repair\n- Left-ventricular assist device\n- Radiation-induced renovascular disease with clinical syndromes\n- Other diseases: e.g., Takayasu arteritis, extrinsic vascular compression\n- Pediatric patients with mid aortic syndrome or fibromuscular variants\n\n【5】#### Characteristics suggestive of clinical benefit from revascularization\n\n【6】- Recent onset or exacerbation (<1 y) of hypertension删除32:<u>*</u>\n- Absence of proteinuria删除32:<u>*</u>\n- Identifiable activation of renin–angiotensin system删除32:<u>*</u>\n- Hyperreninemia删除32:<u>*</u>\n- With unilateral renal artery stenosis, lateralization of renal vein renin删除32:<u>*</u>\n- Younger age\n- Radiographic evidence of progressive renal artery occlusion\n- Treatment-resistant hypertension (documentation of hypertension by ambulatory blood pressure and medication adherence)\n- Angiotensin-dependent glomerular filtration rate\n\n【7】\\删除32:<u>*</u>Further details are available in the text.\n\n【8】Considered in aggregate, these trials indicate that most patients with atherosclerotic disease do not benefit from vascular intervention when treated with optimal medical therapy. Most importantly, these data do not clarify the criteria to identify people with clinical conditions and hemodynamically severe renal artery occlusive disease who may benefit from revascularization.\n\n【9】### PATIENT POPULATIONS AND CHARACTERISTICS THAT WARRANT CONSIDERATION FOR REVASCULARIZATION\n\n【10】#### Fibromuscular Dysplasia\n\n【11】Hypertension is diagnosed at a similar age in patients with FMD and in patients with essential hypertension. FMD-related renovascular hypertension  should be suspected in those patients (particularly women) with early-onset, accelerated, malignant, or resistant hypertension, a small kidney without uropathy, arterial bruit in the abdomen, flank, or neck, or FMD in another vascular territory 删除9:<u>(Table 2)</u>. The prevalence may be as high as 75% among hypertensive women <50 years of age, and computed tomographic angiography is the initial imaging modality of choice for diagnosis of renal FMD.\n\n【12】When FMD-related renovascular hypertension is suspected, catheter-based angiography with hemodynamic assessment is warranted to determine the need for angioplasty and assess for gradient obliteration after angioplasty. Angioplasty without stenting is the recommended procedure when revascularization is indicated, and a consensus-based protocol for catheter-based angiography and angioplasty has been recently published. Randomized controlled trials of revascularization for hypertension in patients with FMD are not available. However, revascularization has been associated with cure of hypertension in observational studies. In a meta-analysis, cure rates, defined as <140/90 mm Hg without treatment, were 36% and 54% in 47 angioplasty and 23 surgery studies, respectively. Among those who underwent angioplasty, the probability of cure significantly decreased with increasing age and duration of hypertension. Also, angioplasty may be more effective in patients with focal versus multifocal FMD .\n\n【13】### Refractory Hypertension\n\n【14】Treatment-resistant hypertension, as defined by uncontrolled hypertension despite ≥3 hypertensive classes of medications including a diuretic or by hypertension requiring ≥4 antihypertensive classes of medications, is associated with worse cardiovascular outcomes and increased incidence of secondary hypertension. The true prevalence of ARVD in resistant hypertension is estimated to be 14% to 23% on the basis of studies in consecutive patients with poorly controlled hypertension undergoing cardiac catheterization and 24% in patients with resistant hypertension referred for renal arteriography. Multiple retrospective studies of patients with ARVD and resistant hypertension who underwent percutaneous angioplasty indicate that antihypertensive pill burden can decrease 删除9:<u>(Table 1)</u>. However, in controlled clinical trials, there are minimal differences in the number of medications in patients managed with revascularization and medical therapy versus medical therapy alone.\n\n【15】### Progressive Kidney Function Decline\n\n【16】Progressive kidney function decline associated with severe hypertension and ARVD is common, but the incidence of potentially preventable clinical renal disease is unknown. In patients with existing renovascular disease, risk factors for progressive loss of kidney function or renal artery occlusion include severely elevated", "index": 63, "show": true, "start": 50, "end": 137, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 16:41:40", "endTime": "2024/08/06 16:43:50", "cost": 130.773}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:43:50", "grab_time": "2024-08-06 00:41:39"}
{"id": 2211586, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "831fdb7c-993d-4909-970f-4856a74eff65", "title": "2023 NICE 诊断指南：帕金森病远程监测设备[DG51]", "text": "【0】页码:17\n2023 NICE 诊断指南：帕金森病远程监测设备[DG51]\n### How much remote monitoring devices would change decisions about care in the NHS is uncertain\n\n#### 3.8 |删除段内换行|The clinical experts said that, as well as changes to medication, symptoms can be managed with other changes to care like physiotherapy and exercise. Only the PKG had data on how the technologies can change decisions about care. The proportion of people who had a change in clinical management as a result of the PKG varied considerably (between 31.8% and 79%). A UK study reported that the PKG provided additional information in 45.5% of cases. In studies of clinician opinion, between 4% and 41% agreed that the PKG provided enough additional information to consider making treatment adjustments. The committee concluded that there was uncertainty about how much using remote monitoring devices would change care for people in the NHS.\n\n【2】### Cost effectiveness\n\n【3】#### Device cost is a major driver of cost effectiveness\n\n#### 3.9 |删除段内换行|In the EAG's model, the intervention arm resulted in a higher cost than standard care. Device cost had the biggest impact on this. The EAG said that the device cost depended on how the devices were modelled as being used 删除9:<u>(see section 3.3)</u> and the cost per use. The technologies have differing payment mechanisms: pay per use, a subscription model or outright purchase of the device. The committee noted that the payment options differed in terms of upfront investment and how reversible a decision to use a technology would be. The committee recalled that the technologies could be used in various ways in the NHS and noted that the EAG had modelled use at varying frequencies. This included one-time use (at baseline) and routine use (every 6 months) in its base cases, and a recurrent use scenario analysis (at 6 and 18 months in place of clinic。", "tags": {}, "lang": "en", "attr": {"page_num": 17, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 NICE 诊断指南：帕金森病远程监测设备[DG51].pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "How much remote monitoring", "content": "【0】页码:17\n2023 NICE 诊断指南：帕金森病远程监测设备[DG51]\n### How much remote monitoring devices would change decisions about care in the NHS is uncertain\n\n#### 3.8 |删除段内换行|The clinical experts said that, as well as changes to medication, symptoms can be managed with other changes to care like physiotherapy and exercise. Only the PKG had data on how the technologies can change decisions about care. The proportion of people who had a change in clinical management as a result of the PKG varied considerably (between 31.8% and 79%). A UK study reported that the PKG provided additional information in 45.5% of cases. In studies of clinician opinion, between 4% and 41% agreed that the PKG provided enough additional information to consider making treatment adjustments. The committee concluded that there was uncertainty about how much using remote monitoring devices would change care for people in the NHS.\n\n【2】### Cost effectiveness\n\n【3】#### Device cost is a major driver of cost effectiveness\n\n#### 3.9 |删除段内换行|In the EAG's model, the intervention arm resulted in a higher cost than standard care. Device cost had the biggest impact on this. The EAG said that the device cost depended on how the devices were modelled as being used 删除9:<u>(see section 3.3)</u> and the cost per use. The technologies have differing payment mechanisms: pay per use, a subscription model or outright purchase of the device. The committee noted that the payment options differed in terms of upfront investment and how reversible a decision to use a technology would be. The committee recalled that the technologies could be used in various ways in the NHS and noted that the EAG had modelled use at varying frequencies. This included one-time use (at baseline) and routine use (every 6 months) in its base cases, and a recurrent use scenario analysis (at 6 and 18 months in place of clinic。", "index": 45, "show": true, "start": 45, "end": 71, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "0"}], "startTime": "2024/08/06 15:39:00", "endTime": "2024/08/06 15:39:46", "cost": 46.155}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-05 23:39:46", "grab_time": "2024-08-05 23:39:00"}
{"id": 2211585, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "0f07ba79-2941-49f4-b79a-ebbde8e4f169", "title": "脑心清片治疗缺血性脑血管病临床应用专家共识", "text": "【0】页码:8\n脑心清片治疗缺血性脑血管病临床应用专家共识\n### 6.2 疗效特点\n\n【1】脑心清片具有改善缺血性脑血管病（ICVD）患者的血压、血糖、血脂（C 级证据，强推荐）、同型半胱氨酸、血流变参数（C 级证据，强推荐），血流动力学的作用(等级不明)，能有效降低 ICVD 的复发率，可用于该病的二级预防。ICVD 包括短暂性脑缺血发作 (TIA) 和急性缺血性脑卒中 (AIS)，脑心清片对 TIA 和 AIS 均有肯定疗效，可以提高患者治疗 TIA 的临床疗效，降低 AIS 患者 NT-proBNP (C 级证据，弱推荐)， LDL-C (C 级证据，强推荐) 及 CRP (C 级证据，强推荐)，减少神经功能缺损，改善患者营养状态及脑卒中后症状，提高临床疗效（B 级证据，强推荐）。此外，脑心清片能改善缺血性脑卒中恢复期患者的神经功能损害状况，改善头晕头痛、失眠多梦、上肢不遂、下肢不遂、口膀角麻的中医证候，增加患者生活质量和生活能力，降低致残率。根据机制研究，脑心清片在使用过程中安全性良好。\n\n【2】### 6.3 用法用量\n\n【3】脑心清片的推荐用药剂量为 1 片/次~2 片/次（规格：各种中提取物 100 mg/片）或 2 片/次~4 片/次（规格：含柠檬提取物 50 mg/片），3 次/日，餐后 30 min 服药。\n\n【4】脑心清片 1 个月~2 个月为基础疗程，可进行 1 个~2 个基础疗程。结束后由临床医生进行评估，决定是否进入下一个阶段的治疗。\n\n【5】### 6.4 联合用药\n\n【6】若患者仅出现眩晕头痛、失眠多梦等症状可单独服用脑心清片，也可根据病情联合降脂药、抗血小板药、抗凝药等常规治疗。\n\n【7】### 7 安全性\n\n【8】#### 7.1 不良反应\n\n【9】用药初期偶尔会出现胃肠道不适、便溏等，服用几天后可自行消失。若患者出现不良反应，需要在医生指导下减量或者停用用药，进行观察并对症治疗。\n\n【10】#### 7.2 禁忌\n\n【11】本文件建议在说明书描述外补充以下禁忌症：\n- 药物初及主要成分过敏者禁用；\n- 妊娠期或哺乳期女性禁用。", "tags": {}, "lang": "zh", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/脑心清片治疗缺血性脑血管病临床应用专家共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "中安全性良好。", "content": "【0】页码:8\n脑心清片治疗缺血性脑血管病临床应用专家共识\n### 6.2 疗效特点\n\n【1】脑心清片具有改善缺血性脑血管病（ICVD）患者的血压、血糖、血脂（C 级证据，强推荐）、同型半胱氨酸、血流变参数（C 级证据，强推荐），血流动力学的作用(等级不明)，能有效降低 ICVD 的复发率，可用于该病的二级预防。ICVD 包括短暂性脑缺血发作 (TIA) 和急性缺血性脑卒中 (AIS)，脑心清片对 TIA 和 AIS 均有肯定疗效，可以提高患者治疗 TIA 的临床疗效，降低 AIS 患者 NT-proBNP (C 级证据，弱推荐)， LDL-C (C 级证据，强推荐) 及 CRP (C 级证据，强推荐)，减少神经功能缺损，改善患者营养状态及脑卒中后症状，提高临床疗效（B 级证据，强推荐）。此外，脑心清片能改善缺血性脑卒中恢复期患者的神经功能损害状况，改善头晕头痛、失眠多梦、上肢不遂、下肢不遂、口膀角麻的中医证候，增加患者生活质量和生活能力，降低致残率。根据机制研究，脑心清片在使用过程中安全性良好。\n\n【2】### 6.3 用法用量\n\n【3】脑心清片的推荐用药剂量为 1 片/次~2 片/次（规格：各种中提取物 100 mg/片）或 2 片/次~4 片/次（规格：含柠檬提取物 50 mg/片），3 次/日，餐后 30 min 服药。\n\n【4】脑心清片 1 个月~2 个月为基础疗程，可进行 1 个~2 个基础疗程。结束后由临床医生进行评估，决定是否进入下一个阶段的治疗。\n\n【5】### 6.4 联合用药\n\n【6】若患者仅出现眩晕头痛、失眠多梦等症状可单独服用脑心清片，也可根据病情联合降脂药、抗血小板药、抗凝药等常规治疗。\n\n【7】### 7 安全性\n\n【8】#### 7.1 不良反应\n\n【9】用药初期偶尔会出现胃肠道不适、便溏等，服用几天后可自行消失。若患者出现不良反应，需要在医生指导下减量或者停用用药，进行观察并对症治疗。\n\n【10】#### 7.2 禁忌\n\n【11】本文件建议在说明书描述外补充以下禁忌症：\n- 药物初及主要成分过敏者禁用；\n- 妊娠期或哺乳期女性禁用。", "index": 448, "show": true, "start": 448, "end": 455, "province": ["语义有效性", "语义不完整"], "isEdit": false, "comment": "1"}, {"text": "【4】脑心清片 1 个月~2 个月为基础疗程，可进行 1 个~2 个基础疗程。结束后由临床医生进行评估，决定是否进入下一个阶段的治疗。", "content": "【0】页码:8\n脑心清片治疗缺血性脑血管病临床应用专家共识\n### 6.2 疗效特点\n\n【1】脑心清片具有改善缺血性脑血管病（ICVD）患者的血压、血糖、血脂（C 级证据，强推荐）、同型半胱氨酸、血流变参数（C 级证据，强推荐），血流动力学的作用(等级不明)，能有效降低 ICVD 的复发率，可用于该病的二级预防。ICVD 包括短暂性脑缺血发作 (TIA) 和急性缺血性脑卒中 (AIS)，脑心清片对 TIA 和 AIS 均有肯定疗效，可以提高患者治疗 TIA 的临床疗效，降低 AIS 患者 NT-proBNP (C 级证据，弱推荐)， LDL-C (C 级证据，强推荐) 及 CRP (C 级证据，强推荐)，减少神经功能缺损，改善患者营养状态及脑卒中后症状，提高临床疗效（B 级证据，强推荐）。此外，脑心清片能改善缺血性脑卒中恢复期患者的神经功能损害状况，改善头晕头痛、失眠多梦、上肢不遂、下肢不遂、口膀角麻的中医证候，增加患者生活质量和生活能力，降低致残率。根据机制研究，脑心清片在使用过程<mark>中安全性良好。</mark>\n\n【2】### 6.3 用法用量\n\n【3】脑心清片的推荐用药剂量为 1 片/次~2 片/次（规格：各种中提取物 100 mg/片）或 2 片/次~4 片/次（规格：含柠檬提取物 50 mg/片），3 次/日，餐后 30 min 服药。\n\n【4】脑心清片 1 个月~2 个月为基础疗程，可进行 1 个~2 个基础疗程。结束后由临床医生进行评估，决定是否进入下一个阶段的治疗。\n\n【5】### 6.4 联合用药\n\n【6】若患者仅出现眩晕头痛、失眠多梦等症状可单独服用脑心清片，也可根据病情联合降脂药、抗血小板药、抗凝药等常规治疗。\n\n【7】### 7 安全性\n\n【8】#### 7.1 不良反应\n\n【9】用药初期偶尔会出现胃肠道不适、便溏等，服用几天后可自行消失。若患者出现不良反应，需要在医生指导下减量或者停用用药，进行观察并对症治疗。\n\n【10】#### 7.2 禁忌\n\n【11】本文件建议在说明书描述外补充以下禁忌症：\n- 药物初及主要成分过敏者禁用；\n- 妊娠期或哺乳期女性禁用。", "index": 588, "show": true, "start": 575, "end": 642, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/06 15:36:50", "endTime": "2024/08/06 15:38:03", "cost": 73.646}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-05 23:38:03", "grab_time": "2024-08-05 23:36:49"}
{"id": 2211584, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "aac47941-f0e8-437b-bd0d-a7d7ebcee843", "title": "【心血管领域】（证据总结）2021+WHO指南：成人高血压的药物治疗", "text": "页码:125\n【心血管领域】（证据总结）2021+WHO指南：成人高血压的药物治疗\n### Explanations|删除段内换行|a. The trial that has most of the weight of the pooled estimate (77.5%) was judged at unclear risk of bias in the domain of random sequence generation.\nb. Rating the certainty that there is no important effect 删除19:<u>(using a threshold of 10 per 1000 patients)</u>, the lower end of the 95% CI crossed this threshold, suggesting that there may be an important benefit.\nc. We downgraded one level because the ACCOMPLISH 2008 trial that has most of the weight of the pooled estimate (83.4%) was judged at unclear risk of bias in the domain of random sequence generation. In addition, the COLM 2014 trial was judged at high risk of Blinding of participants and personnel (performance bias), Open-label, however with blinded end point. The weight of the COLM 2014 of the pooled effect estimates is 16.6%.\nd. We downgraded one level because the ACCOMPLISH 2008 trial that has most of the weight of the pooled estimate (86.6%) was judged at unclear risk of bias in the domain of random sequence generation. In addition, the COLM 2014 trial was judged at high risk of Blinding of participants and personnel (performance bias), Open-label, however with blinded end point. The weight of the COLM 2014 of the pooled effect estimates is 33.2%.\ne. The trial that has most of the weight of the pooled estimate (77.6%) was judged at unclear risk of bias in the domain of random sequence generation. In addition, the COLM 2014 trial was judged at high risk of Blinding of participants and personnel (performance bias), Open-label, however with blinded end point. The weight of the COLM 2014 of the pooled effect estimates is 12.3%.\nf. We downgraded one level because the ACCOMPLISH 2008 trial that has most of the weight of the pooled estimate (40.5%) was judged at unclear risk of bias in the domain of random sequence generation. In addition, the COLM 2014 trial was judged at high risk of Blinding of participants and personnel (performance bias), Open-label, however with blinded end point. The weight of the COLM 2014 of the pooled effect estimates is 21%.\ng. The point estimates vary importantly with regards to direction and magnitude of effect, and some of the CIs do not overlap. There is high statistical heterogeneity, as reflected by the I-squared (74%).\nh. We downgraded one level because the ACCOMPLISH 2008 trial that has most of the weight of the pooled estimate (47.5%) was judged at unclear risk of bias in the domain of random sequence generation. In addition, the COLM 2014 trial was judged at high risk of Blinding of participants and personnel (performance bias), Open-label, however with blinded end point. The weight of the COLM 2014 of the pooled effect estimates is 16.6%.\ni. The point estimates vary importantly with regards to direction and magnitude of effect, and some of the CIs do not overlap. There is high statistical heterogeneity, as reflected by the I-squared (76%).", "tags": {}, "lang": "en", "attr": {"page_num": 125, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【心血管领域】（证据总结）2021+WHO指南：成人高血压的药物治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "|删除段内换行|a. The trial that", "content": "页码:125\n【心血管领域】（证据总结）2021+WHO指南：成人高血压的药物治疗\n### Explanations|删除段内换行|a. The trial that has most of the weight of the pooled estimate (77.5%) was judged at unclear risk of bias in the domain of random sequence generation.\nb. Rating the certainty that there is no important effect 删除19:<u>(using a threshold of 10 per 1000 patients)</u>, the lower end of the 95% CI crossed this threshold, suggesting that there may be an important benefit.\nc. We downgraded one level because the ACCOMPLISH 2008 trial that has most of the weight of the pooled estimate (83.4%) was judged at unclear risk of bias in the domain of random sequence generation. In addition, the COLM 2014 trial was judged at high risk of Blinding of participants and personnel (performance bias), Open-label, however with blinded end point. The weight of the COLM 2014 of the pooled effect estimates is 16.6%.\nd. We downgraded one level because the ACCOMPLISH 2008 trial that has most of the weight of the pooled estimate (86.6%) was judged at unclear risk of bias in the domain of random sequence generation. In addition, the COLM 2014 trial was judged at high risk of Blinding of participants and personnel (performance bias), Open-label, however with blinded end point. The weight of the COLM 2014 of the pooled effect estimates is 33.2%.\ne. The trial that has most of the weight of the pooled estimate (77.6%) was judged at unclear risk of bias in the domain of random sequence generation. In addition, the COLM 2014 trial was judged at high risk of Blinding of participants and personnel (performance bias), Open-label, however with blinded end point. The weight of the COLM 2014 of the pooled effect estimates is 12.3%.\nf. We downgraded one level because the ACCOMPLISH 2008 trial that has most of the weight of the pooled estimate (40.5%) was judged at unclear risk of bias in the domain of random sequence generation. In addition, the COLM 2014 trial was judged at high risk of Blinding of participants and personnel (performance bias), Open-label, however with blinded end point. The weight of the COLM 2014 of the pooled effect estimates is 21%.\ng. The point estimates vary importantly with regards to direction and magnitude of effect, and some of the CIs do not overlap. There is high statistical heterogeneity, as reflected by the I-squared (74%).\nh. We downgraded one level because the ACCOMPLISH 2008 trial that has most of the weight of the pooled estimate (47.5%) was judged at unclear risk of bias in the domain of random sequence generation. In addition, the COLM 2014 trial was judged at high risk of Blinding of participants and personnel (performance bias), Open-label, however with blinded end point. The weight of the COLM 2014 of the pooled effect estimates is 16.6%.\ni. The point estimates vary importantly with regards to direction and magnitude of effect, and some of the CIs do not overlap. There is high statistical heterogeneity, as reflected by the I-squared (76%).", "index": 58, "show": true, "start": 58, "end": 83, "province": ["格式规范性", "缺少换行"], "isEdit": false}], "startTime": "2024/08/06 16:02:52", "endTime": "2024/08/06 16:03:55", "cost": 62.913}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:03:55", "grab_time": "2024-08-06 00:02:52"}
{"id": 2211583, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "aa94d3d5-a2ce-435c-ad5f-f74f0db1c8b7", "title": "2023 法国建议：淋巴管平滑肌瘤病的诊断与治疗", "text": "【0】页码:18\n2023 法国建议：淋巴管平滑肌瘤病的诊断与治疗\nThe multidisciplinary team of the expert (reference or competence center for rare pulmonary diseases establishes the diagnosis, evaluates the risk of complications, informs the patient, establishes the therapeutic indications, starts the specific treatment if necessary, and organizes the follow-up.\n\n【1】A joint follow-up, organized within the framework of a health care network, is recommended, involving the treating pulmonologist, the treating physician, and the reference or competence center. Visits to a specialized center (reference center or center of competence) are made at least once a year if there is joint follow-up with the treating pulmonologist, or more frequently if the patient's condition deteriorates.\n\n【2】The local pulmonologist, in collaboration with the reference or competence center for rare pulmonary diseases, ensures the clinical and pulmonary function testing follow-up, the monitoring of any specific treatments and the implementation and monitoring of symptomatic treatment.\n\n【3】The general practitioner ensures the follow-up of the patient with the local pulmonologist in coordination with the reference or competence center, prepares the care management file with the patient if necessary, and provides psychological support.\n\n【4】### 5.3. Frequency and structure of consultations\n\n【5】The frequency of these consultations and the examinations carried out must be adapted to:\n\n【6】- The patient's clinical state.\n- The severity and progression of the disease during treatment.\n- Any treatment selected.\nAt least one annual consultation in a reference or competence center is recommended.\nThe follow-up clinical examination is related to the one conducted during the initial evaluation. The frequency of consultations is adapted to the clinical evolution of the disease.\n\n【7】### 5.3.2. Paraclinical examinations\n\n【8】Disease progression can be assessed by repeating lung function tests at 3–6-month intervals during the first year after diagnosis, and then every 3–12 months depending on severity and rate of disease progression. This could include, for example, a clinical examination and spirometry test every 3 months and a plethysmography and measurement of DLCO every 6 months during the first year after diagnosis; then clinical examination, spirometry, plethysmography, and measurement of DLCO every 6–12 months thereafter.\n\n【9】Follow-up with chest CT should be adapted according to disease progression and history of complications (pneumothorax, chylothorax), while being careful to limit radiation exposure. For example, chest CT scans can be done every 3–5 years in patients with stable clinical manifestations and respiratory function, using a \"low dose\" radiation protocol.\n\n【10】In addition, regular therapeutic drug monitoring should be performed during treatment with mTOR inhibitors 删除9:<u>(see Appendix E)</u>.\n\n【11】For the follow-up of renal angiomyolipomas, an abdominalpelvic MRI is recommended every 1–3 years. Where MRI is not available, an abdominopelvic CT scan can be performed. Ultrasound is less accurate than MRI or CT for measuring lesions and therefore less reliable for follow-up. When the initial workup does not reveal an angiomyolipoma, an abdominopelvic MRI or renal ultrasound may be performed every 5 years up until menopause, and then once every 10 years.\n\n【12】### Funding\n\n【13】参考删除-3:<u>Direction Générale de l'Offre de Soins, France, 2019.</u>\n\n【14】### Declaration of Competing Interest\n\n| Name                        | Declaration of Interest                                                                                       |\n|-----------------------------|--------------------------------------------------------------------------------------------------------------|\n| Vincent COTTIN              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Elodie BLANCHARD            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Mailéne KERJOUAN            | declares research fees paid by Pfizer and Novartis to her institution.                                         |\n| Romain LAZOR                | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Martine REYNAUD-GAUBERT     | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Romain LAZOR                | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Camille TAILLE              | declares consulting fees paid to her by Novartis.                                                             |\n| Yurdagul UZUNHAN            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Lidwine WEMEAU              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Claire ANDRÉJAK             | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Dany BAUD                   | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Philippe BONNIAUD           | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Pierre-Yves BRILLET         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Alain CALENDER              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Tana CHALARABLYESSE         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Christophe PAPON            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Nicolas DESBAILLETS         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Gilbert FERRETTI            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Anne GUILLERMET             | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Laurane HARDELIN            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Marianne KAMBOUCHER         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Violette LECLERC (deceased) |                                                                                                               |\n| Matthieu LEDELRIN           | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Marie-Claire MAILING        | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Alain MANCEL                | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Sylvain MARCHAND-ADAM       | declares consulting fees paid by Novartis.                                                                    |\n| Jean-Michel MAURY           | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Jean-Marc NACCACHE          | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Mouhand NASSER              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Hilarie NUNES               | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Gaële PAGNOUX               | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Grégoire PRÉVOT             | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Christine ROUSSET-JABLONSKI | has no conflict of interest to disclose in relation with the content of the manuscript.                        |", "tags": {}, "lang": "en", "attr": {"page_num": 18, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 法国建议：淋巴管平滑肌瘤病的诊断与治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【6】- The patient’s clinical state.\n\nThe severity and progression of the disease during treatment.\nAny treatment selected.\nAt least one annual consultation in a reference or competence center is recommended.\nThe follow-up clinical examination is related to the one conducted during the initial evaluation. The frequency of consultations is adapted to the clinical evolution of the disease.", "content": "【0】页码:18\n2023 法国建议：淋巴管平滑肌瘤病的诊断与治疗\nThe multidisciplinary team of the expert (reference or competence center for rare pulmonary diseases establishes the diagnosis, evaluates the risk of complications, informs the patient, establishes the therapeutic indications, starts the specific treatment if necessary, and organizes the follow-up.\n\n【1】A joint follow-up, organized within the framework of a health care network, is recommended, involving the treating pulmonologist, the treating physician, and the reference or competence center. Visits to a specialized center (reference center or center of competence) are made at least once a year if there is joint follow-up with the treating pulmonologist, or more frequently if the patient's condition deteriorates.\n\n【2】The local pulmonologist, in collaboration with the reference or competence center for rare pulmonary diseases, ensures the clinical and pulmonary function testing follow-up, the monitoring of any specific treatments and the implementation and monitoring of symptomatic treatment.\n\n【3】The general practitioner ensures the follow-up of the patient with the local pulmonologist in coordination with the reference or competence center, prepares the care management file with the patient if necessary, and provides psychological support.\n\n【4】### 5.3. Frequency and structure of consultations\n\n【5】The frequency of these consultations and the examinations carried out must be adapted to:\n\n【6】- The patient's clinical state.\n- The severity and progression of the disease during treatment.\n- Any treatment selected.\nAt least one annual consultation in a reference or competence center is recommended.\nThe follow-up clinical examination is related to the one conducted during the initial evaluation. The frequency of consultations is adapted to the clinical evolution of the disease.\n\n【7】### 5.3.2. Paraclinical examinations\n\n【8】Disease progression can be assessed by repeating lung function tests at 3–6-month intervals during the first year after diagnosis, and then every 3–12 months depending on severity and rate of disease progression. This could include, for example, a clinical examination and spirometry test every 3 months and a plethysmography and measurement of DLCO every 6 months during the first year after diagnosis; then clinical examination, spirometry, plethysmography, and measurement of DLCO every 6–12 months thereafter.\n\n【9】Follow-up with chest CT should be adapted according to disease progression and history of complications (pneumothorax, chylothorax), while being careful to limit radiation exposure. For example, chest CT scans can be done every 3–5 years in patients with stable clinical manifestations and respiratory function, using a \"low dose\" radiation protocol.\n\n【10】In addition, regular therapeutic drug monitoring should be performed during treatment with mTOR inhibitors 删除9:<u>(see Appendix E)</u>.\n\n【11】For the follow-up of renal angiomyolipomas, an abdominalpelvic MRI is recommended every 1–3 years. Where MRI is not available, an abdominopelvic CT scan can be performed. Ultrasound is less accurate than MRI or CT for measuring lesions and therefore less reliable for follow-up. When the initial workup does not reveal an angiomyolipoma, an abdominopelvic MRI or renal ultrasound may be performed every 5 years up until menopause, and then once every 10 years.\n\n【12】### Funding\n\n【13】参考删除-3:<u>Direction Générale de l'Offre de Soins, France, 2019.</u>\n\n【14】### Declaration of Competing Interest\n\n| Name                        | Declaration of Interest                                                                                       |\n|-----------------------------|--------------------------------------------------------------------------------------------------------------|\n| Vincent COTTIN              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Elodie BLANCHARD            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Mailéne KERJOUAN            | declares research fees paid by Pfizer and Novartis to her institution.                                         |\n| Romain LAZOR                | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Martine REYNAUD-GAUBERT     | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Romain LAZOR                | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Camille TAILLE              | declares consulting fees paid to her by Novartis.                                                             |\n| Yurdagul UZUNHAN            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Lidwine WEMEAU              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Claire ANDRÉJAK             | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Dany BAUD                   | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Philippe BONNIAUD           | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Pierre-Yves BRILLET         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Alain CALENDER              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Tana CHALARABLYESSE         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Christophe PAPON            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Nicolas DESBAILLETS         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Gilbert FERRETTI            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Anne GUILLERMET             | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Laurane HARDELIN            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Marianne KAMBOUCHER         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Violette LECLERC (deceased) |                                                                                                               |\n| Matthieu LEDELRIN           | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Marie-Claire MAILING        | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Alain MANCEL                | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Sylvain MARCHAND-ADAM       | declares consulting fees paid by Novartis.                                                                    |\n| Jean-Michel MAURY           | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Jean-Marc NACCACHE          | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Mouhand NASSER              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Hilarie NUNES               | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Gaële PAGNOUX               | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Grégoire PRÉVOT             | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Christine ROUSSET-JABLONSKI | has no conflict of interest to disclose in relation with the content of the manuscript.                        |", "index": -1, "show": true, "start": -1, "end": 387, "province": ["格式规范性", "序号格式不一致"], "isEdit": false}, {"text": "【12】### Funding\n\n【13】参考删除-3:Direction Générale de l’Offre de Soins, France, 2019.\n\n【14】### Declaration of Competing Interest", "content": "【0】页码:18\n2023 法国建议：淋巴管平滑肌瘤病的诊断与治疗\nThe multidisciplinary team of the expert (reference or competence center for rare pulmonary diseases establishes the diagnosis, evaluates the risk of complications, informs the patient, establishes the therapeutic indications, starts the specific treatment if necessary, and organizes the follow-up.\n\n【1】A joint follow-up, organized within the framework of a health care network, is recommended, involving the treating pulmonologist, the treating physician, and the reference or competence center. Visits to a specialized center (reference center or center of competence) are made at least once a year if there is joint follow-up with the treating pulmonologist, or more frequently if the patient's condition deteriorates.\n\n【2】The local pulmonologist, in collaboration with the reference or competence center for rare pulmonary diseases, ensures the clinical and pulmonary function testing follow-up, the monitoring of any specific treatments and the implementation and monitoring of symptomatic treatment.\n\n【3】The general practitioner ensures the follow-up of the patient with the local pulmonologist in coordination with the reference or competence center, prepares the care management file with the patient if necessary, and provides psychological support.\n\n【4】### 5.3. Frequency and structure of consultations\n\n【5】The frequency of these consultations and the examinations carried out must be adapted to:\n\n【6】- The patient's clinical state.\n- The severity and progression of the disease during treatment.\n- Any treatment selected.\nAt least one annual consultation in a reference or competence center is recommended.\nThe follow-up clinical examination is related to the one conducted during the initial evaluation. The frequency of consultations is adapted to the clinical evolution of the disease.\n\n【7】### 5.3.2. Paraclinical examinations\n\n【8】Disease progression can be assessed by repeating lung function tests at 3–6-month intervals during the first year after diagnosis, and then every 3–12 months depending on severity and rate of disease progression. This could include, for example, a clinical examination and spirometry test every 3 months and a plethysmography and measurement of DLCO every 6 months during the first year after diagnosis; then clinical examination, spirometry, plethysmography, and measurement of DLCO every 6–12 months thereafter.\n\n【9】Follow-up with chest CT should be adapted according to disease progression and history of complications (pneumothorax, chylothorax), while being careful to limit radiation exposure. For example, chest CT scans can be done every 3–5 years in patients with stable clinical manifestations and respiratory function, using a \"low dose\" radiation protocol.\n\n【10】In addition, regular therapeutic drug monitoring should be performed during treatment with mTOR inhibitors 删除9:<u>(see Appendix E)</u>.\n\n【11】For the follow-up of renal angiomyolipomas, an abdominalpelvic MRI is recommended every 1–3 years. Where MRI is not available, an abdominopelvic CT scan can be performed. Ultrasound is less accurate than MRI or CT for measuring lesions and therefore less reliable for follow-up. When the initial workup does not reveal an angiomyolipoma, an abdominopelvic MRI or renal ultrasound may be performed every 5 years up until menopause, and then once every 10 years.\n\n【12】### Funding\n\n【13】参考删除-3:<u>Direction Générale de l'Offre de Soins, France, 2019.</u>\n\n【14】### Declaration of Competing Interest\n\n| Name                        | Declaration of Interest                                                                                       |\n|-----------------------------|--------------------------------------------------------------------------------------------------------------|\n| Vincent COTTIN              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Elodie BLANCHARD            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Mailéne KERJOUAN            | declares research fees paid by Pfizer and Novartis to her institution.                                         |\n| Romain LAZOR                | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Martine REYNAUD-GAUBERT     | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Romain LAZOR                | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Camille TAILLE              | declares consulting fees paid to her by Novartis.                                                             |\n| Yurdagul UZUNHAN            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Lidwine WEMEAU              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Claire ANDRÉJAK             | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Dany BAUD                   | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Philippe BONNIAUD           | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Pierre-Yves BRILLET         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Alain CALENDER              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Tana CHALARABLYESSE         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Christophe PAPON            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Nicolas DESBAILLETS         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Gilbert FERRETTI            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Anne GUILLERMET             | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Laurane HARDELIN            | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Marianne KAMBOUCHER         | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Violette LECLERC (deceased) |                                                                                                               |\n| Matthieu LEDELRIN           | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Marie-Claire MAILING        | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Alain MANCEL                | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Sylvain MARCHAND-ADAM       | declares consulting fees paid by Novartis.                                                                    |\n| Jean-Michel MAURY           | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Jean-Marc NACCACHE          | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Mouhand NASSER              | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Hilarie NUNES               | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Gaële PAGNOUX               | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Grégoire PRÉVOT             | has no conflict of interest to disclose in relation with the content of the manuscript.                        |\n| Christine ROUSSET-JABLONSKI | has no conflict of interest to disclose in relation with the content of the manuscript.                        |", "index": 3357, "show": true, "start": 3344, "end": 3468, "province": ["信息质量", "有用性-重"], "isEdit": false, "comment": "12到14所有内容为参考文献"}], "startTime": "2024/08/06 17:03:39", "endTime": "2024/08/06 17:08:17", "cost": 278.273}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 01:08:17", "grab_time": "2024-08-06 01:03:39"}
{"id": 2211582, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "0f006251-9936-4688-967d-faa0ece5fe85", "title": "冠状动脉球囊成形术与支架植入术操作规范（2022）", "text": "【0】页码:43\n冠状动脉球囊成形术与支架植入术操作规范（2022）\n（此页包含的内容属于参考文献部分，根据您的要求，我将其忽略。）", "tags": {}, "lang": "zh", "attr": {"page_num": 43, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/冠状动脉球囊成形术与支架植入术操作规范（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:41:43", "endTime": "2024/08/06 15:41:49", "cost": 5.926}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-05 23:41:50", "grab_time": "2024-08-05 23:41:43"}
{"id": 2211581, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "04f1bb0c-68bf-4d0f-b09b-a9d8170aa642", "title": "2023 CDC建议：乙型肝炎病毒感染的筛查和检测", "text": "【0】页码:22\n2023 CDC建议：乙型肝炎病毒感染的筛查和检测\nalcohol screening and brief intervention 删除11:<u>(127)</u>. Depending on the likely route of transmission, the patient might benefit from STI screening, drug treatment, or harm-reduction counseling. A full list of recommended steps for examination, education, laboratory, serology, and imaging is provided 删除9:<u>(Table 2)</u>.\n\n【1】Additional screening might be recommended for blood donors, newly arrived refugees, and persons initiating cytotoxic or immunosuppressive and additional testing might be recommended for patients on hemodialysis, health care personnel, perinatally exposed infants, and persons involved in exposure events who might warrant postexposure prophylaxis and postvaccination serologic testing. These recommendations are described elsewhere 删除11:<u>(14,15,104,106–110)</u>. Providers should follow the more conservative approach when recommendations differ.\n\n【2】### Future Directions\n\n【3】CDC will review these recommendations as new treatments, tests, epidemiology, HepB vaccination rates, and experiences gained from implementation of these recommendations become available; recommendations will be revised as needed. The work group did not conduct a systematic review to reassess any of the recommendations for HBV infection from those provided in earlier guidelines; future recommendations might modify the groups recommended for periodic testing. Additional data on the ideal frequency of periodic testing is needed. Continued collaboration with laboratories to bundle the three HBV tests (HBsAg, anti-HBs, and anti-HBc) would facilitate ordering the tests together as a triple panel. In addition, reporting a triple panel summary result will aid providers in correctly interpreting results. Finally, a better understanding of the prevalence of HBV in the United States is needed to inform recommendations for HBV screening among persons with HBV infection.\n\n【4】### Conclusion\n\n【5】Universal screening of adults for HBV infection is cost-effective compared with risk-based screening and averts liver disease and death 删除11:<u>(56)</u>. Although a curative treatment is not yet available, early diagnosis and treatment of chronic HBV infections reduces the risk for cirrhosis, liver cancer, and death 删除11:<u>(10,11)</u>. Risk-based testing alone has not identified most persons living with chronic HBV infection and is insufficient for providers to implement. Along with vaccination strategies, universal screening of adults and appropriate testing of persons at increased risk for HBV infection will improve health outcomes, reduce the prevalence of HBV infection in the United States, and advance viral hepatitis elimination goals.", "tags": {}, "lang": "en", "attr": {"page_num": 22, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 CDC建议：乙型肝炎病毒感染的筛查和检测.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:14:45", "endTime": "2024/08/06 16:15:03", "cost": 18.339}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:15:04", "grab_time": "2024-08-06 00:14:45"}
{"id": 2211580, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "a24e63f1-63aa-4c99-afac-fde1605678fb", "title": "EULAR：风湿和肌肉骨骼疾病（包括系统性红斑狼疮和抗磷脂综合征）的心血管风险管理建议（2022）", "text": "【0】页码:9\nEULAR：风湿和肌肉骨骼疾病（包括系统性红斑狼疮和抗磷脂综合征）的心血管风险管理建议（2022）\n(本页删除)本页被模型判断为参考页删除32:<u>**</u>Recommendation删除32:<u>**</u>\n\n【1】CVR management in RMDs include interactive educational workshops involving health professionals, patients and stakeholders with the support of healthcare professional societies and patient associations, social media dissemination strategies customised to local and national policies such as academic detailing, audits and feedback techniques.\n\n【2】The panel believes that these recommendations will enable healthcare providers and patients to mutually engage in a long-term care pathway tailored to patients’ needs and equipped for improving cardiovascular health in RMDs. As new data accumulates, this first set of ‘best available’ evidence on cardiovascular prevention in gout, vasculitis, SSc, myositis, MCTD, SS, SLE and APS will be timely updated.\n\n【3】删除32:<u>**</u>Author affiliations删除32:<u>**</u>\n\n【4】1. First Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Greece\n2. 删除32:<u>*</u>Rheca, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands删除32:<u>*</u>\n3. Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands\n4. Rheumatology Unit, Department of Internal Medicine, University of Messina, Messina, Italy\n5. 删除32:<u>*</u>EULAR Patient Research Partner, Brussels, Belgium删除32:<u>*</u>\n6. 4th Department of Internal Medicine, 删除32:<u>*</u>Attikon删除32:<u>*</u> University Hospital, Athens, Greece\n7. Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece\n8. Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Huddinge, Sweden\n9. Department of Orthopaedics, Danderyd Hospital Corp, Stockholm, Sweden\n10. 删除32:<u>*</u>Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK删除32:<u>*</u>\n11. NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK\n12. Department of Rheumatology, University Clinic Carl Gustav Carus at the TU Dresden, Dresden, Germany\n13. Department of Rheumatology, University of Basel, Basel, Switzerland\n14. Department of Cardiology, Amsterdam University Medical Centre, location VU University medical center, Amsterdam, The Netherlands\n15. Department of Rheumatology and Clinical Immunology, Amsterdam UMC, VU University, Amsterdam, The Netherlands\n16. Department of Public Health, NHS Grampian, Aberdeen, UK\n17. 删除32:<u>*</u>Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA删除32:<u>*</u>\n18. Amsterdam University Medical Center, location VU University Medical Center, Amsterdam, The Netherlands\n\n【5】删除32:<u>**</u>Twitter删除32:<u>**</u>\n\n【6】Chetan Mukhtyar @mukhtyar\n\n【7】Gaya J Macfarlane @AberdeenEpi and Ariela R Gkoutzoumi @arielatkoutzo\n\n【8】删除32:<u>**</u>Acknowledgements删除32:<u>**</u>\n\n【9】The committee wishes to acknowledge the support of the EULAR Standing Committee on Clinical Affairs and the EULAR Secretariat.\n\n【10】删除32:<u>**</u>Contributions删除32:<u>**</u>\n\n【11】GCD, DV, DH and ET drafted the initial manuscript. NM and MGT convened and supervised the project and edited the manuscript. GCD, DV, EH and JB performed the systematic literature review under the supervision of DH.", "tags": {}, "lang": "en", "attr": {"page_num": 9, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/EULAR：风湿和肌肉骨骼疾病（包括系统性红斑狼疮和抗磷脂综合征）的心血管风险管理建议（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】CVR management in RMDs include interactive educational workshops involving health professionals, patients and stakeholders with the support of healthcare professional societies and patient associations, social media dissemination strategies customised to local and national policies such as academic detailing, audits and feedback techniques.\n\n【2】The panel believes that these recommendations will enable healthcare providers and patients to mutually engage in a long-term care pathway tailored to patients’ needs and equipped for improving cardiovascular health in RMDs. As new data accumulates, this first set of ‘best available’ evidence on cardiovascular prevention in gout, vasculitis, SSc, myositis, MCTD, SS, SLE and APS will be timely updated.", "content": "【0】页码:9\nEULAR：风湿和肌肉骨骼疾病（包括系统性红斑狼疮和抗磷脂综合征）的心血管风险管理建议（2022）\n(本页删除)本页被模型判断为参考页删除32:<u>**</u>Recommendation删除32:<u>**</u>\n\n【1】CVR management in RMDs include interactive educational workshops involving health professionals, patients and stakeholders with the support of healthcare professional societies and patient associations, social media dissemination strategies customised to local and national policies such as academic detailing, audits and feedback techniques.\n\n【2】The panel believes that these recommendations will enable healthcare providers and patients to mutually engage in a long-term care pathway tailored to patients’ needs and equipped for improving cardiovascular health in RMDs. As new data accumulates, this first set of ‘best available’ evidence on cardiovascular prevention in gout, vasculitis, SSc, myositis, MCTD, SS, SLE and APS will be timely updated.\n\n【3】删除32:<u>**</u>Author affiliations删除32:<u>**</u>\n\n【4】1. First Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Greece\n2. 删除32:<u>*</u>Rheca, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands删除32:<u>*</u>\n3. Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands\n4. Rheumatology Unit, Department of Internal Medicine, University of Messina, Messina, Italy\n5. 删除32:<u>*</u>EULAR Patient Research Partner, Brussels, Belgium删除32:<u>*</u>\n6. 4th Department of Internal Medicine, 删除32:<u>*</u>Attikon删除32:<u>*</u> University Hospital, Athens, Greece\n7. Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece\n8. Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Huddinge, Sweden\n9. Department of Orthopaedics, Danderyd Hospital Corp, Stockholm, Sweden\n10. 删除32:<u>*</u>Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK删除32:<u>*</u>\n11. NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK\n12. Department of Rheumatology, University Clinic Carl Gustav Carus at the TU Dresden, Dresden, Germany\n13. Department of Rheumatology, University of Basel, Basel, Switzerland\n14. Department of Cardiology, Amsterdam University Medical Centre, location VU University medical center, Amsterdam, The Netherlands\n15. Department of Rheumatology and Clinical Immunology, Amsterdam UMC, VU University, Amsterdam, The Netherlands\n16. Department of Public Health, NHS Grampian, Aberdeen, UK\n17. 删除32:<u>*</u>Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA删除32:<u>*</u>\n18. Amsterdam University Medical Center, location VU University Medical Center, Amsterdam, The Netherlands\n\n【5】删除32:<u>**</u>Twitter删除32:<u>**</u>\n\n【6】Chetan Mukhtyar @mukhtyar\n\n【7】Gaya J Macfarlane @AberdeenEpi and Ariela R Gkoutzoumi @arielatkoutzo\n\n【8】删除32:<u>**</u>Acknowledgements删除32:<u>**</u>\n\n【9】The committee wishes to acknowledge the support of the EULAR Standing Committee on Clinical Affairs and the EULAR Secretariat.\n\n【10】删除32:<u>**</u>Contributions删除32:<u>**</u>\n\n【11】GCD, DV, DH and ET drafted the initial manuscript. NM and MGT convened and supervised the project and edited the manuscript. GCD, DV, EH and JB performed the systematic literature review under the supervision of DH.", "index": 119, "show": true, "start": 119, "end": 873, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 15:48:35", "endTime": "2024/08/06 15:49:10", "cost": 34.585}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-05 23:49:10", "grab_time": "2024-08-05 23:48:35"}
{"id": 2211579, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "f9f35af0-0c0d-491d-81d0-67a6f068b52b", "title": "2023 DGOU多学科建议：多发性骨髓瘤患者病理性胸腰椎骨折的管理", "text": "【0】页码:3\n2023 DGOU多学科建议：多发性骨髓瘤患者病理性胸腰椎骨折的管理\n删除图片描述:<u>![](2_0.png)</u>\n\n【1】### Diagnostic Workup\n\n【2】删除32:<u>**</u>Clinical diagnostics.删除32:<u>**</u> In the majority of patients with MM, clinical symptoms are nonspecific and have been lasting for a longer period. Anemia is reported to be present in 73% of patients, followed by unspecific bone pain in 58% and fatigue (32%).\n\n【3】Additionally, 25% of affected patients suffer from weight loss. The diagnosis of MM requires the presence of >= 10% monoclonal plasma cells in the bone marrow or biopsy-proven extramedullary or bony plasmacytoma and at least one myeloma-defining event, defined by the SLiM-CRAB-Criteria 删除9:<u>(See Table 1)</u>. Besides, most patients show typical laboratory findings including elevated levels of monoclonal protein in serum and/or urine protein electrophoresis, an abnormal free-light chain ratio and a positive immunofixation. Therefore, a standard work-up in patients with suspected myeloma includes a full differential blood cell count, serum-chemistry for kidney and liver function tests, albumin, calcium and previously described diagnostics for monoclonal protein in serum and urine. Apart, a bone marrow biopsy and an appropriate imaging survey are mandatory. In a recent publication, different characteristics were shown to be predictive for MM vertebral collapse fractures. Stage 2 and 3 of the International Staging system (ISS) for Multiple Myeloma, patients’ gender, lower back pain, lower Houndsfield Units in a CT-scan, abnormal alignment and lytic lesions were all associated to a higher VCF incidence.\n\n【4】删除32:<u>**</u>Imaging.删除32:<u>**</u> The gold standard in imaging for detection of osteolytic bone lesions in patients with MM is whole-body low-dose computed tomography (CT). It shows considerably higher sensitivity compared to conventional radiographs. In patients with signs or suspicion of vertebral body fractures, a regular CT of the vertebral spine with sagittal and coronal plane reconstructions is recommended. Additionally, a total", "tags": {}, "lang": "en", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 DGOU多学科建议：多发性骨髓瘤患者病理性胸腰椎骨折的管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": []}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-05 23:54:56", "grab_time": "2024-08-05 23:39:41"}
{"id": 2211578, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "ad0bf19e-3126-481b-ad48-50ecc4aa6d4e", "title": "2023 ERS临床实践指南：慢性阻塞性肺病或间质性肺病患者的姑息治疗", "text": "【0】页码:145\n2023 ERS临床实践指南：慢性阻塞性肺病或间质性肺病患者的姑息治疗\n图片中仅包含参考文献部分，忽略即可。", "tags": {}, "lang": "zh", "attr": {"page_num": 145, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ERS临床实践指南：慢性阻塞性肺病或间质性肺病患者的姑息治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:56:05", "endTime": "2024/08/06 16:56:11", "cost": 5.718}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:56:11", "grab_time": "2024-08-06 00:56:05"}
{"id": 2211577, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "5c56391f-798e-459e-afa7-29387a482c7f", "title": "WFSBP睡眠障碍特别工作组的共识声明生物标记物诊断失眠的潜力(1)", "text": "【0】页码:11\nWFSBP睡眠障碍特别工作组的共识声明生物标记物诊断失眠的潜力(1)\n(本页删除)本页被模型判断为参考页## Results\n\n【1】### Study Design and Methods\n\n【2】#### Type of study\n- Case-control\n\n【3】#### Type and number of subjects\n- 170 INS,删除16:<u> 28 </u>NS\n\n【4】#### Instruments and methods\n- ACT (Actiwatch-Score); PSG\n\n【5】#### Results\n- Comparison of ACT, PSG, and AU: ACT vs PSG, TST ρ = 0.90, SOL ρ = 0.93, WASO ρ = 0.84, SE ρ = 0.92; INS: TST ρ = 0.92, SOL ρ = 0.93, WASO ρ = 0.78, SE ρ = 0.89; NS: TST ρ = 0.84, SOL ρ = 0.81, WASO ρ = 0.75, SE ρ = 0.90\n\n【6】#### Main conclusions\n- One of the few large studies examining the agreement between actimetric and PSG data for assessing sleep in INS using single-moment loggers\n\n【7】#### Comments\n- Actigraphy has clear advantages for clinical use and in evaluating treatment efficacy in INS. Suggests an integrated use of both PSG and actimetry.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【9】#### Type of study\n- Case-control\n\n【10】#### Type and number of subjects\n- 151 INS,删除16:<u> 32 </u>HC\n\n【11】#### Instruments and methods\n- ACT (Actiwatch-S); PSG\n\n【12】#### Results\n- ACT differentiates INS from NS: TST ρ = 0.93, SOL ρ = 0.94, WASO ρ = 0.88, SE ρ = 0.93; PSG TST ρ = 0.94, SOL ρ = 0.93, WASO ρ = 0.86, SE ρ = 0.92\n\n【13】#### Main conclusions\n- ACT is effective in discriminating INS from HC. One of the few large studies validating the effectiveness of ACT in clinical populations.\n\n【14】#### Comments\n- Validation in clinical populations indicates strong correlations between ACT and PSG measures for sleep parameters.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【16】#### Type of study\n- Case-control\n\n【17】#### Type and number of subjects\n- 12 INS,删除16:<u> 12 </u>HC\n\n【18】#### Instruments and methods\n- ECG for HRV, PSG over 3 nights, Sleep laboratory study\n\n【19】#### Results\n- Reading HRV underpaced autonomic nervous system activity in INS (HF and LF reduced); PSG: SOL prolonged, TST reduced, SE reduced, WASO increased; Reduced HF, LF, and TP in REM and NREM\n\n【20】#### Main conclusions\n- HRV indices are linked with parasympathetic system activity and altered in INS, suggesting autonomic dysfunction during sleep.\n\n【21】#### Comments\n- Results indicate that HRV measures provide additional information about sleep state-related physiological changes in INS.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【23】#### Type of study\n- Case-control\n\n【24】#### Type and number of subjects\n- 18 INS,删除16:<u> 12 </u>HC\n\n【25】#### Instruments and methods\n- PSG; Actigraphy; Sleep laboratory study\n\n【26】#### Results\n- Heart rate variability (HRV) indicators (HF, LF, TP) are lower in INS; PSG: SE reduced, TST reduced, SOL prolonged\n\n【27】#### Main conclusions\n- HRV and PSG data both indicate autonomic nervous system dysregulation in INS.\n\n【28】#### Comments\n- Confirms autonomic dysfunction in INS using HRV and PSG data. Suggests the use of HRV as a complementary tool for diagnosing INS.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【30】#### Type of study\n- Case-control\n\n【31】#### Type and number of subjects\n- 58 INS,删除16:<u> 46 </u>HC\n\n【32】#### Instruments and methods\n- PSG; Actigraphy; HRV analysis\n\n【33】#### Results\n- INS showed prolonged SOL, reduced TST, SE, and increased WASO compared to HC; Reduced HRV measures (HF, LF, TP)\n\n【34】#### Main conclusions\n- HRV and PSG measurements highlight autonomic dysregulation in INS, confirming previous findings.\n\n【35】#### Comments\n- Supports the integration of HRV and PSG for a comprehensive assessment of sleep disturbances and autonomic function in INS.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【37】#### Type of study\n- Case-control\n\n【38】#### Type and number of subjects\n- 12 INS,删除16:<u> 12 </u>HC\n\n【39】#### Instruments and methods\n- ECG for HRV, PSG over 3 nights, Sleep laboratory study\n\n【40】#### Results\n- Reading HRV underpaced autonomic nervous system activity in INS (HF and LF reduced); PSG: SOL prolonged, TST reduced, SE reduced, WASO increased; Reduced HF, LF, and TP in REM and NREM\n\n【41】#### Main conclusions\n- HRV indices are linked with parasympathetic system activity and altered in INS, suggesting autonomic dysfunction during sleep.\n\n【42】#### Comments\n- Results indicate that HRV measures provide additional information about sleep state-related physiological changes in INS.", "tags": {}, "lang": "en", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WFSBP睡眠障碍特别工作组的共识声明生物标记物诊断失眠的潜力(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "(本页删除)本页被模型判断为参考页", "content": "【0】页码:11\nWFSBP睡眠障碍特别工作组的共识声明生物标记物诊断失眠的潜力(1)\n(本页删除)本页被模型判断为参考页## Results\n\n【1】### Study Design and Methods\n\n【2】#### Type of study\n- Case-control\n\n【3】#### Type and number of subjects\n- 170 INS,删除16:<u> 28 </u>NS\n\n【4】#### Instruments and methods\n- ACT (Actiwatch-Score); PSG\n\n【5】#### Results\n- Comparison of ACT, PSG, and AU: ACT vs PSG, TST ρ = 0.90, SOL ρ = 0.93, WASO ρ = 0.84, SE ρ = 0.92; INS: TST ρ = 0.92, SOL ρ = 0.93, WASO ρ = 0.78, SE ρ = 0.89; NS: TST ρ = 0.84, SOL ρ = 0.81, WASO ρ = 0.75, SE ρ = 0.90\n\n【6】#### Main conclusions\n- One of the few large studies examining the agreement between actimetric and PSG data for assessing sleep in INS using single-moment loggers\n\n【7】#### Comments\n- Actigraphy has clear advantages for clinical use and in evaluating treatment efficacy in INS. Suggests an integrated use of both PSG and actimetry.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【9】#### Type of study\n- Case-control\n\n【10】#### Type and number of subjects\n- 151 INS,删除16:<u> 32 </u>HC\n\n【11】#### Instruments and methods\n- ACT (Actiwatch-S); PSG\n\n【12】#### Results\n- ACT differentiates INS from NS: TST ρ = 0.93, SOL ρ = 0.94, WASO ρ = 0.88, SE ρ = 0.93; PSG TST ρ = 0.94, SOL ρ = 0.93, WASO ρ = 0.86, SE ρ = 0.92\n\n【13】#### Main conclusions\n- ACT is effective in discriminating INS from HC. One of the few large studies validating the effectiveness of ACT in clinical populations.\n\n【14】#### Comments\n- Validation in clinical populations indicates strong correlations between ACT and PSG measures for sleep parameters.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【16】#### Type of study\n- Case-control\n\n【17】#### Type and number of subjects\n- 12 INS,删除16:<u> 12 </u>HC\n\n【18】#### Instruments and methods\n- ECG for HRV, PSG over 3 nights, Sleep laboratory study\n\n【19】#### Results\n- Reading HRV underpaced autonomic nervous system activity in INS (HF and LF reduced); PSG: SOL prolonged, TST reduced, SE reduced, WASO increased; Reduced HF, LF, and TP in REM and NREM\n\n【20】#### Main conclusions\n- HRV indices are linked with parasympathetic system activity and altered in INS, suggesting autonomic dysfunction during sleep.\n\n【21】#### Comments\n- Results indicate that HRV measures provide additional information about sleep state-related physiological changes in INS.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【23】#### Type of study\n- Case-control\n\n【24】#### Type and number of subjects\n- 18 INS,删除16:<u> 12 </u>HC\n\n【25】#### Instruments and methods\n- PSG; Actigraphy; Sleep laboratory study\n\n【26】#### Results\n- Heart rate variability (HRV) indicators (HF, LF, TP) are lower in INS; PSG: SE reduced, TST reduced, SOL prolonged\n\n【27】#### Main conclusions\n- HRV and PSG data both indicate autonomic nervous system dysregulation in INS.\n\n【28】#### Comments\n- Confirms autonomic dysfunction in INS using HRV and PSG data. Suggests the use of HRV as a complementary tool for diagnosing INS.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【30】#### Type of study\n- Case-control\n\n【31】#### Type and number of subjects\n- 58 INS,删除16:<u> 46 </u>HC\n\n【32】#### Instruments and methods\n- PSG; Actigraphy; HRV analysis\n\n【33】#### Results\n- INS showed prolonged SOL, reduced TST, SE, and increased WASO compared to HC; Reduced HRV measures (HF, LF, TP)\n\n【34】#### Main conclusions\n- HRV and PSG measurements highlight autonomic dysregulation in INS, confirming previous findings.\n\n【35】#### Comments\n- Supports the integration of HRV and PSG for a comprehensive assessment of sleep disturbances and autonomic function in INS.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【37】#### Type of study\n- Case-control\n\n【38】#### Type and number of subjects\n- 12 INS,删除16:<u> 12 </u>HC\n\n【39】#### Instruments and methods\n- ECG for HRV, PSG over 3 nights, Sleep laboratory study\n\n【40】#### Results\n- Reading HRV underpaced autonomic nervous system activity in INS (HF and LF reduced); PSG: SOL prolonged, TST reduced, SE reduced, WASO increased; Reduced HF, LF, and TP in REM and NREM\n\n【41】#### Main conclusions\n- HRV indices are linked with parasympathetic system activity and altered in INS, suggesting autonomic dysfunction during sleep.\n\n【42】#### Comments\n- Results indicate that HRV measures provide additional information about sleep state-related physiological changes in INS.", "index": 44, "show": true, "start": 44, "end": 61, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "【1】### Study Design and Methods\n\n【2】#### Type of study\n\nCase-control\n【3】#### Type and number of subjects\n\n170 INS,删除16: 28 NS\n【4】#### Instruments and methods\n\nACT (Actiwatch-Score); PSG\n【5】#### Results\n\nComparison of ACT, PSG, and AU: ACT vs PSG, TST ρ = 0.90, SOL ρ = 0.93, WASO ρ = 0.84, SE ρ = 0.92; INS: TST ρ = 0.92, SOL ρ = 0.93, WASO ρ = 0.78, SE ρ = 0.89; NS: TST ρ = 0.84, SOL ρ = 0.81, WASO ρ = 0.75, SE ρ = 0.90\n【6】#### Main conclusions\n\nOne of the few large studies examining the agreement between actimetric and PSG data for assessing sleep in INS using single-moment loggers\n【7】#### Comments\n\nActigraphy has clear advantages for clinical use and in evaluating treatment efficacy in INS. Suggests an integrated use of both PSG and actimetry.\n—|删除段之间换行|#### Study Design and Methods\n\n【9】#### Type of study\n\nCase-control\n【10】#### Type and number of subjects\n\n151 INS,删除16: 32 HC\n【11】#### Instruments and methods\n\nACT (Actiwatch-S); PSG\n【12】#### Results\n\nACT differentiates INS from NS: TST ρ = 0.93, SOL ρ = 0.94, WASO ρ = 0.88, SE ρ = 0.93; PSG TST ρ = 0.94, SOL ρ = 0.93, WASO ρ = 0.86, SE ρ = 0.92\n【13】#### Main conclusions\n\nACT is effective in discriminating INS from HC. One of the few large studies validating the effectiveness of ACT in clinical populations.\n【14】#### Comments\n\nValidation in clinical populations indicates strong correlations between ACT and PSG measures for sleep parameters.\n—|删除段之间换行|#### Study Design and Methods\n\n【16】#### Type of study\n\nCase-control\n【17】#### Type and number of subjects\n\n12 INS,删除16: 12 HC\n【18】#### Instruments and methods\n\nECG for HRV, PSG over 3 nights, Sleep laboratory study\n【19】#### Results\n\nReading HRV underpaced autonomic nervous system activity in INS (HF and LF reduced); PSG: SOL prolonged, TST reduced, SE reduced, WASO increased; Reduced HF, LF, and TP in REM and NREM\n【20】#### Main conclusions\n\nHRV indices are linked with parasympathetic system activity and altered in INS, suggesting autonomic dysfunction during sleep.\n【21】#### Comments\n\nResults indicate that HRV measures provide additional information about sleep state-related physiological changes in INS.\n—|删除段之间换行|#### Study Design and Methods\n\n【23】#### Type of study\n\nCase-control\n【24】#### Type and number of subjects\n\n18 INS,删除16: 12 HC\n【25】#### Instruments and methods\n\nPSG; Actigraphy; Sleep laboratory study\n【26】#### Results\n\nHeart rate variability (HRV) indicators (HF, LF, TP) are lower in INS; PSG: SE reduced, TST reduced, SOL prolonged\n【27】#### Main conclusions\n\nHRV and PSG data both indicate autonomic nervous system dysregulation in INS.\n【28】#### Comments\n\nConfirms autonomic dysfunction in INS using HRV and PSG data. Suggests the use of HRV as a complementary tool for diagnosing INS.\n—|删除段之间换行|#### Study Design and Methods\n\n【30】#### Type of study\n\nCase-control\n【31】#### Type and number of subjects\n\n58 INS,删除16: 46 HC\n【32】#### Instruments and methods\n\nPSG; Actigraphy; HRV analysis\n【33】#### Results\n\nINS showed prolonged SOL, reduced TST, SE, and increased WASO compared to HC; Reduced HRV measures (HF, LF, TP)\n【34】#### Main conclusions\n\nHRV and PSG measurements highlight autonomic dysregulation in INS, confirming previous findings.\n【35】#### Comments\n\nSupports the integration of HRV and PSG for a comprehensive assessment of sleep disturbances and autonomic function in INS.\n—|删除段之间换行|#### Study Design and Methods\n\n【37】#### Type of study\n\nCase-control\n【38】#### Type and number of subjects\n\n12 INS,删除16: 12 HC\n【39】#### Instruments and methods\n\nECG for HRV, PSG over 3 nights, Sleep laboratory study\n【40】#### Results\n\nReading HRV underpaced autonomic nervous system activity in INS (HF and LF reduced); PSG: SOL prolonged, TST reduced, SE reduced, WASO increased; Reduced HF, LF, and TP in REM and NREM\n【41】#### Main conclusions\n\nHRV indices are linked with parasympathetic system activity and altered in INS, suggesting autonomic dysfunction during sleep.\n【42】#### Comments\n\nResults indicate that HRV measures provide additional information about sleep state-related physiological changes in INS.", "content": "【0】页码:11\nWFSBP睡眠障碍特别工作组的共识声明生物标记物诊断失眠的潜力(1)\n<mark>(本页删除)本页被模型判断为参考页</mark>## Results\n\n【1】### Study Design and Methods\n\n【2】#### Type of study\n- Case-control\n\n【3】#### Type and number of subjects\n- 170 INS,删除16:<u> 28 </u>NS\n\n【4】#### Instruments and methods\n- ACT (Actiwatch-Score); PSG\n\n【5】#### Results\n- Comparison of ACT, PSG, and AU: ACT vs PSG, TST ρ = 0.90, SOL ρ = 0.93, WASO ρ = 0.84, SE ρ = 0.92; INS: TST ρ = 0.92, SOL ρ = 0.93, WASO ρ = 0.78, SE ρ = 0.89; NS: TST ρ = 0.84, SOL ρ = 0.81, WASO ρ = 0.75, SE ρ = 0.90\n\n【6】#### Main conclusions\n- One of the few large studies examining the agreement between actimetric and PSG data for assessing sleep in INS using single-moment loggers\n\n【7】#### Comments\n- Actigraphy has clear advantages for clinical use and in evaluating treatment efficacy in INS. Suggests an integrated use of both PSG and actimetry.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【9】#### Type of study\n- Case-control\n\n【10】#### Type and number of subjects\n- 151 INS,删除16:<u> 32 </u>HC\n\n【11】#### Instruments and methods\n- ACT (Actiwatch-S); PSG\n\n【12】#### Results\n- ACT differentiates INS from NS: TST ρ = 0.93, SOL ρ = 0.94, WASO ρ = 0.88, SE ρ = 0.93; PSG TST ρ = 0.94, SOL ρ = 0.93, WASO ρ = 0.86, SE ρ = 0.92\n\n【13】#### Main conclusions\n- ACT is effective in discriminating INS from HC. One of the few large studies validating the effectiveness of ACT in clinical populations.\n\n【14】#### Comments\n- Validation in clinical populations indicates strong correlations between ACT and PSG measures for sleep parameters.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【16】#### Type of study\n- Case-control\n\n【17】#### Type and number of subjects\n- 12 INS,删除16:<u> 12 </u>HC\n\n【18】#### Instruments and methods\n- ECG for HRV, PSG over 3 nights, Sleep laboratory study\n\n【19】#### Results\n- Reading HRV underpaced autonomic nervous system activity in INS (HF and LF reduced); PSG: SOL prolonged, TST reduced, SE reduced, WASO increased; Reduced HF, LF, and TP in REM and NREM\n\n【20】#### Main conclusions\n- HRV indices are linked with parasympathetic system activity and altered in INS, suggesting autonomic dysfunction during sleep.\n\n【21】#### Comments\n- Results indicate that HRV measures provide additional information about sleep state-related physiological changes in INS.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【23】#### Type of study\n- Case-control\n\n【24】#### Type and number of subjects\n- 18 INS,删除16:<u> 12 </u>HC\n\n【25】#### Instruments and methods\n- PSG; Actigraphy; Sleep laboratory study\n\n【26】#### Results\n- Heart rate variability (HRV) indicators (HF, LF, TP) are lower in INS; PSG: SE reduced, TST reduced, SOL prolonged\n\n【27】#### Main conclusions\n- HRV and PSG data both indicate autonomic nervous system dysregulation in INS.\n\n【28】#### Comments\n- Confirms autonomic dysfunction in INS using HRV and PSG data. Suggests the use of HRV as a complementary tool for diagnosing INS.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【30】#### Type of study\n- Case-control\n\n【31】#### Type and number of subjects\n- 58 INS,删除16:<u> 46 </u>HC\n\n【32】#### Instruments and methods\n- PSG; Actigraphy; HRV analysis\n\n【33】#### Results\n- INS showed prolonged SOL, reduced TST, SE, and increased WASO compared to HC; Reduced HRV measures (HF, LF, TP)\n\n【34】#### Main conclusions\n- HRV and PSG measurements highlight autonomic dysregulation in INS, confirming previous findings.\n\n【35】#### Comments\n- Supports the integration of HRV and PSG for a comprehensive assessment of sleep disturbances and autonomic function in INS.\n\n---|删除段之间换行|#### Study Design and Methods\n\n【37】#### Type of study\n- Case-control\n\n【38】#### Type and number of subjects\n- 12 INS,删除16:<u> 12 </u>HC\n\n【39】#### Instruments and methods\n- ECG for HRV, PSG over 3 nights, Sleep laboratory study\n\n【40】#### Results\n- Reading HRV underpaced autonomic nervous system activity in INS (HF and LF reduced); PSG: SOL prolonged, TST reduced, SE reduced, WASO increased; Reduced HF, LF, and TP in REM and NREM\n\n【41】#### Main conclusions\n- HRV indices are linked with parasympathetic system activity and altered in INS, suggesting autonomic dysfunction during sleep.\n\n【42】#### Comments\n- Results indicate that HRV measures provide additional information about sleep state-related physiological changes in INS.", "index": 86, "show": true, "start": 73, "end": 4120, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "全篇表格内容，表格格式错误"}], "startTime": "2024/08/07 09:48:08", "endTime": "2024/08/07 09:49:07", "cost": 58.952}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 17:49:06", "grab_time": "2024-08-06 17:48:06"}
{"id": 2211576, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "50b5af6e-4dbd-41cd-9929-ee6f7ab8ffc8", "title": "2021 JGS日本青光眼指南（第5版）", "text": "【0】页码:42\n2021 JGS日本青光眼指南（第5版）\n2. 删除32:<u>**</u>Factors that may lead to consideration of surgery when a fourth additional eye drops is needed删除32:<u>**</u>\nAdherence and persistence rates of eye drops, as well as the effect on trabeculectomy, were suggested.\n\n【1】(a) 删除32:<u>**</u>Adherence and persistence rates in concomitant use of four eye drops删除32:<u>**</u>\nThe success of glaucoma treatment depends not only on the efficacy of the combination eye drop therapy but also on the patient’s ability to adhere to the ophthalmic dosing regimen for all eye drops. In a case-control study, Djaffari et al. compared the dispensing records and medical records of 181 patients with open-angle glaucoma, ocular hypertension, or suspected glaucoma (number of eye drops used: 1–4) and reported that adherence decreased significantly as the number of eye drops increased 删除12:<u>删除14:<u>[180]</u></u>. In a case-control study, Neelakantan et al. reported that 29 patients with glaucoma (69% POAG, 31% another glaucoma) with inadequate IOP control with three eye drops had a chance of improvement in efficacy (>20% IOP reduction with three drugs at fixed concentrations after washout) and safety (no side effects leading to discontinuation of eye drops and no need for surgery) after the addition of a fourth eye drops 删除12:<u>删除14:<u>[181]</u></u>. They reported that the cumulative Kaplan-Meier rates (success rate) of achieving both efficacy and safety were low (31% in 6 months, 14% in 1 year).\n\n【2】(b) 删除32:<u>**</u>Effects of concomitant use of four eye drops on IOP lowering and trabeculectomy删除32:<u>**</u>\nJohnson et al. conducted a randomized controlled trial in which 1,400 POAG patients using 1 to 4 eye drops without prior glaucoma surgery (other than laser trabeculoplasty) were given a washout before MIGS 删除12:<u>删除14:<u>[182]</u></u>. Although IOP increased in the patient group with a greater number of eye drops, there was no significant difference in terms of IOP increase range between the group with three eye drops and that with four eye drops. As for the reason for these facts, it is suggested that the prescribed eye drops may not have been administered properly; i.e., poor adherence, or the effect of the additional eye drops may have been low. In a retrospective cohort study by Fendi et al., multivariate analysis was performed on 120 glaucoma eyes (POAG: 58 eyes, primary angle-closure glaucoma: 31 eyes, secondary glaucoma: 31 eyes) who underwent trabeculectomy 删除12:<u>删除14:<u>[183]</u></u>. The “use of four or more glaucoma eye drops before surgery” has been revealed as one of the risk factors for poor outcomes.\n\n【3】In all reports, up to three IOP-lowering eye drops were commonly used, and four or more eye drops were remarkably less commonly used. In general, when IOP control is poor or the target IOP cannot be achieved even using a combination of three IOP-lowering eye drops (including fixed combination eye drops), treatment alternatives, including glaucoma surgery, should be considered.\n\n【4】In recent years, the advent of MIGS, fixed combination eye drops, preservative-free ophthalmic solutions, and new glaucoma treatments have been launched consecutively, and it is necessary to wait for future evidence to observe how the evidence to date will shift.\n\n【5】删除32:<u>**</u>FQ3: Are treatments other than IOP reduction (neuroprotection, improved blood flow) helpful?删除32:<u>**</u>\n(Yu Yokoyama, Kazuko Omodaka)\n\n【6】There are several reports on IOP-independent neuroprotection in a variety of agents. However, it is difficult to determine the sufficiency of the results obtained in clinical studies to demonstrate neuroprotection. Sena et al. stated in a 2017 systematic review on neuroprotection for glaucoma treatment that at least 4 years of observation is required to obtain statistically significant results. An RCT using brimonidine tartrate 0.2% as a neuroprotective effect without significant IOP reduction did not show sufficient evidence in the literature search review 删除12:<u>删除14:<u>[81]</u></u>. However, at the time of this review, the only relevant report was the Low-pressure Glaucoma Treatment Study (LoGTS). This review concluded that the evidence shown in LoGTS was insufficient for proving a neuroprotective effect of brimonidine tartrate 0.2% ophthalmic solution.\n\n【7】Here, trials with a 2-year follow-up period were included for a broader review. Literature for trials on neuroprotection in the glaucoma treatment (including α2-adrenergic agonists, NMDA receptor antagonists such as memantine, calcium channel blockers, neurotrophic factors, antioxidants, ginkgo biloba extract, nitric oxide synthase inhibitors, and sleep apnea syndrome treatment) and trials examining improvement in ocular blood flow were searched. A literature search was conducted for the following studies. RCTs and non-English papers (except Japanese) that did not include functional assessment by static automated perimetry or structural assessment of the RNFL or ganglion cell layer as outcomes were excluded. If we included the study in which the effect of the treatment was evaluated in 4 or more follow-up periods, only three studies matched this inclusion criteria.", "tags": {}, "lang": "en", "attr": {"page_num": 42, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2021 JGS日本青光眼指南（第5版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "2. 删除32:Factors that may lead to consideration of surgery when a fourth additional eye drops is needed", "content": "【0】页码:42\n2021 JGS日本青光眼指南（第5版）\n2. 删除32:<u>**</u>Factors that may lead to consideration of surgery when a fourth additional eye drops is needed删除32:<u>**</u>\nAdherence and persistence rates of eye drops, as well as the effect on trabeculectomy, were suggested.\n\n【1】(a) 删除32:<u>**</u>Adherence and persistence rates in concomitant use of four eye drops删除32:<u>**</u>\nThe success of glaucoma treatment depends not only on the efficacy of the combination eye drop therapy but also on the patient’s ability to adhere to the ophthalmic dosing regimen for all eye drops. In a case-control study, Djaffari et al. compared the dispensing records and medical records of 181 patients with open-angle glaucoma, ocular hypertension, or suspected glaucoma (number of eye drops used: 1–4) and reported that adherence decreased significantly as the number of eye drops increased 删除12:<u>删除14:<u>[180]</u></u>. In a case-control study, Neelakantan et al. reported that 29 patients with glaucoma (69% POAG, 31% another glaucoma) with inadequate IOP control with three eye drops had a chance of improvement in efficacy (>20% IOP reduction with three drugs at fixed concentrations after washout) and safety (no side effects leading to discontinuation of eye drops and no need for surgery) after the addition of a fourth eye drops 删除12:<u>删除14:<u>[181]</u></u>. They reported that the cumulative Kaplan-Meier rates (success rate) of achieving both efficacy and safety were low (31% in 6 months, 14% in 1 year).\n\n【2】(b) 删除32:<u>**</u>Effects of concomitant use of four eye drops on IOP lowering and trabeculectomy删除32:<u>**</u>\nJohnson et al. conducted a randomized controlled trial in which 1,400 POAG patients using 1 to 4 eye drops without prior glaucoma surgery (other than laser trabeculoplasty) were given a washout before MIGS 删除12:<u>删除14:<u>[182]</u></u>. Although IOP increased in the patient group with a greater number of eye drops, there was no significant difference in terms of IOP increase range between the group with three eye drops and that with four eye drops. As for the reason for these facts, it is suggested that the prescribed eye drops may not have been administered properly; i.e., poor adherence, or the effect of the additional eye drops may have been low. In a retrospective cohort study by Fendi et al., multivariate analysis was performed on 120 glaucoma eyes (POAG: 58 eyes, primary angle-closure glaucoma: 31 eyes, secondary glaucoma: 31 eyes) who underwent trabeculectomy 删除12:<u>删除14:<u>[183]</u></u>. The “use of four or more glaucoma eye drops before surgery” has been revealed as one of the risk factors for poor outcomes.\n\n【3】In all reports, up to three IOP-lowering eye drops were commonly used, and four or more eye drops were remarkably less commonly used. In general, when IOP control is poor or the target IOP cannot be achieved even using a combination of three IOP-lowering eye drops (including fixed combination eye drops), treatment alternatives, including glaucoma surgery, should be considered.\n\n【4】In recent years, the advent of MIGS, fixed combination eye drops, preservative-free ophthalmic solutions, and new glaucoma treatments have been launched consecutively, and it is necessary to wait for future evidence to observe how the evidence to date will shift.\n\n【5】删除32:<u>**</u>FQ3: Are treatments other than IOP reduction (neuroprotection, improved blood flow) helpful?删除32:<u>**</u>\n(Yu Yokoyama, Kazuko Omodaka)\n\n【6】There are several reports on IOP-independent neuroprotection in a variety of agents. However, it is difficult to determine the sufficiency of the results obtained in clinical studies to demonstrate neuroprotection. Sena et al. stated in a 2017 systematic review on neuroprotection for glaucoma treatment that at least 4 years of observation is required to obtain statistically significant results. An RCT using brimonidine tartrate 0.2% as a neuroprotective effect without significant IOP reduction did not show sufficient evidence in the literature search review 删除12:<u>删除14:<u>[81]</u></u>. However, at the time of this review, the only relevant report was the Low-pressure Glaucoma Treatment Study (LoGTS). This review concluded that the evidence shown in LoGTS was insufficient for proving a neuroprotective effect of brimonidine tartrate 0.2% ophthalmic solution.\n\n【7】Here, trials with a 2-year follow-up period were included for a broader review. Literature for trials on neuroprotection in the glaucoma treatment (including α2-adrenergic agonists, NMDA receptor antagonists such as memantine, calcium channel blockers, neurotrophic factors, antioxidants, ginkgo biloba extract, nitric oxide synthase inhibitors, and sleep apnea syndrome treatment) and trials examining improvement in ocular blood flow were searched. A literature search was conducted for the following studies. RCTs and non-English papers (except Japanese) that did not include functional assessment by static automated perimetry or structural assessment of the RNFL or ganglion cell layer as outcomes were excluded. If we included the study in which the effect of the treatment was evaluated in 4 or more follow-up periods, only three studies matched this inclusion criteria.", "index": 30, "show": true, "start": 30, "end": 132, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "前面缺少一段正文"}], "startTime": "2024/08/06 15:33:26", "endTime": "2024/08/06 15:34:10", "cost": 44.151}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-05 23:34:10", "grab_time": "2024-08-05 23:33:26"}
{"id": 2211575, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "e8113e2b-9bbc-424b-a842-fb3c7cbed625", "title": "前列腺癌根治术后病人留置尿管出院计划证据总结", "text": "【0】页码:4\n前列腺癌根治术后病人留置尿管出院计划证据总结\n### 表1\n\n| 类别 | 证据结论 | 推荐级别 |\n| --- | --- | --- |\n| 出院前干预 | 7 出院前病人/照顾者能获得留置管护理的再说明、包括居管的回避、保护乳液的管制法、引流的清除、引流迹的观察处理、呕吐液和引流物处理及居管的侧倒 | A 级 |\n| 8 出院前病人/照顾者能识别外周居尿管及居尿管位置及腹压的知识 | A 级 |\n| 9 出院前病人/照顾者能获得再提外居尿管系统的相关建议、环境的安全性、所用物品的可及性、措施的合理性 | A 级 |\n| 10 出院前能够提供腹位的宜人建议, 内容包括病患紧密解决的问题、持续任务厕的问题、问题家庭护运需求, 主要服务潜的形的看动作方案等 | B 级 |\n| 11 对上述同家人的病人提供上述方面的健康教育资料 | A 级 |\n| 出院后随访 | 12 出院后病人/照顾者能获得的随访指导内容 | A 级 |\n| 13 目前仍存在与病人携带管和相关关系的发生率、病人及照顾者出院后相关知识掌握、病人术后健康状况恢复,病人出院后指标情况、出院后的发生的案件 | B 级 |\n| 14 特殊监测出院后子期随俗 6 月的案件 | B 级 |\n\n【2】### 3 讨论\n\n【3】#### 3.1 前列腺癌根治术后留置管出院计划证据总结的必要性\n\n【4】前列腺癌根治术后有病人出院后留置管并发症发生率,提高病人和照顾者护理知识及技能管理率。出院计划作为整体护理的一部分目能够减少住院时间,可以帮助前列腺癌根治治疗出院管患者得到持续的卫保健。随机二次价后,证据其提到: 出院前护士、病人、家属其间合作,使病人出院后方能获得连续性照顾,避免疏忽病人与家属对护理上的简态处理删除12:<u>删除14:<u>[23]</u></u>。因此,本研究系统地查了国内外文献,根据 2014 版 JBI 证据系统方法推荐分类别系统,依据研究设计类采用的不同,将证获等级划分为 Level 1~5. 并根据研究设计的严密性与可信性,将证据推荐级别划分为 A 级推荐与 B 级推荐,提炼出第 3 章条款中根的最前提佳推荐意见,分别从前列腺癌根治术后留院留管出院计划针在出院前干预及出院后随访方面进行, 因此证据具有了较高的科学性,为临床护理实践提供参考。\n\n【5】#### 3.2 前列腺癌根治术后留置管出院计划最佳证据总结的共识\n\n【6】第 1 条、第 3 条证据强调前列腺癌术后留置尿管出院计划的原则,强调前列腺癌根治术后留置尿管住院计划对耐局性应放性应: 应在病人出院后主要护理或许是学科团队合作, 共同制定出院期间及出院后护理计划。前列腺癌根治术后,病人携带管者应: 帮助病人和照管者理解居尿管及, 对相对弹性耐应前列腺癌根治术后状病人的具体情况, 对个体耐前扩根治术,使局尿管恢留尿管积需住院管人及,如省居尿管期间居复住病人携带管者议,用药指导,促双主护员的领保障。前泌尿系统证医学证据纳入共计 30篇随机对照研究 (11 964 例老年癌病病人[ 上提示 , 应用出院计划在缩短住院时间] 降低再发院率、病人满意度等方面明显优于对照组删除12:<u>删除14:<u>[23]</u></u>。因此,出院前制定个性化的出院计划, 能使病人及部分的环境影响下, 发根具大的强化功能。 有研究指出在接受人入院 48 h内开展出院计划, 可以早发现危信个案。并制定相关实施计划删除12:<u>删除14:<u>[24]</u></u>， 出院,需要尽早予确验后评估时间,以护主护士主导的人员参与其中, 选择合适的评价工作工具。 根据病人出院时间系统, 整合医生、护士、药剂师、营养师、康复治疗师等多学科团队成的系统,并进病人与照顾者积极参与。 因此,对前列腺癌根治术后留置尿管出院管的病人,以护士为主导的多学科团队成员, 对相对分局不同病援提供有效针对对管管,出院后忍理工作的出院护理计划,确保病人 放心出院删除12:<u>删除14:<u>[25]</u></u>。第 4 条、第 6 条证据强调前列腺癌术前后加强病人/照顾者健康教育, 保证术后, 不局理对加强信病入出院时间的生活,心理社入会条件家庭等的真实情 现,照顾者的动机,条件及权打,出院前留居尿管者的 护，能督病人的防复发,安全性简在期及扬出观、市等第。第 7 条、第 11 条证据为前列腺癌术后病人出院前制定个性化的干预内容提供丁理论依据及指导,出院前病人/照顾者能获得留置尿管的护理知识、疼痛相关知识, 护技突,心理社会支持, 居家环保建议, 对其制定个性 化的干预内容。第 10 条证据提测出院前前列腺癌根治术循的健康教育的日清及护目，内容包括前院防未解决定问题,持续存在的问题,间家庭连需求,主要服 解及潜在物问，药物治疗方案的看指等。第 13 第 14 满证据强调前列腺癌术后留院管出院计划不同的 出的访的重性。出院内容包括病人居尿管相关知健康掌接,病人术后健康状况恢复,病人出院后指标情况、出院后复", "tags": {}, "lang": "zh", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/前列腺癌根治术后病人留置尿管出院计划证据总结.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "表1", "content": "【0】页码:4\n前列腺癌根治术后病人留置尿管出院计划证据总结\n### 表1\n\n| 类别 | 证据结论 | 推荐级别 |\n| --- | --- | --- |\n| 出院前干预 | 7 出院前病人/照顾者能获得留置管护理的再说明、包括居管的回避、保护乳液的管制法、引流的清除、引流迹的观察处理、呕吐液和引流物处理及居管的侧倒 | A 级 |\n| 8 出院前病人/照顾者能识别外周居尿管及居尿管位置及腹压的知识 | A 级 |\n| 9 出院前病人/照顾者能获得再提外居尿管系统的相关建议、环境的安全性、所用物品的可及性、措施的合理性 | A 级 |\n| 10 出院前能够提供腹位的宜人建议, 内容包括病患紧密解决的问题、持续任务厕的问题、问题家庭护运需求, 主要服务潜的形的看动作方案等 | B 级 |\n| 11 对上述同家人的病人提供上述方面的健康教育资料 | A 级 |\n| 出院后随访 | 12 出院后病人/照顾者能获得的随访指导内容 | A 级 |\n| 13 目前仍存在与病人携带管和相关关系的发生率、病人及照顾者出院后相关知识掌握、病人术后健康状况恢复,病人出院后指标情况、出院后的发生的案件 | B 级 |\n| 14 特殊监测出院后子期随俗 6 月的案件 | B 级 |\n\n【2】### 3 讨论\n\n【3】#### 3.1 前列腺癌根治术后留置管出院计划证据总结的必要性\n\n【4】前列腺癌根治术后有病人出院后留置管并发症发生率,提高病人和照顾者护理知识及技能管理率。出院计划作为整体护理的一部分目能够减少住院时间,可以帮助前列腺癌根治治疗出院管患者得到持续的卫保健。随机二次价后,证据其提到: 出院前护士、病人、家属其间合作,使病人出院后方能获得连续性照顾,避免疏忽病人与家属对护理上的简态处理删除12:<u>删除14:<u>[23]</u></u>。因此,本研究系统地查了国内外文献,根据 2014 版 JBI 证据系统方法推荐分类别系统,依据研究设计类采用的不同,将证获等级划分为 Level 1~5. 并根据研究设计的严密性与可信性,将证据推荐级别划分为 A 级推荐与 B 级推荐,提炼出第 3 章条款中根的最前提佳推荐意见,分别从前列腺癌根治术后留院留管出院计划针在出院前干预及出院后随访方面进行, 因此证据具有了较高的科学性,为临床护理实践提供参考。\n\n【5】#### 3.2 前列腺癌根治术后留置管出院计划最佳证据总结的共识\n\n【6】第 1 条、第 3 条证据强调前列腺癌术后留置尿管出院计划的原则,强调前列腺癌根治术后留置尿管住院计划对耐局性应放性应: 应在病人出院后主要护理或许是学科团队合作, 共同制定出院期间及出院后护理计划。前列腺癌根治术后,病人携带管者应: 帮助病人和照管者理解居尿管及, 对相对弹性耐应前列腺癌根治术后状病人的具体情况, 对个体耐前扩根治术,使局尿管恢留尿管积需住院管人及,如省居尿管期间居复住病人携带管者议,用药指导,促双主护员的领保障。前泌尿系统证医学证据纳入共计 30篇随机对照研究 (11 964 例老年癌病病人[ 上提示 , 应用出院计划在缩短住院时间] 降低再发院率、病人满意度等方面明显优于对照组删除12:<u>删除14:<u>[23]</u></u>。因此,出院前制定个性化的出院计划, 能使病人及部分的环境影响下, 发根具大的强化功能。 有研究指出在接受人入院 48 h内开展出院计划, 可以早发现危信个案。并制定相关实施计划删除12:<u>删除14:<u>[24]</u></u>， 出院,需要尽早予确验后评估时间,以护主护士主导的人员参与其中, 选择合适的评价工作工具。 根据病人出院时间系统, 整合医生、护士、药剂师、营养师、康复治疗师等多学科团队成的系统,并进病人与照顾者积极参与。 因此,对前列腺癌根治术后留置尿管出院管的病人,以护士为主导的多学科团队成员, 对相对分局不同病援提供有效针对对管管,出院后忍理工作的出院护理计划,确保病人 放心出院删除12:<u>删除14:<u>[25]</u></u>。第 4 条、第 6 条证据强调前列腺癌术前后加强病人/照顾者健康教育, 保证术后, 不局理对加强信病入出院时间的生活,心理社入会条件家庭等的真实情 现,照顾者的动机,条件及权打,出院前留居尿管者的 护，能督病人的防复发,安全性简在期及扬出观、市等第。第 7 条、第 11 条证据为前列腺癌术后病人出院前制定个性化的干预内容提供丁理论依据及指导,出院前病人/照顾者能获得留置尿管的护理知识、疼痛相关知识, 护技突,心理社会支持, 居家环保建议, 对其制定个性 化的干预内容。第 10 条证据提测出院前前列腺癌根治术循的健康教育的日清及护目，内容包括前院防未解决定问题,持续存在的问题,间家庭连需求,主要服 解及潜在物问，药物治疗方案的看指等。第 13 第 14 满证据强调前列腺癌术后留院管出院计划不同的 出的访的重性。出院内容包括病人居尿管相关知健康掌接,病人术后健康状况恢复,病人出院后指标情况、出院后复", "index": 35, "show": true, "start": 35, "end": 37, "province": ["格式规范性", "表格格式错误"], "isEdit": false}], "startTime": "2024/08/06 16:31:58", "endTime": "2024/08/06 16:32:52", "cost": 53.302}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:32:52", "grab_time": "2024-08-06 00:31:58"}
{"id": 2211574, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "7a0da401-46cb-4cc2-ab12-e449d78e0b4c", "title": "（2023.V2）NCCN临床实践指南： 慢性髓性白血病", "text": "【0】页码:69\n（2023.V2）NCCN临床实践指南： 慢性髓性白血病\n疑似页眉<u># NCCN Guidelines Version 2.2023\n## Chronic Myeloid Leukemia</u>\n\n【1】### Table 14. TKI Therapy for Disease Progression to AP-CML: Long-Term Follow-up Data from Phase II/III Studies\n\n| TKI                         | No. of Patients             | Median Follow-up | MCyR             | CCyR         | OS                     | PFS                     |\n|-----------------------------|-----------------------------|------------------|------------------|--------------|-----------------------|-------------------------|\n| Dasatinib删除23:<u><sup>266,a</sup></u>    | Imatinib-R (n = 117)         | 24 months        | 36%              | 29%          | 63%                   | 51%                     |\n| (140 mg once daily)         | Imatinib-I (n = 41)          |                  | 46%              | 41%          |                       |                         |\n| Nilotinib删除23:<u><sup>269,b</sup></u>   | Imatinib-R (n = 109)          | 24 months        | 30%              | 19%          | 70%                   | 33%                     |\n| (400 mg twice daily)        | Imatinib-I (n = 27)           |                  | 41%              | 30%          |                       |                         |\n| Bosutinib删除23:<u><sup>271,c</sup></u>   | Prior imatinib only (n = 49)  | 48 months        | 48%              | 35%          | 66%                   | —                       |\n| (500 mg once daily)         | Imatinib followed by dasatinib or nilotinib (n = 30)| | 27%              | 23%          | 45%                   | —                       |\n| Ponatinib删除23:<u><sup>145,d</sup></u>   | Dasatinib or nilotinib-R or I (n = 65) | 32 months        | 45%              | 28%          | 48%                   | 19% at 5 years          |\n| (45 mg once daily)          | T315I mutation (n = 18)      |                  | 67%              | 44%          | 52%                   | 29% at 5 years          |\n\n【3】I, Intolerant; R, Resistant; CCyR, Complete cytogenetic response; MCyR, major cytogenetic response; OS, overall survival; PFS, progression-free survival\n\n【4】a. Primary endpoint: Major hematologic response (MaHR). The rate of MaHR at 5 years was 67% for 140 mg once daily and 69% for 70 mg twice daily 删除19:<u>(Ottmann O, et al. Blood Cancer J 2018;8:88)</u>.  \nb. Primary endpoint: Confirmed complete hematologic response rate, achieved in 30% of patients with imatinib-resistant disease and 37% of imatinib-intolerant patients.  \nc. Primary endpoint: Confirmed overall hematologic response by 48 weeks.  \nd. Primary endpoint: MaHR at any time within the first 6 months.", "tags": {}, "lang": "en", "attr": {"page_num": 69, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V2）NCCN临床实践指南： 慢性髓性白血病.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】### Table 14. TKI Therapy for Disease Progression to AP-CML: Long-Term Follow-up Data from Phase II/III Studies", "content": "【0】页码:69\n（2023.V2）NCCN临床实践指南： 慢性髓性白血病\n疑似页眉<u># NCCN Guidelines Version 2.2023\n## Chronic Myeloid Leukemia</u>\n\n【1】### Table 14. TKI Therapy for Disease Progression to AP-CML: Long-Term Follow-up Data from Phase II/III Studies\n\n| TKI                         | No. of Patients             | Median Follow-up | MCyR             | CCyR         | OS                     | PFS                     |\n|-----------------------------|-----------------------------|------------------|------------------|--------------|-----------------------|-------------------------|\n| Dasatinib删除23:<u><sup>266,a</sup></u>    | Imatinib-R (n = 117)         | 24 months        | 36%              | 29%          | 63%                   | 51%                     |\n| (140 mg once daily)         | Imatinib-I (n = 41)          |                  | 46%              | 41%          |                       |                         |\n| Nilotinib删除23:<u><sup>269,b</sup></u>   | Imatinib-R (n = 109)          | 24 months        | 30%              | 19%          | 70%                   | 33%                     |\n| (400 mg twice daily)        | Imatinib-I (n = 27)           |                  | 41%              | 30%          |                       |                         |\n| Bosutinib删除23:<u><sup>271,c</sup></u>   | Prior imatinib only (n = 49)  | 48 months        | 48%              | 35%          | 66%                   | —                       |\n| (500 mg once daily)         | Imatinib followed by dasatinib or nilotinib (n = 30)| | 27%              | 23%          | 45%                   | —                       |\n| Ponatinib删除23:<u><sup>145,d</sup></u>   | Dasatinib or nilotinib-R or I (n = 65) | 32 months        | 45%              | 28%          | 48%                   | 19% at 5 years          |\n| (45 mg once daily)          | T315I mutation (n = 18)      |                  | 67%              | 44%          | 52%                   | 29% at 5 years          |\n\n【3】I, Intolerant; R, Resistant; CCyR, Complete cytogenetic response; MCyR, major cytogenetic response; OS, overall survival; PFS, progression-free survival\n\n【4】a. Primary endpoint: Major hematologic response (MaHR). The rate of MaHR at 5 years was 67% for 140 mg once daily and 69% for 70 mg twice daily 删除19:<u>(Ottmann O, et al. Blood Cancer J 2018;8:88)</u>.  \nb. Primary endpoint: Confirmed complete hematologic response rate, achieved in 30% of patients with imatinib-resistant disease and 37% of imatinib-intolerant patients.  \nc. Primary endpoint: Confirmed overall hematologic response by 48 weeks.  \nd. Primary endpoint: MaHR at any time within the first 6 months.", "index": 111, "show": true, "start": 111, "end": 225, "province": ["格式规范性", "表格格式错误"], "isEdit": false}], "startTime": "2024/08/07 10:05:54", "endTime": "2024/08/07 10:06:29", "cost": 35.093}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 18:06:28", "grab_time": "2024-08-06 18:05:53"}
{"id": 2211573, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "d8f75fcf-616c-4d29-a1eb-049f377215d0", "title": "AHA心脏病与卒中统计报告（2022年更新）", "text": "【0】页码:456\nAHA心脏病与卒中统计报告（2022年更新）\nAbdominal aortic aneurysms (AAAs) represent a significant health risk due to their potential for rupture, leading to high mortality rates. Screening for AAAs has been shown to reduce mortality in specific populations, particularly older men with a history of smoking.\n\n【1】删除32:<u>**</u>Epidemiology and Risk Factors删除32:<u>**</u>\nAAAs are more common in men than women, with the prevalence increasing with age. Smoking is the most significant modifiable risk factor. Other risk factors include hypertension, hyperlipidemia, and a family history of AAAs. There is also evidence suggesting that genetic factors may play a role.\n\n【2】删除32:<u>**</u>Screening and Diagnosis删除32:<u>**</u>\nUltrasound is the preferred method for AAA screening due to its high sensitivity, specificity, and non-invasive nature. Screening is recommended for men aged 65 to 75 who have ever smoked. For women, routine screening is not generally recommended unless they have risk factors such as a family history of AAAs or smoking.\n\n【3】删除32:<u>**</u>Management and Treatment删除32:<u>**</u>\nManagement of AAAs depends on the size and growth rate of the aneurysm. Small AAAs (less than 5.5 cm in diameter) are typically monitored with regular ultrasound surveillance. For larger AAAs (5.5 cm or greater), or those that are rapidly expanding, surgical intervention is often recommended. The two primary surgical options are open surgical repair and endovascular aneurysm repair (EVAR).\n\n【4】删除32:<u>**</u>Survival and Outcomes删除32:<u>**</u>\nThe prognosis for patients with AAAs depends on several factors, including the size of the aneurysm at diagnosis and the patient’s overall health. Early detection and treatment are crucial for improving outcomes. Ruptured AAAs have a high mortality rate, emphasizing the importance of screening and timely intervention.\n\n【5】In summary, AAAs are a significant cause of morbidity and mortality, particularly in older men with a history of smoking. Screening programs and advancements in surgical techniques have improved the management and outcomes of this condition. Regular monitoring and early intervention remain key components in reducing the mortality associated with AAAs.", "tags": {}, "lang": "en", "attr": {"page_num": 456, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/AHA心脏病与卒中统计报告（2022年更新）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】", "content": "【0】页码:456\nAHA心脏病与卒中统计报告（2022年更新）\nAbdominal aortic aneurysms (AAAs) represent a significant health risk due to their potential for rupture, leading to high mortality rates. Screening for AAAs has been shown to reduce mortality in specific populations, particularly older men with a history of smoking.\n\n【1】删除32:<u>**</u>Epidemiology and Risk Factors删除32:<u>**</u>\nAAAs are more common in men than women, with the prevalence increasing with age. Smoking is the most significant modifiable risk factor. Other risk factors include hypertension, hyperlipidemia, and a family history of AAAs. There is also evidence suggesting that genetic factors may play a role.\n\n【2】删除32:<u>**</u>Screening and Diagnosis删除32:<u>**</u>\nUltrasound is the preferred method for AAA screening due to its high sensitivity, specificity, and non-invasive nature. Screening is recommended for men aged 65 to 75 who have ever smoked. For women, routine screening is not generally recommended unless they have risk factors such as a family history of AAAs or smoking.\n\n【3】删除32:<u>**</u>Management and Treatment删除32:<u>**</u>\nManagement of AAAs depends on the size and growth rate of the aneurysm. Small AAAs (less than 5.5 cm in diameter) are typically monitored with regular ultrasound surveillance. For larger AAAs (5.5 cm or greater), or those that are rapidly expanding, surgical intervention is often recommended. The two primary surgical options are open surgical repair and endovascular aneurysm repair (EVAR).\n\n【4】删除32:<u>**</u>Survival and Outcomes删除32:<u>**</u>\nThe prognosis for patients with AAAs depends on several factors, including the size of the aneurysm at diagnosis and the patient’s overall health. Early detection and treatment are crucial for improving outcomes. Ruptured AAAs have a high mortality rate, emphasizing the importance of screening and timely intervention.\n\n【5】In summary, AAAs are a significant cause of morbidity and mortality, particularly in older men with a history of smoking. Screening programs and advancements in surgical techniques have improved the management and outcomes of this condition. Regular monitoring and early intervention remain key components in reducing the mortality associated with AAAs.", "index": 0, "show": true, "start": 0, "end": 3, "province": ["信息质量", "有用性-重"], "isEdit": false, "comment": "PDF中为全篇参考文献"}]}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:59:34", "grab_time": "2024-08-05 23:44:47"}
{"id": 2211572, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "c923a07e-692a-4b3f-9290-7fa96a82b0e3", "title": "2023 WSES共识和临床建议：无神经外科能力医院内孤立性严重创伤性脑损伤患者的早期管理(1)", "text": "【0】页码:5\n2023 WSES共识和临床建议：无神经外科能力医院内孤立性严重创伤性脑损伤患者的早期管理(1)\n删除图片描述:<u>![](4_0.png)</u>\n\n【1】删除32:<u>**</u>Recommendation 4删除32:<u>**</u>  \nWe recommend sedation, intubation and mechanical ventilation for the transfer of all severe TBI patients (agreement %: 95, strong recommendation).\n\n【2】删除32:<u>**</u>Recommendation 5删除32:<u>**</u>  \nWe recommend that the transfer of severe TBI patients should be performed by appropriately trained and certified critical care transport personnel with experience in advanced airway management/life support strategies and basic knowledge of neurocritical care (i.e., medical management of cerebral swelling, herniation) (agreement %: 80.5, weak recommendation).\n\n【3】删除32:<u>**</u>Recommendation 6删除32:<u>**</u>  \nWe recommend that severe salvageable TBI patients with signs/elevated risk of herniation and need for neurosurgery (brain CT scan already done in spoke hospital with neurosurgical consultation) should be directly transported from the spoke center to the OR at the hub center (agreement %: 85.1, strong recommendation).\n\n【4】删除32:<u>**</u>Recommendation 7删除32:<u>**</u>  \nWe recommend, in severe TBI patients needing transfer to the hub center, an invasive monitoring of arterial blood pressure (ABP) in addition to the standard cardiorespiratory monitoring [electrocardiogram (ECG), heart rate (HR), peripheral oxygen saturation (SpO删除29:<u>₂</u>) and end-tidal carbon dioxide (ETCO删除29:<u>₂</u>)] (agreement %: 82.9, weak recommendation).\n\n【5】删除32:<u>**</u>Recommendation 8删除32:<u>**</u>  \nWe recommend maintaining systolic arterial pressure (SAP) >110 mmHg or mean arterial pressure (MAP) >80 mmHg删除32:<u>*</u> in severe isolated TBI patients (agreement %: 90, strong recommendation).", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 WSES共识和临床建议：无神经外科能力医院内孤立性严重创伤性脑损伤患者的早期管理(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:16:52", "endTime": "2024/08/06 16:17:15", "cost": 23.091}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:17:15", "grab_time": "2024-08-06 00:16:52"}
{"id": 2211571, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "40767163-0d0e-49f5-b7d4-984712cbb509", "title": "（2024.V1）NCCN临床实践指南：姑息治疗", "text": "【0】页码:81\n（2024.V1）NCCN临床实践指南：姑息治疗\n疑似页眉<u># NCCN Guidelines Version 1.2024\n## Palliative Care</u>\n\n【1】### End-of-Life Care Issues\n\n【2】#### Preparing Patients/Families/Caregivers for End of Life and Transition to Hospice Care\n\n【3】A multicenter survey of acute care hospitals revealed discordance between patients' stated values and corresponding treatment preferences for end-of-life care. The study highlighted the need for medical decision support to ensure that patient preferences were grounded in a clear understanding of their illness and end-of-life treatment options. Specialty palliative care consultation should be considered to assist in conflict resolution when the patient, family, and/or medical professional team do not agree on the benefit/efficacy of interventions.\n\n【4】For patients with an estimated life expectancy of years or longer to months, health care professionals should engage in clear, consistent discussion with the patient, family, and caregiver(s) about prognosis and anticipated care needs on an ongoing basis. Advance care planning should be initiated, along with an assessment of decision-making capacity and the need to identify a surrogate decision maker. Providers should elicit values and preferences with respect to quality-of-life and determine the need for specialized palliative care or eligibility and readiness for hospice care as appropriate. When the patient's functional status indicates a 6- to 12-month prognosis, a dedicated \"hospice information\" visit with the oncologist may ease transition to hospice care in the future by preparing the patient, family, and caregiver(s), and reassuring them that their oncologist can remain involved.\n\n【5】For patients with an estimated life expectancy of months to weeks or weeks to days, the oncology team should assess patient/family/caregiver understanding of the dying process and provide education as needed. Providers should address potential need for transitions in care while ensuring continued involvement of the primary care physician and primary oncology team. Referrals should be made to hospice care agencies, as well as for psychosocial assessment, legacy work, grief counseling, spiritual assessment, and funeral/memorial service planning, as necessary. The goals and needs of the patient and family regarding the dying process should be respected.\n\n【6】Dying patients may wish to prepare for death and to help prepare family members to go on without them. Both patients and families benefit from education on the dying process. Families should be guided through their anticipatory grief, and arrangements should be made to ensure that the patient, family, and caregiver needs and goals regarding the dying process are respected. Planning to ensure continuing care and referrals to appropriate care is important. Arrangements should be available to ensure that the patient does not die alone unless that is the patient's preference. Other involved health care professionals should be informed of the patient's death.\n\n【7】### Requests for Hastened Death or Medical Aid in Dying\n\n【8】The most appropriate initial response to a request for hastened death or medical aid in dying (MAID) is to explore the meanings behind that request and intensify palliative care interventions. The AAHPM has released a position statement and advisory brief regarding this topic with guidance for health care professionals on how to evaluate and respond to these requests. The Panel recommends that patients requesting hastened death should be referred to a palliative care specialist. Open exploration of the patient's request for hastened death may identify unmet needs and new palliative care interventions that may be helpful. Concerns related to the withdrawal of life-sustaining treatment, voluntary cessation of eating and drinking, and/or sedation should be discussed with patients and families. Psychiatric consultation to evaluate and treat reversible causes of psychological suffering should be considered. Patients should be assured that their health care team is committed to providing continuing care. Although MAID, under specified conditions, is legal in California,", "tags": {}, "lang": "en", "attr": {"page_num": 81, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2024.V1）NCCN临床实践指南：姑息治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:51:38", "endTime": "2024/08/06 16:02:50", "cost": 671.677}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:02:50", "grab_time": "2024-08-05 23:51:38"}
{"id": 2211570, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "13104f26-cf2e-4fda-b52d-ff284c9fcd51", "title": "美国临床肿瘤学会指南_3期非小细胞肺癌的管理", "text": "【0】页码:8\n美国临床肿瘤学会指南_3期非小细胞肺癌的管理\n### What other recommendations do the guidelines make?\n\n【1】#### Good communication between patients and doctors is vital\n\n【2】Communication between people with cancer and their doctor is known as patient-doctor communication. The guidelines highlight how good patient–doctor communication is very important, and can help doctors to have difficult discussions with their patients about stage III NSCLC diagnosis and treatment options.\n\n【3】The recommendations also highlight the importance of having a multidisciplinary team caring for each patient, so they can benefit from collective medical expertise.\n\n【4】#### Being able to deliver high levels of cancer care to everyone\n\n【5】The guidelines acknowledge that many people with cancer have limited access to medical care or receive disjointed care, such as seeing a different doctor at every appointment without an explanation or having to attend appointments at different hospitals. These factors are often known as health disparities.\n\n【6】The guidelines note that factors such as race and ethnicity, age, education, income, occupation, and insurance status are known to have a negative effect on cancer care outcomes such as survival rates.\n\n【7】ASCO state that awareness of these differences in access to cancer care is important and need to be considered by doctors using the guideline. They recommend that healthcare providers should aim to provide high levels of cancer care to people who may have poor access to care.\n\n【8】#### Taking into account people's individual health requirements\n\n【9】The guidelines may not be applicable to people who have 2 or more other health conditions, as well as stage 3 NSCLC. This is because many of the research studies included in the review did not include people who had other medical conditions.\n\n【10】The guidelines recommend doctors take into account the complexity and individual requirements of any long-term medical conditions when preparing a treatment plan for a person with stage 3 NSCLC.", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/美国临床肿瘤学会指南_3期非小细胞肺癌的管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:01:02", "endTime": "2024/08/06 16:01:15", "cost": 13.217}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:01:15", "grab_time": "2024-08-06 00:01:02"}
{"id": 2211569, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "168db272-1497-4b7d-88c6-ff60aa27d9d5", "title": "NCCN临床实践指南：阴茎癌（2024.V1）-中文版", "text": "【0】页码:40\nNCCN临床实践指南：阴茎癌（2024.V1）-中文版\n(本页删除)本页被模型判断为参考页疑似页眉<u># NCCN Guidelines Version 1.2024\n## 阴茎癌</u>\n\n---|删除段之间换行|### 浰淂\n\n【2】1. Pettaway CA, Lynch D, Jr, Davis D. Tumors of the Penis. In: Wein AJ, Kavoussi L, Novick AC, et al., eds. Campbell-Walsh Urology (ed 9). Philadelphia: Saunders; 2007:959-992.\n2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36633525.</u>\n3. Bray F, Colombet M, Mery L, et al. Cancer Incidence in Five Continents. Vol. XI. Lyon, France: International Agency for Research on Cancer; 2017删除1:<u>. Available at: https://cis.iarc.fr. Accessed July 删除13:<u>13, 2023</u>.</u>\n4. Pow-Sang MR, Ferreira U, Pow-Sang JM, et al. Epidemiology and natural history of penile cancer. Urology 2010;76:S2-6删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20691882.</u>\n5. Horenblas S. Lymphadenectomy for squamous cell carcinoma of the penis. Part 2: the value and technique of lymph node dissection. BJU Int 2001;88:473-483删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11589660.</u>\n6. PubMed Overview删除1:<u>. Available at: https://pubmed.ncbi.nlm.nih.gov/about/. Accessed July 7, 2023.</u>\n7. Freedman-Cass DA, Fischer T, Alpert AB, et al. The value and process of inclusion: Using sensitive, respectful, and inclusive language and images in NCCN content. J Natl Compr Canc Netw 2023;21:434-441删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37156485.</u>\n8. Hernandez BY, Barnholtz-Sloan J, German RR, et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer 2008;113:2883-2891删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18980292.</u>\n9. Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 2000;(B9:189-193删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11144896.</u>\n10. Sufrin G, Huben R. Benign and malignant lesions of the penis. In: YG SS, ed. Adult and Pediatric Urology (ed 2). Chicago: Year Book Medical Publisher; 1991:删除13:<u>1643.\n11</u>. Daling JR, Madeleine MM, Johnson LG, et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in-situ and invasive disease. Int J Cancer 2005;116:606-616删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15825185.</u>\n12. Sarkar FH, Miles BJ, Plieth DH, Crissman JD. Detection of human papillomavirus in squamous neoplasm of the penis. J Urol 1992;147:389-392删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1310122.</u>\n13. Olesen TB, Sand FL, Rasmussen CL, et al. Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol 2019;20:145 -158删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30573285.</u>\n14. Sand FL, Rasmussen CL, Frederiksen MH, et al. Prognostic significance of HPV and p16 status in men diagnosed with penile cancer: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2018;27:1123-1132删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29987099.</u>\n15. Zhang J, Zhang H, Xiu Y, et al. Prognostic significance of p16(INK4a) expression in penile squamous cell carcinoma: A meta analysis with trial sequential analysis. Biomed Res Int 2018;2018:8345893删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30105253.</u>\n16. Parza K, Mutasiman A, Ionescu F, et al. The prognostic role of human papillomavirus and p16 status in penile squamous cell carcinoma-A systematic review. Cancers (Basel) 2023;15删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37509374.</u>\n17. Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS 2018;32:795-808删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29369827.</u>\n18. Goncalves HM, Silva J, Pintado Maury I, et al. The prevalence and risk-factors of oral HPV DNA detection among HIV-infected men between men who have sex with men and heterosexual men. Infect Dis (Lond) 2021;53:19-30删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32915107.</u>\n19. Morris BJ, Gray RH, Castellsague X, et al. The strong protective effect of circumcision against cancer of the penis. Adv Urol 2011;2011:812368删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21687572.</u>\n20. Tseng HF, Morgenstern H, Mack T, Peters RK. Risk factors for penile cancer: results of a population-based case-control study in Los Angeles County (United States). Cancer Causes Control 2001;12:267-277删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11405332.</u>\n21. Andea AC, Sheridan TB, Coleman AM, et al. History of", "tags": {}, "lang": "en", "attr": {"page_num": 40, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/NCCN临床实践指南：阴茎癌（2024.V1）-中文版.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:44:49", "endTime": "2024/08/06 16:44:58", "cost": 9.008}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:44:58", "grab_time": "2024-08-06 00:44:49"}
{"id": 2211568, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "77c3efa2-cf48-43d9-92f4-111725f8d6b7", "title": "2023年加拿大肾癌论坛共识声明：肾细胞癌的辅助治疗 (2)", "text": "【0】页码:8\n2023年加拿大肾癌论坛共识声明：肾细胞癌的辅助治疗 (2)\nCKCF consensus: Adjuvant RCC therapy\n\n【1】are available to help with risk stratification. Referral to medical oncology should be considered for eligible clear-cell RCC patients based on the Keynote-564 risk groups, given that treatment is now accessible in Canada.\n\n【2】#### Interpretation of Keynote-564 in the context of all adjuvant clinical trials\n\n【3】Given that ICI-based adjuvant trials have not reported consistent results, it is important for clinicians to appreciate the limitations of the available studies, as well as possible explanations for the disparate results. Important limitations of Keynote-564 include relatively short followup and evolving information regarding appropriate subsequent treatments received at the time of recurrence, which has implications for subsequent OS results. Acknowledging the limitations of cross-trial comparisons with IMmotion 010 and CheckMate 914 (Part A), potential explanations for discrepant outcomes may also include: differences in the classification of patient populations, particularly in terms of defining intermediate-high-risk, definition and prevalence of M1 NED patients, prevalence of patients with sarcomatoid features, mechanism of agents studied (anti-PD-1 ± anti-CTLA-4 vs. anti-PD-L1 ICIs), necessary quantitative or qualitative tumor burden required for combination ICI benefit, duration of therapy (six months vs. one year), safety and tolerability, among other postulations. Pending data from ongoing trials, such as CheckMate 914 Part B (nivolumab) and RAMPART (durvalumab vs. durvalumab plus tremelimumab vs. active monitoring), are eagerly awaited.\n\n【4】#### Overall survival\n\n【5】While DFS is an important clinical and regulatory approval endpoint, patients and clinicians are particularly interested in whether an intervention can meaningfully improve life span. This is particularly true when considering an adjuvant treatment because this therapy exposes many patients — who may never recur — to toxicity. Therefore, if patients who recur could achieve similar OS and quality of life outcomes with salvage therapy at the time of recurrence, this latter option may be more desirable for many patients.\n\n【6】The panelists strongly believe OS data should be closely followed and may ultimately determine if adjuvant therapy is widely adopted in Canada. Further, when interpreting OS data from Keynote-564, it is important to examine what therapy patients received at the time of disease recurrence. Patients enrolled in clinical trials of adjuvant therapy should receive the best available standard-of-care treatment on disease recurrence, which has important ethical and critical appraisal implications. At the last followup in Keynote-删除13:<u>564, 17</u>% of patients in the placebo arm vs. 12% in the pembrolizumab arm received subsequent VEGF-TKI treatment, and 12% vs. 3%, received subsequent ICI-based therapy, respectively.\n\n【7】#### Risks of adjuvant immunotherapy\n\n【8】ICI-based therapy is generally well-tolerated when considering other available systemic treatments for mRCC; however, the risk tolerance profile in a palliative setting may be different than in an adjuvant setting, as a significant number of patients may never be destined for recurrence. When considering reported toxicities in Keynote-564, grade 3 or higher adverse events (AEs) were observed in 32% of patients in the pembrolizumab arm, compared to 18% in the placebo arm. AEs led to therapy discontinuation in 21% of patients receiving pembrolizumab vs. 2% in the placebo arm. High-grade immune-mediated AEs were 9% vs. 1%, and high-dose systemic corticosteroid treatment (defined as ≥40 mg per day) was required in 8% vs. 1%, respectively. While some adverse events are self-limiting or resolve with supportive treatments, others like thyroid disease and diabetes may expose the patient to lifelong morbidity and treatments to replenish endocrine dysfunction. Patients and physicians should carefully consider the risks of ICI treatment and balance them against potential benefits in a curative-intent clinical context.\n\n【9】#### Future directions\n\n【10】Several questions remain in this rapidly evolving field. If adjuvant therapy is felt to be beneficial, determining the optimal duration of therapy is also vital. Based on Keynote-564, recommendations are for one year of therapy. Data reporting utility and tolerance of one year of adjuvant therapy in the real-world setting will be helpful to understand generalizability of trial results. Further, to what extent will adjuvant therapy affect the activity and efficacy of downstream treatments at the time of potential future recurrence? The Canadian Kidney Cancer Information Systemic (CKCis) and the IMDC may help us understand the effects of next-line access on the real-world experience of RCC patients who receive adjuvant ICI.\n\n【11】Future opportunities include adjuvant studies for the variant or non-clear-cell patient populations, the potential role of neoadjuvant treatment (beyond PROSPER-RCC), blood biomarkers or radiomics to potentially refine patient selection and understand microscopic disease clearance (i.e., cfctDNA), and longer-term followup for toxicity, as well as health-related quality of life metrics that are better tailored for the adjuvant setting.", "tags": {}, "lang": "en", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023年加拿大肾癌论坛共识声明：肾细胞癌的辅助治疗 (2).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:28:51", "endTime": "2024/08/06 15:29:19", "cost": 28.624}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-05 23:29:19", "grab_time": "2024-08-05 23:28:50"}
{"id": 2211567, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "d91bb962-4bb6-4e76-b415-745c72049ce3", "title": "2024更新—2016 NICE指南：结核病（NG.33）", "text": "【0】页码:68\n2024更新—2016 NICE指南：结核病（NG.33）\n- be supported by frequent contact with any key workers who work with the person. 删除24:<u>[2006 amended 2011, amended 2016]</u>\n\n#### 1.7.1.8|删除段内换行|Multidisciplinary TB teams should aim to find people with active TB who are lost to follow-up, or who stop using services before completing diagnostic investigations. They should report all those lost to follow-up to local Public Health England teams, GPs, the referring organisation and specialist outreach teams. 删除12:<u>删除14:<u>删除24:<u>[2012]</u></u></u>\n\n【2】### 1.7.2 Other strategies to encourage people to follow their treatment plan\n\n#### 1.7.2.1|删除段内换行|To encourage people to follow their treatment plan, involve people in treatment decisions for active or latent TB from the start. Emphasise the importance of following the treatment plan when agreeing the regimen. 删除12:<u>删除14:<u>删除24:<u>[2016]</u></u></u>\n\n#### 1.7.2.2|删除段内换行|Multidisciplinary TB teams should implement strategies for active and latent TB to encourage people to follow the treatment plan and prevent people stopping treatment early. These could include:\n\n【5】- reminder letters, printed information, telephone calls, texts and apps using an appropriate language 删除24:<u>[2006, amended 2016]</u>\n\n【6】- health education counselling and patient-centred interviews 删除24:<u>[2006, amended 2016]</u>\n\n【7】- tailored health education booklets from quality sources 删除9:<u>(see section on providing information for the public about TB)</u> 删除24:<u>[2006, amended 2016]</u>\n\n【8】- home visits 删除12:<u>删除14:<u>删除24:<u>[2006]</u></u></u>\n\n【9】- random urine tests and other monitoring (for example, pill counts) 删除12:<u>删除14:<u>删除24:<u>[2006]</u></u></u>\n\n【10】- access to free TB treatment for everyone (irrespective of eligibility for other NHS care) and information about help with paying for prescriptions 删除24:<u>[删除13:<u>2006, 2012</u>, amended 2016]</u>\n\n【11】- social and psychological support (including cultural case management and", "tags": {}, "lang": "en", "attr": {"page_num": 68, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024更新—2016 NICE指南：结核病（NG.33）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:08:12", "endTime": "2024/08/06 17:08:35", "cost": 23.718}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 01:08:35", "grab_time": "2024-08-06 01:08:11"}
{"id": 2211566, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "aef0f12c-f00e-4dbe-b890-f6762384ca4b", "title": "（2023.V1）NCCN临床实践指南：骨癌", "text": "【0】页码:5\n（2023.V1）NCCN临床实践指南：骨癌\n### 2.1 半监督学习算法的分类\n\n【1】半监督学习算法可以分为以下几类：\n\n【2】1. 基于生成模型的方法\n2. 基于低维流形的方法\n3. 基于图的方法\n4. 基于分歧的方法\n\n【3】#### 2.1.1 基于生成模型的方法\n\n生成模型试图学习输入数据的联合概率分布 $P(x, y)$，然后通过贝叶斯公式计算 $P(y|x)$。常见的生成模型包括混合高斯模型、朴素贝叶斯模型等。\n\n【5】#### 2.1.2 基于低维流形的方法\n\n【6】基于低维流形的方法假设数据分布在一个低维流形上，通过寻找这个流形来进行分类。常见的方法有半监督流形正则化（Semi-supervised Manifold Regularization, SSMR）、局部线性嵌入（Locally Linear Embedding, LLE）等。\n\n【7】#### 2.1.3 基于图的方法\n\n【8】基于图的方法将数据表示为图结构，其中节点表示数据点，边表示数据点之间的相似性。然后通过图上的传播算法进行半监督学习。常见的方法有图正则化（Graph Regularization）、拉普拉斯正则化（Laplacian Regularization）等。\n\n【9】#### 2.1.4 基于分歧的方法\n\n【10】基于分歧的方法利用不同模型的分歧来进行半监督学习。主要思想是如果不同的模型对同一个未标记数据点的预测结果有很大差异，那么这个数据点的信息可以用来改进模型。常见的方法有 co-training、multi-view learning 等。\n\n【11】### 2.2 半监督学习的应用\n\n【12】半监督学习在许多领域有广泛的应用，以下是一些典型的应用场景：\n\n【13】1. 删除32:<u>**</u>文本分类删除32:<u>**</u>：在文本分类中，标记数据的获取成本较高，而未标记数据通常较多。半监督学习可以利用大量的未标记数据来提高分类器的性能。\n2. 删除32:<u>**</u>图像分类删除32:<u>**</u>：在图像分类任务中，标记数据的获取通常需要大量的人力资源，而未标记数据则相对容易获得。半监督学习能够有效利用未标记数据来提升分类性能。\n3. 删除32:<u>**</u>生物信息学删除32:<u>**</u>：在生物信息学中，标记数据的获取成本高且时间长，而未标记数据相对较多。半监督学习能够利用这些未标记数据来提高模型的预测性能。\n\n【14】### 2.3 半监督学习的挑战\n\n【15】尽管半监督学习在理论和应用上都有许多优点，但仍然面临一些挑战：\n\n【16】1. 删除32:<u>**</u>模型假设删除32:<u>**</u>：半监督学习方法通常依赖于一些假设，如平滑假设、低维流形假设等。如果这些假设不成立，模型的性能可能会大打折扣。\n2. 删除32:<u>**</u>标记和未标记数据的比例删除32:<u>**</u>：在半监督学习中，标记数据和未标记数据的比例对模型的性能有很大影响。如果标记数据太少，模型可能难以学习有效的信息。\n3. 删除32:<u>**</u>计算复杂度删除32:<u>**</u>：一些半监督学习方法计算复杂度较高，特别是在处理大规模数据时，这成为一个瓶颈。\n\n【17】#### 表 2.1 常见的半监督学习算法\n\n| 算法类型           | 代表算法             | 优点                          | 缺点                          |\n|--------------------|----------------------|-------------------------------|----------------", "tags": {}, "lang": "zh", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V1）NCCN临床实践指南：骨癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:5\n\n（2023.V1）NCCN临床实践指南：骨癌\n\n2.1 半监督学习算法的分类\n【1】半监督学习算法可以分为以下几类：\n\n【2】1. 基于生成模型的方法\n\n2. 基于低维流形的方法\n\n3. 基于图的方法\n\n4. 基于分歧的方法\n\n【3】#### 2.1.1 基于生成模型的方法\n\n生成模型试图学习输入数据的联合概率分布 \n𝑃\n(\n𝑥\n,\n𝑦\n)\n，然后通过贝叶斯公式计算 \n𝑃\n(\n𝑦\n|\n𝑥\n)\n。常见的生成模型包括混合高斯模型、朴素贝叶斯模型等。\n\n【5】#### 2.1.2 基于低维流形的方法\n\n【6】基于低维流形的方法假设数据分布在一个低维流形上，通过寻找这个流形来进行分类。常见的方法有半监督流形正则化（Semi-supervised Manifold Regularization, SSMR）、局部线性嵌入（Locally Linear Embedding, LLE）等。\n\n【7】#### 2.1.3 基于图的方法\n\n【8】基于图的方法将数据表示为图结构，其中节点表示数据点，边表示数据点之间的相似性。然后通过图上的传播算法进行半监督学习。常见的方法有图正则化（Graph Regularization）、拉普拉斯正则化（Laplacian Regularization）等。\n\n【9】#### 2.1.4 基于分歧的方法\n\n【10】基于分歧的方法利用不同模型的分歧来进行半监督学习。主要思想是如果不同的模型对同一个未标记数据点的预测结果有很大差异，那么这个数据点的信息可以用来改进模型。常见的方法有 co-training、multi-view learning 等。\n\n【11】### 2.2 半监督学习的应用\n\n【12】半监督学习在许多领域有广泛的应用，以下是一些典型的应用场景：\n\n【13】1. 删除32:文本分类删除32:：在文本分类中，标记数据的获取成本较高，而未标记数据通常较多。半监督学习可以利用大量的未标记数据来提高分类器的性能。\n\n2. 删除32:图像分类删除32:：在图像分类任务中，标记数据的获取通常需要大量的人力资源，而未标记数据则相对容易获得。半监督学习能够有效利用未标记数据来提升分类性能。\n\n3. 删除32:生物信息学删除32:：在生物信息学中，标记数据的获取成本高且时间长，而未标记数据相对较多。半监督学习能够利用这些未标记数据来提高模型的预测性能。\n\n【14】### 2.3 半监督学习的挑战\n\n【15】尽管半监督学习在理论和应用上都有许多优点，但仍然面临一些挑战：\n\n【16】1. 删除32:模型假设删除32:：半监督学习方法通常依赖于一些假设，如平滑假设、低维流形假设等。如果这些假设不成立，模型的性能可能会大打折扣。\n\n2. 删除32:标记和未标记数据的比例删除32:：在半监督学习中，标记数据和未标记数据的比例对模型的性能有很大影响。如果标记数据太少，模型可能难以学习有效的信息。\n\n3. 删除32:计算复杂度删除32:：一些半监督学习方法计算复杂度较高，特别是在处理大规模数据时，这成为一个瓶颈。\n\n【17】#### 表 2.1 常见的半监督学习算法\n\n算法类型\t代表算法\t优点\t缺点", "content": "【0】页码:5\n（2023.V1）NCCN临床实践指南：骨癌\n### 2.1 半监督学习算法的分类\n\n【1】半监督学习算法可以分为以下几类：\n\n【2】1. 基于生成模型的方法\n2. 基于低维流形的方法\n3. 基于图的方法\n4. 基于分歧的方法\n\n【3】#### 2.1.1 基于生成模型的方法\n\n生成模型试图学习输入数据的联合概率分布 $P(x, y)$，然后通过贝叶斯公式计算 $P(y|x)$。常见的生成模型包括混合高斯模型、朴素贝叶斯模型等。\n\n【5】#### 2.1.2 基于低维流形的方法\n\n【6】基于低维流形的方法假设数据分布在一个低维流形上，通过寻找这个流形来进行分类。常见的方法有半监督流形正则化（Semi-supervised Manifold Regularization, SSMR）、局部线性嵌入（Locally Linear Embedding, LLE）等。\n\n【7】#### 2.1.3 基于图的方法\n\n【8】基于图的方法将数据表示为图结构，其中节点表示数据点，边表示数据点之间的相似性。然后通过图上的传播算法进行半监督学习。常见的方法有图正则化（Graph Regularization）、拉普拉斯正则化（Laplacian Regularization）等。\n\n【9】#### 2.1.4 基于分歧的方法\n\n【10】基于分歧的方法利用不同模型的分歧来进行半监督学习。主要思想是如果不同的模型对同一个未标记数据点的预测结果有很大差异，那么这个数据点的信息可以用来改进模型。常见的方法有 co-training、multi-view learning 等。\n\n【11】### 2.2 半监督学习的应用\n\n【12】半监督学习在许多领域有广泛的应用，以下是一些典型的应用场景：\n\n【13】1. 删除32:<u>**</u>文本分类删除32:<u>**</u>：在文本分类中，标记数据的获取成本较高，而未标记数据通常较多。半监督学习可以利用大量的未标记数据来提高分类器的性能。\n2. 删除32:<u>**</u>图像分类删除32:<u>**</u>：在图像分类任务中，标记数据的获取通常需要大量的人力资源，而未标记数据则相对容易获得。半监督学习能够有效利用未标记数据来提升分类性能。\n3. 删除32:<u>**</u>生物信息学删除32:<u>**</u>：在生物信息学中，标记数据的获取成本高且时间长，而未标记数据相对较多。半监督学习能够利用这些未标记数据来提高模型的预测性能。\n\n【14】### 2.3 半监督学习的挑战\n\n【15】尽管半监督学习在理论和应用上都有许多优点，但仍然面临一些挑战：\n\n【16】1. 删除32:<u>**</u>模型假设删除32:<u>**</u>：半监督学习方法通常依赖于一些假设，如平滑假设、低维流形假设等。如果这些假设不成立，模型的性能可能会大打折扣。\n2. 删除32:<u>**</u>标记和未标记数据的比例删除32:<u>**</u>：在半监督学习中，标记数据和未标记数据的比例对模型的性能有很大影响。如果标记数据太少，模型可能难以学习有效的信息。\n3. 删除32:<u>**</u>计算复杂度删除32:<u>**</u>：一些半监督学习方法计算复杂度较高，特别是在处理大规模数据时，这成为一个瓶颈。\n\n【17】#### 表 2.1 常见的半监督学习算法\n\n| 算法类型           | 代表算法             | 优点                          | 缺点                          |\n|--------------------|----------------------|-------------------------------|----------------", "index": 0, "show": true, "start": 0, "end": 1338, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "与原文不一致"}], "startTime": "2024/08/07 10:01:38", "endTime": "2024/08/07 10:02:17", "cost": 39.819}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 18:02:17", "grab_time": "2024-08-06 18:01:37"}
{"id": 2211565, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "3c7b5934-6a3c-453f-acdc-c45cbbacba3f", "title": "2023 ESGO_ESTRO_ESP指南：宫颈癌患者的管理（更新版）", "text": "【0】页码:11\n2023 ESGO_ESTRO_ESP指南：宫颈癌患者的管理（更新版）\n## Role of Surgery in T1B3 and T2a2 (LN Negative) Tumors\n\n【1】- There is limited evidence to guide the choice between surgical treatment vs CTRT with IGBT in LN negative patients with T1b3 and T2a2 tumors. Histology, tumor size, completeness of the cervical rim, uterine corpus invasion, magnitude of vaginal invasion, age, comorbidity, menopausal status, body mass index, hemoglobin and experience with type C radical hysterectomy are some of the factors to consider 删除12:<u>[IV, B]</u>.\n- For surgery, avoidance of the combination of radical surgery and post-operative external radiotherapy requires acceptance for modifications of the traditional selection criteria (tumor size, degree of invasion, LVSI) for adjuvant treatment 删除12:<u>[IV, B]</u>.\n- The patient should be discussed in a multidisciplinary team and should be counseled for the advantages and disadvantages of both treatment options (surgery vs radiotherapy) in relation to the individual presence of prognostic factors 删除12:<u>[IV, A]</u>.\n- Given the limited number of patients with T1b3 and T2a2 (<10%) tumors, treatment should be centralized 删除12:<u>[IV, B]</u>.\n- Type C radical hysterectomy is recommended. LN staging should follow the same principles as in T1b1-2 tumors 删除12:<u>[IV, A]</u>.\n- NACT followed by radical surgery should not be performed outside clinical trials 删除12:<u>[I, E]</u>.\n\n【2】## Recurrent/Metastatic Disease\n\n【3】### General Recommendations\n\n【4】- Treatment of recurrent disease requires centralization and involvement of a broad multidisciplinary team including a gynecological oncologist, radiation oncologist, radiologist, pathologist, medical oncologist, urologist, and plastic surgeon. A structured program for multidisciplinary diagnostic work-up, treatment, and follow-up must be present in centers responsible for the treatment 删除12:<u>[IV, A]</u>.\n- Participation in clinical trials is encouraged 删除12:<u>[V, B]</u>.\n- Early involvement of a palliative care specialist is encouraged 删除12:<u>[V, B]</u>.\n- The patient should be carefully counseled regarding treatment options, risks and consequences 删除12:<u>[V, A]</u>.\n\n【5】## Diagnostic Work-up\n\n【6】- The aim of the diagnostic work-up is to determine the extent of the locoregional and/or metastatic disease 删除12:<u>[IV, B]</u>.\n- The recurrence should be confirmed by histological examination if feasible 删除12:<u>[IV, B]</u>.\n- Patients with multiple nodal/distant metastases (ie, not oligometastatic disease) or multifocal local disease with extensive pelvic wall involvement should not be considered as candidates for radical treatment 删除12:<u>[IV, D]</u>.\n- Patients with oligometastatic or oligorecurrent disease should be considered for radical and potentially curative treatment options 删除12:<u>[IV, B]</u>.\n- The prognostic factors should be evaluated carefully and balanced in relation to the major morbidity caused by the treatment 删除12:<u>[IV, A]</u>.\n\n【7】## Locoregional Recurrent Disease - Central Pelvic Recurrence After Primary Surgery\n\n【8】- Definitive CTRT combined with IGBT is the treatment of choice in radiotherapy naïve patients 删除12:<u>[IV, A]</u>. The use of boost by external beam techniques to replace IGBT is not recommended 删除12:<u>[IV, D]</u>.\n- Small superficial lesions (ie, <5 mm thickness) in the vagina can be treated by surgery or brachytherapy using combined intracavitary-interstitial techniques 删除12:<u>[IV, C]</u>.\n\n【9】## Locoregional Recurrent Disease - Pelvic Sidewall Recurrence After Primary Surgery\n\n【10】- Definitive CTRT is the preferred option in radiotherapy naïve patients 删除12:<u>[IV, A]</u>.\n- When radical radiotherapy is not feasible, extended pelvic surgery can be considered. Surgery must aim for a complete tumor resection (R=0) also with the help of special techniques (laterally extended endopelvic resection (LEER), out of box procedures), if required 删除12:<u>[IV, B]</u>.\n- Combined operative-radiotherapy procedures using intraoperative radiotherapy or IGBT are an option if free surgical margins are not achievable 删除12:<u>[IV, B]</u>.\n\n【11】## Locoregional Recurrent Disease - Central Pelvic or Pelvic Sidewall Recurrence After Radiotherapy\n\n【12】- Pelvic exenteration is recommended for central pelvic recurrence where there is no involvement of the pelvic sidewall, extrapelvic nodes or peritoneal disease 删除12:<u>[IV, B]</u>.", "tags": {}, "lang": "en", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ESGO_ESTRO_ESP指南：宫颈癌患者的管理（更新版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:19:50", "endTime": "2024/08/06 17:22:05", "cost": 135.005}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 01:22:05", "grab_time": "2024-08-06 01:19:50"}
{"id": 2211564, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "e3f1a354-0833-454f-9a98-48a535c265d3", "title": "【神经领域】中国脑卒中防治指导规范（2021年版）", "text": "【0】页码:391\n【神经领域】中国脑卒中防治指导规范（2021年版）\n# 一、概述\n\n【1】脑卒中是我国居民死亡、致残的首位病因，具有发病率高、致残率高、死亡率高和复发率高的特点。全球疾病负担 (global burden of disease，GBD) 最新数据显示，我国2017年缺血性脑卒中发病率为156/10万，出血性脑卒中发病率为62/10万。删除27:<u>2017</u>年我国脑出血与脑梗死患者住院人均费用分别为525元和607元，相比2007年分别增长118%和60%。对个人、家庭和社会造成沉重负担。脑卒中的临床治疗策略中，护理贯穿卒中预防、救护、治疗和康复的每一个环节之中。为了总结和推荐脑卒中护理干预的临床循证依据，在国内建立脑卒中护理规范，2015年由国家卫生计生委脑卒中防治工程办公室组建脑卒中护理指南编写小组，基于国内外脑卒中相关研究进展和指南，对脑卒中护理内容进行收集和整理，共同编写了《中国脑卒中护理指导规范》，近年来随着国内外同行不断对脑卒中的防治及护理的探索，与之前的循证医学证据相比，新的高质量的证据已经发生了巨大的变化，编写组对2015年的《中国脑卒中护理指导规范》进行了相应的更新，旨在为广大的护理人员提供临床护理干预的最新循证依据。文献检索至2020年12月，文中的推荐级别和证据级别及证据类型参照《JBI证据预分类及证据推荐级别系统（2014版）》，见表14-1 ~ 表删除28:<u>14-3</u>。\n\n【2】表14-1 推荐级别及证据类型\n\n| 推荐级别 | 判断标准 |\n|----------|-----------|\n| A级推荐：强推荐 | 1. 明确显示干预措施利大于弊或弊大于利<br>2. 高质量证据支持应用<br>3. 对资源分配有力或无影响<br>4. 考虑了患者的价值观、意愿和体验 |\n| B级推荐：弱推荐 | 1. 干预措施利大于弊或弊大于利，尽管证据尚不够明确<br>2. 有证据支持应用，尽管证据质量不够高<br>3. 对资源分配有力、无影响或有较小影响<br>4. 部分考虑或并未考虑患者的价值观、意愿和体验 |", "tags": {}, "lang": "zh", "attr": {"page_num": 391, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【神经领域】中国脑卒中防治指导规范（2021年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "删除28:14-3", "content": "【0】页码:391\n【神经领域】中国脑卒中防治指导规范（2021年版）\n# 一、概述\n\n【1】脑卒中是我国居民死亡、致残的首位病因，具有发病率高、致残率高、死亡率高和复发率高的特点。全球疾病负担 (global burden of disease，GBD) 最新数据显示，我国2017年缺血性脑卒中发病率为156/10万，出血性脑卒中发病率为62/10万。删除27:<u>2017</u>年我国脑出血与脑梗死患者住院人均费用分别为525元和607元，相比2007年分别增长118%和60%。对个人、家庭和社会造成沉重负担。脑卒中的临床治疗策略中，护理贯穿卒中预防、救护、治疗和康复的每一个环节之中。为了总结和推荐脑卒中护理干预的临床循证依据，在国内建立脑卒中护理规范，2015年由国家卫生计生委脑卒中防治工程办公室组建脑卒中护理指南编写小组，基于国内外脑卒中相关研究进展和指南，对脑卒中护理内容进行收集和整理，共同编写了《中国脑卒中护理指导规范》，近年来随着国内外同行不断对脑卒中的防治及护理的探索，与之前的循证医学证据相比，新的高质量的证据已经发生了巨大的变化，编写组对2015年的《中国脑卒中护理指导规范》进行了相应的更新，旨在为广大的护理人员提供临床护理干预的最新循证依据。文献检索至2020年12月，文中的推荐级别和证据级别及证据类型参照《JBI证据预分类及证据推荐级别系统（2014版）》，见表14-1 ~ 表删除28:<u>14-3</u>。\n\n【2】表14-1 推荐级别及证据类型\n\n| 推荐级别 | 判断标准 |\n|----------|-----------|\n| A级推荐：强推荐 | 1. 明确显示干预措施利大于弊或弊大于利<br>2. 高质量证据支持应用<br>3. 对资源分配有力或无影响<br>4. 考虑了患者的价值观、意愿和体验 |\n| B级推荐：弱推荐 | 1. 干预措施利大于弊或弊大于利，尽管证据尚不够明确<br>2. 有证据支持应用，尽管证据质量不够高<br>3. 对资源分配有力、无影响或有较小影响<br>4. 部分考虑或并未考虑患者的价值观、意愿和体验 |", "index": 610, "show": true, "start": 610, "end": 619, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 16:38:45", "endTime": "2024/08/06 16:39:31", "cost": 46.173}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:39:31", "grab_time": "2024-08-06 00:38:44"}
{"id": 2211563, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "6e3fd65d-7cbf-49e2-b4ab-0470a48b908d", "title": "应用时间范围和其他连续血糖监测指标实现以患者为中心的糖尿病血糖控制的专家建议（2022）", "text": "【0】页码:9\n应用时间范围和其他连续血糖监测指标实现以患者为中心的糖尿病血糖控制的专家建议（2022）\n### 五、综合实验\n\n【1】#### 5.1 实验环境\n\n【2】实验所需软硬件环境如表1所示。\n\n| 硬件平台 | 软件平台 |\n| -------- | -------- |\n| CPU: Intel Core i7 9700k | 操作系统：Windows 10 64bit |\n| 内存: 32GB | 编译器：GCC 7.3.0 |\n| 硬盘: 1TB SSD | OpenMP 4.5 |\n\n【4】表1 实验所需软硬件环境\n\n【5】#### 5.2 实验内容与步骤\n\n【6】##### 5.2.1 数据集准备\n\n【7】本实验采用的数据集包括三个部分：\n- 数据集1：描述xxx\n- 数据集2：描述xxx\n- 数据集3：描述xxx\n\n【8】##### 5.2.2 实验步骤\n\n【9】实验主要包括以下几个步骤：\n1. 数据预处理\n2. 特征提取\n3. 模型训练\n4. 模型测试\n5. 结果分析\n\n【10】#### 5.3 实验结果与分析\n\n【11】##### 5.3.1 数据预处理\n\n【12】数据预处理阶段，我们采用了xxx方法对数据进行了清洗，具体步骤如下：\n1. 去除空值\n2. 标准化处理\n3. 特征选择\n\n【13】##### 5.3.2 特征提取\n\n【14】特征提取阶段，我们使用了xxx算法提取特征，得到了以下结果：\n$$\nX = \\{x_1, x_2, \\ldots, x_n\\}\n$$\n\n【15】其中，$x_i$ 表示提取的第 $i$ 个特征。\n\n【16】##### 5.3.3 模型训练\n\n【17】模型训练阶段，我们采用了xxx模型，并使用了以下参数：\n- 参数1：xxx\n- 参数2：xxx\n\n【18】训练过程中，我们使用了xxx方法进行优化，具体公式如下：\n$$\n\\theta = \\arg\\min_\\theta L(\\theta)\n$$\n\n【19】其中，$L(\\theta)$ 表示损失函数。\n\n【20】##### 5.3.4 模型测试\n\n【21】在模型测试阶段，我们对比了xxx和yyy两种方法的表现，结果如表2所示。\n\n| 方法 | 准确率 | 召回率 | F1分数 |\n| ---- | ------ | ------ | ------ |\n| 方法xxx | 0.85 | 0.80 | 0.82 |\n| 方法yyy | 0.90 | 0.85 | 0.87 |\n\n【23】表2 模型测试结果比较\n\n【24】##### 5.3.5 结果分析\n\n【25】从表2的结果可以看出，方法yyy在准确率、召回率和F1分数上都优于方法xxx。这表明，方法yyy在处理xxx问题上具有更好的性能。\n\n【26】#### 5.4 本章小结\n\n【27】本章通过对xxx方法的实验验证，证明了其在xxx问题上的有效性。实验结果表明，采用yyy方法能够显著提高模型的准确率和稳定性。", "tags": {}, "lang": "zh", "attr": {"page_num": 9, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/应用时间范围和其他连续血糖监测指标实现以患者为中心的糖尿病血糖控制的专家建议（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:9\n\n应用时间范围和其他连续血糖监测指标实现以患者为中心的糖尿病血糖控制的专家建议（2022）\n\n五、综合实验\n【1】#### 5.1 实验环境\n\n【2】实验所需软硬件环境如表1所示。\n\n硬件平台\t软件平台\nCPU: Intel Core i7 9700k\t操作系统：Windows 10 64bit\n内存: 32GB\t编译器：GCC 7.3.0\n硬盘: 1TB SSD\tOpenMP 4.5\n【4】表1 实验所需软硬件环境\n\n【5】#### 5.2 实验内容与步骤\n\n【6】##### 5.2.1 数据集准备\n\n【7】本实验采用的数据集包括三个部分：\n\n数据集1：描述xxx\n数据集2：描述xxx\n数据集3：描述xxx\n【8】##### 5.2.2 实验步骤\n\n【9】实验主要包括以下几个步骤：\n\n数据预处理\n特征提取\n模型训练\n模型测试\n结果分析\n【10】#### 5.3 实验结果与分析\n\n【11】##### 5.3.1 数据预处理\n\n【12】数据预处理阶段，我们采用了xxx方法对数据进行了清洗，具体步骤如下：\n\n去除空值\n标准化处理\n特征选择\n【13】##### 5.3.2 特征提取\n\n【14】特征提取阶段，我们使用了xxx算法提取特征，得到了以下结果：\n\n𝑋\n=\n{\n𝑥\n1\n,\n𝑥\n2\n,\n…\n,\n𝑥\n𝑛\n}\n【15】其中，\n𝑥\n𝑖\n 表示提取的第 \n𝑖\n 个特征。\n\n【16】##### 5.3.3 模型训练\n\n【17】模型训练阶段，我们采用了xxx模型，并使用了以下参数：\n\n参数1：xxx\n参数2：xxx\n【18】训练过程中，我们使用了xxx方法进行优化，具体公式如下：\n\n𝜃\n=\narg\n⁡\nmin\n𝜃\n𝐿\n(\n𝜃\n)\n【19】其中，\n𝐿\n(\n𝜃\n)\n 表示损失函数。\n\n【20】##### 5.3.4 模型测试\n\n【21】在模型测试阶段，我们对比了xxx和yyy两种方法的表现，结果如表2所示。\n\n方法\t准确率\t召回率\tF1分数\n方法xxx\t0.85\t0.80\t0.82\n方法yyy\t0.90\t0.85\t0.87\n【23】表2 模型测试结果比较\n\n【24】##### 5.3.5 结果分析\n\n【25】从表2的结果可以看出，方法yyy在准确率、召回率和F1分数上都优于方法xxx。这表明，方法yyy在处理xxx问题上具有更好的性能。\n\n【26】#### 5.4 本章小结\n\n【27】本章通过对xxx方法的实验验证，证明了其在xxx问题上的有效性。实验结果表明，采用yyy方法能够显著提高模型的准确率和稳定性。\n\n\n", "content": "【0】页码:9\n应用时间范围和其他连续血糖监测指标实现以患者为中心的糖尿病血糖控制的专家建议（2022）\n### 五、综合实验\n\n【1】#### 5.1 实验环境\n\n【2】实验所需软硬件环境如表1所示。\n\n| 硬件平台 | 软件平台 |\n| -------- | -------- |\n| CPU: Intel Core i7 9700k | 操作系统：Windows 10 64bit |\n| 内存: 32GB | 编译器：GCC 7.3.0 |\n| 硬盘: 1TB SSD | OpenMP 4.5 |\n\n【4】表1 实验所需软硬件环境\n\n【5】#### 5.2 实验内容与步骤\n\n【6】##### 5.2.1 数据集准备\n\n【7】本实验采用的数据集包括三个部分：\n- 数据集1：描述xxx\n- 数据集2：描述xxx\n- 数据集3：描述xxx\n\n【8】##### 5.2.2 实验步骤\n\n【9】实验主要包括以下几个步骤：\n1. 数据预处理\n2. 特征提取\n3. 模型训练\n4. 模型测试\n5. 结果分析\n\n【10】#### 5.3 实验结果与分析\n\n【11】##### 5.3.1 数据预处理\n\n【12】数据预处理阶段，我们采用了xxx方法对数据进行了清洗，具体步骤如下：\n1. 去除空值\n2. 标准化处理\n3. 特征选择\n\n【13】##### 5.3.2 特征提取\n\n【14】特征提取阶段，我们使用了xxx算法提取特征，得到了以下结果：\n$$\nX = \\{x_1, x_2, \\ldots, x_n\\}\n$$\n\n【15】其中，$x_i$ 表示提取的第 $i$ 个特征。\n\n【16】##### 5.3.3 模型训练\n\n【17】模型训练阶段，我们采用了xxx模型，并使用了以下参数：\n- 参数1：xxx\n- 参数2：xxx\n\n【18】训练过程中，我们使用了xxx方法进行优化，具体公式如下：\n$$\n\\theta = \\arg\\min_\\theta L(\\theta)\n$$\n\n【19】其中，$L(\\theta)$ 表示损失函数。\n\n【20】##### 5.3.4 模型测试\n\n【21】在模型测试阶段，我们对比了xxx和yyy两种方法的表现，结果如表2所示。\n\n| 方法 | 准确率 | 召回率 | F1分数 |\n| ---- | ------ | ------ | ------ |\n| 方法xxx | 0.85 | 0.80 | 0.82 |\n| 方法yyy | 0.90 | 0.85 | 0.87 |\n\n【23】表2 模型测试结果比较\n\n【24】##### 5.3.5 结果分析\n\n【25】从表2的结果可以看出，方法yyy在准确率、召回率和F1分数上都优于方法xxx。这表明，方法yyy在处理xxx问题上具有更好的性能。\n\n【26】#### 5.4 本章小结\n\n【27】本章通过对xxx方法的实验验证，证明了其在xxx问题上的有效性。实验结果表明，采用yyy方法能够显著提高模型的准确率和稳定性。", "index": 0, "show": true, "start": 0, "end": 1089, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "与原文不一致"}], "startTime": "2024/08/07 09:53:10", "endTime": "2024/08/07 09:53:43", "cost": 33.315}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 17:53:43", "grab_time": "2024-08-06 17:53:09"}
{"id": 2211562, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "e81a12d2-956c-4c98-bdf5-ffb59fcad41a", "title": "中枢神经系统肿瘤_2023.V1_EN (2)", "text": "【0】页码:130\n中枢神经系统肿瘤_2023.V1_EN (2)\n(or contrast-enhanced CT if MRI is contraindicated) suggests PCNSL, clinicians are advised to hold the use of steroids if possible before diagnosis is established, since the imaging and histologic features of PCNSL can be profoundly affected by these drugs.\n\n【1】Patients with an enhancing brain lesion consistent with PCNSL should receive a biopsy (if lesion is amenable to biopsy), as this is the most direct and rapid route to achieve a pathologic diagnosis. Because the role of maximal surgical resection is limited to alleviating symptoms of raised intracranial pressure or preventing herniation, stereotactic biopsy is generally preferred to minimize invasiveness. Even with molecular marker testing, however, a biopsy can occasionally be falsely negative, particularly if the patient had been treated previously with steroids. Thus, if a biopsy is nondiagnostic, the panel recommends that the steroids be tapered and that the patient be followed closely, both clinically and radiographically. If and when the lesion recurs, there should be a prompt repeat CSF evaluation or rebiopsy before the initiation of steroids. If, on the other hand, no definitive diagnosis of lymphoma is made from biopsy and the patient has not received steroid therapy, workup for other diagnoses (for example, inflammatory processes) or repeat CSF evaluation/rebiopsy is recommended. In some cases, diagnosis can be made by CSF analysis or by pathologic diagnosis of vitreoretinal disease.\n\n【2】### Evaluation for Extent of Disease\nOnce the diagnosis of PCNSL is established, the patient should undergo a thorough staging workup detailed by The International PCNSL Collaborative Group. This workup involves a complete CNS evaluation including imaging of the entire neuroaxis (MRI of the spine with contrast). If possible, this should be done before CSF analysis is attempted to avoid post-lumbar puncture artifacts that can be mistaken for leptomeningeal disease on imaging.\n\n【3】A lumbar puncture with evaluation of CSF (15–20 mL of spinal fluid) should be considered, if it can be done safely and without concern for herniation from increased intracranial pressure, and if it will not delay diagnosis and treatment. A delay in treatment may compromise patient outcomes. Caution should be taken in patients who are anticoagulated, thrombocytopenic, or who have a bulky intracranial mass. CSF analysis should include flow cytometric analysis, CSF cytology, and cell count. The yield for a positive diagnostic test can be increased by the use of molecular markers of monoclonality, such as an immunoglobulin gene rearrangement.\n\n【4】Since disease is sometimes detected in the retina and optic nerve, a full ophthalmologic exam should be done, which should include a slit-lamp eye examination. In some cases, the diagnosis of lymphoma is made by vitrectomy; in this case, flow cytometric analysis is recommended. In addition, blood work (CBC and chemistry panel) and a contrast-enhanced body CT or PET/CT are required to rule out systemic involvement. Elevated lactate dehydrogenase (LDH) serum level is associated with worse survival in patients with PCNSL, and LDH should be evaluated as part of the workup for this disease. Bone marrow biopsy is a category 2B option that may be considered. In men >60 years of age, testicular ultrasound may be considered (category 2B). In these patients, regular testicular examination is encouraged. If both testicular examination and CT or PET/CT imaging are negative, then testicular ultrasound may not be necessary.\n\n【5】An HIV blood test should also be performed, because both prognosis and treatment of patients with HIV-related PCNSL may be different than that of patients who are otherwise immunocompetent. HIV-positive patients should receive highly active retroviral therapy in addition to their cancer therapy.", "tags": {}, "lang": "en", "attr": {"page_num": 130, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/中枢神经系统肿瘤_2023.V1_EN (2).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:01:04", "endTime": "2024/08/06 17:01:23", "cost": 18.939}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 01:01:23", "grab_time": "2024-08-06 01:01:04"}
{"id": 2211561, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "fff60171-d5a4-450c-9bc2-a327a0580961", "title": "中国婴幼儿全身麻醉下眼病检查专家共识（2022年）", "text": "【0】页码:5\n中国婴幼儿全身麻醉下眼病检查专家共识（2022年）\n紫质眼病，做好清洁及取分类处理。查看标定\n结束并打开的检查结果。\n\n【1】  ①注意事项：a. 行 PVEP 检查在高度散大瞳孔和\n新生视力者双眼佩戴不同眼罩; b.注意无替代假\n护镜、手套; c.确保试验每次递增体持续超时间\n\n【2】    ③ 居平体感得益用。  \n\n【3】  二、表\n    大人可防问/击装后重新对标定视紫质/表\n变化，滴平消毒湿润后，进入原收集\n\n【4】    六、角膜设备清洁删除12:<u>删除14:<u>[33,34]</u></u>\n1.直接触患者眼检查器械包括镜片，包括手持对\n裂胶灯镜头镜，包括非接触脱炎针，非接触眼压计, OCT 检查仪等，可使用75%乙醇30s 过程化复灭 \n球表。\n\n【5】  2.接触类眼科检查器械清洁在：在使用过程中视\n  压手眼内干；前房角镜、三面镜和相关检查器械\n  科检查器械，应用单用染预防性湿润进行消毒\n\n【6】甲详细清洁水（大水水力冲洗 2-3 min 。有可用） \n用户\n电指定的消毒液清洗浸泡老生抗生有发滴乀整即可  ，此外须预留\n\n【7】删除32:<u>**</u>全面生活保护入干洗道筋处理呈区局防湿泵白\n    亲音科艳异用坚升问设备清浸剂潜连汎，继续临\n洗清润灭裂作用清洁解手和康。】\n 进行清洁删除32:<u>**</u>\n\n【8】[表参水浴提请]\n 麻下午以上", "tags": {}, "lang": "zh", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/中国婴幼儿全身麻醉下眼病检查专家共识（2022年）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:5\n\n中国婴幼儿全身麻醉下眼病检查专家共识（2022年）\n\n紫质眼病，做好清洁及取分类处理。查看标定\n\n结束并打开的检查结果。\n\n【1】  ①注意事项：a. 行 PVEP 检查在高度散大瞳孔和\n\n新生视力者双眼佩戴不同眼罩; b.注意无替代假\n\n护镜、手套; c.确保试验每次递增体持续超时间\n\n【2】    ③ 居平体感得益用。\n\n【3】  二、表\n\n大人可防问/击装后重新对标定视紫质/表\n\n变化，滴平消毒湿润后，进入原收集\n\n【4】    六、角膜设备清洁删除12:删除14:[33,34]\n\n1.直接触患者眼检查器械包括镜片，包括手持对\n\n裂胶灯镜头镜，包括非接触脱炎针，非接触眼压计, OCT 检查仪等，可使用75%乙醇30s 过程化复灭\n\n球表。\n\n【5】  2.接触类眼科检查器械清洁在：在使用过程中视\n\n压手眼内干；前房角镜、三面镜和相关检查器械\n\n科检查器械，应用单用染预防性湿润进行消毒\n\n【6】甲详细清洁水（大水水力冲洗 2-3 min 。有可用）\n\n用户\n\n电指定的消毒液清洗浸泡老生抗生有发滴乀整即可  ，此外须预留\n\n【7】删除32:全面生活保护入干洗道筋处理呈区局防湿泵白\n\n亲音科艳异用坚升问设备清浸剂潜连汎，继续临\n\n洗清润灭裂作用清洁解手和康。】\n\n进行清洁删除32:\n\n【8】[表参水浴提请]\n\n麻下午以上", "content": "【0】页码:5\n中国婴幼儿全身麻醉下眼病检查专家共识（2022年）\n紫质眼病，做好清洁及取分类处理。查看标定\n结束并打开的检查结果。\n\n【1】  ①注意事项：a. 行 PVEP 检查在高度散大瞳孔和\n新生视力者双眼佩戴不同眼罩; b.注意无替代假\n护镜、手套; c.确保试验每次递增体持续超时间\n\n【2】    ③ 居平体感得益用。  \n\n【3】  二、表\n大人可防问/击装后重新对标定视紫质/表\n变化，滴平消毒湿润后，进入原收集\n\n【4】    六、角膜设备清洁删除12:<u>删除14:<u>[33,34]</u></u>\n1.直接触患者眼检查器械包括镜片，包括手持对\n裂胶灯镜头镜，包括非接触脱炎针，非接触眼压计, OCT 检查仪等，可使用75%乙醇30s 过程化复灭 \n球表。\n\n【5】  2.接触类眼科检查器械清洁在：在使用过程中视\n  压手眼内干；前房角镜、三面镜和相关检查器械\n  科检查器械，应用单用染预防性湿润进行消毒\n\n【6】甲详细清洁水（大水水力冲洗 2-3 min 。有可用） \n用户\n电指定的消毒液清洗浸泡老生抗生有发滴乀整即可  ，此外须预留\n\n【7】删除32:<u>**</u>全面生活保护入干洗道筋处理呈区局防湿泵白\n亲音科艳异用坚升问设备清浸剂潜连汎，继续临\n洗清润灭裂作用清洁解手和康。】\n 进行清洁删除32:<u>**</u>\n\n【8】[表参水浴提请]\n 麻下午以上", "index": 0, "show": true, "start": 0, "end": 578, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "与原文不一致，缺少内容"}], "startTime": "2024/08/06 16:10:13", "endTime": "2024/08/06 16:10:56", "cost": 42.108}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:10:56", "grab_time": "2024-08-06 00:10:13"}
{"id": 2211560, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "9261a144-f79c-4c21-bdc0-d6cd80141789", "title": "（2023.V2）NCCN临床实践指南：骨癌", "text": "【0】页码:76\n（2023.V2）NCCN临床实践指南：骨癌\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】疑似页眉<u>### NCCN Guidelines Version 2.2023: Bone Cancer</u>\n\n【2】参考删除-3:<u>40. Ashford RU, McCarthy SW, Scolyer RA, et al. Surgical biopsy with intra-operative frozen section. An accurate and cost-effective method for diagnosis of musculoskeletal sarcomas. J Bone Joint Surg Br 2006;88:1207-1211删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/16943474]</u>.</u></u>\n\n【3】参考删除-3:<u>41. Skrzynski MC, Biermann JS, Montag A, Simon MA. Diagnostic accuracy and charge-savings of outpatient core needle biopsy compared with open biopsy of musculoskeletal tumors. J Bone Joint Surg Am 1996;78:644-649删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/8642019]</u>.</u></u>\n\n【4】参考删除-3:<u>42. Welker JA, Henshaw RM, Jelinek JJ, et al. The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses. Cancer 2000;89:2677-2686删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/11135231]</u>.</u></u>\n\n【5】参考删除-3:<u>43. Mitsuyoshi G, Naito N, Kawai A, et al. Accurate diagnosis of musculoskeletal lesions by core needle biopsy. J Surg Oncol 2006;94:21-27删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/16788939]</u>.</u></u>\n\n【6】参考删除-3:<u>44. Adams SC, Potter BK, Pitcher DJ, Temple HT. Office-based core needle biopsy of bone and soft tissue malignancies: an accurate alternative to open biopsy with infrequent complications. Clin Orthop Relat Res 2010;468:2774-2780删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/20582496]</u>.</u></u>\n\n【7】参考删除-3:<u>45. Rimondi E, Rossi G, Bartalena T, et al. Percutaneous CT-guided biopsy of the musculoskeletal system: results of 2027 cases. Eur J Radiol 2011;77:34-42删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/20832220]</u>.</u></u>\n\n【8】参考删除-3:<u>46. Googan A, Path MRC, Munk PL. Image-guided musculoskeletal biopsy. Radiol Clin North Am 2008;46:455-473, v删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/18707857]</u>.</u></u>\n\n【9】参考删除-3:<u>47. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 1996;78:656-663删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/8642021]</u>.</u></u>\n\n【10】参考删除-3:<u>48. Davies NM, Livesley PJ, Cannon SR. Recurrence of osteosarcoma in a needle biopsy track. J Bone Joint Surg Br 1993;75:977-978删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/8245097]</u>.</u></u>\n\n【11】参考删除-3:<u>49. Saghieh S, Masrouha KZ, Musallam KM, et al. The risk of local recurrence along the core-needle biopsy tract in patients with bone sarcomas. Iowa Orthop J 2010;30:80-83删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/21045976]</u>.</u></u>\n\n【12】参考删除-3:<u>50. Seeger LL. Revisiting tract seeding and compartmental anatomy for percutaneous image-guided musculoskeletal biopsies. Skeletal Radiol 2019;48:499-501删除1:<u>. Available at: 删除24:<u>[https://pubmed.ncbi.nlm.nih.gov/30613392/]</u>.</u></u>\n\n【13】参考删除-3:<u>51. Yang YJ, Damron TA. Comparison of needle core biopsy and fine-needle aspiration for diagnostic accuracy in musculoskeletal lesions. Arch Pathol Lab Med 2004;128:759-764删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/15214827]</u>.</u></u>\n\n【14】参考删除-3:<u>52. Patel S, Delaney TF. Advanced-technology radiation therapy for bone sarcomas. Cancer Control 2008;15:21-37删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/18094658]</u>.</u></u>\n\n【15】参考删除-3:<u>53. McGovern SL, Mahajan A. Progress in radiotherapy for pediatric sarcomas. Curr Oncol Rep 2012;14:320-326删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/22532264]</u>.</u></u>\n\n【16】参考删除-3:<u>54. Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008;13:320-329删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/18378543]</u>.</u></u>\n\n【17】参考删除-3:<u>55. Riedel RF, Larrier N, Dodd L, et al. The clinical management of chondrosarcoma. Curr Treat Options Oncol 2009;10:94-106删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/19238552]</u>.</u></u>\n\n【18】参考删除-3:<u>56. Mankin HJ, Cantelar KP, Schiller AL, Lippiello L. The biology of human chondrosarcoma. I1. Variation in chemical composition among types and subtypes of benign and malignant cartilage tumors. J Bone Joint Surg Am 1980;62:176-188删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/7358749]</u>.</u></u>\n\n【19】参考删除-3:<u>57. Nicolae A, Pfander D, Gomez-Brouchet A, et al. Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression. Nat Commun 2019;10:4622删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/31604942]</u>.</u></u>\n\n【20】参考删除-3:<u>58. Chow W, Frankel P, Ruel C, et al. Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma. Cancer 2020;126:105-111删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/31509242]</u>.</u></u>", "tags": {}, "lang": "en", "attr": {"page_num": 76, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V2）NCCN临床实践指南：骨癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:01:17", "endTime": "2024/08/06 16:01:23", "cost": 5.377}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:01:23", "grab_time": "2024-08-06 00:01:17"}
{"id": 2211559, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "145cc19b-e45b-4739-b72e-50166050880f", "title": "2023 ACC／AHA／ASE／ASNC／ASPC／HFSA／HRS／SCAI／SCCT／SCMR／STS报告：慢性冠状动脉疾病的检测和风险评估的多模态适当使用标准", "text": "【0】页码:17\n2023 ACC／AHA／ASE／ASNC／ASPC／HFSA／HRS／SCAI／SCCT／SCMR／STS报告：慢性冠状动脉疾病的检测和风险评估的多模态适当使用标准\nand prior chemotherapy with vasotoxicity potential are included as additional considerations. The reason for these changes was to better align recommendations for CCD testing with the patient groups described in the clinical guidelines on prevention and the management of blood cholesterol.\n\n【1】The remainder of the tables, Tables 2.2, 2.3, and 2.4, include a few additional clinical scenarios closing potential gaps in the prior AUC and acknowledging ongoing changes in clinical practice. In Table 2.2, scenarios have been added for assessing graft patency before redo sternotomy, for viability assessment, and for management of patient with or at risk for silent ischemia. Table 2.3 now provides recommendations for unsupervised exercise prescriptions in patients with and without known heart disease. Last, Table 2.4 adds guidance on screening for transplant vasculopathy, testing in new paroxysmal sustained VT and atrial flutter, and a new heading for cardio-oncology and assessment of patients with a history of chest radiation. This table includes scenarios for syncope that have changed to align this AUC document with the 2017 ACC/AHA/HRS syncope guideline, which provides recommendations for cardiovascular testing based on history, physical examination, and ECG.\n\n【2】Because of these changes to the clinical scenarios, it is difficult to compare the ratings for individual scenarios and tests with those in prior documents 删除9:<u>(Table 1.1)</u>. Substantial changes to scenarios for the assessment of patients with prior testing and prior MI/revascularization make comparisons to the prior document immaterial 删除9:<u>(Tables 1.2 and 1.3)</u>. Although patients without symptoms in Table 2.1 are categorized in a different fashion than in the 2013 document, the rating panel felt that most testing is not likely warranted for these patients. One exception is CAC scoring, which has greater support across the spectrum of risk. Ratings in Tables 2.2 and 2.3 are largely unchanged. In Table 2.4 of this document, many of the scenario ratings are identical to those from 2013. Testing in the setting of new-onset atrial fibrillation is generally considered rarely appropriate in this document, whereas some test options were previously rated as may be appropriate.\n\n【3】删除32:<u>**</u>Future Directions删除32:<u>**</u>\n\n【4】The ACC is well into 2 decades of publishing AUC to help guide clinicians on appropriateness of tests and procedures for patients. We anticipate that these documents will continue to play an important role in day-to-day practice and may soon have a larger role in measuring quality at a health system level and through societal clinical registries. Current decision-support systems are often difficult to navigate, and we are hopeful that electronic health record vendors will continue to work on strategies to implement AUC in a way that automatically gathers relevant data for making appropriateness determinations. At present, administrative data lack the clinical granularity necessary to capture the relevant details of clinical scenarios to apply appropriateness criteria. In the future, patient-reported symptom profiles may help enhance the patient voice and further automate the process.\n\n【5】删除32:<u>**</u>Limitations删除32:<u>**</u>\n\n【6】As with all previous versions of the AUC, there are limitations to the exercise of trying to simplify myriad patient presentations to a brief list of clinical scenarios. Some patients will inevitably not fit the precise definitions provided. The time scale for drafting and revising such documents means the recommendations will inherently lag behind published evidence. For example, work on developing the clinical scenarios and rating the test options preceded the publication of recent chest pain guidelines as well as the pending chronic coronary disease management guidelines by multiple years. Although the writing group worked internally with the ACC to eliminate any disagreements with these documents, they could not be inherently part of the development of these AUC. The ACC is developing new strategies to \"chunk\" guidelines and other documents so that they will be easier to update on a shorter timetable.\n\n【7】删除32:<u>**</u>9. CONCLUSIONS删除32:<u>**</u>\n\n【8】The 2023 AUC for multimodality imaging in CCD has been substantially revised in an effort to make application easier and more closely aligned to how clinical decisions are made in practice. Special attention has been paid to aligning this document with clinical practice guidelines and contemporary scientific studies. Several innovations have been introduced, most notably a column of ratings for \"no test,\" reinforcing the concept that not every patient encounter warrants cardiovascular testing.\n\n【9】删除32:<u>**</u>ACC PRESIDENT AND STAFF删除32:<u>**</u>\n\n【10】B. Hadley Wilson, MD, FACC, President  \nCathy C. Gates, Chief Executive Officer  \nJoseph M. Allen, MA, Team Lead, Clinical Standards and Solution Sets  \nAmy Dearborn, Team Lead, Clinical Policy Content Development  \nMaría Velásquez, Project Manager, Appropriate Use Criteria  \nGrace Ronan, Team Lead, Clinical Policy Publications", "tags": {}, "lang": "en", "attr": {"page_num": 17, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ACC／AHA／ASE／ASNC／ASPC／HFSA／HRS／SCAI／SCCT／SCMR／STS报告：慢性冠状动脉疾病的检测和风险评估的多模态适当使用标准.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【9】删除32:ACC PRESIDENT AND STAFF删除32:\n\n【10】B. Hadley Wilson, MD, FACC, President\n\nCathy C. Gates, Chief Executive Officer\n\nJoseph M. Allen, MA, Team Lead, Clinical Standards and Solution Sets\n\nAmy Dearborn, Team Lead, Clinical Policy Content Development\n\nMaría Velásquez, Project Manager, Appropriate Use Criteria\n\nGrace Ronan, Team Lead, Clinical Policy Publications", "content": "【0】页码:17\n2023 ACC／AHA／ASE／ASNC／ASPC／HFSA／HRS／SCAI／SCCT／SCMR／STS报告：慢性冠状动脉疾病的检测和风险评估的多模态适当使用标准\nand prior chemotherapy with vasotoxicity potential are included as additional considerations. The reason for these changes was to better align recommendations for CCD testing with the patient groups described in the clinical guidelines on prevention and the management of blood cholesterol.\n\n【1】The remainder of the tables, Tables 2.2, 2.3, and 2.4, include a few additional clinical scenarios closing potential gaps in the prior AUC and acknowledging ongoing changes in clinical practice. In Table 2.2, scenarios have been added for assessing graft patency before redo sternotomy, for viability assessment, and for management of patient with or at risk for silent ischemia. Table 2.3 now provides recommendations for unsupervised exercise prescriptions in patients with and without known heart disease. Last, Table 2.4 adds guidance on screening for transplant vasculopathy, testing in new paroxysmal sustained VT and atrial flutter, and a new heading for cardio-oncology and assessment of patients with a history of chest radiation. This table includes scenarios for syncope that have changed to align this AUC document with the 2017 ACC/AHA/HRS syncope guideline, which provides recommendations for cardiovascular testing based on history, physical examination, and ECG.\n\n【2】Because of these changes to the clinical scenarios, it is difficult to compare the ratings for individual scenarios and tests with those in prior documents 删除9:<u>(Table 1.1)</u>. Substantial changes to scenarios for the assessment of patients with prior testing and prior MI/revascularization make comparisons to the prior document immaterial 删除9:<u>(Tables 1.2 and 1.3)</u>. Although patients without symptoms in Table 2.1 are categorized in a different fashion than in the 2013 document, the rating panel felt that most testing is not likely warranted for these patients. One exception is CAC scoring, which has greater support across the spectrum of risk. Ratings in Tables 2.2 and 2.3 are largely unchanged. In Table 2.4 of this document, many of the scenario ratings are identical to those from 2013. Testing in the setting of new-onset atrial fibrillation is generally considered rarely appropriate in this document, whereas some test options were previously rated as may be appropriate.\n\n【3】删除32:<u>**</u>Future Directions删除32:<u>**</u>\n\n【4】The ACC is well into 2 decades of publishing AUC to help guide clinicians on appropriateness of tests and procedures for patients. We anticipate that these documents will continue to play an important role in day-to-day practice and may soon have a larger role in measuring quality at a health system level and through societal clinical registries. Current decision-support systems are often difficult to navigate, and we are hopeful that electronic health record vendors will continue to work on strategies to implement AUC in a way that automatically gathers relevant data for making appropriateness determinations. At present, administrative data lack the clinical granularity necessary to capture the relevant details of clinical scenarios to apply appropriateness criteria. In the future, patient-reported symptom profiles may help enhance the patient voice and further automate the process.\n\n【5】删除32:<u>**</u>Limitations删除32:<u>**</u>\n\n【6】As with all previous versions of the AUC, there are limitations to the exercise of trying to simplify myriad patient presentations to a brief list of clinical scenarios. Some patients will inevitably not fit the precise definitions provided. The time scale for drafting and revising such documents means the recommendations will inherently lag behind published evidence. For example, work on developing the clinical scenarios and rating the test options preceded the publication of recent chest pain guidelines as well as the pending chronic coronary disease management guidelines by multiple years. Although the writing group worked internally with the ACC to eliminate any disagreements with these documents, they could not be inherently part of the development of these AUC. The ACC is developing new strategies to \"chunk\" guidelines and other documents so that they will be easier to update on a shorter timetable.\n\n【7】删除32:<u>**</u>9. CONCLUSIONS删除32:<u>**</u>\n\n【8】The 2023 AUC for multimodality imaging in CCD has been substantially revised in an effort to make application easier and more closely aligned to how clinical decisions are made in practice. Special attention has been paid to aligning this document with clinical practice guidelines and contemporary scientific studies. Several innovations have been introduced, most notably a column of ratings for \"no test,\" reinforcing the concept that not every patient encounter warrants cardiovascular testing.\n\n【9】删除32:<u>**</u>ACC PRESIDENT AND STAFF删除32:<u>**</u>\n\n【10】B. Hadley Wilson, MD, FACC, President  \nCathy C. Gates, Chief Executive Officer  \nJoseph M. Allen, MA, Team Lead, Clinical Standards and Solution Sets  \nAmy Dearborn, Team Lead, Clinical Policy Content Development  \nMaría Velásquez, Project Manager, Appropriate Use Criteria  \nGrace Ronan, Team Lead, Clinical Policy Publications", "index": 4835, "show": true, "start": 4835, "end": 5201, "province": ["文本干净度", "无关文本"], "isEdit": false}], "startTime": "2024/08/07 09:25:30", "endTime": "2024/08/07 09:34:17", "cost": 526.187}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 17:34:14", "grab_time": "2024-08-06 02:20:24"}
{"id": 2211558, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "daa488e0-ec02-4954-83af-3aa82bed8b21", "title": "糖皮质激素治疗新型冠状病毒感染时的血糖管理共识", "text": "【0】页码:5\n糖皮质激素治疗新型冠状病毒感染时的血糖管理共识\n氢化可的松在糖尿病患者中的应用\n\n【1】综述：糖皮质激素（如氢化可的松）在糖尿病患者中的应用存在争议。本文分析了糖皮质激素的使用可能对糖尿病患者产生的影响。\n\n【2】删除32:<u>**</u>1. 糖皮质激素的机制删除32:<u>**</u>\n\n【3】糖皮质激素通过与糖皮质激素受体结合，调节基因表达，从而发挥其抗炎和免疫抑制作用。然而，它们也会影响糖代谢，增加糖尿病患者的血糖水平。\n\n【4】删除32:<u>**</u>2. 糖皮质激素对糖尿病患者的影响删除32:<u>**</u>\n\n【5】研究表明，糖皮质激素治疗可导致糖尿病患者的血糖水平显著升高，增加糖尿病并发症的风险。因此，在使用糖皮质激素时，需密切监测血糖水平，并调整降糖药物的剂量。\n\n【6】删除32:<u>**</u>表1. 糖皮质激素对糖尿病患者的影响删除32:<u>**</u>\n\n| 研究 | 样本量 | 糖皮质激素类型 | 主要发现 |\n| --- | --- | --- | --- |\n| Sinha et al. 删除11:<u>删除19:<u>(2022)</u></u> | 50 | 氢化可的松 | 显著增加血糖水平 |\n| Wu et al. 删除11:<u>删除19:<u>(2020)</u></u> | 100 | 地塞米松 | 糖尿病并发症风险增加 |\n| Morelli et al. 删除11:<u>删除19:<u>(2020)</u></u> | 75 | 泼尼松 | 血糖水平波动 |\n\n【8】删除32:<u>**</u>3. 临床建议删除32:<u>**</u>\n\n【9】对于需要使用糖皮质激素的糖尿病患者，应制定个体化治疗方案，综合考虑糖尿病的类型、患者的具体情况以及糖皮质激素的剂量和使用时间。定期监测血糖水平，必要时调整降糖药物。\n\n【10】删除32:<u>**</u>结论删除32:<u>**</u>\n\n【11】糖皮质激素在糖尿病患者中的应用需要慎重。通过合理的个体化治疗方案，可以减轻糖皮质激素对糖尿病患者的不良影响，提高治疗效果。", "tags": {}, "lang": "zh", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/糖皮质激素治疗新型冠状病毒感染时的血糖管理共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】", "content": "【0】页码:5\n糖皮质激素治疗新型冠状病毒感染时的血糖管理共识\n氢化可的松在糖尿病患者中的应用\n\n【1】综述：糖皮质激素（如氢化可的松）在糖尿病患者中的应用存在争议。本文分析了糖皮质激素的使用可能对糖尿病患者产生的影响。\n\n【2】删除32:<u>**</u>1. 糖皮质激素的机制删除32:<u>**</u>\n\n【3】糖皮质激素通过与糖皮质激素受体结合，调节基因表达，从而发挥其抗炎和免疫抑制作用。然而，它们也会影响糖代谢，增加糖尿病患者的血糖水平。\n\n【4】删除32:<u>**</u>2. 糖皮质激素对糖尿病患者的影响删除32:<u>**</u>\n\n【5】研究表明，糖皮质激素治疗可导致糖尿病患者的血糖水平显著升高，增加糖尿病并发症的风险。因此，在使用糖皮质激素时，需密切监测血糖水平，并调整降糖药物的剂量。\n\n【6】删除32:<u>**</u>表1. 糖皮质激素对糖尿病患者的影响删除32:<u>**</u>\n\n| 研究 | 样本量 | 糖皮质激素类型 | 主要发现 |\n| --- | --- | --- | --- |\n| Sinha et al. 删除11:<u>删除19:<u>(2022)</u></u> | 50 | 氢化可的松 | 显著增加血糖水平 |\n| Wu et al. 删除11:<u>删除19:<u>(2020)</u></u> | 100 | 地塞米松 | 糖尿病并发症风险增加 |\n| Morelli et al. 删除11:<u>删除19:<u>(2020)</u></u> | 75 | 泼尼松 | 血糖水平波动 |\n\n【8】删除32:<u>**</u>3. 临床建议删除32:<u>**</u>\n\n【9】对于需要使用糖皮质激素的糖尿病患者，应制定个体化治疗方案，综合考虑糖尿病的类型、患者的具体情况以及糖皮质激素的剂量和使用时间。定期监测血糖水平，必要时调整降糖药物。\n\n【10】删除32:<u>**</u>结论删除32:<u>**</u>\n\n【11】糖皮质激素在糖尿病患者中的应用需要慎重。通过合理的个体化治疗方案，可以减轻糖皮质激素对糖尿病患者的不良影响，提高治疗效果。", "index": 0, "show": true, "start": 0, "end": 3, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "PDF中为参考文献内容"}], "startTime": "2024/08/06 17:03:04", "endTime": "2024/08/06 17:03:32", "cost": 27.657}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 01:03:32", "grab_time": "2024-08-06 01:03:04"}
{"id": 2211557, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "3e0edea8-4bdb-401d-9b9b-a6d7ad314312", "title": "中枢神经系统肿瘤_2023.V1_EN (2)", "text": "【0】页码:144\n中枢神经系统肿瘤_2023.V1_EN (2)\n疑似页眉<u>NCCN Guidelines Version 1.2023\nCentral Nervous System Cancers</u>\n\n【1】MET exon 14 skipping mutations are present in 3% to 4% of patients with NSCLC.删除17:<u>549-551</u> A phase 2 study of the MET inhibitor capmatinib showed a 53.8% intracranial response rate in 13 patients with NSCLC with a MET exon14 skipping mutation and brain metastases.删除17:<u>552</u>\n\n【2】RET Inhibitors\nRET fusions are found in 1% to 2% of patients with NSCLC.删除17:<u>553,554</u> In the phase I/II LIBRETTO-001 trial, treatment with the RET inhibitor selpercatinib was evaluated in 80 patients with brain metastases.删除17:<u>555</u> Intracranial PFS was 13.7 months. An intracranial ORR of 82% in 22 patients with measurable CNS-involved disease at baseline was observed, with complete responses in 23%. Among 38 intracranial responders, median duration of intracranial response was not reached.\n\n【3】Other Systemic Therapy Options\nA phase I/II study of topotecan plus WBRT has shown a 72% response rate in 75 patients with brain metastases.删除17:<u>556</u> Unfortunately, a follow-up phase III trial including only patients with brain metastases from lung cancer was closed early due to slow accrual.删除17:<u>557</u>\n\n【4】Breast Cancer\nCapecitabine combined with a number of agents has been evaluated in patients with brain metastases from HER2-positive breast cancer. Capecitabine combined with the TKI lapatinib for patients with brain metastases from HER2-positive breast cancer is supported by a systematic review and pooled analysis showing an ORR of 29.2%, a disease control rate of 65.1%, and a 2-year OS rate of 33.4%.删除17:<u>558</u>\n\n【5】In the HER2CLIMB phase III trial, patients with HER2-positive metastatic breast cancer who were previously treated with HER2-directed therapy (N = 612) were randomized to receive trastuzumab and capecitabine combined with either the TKI tucatinib or a placebo.删除17:<u>559</u> Among the patients with brain metastases at baseline (47.5% of the sample), both PFS (HR, 0.46; 95% CI, 0.31–0.67) and OS (HR, 0.58; 95% CI, 0.40–0.85) were superior in the tucatinib arm. The estimated 1-year PFS was 24.9% for these patients who received tucatinib, compared to 0% in patients who received the placebo, with duration of PFS being 7.6 months and 5.4 months, respectively. Exploratory analyses of 291 patients with brain metastases showed that both CNS PFS 删除19:<u>(HR, 0.36; 95% CI, 0.22–0.57; P <.00001)</u> and OS (HR, 0.49; 95% CI, 0.30–0.80; P = .004) were significantly greater in patients who received tucatinib, compared to patients who received the placebo.删除17:<u>560</u> Based on study results, the FDA approved tucatinib in combination with trastuzumab and capecitabine in 2020 for patients with advanced unresectable or metastatic HER2-positive breast cancer (including patients with brain metastases) who were previously treated with HER2-directed therapy.\n\n【6】A phase II study supports use of capecitabine combined with the TKI neratinib in patients with CNS metastases from HER2-positive breast cancer.删除17:<u>561</u> CNS metastases in most of the patients were previously treated with surgery or RT. Results from this study helped inform development of the phase III NALA trial, in which patients with HER2-positive metastatic breast cancer who received at least 2 lines of HER2-directed therapy were randomized to receive capecitabine and neratinib or capecitabine and lapatinib (N = 621).删除17:<u>562</u> Patients in the capecitabine/neratinib arm had superior PFS compared to those in the capecitabine/lapatinib arm (HR, 0.76; 95% CI, 0.63–0.93; P = .006), though there was no OS advantage. Further, patients who received capecitabine/neratinib were less likely to have required intervention for symptomatic CNS metastases than patients in the capecitabine/lapatinib arm (22.8% vs. 29.2%, respectively; P = .043). Subgroup analyses of 101 patients who had known CNS metastases at baseline showed that mean PFS through 24 months was greater in the capecitabine/neratinib arm (7.8 months) than in the capecitabine/lapatinib arm (5.5 months), but this result did not reach statistical significance (HR, 0.66; 95% CI, 0.41–1.05; P = .074).删除17:<u>563</u> Among", "tags": {}, "lang": "en", "attr": {"page_num": 144, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/中枢神经系统肿瘤_2023.V1_EN (2).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:01:39", "endTime": "2024/08/06 17:02:05", "cost": 25.667}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 01:02:05", "grab_time": "2024-08-06 01:01:39"}
{"id": 2211556, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "3edd204a-394f-4c86-a987-7d67d5dc7447", "title": "WHO：疟疾指南（2022）", "text": "【0】页码:24\nWHO：疟疾指南（2022）\nwas first elucidated in the late 19th and early 20th centuries. Since effective vaccines or drugs were not always available for the prevention or treatment of these diseases, control of transmission often had to rely principally on control of the vector. Early control activities included the screening of houses, the use of mosquito nets, the drainage or filling of swamps and other water bodies used by insects for breeding, and the application of oil or Paris green to breeding places. Following the discovery of the insecticidal properties of dichlorodiphenyltrichloroethane (DDT) in the 1940s and subsequent discovery of other insecticides, the focus of malaria vector control shifted to the deployment of insecticides to target both the larval and adult stages of mosquito vectors.\n\n【1】Nowadays, it is well established that effective vector control programmes can make a major contribution to advancing human and economic development. Aside from direct health benefits, reductions in vector-borne diseases enable greater productivity and growth, reduce household poverty, increase equity and women’s empowerment, and strengthen health systems 删除11:<u>(12)</u>. Despite the clear evidence in broad support of vector control efforts, the major vector-borne diseases combined still account for around 17% of the estimated global burden of communicable diseases, claiming more than 700 000 lives every year 删除11:<u>(13)</u>. Recognizing the great potential to enhance efforts in this area, WHO led the development of the Global vector control response 2017–2030 删除11:<u>(13)</u>, which is outlined in the subsequent section.\n\n【2】The control of malaria, unlike that of most other vector-borne diseases, saw a major increase in financial resources from 2000 to about 2010, leading to a significant reduction in the global burden. However, since 2010, total malaria funding has largely stagnated. Moreover, the funding gap between the amount invested and the resources needed has continued to widen significantly in recent years, largely as a result of population growth and the need to switch to more expensive tools. This gap increased from US$ 1.3 billion in 2017 to US$ 2.3 billion in 2018, and to US$ 2.6 billion in 2019 删除11:<u>(3)</u>.\n\n【3】Between 2000 and 2015, the infection prevalence of 删除32:<u>*</u>Plasmodium falciparum删除32:<u>*</u> in endemic Africa was halved and the incidence of clinical disease fell by 40% 删除11:<u>(14)</u>. Malaria control interventions averted an estimated 663 million (credible interval (CI): 542–753 million) clinical cases in Africa, with ITNs making the largest contribution (68% of cases averted). Indoor residual spraying (IRS) contributed an estimated 13% (11–16%), with a larger proportional contribution where intervention coverage was high 删除11:<u>(14)</u>.\n\n【4】### Global vector control response 2017–2030\n\n【5】The vision of WHO and the broader infectious diseases community is a world free of human suffering from vector-borne diseases. In 2017, the World Health Assembly welcomed the Global vector control response 2017–2030 删除11:<u>(13)</u> (GVCR) and adopted a resolution to promote an integrated approach to the control of vector-borne diseases. The approach builds on the concept of integrated vector management (IVM), but with renewed focus on improving human capacity, strengthening infrastructure and systems, improved surveillance, and better coordination and integrated action across sectors and diseases.\n\n【6】The ultimate aim of the GVCR is to reduce the burden and threat of vector-borne diseases through effective, locally adapted, sustainable vector control in full alignment with Sustainable Development Goal 3.3: to end epidemics of malaria by 2030. The 2030 targets are: to reduce mortality due to vector-borne diseases globally by at least 75% 删除19:<u>(relative to 2016)</u>; to reduce case incidence due to vector-borne diseases globally by at least 60% 删除19:<u>(relative to 2016)</u>; and to prevent epidemics of vector-borne diseases in all countries. Detailed national and regional priority activities and associated interim targets for 2017–2020 have also been defined.\n\n【7】Priority activities set out in the GVCR fall within four pillars that are underpinned by two foundational elements:\n\n【8】#### Pillars of action:\n\n【9】- Strengthen inter- and intra-sectoral action and collaboration.\n- Engage and mobilize communities.\n- Enhance vector surveillance, monitoring and evaluation of interventions.\n- Scale up and integrate tools and approaches.\n\n【10】#### Foundations:\n\n【11】- Enhance vector control capacity and capability.\n- Increase basic and applied research, and innovation.\n\n【12】Effective and sustainable vector control is achievable only with sufficient human resources, an enabling infrastructure and a functional health system. National programmes should lead a vector control needs assessment across the relevant sectors 删除11:<u>(15)</u> to help appraise current capacity, define the requisite capacity to conduct proposed activities, identify opportunities for improved efficiency in vector control delivery, and guide resource mobilization to implement the national strategic plan.\n\n【13】In some settings, vector control interventions have the potential to reduce transmission and disease burden of more than one disease. Examples include the deployment of ITNs against malaria and lymphatic filariasis (in settings where 删除32:<u>*</u>Anopheles删除32:<u>*</u> mosquitoes are the principal vector), against malaria and leishmaniasis in India, and larval control for malaria and dengue vectors in cities with particular vector habitats. With the recently documented invasion of 删除32:<u>*</u>Anopheles stephensi删除32:<u>*</u> in the Horn of Africa, the integrated surveillance and control of this vector alongside 删除32:<u>*</u>Aedes删除32:<u>*</u> provides a clear opportunity for GVCR implementation. More approaches effective against 删除32:<u>*</u>Aedes spp.删除32:<u>*</u> mosquitoes generally have the potential to impact dengue, chikungunya, Zika virus disease and possibly yellow fever where their vectors and distributions overlap.\n\n【14】### Prevention, mitigation and management of insecticide resistance", "tags": {}, "lang": "en", "attr": {"page_num": 24, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WHO：疟疾指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "9】- Strengthen inter- and intra-sectoral action and collaboration.\n\nEngage and mobilize communities.\nEnhance vector surveillance, monitoring and evaluation of interventions.\nScale up and integrate tools and approaches.", "content": "【0】页码:24\nWHO：疟疾指南（2022）\nwas first elucidated in the late 19th and early 20th centuries. Since effective vaccines or drugs were not always available for the prevention or treatment of these diseases, control of transmission often had to rely principally on control of the vector. Early control activities included the screening of houses, the use of mosquito nets, the drainage or filling of swamps and other water bodies used by insects for breeding, and the application of oil or Paris green to breeding places. Following the discovery of the insecticidal properties of dichlorodiphenyltrichloroethane (DDT) in the 1940s and subsequent discovery of other insecticides, the focus of malaria vector control shifted to the deployment of insecticides to target both the larval and adult stages of mosquito vectors.\n\n【1】Nowadays, it is well established that effective vector control programmes can make a major contribution to advancing human and economic development. Aside from direct health benefits, reductions in vector-borne diseases enable greater productivity and growth, reduce household poverty, increase equity and women’s empowerment, and strengthen health systems 删除11:<u>(12)</u>. Despite the clear evidence in broad support of vector control efforts, the major vector-borne diseases combined still account for around 17% of the estimated global burden of communicable diseases, claiming more than 700 000 lives every year 删除11:<u>(13)</u>. Recognizing the great potential to enhance efforts in this area, WHO led the development of the Global vector control response 2017–2030 删除11:<u>(13)</u>, which is outlined in the subsequent section.\n\n【2】The control of malaria, unlike that of most other vector-borne diseases, saw a major increase in financial resources from 2000 to about 2010, leading to a significant reduction in the global burden. However, since 2010, total malaria funding has largely stagnated. Moreover, the funding gap between the amount invested and the resources needed has continued to widen significantly in recent years, largely as a result of population growth and the need to switch to more expensive tools. This gap increased from US$ 1.3 billion in 2017 to US$ 2.3 billion in 2018, and to US$ 2.6 billion in 2019 删除11:<u>(3)</u>.\n\n【3】Between 2000 and 2015, the infection prevalence of 删除32:<u>*</u>Plasmodium falciparum删除32:<u>*</u> in endemic Africa was halved and the incidence of clinical disease fell by 40% 删除11:<u>(14)</u>. Malaria control interventions averted an estimated 663 million (credible interval (CI): 542–753 million) clinical cases in Africa, with ITNs making the largest contribution (68% of cases averted). Indoor residual spraying (IRS) contributed an estimated 13% (11–16%), with a larger proportional contribution where intervention coverage was high 删除11:<u>(14)</u>.\n\n【4】### Global vector control response 2017–2030\n\n【5】The vision of WHO and the broader infectious diseases community is a world free of human suffering from vector-borne diseases. In 2017, the World Health Assembly welcomed the Global vector control response 2017–2030 删除11:<u>(13)</u> (GVCR) and adopted a resolution to promote an integrated approach to the control of vector-borne diseases. The approach builds on the concept of integrated vector management (IVM), but with renewed focus on improving human capacity, strengthening infrastructure and systems, improved surveillance, and better coordination and integrated action across sectors and diseases.\n\n【6】The ultimate aim of the GVCR is to reduce the burden and threat of vector-borne diseases through effective, locally adapted, sustainable vector control in full alignment with Sustainable Development Goal 3.3: to end epidemics of malaria by 2030. The 2030 targets are: to reduce mortality due to vector-borne diseases globally by at least 75% 删除19:<u>(relative to 2016)</u>; to reduce case incidence due to vector-borne diseases globally by at least 60% 删除19:<u>(relative to 2016)</u>; and to prevent epidemics of vector-borne diseases in all countries. Detailed national and regional priority activities and associated interim targets for 2017–2020 have also been defined.\n\n【7】Priority activities set out in the GVCR fall within four pillars that are underpinned by two foundational elements:\n\n【8】#### Pillars of action:\n\n【9】- Strengthen inter- and intra-sectoral action and collaboration.\n- Engage and mobilize communities.\n- Enhance vector surveillance, monitoring and evaluation of interventions.\n- Scale up and integrate tools and approaches.\n\n【10】#### Foundations:\n\n【11】- Enhance vector control capacity and capability.\n- Increase basic and applied research, and innovation.\n\n【12】Effective and sustainable vector control is achievable only with sufficient human resources, an enabling infrastructure and a functional health system. National programmes should lead a vector control needs assessment across the relevant sectors 删除11:<u>(15)</u> to help appraise current capacity, define the requisite capacity to conduct proposed activities, identify opportunities for improved efficiency in vector control delivery, and guide resource mobilization to implement the national strategic plan.\n\n【13】In some settings, vector control interventions have the potential to reduce transmission and disease burden of more than one disease. Examples include the deployment of ITNs against malaria and lymphatic filariasis (in settings where 删除32:<u>*</u>Anopheles删除32:<u>*</u> mosquitoes are the principal vector), against malaria and leishmaniasis in India, and larval control for malaria and dengue vectors in cities with particular vector habitats. With the recently documented invasion of 删除32:<u>*</u>Anopheles stephensi删除32:<u>*</u> in the Horn of Africa, the integrated surveillance and control of this vector alongside 删除32:<u>*</u>Aedes删除32:<u>*</u> provides a clear opportunity for GVCR implementation. More approaches effective against 删除32:<u>*</u>Aedes spp.删除32:<u>*</u> mosquitoes generally have the potential to impact dengue, chikungunya, Zika virus disease and possibly yellow fever where their vectors and distributions overlap.\n\n【14】### Prevention, mitigation and management of insecticide resistance", "index": 4314, "show": true, "start": 4314, "end": 4532, "province": ["格式规范性", "序号格式不一致"], "isEdit": false}, {"text": "【11】- Enhance vector control capacity and capability.\n\nIncrease basic and applied research, and innovation.", "content": "【0】页码:24\nWHO：疟疾指南（2022）\nwas first elucidated in the late 19th and early 20th centuries. Since effective vaccines or drugs were not always available for the prevention or treatment of these diseases, control of transmission often had to rely principally on control of the vector. Early control activities included the screening of houses, the use of mosquito nets, the drainage or filling of swamps and other water bodies used by insects for breeding, and the application of oil or Paris green to breeding places. Following the discovery of the insecticidal properties of dichlorodiphenyltrichloroethane (DDT) in the 1940s and subsequent discovery of other insecticides, the focus of malaria vector control shifted to the deployment of insecticides to target both the larval and adult stages of mosquito vectors.\n\n【1】Nowadays, it is well established that effective vector control programmes can make a major contribution to advancing human and economic development. Aside from direct health benefits, reductions in vector-borne diseases enable greater productivity and growth, reduce household poverty, increase equity and women’s empowerment, and strengthen health systems 删除11:<u>(12)</u>. Despite the clear evidence in broad support of vector control efforts, the major vector-borne diseases combined still account for around 17% of the estimated global burden of communicable diseases, claiming more than 700 000 lives every year 删除11:<u>(13)</u>. Recognizing the great potential to enhance efforts in this area, WHO led the development of the Global vector control response 2017–2030 删除11:<u>(13)</u>, which is outlined in the subsequent section.\n\n【2】The control of malaria, unlike that of most other vector-borne diseases, saw a major increase in financial resources from 2000 to about 2010, leading to a significant reduction in the global burden. However, since 2010, total malaria funding has largely stagnated. Moreover, the funding gap between the amount invested and the resources needed has continued to widen significantly in recent years, largely as a result of population growth and the need to switch to more expensive tools. This gap increased from US$ 1.3 billion in 2017 to US$ 2.3 billion in 2018, and to US$ 2.6 billion in 2019 删除11:<u>(3)</u>.\n\n【3】Between 2000 and 2015, the infection prevalence of 删除32:<u>*</u>Plasmodium falciparum删除32:<u>*</u> in endemic Africa was halved and the incidence of clinical disease fell by 40% 删除11:<u>(14)</u>. Malaria control interventions averted an estimated 663 million (credible interval (CI): 542–753 million) clinical cases in Africa, with ITNs making the largest contribution (68% of cases averted). Indoor residual spraying (IRS) contributed an estimated 13% (11–16%), with a larger proportional contribution where intervention coverage was high 删除11:<u>(14)</u>.\n\n【4】### Global vector control response 2017–2030\n\n【5】The vision of WHO and the broader infectious diseases community is a world free of human suffering from vector-borne diseases. In 2017, the World Health Assembly welcomed the Global vector control response 2017–2030 删除11:<u>(13)</u> (GVCR) and adopted a resolution to promote an integrated approach to the control of vector-borne diseases. The approach builds on the concept of integrated vector management (IVM), but with renewed focus on improving human capacity, strengthening infrastructure and systems, improved surveillance, and better coordination and integrated action across sectors and diseases.\n\n【6】The ultimate aim of the GVCR is to reduce the burden and threat of vector-borne diseases through effective, locally adapted, sustainable vector control in full alignment with Sustainable Development Goal 3.3: to end epidemics of malaria by 2030. The 2030 targets are: to reduce mortality due to vector-borne diseases globally by at least 75% 删除19:<u>(relative to 2016)</u>; to reduce case incidence due to vector-borne diseases globally by at least 60% 删除19:<u>(relative to 2016)</u>; and to prevent epidemics of vector-borne diseases in all countries. Detailed national and regional priority activities and associated interim targets for 2017–2020 have also been defined.\n\n【7】Priority activities set out in the GVCR fall within four pillars that are underpinned by two foundational elements:\n\n【8】#### Pillars of action:\n\n【<mark>9】- Strengthen inter- and intra-sectoral action and collaboration.\n\nEngage and mobilize communities.\nEnhance vector surveillance, monitoring and evaluation of interventions.\nScale up and integrate tools and approaches.</mark>ches.\n\n【10】#### Foundations:\n\n【11】- Enhance vector control capacity and capability.\n- Increase basic and applied research, and innovation.\n\n【12】Effective and sustainable vector control is achievable only with sufficient human resources, an enabling infrastructure and a functional health system. National programmes should lead a vector control needs assessment across the relevant sectors 删除11:<u>(15)</u> to help appraise current capacity, define the requisite capacity to conduct proposed activities, identify opportunities for improved efficiency in vector control delivery, and guide resource mobilization to implement the national strategic plan.\n\n【13】In some settings, vector control interventions have the potential to reduce transmission and disease burden of more than one disease. Examples include the deployment of ITNs against malaria and lymphatic filariasis (in settings where 删除32:<u>*</u>Anopheles删除32:<u>*</u> mosquitoes are the principal vector), against malaria and leishmaniasis in India, and larval control for malaria and dengue vectors in cities with particular vector habitats. With the recently documented invasion of 删除32:<u>*</u>Anopheles stephensi删除32:<u>*</u> in the Horn of Africa, the integrated surveillance and control of this vector alongside 删除32:<u>*</u>Aedes删除32:<u>*</u> provides a clear opportunity for GVCR implementation. More approaches effective against 删除32:<u>*</u>Aedes spp.删除32:<u>*</u> mosquitoes generally have the potential to impact dengue, chikungunya, Zika virus disease and possibly yellow fever where their vectors and distributions overlap.\n\n【14】### Prevention, mitigation and management of insecticide resistance", "index": 4575, "show": true, "start": 4562, "end": 4669, "province": ["格式规范性", "序号格式不一致"], "isEdit": false}], "startTime": "2024/08/06 16:40:11", "endTime": "2024/08/06 16:41:02", "cost": 50.594}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:12", "update_time": "2024-08-06 00:41:02", "grab_time": "2024-08-06 00:40:11"}
{"id": 2211555, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "45c8d88d-c456-4e1e-b35d-11328eeb98cc", "title": "【神经领域】中国脑卒中防治指导规范（2021年版）", "text": "【0】页码:483\n【神经领域】中国脑卒中防治指导规范（2021年版）\n升高、凝血酶原时间（PT）延长的ICH患者, 应停止服用VKA, 补充维生素K依赖的凝血因子, 并静脉应用维生素K（初始剂量10mg）。使用凝血酶原复合物（prothrombin complex concentrates，PCCs）比使用新鲜冷冻血浆（fresh frozen plasma，FFP）并发症更少，纠正INR更为迅速，可作为首选，推荐剂量为20～30IU/kg, 在特殊情况下可增加剂量至30～40IU/kg。重组活化凝血因子VIIa（recombinant activated coagulation factor VIIa, rFVIIa）尽管能降低INR值，但并不能完全纠正凝血异常, 不作为常规推荐。急性期在证据提示出血停止的情况下, 因机制性癫痫、深静脉血栓、肺栓塞等因素, 必须使用抗凝药物的患者, 可给予普通肝素或低分子肝素, 具体剂量由相关专科医师决定。脑出血后抗凝药物的恢复使用尚缺乏随机对照试验的证据, 在非机制性癫痫患者中, 至少在4周内避免口服抗凝药物；对于有机制性癫痫的患者, 德国口服抗凝药的相关脑出血多中心分析（geRman-widE mulTIcenter Analysis of oRal Anticoagulation-associated intraCerebral Hemorrhage, RETRACE）研究结果提示，出血后14天内开始使用抗凝药物会增加再出血概率, 但综合考虑出血及血栓形成风险，ICH后6天开始应用抗凝药物可能获益最佳。\n\n【1】（2）抗血小板药物的逆转：使用抗血小板药物的ICH患者在临床上比较常见，抗血小板药物的使用与出血血肿中的扩大和患者不良预后的相关性目前尚无定论。血凝阻抗集合同度测定可在10分钟内评估血小板功能，该检测系统对阿司匹林、氯吡格雷以及GPIIb/IIIa受体拮抗剂都敏感。对于血小板功能低下、血肿有扩大倾向或需急诊清除血肿的患者, 可从输入1U的单采血小板或5U的多采血小板，输入后能提供约20×10删除21:<u>^9-30</u>×10删除21:<u>^9</u>的血小板，出血后何时复用抗血小板药物，目前无定论。最近的重启或停止抗血栓随机研究（Restart or Stop Antithrombotics Randomised Trial，RESTART）研究提示，ICH发生最短天可开始阿司匹林药治疗。此外，复用抗血小板药物甚至可以预防脑出血的复发，这颠覆了人们以往的认知。\n\n【2】（3）新型抗凝药物的逆转: 对于服用达比加群、利伐沙班或阿哌沙班等新型抗凝药物的ICH患者, 各个化学修饰型第8因子旁路活性抑制剂（factor VIII inhibitor-bypassing activity, FEIBA）、PCCs或者rFVIIa治疗。如果患者在发病前2小时内服用过达比加群、利伐沙班或阿哌沙班, 可考虑使用活性炭。服用达比加群的患者还可考虑左旋布洛芬。", "tags": {}, "lang": "zh", "attr": {"page_num": 483, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【神经领域】中国脑卒中防治指导规范（2021年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:42:44", "endTime": "2024/08/06 15:43:16", "cost": 31.891}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:43:17", "grab_time": "2024-08-05 23:42:44"}
{"id": 2211554, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "6acc6f37-8d5f-4d0c-8187-b15d5ef5c609", "title": "（2023.V4）NCCN临床实践指南：B细胞淋巴瘤", "text": "【0】页码:123\n（2023.V4）NCCN临床实践指南：B细胞淋巴瘤\n疑似页眉<u># NCCN Guidelines Version 4.2023\n## B-Cell Lymphomas</u>\n\n### USE OF IMMUNOPHENOTYPING/GENETIC TESTING IN DIFFERENTIAL DIAGNOSIS OF MATURE B-CELL AND NK/T-CELL NEOPLASMS删除23:<u><sup>a</sup></u> (TO BE USED IN CONJUNCTION WITH CLINICAL AND MORPHOLOGIC CORRELATION)\n |删除段内换行|#### B-CELL NEOPLASMS\n\n【2】删除图片描述:<u>![](122_0.png) </u>\n\n【3】删除32:<u>*</u> Panel: CD3, CD5, CD10删除23:<u><sup>r</sup></u> BCL2, BCL6, IRF4/MUM1, CD21/23 (Follicular dendritic cell 删除12:<u>[FDC]</u> markers)\n\n【4】删除图片描述:<u>![](122_1.png)</u>\n#### PCFCL\n删除32:<u>*</u> BCL6+ \n删除32:<u>*</u> IRF4/MUM1- \n删除32:<u>*</u> (FDC+/-) \n删除32:<u>*</u> Small/medium/large cells \n删除32:<u>*</u> Many CD3+ cells\n\n【5】删除图片描述:<u>![](122_2.png)</u>\n#### PCMZL\n删除32:<u>*</u> BCL6- (positive GC) \n删除32:<u>*</u> IRF4/MUM1+/- \n删除32:<u>*</u> (FDC ± follicular, disrupted) \n删除32:<u>*</u> Small/medium cells \n删除32:<u>*</u> (Larger cells in GC)\n\n【6】删除图片描述:<u>![](122_3.png)</u>\n#### PC-DLBCL, leg type\n删除32:<u>*</u> BCL2 strongly + \n删除32:<u>*</u> BCL6+/- \n删除32:<u>*</u> IRF4/MUM1+ \n删除32:<u>*</u> (FDC-) \n删除32:<u>*</u> Large round cells \n删除32:<u>*</u> Few CD3+ T cells\n\n【7】删除图片描述:<u>![](122_4.png)</u>\n#### PCMZL\n删除32:<u>*</u> BCL6- (positive GC) \n删除32:<u>*</u> IRF4/MUM1+/- \n删除32:<u>*</u> (FDC + follicular, disrupted) \n删除32:<u>*</u> Small/medium cells\n\n【8】删除图片描述:<u>![](122_5.png)</u>\n#### PCFCL\n删除32:<u>*</u> BCL2 weakly + \n删除32:<u>*</u> BCL6+ \n删除32:<u>*</u> IRF4/MUM1- \n删除32:<u>*</u> (FDC±, follicular) \n删除32:<u>*</u> Small/medium/large cells \n删除32:<u>*</u> Many CD3+ T cells\n\n---|删除段之间换行|删除32:<u>*</u> 删除32:<u>**</u>Primary cutaneous marginal zone lymphoma (PCMZL)删除32:<u>**</u>\n删除32:<u>*</u> 删除32:<u>**</u>Primary cutaneous follicle center lymphoma (PCFCL)删除32:<u>**</u>\n删除32:<u>*</u> 删除32:<u>**</u>Primary cutaneous DLBCL, leg type (PC-DLBCL)删除32:<u>**</u>\n\n【10】<sup>a</sup> These are meant to be general guidelines. Interpretation of results should be based on individual circumstances and may vary. Not all tests will be required in every case.\n\n【11】<sup>r</sup> These are assessed both in follicles (if present) and in intrafollicular/diffuse areas. CD10+ BCL6 + germinal centers are present in PCMZL, while both follicular and interfollicular/diffuse areas (tumor cells) are positive for BCL6+/- CD10 in PCFCL.\n\n【12】删除32:<u>**</u>Note:删除32:<u>**</u> All recommendations are category 2A unless otherwise indicated.\n\n【13】删除32:<u>**</u>Clinical Trials:删除32:<u>**</u> NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.", "tags": {}, "lang": "en", "attr": {"page_num": 123, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V4）NCCN临床实践指南：B细胞淋巴瘤.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "USE OF IMMUNOPHENOTYPING/GENETIC TESTING IN DIFFERENTIAL DIAGNOSIS OF MATURE B-CELL AND NK/T-CELL NEOPLASMS删除23:a (TO BE USED IN CONJUNCTION WITH CLINICAL AND MORPHOLOGIC CORRELATION)\n|删除段内换行|#### B-CELL NEOPLASMS\n\n【2】删除图片描述: \n\n【3】删除32:* Panel: CD3, CD5, CD10删除23:r BCL2, BCL6, IRF4/MUM1, CD21/23 (Follicular dendritic cell 删除12:[FDC] markers)\n\n【4】删除图片描述:\n\nPCFCL\n删除32: BCL6+\n\n删除32: IRF4/MUM1-\n\n删除32: (FDC+/-)\n\n删除32: Small/medium/large cells\n\n删除32:* Many CD3+ cells\n\n【5】删除图片描述:\n\nPCMZL\n删除32: BCL6- (positive GC)\n\n删除32: IRF4/MUM1+/-\n\n删除32: (FDC ± follicular, disrupted)\n\n删除32: Small/medium cells\n\n删除32:* (Larger cells in GC)\n\n【6】删除图片描述:\n\nPC-DLBCL, leg type\n删除32: BCL2 strongly +\n\n删除32: BCL6+/-\n\n删除32: IRF4/MUM1+\n\n删除32: (FDC-)\n\n删除32: Large round cells\n\n删除32: Few CD3+ T cells\n\n【7】删除图片描述:\n\nPCMZL\n删除32: BCL6- (positive GC)\n\n删除32: IRF4/MUM1+/-\n\n删除32: (FDC + follicular, disrupted)\n\n删除32: Small/medium cells\n\n【8】删除图片描述:\n\nPCFCL\n删除32: BCL2 weakly +\n\n删除32: BCL6+\n\n删除32: IRF4/MUM1-\n\n删除32: (FDC±, follicular)\n\n删除32: Small/medium/large cells\n\n删除32: Many CD3+ T cells", "content": "【0】页码:123\n（2023.V4）NCCN临床实践指南：B细胞淋巴瘤\n疑似页眉<u># NCCN Guidelines Version 4.2023\n## B-Cell Lymphomas</u>\n\n### USE OF IMMUNOPHENOTYPING/GENETIC TESTING IN DIFFERENTIAL DIAGNOSIS OF MATURE B-CELL AND NK/T-CELL NEOPLASMS删除23:<u><sup>a</sup></u> (TO BE USED IN CONJUNCTION WITH CLINICAL AND MORPHOLOGIC CORRELATION)\n |删除段内换行|#### B-CELL NEOPLASMS\n\n【2】删除图片描述:<u>![](122_0.png) </u>\n\n【3】删除32:<u>*</u> Panel: CD3, CD5, CD10删除23:<u><sup>r</sup></u> BCL2, BCL6, IRF4/MUM1, CD21/23 (Follicular dendritic cell 删除12:<u>[FDC]</u> markers)\n\n【4】删除图片描述:<u>![](122_1.png)</u>\n#### PCFCL\n删除32:<u>*</u> BCL6+ \n删除32:<u>*</u> IRF4/MUM1- \n删除32:<u>*</u> (FDC+/-) \n删除32:<u>*</u> Small/medium/large cells \n删除32:<u>*</u> Many CD3+ cells\n\n【5】删除图片描述:<u>![](122_2.png)</u>\n#### PCMZL\n删除32:<u>*</u> BCL6- (positive GC) \n删除32:<u>*</u> IRF4/MUM1+/- \n删除32:<u>*</u> (FDC ± follicular, disrupted) \n删除32:<u>*</u> Small/medium cells \n删除32:<u>*</u> (Larger cells in GC)\n\n【6】删除图片描述:<u>![](122_3.png)</u>\n#### PC-DLBCL, leg type\n删除32:<u>*</u> BCL2 strongly + \n删除32:<u>*</u> BCL6+/- \n删除32:<u>*</u> IRF4/MUM1+ \n删除32:<u>*</u> (FDC-) \n删除32:<u>*</u> Large round cells \n删除32:<u>*</u> Few CD3+ T cells\n\n【7】删除图片描述:<u>![](122_4.png)</u>\n#### PCMZL\n删除32:<u>*</u> BCL6- (positive GC) \n删除32:<u>*</u> IRF4/MUM1+/- \n删除32:<u>*</u> (FDC + follicular, disrupted) \n删除32:<u>*</u> Small/medium cells\n\n【8】删除图片描述:<u>![](122_5.png)</u>\n#### PCFCL\n删除32:<u>*</u> BCL2 weakly + \n删除32:<u>*</u> BCL6+ \n删除32:<u>*</u> IRF4/MUM1- \n删除32:<u>*</u> (FDC±, follicular) \n删除32:<u>*</u> Small/medium/large cells \n删除32:<u>*</u> Many CD3+ T cells\n\n---|删除段之间换行|删除32:<u>*</u> 删除32:<u>**</u>Primary cutaneous marginal zone lymphoma (PCMZL)删除32:<u>**</u>\n删除32:<u>*</u> 删除32:<u>**</u>Primary cutaneous follicle center lymphoma (PCFCL)删除32:<u>**</u>\n删除32:<u>*</u> 删除32:<u>**</u>Primary cutaneous DLBCL, leg type (PC-DLBCL)删除32:<u>**</u>\n\n【10】<sup>a</sup> These are meant to be general guidelines. Interpretation of results should be based on individual circumstances and may vary. Not all tests will be required in every case.\n\n【11】<sup>r</sup> These are assessed both in follicles (if present) and in intrafollicular/diffuse areas. CD10+ BCL6 + germinal centers are present in PCMZL, while both follicular and interfollicular/diffuse areas (tumor cells) are positive for BCL6+/- CD10 in PCFCL.\n\n【12】删除32:<u>**</u>Note:删除32:<u>**</u> All recommendations are category 2A unless otherwise indicated.\n\n【13】删除32:<u>**</u>Clinical Trials:删除32:<u>**</u> NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.", "index": 1561, "show": true, "start": 1561, "end": 2613, "province": ["信息质量", "有用性-轻"], "isEdit": false}], "startTime": "2024/08/06 16:37:30", "endTime": "2024/08/06 16:38:54", "cost": 83.958}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:38:54", "grab_time": "2024-08-06 00:37:30"}
{"id": 2211553, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "6ffb9f7b-ef90-4990-a71b-4cc073d6bbbe", "title": "中国血脂管理指南（2023年）", "text": "【0】页码:7\n中国血脂管理指南（2023年）\n治疗指南（2016年修订版）》也提到：依据ASCVD发病风险采取不同强度下预防措施是血脂异常防治的核心策略。ASCVD总体风险评估是血脂异常治疗决策的基础，推荐采用基于我国人群长期队列研究建立的“ASCVD总体发病风险评估流程图”进行风险评估和分层图。本综述订正《中⽂肥⼤⼈⾎脂异常防治指南（2016年修订版)》对ASCVD风险评估指标推荐建议的基础上，结合最新研究证据和国内外指南与共识，对\n\n【1】删除图片描述:<u>![](6_0.png)</u>\n\n【2】2016版指南的风险评估流程进行了更新：（1）按是否患有ASCVD分为二级预防和一级预防两类情况；（2）在已诊断ASCVD的一二级预防⼈群中进一步划分出超(极)⾼危的危险分层；（3）在尚无ASCVD的一级预防人群中，增加慢性肾脏病(chronic kidney disease，CKD) 3-4期作为⾮超(极)高危的三种情况之一。 ASCVD总体风险评估流程如图1所示。\n\n【3】首先，按照是否患有ASCVD划分为二级预防和一级预防两类情况。在已诊断ASCVD的⼈群中，将发生过≥2次严重ASCVD事件或发生过1次严重ASCVD事件，且合并≥2个高危因素者列为超高", "tags": {}, "lang": "zh", "attr": {"page_num": 7, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/中国血脂管理指南（2023年）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】2016版指南的风险评估", "content": "【0】页码:7\n中国血脂管理指南（2023年）\n治疗指南（2016年修订版）》也提到：依据ASCVD发病风险采取不同强度下预防措施是血脂异常防治的核心策略。ASCVD总体风险评估是血脂异常治疗决策的基础，推荐采用基于我国人群长期队列研究建立的“ASCVD总体发病风险评估流程图”进行风险评估和分层图。本综述订正《中⽂肥⼤⼈⾎脂异常防治指南（2016年修订版)》对ASCVD风险评估指标推荐建议的基础上，结合最新研究证据和国内外指南与共识，对\n\n【1】删除图片描述:<u>![](6_0.png)</u>\n\n【2】2016版指南的风险评估流程进行了更新：（1）按是否患有ASCVD分为二级预防和一级预防两类情况；（2）在已诊断ASCVD的一二级预防⼈群中进一步划分出超(极)⾼危的危险分层；（3）在尚无ASCVD的一级预防人群中，增加慢性肾脏病(chronic kidney disease，CKD) 3-4期作为⾮超(极)高危的三种情况之一。 ASCVD总体风险评估流程如图1所示。\n\n【3】首先，按照是否患有ASCVD划分为二级预防和一级预防两类情况。在已诊断ASCVD的⼈群中，将发生过≥2次严重ASCVD事件或发生过1次严重ASCVD事件，且合并≥2个高危因素者列为超高", "index": 253, "show": true, "start": 253, "end": 268, "province": ["格式规范性", "多余换行"], "isEdit": false}], "startTime": "2024/08/07 09:54:26", "endTime": "2024/08/07 09:54:54", "cost": 27.47}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 17:54:53", "grab_time": "2024-08-06 17:54:25"}
{"id": 2211552, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "09921e0b-fe3e-4bb7-98fe-5808d9e9279d", "title": "2023 NICE 医疗技术创新简报：Fasciotens 用于腹壁闭合 [MIB321]", "text": "【0】页码:5\n2023 NICE 医疗技术创新简报：Fasciotens 用于腹壁闭合 [MIB321]\n## Regulatory information\n\n【1】Fasciotens hernia and abdomen are CE marked class I sterile medical devices.\n\n【2】## Equality considerations\n\n【3】NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others.\n\n【4】No equality issues were identified.\n\n【5】## Clinical and technical evidence\n\n【6】A literature search was carried out for this briefing in accordance with the [interim process and methods statement for medtech innovation briefings]. This briefing includes the most relevant or best available published evidence relating to the clinical effectiveness of the technology. Further information about how the evidence for this briefing was selected is available on request by contacting mibs@nice.org.uk.\n\n【7】## Published evidence\n\n【8】Six studies are summarised in this briefing, including a total of 96 people. The evidence includes 1 prospective observational study, 2 retrospective observational studies and 3 case studies.\n\n【9】The clinical evidence and its strengths and limitations are summarised in the overall assessment of the evidence.\n\n【10】## Overall assessment of the evidence\n\n【11】The evidence base for fasciotens abdomen is limited and comes from non-comparative observational studies and case studies that involve a relatively small number of people. None of the included studies were done in the UK and results may not be generalisable to clinical practice in the NHS. The evidence suggests that the fasciotens devices may be a useful technique to aid abdominal wall closure. Further evidence from larger randomised", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 NICE 医疗技术创新简报：Fasciotens 用于腹壁闭合 [MIB321].pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:14:22", "endTime": "2024/08/06 16:14:43", "cost": 21.026}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:14:43", "grab_time": "2024-08-06 00:14:22"}
{"id": 2211551, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "d3340a53-e92f-4db9-80be-000f7be5fae2", "title": "乳腺癌诊疗指南（2022年版）", "text": "【0】页码:99\n乳腺癌诊疗指南（2022年版）\n### 附件10 常用的辅助化疗方案\n\n【1】#### TAC方案\n- 多西他赛 75 mg / m² iv 第1天\n- 多柔比星 50 mg / m² iv 第1天\n- 环磷酰胺 500 mg / m² iv 第1天\n\n【2】21天为1个周期，共6个周期（所有周期均用G-CSF支持）。\n\n【3】#### 补量密集AC→P方案\n- 多柔比星 60 mg / m² iv 第1天\n- 环磷酰胺 600 mg / m² iv 第1天\n\n【4】14天为1个周期，共4个周期\n\n【5】- 序贯以紫杉醇 175 mg / m² iv 3小时 第1天\n\n【6】14天为1个周期，共4个周期（所有周期均用G-CSF支持）。\n\n【7】#### AC→P / T方案\n- 多柔比星 60 mg / m² iv 第1天\n- 环磷酰胺 600 mg / m² iv 第1天\n\n【8】21天为1个周期，共4个周期\n\n【9】- 序贯紫杉醇 80 mg / m² iv 1小时 第1天，每周1次，共12周\n- 或紫杉醇 175 mg / m² iv 1小时 第1天，每3周1次，共12周", "tags": {}, "lang": "None", "attr": {"page_num": 99, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/乳腺癌诊疗指南（2022年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:18:53", "endTime": "2024/08/06 16:24:34", "cost": 341.19}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:24:35", "grab_time": "2024-08-06 00:18:53"}
{"id": 2211550, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "1f177b73-a538-4cc0-b4f8-3ba7bb0d87f8", "title": "WHO：终止妊娠护理指南（2022）", "text": "【0】页码:8\nWHO：终止妊娠护理指南（2022）\n图片中没有正文内容可供转换，仅包含“删除32:<u>**</u>小狗科研公开课删除32:<u>**</u>”的水印。", "tags": {}, "lang": "zh", "attr": {"page_num": 8, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WHO：终止妊娠护理指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:31:50", "endTime": "2024/08/06 15:31:58", "cost": 7.962}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:31:58", "grab_time": "2024-08-05 23:31:50"}
{"id": 2211549, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "6a593288-cb5c-4250-a87c-5b0dba418e1b", "title": "2023 UKKA临床实践指南：血液透析血管通路", "text": "【0】页码:25\n2023 UKKA临床实践指南：血液透析血管通路\n删除图片描述:<u>![](24_0.png)</u>\n\n【1】However, too early a referral may expose patients to creation and maintenance of an access that may never be required, due to competing events, such as transplantation, or death before kidney failure develops. These issues are particularly relevant in older people, in whom competing illness is more common, and fistula outcomes less favourable. In a large American study, Hod reported outcomes in 17 511 patients over 67 who started dialysis after prior fistula formation: 45% used a graft or catheter for dialysis initiation, rather than the fistula as planned 删除11:<u>(6)</u>. Looking at the timing of fistula formation, successful fistula dialysis was less likely with formation only 1-3 months before dialysis (OR 0.删除13:<u>49, 95</u>%CI 0.44-0.53) or 3-6 months before (OR 0.删除13:<u>93, 95</u>%CI 0.85-1.02), but formation over a year before was no better than 6-12 months before starting dialysis. There is therefore an optimal window for access referral and formation, that is around 6-12 months before dialysis initiation, though predicting the latter event is difficult. This window may also be affected by institutional factors such as the expected time waiting for surgery, or for procedures to assist maturation. These issues are well summarised in a review article by Woo 删除11:<u>(4)</u>.\n\n【2】删除图片描述:<u>![](24_1.png)</u>\n\n【3】In children, sufficient time is necessary for psychological preparation as well as pre-operative investigation, fistula maturation, and any further intervention for non-maturation. Whilst paediatric registries report a median(IQR) interval of 62删除11:<u>(37-134)</u> days between AV access formation and cannulation, independent of age 删除11:<u>(9, 10)</u>, angioplasty to assist maturation is required in 17–28% of fistulas in children 删除11:<u>(9,11-14)</u>, and with time allowed for psychological preparation the overall process from pre-operative assessment until the fistula is functional (regardless of fistula location) requires an average of 6 months 删除11:<u>(9,15,16)</u>. Access referral is usually considered when GFR is below 30 ml/min/1.73m² (estimated by Schwartz formula 删除11:<u>(17)</u>), or otherwise when haemodialysis is expected within 6-12 months 删除11:<u>(18)</u>.\n\n【4】Education however has no time window limitation, and counselling patients about the main risks and benefits of each access type is widely regarded as worthwhile, as explored and summarised by Moist 删除11:<u>(19)</u>. Improved patient understanding allows more informed decision making, and facilitates delivery of a more personalised vascular access strategy 删除11:<u>(20)</u>, and observational data suggest that access education programs are associated with increased AV access at dialysis initiation 删除11:<u>(21,22)</u>. A structured approach to education should be encouraged, that focuses on simple concepts, reflecting on individual circumstances and goals, and may be delivered through a variety of different methods, such as face to face, group education, or written literature.", "tags": {}, "lang": "en", "attr": {"page_num": 25, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 UKKA临床实践指南：血液透析血管通路.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "49, 95", "content": "【0】页码:25\n2023 UKKA临床实践指南：血液透析血管通路\n删除图片描述:<u>![](24_0.png)</u>\n\n【1】However, too early a referral may expose patients to creation and maintenance of an access that may never be required, due to competing events, such as transplantation, or death before kidney failure develops. These issues are particularly relevant in older people, in whom competing illness is more common, and fistula outcomes less favourable. In a large American study, Hod reported outcomes in 17 511 patients over 67 who started dialysis after prior fistula formation: 45% used a graft or catheter for dialysis initiation, rather than the fistula as planned 删除11:<u>(6)</u>. Looking at the timing of fistula formation, successful fistula dialysis was less likely with formation only 1-3 months before dialysis (OR 0.删除13:<u>49, 95</u>%CI 0.44-0.53) or 3-6 months before (OR 0.删除13:<u>93, 95</u>%CI 0.85-1.02), but formation over a year before was no better than 6-12 months before starting dialysis. There is therefore an optimal window for access referral and formation, that is around 6-12 months before dialysis initiation, though predicting the latter event is difficult. This window may also be affected by institutional factors such as the expected time waiting for surgery, or for procedures to assist maturation. These issues are well summarised in a review article by Woo 删除11:<u>(4)</u>.\n\n【2】删除图片描述:<u>![](24_1.png)</u>\n\n【3】In children, sufficient time is necessary for psychological preparation as well as pre-operative investigation, fistula maturation, and any further intervention for non-maturation. Whilst paediatric registries report a median(IQR) interval of 62删除11:<u>(37-134)</u> days between AV access formation and cannulation, independent of age 删除11:<u>(9, 10)</u>, angioplasty to assist maturation is required in 17–28% of fistulas in children 删除11:<u>(9,11-14)</u>, and with time allowed for psychological preparation the overall process from pre-operative assessment until the fistula is functional (regardless of fistula location) requires an average of 6 months 删除11:<u>(9,15,16)</u>. Access referral is usually considered when GFR is below 30 ml/min/1.73m² (estimated by Schwartz formula 删除11:<u>(17)</u>), or otherwise when haemodialysis is expected within 6-12 months 删除11:<u>(18)</u>.\n\n【4】Education however has no time window limitation, and counselling patients about the main risks and benefits of each access type is widely regarded as worthwhile, as explored and summarised by Moist 删除11:<u>(19)</u>. Improved patient understanding allows more informed decision making, and facilitates delivery of a more personalised vascular access strategy 删除11:<u>(20)</u>, and observational data suggest that access education programs are associated with increased AV access at dialysis initiation 删除11:<u>(21,22)</u>. A structured approach to education should be encouraged, that focuses on simple concepts, reflecting on individual circumstances and goals, and may be delivered through a variety of different methods, such as face to face, group education, or written literature.", "index": 795, "show": true, "start": 795, "end": 801, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "93, 95", "content": "【0】页码:25\n2023 UKKA临床实践指南：血液透析血管通路\n删除图片描述:<u>![](24_0.png)</u>\n\n【1】However, too early a referral may expose patients to creation and maintenance of an access that may never be required, due to competing events, such as transplantation, or death before kidney failure develops. These issues are particularly relevant in older people, in whom competing illness is more common, and fistula outcomes less favourable. In a large American study, Hod reported outcomes in 17 511 patients over 67 who started dialysis after prior fistula formation: 45% used a graft or catheter for dialysis initiation, rather than the fistula as planned 删除11:<u>(6)</u>. Looking at the timing of fistula formation, successful fistula dialysis was less likely with formation only 1-3 months before dialysis (OR 0.删除13:<u><mark>49, 95</mark></u>%CI 0.44-0.53) or 3-6 months before (OR 0.删除13:<u>93, 95</u>%CI 0.85-1.02), but formation over a year before was no better than 6-12 months before starting dialysis. There is therefore an optimal window for access referral and formation, that is around 6-12 months before dialysis initiation, though predicting the latter event is difficult. This window may also be affected by institutional factors such as the expected time waiting for surgery, or for procedures to assist maturation. These issues are well summarised in a review article by Woo 删除11:<u>(4)</u>.\n\n【2】删除图片描述:<u>![](24_1.png)</u>\n\n【3】In children, sufficient time is necessary for psychological preparation as well as pre-operative investigation, fistula maturation, and any further intervention for non-maturation. Whilst paediatric registries report a median(IQR) interval of 62删除11:<u>(37-134)</u> days between AV access formation and cannulation, independent of age 删除11:<u>(9, 10)</u>, angioplasty to assist maturation is required in 17–28% of fistulas in children 删除11:<u>(9,11-14)</u>, and with time allowed for psychological preparation the overall process from pre-operative assessment until the fistula is functional (regardless of fistula location) requires an average of 6 months 删除11:<u>(9,15,16)</u>. Access referral is usually considered when GFR is below 30 ml/min/1.73m² (estimated by Schwartz formula 删除11:<u>(17)</u>), or otherwise when haemodialysis is expected within 6-12 months 删除11:<u>(18)</u>.\n\n【4】Education however has no time window limitation, and counselling patients about the main risks and benefits of each access type is widely regarded as worthwhile, as explored and summarised by Moist 删除11:<u>(19)</u>. Improved patient understanding allows more informed decision making, and facilitates delivery of a more personalised vascular access strategy 删除11:<u>(20)</u>, and observational data suggest that access education programs are associated with increased AV access at dialysis initiation 删除11:<u>(21,22)</u>. A structured approach to education should be encouraged, that focuses on simple concepts, reflecting on individual circumstances and goals, and may be delivered through a variety of different methods, such as face to face, group education, or written literature.", "index": 868, "show": true, "start": 855, "end": 861, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "【1】However, too early a referral may", "content": "【0】页码:25\n2023 UKKA临床实践指南：血液透析血管通路\n删除图片描述:<u>![](24_0.png)</u>\n\n【1】However, too early a referral may expose patients to creation and maintenance of an access that may never be required, due to competing events, such as transplantation, or death before kidney failure develops. These issues are particularly relevant in older people, in whom competing illness is more common, and fistula outcomes less favourable. In a large American study, Hod reported outcomes in 17 511 patients over 67 who started dialysis after prior fistula formation: 45% used a graft or catheter for dialysis initiation, rather than the fistula as planned 删除11:<u>(6)</u>. Looking at the timing of fistula formation, successful fistula dialysis was less likely with formation only 1-3 months before dialysis (OR 0.删除13:<u><mark>49, 95</mark></u>%CI 0.44-0.53) or 3-6 months before (OR 0.删除13:<u><mark>93, 95</mark></u>%CI 0.85-1.02), but formation over a year before was no better than 6-12 months before starting dialysis. There is therefore an optimal window for access referral and formation, that is around 6-12 months before dialysis initiation, though predicting the latter event is difficult. This window may also be affected by institutional factors such as the expected time waiting for surgery, or for procedures to assist maturation. These issues are well summarised in a review article by Woo 删除11:<u>(4)</u>.\n\n【2】删除图片描述:<u>![](24_1.png)</u>\n\n【3】In children, sufficient time is necessary for psychological preparation as well as pre-operative investigation, fistula maturation, and any further intervention for non-maturation. Whilst paediatric registries report a median(IQR) interval of 62删除11:<u>(37-134)</u> days between AV access formation and cannulation, independent of age 删除11:<u>(9, 10)</u>, angioplasty to assist maturation is required in 17–28% of fistulas in children 删除11:<u>(9,11-14)</u>, and with time allowed for psychological preparation the overall process from pre-operative assessment until the fistula is functional (regardless of fistula location) requires an average of 6 months 删除11:<u>(9,15,16)</u>. Access referral is usually considered when GFR is below 30 ml/min/1.73m² (estimated by Schwartz formula 删除11:<u>(17)</u>), or otherwise when haemodialysis is expected within 6-12 months 删除11:<u>(18)</u>.\n\n【4】Education however has no time window limitation, and counselling patients about the main risks and benefits of each access type is widely regarded as worthwhile, as explored and summarised by Moist 删除11:<u>(19)</u>. Improved patient understanding allows more informed decision making, and facilitates delivery of a more personalised vascular access strategy 删除11:<u>(20)</u>, and observational data suggest that access education programs are associated with increased AV access at dialysis initiation 删除11:<u>(21,22)</u>. A structured approach to education should be encouraged, that focuses on simple concepts, reflecting on individual circumstances and goals, and may be delivered through a variety of different methods, such as face to face, group education, or written literature.", "index": 63, "show": true, "start": 63, "end": 99, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "前面缺少一段正文"}, {"text": "【3】In children, sufficient time is necessary ", "content": "【0】页码:25\n2023 UKKA临床实践指南：血液透析血管通路\n删除图片描述:<u>![](24_0.png)</u>\n\n<mark>【1】However, too early a referral may</mark> expose patients to creation and maintenance of an access that may never be required, due to competing events, such as transplantation, or death before kidney failure develops. These issues are particularly relevant in older people, in whom competing illness is more common, and fistula outcomes less favourable. In a large American study, Hod reported outcomes in 17 511 patients over 67 who started dialysis after prior fistula formation: 45% used a graft or catheter for dialysis initiation, rather than the fistula as planned 删除11:<u>(6)</u>. Looking at the timing of fistula formation, successful fistula dialysis was less likely with formation only 1-3 months before dialysis (OR 0.删除13:<u><mark>49, 95</mark></u>%CI 0.44-0.53) or 3-6 months before (OR 0.删除13:<u><mark>93, 95</mark></u>%CI 0.85-1.02), but formation over a year before was no better than 6-12 months before starting dialysis. There is therefore an optimal window for access referral and formation, that is around 6-12 months before dialysis initiation, though predicting the latter event is difficult. This window may also be affected by institutional factors such as the expected time waiting for surgery, or for procedures to assist maturation. These issues are well summarised in a review article by Woo 删除11:<u>(4)</u>.\n\n【2】删除图片描述:<u>![](24_1.png)</u>\n\n【3】In children, sufficient time is necessary for psychological preparation as well as pre-operative investigation, fistula maturation, and any further intervention for non-maturation. Whilst paediatric registries report a median(IQR) interval of 62删除11:<u>(37-134)</u> days between AV access formation and cannulation, independent of age 删除11:<u>(9, 10)</u>, angioplasty to assist maturation is required in 17–28% of fistulas in children 删除11:<u>(9,11-14)</u>, and with time allowed for psychological preparation the overall process from pre-operative assessment until the fistula is functional (regardless of fistula location) requires an average of 6 months 删除11:<u>(9,15,16)</u>. Access referral is usually considered when GFR is below 30 ml/min/1.73m² (estimated by Schwartz formula 删除11:<u>(17)</u>), or otherwise when haemodialysis is expected within 6-12 months 删除11:<u>(18)</u>.\n\n【4】Education however has no time window limitation, and counselling patients about the main risks and benefits of each access type is widely regarded as worthwhile, as explored and summarised by Moist 删除11:<u>(19)</u>. Improved patient understanding allows more informed decision making, and facilitates delivery of a more personalised vascular access strategy 删除11:<u>(20)</u>, and observational data suggest that access education programs are associated with increased AV access at dialysis initiation 删除11:<u>(21,22)</u>. A structured approach to education should be encouraged, that focuses on simple concepts, reflecting on individual circumstances and goals, and may be delivered through a variety of different methods, such as face to face, group education, or written literature.", "index": 1441, "show": true, "start": 1402, "end": 1447, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "前面缺少一段内容"}], "startTime": "2024/08/06 16:10:50", "endTime": "2024/08/06 16:12:02", "cost": 72.701}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:12:03", "grab_time": "2024-08-06 00:10:50"}
{"id": 2211548, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "42907288-11da-4092-89a5-faac8f9bfe95", "title": "（2024.V1）NCCN临床实践指南：膀胱癌", "text": "【0】页码:43\n（2024.V1）NCCN临床实践指南：膀胱癌\n疑似页眉<u># NCCN Guidelines Version 1.2024 Bladder Cancer</u>\n\n【1】## PRINCIPLES OF SYSTEMIC THERAPY\n\n【2】### Neoadjuvant Chemotherapy (preferred for bladder)\n\n【3】删除32:<u>**</u>Preferred regimen删除32:<u>**</u>\n\n【4】- DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin) with growth factor support for 3–6 cycles删除23:<u><sup>1,2</sup></u>\n\n【5】删除32:<u>**</u>Other recommended regimens删除32:<u>**</u>\n\n【6】- Gemcitabine and cisplatin for 4 cycles删除23:<u><sup>3,4</sup></u>\n\n【7】### Adjuvant Therapy\n\n【8】#### No previous platinum-based neoadjuvant therapy (pT3, pT4a, pN+)\n\n【9】删除32:<u>**</u>Preferred regimen删除32:<u>**</u>\n\n【10】- DDMVAC with growth factor support for 3–6 cycles删除23:<u><sup>1,2</sup></u>\n\n【11】删除32:<u>**</u>Other recommended regimens删除32:<u>**</u>\n\n【12】- Gemcitabine and cisplatin for 4 cycles删除23:<u><sup>3,4</sup></u>\n- Nivolumab删除23:<u><sup>5</sup></u>\n\n【13】#### Previous platinum-based neoadjuvant therapy (ypT2–ypT4a or ypN+)\n\n【14】删除32:<u>**</u>Other recommended regimen删除32:<u>**</u>\n\n【15】- Nivolumab删除23:<u><sup>5</sup></u>\n\n【16】- For patients who are not candidates for cisplatin, there are no data to support a recommendation for perioperative chemotherapy.\n- Randomized trials and meta-analyses show a survival benefit for cisplatin-based neoadjuvant chemotherapy (3 or 4 cycles) for MIBC.删除23:<u><sup>1,6,7</sup></u>\n- Meta-analysis suggests overall survival benefit with adjuvant cisplatin-based chemotherapy for pathologic T3, T4 or N+ disease at cystectomy, if it was not given as neoadjuvant.\n- Neoadjuvant chemotherapy is preferred over adjuvant-based chemotherapy on a higher level of evidence data.\n- DDMVAC is preferred over standard MVAC based on category 1 evidence for metastatic disease showing DDMVAC to be better tolerated and more effective than conventional MVAC in advanced disease.删除23:<u><sup>2,8</sup></u> Based on these data, the traditional dose and schedule for MVAC is no longer recommended.\n- Perioperative gemcitabine and cisplatin is a reasonable alternative to DDMVAC based on category 1 evidence for metastatic disease showing equivalence to conventional MVAC in the setting of advanced disease.删除23:<u><sup>4,9</sup></u>\n- For gemcitabine/cisplatin, a 21-day cycle is preferred. Better dose compliance may be achieved with fewer delays in dosing using the 21-day schedule.删除23:<u><sup>10</sup></u>\n- Neoadjuvant chemotherapy is preferred for patients with UTUC, particularly for higher stage and/or grade tumors or concerning radiographic findings, as renal function will decline after nephroureterectomy and may preclude adjuvant therapy.\n- Multicenter data supports the use of neoadjuvant, split-dose cisplatin-based chemotherapy (gemcitabine and cisplatin) for patients with high-grade UTUC.删除23:<u><sup>11</sup></u> Staging for UTUC is less precise than for bladder cancers and understaging is common, necessitating discussion on the risk of under- versus over-treatment.\n- Adjuvant therapy should be considered if neoadjuvant therapy was not given for UTUC.删除23:<u><sup>12</sup></u>\n- Carboplatin should not be substituted for cisplatin in the perioperative bladder cancer setting.\n- For patients with reduced renal function or in whom full-dose administration of cisplatin may be considered (such as 35 mg/m<sup>2</sup> on days 1 and 2 or days 1 and 8) (category 2B). While safer, the relative efficacy of the cisplatin-containing combination administered with such modifications remains undefined.\n- For patients with borderline renal function, estimate GFR to assess eligibility for cisplatin. Consider timed urine collection, which may more accurately determine eligibility for cisplatin.", "tags": {}, "lang": "en", "attr": {"page_num": 43, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2024.V1）NCCN临床实践指南：膀胱癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:05:23", "endTime": "2024/08/06 17:06:09", "cost": 46.373}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 01:06:09", "grab_time": "2024-08-06 01:05:23"}
{"id": 2211547, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "64c83840-5568-4be5-890f-8e98c392d373", "title": "抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识（2022版）(1)", "text": "【0】页码:5\n抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识（2022版）(1)\n### 3.3 子宫内膜癌\n子宫内膜瘤如斑抗血管生成TKI的探索性研究如表4删除14:<u>[11,39,53,54]</u>所示。目前NCCN子宫内膜瘤指南删除19:<u>(2022 v1)</u>推荐伽伐尼尼联合帕博利珠单抗用于复发性转移性子宫内膜癌治疗删除12:<u>删除14:<u>[55]</u></u>。一项炎现期随机对取KEYNOTE-775试验删除12:<u>删除14:<u>[53]</u></u>入组 697例晚期子宫内膜癌患者，分析阻乙烯治疗中接受伽伐尼尼L联合帕博利珠单抗与医生选择治疗方案，结果人群的中位PFS(7.2个月 vs 3.8个月，HR=0.删除13:<u>56, 95</u>%CI: 0.47~0.66)和中位OS(18.3个月 vs 11.4个月，HR=0.删除13:<u>62, 95</u>%CI: 0.51~0.75)显著长于单纯化疗。该研究还显示,联合治疗使帽能必要基因直率(mismatch repair proficient, pMMR)患者的中位PFS延长2.8个月,复发或死亡风险降低48%,中位OS延长5.4个月，死亡风险降低32%,ORR提高15.2%。在安全性方面，伽伐尼尼联合帕抑珠单抗组3级及以上不良事件发生率为88.9%，化疗组为72.7%;因不良事件导致伽伐尼尼耐受性下降例为66.5%。该研究表明,在既往至少接受过一种全身药物治疗的晚期复发子宫内膜癌患者中,帕博利珠单抗联合伽伐尼尼治疗可以带接占pMMR在内患者的疗直。基于这研究，美国食品药品管理局(FDA)于2021年7月正式批准帕博利珠联合伽伐尼尼用子低接受系统治疗后出现疾病进展的晚期/复发卵巢工程高度不稳定(microsatellite instability-high,MSI-H)/错配修复基因缺陷(mismatch repair deficient,dMMR)子宫内膜癌患者(不适宜手术或放疗者)在。一项安罗伐尼尼联合信渴单抗治疗复发性晚期子宫内膜癌的有效性和安全性的前瞻性单中心单臂II期临床研究删除12:<u>删除14:<u>[11]</u></u>。使用安罗伐尼与信渴组单抗晚期有治疗复发性晚期子宫内膜癌患者，在可评估的23例患者中，0RR为73.9%(95%CI:51.6%~89.8%),DCR为91.3%(95%CI:72.0%~98.9%),中位PFS未到达,6个月PFS率为76.7%,12个月PFS率为57.1%;安全性方面3/4级治疗相关不良事件发生率为50%，但大多数无管理论治疗。\n\n【1】删除32:<u>*</u>专家提示:对于二线化疗后进展/复发/转移子宫内膜癌的治疗，推荐采用化伐尼尼联合帕博利珠单抗(1类);安罗净尼联合信渴单抗推荐类别为PD-11抑制剂如中福单抗费替伐尼等(2B类);安罗净尼联合伐尼尼推荐类别为PD-11抑制剂如中福单抗费替伐尼等(2B类)。删除32:<u>*</u>\n\n【2】### 4 抗血管生成TKI不良反应管理与注意事项\n抗血管生成TKI具有复发的作用机制，其不良反应发生谱也不同于化疗、免疫治疗及放疗等。因此，抗血管生成TKI的不良 胀需要治疗抽者和医生师共同关注并抗肿瘤药物使用经验医师的指导和监下服用,并关注其不良反应(表5删除14:<u>[12,18,46,50,52-54,56,58]</u>)。\n\n【3】#### 表4  VEGFR-TKI类药物用子治疗子宫内膜瘤的调查性试验\n\n【4】删除图片描述:<u>![4_0.png](4_0.png)</u>\n\n| 药品/型号名称 | 复发晚期子宫内膜癌患者 | 剂量 | ORR | CBR | PFS | OS |\n|---------------|------------------------ |------|-----|-----|-----|----|\n| 安罗净尼 | II期前瞻性单中心单臂临床研究 | 安罗净尼+信渴单抗 | 12 mg/d, d1-14, q3w | 73.9 | 91.3 | NR | 2A |\n| 安罗净尼联合帕博利珠 | I / II 期前瞻性临床试验 | 安罗净尼+帕博利珠联合标准化疗 | 8 mg/d, d1-14, q3w | 58.0 | 79.0 | 9.0 | 2B |\n| 阿帕替尼 | 晚期复发性子宫内膜癌患者单剂量试验 | 阿帕替尼+卡莉单抗联合 | 250 mg/d | 47.6 | 85.7 | 11.8 | 2B |\n\n【6】删除32:<u>*</u> ORR: 近期客观率(objective response rate)\n删除32:<u>*</u> DCR: 疾响应群值(disease control rate)\n删除32:<u>*</u> CBR: 临床获益率(clinical benefit rate)\n删除32:<u>*</u> PFS: 无进展生存期(progression free survival)\n删除32:<u>*</u> OS: 生存期(overall survival)\n删除32:<u>*</u> NR: 未达到(not yet reached)", "tags": {}, "lang": "zh", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识（2022版）(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【4】删除图片描述:\n\n药品/型号名称\t复发晚期子宫内膜癌患者\t剂量\tORR\tCBR\tPFS\tOS\n安罗净尼\tII期前瞻性单中心单臂临床研究\t安罗净尼+信渴单抗\t12 mg/d, d1-14, q3w\t73.9\t91.3\tNR\n安罗净尼联合帕博利珠\tI / II 期前瞻性临床试验\t安罗净尼+帕博利珠联合标准化疗\t8 mg/d, d1-14, q3w\t58.0\t79.0\t9.0\n阿帕替尼\t晚期复发性子宫内膜癌患者单剂量试验\t阿帕替尼+卡莉单抗联合\t250 mg/d\t47.6\t85.7\t11.8", "content": "【0】页码:5\n抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识（2022版）(1)\n### 3.3 子宫内膜癌\n子宫内膜瘤如斑抗血管生成TKI的探索性研究如表4删除14:<u>[11,39,53,54]</u>所示。目前NCCN子宫内膜瘤指南删除19:<u>(2022 v1)</u>推荐伽伐尼尼联合帕博利珠单抗用于复发性转移性子宫内膜癌治疗删除12:<u>删除14:<u>[55]</u></u>。一项炎现期随机对取KEYNOTE-775试验删除12:<u>删除14:<u>[53]</u></u>入组 697例晚期子宫内膜癌患者，分析阻乙烯治疗中接受伽伐尼尼L联合帕博利珠单抗与医生选择治疗方案，结果人群的中位PFS(7.2个月 vs 3.8个月，HR=0.删除13:<u>56, 95</u>%CI: 0.47~0.66)和中位OS(18.3个月 vs 11.4个月，HR=0.删除13:<u>62, 95</u>%CI: 0.51~0.75)显著长于单纯化疗。该研究还显示,联合治疗使帽能必要基因直率(mismatch repair proficient, pMMR)患者的中位PFS延长2.8个月,复发或死亡风险降低48%,中位OS延长5.4个月，死亡风险降低32%,ORR提高15.2%。在安全性方面，伽伐尼尼联合帕抑珠单抗组3级及以上不良事件发生率为88.9%，化疗组为72.7%;因不良事件导致伽伐尼尼耐受性下降例为66.5%。该研究表明,在既往至少接受过一种全身药物治疗的晚期复发子宫内膜癌患者中,帕博利珠单抗联合伽伐尼尼治疗可以带接占pMMR在内患者的疗直。基于这研究，美国食品药品管理局(FDA)于2021年7月正式批准帕博利珠联合伽伐尼尼用子低接受系统治疗后出现疾病进展的晚期/复发卵巢工程高度不稳定(microsatellite instability-high,MSI-H)/错配修复基因缺陷(mismatch repair deficient,dMMR)子宫内膜癌患者(不适宜手术或放疗者)在。一项安罗伐尼尼联合信渴单抗治疗复发性晚期子宫内膜癌的有效性和安全性的前瞻性单中心单臂II期临床研究删除12:<u>删除14:<u>[11]</u></u>。使用安罗伐尼与信渴组单抗晚期有治疗复发性晚期子宫内膜癌患者，在可评估的23例患者中，0RR为73.9%(95%CI:51.6%~89.8%),DCR为91.3%(95%CI:72.0%~98.9%),中位PFS未到达,6个月PFS率为76.7%,12个月PFS率为57.1%;安全性方面3/4级治疗相关不良事件发生率为50%，但大多数无管理论治疗。\n\n【1】删除32:<u>*</u>专家提示:对于二线化疗后进展/复发/转移子宫内膜癌的治疗，推荐采用化伐尼尼联合帕博利珠单抗(1类);安罗净尼联合信渴单抗推荐类别为PD-11抑制剂如中福单抗费替伐尼等(2B类);安罗净尼联合伐尼尼推荐类别为PD-11抑制剂如中福单抗费替伐尼等(2B类)。删除32:<u>*</u>\n\n【2】### 4 抗血管生成TKI不良反应管理与注意事项\n抗血管生成TKI具有复发的作用机制，其不良反应发生谱也不同于化疗、免疫治疗及放疗等。因此，抗血管生成TKI的不良 胀需要治疗抽者和医生师共同关注并抗肿瘤药物使用经验医师的指导和监下服用,并关注其不良反应(表5删除14:<u>[12,18,46,50,52-54,56,58]</u>)。\n\n【3】#### 表4  VEGFR-TKI类药物用子治疗子宫内膜瘤的调查性试验\n\n【4】删除图片描述:<u>![4_0.png](4_0.png)</u>\n\n| 药品/型号名称 | 复发晚期子宫内膜癌患者 | 剂量 | ORR | CBR | PFS | OS |\n|---------------|------------------------ |------|-----|-----|-----|----|\n| 安罗净尼 | II期前瞻性单中心单臂临床研究 | 安罗净尼+信渴单抗 | 12 mg/d, d1-14, q3w | 73.9 | 91.3 | NR | 2A |\n| 安罗净尼联合帕博利珠 | I / II 期前瞻性临床试验 | 安罗净尼+帕博利珠联合标准化疗 | 8 mg/d, d1-14, q3w | 58.0 | 79.0 | 9.0 | 2B |\n| 阿帕替尼 | 晚期复发性子宫内膜癌患者单剂量试验 | 阿帕替尼+卡莉单抗联合 | 250 mg/d | 47.6 | 85.7 | 11.8 | 2B |\n\n【6】删除32:<u>*</u> ORR: 近期客观率(objective response rate)\n删除32:<u>*</u> DCR: 疾响应群值(disease control rate)\n删除32:<u>*</u> CBR: 临床获益率(clinical benefit rate)\n删除32:<u>*</u> PFS: 无进展生存期(progression free survival)\n删除32:<u>*</u> OS: 生存期(overall survival)\n删除32:<u>*</u> NR: 未达到(not yet reached)", "index": 1505, "show": true, "start": 1505, "end": 1753, "province": ["格式规范性", "表格格式错误"], "isEdit": false}], "startTime": "2024/08/06 15:27:34", "endTime": "2024/08/06 15:29:25", "cost": 110.732}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:29:25", "grab_time": "2024-08-05 23:27:30"}
{"id": 2211546, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "aed688ff-6c85-41a5-b842-8302cfdba9ce", "title": "ESCMID：SARS-CoV-2的诊断检测指南（2022）", "text": "【0】页码:11\nESCMID：SARS-CoV-2的诊断检测指南（2022）\n抱歉，我无法提供该图片中的内容。", "tags": {}, "lang": "zh", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ESCMID：SARS-CoV-2的诊断检测指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "抱歉，我无法提供该图片中的内容。", "content": "【0】页码:11\nESCMID：SARS-CoV-2的诊断检测指南（2022）\n抱歉，我无法提供该图片中的内容。", "index": 40, "show": true, "start": 40, "end": 56, "province": ["信息质量", "有用性-重"], "isEdit": false, "comment": "PDF中为参考文献"}], "startTime": "2024/08/06 15:45:21", "endTime": "2024/08/06 15:45:43", "cost": 22.036}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:45:43", "grab_time": "2024-08-05 23:45:21"}
{"id": 2211545, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "6a4352bb-b2cb-411a-b2fb-f40cdd98dafd", "title": "_NCCN临床实 践指南： 肾癌（2023.V2）-中文版(1)", "text": "【0】页码:17\n_NCCN临床实 践指南： 肾癌（2023.V2）-中文版(1)\n(本页删除)本页被模型判断为参考页疑似页眉<u># NCCN Guidelines Version 2.2023\n## 肾癌</u>\n\n【1】### 复发或Ⅳ期疾病的全身治疗原则\n\n【2】#### 非透明细胞组织学的全身治疗\n\n| 首选方案 | 其他推荐方案 | 在某些情况下有用 |\n| -------- | ----------- | ---------------- |\n| 临床试验    | 乐伐替尼 + 依维莫司 | 阿昔替尼 |\n| 帕博昔尼   | 纳武单抗 | 贝伐单抗 |\n| 舒尼替尼  | 劳拉替尼 + 尼洛替尼 用于选定的晚期乳头状RCC患者，包括遗传性平滑肌瘤病相关癌(HLRCC)相关RCC  |\n|           | 帕博昔尼 + 依维莫司 | 尼沃单抗 |\n|           | 贝伐单抗 + 依维莫司  | 依维莫司 |\n|           | 舒尼替尼 | 帕唑帕尼 |\n|           |  砷西罗莫司（现后仅限风险组为1类；其他风险组为2A类）|\n\n【4】b \\[见NCCN指南晚期治疗相关监管管理\\]\n\n【5】c 晚期RCC试验中用于非肿瘤部位受影响的低风险模型包括以下6个短生存期预测因素中的至少3个：从诊断到开始全身治疗的<1年，Karnofsky体能状态评分60-70，血红蛋白< LLN，校正钙> 10 mg/dL，LDH> 1.5 \\(ULN\\)，多部位转移。Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.\n\n【6】f FDA批准的治疗移动及伤及见代理米帕卢合适的替代品。\n\n【7】h 对于具金曲型或微型亚型，在细胞毒化疗（卡铂+吉西他滨、卡铂+紫杉醇或顺铂+吉西他滨）和自前用于尿路上皮的其他类别化疗表现则部分缓解。吉西他滨+多柔比霉在肾输尿管分癌转移（Roubaud G,et al.Oncology 2011;80:214-218;Shah AY,et al.BJU Int 2017;120:782-792）。口服袜的治疗通常不会在膀胱输尿管分癌中产生缓解。在临床试验之外，以细类为基础的化疗方案还灵异各种输尿管细的首选疗法。\n\n【8】Version 2.2023, 08/03/22 删除5:<u>©</u> 2022 National Comprehensive Cancer Network删除5:<u>®</u> (NCCN删除5:<u>®</u>). All rights reserved. NCCN Guidelines删除5:<u>®</u> and this illustration may not be reproduced in any form without the express written permission of NCCN.", "tags": {}, "lang": "en", "attr": {"page_num": 17, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_NCCN临床实 践指南： 肾癌（2023.V2）-中文版(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "(本页删除)", "content": "【0】页码:17\n_NCCN临床实 践指南： 肾癌（2023.V2）-中文版(1)\n(本页删除)本页被模型判断为参考页疑似页眉<u># NCCN Guidelines Version 2.2023\n## 肾癌</u>\n\n【1】### 复发或Ⅳ期疾病的全身治疗原则\n\n【2】#### 非透明细胞组织学的全身治疗\n\n| 首选方案 | 其他推荐方案 | 在某些情况下有用 |\n| -------- | ----------- | ---------------- |\n| 临床试验    | 乐伐替尼 + 依维莫司 | 阿昔替尼 |\n| 帕博昔尼   | 纳武单抗 | 贝伐单抗 |\n| 舒尼替尼  | 劳拉替尼 + 尼洛替尼 用于选定的晚期乳头状RCC患者，包括遗传性平滑肌瘤病相关癌(HLRCC)相关RCC  |\n|           | 帕博昔尼 + 依维莫司 | 尼沃单抗 |\n|           | 贝伐单抗 + 依维莫司  | 依维莫司 |\n|           | 舒尼替尼 | 帕唑帕尼 |\n|           |  砷西罗莫司（现后仅限风险组为1类；其他风险组为2A类）|\n\n【4】b \\[见NCCN指南晚期治疗相关监管管理\\]\n\n【5】c 晚期RCC试验中用于非肿瘤部位受影响的低风险模型包括以下6个短生存期预测因素中的至少3个：从诊断到开始全身治疗的<1年，Karnofsky体能状态评分60-70，血红蛋白< LLN，校正钙> 10 mg/dL，LDH> 1.5 \\(ULN\\)，多部位转移。Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.\n\n【6】f FDA批准的治疗移动及伤及见代理米帕卢合适的替代品。\n\n【7】h 对于具金曲型或微型亚型，在细胞毒化疗（卡铂+吉西他滨、卡铂+紫杉醇或顺铂+吉西他滨）和自前用于尿路上皮的其他类别化疗表现则部分缓解。吉西他滨+多柔比霉在肾输尿管分癌转移（Roubaud G,et al.Oncology 2011;80:214-218;Shah AY,et al.BJU Int 2017;120:782-792）。口服袜的治疗通常不会在膀胱输尿管分癌中产生缓解。在临床试验之外，以细类为基础的化疗方案还灵异各种输尿管细的首选疗法。\n\n【8】Version 2.2023, 08/03/22 删除5:<u>©</u> 2022 National Comprehensive Cancer Network删除5:<u>®</u> (NCCN删除5:<u>®</u>). All rights reserved. NCCN Guidelines删除5:<u>®</u> and this illustration may not be reproduced in any form without the express written permission of NCCN.", "index": 42, "show": true, "start": 42, "end": 48, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "【2】", "content": "【0】页码:17\n_NCCN临床实 践指南： 肾癌（2023.V2）-中文版(1)\n<mark>(本页删除)</mark>本页被模型判断为参考页疑似页眉<u># NCCN Guidelines Version 2.2023\n## 肾癌</u>\n\n【1】### 复发或Ⅳ期疾病的全身治疗原则\n\n【2】#### 非透明细胞组织学的全身治疗\n\n| 首选方案 | 其他推荐方案 | 在某些情况下有用 |\n| -------- | ----------- | ---------------- |\n| 临床试验    | 乐伐替尼 + 依维莫司 | 阿昔替尼 |\n| 帕博昔尼   | 纳武单抗 | 贝伐单抗 |\n| 舒尼替尼  | 劳拉替尼 + 尼洛替尼 用于选定的晚期乳头状RCC患者，包括遗传性平滑肌瘤病相关癌(HLRCC)相关RCC  |\n|           | 帕博昔尼 + 依维莫司 | 尼沃单抗 |\n|           | 贝伐单抗 + 依维莫司  | 依维莫司 |\n|           | 舒尼替尼 | 帕唑帕尼 |\n|           |  砷西罗莫司（现后仅限风险组为1类；其他风险组为2A类）|\n\n【4】b \\[见NCCN指南晚期治疗相关监管管理\\]\n\n【5】c 晚期RCC试验中用于非肿瘤部位受影响的低风险模型包括以下6个短生存期预测因素中的至少3个：从诊断到开始全身治疗的<1年，Karnofsky体能状态评分60-70，血红蛋白< LLN，校正钙> 10 mg/dL，LDH> 1.5 \\(ULN\\)，多部位转移。Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.\n\n【6】f FDA批准的治疗移动及伤及见代理米帕卢合适的替代品。\n\n【7】h 对于具金曲型或微型亚型，在细胞毒化疗（卡铂+吉西他滨、卡铂+紫杉醇或顺铂+吉西他滨）和自前用于尿路上皮的其他类别化疗表现则部分缓解。吉西他滨+多柔比霉在肾输尿管分癌转移（Roubaud G,et al.Oncology 2011;80:214-218;Shah AY,et al.BJU Int 2017;120:782-792）。口服袜的治疗通常不会在膀胱输尿管分癌中产生缓解。在临床试验之外，以细类为基础的化疗方案还灵异各种输尿管细的首选疗法。\n\n【8】Version 2.2023, 08/03/22 删除5:<u>©</u> 2022 National Comprehensive Cancer Network删除5:<u>®</u> (NCCN删除5:<u>®</u>). All rights reserved. NCCN Guidelines删除5:<u>®</u> and this illustration may not be reproduced in any form without the express written permission of NCCN.", "index": 146, "show": true, "start": 133, "end": 136, "province": ["格式规范性", "表格格式错误"], "isEdit": false}], "startTime": "2024/08/06 16:47:15", "endTime": "2024/08/06 16:48:36", "cost": 81.361}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:48:36", "grab_time": "2024-08-06 00:47:15"}
{"id": 2211544, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "1885f48c-fac3-4554-9abd-92251a7cf82a", "title": "2023 NICE 高度专业化的技术指南：用于治疗症状前脊髓性肌萎缩症的 Onasemnogene abeparvovec【HST24】", "text": "【0】页码:18\n2023 NICE 高度专业化的技术指南：用于治疗症状前脊髓性肌萎缩症的 Onasemnogene abeparvovec【HST24】\n### Other factors\n\n【1】#### Equality issues\n\n【2】3.14 During the evaluation, some consultees highlighted that, because onasemnogene abeparvovec would be provided at a limited number of highly specialised centres, there was the potential for issues of equity of access based on geographic location. The committee acknowledged that onasemnogene abeparvovec would only be delivered in a small number of highly specialised centres because there is a need to concentrate expertise. The committee understood that NHS England selected the centres to provide this service and were responsible for implementing this service.\n\n【3】### Conclusion\n\n【4】#### Recommendation\n\n【5】3.15 The committee considered the evidence from SPR1NT and the company's and EAG's cost-effectiveness results. Taking this into account, it concluded that onasemnogene abeparvovec is likely to provide value for money in the context of a highly specialised service if used in babies aged 12 months and under. So, onasemnogene abeparvovec is recommended as an option for presymptomatic SMA in this age group.", "tags": {}, "lang": "en", "attr": {"page_num": 18, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 NICE 高度专业化的技术指南：用于治疗症状前脊髓性肌萎缩症的 Onasemnogene abeparvovec【HST24】.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:54:34", "endTime": "2024/08/06 15:54:48", "cost": 14.302}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:54:49", "grab_time": "2024-08-05 23:54:34"}
{"id": 2211543, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "91d7bb1b-0688-4af1-ac86-f3f36900ed75", "title": "SMFM：妊娠期心脏病患者的抗凝治疗指南（2022）", "text": "【0】页码:89\nSMFM：妊娠期心脏病患者的抗凝治疗指南（2022）\nRecommendation statement\n\n【1】删除32:<u>**</u>For pregnant individuals with left ventricular systolic dysfunction and an ejection fraction < 35%, we recommend adjusted-dose LMWH.删除32:<u>**</u>\n\n| GRADE | 1C |\n| --- | --- |\n| Other organization recommendations | n/a |\n\n| Category A Evidence: | Category B Evidence: | Category C Evidence: |\n| --- | --- | --- |\n| n/a | n/a | 删除32:<u>**</u>Katsuragi 2012:删除32:<u>**</u> Literature review: Anticoagulation therapy should be considered for all pregnant and postpartum women with cardiomyopathy and LVEF <35%. <br> 删除32:<u>**</u>Kido 2019:删除32:<u>**</u> Literature review: left ventricular noncompaction (LVNC) itself is not associated with increase in thromboembolism event rates. Therapeutic anticoagulation therapy should not be considered only for LVNC, unless there is risk factor for thromboembolism. Current literature justifies prophylactic therapeutic anticoagulation in LVNC with low left ventricular ejection fraction (EF < 40%) and/or atrial fibrillation. <br> 删除32:<u>**</u>Goland 2012:删除32:<u>**</u> Editorial: Because of the increased risk of thromboembolic events during pregnancy, all patients with dilated cardiomyopathies and left ventricular ejection fraction 40% or less should be anticoagulated even in the absence of the other risk factors for TE events mentioned earlier. LMWH are the preferred drugs for |", "tags": {}, "lang": "en", "attr": {"page_num": 89, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/SMFM：妊娠期心脏病患者的抗凝治疗指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:29:22", "endTime": "2024/08/06 15:29:49", "cost": 27.581}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:29:49", "grab_time": "2024-08-05 23:29:21"}
{"id": 2211542, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "ce77b675-5fe9-4195-8460-f195afc940db", "title": "1_成人慢性肾脏病食养指南（2024年版）", "text": "【0】页码:17\n1_成人慢性肾脏病食养指南（2024年版）\n#### 附录1\n\n【1】### 成人慢性肾脏病患者的食物选择\n\n【2】#### 一、食物选择\n\n【3】慢性肾脏病患者的膳食既要控制能量和蛋白质，又要兼顾减少钠、钾、磷等食物的摄入，还要调整水分。做好慢性肾脏病膳食管理，可以以下四点着手: \n- 第一，根据慢性肾脏病不同疾病分期营养管理原则做好食物选择，计划好 1 天需要的食物品种和数量；\n- 第二，做好食物称量，确定好食物品种后，用电子秤称好 1 天所需食物 (包括油、盐等调味品) 的量；\n- 第三，做好食物烹调方法选择，尽量选择清蒸、炖、煮的 方法，为减少食物中磷和钠的量，食物烹调前先飞水、后烹调，最后不调味品；\n- 第四，慢性肾脏病患者的家庭照料者有条件时可多学习烹调方法，丰富膳食种类。\n\n【4】食物营养成分和营养标签是慢性肾脏病患者选择食物的重要参考资料，学会看食物营养成分和营养标签是管理好慢性肾脏病的必备技能。在保障能量充足和控制总蛋白质量的基础上，当需要控制膳食中的钠、钾、磷时，可参考常见食物钠、钾、磷、蛋白质及磷/蛋白质比值及含量表 (表 1.1) 来选择低钠、低钾、低磷的食物。", "tags": {}, "lang": "zh", "attr": {"page_num": 17, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/1_成人慢性肾脏病食养指南（2024年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:20:16", "endTime": "2024/08/06 16:21:27", "cost": 70.879}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:21:27", "grab_time": "2024-08-06 00:20:16"}
{"id": 2211541, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "eb352e3f-256c-42f7-a3da-71cb57c1ae2d", "title": "早产儿和低出生体重儿袋鼠式护理临床实践指南（2022）", "text": "【0】页码:7\n早产儿和低出生体重儿袋鼠式护理临床实践指南（2022）\nStates Agency for International Development, USAID》(爱袋鼠护理实施指南)，西班牙也发表袋鼠式护理基金会(kangaroo foundation)《早产儿和低 出生体重儿童的爱袋鼠式护理：基于证据的临床实践 指南》，香港地区/袋鼠式护理项目实地挨大指南均推荐将早产儿和LBWI作为KMC的适用入选标         准。]删除11:<u>(10-107,109)</u> 不仅针对狭义上的早产儿(32 w<胎龄 <37 w)且LBWI(≤1 500 g出生体重<500 g)， KMC可随较超早产儿和超低出生体重儿同样适 用。 删除27:<u>4</u>项研究表明: KMC在超低出生体重儿和超 早产儿中的应用安全、可行。其中2项前瞻对策性  研究(n=48)显示实施KMC前后超早产儿生命体 征差异无统计学意义]删除11:<u>(110-111)</u>; 还有l项RCT (n=123) 和1项回顾性研究(n=265)表明。早期KMC前   短且早产儿和超低出生体重儿住院天数吻异的时 间，达完全经口喂养时间，并提高前临时纯母乳喂养率](12D-13)。 另1项回顾性研究(n=145)表中：至第3周期的超低出生体重儿和KMC前短及无创辅助通气网疗 天数的时间。\n\n【1】推荐说明:基于现有的肖指南，综合现行试 严、专家共识，并参考多实施前不同地区政策和本，将早产儿和LBWI作为KMC的适用对象。如果 KMC无 绝对禁忌，即使是婴儿在所动脉肺导管留置、频繁呕哭、胸腔闭式引流管留置、外周动脉导管留置、机械通气等一等情况均不累 KMC的实  生命体征平稳的情况下均可实施KMC{172eterangan in brain 头振的低出在体重儿出生时向的用是安全的故本推 荐实施KMC的车用对象包括超早产儿和超低出生体重儿。 但是早产儿和超低出生体重儿KMC的提供 育后动刚有行读物仍需要更多研究以恩，是未米 的 研究方向之一。\n\n【2】临床问题8：KMC的开始时间？\n\n【3】推荐意见17:推荐在体征平稳的早产儿和 LBWI出生后即刻开始KMC(证据等级A; 推荐 强度：强推荐)。\n\n【4】推荐意见18：因故无法在生后即刻实施KMC 时，待条件允许后应尽快达到(证据等级C；推  推荐强度:弱推荐)。\n\n证据摘要:本问题共纳入2项RCT指个出 生后即刻开始KMC的益声。其申1项RCT (n= 321)]结果表明：生后即刻开始KMC可降低早产 儿生后28 d内的死亡率] (RR=0.删除13:<u>75, 95</u>%CI (0.64， 0.89)，P<0.001)，低体温发牛率(RR=0.删除13:<u>65, 95</u>%CI  删除11:<u>(0.51, 083)</u>，P<o.05|及败血症发生率{RR=0.82， 95%CI (0.73，033)， P<0.05| ）。另1项RCT(n=160)显示:相比较早期推动时出生后8.5删除11:<u>(7.0  -10.0)</u>天]KMC.,早期去掉时出生后1.5 删除11:<u>(1.0-3.3)</u>天}KMC提高LBW1的纯母乳喂养率 (86.3% vs. 45.0%， P<0.05)，且延生呼吸暂停的频率 更低($(11.9%vs. 20%， P<0.05)。这将伴再时转变到 LBWI出院早。\n\n【6】推荐说明!基于现有的证据。参考期证据 综合并考虑KMC实施后的评估标准和推荀规 定，37年发布《新策略兰教学)的多中心】 RCT纳入了321例出生体重在1000-1799 8的  新生儿(排除在生后1小时伉次变引生呼吸窘迫有先天性膈疝患儿)，即刻KMC组日动时为出生后1.3天(1.08-2.7 h),核对时问均为169 (13.0-19.7 h)， 该研究结果表明，相比非即刻组先找之家常规护 理(暖箱/婴儿保凤等)，再在特零定标准开始KMC  1小时内均为生后删除11:<u>(3.38-10.14)</u>，持美均时间 为1.53 (0.3-3.3 h)，即刻KMC组能显者降低并先 明出院较发日]这些与B对(早现报告：生后最触发   触时”中指出的“ Kmc鼓励早现实施和母乳喂 养在生后即刻进行”的观点一致。故推荐出生 后低患异常无特性母状式生具呼吸掌管发育期。   抱砷处理儿，即刻期开始KMC。无法即刻实施KMC者，可在生命体征基本稳定后尽快启动。\n\n【7】删除32:<u>**</u>临床问题8.2:实施KMC的救护设备?删除32:<u>**</u>\n\n【8】推荐意见19:推荐提供有助于KMC实施的设备。如细肩包、婴儿用束风、脉克娇搏及 删除32:<u>**</u>监护设备等(证据等级C, 推荐强度:弱推荐) 。删除32:<u>**</u>\n\n【9】证据摘要:本问题共纳入4项系统评价(R).\n证据家显示实施KMC的病，其设备有俯规范。删除27:<u>4</u>项 系家评价校园，无足认为相似设备支持器一种KMC施伊住性因素，而够察数据，缺乏教入相等举实施KMC的评渠采证。\n\n【10】推荐说明:基于hu和推理，结合现有指南规 点，并参考早产儿和LBWI寒够的偏Good,推荐建服 供KMC需带来化测入用婴床风、脉率绑及监护设备等关键KMC的顺利开展。\n\n【11】临床问题10：性效率KMC?\n\n推荐意思20.推荐使用亲父母亲实施KMC\n  (证据等级: B; 推荐强度:强推荐)。\n证据摘塑:本问题共纳入4项研究，包括 3  项 RCT121-123]|和 1篇指南(袋鼠式护理宝随机对策性 早产 儿喂养作指南 )】较较父亲新朗实施KMC   父亲共，其中3项RCT 00520纳）表明:大父亲的\n亲实施KMC在缓解等为面作州有获似(120-以上8", "tags": {}, "lang": "zh", "attr": {"page_num": 7, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/早产儿和低出生体重儿袋鼠式护理临床实践指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "®", "content": "【0】页码:7\n早产儿和低出生体重儿袋鼠式护理临床实践指南（2022）\nStates Agency for International Development, USAID》(爱袋鼠护理实施指南)，西班牙也发表袋鼠式护理基金会(kangaroo foundation)《早产儿和低 出生体重儿童的爱袋鼠式护理：基于证据的临床实践 指南》，香港地区/袋鼠式护理项目实地挨大指南均推荐将早产儿和LBWI作为KMC的适用入选标         准。]删除11:<u>(10-107,109)</u> 不仅针对狭义上的早产儿(32 w<胎龄 <37 w)且LBWI(≤1 500 g出生体重<500 g)， KMC可随较超早产儿和超低出生体重儿同样适 用。 删除27:<u>4</u>项研究表明: KMC在超低出生体重儿和超 早产儿中的应用安全、可行。其中2项前瞻对策性  研究(n=48)显示实施KMC前后超早产儿生命体 征差异无统计学意义]删除11:<u>(110-111)</u>; 还有l项RCT (n=123) 和1项回顾性研究(n=265)表明。早期KMC前   短且早产儿和超低出生体重儿住院天数吻异的时 间，达完全经口喂养时间，并提高前临时纯母乳喂养率](12D-13)。 另1项回顾性研究(n=145)表中：至第3周期的超低出生体重儿和KMC前短及无创辅助通气网疗 天数的时间。\n\n【1】推荐说明:基于现有的肖指南，综合现行试 严、专家共识，并参考多实施前不同地区政策和本，将早产儿和LBWI作为KMC的适用对象。如果 KMC无 绝对禁忌，即使是婴儿在所动脉肺导管留置、频繁呕哭、胸腔闭式引流管留置、外周动脉导管留置、机械通气等一等情况均不累 KMC的实  生命体征平稳的情况下均可实施KMC{172eterangan in brain 头振的低出在体重儿出生时向的用是安全的故本推 荐实施KMC的车用对象包括超早产儿和超低出生体重儿。 但是早产儿和超低出生体重儿KMC的提供 育后动刚有行读物仍需要更多研究以恩，是未米 的 研究方向之一。\n\n【2】临床问题8：KMC的开始时间？\n\n【3】推荐意见17:推荐在体征平稳的早产儿和 LBWI出生后即刻开始KMC(证据等级A; 推荐 强度：强推荐)。\n\n【4】推荐意见18：因故无法在生后即刻实施KMC 时，待条件允许后应尽快达到(证据等级C；推  推荐强度:弱推荐)。\n\n证据摘要:本问题共纳入2项RCT指个出 生后即刻开始KMC的益声。其申1项RCT (n= 321)]结果表明：生后即刻开始KMC可降低早产 儿生后28 d内的死亡率] (RR=0.删除13:<u>75, 95</u>%CI (0.64， 0.89)，P<0.001)，低体温发牛率(RR=0.删除13:<u>65, 95</u>%CI  删除11:<u>(0.51, 083)</u>，P<o.05|及败血症发生率{RR=0.82， 95%CI (0.73，033)， P<0.05| ）。另1项RCT(n=160)显示:相比较早期推动时出生后8.5删除11:<u>(7.0  -10.0)</u>天]KMC.,早期去掉时出生后1.5 删除11:<u>(1.0-3.3)</u>天}KMC提高LBW1的纯母乳喂养率 (86.3% vs. 45.0%， P<0.05)，且延生呼吸暂停的频率 更低($(11.9%vs. 20%， P<0.05)。这将伴再时转变到 LBWI出院早。\n\n【6】推荐说明!基于现有的证据。参考期证据 综合并考虑KMC实施后的评估标准和推荀规 定，37年发布《新策略兰教学)的多中心】 RCT纳入了321例出生体重在1000-1799 8的  新生儿(排除在生后1小时伉次变引生呼吸窘迫有先天性膈疝患儿)，即刻KMC组日动时为出生后1.3天(1.08-2.7 h),核对时问均为169 (13.0-19.7 h)， 该研究结果表明，相比非即刻组先找之家常规护 理(暖箱/婴儿保凤等)，再在特零定标准开始KMC  1小时内均为生后删除11:<u>(3.38-10.14)</u>，持美均时间 为1.53 (0.3-3.3 h)，即刻KMC组能显者降低并先 明出院较发日]这些与B对(早现报告：生后最触发   触时”中指出的“ Kmc鼓励早现实施和母乳喂 养在生后即刻进行”的观点一致。故推荐出生 后低患异常无特性母状式生具呼吸掌管发育期。   抱砷处理儿，即刻期开始KMC。无法即刻实施KMC者，可在生命体征基本稳定后尽快启动。\n\n【7】删除32:<u>**</u>临床问题8.2:实施KMC的救护设备?删除32:<u>**</u>\n\n【8】推荐意见19:推荐提供有助于KMC实施的设备。如细肩包、婴儿用束风、脉克娇搏及 删除32:<u>**</u>监护设备等(证据等级C, 推荐强度:弱推荐) 。删除32:<u>**</u>\n\n【9】证据摘要:本问题共纳入4项系统评价(R).\n证据家显示实施KMC的病，其设备有俯规范。删除27:<u>4</u>项 系家评价校园，无足认为相似设备支持器一种KMC施伊住性因素，而够察数据，缺乏教入相等举实施KMC的评渠采证。\n\n【10】推荐说明:基于hu和推理，结合现有指南规 点，并参考早产儿和LBWI寒够的偏Good,推荐建服 供KMC需带来化测入用婴床风、脉率绑及监护设备等关键KMC的顺利开展。\n\n【11】临床问题10：性效率KMC?\n\n推荐意思20.推荐使用亲父母亲实施KMC\n  (证据等级: B; 推荐强度:强推荐)。\n证据摘塑:本问题共纳入4项研究，包括 3  项 RCT121-123]|和 1篇指南(袋鼠式护理宝随机对策性 早产 儿喂养作指南 )】较较父亲新朗实施KMC   父亲共，其中3项RCT 00520纳）表明:大父亲的\n亲实施KMC在缓解等为面作州有获似(120-以上8", "index": 19, "show": true, "start": 19, "end": 20, "province": ["文本干净度", "无关文本"], "isEdit": false}, {"text": "(证据等级: B; 推荐强度:强推荐)。", "content": "【0】页码:7\n早产儿和低出生体重儿袋<mark>®</mark>式护理临床实践指南（2022）\nStates Agency for International Development, USAID》(爱袋鼠护理实施指南)，西班牙也发表袋鼠式护理基金会(kangaroo foundation)《早产儿和低 出生体重儿童的爱袋鼠式护理：基于证据的临床实践 指南》，香港地区/袋鼠式护理项目实地挨大指南均推荐将早产儿和LBWI作为KMC的适用入选标         准。]删除11:<u>(10-107,109)</u> 不仅针对狭义上的早产儿(32 w<胎龄 <37 w)且LBWI(≤1 500 g出生体重<500 g)， KMC可随较超早产儿和超低出生体重儿同样适 用。 删除27:<u>4</u>项研究表明: KMC在超低出生体重儿和超 早产儿中的应用安全、可行。其中2项前瞻对策性  研究(n=48)显示实施KMC前后超早产儿生命体 征差异无统计学意义]删除11:<u>(110-111)</u>; 还有l项RCT (n=123) 和1项回顾性研究(n=265)表明。早期KMC前   短且早产儿和超低出生体重儿住院天数吻异的时 间，达完全经口喂养时间，并提高前临时纯母乳喂养率](12D-13)。 另1项回顾性研究(n=145)表中：至第3周期的超低出生体重儿和KMC前短及无创辅助通气网疗 天数的时间。\n\n【1】推荐说明:基于现有的肖指南，综合现行试 严、专家共识，并参考多实施前不同地区政策和本，将早产儿和LBWI作为KMC的适用对象。如果 KMC无 绝对禁忌，即使是婴儿在所动脉肺导管留置、频繁呕哭、胸腔闭式引流管留置、外周动脉导管留置、机械通气等一等情况均不累 KMC的实  生命体征平稳的情况下均可实施KMC{172eterangan in brain 头振的低出在体重儿出生时向的用是安全的故本推 荐实施KMC的车用对象包括超早产儿和超低出生体重儿。 但是早产儿和超低出生体重儿KMC的提供 育后动刚有行读物仍需要更多研究以恩，是未米 的 研究方向之一。\n\n【2】临床问题8：KMC的开始时间？\n\n【3】推荐意见17:推荐在体征平稳的早产儿和 LBWI出生后即刻开始KMC(证据等级A; 推荐 强度：强推荐)。\n\n【4】推荐意见18：因故无法在生后即刻实施KMC 时，待条件允许后应尽快达到(证据等级C；推  推荐强度:弱推荐)。\n\n证据摘要:本问题共纳入2项RCT指个出 生后即刻开始KMC的益声。其申1项RCT (n= 321)]结果表明：生后即刻开始KMC可降低早产 儿生后28 d内的死亡率] (RR=0.删除13:<u>75, 95</u>%CI (0.64， 0.89)，P<0.001)，低体温发牛率(RR=0.删除13:<u>65, 95</u>%CI  删除11:<u>(0.51, 083)</u>，P<o.05|及败血症发生率{RR=0.82， 95%CI (0.73，033)， P<0.05| ）。另1项RCT(n=160)显示:相比较早期推动时出生后8.5删除11:<u>(7.0  -10.0)</u>天]KMC.,早期去掉时出生后1.5 删除11:<u>(1.0-3.3)</u>天}KMC提高LBW1的纯母乳喂养率 (86.3% vs. 45.0%， P<0.05)，且延生呼吸暂停的频率 更低($(11.9%vs. 20%， P<0.05)。这将伴再时转变到 LBWI出院早。\n\n【6】推荐说明!基于现有的证据。参考期证据 综合并考虑KMC实施后的评估标准和推荀规 定，37年发布《新策略兰教学)的多中心】 RCT纳入了321例出生体重在1000-1799 8的  新生儿(排除在生后1小时伉次变引生呼吸窘迫有先天性膈疝患儿)，即刻KMC组日动时为出生后1.3天(1.08-2.7 h),核对时问均为169 (13.0-19.7 h)， 该研究结果表明，相比非即刻组先找之家常规护 理(暖箱/婴儿保凤等)，再在特零定标准开始KMC  1小时内均为生后删除11:<u>(3.38-10.14)</u>，持美均时间 为1.53 (0.3-3.3 h)，即刻KMC组能显者降低并先 明出院较发日]这些与B对(早现报告：生后最触发   触时”中指出的“ Kmc鼓励早现实施和母乳喂 养在生后即刻进行”的观点一致。故推荐出生 后低患异常无特性母状式生具呼吸掌管发育期。   抱砷处理儿，即刻期开始KMC。无法即刻实施KMC者，可在生命体征基本稳定后尽快启动。\n\n【7】删除32:<u>**</u>临床问题8.2:实施KMC的救护设备?删除32:<u>**</u>\n\n【8】推荐意见19:推荐提供有助于KMC实施的设备。如细肩包、婴儿用束风、脉克娇搏及 删除32:<u>**</u>监护设备等(证据等级C, 推荐强度:弱推荐) 。删除32:<u>**</u>\n\n【9】证据摘要:本问题共纳入4项系统评价(R).\n证据家显示实施KMC的病，其设备有俯规范。删除27:<u>4</u>项 系家评价校园，无足认为相似设备支持器一种KMC施伊住性因素，而够察数据，缺乏教入相等举实施KMC的评渠采证。\n\n【10】推荐说明:基于hu和推理，结合现有指南规 点，并参考早产儿和LBWI寒够的偏Good,推荐建服 供KMC需带来化测入用婴床风、脉率绑及监护设备等关键KMC的顺利开展。\n\n【11】临床问题10：性效率KMC?\n\n推荐意思20.推荐使用亲父母亲实施KMC\n  (证据等级: B; 推荐强度:强推荐)。\n证据摘塑:本问题共纳入4项研究，包括 3  项 RCT121-123]|和 1篇指南(袋鼠式护理宝随机对策性 早产 儿喂养作指南 )】较较父亲新朗实施KMC   父亲共，其中3项RCT 00520纳）表明:大父亲的\n亲实施KMC在缓解等为面作州有获似(120-以上8", "index": 0, "show": true, "start": 0, "end": 20, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "后面缺少一段"}], "startTime": "2024/08/06 17:12:37", "endTime": "2024/08/06 17:17:43", "cost": 305.988}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 01:17:43", "grab_time": "2024-08-06 01:12:37"}
{"id": 2211540, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "e5eabb45-f263-4e94-a712-ad70ed30a4ba", "title": "_（2024.V1）NCCN 临床实践指南：结肠癌", "text": "【0】页码:170\n_（2024.V1）NCCN 临床实践指南：结肠癌\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】疑似页眉<u>### NCCN Guidelines Version 1.2024 - Colon Cancer</u>\n\n【2】参考删除-3:<u>365. Hanna NN, Onukwugha E, Choti MA, et al. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data. Colorectal Dis 2012;14:48-55删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21689262.</u></u>\n\n【3】参考删除-3:<u>366. McCleary NJ, Meyerhardt JA, Green E, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013;31:2600-2606删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23733765.</u></u>\n\n【4】参考删除-3:<u>367. Haller DG, O'Connell MJ, Cartwright TH, et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol 2015;26:715-724删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25595934.</u></u>\n\n【5】参考删除-3:<u>368. Rosati G, Lonardi S, Galli F, et al. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. Eur J Cancer 2021;148:190-201删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33747415.</u></u>\n\n【6】369. Cheung WY, Renfro LA, Kerr D, et al. Determinants of early mortality among 37,568 patients with colon cancer who participated in 25 clinical trials from the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol 2016;34:1182-1189删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26858337.</u>\n\n【7】参考删除-3:<u>370. Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011;305:2335-2342删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21642686.</u></u>\n\n【8】参考删除-3:<u>371. Sun Z, Adam MA, Kim J, et al. Determining the optimal timing for initiation of adjuvant chemotherapy after resection for stage II and III colon cancer. Dis Colon Rectum 2016;59:87-93删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26734965.</u></u>\n\n【9】参考删除-3:<u>372. Bos AC, van Erning FN, van Gestel YR, et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer 2015;51:2553-2561删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26360411.</u></u>\n\n【10】参考删除-3:<u>373. Sargent D, Grothey A, Gray R. Time to initiation of adjuvant chemotherapy and survival in colorectal cancer. JAMA 2011;306:1199; author reply 1200删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21934049.</u></u>\n\n【11】374. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000;355:1588-1596删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10821362.</u>\n\n【12】参考删除-3:<u>375. Jager E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996;14:2274-2279删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8708717.</u></u>\n\n【13】376. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989;63:1026-1030删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2645076.</u>\n\n【14】参考删除-3:<u>377. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012;104:211-227删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22266473.</u></u>\n\n【15】参考删除-3:<u>378. Sanoff HK, Carpenter WR, Freburger J, et al. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: A population-based analysis. Cancer 2012;118:4309-4320删除1:<u>. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22249436.</u></u>", "tags": {}, "lang": "en", "attr": {"page_num": 170, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_（2024.V1）NCCN 临床实践指南：结肠癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:38:48", "endTime": "2024/08/06 15:38:58", "cost": 10.094}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:38:58", "grab_time": "2024-08-05 23:38:47"}
{"id": 2211539, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "b113361e-5c91-47e4-904f-0bdd1df9fa0d", "title": "2023 ESO指南：烟雾血管病", "text": "【0】页码:18\n2023 ESO指南：烟雾血管病\n删除图片描述:<u>Figure 4. Meta-analysis (for PICO 6) showing disability risk in adult MMD patients who underwent direct or combined revascularization surgery compared to indirect revascularization surgery.</u>\n\n【1】direct or combined revascularization surgery compared to indirect revascularization surgery [RR 0.58 (95% CI: 0.24–1.39)]. The certainty evaluated by GRADE in this estimate was very low due to concern on the risk of bias, substantial heterogeneity and limited precision in the effect estimate 删除9:<u>(Table 6, GRADE profile, Figure 3, Supplemental Materials-Table 6)</u>.\n\n【2】The three studies focussing on disability as primary outcome (mRS>2–5) failed to reveal a clear superiority of any of the bypass strategies. This is most likely because an unfavourable, peri- or postoperative course leading to disability is fortunately a very rare event. Gao et al.删除21:<u>^14 </u>had also studied the disability for their 371 patients. Accordingly, out of the 281 patients undergoing combined revascularization only 1% and out of the 90 patients undergoing indirect revascularization only 2% had a disabling stroke. The study by Kim et al.删除21:<u>^143 </u>focused only on outcome as measured by the mRS. Fifty-one patients were treated with a combined and 45 patients with an indirect bypass. All patients were adults with a mean age of 38 years (range: 18–68). The follow-up period only covered the perioperative period up to 6 weeks following surgery, rather reflecting the risk and complications of the bypass strategies. During this early postoperative time, 10% of the combined group and 7% of the indirect group were categorized as disabled (RR 1.47 删除12:<u>[0.37–5.81]</u>). However, these data have to be interpreted carefully due to the short follow-up period and the bias that some patients were already disabled prior to surgery as a consequence of their strokes. Lai et al.删除21:<u>^144 </u>in contrast, followed up their patients at least 6 months, which is still relatively short. They included a total of 96 patients, 44 treated by combined and 52 treated by indirect revascularization strategies. Patients were all adults with a mean age of 42 ± 11 years (range: 18–69). In this study, the disability rate was comparable, but surprisingly high among the groups, with 30% and 35% for combined and indirect techniques, respectively (RR 0.85 删除12:<u>[0.47–1.54]</u>). Analysing these three studies together was hampered by the large heterogeneity of follow-up periods and frequencies for patients presenting with disability. The meta-analysis findings  revealed a non-significant association between direct or combined revascularization surgery versus indirect revascularization surgery in reducing the disability risk in patients with MMD . The certainty evaluated by GRADE was low due to low to moderate risk of bias, heterogeneity and imprecision in the summary estimate 删除9:<u>(Table 6, GRADE profile, Supplemental Materials-Table 6)</u>.\n\n【3】删除图片描述:<u>!删除9:<u>[]删除9:<u>(17_0.png)</u>\n删除图片描述:<u>![]</u>(17_1.png)</u></u>\n删除图片描述:<u>![](17_2.png)</u>\n\n【4】Additional information. Indirect revascularization relies on neovascularization of the cortical surface via angiogenic mechanisms from pedicle-based grafts. The variability of techniques and tissues used as vascularised grafts is huge. Several variations of indirect revascularization have been developed: EMS, encephalo-arterio-synangiosis (EAS), encephalo-myo-arterio-synangiosis (EMAS), encephalo-duro-synangiosis (EDS), EDAS, EDAMS, EDAGS, as well as various combinations of these. The variety of indirect techniques is large, and it remains unknown which, if any, of these techniques is superior to the others. In general, indirect techniques are easier to perform since they do not include a direct anastomosis. Moreover, cerebral revascularization, along with the haemodynamic protection of the brain, may take months to develop.\n\n【5】All studies agreed that the perioperative complications did not differ between direct/combined versus indirect revascularization techniques: Kim et al.删除21:<u>^143,145 </u>confirm that procedures that include a direct intervention are not more risky with respect to stroke, irreversible/transient ischaemic neurological deficit, haemorrhage, skin necrosis, and infection. Deng et al.删除21:<u>^146 </u>comparing direct versus indirect revascularization among adults, also did not detect any significant increase in perioperative complications by direct revascularization techniques. Furthermore, another meta-analysis that focused on perioperative complications in adults demonstrated that despite a higher incidence of haemorrhagic complications in the direct bypass group, direct and combined revascularization techniques were superior in providing long-term favourable outcome.删除21:<u>^147 </u>Here, the beneficial effects of combined revascularization techniques (via the direct bypass component) outweighed the higher complication rate.", "tags": {}, "lang": "en", "attr": {"page_num": 18, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ESO指南：烟雾血管病.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【2】", "content": "【0】页码:18\n2023 ESO指南：烟雾血管病\n删除图片描述:<u>Figure 4. Meta-analysis (for PICO 6) showing disability risk in adult MMD patients who underwent direct or combined revascularization surgery compared to indirect revascularization surgery.</u>\n\n【1】direct or combined revascularization surgery compared to indirect revascularization surgery [RR 0.58 (95% CI: 0.24–1.39)]. The certainty evaluated by GRADE in this estimate was very low due to concern on the risk of bias, substantial heterogeneity and limited precision in the effect estimate 删除9:<u>(Table 6, GRADE profile, Figure 3, Supplemental Materials-Table 6)</u>.\n\n【2】The three studies focussing on disability as primary outcome (mRS>2–5) failed to reveal a clear superiority of any of the bypass strategies. This is most likely because an unfavourable, peri- or postoperative course leading to disability is fortunately a very rare event. Gao et al.删除21:<u>^14 </u>had also studied the disability for their 371 patients. Accordingly, out of the 281 patients undergoing combined revascularization only 1% and out of the 90 patients undergoing indirect revascularization only 2% had a disabling stroke. The study by Kim et al.删除21:<u>^143 </u>focused only on outcome as measured by the mRS. Fifty-one patients were treated with a combined and 45 patients with an indirect bypass. All patients were adults with a mean age of 38 years (range: 18–68). The follow-up period only covered the perioperative period up to 6 weeks following surgery, rather reflecting the risk and complications of the bypass strategies. During this early postoperative time, 10% of the combined group and 7% of the indirect group were categorized as disabled (RR 1.47 删除12:<u>[0.37–5.81]</u>). However, these data have to be interpreted carefully due to the short follow-up period and the bias that some patients were already disabled prior to surgery as a consequence of their strokes. Lai et al.删除21:<u>^144 </u>in contrast, followed up their patients at least 6 months, which is still relatively short. They included a total of 96 patients, 44 treated by combined and 52 treated by indirect revascularization strategies. Patients were all adults with a mean age of 42 ± 11 years (range: 18–69). In this study, the disability rate was comparable, but surprisingly high among the groups, with 30% and 35% for combined and indirect techniques, respectively (RR 0.85 删除12:<u>[0.47–1.54]</u>). Analysing these three studies together was hampered by the large heterogeneity of follow-up periods and frequencies for patients presenting with disability. The meta-analysis findings  revealed a non-significant association between direct or combined revascularization surgery versus indirect revascularization surgery in reducing the disability risk in patients with MMD . The certainty evaluated by GRADE was low due to low to moderate risk of bias, heterogeneity and imprecision in the summary estimate 删除9:<u>(Table 6, GRADE profile, Supplemental Materials-Table 6)</u>.\n\n【3】删除图片描述:<u>!删除9:<u>[]删除9:<u>(17_0.png)</u>\n删除图片描述:<u>![]</u>(17_1.png)</u></u>\n删除图片描述:<u>![](17_2.png)</u>\n\n【4】Additional information. Indirect revascularization relies on neovascularization of the cortical surface via angiogenic mechanisms from pedicle-based grafts. The variability of techniques and tissues used as vascularised grafts is huge. Several variations of indirect revascularization have been developed: EMS, encephalo-arterio-synangiosis (EAS), encephalo-myo-arterio-synangiosis (EMAS), encephalo-duro-synangiosis (EDS), EDAS, EDAMS, EDAGS, as well as various combinations of these. The variety of indirect techniques is large, and it remains unknown which, if any, of these techniques is superior to the others. In general, indirect techniques are easier to perform since they do not include a direct anastomosis. Moreover, cerebral revascularization, along with the haemodynamic protection of the brain, may take months to develop.\n\n【5】All studies agreed that the perioperative complications did not differ between direct/combined versus indirect revascularization techniques: Kim et al.删除21:<u>^143,145 </u>confirm that procedures that include a direct intervention are not more risky with respect to stroke, irreversible/transient ischaemic neurological deficit, haemorrhage, skin necrosis, and infection. Deng et al.删除21:<u>^146 </u>comparing direct versus indirect revascularization among adults, also did not detect any significant increase in perioperative complications by direct revascularization techniques. Furthermore, another meta-analysis that focused on perioperative complications in adults demonstrated that despite a higher incidence of haemorrhagic complications in the direct bypass group, direct and combined revascularization techniques were superior in providing long-term favourable outcome.删除21:<u>^147 </u>Here, the beneficial effects of combined revascularization techniques (via the direct bypass component) outweighed the higher complication rate.", "index": 607, "show": true, "start": 607, "end": 610, "comment": "删除12:[0.37–5.81", "isEdit": false, "province": ["语义有效性", "错误删除"]}], "startTime": "2024/08/06 15:49:18", "endTime": "2024/08/06 15:50:27", "cost": 69.202}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:50:27", "grab_time": "2024-08-05 23:49:17"}
{"id": 2211538, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "1eeedcca-4eb0-477f-bfac-86a41237bba3", "title": "【神经领域】中国脑卒中防治指导规范（2021年版）", "text": "【0】页码:324\n【神经领域】中国脑卒中防治指导规范（2021年版）\n9. 主动脉弓夹层\n10. 近1周内存在不易压止血部位的动脉穿刺\n11. 血压升高（收缩压≥180mmHg，或舒张压≥100mmHg）\n12. 急性出血倾向，包括血小板计数低于10×10删除21:<u>^9</u>/L或其他情况\n删除13:<u>13. 24</u>小时内接受过低分子肝素治疗\n14. 口服抗凝剂且INR>1.7或PT>15秒\n删除13:<u>15. 48</u>小时内使用凝血酶抑制剂或Xa因子抑制剂，或各种实验室检查异常（如APTT、INR、血小板计数、ECT、TT或Xa因子活性测定等）\n16. 血糖<2.8mmol/L（50mg/L）或>22.2mmol/L(400mg/L)\n17. 头CT或MR提示近期梗死（梗死面积>1/3大脑中动脉供血区）\n\n【1】### 相关禁忌证\n下列情况需谨慎考虑其相对溶栓的风险与获益（即虽然存在一项或多项相对禁忌证，但并非绝对不能溶栓）：\n1. 轻型非致残性脑卒中\n2. 症状迅速改善的脑卒中\n3. 术后发生后出现的神经功能损害（与此次脑卒中发生相关）\n4. 颅外影颈动脉夹层\n5. 近2周内有大型外科手术或严重外伤（未伤及头颅）\n6. 近3周内有胃肠或泌尿系系统出血\n7. 孕产妇\n8. 癫痫\n9. 既往疾病遗留较重神经功能残疾\n10. 未破裂且未经治疗的动脉瘤或畸形、颅内小动脉瘤（<10mm）\n11. 少量脑内微出血（1~10个）\n12. 使用违禁药物\n13. 类脑卒中（stroke mimics）\n\n【2】注：rt-PA、重组组织型纤溶酶原激活剂，见表11-2；INR，国际标准化比率；APTT，活化部分凝血酶时间；\nCT，非静脉肾髓结时间；TT，凝血酶时间，1mmHg=0.133kPa，见表删除28:<u>11-4</u>。", "tags": {}, "lang": "zh", "attr": {"page_num": 324, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【神经领域】中国脑卒中防治指导规范（2021年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "13. 24", "content": "【0】页码:324\n【神经领域】中国脑卒中防治指导规范（2021年版）\n9. 主动脉弓夹层\n10. 近1周内存在不易压止血部位的动脉穿刺\n11. 血压升高（收缩压≥180mmHg，或舒张压≥100mmHg）\n12. 急性出血倾向，包括血小板计数低于10×10删除21:<u>^9</u>/L或其他情况\n删除13:<u>13. 24</u>小时内接受过低分子肝素治疗\n14. 口服抗凝剂且INR>1.7或PT>15秒\n删除13:<u>15. 48</u>小时内使用凝血酶抑制剂或Xa因子抑制剂，或各种实验室检查异常（如APTT、INR、血小板计数、ECT、TT或Xa因子活性测定等）\n16. 血糖<2.8mmol/L（50mg/L）或>22.2mmol/L(400mg/L)\n17. 头CT或MR提示近期梗死（梗死面积>1/3大脑中动脉供血区）\n\n【1】### 相关禁忌证\n下列情况需谨慎考虑其相对溶栓的风险与获益（即虽然存在一项或多项相对禁忌证，但并非绝对不能溶栓）：\n1. 轻型非致残性脑卒中\n2. 症状迅速改善的脑卒中\n3. 术后发生后出现的神经功能损害（与此次脑卒中发生相关）\n4. 颅外影颈动脉夹层\n5. 近2周内有大型外科手术或严重外伤（未伤及头颅）\n6. 近3周内有胃肠或泌尿系系统出血\n7. 孕产妇\n8. 癫痫\n9. 既往疾病遗留较重神经功能残疾\n10. 未破裂且未经治疗的动脉瘤或畸形、颅内小动脉瘤（<10mm）\n11. 少量脑内微出血（1~10个）\n12. 使用违禁药物\n13. 类脑卒中（stroke mimics）\n\n【2】注：rt-PA、重组组织型纤溶酶原激活剂，见表11-2；INR，国际标准化比率；APTT，活化部分凝血酶时间；\nCT，非静脉肾髓结时间；TT，凝血酶时间，1mmHg=0.133kPa，见表删除28:<u>11-4</u>。", "index": 159, "show": true, "start": 159, "end": 165, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "【2】注：rt-PA、重组组织型纤溶酶原激活剂，见表11-2；INR，国际标准化比率；APTT，活化部分凝血酶时间；\n\nCT，非静脉肾髓结时间；TT，凝血酶时间，1mmHg=0.133kPa，见表", "content": "【0】页码:324\n【神经领域】中国脑卒中防治指导规范（2021年版）\n9. 主动脉弓夹层\n10. 近1周内存在不易压止血部位的动脉穿刺\n11. 血压升高（收缩压≥180mmHg，或舒张压≥100mmHg）\n12. 急性出血倾向，包括血小板计数低于10×10删除21:<u>^9</u>/L或其他情况\n删除13:<u><mark>13. 24</mark></u>小时内接受过低分子肝素治疗\n14. 口服抗凝剂且INR>1.7或PT>15秒\n删除13:<u>15. 48</u>小时内使用凝血酶抑制剂或Xa因子抑制剂，或各种实验室检查异常（如APTT、INR、血小板计数、ECT、TT或Xa因子活性测定等）\n16. 血糖<2.8mmol/L（50mg/L）或>22.2mmol/L(400mg/L)\n17. 头CT或MR提示近期梗死（梗死面积>1/3大脑中动脉供血区）\n\n【1】### 相关禁忌证\n下列情况需谨慎考虑其相对溶栓的风险与获益（即虽然存在一项或多项相对禁忌证，但并非绝对不能溶栓）：\n1. 轻型非致残性脑卒中\n2. 症状迅速改善的脑卒中\n3. 术后发生后出现的神经功能损害（与此次脑卒中发生相关）\n4. 颅外影颈动脉夹层\n5. 近2周内有大型外科手术或严重外伤（未伤及头颅）\n6. 近3周内有胃肠或泌尿系系统出血\n7. 孕产妇\n8. 癫痫\n9. 既往疾病遗留较重神经功能残疾\n10. 未破裂且未经治疗的动脉瘤或畸形、颅内小动脉瘤（<10mm）\n11. 少量脑内微出血（1~10个）\n12. 使用违禁药物\n13. 类脑卒中（stroke mimics）\n\n【2】注：rt-PA、重组组织型纤溶酶原激活剂，见表11-2；INR，国际标准化比率；APTT，活化部分凝血酶时间；\nCT，非静脉肾髓结时间；TT，凝血酶时间，1mmHg=0.133kPa，见表删除28:<u>11-4</u>。", "index": 683, "show": true, "start": 670, "end": 768, "province": ["格式规范性", "多余换行"], "isEdit": false, "comment": "且中间缺字"}], "startTime": "2024/08/06 16:15:42", "endTime": "2024/08/06 16:17:37", "cost": 115.308}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:17:37", "grab_time": "2024-08-06 00:15:30"}
{"id": 2211537, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "9b029a25-293d-415b-816c-87dbd63769d8", "title": "【神经领域】2021+MSTCG立场声明：多发性硬化的疾病修饰疗法", "text": "【0】页码:9\n【神经领域】2021+MSTCG立场声明：多发性硬化的疾病修饰疗法\n删除图片描述:<u>![](8_0.png)</u>\n\n| Substance          | Indication       | Mechanism                                              | Risks for immune system  | Other risks                                               | Blood count checks                                                                                                                         | Other control examinations                                                                                                      |\n|--------------------|------------------|--------------------------------------------------------|--------------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|\n|                    |                  |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                               |\n| (Azathioprine)     | Mild/ moderate   | Purine DNA/RNA synthesis is prevented through cleavage | Leuko/lymphopenia 12% Red cell dysplasia, anaemia (6-28%) Megaloblastic anaemia Hepatic dysfunction                                 | IM and CMV retinitis Pancreatitis secondary infections neutropenic sepsis                                                                   | increased risk of solid malignancies (cervix, skin) vaccination to prevent infection                                             |\n| Injection          | RMS off-label use|                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                               |\n| Glatiramer acetate | Mild/ moderate   | Th1/Th2 shift; APC modulation                                 | reduced CD8+ CIS, natural regulation T3, slighty increased adaptive immunity highly antigen MHC1 coupled activation leading to enhanced T-cel production of BNDF                             |                        |                                                        | Before therapy blood count , hepatic and renal function parameters every 24 months liver, lipid, and blood count checks (re-checks every 2 years                                                                                   |\n|                    | RMS              |                                                        |                          |                                                           |                                                                                                                                             | during therapy every 3-6 months or at least every 24 months                                                                                                                                              | during therapy every 3-6 months)                                                                                                                                              |\n|                    |                  |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                               |\n| IFNβ               | Mild/ moderate   | Th1/Th2 shift: APC modulation                                  | reduced CD8+ CIS, natural regulation T3, slighty increased adaptive immunity highly antigen MHC1 coupled activation leading to enhanced T-cel production of BNDF                             |                        |                                                        | Before therapy blood count , hepatic and renal function parameters every 14 months liver, lipid, and blood count checks (re-checks every 2 years                                                                                   |\n|                    | RMS              |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                                              |\n|                    | RMS with relapse |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                               |\n|                    |                  |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                               |\n| Natalizumab        | Moderate/        | Inhibition of T-cell migration: Injection treatment on PML risk                            | lymphoid organ swelling improved NMES at BBB prevention of leukocytes migration at the BBB                            |                         |                                                                                                                                             |\n|                    | severe RMS       |                                                        |       with relapses         |                                                           | Before therapy blood count , hepatic and renal function parameters every 14 months liver, lipid, and blood count checks (re-checks every 2 years                                                                                   |\n|                    |                  |                                                        |                          |                                                           |                                                                                                                                             | during therapy CRP, full blood count control 4-6 months thereafter                                                                                                                                                     |\n|                    |                  |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                                                            |                                                                                          Injection-related reactions;\n\nOdumumabB                        |  Severe RMS           | Monoclonal antibody infusion recreational uses   | Highly active against CD20 B cell infections leading to depletion  \n| deseled B lymphocyte count                                      |   |    RMS with relapses      |                                                             | infusion rapid administration migraine-specific antibody reaction First dose should be divided into 5 (at least 5) doses thereafter with urinary output correction-fluid homeostatic balance monitored to prevent                                                                                                                                                    \n\n【3】                                                                  6-12-month intervals thereafter; CMV re-emergence must be ruled-out  hepatic/renal failure PML injection upper respiratory infections complete interval intervals eliminated", "tags": {}, "lang": "en", "attr": {"page_num": 9, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【神经领域】2021+MSTCG立场声明：多发性硬化的疾病修饰疗法.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:9\n\n【神经领域】2021+MSTCG立场声明：多发性硬化的疾病修饰疗法\n\n删除图片描述:\n\nSubstance\tIndication\tMechanism\tRisks for immune system\tOther risks\tBlood count checks\tOther control examinations\n(Azathioprine)\tMild/ moderate\tPurine DNA/RNA synthesis is prevented through cleavage\tLeuko/lymphopenia 12% Red cell dysplasia, anaemia (6-28%) Megaloblastic anaemia Hepatic dysfunction\tIM and CMV retinitis Pancreatitis secondary infections neutropenic sepsis\tincreased risk of solid malignancies (cervix, skin) vaccination to prevent infection\t\nInjection\tRMS off-label use\t\t\t\t\t\nGlatiramer acetate\tMild/ moderate\tTh1/Th2 shift; APC modulation\treduced CD8+ CIS, natural regulation T3, slighty increased adaptive immunity highly antigen MHC1 coupled activation leading to enhanced T-cel production of BNDF\t\t\tBefore therapy blood count , hepatic and renal function parameters every 24 months liver, lipid, and blood count checks (re-checks every 2 years\nRMS\t\t\t\t\tduring therapy every 3-6 months or at least every 24 months\nIFNβ\tMild/ moderate\tTh1/Th2 shift: APC modulation\treduced CD8+ CIS, natural regulation T3, slighty increased adaptive immunity highly antigen MHC1 coupled activation leading to enhanced T-cel production of BNDF\t\t\tBefore therapy blood count , hepatic and renal function parameters every 14 months liver, lipid, and blood count checks (re-checks every 2 years\nRMS\t\t\t\t\t\nRMS with relapse\t\t\t\t\t\nNatalizumab\tModerate/\tInhibition of T-cell migration: Injection treatment on PML risk\tlymphoid organ swelling improved NMES at BBB prevention of leukocytes migration at the BBB\t\t\t\nsevere RMS\t\twith relapses\t\tBefore therapy blood count , hepatic and renal function parameters every 14 months liver, lipid, and blood count checks (re-checks every 2 years\t\nduring therapy CRP, full blood count control 4-6 months thereafter\nOdumumabB                        |  Severe RMS           | Monoclonal antibody infusion recreational uses   | Highly active against CD20 B cell infections leading to depletion\n\n| deseled B lymphocyte count                                      |   |    RMS with relapses      |                                                             | infusion rapid administration migraine-specific antibody reaction First dose should be divided into 5 (at least 5) doses thereafter with urinary output correction-fluid homeostatic balance monitored to prevent\n\n【3】                                                                  6-12-month intervals thereafter; CMV re-emergence must be ruled-out  hepatic/renal failure PML injection upper respiratory infections complete interval intervals eliminated", "content": "【0】页码:9\n【神经领域】2021+MSTCG立场声明：多发性硬化的疾病修饰疗法\n删除图片描述:<u>![](8_0.png)</u>\n\n| Substance          | Indication       | Mechanism                                              | Risks for immune system  | Other risks                                               | Blood count checks                                                                                                                         | Other control examinations                                                                                                      |\n|--------------------|------------------|--------------------------------------------------------|--------------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|\n|                    |                  |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                               |\n| (Azathioprine)     | Mild/ moderate   | Purine DNA/RNA synthesis is prevented through cleavage | Leuko/lymphopenia 12% Red cell dysplasia, anaemia (6-28%) Megaloblastic anaemia Hepatic dysfunction                                 | IM and CMV retinitis Pancreatitis secondary infections neutropenic sepsis                                                                   | increased risk of solid malignancies (cervix, skin) vaccination to prevent infection                                             |\n| Injection          | RMS off-label use|                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                               |\n| Glatiramer acetate | Mild/ moderate   | Th1/Th2 shift; APC modulation                                 | reduced CD8+ CIS, natural regulation T3, slighty increased adaptive immunity highly antigen MHC1 coupled activation leading to enhanced T-cel production of BNDF                             |                        |                                                        | Before therapy blood count , hepatic and renal function parameters every 24 months liver, lipid, and blood count checks (re-checks every 2 years                                                                                   |\n|                    | RMS              |                                                        |                          |                                                           |                                                                                                                                             | during therapy every 3-6 months or at least every 24 months                                                                                                                                              | during therapy every 3-6 months)                                                                                                                                              |\n|                    |                  |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                               |\n| IFNβ               | Mild/ moderate   | Th1/Th2 shift: APC modulation                                  | reduced CD8+ CIS, natural regulation T3, slighty increased adaptive immunity highly antigen MHC1 coupled activation leading to enhanced T-cel production of BNDF                             |                        |                                                        | Before therapy blood count , hepatic and renal function parameters every 14 months liver, lipid, and blood count checks (re-checks every 2 years                                                                                   |\n|                    | RMS              |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                                              |\n|                    | RMS with relapse |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                               |\n|                    |                  |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                               |\n| Natalizumab        | Moderate/        | Inhibition of T-cell migration: Injection treatment on PML risk                            | lymphoid organ swelling improved NMES at BBB prevention of leukocytes migration at the BBB                            |                         |                                                                                                                                             |\n|                    | severe RMS       |                                                        |       with relapses         |                                                           | Before therapy blood count , hepatic and renal function parameters every 14 months liver, lipid, and blood count checks (re-checks every 2 years                                                                                   |\n|                    |                  |                                                        |                          |                                                           |                                                                                                                                             | during therapy CRP, full blood count control 4-6 months thereafter                                                                                                                                                     |\n|                    |                  |                                                        |                          |                                                           |                                                                                                                                             |                                                                                                                                                            |                                                                                          Injection-related reactions;\n\nOdumumabB                        |  Severe RMS           | Monoclonal antibody infusion recreational uses   | Highly active against CD20 B cell infections leading to depletion  \n| deseled B lymphocyte count                                      |   |    RMS with relapses      |                                                             | infusion rapid administration migraine-specific antibody reaction First dose should be divided into 5 (at least 5) doses thereafter with urinary output correction-fluid homeostatic balance monitored to prevent                                                                                                                                                    \n\n【3】                                                                  6-12-month intervals thereafter; CMV re-emergence must be ruled-out  hepatic/renal failure PML injection upper respiratory infections complete interval intervals eliminated", "index": 0, "show": true, "start": 0, "end": 2584, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "与原文不一致"}], "startTime": "2024/08/07 10:34:15", "endTime": "2024/08/07 10:34:36", "cost": 21.125}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 18:34:36", "grab_time": "2024-08-06 18:09:46"}
{"id": 2211536, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "33b968c6-ec70-4925-bf17-8e768b33421e", "title": "2023 ESPEN实践指南：家庭肠外营养", "text": "【0】页码:5\n2023 ESPEN实践指南：家庭肠外营养\n## 3. Recommendations\n\n【1】### 3.1. Indications for HPN\n\n【2】#### 3.1.1. Indications\n\n【3】1. 删除32:<u>**</u>HPN should be administered to those patients unable to meet their nutritional requirements via the oral and/or enteral route and who can be safely managed outside of the hospital.删除32:<u>**</u> (R1, grade GPP, strong consensus 95.8%)\n\n【4】删除图片描述:<u>   ![4_0.png](4_0.png)</u>\n\n【5】#### 3.1.2. Criteria for effectiveness\n\n【6】2. 删除32:<u>**</u>HPN should be prescribed as the primary and life-saving therapy for patients with transient-reversible or permanent-irreversible CIF due to non-malignant disease.删除32:<u>**</u> (R2, grade B, strong consensus 94.7%)\n\n【7】删除图片描述:<u>   ![4_1.png](4_1.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ESPEN实践指南：家庭肠外营养.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "3. Recommendations", "content": "【0】页码:5\n2023 ESPEN实践指南：家庭肠外营养\n## 3. Recommendations\n\n【1】### 3.1. Indications for HPN\n\n【2】#### 3.1.1. Indications\n\n【3】1. 删除32:<u>**</u>HPN should be administered to those patients unable to meet their nutritional requirements via the oral and/or enteral route and who can be safely managed outside of the hospital.删除32:<u>**</u> (R1, grade GPP, strong consensus 95.8%)\n\n【4】删除图片描述:<u>   ![4_0.png](4_0.png)</u>\n\n【5】#### 3.1.2. Criteria for effectiveness\n\n【6】2. 删除32:<u>**</u>HPN should be prescribed as the primary and life-saving therapy for patients with transient-reversible or permanent-irreversible CIF due to non-malignant disease.删除32:<u>**</u> (R2, grade B, strong consensus 94.7%)\n\n【7】删除图片描述:<u>   ![4_1.png](4_1.png)</u>", "index": 33, "show": true, "start": 33, "end": 51, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "0"}, {"text": "【5】#### 3.1.2. Criteria for effectiveness", "content": "【0】页码:5\n2023 ESPEN实践指南：家庭肠外营养\n## <mark>3. Recommendations</mark>\n\n【1】### 3.1. Indications for HPN\n\n【2】#### 3.1.1. Indications\n\n【3】1. 删除32:<u>**</u>HPN should be administered to those patients unable to meet their nutritional requirements via the oral and/or enteral route and who can be safely managed outside of the hospital.删除32:<u>**</u> (R1, grade GPP, strong consensus 95.8%)\n\n【4】删除图片描述:<u>   ![4_0.png](4_0.png)</u>\n\n【5】#### 3.1.2. Criteria for effectiveness\n\n【6】2. 删除32:<u>**</u>HPN should be prescribed as the primary and life-saving therapy for patients with transient-reversible or permanent-irreversible CIF due to non-malignant disease.删除32:<u>**</u> (R2, grade B, strong consensus 94.7%)\n\n【7】删除图片描述:<u>   ![4_1.png](4_1.png)</u>", "index": 423, "show": true, "start": 410, "end": 451, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/07 09:46:01", "endTime": "2024/08/07 09:46:41", "cost": 39.579}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 17:46:40", "grab_time": "2024-08-06 17:46:00"}
{"id": 2211535, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "80794575-8c6c-4aea-ab6f-ed8979e82210", "title": "e1f423b0329dc933048fbf5521bb0912(1)", "text": "【0】页码:5\ne1f423b0329dc933048fbf5521bb0912(1)\nA progressive DT (i.e. recurrence or evolution confirmed by subsequent examinations) showed that even in the placebo group, the two thirds of tumors stabilized or exhibited regression, of which 20% were significant according to RECIST_1 (reduction of at least 30% in the sum of the diameters of the target lesions; 删除12:<u>删除14:<u>[34]</u></u>). The ESMO guidelines and the European consensus now recommend to start with active surveillance or medical therapy alone in advanced DT, depending on the symptomatology 删除12:<u>删除14:<u>[17,10]</u></u>.\n\n【1】### 3.2. Surgery, indications, modalities\n\n【2】#### 3.2.1. Indications and modalities of emergency surgery\n\n【3】Patients with surgical complication at diagnosis need to be operated on. It may be occlusion, digestive perforation, or mesenteric ischemia. If the resection of the tumor is not mutilating and requires only limited digestive resection, the treatment of the complication is done at the same time as the excision of the tumor. If the removal of the tumor would involve major digestive sacrifices, it is preferable to limit surgical treatment to the complication and leave the tumor in place, with systematic biopsy for histological confirmation. Medical treatment will be discussed postoperatively. Patients who present a pelvic abscess or fistulizations occurring in the context of an already operated polyposis will be preferentially treated by percutaneous drainage.\n\n【4】In the absence of a mechanical complication, a large initial size at diagnosis or a life-threatening location (such as cervical, mediastinal, intra-abdominal and mesenteric locations) are not by themselves an immediate operative indication. Indeed, after the diagnosis provided by the biopsy, spontaneous regressions can be observed regardless of the starting size and location. However, in life-threatening locations, in particular in mesenteric locations, or when symptoms are present, a medical treatment should be discussed in an expert center 删除12:<u>删除14:<u>[17,10,35]</u></u>. Surgery ultimately has limited indication in these unfavorable situations with a large tumor volume, because both mutilating and exposing a high risk of recurrence and complications. In addition, imaging underestimates the extension in the mesentery location and surgery is often macroscopically incomplete in these locations.\n\n【5】Recurrences are as likely to regress as primary tumors and they are neither an indication for immediate surgery 删除12:<u>删除14:<u>[30,34]</u></u>. Indeed, in nearly 50% of early relapse after surgery, the lesion stabilizes, or even regresses spontaneously after an initially rapid growth. Moreover, surgery has an ambiguous role on macro or microremnants (which are not different from keloids on a microscopic level), because induced healing tissue factors constitute also growth factors for DT.\n\n【6】#### 3.2.2. Indications and modalities of deferred surgery (“second line”)\n\n【7】The main potential indications for surgery are the progression or appearance of symptoms despite appropriate medical treatment. The first step in the event of progression is to verify that it is indeed a DT, in particular for retro-peritoneal locations. The molecular analysis must have been carried out with a search for the CTNNB1 mutation of the $\\beta$-catenin and APC gene 删除12:<u>删除14:<u>[10]</u></u>. With current sequencing techniques, non-mutated DT are very rare 删除12:<u>删除14:<u>[6]</u></u>. Cases of a diagnosis of “progressive DT” invalidated after histological review in an expert center and molecular biology analysis are frequent. This rereading must be systematized, particularly if a medical treatment is planned 删除12:<u>删除14:<u>[3]</u></u>.\n\n【8】#### 3.2.3. When discussing surgery?\n\n【9】The indication for local treatment will depend on the initial size, progression kinetics, location, symptoms, and age of the patient. It is obvious that for an initial lesion of small size (2 to 3 cm) in a favorable location (abdominal wall for example), a doubling of the size of the tumor can be tolerated knowing that a secondarily slowing down, a stabilization or even a regression can occur. However, the same initial size in an unfavorable location, close to major vasculo-nervous axes, will encourage early treatment. The evolution curve is the central element of the decision. Patients should therefore be monitored closely after diagnosis, as the evolution profile must be categorized at this time. The monitoring can be then spaced in time if the tumor is indolent or stabilizes. Thus, a first check-up is recommended one or two months after the initial imaging, then three months later if the disease is stable and then six months later . Medical treatment is discussed before local invasive treatment, as they can stabilize the tumor and avoid sequelae 删除12:<u>删除14:<u>[10]</u></u>. At last, the decision to operate must be taken in a multidisciplinary discussion but not too late after considering the developmental curve of DT.", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/e1f423b0329dc933048fbf5521bb0912(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:17:58", "endTime": "2024/08/06 16:18:14", "cost": 15.434}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:18:14", "grab_time": "2024-08-06 00:17:58"}
{"id": 2211534, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "e6bd7615-83aa-4073-a90a-f9b0c00a2642", "title": "AGA：腹泻型肠易激综合征药物治疗的临床实践指南（2022）", "text": "【0】页码:11\nAGA：腹泻型肠易激综合征药物治疗的临床实践指南（2022）\n### 5. Should Tricyclic Antidepressants Be Used in Patients With Irritable Bowel Syndrome?\n\n【1】#### The AGA suggests using TCAs in patients with IBS. (Conditional recommendation; Low certainty in the evidence of effects)\n\n【2】This recommendation is unchanged from the 2014 IBS guideline. TCAs have been used to treat IBS symptoms due to their peripheral and central (ie, supraspinal and spinal) actions, which can affect motility, secretion, and sensation. IBS and other functional gastrointestinal disorders have been redefined in Rome IV as disorders of gut-brain interactions, characterized by any combination of motility disturbance, visceral hypersensitivity, altered mucosal and immune function, altered gut microbiota, and altered central nervous system processing. Consistent with this redefinition and based on the fact that TCAs and other antidepressants have physiologic effects separate from the effect on mood, these agents have been relabeled as gut-brain neuromodulators.\n\n【3】#### Summary of the evidence.\n\n【4】The efficacy of TCAs in IBS was previously evaluated in the prior TR. Based on 8 placebo-controlled RCTs in 523 patients (TCAs n = 297; placebo n = 122). But 1 study tested 2 or multiple IBS with different subtypes. The type of TCA studied included amitriptyline (n = 5), desipramine (n = 2), trimipramine (n = 1), imipramine (n = 1), and doxepin (n = 1). The dose of the TCA varied from 10 mg up to 150 mg and most studies used >50 mg per day. Global assessments differed among the trials and abdominal pain responses was assessed in 4 trials. Compared with placebo, TCAs were associated with global symptom relief (RR, 0.67; 95% CI, 0.54-0.82) and abdominal pain relief (RR, 0.76-0.94). However, the quality of evidence was rated down due to indirectness, risk of bias, and imprecision. Based on data from 22 clinical trials in depression (as long-term, high-quality data on adverse effects with TCAs in IBS were not available), TCAs showed a significantly higher rate of withdrawals due to adverse effects compared with placebo (RR, 2.11; 95% CI, 1.35-3.28). The overall certainty in evidence for TCAs was low.\n\n【5】#### Rationale.\n\n【6】TCAs were associated with greater responses of adequate relief and abdominal pain relief compared with placebo; however, only global relief response met the threshold for being clinically meaningful. The beneficial effects of TCAs on IBS symptoms appear to be independent of effects on depression and may take several weeks. Most studies evaluated higher doses of TCAs (ie, 50 mg and higher) than those used in clinical practice. There was 1 study demonstrating that amitriptyline 10 mg at bedtime had greater efficacy that placebo in patients with IBS-D. TCAs have multiple actions, including inhibition of serotonin and noradrenergic reuptake and blockade of muscarinic 1, α1 adrenergic, and histamine 1 receptors. These effects are beneficial (eg, reduce diarrhea and abdominal pain), but also can cause adverse events (eg, dry mouth, sedation, and constipation). Therefore, the selection of TCA should be based on the patient’s symptom presentation.\n\n【7】### 6. Should Selective Serotonin Reuptake Inhibitors Be Used in Patients With Irritable Bowel Syndrome?\n\n【8】#### The AGA suggests against using SSRIs for patients with IBS. (Conditional recommendation, low certainty in the evidence)\n\n【9】This recommendation is unchanged from the 2014 IBS guideline. SSRIs are approved for the treatment of mood disorders, such as anxiety and depression, but are also used in clinical practice to treat chronic pain conditions. SSRIs selectively inhibit the reuptake of 5-HT at presynaptic nerve endings, which results in an increased synaptic concentration of 5-HT. The use of SSRIs in IBS has been of considerable interest because IBS is considered a gut-brain disorder and these agents have centrally mediated effects and increase gastric and intestinal motility, although they do not appear to have a major impact on visceral sensation.\n\n【10】#### Summary of the evidence.\n\n【11】The efficacy of SSRIs in IBS was studied in 7 RCTs. Of the studies enrolled a mixture of all 3 main bowel habit subtypes. Patients with current psychiatric disease were generally excluded. The duration of treatment ranged from 6 to 12 weeks. Different SSRIs were evaluated: fluoxetine 20 mg daily, citalopram 20 mg daily that could be increased, paroxetine-CR 12.5-50 mg daily, and 3 studies used cipolapram a starting dose of 20 mg that was increased to 40 mg daily after 2, 3, or 4 weeks. Compared with placebo, SSRIs showed possible improvement in symptom relief (RR, 0.74; 95% CI, 0.52-1.06) and in abdominal pain or discomfort; however, the upper boundary of the CI suggested worsening symptoms of global relief or abdominal pain. The certainty in evidence for this outcome was rated as low due to serious inconsistency and imprecision. Two studies compared changes in IBS-specific QOL between the SSRI and placebo groups. One study found a significantly greater improvement in food avoidance score and the other study did not detect any differences. The other critical or important outcomes could not be assessed on the basis of the available data. There were no long-term data with SSRIs in IBS or depression to assess adverse events leading to treatment withdrawal.\n\n【12】#### Rationale.\n\n【13】SSRIs did not significantly improve global symptoms or abdominal pain in IBS, although the overall certainty in evidence is low. Multiple factors, including those arising from central and peripheral processes, contribute to the severity of IBS symptoms. In some patients, SSRIs may improve the perception of overall IBS symptoms and well-being by improving gastrointestinal symptoms, coexistent alterations in mood, and extraintestinal symptoms.", "tags": {}, "lang": "en", "attr": {"page_num": 11, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/AGA：腹泻型肠易激综合征药物治疗的临床实践指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【6】TCAs were associated with greater responses of adequate relief and abdominal pain relief compared with placebo; however, only global relief response met the threshold for being clinically meaningful. The beneficial effects of TCAs on IBS symptoms appear to be independent of effects on depression and may take several weeks. Most studies evaluated higher doses of TCAs (ie, 50 mg and higher) than those used in clinical practice. There was 1 study demonstrating that amitriptyline 10 mg at bedtime had greater efficacy that placebo in patients with IBS-D. TCAs have multiple actions, including inhibition of serotonin and noradrenergic reuptake and blockade of muscarinic 1, α1 adrenergic, and histamine 1 receptors. These effects are beneficial (eg, reduce diarrhea and abdominal pain), but also can cause adverse events (eg, dry mouth, sedation, and constipation). Therefore, the selection of TCA should be based on the patient’s symptom presentation.", "content": "【0】页码:11\nAGA：腹泻型肠易激综合征药物治疗的临床实践指南（2022）\n### 5. Should Tricyclic Antidepressants Be Used in Patients With Irritable Bowel Syndrome?\n\n【1】#### The AGA suggests using TCAs in patients with IBS. (Conditional recommendation; Low certainty in the evidence of effects)\n\n【2】This recommendation is unchanged from the 2014 IBS guideline. TCAs have been used to treat IBS symptoms due to their peripheral and central (ie, supraspinal and spinal) actions, which can affect motility, secretion, and sensation. IBS and other functional gastrointestinal disorders have been redefined in Rome IV as disorders of gut-brain interactions, characterized by any combination of motility disturbance, visceral hypersensitivity, altered mucosal and immune function, altered gut microbiota, and altered central nervous system processing. Consistent with this redefinition and based on the fact that TCAs and other antidepressants have physiologic effects separate from the effect on mood, these agents have been relabeled as gut-brain neuromodulators.\n\n【3】#### Summary of the evidence.\n\n【4】The efficacy of TCAs in IBS was previously evaluated in the prior TR. Based on 8 placebo-controlled RCTs in 523 patients (TCAs n = 297; placebo n = 122). But 1 study tested 2 or multiple IBS with different subtypes. The type of TCA studied included amitriptyline (n = 5), desipramine (n = 2), trimipramine (n = 1), imipramine (n = 1), and doxepin (n = 1). The dose of the TCA varied from 10 mg up to 150 mg and most studies used >50 mg per day. Global assessments differed among the trials and abdominal pain responses was assessed in 4 trials. Compared with placebo, TCAs were associated with global symptom relief (RR, 0.67; 95% CI, 0.54-0.82) and abdominal pain relief (RR, 0.76-0.94). However, the quality of evidence was rated down due to indirectness, risk of bias, and imprecision. Based on data from 22 clinical trials in depression (as long-term, high-quality data on adverse effects with TCAs in IBS were not available), TCAs showed a significantly higher rate of withdrawals due to adverse effects compared with placebo (RR, 2.11; 95% CI, 1.35-3.28). The overall certainty in evidence for TCAs was low.\n\n【5】#### Rationale.\n\n【6】TCAs were associated with greater responses of adequate relief and abdominal pain relief compared with placebo; however, only global relief response met the threshold for being clinically meaningful. The beneficial effects of TCAs on IBS symptoms appear to be independent of effects on depression and may take several weeks. Most studies evaluated higher doses of TCAs (ie, 50 mg and higher) than those used in clinical practice. There was 1 study demonstrating that amitriptyline 10 mg at bedtime had greater efficacy that placebo in patients with IBS-D. TCAs have multiple actions, including inhibition of serotonin and noradrenergic reuptake and blockade of muscarinic 1, α1 adrenergic, and histamine 1 receptors. These effects are beneficial (eg, reduce diarrhea and abdominal pain), but also can cause adverse events (eg, dry mouth, sedation, and constipation). Therefore, the selection of TCA should be based on the patient’s symptom presentation.\n\n【7】### 6. Should Selective Serotonin Reuptake Inhibitors Be Used in Patients With Irritable Bowel Syndrome?\n\n【8】#### The AGA suggests against using SSRIs for patients with IBS. (Conditional recommendation, low certainty in the evidence)\n\n【9】This recommendation is unchanged from the 2014 IBS guideline. SSRIs are approved for the treatment of mood disorders, such as anxiety and depression, but are also used in clinical practice to treat chronic pain conditions. SSRIs selectively inhibit the reuptake of 5-HT at presynaptic nerve endings, which results in an increased synaptic concentration of 5-HT. The use of SSRIs in IBS has been of considerable interest because IBS is considered a gut-brain disorder and these agents have centrally mediated effects and increase gastric and intestinal motility, although they do not appear to have a major impact on visceral sensation.\n\n【10】#### Summary of the evidence.\n\n【11】The efficacy of SSRIs in IBS was studied in 7 RCTs. Of the studies enrolled a mixture of all 3 main bowel habit subtypes. Patients with current psychiatric disease were generally excluded. The duration of treatment ranged from 6 to 12 weeks. Different SSRIs were evaluated: fluoxetine 20 mg daily, citalopram 20 mg daily that could be increased, paroxetine-CR 12.5-50 mg daily, and 3 studies used cipolapram a starting dose of 20 mg that was increased to 40 mg daily after 2, 3, or 4 weeks. Compared with placebo, SSRIs showed possible improvement in symptom relief (RR, 0.74; 95% CI, 0.52-1.06) and in abdominal pain or discomfort; however, the upper boundary of the CI suggested worsening symptoms of global relief or abdominal pain. The certainty in evidence for this outcome was rated as low due to serious inconsistency and imprecision. Two studies compared changes in IBS-specific QOL between the SSRI and placebo groups. One study found a significantly greater improvement in food avoidance score and the other study did not detect any differences. The other critical or important outcomes could not be assessed on the basis of the available data. There were no long-term data with SSRIs in IBS or depression to assess adverse events leading to treatment withdrawal.\n\n【12】#### Rationale.\n\n【13】SSRIs did not significantly improve global symptoms or abdominal pain in IBS, although the overall certainty in evidence is low. Multiple factors, including those arising from central and peripheral processes, contribute to the severity of IBS symptoms. In some patients, SSRIs may improve the perception of overall IBS symptoms and well-being by improving gastrointestinal symptoms, coexistent alterations in mood, and extraintestinal symptoms.", "index": 2199, "show": true, "start": 2199, "end": 3155, "province": ["格式规范性", "多余换行"], "isEdit": false}, {"text": "【11】The efficacy of SSRIs in IBS was studied in 7 RCTs. Of the studies enrolled a mixture of all 3 main bowel habit subtypes. Patients with current psychiatric disease were generally excluded. The duration of treatment ranged from 6 to 12 weeks. Different SSRIs were evaluated: fluoxetine 20 mg daily, citalopram 20 mg daily that could be increased, paroxetine-CR 12.5-50 mg daily, and 3 studies used cipolapram a starting dose of 20 mg that was increased to 40 mg daily after 2, 3, or 4 weeks. Compared with placebo, SSRIs showed possible improvement in symptom relief (RR, 0.74; 95% CI, 0.52-1.06) and in abdominal pain or discomfort; however, the upper boundary of the CI suggested worsening symptoms of global relief or abdominal pain. The certainty in evidence for this outcome was rated as low due to serious inconsistency and imprecision. Two studies compared changes in IBS-specific QOL between the SSRI and placebo groups. One study found a significantly greater improvement in food avoidance score and the other study did not detect any differences. The other critical or important outcomes could not be assessed on the basis of the available data. There were no long-term data with SSRIs in IBS or depression to assess adverse events leading to treatment withdrawal.", "content": "【0】页码:11\nAGA：腹泻型肠易激综合征药物治疗的临床实践指南（2022）\n### 5. Should Tricyclic Antidepressants Be Used in Patients With Irritable Bowel Syndrome?\n\n【1】#### The AGA suggests using TCAs in patients with IBS. (Conditional recommendation; Low certainty in the evidence of effects)\n\n【2】This recommendation is unchanged from the 2014 IBS guideline. TCAs have been used to treat IBS symptoms due to their peripheral and central (ie, supraspinal and spinal) actions, which can affect motility, secretion, and sensation. IBS and other functional gastrointestinal disorders have been redefined in Rome IV as disorders of gut-brain interactions, characterized by any combination of motility disturbance, visceral hypersensitivity, altered mucosal and immune function, altered gut microbiota, and altered central nervous system processing. Consistent with this redefinition and based on the fact that TCAs and other antidepressants have physiologic effects separate from the effect on mood, these agents have been relabeled as gut-brain neuromodulators.\n\n【3】#### Summary of the evidence.\n\n【4】The efficacy of TCAs in IBS was previously evaluated in the prior TR. Based on 8 placebo-controlled RCTs in 523 patients (TCAs n = 297; placebo n = 122). But 1 study tested 2 or multiple IBS with different subtypes. The type of TCA studied included amitriptyline (n = 5), desipramine (n = 2), trimipramine (n = 1), imipramine (n = 1), and doxepin (n = 1). The dose of the TCA varied from 10 mg up to 150 mg and most studies used >50 mg per day. Global assessments differed among the trials and abdominal pain responses was assessed in 4 trials. Compared with placebo, TCAs were associated with global symptom relief (RR, 0.67; 95% CI, 0.54-0.82) and abdominal pain relief (RR, 0.76-0.94). However, the quality of evidence was rated down due to indirectness, risk of bias, and imprecision. Based on data from 22 clinical trials in depression (as long-term, high-quality data on adverse effects with TCAs in IBS were not available), TCAs showed a significantly higher rate of withdrawals due to adverse effects compared with placebo (RR, 2.11; 95% CI, 1.35-3.28). The overall certainty in evidence for TCAs was low.\n\n【5】#### Rationale.\n\n<mark>【6】TCAs were associated with greater responses of adequate relief and abdominal pain relief compared with placebo; however, only global relief response met the threshold for being clinically meaningful. The beneficial effects of TCAs on IBS symptoms appear to be independent of effects on depression and may take several weeks. Most studies evaluated higher doses of TCAs (ie, 50 mg and higher) than those used in clinical practice. There was 1 study demonstrating that amitriptyline 10 mg at bedtime had greater efficacy that placebo in patients with IBS-D. TCAs have multiple actions, including inhibition of serotonin and noradrenergic reuptake and blockade of muscarinic 1, α1 adrenergic, and histamine 1 receptors. These effects are beneficial (eg, reduce diarrhea and abdominal pain), but also can cause adverse events (eg, dry mouth, sedation, and constipation). Therefore, the selection of TCA should be based on the patient’s symptom presentation.</mark>\n\n【7】### 6. Should Selective Serotonin Reuptake Inhibitors Be Used in Patients With Irritable Bowel Syndrome?\n\n【8】#### The AGA suggests against using SSRIs for patients with IBS. (Conditional recommendation, low certainty in the evidence)\n\n【9】This recommendation is unchanged from the 2014 IBS guideline. SSRIs are approved for the treatment of mood disorders, such as anxiety and depression, but are also used in clinical practice to treat chronic pain conditions. SSRIs selectively inhibit the reuptake of 5-HT at presynaptic nerve endings, which results in an increased synaptic concentration of 5-HT. The use of SSRIs in IBS has been of considerable interest because IBS is considered a gut-brain disorder and these agents have centrally mediated effects and increase gastric and intestinal motility, although they do not appear to have a major impact on visceral sensation.\n\n【10】#### Summary of the evidence.\n\n【11】The efficacy of SSRIs in IBS was studied in 7 RCTs. Of the studies enrolled a mixture of all 3 main bowel habit subtypes. Patients with current psychiatric disease were generally excluded. The duration of treatment ranged from 6 to 12 weeks. Different SSRIs were evaluated: fluoxetine 20 mg daily, citalopram 20 mg daily that could be increased, paroxetine-CR 12.5-50 mg daily, and 3 studies used cipolapram a starting dose of 20 mg that was increased to 40 mg daily after 2, 3, or 4 weeks. Compared with placebo, SSRIs showed possible improvement in symptom relief (RR, 0.74; 95% CI, 0.52-1.06) and in abdominal pain or discomfort; however, the upper boundary of the CI suggested worsening symptoms of global relief or abdominal pain. The certainty in evidence for this outcome was rated as low due to serious inconsistency and imprecision. Two studies compared changes in IBS-specific QOL between the SSRI and placebo groups. One study found a significantly greater improvement in food avoidance score and the other study did not detect any differences. The other critical or important outcomes could not be assessed on the basis of the available data. There were no long-term data with SSRIs in IBS or depression to assess adverse events leading to treatment withdrawal.\n\n【12】#### Rationale.\n\n【13】SSRIs did not significantly improve global symptoms or abdominal pain in IBS, although the overall certainty in evidence is low. Multiple factors, including those arising from central and peripheral processes, contribute to the severity of IBS symptoms. In some patients, SSRIs may improve the perception of overall IBS symptoms and well-being by improving gastrointestinal symptoms, coexistent alterations in mood, and extraintestinal symptoms.", "index": 4083, "show": true, "start": 4070, "end": 5347, "province": ["格式规范性", "多余换行"], "isEdit": false}, {"text": "【13】SSRIs did not significantly improve global symptoms or abdominal pain in IBS, although the overall certainty in evidence is low. Multiple factors, including those arising from central and peripheral processes, contribute to the severity of IBS symptoms. In some patients, SSRIs may improve the perception of overall IBS symptoms and well-being by improving gastrointestinal symptoms, coexistent alterations in mood, and extraintestinal symptoms.", "content": "【0】页码:11\nAGA：腹泻型肠易激综合征药物治疗的临床实践指南（2022）\n### 5. Should Tricyclic Antidepressants Be Used in Patients With Irritable Bowel Syndrome?\n\n【1】#### The AGA suggests using TCAs in patients with IBS. (Conditional recommendation; Low certainty in the evidence of effects)\n\n【2】This recommendation is unchanged from the 2014 IBS guideline. TCAs have been used to treat IBS symptoms due to their peripheral and central (ie, supraspinal and spinal) actions, which can affect motility, secretion, and sensation. IBS and other functional gastrointestinal disorders have been redefined in Rome IV as disorders of gut-brain interactions, characterized by any combination of motility disturbance, visceral hypersensitivity, altered mucosal and immune function, altered gut microbiota, and altered central nervous system processing. Consistent with this redefinition and based on the fact that TCAs and other antidepressants have physiologic effects separate from the effect on mood, these agents have been relabeled as gut-brain neuromodulators.\n\n【3】#### Summary of the evidence.\n\n【4】The efficacy of TCAs in IBS was previously evaluated in the prior TR. Based on 8 placebo-controlled RCTs in 523 patients (TCAs n = 297; placebo n = 122). But 1 study tested 2 or multiple IBS with different subtypes. The type of TCA studied included amitriptyline (n = 5), desipramine (n = 2), trimipramine (n = 1), imipramine (n = 1), and doxepin (n = 1). The dose of the TCA varied from 10 mg up to 150 mg and most studies used >50 mg per day. Global assessments differed among the trials and abdominal pain responses was assessed in 4 trials. Compared with placebo, TCAs were associated with global symptom relief (RR, 0.67; 95% CI, 0.54-0.82) and abdominal pain relief (RR, 0.76-0.94). However, the quality of evidence was rated down due to indirectness, risk of bias, and imprecision. Based on data from 22 clinical trials in depression (as long-term, high-quality data on adverse effects with TCAs in IBS were not available), TCAs showed a significantly higher rate of withdrawals due to adverse effects compared with placebo (RR, 2.11; 95% CI, 1.35-3.28). The overall certainty in evidence for TCAs was low.\n\n【5】#### Rationale.\n\n<mark>【6】TCAs were associated with greater responses of adequate relief and abdominal pain relief compared with placebo; however, only global relief response met the threshold for being clinically meaningful. The beneficial effects of TCAs on IBS symptoms appear to be independent of effects on depression and may take several weeks. Most studies evaluated higher doses of TCAs (ie, 50 mg and higher) than those used in clinical practice. There was 1 study demonstrating that amitriptyline 10 mg at bedtime had greater efficacy that placebo in patients with IBS-D. TCAs have multiple actions, including inhibition of serotonin and noradrenergic reuptake and blockade of muscarinic 1, α1 adrenergic, and histamine 1 receptors. These effects are beneficial (eg, reduce diarrhea and abdominal pain), but also can cause adverse events (eg, dry mouth, sedation, and constipation). Therefore, the selection of TCA should be based on the patient’s symptom presentation.</mark>\n\n【7】### 6. Should Selective Serotonin Reuptake Inhibitors Be Used in Patients With Irritable Bowel Syndrome?\n\n【8】#### The AGA suggests against using SSRIs for patients with IBS. (Conditional recommendation, low certainty in the evidence)\n\n【9】This recommendation is unchanged from the 2014 IBS guideline. SSRIs are approved for the treatment of mood disorders, such as anxiety and depression, but are also used in clinical practice to treat chronic pain conditions. SSRIs selectively inhibit the reuptake of 5-HT at presynaptic nerve endings, which results in an increased synaptic concentration of 5-HT. The use of SSRIs in IBS has been of considerable interest because IBS is considered a gut-brain disorder and these agents have centrally mediated effects and increase gastric and intestinal motility, although they do not appear to have a major impact on visceral sensation.\n\n【10】#### Summary of the evidence.\n\n<mark>【11】The efficacy of SSRIs in IBS was studied in 7 RCTs. Of the studies enrolled a mixture of all 3 main bowel habit subtypes. Patients with current psychiatric disease were generally excluded. The duration of treatment ranged from 6 to 12 weeks. Different SSRIs were evaluated: fluoxetine 20 mg daily, citalopram 20 mg daily that could be increased, paroxetine-CR 12.5-50 mg daily, and 3 studies used cipolapram a starting dose of 20 mg that was increased to 40 mg daily after 2, 3, or 4 weeks. Compared with placebo, SSRIs showed possible improvement in symptom relief (RR, 0.74; 95% CI, 0.52-1.06) and in abdominal pain or discomfort; however, the upper boundary of the CI suggested worsening symptoms of global relief or abdominal pain. The certainty in evidence for this outcome was rated as low due to serious inconsistency and imprecision. Two studies compared changes in IBS-specific QOL between the SSRI and placebo groups. One study found a significantly greater improvement in food avoidance score and the other study did not detect any differences. The other critical or important outcomes could not be assessed on the basis of the available data. There were no long-term data with SSRIs in IBS or depression to assess adverse events leading to treatment withdrawal.</mark>\n\n【12】#### Rationale.\n\n【13】SSRIs did not significantly improve global symptoms or abdominal pain in IBS, although the overall certainty in evidence is low. Multiple factors, including those arising from central and peripheral processes, contribute to the severity of IBS symptoms. In some patients, SSRIs may improve the perception of overall IBS symptoms and well-being by improving gastrointestinal symptoms, coexistent alterations in mood, and extraintestinal symptoms.", "index": 5396, "show": true, "start": 5370, "end": 5819, "province": ["格式规范性", "多余换行"], "isEdit": false}], "startTime": "2024/08/06 16:09:06", "endTime": "2024/08/06 16:09:57", "cost": 50.883}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:09:58", "grab_time": "2024-08-06 00:05:06"}
{"id": 2211533, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "90562d8e-9ccd-4c91-baa9-5482809710ad", "title": "NICE：大于16岁人群卒中和短暂性脑缺血发作的诊断和初期管理指南（NG.128）（2022）", "text": "【0】页码:18\nNICE：大于16岁人群卒中和短暂性脑缺血发作的诊断和初期管理指南（NG.128）（2022）\nstroke who are adequately nourished on admission. 删除12:<u>删除14:<u>删除24:<u>[2008]</u></u></u>\n\n【1】1.6.10 Start nutrition support for people with stroke who are at risk of malnutrition. This may include oral nutritional supplements, specialist dietary advice and/or tube feeding. 删除12:<u>删除14:<u>删除24:<u>[2008]</u></u></u>\n\n【2】### Hydration\n\n【3】1.6.11 Assess, on admission, the hydration of everyone with acute stroke. Review hydration regularly and manage it so that normal hydration is maintained. 删除12:<u>删除14:<u>删除24:<u>[2008]</u></u></u>\n\n【4】## 1.7 Optimal positioning and early mobilisation for people with acute stroke\n\n【5】### Optimal positioning\n\n【6】1.7.1 Assess the individual clinical needs and personal preferences of people with acute stroke to determine their optimal head position. Take into account factors such as their comfort, physical and cognitive abilities and postural control. 删除12:<u>删除14:<u>删除24:<u>[2019]</u></u></u>\n\n【7】> For a short explanation of why the committee made this recommendation and how it might affect practice, see the [rationale and impact section on optimal positioning for people with acute stroke](#).\n>\n> Full details of the evidence and the committee's discussion are in [evidence review G: head positioning](#).\n\n【8】### Early mobilisation\n\n【9】1.7.2 Help people with acute stroke to sit out of bed, stand or walk as soon as their clinical condition permits as part of an active management programme in a specialist stroke unit. 删除12:<u>删除14:<u>删除24:<u>[2019]</u></u></u>\n\n【10】1.7.3 If people need help to sit out of bed, stand or walk, do not offer high-intensity mobilisation in the first 24 hours after symptom onset. 删除12:<u>删除14:<u>删除24:<u>[2019]</u></u></u>", "tags": {}, "lang": "en", "attr": {"page_num": 18, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/NICE：大于16岁人群卒中和短暂性脑缺血发作的诊断和初期管理指南（NG.128）（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:45:31", "endTime": "2024/08/06 16:47:13", "cost": 101.962}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:47:13", "grab_time": "2024-08-06 00:45:31"}
{"id": 2211532, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "474f26ee-8695-45c3-b316-f4b6749cd8ff", "title": "_非气管插管患者清 醒俯卧位实施策略中国专家共识（2023）", "text": "【0】页码:13\n_非气管插管患者清 醒俯卧位实施策略中国专家共识（2023）\n### 6.健康教育\n\n【1】#### 6.1 实施常规雾化前定位扪，向为患者提供雾化前的教育培训，指导患者方法及不良事件的处理。（A 级推荐，强一致性 96.67%一致）\n\n【2】#### 6.2 需告知患者及家属关于雾化前的停药原因、益处及不良反应。（A 级推荐，强一致性96.67%一致）\n\n【3】护士单独进行雾化前雾化前有效果与患者的耐受性和依从性均相关17（证据级别：Level 1c）。项目随机研究纳入了 48 例需要 CPAP 和（或）HFNC的患者，其中只有 1 例患者缩短每天 2 次至少 2 h 的雾化目 · 特殊2 h（证据级别：Level 3c）。而耐雾患者在雾化同时与治疗方案好相关18（证据级别：Level 3c）。因此，在进行首次的雾化治疗前，应向患者提供明确的雾化健康教育，并告知患及家属关干雾化前的停药原因和益处，从而提高患者对疾病的认知度、取得患者最大程度的配合，从而延长雾化前停药治疗时间。\n\n【4】### 7. 结论\n\n【5】本共识围绕非气管插管患者清痰雾化的流程证据汇集、评价、实施、监测与安全管理，总口吐机、并发症预防和健康教育了 7 个型号进行原则性。对非气管插患者清消雾化的实施前、中、后分别具体作证据进行了详细说明，针对科清雾的临床实践讲究规范性的管理给出了明确的推荐意见，司为临床医护人员提供参考与参考。同时除本科室之间存在差异、开展清除雾化治疗情况，中医护人员需充分综合考考虑各种各样的实施因素，想患者疾病状态、患者及家属意度，科全人员资、医护人员认知水平等，进而为制定个体化的雾化方案方案。本共识是基于文献证据总结和专家意见制订而成，未来且注根据变化、其内容也将随着医学进展的变而不断更新。", "tags": {}, "lang": "zh", "attr": {"page_num": 13, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_非气管插管患者清 醒俯卧位实施策略中国专家共识（2023）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/07 09:53:47", "endTime": "2024/08/07 09:54:24", "cost": 37.002}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 17:54:23", "grab_time": "2024-08-06 17:53:46"}
{"id": 2211531, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "6e0b0cb2-c9ab-4ea5-a702-bf38879f4aa5", "title": "_2024 ESO指南：脑小血管病—第2部分：腔隙性缺血性卒中", "text": "【0】页码:44\n_2024 ESO指南：脑小血管病—第2部分：腔隙性缺血性卒中\n删除32:<u>**</u>Table 7: GRADE evidence profile for PICO 8: lowering lipid-lowering agents (considering a particular agent, does it largely。)删除32:<u>**</u>\n\n| Effect | Certainty Importance | Absolute (95% CI) | RR (95% CI) | Certainty assessment | No of patients | Stroke | Transient Ischaemic Attack | Lipid-lowering agents vs Placebo | Bias | Indirectness | Imprecision | Considerations |\n| ------ | --------------------- | ---------------- | ----------- | -------------------- | -------------- | ------ | ------------------------- | ------------------------------- | ---- | ----------- | ----------- | ------------- |\n|        |                       |                  |             | Risk of bias          | Inconsistency  | Indirectness | Imprecision | Other considerations | Stroke | Transient Ischaemic Attack |                      |              |                         |\n|        |                       |                  |             | 删除11:<u>(0.77, 1.12)</u>          | serious        | serious     | not serious  | not serious            | 1 fewer per 1000 (from 8 fewer to 6 more) | 删除24:<u>[81/8205]</u> (15.4%) | CRITICAL      |                  |\n\n【2】### PICO 9:\n\n【3】In patients with lacunar ischaemic stroke, does treatment with lifestyle interventions (e.g. smoking cessation, dietary interventions, weight reduction, physical exercise, cognitive/behavioural or social interventions, sleep disorder/sleep apnoea interventions, or a mixture of these), compared to less intense or avoiding this intervention, reduce recurrent ischaemic stroke, dependency, death, cognitive impairment or dementia, haemorrhagic stroke, MACE, mobility or gait disorder, and mood disorders?\n\n【4】Lifestyle factors such as smoking, physical inactivity, diet and sodium intake are well-known modifiable risk factors for stroke and have been associated with the severity of SVD brain changes in observational studies. Rigorous management of lifestyle factors has been recommended alongside evidence-based medications. However, trials investigating the impact of lifestyle and behavioural interventions in SVD are still scarce. The ESO Guideline on covert cerebral SVD in 2021 gave no recommendation for any specific lifestyle intervention due to insufficient direct evidence but stated that it is reasonable to promote healthy lifestyle interventions as recommended in primary prevention for vascular disease. None of the previous stroke prevention guidelines have explicitly referred to stroke subtype when discussing lifestyle modifications. Here, we evaluate the evidence for different lifestyle interventions on adverse outcomes in patients with clinically evident lacunar stroke.\n\n【5】### Analysis of current evidence\n\n【6】The literature search identified two RCTs addressing the effect of lifestyle interventions in reducing adverse clinical outcomes in patients with lacunar stroke (Supplement PRISMA diagram), one on physical exercise and the other on a dietary intervention (nutritional supplement). As it was not possible to pool the studies for meta-analysis, we describe the results narratively. Summary of the main findings is given in Supplemental Table 16.\n\n【7】### Physical exercise\n\n【8】The HITPALS study included patients with acute/postacute lacunar stroke or TIA with MRI-confirmed signs of a previous lacunar stroke. The patients were randomised within 3 weeks after the symptom onset to 3-month home-based high-intensity interval training (15 min a day, 5 days per week, with weekly telephone calls to ensure compliance) or usual care including encouragement to lifestyle changes (baseline n = 31 + 32). The primary outcome was cardiorespiratory fitness (Graded Cycling Test with Talk Test), while the secondary outcomes included measures of post-stroke fatigue, depression, mental well-being, chronic stress, cognition (Montreal Cognitive Assessment), blood pressure, BMI and physical activity. The home-based training protocol", "tags": {}, "lang": "en", "attr": {"page_num": 44, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_2024 ESO指南：脑小血管病—第2部分：腔隙性缺血性卒中.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": ":Table 7: GRADE evidence profile for PICO 8: lowering lipid-lowering agents (considering a particular agent, does it largely。)", "content": "【0】页码:44\n_2024 ESO指南：脑小血管病—第2部分：腔隙性缺血性卒中\n删除32:<u>**</u>Table 7: GRADE evidence profile for PICO 8: lowering lipid-lowering agents (considering a particular agent, does it largely。)删除32:<u>**</u>\n\n| Effect | Certainty Importance | Absolute (95% CI) | RR (95% CI) | Certainty assessment | No of patients | Stroke | Transient Ischaemic Attack | Lipid-lowering agents vs Placebo | Bias | Indirectness | Imprecision | Considerations |\n| ------ | --------------------- | ---------------- | ----------- | -------------------- | -------------- | ------ | ------------------------- | ------------------------------- | ---- | ----------- | ----------- | ------------- |\n|        |                       |                  |             | Risk of bias          | Inconsistency  | Indirectness | Imprecision | Other considerations | Stroke | Transient Ischaemic Attack |                      |              |                         |\n|        |                       |                  |             | 删除11:<u>(0.77, 1.12)</u>          | serious        | serious     | not serious  | not serious            | 1 fewer per 1000 (from 8 fewer to 6 more) | 删除24:<u>[81/8205]</u> (15.4%) | CRITICAL      |                  |\n\n【2】### PICO 9:\n\n【3】In patients with lacunar ischaemic stroke, does treatment with lifestyle interventions (e.g. smoking cessation, dietary interventions, weight reduction, physical exercise, cognitive/behavioural or social interventions, sleep disorder/sleep apnoea interventions, or a mixture of these), compared to less intense or avoiding this intervention, reduce recurrent ischaemic stroke, dependency, death, cognitive impairment or dementia, haemorrhagic stroke, MACE, mobility or gait disorder, and mood disorders?\n\n【4】Lifestyle factors such as smoking, physical inactivity, diet and sodium intake are well-known modifiable risk factors for stroke and have been associated with the severity of SVD brain changes in observational studies. Rigorous management of lifestyle factors has been recommended alongside evidence-based medications. However, trials investigating the impact of lifestyle and behavioural interventions in SVD are still scarce. The ESO Guideline on covert cerebral SVD in 2021 gave no recommendation for any specific lifestyle intervention due to insufficient direct evidence but stated that it is reasonable to promote healthy lifestyle interventions as recommended in primary prevention for vascular disease. None of the previous stroke prevention guidelines have explicitly referred to stroke subtype when discussing lifestyle modifications. Here, we evaluate the evidence for different lifestyle interventions on adverse outcomes in patients with clinically evident lacunar stroke.\n\n【5】### Analysis of current evidence\n\n【6】The literature search identified two RCTs addressing the effect of lifestyle interventions in reducing adverse clinical outcomes in patients with lacunar stroke (Supplement PRISMA diagram), one on physical exercise and the other on a dietary intervention (nutritional supplement). As it was not possible to pool the studies for meta-analysis, we describe the results narratively. Summary of the main findings is given in Supplemental Table 16.\n\n【7】### Physical exercise\n\n【8】The HITPALS study included patients with acute/postacute lacunar stroke or TIA with MRI-confirmed signs of a previous lacunar stroke. The patients were randomised within 3 weeks after the symptom onset to 3-month home-based high-intensity interval training (15 min a day, 5 days per week, with weekly telephone calls to ensure compliance) or usual care including encouragement to lifestyle changes (baseline n = 31 + 32). The primary outcome was cardiorespiratory fitness (Graded Cycling Test with Talk Test), while the secondary outcomes included measures of post-stroke fatigue, depression, mental well-being, chronic stress, cognition (Montreal Cognitive Assessment), blood pressure, BMI and physical activity. The home-based training protocol", "index": 45, "show": true, "start": 45, "end": 171, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "0"}], "startTime": "2024/08/06 16:35:38", "endTime": "2024/08/06 16:37:25", "cost": 107.257}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:37:25", "grab_time": "2024-08-06 00:35:37"}
{"id": 2211530, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "4c26a101-2c6b-4e52-adee-a876990618f6", "title": "（2023.V2）NCCN临床实践指南：儿童急性淋巴细胞白血病", "text": "【0】页码:101\n（2023.V2）NCCN临床实践指南：儿童急性淋巴细胞白血病\n疑似页眉<u>NCCN Guidelines Version 2.2023  \nPediatric Acute Lymphoblastic Leukemia</u>\n\n【1】To monitor for late effects related to cumulative anthracycline exposure, an echocardiogram should be performed with frequency based on cumulative anthracycline dose or sooner, as clinically indicated. In addition, given the increased risk of neurotoxicity associated with ALL treatment in survivors, neuropsychological testing as clinically indicated is recommended. Patients with a history of pediatric ALL are also at risk for developing obesity; therefore, monitor for healthy weight and encourage healthy lifestyle choices. Further recommendations for survivorship are available in the [NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology] and [NCCN Guidelines for Survivorship]. As previously discussed in NCCN Recommendations for Evaluation and Treatment of Extramedullary Involvement, the COG has published guidelines on long-term survivorship issues for survivors of childhood cancers. These guidelines serve as a resource for clinicians and family members/caretakers, and have the goal of providing screening and management recommendations for late effects (those that may impact growth, cognitive function, emotional concerns, reproductive health, risks for secondary malignancies, and other important health issues) that may arise during the lifetime of an AYA cancer survivor as a result of the therapeutic agents used during the course of antitumor treatment.\n\n【2】### Supportive Care for Pediatric Patients with ALL\n\n【3】Given the highly complex and intensive treatment protocols used in the management of ALL, supportive care issues are important considerations to ensure that patients derive the most benefit from ALL therapy. Although differences may exist between institutional standards and practices, supportive care measures for patients with ALL generally include the use of antiemetics for prevention of nausea and vomiting, blood product transfusions for severe cytopenias, nutritional support for prevention of weight loss, gastroenterology support, pain management, prevention and management of infectious complications, and prophylaxis for TLS. In addition, both short- and long-term consequences of potential toxicities associated with specific agents used in ALL regimens should be considered, such as with steroids (eg, risks for hyperglycemia or peptic ulcerations in the acute setting; risks for avascular necrosis with long-term use) and asparaginase (eg, risks for hypersensitivity reactions, hyperglycemia, coagulopathy, hepatotoxicity, and/or pancreatitis). Supportive care measures should be tailored to meet the individual needs of each patient based on factors such as age, performance status, extent of cytopenias before and during therapy, risks for infectious complications, disease status, and the specific agents used in the ALL treatment regimen.\n\n【4】### NCCN Recommendations for Supportive Care\n\n【5】For comprehensive supportive care recommendations made by the Pediatric ALL Panel, see the Principles of Supportive Care section in the algorithm.\n\n【6】#### Infection Control\n\n【7】Patients with ALL undergoing intensive chemotherapy or allogeneic HCT are highly susceptible to infections. Immunosuppression caused by the underlying disease and therapeutic regimens can predispose patients to common bacterial and viral infections, and to various opportunistic infections (eg, candidiasis, invasive mold infections, _Pneumocystis jirovecii_, CMV reactivation and infection), particularly during periods of prolonged neutropenia. During induction, all patients with fever (as defined by the Infectious Diseases Society of America or institutional standards) should be evaluated by a medical provider and treated promptly with broad-spectrum antibiotics, regardless of neutrophil count.\n\n【8】Patients with ALL should take appropriate antibacterial and antifungal prophylaxis throughout therapy and also be closely monitored for any signs or symptoms of infections. All patients with ALL are at high risk for _Pneumocystis jirovecii_ (Pneumocystis carinii) and should take prophylaxis throughout anti-leukemic therapy. Trimethoprim/sulfamethoxazole", "tags": {}, "lang": "en", "attr": {"page_num": 101, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V2）NCCN临床实践指南：儿童急性淋巴细胞白血病.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:10:22", "endTime": "2024/08/06 16:10:41", "cost": 19.006}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:10:41", "grab_time": "2024-08-06 00:10:22"}
{"id": 2211529, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "22ad3e9d-6ec4-4437-8066-629abfc1021e", "title": "SEER数据库编码和分级手册2023", "text": "【0】页码:138\nSEER数据库编码和分级手册2023\n# Summary Stage\n\n【1】删除图片描述:<u>![](137_0.png)</u>", "tags": {}, "lang": "None", "attr": {"page_num": 138, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/SEER数据库编码和分级手册2023.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Summary Stage", "content": "【0】页码:138\nSEER数据库编码和分级手册2023\n# Summary Stage\n\n【1】删除图片描述:<u>![](137_0.png)</u>", "index": 31, "show": true, "start": 31, "end": 44, "province": ["信息质量", "有用性-轻"], "isEdit": false}], "startTime": "2024/08/06 16:23:25", "endTime": "2024/08/06 16:23:47", "cost": 22.145}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:23:47", "grab_time": "2024-08-06 00:23:25"}
{"id": 2211528, "user_id": null, "user_name": null, "task_id": 1534, "source_info": {"seq_id": "431bed1f-1d5b-4fb1-bed5-6e769fb5c920", "title": "（2023.V2）NCCN临床实践指南：甲状腺癌", "text": "【0】页码:22\n（2023.V2）NCCN临床实践指南：甲状腺癌\n### 1. 引言\n\n【1】近年来，深度学习在计算机视觉领域取得了显著的进展。卷积神经网络（CNN）已经成为图像识别、对象检测和语义分割等任务的主流方法。然而，这些方法通常需要大量的标注数据进行训练，获取和标注数据通常非常昂贵且耗时。\n\n【2】### 2. 方法\n\n【3】#### 2.1 模型架构\n\n【4】本文提出了一种新的卷积神经网络架构，旨在减少所需的标注数据量。该架构包括多个卷积层和池化层，以及一个全连接层。其核心思想是利用迁移学习，通过在大规模数据集上预训练模型，然后在目标任务上进行微调。\n\n【5】$$\nL(x) = - \\sum_{i=1}^{n} y_i \\log(\\hat{y}_i)\n$$\n\n【6】其中，$L(x)$ 表示损失函数，$y_i$ 表示真实标签，$\\hat{y}_i$ 表示预测标签。\n\n【7】#### 2.2 数据增强\n\n【8】为了进一步减少对标注数据的依赖，本文采用了一系列数据增强技术。这些技术包括旋转、缩放、裁剪和颜色抖动等。\n\n【9】### 3. 实验\n\n【10】#### 3.1 数据集\n\n【11】实验在多个公开数据集上进行，包括ImageNet、CIFAR-10和MNIST。\n\n【12】#### 3.2 实验结果\n\n【13】实验结果表明，所提出的方法在不同的数据集上均取得了优异的性能。\n\n| 数据集   | 精度   | 召回率 |\n| -------- | ------ | ------ |\n| ImageNet | 85.7%  | 84.3%  |\n| CIFAR-10 | 92.4%  | 91.5%  |\n| MNIST    | 98.2%  | 98.0%  |\n\n【15】### 4. 结论\n\n【16】本文提出了一种新的卷积神经网络架构，通过结合迁移学习和数据增强技术，显著减少了对标注数据的需求。实验结果验证了该方法的有效性，在多个公开数据集上取得了优异的性能。\n\n---|删除段之间换行|（注：上述内容为图片文字的Markdown格式转换，忽略了图片中的参考文献和目录部分。）", "tags": {}, "lang": "zh", "attr": {"page_num": 22, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V2）NCCN临床实践指南：甲状腺癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": null, "finished": false, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 18:34:41", "grab_time": "2024-08-06 18:34:38"}
{"id": 2211527, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "d8d9a123-4944-42cd-8013-ad84d85e1861", "title": "_2024 ESMO临床实践指南：胃癌患者的 诊断、治疗和随访——泛亚洲人群适用(1)", "text": "【0】页码:19\n_2024 ESMO临床实践指南：胃癌患者的 诊断、治疗和随访——泛亚洲人群适用(1)\n(本页删除)本页被模型判断为参考页### 正文内容\n\n【1】16. Liou JM, Malfertheiner P, Lee YC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69删除11:<u>(12)</u>:2093-删除13:<u>2112.\n17</u>. Lordick F, Cajo Montero L, Castelo-Branco L, et al. Ann Oncol 2022;33删除11:<u>(10)</u>:1005-1020. ESMO Gastric Cancer: Living Guideline.v1.1 ed 2023删除1:<u>. Available at: https://www.esmo.org/living-guidelines/esmo-gastric-cancer-living-guideline. Accessed January 删除13:<u>31, 2024</u>.</u>\n18. Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 2020;382删除11:<u>(5)</u>:427-删除13:<u>436.\n19</u>. Ford AC, Yuan Y, Forman D, et al. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020;7删除11:<u>(7)</u>:CD005583.\n20. Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69删除11:<u>(12)</u>:2113-删除13:<u>2121.\n21</u>. International Agency for Research on Cancer WHO. Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC Working Group Report. 2014;8.\n22. Choi KS, Jun JK, Suh M, et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea. Br J Cancer. 2015;112删除11:<u>(4)</u>:608-删除13:<u>612.\n23</u>. Fan X, Qin Y, Zhang Y, et al. Screening for gastric cancer in China: advances, challenges and visions. Chin J Cancer Res. 2021;33删除11:<u>(2)</u>:168-删除13:<u>180.\n24</u>. Mabe K, Inoue K, Kamada T, et al. Endoscopic screening for gastric cancer in Japan: current status and future perspectives. Dig Endosc. 2022;34删除11:<u>(3)</u>:412-删除13:<u>419.\n25</u>. Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26删除11:<u>(1)</u>:1-删除13:<u>25.\n26</u>. Carneiro F, Fukayama M, Grabowski P, et al. Gastric adenocarcinoma. In: Tumours of the Stomach. Vol 1. Lyon, France: IARC;2019:85-删除13:<u>95.\n27</u>. Shitara K, Lordick F, Bang Y, et al. Zoledronic acid plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, unresectable, locally advanced unresectable or metastatic gastric or gastrooesophageal junction adenocarcinoma (SPOTLIGHT): a randomized, double-blind, phase 3 trial. Lancet. 2023;401删除11:<u>删除19:<u>(10389)</u></u>:1655-删除13:<u>1668.\n28</u>. Shah MA, Shitara K, Ajani JA, et al. Zanidatamab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29删除11:<u>(8)</u>:2133-删除13:<u>2143.\n29</u>. Kang YK, Yook JH, Park YK, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2013;29删除11:<u>(6)</u>:2093-删除13:<u>2103.\n30</u>. Yoshida K, Yasufuku I, Terashima M, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer in Japan (INTEGRATE-J). Ann Gastroenterol Surg. 2022;6删除11:<u>(1)</u>:227-删除13:<u>240.\n31</u>. Hosogi H, Shinohara H, Tsunoda S, et al. Staging laparoscopy for advanced gastric cancer: significance of preoperative clinicopathological factors. Langenbecks Arch Surg. 2017;402删除11:<u>(1)</u>:33-删除13:<u>39.\n32</u>. Irino T, Sano T, Hiki N, et al. Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. Surg Endosc. 2018;32删除11:<u>(1)</u>:268-删除13:<u>273.\n33</u>. Miki Y, Tokunaga M, Tanizawa Y, et al. Staging laparoscopy for patients with cM0, type 2, and large type 3 gastric cancer. World J Surg. 2015;39删除11:<u>(1)</u>:2742-删除13:<u>2747.\n34</u>. Yamagata Y, Kaminura K, Kawashima Y, et al. Staging laparoscopy in advanced gastric cancer: usefulness and issues requiring improvement. Hepatogastroenterology. 2013;60删除11:<u>(124)</u>:751-删除13:<u>755.\n35</u>. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355删除11:<u>(1)</u>:11-删除13:<u>20.\n36</u>. Yoo HM, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29删除11:<u>(31)</u>:1715-删除13:<u>1721.\n37</u>. Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-esophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an openlabel, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22删除11:<u>(8)</u>:1081-删除13:<u>1092.\n38</u>. Zhang X, Li Z, Liang H, et al. Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy: an updated analysis of RESOLVE trial. Ann Oncol. 2023;34删除11:<u>(1)</u>:18-删除13:<u>78.\n39</u>. Kang YK, Kim HJ, Yook JH, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial. J Clin Oncol. 2023;41:删除13:<u>1067.\n40</u>. Iwasaki Y, Terashima M, Mizusawa J, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer 删除19:<u>(JCOG0501)</u>: an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021;24删除11:<u>(2)</u>:492-删除13:<u>502.\n41</u>. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24删除11:<u>(1)</u>:1-删除13:<u>21.\n42</u>. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomized, phase 2/3 trial. Lancet. 2019;393删除11:<u>删除19:<u>(10184)</u></u>:1948-删除13:<u>1957.\n43</u>. Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Palbociclib-complete response (PCR) for resected tumors plus S-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLON) in HER2-positive resected gastric or gastroesophageal junction cancer (GC/GEJ): interim results of the global, phase III MATTERHORN study. J Clin Oncol. 2023;34:3153-删除13:<u>3154.\n44</u>. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet. 2012;379删除11:<u>删除19:<u>(9813)</u></u>:315-删除13:<u>321.\n45</u>. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15删除11:<u>(12)</u>:1389-删除13:<u>1396.\n46</u>. Yoshida K, Koga Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37删除11:<u>(15)</u>:1296-删除13:<u>1304.\n47</u>. Fom SS, Choi WW, Bom BW, et al. A comprehensive and comparative review of global gastric cancer treatment guidelines. J Gastric Cancer. 2022;21删除11:<u>(1)</u>:3-删除13:<u>23.\n48</u>. Guideline Committee of the Korean Gastric Cancer Association (KCGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer. 2019;19删除11:<u>(1)</u>:1-删除13:<u>48.\n49</u>. Park SH, Kim DY, Sohn TS, et al. Randomized phase III trial comparing adjuvant single-agent S1, S1 with oxaliplatin, and postoperative chemoradiation with S1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021;32删除11:<u>(3)</u>:368-删除13:<u>374.\n50</u>. Li Y, Zhang Z, Meng Q, et al. Efficacy of different number of XELOX or SOX chemotherapy cycles after D2 resection for stage III gastric cancer. J Gastric Cancer. 2022;22删除11:<u>(2)</u>:107-删除13:<u>119.\n51</u>. Zaanan A, Bouche O, de la Fouchardiere C, et al. S-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced 删除9:<u>(LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ)</u> adenocarcinoma (GASTFOX-PRODIGE 51): a randomized phase III trial sponsored by the FFCD. Ann Oncol. 2023;34:51318 (LBA 17).", "tags": {}, "lang": "en", "attr": {"page_num": 19, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_2024 ESMO临床实践指南：胃癌患者的 诊断、治疗和随访——泛亚洲人群适用(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:10:31", "endTime": "2024/08/06 17:10:49", "cost": 18.28}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 01:10:49", "grab_time": "2024-08-06 01:10:31"}
{"id": 2211526, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "56b0ba62-3712-4633-9583-6e279a32c7a5", "title": "【神经领域】中国脑卒中防治指导规范（2021年版）", "text": "【0】页码:307\n【神经领域】中国脑卒中防治指导规范（2021年版）\n(本页删除)本页被模型判断为参考页### 10. 中国脑卒中血管超声检测指导规范参考文献\n\n【1】#### 参考文献\n\n【2】删除14:<u>[1] </u>中国医师协会超声医师分会. 血管超声规范化操作指南删除12:<u>[J]</u>. 中华超声影像学杂志, 删除13:<u>2009, 18</u>删除11:<u>(10)</u>:911-920.\n\n【3】删除14:<u>[2] </u>华扬. 实用颈动脉和颅脑血管超声诊断学删除12:<u>[J]</u>. 北京: 科学出版社, 2002.\n\n【4】删除14:<u>[3] </u>温朝阳,潘一砂主译. 血管超声经典教程(第6版)删除12:<u>[J]</u>. 北京: 人民军医出版社, 2015.\n\n【5】参考删除-3:<u>删除12:<u>删除14:<u>[4]</u></u> De Bray J M, Baud J M , Dauzat M . Consensus Concerning the Morphology and the Risk of Carotid Plaques删除12:<u>[J]</u>. Cerebrovascular Diseases, 1997, 7删除11:<u>(5)</u>:289-296.</u>\n\n【6】参考删除-3:<u>删除12:<u>删除14:<u>[5]</u></u> Joakimsen O, Bnaa K H, Stensland-Bugge E. Reproducibility of Ultrasound Assessment of Carotid Plaque Occurrence, Thickness, and Morphology. The Tromso Study删除12:<u>[J]</u>. Stroke, 删除13:<u>1997, 28</u>删除11:<u>(11)</u>:2201-2207.</u>\n\n【7】参考删除-3:<u>删除12:<u>删除14:<u>[6]</u></u> Grant E G, Benson C B, Moneta G L, et al. Carotid Artery Stenosis: Gray-scale and Doppler US Diagnosis--Society of Radiologists in Ultrasound Consensus Conference删除12:<u>[J]</u>. Radiology, 删除13:<u>2003, 229</u>:删除11:<u>(2)</u>:340-346.</u>\n\n【8】删除14:<u>[7] </u>华扬, 刘富德, 凌晨, 等. 超声检查对颈动脉狭窄50%~69%和70%~99%诊断准确性的评估删除12:<u>[J]</u>. 中国脑血管病杂志, 2006, 3删除11:<u>(5)</u>:211-218.\n\n【9】删除14:<u>[8] </u>赵新宇, 华扬, 贾茂云, 彩色多普勒血流显像评价不同类型颅内动脉闭塞患者血管结构与血流动力学变化删除12:<u>[J]</u>. 中华医学超声杂志(电子版), 2011, 8删除11:<u>(12)</u>:2493-2500.\n\n【10】参考删除-3:<u>删除12:<u>删除14:<u>[9]</u></u> Hua Y, Meng X F, Jia L Y, et al. Color Doppler Imaging Evaluation of Proximal Vertebral Artery Stenosis删除12:<u>[J]</u>. AJR Am J Roentgenol, 删除13:<u>2009, 19</u>删除11:<u>(11)</u> :1434-1438.</u>\n\n【11】删除14:<u>[10] </u>周贤华, 华扬, 凌晨, 等. 血管超声对椎动脉闭塞的血流动力学评价删除12:<u>[J]</u>. 国际版血管病杂", "tags": {}, "lang": "en", "attr": {"page_num": 307, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【神经领域】中国脑卒中防治指导规范（2021年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:11:58", "endTime": "2024/08/06 16:12:12", "cost": 13.954}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:12:12", "grab_time": "2024-08-06 00:11:58"}
{"id": 2211525, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "c3227058-b543-4961-b9a3-40b1c3a221fc", "title": "WHO：新冠治疗动态指南（2022）", "text": "【0】页码:70\nWHO：新冠治疗动态指南（2022）\nCOVID-19 warrant rapid serological tests with adequate performance characteristics. Health care systems would need to implement such tests, as outlined in the acceptability and feasibility section.\n\n【1】Monitoring: Although the available trials have not convincingly shown that casirivimab-imdevimab results in allergic reactions, the possibility remains. Administer through an intravenous line containing a sterile in-line or add-on 0.2 micron filter. Following infusion, patients should undergo monitoring for allergic reactions.\n\n【2】Evidence To Decision\n\n【3】Benefits and harms \nIn the overall population of patients with severe and critical COVID-19, casirivimab-imdevimab may not have an impact on mortality and the impact on mechanical ventilation and duration of hospitalization is very uncertain.\n\n【4】A credible subgroup effect demonstrated that casirivimab-imdevimab probably reduces mortality in patients who are seronegative, with the absolute effects ranging from 39 fewer per 1000 (95% CI 62 fewer-13 fewer) in the severely ill to 69 fewer (95% CI 110 fewer-23 fewer) in the critically ill. In seronegative patients, the intervention possibly reduces the need for mechanical ventilation 删除19:<u>(absolute effect estimate 42 fewer per 1000; 95% CI 74 fewer-6 fewer)</u>. Aside from the credible subgroup effect for serological status, we found no evidence of subgroup effects on age or time from onset of illness in the non-severe, or on age, time from onset of illness, and severity in the severe and critically ill.\n\n【5】Certainty of the Evidence\nIn patients with severe and critical COVID-19, evidence for mortality was of low certainty because of imprecision and high likelihood that casirivimab-imdevimab has, in the seronegative and seropositive patients included in the overall group, very different effects. In this population, the evidence regarding the impact of the intervention on need for mechanical ventilation and duration of hospitalization was very low certainty given additional concerns with risk of bias.\n\n【6】For patients with severe and critical COVID-19 who are seronegative, evidence for mortality was rated as moderate as a result of concerns regarding imprecision 删除19:<u>(the confidence interval includes effects as small as 14 in 1000 that some patients may perceive as trivial)</u> and indirectness (variants may emerge in which casirivimab-imdevimab antibodies may have reduced effect). For mechanical ventilation, the GDG noted risk of bias from lack of blinding as an additional concern, resulting in low certainty evidence. For duration of hospitalization, the GDG also found very serious imprecision, resulting in very low certainty evidence.\n\n【7】Values and preferences\nApplying the agreed values and preferences 删除9:<u>(see Section 7)</u>, the GDG inferred that most if not all well-informed patients with severe or critical COVID-19 and seronegative status would choose to receive casirivimab-imdevimab. Other patients – those whose are seropositive or whose status is uncertain – are likely to decline the intervention.\n\n【8】Although the GDG focused on an individual patient perspective, they also considered a population perspective in which feasibility, acceptability, equity and cost are important considerations. In this case, feasibility concerns played an important role in the conditional recommendation. For the severe and critical patients, both limited availability of therapeutics and the requirement for serological testing as part of clinical decision-making to identify the seronegative patients proved important.\n\n【9】Resources and other considerations\n\n【10】Cost and availability \nGiven the cost and availability of casirivimab-imdevimab, and the challenges associated with serological testing, the obstacles to ensuring access in low- and middle-income countries may prove formidable. Thus, the panel's suggestion that patients who are seronegative receive the intervention may exacerbate health inequity. On the other hand, given the demonstrated benefits for patients, the recommendations should provide a stimulus to engage all possible mechanisms to improve global access to the intervention. Individual countries may formulate their guidelines considering available resources and prioritize treatment options accordingly.", "tags": {}, "lang": "en", "attr": {"page_num": 70, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WHO：新冠治疗动态指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:36:15", "endTime": "2024/08/06 15:36:34", "cost": 18.816}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:36:34", "grab_time": "2024-08-05 23:36:15"}
{"id": 2211524, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "4013728c-ec88-4824-8631-7d2c8a3550e2", "title": "儿童重症患者血浆和血小板输注的专家共识建议（2022）", "text": "【0】页码:17\n儿童重症患者血浆和血小板输注的专家共识建议（2022）\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】23. Delaney M, Karam O, Lieberman L, et al; the Pediatric Critical Care Transfusion and Anemia Expertise Initiative−Control/Avoidance of Bleeding (TAXI-CAB) in collaboration with the Pediatric Critical Care Blood Research Network (BloodNet) and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: What laboratory tests and physiologic triggers should guide the decision to administer a platelet or plasma transfusion in critically ill children and what product attributes are optimal to guide specific product selection? From the Transfusion and Anemia EXpertise Initiative−Control/Avoidance of Bleeding (TAXI-CAB). 删除32:<u>*</u>Pediatr Crit Care Med删除32:<u>*</u> 2022; 23 (Suppl 1):e1–e13\n\n【2】24. Russell R, Bauer DF, Goobie SM, et al; the Pediatric Critical Care Transfusion and Anemia Expertise Initiative−Control/Avoidance of Bleeding (TAXI-CAB) in collaboration with the Pediatric Critical Care Blood Research Network (BloodNet) and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Plasma and platelet transfusion strategies in children following severe trauma, traumatic brain injury and/or intracranial hemorrhage: From the Transfusion and Anemia EXpertise Initiative−Control/Avoidance of Bleeding (TAXI-CAB). 删除32:<u>*</u>Pediatr Crit Care Med删除32:<u>*</u> 2022; 23:e14–e25\n\n【3】25. Cholette JM, Muszynski JA, Jbla JC, et al; the Pediatric Critical Care Transfusion and Anemia EXpertise Initiative−Control/Avoidance of Bleeding (TAXI-CAB) in collaboration with the Pediatric Critical Care Blood Research Network (BloodNet) and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Plasma and platelet transfusion strategies in neonates and children undergoing cardiac surgery with cardiopulmonary bypass or neonates and children supported by extracorporeal membrane oxygenation: From the Transfusion and Anemia EXpertise Initiative−Control/Avoidance of Bleeding (TAXICAB). 删除32:<u>*</u>Pediatr Crit Care Med删除32:<u>*</u> 2022; 23:e25–e36\n\n【4】26. Lieberman L, Karam O, Stanworth SJ, et al; the Pediatric Critical Care Transfusion and Anemia EXpertise Initiative−Control/Avoidance of Bleeding (TAXI−CAB) in collaboration with the Pediatric Critical Care Blood Research Network (BloodNet) and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Plasma and platelet transfusion strategies in critically ill children with malignancy, acute liver failure and/or liver transplantation, or sepsis: From the Transfusion and Anemia EXpertise Initiative−Control/Avoidance of Bleeding (TAXI-CAB). 删除32:<u>*</u>Pediatr Crit Care Med删除32:<u>*</u> 2022; 23:e37–e49\n\n【5】27. Tucci M, Crighton G, Goobie SM, et al; the Pediatric Critical Care Transfusion and Anemia EXpertise Initiative−Control/Avoidance of Bleeding (TAXI-CAB) in collaboration with the Pediatric Critical Care Blood Research Network (BloodNet) and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Plasma and platelet transfusion strategies in critically ill children following non-cardiac surgery and critically ill children undergoing invasive procedures outside the operating room: From the Transfusion and Anemia EXpertise Initiative−Control/Avoidance of Bleeding (TAXI-CAB). 删除32:<u>*</u>Pediatr Crit Care Med删除32:<u>*</u> 2022; 23:e50–e62\n\n【6】28. Nellis ME, Remy KE, Lacroix J, et al; the Pediatric Critical Care Transfusion and Anemia EXpertise Initiative−Control/Avoidance of Bleeding (TAXI-CAB) in collaboration with the Pediatric Critical Care Blood Research Network (BloodNet) and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Research priorities for plasma and platelet transfusion strategies in critically ill children: From the Transfusion and Anemia EXpertise Initiative−Control/Avoidance of Bleeding (TAXI-CAB). 删除32:<u>*</u>Pediatr Crit Care Med删除32:<u>*</u> 2022; 23:e63–e73\n\n【7】参考删除-3:<u>29. Hayden JA, van der Windt DA, Cartwright JL, et al: Assessing bias in studies of prognostic factors. 删除32:<u>*</u>Ann Intern Med删除32:<u>*</u> 2013; 158:280–286</u>\n\n【8】参考删除-3:<u>30. Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group: GRADE: Going from evidence to recommendations. 删除32:<u>*</u>BMJ删除32:<u>*</u> 2008; 336:1049–1051</u>\n\n【9】参考删除-3:<u>31. Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group: What is \"quality of evidence\" and why is it important to clinicians? 删除32:<u>*</u>BMJ删除32:<u>*</u> 2008; 336:995–998</u>\n\n【10】参考删除-3:<u>32. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. 删除32:<u>*</u>BMJ删除32:<u>*</u> 2008; 336:924–926</u>\n\n【11】参考删除-3:<u>33. Nellis ME, Tucci M, Lacroix J, et al; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network; and the Pediatric Critical Care Blood Research Network (BloodNet): Bleeding assessment scale in critically ill children (BASIC): Physician driven diagnostic criteria for bleeding severity. 删除32:<u>*</u>Crit Care Med删除32:<u>*</u> 2019; 47:1766–1772</u>\n\n【12】参考删除-3:<u>34. Fitch K, Bernstein SJ, Aguilar MD, et al: The RAND/UCLA Appropriateness Method User’s Manual. Santa Monica, RAND Corporation, 2001</u>\n\n【13】参考删除-3:<u>35. Doctor A, Cholette JM, Remy KE, et al: Recommendations on RBC transfusion in general critically ill children based on hemoglobin and/or physiologic thresholds from the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. 删除32:<u>*</u>Pediatr Crit Care Med删除32:<u>*</u> 2018; 19(Suppl 1):S98–S113</u>\n\n【14】参考删除-3:<u>36. Callum JL, Dzik WH: The use of blood components prior to invasive bedside procedures: A critical appraisal. In: Transfusion Therapy: Clinical Principles and Practice. Third Edition, Mintz PD (Ed.). Bethesda, MD, AABB Press, 2011, pp 153–177</u>\n\n【15】参考删除-3:<u>37. Zwifelhofer NMJ, Bercovitz RS, Cole R, et al: Platelet function changes during neonatal cardiopulmonary bypass surgery: Mechanistic basis and lack of correlation with excessive bleeding. 删除32:<u>*</u>Thromb Haemost删除32:<u>*</u> 2020; 120:94–106</u>\n\n【16】参考删除-3:<u>38. Tanous O, Steinberg Shemer O, Yacobovich J, et al: Evaluating platelet function disorders in children with bleeding tendency - a single center study. 删除32:<u>*</u>Platelets删除32:<u>*</u> 2017; 28:676–681</u>\n\n【17】参考删除-3:<u>39. Karam O, Goel R, Platton S, et al: Epidemiology of hemostatic transfusions in children supported by extracorporeal membrane oxygenation. 删除32:<u>*</u>Crit Care Med删除32:<u>*</u> 2020; 48:e698–e705</u>", "tags": {}, "lang": "en", "attr": {"page_num": 17, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/儿童重症患者血浆和血小板输注的专家共识建议（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:37:21", "endTime": "2024/08/06 15:37:29", "cost": 7.985}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:37:29", "grab_time": "2024-08-05 23:37:20"}
{"id": 2211523, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "51bbb854-11db-48a5-905e-b4b60c752b86", "title": "中国民族医药治疗成人失眠的专家共识（2022）", "text": "【0】页码:1\n中国民族医药治疗成人失眠的专家共识（2022）\n# 中国民族医药治疗成人失眠的专家共识\n\n【1】中国民族医药学会睡眠分会\n\n【2】关键词: 民族医药; 失眠; 共识; 非药物疗法\n\n【3】删除25:<u>doi: 10.3969/j.issn.1006-2157.2022.01.004        中国分类号: R256.23</u>\n\n【4】## Expert consensus on the treatment of adult insomnia with traditional Chinese medicine\n\n【5】Sleep Medicine Branch of the Chinese Medical Association of Minorities\n\n【6】Keywords: traditional Chinese medicine; insomnia; consensus; non-drug therapy\n\n【7】失眠是临床最常见的睡眠障碍类型。成人中符合其诊断标准者高达10% ~ 15%，住在非慢性化病程中约50%患者的病程可持续10年以上，严重损害了患者的身体健康、影响患者的生活质量、甚至危及公共安全，对个体和社会均造成严重负面删除11:<u>(1)</u>。\n\n【8】民族医药包括中医药及藏医药、羌医药、维吾尔医药等民族医药体系。治疗成人失眠目标是提高患者的诊断和生活质量删除11:<u>(1)</u>。为了规范民族医药治疗成人失眠，中国民族医药学会睡眠分会组织多学科、各民族医药专家对民族医学治疗成人失眠的大量研究成果进行整理总结，经过去专家讨论审定，制订了本共识。包括定义、分类、流行病学、临床表现、诊断标准、治疗机制、药物治疗、非药物治疗、针灸治疗、少数民族医药特色疗法、心理治疗和物理治疗等内容，分期为临床提供参考。\n\n【9】本共识主要对于成人失眠制定提供中国医药和少数民族医药为主要内容的预防、保健、诊断、治疗建议、指导临床医生,护提高人认规范治疗、护理，并提高患者的就眠质量。\n\n【10】### 1. 西医共识\n\n【11】#### 1.1 定义\n\n【12】成人失眠是指成年人难以躺卧、缠眠或休息时持续的入睡困难和/或睡眠维持困难并导致睡眠质量不满意及日间特征的睡眠障碍删除11:<u>(1)</u>。\n\n【13】#### 1.2 流行病学\n\n【14】流行病学研究发现,中国成年人群中有失眠症状者高达57%,女性患病风险为男性的1.4倍。删除27:<u>45</u>岁以上人群则高达1.7倍。70%~80%的精神障碍患者均有失眠症状。50%的失眠患者患有1种或以上精神障碍。成人失眠的主要危险因素为年龄、性别、遗传等，其他可以伴有力量重度、失眠的患病率随年龄增长而增加删除11:<u>(2)</u>。\n\n【15】#### 1.3 临床表现\n\n【16】删除11:<u>(1)</u> 入睡困难: 睡眠潜伏期>30 min。  \n删除11:<u>(2)</u> 睡眠维持困难: 睡眠的次数超过2次者夜醒超过2次，夜醒次数超过2次。各夜醒时间>40 min;或醒时间占睡眠时间的10%以上。  \n删除11:<u>(3)</u> 早醒: 睡眠时间较正常的日常提前30 min以上，甚至比平时早醒1~2 h，总的睡眠时间少于6h。  \n删除11:<u>(4)</u> 睡眠表浅: 睡眠非快速眼动期 (NREM) III 或IV期深度睡眠减少,小于总睡眠时间的10%。NREM 所占比例减少，睡眠的深度不足,睡眠质量下降,睡眠少,多梦。  \n删除11:<u>(5)</u> 日间症状: 次日感到头昏、精神不振、嗜睡、乏力等。\n\n【17】#### 1.4 诊断\n\n【18】成年失眠的诊断目前遵循《睡眠障碍国际分类 (第3版)》标准(ICSD)删除11:<u>(3)</u>的诊断标准。\n\n【19】#### 1.4.1 诊断标准 \n删除11:<u>(1)</u> 睡眠困难标准: 符合以下1项或以下三项中的≥1项:  \n    ① 入睡困难;  \n    ② 睡眠维持困难;  \n    ③ 也早醒;  \n删除11:<u>(2)</u> 睡眠潜伏期(晚上适当的时间术床后床睡觉)，没", "tags": {}, "lang": "zh", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/中国民族医药治疗成人失眠的专家共识（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "③ 也早醒;", "content": "【0】页码:1\n中国民族医药治疗成人失眠的专家共识（2022）\n# 中国民族医药治疗成人失眠的专家共识\n\n【1】中国民族医药学会睡眠分会\n\n【2】关键词: 民族医药; 失眠; 共识; 非药物疗法\n\n【3】删除25:<u>doi: 10.3969/j.issn.1006-2157.2022.01.004        中国分类号: R256.23</u>\n\n【4】## Expert consensus on the treatment of adult insomnia with traditional Chinese medicine\n\n【5】Sleep Medicine Branch of the Chinese Medical Association of Minorities\n\n【6】Keywords: traditional Chinese medicine; insomnia; consensus; non-drug therapy\n\n【7】失眠是临床最常见的睡眠障碍类型。成人中符合其诊断标准者高达10% ~ 15%，住在非慢性化病程中约50%患者的病程可持续10年以上，严重损害了患者的身体健康、影响患者的生活质量、甚至危及公共安全，对个体和社会均造成严重负面删除11:<u>(1)</u>。\n\n【8】民族医药包括中医药及藏医药、羌医药、维吾尔医药等民族医药体系。治疗成人失眠目标是提高患者的诊断和生活质量删除11:<u>(1)</u>。为了规范民族医药治疗成人失眠，中国民族医药学会睡眠分会组织多学科、各民族医药专家对民族医学治疗成人失眠的大量研究成果进行整理总结，经过去专家讨论审定，制订了本共识。包括定义、分类、流行病学、临床表现、诊断标准、治疗机制、药物治疗、非药物治疗、针灸治疗、少数民族医药特色疗法、心理治疗和物理治疗等内容，分期为临床提供参考。\n\n【9】本共识主要对于成人失眠制定提供中国医药和少数民族医药为主要内容的预防、保健、诊断、治疗建议、指导临床医生,护提高人认规范治疗、护理，并提高患者的就眠质量。\n\n【10】### 1. 西医共识\n\n【11】#### 1.1 定义\n\n【12】成人失眠是指成年人难以躺卧、缠眠或休息时持续的入睡困难和/或睡眠维持困难并导致睡眠质量不满意及日间特征的睡眠障碍删除11:<u>(1)</u>。\n\n【13】#### 1.2 流行病学\n\n【14】流行病学研究发现,中国成年人群中有失眠症状者高达57%,女性患病风险为男性的1.4倍。删除27:<u>45</u>岁以上人群则高达1.7倍。70%~80%的精神障碍患者均有失眠症状。50%的失眠患者患有1种或以上精神障碍。成人失眠的主要危险因素为年龄、性别、遗传等，其他可以伴有力量重度、失眠的患病率随年龄增长而增加删除11:<u>(2)</u>。\n\n【15】#### 1.3 临床表现\n\n【16】删除11:<u>(1)</u> 入睡困难: 睡眠潜伏期>30 min。  \n删除11:<u>(2)</u> 睡眠维持困难: 睡眠的次数超过2次者夜醒超过2次，夜醒次数超过2次。各夜醒时间>40 min;或醒时间占睡眠时间的10%以上。  \n删除11:<u>(3)</u> 早醒: 睡眠时间较正常的日常提前30 min以上，甚至比平时早醒1~2 h，总的睡眠时间少于6h。  \n删除11:<u>(4)</u> 睡眠表浅: 睡眠非快速眼动期 (NREM) III 或IV期深度睡眠减少,小于总睡眠时间的10%。NREM 所占比例减少，睡眠的深度不足,睡眠质量下降,睡眠少,多梦。  \n删除11:<u>(5)</u> 日间症状: 次日感到头昏、精神不振、嗜睡、乏力等。\n\n【17】#### 1.4 诊断\n\n【18】成年失眠的诊断目前遵循《睡眠障碍国际分类 (第3版)》标准(ICSD)删除11:<u>(3)</u>的诊断标准。\n\n【19】#### 1.4.1 诊断标准 \n删除11:<u>(1)</u> 睡眠困难标准: 符合以下1项或以下三项中的≥1项:  \n① 入睡困难;  \n② 睡眠维持困难;  \n③ 也早醒;  \n删除11:<u>(2)</u> 睡眠潜伏期(晚上适当的时间术床后床睡觉)，没", "index": 1709, "show": true, "start": 1709, "end": 1715, "province": ["语义有效性", "语义不完整"], "isEdit": false, "comment": "【19】"}, {"text": "睡眠潜伏期(晚上适当的时间术床后床睡觉)，没", "content": "【0】页码:1\n中国民族医药治疗成人失眠的专家共识（2022）\n# 中国民族医药治疗成人失眠的专家共识\n\n【1】中国民族医药学会睡眠分会\n\n【2】关键词: 民族医药; 失眠; 共识; 非药物疗法\n\n【3】删除25:<u>doi: 10.3969/j.issn.1006-2157.2022.01.004        中国分类号: R256.23</u>\n\n【4】## Expert consensus on the treatment of adult insomnia with traditional Chinese medicine\n\n【5】Sleep Medicine Branch of the Chinese Medical Association of Minorities\n\n【6】Keywords: traditional Chinese medicine; insomnia; consensus; non-drug therapy\n\n【7】失眠是临床最常见的睡眠障碍类型。成人中符合其诊断标准者高达10% ~ 15%，住在非慢性化病程中约50%患者的病程可持续10年以上，严重损害了患者的身体健康、影响患者的生活质量、甚至危及公共安全，对个体和社会均造成严重负面删除11:<u>(1)</u>。\n\n【8】民族医药包括中医药及藏医药、羌医药、维吾尔医药等民族医药体系。治疗成人失眠目标是提高患者的诊断和生活质量删除11:<u>(1)</u>。为了规范民族医药治疗成人失眠，中国民族医药学会睡眠分会组织多学科、各民族医药专家对民族医学治疗成人失眠的大量研究成果进行整理总结，经过去专家讨论审定，制订了本共识。包括定义、分类、流行病学、临床表现、诊断标准、治疗机制、药物治疗、非药物治疗、针灸治疗、少数民族医药特色疗法、心理治疗和物理治疗等内容，分期为临床提供参考。\n\n【9】本共识主要对于成人失眠制定提供中国医药和少数民族医药为主要内容的预防、保健、诊断、治疗建议、指导临床医生,护提高人认规范治疗、护理，并提高患者的就眠质量。\n\n【10】### 1. 西医共识\n\n【11】#### 1.1 定义\n\n【12】成人失眠是指成年人难以躺卧、缠眠或休息时持续的入睡困难和/或睡眠维持困难并导致睡眠质量不满意及日间特征的睡眠障碍删除11:<u>(1)</u>。\n\n【13】#### 1.2 流行病学\n\n【14】流行病学研究发现,中国成年人群中有失眠症状者高达57%,女性患病风险为男性的1.4倍。删除27:<u>45</u>岁以上人群则高达1.7倍。70%~80%的精神障碍患者均有失眠症状。50%的失眠患者患有1种或以上精神障碍。成人失眠的主要危险因素为年龄、性别、遗传等，其他可以伴有力量重度、失眠的患病率随年龄增长而增加删除11:<u>(2)</u>。\n\n【15】#### 1.3 临床表现\n\n【16】删除11:<u>(1)</u> 入睡困难: 睡眠潜伏期>30 min。  \n删除11:<u>(2)</u> 睡眠维持困难: 睡眠的次数超过2次者夜醒超过2次，夜醒次数超过2次。各夜醒时间>40 min;或醒时间占睡眠时间的10%以上。  \n删除11:<u>(3)</u> 早醒: 睡眠时间较正常的日常提前30 min以上，甚至比平时早醒1~2 h，总的睡眠时间少于6h。  \n删除11:<u>(4)</u> 睡眠表浅: 睡眠非快速眼动期 (NREM) III 或IV期深度睡眠减少,小于总睡眠时间的10%。NREM 所占比例减少，睡眠的深度不足,睡眠质量下降,睡眠少,多梦。  \n删除11:<u>(5)</u> 日间症状: 次日感到头昏、精神不振、嗜睡、乏力等。\n\n【17】#### 1.4 诊断\n\n【18】成年失眠的诊断目前遵循《睡眠障碍国际分类 (第3版)》标准(ICSD)删除11:<u>(3)</u>的诊断标准。\n\n【19】#### 1.4.1 诊断标准 \n删除11:<u>(1)</u> 睡眠困难标准: 符合以下1项或以下三项中的≥1项:  \n① 入睡困难;  \n② 睡眠维持困难;  \n<mark>③ 也早醒;</mark>  \n删除11:<u>(2)</u> 睡眠潜伏期(晚上适当的时间术床后床睡觉)，没", "index": 1747, "show": true, "start": 1734, "end": 1756, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "【19】"}], "startTime": "2024/08/06 15:50:20", "endTime": "2024/08/06 15:51:50", "cost": 90.489}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:51:50", "grab_time": "2024-08-05 23:50:20"}
{"id": 2211522, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "33279b1c-c722-484e-bab4-5dc233dcaad8", "title": "患者药物吸入能力评估上海专家共识", "text": "页码:6\n患者药物吸入能力评估上海专家共识\n(本页删除)本页被模型判断为参考页PAUWELS R. NEWMAN S. BORGSTRÖM L. Airway |删除段内换行|deposition and airway effects of antiasthma drugs delivered |删除段内换行|from metered-dose inhalers删除12:<u>[J]</u>. Eur Respir J, 删除13:<u>1997, 10</u>删除11:<u>(9)</u>: \n2127-2138. DOI: 10.1183/09031936.97.10092127.\n\nHAIDL P, HEINDL S, SIEMON K. et al. Inhalation |删除段内换行|device requirements for patients' inhalation maneuvers删除12:<u>[J]</u>. \nRespir Med. 删除13:<u>2016, 118</u>: 65-75. DOI: 10.1016/j.rmed. \n2016.07.013.\n\nFARR S J. ROWE A M. RUBSAMEN R. et al. Aerosol |删除段内换行|deposition in the human lung following administration from a |删除段内换行|microprocessor controlled pressurised metered dose inhaler \n删除12:<u>[J]</u>. Thorax. 删除13:<u>1995, 50</u>删除11:<u>(6)</u>: 639-644. DOI: 10.1136/thx. \n50.6.639.\n\nLEACH C. Effect of formulation parameters on |删除段内换行|hydrofluoroalkane-beclomethasone dipropionate drug |删除段内换行|deposition in humans删除12:<u>[J]</u>. J Allergy Clin Immunol. 删除13:<u>1999, \n104</u>(6 Suppl): S250-S252. DOI: 10.1016/s0091-6749删除11:<u>(99)</u> \n70041-2.\n\nBRAND P, HEDERER B, AUSTEN G. et al. Higher lung |删除段内换行|deposition with respimat soft mist inhaler than HFA-MDI in |删除段内换行|COPD patients with poor technique 删除12:<u>[J]</u>. Int J Chron \nObstruct Pulmon Dis. 2008, 3删除11:<u>(4)</u>: 763-770.\n\nEVERARD M L, DEVADASON S G, LE SOUEF P N. \nHow early in the inspiratory manouevre affects the aerosol |删除段内换行|particle size distribution from a Turbuhaler 删除12:<u>[J]</u>. Respir", "tags": {}, "lang": "en", "attr": {"page_num": 6, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/患者药物吸入能力评估上海专家共识.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:40:37", "endTime": "2024/08/06 15:40:43", "cost": 6.371}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:40:43", "grab_time": "2024-08-05 23:40:36"}
{"id": 2211521, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "402a3f5a-1e95-4f4a-80a5-878e10a60f3f", "title": "2023 BTS指南：儿童睡眠呼吸障碍的诊断和监测", "text": "【0】页码:14\n2023 BTS指南：儿童睡眠呼吸障碍的诊断和监测\n### Table 12  Diagnostic accuracy of 4 hours polysomnography (PSG) sleep monitoring\n\n| Age                  | ≤6 months                        | >6 months, <2 years               | Combined data (<2 years)          |\n|----------------------|----------------------------------|----------------------------------|----------------------------------|\n| Diagnosis            | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) |\n| Total AHI            | 1.00 (4/8)(8/8)                  | -- (0/0)                          | 0.93 (52/56)                      | 1.00 (1/1)                      | 0.96 (100/104)                    | 1.00 (1/1)                      |\n| Obstructive AHI      | 0.98 (46/47)                     | 0.83 (33/40)                      | 0.91 (41/45)                      | 0.92 (11/12)                    | 0.95 (87/92)                      | 0.92 (12/13)                    |\n| Central AHI          | 1.00 (8/8)                       | 0.83 (33/40)                      | 0.72 (13/18)                      | 0.87 (34/39)                    | 0.81 (21/26)                      | 0.85 (67/79)                    |\n\n【2】AHI, Apnoea–Hypopnoea Index; AI, apnoea index; D+, number of subjects with the disease; D-, number of subjects without the disease; TN, true negative; TP, true positive.\n\n---|删除段之间换行|删除32:<u>**</u>Good practice point删除32:<u>**</u>\n\n【4】删除5:<u>✓</u> Based on the Australasian Sleep Association's ‘Overnight oximetry for evaluating paediatric obstructive sleep apnoea: Technical specifications and interpretation guidelines’, a short pulse oximetry averaging time of 2–3 s should be used when diagnosing SDB in children.\n\n---|删除段之间换行|删除32:<u>**</u>Optimal monitoring time for pulse oximetry and CRSS删除32:<u>**</u>\n\n【6】For almost all conditions in children, episodes of SDB occur during REM sleep which is accurately determined using PSG. When using level 2, 3 or 4 investigations 删除9:<u>(table 4)</u>, surrogate markers such as heart rate variability are used to determine REM sleep which is often described as active sleep. In children, REM density and duration increase over the course of the night, however AHI does not increase across REM cycles. Thus, the number of REM cycles captured during a period of monitoring might impact data output. Measuring equipment might need upgrading, with regular re-applying during data capture required to reduce potential missing data or artefacts.\n\n【7】Understanding the implications of shorter duration studies on diagnostic accuracy would therefore guide clinicians on the need to repeat studies of short duration, leading to the next clinical question:\n\n【8】Q6 For children with suspected SDB, what is the optimal monitoring time when using pulse oximetry or CRSS?\n\n【9】There was very limited evidence to support this review, with only one study reporting on the diagnostic accuracy of 4 hours of PSG sleep monitoring (containing at least one cycle of REM) to diagnose total AHI, obstructive AHI and CAI in children under 2 years of age with suspected SDB. Full night PSG was used as the gold standard and the results are summarised in table 12.\n\n【10】The Q6 Evidence Statement and GPP are presented below and the full evidence review is presented in online supplemental appendix 6.\n\n---|删除段之间换行|删除32:<u>**</u>Evidence statement删除32:<u>**</u>\n\n【12】There was minimal evidence to support this review.\n\n【13】- Four hours of PSG monitoring appears to have a high specificity and high sensitivity for diagnosing SDB in children less than 2 years of age when using full night PSG as the gold standard. (Ungraded)\n\n---|删除段之间换行|删除32:<u>**</u>Recommendations删除32:<u>**</u>\n\n【15】No recommendations can be made based on the limited evidence.\n\n【16】删除32:<u>**</u>Good practice point删除32:<u>**</u>\n\n【17】删除5:<u>✓</u> Sleep studies, using pulse oximetry or a CRSS, with 4–6 hours of continuous sleep duration should be adequate for diagnosing moderate-to-severe SDB in children. The sleep duration is defined as continuous to allow adequate opportunity for all sleep stages to occur. Combining short episodes of sleep interspersed with wake to create 4–6 hours of sleep recording may miss parts of the sleep cycle and is not advised. This includes children under the age of 2 years, where REM cycles are more evenly dispersed through the night. If a child is older than 2 years of age (when REM sleep is greater in the latter half of the night), or if a mixed disease is to be excluded, a period of longer than 6 hours is advised.\n\n【18】Is one night of pulse oximetry or CRSS monitoring enough? In the UK there is a desire to use investigations that are simple and practical to undertake, but there is uncertainty as to whether a single night of pulse oximetry or CRSS monitoring provides adequate data, or whether there are certain instances where monitoring over several nights may provide an improved diagnostic accuracy for diagnosing SDB. This led to the next clinical question:\n\n【19】Q7 Evidence statement, Recommendation and GPPs are presented below and the full evidence review is presented in online supplemental appendix 7.\n\n---|删除段之间换行|删除32:<u>**</u>Evidence statement删除32:<u>**</u>\n\n【21】This review had very limited supporting evidence.\n\n【22】- Between-night pulse oximetry metric variations appear to be limited in children without comorbidities. (Ungraded)\n- There is not enough evidence to comment on night-to-night variability in pulse oximetry metrics in children with comorbidities, or CRSS metrics in children with, or without comorbidities.\n\n---|删除段之间换行|删除32:<u>**</u>Recommendation删除32:<u>**</u>\n\n【24】删除5:<u>✓</u> A single night of pulse oximetry monitoring, ideally consisting of 6 hours of continuous sleep duration, can be considered adequate for identifying SDB in children without comorbidities. (Conditional—by consensus)\n\n---|删除段之间换行|删除32:<u>**</u>Good practice points删除32:<u>**</u>\n\n【26】删除5:<u>✓</u> A single night of CRSS monitoring should also be considered adequate for identifying SDB in children without comorbidities.\n\n【27】删除5:<u>✓</u> If it is anticipated that a child will poorly tolerate a pulse oximetry probe, consider providing a pulse oximeter for more than one night to acquire at least one night of technically adequate data. Alongside the sleep log data, information on how typical the period of sleep was for the child should also be collected.\n\n【28】---", "tags": {}, "lang": "en", "attr": {"page_num": 14, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 BTS指南：儿童睡眠呼吸障碍的诊断和监测.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "In the UK there is a desire to use investigations that are simple and practical to undertake, but there is uncertainty as to whether a single night of pulse oximetry or CRSS monitoring provides adequate data, or whether there are certain instances where monitoring over several nights may provide an improved diagnostic accuracy for diagnosing SDB. This led to the next clinical question:", "content": "【0】页码:14\n2023 BTS指南：儿童睡眠呼吸障碍的诊断和监测\n### Table 12  Diagnostic accuracy of 4 hours polysomnography (PSG) sleep monitoring\n\n| Age                  | ≤6 months                        | >6 months, <2 years               | Combined data (<2 years)          |\n|----------------------|----------------------------------|----------------------------------|----------------------------------|\n| Diagnosis            | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) |\n| Total AHI            | 1.00 (4/8)(8/8)                  | -- (0/0)                          | 0.93 (52/56)                      | 1.00 (1/1)                      | 0.96 (100/104)                    | 1.00 (1/1)                      |\n| Obstructive AHI      | 0.98 (46/47)                     | 0.83 (33/40)                      | 0.91 (41/45)                      | 0.92 (11/12)                    | 0.95 (87/92)                      | 0.92 (12/13)                    |\n| Central AHI          | 1.00 (8/8)                       | 0.83 (33/40)                      | 0.72 (13/18)                      | 0.87 (34/39)                    | 0.81 (21/26)                      | 0.85 (67/79)                    |\n\n【2】AHI, Apnoea–Hypopnoea Index; AI, apnoea index; D+, number of subjects with the disease; D-, number of subjects without the disease; TN, true negative; TP, true positive.\n\n---|删除段之间换行|删除32:<u>**</u>Good practice point删除32:<u>**</u>\n\n【4】删除5:<u>✓</u> Based on the Australasian Sleep Association's ‘Overnight oximetry for evaluating paediatric obstructive sleep apnoea: Technical specifications and interpretation guidelines’, a short pulse oximetry averaging time of 2–3 s should be used when diagnosing SDB in children.\n\n---|删除段之间换行|删除32:<u>**</u>Optimal monitoring time for pulse oximetry and CRSS删除32:<u>**</u>\n\n【6】For almost all conditions in children, episodes of SDB occur during REM sleep which is accurately determined using PSG. When using level 2, 3 or 4 investigations 删除9:<u>(table 4)</u>, surrogate markers such as heart rate variability are used to determine REM sleep which is often described as active sleep. In children, REM density and duration increase over the course of the night, however AHI does not increase across REM cycles. Thus, the number of REM cycles captured during a period of monitoring might impact data output. Measuring equipment might need upgrading, with regular re-applying during data capture required to reduce potential missing data or artefacts.\n\n【7】Understanding the implications of shorter duration studies on diagnostic accuracy would therefore guide clinicians on the need to repeat studies of short duration, leading to the next clinical question:\n\n【8】Q6 For children with suspected SDB, what is the optimal monitoring time when using pulse oximetry or CRSS?\n\n【9】There was very limited evidence to support this review, with only one study reporting on the diagnostic accuracy of 4 hours of PSG sleep monitoring (containing at least one cycle of REM) to diagnose total AHI, obstructive AHI and CAI in children under 2 years of age with suspected SDB. Full night PSG was used as the gold standard and the results are summarised in table 12.\n\n【10】The Q6 Evidence Statement and GPP are presented below and the full evidence review is presented in online supplemental appendix 6.\n\n---|删除段之间换行|删除32:<u>**</u>Evidence statement删除32:<u>**</u>\n\n【12】There was minimal evidence to support this review.\n\n【13】- Four hours of PSG monitoring appears to have a high specificity and high sensitivity for diagnosing SDB in children less than 2 years of age when using full night PSG as the gold standard. (Ungraded)\n\n---|删除段之间换行|删除32:<u>**</u>Recommendations删除32:<u>**</u>\n\n【15】No recommendations can be made based on the limited evidence.\n\n【16】删除32:<u>**</u>Good practice point删除32:<u>**</u>\n\n【17】删除5:<u>✓</u> Sleep studies, using pulse oximetry or a CRSS, with 4–6 hours of continuous sleep duration should be adequate for diagnosing moderate-to-severe SDB in children. The sleep duration is defined as continuous to allow adequate opportunity for all sleep stages to occur. Combining short episodes of sleep interspersed with wake to create 4–6 hours of sleep recording may miss parts of the sleep cycle and is not advised. This includes children under the age of 2 years, where REM cycles are more evenly dispersed through the night. If a child is older than 2 years of age (when REM sleep is greater in the latter half of the night), or if a mixed disease is to be excluded, a period of longer than 6 hours is advised.\n\n【18】Is one night of pulse oximetry or CRSS monitoring enough? In the UK there is a desire to use investigations that are simple and practical to undertake, but there is uncertainty as to whether a single night of pulse oximetry or CRSS monitoring provides adequate data, or whether there are certain instances where monitoring over several nights may provide an improved diagnostic accuracy for diagnosing SDB. This led to the next clinical question:\n\n【19】Q7 Evidence statement, Recommendation and GPPs are presented below and the full evidence review is presented in online supplemental appendix 7.\n\n---|删除段之间换行|删除32:<u>**</u>Evidence statement删除32:<u>**</u>\n\n【21】This review had very limited supporting evidence.\n\n【22】- Between-night pulse oximetry metric variations appear to be limited in children without comorbidities. (Ungraded)\n- There is not enough evidence to comment on night-to-night variability in pulse oximetry metrics in children with comorbidities, or CRSS metrics in children with, or without comorbidities.\n\n---|删除段之间换行|删除32:<u>**</u>Recommendation删除32:<u>**</u>\n\n【24】删除5:<u>✓</u> A single night of pulse oximetry monitoring, ideally consisting of 6 hours of continuous sleep duration, can be considered adequate for identifying SDB in children without comorbidities. (Conditional—by consensus)\n\n---|删除段之间换行|删除32:<u>**</u>Good practice points删除32:<u>**</u>\n\n【26】删除5:<u>✓</u> A single night of CRSS monitoring should also be considered adequate for identifying SDB in children without comorbidities.\n\n【27】删除5:<u>✓</u> If it is anticipated that a child will poorly tolerate a pulse oximetry probe, consider providing a pulse oximeter for more than one night to acquire at least one night of technically adequate data. Alongside the sleep log data, information on how typical the period of sleep was for the child should also be collected.\n\n【28】---", "index": 4678, "show": true, "start": 4678, "end": 5066, "province": ["格式规范性", "缺少换行"], "isEdit": false, "comment": "18"}, {"text": "【19】Q7 Evidence statement, Recommendation and GPPs are presented below and the full evidence review is presented in online supplemental appendix 7.", "content": "【0】页码:14\n2023 BTS指南：儿童睡眠呼吸障碍的诊断和监测\n### Table 12  Diagnostic accuracy of 4 hours polysomnography (PSG) sleep monitoring\n\n| Age                  | ≤6 months                        | >6 months, <2 years               | Combined data (<2 years)          |\n|----------------------|----------------------------------|----------------------------------|----------------------------------|\n| Diagnosis            | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) |\n| Total AHI            | 1.00 (4/8)(8/8)                  | -- (0/0)                          | 0.93 (52/56)                      | 1.00 (1/1)                      | 0.96 (100/104)                    | 1.00 (1/1)                      |\n| Obstructive AHI      | 0.98 (46/47)                     | 0.83 (33/40)                      | 0.91 (41/45)                      | 0.92 (11/12)                    | 0.95 (87/92)                      | 0.92 (12/13)                    |\n| Central AHI          | 1.00 (8/8)                       | 0.83 (33/40)                      | 0.72 (13/18)                      | 0.87 (34/39)                    | 0.81 (21/26)                      | 0.85 (67/79)                    |\n\n【2】AHI, Apnoea–Hypopnoea Index; AI, apnoea index; D+, number of subjects with the disease; D-, number of subjects without the disease; TN, true negative; TP, true positive.\n\n---|删除段之间换行|删除32:<u>**</u>Good practice point删除32:<u>**</u>\n\n【4】删除5:<u>✓</u> Based on the Australasian Sleep Association's ‘Overnight oximetry for evaluating paediatric obstructive sleep apnoea: Technical specifications and interpretation guidelines’, a short pulse oximetry averaging time of 2–3 s should be used when diagnosing SDB in children.\n\n---|删除段之间换行|删除32:<u>**</u>Optimal monitoring time for pulse oximetry and CRSS删除32:<u>**</u>\n\n【6】For almost all conditions in children, episodes of SDB occur during REM sleep which is accurately determined using PSG. When using level 2, 3 or 4 investigations 删除9:<u>(table 4)</u>, surrogate markers such as heart rate variability are used to determine REM sleep which is often described as active sleep. In children, REM density and duration increase over the course of the night, however AHI does not increase across REM cycles. Thus, the number of REM cycles captured during a period of monitoring might impact data output. Measuring equipment might need upgrading, with regular re-applying during data capture required to reduce potential missing data or artefacts.\n\n【7】Understanding the implications of shorter duration studies on diagnostic accuracy would therefore guide clinicians on the need to repeat studies of short duration, leading to the next clinical question:\n\n【8】Q6 For children with suspected SDB, what is the optimal monitoring time when using pulse oximetry or CRSS?\n\n【9】There was very limited evidence to support this review, with only one study reporting on the diagnostic accuracy of 4 hours of PSG sleep monitoring (containing at least one cycle of REM) to diagnose total AHI, obstructive AHI and CAI in children under 2 years of age with suspected SDB. Full night PSG was used as the gold standard and the results are summarised in table 12.\n\n【10】The Q6 Evidence Statement and GPP are presented below and the full evidence review is presented in online supplemental appendix 6.\n\n---|删除段之间换行|删除32:<u>**</u>Evidence statement删除32:<u>**</u>\n\n【12】There was minimal evidence to support this review.\n\n【13】- Four hours of PSG monitoring appears to have a high specificity and high sensitivity for diagnosing SDB in children less than 2 years of age when using full night PSG as the gold standard. (Ungraded)\n\n---|删除段之间换行|删除32:<u>**</u>Recommendations删除32:<u>**</u>\n\n【15】No recommendations can be made based on the limited evidence.\n\n【16】删除32:<u>**</u>Good practice point删除32:<u>**</u>\n\n【17】删除5:<u>✓</u> Sleep studies, using pulse oximetry or a CRSS, with 4–6 hours of continuous sleep duration should be adequate for diagnosing moderate-to-severe SDB in children. The sleep duration is defined as continuous to allow adequate opportunity for all sleep stages to occur. Combining short episodes of sleep interspersed with wake to create 4–6 hours of sleep recording may miss parts of the sleep cycle and is not advised. This includes children under the age of 2 years, where REM cycles are more evenly dispersed through the night. If a child is older than 2 years of age (when REM sleep is greater in the latter half of the night), or if a mixed disease is to be excluded, a period of longer than 6 hours is advised.\n\n【18】Is one night of pulse oximetry or CRSS monitoring enough? <mark>In the UK there is a desire to use investigations that are simple and practical to undertake, but there is uncertainty as to whether a single night of pulse oximetry or CRSS monitoring provides adequate data, or whether there are certain instances where monitoring over several nights may provide an improved diagnostic accuracy for diagnosing SDB. This led to the next clinical question:</mark>\n\n【19】Q7 Evidence statement, Recommendation and GPPs are presented below and the full evidence review is presented in online supplemental appendix 7.\n\n---|删除段之间换行|删除32:<u>**</u>Evidence statement删除32:<u>**</u>\n\n【21】This review had very limited supporting evidence.\n\n【22】- Between-night pulse oximetry metric variations appear to be limited in children without comorbidities. (Ungraded)\n- There is not enough evidence to comment on night-to-night variability in pulse oximetry metrics in children with comorbidities, or CRSS metrics in children with, or without comorbidities.\n\n---|删除段之间换行|删除32:<u>**</u>Recommendation删除32:<u>**</u>\n\n【24】删除5:<u>✓</u> A single night of pulse oximetry monitoring, ideally consisting of 6 hours of continuous sleep duration, can be considered adequate for identifying SDB in children without comorbidities. (Conditional—by consensus)\n\n---|删除段之间换行|删除32:<u>**</u>Good practice points删除32:<u>**</u>\n\n【26】删除5:<u>✓</u> A single night of CRSS monitoring should also be considered adequate for identifying SDB in children without comorbidities.\n\n【27】删除5:<u>✓</u> If it is anticipated that a child will poorly tolerate a pulse oximetry probe, consider providing a pulse oximeter for more than one night to acquire at least one night of technically adequate data. Alongside the sleep log data, information on how typical the period of sleep was for the child should also be collected.\n\n【28】---", "index": 5081, "show": true, "start": 5068, "end": 5215, "province": ["语义有效性", "语义不完整"], "isEdit": false}, {"text": "Table 12 Diagnostic accuracy of 4 hours polysomnography (PSG) sleep monitoring\nAge\t≤6 months\t>6 months, <2 years\tCombined data (<2 years)\nDiagnosis\tSensitivity (TP/(D+))\tSpecificity (TN/(D-))\tSensitivity (TP/(D+))\nTotal AHI\t1.00 (4/8)(8/8)\t– (0/0)\t0.93 (52/56)\nObstructive AHI\t0.98 (46/47)\t0.83 (33/40)\t0.91 (41/45)\nCentral AHI\t1.00 (8/8)\t0.83 (33/40)\t0.72 (13/18)", "content": "【0】页码:14\n2023 BTS指南：儿童睡眠呼吸障碍的诊断和监测\n### Table 12  Diagnostic accuracy of 4 hours polysomnography (PSG) sleep monitoring\n\n| Age                  | ≤6 months                        | >6 months, <2 years               | Combined data (<2 years)          |\n|----------------------|----------------------------------|----------------------------------|----------------------------------|\n| Diagnosis            | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) | Sensitivity (TP/(D+)) | Specificity (TN/(D-)) |\n| Total AHI            | 1.00 (4/8)(8/8)                  | -- (0/0)                          | 0.93 (52/56)                      | 1.00 (1/1)                      | 0.96 (100/104)                    | 1.00 (1/1)                      |\n| Obstructive AHI      | 0.98 (46/47)                     | 0.83 (33/40)                      | 0.91 (41/45)                      | 0.92 (11/12)                    | 0.95 (87/92)                      | 0.92 (12/13)                    |\n| Central AHI          | 1.00 (8/8)                       | 0.83 (33/40)                      | 0.72 (13/18)                      | 0.87 (34/39)                    | 0.81 (21/26)                      | 0.85 (67/79)                    |\n\n【2】AHI, Apnoea–Hypopnoea Index; AI, apnoea index; D+, number of subjects with the disease; D-, number of subjects without the disease; TN, true negative; TP, true positive.\n\n---|删除段之间换行|删除32:<u>**</u>Good practice point删除32:<u>**</u>\n\n【4】删除5:<u>✓</u> Based on the Australasian Sleep Association's ‘Overnight oximetry for evaluating paediatric obstructive sleep apnoea: Technical specifications and interpretation guidelines’, a short pulse oximetry averaging time of 2–3 s should be used when diagnosing SDB in children.\n\n---|删除段之间换行|删除32:<u>**</u>Optimal monitoring time for pulse oximetry and CRSS删除32:<u>**</u>\n\n【6】For almost all conditions in children, episodes of SDB occur during REM sleep which is accurately determined using PSG. When using level 2, 3 or 4 investigations 删除9:<u>(table 4)</u>, surrogate markers such as heart rate variability are used to determine REM sleep which is often described as active sleep. In children, REM density and duration increase over the course of the night, however AHI does not increase across REM cycles. Thus, the number of REM cycles captured during a period of monitoring might impact data output. Measuring equipment might need upgrading, with regular re-applying during data capture required to reduce potential missing data or artefacts.\n\n【7】Understanding the implications of shorter duration studies on diagnostic accuracy would therefore guide clinicians on the need to repeat studies of short duration, leading to the next clinical question:\n\n【8】Q6 For children with suspected SDB, what is the optimal monitoring time when using pulse oximetry or CRSS?\n\n【9】There was very limited evidence to support this review, with only one study reporting on the diagnostic accuracy of 4 hours of PSG sleep monitoring (containing at least one cycle of REM) to diagnose total AHI, obstructive AHI and CAI in children under 2 years of age with suspected SDB. Full night PSG was used as the gold standard and the results are summarised in table 12.\n\n【10】The Q6 Evidence Statement and GPP are presented below and the full evidence review is presented in online supplemental appendix 6.\n\n---|删除段之间换行|删除32:<u>**</u>Evidence statement删除32:<u>**</u>\n\n【12】There was minimal evidence to support this review.\n\n【13】- Four hours of PSG monitoring appears to have a high specificity and high sensitivity for diagnosing SDB in children less than 2 years of age when using full night PSG as the gold standard. (Ungraded)\n\n---|删除段之间换行|删除32:<u>**</u>Recommendations删除32:<u>**</u>\n\n【15】No recommendations can be made based on the limited evidence.\n\n【16】删除32:<u>**</u>Good practice point删除32:<u>**</u>\n\n【17】删除5:<u>✓</u> Sleep studies, using pulse oximetry or a CRSS, with 4–6 hours of continuous sleep duration should be adequate for diagnosing moderate-to-severe SDB in children. The sleep duration is defined as continuous to allow adequate opportunity for all sleep stages to occur. Combining short episodes of sleep interspersed with wake to create 4–6 hours of sleep recording may miss parts of the sleep cycle and is not advised. This includes children under the age of 2 years, where REM cycles are more evenly dispersed through the night. If a child is older than 2 years of age (when REM sleep is greater in the latter half of the night), or if a mixed disease is to be excluded, a period of longer than 6 hours is advised.\n\n【18】Is one night of pulse oximetry or CRSS monitoring enough? <mark>In the UK there is a desire to use investigations that are simple and practical to undertake, but there is uncertainty as to whether a single night of pulse oximetry or CRSS monitoring provides adequate data, or whether there are certain instances where monitoring over several nights may provide an improved diagnostic accuracy for diagnosing SDB. This led to the next clinical question:</mark>\n\n<mark>【19】Q7 Evidence statement, Recommendation and GPPs are presented below and the full evidence review is presented in online supplemental appendix 7.</mark>\n\n---|删除段之间换行|删除32:<u>**</u>Evidence statement删除32:<u>**</u>\n\n【21】This review had very limited supporting evidence.\n\n【22】- Between-night pulse oximetry metric variations appear to be limited in children without comorbidities. (Ungraded)\n- There is not enough evidence to comment on night-to-night variability in pulse oximetry metrics in children with comorbidities, or CRSS metrics in children with, or without comorbidities.\n\n---|删除段之间换行|删除32:<u>**</u>Recommendation删除32:<u>**</u>\n\n【24】删除5:<u>✓</u> A single night of pulse oximetry monitoring, ideally consisting of 6 hours of continuous sleep duration, can be considered adequate for identifying SDB in children without comorbidities. (Conditional—by consensus)\n\n---|删除段之间换行|删除32:<u>**</u>Good practice points删除32:<u>**</u>\n\n【26】删除5:<u>✓</u> A single night of CRSS monitoring should also be considered adequate for identifying SDB in children without comorbidities.\n\n【27】删除5:<u>✓</u> If it is anticipated that a child will poorly tolerate a pulse oximetry probe, consider providing a pulse oximeter for more than one night to acquire at least one night of technically adequate data. Alongside the sleep log data, information on how typical the period of sleep was for the child should also be collected.\n\n【28】---", "index": 39, "show": true, "start": 39, "end": 403, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "0"}], "startTime": "2024/08/06 16:32:57", "endTime": "2024/08/06 16:35:35", "cost": 158.142}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:35:35", "grab_time": "2024-08-06 00:32:57"}
{"id": 2211520, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "0526520a-588f-460a-9e9b-e14859096043", "title": "1_2023+KAUTII指南：淋球菌感染", "text": "【0】页码:5\n1_2023+KAUTII指南：淋球菌感染\ncorresponded to fT>MIC of 236 hours, consistent with Monte Carlo simulation results 删除12:<u>删除14:<u>[23]</u></u>. Converting this to a human dose, 500 mg of ceftriaxone corresponds to 5 mg/kg of body weight in a person of 80 to 100 kg, while 250 mg of ceftriaxone corresponds to 3 mg/kg of body weight. Although ceftriaxone-resistant strains with MIC>0.125 mg/L have not been reported in Korea yet, the distribution of ceftriaxone MICs has increased (i.e., with an increase of reduced susceptibility) 删除12:<u>删除14:<u>[17]</u></u>. Ceftriaxone-resistant 删除32:<u>*</u>N. gonorrhoeae删除32:<u>*</u> strains have already been identified worldwide including the UK 删除12:<u>删除14:<u>[14,15,24,25]</u></u>. Although low-dose ceftriaxone might be suitable for treating most gonococcal species, high-dose ceftriaxone is more effective for most isolates with increased MICs than low dose 删除12:<u>删除14:<u>[23]</u></u>. Therefore, the recommended dose of ceftriaxone was increased to 500 mg for adults weighing less than 100 kg and to 1 g for adults weighing more than 100 kg to successfully treat the strain with reduced susceptibility . Intramuscular injection is thought to be helpful in maintaining concentrations above the MIC for more than 24 hours due to the “depot effect” 删除12:<u>删除14:<u>[26]</u></u>. In the US FDA approval label of ceftriaxone , there is no significant difference in 24-hour plasma concentrations between intramuscular and intravenous administration. Moreover, intramuscular injection of ceftriaxone can cause pain, which most patients complain about. In the past, when intramuscular injection of 250 mg ceftriaxone was recommended, pain was not greatly considered. However, when its dose was increased to 500 mg or 1 g, the pain could not be ignored. Ceftriaxone 500 mg should be dissolved in 2 mL of 1% lidocaine hydrochloride solution and injected deep into buttocks 删除12:<u>删除14:<u>[27]</u></u>.\n\n【1】### 3. Alternative therapy: Gentamicin plus azithromycin\n\n【2】A large randomized controlled-trial has investigated the efficacy and safety of gentamicin for treating gonorrhea 删除12:<u>删除14:<u>[21]</u></u>. In that study, gentamicin was used in combination with 1 g of azithromycin. Microbiological cure (negative NAAT after 2 weeks of treatment) was achieved in 94% of urogenital infections, 90% of rectal infections, and 80% of pharyngeal infections 删除12:<u>删除14:<u>[21]</u></u>. Another randomized trial has used a 2 g dose of azithromycin in combination with gentamicin 删除12:<u>删除14:<u>[28]</u></u>. Although gonococcal infection was 100% eliminated in that study, its objectives included very few non-genital infections, which was insufficient to provide a reliable estimate of the efficacy of this treatment regimen for rectal or pharyngeal infections 删除12:<u>删除14:<u>[28]</u></u>. In particular, when using 2 g of azithromycin, gastrointestinal adverse reactions (mainly vomiting within 1 hour after administration) occurred in 3%–4% of patients treated with gentamicin plus azithromycin 删除12:<u>删除14:<u>[28]</u></u>. Nevertheless, gentamicin plus azithromycin therapy can be considered as an alternative to ceftriaxone for cephalosporin- allergic patients with genital gonococcal infections. Since spectinomycin is available in Korea, it is recommended as an alternative therapy to ceftriaxone. In a previous meta-analysis study, cure rates of spectinomycin and ceftriaxone were not significantly different (82.6% vs. 88.0%, p=0.05) 删除12:<u>删除14:<u>[29]</u></u>. According to results of analysis of antimicrobial resistance of gonorrhea in Korea, strains resistant to spectinomycin were not observed in 2017 or 2018 删除12:<u>删除14:<u>[30]</u></u>. Gentamicin plus azith- romycin or spectinomycin is less effective for non-genital infections, especially pharyngeal gonococcal infections than for urogenital gonococcal infection 删除12:<u>删除14:<u>[31]</u></u>. Thus, it is not recommended.\n\n【3】### 4. Alternative therapy: Cefixime\n\nThe 800 mg oral dose of cefixime should only be considered as an alternative therapy to cephalosporins because it does not provide as high or sustained blood bactericidal levels as ceftriaxone 500 mg IM 删除12:<u>删除14:<u>[32]</u></u>. It also shows limited efficacy for treating of pharyngeal gonorrhea (81% cure, 95% confidence interval 61%–92%) 删除12:<u>删除14:<u>[33]</u></u>. In particular, sensitivity of gonorrhoeae isolated in Korea to cefixime decreased from 91% in 2018 to 77% in 2019 删除12:<u>删除14:<u>[30]</u></u>. Cefixime susceptibility decreased significantly from 2014. Proportions of non-suscep-|删除段之间换行|删除图片描述:<u>![](4_0.png)</u>\n\n【5】删除图片描述:<u>删除32:<u>**</u>Fig. 1. Ceftriaxone dosage based on body weight for uncomplicated urethral/cervical/rectal gonorrheal infection in adults/adolescents. IM, intramuscular injection; IV, intravenous injection.删除32:<u>**</u></u>\n\n【6】疑似页脚<u>Investig Clin Urol 2024;65:1-8.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/1_2023+KAUTII指南：淋球菌感染.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:07:53", "endTime": "2024/08/06 17:08:15", "cost": 22.653}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 01:08:15", "grab_time": "2024-08-06 01:07:52"}
{"id": 2211519, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "567ef805-7e4e-4266-bef2-d1ade69ee82e", "title": "乳腺癌诊疗指南（2022年版）", "text": "【0】页码:32\n乳腺癌诊疗指南（2022年版）\n者，经全身治疗后降期，亦可选择全乳切除术。\n\n【1】Halsted传统根治术中采用的乳房切除术需同时切除胸大小肌、创伤大、并发症发生率高。目前已被改良根治术所取代。其切除范围包括上至锁骨下、下至腹直肌前鞘、内至胸骨旁、外至背阔肌的解剖边界内，连同胸大肌筋膜完整切除病灶腺组织及乳头乳晕复合体，只有当胸肌受累时才需切除部分或全部胸肌。部分学者认为可保留胸大肌筋膜，尤其是需要进行术中即刻假体/扩张器重建时。\n\n【2】目前的乳房切除术已由改良根治术发展为保留皮肤的乳房切除+乳腺重建，并，两者治疗效果类同，但局者美容效果更好。也少见保留乳头乳晕的乳房切除术在临床上的应用也屡次，这些缺乏长期研究数据。需进一步完善患者选择问题。\n\n【3】（2）保留乳房手术：严格掌握保乳手术适应证。实施保乳手术的医疗单位应具备保乳手术切缘的组织学检查设备与技术，保证切缘阴性；保乳术后放射治疗的设备与技术。保留乳房手术后美容效果评价标准见附件删除28:<u>7</u>。\n\n【4】保乳手术适用于患者有保乳意愿，乳腺肿瘤可以完整切除，达到阴性切缘，并可获得良好的美容效果，同时可接受术后辅助放疗的患者有年轻不作为保乳手术的禁忌，<35岁患者有相对高的复发和再发乳腺癌的风险，在选择保乳时，应向患者充分交待可能存在的风险。\n\n【5】保乳手术的绝对禁忌证包括病变广泛或弥漫分布的惡", "tags": {}, "lang": "zh", "attr": {"page_num": 32, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/乳腺癌诊疗指南（2022年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "删除28:7。", "content": "【0】页码:32\n乳腺癌诊疗指南（2022年版）\n者，经全身治疗后降期，亦可选择全乳切除术。\n\n【1】Halsted传统根治术中采用的乳房切除术需同时切除胸大小肌、创伤大、并发症发生率高。目前已被改良根治术所取代。其切除范围包括上至锁骨下、下至腹直肌前鞘、内至胸骨旁、外至背阔肌的解剖边界内，连同胸大肌筋膜完整切除病灶腺组织及乳头乳晕复合体，只有当胸肌受累时才需切除部分或全部胸肌。部分学者认为可保留胸大肌筋膜，尤其是需要进行术中即刻假体/扩张器重建时。\n\n【2】目前的乳房切除术已由改良根治术发展为保留皮肤的乳房切除+乳腺重建，并，两者治疗效果类同，但局者美容效果更好。也少见保留乳头乳晕的乳房切除术在临床上的应用也屡次，这些缺乏长期研究数据。需进一步完善患者选择问题。\n\n【3】（2）保留乳房手术：严格掌握保乳手术适应证。实施保乳手术的医疗单位应具备保乳手术切缘的组织学检查设备与技术，保证切缘阴性；保乳术后放射治疗的设备与技术。保留乳房手术后美容效果评价标准见附件删除28:<u>7</u>。\n\n【4】保乳手术适用于患者有保乳意愿，乳腺肿瘤可以完整切除，达到阴性切缘，并可获得良好的美容效果，同时可接受术后辅助放疗的患者有年轻不作为保乳手术的禁忌，<35岁患者有相对高的复发和再发乳腺癌的风险，在选择保乳时，应向患者充分交待可能存在的风险。\n\n【5】保乳手术的绝对禁忌证包括病变广泛或弥漫分布的惡", "index": 435, "show": true, "start": 435, "end": 442, "province": ["语义有效性", "错误删除"], "isEdit": false, "comment": "3"}], "startTime": "2024/08/06 17:02:47", "endTime": "2024/08/06 17:03:18", "cost": 30.827}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 01:03:18", "grab_time": "2024-08-06 01:02:46"}
{"id": 2211518, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "379c5422-6bb8-4b86-a1b7-b3ab6038e59d", "title": "2023+临床共识指南：携带种系SDHD致病变异患者的嗜铬细胞瘤和副神经节瘤的管理", "text": "【0】页码:15\n2023+临床共识指南：携带种系SDHD致病变异患者的嗜铬细胞瘤和副神经节瘤的管理\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】以下是转换后的Markdown格式的内容：\n\n【2】1. Arlt A, Arocauzk A, Gamlpr C, et al. Prospective comparison of [删除21:<u>^18</u>F]-DOPA[删除21:<u>^18</u>F]-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas as sporadic cases. Eur J Nucl Med Imaging 2016; 43: 1428-57.\n\n【3】参考删除-3:<u>2. Han S, Suh CH, Won KS, Kim YJ. Performance of 删除21:<u>^68</u>Ga-DOTA-conjugated somatostatin receptor imaging peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and meta-analysis. J Nucl Med 2019; 60: 369-76.</u>\n\n【4】参考删除-3:<u>3. Gild ML, Naik N, Hoang J, et al. Role of DOTATATE-PET/CT in preoperative assessment of pheochromocytoma and paragangliomas. Clin Endocrinol 2018; 89: 139-47.</u>\n\n【5】参考删除-3:<u>4. King KS, Chen CC, Alexopoulos DK, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 删除17:<u>18</u>F-fluorodeoxyglucose, 删除17:<u>18</u>F-fluoro-2-deoxy-glucose PET, 删除17:<u>123</u>I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab 2011; 96: 2779-85.</u>\n\n【6】5. Amodru V, Hamedi A, Levillain H, et al. Tumour multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: an 删除21:<u>^18</u>F-FDOPA PET/CT study. Head Neck 2019; 41: 1565-71.\n\n【7】6. Taieb D, Hicks RJ, Hindie E, et al. European Association of Nuclear Medicine practice guidelines/Society of Nuclear Medicine and Molecular Imaging practice guidelines for radionuclide imaging of pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2019; 46: 2112-37.\n\n【8】参考删除-3:<u>7. Gabriel S, Biecheler M, Sebag F, et al. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (删除21:<u>^18</u>)F-FDOPA PET: focus on missed lesions. Clin Endocrinol 2013; 79: 170-77.</u>\n\n【9】参考删除-3:<u>8. Meiderer M, Flottorp K, Rossmann H, et al. High incidence of extraadrenal paraganglioma in families with SDHx syndromes detected by functional imaging with [删除21:<u>^18</u>F]-fluorodihydroxyphenylalanine PET. Eur J Nucl Med Mol Imaging 2013; 40: 889-96.</u>\n\n【10】参考删除-3:<u>9. Blanchet EM, Gabriel S, Martucci V, et al. 删除17:<u>18</u>F-FDOPA PET/CT as a predictor of hereditary head and neck paragangliomas. Clin Endocrinol 2014; 43: 325-32.</u>\n\n【11】参考删除-3:<u>10. Timmers HJ, Chen CC, Carrasquillo JA, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (删除21:<u>^18</u>F-FDG) positron emission tomography. J Natl Cancer Inst 2004; 96: 706-08.</u>\n\n【12】参考删除-3:<u>11. Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 删除21:<u>^18</u>F-fluoro-L-DOPA, 删除21:<u>^18</u>F-fluorodihydroxyphenylalanine, and 删除21:<u>^18</u>F-fluorodeoxyglucose for tumor imaging in patients with pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009; 94: 4757-67.</u>\n\n【13】参考删除-3:<u>12. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 2007; 25: 2262-69.</u>\n\n【14】参考删除-3:<u>13. Álvarez-Morujo RI, Ruiz Mar, Serafini DP, Delgado I, Frelander F, Yurrita BS. Management of multicentric paragangliomas: review of 24 patients with 66 tumors. Head Neck 2022; 36: 267-76.</u>\n\n【15】参考删除-3:<u>14. Moore MG, Netterville JL, Mendenhall WM, Isaacson B, Nussenbaum B. Head and neck paragangliomas: an update on evaluation and management. Oncology Head Neck Surg 2016; 154: 597-605.</u>\n\n【16】参考删除-3:<u>15. Sniezek JC, Netterville JL, Sabri AH. Vagal paragangliomas. Otolaryngol Clin North Am 2001; 34: 925-33.</u>\n\n【17】参考删除-3:<u>16. Wang SJ, Safford SD, Balcom HM, et al. Subtotal resection for management of large jugular paragangliomas with functional lower cranial nerve deficits. Otolaryngol Head Neck Surg 2011; 154: 991-95.</u>\n\n【18】参考删除-3:<u>17. Wang SJ, Carlson ML, Sweeney AD, Bough MG, Wanna GB. Contemporary management of jugular paragangliomas. Otolaryngol Clin North Am 2015; 48: 331-41.</u>\n\n【19】参考删除-3:<u>18. Lloyd S, O’Donohue R, Tyrone J, Group BC. British Skull Base Society clinical consensus document for management of head and neck paragangliomas. Otolaryngol Head Neck Surg 2021; 150: 205-09.</u>\n\n【20】参考删除-3:<u>19. Netterville JL, Jackson CG, Miller FR, Wanamaker JR, Glasscock ME. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg 1998; 124: 1133-40.</u>\n\n【21】参考删除-3:<u>20. Carlson ML, Sweeney AD, Wanna GB, Netterville JL, Haynes DS. Natural history of glomus vagale: a review of 16 tumors managed with primary observation. Otolaryngol Head Neck Surg 2013; 152: 98-05.</u>\n\n【22】参考删除-3:<u>21. Jansen JC, van den Berg R, Kuiper A, van der Mey AG, Zwinderman AH, Cornelisse CJ. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer 2000; 83: 2511-16.</u>\n\n【23】参考删除-3:<u>22. Langerman A, Athavale SM, Rangarajan SV, Sinard RJ, Netterville JL. Natural history of cervical paragangliomas: outcomes of observation of 43 patients. Arch Otolaryngol Head Neck Surg 2012; 138: 341-45.</u>\n\n【24】23. Taieb D, Kalaisel A, Boedeker CC, et al. Current approaches and recent developments in the管理头颈部副神经节瘤。Endocr Relat Cancer 2014; 21: R85-99.\n\n【25】参考删除-3:<u>24. Hu K, Persky MS. Multidisciplinary management of paragangliomas of the head and neck. Int J Oncology 2003; 17: 983-93.</u>\n\n【26】参考删除-3:<u>25. Papaspyrou K, Mewes T, Rossmann H, et al. Head and neck paragangliomas: report of 175 patients 删除11:<u>删除19:<u>(1989-2010)</u></u>. Head Neck 2012; 34: 632-37.</u>\n\n【27】参考删除-3:<u>26. Prasad SC, Mincione HA, D’Orazio F, et al. The role of wait-and-scan and the efficacy of radiotherapy in the treatment of temporal bone paragangliomas. Otol Neurotol 2014; 35: 922-31.</u>\n\n【28】27. Fisch U, Mattox D. Microsurgery of the skull base. Stuttgart, New York: Georg Thieme Verlag, 1988: 148-281.\n\n【29】28. Jackson CG, Glasscock ME 3rd, Harris PF. Glomus tumors. Diagnosis, classification, and management of", "tags": {}, "lang": "en", "attr": {"page_num": 15, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023+临床共识指南：携带种系SDHD致病变异患者的嗜铬细胞瘤和副神经节瘤的管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:40:03", "endTime": "2024/08/06 15:40:12", "cost": 9.186}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:40:13", "grab_time": "2024-08-05 23:40:03"}
{"id": 2211517, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "49d270d0-23bb-4de1-84b1-262f7af10991", "title": "2022 AASLD实践指南：原发性硬化性胆管炎和胆管癌", "text": "【0】页码:30\n2022 AASLD实践指南：原发性硬化性胆管炎和胆管癌\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364–9.\n\n【2】参考删除-3:<u>2. Lindkvist B, Benito de Valle M, Gullberg B, Björnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52:571–7.</u>\n\n【3】参考删除-3:<u>3. Barner-Rasmussen M, Pukkala E, Jussila A, Färkkilä M. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol. 2020;55:74–81.</u>\n\n【4】参考删除-3:<u>4. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–8.</u>\n\n【5】参考删除-3:<u>5. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008;48:939–44.</u>\n\n【6】参考删除-3:<u>6. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology. 2004;126:1929–30.</u>\n\n【7】参考删除-3:<u>7. Liang H, Manne S, Shick J, Lissoos T, Dolin P. Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom (Medicine Baltimore). 2017;96:e7116.</u>\n\n【8】参考删除-3:<u>8. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–9.</u>\n\n【9】参考删除-3:<u>9. Toy E, Balasubramaniam S, Selmi C, Li CS, Bowlus CL. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol. 2011;11:83.</u>\n\n【10】参考删除-3:<u>10. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99–103.</u>\n\n【11】参考删除-3:<u>11. Boonstra K, van Erpecum KJ, Van Nieuwkerk CM, Drenth JP, Witteman BJ, Poen AC, van Buuren HR, Beuers U, Ponsioen CY, on behalf of the Epi PSC PBC group. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2270–6.</u>\n\n【12】参考删除-3:<u>12. Ponsioen CY, Reitsma JB, Boberg KM, Rasmussen Jr HH, Fausa O, Schrumpf E, Orholm M, Chazouilleres O, Chapman RW, Sánchez-Tapias JM, et al. Validation of a scoring system to predict outcome</u>", "tags": {}, "lang": "en", "attr": {"page_num": 30, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2022 AASLD实践指南：原发性硬化性胆管炎和胆管癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:12:09", "endTime": "2024/08/06 16:12:44", "cost": 34.453}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 00:12:44", "grab_time": "2024-08-06 00:12:08"}
{"id": 2211516, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "6decbfe1-b828-4836-94b8-82b675231482", "title": "NICE：儿童、青少年以及成人癫痫指南（NG.217）（2022）", "text": "【0】页码:117\nNICE：儿童、青少年以及成人癫痫指南（NG.217）（2022）\n## Epilepsies in children, young people and adults (NG217)\n\n【1】The evidence suggested that triple therapy with sodium valproate, clobazam, and stiripentol was effective at reducing seizures in children and young people whose seizures were previously treated unsuccessfully with clobazam and sodium valproate in combination. Although the evidence was limited, the committee agreed that it supported this as first-line add-on therapy. The committee also highlighted that careful titration of doses and regular review are important because of possible adverse effects such as sedation.\n\n【2】The committee agreed that the NICE technology appraisal guidance on cannabidiol with clobazam for treating seizures associated with Dravet syndrome supports the use of this combination as a second-line treatment option.\n\n【3】There was an absence of evidence to guide further treatment if seizures continue. The committee recommended further treatment options based on their experience and expert opinion, and agreed that these should be considered only under the supervision of a neurologist with expertise in epilepsy or a ketogenic diet team, as appropriate. The use of potassium bromide is unusual in practice, but the committee noted that for some people with Dravet syndrome, it can be effective.\n\n【4】The committee were aware of ongoing trials but agreed that further research on treating Dravet syndrome when first-line therapy is unsuccessful or not tolerated would be beneficial and they developed a recommendation for research on complex epilepsy syndromes to help inform future guidance.\n\n【5】### How the recommendations might affect practice\n\n【6】The recommendations will not change current practice, but will reinforce best practice.\n\n【7】### Lennox–Gastaut syndrome\n\n【8】删除32:<u>**</u>Recommendations 6.2.1 to 6.2.9删除32:<u>**</u>\n\n【9】### Why the committee made the recommendations\n\n【10】Lennox–Gastaut syndrome is a severe developmental and epileptic encephalopathy with onset in childhood. It can be difficult to diagnose, so children may be started on antiseizure medication before a final diagnosis is established.\n\n【11】Lennox–Gastaut syndrome is complex to treat and the response to treatment is variable. Based on", "tags": {}, "lang": "en", "attr": {"page_num": 117, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/NICE：儿童、青少年以及成人癫痫指南（NG.217）（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Epilepsies in children, young people and adults (NG217)", "content": "【0】页码:117\nNICE：儿童、青少年以及成人癫痫指南（NG.217）（2022）\n## Epilepsies in children, young people and adults (NG217)\n\n【1】The evidence suggested that triple therapy with sodium valproate, clobazam, and stiripentol was effective at reducing seizures in children and young people whose seizures were previously treated unsuccessfully with clobazam and sodium valproate in combination. Although the evidence was limited, the committee agreed that it supported this as first-line add-on therapy. The committee also highlighted that careful titration of doses and regular review are important because of possible adverse effects such as sedation.\n\n【2】The committee agreed that the NICE technology appraisal guidance on cannabidiol with clobazam for treating seizures associated with Dravet syndrome supports the use of this combination as a second-line treatment option.\n\n【3】There was an absence of evidence to guide further treatment if seizures continue. The committee recommended further treatment options based on their experience and expert opinion, and agreed that these should be considered only under the supervision of a neurologist with expertise in epilepsy or a ketogenic diet team, as appropriate. The use of potassium bromide is unusual in practice, but the committee noted that for some people with Dravet syndrome, it can be effective.\n\n【4】The committee were aware of ongoing trials but agreed that further research on treating Dravet syndrome when first-line therapy is unsuccessful or not tolerated would be beneficial and they developed a recommendation for research on complex epilepsy syndromes to help inform future guidance.\n\n【5】### How the recommendations might affect practice\n\n【6】The recommendations will not change current practice, but will reinforce best practice.\n\n【7】### Lennox–Gastaut syndrome\n\n【8】删除32:<u>**</u>Recommendations 6.2.1 to 6.2.9删除32:<u>**</u>\n\n【9】### Why the committee made the recommendations\n\n【10】Lennox–Gastaut syndrome is a severe developmental and epileptic encephalopathy with onset in childhood. It can be difficult to diagnose, so children may be started on antiseizure medication before a final diagnosis is established.\n\n【11】Lennox–Gastaut syndrome is complex to treat and the response to treatment is variable. Based on", "index": 47, "show": true, "start": 47, "end": 102, "province": ["文本干净度", "页眉"], "isEdit": false}], "startTime": "2024/08/06 17:00:59", "endTime": "2024/08/06 17:01:37", "cost": 37.256}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-06 01:01:37", "grab_time": "2024-08-06 01:00:59"}
{"id": 2211515, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "31942a18-c75a-4922-9fed-81db2add41a3", "title": "_（2023.V2）NCCN临床实践指南：系统性肥大细胞增多症", "text": "【0】页码:68\n_（2023.V2）NCCN临床实践指南：系统性肥大细胞增多症\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】疑似页眉<u>### NCCN Guidelines Version 2.2023\n## Systemic Mastocytosis</u>\n\n【2】46. Caughey GH. Tryptase genetics and anaphylaxis. J Allergy Clin Immunol 2006;117:1411-1414删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/16751005]</u>.</u>\n\n【3】参考删除-3:<u>47. Sperr WR, El-Samahi A, Kundi M, et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009;39:914-923删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/19522836]</u>.</u></u>\n\n【4】参考删除-3:<u>48. Aberer E, Savic S, Bretterklieber A, et al. Disease spectrum in patients with elevated serum tryptase levels. Australas J Dermatol 2015;56:7-13删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/24755854]</u>.</u></u>\n\n【5】参考删除-3:<u>49. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987;316:1622-1626删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/3295549]</u>.</u></u>\n\n【6】参考删除-3:<u>50. Horny HP, Sotlar K, Valent P. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology 2010;77:169-180删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/20616612]</u>.</u></u>\n\n【7】参考删除-3:<u>51. Butterfield JH, Li CY. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? Am J Clin Pathol 2004;121:264-267删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/14983941]</u>.</u></u>\n\n【8】参考删除-3:<u>52. Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011;24:1157-1168删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/21552214]</u>.</u></u>\n\n【9】参考删除-3:<u>53. Reichard KK, Chen D, Pardanani A, et al. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. Am J Clin Pathol 2015;144:493-502删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/26276780]</u>.</u></u>\n\n【10】参考删除-3:<u>54. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001;32:545-552删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/11381374]</u>.</u></u>\n\n【11】参考删除-3:<u>55. Horny HP, Sotlar K, Valent P. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells. Immunol Allergy Clin North Am 2014;34:315-321删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/24745676]</u>.</u></u>\n\n【12】参考删除-3:<u>56. Teodosio C, Mayado A, Sanchez-Munoz L, et al. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. J Leukoc Biol 2015;97:49-59删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/25381388]</u>.</u></u>\n\n【13】参考删除-3:<u>57. Escribano L, Diaz Agustin B, Bravo P, et al. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults. Leuk Lymphoma 1999;35:227-235删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/10706445]</u>.</u></u>\n\n【14】58. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319-1325删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/15371947]</u>.</u>\n\n【15】参考删除-3:<u>59. Pardanani A, Kimlinger T, Reeder T, et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004;28:777-783删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/15033275]</u>.</u></u>\n\n【16】参考删除-3:<u>60. Morgado JM, Sanchez-Munoz L, Teodosio CG, et al. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. Mod Pathol 2012;25:516-521删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/22222639]</u>.</u></u>\n\n【17】参考删除-3:<u>61. Chisholm KM, Merker JD, Gotlib JR, et al. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry.</u>\n\n【18】MS-26", "tags": {}, "lang": "en", "attr": {"page_num": 68, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_（2023.V2）NCCN临床实践指南：系统性肥大细胞增多症.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:40:15", "endTime": "2024/08/06 15:40:21", "cost": 6.476}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:40:21", "grab_time": "2024-08-05 23:40:14"}
{"id": 2211514, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "665a8ec6-c659-4580-b435-038908797db3", "title": "_（2023.V2）NCCN临床实践指南：系统性肥大细胞增多症", "text": "【0】页码:78\n_（2023.V2）NCCN临床实践指南：系统性肥大细胞增多症\n(本页删除)本页被模型判断为参考页疑似页眉<u>NCCN Guidelines Version 2.2023 \nSystemic Mastocytosis</u>\n\n【1】Arch Allergy Immunol 2015;167:47-56删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/26160029]</u>.</u>\n\n197. Guyen AC, Saff RR, Conroy M, et al. Comprehensive allergy |删除段内换行|evaluation is useful in the subsequent care of patients with drug |删除段内换行|hypersensitivity reactions during anesthesia. J Allergy Clin Immunol Pract \n2015;3:94-100删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/25577625]</u>.</u>\n\n198. Woidacki K, Zenclussen AC, Siebenhaar F. Mast cell-mediated and |删除段内换行|associated disorders in pregnancy: a risky game with an uncertain |删除段内换行|outcome? Front Immunol 2014;5:231删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/24904581]</u>.</u>\n\n199. Worobec AS, Akin C, Scott LM, Metcalfe DD. Mastocytosis |删除段内换行|complicating pregnancy. Obstet Gynecol 2000;95:391-395删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/10711550]</u>.</u>\n\n200. Ciach K, Niedoszytko M, Abacjew-Chmyłko A, et al. Pregnancy and |删除段内换行|delivery in patients with mastocytosis treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM). PLoS One 2016;11:e0146924删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/26796887]</u>.</u>\n\n201. Matito A, Alvarez-Twose I, Morgado JM, et al. Clinical impact of |删除段内换行|pregnancy in mastocytosis: a study of the Spanish Network on \nMastocytosis (REMA) in 45 cases. Int Arch Allergy Immunol \n2011;156:104-111删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/21447966]</u>.</u>\n\n202. Kar S, Krishnan A, Preetha K, Mohanar A. A review of |删除段内换行|antihistamines used during pregnancy. J Pharmacol Pharmacother \n2012;3:105-108删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/22629082]</u>.</u>\n\n【8】删除图片描述:<u>![](77_0.png)</u>\n\n204. Lei D, Akin C, Kovalszki A. Management of mastocytosis in |删除段内换行|pregnancy: a review. J Allergy Clin Immunol Pract 2017;5:1217-1223.删除1:<u>\nAvailable at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/28739366]</u>.</u>\n\n205. Beauverd Y, Radia D, Cargo C, et al. Pegylated interferon alpha-2a |删除段内换行|for essential thrombocythemia during pregnancy: outcome and safety. A |删除段内换行|case series. Haematologica 2016;101:e182-184. Available at:删除1:<u>\n删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/26819057]</u>.</u>\n\n206. Bonadonna P, Brockow K, Niedoszytko M, et al. COVID-19 \nvaccination in mastocytosis: Recommendations of the European \nCompetence Network on Mastocytosis (ECNM) and American Initiative in |删除段内换行|Mast Cell Diseases (AIM). J Allergy Clin Immunol Pract 2021;9:2139-2144删除1:<u>. Available at: 删除24:<u>[https://www.ncbi.nlm.nih.gov/pubmed/33831618]</u>.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 78, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_（2023.V2）NCCN临床实践指南：系统性肥大细胞增多症.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:55:45", "endTime": "2024/08/06 15:55:53", "cost": 7.516}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:11", "update_time": "2024-08-05 23:55:53", "grab_time": "2024-08-05 23:54:04"}
{"id": 2211513, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "336acf1c-89b3-4c1d-928b-f00273b191f8", "title": "ESAIC_ESRA：服用抗栓药物患者的局部麻醉指南（2022）", "text": "【0】页码:1\nESAIC_ESRA：服用抗栓药物患者的局部麻醉指南（2022）\n# Regional anaesthesia in patients on antithrombotic drugs\n## Joint ESAIC/ESRA guidelines\n\n【1】参考删除-1:<u>Sibylle Kietaibl, Raquel Ferrandis, Anne Godier, Juan Llau, Clara Lobo, Alan JR Macfarlane, Christoph J. Schlimp, Erik Vandermeulen, Thomas Volk, Christian von Heymann, Morné Wolmarans and Arash Afshari</u>\n\n【2】删除32:<u>**</u>BACKGROUND删除32:<u>**</u> Bleeding is a potential complication after neuraxial and peripheral nerve blocks. The risk is increased in patients on antiplatelet and anticoagulant drugs. This joint guideline from the European Society of Anaesthesiology and Intensive Care and the European Society of Regional Anaesthesia aims to provide an evidence-based set of recommendations and suggestions on how to reduce the risk of antithrombotic drug-induced haematoma formation related to the practice of regional anaesthesia and analgesia.\n\n【3】删除32:<u>**</u>DESIGN删除32:<u>**</u> A systematic literature search was performed, studying the evidence on timing of regional anaesthetic intervention with the outcome being peripheral and neuraxial haematoma. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) was used for assessing the methodological quality of the included studies and for formulating recommendations. A Delphi process was used to prepare a clinical practice guideline.\n\n【4】删除32:<u>**</u>RESULTS删除32:<u>**</u> Clinical studies were limited in number and the certainty of evidence was assessed to be GRADE C throughout. Forty clinical practice statements were formulated. Using the Delphi-process, strong consensus (>90% agreement) was achieved in 57.5% of recommendations and consensus (75 to 90% agreement) in 42.5%.\n\n【5】删除32:<u>**</u>DISCUSSION删除32:<u>**</u> Specific time intervals should be observed concerning the administration of antithrombotic drugs both prior to, and after, neuraxial procedures or those peripheral nerve blocks with higher bleeding risk (deep, noncompressible). These time intervals vary according to the type and dose of anticoagulant drugs, renal function and whether a traumatic puncture has occurred. Drug measurements may be used to guide certain time intervals, whilst specific reversal for vitamin K antagonists and bridging therapies are also recommended. Drug guidance, coagulation and bleeding risk scores do not modify the time intervals. In peripheral nerve blocks with low bleeding risk (superficial, compressible), these time intervals do not apply.\n\n【6】删除32:<u>**</u>CONCLUSION删除32:<u>**</u> In patients taking antiplatelet or anticoagulant medications, practitioners must consider the bleeding risk both before and after nerve blockade and during insertion or removal of a catheter. Healthcare teams managing such patients must be aware of the risk and be competent in detecting and managing any possible haematomas.", "tags": {}, "lang": "en", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ESAIC_ESRA：服用抗栓药物患者的局部麻醉指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:15:11", "endTime": "2024/08/06 16:15:40", "cost": 28.966}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:15:40", "grab_time": "2024-08-06 00:15:11"}
{"id": 2211512, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "4609dcd3-2214-4cd1-837f-a865d3bdd7d5", "title": "2023更新—2015 NICE指南：糖尿病足问题的预防和管理（NG.19）", "text": "【0】页码:2\n2023更新—2015 NICE指南：糖尿病足问题的预防和管理（NG.19）\n### Your responsibility\n\n【1】The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.\n\n【2】All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme].\n\n【3】Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.\n\n【4】Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations] wherever possible.", "tags": {}, "lang": "en", "attr": {"page_num": 2, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023更新—2015 NICE指南：糖尿病足问题的预防和管理（NG.19）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:14:56", "endTime": "2024/08/06 16:15:04", "cost": 7.45}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:15:04", "grab_time": "2024-08-06 00:14:56"}
{"id": 2211511, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "e0a0870f-b30c-43c3-981d-795e605300a8", "title": "【神经领域】中国脑卒中防治指导规范（2021年版）", "text": "【0】页码:547\n【神经领域】中国脑卒中防治指导规范（2021年版）\n进行VCI的治疗旨在积极病因治疗，改善临床症状，减缓认知损害的进展，控制并发症，改善患者生活质量。\n\n【1】（一）病因治疗\n\n【2】血管危险因素和脑血管病变是VCI的始动环节，及早控制危险因素和治疗脑血管病是治疗VCI最根本的措施。\n\n【3】（二）认知损害的治疗\n\n【4】1.胆碱酯酶抑制剂 VaD和AD在神经疾病理和神经化学方面存在一定重叠，约30%的脑卒中后痴呆或皮层下血管性痴呆（subcortical vascular dementia，SIVD）的患者表现出与AD相同的病理改变。VaD患者脑内亦存在乙酰胆碱能通路受损，为胆碱酯酶抑制剂治疗VaD提供了理论基础，胆碱酯酶抑制剂可用于治于轻度至中度VaD。亚组分析显示，胆碱酯酶抑制剂能更好地改善脉有多发皮层梗死和海马萎缩的VaD患者的认知功能，美金刚对于SIVD的患者更有效。\n\n【5】（1）多奈哌齐：国际上数项随机、双盲、安慰剂，对照研究显示，多奈哌齐可改善VaD患者的认知功能，对患者的整体功能、日常生活能力亦有改善作用，且存在剂量-效应关系，10mg/d多奈哌齐可改善VaD患者的行为症状，疗效优于5mg/d。\n\n【6】（2）加兰他敏：加兰他敏是第二代胆碱酯酶抑制剂，能改善VaD患者的认知功能，特别是执行功能，对总体认知功能也有改善的趋势，另一项大型研究显示加兰他敏并不能显著改善患者的ADAS-Cog评分，但可改善患者认知功能、精神行为症状和日常生活能力。加兰他敏的主要不良反应为胃肠道症状，过量应用可引起心动过缓、头晕等，癫痫、机械性肠梗阻、支气管哮喘、心绞痛、心动过缓者禁用。\n\n【7】（3）卡巴拉汀：卡巴拉汀对VaD的治疗是否有效尚未有明确结论。有研究表明卡巴拉汀对VaD患者的认知功能损害具有改善作用，但目前的研究证据显示其对日常生活能力无明显改善作用。\n\n【8】（4）石杉碱甲：石杉碱甲是从石杉科植物千层塔中分离出的一种生物碱，分子量小，脂溶性高，更易透过血脑屏障，具有很高的口服生物利用度，可同时抑制胆碱酯酶活性。 然而，其对于VaD的疗效仅在小规模的临床试验得到证实，尚需大规模、多中心、随机对照临床试验得出结论。\n\n【9】2.非竞争性NMDA受体拮抗剂：美金刚可改善轻度至中度VaD患者的认知功能、行为和日常生活能力。", "tags": {}, "lang": "zh", "attr": {"page_num": 547, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/【神经领域】中国脑卒中防治指导规范（2021年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:48:51", "endTime": "2024/08/06 15:49:18", "cost": 27.276}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-05 23:49:18", "grab_time": "2024-08-05 23:48:51"}
{"id": 2211510, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "ace50135-1dbe-47ae-8698-e917ba66be48", "title": "2023 ESMO临床实践指南：非致癌基因依赖转移性非小细胞肺癌的诊断，治疗和随访", "text": "【0】页码:2\n2023 ESMO临床实践指南：非致癌基因依赖转移性非小细胞肺癌的诊断，治疗和随访\n删除图片描述:<u>![](/mnt/data/file.png)</u>\n\n【1】Amongst other NSCLC immunotherapy biomarkers, the SP142 assay for atezolizumab scores PD-L1 in both TCs and ICs. The value of IC PD-L1 expression beyond this registrational setting, notably as a single predictive biomarker in NSCLC, is not established. The presence or absence of various IC types may be important, but data showing clinical utility are lacking. Therefore, this is not currently a recommended practice outside of trials and academic study. Tumour mutational burden as a surrogate predictor of tumour immunogenicity is capable of enriching NSCLC populations for response but compelling evidence for adoption of this complex biomarker, as well as its standardisation, is lacking.\n\n【2】Mutations in, for example, 删除32:<u>**</u>STK11删除32:<u>**</u> and 删除32:<u>**</u>KEAP1删除32:<u>**</u> are associated with a poor prognosis, and exploratory subgroup analysis of clinical trials suggest they are, especially in 删除32:<u>**</u>KRAS删除32:<u>**</u>-mutated tumours, associated with lower immune checkpoint inhibitor (ICI) efficacy. The predictive value should be confirmed in prospective trials.\n\n【3】## Recommendations\n\n【4】- Preferably, a metastatic lesion is biopsied for diagnostic as well as staging purposes 删除15:<u>(IV, B)</u>\n- Bronchoscopy is a technique ideally suited to central lesions and can be used with bronchial washing, brushing, and bronchial and transbronchial biopsy 删除15:<u>(IV, A)</u>\n- Endobronchial ultrasound (EBUS) and/or endoscopic ultrasound (EUS) allows for evaluation of regional lymph nodes 删除15:<u>(IV, A)</u>\n- Transthoracic fine-needle aspiration and/or core biopsy, thoracic imaging guidance [typically computed tomography (CT)], is indicated in case of mild to peripheral lesions 删除15:<u>(IV, A)</u>\n- In the presence of a pleural effusion, thoracentesis could represent both a diagnostic tool and a symptomatic treatment 删除15:<u>(IV, A)</u>\n- When less invasive techniques (EBUS, EUS, transthoracic fine-needle aspiration, core biopsy) cannot allow for accurate diagnosis, more invasive, surgical approaches (mediastinoscopy, mediastinotomy, thoracoscopy, etc.) in the diagnostic work-up should be considered 删除15:<u>(IV, B)</u>\n- Systematic collaboration and constant communication between pathologists and interventionalists are encouraged to improve diagnostic yields. This may include use of rapid onsite sample evaluation (ROSE) 删除15:<u>(IV, A)</u>\n- Adequate tissue material for histological diagnosis and molecular testing should be obtained to allow for individual treatment decisions. This may require re-biopsy, where possible, when initial sampling is inadequate 删除15:<u>(IV, A)</u>\n- Pathological diagnosis should be made according to the 2021 WHO classification of lung tumours 删除15:<u>(IV, A)</u>\n- Specific subtyping of all NSCLCs is necessary for therapeutic decision making and should be carried out wherever possible. IHC stains should be used to reduce the NSCLC-NOS otherwise specified rate to fewer than 10% of cases diagnosed 删除15:<u>(IV, A)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 2, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ESMO临床实践指南：非致癌基因依赖转移性非小细胞肺癌的诊断，治疗和随访.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】Amongst other NSCLC immunotherapy biomarkers, the SP142 assay for atezolizumab scores PD-L1 in both TCs and ICs. The value of IC PD-L1 expression beyond this registrational setting, notably as a single predictive biomarker in NSCLC, is not established. ", "content": "【0】页码:2\n2023 ESMO临床实践指南：非致癌基因依赖转移性非小细胞肺癌的诊断，治疗和随访\n删除图片描述:<u>![](/mnt/data/file.png)</u>\n\n【1】Amongst other NSCLC immunotherapy biomarkers, the SP142 assay for atezolizumab scores PD-L1 in both TCs and ICs. The value of IC PD-L1 expression beyond this registrational setting, notably as a single predictive biomarker in NSCLC, is not established. The presence or absence of various IC types may be important, but data showing clinical utility are lacking. Therefore, this is not currently a recommended practice outside of trials and academic study. Tumour mutational burden as a surrogate predictor of tumour immunogenicity is capable of enriching NSCLC populations for response but compelling evidence for adoption of this complex biomarker, as well as its standardisation, is lacking.\n\n【2】Mutations in, for example, 删除32:<u>**</u>STK11删除32:<u>**</u> and 删除32:<u>**</u>KEAP1删除32:<u>**</u> are associated with a poor prognosis, and exploratory subgroup analysis of clinical trials suggest they are, especially in 删除32:<u>**</u>KRAS删除32:<u>**</u>-mutated tumours, associated with lower immune checkpoint inhibitor (ICI) efficacy. The predictive value should be confirmed in prospective trials.\n\n【3】## Recommendations\n\n【4】- Preferably, a metastatic lesion is biopsied for diagnostic as well as staging purposes 删除15:<u>(IV, B)</u>\n- Bronchoscopy is a technique ideally suited to central lesions and can be used with bronchial washing, brushing, and bronchial and transbronchial biopsy 删除15:<u>(IV, A)</u>\n- Endobronchial ultrasound (EBUS) and/or endoscopic ultrasound (EUS) allows for evaluation of regional lymph nodes 删除15:<u>(IV, A)</u>\n- Transthoracic fine-needle aspiration and/or core biopsy, thoracic imaging guidance [typically computed tomography (CT)], is indicated in case of mild to peripheral lesions 删除15:<u>(IV, A)</u>\n- In the presence of a pleural effusion, thoracentesis could represent both a diagnostic tool and a symptomatic treatment 删除15:<u>(IV, A)</u>\n- When less invasive techniques (EBUS, EUS, transthoracic fine-needle aspiration, core biopsy) cannot allow for accurate diagnosis, more invasive, surgical approaches (mediastinoscopy, mediastinotomy, thoracoscopy, etc.) in the diagnostic work-up should be considered 删除15:<u>(IV, B)</u>\n- Systematic collaboration and constant communication between pathologists and interventionalists are encouraged to improve diagnostic yields. This may include use of rapid onsite sample evaluation (ROSE) 删除15:<u>(IV, A)</u>\n- Adequate tissue material for histological diagnosis and molecular testing should be obtained to allow for individual treatment decisions. This may require re-biopsy, where possible, when initial sampling is inadequate 删除15:<u>(IV, A)</u>\n- Pathological diagnosis should be made according to the 2021 WHO classification of lung tumours 删除15:<u>(IV, A)</u>\n- Specific subtyping of all NSCLCs is necessary for therapeutic decision making and should be carried out wherever possible. IHC stains should be used to reduce the NSCLC-NOS otherwise specified rate to fewer than 10% of cases diagnosed 删除15:<u>(IV, A)</u>", "index": 89, "show": true, "start": 89, "end": 345, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/06 17:12:26", "endTime": "2024/08/06 17:13:15", "cost": 49.647}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 01:13:16", "grab_time": "2024-08-06 01:12:26"}
{"id": 2211509, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "e4f6a679-aae4-4508-8bdf-117cc851f859", "title": "2023 EAU指南：上尿路移行细胞癌（更新版）", "text": "【0】页码:14\n2023 EAU指南：上尿路移行细胞癌（更新版）\n(本页删除)本页被模型判断为参考页删除14:<u>[53] </u>Catto R, Roupret M, Sallustio P, et al. Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma. Eur Urol 2021;74:92–801.\n删除12:<u>删除14:<u>[54]</u></u> Mushtaq N, Kova S, Gupta A, et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 2011;108:E304–9.\n删除12:<u>删除14:<u>[55]</u></u> Kaczmarek K, Lemie.et M, Goda A, Slojewski M. Survival differences of patients with ureteral versus pelviscalyceal tumours: a systematic review and meta-analysis. Arch Med Sci 2021;17:603–12.\n删除12:<u>删除14:<u>[56]</u></u> Jeion MA, Hus CT, Chipollini J. Urothelial carcinoma of the renal pelvis and ureter: does location make a difference? Clin Genitourin Cancer 2020;18:45–49.e1.\n删除12:<u>删除14:<u>[57]</u></u> Forester B, Palou J, Mari A, et al. The performance of tumor size as risk stratification parameter in upper tract urothelial carcinoma (UTUC). Clin Genitourin Cancer 2021;19:272.e1–e7.\n删除12:<u>删除14:<u>[58]</u></u> Linder AK, Schaichiter C, Tlüchmer G, et al. Lynch syndrome: its impact on urethal carcinoma. Int J Mol Sci 2021;22:531.\n删除12:<u>删除14:<u>[59]</u></u> Rink M, Xylinas E, Margulis V, et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol 2013;63:1082–90.\n删除12:<u>删除14:<u>[60]</u></u> Xylinas E, Kiltuh LA, Rieken M, et al. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int 2014;114:56–61.\n删除12:<u>删除14:<u>[61]</u></u> Razza SR, Mistrett C, May A, Davaro F, Siddiquai SA, Hamilton Z. lymph node density for stratification of survival outcomes with upper tract invasive upper rat urothelial carcinoma. Can J Urol 2016;29:5852–8.\n删除12:<u>删除14:<u>[62]</u></u> Nazzani B, Mazzone E, Preisser F, et al. Rates of lymph node invasion and its impact on cancer specific mortality in upper tract urothelial carcinoma: a large population-based study. Int J Urol 2019;47:1235–48.\n删除12:<u>删除14:<u>[63]</u></u> Brown GE, MaricxiePI R l, Raman J, et al. A delay in radical nephroureterectomy results in decreased disease-specific survival in patients with high grade upper tract urothelial carcinoma: a National Cancer Database Study. Urol Oncol 2018;36:16.e510–8.\n删除12:<u>删除14:<u>[64]</u></u> Liu W, Sun L, Guan F, Wang F, Zhang G. Prognostic value of inflammation in the upper urinary tract urothelial carcinoma treated by radical nephroureterectomy: a systematic review and meta-analysis. Dis Markers 2019;2019:7386410.\n删除12:<u>删除14:<u>[65]</u></u> Kluth LA, Xylinas E, Kent M, et al. Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU Int 2014:113:911–7.\n删除12:<u>删除14:<u>[66]</u></u> Ariai A, Bhate FK, Chamás GK. Comparative analysis of comorbidity and performance indices in prediction of oncological outcomes of patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. Urol Oncol 2014;32:1164–70.\n删除12:<u>删除14:<u>[67]</u></u> Colin P, Ouzuane A, Yates DR, et al. Influence of positive surgical margins after radical nephroureterectomy upon upper urinary tract urothelial carcinoma survival. Ann Surg Oncol 2012;19:3613–20.\n删除12:<u>删除14:<u>[68]</u></u> Scopano S, Rouprêt M, Renard-Penna R, Campan P, Cossuation O, Comarault F. Impact of the expression of Aurora-A, p53, and MRE11 on the prognosis of urothelial carcinomas of the upper urinary tract. Eur Urol 2012;30:182–7.\n删除12:<u>删除14:<u>[69]</u></u> Seisen T, Colin P, Hupertan V, et al. Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localized and/or locally advanced upper tract urothelial carcinomas without metastasis. BJU Int 2014;114:733–40.\n删除12:<u>删除14:<u>[70]</u></u> Yoshida T, Kobayashi K T, Kawauta T, et al. Development and external validation of a preoperative nomogram for predicting pathological locally advanced disease of clinically localized upper urinary tract carcinoma. Cancer Med 2020;9:3737–41.\n删除12:<u>删除14:<u>[71]</u></u> Krabbe LM, Eminaga O, Shariat SF, et al. Postoperative upper urinary tract relapse-free survival in patients with high grade upper tract urothelial carcinoma. J Urol 2017;197:580–9.\n删除12:<u>删除14:<u>[72]</u></u> Zhang GL, Zhou W. A model for the prediction of survival in patients with upper tract urothelial carcinoma after surgery. Dose Response 2019:17.\n删除12:<u>删除14:<u>[73]</u></u> Seisen T, Pierre C, Colin P, et al. A systematic review and metaanalysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 2015;67:1122–33.\n删除12:<u>删除14:<u>[75]</u></u> Zhang K, Bu R, Liu Z, Wu BA. Designbelment and validation of a model for predicting intravesical recurrence in organ-confined upper urinary tract urothelial carcinoma patients after radical nephroureterectomy: a retrospective study in one center with long-term follow-up. Pathol Oncol Res 2020;26:1741–8.\n删除12:<u>删除14:<u>[76]</u></u> Sheu ZI, Huang CP, Chang CH, et al. Tumor distribution affects bladder recurrence but not survival outcome of multifocal upper tract urothelial carcinoma treated with radical nephroureterectomy. Sci Rep 2021:11:19059.\n删除12:<u>删除14:<u>[77]</u></u> Guo RD, Hong R, Xiong GY, et al. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis. BJU Int 2018:121:184–93.\n删除12:<u>删除14:<u>[78]</u></u> Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma:a systematic review by the EA and non-muscle invasive bladder cancer guidelines panel. Eur Urol 2016;70:1052–68.\n删除12:<u>删除14:<u>[79]</u></u> Villa L, Celunet J, Lefermed J, et al. Early repeat ureteroscopy within 6–8 weeks after a primary endoscopic treatment in patients with upper tract urothelial carcinoma: preliminary findings. World J Urol 2014:33:1201–6.\n删除12:<u>删除14:<u>[80]</u></u> Venmada G, Kim EH, Bhayani SB, Vetter JM, Strope SA. Survival comparisons of kidney sparing modifications and nephroureterectomy in patients with upper tract urothelial cance: a matched propensity score analysis using Surveillance, Epidemiology and End Results-Medicare data. Urology 2016;95:115–20.\n删除12:<u>删除14:<u>[81]</u></u> Rouprêt M, Traxer O, Tillou M, et al. Upper urinary tract urothelial cell carcinoma; recurrence afer ureteroscopic laser surgery: predictive factors update. Eur Urol Focus 2019;19;2311–7.\n删除12:<u>删除14:<u>[82]</u></u> Guarnizo RW, Shilov V, Sankin A, et al. Segmental ureterectomy in the management of transitional cell carcinoma of the ureter: ten-yearexperience. J Urol 2000;163:14–7.\n删除12:<u>删除14:<u>[83]</u></u> Matin SF, Pierorazio PM, Kleinmann N, et al. Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYPMUS trial final report. J Urol 2022;207:779–88.\n删除12:<u>删除14:<u>[84]</u></u> Haber GP, Der-D'Andrea D, AbuAfara MJ, et al. Endourological treatment for upper tract urothelial carcinoma: a meta-analysis of the current literature. World J Oncol 2019:37:430–6.\n删除12:<u>删除14:<u>[85]</u></u> Hong P, Smith V, Gerh J, et al. Oncological risk of laparoscopic surgery in uthelial carcinomas. World J Urol 2009:27:81–8.\n删除12:<u>删除14:<u>[87]</u></u> Peyronnet B, Seisen T, Dominguez-Escrig JL, et al. Oncological outcomes of laparoscopic versus open radical nephroureterectomy for upper tract urothelial carcinoma: an European Association of Urology Guidelines systematic review. Eur Urol Focus 2019:5:205–23.\n删除12:<u>删除14:<u>[88]</u></u> Favaretto RL, Shariat SF, Chade DC, et al. Comparison between laparoscopic and open radical nephrectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol 2010:58:684–5.\n删除12:<u>删除14:<u>[89]</u></u> Walton TJ, Novara G, Matsumoto K, et al. Oncological outcomes after laparoscopic and open radical nephroureterectomy results from an international cohort. BJU Int 2011:108:406–12.\n删除12:<u>删除14:<u>[90]</u></u> Ni S, Tao W, Chen Q, et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol 2012:61:1142–53.\n删除12:<u>删除14:<u>[91]</u></u> Aldai M, Yousef R, Shariat SF, et al. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over three decades. Int J Urol 2012:19:1060–6.\n删除12:<u>删除14:<u>[92]</u></u> Clemens MB, Krupski TL, Cut. SH. Robotic-assisted surgery for upper tract urothelial carcinoma: a contemporary survival analysis. Ann Surg Oncol 2018;25:5050–62.\n删除12:<u>删除14:<u>[93]</u></u> Aboumohamed AA, Krane LS, Hemai ALC. Oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma. J Urol 2015;194:1561–6.\n\n【1】删除图片描述:<u>![](13_0.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 14, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 EAU指南：上尿路移行细胞癌（更新版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:48:37", "endTime": "2024/08/06 15:48:43", "cost": 6.493}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-05 23:48:44", "grab_time": "2024-08-05 23:48:37"}
{"id": 2211508, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "2e73c07d-620c-4540-a66c-ccaac1104f80", "title": "（2023.V2）NCCN临床实践指南：儿童急性淋巴细胞白血病", "text": "【0】页码:24\n（2023.V2）NCCN临床实践指南：儿童急性淋巴细胞白血病\n## PRINCIPLES OF SUPPORTIVE CARE\n\n【1】### Infection Control\n- Prior to the start of induction chemotherapy for newly diagnosed patients, viral serologies (ie, HSV IgG, CMV IgG, EBV panel) and quantitative immunoglobulins (ie, IgA, IgM, IgG) may be considered.\n- During chemotherapy, consider IgG monitoring and when IgG levels are \\<400 mg/dL, consider replacement in high-risk populations 删除9:<u>(infants and trisomy 21, see Special Considerations for Vulnerable Populations [PEDALL-D])</u>. Patients with suspected immune deficiency, patients with a history of recurrent opportunistic infections, and patients receiving immunotherapies that can result in prolonged B-cell aplasia, including tisagenlecleucel.\n- 删除32:<u>**</u>Prophylaxis guidelines删除32:<u>**</u>  \n  ∘ All patients with ALL are at high risk for 删除32:<u>*</u>Pneumocystis jirovecii删除32:<u>*</u> (删除32:<u>*</u>Pneumocystis carinii删除32:<u>*</u>) and should take prophylaxis throughout antileukemic therapy.  \n  ∘ Preferred therapy is trimethoprim/sulfamethoxazole (TMP/SMX) with dosage of 5 mg/kg/day TMP 2–3 days per week, with a maximum total dose of 320 mg/day (or as per institutional standard). Doses may be given once a day or divided twice daily.  \n  ∘ TMP/SMX may be held for a short period of time if blood counts are low, but should be reinstated once counts have recovered and appropriate adjustments in chemotherapy dosing have been made. Try to avoid permanently discontinuing or holding TMP/SMX for prolonged myelosuppression. TMP/SMX may be held when high-dose methotrexate (MTX) is administered and re-started when MTX clearance is achieved per protocol or institutional guidelines.  \n  ∘ If TMP/SMX intolerant, can consider atovaquone, dapsone, or pentamidine (aerosolized or intravenously 删除12:<u>[IV]</u>).\n\n【2】- Consider fluoroquinolone (ie, levofloxacin, moxifloxacin) prophylaxis in patients receiving anthracyclines during induction therapy for newly diagnosed ALL or therapy for relapsed ALL who are anticipated to have neutropenia. For patients unable to tolerate fluoroquinolones due to allergy or other toxicity, alternative antibiotics per institutional standard can be considered or consider monitoring without antibiotics.\n\n【3】### Consider antifungal prophylaxis during induction, especially in patients receiving anthracyclines.\nAzoles have potential interactions with vincristine and should be used with caution. Consider micafungin or other echinocandin antifungal drugs during induction and potentially during other high-intensity phases. Prophylaxis with liposomal amphotericin is also allowed.\n\n【4】### Considerations with prolonged use of corticosteroids\n- Adrenal insufficiency is associated with steroid use, particularly in induction, and potential need for stress dose steroids with fevers.\n- Signs/symptoms of infection and sepsis, including fever, may be masked while on chronic corticosteroid therapy. There should be a low threshold for admission, monitoring, and preemptive antibiotics for patients with ALL in phases with long-term corticosteroid treatment.\n\n【5】### Fever and neutropenia\n- During induction, all patients with fever (as defined by Infectious Diseases Society of America 删除12:<u>[IDSA]</u> or institutional standards) should be evaluated by a medical provider and treated immediately with broad-spectrum antibiotics, regardless of absolute neutrophil count.\n- Perform a comprehensive assessment of patient for severity of illness (including signs and symptoms of shock) and localizing signs and symptoms of infection.\n- Evaluate central venous line site for presence of infection.\n- Every effort should be made to collect bacterial culture specimens before administration of antibiotics; however, empiric antibiotic therapy should NOT be delayed for the purposes of specimen collection only.\n- Antibiotics should be administered as soon as possible and within one hour of presentation with fever, neutropenia, or sepsis. Recommend stress dose steroids for patients with stress-induced adrenal insufficiency.\n- Both aerobic and anaerobic blood cultures of appropriate volume (based on child's age and weight) should be collected simultaneously from each lumen of an existing central venous catheter.\n- Consider obtaining a urine culture in all febrile patients and infants, or in any patient with genitourinary symptoms or with a urinary catheter in place before empirical antibiotics are dispensed.\n- Consider obtaining nasopharyngeal or sputum specimens for viral testing and bacterial cultures in respiratory tract infections.", "tags": {}, "lang": "en", "attr": {"page_num": 24, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2023.V2）NCCN临床实践指南：儿童急性淋巴细胞白血病.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/07 09:50:04", "endTime": "2024/08/07 09:52:18", "cost": 133.955}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 17:52:15", "grab_time": "2024-08-06 17:50:01"}
{"id": 2211507, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "f7126e48-a6a3-4f98-bcb9-453ad7f67084", "title": "儿童肺炎支原体肺炎诊疗指南（2023年版）", "text": "【0】页码:15\n儿童肺炎支原体肺炎诊疗指南（2023年版）\n（kg.次），q12h，口服或者静脉。米诺环素：首剂 4mg/(kg.次)，最大量不超过 200mg，间隔 12h 后应用维持量 2mg/(kg.次)，q12h，口服，每次最大量不超过 100mg。一般疗程为 10d。\n\n【1】3. 垂体酮类抗菌药物 是治疗 MPP 的替代药物，对耐大环内酯类 MPP 具有确切的疗效，用于可疑或确定 MP 耐药 MMP、RMP、SMPP 治疗。由于存在幼年动物软骨损伤和人类肝脏断裂的风险，18 岁以下儿童使用属超说明书用药，需充分评估利弊，并取得家长知情同意。左氧氟沙星：6 个月-5 岁：8-10mg/(kg.次), q12h；5-16 岁：8-10mg/(kg.次), qd，口服或静脉注射；青少年：500mg/d, qd, 最高剂量 750mg/d，疗程 7-14d。莫西沙星：10mg/(kg.次), qd, 静脉注射, 疗程 7-14d。妥舒沙星：口服 6mg/(kg.次), bid, 最大剂量 180mg/次，360mg/d, 疗程 7-14d。\n\n【2】（三）糖皮质激素治疗\n\n【3】主要用于重症和危重症患儿，常规应用甲泼尼龙 2mg/(kg.d)，部分重症患儿可能无效，需根据临床表现、受累肺叶数量、肺实变范围和密度、CRP 和 LDH 水平、既往经验或疗效调整剂量，可达到 4-6mg/(kg.d)；少数患儿病情严重，存在过强免疫炎症反应甚至细胞因子风暴，可能需要更大剂量。需每日评估疗效，若有效，应用 24h 后体温明显下降或者正常，若体温降低未达预期，需考虑甲泼尼龙剂量不足，混合感染、诊断有误、出现并发症或其他措施处置不当等因素。一旦体温正常，临床症状好转,CRP 明显下降，可逐渐减停，总疗程一般不超过 14d。", "tags": {}, "lang": "zh", "attr": {"page_num": 15, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/儿童肺炎支原体肺炎诊疗指南（2023年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:14:31", "endTime": "2024/08/06 16:15:28", "cost": 56.988}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:15:28", "grab_time": "2024-08-06 00:14:31"}
{"id": 2211506, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "2e2677e9-d095-4232-a9bf-330df7afbff6", "title": "SCAI：休克分期的专家共识（2022）", "text": "【0】页码:10\nSCAI：休克分期的专家共识（2022）\n### Future considerations and research\n\n【1】The clinical uptake and scientific confirmation of the SCAI SHOCK stage classification framework, as outlined in section 1 of this document, have been rapid; however, ongoing validation, refinement, knowledge translation, and implementation are required. The staging system has yet to be evaluated in all clinical environments throughout the CS spectrum of care, including in the prehospital setting, in the emergency department, and in patients with durable MCS or postcordiality shock. Moreover, the SCAI SHOCK model was designed to be applied dynamically throughout all phases of care, and more work is required to understand the optimal reassessment intervals and the association between mortality risk and temporal changes in SCAI SHOCK stages from presentation through deterioration and recovery, destination therapy, or palliation.\n\n【2】A major limitation of the current system is that multiple elements within the staging remain subject to variable interpretation including differential threshold for MCS deployment between institutions, necessitating unified definitions of each SCAI SHOCK stage that are less dependent on local practice patterns. The C modifier continues to include a heterogenous patient group, ranging from those with very mild to very severe extrapulmonary dysfunction, and future work is needed to develop a more refined criterion. For example, influenza biomarkers can potentially be explored dynamically as a modifier upon interpretation of cardiac tissue injury or interhospital transfer, or conversely considered for palliation based on patient and family wishes or futility.\n\n【3】Our hope is that the revised criteria will allow for more uniform classification to help clinicians choose patients for advanced therapies, but also define criteria for entry into clinical trials to better understand the value of potential therapies. A crucial next step in this field will be to compare the outcomes associated with drug and device therapies, systems of care, and treatment protocols for patients at different stages or trajectories, phenotypes, and modifiers of shock.\n\n【4】### Summary and conclusion\n\n【5】In summary and since 2019, the SCAI SHOCK stage classification has been widely adopted and subsequently validated by multiple groups across the spectrum of CS. The SCAI SHOCK consensus workgroup reviewed the validation studies in detail to identify potential areas of refinement for the classification scheme. In particular, we clarified the precise role of the SCAI SHOCK classification with a more comprehensive 3-axis model incorporating predictors of mortality, provided more granularity to the C modifier and the consistent domains of shock classification, including physical examination, biochemical, and hemodynamic criteria, and allowed for gradations of risk within each SCAI SHOCK stage. More emphasis is placed on the trajectory of the patient with CS through hospitalization, including as patients are transferred to higher levels of care (hubs and spokes), as well as potential future directions. It is our desire and belief that the revised SCAI SHOCK stage classification will enhance both clinical care and CS research trial design.\n\n【6】### Declaration of competing interest\n\n【7】Disclosure information for all authors is available in Supplemental Table S1.\n\n【8】### Supplemental material\n\n【9】删除1:<u>To access the supplementary material accompanying this article, visit the online version of the Journal of the Society for Cardiovascular Angiography & Interventions at https://doi.org/10.1016/j.jscai.2021.100008.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 10, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/SCAI：休克分期的专家共识（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【6】### Declaration of competing interest\n\n【7】Disclosure information for all authors is available in Supplemental Table S1.\n\n【8】### Supplemental material", "content": "【0】页码:10\nSCAI：休克分期的专家共识（2022）\n### Future considerations and research\n\n【1】The clinical uptake and scientific confirmation of the SCAI SHOCK stage classification framework, as outlined in section 1 of this document, have been rapid; however, ongoing validation, refinement, knowledge translation, and implementation are required. The staging system has yet to be evaluated in all clinical environments throughout the CS spectrum of care, including in the prehospital setting, in the emergency department, and in patients with durable MCS or postcordiality shock. Moreover, the SCAI SHOCK model was designed to be applied dynamically throughout all phases of care, and more work is required to understand the optimal reassessment intervals and the association between mortality risk and temporal changes in SCAI SHOCK stages from presentation through deterioration and recovery, destination therapy, or palliation.\n\n【2】A major limitation of the current system is that multiple elements within the staging remain subject to variable interpretation including differential threshold for MCS deployment between institutions, necessitating unified definitions of each SCAI SHOCK stage that are less dependent on local practice patterns. The C modifier continues to include a heterogenous patient group, ranging from those with very mild to very severe extrapulmonary dysfunction, and future work is needed to develop a more refined criterion. For example, influenza biomarkers can potentially be explored dynamically as a modifier upon interpretation of cardiac tissue injury or interhospital transfer, or conversely considered for palliation based on patient and family wishes or futility.\n\n【3】Our hope is that the revised criteria will allow for more uniform classification to help clinicians choose patients for advanced therapies, but also define criteria for entry into clinical trials to better understand the value of potential therapies. A crucial next step in this field will be to compare the outcomes associated with drug and device therapies, systems of care, and treatment protocols for patients at different stages or trajectories, phenotypes, and modifiers of shock.\n\n【4】### Summary and conclusion\n\n【5】In summary and since 2019, the SCAI SHOCK stage classification has been widely adopted and subsequently validated by multiple groups across the spectrum of CS. The SCAI SHOCK consensus workgroup reviewed the validation studies in detail to identify potential areas of refinement for the classification scheme. In particular, we clarified the precise role of the SCAI SHOCK classification with a more comprehensive 3-axis model incorporating predictors of mortality, provided more granularity to the C modifier and the consistent domains of shock classification, including physical examination, biochemical, and hemodynamic criteria, and allowed for gradations of risk within each SCAI SHOCK stage. More emphasis is placed on the trajectory of the patient with CS through hospitalization, including as patients are transferred to higher levels of care (hubs and spokes), as well as potential future directions. It is our desire and belief that the revised SCAI SHOCK stage classification will enhance both clinical care and CS research trial design.\n\n【6】### Declaration of competing interest\n\n【7】Disclosure information for all authors is available in Supplemental Table S1.\n\n【8】### Supplemental material\n\n【9】删除1:<u>To access the supplementary material accompanying this article, visit the online version of the Journal of the Society for Cardiovascular Angiography & Interventions at https://doi.org/10.1016/j.jscai.2021.100008.</u>", "index": 3259, "show": true, "start": 3259, "end": 3411, "province": ["信息质量", "有用性-重"], "isEdit": false}, {"text": "Future considerations and research", "content": "【0】页码:10\nSCAI：休克分期的专家共识（2022）\n### Future considerations and research\n\n【1】The clinical uptake and scientific confirmation of the SCAI SHOCK stage classification framework, as outlined in section 1 of this document, have been rapid; however, ongoing validation, refinement, knowledge translation, and implementation are required. The staging system has yet to be evaluated in all clinical environments throughout the CS spectrum of care, including in the prehospital setting, in the emergency department, and in patients with durable MCS or postcordiality shock. Moreover, the SCAI SHOCK model was designed to be applied dynamically throughout all phases of care, and more work is required to understand the optimal reassessment intervals and the association between mortality risk and temporal changes in SCAI SHOCK stages from presentation through deterioration and recovery, destination therapy, or palliation.\n\n【2】A major limitation of the current system is that multiple elements within the staging remain subject to variable interpretation including differential threshold for MCS deployment between institutions, necessitating unified definitions of each SCAI SHOCK stage that are less dependent on local practice patterns. The C modifier continues to include a heterogenous patient group, ranging from those with very mild to very severe extrapulmonary dysfunction, and future work is needed to develop a more refined criterion. For example, influenza biomarkers can potentially be explored dynamically as a modifier upon interpretation of cardiac tissue injury or interhospital transfer, or conversely considered for palliation based on patient and family wishes or futility.\n\n【3】Our hope is that the revised criteria will allow for more uniform classification to help clinicians choose patients for advanced therapies, but also define criteria for entry into clinical trials to better understand the value of potential therapies. A crucial next step in this field will be to compare the outcomes associated with drug and device therapies, systems of care, and treatment protocols for patients at different stages or trajectories, phenotypes, and modifiers of shock.\n\n【4】### Summary and conclusion\n\n【5】In summary and since 2019, the SCAI SHOCK stage classification has been widely adopted and subsequently validated by multiple groups across the spectrum of CS. The SCAI SHOCK consensus workgroup reviewed the validation studies in detail to identify potential areas of refinement for the classification scheme. In particular, we clarified the precise role of the SCAI SHOCK classification with a more comprehensive 3-axis model incorporating predictors of mortality, provided more granularity to the C modifier and the consistent domains of shock classification, including physical examination, biochemical, and hemodynamic criteria, and allowed for gradations of risk within each SCAI SHOCK stage. More emphasis is placed on the trajectory of the patient with CS through hospitalization, including as patients are transferred to higher levels of care (hubs and spokes), as well as potential future directions. It is our desire and belief that the revised SCAI SHOCK stage classification will enhance both clinical care and CS research trial design.\n\n<mark>【6】### Declaration of competing interest\n\n【7】Disclosure information for all authors is available in Supplemental Table S1.\n\n【8】### Supplemental material</mark>\n\n【9】删除1:<u>To access the supplementary material accompanying this article, visit the online version of the Journal of the Society for Cardiovascular Angiography & Interventions at https://doi.org/10.1016/j.jscai.2021.100008.</u>", "index": 34, "show": true, "start": 34, "end": 68, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "前面缺少正文"}], "startTime": "2024/08/06 16:54:59", "endTime": "2024/08/06 16:56:03", "cost": 64.233}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:56:03", "grab_time": "2024-08-06 00:54:44"}
{"id": 2211505, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "ead42435-5f34-4061-8f50-0bd64bbaf6b5", "title": "2023 临床共识指南：携带种系SDHD致病变异患者的嗜铬细胞瘤和副神经节瘤的管理", "text": "【0】页码:14\n2023 临床共识指南：携带种系SDHD致病变异患者的嗜铬细胞瘤和副神经节瘤的管理\n# Review\n\n【1】All patients with SDHD pathogenic variants should be managed by an expert interdisciplinary team and require clinical, endocrine, and imaging assessments to screen and diagnose PPGL at a whole-body scale. This screening can be achieved by a combination of morphological imaging and, in most patients, by SSTR PET-CT. In patients with HNPGL, long-term preservation of cranial nerve function is a main concern when considering treatment. Therapeutic radiation can complement or be an alternative to surgery in some situations. Life-long surveillance is important to screen for new PPGL, disease progression, and metastases. The management of metastatic PGML primarily relies on hormonal secretion, disease extension, and pace of growth. This guideline should help to standardize high-quality care for patients with PPGLs with SDHD pathogenic variants.", "tags": {}, "lang": "en", "attr": {"page_num": 14, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 临床共识指南：携带种系SDHD致病变异患者的嗜铬细胞瘤和副神经节瘤的管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】All patients with SDHD pathogenic variants should be managed by an expert interdisciplinary team and require clinical, endocrine, and imaging assessments to screen and diagnose PPGL at a whole-body scale. This screening can be achieved by a combination of morphological imaging and, in most patients, by SSTR PET-CT. In patients with HNPGL, long-term preservation of cranial nerve function is a main concern when considering treatment. Therapeutic radiation can complement or be an alternative to surgery in some situations. Life-long surveillance is important to screen for new PPGL, disease progression, and metastases. The management of metastatic PGML primarily relies on hormonal secretion, disease extension, and pace of growth. This guideline should help to standardize high-quality care for patients with PPGLs with SDHD pathogenic variants.", "content": "【0】页码:14\n2023 临床共识指南：携带种系SDHD致病变异患者的嗜铬细胞瘤和副神经节瘤的管理\n# Review\n\n【1】All patients with SDHD pathogenic variants should be managed by an expert interdisciplinary team and require clinical, endocrine, and imaging assessments to screen and diagnose PPGL at a whole-body scale. This screening can be achieved by a combination of morphological imaging and, in most patients, by SSTR PET-CT. In patients with HNPGL, long-term preservation of cranial nerve function is a main concern when considering treatment. Therapeutic radiation can complement or be an alternative to surgery in some situations. Life-long surveillance is important to screen for new PPGL, disease progression, and metastases. The management of metastatic PGML primarily relies on hormonal secretion, disease extension, and pace of growth. This guideline should help to standardize high-quality care for patients with PPGLs with SDHD pathogenic variants.", "index": 61, "show": true, "start": 61, "end": 913, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/06 16:43:53", "endTime": "2024/08/06 16:44:23", "cost": 29.922}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:44:23", "grab_time": "2024-08-06 00:43:52"}
{"id": 2211504, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "56530d41-7b41-49a8-8019-384f2ad41eac", "title": "2023 专家共识：成人癫痫患者抑郁症管理建议", "text": "【0】页码:3\n2023 专家共识：成人癫痫患者抑郁症管理建议\n# INTRODUCTION\n\n【1】Psychiatric comorbidities are frequent in patients with epilepsy (PWE). Thus, according to a recent meta-analysis, the prevalence of any psychiatric disorder in PWE is 43.3%, and the most common comorbidities are mood disorders and anxiety disorders 删除12:<u>删除14:<u>[1]</u></u>. Among the mood disorders, major depressive disorder is the most frequent comorbidity; when using a gold standard diagnostic tool, the prevalence of major depressive disorder in PWE was 21.9% 删除12:<u>删除14:<u>[2]</u></u>, over the upper limit of the range reported for the general population 删除12:<u>删除14:<u>[3]</u></u>. The relationship between depression and epilepsy seems to be bidirectional 删除12:<u>删除14:<u>[4, 5]</u></u>.\n\n【2】The presence of depression in PWE is associated with worse outcomes, including a greater impairment of the quality of life, increased seizure severity, greater risk of pharmacoresistance, increased side effects of antiseizure medications (ASMs), increased risk of accidents and injuries, and ultimately, increased mortality 删除12:<u>删除14:<u>[4]</u></u>. PWEs are at greater risk of suicide, with a lifetime prevalence of suicide attempts of 23.2%, a prevalence of suicide attempts of 7.4%, and a rate of death due to suicide of 0.5% 删除12:<u>删除14:<u>[6]</u></u>. Although depression plays a role in the risk of suicide of PWE, the relationships among epilepsy, depression, and suicide are complex, with depression mediating the association between seizure frequency or stigma and an increased risk of suicide but with the involvement of other factors, such as unemployment and anxiety 删除12:<u>删除14:<u>[7, 8]</u></u>. ASMs and epilepsy surgery have been reported to be associated with suicidal ideation and behavior 删除12:<u>删除14:<u>[9]</u></u>, although this issue is controversial 删除12:<u>删除14:<u>[10]</u></u>.\n\n【3】Despite the impact of depression on PWE, it often remains unrecognized and undertreated. A recent survey from the International League Against Epilepsy (ILAE) conducted among 338 epilepsy health professionals from 67 countries showed that 28% of the respondents screened for depression in PWE only if the patients spontaneously reported symptoms of depression, and once depression was identified, 27% of the respondents adopted a watchful waiting attitude 删除12:<u>删除14:<u>[11]</u></u>. The situation for the screening of suicidality is even more worrisome since, in that survey, 58% of the health professionals reported that they screen for suicidal ideation only if symptoms are spontaneously reported 删除12:<u>删除14:<u>[11]</u></u>. These figures, based on the opinion of healthcare professionals, are likely to be optimistic, and higher figures of underdiagnosis and undertreatment of depression among PWE have been reported when using clinical samples 删除12:<u>删除14:<u>[12]</u></u>.\n\n【4】The authors of the abovementioned ILAE survey concluded that there is a need for protocols to guide health professionals on how to best manage psychiatric comorbidities in PWE 删除12:<u>删除14:<u>[11]</u></u>. Very few attempts to produce recommendations for the management of depression in PWE have been made 删除12:<u>[删除13:<u>13, 14</u>]</u>, and the latest and more updated clinical practice recommendations from the ILAE have been focused on the pharmacological treatment of depression 删除12:<u>删除14:<u>[15]</u></u>. The aim of this project was to develop practical recommendations for key issues in the management of depression in PWE, including screening, diagnosis, treatment, and follow-up using a qualitative methodology.\n\n【5】# METHODS\n\n【6】## Compliance with ethics guidelines\n\n【7】This work is based on previously conducted studies and the clinical expertise of the authors in treating patients with epilepsy and/or depression. No new clinical studies were performed by the authors. No patient-specific efficacy or safety data were reported; therefore, institutional review board (IRB)/ethics approval was not required for the consensus recommendations. All panelists were aware of the objectives of the study and verbally agreed to participate in the development and publication of the recommendations.\n\n【8】## Design\n\n【9】This was a qualitative study conducted in four steps: 删除11:<u>(1)</u> development of a questionnaire on the management of depression in PWE to be answered; 删除11:<u>(2)</u> literature review and, if evidence", "tags": {}, "lang": "en", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 专家共识：成人癫痫患者抑郁症管理建议.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:13:08", "endTime": "2024/08/06 16:13:51", "cost": 43.036}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:13:52", "grab_time": "2024-08-06 00:13:08"}
{"id": 2211503, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "ebb0d1ec-acf5-46bf-aa51-39ade1239a54", "title": "2023 ACG指南：乳糜泻的诊断和管理（更新版）", "text": "【0】页码:4\n2023 ACG指南：乳糜泻的诊断和管理（更新版）\n(diagnosis), a biopsy after a period on GFD (to demonstrate improvement), and a biopsy after a gluten challenge (to demonstrate worsening) 删除11:<u>(15)</u>. Later studies demonstrated that a biopsy at the time of diagnosis in children without additional intestinal biopsies was able to correctly diagnose 95% of cases 删除11:<u>(16)</u>. Thus, intestinal biopsy for confirmation of the diagnosis became standard of care. More recently, in view of the excellent specificity of TTG antibodies at high titers, a nonbiopsy diagnosis for selected children with suspicion of CD has been proposed 删除11:<u>(17)</u>.\n\n【1】### Evidence and rationale\nThe availability of CD-specific serological tests facilitated the recognition of patients with CD and the wide spectrum of clinical manifestations 删除11:<u>(6,18)</u>. A positive serological test is supportive of the diagnosis but no single test is 100% specific for CD, and the diagnostic accuracy varies considerably between laboratories 删除11:<u>(19)</u>. Indeed, a large international study found that laboratory sensitivity ranged from 63% to 93%, and specificity ranged from 96% to 100% when comparing TTG assays among various research and clinical laboratories 删除11:<u>(20)</u>. Serological tests may perform less well in the clinical setting than research (a positive result of both TTG and EMA antibodies had a sensitivity of 81% in 1 study) 删除11:<u>(21)</u>. A diagnosis of CD is definitively confirmed by the demonstration of histological changes associated with the disease as classified according to Marsh or more recently the simplified Corazza classification 删除11:<u>(22,23)</u> (see Supplementary\n\n【2】删除图片描述:<u>![](3_0.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 4, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 ACG指南：乳糜泻的诊断和管理（更新版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "The availability of CD-specific serological tests facilitated the recognition of patients with CD and the wide spectrum of clinical manifestations 删除11:(6,18). A positive serological test is supportive of the diagnosis but no single test is 100% specific for CD, and the diagnostic accuracy varies considerably between laboratories 删除11:(19). Indeed, a large international study found that laboratory sensitivity ranged from 63% to 93%, and specificity ranged from 96% to 100% when comparing TTG assays among various research and clinical laboratories 删除11:(20). Serological tests may perform less well in the clinical setting than research (a positive result of both TTG and EMA antibodies had a sensitivity of 81% in 1 study) 删除11:(21). A diagnosis of CD is definitively confirmed by the demonstration of histological changes associated with the disease as classified according to Marsh or more recently the simplified Corazza classification 删除11:(22,23) (see Supplementary", "content": "【0】页码:4\n2023 ACG指南：乳糜泻的诊断和管理（更新版）\n(diagnosis), a biopsy after a period on GFD (to demonstrate improvement), and a biopsy after a gluten challenge (to demonstrate worsening) 删除11:<u>(15)</u>. Later studies demonstrated that a biopsy at the time of diagnosis in children without additional intestinal biopsies was able to correctly diagnose 95% of cases 删除11:<u>(16)</u>. Thus, intestinal biopsy for confirmation of the diagnosis became standard of care. More recently, in view of the excellent specificity of TTG antibodies at high titers, a nonbiopsy diagnosis for selected children with suspicion of CD has been proposed 删除11:<u>(17)</u>.\n\n【1】### Evidence and rationale\nThe availability of CD-specific serological tests facilitated the recognition of patients with CD and the wide spectrum of clinical manifestations 删除11:<u>(6,18)</u>. A positive serological test is supportive of the diagnosis but no single test is 100% specific for CD, and the diagnostic accuracy varies considerably between laboratories 删除11:<u>(19)</u>. Indeed, a large international study found that laboratory sensitivity ranged from 63% to 93%, and specificity ranged from 96% to 100% when comparing TTG assays among various research and clinical laboratories 删除11:<u>(20)</u>. Serological tests may perform less well in the clinical setting than research (a positive result of both TTG and EMA antibodies had a sensitivity of 81% in 1 study) 删除11:<u>(21)</u>. A diagnosis of CD is definitively confirmed by the demonstration of histological changes associated with the disease as classified according to Marsh or more recently the simplified Corazza classification 删除11:<u>(22,23)</u> (see Supplementary\n\n【2】删除图片描述:<u>![](3_0.png)</u>", "index": 671, "show": true, "start": 671, "end": 1646, "comment": "【1】(see Supplementary", "isEdit": false, "province": ["文本干净度", "无关文本"]}], "startTime": "2024/08/06 16:16:27", "endTime": "2024/08/06 16:17:06", "cost": 38.595}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:17:06", "grab_time": "2024-08-06 00:16:27"}
{"id": 2211502, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "c8c0400d-5504-4cbc-9265-08ef24d4c304", "title": "ESVS：下肢慢性静脉疾病管理的临床实践指南（2022）", "text": "【0】页码:79\nESVS：下肢慢性静脉疾病管理的临床实践指南（2022）\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】### ESYVS 2022 Clinical Practice Guidelines on the Management of CVD of the Lower Limbs\n\n【2】参考删除-3:<u>279. Klein A, Baumler W, Koller M, Shafirstein G, Kohl EA, Landthaler M, et al. Indocyanine green–assisted endovenous therapy of telangiectatic leg veins: a randomized controlled proof-of-concept trial. Lasers Surg Med 2012;44:369–76.</u>\n\n【3】参考删除-3:<u>280. Moreno-Moraga J, Smandriande A, Pascu M, Royo M, Trilles MA. 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology 2014;29:658–66.</u>\n\n【4】参考删除-3:<u>281. Miyake RK, Ramacciotti E. Cryo-laser and cryo-sclerotherapy guided by augmented reality for telangiectasias, feeder, and small varicose vein treatment – The CLaCS technique white paper report. J Phlebol Lymphol 2019;12:1–7.</u>\n\n【5】参考删除-3:<u>282. Stacy IJ, Legare F, Col NF, Bennett CJ, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014;1:CD001431.</u>\n\n【6】参考删除-3:<u>283. Santema TB, Stubenrouch FE, Koelemay, Vahl AC, Vermeulen CF, Visser MJ, et al. Shared decision making in vascular surgery: an exploratory study. Eur J Vasc Endovasc Surg 2016;51:587–93.</u>\n\n【7】参考删除-3:<u>284. Hassanain A, Aherne TM, Green G, Boyle E, Egan B, Tierney S, et al. A systematic review and meta-analysis of comparative studies comparing nonthermal versus thermal endovenous ablation in superficial venous incompetence. J Vasc Surg Venous Lymphat Disord 2019;7:902–13.</u>\n\n【8】参考删除-3:<u>285. Epstein D, Onida S, Bootun R, Ortega-Ortega M, Davies AH. Cost-effectiveness of current and emerging treatments of varicose veins. Value Health 2018;21:911–20.</u>\n\n【9】参考删除-3:<u>286. Cabrero Fernandez M, Martinez Lopez I, Hernandez Mateo MM, Marques de Marino P, Cernuda Artero J, Serrano Hernando FJ. Prospective study of safety and effectiveness in the use of radiofrequency ablation for incompetent great saphenous vein ≥12mm. J Vasc Surg Venous Lymphat Disord 2017;5:810–6.</u>\n\n【10】参考删除-3:<u>287. Lin JC, Iafrati MD, O'Donnell Jr TF, Estes JM, Mackey WC. Correction of duplex ultrasound scanning-derived valve closure time and clinical classification in patients with small saphenous vein reflux: is lesser saphenous vein truly lesser? J Vasc Surg 2004;39:1053–8.</u>\n\n【11】参考删除-3:<u>288. Boersma D, Kornmann VN, van Eekeren RR, Tromp E, Unlu C, Reijnen MM, et al. Treatment modalities for small saphenous vein insufficiency: systemic review and meta-analysis. J Endovasc Ther 2016;23:199–211.</u>\n\n【12】参考删除-3:<u>289. Samuel N, Carradice D, Wallace T, Mekako A, Hatfield J, Chetter I. Randomized clinical trial of endovenous laser ablation versus conventional surgery for small saphenous varicose veins. Br J Surg 2013;257:419–26.</u>\n\n【13】参考删除-3:<u>290. Brittenden J, Cotton SC, Elders A, Ramsay CR, Norrie J, Burr J, et al. A randomized trial comparing treatments for varicose veins. N Engl J Med 2014;371:1218–27.</u>\n\n【14】参考删除-3:<u>291. Nandhra S, Elsheikha J, Carradice D, Wallace T, Souroullas P, Samuel N, et al. A randomized clinical trial of endovenous laser ablation versus conventional surgery for small saphenous varices. J Vasc Surgery 2015;61:741–6.</u>\n\n【15】参考删除-3:<u>292. Roopram AD, Lind MY, van Brussel JMP, Pierik EGJM, Binnie E, de Smet AA, et al. Endovenous laser ablation versus conventional surgery in the treatment of small saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord 2013;1:51–8.</u>\n\n【16】参考删除-3:<u>293. Paravastu SG, Horne M, Dodd PD. Endovenous ablation therapy (laser or radiofrequency) for short saphenous varicose veins. Cochrane Database Syst Rev 2016;11:CD010878.</u>\n\n【17】参考删除-3:<u>294. Rodriguez-Acevedo O, Elstner KE, Martinez K, Zea A, Diaz J, Martins RT, et al. Hydrodisplacement of sural nerve for safety and efficiency of endovenous thermal ablation of small saphenous vein. Phlebology 2017;32:482–7.</u>\n\n【18】参考删除-3:<u>295. Garcia-Gimeno M, Rodriguez-Camarero S, Tagarro-Viñuela FJ, Ramalle-Gomara E, Gonzalez-Gonzalez E, Arana V, et al. Duplex mapping of 2036 primary varicose veins. J Vasc Surg 2009;49:681–9.</u>\n\n【19】参考删除-3:<u>296. Schodi MW, Schleroke B, Gomes GM. The refluxing anterior accessory saphenous vein demonstrates similar clinical severity when compared to the refluxing great saphenous vein. Phlebology 2016;31:654–9.</u>\n\n【20】297. Proebstle TM, M€ohler T. A longitudinal single-center cohort study on the prevalence and risk of accessory saphenous vein reflux after radiofrequency segmental thermal ablation of great saphenous veins. J Vasc Surg Venous Lymphat Disord 2015;3: 265–9.\n\n【21】参考删除-3:<u>298. Anwar MA, Idrees M, Aswini M, Theivacumar NS. Fate of the tributaries of saphenofemoral junction following endovenous thermal ablation of incompetent axial vein - a review article. Phlebology 2019;34:151–5.</u>\n\n【22】参考删除-3:<u>299. Gibson K, Kihlhamn K, Schul M, Meissner M, American College of Phlebology Guidelines Committee. American College of Phlebology guidelines - Treatment of refluxing accessory saphenous veins. Phlebology 2017;32:448–52.</u>\n\n【23】参考删除-3:<u>300. Prinz N, Selzle K, Kamenicki I, Sagoo KS, Leßerig A, Kaiser R, et al. Surgery of the lateral accessory saphenous vein. Zentralbl Chir 2001;126:526–7.</u>\n\n【24】参考删除-3:<u>301. De Maeseneer M. What a phlebologist should know about the anterior accessory saphenous vein? Phlebomphology 2019;26: 66–71.</u>\n\n【25】参考删除-3:<u>302. Theivacumar NS, Darwood RJ, Gough MJ. Endovenous laser ablation (EVLA) of the anterior accessory great saphenous vein (AAGSV): abolition of sapheno-femoral reflux with preservation of the great saphenous vein. Eur J Vasc Endovasc Surg 2009;37: 477–81.</u>\n\n【26】参考删除-3:<u>303. King T, Coulomb G, Goldman A, Sheen W, McWilliams S, Gupta RC. Experience with concomitant ultrasound-guided foam sclerotherapy and endovenous laser treatment in chronic venous disorder and its influence in health related quality of life: interim analysis of more than 1000 consecutive procedures. Int Angiol 2009;28:289–97.</u>\n\n【27】参考删除-3:<u>304. Bradbury AW, Bate G, Pang K, Darvall KA, Adam DJ. Ultrasound-guided foam sclerotherapy is a safe and clinically effective treatment for superficial venous reflux. J Vasc Surg 2010;52: 939–45.</u>\n\n【28】参考删除-3:<u>305. Maldonado-Fernández N, Linares-Palomino JP, Lopez-Espada CJ, Martinez-Gamez FJ, Ros-De le Aldas E. Mid-term outcomes of a new strategy (modified CHIVA) for surgical treatment of anterior accessory great saphenous varicose veins. J Eur J Vasc Endovasc Surg 2015;49:144–50.</u>\n\n【29】参考删除-3:<u>306. Lane TR, Kelleher D, Shepherd AC, Franklin IJ, Davies AH. Ambulatory conservative saphenous ablation for non-truncal (AVULS) a randomized clinical trial. Ann Surg 2015;261:654–61.</u>\n\n【30】参考删除-3:<u>307. Mohamed A, Leung C, Hitchman L, Wallace T, Smith G, Carradice D, et al. A prospective observational cohort study of concomitant versus sequential phlebectomy for tributary varicosities following axial mechanochemical ablation. Phlebology 2019;34:627–35.</u>\n\n【31】参考删除-3:<u>308. Blomgren L. Residual incompetent tributaries after varicose vein surgery increased the need for reintervention after 8 years. J Vasc Surg Venous Lymphat Disord 2020;8:38–42.</u>\n\n【32】参考删除-3:<u>309. Aherne TM, Ryan EJ, Boland MR, Jickett W, Hassanain A, Tabassum M, et al. Concomitant vs. staged treatment of varicose tributaries as an adjunct to endovenous ablation: a systematic review and meta-analysis. Int J Vasc Endovasc Surg 2020;6: 430–42.</u>\n\n【33】参考删除-3:<u>310. ElSheikha J, Nandhra S, Carradice D, Wallace T, Samuel N, Smith GE, et al. Clinical outcomes at 5 and quality of life 5 years after a randomized trial of concomitant or sequential phlebectomy with endovenous ablation. Eur J Vasc Endovasc Surg 2014;11:1093–7.</u>\n\n【34】311. Watanabe S, Nishio S, Tsuji T, Fujita S, Kyo E. Effect of tri-butary sclerotherapy combined with", "tags": {}, "lang": "en", "attr": {"page_num": 79, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ESVS：下肢慢性静脉疾病管理的临床实践指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:50:51", "endTime": "2024/08/06 16:51:04", "cost": 12.847}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:51:04", "grab_time": "2024-08-06 00:50:51"}
{"id": 2211501, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "ab9c988c-af6e-4ed3-844a-4cd8d26ece06", "title": "（2024.V1）NCCN临床实践指南：膀胱癌", "text": "【0】页码:31\n（2024.V1）NCCN临床实践指南：膀胱癌\n疑似页眉<u># NCCN Guidelines Version 1.2024\n# Bladder Cancer</u>\n\n【1】## BLADDER CANCER: NON-UROTHELIAL AND UROTHELIAL WITH SUBTYPE HISTOLOGY\n\n【2】删除图片描述:<u>![](30_0.png)</u>\n\n【3】### Mixed Histology:\n- Urothelial carcinoma plus squamous differentiation, adenocarcinoma differentiation, micropapillary, nested, plasmacytoid, and sarcomatoid should be identified because of the potential to have a more aggressive natural history.\n- These are usually treated in a similar manner to pure urothelial carcinoma of the bladder.\n- Micropapillary, plasmacytoid, and sarcomatoid histologies are generally at higher risk for progression to muscle invasive disease and a more aggressive approach should be considered.\n\n【4】### Pure Squamous:\n- There is no proven role for neoadjuvant/adjuvant chemotherapy for pure squamous cell carcinoma of the bladder.\n- Local control with surgery or chemoradiotherapy and best supportive care 删除9:<u>(See NCCN Guidelines for Palliative Care)</u> are recommended.\n- For advanced disease, clinical trial is preferred. For selected patients, combination chemotherapy with paclitaxel, ifosfamide, and cisplatin may be considered.\n- Consider postoperative RT in selected cases (positive margins).\n\n【5】### Pure Adenocarcinoma Including Urachal Carcinoma:\n- There is no proven role for neoadjuvant/adjuvant chemotherapy for pure adenocarcinomas of the bladder including urachal carcinoma.\n- Local control with surgery or RT and best supportive care 删除9:<u>(See NCCN Guidelines for Palliative Care)</u> are recommended.\n- For urachal carcinoma with localized disease, a partial or complete cystectomy with en bloc resection of the urachal ligament with umbilicus and lymph node dissection is recommended.\n- For node-positive disease, consider chemotherapy with colorectal regimen (FOLFOX [oxaliplatin, leucovorin, and 5-FU] or GemCis [gemcitabine and cisplatin]). Consider post-chemotherapy surgical consolidation in responding disease.\n- For advanced disease, clinical trial is preferred. For selected patients, combination chemotherapy with a 5-FU-based regimen (FOLFOX or GemCis) or ITP (paclitaxel, ifosfamide, and cisplatin) is an option. Alternatively, combination paclitaxel and platinum may be considered.\n- For non-urachal pure adenocarcinoma, consider additional metastatic workup. See NCCN Guidelines for Occult Primary.\n\n【6】### Primary Bladder Sarcoma:\n- Treatment as per NCCN Guidelines for Soft Tissue Sarcoma.\n\n【7】(Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.)", "tags": {}, "lang": "en", "attr": {"page_num": 31, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2024.V1）NCCN临床实践指南：膀胱癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【7】(Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.)", "content": "【0】页码:31\n（2024.V1）NCCN临床实践指南：膀胱癌\n疑似页眉<u># NCCN Guidelines Version 1.2024\n# Bladder Cancer</u>\n\n【1】## BLADDER CANCER: NON-UROTHELIAL AND UROTHELIAL WITH SUBTYPE HISTOLOGY\n\n【2】删除图片描述:<u>![](30_0.png)</u>\n\n【3】### Mixed Histology:\n- Urothelial carcinoma plus squamous differentiation, adenocarcinoma differentiation, micropapillary, nested, plasmacytoid, and sarcomatoid should be identified because of the potential to have a more aggressive natural history.\n- These are usually treated in a similar manner to pure urothelial carcinoma of the bladder.\n- Micropapillary, plasmacytoid, and sarcomatoid histologies are generally at higher risk for progression to muscle invasive disease and a more aggressive approach should be considered.\n\n【4】### Pure Squamous:\n- There is no proven role for neoadjuvant/adjuvant chemotherapy for pure squamous cell carcinoma of the bladder.\n- Local control with surgery or chemoradiotherapy and best supportive care 删除9:<u>(See NCCN Guidelines for Palliative Care)</u> are recommended.\n- For advanced disease, clinical trial is preferred. For selected patients, combination chemotherapy with paclitaxel, ifosfamide, and cisplatin may be considered.\n- Consider postoperative RT in selected cases (positive margins).\n\n【5】### Pure Adenocarcinoma Including Urachal Carcinoma:\n- There is no proven role for neoadjuvant/adjuvant chemotherapy for pure adenocarcinomas of the bladder including urachal carcinoma.\n- Local control with surgery or RT and best supportive care 删除9:<u>(See NCCN Guidelines for Palliative Care)</u> are recommended.\n- For urachal carcinoma with localized disease, a partial or complete cystectomy with en bloc resection of the urachal ligament with umbilicus and lymph node dissection is recommended.\n- For node-positive disease, consider chemotherapy with colorectal regimen (FOLFOX [oxaliplatin, leucovorin, and 5-FU] or GemCis [gemcitabine and cisplatin]). Consider post-chemotherapy surgical consolidation in responding disease.\n- For advanced disease, clinical trial is preferred. For selected patients, combination chemotherapy with a 5-FU-based regimen (FOLFOX or GemCis) or ITP (paclitaxel, ifosfamide, and cisplatin) is an option. Alternatively, combination paclitaxel and platinum may be considered.\n- For non-urachal pure adenocarcinoma, consider additional metastatic workup. See NCCN Guidelines for Occult Primary.\n\n【6】### Primary Bladder Sarcoma:\n- Treatment as per NCCN Guidelines for Soft Tissue Sarcoma.\n\n【7】(Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.)", "index": 2470, "show": true, "start": 2470, "end": 2710, "province": ["信息质量", "有用性-轻"], "isEdit": false}], "startTime": "2024/08/06 16:31:18", "endTime": "2024/08/06 16:32:11", "cost": 53.823}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:32:11", "grab_time": "2024-08-06 00:31:17"}
{"id": 2211500, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "f4335af6-e6a9-4cb0-8598-ed180091ea52", "title": "嗅觉相关的过敏和鼻科学的共识声明（2022）", "text": "【0】页码:104\n嗅觉相关的过敏和鼻科学的共识声明（2022）\n(本页删除)本页被模型判断为参考页### TABLE VII.F.12 (Continued)\n\n| Topic           | Study                 | Year | LOE | Study design | Study groups                     | Clinical end point                          | Conclusions                                                                                                                                   |\n|-----------------|-----------------------|------|-----|--------------|----------------------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|\n|                 | OuYang et al 765      | 2020 | 4   | Case-control | 18 MS 20 matched HCs             | fMRI to lavender and rose odorants        | MS had reductions in activation in right insula, amygdala, inferior frontal gyrus, and frontomarginal gyrus, and left supramarginal gyrus     |\n|                 | Almasi et al 766      | 2021 | 3   | Cohort       | 48 MS                            | Sniff Magnitude Test                       | 14.6% of the study group had OD (8.3% hyposmia and 6.3% anosmia). Such dysfunction was related to longer disease duration, higher hospital administration rate, lower MMSE, and disease progression. |\n| Parkinson disease | Ansari and Johnson 767 | 1975 | 4   | Case-control | 22 PD 37 sex- and age-matched HCs | Amyl acetate thresholds                    | Olfactory thresholds in PD showed a significant decrease; 9 of these had moderately or rapidly progressive disease. Significant negative correlation between rate of disease progression and olfactory test scores. |\n|                 | Ward, Hess and Calne 768 | 1983 | 4   | Case-control | 72 PD 53 HCs                      | Phenylethylmeth- carbinol and amyl acetate detection thresholds Discrimination test | 70% were impaired on all olfactory tests; 39% scored 2 standard deviations below the mean of the HCs. 17% and none of the HCs were totally anosmic. Repeated amyl acetate trials showed larger decline in PD than in HCs. |\n|                 | Serby et al 769       | 1985 | 4   | Case-control | 5 PD 11 AD 12 alcoholics with dementia 10 alcoholics without dementia 19 young HCs 16 middle-aged HCs 20 older HCs | 10-odor 2-alternative forced-choice ID test presented twice Analogous tactile test | PD and AD test scores similarly compromised relative to other groups. Only those who performed well on tactile test included to rule out dementia-related test-taking difficulties. |\n|                 | Quinn et al 770       | 1987 | 4   | Case-control | 28 PD 40 HCs                      | Amyl acetate detection threshold           | PD exhibited impaired threshold compared with HCs. No significant correlation between threshold values and age, sex, disease duration, or drug therapy. No effect of on/off dopamine therapy. |", "tags": {}, "lang": "en", "attr": {"page_num": 104, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/嗅觉相关的过敏和鼻科学的共识声明（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "(本页删除)", "content": "【0】页码:104\n嗅觉相关的过敏和鼻科学的共识声明（2022）\n(本页删除)本页被模型判断为参考页### TABLE VII.F.12 (Continued)\n\n| Topic           | Study                 | Year | LOE | Study design | Study groups                     | Clinical end point                          | Conclusions                                                                                                                                   |\n|-----------------|-----------------------|------|-----|--------------|----------------------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|\n|                 | OuYang et al 765      | 2020 | 4   | Case-control | 18 MS 20 matched HCs             | fMRI to lavender and rose odorants        | MS had reductions in activation in right insula, amygdala, inferior frontal gyrus, and frontomarginal gyrus, and left supramarginal gyrus     |\n|                 | Almasi et al 766      | 2021 | 3   | Cohort       | 48 MS                            | Sniff Magnitude Test                       | 14.6% of the study group had OD (8.3% hyposmia and 6.3% anosmia). Such dysfunction was related to longer disease duration, higher hospital administration rate, lower MMSE, and disease progression. |\n| Parkinson disease | Ansari and Johnson 767 | 1975 | 4   | Case-control | 22 PD 37 sex- and age-matched HCs | Amyl acetate thresholds                    | Olfactory thresholds in PD showed a significant decrease; 9 of these had moderately or rapidly progressive disease. Significant negative correlation between rate of disease progression and olfactory test scores. |\n|                 | Ward, Hess and Calne 768 | 1983 | 4   | Case-control | 72 PD 53 HCs                      | Phenylethylmeth- carbinol and amyl acetate detection thresholds Discrimination test | 70% were impaired on all olfactory tests; 39% scored 2 standard deviations below the mean of the HCs. 17% and none of the HCs were totally anosmic. Repeated amyl acetate trials showed larger decline in PD than in HCs. |\n|                 | Serby et al 769       | 1985 | 4   | Case-control | 5 PD 11 AD 12 alcoholics with dementia 10 alcoholics without dementia 19 young HCs 16 middle-aged HCs 20 older HCs | 10-odor 2-alternative forced-choice ID test presented twice Analogous tactile test | PD and AD test scores similarly compromised relative to other groups. Only those who performed well on tactile test included to rule out dementia-related test-taking difficulties. |\n|                 | Quinn et al 770       | 1987 | 4   | Case-control | 28 PD 40 HCs                      | Amyl acetate detection threshold           | PD exhibited impaired threshold compared with HCs. No significant correlation between threshold values and age, sex, disease duration, or drug therapy. No effect of on/off dopamine therapy. |", "index": 33, "show": true, "start": 33, "end": 39, "province": ["语义有效性", "错误删除"], "isEdit": false}, {"text": "770", "content": "【0】页码:104\n嗅觉相关的过敏和鼻科学的共识声明（2022）\n<mark>(本页删除)</mark>本页被模型判断为参考页### TABLE VII.F.12 (Continued)\n\n| Topic           | Study                 | Year | LOE | Study design | Study groups                     | Clinical end point                          | Conclusions                                                                                                                                   |\n|-----------------|-----------------------|------|-----|--------------|----------------------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|\n|                 | OuYang et al 765      | 2020 | 4   | Case-control | 18 MS 20 matched HCs             | fMRI to lavender and rose odorants        | MS had reductions in activation in right insula, amygdala, inferior frontal gyrus, and frontomarginal gyrus, and left supramarginal gyrus     |\n|                 | Almasi et al 766      | 2021 | 3   | Cohort       | 48 MS                            | Sniff Magnitude Test                       | 14.6% of the study group had OD (8.3% hyposmia and 6.3% anosmia). Such dysfunction was related to longer disease duration, higher hospital administration rate, lower MMSE, and disease progression. |\n| Parkinson disease | Ansari and Johnson 767 | 1975 | 4   | Case-control | 22 PD 37 sex- and age-matched HCs | Amyl acetate thresholds                    | Olfactory thresholds in PD showed a significant decrease; 9 of these had moderately or rapidly progressive disease. Significant negative correlation between rate of disease progression and olfactory test scores. |\n|                 | Ward, Hess and Calne 768 | 1983 | 4   | Case-control | 72 PD 53 HCs                      | Phenylethylmeth- carbinol and amyl acetate detection thresholds Discrimination test | 70% were impaired on all olfactory tests; 39% scored 2 standard deviations below the mean of the HCs. 17% and none of the HCs were totally anosmic. Repeated amyl acetate trials showed larger decline in PD than in HCs. |\n|                 | Serby et al 769       | 1985 | 4   | Case-control | 5 PD 11 AD 12 alcoholics with dementia 10 alcoholics without dementia 19 young HCs 16 middle-aged HCs 20 older HCs | 10-odor 2-alternative forced-choice ID test presented twice Analogous tactile test | PD and AD test scores similarly compromised relative to other groups. Only those who performed well on tactile test included to rule out dementia-related test-taking difficulties. |\n|                 | Quinn et al 770       | 1987 | 4   | Case-control | 28 PD 40 HCs                      | Amyl acetate detection threshold           | PD exhibited impaired threshold compared with HCs. No significant correlation between threshold values and age, sex, disease duration, or drug therapy. No effect of on/off dopamine therapy. |", "index": 2609, "show": true, "start": 2596, "end": 2599, "province": ["文本干净度", "页码/数字"], "isEdit": false}, {"text": "769", "content": "【0】页码:104\n嗅觉相关的过敏和鼻科学的共识声明（2022）\n<mark>(本页删除)</mark>本页被模型判断为参考页### TABLE VII.F.12 (Continued)\n\n| Topic           | Study                 | Year | LOE | Study design | Study groups                     | Clinical end point                          | Conclusions                                                                                                                                   |\n|-----------------|-----------------------|------|-----|--------------|----------------------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|\n|                 | OuYang et al 765      | 2020 | 4   | Case-control | 18 MS 20 matched HCs             | fMRI to lavender and rose odorants        | MS had reductions in activation in right insula, amygdala, inferior frontal gyrus, and frontomarginal gyrus, and left supramarginal gyrus     |\n|                 | Almasi et al 766      | 2021 | 3   | Cohort       | 48 MS                            | Sniff Magnitude Test                       | 14.6% of the study group had OD (8.3% hyposmia and 6.3% anosmia). Such dysfunction was related to longer disease duration, higher hospital administration rate, lower MMSE, and disease progression. |\n| Parkinson disease | Ansari and Johnson 767 | 1975 | 4   | Case-control | 22 PD 37 sex- and age-matched HCs | Amyl acetate thresholds                    | Olfactory thresholds in PD showed a significant decrease; 9 of these had moderately or rapidly progressive disease. Significant negative correlation between rate of disease progression and olfactory test scores. |\n|                 | Ward, Hess and Calne 768 | 1983 | 4   | Case-control | 72 PD 53 HCs                      | Phenylethylmeth- carbinol and amyl acetate detection thresholds Discrimination test | 70% were impaired on all olfactory tests; 39% scored 2 standard deviations below the mean of the HCs. 17% and none of the HCs were totally anosmic. Repeated amyl acetate trials showed larger decline in PD than in HCs. |\n|                 | Serby et al 769       | 1985 | 4   | Case-control | 5 PD 11 AD 12 alcoholics with dementia 10 alcoholics without dementia 19 young HCs 16 middle-aged HCs 20 older HCs | 10-odor 2-alternative forced-choice ID test presented twice Analogous tactile test | PD and AD test scores similarly compromised relative to other groups. Only those who performed well on tactile test included to rule out dementia-related test-taking difficulties. |\n|                 | Quinn et al <mark>770</mark>       | 1987 | 4   | Case-control | 28 PD 40 HCs                      | Amyl acetate detection threshold           | PD exhibited impaired threshold compared with HCs. No significant correlation between threshold values and age, sex, disease duration, or drug therapy. No effect of on/off dopamine therapy. |", "index": 2153, "show": true, "start": 2140, "end": 2143, "province": ["文本干净度", "页码/数字"], "isEdit": false}, {"text": "768", "content": "【0】页码:104\n嗅觉相关的过敏和鼻科学的共识声明（2022）\n<mark>(本页删除)</mark>本页被模型判断为参考页### TABLE VII.F.12 (Continued)\n\n| Topic           | Study                 | Year | LOE | Study design | Study groups                     | Clinical end point                          | Conclusions                                                                                                                                   |\n|-----------------|-----------------------|------|-----|--------------|----------------------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|\n|                 | OuYang et al 765      | 2020 | 4   | Case-control | 18 MS 20 matched HCs             | fMRI to lavender and rose odorants        | MS had reductions in activation in right insula, amygdala, inferior frontal gyrus, and frontomarginal gyrus, and left supramarginal gyrus     |\n|                 | Almasi et al 766      | 2021 | 3   | Cohort       | 48 MS                            | Sniff Magnitude Test                       | 14.6% of the study group had OD (8.3% hyposmia and 6.3% anosmia). Such dysfunction was related to longer disease duration, higher hospital administration rate, lower MMSE, and disease progression. |\n| Parkinson disease | Ansari and Johnson 767 | 1975 | 4   | Case-control | 22 PD 37 sex- and age-matched HCs | Amyl acetate thresholds                    | Olfactory thresholds in PD showed a significant decrease; 9 of these had moderately or rapidly progressive disease. Significant negative correlation between rate of disease progression and olfactory test scores. |\n|                 | Ward, Hess and Calne 768 | 1983 | 4   | Case-control | 72 PD 53 HCs                      | Phenylethylmeth- carbinol and amyl acetate detection thresholds Discrimination test | 70% were impaired on all olfactory tests; 39% scored 2 standard deviations below the mean of the HCs. 17% and none of the HCs were totally anosmic. Repeated amyl acetate trials showed larger decline in PD than in HCs. |\n|                 | Serby et al <mark>769</mark>       | 1985 | 4   | Case-control | 5 PD 11 AD 12 alcoholics with dementia 10 alcoholics without dementia 19 young HCs 16 middle-aged HCs 20 older HCs | 10-odor 2-alternative forced-choice ID test presented twice Analogous tactile test | PD and AD test scores similarly compromised relative to other groups. Only those who performed well on tactile test included to rule out dementia-related test-taking difficulties. |\n|                 | Quinn et al <mark>770</mark>       | 1987 | 4   | Case-control | 28 PD 40 HCs                      | Amyl acetate detection threshold           | PD exhibited impaired threshold compared with HCs. No significant correlation between threshold values and age, sex, disease duration, or drug therapy. No effect of on/off dopamine therapy. |", "index": 1745, "show": true, "start": 1732, "end": 1735, "province": ["文本干净度", "页码/数字"], "isEdit": false}, {"text": "767", "content": "【0】页码:104\n嗅觉相关的过敏和鼻科学的共识声明（2022）\n<mark>(本页删除)</mark>本页被模型判断为参考页### TABLE VII.F.12 (Continued)\n\n| Topic           | Study                 | Year | LOE | Study design | Study groups                     | Clinical end point                          | Conclusions                                                                                                                                   |\n|-----------------|-----------------------|------|-----|--------------|----------------------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|\n|                 | OuYang et al 765      | 2020 | 4   | Case-control | 18 MS 20 matched HCs             | fMRI to lavender and rose odorants        | MS had reductions in activation in right insula, amygdala, inferior frontal gyrus, and frontomarginal gyrus, and left supramarginal gyrus     |\n|                 | Almasi et al 766      | 2021 | 3   | Cohort       | 48 MS                            | Sniff Magnitude Test                       | 14.6% of the study group had OD (8.3% hyposmia and 6.3% anosmia). Such dysfunction was related to longer disease duration, higher hospital administration rate, lower MMSE, and disease progression. |\n| Parkinson disease | Ansari and Johnson 767 | 1975 | 4   | Case-control | 22 PD 37 sex- and age-matched HCs | Amyl acetate thresholds                    | Olfactory thresholds in PD showed a significant decrease; 9 of these had moderately or rapidly progressive disease. Significant negative correlation between rate of disease progression and olfactory test scores. |\n|                 | Ward, Hess and Calne <mark>768</mark> | 1983 | 4   | Case-control | 72 PD 53 HCs                      | Phenylethylmeth- carbinol and amyl acetate detection thresholds Discrimination test | 70% were impaired on all olfactory tests; 39% scored 2 standard deviations below the mean of the HCs. 17% and none of the HCs were totally anosmic. Repeated amyl acetate trials showed larger decline in PD than in HCs. |\n|                 | Serby et al <mark>769</mark>       | 1985 | 4   | Case-control | 5 PD 11 AD 12 alcoholics with dementia 10 alcoholics without dementia 19 young HCs 16 middle-aged HCs 20 older HCs | 10-odor 2-alternative forced-choice ID test presented twice Analogous tactile test | PD and AD test scores similarly compromised relative to other groups. Only those who performed well on tactile test included to rule out dementia-related test-taking difficulties. |\n|                 | Quinn et al <mark>770</mark>       | 1987 | 4   | Case-control | 28 PD 40 HCs                      | Amyl acetate detection threshold           | PD exhibited impaired threshold compared with HCs. No significant correlation between threshold values and age, sex, disease duration, or drug therapy. No effect of on/off dopamine therapy. |", "index": 1375, "show": true, "start": 1362, "end": 1365, "province": ["文本干净度", "页码/数字"], "isEdit": false}, {"text": "766", "content": "【0】页码:104\n嗅觉相关的过敏和鼻科学的共识声明（2022）\n<mark>(本页删除)</mark>本页被模型判断为参考页### TABLE VII.F.12 (Continued)\n\n| Topic           | Study                 | Year | LOE | Study design | Study groups                     | Clinical end point                          | Conclusions                                                                                                                                   |\n|-----------------|-----------------------|------|-----|--------------|----------------------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|\n|                 | OuYang et al 765      | 2020 | 4   | Case-control | 18 MS 20 matched HCs             | fMRI to lavender and rose odorants        | MS had reductions in activation in right insula, amygdala, inferior frontal gyrus, and frontomarginal gyrus, and left supramarginal gyrus     |\n|                 | Almasi et al 766      | 2021 | 3   | Cohort       | 48 MS                            | Sniff Magnitude Test                       | 14.6% of the study group had OD (8.3% hyposmia and 6.3% anosmia). Such dysfunction was related to longer disease duration, higher hospital administration rate, lower MMSE, and disease progression. |\n| Parkinson disease | Ansari and Johnson <mark>767</mark> | 1975 | 4   | Case-control | 22 PD 37 sex- and age-matched HCs | Amyl acetate thresholds                    | Olfactory thresholds in PD showed a significant decrease; 9 of these had moderately or rapidly progressive disease. Significant negative correlation between rate of disease progression and olfactory test scores. |\n|                 | Ward, Hess and Calne <mark>768</mark> | 1983 | 4   | Case-control | 72 PD 53 HCs                      | Phenylethylmeth- carbinol and amyl acetate detection thresholds Discrimination test | 70% were impaired on all olfactory tests; 39% scored 2 standard deviations below the mean of the HCs. 17% and none of the HCs were totally anosmic. Repeated amyl acetate trials showed larger decline in PD than in HCs. |\n|                 | Serby et al <mark>769</mark>       | 1985 | 4   | Case-control | 5 PD 11 AD 12 alcoholics with dementia 10 alcoholics without dementia 19 young HCs 16 middle-aged HCs 20 older HCs | 10-odor 2-alternative forced-choice ID test presented twice Analogous tactile test | PD and AD test scores similarly compromised relative to other groups. Only those who performed well on tactile test included to rule out dementia-related test-taking difficulties. |\n|                 | Quinn et al <mark>770</mark>       | 1987 | 4   | Case-control | 28 PD 40 HCs                      | Amyl acetate detection threshold           | PD exhibited impaired threshold compared with HCs. No significant correlation between threshold values and age, sex, disease duration, or drug therapy. No effect of on/off dopamine therapy. |", "index": 1016, "show": true, "start": 1003, "end": 1006, "province": ["文本干净度", "页码/数字"], "isEdit": false}, {"text": "765", "content": "【0】页码:104\n嗅觉相关的过敏和鼻科学的共识声明（2022）\n<mark>(本页删除)</mark>本页被模型判断为参考页### TABLE VII.F.12 (Continued)\n\n| Topic           | Study                 | Year | LOE | Study design | Study groups                     | Clinical end point                          | Conclusions                                                                                                                                   |\n|-----------------|-----------------------|------|-----|--------------|----------------------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|\n|                 | OuYang et al 765      | 2020 | 4   | Case-control | 18 MS 20 matched HCs             | fMRI to lavender and rose odorants        | MS had reductions in activation in right insula, amygdala, inferior frontal gyrus, and frontomarginal gyrus, and left supramarginal gyrus     |\n|                 | Almasi et al <mark>766</mark>      | 2021 | 3   | Cohort       | 48 MS                            | Sniff Magnitude Test                       | 14.6% of the study group had OD (8.3% hyposmia and 6.3% anosmia). Such dysfunction was related to longer disease duration, higher hospital administration rate, lower MMSE, and disease progression. |\n| Parkinson disease | Ansari and Johnson <mark>767</mark> | 1975 | 4   | Case-control | 22 PD 37 sex- and age-matched HCs | Amyl acetate thresholds                    | Olfactory thresholds in PD showed a significant decrease; 9 of these had moderately or rapidly progressive disease. Significant negative correlation between rate of disease progression and olfactory test scores. |\n|                 | Ward, Hess and Calne <mark>768</mark> | 1983 | 4   | Case-control | 72 PD 53 HCs                      | Phenylethylmeth- carbinol and amyl acetate detection thresholds Discrimination test | 70% were impaired on all olfactory tests; 39% scored 2 standard deviations below the mean of the HCs. 17% and none of the HCs were totally anosmic. Repeated amyl acetate trials showed larger decline in PD than in HCs. |\n|                 | Serby et al <mark>769</mark>       | 1985 | 4   | Case-control | 5 PD 11 AD 12 alcoholics with dementia 10 alcoholics without dementia 19 young HCs 16 middle-aged HCs 20 older HCs | 10-odor 2-alternative forced-choice ID test presented twice Analogous tactile test | PD and AD test scores similarly compromised relative to other groups. Only those who performed well on tactile test included to rule out dementia-related test-taking difficulties. |\n|                 | Quinn et al <mark>770</mark>       | 1987 | 4   | Case-control | 28 PD 40 HCs                      | Amyl acetate detection threshold           | PD exhibited impaired threshold compared with HCs. No significant correlation between threshold values and age, sex, disease duration, or drug therapy. No effect of on/off dopamine therapy. |", "index": 721, "show": true, "start": 708, "end": 711, "province": ["文本干净度", "页码/数字"], "isEdit": false}], "startTime": "2024/08/07 09:56:23", "endTime": "2024/08/07 09:58:19", "cost": 116.295}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 17:58:18", "grab_time": "2024-08-06 17:56:22"}
{"id": 2211499, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "95965acf-85c4-4cf6-83f2-0bfdf2a02ed4", "title": "2023更新—2015 NICE指南：糖尿病足问题的预防和管理（NG.19）", "text": "【0】页码:47\n2023更新—2015 NICE指南：糖尿病足问题的预防和管理（NG.19）\n(本页删除)本页被模型判断为目录页# Accreditation\n删除图片描述:<u>![](46_0.png)</u>", "tags": {}, "lang": "en", "attr": {"page_num": 47, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023更新—2015 NICE指南：糖尿病足问题的预防和管理（NG.19）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:06:02", "endTime": "2024/08/06 16:06:09", "cost": 7.395}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:06:10", "grab_time": "2024-08-06 00:06:02"}
{"id": 2211498, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "f2085982-66a1-420c-9274-96000d650b7b", "title": "口腔颌面外科围手术期血糖管理专家共识（2022）", "text": "【0】页码:3\n口腔颌面外科围手术期血糖管理专家共识（2022）\n实用口腔医学杂志 (J Pract Stomatol) 2022 Jan 38删除11:<u>(1)</u>\n\n【1】表1 血糖检测方法比较\n\n| 指标         | 便携式血糖仪/指尖血糖自测 | 实验室血糖仪/静脉血糖检测 |\n|--------------|----------------------------|-----------------------------|\n| 优点         | 快速方便操作简单，病人可自测 | 准确度高，批间差异小       |\n| 缺点         | 不适合高血糖和低血糖危重症患者 | 不能连续监测，需血样量大，不便 |\n| 适应症       | 糖尿病病人短期、居家和门诊血糖监测 | 住院病人血糖监测           |\n\n【3】表2 围手术期糖化血红蛋白 (HbA1c) 临床的应用\n\n|              | 既往无糖尿病病史                            | 既往有糖尿病病史                               |\n|--------------|-------------------------------------------|----------------------------------------------|\n| HbA1c ≤ 6.5% | 糖尿病的可能性很小，围手术期血糖控制目标：血糖 ≤ 10.0 mmol/L，因手术和糖皮质激素应用有高血糖风险 | 建议：注意术后高血糖的监测和管理                      |\n| HbA1c 6.5% - 7% | 诊断为糖尿病，近期糖血管前评估干预需优化 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c 7% - 7.5% | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c > 8.5% | 建议：注意术后高血糖的监测和管理                      | 建议：注意术后高血糖的监测和管理                      |\n\n【5】推荐意见: 除血糖外，糖化血红蛋白 (HbA1c) 水平高低也是评估高血糖状态下手术风险指标之一。建议术前根据评估结论合理确定血红蛋白 (HbA1c)、电解质、尿酸水平。怀疑存在高血糖个体需进一步常规进行血酮或尿酮检测。\n\n【6】3 低血糖及管理\n\n【7】3.1 低血糖的临床表现\n3.1.1 交感神经兴奋：心悸、出汗、饥饿感、震颤乏力。\n3.1.2 中枢神经症状：表现淡漠、嗜睡、反应迟钝、抽搐等昏迷。\n\n【8】3.2 隐匿性低血糖表现：针对老年患者，低血糖症状往往不典型。公认有异常认知障碍为临床表现者，反复低血糖发作，可能出现无明显的低血糖症。\n\n【9】表3 低血糖分级\n\n| 级别     | 血糖值 (mmol/L)              |\n|----------|------------------------------|\n| 1 级     | 3.0 ≤ 血糖值 < 3.9           |\n| 2 级     | 血糖值 < 3.0                 |\n| 3 级     | 严重认知功能障碍中枢系统症状 需要他人援助 |\n\n【11】删除图片描述:<u>图1 低血糖诊治流程</u>\n\n【12】3.3 低血糖的诊断\n参照《中文2型糖尿病防治指南》删除19:<u>(2020 年版)</u> 对低血糖的诊断 (表 3)：无糖尿病病史的患者，血糖 < 2.8 mmol/L 是低血糖。而有糖尿病史的患者血糖 < 3.9 mmol/L 视为严重低血糖。\n\n【13】3.4 处理流程 删除9:<u>(图 1)</u>\n\n【14】4 围手术期血糖管理\n4.1 术前血糖管理", "tags": {}, "lang": "zh", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/口腔颌面外科围手术期血糖管理专家共识（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【1】表1 血糖检测方法比较", "content": "【0】页码:3\n口腔颌面外科围手术期血糖管理专家共识（2022）\n实用口腔医学杂志 (J Pract Stomatol) 2022 Jan 38删除11:<u>(1)</u>\n\n【1】表1 血糖检测方法比较\n\n| 指标         | 便携式血糖仪/指尖血糖自测 | 实验室血糖仪/静脉血糖检测 |\n|--------------|----------------------------|-----------------------------|\n| 优点         | 快速方便操作简单，病人可自测 | 准确度高，批间差异小       |\n| 缺点         | 不适合高血糖和低血糖危重症患者 | 不能连续监测，需血样量大，不便 |\n| 适应症       | 糖尿病病人短期、居家和门诊血糖监测 | 住院病人血糖监测           |\n\n【3】表2 围手术期糖化血红蛋白 (HbA1c) 临床的应用\n\n|              | 既往无糖尿病病史                            | 既往有糖尿病病史                               |\n|--------------|-------------------------------------------|----------------------------------------------|\n| HbA1c ≤ 6.5% | 糖尿病的可能性很小，围手术期血糖控制目标：血糖 ≤ 10.0 mmol/L，因手术和糖皮质激素应用有高血糖风险 | 建议：注意术后高血糖的监测和管理                      |\n| HbA1c 6.5% - 7% | 诊断为糖尿病，近期糖血管前评估干预需优化 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c 7% - 7.5% | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c > 8.5% | 建议：注意术后高血糖的监测和管理                      | 建议：注意术后高血糖的监测和管理                      |\n\n【5】推荐意见: 除血糖外，糖化血红蛋白 (HbA1c) 水平高低也是评估高血糖状态下手术风险指标之一。建议术前根据评估结论合理确定血红蛋白 (HbA1c)、电解质、尿酸水平。怀疑存在高血糖个体需进一步常规进行血酮或尿酮检测。\n\n【6】3 低血糖及管理\n\n【7】3.1 低血糖的临床表现\n3.1.1 交感神经兴奋：心悸、出汗、饥饿感、震颤乏力。\n3.1.2 中枢神经症状：表现淡漠、嗜睡、反应迟钝、抽搐等昏迷。\n\n【8】3.2 隐匿性低血糖表现：针对老年患者，低血糖症状往往不典型。公认有异常认知障碍为临床表现者，反复低血糖发作，可能出现无明显的低血糖症。\n\n【9】表3 低血糖分级\n\n| 级别     | 血糖值 (mmol/L)              |\n|----------|------------------------------|\n| 1 级     | 3.0 ≤ 血糖值 < 3.9           |\n| 2 级     | 血糖值 < 3.0                 |\n| 3 级     | 严重认知功能障碍中枢系统症状 需要他人援助 |\n\n【11】删除图片描述:<u>图1 低血糖诊治流程</u>\n\n【12】3.3 低血糖的诊断\n参照《中文2型糖尿病防治指南》删除19:<u>(2020 年版)</u> 对低血糖的诊断 (表 3)：无糖尿病病史的患者，血糖 < 2.8 mmol/L 是低血糖。而有糖尿病史的患者血糖 < 3.9 mmol/L 视为严重低血糖。\n\n【13】3.4 处理流程 删除9:<u>(图 1)</u>\n\n【14】4 围手术期血糖管理\n4.1 术前血糖管理", "index": 89, "show": true, "start": 89, "end": 103, "province": ["格式规范性", "表格格式错误"], "isEdit": false}, {"text": "【7】3.1 低血糖的临床表现", "content": "【0】页码:3\n口腔颌面外科围手术期血糖管理专家共识（2022）\n实用口腔医学杂志 (J Pract Stomatol) 2022 Jan 38删除11:<u>(1)</u>\n\n<mark>【1】表1 血糖检测方法比较</mark>\n\n| 指标         | 便携式血糖仪/指尖血糖自测 | 实验室血糖仪/静脉血糖检测 |\n|--------------|----------------------------|-----------------------------|\n| 优点         | 快速方便操作简单，病人可自测 | 准确度高，批间差异小       |\n| 缺点         | 不适合高血糖和低血糖危重症患者 | 不能连续监测，需血样量大，不便 |\n| 适应症       | 糖尿病病人短期、居家和门诊血糖监测 | 住院病人血糖监测           |\n\n<mark>【3】表2 围手术期糖化血红蛋白 (HbA1c) 临床的应用</mark>\n\n|              | 既往无糖尿病病史                            | 既往有糖尿病病史                               |\n|--------------|-------------------------------------------|----------------------------------------------|\n| HbA1c ≤ 6.5% | 糖尿病的可能性很小，围手术期血糖控制目标：血糖 ≤ 10.0 mmol/L，因手术和糖皮质激素应用有高血糖风险 | 建议：注意术后高血糖的监测和管理                      |\n| HbA1c 6.5% - 7% | 诊断为糖尿病，近期糖血管前评估干预需优化 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c 7% - 7.5% | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c > 8.5% | 建议：注意术后高血糖的监测和管理                      | 建议：注意术后高血糖的监测和管理                      |\n\n【5】推荐意见: 除血糖外，糖化血红蛋白 (HbA1c) 水平高低也是评估高血糖状态下手术风险指标之一。建议术前根据评估结论合理确定血红蛋白 (HbA1c)、电解质、尿酸水平。怀疑存在高血糖个体需进一步常规进行血酮或尿酮检测。\n\n【6】3 低血糖及管理\n\n【7】3.1 低血糖的临床表现\n3.1.1 交感神经兴奋：心悸、出汗、饥饿感、震颤乏力。\n3.1.2 中枢神经症状：表现淡漠、嗜睡、反应迟钝、抽搐等昏迷。\n\n【8】3.2 隐匿性低血糖表现：针对老年患者，低血糖症状往往不典型。公认有异常认知障碍为临床表现者，反复低血糖发作，可能出现无明显的低血糖症。\n\n【9】表3 低血糖分级\n\n| 级别     | 血糖值 (mmol/L)              |\n|----------|------------------------------|\n| 1 级     | 3.0 ≤ 血糖值 < 3.9           |\n| 2 级     | 血糖值 < 3.0                 |\n| 3 级     | 严重认知功能障碍中枢系统症状 需要他人援助 |\n\n【11】删除图片描述:<u>图1 低血糖诊治流程</u>\n\n【12】3.3 低血糖的诊断\n参照《中文2型糖尿病防治指南》删除19:<u>(2020 年版)</u> 对低血糖的诊断 (表 3)：无糖尿病病史的患者，血糖 < 2.8 mmol/L 是低血糖。而有糖尿病史的患者血糖 < 3.9 mmol/L 视为严重低血糖。\n\n【13】3.4 处理流程 删除9:<u>(图 1)</u>\n\n【14】4 围手术期血糖管理\n4.1 术前血糖管理", "index": 1181, "show": true, "start": 1155, "end": 1170, "province": ["信息质量", "完整性"], "isEdit": false}, {"text": "表2 围手术期糖化血红蛋白 (HbA1c) 临床的应用", "content": "【0】页码:3\n口腔颌面外科围手术期血糖管理专家共识（2022）\n实用口腔医学杂志 (J Pract Stomatol) 2022 Jan 38删除11:<u>(1)</u>\n\n<mark>【1】表1 血糖检测方法比较</mark>\n\n| 指标         | 便携式血糖仪/指尖血糖自测 | 实验室血糖仪/静脉血糖检测 |\n|--------------|----------------------------|-----------------------------|\n| 优点         | 快速方便操作简单，病人可自测 | 准确度高，批间差异小       |\n| 缺点         | 不适合高血糖和低血糖危重症患者 | 不能连续监测，需血样量大，不便 |\n| 适应症       | 糖尿病病人短期、居家和门诊血糖监测 | 住院病人血糖监测           |\n\n【3】表2 围手术期糖化血红蛋白 (HbA1c) 临床的应用\n\n|              | 既往无糖尿病病史                            | 既往有糖尿病病史                               |\n|--------------|-------------------------------------------|----------------------------------------------|\n| HbA1c ≤ 6.5% | 糖尿病的可能性很小，围手术期血糖控制目标：血糖 ≤ 10.0 mmol/L，因手术和糖皮质激素应用有高血糖风险 | 建议：注意术后高血糖的监测和管理                      |\n| HbA1c 6.5% - 7% | 诊断为糖尿病，近期糖血管前评估干预需优化 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c 7% - 7.5% | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c > 8.5% | 建议：注意术后高血糖的监测和管理                      | 建议：注意术后高血糖的监测和管理                      |\n\n【5】推荐意见: 除血糖外，糖化血红蛋白 (HbA1c) 水平高低也是评估高血糖状态下手术风险指标之一。建议术前根据评估结论合理确定血红蛋白 (HbA1c)、电解质、尿酸水平。怀疑存在高血糖个体需进一步常规进行血酮或尿酮检测。\n\n【6】3 低血糖及管理\n\n【7】3.1 低血糖的临床<mark>【7】3.1 低血糖的临床表现</mark>：心悸、出汗、饥饿感、震颤乏力。\n3.1.2 中枢神经症状：表现淡漠、嗜睡、反应迟钝、抽搐等昏迷。\n\n【8】3.2 隐匿性低血糖表现：针对老年患者，低血糖症状往往不典型。公认有异常认知障碍为临床表现者，反复低血糖发作，可能出现无明显的低血糖症。\n\n【9】表3 低血糖分级\n\n| 级别     | 血糖值 (mmol/L)              |\n|----------|------------------------------|\n| 1 级     | 3.0 ≤ 血糖值 < 3.9           |\n| 2 级     | 血糖值 < 3.0                 |\n| 3 级     | 严重认知功能障碍中枢系统症状 需要他人援助 |\n\n【11】删除图片描述:<u>图1 低血糖诊治流程</u>\n\n【12】3.3 低血糖的诊断\n参照《中文2型糖尿病防治指南》删除19:<u>(2020 年版)</u> 对低血糖的诊断 (表 3)：无糖尿病病史的患者，血糖 < 2.8 mmol/L 是低血糖。而有糖尿病史的患者血糖 < 3.9 mmol/L 视为严重低血糖。\n\n【13】3.4 处理流程 删除9:<u>(图 1)</u>\n\n【14】4 围手术期血糖管理\n4.1 术前血糖管理", "index": 402, "show": true, "start": 389, "end": 416, "province": ["格式规范性", "表格格式错误"], "isEdit": false, "comment": "【3】"}, {"text": "【3】", "content": "【0】页码:3\n口腔颌面外科围手术期血糖管理专家共识（2022）\n实用口腔医学杂志 (J Pract Stomatol) 2022 Jan 38删除11:<u>(1)</u>\n\n<mark>【1】表1 血糖检测方法比较</mark>\n\n| 指标         | 便携式血糖仪/指尖血糖自测 | 实验室血糖仪/静脉血糖检测 |\n|--------------|----------------------------|-----------------------------|\n| 优点         | 快速方便操作简单，病人可自测 | 准确度高，批间差异小       |\n| 缺点         | 不适合高血糖和低血糖危重症患者 | 不能连续监测，需血样量大，不便 |\n| 适应症       | 糖尿病病人短期、居家和门诊血糖监测 | 住院病人血糖监测           |\n\n【3】<mark>表2 围手术期糖化血红蛋白 (HbA1c) 临床的应用</mark>\n\n|              | 既往无糖尿病病史                            | 既往有糖尿病病史                               |\n|--------------|-------------------------------------------|----------------------------------------------|\n| HbA1c ≤ 6.5% | 糖尿病的可能性很小，围手术期血糖控制目标：血糖 ≤ 10.0 mmol/L，因手术和糖皮质激素应用有高血糖风险 | 建议：注意术后高血糖的监测和管理                      |\n| HbA1c 6.5% - 7% | 诊断为糖尿病，近期糖血管前评估干预需优化 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c 7% - 7.5% | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c > 8.5% | 建议：注意术后高血糖的监测和管理                      | 建议：注意术后高血糖的监测和管理                      |\n\n【5】推荐意见: 除血糖外，糖化血红蛋白 (HbA1c) 水平高低也是评估高血糖状态下手术风险指标之一。建议术前根据评估结论合理确定血红蛋白 (HbA1c)、电解质、尿酸水平。怀疑存在高血糖个体需进一步常规进行血酮或尿酮检测。\n\n【6】3 低血糖及管理\n\n【7】3.1 低血糖的临床<mark>【7】3.1 低血糖的临床表现</mark>：心悸、出汗、饥饿感、震颤乏力。\n3.1.2 中枢神经症状：表现淡漠、嗜睡、反应迟钝、抽搐等昏迷。\n\n【8】3.2 隐匿性低血糖表现：针对老年患者，低血糖症状往往不典型。公认有异常认知障碍为临床表现者，反复低血糖发作，可能出现无明显的低血糖症。\n\n【9】表3 低血糖分级\n\n| 级别     | 血糖值 (mmol/L)              |\n|----------|------------------------------|\n| 1 级     | 3.0 ≤ 血糖值 < 3.9           |\n| 2 级     | 血糖值 < 3.0                 |\n| 3 级     | 严重认知功能障碍中枢系统症状 需要他人援助 |\n\n【11】删除图片描述:<u>图1 低血糖诊治流程</u>\n\n【12】3.3 低血糖的诊断\n参照《中文2型糖尿病防治指南》删除19:<u>(2020 年版)</u> 对低血糖的诊断 (表 3)：无糖尿病病史的患者，血糖 < 2.8 mmol/L 是低血糖。而有糖尿病史的患者血糖 < 3.9 mmol/L 视为严重低血糖。\n\n【13】3.4 处理流程 删除9:<u>(图 1)</u>\n\n【14】4 围手术期血糖管理\n4.1 术前血糖管理", "index": 399, "show": true, "start": 386, "end": 389, "province": ["信息质量", "完整性"], "isEdit": false}, {"text": "【9】表3 低血糖分级\n\n级别\t血糖值 (mmol/L)\n1 级\t3.0 ≤ 血糖值 < 3.9\n2 级\t血糖值 < 3.0\n3 级\t严重认知功能障碍中枢系统症状 需要他人援助\n【11】删除图片描述:图1 低血糖诊治流程\n\n【12】3.3 低血糖的诊断\n\n参照《中文2型糖尿病防治指南》删除19:(2020 年版) 对低血糖的诊断 (表 3)：无糖尿病病史的患者，血糖 < 2.8 mmol/L 是低血糖。而有糖尿病史的患者血糖 < 3.9 mmol/L 视为严重低血糖。\n\n【13】3.4 处理流程 删除9:(图 1)\n\n【14】4 围手术期血糖管理\n\n4.1 术前血糖管理", "content": "【0】页码:3\n口腔颌面外科围手术期血糖管理专家共识（2022）\n实用口腔医学杂志 (J Pract Stomatol) 2022 Jan 38删除11:<u>(1)</u>\n\n<mark>【1】表1 血糖检测方法比较</mark>\n\n| 指标         | 便携式血糖仪/指尖血糖自测 | 实验室血糖仪/静脉血糖检测 |\n|--------------|----------------------------|-----------------------------|\n| 优点         | 快速方便操作简单，病人可自测 | 准确度高，批间差异小       |\n| 缺点         | 不适合高血糖和低血糖危重症患者 | 不能连续监测，需血样量大，不便 |\n| 适应症       | 糖尿病病人短期、居家和门诊血糖监测 | 住院病人血糖监测           |\n\n<mark>【3】</mark><mark>表2 围手术期糖化血红蛋白 (HbA1c) 临床的应用</mark>\n\n|              | 既往无糖尿病病史                            | 既往有糖尿病病史                               |\n|--------------|-------------------------------------------|----------------------------------------------|\n| HbA1c ≤ 6.5% | 糖尿病的可能性很小，围手术期血糖控制目标：血糖 ≤ 10.0 mmol/L，因手术和糖皮质激素应用有高血糖风险 | 建议：注意术后高血糖的监测和管理                      |\n| HbA1c 6.5% - 7% | 诊断为糖尿病，近期糖血管前评估干预需优化 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c 7% - 7.5% | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 | 血糖控制目标：血糖 ≤ 10.0 mmol/L，必要时使用降糖药物，防止血糖波动 |\n| HbA1c > 8.5% | 建议：注意术后高血糖的监测和管理                      | 建议：注意术后高血糖的监测和管理                      |\n\n【5】推荐意见: 除血糖外，糖化血红蛋白 (HbA1c) 水平高低也是评估高血糖状态下手术风险指标之一。建议术前根据评估结论合理确定血红蛋白 (HbA1c)、电解质、尿酸水平。怀疑存在高血糖个体需进一步常规进行血酮或尿酮检测。\n\n【6】3 低血糖及管理\n\n【7】3.1 低血糖的临床<mark>【7】3.1 低血糖的临床表现</mark>：心悸、出汗、饥饿感、震颤乏力。\n3.1.2 中枢神经症状：表现淡漠、嗜睡、反应迟钝、抽搐等昏迷。\n\n【8】3.2 隐匿性低血糖表现：针对老年患者，低血糖症状往往不典型。公认有异常认知障碍为临床表现者，反复低血糖发作，可能出现无明显的低血糖症。\n\n【9】表3 低血糖分级\n\n| 级别     | 血糖值 (mmol/L)              |\n|----------|------------------------------|\n| 1 级     | 3.0 ≤ 血糖值 < 3.9           |\n| 2 级     | 血糖值 < 3.0                 |\n| 3 级     | 严重认知功能障碍中枢系统症状 需要他人援助 |\n\n【11】删除图片描述:<u>图1 低血糖诊治流程</u>\n\n【12】3.3 低血糖的诊断\n参照《中文2型糖尿病防治指南》删除19:<u>(2020 年版)</u> 对低血糖的诊断 (表 3)：无糖尿病病史的患者，血糖 < 2.8 mmol/L 是低血糖。而有糖尿病史的患者血糖 < 3.9 mmol/L 视为严重低血糖。\n\n【13】3.4 处理流程 删除9:<u>(图 1)</u>\n\n【14】4 围手术期血糖管理\n4.1 术前血糖管理", "index": 1359, "show": true, "start": 1307, "end": 1595, "province": ["语义有效性", "栏目混乱-中"], "isEdit": false}], "startTime": "2024/08/07 10:00:04", "endTime": "2024/08/07 10:03:39", "cost": 214.452}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 18:03:39", "grab_time": "2024-08-06 18:00:03"}
{"id": 2211497, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "1d65f8e3-b348-41e4-b19d-c2997bdb1274", "title": "IDSA：抗菌药物耐药性革兰氏阴性菌感染的治疗指南第2版（2022）", "text": "【0】页码:29\nIDSA：抗菌药物耐药性革兰氏阴性菌感染的治疗指南第2版（2022）\n### Carbapenem-Resistant 删除32:<u>*</u>Acinetobacter baumannii删除32:<u>*</u>\n\n【1】参考删除-3:<u>Carbapenem-resistant 删除32:<u>*</u>Acinetobacter baumannii删除32:<u>*</u> (CRAB) infections pose significant challenges in healthcare settings 删除12:<u>删除14:<u>[6, 8]</u></u>. In this guidance document, for simplicity, we will use the term \"CRAB\" although we recognize that a laboratory may not be able to accurately separate carbapenem-resistant 删除32:<u>*</u>A. baumannii删除32:<u>*</u> from other species within the 删除32:<u>*</u>baumannii删除32:<u>*</u> and 删除32:<u>*</u>calcoaceticus删除32:<u>*</u> complexes 删除12:<u>删除14:<u>[84]</u></u>.</u>\n\n【2】The management of CRAB infections is difficult for several reasons. Firstly, CRAB is most commonly recovered from respiratory specimens or wounds. Therefore, it is not always clear if an isolate is a colonizing organism in patients who are ill for reasons attributable to their underlying host status (e.g., patients requiring mechanical ventilation, patients with extensive burns), or if CRAB represents a true pathogen capable of contributing to excess mortality, leading to uncertainty about the need for antibiotic therapy. For the same reason, it is challenging to determine if poor clinical outcomes are attributable to suboptimal antibiotic therapy or to underlying host factors.\n\n【3】Secondly, once 删除32:<u>*</u>A. baumannii删除32:<u>*</u> exhibits carbapenem resistance, it generally has acquired resistance to most other antibiotics expected to be active against wild-type 删除32:<u>*</u>A. baumannii删除32:<u>*</u> leaving few remaining therapeutic options. The production of carbapenemases such as OXA-24/40-like carbapenemases and OXA-23-like carbapenemases mediates resistance to carbapenems 删除12:<u>[删除13:<u>84, 85</u>]</u>. CRAB isolates may also produce metallo-β-lactamases and additional serine carbapenemases, further limiting the utility of carbapenem agents. Sulbactam resistance is not completely understood but appears to be driven primarily via mutations targeting penicillin-binding proteins (PBPs); β-lactamase production may also contribute 删除12:<u>删除14:<u>[86-88]</u></u>. Aminoglycoside modifying enzymes or 16S rRNA methyltransferases generally preclude aminoglycosides as treatment options for CRAB, including plazomicin 删除12:<u>删除14:<u>[89-91]</u></u>. Mutations in the chromosomally-encoded quinolone resistance determining regions upregulate efflux pumps and generally mediate resistance to fluoroquinolones 删除12:<u>删除14:<u>[90]</u></u>.\n\n【4】Finally, there is no clear “standard of care” antibiotic regimen for CRAB infections against which to estimate the effectiveness of various treatment regimens. Robust comparative", "tags": {}, "lang": "en", "attr": {"page_num": 29, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/IDSA：抗菌药物耐药性革兰氏阴性菌感染的治疗指南第2版（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Carbapenem-resistant 删除32:Acinetobacter baumannii删除32: (CRAB) infections pose significant challenges in healthcare settings 删除12:删除14:[6, 8]. In this guidance document, for simplicity, we will use the term “CRAB” although we recognize that a laboratory may not be able to accurately separate carbapenem-resistant 删除32:A. baumannii删除32: from other species within the 删除32:baumannii删除32: and 删除32:calcoaceticus删除32: complexes ", "content": "【0】页码:29\nIDSA：抗菌药物耐药性革兰氏阴性菌感染的治疗指南第2版（2022）\n### Carbapenem-Resistant 删除32:<u>*</u>Acinetobacter baumannii删除32:<u>*</u>\n\n【1】参考删除-3:<u>Carbapenem-resistant 删除32:<u>*</u>Acinetobacter baumannii删除32:<u>*</u> (CRAB) infections pose significant challenges in healthcare settings 删除12:<u>删除14:<u>[6, 8]</u></u>. In this guidance document, for simplicity, we will use the term \"CRAB\" although we recognize that a laboratory may not be able to accurately separate carbapenem-resistant 删除32:<u>*</u>A. baumannii删除32:<u>*</u> from other species within the 删除32:<u>*</u>baumannii删除32:<u>*</u> and 删除32:<u>*</u>calcoaceticus删除32:<u>*</u> complexes 删除12:<u>删除14:<u>[84]</u></u>.</u>\n\n【2】The management of CRAB infections is difficult for several reasons. Firstly, CRAB is most commonly recovered from respiratory specimens or wounds. Therefore, it is not always clear if an isolate is a colonizing organism in patients who are ill for reasons attributable to their underlying host status (e.g., patients requiring mechanical ventilation, patients with extensive burns), or if CRAB represents a true pathogen capable of contributing to excess mortality, leading to uncertainty about the need for antibiotic therapy. For the same reason, it is challenging to determine if poor clinical outcomes are attributable to suboptimal antibiotic therapy or to underlying host factors.\n\n【3】Secondly, once 删除32:<u>*</u>A. baumannii删除32:<u>*</u> exhibits carbapenem resistance, it generally has acquired resistance to most other antibiotics expected to be active against wild-type 删除32:<u>*</u>A. baumannii删除32:<u>*</u> leaving few remaining therapeutic options. The production of carbapenemases such as OXA-24/40-like carbapenemases and OXA-23-like carbapenemases mediates resistance to carbapenems 删除12:<u>[删除13:<u>84, 85</u>]</u>. CRAB isolates may also produce metallo-β-lactamases and additional serine carbapenemases, further limiting the utility of carbapenem agents. Sulbactam resistance is not completely understood but appears to be driven primarily via mutations targeting penicillin-binding proteins (PBPs); β-lactamase production may also contribute 删除12:<u>删除14:<u>[86-88]</u></u>. Aminoglycoside modifying enzymes or 16S rRNA methyltransferases generally preclude aminoglycosides as treatment options for CRAB, including plazomicin 删除12:<u>删除14:<u>[89-91]</u></u>. Mutations in the chromosomally-encoded quinolone resistance determining regions upregulate efflux pumps and generally mediate resistance to fluoroquinolones 删除12:<u>删除14:<u>[90]</u></u>.\n\n【4】Finally, there is no clear “standard of care” antibiotic regimen for CRAB infections against which to estimate the effectiveness of various treatment regimens. Robust comparative", "index": 133, "show": true, "start": 133, "end": 557, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 16:53:10", "endTime": "2024/08/06 16:54:42", "cost": 91.934}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:54:42", "grab_time": "2024-08-06 00:53:10"}
{"id": 2211496, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "9efdcc3a-cd33-4d19-8017-50f2422b1ff1", "title": "2024 德国指南：成人非心脏手术的术中血流动力学监测与管理", "text": "【0】页码:15\n2024 德国指南：成人非心脏手术的术中血流动力学监测与管理\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】参考删除-3:<u>118. van der Zee TJ, Engels HJ, Gommers D, Groeneveld AB. Targeting urine output and 30-day mortality in goal-directed therapy: a systematic review with meta-analysis and meta-regression. BMC Anesthesiol. 2017;17:22删除1:<u>. https://doi.org/10.1186/s12871-017-0316-4.</u></u>\n\n【2】参考删除-3:<u>119. Kraut JA, Madias NE. Lactic acidosis. N Engl J Med. 2014;371:2309–19删除1:<u>. https://doi.org/10.1056/NEJMra1309483.</u></u>\n\n【3】参考删除-3:<u>120. Vincent JL, De Backer D. Oxygen transport-the oxygen delivery controversy. Intensive Care Med. 2004删除1:<u>. https://doi.org/10.1007/s00134-004-2384-4. 30:1990-6.</u></u>\n\n【4】参考删除-3:<u>121. Smith ZR, Hombg M, Recht MA. Medication-Induced Hyperlactatemia and Lactic Acidosis: a systematic review of the literature. Pharmacotherapy. 2019;39:946–63删除1:<u>. https://doi.org/10.1002/phar.2316.</u></u>\n\n【5】参考删除-3:<u>122. Andersen LW, Mackenhauer J, Roberts JC, Berg KM, Cocchi MN, Donnino MW. Etiology and therapeutic approach to elevated lactate levels. Mayo Clin Proc. 2013;88:1127–40删除1:<u>. https://doi.org/10.1016/j.mayocp.2013.06.012.</u></u>\n\n【6】参考删除-3:<u>123. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, Jaeschke R, Mancebo J, Pinsky MR, Teboul JL, Vincent JL, Rhodes A. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40:1795–815删除1:<u>. https://doi.org/10.1007/s00134-014-3525-z.</u></u>\n\n【7】124. Shepherd SJ, Pearse RM. Role of central and mixed venous oxygen saturation measurement in perioperative care. Anesthesiology. 2009;111:649–56删除1:<u>. https://doi.org/10.1097/ALN.0b013e3181aae59d.</u>\n\n【8】参考删除-3:<u>125. Walley KR. Use of central venous oxygen saturation to guide therapy. Am J Respir Crit Care Med. 2011;184:514-20删除1:<u>. https://doi.org/10.1164/rccm.201010-1584CI.</u></u>\n\n【9】参考删除-3:<u>126. Gifford FA. What’s the use of measurement? Event review: use of venous oxygen saturations as a goal - a yet unfinished puzzle. Crit Care. 2011;15:232删除1:<u>. https://doi.org/10.1186/cc10531.</u></u>\n\n【10】参考删除-3:<u>127. Ho KM, Harding R, Chamberlain J. The impact of arterial oxygen tension on venous oxygen saturation in circulatory failure. Shock. 2008;29:3–6删除1:<u>. https://doi.org/10.1097/SHK.0b013e318067edcf.</u></u>\n\n【11】参考删除-3:<u>128. Collaborative Study Group on Perioperative ScvO2 Monitoring. Multicentre study on pre-and postoperative central venous oxygen saturation in high-risk surgical patients. Crit Care. 2006;10:R158删除1:<u>. https://doi.org/10.1186/cc5094.</u></u>\n\n【12】参考删除-3:<u>129. Futier E, Robin E, Jabaudon M, Guerin R, Petit A, Bazin JE, Constantin JM, Vallet B. Central venous O2 saturation and venous-to-arterial CO2 difference as complementary tools for goal-directed therapy during high-risk surgery. Crit Care. 2010;14:R193删除1:<u>. https://doi.org/10.1186/cc9310.</u></u>\n\n【13】参考删除-3:<u>130. Jammer I, Ulvik A, Erichsen C, Lodemel O, Ostgaard G. Does central venous oxygen saturation-directed fluid therapy affect postoperative morbidity after colorectal surgery? A randomized assessor-blinded controlled trial. Anesthesiology. 2010;113:1072–80删除1:<u>. https://doi.org/10.1097/ALN.0b013e3181f97337.</u></u>\n\n【14】参考删除-3:<u>131. Popel AS, Johnson PC. Microcirculation and Hemorheology. Annu Rev Fluid Mech. 2005;37:43–69删除1:<u>. https://doi.org/10.1146/annurev.fluid.37.042604.133933.</u></u>\n\n【15】132. Ince C, Boerma EC, Cecconi M, De Backer D, Shapiro NI, Duranteau J, Pinsky MR, Artigas A, Teboul JL, Reiss IK, Amedee A, Hutchings SD, Donati A, Maggiorini M, Taccone FS, Hernandez G, Payen D, Tribboel D, Martin DS, Zarbock A, Monnet X, Dubin A, Bakker J, Vincent JL, Schereren TWL. Second consensus on the assessment of sublingual microcirculation in critically ill patients: results from a task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2018;44:281–99删除1:<u>. https://doi.org/10.1007/s00134-018-5070-7. Cardiovascular Dynamics Section of the ESICM.</u>\n\n【16】参考删除-3:<u>133. den Uil CA, Bezemer R, Miranda DR, Ince C, Lagrand WK, Hartman M, Bogers AJ, Spork MP, Simoens ML. Intra-operative assessment of human pulmonary alveoli in vivo using Side stream Dark Field imaging: a feasibility study. Med Sci Monit. 2009;15:MT137-141.</u>\n\n【17】参考删除-3:<u>134. Nilsson I, Eriksson S, Blind PJ, Risberg P, Sturesson C. Microcirculation changes during liver resection: a clinical study. Microvasc Res. 2014;94:47–51删除1:<u>. https://doi.org/10.1016/j.mvr.2014.05.002.</u></u>\n\n【18】参考删除-3:<u>135. Bansch P, Fischer B, Bentzer P. Changes in the sublingual microcirculation during major abdominal surgery and post-operative morbidity. Acta Anaesthesiol Scand. 2014;58:89–97删除1:<u>. https://doi.org/10.1111/aas.12204.</u></u>\n\n【19】参考删除-3:<u>136. Stens J, de Wolf Sp, van de Zwan N, König NJ, Dekker NA, Hering P, Boer C. Microcirculatory perfusion during different perioperative hemodynamic strategies. Microcirculation. 2015;22:267–75删除1:<u>. https://doi.org/10.1111/micc.12194.</u></u>\n\n【20】参考删除-3:<u>137. Flick M, Breinskiel L, Pein S, Scheeren TWL, Duranteau J, Saugel B. The effect of moderate intraoperative blood loss and norepinephrine therapy on sublingual microcirculatory perfusion in patients undergoing radical prostatectomy: an observational study. Eur J Anaesthesiol. 2021;38:459–67删除1:<u>. https://doi.org/10.1097/EJA.0000000000001451.</u></u>\n\n【21】参考删除-3:<u>138. Flick M, Schreiber TH, Morin J, Krause E, Sade R, Boer HD, Kaufmann M, Ten Cate H, Chilli MP, Saugel B. Microcirculatory alterations impair blood glucose control in cardiac surgery patients: a pilot study. Acta Anaesthesiol Scand. 2018;62:803–12删除1:<u>. https://doi.org/10.1111/aas.13108.</u></u>\n\n【22】参考删除-3:<u>139. Astapenko D, Benes J, Pouska J, Chytra I, Cerny V. Endothelial glycocalyx in acute care surgery – what anaesthesiologists need to know for clinical practice. BMC Anesthesiol. 2019;19:238删除1:<u>. https://doi.org/10.1186/s12871-019-0896-z.</u></u>\n\n【23】参考删除-3:<u>140. Bickler PE, Feiner JR, Rollins MD. Factors affecting the performance of 5 cerebral oximeters during hypoxia in healthy volunteers. Anesth Analg. 2013;117:813–23删除1:<u>. https://doi.org/10.1213/ANE.0b013e31829d7f63.</u></u>\n\n【24】参考删除-3:<u>141. Henson LC, Calalang C, Temp JA, Ward DS. Accuracy of a cerebral oximeter in healthy volunteers under conditions of isocapnic hypoxia. Anesthesiology. 1998;88:58–65删除1:<u>. https://doi.org/10.1097/00000542-199801000-00011.</u></u>\n\n【25】参考删除-3:<u>142. Heringlake M, Garbers C, Kabler JH, Anderson I, Heinze H, Schön J, Berger KU, Dibbelt L, Sievers HH, Hanke T. Preoperative cerebral oxygen saturation and clinical outcomes in cardiac surgery. Anesthesiology. 2011;114:58–69删除1:<u>. https://doi.org/10.1097/ALN.0b013e3181fc84fc.</u></u>\n\n【26】参考删除-3:<u>143. Nielsen HB. Systematic review of near-infrared spectroscopy determined cerebral oxygenation during non-cardiac surgery. Front Physiol. 2014;5:93删除1:<u>. https://doi.org/10.3389/fphys.2014.00093.</u></u>", "tags": {}, "lang": "en", "attr": {"page_num": 15, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024 德国指南：成人非心脏手术的术中血流动力学监测与管理.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:14:48", "endTime": "2024/08/06 16:14:54", "cost": 6.155}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:14:54", "grab_time": "2024-08-06 00:14:47"}
{"id": 2211495, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "3e73004b-2372-4021-83c7-0a862e02d6a0", "title": "抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识（2022版）", "text": "【0】页码:1\n抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识（2022版）\n删除图片描述:<u>![](0_0.png)</u>\n\n【1】删除32:<u>**</u>【摘要】妇科常见的三大类肿瘤为宫颈癌、子宫内膜癌和卵巢癌。近年来,靶向治疗的出现促进了妇科肿瘤的治疗效果,妇科肿瘤的治疗标准不断更新,增加了宫腔向病灶局部特殊异性靶向作用,在妇科肿瘤的治疗中占据了重要的位置,已成为继手术、放疗、化疗后的又一重要治疗选择,尤其是近年来在杀小分子激酶靶向抑制剂和抗血管生成治疗物质性靶向治疗中取得了一定疗效。目前国内外最先批准的小分子激酶靶向抑制剂药物已在妇科肿瘤临床应用的治疗中获批准,为此中国临床肿瘤学会(CSCO)妇科肿瘤专家委员会组织相应专家制定了本共识,以期为复发转移或晚期妇科肿瘤的临床治疗提供参考。删除32:<u>**</u>\n\n【2】删除32:<u>**</u>【关键词】妇科肿瘤;抗血管生成治疗物质;小分子激酶靶向抑制剂;专家共识删除32:<u>**</u>\n\n【3】删除32:<u>**</u>【中图分类号】R737.3 【文献标识码】A 【文章编号】1674-5671删除11:<u>删除19:<u>(2023)</u></u>01-0001-10删除32:<u>**</u>\n\n【4】DOI: 10.3969/j.issn.删除17:<u>1674-5671.2023.01.01</u>\n\n---|删除段之间换行|删除图片描述:<u>![](0_1.png)</u>\n\n【6】近年来,妇科恶性肿瘤发病率逐年升高,严重危害女性生命健康。统计数据显示,2022年我国宫颈癌、子宫内膜癌和卵巢癌的发病病例分别为11.1万例,8.4万例和5.7万例,死亡病例数分别为6.1万例,1.7万例和3.9万例。妇科肿瘤的治疗以手术、放疗和化疗为主,肿瘤的发病叠发现象显现的妇科肿瘤治疗中提高生存率的瓶颈,亟须多学科高清的妇科肿瘤治疗物质性靶向临床治疗方案的重视和实践。\n\n【7】靶向治疗的出现促进了妇科肿瘤的治疗效果,为妇科肿瘤的治疗带来了新的曙光。目前国内外最先在妇科肿瘤中开展了抗血管生成和小分子激酶靶向抑制剂(tyrosine kinase inhibitors, TKI)相关系列的临床研究,旨在探讨TKI单或联用方案在妇科肿瘤中的有效性与安全性。\n\n【8】但是,现今仍缺乏针对抗血管生成和TKI在妇科肿瘤临床应用的相关指示性共识。为此,中国临床肿瘤学会(CSCO)妇科肿瘤专家委员会组织相关专家制定了本专家共识,以期为抗血管生成和TKI的临床实践提供参考。\n\n【9】本共识基于可靠医学并考虑部分先进害非主流疗，利用CNKI,万方，维普、Pubmed ,Embase 等数据库以及 ASCO ,欧洲肿瘤妇科医学会 (ESMO) ,美国妇科肿瘤学会 (SGO)等国际会议摘要，对国内外截至2022年10月31日关于妇科恶性肿瘤抗血管生成TKI药物治疗的英文文献进行系统综述。中文文献检索主题词为\"抗血管生成\"“妇科肿瘤\"“卵巢癌\"“子宫内膜癌”“宫颈癌”“索拉非尼”“仑伐替尼”“安罗替尼”“阿帕替尼”。英文文献检索主题词为\"antiangiogenesis\"“cervical cancer\"“ovarian cancer\"“endometrial cancer\"“sorafenib”\"pazopanib”“lenvatinib”\"anlotinib”\"apatinib”。\n\n【10】对相关内容进行系统含,纳筛所文献，参照中国临床肿瘤学会CSCO指南证据和推荐体系系统，以及综合CSCO妇科肿瘤专家委员会专家的意见制证推荐措施。\n\n---|删除段之间换行|删除32:<u>**</u>表 1 本共识的推荐级别及其表述含义删除32:<u>**</u>\n\n---|删除段之间换行|", "tags": {}, "lang": "zh", "attr": {"page_num": 1, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识（2022版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【3】删除32:【中图分类号】R737.3 【文献标识码】A 【文章编号】1674-5671删除11:删除19:(2023)01-0001-10删除32:\n\n【4】DOI: 10.3969/j.issn.删除17:1674-5671.2023.01.01", "content": "【0】页码:1\n抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识（2022版）\n删除图片描述:<u>![](0_0.png)</u>\n\n【1】删除32:<u>**</u>【摘要】妇科常见的三大类肿瘤为宫颈癌、子宫内膜癌和卵巢癌。近年来,靶向治疗的出现促进了妇科肿瘤的治疗效果,妇科肿瘤的治疗标准不断更新,增加了宫腔向病灶局部特殊异性靶向作用,在妇科肿瘤的治疗中占据了重要的位置,已成为继手术、放疗、化疗后的又一重要治疗选择,尤其是近年来在杀小分子激酶靶向抑制剂和抗血管生成治疗物质性靶向治疗中取得了一定疗效。目前国内外最先批准的小分子激酶靶向抑制剂药物已在妇科肿瘤临床应用的治疗中获批准,为此中国临床肿瘤学会(CSCO)妇科肿瘤专家委员会组织相应专家制定了本共识,以期为复发转移或晚期妇科肿瘤的临床治疗提供参考。删除32:<u>**</u>\n\n【2】删除32:<u>**</u>【关键词】妇科肿瘤;抗血管生成治疗物质;小分子激酶靶向抑制剂;专家共识删除32:<u>**</u>\n\n【3】删除32:<u>**</u>【中图分类号】R737.3 【文献标识码】A 【文章编号】1674-5671删除11:<u>删除19:<u>(2023)</u></u>01-0001-10删除32:<u>**</u>\n\n【4】DOI: 10.3969/j.issn.删除17:<u>1674-5671.2023.01.01</u>\n\n---|删除段之间换行|删除图片描述:<u>![](0_1.png)</u>\n\n【6】近年来,妇科恶性肿瘤发病率逐年升高,严重危害女性生命健康。统计数据显示,2022年我国宫颈癌、子宫内膜癌和卵巢癌的发病病例分别为11.1万例,8.4万例和5.7万例,死亡病例数分别为6.1万例,1.7万例和3.9万例。妇科肿瘤的治疗以手术、放疗和化疗为主,肿瘤的发病叠发现象显现的妇科肿瘤治疗中提高生存率的瓶颈,亟须多学科高清的妇科肿瘤治疗物质性靶向临床治疗方案的重视和实践。\n\n【7】靶向治疗的出现促进了妇科肿瘤的治疗效果,为妇科肿瘤的治疗带来了新的曙光。目前国内外最先在妇科肿瘤中开展了抗血管生成和小分子激酶靶向抑制剂(tyrosine kinase inhibitors, TKI)相关系列的临床研究,旨在探讨TKI单或联用方案在妇科肿瘤中的有效性与安全性。\n\n【8】但是,现今仍缺乏针对抗血管生成和TKI在妇科肿瘤临床应用的相关指示性共识。为此,中国临床肿瘤学会(CSCO)妇科肿瘤专家委员会组织相关专家制定了本专家共识,以期为抗血管生成和TKI的临床实践提供参考。\n\n【9】本共识基于可靠医学并考虑部分先进害非主流疗，利用CNKI,万方，维普、Pubmed ,Embase 等数据库以及 ASCO ,欧洲肿瘤妇科医学会 (ESMO) ,美国妇科肿瘤学会 (SGO)等国际会议摘要，对国内外截至2022年10月31日关于妇科恶性肿瘤抗血管生成TKI药物治疗的英文文献进行系统综述。中文文献检索主题词为\"抗血管生成\"“妇科肿瘤\"“卵巢癌\"“子宫内膜癌”“宫颈癌”“索拉非尼”“仑伐替尼”“安罗替尼”“阿帕替尼”。英文文献检索主题词为\"antiangiogenesis\"“cervical cancer\"“ovarian cancer\"“endometrial cancer\"“sorafenib”\"pazopanib”“lenvatinib”\"anlotinib”\"apatinib”。\n\n【10】对相关内容进行系统含,纳筛所文献，参照中国临床肿瘤学会CSCO指南证据和推荐体系系统，以及综合CSCO妇科肿瘤专家委员会专家的意见制证推荐措施。\n\n---|删除段之间换行|删除32:<u>**</u>表 1 本共识的推荐级别及其表述含义删除32:<u>**</u>\n\n---|删除段之间换行|", "index": 455, "show": true, "start": 455, "end": 582, "province": ["文本干净度", "无关文本"], "isEdit": false}, {"text": "表 1 本共识的推荐级别及其表述含义", "content": "【0】页码:1\n抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识（2022版）\n删除图片描述:<u>![](0_0.png)</u>\n\n【1】删除32:<u>**</u>【摘要】妇科常见的三大类肿瘤为宫颈癌、子宫内膜癌和卵巢癌。近年来,靶向治疗的出现促进了妇科肿瘤的治疗效果,妇科肿瘤的治疗标准不断更新,增加了宫腔向病灶局部特殊异性靶向作用,在妇科肿瘤的治疗中占据了重要的位置,已成为继手术、放疗、化疗后的又一重要治疗选择,尤其是近年来在杀小分子激酶靶向抑制剂和抗血管生成治疗物质性靶向治疗中取得了一定疗效。目前国内外最先批准的小分子激酶靶向抑制剂药物已在妇科肿瘤临床应用的治疗中获批准,为此中国临床肿瘤学会(CSCO)妇科肿瘤专家委员会组织相应专家制定了本共识,以期为复发转移或晚期妇科肿瘤的临床治疗提供参考。删除32:<u>**</u>\n\n【2】删除32:<u>**</u>【关键词】妇科肿瘤;抗血管生成治疗物质;小分子激酶靶向抑制剂;专家共识删除32:<u>**</u>\n\n<mark>【3】删除32:【中图分类号】R737.3 【文献标识码】A 【文章编号】1674-5671删除11:删除19:(2023)01-0001-10删除32:\n\n【4】DOI: 10.3969/j.issn.删除17:1674-5671.2023.01.01</mark>j.issn.删除17:<u>1674-5671.2023.01.01</u>\n\n---|删除段之间换行|删除图片描述:<u>![](0_1.png)</u>\n\n【6】近年来,妇科恶性肿瘤发病率逐年升高,严重危害女性生命健康。统计数据显示,2022年我国宫颈癌、子宫内膜癌和卵巢癌的发病病例分别为11.1万例,8.4万例和5.7万例,死亡病例数分别为6.1万例,1.7万例和3.9万例。妇科肿瘤的治疗以手术、放疗和化疗为主,肿瘤的发病叠发现象显现的妇科肿瘤治疗中提高生存率的瓶颈,亟须多学科高清的妇科肿瘤治疗物质性靶向临床治疗方案的重视和实践。\n\n【7】靶向治疗的出现促进了妇科肿瘤的治疗效果,为妇科肿瘤的治疗带来了新的曙光。目前国内外最先在妇科肿瘤中开展了抗血管生成和小分子激酶靶向抑制剂(tyrosine kinase inhibitors, TKI)相关系列的临床研究,旨在探讨TKI单或联用方案在妇科肿瘤中的有效性与安全性。\n\n【8】但是,现今仍缺乏针对抗血管生成和TKI在妇科肿瘤临床应用的相关指示性共识。为此,中国临床肿瘤学会(CSCO)妇科肿瘤专家委员会组织相关专家制定了本专家共识,以期为抗血管生成和TKI的临床实践提供参考。\n\n【9】本共识基于可靠医学并考虑部分先进害非主流疗，利用CNKI,万方，维普、Pubmed ,Embase 等数据库以及 ASCO ,欧洲肿瘤妇科医学会 (ESMO) ,美国妇科肿瘤学会 (SGO)等国际会议摘要，对国内外截至2022年10月31日关于妇科恶性肿瘤抗血管生成TKI药物治疗的英文文献进行系统综述。中文文献检索主题词为\"抗血管生成\"“妇科肿瘤\"“卵巢癌\"“子宫内膜癌”“宫颈癌”“索拉非尼”“仑伐替尼”“安罗替尼”“阿帕替尼”。英文文献检索主题词为\"antiangiogenesis\"“cervical cancer\"“ovarian cancer\"“endometrial cancer\"“sorafenib”\"pazopanib”“lenvatinib”\"anlotinib”\"apatinib”。\n\n【10】对相关内容进行系统含,纳筛所文献，参照中国临床肿瘤学会CSCO指南证据和推荐体系系统，以及综合CSCO妇科肿瘤专家委员会专家的意见制证推荐措施。\n\n---|删除段之间换行|删除32:<u>**</u>表 1 本共识的推荐级别及其表述含义删除32:<u>**</u>\n\n---|删除段之间换行|", "index": 1581, "show": true, "start": 1568, "end": 1586, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "【10】"}], "startTime": "2024/08/07 09:44:33", "endTime": "2024/08/07 09:46:05", "cost": 91.256}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 17:46:04", "grab_time": "2024-08-06 01:25:17"}
{"id": 2211494, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "99dd818f-5001-495f-91b0-6eba4d0d030b", "title": "CUA：睾丸生殖细胞癌管理的共识指南（2022）", "text": "【0】页码:13\nCUA：睾丸生殖细胞癌管理的共识指南（2022）\n删除图片描述:<u>![image]</u>\n\n【1】#### C端市场\n\n【2】C端市场规模较大，产品功能趋于同质化。移动互联网、物联网技术的迅猛发展，促进了个人健康管理智能硬件的普及。未来几年，C端市场的市场规模将进一步扩大。\n\n【3】#### B端市场\n\n【4】B端市场的主要客户包括医院、体检机构和健康管理机构等。相较于C端市场，B端市场对产品的专业性要求更高，且产品种类更为丰富。近年来，随着健康意识的提高和国家政策的推动，B端市场发展迅速，未来前景广阔。\n\n| 市场类型 | 主要客户 | 产品功能 | 市场规模 | 发展前景 |\n| -------- | -------- | -------- | -------- | -------- |\n| C端市场  | 个人用户  | 同质化   | 较大     | 扩大     |\n| B端市场  | 医院、体检机构、健康管理机构 | 专业性高 | 较小     | 广阔     |\n\n【6】#### 健康管理市场的趋势分析\n\n【7】1. 删除32:<u>**</u>市场需求增加删除32:<u>**</u>：随着人们健康意识的提高，健康管理市场需求增加。\n2. 删除32:<u>**</u>技术进步推动删除32:<u>**</u>：移动互联网、物联网技术的迅猛发展推动了健康管理智能硬件的普及和应用。\n3. 删除32:<u>**</u>政策支持删除32:<u>**</u>：国家出台的一系列健康管理相关政策，为市场发展提供了良好的政策环境。\n4. 删除32:<u>**</u>消费能力增强删除32:<u>**</u>：居民收入水平提高，消费能力增强，推动健康管理产品的消费增长。\n\n【8】#### 未来展望\n\n【9】未来几年，健康管理市场将持续增长。C端市场将保持快速增长，而B端市场的专业化和多元化趋势将更加明显。政策支持、技术进步和市场需求增加将成为驱动市场发展的主要因素。", "tags": {}, "lang": "zh", "attr": {"page_num": 13, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/CUA：睾丸生殖细胞癌管理的共识指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【0】页码:13\n\nCUA：睾丸生殖细胞癌管理的共识指南（2022）\n\n删除图片描述:![image]\n\n【1】#### C端市场\n\n【2】C端市场规模较大，产品功能趋于同质化。移动互联网、物联网技术的迅猛发展，促进了个人健康管理智能硬件的普及。未来几年，C端市场的市场规模将进一步扩大。\n\n【3】#### B端市场\n\n【4】B端市场的主要客户包括医院、体检机构和健康管理机构等。相较于C端市场，B端市场对产品的专业性要求更高，且产品种类更为丰富。近年来，随着健康意识的提高和国家政策的推动，B端市场发展迅速，未来前景广阔。\n\n市场类型\t主要客户\t产品功能\t市场规模\t发展前景\nC端市场\t个人用户\t同质化\t较大\t扩大\nB端市场\t医院、体检机构、健康管理机构\t专业性高\t较小\t广阔\n【6】#### 健康管理市场的趋势分析\n\n【7】1. 删除32:市场需求增加删除32:：随着人们健康意识的提高，健康管理市场需求增加。\n\n2. 删除32:技术进步推动删除32:：移动互联网、物联网技术的迅猛发展推动了健康管理智能硬件的普及和应用。\n\n3. 删除32:政策支持删除32:：国家出台的一系列健康管理相关政策，为市场发展提供了良好的政策环境。\n\n4. 删除32:消费能力增强删除32:：居民收入水平提高，消费能力增强，推动健康管理产品的消费增长。\n\n【8】#### 未来展望\n\n【9】未来几年，健康管理市场将持续增长。C端市场将保持快速增长，而B端市场的专业化和多元化趋势将更加明显。政策支持、技术进步和市场需求增加将成为驱动市场发展的主要因素。", "content": "【0】页码:13\nCUA：睾丸生殖细胞癌管理的共识指南（2022）\n删除图片描述:<u>![image]</u>\n\n【1】#### C端市场\n\n【2】C端市场规模较大，产品功能趋于同质化。移动互联网、物联网技术的迅猛发展，促进了个人健康管理智能硬件的普及。未来几年，C端市场的市场规模将进一步扩大。\n\n【3】#### B端市场\n\n【4】B端市场的主要客户包括医院、体检机构和健康管理机构等。相较于C端市场，B端市场对产品的专业性要求更高，且产品种类更为丰富。近年来，随着健康意识的提高和国家政策的推动，B端市场发展迅速，未来前景广阔。\n\n| 市场类型 | 主要客户 | 产品功能 | 市场规模 | 发展前景 |\n| -------- | -------- | -------- | -------- | -------- |\n| C端市场  | 个人用户  | 同质化   | 较大     | 扩大     |\n| B端市场  | 医院、体检机构、健康管理机构 | 专业性高 | 较小     | 广阔     |\n\n【6】#### 健康管理市场的趋势分析\n\n【7】1. 删除32:<u>**</u>市场需求增加删除32:<u>**</u>：随着人们健康意识的提高，健康管理市场需求增加。\n2. 删除32:<u>**</u>技术进步推动删除32:<u>**</u>：移动互联网、物联网技术的迅猛发展推动了健康管理智能硬件的普及和应用。\n3. 删除32:<u>**</u>政策支持删除32:<u>**</u>：国家出台的一系列健康管理相关政策，为市场发展提供了良好的政策环境。\n4. 删除32:<u>**</u>消费能力增强删除32:<u>**</u>：居民收入水平提高，消费能力增强，推动健康管理产品的消费增长。\n\n【8】#### 未来展望\n\n【9】未来几年，健康管理市场将持续增长。C端市场将保持快速增长，而B端市场的专业化和多元化趋势将更加明显。政策支持、技术进步和市场需求增加将成为驱动市场发展的主要因素。", "index": 0, "show": true, "start": 0, "end": 668, "province": ["格式规范性", "格式杂乱"], "isEdit": false, "comment": "与原文不一致"}], "startTime": "2024/08/06 17:32:49", "endTime": "2024/08/06 17:33:22", "cost": 32.844}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 01:33:22", "grab_time": "2024-08-06 01:32:49"}
{"id": 2211493, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "aa47b042-0a95-44a1-b122-a446c5d8cc16", "title": "_（2023.V3）NCCN 临床实践指南：胃癌", "text": "【0】页码:79\n_（2023.V3）NCCN 临床实践指南：胃癌\n(本页删除)本页被模型判断为参考页# Discussion\nThis discussion corresponds to the NCCN Guidelines for Gastric Cancer. Last updated on January 删除13:<u>11, 2022</u>.\n\n【1】# Table of Contents\n\n【2】- Overview 。。。。。。。。。。。。。。。 MS-2\n- Guidelines Update Methodology 。。。。。。。。. MS-3\n- Literature Search Criteria 。。。。。。。。。。 MS-3\n- Sensitive/Inclusive Language Usage 。。。。。。。。 MS-3\n- Hereditary Cancer Predisposition Syndromes Associated with an Increased Risk for Gastric Cancer 。。。。。。。。。。。 MS-4\n  - Hereditary Diffuse Gastric Cancer 。。。。。。。。 MS-4\n  - Lynch Syndrome 。。。。。。。。。。。。。 MS-4\n  - Juvenile Polyposis Syndrome 。。。。。。。。。 MS-5\n  - Peutz Jeghers Syndrome 。。。。。。。。。。. MS-5\n  - Familial Adenomatous Polyposis 。。。。。。。。 MS-5\n  - Less Common Hereditary Cancer Predisposition Syndromes 。 MS-6\n- Staging 。。。。。。。。。。。。。。。. MS-6\n- Pathologic Review and Biomarker Testing 。。。。。 MS-8\n  - Principles of Pathologic Review 。。。。。。。。. MS-8\n  - Assessment of Treatment Response 。。。。。。。 MS-9\n  - Principles of Biomarker Testing 。。。。。。。。. MS-9\n  - Assessment of HER2 Overexpression 。。。。。。。 MS-10\n  - MSI and MMR Testing 。。。。。。。。。。。 MS-11\n  - PD-L1 Testing 。。。。。。。。。。。。。 MS-11\n  - Liquid Biopsy 。。。。。。。。。。。。。 MS-11\n  - Emerging Biomarker: Tumor Epstein-Barr Virus 。。。。 MS-12\n- Surgery 。。。。。。。。。。。。。。。. MS-12\n  - Principles of Surgery 。。。。。。。。。。。 MS-12\n  - Lymph Node Dissection 。。。。。。。。。。。 MS-13\n  - Laparoscopic Resection 。。。。。。。。。。 MS-14\n  - Hyperthermic Intraperitoneal Chemotherapy (HIPEC) 。。. MS-15\n- Endoscopic Therapies 。。。。。。。。。。。 MS-16\n  - Principles of Endoscopy 。。。。。。。。。。. MS-16\n  - Diagnosis 。。。。。。。。。。。。。。. MS-16\n- Staging 。。。。。。。。。。。。。。。 MS-16\n- Treatment 。。。。。。。。。。。。。。 MS-17\n- Surveillance 。。。。。。。。。。。。。。 MS-18\n- Radiation Therapy 。。。。。。。。。。。。 MS-18\n  - Principles of Radiation Therapy 。。。。。。。。. MS-19\n  - General Guidelines 。。。。。。。。。。。。 MS-19\n  - Simulation and Treatment Planning 。。。。。。。 MS-19\n  - Target Volume 。。。。。。。。。。。。。 MS-19\n  - Normal Tissue Tolerance and Dose Limits 。。。。。 MS-20\n  - Supportive Care。。。。。。。。。。。。。 MS-20\n- Combined Modality Therapy 。。。。。。。。。 MS-20\n  - Perioperative Chemotherapy 。。。。。。。。。 MS-20\n  - Preoperative Chemoradiation Therapy 。。。。。。。 MS-21\n  - Postoperative Chemoradiation Therapy 。。。。。。 MS-22\n  - Postoperative Chemotherapy 。。。。。。。。。 MS-23\n  - Chemoradiation for Unresectable Disease 。。。。。. MS-24\n- Systemic Therapy for Locally Advanced or Metastatic Disease 。 MS-24\n  - First-Line Therapy 。。。。。。。。。。。。 MS-24\n  - Second-Line and Subsequent Therapy 。。。。。。. MS-26\n- Targeted Therapies 。。。。。。。。。。。 MS-27\n  - Trastuzumab 。。。。。。。。。。。。。 MS-27\n  - Fam-trastuzumab deruxtecan-nxki 。。。。。。。。 MS-28\n  - Ramucirumab 。。。。。。。。。。。。。 MS-28\n  - Nivoluma 。。。。。。。。。。。。。。 MS-29\n  - Pembrolizumab 。。。。。。。。。。。。。 MS-30\n  - Dostarlimab-gxly 。。。。。。。。。。。。 MS-30\n  - Entrectinib and Larotrectinib 。。。。。。。。。 MS-30\n- Treatment Guidelines 。。。。。。。。。。 MS-32\n  - Workup 。。。。。。。。。。。。。。。 MS-32\n  - Additional Evaluation 。。。。。。。。。。。 MS-32\n  - Primary Treatment 。。。。。。。。。。。。 MS-33", "tags": {}, "lang": "en", "attr": {"page_num": 79, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/_（2023.V3）NCCN 临床实践指南：胃癌.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:06:11", "endTime": "2024/08/06 17:06:21", "cost": 9.922}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 01:06:21", "grab_time": "2024-08-06 01:06:11"}
{"id": 2211492, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "3e005ef3-980d-4962-9694-ebeb8d541bc3", "title": "（2024.V1）NCCN临床实践指南：皮肤黑色素瘤(1)(1)", "text": "【0】页码:208\n（2024.V1）NCCN临床实践指南：皮肤黑色素瘤(1)(1)\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】疑似页眉<u>NCCN Guidelines Version 1.2024  \nMelanoma: Cutaneous</u>\n\n【2】参考删除-3:<u>167. Read RL, Pasquali S, Haydu L, et al. Quality assurance in melanoma surgery: The evolving experience at a large tertiary referral centre. Eur J Surg Oncol 2015;41:830-836删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/25595509]</u>.</u></u>\n\n【3】168. White I, Mills JK, Diggs B, et al. Sentinel lymph node biopsy for melanoma: comparison of lymphocele rates by surgical technique. Am Surg 2013;79:388-392删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/23574849]</u>.</u>\n\n【4】参考删除-3:<u>169. Fontaine D, Parkhill W, Greer W, Walsh N. Partial regression of primary cutaneous melanoma: Is there an association with sub-clinical sentinel lymph node metastasis? Am J Dermatopathol 2003;25:371-376删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/14501285]</u>.</u></u>\n\n【5】参考删除-3:<u>170. Borbognoni L, Urso C, Vaggelli L, et al. Sentinel node biopsy procedures with an analysis of recurrence patterns and prognosis in melanoma patients: technical advantages using computer-assisted gamma probe with adjustable collimation. Melanoma Res 2004;14:311-319删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/15305163]</u>.</u></u>\n\n【6】参考删除-3:<u>171. Krupfer LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 2006;107:2436-2445删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/17058288]</u>.</u></u>\n\n【7】参考删除-3:<u>172. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006;24:4464-4471删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/16983115]</u>.</u></u>\n\n【8】参考删除-3:<u>173. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014;370:599-609删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/24521106]</u>.</u></u>\n\n【9】参考删除-3:<u>174. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol 2006;13:1655-1663删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/17016755]</u>.</u></u>\n\n【10】参考删除-3:<u>175. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012;30:2678-2683删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/22711850]</u>.</u></u>\n\n【11】176. Spiejers MJ, Bastiaannet E, Sloot S, et al. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for Sentinel lymph node status and survival of cutaneous melanoma patients. Ann Surg Oncol 2015;22:2978-2987删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/25605514]</u>.</u>\n\n【12】参考删除-3:<u>177. Munsch C, Lauwers-Cances V, Lamant L, et al. Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients. Dermatology 2014;229:183-189删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/25171688]</u>.</u></u>\n\n【13】参考删除-3:<u>178. Morris KT, Busam KJ, Bero S, et al. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol 2008;15:316-322删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/18004626]</u>.</u></u>\n\n【14】参考删除-3:<u>179. Baker JJ, Meyers MO, Deal AM, et al. Prognostic significance of tumor-mitotic rate in T2 melanoma staged with sentinel lymphadenectomy. J Surg Oncol 2015;111:711-715删除1:<u>. Available at: 删除24:<u>[http://www.ncbi.nlm.nih.gov/pubmed/25663414]</u>.</u></u>", "tags": {}, "lang": "en", "attr": {"page_num": 208, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2024.V1）NCCN临床实践指南：皮肤黑色素瘤(1)(1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:41:51", "endTime": "2024/08/06 15:42:00", "cost": 8.207}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-05 23:42:00", "grab_time": "2024-08-05 23:41:51"}
{"id": 2211491, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "fcc308bc-43bb-4320-8130-7db3bfc1dba2", "title": "ERS：成人哮喘的诊断指南（2022）", "text": "【0】页码:59\nERS：成人哮喘的诊断指南（2022）\nTable 2: PICO questions\n\n【1】删除32:<u>**</u>PICO 1删除32:<u>**</u> Can airway obstruction measured by spirometry help diagnose asthma in adults with episodic/chronic suggestive symptoms?\n\n【2】- 删除32:<u>**</u>In patients with episodic/chronic symptoms suggestive of asthma删除32:<u>**</u>\n  - 删除32:<u>**</u>Index test:删除32:<u>**</u> FEV删除29:<u>₁</u>/FVC ratio\n  - 删除32:<u>**</u>Gold standard:删除32:<u>**</u> Excessive airway calibre fluctuation 删除9:<u>(see definition, Table 1)</u>\n  - 删除32:<u>**</u>Outcomes:删除32:<u>**</u> Diagnostic accuracy (sensitivity, specificity)\n  - 删除32:<u>**</u>Time:删除32:<u>**</u> Depending from the gold standard chosen: 2 weeks for PEF recording, 6 months follow up with repeated spirometry tests for reversibility test, one day for bronchial challenge\n\n【3】删除32:<u>**</u>PICO 2:删除32:<u>**</u> Can PEF variability testing help diagnose asthma in adults with episodic/chronic suggestive symptoms?\n\n【4】- 删除32:<u>**</u>In patients with episodic/chronic symptoms suggestive of asthma删除32:<u>**</u>\n  - 删除32:<u>**</u>Index test:删除32:<u>**</u> Peak flow variability (Minimal 2 weeks for Peak Flow recording as an index test)\n  - 删除32:<u>**</u>Gold standard:删除32:<u>**</u> Excessive airway calibre fluctuation 删除9:<u>(see definition, Table 1)</u>\n  - 删除32:<u>**</u>Outcomes:删除32:<u>**</u> Diagnostic accuracy (sensitivity, specificity)\n  - 删除32:<u>**</u>Time:删除32:<u>**</u> Depending from the gold standard chosen: 2 weeks for PEF recording, 6 months follow up with repeated spirometry tests for reversibility test, one day for bronchial challenge\n\n【5】删除32:<u>**</u>PICO 3:删除32:<u>**</u> Can measuring fractional exhaled nitric oxide (FeNO) help diagnose asthma in adults with episodic/chronic suggestive symptoms?\n\n【6】- 删除32:<u>**</u>In patients with episodic/chronic symptoms suggestive of asthma删除32:<u>**</u>\n  - 删除32:<u>**</u>Index test:删除32:<u>**</u> FeNO\n  - 删除32:<u>**</u>Gold standard:删除32:<u>**</u> Excessive airway calibre fluctuation 删除9:<u>(see definition, Table 1)</u>\n  - 删除32:<u>**</u>Outcomes:删除32:<u>**</u> Diagnostic accuracy (sensitivity, specificity)", "tags": {}, "lang": "en", "attr": {"page_num": 59, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/ERS：成人哮喘的诊断指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:10:13", "endTime": "2024/08/06 17:10:59", "cost": 46.346}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 01:10:59", "grab_time": "2024-08-06 01:10:13"}
{"id": 2211490, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "5c919808-2fe1-4477-88c5-ac709de5a818", "title": "单臂临床试验设计用于支持抗肿瘤药上市申请的适用性技术指导原则", "text": "【0】页码:17\n单臂临床试验设计用于支持抗肿瘤药上市申请的适用性技术指导原则\n分地分析，并建议以此为基础，在已知的安全剂量范围内，选择至少 2 个候选给药方案，开展一定样本量的对照研究以对比两个给药方案的安全性和有效性；在开展关键 SAT 前，确定合理的给药策略。\n\n【1】（二）关注缓解质量\n\n【2】SAT 通常采用发生客观缓解的患者比例（如 ORR）为主要终点；为保证数据的完整性，原则上不接受单臂临床试验期中分析结果提交上市申请。SAT 中的缓解率，体现的是患者接受治疗后产生应答的概率；患者接受治疗后，是否会获得生存期的延长，在缺乏平行对照的 SAT 中，很难直接判断。因此，在对缓解率进行评估时，还需要关注缓解的“质量”，即产生应答的患者是否有更转化为生存获益。\n\n【3】缓解质量可以体现在如下方面：\n\n【4】（1）缓解深度。\n\n【5】例如，在以 ORR 为主要终点的研究中，关注其中发生完全缓解（complete response，CR）的比例，或者 MRD 阴性患者的比例。通常而言，缓解深度越深，代表患者残留的肿瘤负荷越少，生存期延长的可能性越高。\n\n【6】（2）缓解持续性。\n\n【7】单臂研究中，须关注 DOR，同时 PFS/PFS 率、OS/OS 率也是重要的支持数据。\n\n【8】随着药物研发进展，新机制、新结构的创新性治疗药物", "tags": {}, "lang": "zh", "attr": {"page_num": 17, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/单臂临床试验设计用于支持抗肿瘤药上市申请的适用性技术指导原则.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:09:13", "endTime": "2024/08/06 16:09:26", "cost": 12.697}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:09:26", "grab_time": "2024-08-06 00:09:13"}
{"id": 2211489, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "06266059-f00c-4b6d-94cc-78e03028e709", "title": "SMFM：妊娠期心脏病患者的抗凝治疗指南（2022）", "text": "【0】页码:14\nSMFM：妊娠期心脏病患者的抗凝治疗指南（2022）\nimmediately postpartum. Various strategies may be used to achieve these goals and will likely be driven by obstetrical, anesthetic, and maternal factors. Current guidelines from the ACC/AHA and the European Society of Cardiology recommend transitioning all pregnant individuals with mechanical heart valves on warfarin to LMWH or intravenous (IV) UFH at 36 weeks; the latter approach necessitates inpatient care until delivery. Patients anticoagulated with LMWH in the second or third trimester may continue such therapy until 36 to 48 hours before their planned delivery, at which time they should be admitted for transition to IV UFH. The rationale for using IV UFH instead of LMWH around the time of delivery is the shorter half-life of this agent (60–90 minutes), ease of obtaining therapeutic levels, frequent titration capabilities during labor, and availability of an effective antidote (protamine sulfate) in cases of unexpected hemorrhagic complications.\n\n【1】For pregnant individuals with a mechanical heart valve anticoagulated with warfarin during the second and third trimesters, we recommend transitioning to dose-adjusted LMWH at 35 to 36 weeks of gestation (with planned delivery at 37 to 38 weeks of gestation) provided anti-Xa levels are monitored weekly using both trough (>0.6 U/mL) and peak (0.8–1.2 U/mL for aortic valves and 1.0-1.2 u/mL for mitral valves) levels; then transitioning these patients to bridging anticoagulation with IV UFH in an inpatient setting 36 to 48 hours before planned delivery (GRADE 1C). For pregnant individuals with a mechanical heart valve anticoagulated with dose-adjusted LMWH during the second and third trimesters, we recommend transitioning to IV UFH in an inpatient setting 36 to 48 hours before planned delivery (GRADE 1C).\n\n【2】How should therapeutic anticoagulation be managed during labor and delivery in pregnant individuals with a mechanical heart valve?", "tags": {}, "lang": "en", "attr": {"page_num": 14, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/SMFM：妊娠期心脏病患者的抗凝治疗指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "immediately postpartum. Various strategies may be used to achieve these goals and will likely be driven by obstetrical, anesthetic, and maternal factors. Current guidelines from the ACC/AHA and the European Society of Cardiology recommend transitioning all pregnant individuals with mechanical heart valves on warfarin to LMWH or intravenous (IV) UFH at 36 weeks; the latter approach necessitates inpatient care until delivery. Patients anticoagulated with LMWH in the second or third trimester may continue such therapy until 36 to 48 hours before their planned delivery, at which time they should be admitted for transition to IV UFH. The rationale for using IV UFH instead of LMWH around the time of delivery is the shorter half-life of this agent (60–90 minutes), ease of obtaining therapeutic levels, frequent titration capabilities during labor, and availability of an effective antidote (protamine sulfate) in cases of unexpected hemorrhagic complications.\n\n【1】For pregnant individuals with a mechanical heart valve anticoagulated with warfarin during the second and third trimesters, we recommend transitioning to dose-adjusted LMWH at 35 to 36 weeks of gestation (with planned delivery at 37 to 38 weeks of gestation) provided anti-Xa levels are monitored weekly using both trough (>0.6 U/mL) and peak (0.8–1.2 U/mL for aortic valves and 1.0-1.2 u/mL for mitral valves) levels; then transitioning these patients to bridging anticoagulation with IV UFH in an inpatient setting 36 to 48 hours before planned delivery (GRADE 1C). For pregnant individuals with a mechanical heart valve anticoagulated with dose-adjusted LMWH during the second and third trimesters, we recommend transitioning to IV UFH in an inpatient setting 36 to 48 hours before planned delivery (GRADE 1C).", "content": "【0】页码:14\nSMFM：妊娠期心脏病患者的抗凝治疗指南（2022）\nimmediately postpartum. Various strategies may be used to achieve these goals and will likely be driven by obstetrical, anesthetic, and maternal factors. Current guidelines from the ACC/AHA and the European Society of Cardiology recommend transitioning all pregnant individuals with mechanical heart valves on warfarin to LMWH or intravenous (IV) UFH at 36 weeks; the latter approach necessitates inpatient care until delivery. Patients anticoagulated with LMWH in the second or third trimester may continue such therapy until 36 to 48 hours before their planned delivery, at which time they should be admitted for transition to IV UFH. The rationale for using IV UFH instead of LMWH around the time of delivery is the shorter half-life of this agent (60–90 minutes), ease of obtaining therapeutic levels, frequent titration capabilities during labor, and availability of an effective antidote (protamine sulfate) in cases of unexpected hemorrhagic complications.\n\n【1】For pregnant individuals with a mechanical heart valve anticoagulated with warfarin during the second and third trimesters, we recommend transitioning to dose-adjusted LMWH at 35 to 36 weeks of gestation (with planned delivery at 37 to 38 weeks of gestation) provided anti-Xa levels are monitored weekly using both trough (>0.6 U/mL) and peak (0.8–1.2 U/mL for aortic valves and 1.0-1.2 u/mL for mitral valves) levels; then transitioning these patients to bridging anticoagulation with IV UFH in an inpatient setting 36 to 48 hours before planned delivery (GRADE 1C). For pregnant individuals with a mechanical heart valve anticoagulated with dose-adjusted LMWH during the second and third trimesters, we recommend transitioning to IV UFH in an inpatient setting 36 to 48 hours before planned delivery (GRADE 1C).\n\n【2】How should therapeutic anticoagulation be managed during labor and delivery in pregnant individuals with a mechanical heart valve?", "index": 36, "show": true, "start": 36, "end": 1817, "province": ["格式规范性", "多余换行"], "isEdit": false}], "startTime": "2024/08/06 16:27:08", "endTime": "2024/08/06 16:27:35", "cost": 27.489}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:27:35", "grab_time": "2024-08-06 00:27:08"}
{"id": 2211488, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "e3eb4cf4-743f-405e-b490-655648524442", "title": "2024+共识指南：儿童和青少年垂体腺瘤的诊断和管理—第2部分：特定疾病", "text": "【0】页码:14\n2024+共识指南：儿童和青少年垂体腺瘤的诊断和管理—第2部分：特定疾病\n# Consensus statement\n\n【1】and can cause pre-operative tumour shrinkage. In one paediatric patient, somatostatin analogues reduced thyroid hormone levels and tumour size, thereby postponing definitive surgery. Out of 44 patients aged 11–73 years on pre-operative somatostatin analogue treatment, 84% had normalization of thyroid function levels and 61% showed tumour shrinkage.\n\n【2】Surgery offers a potentially definitive cure. Even partial tumour debulking can be worthwhile in reducing TSH and free T4 levels, decompressing the optic apparatus or improving the effectiveness of subsequent medical therapy.\n\n【3】## Follow-up and surveillance.\n\n【4】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R47. Disease monitoring with regular thyroid function tests and regular MRI surveillance, similar to the protocols described for NFPA, is suggested in CYP with confirmed TSHomas删除32:<u>**</u> (weak recommendation, low-quality evidence, GDG consensus).\n\n【5】There is no evidence base to inform a surveillance schedule in CYP with TSHoma and the natural history of disease progression is unknown. We therefore suggest a pragmatic approach to biochemical and MRI surveillance to detect secondary hyperthyroidism and to identify those with rapid tumour progression or recurrence early, even if asymptomatic. Continued monitoring of thyroid function tests for 6 months after initial treatment, but the optimum interval currently remains unclear. Long-term biochemical and MRI surveillance should be individualized.\n\n【6】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R48. Consider pituitary radiotherapy in CYP with post-operative tumour remnant and at resistance to medical therapy or relapsing TSHomas if re-operation is not an option删除32:<u>**</u> (moderate recommendation, low-quality evidence, Delphi 92% and GDG consensus).\n\n【7】If surgery is unsuccessful or contraindicated and the paediatric patient with TSHoma fails to achieve normal thyroid function or shows tumour growth on somatostatin analogue therapy, radiotherapy could be considered.\n\n【8】## Incidentalomas and NFPAs\n\n【9】### Epidemiology and aetiology.\nClinically non-secreting pituitary adenomas account for 4–6% of all paediatric pituitary adenomas and for 10% of cases in a surgical series, in stark difference to adult pituitary patients where NFPAs account for 15–30% of clinically relevant pituitary adenomas and 50–60% of cases in a surgical series. Depending on case selection criteria, NFPAs represent 13–56% of incidentally discovered pituitary lesions (incidentalomas) in large retrospective radiological series of CYP. NFPAs also represent 25% of MEN1-associated pituitary lesions in CYP, and silent lesions detected by screening can be seen in patients with AIP variants. NFPAs in CYP usually present in the second decade of life, with increasing incidence thereafter. There is no consistent sex or female predisposition, although a 2019 surgical series in CYP reported a slight female predominance.\n\n【10】### Presentation.\nCYP with NFPAs, by definition, do not have features of a hypersecretory syndrome. Symptomatic NFPAs are macroadenomas, whereas microadenomas are usually discovered as a coincidental finding on an MRI scan. The clinical features of macroadenomas at presentation result from mass effects on surrounding structures. These include headache, visual field defects, pituitary apoplexy (probably more common than in adult NFPA) with or without mild prolactin elevation, or hypopituitarism manifesting as secondary amenorrhea, delayed puberty, hypothyroidism, hypocortisolaemia, growth failure and/or hyperprolactinaemia. Headache, visual impairment and hypogonadism were the most common presenting features in a surgical series in CYP. Immunohistochemistry for pituitary hormones in 14 NFPAs, from CYP aged 12–19 years, revealed plurihormonal tumours, 3 silent lactotrophs, 1 each of silent gonadotroph and a corticotroph, and 3 hormone-negative tumours (transcription factor staining not reported). These proportions are different from those in adult patients, where silent gonadotrophinomas represent the majority of NFPAs. Non-functioning pituitary microadenomas do not usually cause hypopituitarism or visual abnormalities.\n\n【11】## Diagnosis and investigation.\n\n【12】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R49. Identification of a pituitary incidentaloma or NFPA requires exclusion of clinical or laboratory evidence of pituitary hormone hypersecretion (except mild hyperprolactinaemia from pituitary stalk disruption); exclusion of elevation of serum levels of α-fetoprotein (AFP) and β-human chorionic gonadotropin (BHC) and the absence of other suprasellar tumours in all CYP with suspected NFPA删除32:<u>**</u> (strong recommendation, low-quality evidence, Delphi 100%).\n\n【13】If a pituitary mass is suspected on MRI, baseline and dynamic pituitary investigations should be undertaken as indicated clinically to confirm the absence of pituitary hormone excess from a functioning adenoma or the presence of hormone deficiency. The MRI appearance of a small Rathke cleft cyst or pars intermedia cyst can present a differential diagnosis for a clinically non-functioning microadenoma. Stalk compression from macroadenomas, or rarely microadenomas, can cause mild hyperprolactinaemia, usually below 2,000 mIU/l (94 μg/l).\n\n【14】Intracranial germ-cell tumours, more common in the adolescent age group than NFPAs, can present with similar MRI appearances. AFP and BHC (markers of germ-cell tumours) should be measured in the serum and, if clinically or radiologically indicated, also in the cerebrospinal fluid.\n\n【15】Hypopituitarism is common in children with symptomatic non-functioning pituitary macroadenoma. Basal and dynamic pituitary assessment is recommended following diagnosis of an NFPA together with prompt replacement therapy of thy cortisol, thyroid hormone, sex steroid and GH deficiency to optimize surgical, growth and well-being outcomes. Arginine vasopressin deficiency (also known as central diabetes insipidus) is an extremely infrequent finding at diagnosis of an NFPA unless the tumour has undergone apoplexy, and its presence strongly suggests an alternative diagnosis such as a craniopharyngioma, histiocytosis or germ-cell tumour.\n\n【16】Visual deterioration is a well-described presentation of NFPA in CYP, and an urgent indication for surgery to decompress the optic apparatus if sight is threatened. Thus, early assessment of visual acuity and visual fields is mandated.", "tags": {}, "lang": "en", "attr": {"page_num": 14, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2024+共识指南：儿童和青少年垂体腺瘤的诊断和管理—第2部分：特定疾病.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【9】### Epidemiology and aetiology.\n\nClinically non-secreting pituitary adenomas account for 4–6% of all paediatric pituitary adenomas and for 10% of cases in a surgical series, in stark difference to adult pituitary patients where NFPAs account for 15–30% of clinically relevant pituitary adenomas and 50–60% of cases in a surgical series. Depending on case selection criteria, NFPAs represent 13–56% of incidentally discovered pituitary lesions (incidentalomas) in large retrospective radiological series of CYP. NFPAs also represent 25% of MEN1-associated pituitary lesions in CYP, and silent lesions detected by screening can be seen in patients with AIP variants. NFPAs in CYP usually present in the second decade of life, with increasing incidence thereafter. There is no consistent sex or female predisposition, although a 2019 surgical series in CYP reported a slight female predominance.", "content": "【0】页码:14\n2024+共识指南：儿童和青少年垂体腺瘤的诊断和管理—第2部分：特定疾病\n# Consensus statement\n\n【1】and can cause pre-operative tumour shrinkage. In one paediatric patient, somatostatin analogues reduced thyroid hormone levels and tumour size, thereby postponing definitive surgery. Out of 44 patients aged 11–73 years on pre-operative somatostatin analogue treatment, 84% had normalization of thyroid function levels and 61% showed tumour shrinkage.\n\n【2】Surgery offers a potentially definitive cure. Even partial tumour debulking can be worthwhile in reducing TSH and free T4 levels, decompressing the optic apparatus or improving the effectiveness of subsequent medical therapy.\n\n【3】## Follow-up and surveillance.\n\n【4】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R47. Disease monitoring with regular thyroid function tests and regular MRI surveillance, similar to the protocols described for NFPA, is suggested in CYP with confirmed TSHomas删除32:<u>**</u> (weak recommendation, low-quality evidence, GDG consensus).\n\n【5】There is no evidence base to inform a surveillance schedule in CYP with TSHoma and the natural history of disease progression is unknown. We therefore suggest a pragmatic approach to biochemical and MRI surveillance to detect secondary hyperthyroidism and to identify those with rapid tumour progression or recurrence early, even if asymptomatic. Continued monitoring of thyroid function tests for 6 months after initial treatment, but the optimum interval currently remains unclear. Long-term biochemical and MRI surveillance should be individualized.\n\n【6】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R48. Consider pituitary radiotherapy in CYP with post-operative tumour remnant and at resistance to medical therapy or relapsing TSHomas if re-operation is not an option删除32:<u>**</u> (moderate recommendation, low-quality evidence, Delphi 92% and GDG consensus).\n\n【7】If surgery is unsuccessful or contraindicated and the paediatric patient with TSHoma fails to achieve normal thyroid function or shows tumour growth on somatostatin analogue therapy, radiotherapy could be considered.\n\n【8】## Incidentalomas and NFPAs\n\n【9】### Epidemiology and aetiology.\nClinically non-secreting pituitary adenomas account for 4–6% of all paediatric pituitary adenomas and for 10% of cases in a surgical series, in stark difference to adult pituitary patients where NFPAs account for 15–30% of clinically relevant pituitary adenomas and 50–60% of cases in a surgical series. Depending on case selection criteria, NFPAs represent 13–56% of incidentally discovered pituitary lesions (incidentalomas) in large retrospective radiological series of CYP. NFPAs also represent 25% of MEN1-associated pituitary lesions in CYP, and silent lesions detected by screening can be seen in patients with AIP variants. NFPAs in CYP usually present in the second decade of life, with increasing incidence thereafter. There is no consistent sex or female predisposition, although a 2019 surgical series in CYP reported a slight female predominance.\n\n【10】### Presentation.\nCYP with NFPAs, by definition, do not have features of a hypersecretory syndrome. Symptomatic NFPAs are macroadenomas, whereas microadenomas are usually discovered as a coincidental finding on an MRI scan. The clinical features of macroadenomas at presentation result from mass effects on surrounding structures. These include headache, visual field defects, pituitary apoplexy (probably more common than in adult NFPA) with or without mild prolactin elevation, or hypopituitarism manifesting as secondary amenorrhea, delayed puberty, hypothyroidism, hypocortisolaemia, growth failure and/or hyperprolactinaemia. Headache, visual impairment and hypogonadism were the most common presenting features in a surgical series in CYP. Immunohistochemistry for pituitary hormones in 14 NFPAs, from CYP aged 12–19 years, revealed plurihormonal tumours, 3 silent lactotrophs, 1 each of silent gonadotroph and a corticotroph, and 3 hormone-negative tumours (transcription factor staining not reported). These proportions are different from those in adult patients, where silent gonadotrophinomas represent the majority of NFPAs. Non-functioning pituitary microadenomas do not usually cause hypopituitarism or visual abnormalities.\n\n【11】## Diagnosis and investigation.\n\n【12】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R49. Identification of a pituitary incidentaloma or NFPA requires exclusion of clinical or laboratory evidence of pituitary hormone hypersecretion (except mild hyperprolactinaemia from pituitary stalk disruption); exclusion of elevation of serum levels of α-fetoprotein (AFP) and β-human chorionic gonadotropin (BHC) and the absence of other suprasellar tumours in all CYP with suspected NFPA删除32:<u>**</u> (strong recommendation, low-quality evidence, Delphi 100%).\n\n【13】If a pituitary mass is suspected on MRI, baseline and dynamic pituitary investigations should be undertaken as indicated clinically to confirm the absence of pituitary hormone excess from a functioning adenoma or the presence of hormone deficiency. The MRI appearance of a small Rathke cleft cyst or pars intermedia cyst can present a differential diagnosis for a clinically non-functioning microadenoma. Stalk compression from macroadenomas, or rarely microadenomas, can cause mild hyperprolactinaemia, usually below 2,000 mIU/l (94 μg/l).\n\n【14】Intracranial germ-cell tumours, more common in the adolescent age group than NFPAs, can present with similar MRI appearances. AFP and BHC (markers of germ-cell tumours) should be measured in the serum and, if clinically or radiologically indicated, also in the cerebrospinal fluid.\n\n【15】Hypopituitarism is common in children with symptomatic non-functioning pituitary macroadenoma. Basal and dynamic pituitary assessment is recommended following diagnosis of an NFPA together with prompt replacement therapy of thy cortisol, thyroid hormone, sex steroid and GH deficiency to optimize surgical, growth and well-being outcomes. Arginine vasopressin deficiency (also known as central diabetes insipidus) is an extremely infrequent finding at diagnosis of an NFPA unless the tumour has undergone apoplexy, and its presence strongly suggests an alternative diagnosis such as a craniopharyngioma, histiocytosis or germ-cell tumour.\n\n【16】Visual deterioration is a well-described presentation of NFPA in CYP, and an urgent indication for surgery to decompress the optic apparatus if sight is threatened. Thus, early assessment of visual acuity and visual fields is mandated.", "index": 2094, "show": true, "start": 2094, "end": 2989, "province": ["格式规范性", "多余换行"], "isEdit": false}, {"text": "【10】### Presentation.\n\nCYP with NFPAs, by definition, do not have features of a hypersecretory syndrome. Symptomatic NFPAs are macroadenomas, whereas microadenomas are usually discovered as a coincidental finding on an MRI scan. The clinical features of macroadenomas at presentation result from mass effects on surrounding structures. These include headache, visual field defects, pituitary apoplexy (probably more common than in adult NFPA) with or without mild prolactin elevation, or hypopituitarism manifesting as secondary amenorrhea, delayed puberty, hypothyroidism, hypocortisolaemia, growth failure and/or hyperprolactinaemia. Headache, visual impairment and hypogonadism were the most common presenting features in a surgical series in CYP. Immunohistochemistry for pituitary hormones in 14 NFPAs, from CYP aged 12–19 years, revealed plurihormonal tumours, 3 silent lactotrophs, 1 each of silent gonadotroph and a corticotroph, and 3 hormone-negative tumours (transcription factor staining not reported). These proportions are different from those in adult patients, where silent gonadotrophinomas represent the majority of NFPAs. Non-functioning pituitary microadenomas do not usually cause hypopituitarism or visual abnormalities.", "content": "【0】页码:14\n2024+共识指南：儿童和青少年垂体腺瘤的诊断和管理—第2部分：特定疾病\n# Consensus statement\n\n【1】and can cause pre-operative tumour shrinkage. In one paediatric patient, somatostatin analogues reduced thyroid hormone levels and tumour size, thereby postponing definitive surgery. Out of 44 patients aged 11–73 years on pre-operative somatostatin analogue treatment, 84% had normalization of thyroid function levels and 61% showed tumour shrinkage.\n\n【2】Surgery offers a potentially definitive cure. Even partial tumour debulking can be worthwhile in reducing TSH and free T4 levels, decompressing the optic apparatus or improving the effectiveness of subsequent medical therapy.\n\n【3】## Follow-up and surveillance.\n\n【4】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R47. Disease monitoring with regular thyroid function tests and regular MRI surveillance, similar to the protocols described for NFPA, is suggested in CYP with confirmed TSHomas删除32:<u>**</u> (weak recommendation, low-quality evidence, GDG consensus).\n\n【5】There is no evidence base to inform a surveillance schedule in CYP with TSHoma and the natural history of disease progression is unknown. We therefore suggest a pragmatic approach to biochemical and MRI surveillance to detect secondary hyperthyroidism and to identify those with rapid tumour progression or recurrence early, even if asymptomatic. Continued monitoring of thyroid function tests for 6 months after initial treatment, but the optimum interval currently remains unclear. Long-term biochemical and MRI surveillance should be individualized.\n\n【6】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R48. Consider pituitary radiotherapy in CYP with post-operative tumour remnant and at resistance to medical therapy or relapsing TSHomas if re-operation is not an option删除32:<u>**</u> (moderate recommendation, low-quality evidence, Delphi 92% and GDG consensus).\n\n【7】If surgery is unsuccessful or contraindicated and the paediatric patient with TSHoma fails to achieve normal thyroid function or shows tumour growth on somatostatin analogue therapy, radiotherapy could be considered.\n\n【8】## Incidentalomas and NFPAs\n\n<mark>【9】### Epidemiology and aetiology.\n\nClinically non-secreting pituitary adenomas account for 4–6% of all paediatric pituitary adenomas and for 10% of cases in a surgical series, in stark difference to adult pituitary patients where NFPAs account for 15–30% of clinically relevant pituitary adenomas and 50–60% of cases in a surgical series. Depending on case selection criteria, NFPAs represent 13–56% of incidentally discovered pituitary lesions (incidentalomas) in large retrospective radiological series of CYP. NFPAs also represent 25% of MEN1-associated pituitary lesions in CYP, and silent lesions detected by screening can be seen in patients with AIP variants. NFPAs in CYP usually present in the second decade of life, with increasing incidence thereafter. There is no consistent sex or female predisposition, although a 2019 surgical series in CYP reported a slight female predominance.</mark>\n【10】### Presentation.\nCYP with NFPAs, by definition, do not have features of a hypersecretory syndrome. Symptomatic NFPAs are macroadenomas, whereas microadenomas are usually discovered as a coincidental finding on an MRI scan. The clinical features of macroadenomas at presentation result from mass effects on surrounding structures. These include headache, visual field defects, pituitary apoplexy (probably more common than in adult NFPA) with or without mild prolactin elevation, or hypopituitarism manifesting as secondary amenorrhea, delayed puberty, hypothyroidism, hypocortisolaemia, growth failure and/or hyperprolactinaemia. Headache, visual impairment and hypogonadism were the most common presenting features in a surgical series in CYP. Immunohistochemistry for pituitary hormones in 14 NFPAs, from CYP aged 12–19 years, revealed plurihormonal tumours, 3 silent lactotrophs, 1 each of silent gonadotroph and a corticotroph, and 3 hormone-negative tumours (transcription factor staining not reported). These proportions are different from those in adult patients, where silent gonadotrophinomas represent the majority of NFPAs. Non-functioning pituitary microadenomas do not usually cause hypopituitarism or visual abnormalities.\n\n【11】## Diagnosis and investigation.\n\n【12】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R49. Identification of a pituitary incidentaloma or NFPA requires exclusion of clinical or laboratory evidence of pituitary hormone hypersecretion (except mild hyperprolactinaemia from pituitary stalk disruption); exclusion of elevation of serum levels of α-fetoprotein (AFP) and β-human chorionic gonadotropin (BHC) and the absence of other suprasellar tumours in all CYP with suspected NFPA删除32:<u>**</u> (strong recommendation, low-quality evidence, Delphi 100%).\n\n【13】If a pituitary mass is suspected on MRI, baseline and dynamic pituitary investigations should be undertaken as indicated clinically to confirm the absence of pituitary hormone excess from a functioning adenoma or the presence of hormone deficiency. The MRI appearance of a small Rathke cleft cyst or pars intermedia cyst can present a differential diagnosis for a clinically non-functioning microadenoma. Stalk compression from macroadenomas, or rarely microadenomas, can cause mild hyperprolactinaemia, usually below 2,000 mIU/l (94 μg/l).\n\n【14】Intracranial germ-cell tumours, more common in the adolescent age group than NFPAs, can present with similar MRI appearances. AFP and BHC (markers of germ-cell tumours) should be measured in the serum and, if clinically or radiologically indicated, also in the cerebrospinal fluid.\n\n【15】Hypopituitarism is common in children with symptomatic non-functioning pituitary macroadenoma. Basal and dynamic pituitary assessment is recommended following diagnosis of an NFPA together with prompt replacement therapy of thy cortisol, thyroid hormone, sex steroid and GH deficiency to optimize surgical, growth and well-being outcomes. Arginine vasopressin deficiency (also known as central diabetes insipidus) is an extremely infrequent finding at diagnosis of an NFPA unless the tumour has undergone apoplexy, and its presence strongly suggests an alternative diagnosis such as a craniopharyngioma, histiocytosis or germ-cell tumour.\n\n【16】Visual deterioration is a well-described presentation of NFPA in CYP, and an urgent indication for surgery to decompress the optic apparatus if sight is threatened. Thus, early assessment of visual acuity and visual fields is mandated.", "index": 3003, "show": true, "start": 2990, "end": 4232, "province": ["格式规范性", "多余换行"], "isEdit": false}, {"text": "Part 2: R49. Identification of a pituitary incidentaloma or NFPA requires exclusion of clinical or laboratory evidence of pituitary hormone hypersecretion (except mild hyperprolactinaemia from pituitary stalk disruption); exclusion of elevation of serum levels of α-fetoprotein (AFP) and β-human chorionic gonadotropin (BHC) and the absence of other suprasellar tumours in all CYP with suspected NFPA删除32: (strong recommendation, low-quality evidence, Delphi 100%).", "content": "【0】页码:14\n2024+共识指南：儿童和青少年垂体腺瘤的诊断和管理—第2部分：特定疾病\n# Consensus statement\n\n【1】and can cause pre-operative tumour shrinkage. In one paediatric patient, somatostatin analogues reduced thyroid hormone levels and tumour size, thereby postponing definitive surgery. Out of 44 patients aged 11–73 years on pre-operative somatostatin analogue treatment, 84% had normalization of thyroid function levels and 61% showed tumour shrinkage.\n\n【2】Surgery offers a potentially definitive cure. Even partial tumour debulking can be worthwhile in reducing TSH and free T4 levels, decompressing the optic apparatus or improving the effectiveness of subsequent medical therapy.\n\n【3】## Follow-up and surveillance.\n\n【4】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R47. Disease monitoring with regular thyroid function tests and regular MRI surveillance, similar to the protocols described for NFPA, is suggested in CYP with confirmed TSHomas删除32:<u>**</u> (weak recommendation, low-quality evidence, GDG consensus).\n\n【5】There is no evidence base to inform a surveillance schedule in CYP with TSHoma and the natural history of disease progression is unknown. We therefore suggest a pragmatic approach to biochemical and MRI surveillance to detect secondary hyperthyroidism and to identify those with rapid tumour progression or recurrence early, even if asymptomatic. Continued monitoring of thyroid function tests for 6 months after initial treatment, but the optimum interval currently remains unclear. Long-term biochemical and MRI surveillance should be individualized.\n\n【6】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R48. Consider pituitary radiotherapy in CYP with post-operative tumour remnant and at resistance to medical therapy or relapsing TSHomas if re-operation is not an option删除32:<u>**</u> (moderate recommendation, low-quality evidence, Delphi 92% and GDG consensus).\n\n【7】If surgery is unsuccessful or contraindicated and the paediatric patient with TSHoma fails to achieve normal thyroid function or shows tumour growth on somatostatin analogue therapy, radiotherapy could be considered.\n\n【8】## Incidentalomas and NFPAs\n\n<mark>【9】### Epidemiology and aetiology.\n\nClinically non-secreting pituitary adenomas account for 4–6% of all paediatric pituitary adenomas and for 10% of cases in a surgical series, in stark difference to adult pituitary patients where NFPAs account for 15–30% of clinically relevant pituitary adenomas and 50–60% of cases in a surgical series. Depending on case selection criteria, NFPAs represent 13–56% of incidentally discovered pituitary lesions (incidentalomas) in large retrospective radiological series of CYP. NFPAs also represent 25% of MEN1-associated pituitary lesions in CYP, and silent lesions detected by screening can be seen in patients with AIP variants. NFPAs in CYP usually present in the second decade of life, with increasing incidence thereafter. There is no consistent sex or female predisposition, although a 2019 surgical series in CYP reported a slight female predominance.</mark>\n<mark>【10】### Presentation.\n\nCYP with NFPAs, by definition, do not have features of a hypersecretory syndrome. Symptomatic NFPAs are macroadenomas, whereas microadenomas are usually discovered as a coincidental finding on an MRI scan. The clinical features of macroadenomas at presentation result from mass effects on surrounding structures. These include headache, visual field defects, pituitary apoplexy (probably more common than in adult NFPA) with or without mild prolactin elevation, or hypopituitarism manifesting as secondary amenorrhea, delayed puberty, hypothyroidism, hypocortisolaemia, growth failure and/or hyperprolactinaemia. Headache, visual impairment and hypogonadism were the most common presenting features in a surgical series in CYP. Immunohistochemistry for pituitary hormones in 14 NFPAs, from CYP aged 12–19 years, revealed plurihormonal tumours, 3 silent lactotrophs, 1 each of silent gonadotroph and a corticotroph, and 3 hormone-negative tumours (transcription factor staining not reported). These proportions are different from those in adult patients, where silent gonadotrophinomas represent the majority of NFPAs. Non-functioning pituitary microadenomas do not usually cause hypopituitarism or visual abnormalities.</mark>\n【11】## Diagnosis and investigation.\n\n【12】删除32:<u>*</u> 删除32:<u>**</u>Part 2: R49. Identification of a pituitary incidentaloma or NFPA requires exclusion of clinical or laboratory evidence of pituitary hormone hypersecretion (except mild hyperprolactinaemia from pituitary stalk disruption); exclusion of elevation of serum levels of α-fetoprotein (AFP) and β-human chorionic gonadotropin (BHC) and the absence of other suprasellar tumours in all CYP with suspected NFPA删除32:<u>**</u> (strong recommendation, low-quality evidence, Delphi 100%).\n\n【13】If a pituitary mass is suspected on MRI, baseline and dynamic pituitary investigations should be undertaken as indicated clinically to confirm the absence of pituitary hormone excess from a functioning adenoma or the presence of hormone deficiency. The MRI appearance of a small Rathke cleft cyst or pars intermedia cyst can present a differential diagnosis for a clinically non-functioning microadenoma. Stalk compression from macroadenomas, or rarely microadenomas, can cause mild hyperprolactinaemia, usually below 2,000 mIU/l (94 μg/l).\n\n【14】Intracranial germ-cell tumours, more common in the adolescent age group than NFPAs, can present with similar MRI appearances. AFP and BHC (markers of germ-cell tumours) should be measured in the serum and, if clinically or radiologically indicated, also in the cerebrospinal fluid.\n\n【15】Hypopituitarism is common in children with symptomatic non-functioning pituitary macroadenoma. Basal and dynamic pituitary assessment is recommended following diagnosis of an NFPA together with prompt replacement therapy of thy cortisol, thyroid hormone, sex steroid and GH deficiency to optimize surgical, growth and well-being outcomes. Arginine vasopressin deficiency (also known as central diabetes insipidus) is an extremely infrequent finding at diagnosis of an NFPA unless the tumour has undergone apoplexy, and its presence strongly suggests an alternative diagnosis such as a craniopharyngioma, histiocytosis or germ-cell tumour.\n\n【16】Visual deterioration is a well-described presentation of NFPA in CYP, and an urgent indication for surgery to decompress the optic apparatus if sight is threatened. Thus, early assessment of visual acuity and visual fields is mandated.", "index": 4328, "show": true, "start": 4302, "end": 4767, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "后面缺少一段正文"}], "startTime": "2024/08/06 15:52:35", "endTime": "2024/08/06 15:54:04", "cost": 89.014}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-05 23:54:05", "grab_time": "2024-08-05 23:52:35"}
{"id": 2211487, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "3c3cfc40-59ae-47de-b69e-b5f9809e664d", "title": "2023 EACVI_ESC临床共识声明：胸主动脉疾病多模式成像 (1)", "text": "【0】页码:15\n2023 EACVI_ESC临床共识声明：胸主动脉疾病多模式成像 (1)\nTable 2  Risk score for acute aortic syndrome 删除19:<u>(adapted from Ohle et al.)</u>\n\n| Clinical history                                          | Point score           | Score                                  |\n|----------------------------------------------------------|-----------------------|----------------------------------------|\n| Marfan syndrome (or other connective tissue diseases)    | No risk factors: 0; Any non-aneurysmal risk factors: 1; aortic aneurysm: 2 | 0: Low-risk probability (< 0.5%)<br>1: Moderate-risk probability (0.5–5%)<br>≥2: High-risk probability (>5%) |\n| Family history of aortic disease                         |                       |                                        |\n| Known aortic valve disease                               |                       |                                        |\n| Known thoracic aortic aneurysm                           |                       |                                        |\n| Previous aortic manipulation (including cardiac surgery) |                       |                                        |\n| Symptoms                                                 |                       |                                        |\n| Chest, back, or abdominal pain described as any of the following: <br>• abrupt onset<br>• severe intensity<br>• ripping or tearing | No high-risk pain features: 0; 1 or 2 high-risk pain features: 1; 3 or more high-risk pain features: 2 | |\n| Clinical examination (signs)                             | No high-risk physical examination findings: 0; any high-risk physical examination findings: 2 | |\n| Evidence of perfusion deficit:<br>• systolic blood pressure difference<br>• focal neurological deficit (in conjunction with pain)<br>• pulse deficit<br>• aortic diastolic murmur (new and with pain)<br>• Hypotension or shock | |\n\n【2】参考删除-3:<u>Notes: \nOhle R, Yan JW, Yadav K, Coumoyer A, Savage DWJ, Jetty P, et al. Diagnosing acute aortic syndrome: A Canadian clinical practice guideline. CMAJ 2020 Jul 20; 192: E832-E843.</u>\n\n【3】Traumatic and iatrogenic injury to the thoracic aorta\nA variety of aortic lesions can result from blunt aortic trauma such as aortic transection, pseudoaneurysm formation, IMH, or AD. The most common location of aorta traumatic injury is at the aortic isthmus just distal to the left subclavian artery. The second most common location is the supravalvular portion of the ascending aorta. Contrast-enhanced CT is currently the preferred first-line imaging technique for blunt aortic injury, especially for patients with multiple injuries. TOE and aortography might be of help when CT findings are equivocal. In some haemodynamically unstable patients, TOE may be a first-line test, especially if CT requires transportation to a remote area.\n\n【4】Iatrogenic injury to the thoracic aorta may occur in the setting of catheter-based interventions, during surgery or endovascular treatment. Usually, the diagnosis of this lesion is straightforward during angiography, characterized by stagnation of contrast at the level of the aortic root or ascending aorta or by the development of IMH. In this setting, IMH diagnosis requires an additional TOE or CT.\n\n【5】Advantages, limitations, and comparison among the different imaging modalities in the evaluation of AAS are summarized in Table 2. Because of the importance of prompt recognition to their successful treatment, this table not only emphasizes the diagnostic power of each technique but also suggests that not any single modality is preferred for all patients and that the choice of imaging modality depends on the patient's clinical condition and local institutional factors such as expertise and availability.\n\n【6】Imaging follow-up after AAS\nAs patients are still at risk of complications after an AAS, follow-up by CT or CMR is indicated depending on availability and patient characteristics at 1–3, 6, 12 months, and annually thereafter. After an ascending AD repair, complications such as local bleeding, graft infection, and pseudoaneurysm can be present. Slight fibrotic peri-graft thickening is common following surgery; however, large or asymmetrical thickening may represent localized haematoma caused by anastomotic leakage, often observed at the site of the remaining colored aorta.\n\n【7】Various poor prognostic imaging signs should be considered after the acute phase of AD. A persistent patent FL in the descending thoracic aorta and a maximum aorta diameter >45 mm have been related to an increased growth rate with a high risk of rupture if the maximum diameter is >60 mm or annual growth >5 mm. A large entry tear (diameter >10 mm) in the proximal descending aorta is another established predictor of adverse events. An absolute tear area difference (proximal vs. distal tears) >1.2 cm² has been also considered as an important risk factor. However, it may be difficult to identify the distal re-entry communication; thus, in the presence of a large entry tear, indirect signs such as TL compression or partial FL thrombosis should be considered. High systolic antegrade flow in the FL with significant retrograde diastolic flow assessed by 2D phase-contrast MRI identifies patients with a higher risk of complications. 删除17:<u>2</u>D phase-contrast and 4D-flow MRI also hold promise in the functional assessment of FL flow after AD.\n\n【8】IMH evolution is very dynamic and may result in complete resorption with or without aorta dilation, focal intimal disruption leading to ulcer-like images, or less frequently classical AD. Given their wider field of view, CMR and CT are better than TOE at defining this dynamic evolution. CMR allows monitoring the evolution of intramural bleeding and can depict episodes of new asymptomatic intramural re-bleeding. An aorta diameter >50 mm and enlargement of focal intimal disruptions have been considered risk factors for adverse outcomes, particularly in the ascending aorta.\n\n【9】Many patients with PAD do not need immediate aortic repair but do require close follow-up with serial imaging studies (by CT or CMR) to detect disease progression. In these cases, size and enlargement are the only predictors of complications and both CT and CMR are the preferred imaging modalities for follow-up.", "tags": {}, "lang": "en", "attr": {"page_num": 15, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 EACVI_ESC临床共识声明：胸主动脉疾病多模式成像 (1).pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:30:01", "endTime": "2024/08/06 16:31:20", "cost": 79.024}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:31:20", "grab_time": "2024-08-06 00:30:01"}
{"id": 2211486, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "357a18ff-b3ee-4db8-a57e-f212122f3308", "title": "HHS：HIV感染的成人及青少年应用抗逆转录病毒药物治疗指南（2022）", "text": "【0】页码:66\nHHS：HIV感染的成人及青少年应用抗逆转录病毒药物治疗指南（2022）\nRegimens and medications listed in 删除9:<u>[Table 10]</u> are not recommended as initial therapy. In most instances, a clinician is urged to consider switching a patient who is on one of the regimens listed in Table 10 to a recommended regimen.\n\n【1】In addition to these tables, several other tables provide clinicians with guidance on selecting and prescribing an optimal regimen for an individual patient. 删除9:<u>[Table 9]</u> lists the potential advantages and disadvantages of the different ARV drug components. Appendix B, Tables 3–10 list characteristics of individual ARV agents (e.g., formulations; dosing recommendations, PKs, common adverse effects). Appendix B, 删除9:<u>[Table 11]</u> provides ARV dosing recommendations for patients who have renal or hepatic insufficiency.\n\n【2】### Changes Since the Last Revision of the Guidelines\nSince the last revision of these guidelines, the Panel has made several important changes to the recommendations for initial therapy in people with HIV. Among these changes, the following deserve emphasis:\n\n【3】- Raltegravir (RAL), in combination with FTC or 3TC and TDF or TAF, is now recommended as an Initial Regimen in Certain Clinical Circumstances. This change is made primarily because RAL has a lower barrier to resistance than DTG or bictegravir 删除9:<u>(BIC), it is not part of any single-tablet regimen (STR)</u>, and RAL-containing regimens have a higher pill burden than those containing DTG or BIC.\n\n【4】- The Panel previously recommended DTG as an alternative ARV in individuals of childbearing potential who are trying to conceive or who are sexually active and not using effective contraception, because preliminary data from a birth outcome surveillance study in Botswana raised concern that DTG use around the time of conception may be associated with an increased risk of infant neural tube defects (NTDs). Additional results from the same study have shown that the prevalence of infant NTDs, in association with DTG exposure at conception, is substantially lower than in the preliminary data. This rate was slightly higher than with non-DTG containing regimens, but the difference was not statistically significant. Because of these newer data, the Panel now considers DTG a recommended option for people of childbearing potential. Before initiating a DTG-based regimen, clinicians should discuss the risks and benefits of using DTG with people of childbearing potential to allow them to make an informed decision. Clinicians should refer to the Perinatal Guidelines for more detailed recommendations on the safety and effectiveness of ARV drugs during conception and throughout pregnancy.\n\n【5】- Data from studies showing increased weight gain with particular ARV medications, including some INSTIs and TAF and especially in certain patient populations (i.e., women, Black and Hispanic populations), are updated.\n\n【6】### Table 6. Recommended Antiretroviral Regimens for Initial Therapy 删除19:<u>(Last updated June 3, 2021; last reviewed June 3, 2021)</u>\n\n【7】Selection of a regimen should be individualized based on virologic efficacy, potential adverse effects, childbearing potential and use of effective contraception, pill burden, dosing frequency, drug-drug interaction potential, comorbid conditions, cost, access, and resistance test results. A pregnancy test should be performed in people of childbearing potential, and choice of antiretroviral therapy (ART) for individuals who are pregnant should be guided by recommendations from the Perinatal Guidelines. Drug classes and regimens within each class are arranged first by evidence rating and, when ratings are equal, in alphabetical order. 删除9:<u>[Table 7]</u> provides ARV recommendations based on specific clinical scenarios.", "tags": {}, "lang": "en", "attr": {"page_num": 66, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/HHS：HIV感染的成人及青少年应用抗逆转录病毒药物治疗指南（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Regimens and medications listed in 删除9:[Table 10] are not recommended as initial therapy. In most instances, a clinician is urged to consider switching a patient who is on one of the regimens listed in Table 10 to a recommended regimen.", "content": "【0】页码:66\nHHS：HIV感染的成人及青少年应用抗逆转录病毒药物治疗指南（2022）\nRegimens and medications listed in 删除9:<u>[Table 10]</u> are not recommended as initial therapy. In most instances, a clinician is urged to consider switching a patient who is on one of the regimens listed in Table 10 to a recommended regimen.\n\n【1】In addition to these tables, several other tables provide clinicians with guidance on selecting and prescribing an optimal regimen for an individual patient. 删除9:<u>[Table 9]</u> lists the potential advantages and disadvantages of the different ARV drug components. Appendix B, Tables 3–10 list characteristics of individual ARV agents (e.g., formulations; dosing recommendations, PKs, common adverse effects). Appendix B, 删除9:<u>[Table 11]</u> provides ARV dosing recommendations for patients who have renal or hepatic insufficiency.\n\n【2】### Changes Since the Last Revision of the Guidelines\nSince the last revision of these guidelines, the Panel has made several important changes to the recommendations for initial therapy in people with HIV. Among these changes, the following deserve emphasis:\n\n【3】- Raltegravir (RAL), in combination with FTC or 3TC and TDF or TAF, is now recommended as an Initial Regimen in Certain Clinical Circumstances. This change is made primarily because RAL has a lower barrier to resistance than DTG or bictegravir 删除9:<u>(BIC), it is not part of any single-tablet regimen (STR)</u>, and RAL-containing regimens have a higher pill burden than those containing DTG or BIC.\n\n【4】- The Panel previously recommended DTG as an alternative ARV in individuals of childbearing potential who are trying to conceive or who are sexually active and not using effective contraception, because preliminary data from a birth outcome surveillance study in Botswana raised concern that DTG use around the time of conception may be associated with an increased risk of infant neural tube defects (NTDs). Additional results from the same study have shown that the prevalence of infant NTDs, in association with DTG exposure at conception, is substantially lower than in the preliminary data. This rate was slightly higher than with non-DTG containing regimens, but the difference was not statistically significant. Because of these newer data, the Panel now considers DTG a recommended option for people of childbearing potential. Before initiating a DTG-based regimen, clinicians should discuss the risks and benefits of using DTG with people of childbearing potential to allow them to make an informed decision. Clinicians should refer to the Perinatal Guidelines for more detailed recommendations on the safety and effectiveness of ARV drugs during conception and throughout pregnancy.\n\n【5】- Data from studies showing increased weight gain with particular ARV medications, including some INSTIs and TAF and especially in certain patient populations (i.e., women, Black and Hispanic populations), are updated.\n\n【6】### Table 6. Recommended Antiretroviral Regimens for Initial Therapy 删除19:<u>(Last updated June 3, 2021; last reviewed June 3, 2021)</u>\n\n【7】Selection of a regimen should be individualized based on virologic efficacy, potential adverse effects, childbearing potential and use of effective contraception, pill burden, dosing frequency, drug-drug interaction potential, comorbid conditions, cost, access, and resistance test results. A pregnancy test should be performed in people of childbearing potential, and choice of antiretroviral therapy (ART) for individuals who are pregnant should be guided by recommendations from the Perinatal Guidelines. Drug classes and regimens within each class are arranged first by evidence rating and, when ratings are equal, in alphabetical order. 删除9:<u>[Table 7]</u> provides ARV recommendations based on specific clinical scenarios.", "index": 46, "show": true, "start": 46, "end": 282, "province": ["信息质量", "完整性"], "isEdit": false, "comment": "0"}], "startTime": "2024/08/06 16:46:29", "endTime": "2024/08/06 16:58:57", "cost": 748.085}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:58:58", "grab_time": "2024-08-06 00:46:29"}
{"id": 2211485, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "d3d94965-48ea-4a38-9320-8b5090285ec7", "title": "WHO：促进积极产后体验的产妇和新生儿护理建议（2022）", "text": "【0】页码:38\nWHO：促进积极产后体验的产妇和新生儿护理建议（2022）\nreceiving ice packs and cold gel pads were considered in this comparison. Primary authors reported data in different ways, so they were presented combined in a meta-analysis when possible, or separately.\n\n【1】### Maternal outcomes\n\n【2】删除32:<u>**</u>Relief of symptoms:删除32:<u>**</u> It is uncertain whether ice packs reduce perineal pain, perineal oedema and perineal bruising within 4–6 hours after birth when compared with cold gel pads (very low-certainty evidence). It is uncertain whether ice packs reduce perineal pain, redness, oedema, bruising, discharge or wound gaping within 24 hours, or 24–48 hours after birth, when compared with cold gel pads (very low-certainty evidence).\n\n【3】删除32:<u>**</u>Health service use:删除32:<u>**</u> It is uncertain whether ice packs affect additional prescription or non-prescription analgesia for relief of perineal pain within 24 hours, or 24–48 hours after birth, when compared with cold gel pads (very low-certainty evidence).\n\n【4】删除32:<u>**</u>Maternal functioning/well-being:删除32:<u>**</u> It is uncertain whether ice packs reduce pain associated with sitting within 24 hours of birth, or 24–48 hours after vaginal birth, when compared with cold gel pads (very low-certainty evidence). It is uncertain whether ice packs reduce pain associated with walking within 24 hours of birth, or 24–48 hours after birth, when compared with cold gel pads (very low-certainty evidence). It is uncertain whether ice packs reduce pain associated with feeding the baby within 24 hours, or 24–48 hours after birth, when compared with cold gel pads (very low-certainty evidence).\n\n【5】删除32:<u>**</u>Experience of postnatal care:删除32:<u>**</u> It is uncertain whether ice packs affect women’s opinion on treatment affects (good to excellent) at day five, when compared with cold gel pads (very low-certainty evidence). It is uncertain whether ice packs affect women being satisfied with overall perineal care (good to excellent) at day 10, when compared with cold gel pads (very low-certainty evidence).\n\n【6】删除32:<u>**</u>Adverse effects删除32:<u>**</u> directly related to the use of cooling techniques (e.g. cold burn) were not reported in the systematic review.\n\n【7】### Newborn outcomes\n\n【8】删除32:<u>**</u>Breastfeeding status:删除32:<u>**</u> It is uncertain whether ice packs affect the number of women providing any breastmilk to the baby 48 hours after birth, when compared with cold gel pads (very low-certainty evidence).\n\n【9】### Additional considerations\n\n【10】Whether the effects of the interventions differed by type of perineal trauma (episiotomy versus tear) is unknown, as no such subgroup analyses were included in the systematic review (included subgroup analyses were parity and mode of birth).\n\n【11】#### Values\nSee Box 3.1 in section 3.A.2: Interventions for common physiological signs and symptoms.\n\n【12】#### Resources\nNo economic evaluations of non-pharmacological interventions for relieving perineal pain were identified.\n\n【13】#### Additional considerations\nNon-pharmacological interventions such as local cooling are relatively inexpensive where the necessary infrastructure and facilities already exist.\n\n【14】#### Equity\nNo direct evidence was identified on the impact on health equity of non-pharmacological interventions for relieving postpartum perineal pain. Non-pharmacological interventions based on local cooling for relieving postpartum perineal pain may decrease equity, as many of these interventions require access to clean water, refrigeration, ice and cold storage, which is limited in many low-income countries. Access to gel pads for local cooling may also be limited in these settings. However, in settings where women have access to clean water, refrigeration, ice and cold storage, non-pharmacological interventions based on local cooling may increase equity.\n\n【15】#### Acceptability\nSee Box 3.2 in section 3.A.2: Interventions for common physiological signs and symptoms.\n\n【16】#### Feasibility\nSee Box 3.3 in section 3.A.2: Interventions for common physiological signs and symptoms.\n\n【17】#### Additional considerations\nAccess to clean water, refrigeration, ice, cold storage and gel pads is limited in many low-income countries.", "tags": {}, "lang": "en", "attr": {"page_num": 38, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/WHO：促进积极产后体验的产妇和新生儿护理建议（2022）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:27:39", "endTime": "2024/08/06 16:28:19", "cost": 40.142}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:28:19", "grab_time": "2024-08-06 00:27:39"}
{"id": 2211484, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "86348625-1e62-4f77-b83a-78188d5ab438", "title": "闭经诊断与治疗指南（2023版）", "text": "【0】页码:3\n闭经诊断与治疗指南（2023版）\n## 容易出现早发性卵巢功能不全（premature ovarian insufficiency，POI）\n\n【1】2. 删除11:<u>(2)</u> XO/XY 性腺发育不全：染色体核型为 45，X/46，XY，且往往为隐匿型性腺发育不全。性腺可以是残存不全的睾丸或卵巢与条索性腺混合存在，也可以是双侧发育不全的卵巢、卵巢或条索状性腺。临床表现有 Turner 综合征的表现，部分患者有卵巢畸胎瘤。此类患者的性腺容易发生肿瘤。\n\n【2】3. 卵巢性腺发育不全：患者有正常的女性内外生殖器，双侧性腺呈条索状，染色体核型为 46，XX 或 46，XY。患者有性看历均接女孩生活，原发性闭经，青春期明显延，能无基础时期，腺可发育。内外生殖器发育均能，有的卵管、子宫及阴道上了周期期月经未能侧。血 FSH40 UL 佳激素水平低。染色体核型为46,XY者其他核努力发性腺肿瘤。\n\n【3】POI 与卵巢早衰：POI, 指在性龄40岁之前出现的卵巢功能减退，主要表现为月经异常（月经、月经稀发）、FSH≥25 UL，雌激素水平波动性下降波<。根据是否有自凸月经分为：原发性暨细胞功能早馑 POI 和继发性 POI。前者表现为原发性闭经后、后者随着卵巢功能逐渐消，表现是周期掉轴维月经、周期不规则月经稀发、闭经。多数妇女可出现无明显诱因的月经突然惨止。\n\n【4】卵巢早衰（premature ovarian failure，POF）则指女性 40 岁以前出现闭经，Gn 水平升高 (FSH 40 UL) 和雌激素水平降低，伴有行不同程度的低雌激素症状，常被认为是 POI 的终末阶段删除14:<u>[1，2]</u>。POI, POF 的发生与遗传因素、自身免疫功能紊乱、感染因素、化疗、放疗等子杀伤骨穿等或其他因素的攒医疗环境因素等有关删除14:<u>[1，2，3]</u>。然而，1/2以上的 POI 患者病因不可明确，称为特发性 POI删除12:<u>删除14:<u>[1]</u></u>。卵巢储备功能下降至功能衰减，可以延年，通过极期时，临床常表现性月、体检至早较大。\n\n【5】3. ROS：指卵巢毁小卵泡，有较多的原始卵泡，而无生长卵泡，对对膜性外颗粒 Gn 刺激反无反应，称为卵巢破碎综合征删除12:<u>删除14:<u>[1]</u></u>。ROS 的病因常不明确，前端自 Gn 药按龙穿等引起，主要临床表现为原发性闭经，Gn 水水平正常，特别是 FSH 水平异常（常高40-200 UL），抗苗勒激素（AMH）挨近同龄女性的平均水平删除12:<u>删除14:<u>[1]</u></u>。血臂起应检测未有卵失太及岁酸较数目在正常范围。\n\n【6】（二）生殖异常\n子宫性腺综合为先天性与获得性两种，NI及腺二腔水平正常。\n\n【7】1. 先天性：（1）Mayer-Rokitansky-Küster-Hauser (MRKH)综合征：是指指出期时子双侧卵巢管管形极好的宫段极融峡而导致失无生死子宫，或双侧卵巢管管不合而致心鲨上段联，致子段不良下良t，表现为子宫极小，甚至内阴。该类患者卵巢发育，生殖激素水平正常，第二性征会正常，常合并泌尿系统先天性畸形及失无性无阴道。\n\n【8】2. 继发性不敏感综合征：染色体核型为 46,XY。由于雄激素受体异常，引起雄激素部分敏应全部敏部分失应而导致女孩的性麻表现，较女性生正常有则为完全子的性表观 (称为完全型) 或孰有极初男性化表现 (称为部分型)。患者有约女孩性基作表型性表现（称为为部分型）。患者有约女孩性基作表型，通常幼儿期别超可及阴或腺破竖形成外滴。完全型患者成索有表现为阴发性排因，女性生标，青春期胡别人表现似头发育差，阴毛，腺已或未然少。女性别，对月阴、小阴唇除发育有不同程度的男性化，包括术小的阴蒂和阴唇的部分融。雌激素在能撑男性术家，尤其是雌激素部表齐女士水平溪删除12:<u>删除14:<u>[1]</u></u>\n\n【9】3. 莫林柱：因子宫内膜灌 群未术放射性创伤引起子宫内膜基底层损伤反宫腔粘连引起的闭经:\n\n【10】删除11:<u>(1)</u>子宫内膜基底层破坏：如子宫内膜被划引起子宫内膜基质纤不度、较而收适。避 类：化子宫内膜厚后细胞性愈伤组织成放疗,可能双子宫内膜的恭层细暴,而致闭经。若宫内膜癌患者完全表内试.将手致永久性闭经。可表或月发子生其迹发生性不放现.\n（2）宫腔粘连：致子宫内膜损执性综合征 (Asherman 综合征)：是接先性子宫性异常后的突发原因。该综合症月宫内膜异性性性质创后1，常发在非反复宫腔操作如人工流产，剖宫手术，或子宫后血辆。子宫内膜腺由叶割剖6过也。宫腔粘连过程于子瘀粘连，子宫内膜细胞得的普 增和困腺受要期,可同于宫内膜反应或子宫内膜破伽形效果因引起闭经。\n\n【11】（二）下丘脑检测相关闭经。\nGn米腺-激素水平正常。\n\n【12】1. 子宫颈发育异常:先天性子宫颈闭锁除上罕见,另生于环臻来溢-子宫颈发育中差到：子宫小闭症等。若者宫颈使其功能时,月经未渲后因宫管晚塞肠而,出现周期性下腹期,盆血流不经常输管流出然被阻，出,提膝在 分裂其结合于宫颈外周多月闭困, 妊娠松性无子宫狤外闭困发，会当宫腔阻佩时，妊娠松", "tags": {}, "lang": "zh", "attr": {"page_num": 3, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/闭经诊断与治疗指南（2023版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 16:59:31", "endTime": "2024/08/06 17:00:49", "cost": 77.876}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 01:00:50", "grab_time": "2024-08-06 00:59:31"}
{"id": 2211483, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "00b69abd-0ab6-4b4f-af92-d533911cf0dc", "title": "儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）", "text": "【0】页码:5\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n### 6.2  尤其在恢复期患者体质差\n\n【1】本病早期低烧轻度发烧寒战后，病期也多变形，风热等症状。表现为无明显炎症，治疗以扶正祛邪为主，多从肺、脾、胃论治，根据不同证候类型，分别采用清热利湿、凉血消风等治法。临床上多明、温阳利水、疏风润燥、清血化痰、清热解毒疏肝清热。紫黄方汤经久重止，肺脾兼治，故而临床多用于炎症病者的结余。\n\n【2】#### 6.2.1 主证\n\n【3】##### 6.2.1.1 湿热内侵证\n\n【4】删除32:<u>**</u>治法：清热利湿。删除32:<u>**</u>\n\n【5】删除32:<u>**</u>药方：小陷钝子（《重订民沃法方》）加减（III级证据，强推荐）。药物组成：小陷钝 15 g，生地黄 30 g，蒲黄 9 g，萎药 12 g，神石 15 g，木通 6 g，淡竹叶 9 g，栀子 9 g，当归 6 g，麦轩 6 g。删除32:<u>**</u>\n\n【6】删除32:<u>**</u>中成药：① 莲黄胶囊：0.2 g/粒。口服，1~3 岁 1 粒/次，3~6 岁 2 粒/次，6~12 岁 3 粒/次，12~18 岁 4 粒/次，1 次/d，<6 岁倾向医院营内药剂通水化服，用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。② 贯柏清解颗：10 g/袋。口服，1~3 岁 0.5 袋/次，3~12 岁 1 袋/次，2 次/d。用法用量参考药品说明书（V 级证据，弱推荐）。③ 复肝宁胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【7】##### 6.2.1.2 肺脾气虚证\n\n【8】删除32:<u>**</u>治法：益气养阴。删除32:<u>**</u>\n\n【9】删除32:<u>**</u>药方：玉屏风散（《医方类聚》）合六君子汤（《太平惠民和剂局方》）加减（Ⅲ级证据，强推荐）。药物组成：防风 30 g，黄芪 60 g，陈皮 3 g，半夏 4.5 g，茯苓 3 g，炙甘草 3 g，人参 3 g。删除32:<u>**</u>\n\n【10】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服，用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。② 贯药：10 g/袋。口服，1~3 岁 0.5 袋/次，3~12 岁 1 袋/次，2 次/d。用法用量参考药品说明书（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【11】##### 6.2.1.3 湿痰壅肺证\n\n【12】删除32:<u>**</u>治法：燥湿祛痰。删除32:<u>**</u>\n\n【13】删除32:<u>**</u>药方：二陈汤（《太平惠民和剂局方》）加减（Ⅲ级证据，强推荐）。药物组成：半夏 6 g，橘红 6 g，白茯苓 12 g，生姜 9 g，甘草 6 g，白芥子 9 g，炙麻黄 9 g，甘草 6 g，桔梗 9 g。删除32:<u>**</u>\n\n【14】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【15】##### 6.2.1.4 气阴两虚证\n\n【16】删除32:<u>**</u>治法：益气养阴。删除32:<u>**</u>\n\n【17】删除32:<u>**</u>药方：生地黄汤（《未病流派》）加减（Ⅲ级证据，强推荐）。药物组成：人参 6 g，炙甘草 3 g，麦冬 9 g，芦根 9 g，黄芪 15 g，牛膝 9 g。删除32:<u>**</u>\n\n【18】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【19】##### 6.2.1.5 脾胃湿热证\n\n【20】删除32:<u>**</u>治法：温阳利水。删除32:<u>**</u>\n\n【21】删除32:<u>**</u>药方：附子理中丸（《医方类聚》）加减（Ⅲ级证据，强推荐）。药物组成：人参 9 g，白术 9 g，甘草 6 g，茯苓 6 g，生姜 6 g，白芍 9 g，防风 6 g。删除32:<u>**</u>\n\n【22】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>", "tags": {}, "lang": "zh", "attr": {"page_num": 5, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "【14】删除32:中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》(32)（V 级证据，弱推荐）", "content": "【0】页码:5\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n### 6.2  尤其在恢复期患者体质差\n\n【1】本病早期低烧轻度发烧寒战后，病期也多变形，风热等症状。表现为无明显炎症，治疗以扶正祛邪为主，多从肺、脾、胃论治，根据不同证候类型，分别采用清热利湿、凉血消风等治法。临床上多明、温阳利水、疏风润燥、清血化痰、清热解毒疏肝清热。紫黄方汤经久重止，肺脾兼治，故而临床多用于炎症病者的结余。\n\n【2】#### 6.2.1 主证\n\n【3】##### 6.2.1.1 湿热内侵证\n\n【4】删除32:<u>**</u>治法：清热利湿。删除32:<u>**</u>\n\n【5】删除32:<u>**</u>药方：小陷钝子（《重订民沃法方》）加减（III级证据，强推荐）。药物组成：小陷钝 15 g，生地黄 30 g，蒲黄 9 g，萎药 12 g，神石 15 g，木通 6 g，淡竹叶 9 g，栀子 9 g，当归 6 g，麦轩 6 g。删除32:<u>**</u>\n\n【6】删除32:<u>**</u>中成药：① 莲黄胶囊：0.2 g/粒。口服，1~3 岁 1 粒/次，3~6 岁 2 粒/次，6~12 岁 3 粒/次，12~18 岁 4 粒/次，1 次/d，<6 岁倾向医院营内药剂通水化服，用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。② 贯柏清解颗：10 g/袋。口服，1~3 岁 0.5 袋/次，3~12 岁 1 袋/次，2 次/d。用法用量参考药品说明书（V 级证据，弱推荐）。③ 复肝宁胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【7】##### 6.2.1.2 肺脾气虚证\n\n【8】删除32:<u>**</u>治法：益气养阴。删除32:<u>**</u>\n\n【9】删除32:<u>**</u>药方：玉屏风散（《医方类聚》）合六君子汤（《太平惠民和剂局方》）加减（Ⅲ级证据，强推荐）。药物组成：防风 30 g，黄芪 60 g，陈皮 3 g，半夏 4.5 g，茯苓 3 g，炙甘草 3 g，人参 3 g。删除32:<u>**</u>\n\n【10】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服，用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。② 贯药：10 g/袋。口服，1~3 岁 0.5 袋/次，3~12 岁 1 袋/次，2 次/d。用法用量参考药品说明书（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【11】##### 6.2.1.3 湿痰壅肺证\n\n【12】删除32:<u>**</u>治法：燥湿祛痰。删除32:<u>**</u>\n\n【13】删除32:<u>**</u>药方：二陈汤（《太平惠民和剂局方》）加减（Ⅲ级证据，强推荐）。药物组成：半夏 6 g，橘红 6 g，白茯苓 12 g，生姜 9 g，甘草 6 g，白芥子 9 g，炙麻黄 9 g，甘草 6 g，桔梗 9 g。删除32:<u>**</u>\n\n【14】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【15】##### 6.2.1.4 气阴两虚证\n\n【16】删除32:<u>**</u>治法：益气养阴。删除32:<u>**</u>\n\n【17】删除32:<u>**</u>药方：生地黄汤（《未病流派》）加减（Ⅲ级证据，强推荐）。药物组成：人参 6 g，炙甘草 3 g，麦冬 9 g，芦根 9 g，黄芪 15 g，牛膝 9 g。删除32:<u>**</u>\n\n【18】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【19】##### 6.2.1.5 脾胃湿热证\n\n【20】删除32:<u>**</u>治法：温阳利水。删除32:<u>**</u>\n\n【21】删除32:<u>**</u>药方：附子理中丸（《医方类聚》）加减（Ⅲ级证据，强推荐）。药物组成：人参 9 g，白术 9 g，甘草 6 g，茯苓 6 g，生姜 6 g，白芍 9 g，防风 6 g。删除32:<u>**</u>\n\n【22】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>", "index": 1457, "show": true, "start": 1457, "end": 1602, "province": ["语义有效性", "语义不完整"], "isEdit": false}, {"text": "【18】删除32:中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》(32)（V 级证据，弱推荐）", "content": "【0】页码:5\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n### 6.2  尤其在恢复期患者体质差\n\n【1】本病早期低烧轻度发烧寒战后，病期也多变形，风热等症状。表现为无明显炎症，治疗以扶正祛邪为主，多从肺、脾、胃论治，根据不同证候类型，分别采用清热利湿、凉血消风等治法。临床上多明、温阳利水、疏风润燥、清血化痰、清热解毒疏肝清热。紫黄方汤经久重止，肺脾兼治，故而临床多用于炎症病者的结余。\n\n【2】#### 6.2.1 主证\n\n【3】##### 6.2.1.1 湿热内侵证\n\n【4】删除32:<u>**</u>治法：清热利湿。删除32:<u>**</u>\n\n【5】删除32:<u>**</u>药方：小陷钝子（《重订民沃法方》）加减（III级证据，强推荐）。药物组成：小陷钝 15 g，生地黄 30 g，蒲黄 9 g，萎药 12 g，神石 15 g，木通 6 g，淡竹叶 9 g，栀子 9 g，当归 6 g，麦轩 6 g。删除32:<u>**</u>\n\n【6】删除32:<u>**</u>中成药：① 莲黄胶囊：0.2 g/粒。口服，1~3 岁 1 粒/次，3~6 岁 2 粒/次，6~12 岁 3 粒/次，12~18 岁 4 粒/次，1 次/d，<6 岁倾向医院营内药剂通水化服，用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。② 贯柏清解颗：10 g/袋。口服，1~3 岁 0.5 袋/次，3~12 岁 1 袋/次，2 次/d。用法用量参考药品说明书（V 级证据，弱推荐）。③ 复肝宁胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【7】##### 6.2.1.2 肺脾气虚证\n\n【8】删除32:<u>**</u>治法：益气养阴。删除32:<u>**</u>\n\n【9】删除32:<u>**</u>药方：玉屏风散（《医方类聚》）合六君子汤（《太平惠民和剂局方》）加减（Ⅲ级证据，强推荐）。药物组成：防风 30 g，黄芪 60 g，陈皮 3 g，半夏 4.5 g，茯苓 3 g，炙甘草 3 g，人参 3 g。删除32:<u>**</u>\n\n【10】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服，用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。② 贯药：10 g/袋。口服，1~3 岁 0.5 袋/次，3~12 岁 1 袋/次，2 次/d。用法用量参考药品说明书（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【11】##### 6.2.1.3 湿痰壅肺证\n\n【12】删除32:<u>**</u>治法：燥湿祛痰。删除32:<u>**</u>\n\n【13】删除32:<u>**</u>药方：二陈汤（《太平惠民和剂局方》）加减（Ⅲ级证据，强推荐）。药物组成：半夏 6 g，橘红 6 g，白茯苓 12 g，生姜 9 g，甘草 6 g，白芥子 9 g，炙麻黄 9 g，甘草 6 g，桔梗 9 g。删除32:<u>**</u>\n\n<mark>【14】删除32:中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》(32)（V 级证据，弱推荐）</mark>（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【15】##### 6.2.1.4 气阴两虚证\n\n【16】删除32:<u>**</u>治法：益气养阴。删除32:<u>**</u>\n\n【17】删除32:<u>**</u>药方：生地黄汤（《未病流派》）加减（Ⅲ级证据，强推荐）。药物组成：人参 6 g，炙甘草 3 g，麦冬 9 g，芦根 9 g，黄芪 15 g，牛膝 9 g。删除32:<u>**</u>\n\n【18】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【19】##### 6.2.1.5 脾胃湿热证\n\n【20】删除32:<u>**</u>治法：温阳利水。删除32:<u>**</u>\n\n【21】删除32:<u>**</u>药方：附子理中丸（《医方类聚》）加减（Ⅲ级证据，强推荐）。药物组成：人参 9 g，白术 9 g，甘草 6 g，茯苓 6 g，生姜 6 g，白芍 9 g，防风 6 g。删除32:<u>**</u>\n\n【22】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>", "index": 1821, "show": true, "start": 1808, "end": 1953, "province": ["语义有效性", "语义不完整"], "isEdit": false}, {"text": "6.2 尤其在恢复期患者体质差", "content": "【0】页码:5\n儿童过敏性紫癜性肾炎中西医结合诊疗指南（2023）\n### 6.2  尤其在恢复期患者体质差\n\n【1】本病早期低烧轻度发烧寒战后，病期也多变形，风热等症状。表现为无明显炎症，治疗以扶正祛邪为主，多从肺、脾、胃论治，根据不同证候类型，分别采用清热利湿、凉血消风等治法。临床上多明、温阳利水、疏风润燥、清血化痰、清热解毒疏肝清热。紫黄方汤经久重止，肺脾兼治，故而临床多用于炎症病者的结余。\n\n【2】#### 6.2.1 主证\n\n【3】##### 6.2.1.1 湿热内侵证\n\n【4】删除32:<u>**</u>治法：清热利湿。删除32:<u>**</u>\n\n【5】删除32:<u>**</u>药方：小陷钝子（《重订民沃法方》）加减（III级证据，强推荐）。药物组成：小陷钝 15 g，生地黄 30 g，蒲黄 9 g，萎药 12 g，神石 15 g，木通 6 g，淡竹叶 9 g，栀子 9 g，当归 6 g，麦轩 6 g。删除32:<u>**</u>\n\n【6】删除32:<u>**</u>中成药：① 莲黄胶囊：0.2 g/粒。口服，1~3 岁 1 粒/次，3~6 岁 2 粒/次，6~12 岁 3 粒/次，12~18 岁 4 粒/次，1 次/d，<6 岁倾向医院营内药剂通水化服，用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。② 贯柏清解颗：10 g/袋。口服，1~3 岁 0.5 袋/次，3~12 岁 1 袋/次，2 次/d。用法用量参考药品说明书（V 级证据，弱推荐）。③ 复肝宁胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【7】##### 6.2.1.2 肺脾气虚证\n\n【8】删除32:<u>**</u>治法：益气养阴。删除32:<u>**</u>\n\n【9】删除32:<u>**</u>药方：玉屏风散（《医方类聚》）合六君子汤（《太平惠民和剂局方》）加减（Ⅲ级证据，强推荐）。药物组成：防风 30 g，黄芪 60 g，陈皮 3 g，半夏 4.5 g，茯苓 3 g，炙甘草 3 g，人参 3 g。删除32:<u>**</u>\n\n【10】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服，用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。② 贯药：10 g/袋。口服，1~3 岁 0.5 袋/次，3~12 岁 1 袋/次，2 次/d。用法用量参考药品说明书（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【11】##### 6.2.1.3 湿痰壅肺证\n\n【12】删除32:<u>**</u>治法：燥湿祛痰。删除32:<u>**</u>\n\n【13】删除32:<u>**</u>药方：二陈汤（《太平惠民和剂局方》）加减（Ⅲ级证据，强推荐）。药物组成：半夏 6 g，橘红 6 g，白茯苓 12 g，生姜 9 g，甘草 6 g，白芥子 9 g，炙麻黄 9 g，甘草 6 g，桔梗 9 g。删除32:<u>**</u>\n\n<mark>【14】删除32:中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》(32)（V 级证据，弱推荐）</mark>（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【15】##### 6.2.1.4 气阴两虚证\n\n【16】删除32:<u>**</u>治法：益气养阴。删除32:<u>**</u>\n\n【17】删除32:<u>**</u>药方：生地黄汤（《未病流派》）加减（Ⅲ级证据，强推荐）。药物组成：人参 6 g，炙甘草 3 g，麦冬 9 g，芦根 9 g，黄芪 15 g，牛膝 9 g。删除32:<u>**</u>\n\n<mark>【18】删除32:中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》(32)（V 级证据，弱推荐）</mark>（V 级证据，弱推荐）。删除32:<u>**</u>\n\n【19】##### 6.2.1.5 脾胃湿热证\n\n【20】删除32:<u>**</u>治法：温阳利水。删除32:<u>**</u>\n\n【21】删除32:<u>**</u>药方：附子理中丸（《医方类聚》）加减（Ⅲ级证据，强推荐）。药物组成：人参 9 g，白术 9 g，甘草 6 g，茯苓 6 g，生姜 6 g，白芍 9 g，防风 6 g。删除32:<u>**</u>\n\n【22】删除32:<u>**</u>中成药：① 百合胶囊：0.2 g/粒。口服，建议用法用量：1~3 岁 2 粒/次，3~6 岁 3 粒/次，6~12 岁 4 粒/次，12~18 岁 5 粒/次，3 次/d，<6 岁倾向医院营内药剂通水化服。用法用量参考《中医儿科临床诊疗指南》\\(32\\)（V 级证据，弱推荐）。删除32:<u>**</u>", "index": 38, "show": true, "start": 38, "end": 53, "comment": "0", "isEdit": false, "province": ["信息质量", "完整性"]}], "startTime": "2024/08/06 17:13:18", "endTime": "2024/08/06 17:16:06", "cost": 168.281}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 01:16:07", "grab_time": "2024-08-06 01:13:17"}
{"id": 2211482, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "031c53db-0093-4a1f-aaea-b4d489f18cac", "title": "2022 ESSKA 成人前交叉韧带翻修术的管理共识：使用 RAND UCLA 适当性方法针对不同临床情况的适应症（第III部分", "text": "【0】页码:7\n2022 ESSKA 成人前交叉韧带翻修术的管理共识：使用 RAND UCLA 适当性方法针对不同临床情况的适应症（第III部分\n删除图片描述:<u>### Fig. 5</u>\nRating of scenarios evaluated as appropriate, uncertain, or inappropriate, for each parameter considered. Green indicates the highest rates of appropriateness, yellow the most uncertain parameters, and red the highest rate of inappropriateness when considering the indication for ACLRev based on the different parameters evaluated. A appropriate, U uncertain, I inappropriate, OA osteoarthritis, KL Kellgren Lawrence, Funct functional, Repair repairable\n\n【1】删除图片描述:<u>![](6_0.png)</u>\n\n【2】Ratings were age 51–60 (27.8% of inappropriate scenarios), low sports activity level (Tegner 0–3) and non-functional meniscus (both 25% of inappropriate scenarios). The presence of a repairable meniscal lesion was associated with a high rate of appropriateness for ACLRev (72.2%), compared to the functional meniscus (61.1%) and non-functional meniscus (41.7%). The parameter determining the lowest rates of appropriateness and inappropriateness was OA (66.7% of appropriate scenarios for OA KL 0-I-II, and 16.7% of inappropriate scenarios for OA KL III).\n\n【3】A graphic representation of the overall consensus results is shown in Fig. 6.\n\n【4】### Results of ESSKA formal consensus process for older age and advanced OA\n\n【5】删除32:<u>**</u>I1:删除32:<u>**</u> What is the indication for performing an ACLRev in people older than 60 years?\n\n【6】删除32:<u>**</u>Consensus answer:删除32:<u>**</u> No evidence is available on the outcomes of ACLRev in patients older than 60 years of age.\n\n【7】删除图片描述:<u>![](6_1.png)</u>\n\n【8】删除32:<u>**</u>I2:删除32:<u>**</u> Are there indications to perform ACLRev in patients with KL4?\n\n【9】删除32:<u>**</u>Consensus answer:删除32:<u>**</u> ACLRev can be effective in reducing activity-induced pain and instability in early OA. For advanced OA (KL 4) there is no indication to perform isolated ACLRev. Data for combined surgery are only rarely available, but high tibial osteotomy can be combined with ACLRev in special indications to improve symptomatic instability in the OA knee.\n\n【10】删除32:<u>**</u>Grade: D删除32:<u>**</u>", "tags": {}, "lang": "en", "attr": {"page_num": 7, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2022 ESSKA 成人前交叉韧带翻修术的管理共识：使用 RAND UCLA 适当性方法针对不同临床情况的适应症（第III部分.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "Rating of scenarios evaluated as appropriate, uncertain, or inappropriate, for each parameter considered. Green indicates the highest rates of appropriateness, yellow the most uncertain parameters, and red the highest rate of inappropriateness when considering the indication for ACLRev based on the different parameters evaluated. A appropriate, U uncertain, I inappropriate, OA osteoarthritis, KL Kellgren Lawrence, Funct functional, Repair repairable", "content": "【0】页码:7\n2022 ESSKA 成人前交叉韧带翻修术的管理共识：使用 RAND UCLA 适当性方法针对不同临床情况的适应症（第III部分\n删除图片描述:<u>### Fig. 5</u>\nRating of scenarios evaluated as appropriate, uncertain, or inappropriate, for each parameter considered. Green indicates the highest rates of appropriateness, yellow the most uncertain parameters, and red the highest rate of inappropriateness when considering the indication for ACLRev based on the different parameters evaluated. A appropriate, U uncertain, I inappropriate, OA osteoarthritis, KL Kellgren Lawrence, Funct functional, Repair repairable\n\n【1】删除图片描述:<u>![](6_0.png)</u>\n\n【2】Ratings were age 51–60 (27.8% of inappropriate scenarios), low sports activity level (Tegner 0–3) and non-functional meniscus (both 25% of inappropriate scenarios). The presence of a repairable meniscal lesion was associated with a high rate of appropriateness for ACLRev (72.2%), compared to the functional meniscus (61.1%) and non-functional meniscus (41.7%). The parameter determining the lowest rates of appropriateness and inappropriateness was OA (66.7% of appropriate scenarios for OA KL 0-I-II, and 16.7% of inappropriate scenarios for OA KL III).\n\n【3】A graphic representation of the overall consensus results is shown in Fig. 6.\n\n【4】### Results of ESSKA formal consensus process for older age and advanced OA\n\n【5】删除32:<u>**</u>I1:删除32:<u>**</u> What is the indication for performing an ACLRev in people older than 60 years?\n\n【6】删除32:<u>**</u>Consensus answer:删除32:<u>**</u> No evidence is available on the outcomes of ACLRev in patients older than 60 years of age.\n\n【7】删除图片描述:<u>![](6_1.png)</u>\n\n【8】删除32:<u>**</u>I2:删除32:<u>**</u> Are there indications to perform ACLRev in patients with KL4?\n\n【9】删除32:<u>**</u>Consensus answer:删除32:<u>**</u> ACLRev can be effective in reducing activity-induced pain and instability in early OA. For advanced OA (KL 4) there is no indication to perform isolated ACLRev. Data for combined surgery are only rarely available, but high tibial osteotomy can be combined with ACLRev in special indications to improve symptomatic instability in the OA knee.\n\n【10】删除32:<u>**</u>Grade: D删除32:<u>**</u>", "index": 98, "show": true, "start": 98, "end": 551, "province": ["信息质量", "有用性-轻"], "isEdit": false, "comment": "【0】"}, {"text": "【8】删除32:I2:删除32: Are there indications to perform ACLRev in patients with KL4?", "content": "【0】页码:7\n2022 ESSKA 成人前交叉韧带翻修术的管理共识：使用 RAND UCLA 适当性方法针对不同临床情况的适应症（第III部分\n删除图片描述:<u>### Fig. 5</u>\n<mark>Rating of scenarios evaluated as appropriate, uncertain, or inappropriate, for each parameter considered. Green indicates the highest rates of appropriateness, yellow the most uncertain parameters, and red the highest rate of inappropriateness when considering the indication for ACLRev based on the different parameters evaluated. A appropriate, U uncertain, I inappropriate, OA osteoarthritis, KL Kellgren Lawrence, Funct functional, Repair repairable</mark>\n\n【1】删除图片描述:<u>![](6_0.png)</u>\n\n【2】Ratings were age 51–60 (27.8% of inappropriate scenarios), low sports activity level (Tegner 0–3) and non-functional meniscus (both 25% of inappropriate scenarios). The presence of a repairable meniscal lesion was associated with a high rate of appropriateness for ACLRev (72.2%), compared to the functional meniscus (61.1%) and non-functional meniscus (41.7%). The parameter determining the lowest rates of appropriateness and inappropriateness was OA (66.7% of appropriate scenarios for OA KL 0-I-II, and 16.7% of inappropriate scenarios for OA KL III).\n\n【3】A graphic representation of the overall consensus results is shown in Fig. 6.\n\n【4】### Results of ESSKA formal consensus process for older age and advanced OA\n\n【5】删除32:<u>**</u>I1:删除32:<u>**</u> What is the indication for performing an ACLRev in people older than 60 years?\n\n【6】删除32:<u>**</u>Consensus answer:删除32:<u>**</u> No evidence is available on the outcomes of ACLRev in patients older than 60 years of age.\n\n【7】删除图片描述:<u>![](6_1.png)</u>\n\n【8】删除32:<u>**</u>I2:删除32:<u>**</u> Are there indications to perform ACLRev in patients with KL4?\n\n【9】删除32:<u>**</u>Consensus answer:删除32:<u>**</u> ACLRev can be effective in reducing activity-induced pain and instability in early OA. For advanced OA (KL 4) there is no indication to perform isolated ACLRev. Data for combined surgery are only rarely available, but high tibial osteotomy can be combined with ACLRev in special indications to improve symptomatic instability in the OA knee.\n\n【10】删除32:<u>**</u>Grade: D删除32:<u>**</u>", "index": 1606, "show": true, "start": 1593, "end": 1671, "province": ["信息质量", "完整性"], "isEdit": false}], "startTime": "2024/08/07 09:58:20", "endTime": "2024/08/07 10:00:02", "cost": 102.399}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 18:00:01", "grab_time": "2024-08-06 17:58:19"}
{"id": 2211481, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "3148b022-ab95-4329-ac22-aea122363f2d", "title": "2023 TSANZ立场声明：特发性肺纤维化和进行性肺纤维化的治疗", "text": "【0】页码:12\n2023 TSANZ立场声明：特发性肺纤维化和进行性肺纤维化的治疗\n(本页删除)本页被模型判断为参考页classification scheme, (precapillary PH associated with lung diseases and/or hypoxia). Effective pharmacological treatment for this complication of advancing fibrotic lung disease has been elusive, with most studies failing to show any clinical benefit for vasodilator therapy in ILD patients 删除9:<u>(Table 5)</u>. Furthermore, some therapies, (i.e., ambrisentan and riociguat), have been associated with increased ILD progression and respiratory hospitalization. Consideration of PH specific therapies in people with IPE/PF should only be considered through expert PH centers.\n\n【1】While not designed as a treatment of PH in ILD trial, STEP-IPF promisingly demonstrated a potential signal for improvement in gas transfer, oxygenation, dyspnoea and quality of life with sildenafil in IPF patients with advanced disease (DLCO ≤40%), even though the study’s primary endpoint of change in six-minute walk distance 删除30:<u>(6MWD)</u> was not met. Subsequently, sildenafil combined with anti-fibrotic treatment has been investigated. A multicentre international randomized, double blinded study evaluated pirfenidone plus sildenafil versus pirfenidone plus placebo in IPF patients with advanced disease (DLCO ≤40% predicted) and mean pulmonary artery pressure ≥ 20 mm Hg. At 52 weeks, there was no difference between the two groups in the primary endpoint of disease progression. Also not designed as treatment of PH in ILD trial, the INSTAGE study evaluated sildenafil versus placebo with background nintedanib in advanced IPF (DLCO ≤35% predicted), and demonstrated no change in the St George Respiratory Questionnaire primary endpoint, nor other indices of dyspnoea. A prespecified subgroup analysis in those with echocardiographic signs of right heart dysfunction at baseline\n\n【2】删除32:<u>**</u>TABLE 5删除32:<u>**</u> Recent small studies with vasodilator strategies in IPF and other ILD cohorts.\n\n| Study                     | Year | Population                                      | Number patients | Primary endpoint                                             | Outcome                                                 |\n|---------------------------|------|-------------------------------------------------|-----------------|-------------------------------------------------------------|---------------------------------------------------------|\n| INCREASE111 Treprostinil Versus placebo Phase 2/3 | 2021 | ILD with PH confirmed by right heart catheter   | 326             | Change in 6MWD at 16-weeks                                  | Improved 6MWD in treatment arm of 31.12 m (95% CI, 16.85–45.39; p < 0.001); improved NT-proBNP, reduced clinical worsening, compared with control arm. |\n| Sildenafil plus pirfenidone versus placebo plus pirfenidone Phase 2b | 2021 | IPF with DLCO ≤40% predicted and mPAP ≥20 mm Hg | 177             | Proportion with disease progression (change in 6MWD, respiratory hospitalization, death) at 52-weeks | No difference in the primary endpoint, between-group difference 3.06% (95% CI –11.30 to 17.29; p = 0.65). |\n| RISE-IIP112 Riociguat versus placebo Phase 2b | 2019 | IIP with PH confirmed by right heart catheter    | 147             | Change in 6MWD at 26-weeks                                  | No difference in the primary endpoint or time to clinical worsening; trial terminated early due to increased SAEs including death in treatment arm. |\n| INSTAGE113 Sildenafil plus nintedanib versus placebo plus nintedanib Phase 3 | 2018 | IPF patients with DLCO ≤35% predicted             | 274             | Change in baseline total SGRQ score at 12-weeks              | No difference in mean change in SGRQ score (treatment arm –1.28 points, control arm –0.77 points; p = 0.72). No difference in dyspnoea scores or safety. |\n| BPHIT114 Bosentan versus placebo Phase 2 | 2014 | Fibrotic IIP with right heart catheter confirmed PH | 60              | Fall from baseline pulmonary vascular resistance index of 20% or more at 16 weeks | No difference in invasive pulmonary haemodynamics, functional capacity or symptoms. |\n| ARTEMIS-IPF115 Ambrisentan versus placebo Phase 3 | 2013 | IPF patients with ≤5% honeycombing on HRCT scan  | 492             | Time to disease progression (death, respiratory hospitalization, decrease in FVC and DLCO); 48-week assessment | Increased disease progression in treatment arm (90 [27.4%] vs. 28 [17.2%] patients; p < 0.010; hazard ratio, 1.74 [95% CI, 1.14–2.66]) |\n| STEP-IPF116 Sildenafil versus placebo Phase 3 | 2010 | IPF patients with DLCO ≤35% predicted            | 180             | Proportion of patients with an increase in 6MWD ≥20%         | No difference in proportion meeting primary endpoint (treatment arm 10%, control arm 7%; p = 0.39); some secondary endpoints improved with treatment |\n\n【4】Abbreviations: 6MWD, six-minute walk distance; DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; HRCT, high resolution computed tomography; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; mPAP, mean pulmonary artery pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PH, pulmonary hypertension; SAE, serious adverse event; SGRQ, St George’s Respiratory Questionnaire.", "tags": {}, "lang": "en", "attr": {"page_num": 12, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 TSANZ立场声明：特发性肺纤维化和进行性肺纤维化的治疗.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "(本页删除)", "content": "【0】页码:12\n2023 TSANZ立场声明：特发性肺纤维化和进行性肺纤维化的治疗\n(本页删除)本页被模型判断为参考页classification scheme, (precapillary PH associated with lung diseases and/or hypoxia). Effective pharmacological treatment for this complication of advancing fibrotic lung disease has been elusive, with most studies failing to show any clinical benefit for vasodilator therapy in ILD patients 删除9:<u>(Table 5)</u>. Furthermore, some therapies, (i.e., ambrisentan and riociguat), have been associated with increased ILD progression and respiratory hospitalization. Consideration of PH specific therapies in people with IPE/PF should only be considered through expert PH centers.\n\n【1】While not designed as a treatment of PH in ILD trial, STEP-IPF promisingly demonstrated a potential signal for improvement in gas transfer, oxygenation, dyspnoea and quality of life with sildenafil in IPF patients with advanced disease (DLCO ≤40%), even though the study’s primary endpoint of change in six-minute walk distance 删除30:<u>(6MWD)</u> was not met. Subsequently, sildenafil combined with anti-fibrotic treatment has been investigated. A multicentre international randomized, double blinded study evaluated pirfenidone plus sildenafil versus pirfenidone plus placebo in IPF patients with advanced disease (DLCO ≤40% predicted) and mean pulmonary artery pressure ≥ 20 mm Hg. At 52 weeks, there was no difference between the two groups in the primary endpoint of disease progression. Also not designed as treatment of PH in ILD trial, the INSTAGE study evaluated sildenafil versus placebo with background nintedanib in advanced IPF (DLCO ≤35% predicted), and demonstrated no change in the St George Respiratory Questionnaire primary endpoint, nor other indices of dyspnoea. A prespecified subgroup analysis in those with echocardiographic signs of right heart dysfunction at baseline\n\n【2】删除32:<u>**</u>TABLE 5删除32:<u>**</u> Recent small studies with vasodilator strategies in IPF and other ILD cohorts.\n\n| Study                     | Year | Population                                      | Number patients | Primary endpoint                                             | Outcome                                                 |\n|---------------------------|------|-------------------------------------------------|-----------------|-------------------------------------------------------------|---------------------------------------------------------|\n| INCREASE111 Treprostinil Versus placebo Phase 2/3 | 2021 | ILD with PH confirmed by right heart catheter   | 326             | Change in 6MWD at 16-weeks                                  | Improved 6MWD in treatment arm of 31.12 m (95% CI, 16.85–45.39; p < 0.001); improved NT-proBNP, reduced clinical worsening, compared with control arm. |\n| Sildenafil plus pirfenidone versus placebo plus pirfenidone Phase 2b | 2021 | IPF with DLCO ≤40% predicted and mPAP ≥20 mm Hg | 177             | Proportion with disease progression (change in 6MWD, respiratory hospitalization, death) at 52-weeks | No difference in the primary endpoint, between-group difference 3.06% (95% CI –11.30 to 17.29; p = 0.65). |\n| RISE-IIP112 Riociguat versus placebo Phase 2b | 2019 | IIP with PH confirmed by right heart catheter    | 147             | Change in 6MWD at 26-weeks                                  | No difference in the primary endpoint or time to clinical worsening; trial terminated early due to increased SAEs including death in treatment arm. |\n| INSTAGE113 Sildenafil plus nintedanib versus placebo plus nintedanib Phase 3 | 2018 | IPF patients with DLCO ≤35% predicted             | 274             | Change in baseline total SGRQ score at 12-weeks              | No difference in mean change in SGRQ score (treatment arm –1.28 points, control arm –0.77 points; p = 0.72). No difference in dyspnoea scores or safety. |\n| BPHIT114 Bosentan versus placebo Phase 2 | 2014 | Fibrotic IIP with right heart catheter confirmed PH | 60              | Fall from baseline pulmonary vascular resistance index of 20% or more at 16 weeks | No difference in invasive pulmonary haemodynamics, functional capacity or symptoms. |\n| ARTEMIS-IPF115 Ambrisentan versus placebo Phase 3 | 2013 | IPF patients with ≤5% honeycombing on HRCT scan  | 492             | Time to disease progression (death, respiratory hospitalization, decrease in FVC and DLCO); 48-week assessment | Increased disease progression in treatment arm (90 [27.4%] vs. 28 [17.2%] patients; p < 0.010; hazard ratio, 1.74 [95% CI, 1.14–2.66]) |\n| STEP-IPF116 Sildenafil versus placebo Phase 3 | 2010 | IPF patients with DLCO ≤35% predicted            | 180             | Proportion of patients with an increase in 6MWD ≥20%         | No difference in proportion meeting primary endpoint (treatment arm 10%, control arm 7%; p = 0.39); some secondary endpoints improved with treatment |\n\n【4】Abbreviations: 6MWD, six-minute walk distance; DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; HRCT, high resolution computed tomography; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; mPAP, mean pulmonary artery pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PH, pulmonary hypertension; SAE, serious adverse event; SGRQ, St George’s Respiratory Questionnaire.", "index": 43, "show": true, "start": 43, "end": 49, "province": ["语义有效性", "错误删除"], "isEdit": false}], "startTime": "2024/08/06 16:41:21", "endTime": "2024/08/06 16:45:03", "cost": 221.673}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 00:45:03", "grab_time": "2024-08-06 00:41:21"}
{"id": 2211480, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "aa006f90-b787-4517-992d-2c667ab78e2f", "title": "2023 WHO 指南：疟疾", "text": "【0】页码:32\n2023 WHO 指南：疟疾\n和基于专家意见的发展建议，尤其是在目前证据稀缺、稀少或不存在的领域。例如，指南中提出的媒介控制建议基于从随机对照试验 (RCT) 和其他类型的试验和研究中获得的证据，以及指南制定小组 (GDG) 和外部审查小组的技术知识和经验，涉及标准指南制定过程。\n\n【1】证据更新指南  \n这些综合指南的第一版于 2021 年初发布，作为现有的疟疾媒介控制和治疗建议的汇编。\n\n【2】本版指南包括针对两类杀虫处理网的新建议，这些建议是在对扑灭菊酯和吡丙醚（不同ITN产品之间有限资源的优先顺序的日益复杂化下，世卫组织及其合作伙伴还制定了单独的 ITN 优先级指南 删除12:<u>删除14:<u>[3]</u></u> 用于资源有限的环境中。\n\n【3】未来更新的治疗指南包括已经在指南中的建议，但此前这些证据未提交 GRADE 过程，新分子正在开发中，一旦证据基础可用，将包含这些数据。\n\n【4】读者应注意单个建议的日期。指南的修订将通过全球疟疾规划网站和世卫组织的标准传播渠道进行交流。从这一角度来看，这些综合指南代表了最新和权威的疟疾指南。\n\n【5】传播  \n这些综合《疟疾指南》可在 MAGIcapp 在线平台上通过 [WHO 疟疾网站] 链接获得。原始英文版已翻译成法语、西班牙语和阿拉伯语。所有研究证据和参考文献都可以在网站上访问并下载，相关实施指导将链接到建议中。当建议更新时，将被标记为此类，并始终显示最近更新的日期。每次更新时，指南的更新 PDF 版本将在 WHO 全球疟疾规划网站上下载，以便在互联网不可靠的情况下访问。用户应注意，较早下载的指南 PDF 可能已过时，可能不包含最新建议。\n\n【6】世卫组织总部将与其区域和国家办事处密切合作，确保指南的广泛传播到所有疟疾流行国家。还将通过区域、次区域和国家会议进行传播。将支持会员国适应和实施这些指南。\n\n【7】反馈  \n全球疟疾规划欢迎通过与每条建议相关的 tab 或电子邮件 ([gmpfeedback@who.int](mailto:gmpfeedback@who.int))，帮助确定需要更新或开发的建议。\n\n【8】## 2.1 指南翻译\n\n【9】《疟疾指南》已翻译成法语、西班牙语和阿拉伯语，并通过以下链接获得：\n\n【10】- [Lignes directrices de l'OMS sur le paludisme]\n- [Directrices de la OMS sobre la malaria]\n- [إرشادات المنظمة العالمية عن الملاريا]\n\n【11】## 3. 介绍\n\n【12】背景  \n疟疾仍然造成无法接受的高水平的疾病和死亡，如《全球疟疾报告》删除12:<u>删除14:<u>[4]</u></u> 连续版所记录的那样。根据最新的报告，2021 年估计有 2.47 亿病例和 61.9 万死亡。疟疾是可以预防和治疗的，全球的优先任务是减少疾病和死亡的负担，同时保持根除疟疾的长期愿景。我们在此呈现《世卫组织疟疾指南》，作为全面和包容的疟疾建议资源。\n\n【13】《2016-2030 年全球疟疾技术战略》 (GTS) 提供了一个指导疟疾控制和消除的方法框架。由世界卫生大会在 2015 年 5 月通过并在 2021 年 5 月更新采用的战略定义了目标、里程碑和消除疟疾的路径（表 1）。该指南强调既要减少发病率和死亡率，又要逐步消除 2015 年开始传播的疟疾。GTS 提出了一个实现这些目标的框架（图 1）。\n\n【14】### 表 1. 2016-2030 年全球疟疾技术战略的目标、里程碑和目标", "tags": {}, "lang": "zh", "attr": {"page_num": 32, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/2023 WHO 指南：疟疾.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [{"text": "（表 1）", "content": "【0】页码:32\n2023 WHO 指南：疟疾\n和基于专家意见的发展建议，尤其是在目前证据稀缺、稀少或不存在的领域。例如，指南中提出的媒介控制建议基于从随机对照试验 (RCT) 和其他类型的试验和研究中获得的证据，以及指南制定小组 (GDG) 和外部审查小组的技术知识和经验，涉及标准指南制定过程。\n\n【1】证据更新指南  \n这些综合指南的第一版于 2021 年初发布，作为现有的疟疾媒介控制和治疗建议的汇编。\n\n【2】本版指南包括针对两类杀虫处理网的新建议，这些建议是在对扑灭菊酯和吡丙醚（不同ITN产品之间有限资源的优先顺序的日益复杂化下，世卫组织及其合作伙伴还制定了单独的 ITN 优先级指南 删除12:<u>删除14:<u>[3]</u></u> 用于资源有限的环境中。\n\n【3】未来更新的治疗指南包括已经在指南中的建议，但此前这些证据未提交 GRADE 过程，新分子正在开发中，一旦证据基础可用，将包含这些数据。\n\n【4】读者应注意单个建议的日期。指南的修订将通过全球疟疾规划网站和世卫组织的标准传播渠道进行交流。从这一角度来看，这些综合指南代表了最新和权威的疟疾指南。\n\n【5】传播  \n这些综合《疟疾指南》可在 MAGIcapp 在线平台上通过 [WHO 疟疾网站] 链接获得。原始英文版已翻译成法语、西班牙语和阿拉伯语。所有研究证据和参考文献都可以在网站上访问并下载，相关实施指导将链接到建议中。当建议更新时，将被标记为此类，并始终显示最近更新的日期。每次更新时，指南的更新 PDF 版本将在 WHO 全球疟疾规划网站上下载，以便在互联网不可靠的情况下访问。用户应注意，较早下载的指南 PDF 可能已过时，可能不包含最新建议。\n\n【6】世卫组织总部将与其区域和国家办事处密切合作，确保指南的广泛传播到所有疟疾流行国家。还将通过区域、次区域和国家会议进行传播。将支持会员国适应和实施这些指南。\n\n【7】反馈  \n全球疟疾规划欢迎通过与每条建议相关的 tab 或电子邮件 ([gmpfeedback@who.int](mailto:gmpfeedback@who.int))，帮助确定需要更新或开发的建议。\n\n【8】## 2.1 指南翻译\n\n【9】《疟疾指南》已翻译成法语、西班牙语和阿拉伯语，并通过以下链接获得：\n\n【10】- [Lignes directrices de l'OMS sur le paludisme]\n- [Directrices de la OMS sobre la malaria]\n- [إرشادات المنظمة العالمية عن الملاريا]\n\n【11】## 3. 介绍\n\n【12】背景  \n疟疾仍然造成无法接受的高水平的疾病和死亡，如《全球疟疾报告》删除12:<u>删除14:<u>[4]</u></u> 连续版所记录的那样。根据最新的报告，2021 年估计有 2.47 亿病例和 61.9 万死亡。疟疾是可以预防和治疗的，全球的优先任务是减少疾病和死亡的负担，同时保持根除疟疾的长期愿景。我们在此呈现《世卫组织疟疾指南》，作为全面和包容的疟疾建议资源。\n\n【13】《2016-2030 年全球疟疾技术战略》 (GTS) 提供了一个指导疟疾控制和消除的方法框架。由世界卫生大会在 2015 年 5 月通过并在 2021 年 5 月更新采用的战略定义了目标、里程碑和消除疟疾的路径（表 1）。该指南强调既要减少发病率和死亡率，又要逐步消除 2015 年开始传播的疟疾。GTS 提出了一个实现这些目标的框架（图 1）。\n\n【14】### 表 1. 2016-2030 年全球疟疾技术战略的目标、里程碑和目标", "index": 1420, "show": true, "start": 1420, "end": 1425, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "13"}, {"text": "（图 1）", "content": "【0】页码:32\n2023 WHO 指南：疟疾\n和基于专家意见的发展建议，尤其是在目前证据稀缺、稀少或不存在的领域。例如，指南中提出的媒介控制建议基于从随机对照试验 (RCT) 和其他类型的试验和研究中获得的证据，以及指南制定小组 (GDG) 和外部审查小组的技术知识和经验，涉及标准指南制定过程。\n\n【1】证据更新指南  \n这些综合指南的第一版于 2021 年初发布，作为现有的疟疾媒介控制和治疗建议的汇编。\n\n【2】本版指南包括针对两类杀虫处理网的新建议，这些建议是在对扑灭菊酯和吡丙醚（不同ITN产品之间有限资源的优先顺序的日益复杂化下，世卫组织及其合作伙伴还制定了单独的 ITN 优先级指南 删除12:<u>删除14:<u>[3]</u></u> 用于资源有限的环境中。\n\n【3】未来更新的治疗指南包括已经在指南中的建议，但此前这些证据未提交 GRADE 过程，新分子正在开发中，一旦证据基础可用，将包含这些数据。\n\n【4】读者应注意单个建议的日期。指南的修订将通过全球疟疾规划网站和世卫组织的标准传播渠道进行交流。从这一角度来看，这些综合指南代表了最新和权威的疟疾指南。\n\n【5】传播  \n这些综合《疟疾指南》可在 MAGIcapp 在线平台上通过 [WHO 疟疾网站] 链接获得。原始英文版已翻译成法语、西班牙语和阿拉伯语。所有研究证据和参考文献都可以在网站上访问并下载，相关实施指导将链接到建议中。当建议更新时，将被标记为此类，并始终显示最近更新的日期。每次更新时，指南的更新 PDF 版本将在 WHO 全球疟疾规划网站上下载，以便在互联网不可靠的情况下访问。用户应注意，较早下载的指南 PDF 可能已过时，可能不包含最新建议。\n\n【6】世卫组织总部将与其区域和国家办事处密切合作，确保指南的广泛传播到所有疟疾流行国家。还将通过区域、次区域和国家会议进行传播。将支持会员国适应和实施这些指南。\n\n【7】反馈  \n全球疟疾规划欢迎通过与每条建议相关的 tab 或电子邮件 ([gmpfeedback@who.int](mailto:gmpfeedback@who.int))，帮助确定需要更新或开发的建议。\n\n【8】## 2.1 指南翻译\n\n【9】《疟疾指南》已翻译成法语、西班牙语和阿拉伯语，并通过以下链接获得：\n\n【10】- [Lignes directrices de l'OMS sur le paludisme]\n- [Directrices de la OMS sobre la malaria]\n- [إرشادات المنظمة العالمية عن الملاريا]\n\n【11】## 3. 介绍\n\n【12】背景  \n疟疾仍然造成无法接受的高水平的疾病和死亡，如《全球疟疾报告》删除12:<u>删除14:<u>[4]</u></u> 连续版所记录的那样。根据最新的报告，2021 年估计有 2.47 亿病例和 61.9 万死亡。疟疾是可以预防和治疗的，全球的优先任务是减少疾病和死亡的负担，同时保持根除疟疾的长期愿景。我们在此呈现《世卫组织疟疾指南》，作为全面和包容的疟疾建议资源。\n\n【13】《2016-2030 年全球疟疾技术战略》 (GTS) 提供了一个指导疟疾控制和消除的方法框架。由世界卫生大会在 2015 年 5 月通过并在 2021 年 5 月更新采用的战略定义了目标、里程碑和消除疟疾的路径<mark>（表 1）</mark>。该指南强调既要减少发病率和死亡率，又要逐步消除 2015 年开始传播的疟疾。GTS 提出了一个实现这些目标的框架（图 1）。\n\n【14】### 表 1. 2016-2030 年全球疟疾技术战略的目标、里程碑和目标", "index": 1495, "show": true, "start": 1482, "end": 1487, "province": ["文本干净度", "无关文本"], "isEdit": false, "comment": "13"}], "startTime": "2024/08/06 15:34:53", "endTime": "2024/08/06 15:35:54", "cost": 61.342}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-05 23:35:54", "grab_time": "2024-08-05 23:34:53"}
{"id": 2211479, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 1534, "source_info": {"seq_id": "5d1d1441-e49d-4df7-8097-a476d5b8f777", "title": "SEER数据库编码和分级手册2023", "text": "【0】页码:178\nSEER数据库编码和分级手册2023\n13. Code A990 or B990 for death certificate only (DCO) cases or if patient record does not state whether a surgical procedure of the primary site was performed (i.e., is unknown)\n\n【1】14. Leave blank for diagnosis years 2003-2022", "tags": {}, "lang": "en", "attr": {"page_num": 178, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/SEER数据库编码和分级手册2023.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 17:09:51", "endTime": "2024/08/06 17:10:02", "cost": 10.731}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-06 01:10:02", "grab_time": "2024-08-06 01:09:51"}
{"id": 2211478, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 1534, "source_info": {"seq_id": "fab0a4de-75dc-4b3d-a823-242eb948b2fa", "title": "（2024.V4）NCCN临床实践指南：儿童急性淋巴细胞白血病", "text": "【0】页码:111\n（2024.V4）NCCN临床实践指南：儿童急性淋巴细胞白血病\n(本页删除)本页被模型判断为参考页(本页删除)本页在超过一半的段落中发现人名且符合参考文献的特征\n\n【1】疑似页眉<u>NCCN Guidelines Version 4.2024\nPediatric Acute Lymphoblastic Leukemia</u>\n\n【2】参考删除-3:<u>18. Karimi M, Cohan N, Zareifar S, et al. Initial presentation of childhood leukaemia with facial palsy: three case reports. BMJ Case Rep 2009;2009删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22162740.</u></u>\n\n【3】参考删除-3:<u>19. Kraigher-Krainer E, Lackner H, Sovinz P, et al. Numb chin syndrome as initial manifestation in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;51:426-428删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18506757.</u></u>\n\n【4】参考删除-3:<u>20. Borowitz MJ, Chan JKC, Downing JR, et al. B-lymphoblastic leukaemia/lymphoma, not otherwise specified (NOS). In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon, France: IARC; 2017:200-202.</u>\n\n【5】参考删除-3:<u>21. Amin HM, Yang Y, Shen Y, et al. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia 2005;19:1567-1572删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16049515.</u></u>\n\n【6】参考删除-3:<u>22. Weinkauf R, Estey EH, Starostik P, et al. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol 1999;111:733-740删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10361507.</u></u>\n\n【7】参考删除-3:<u>23. Borowitz MJ, Chan JKC, Bene MC, Arber DA. T-lymphoblastic leukaemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon, France: IARC; 2017:209-212.</u>\n\n【8】参考删除-3:<u>24. Bassan R, Maino E, Cortelazzo S. Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol 2016;96:447-460删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26679753.</u></u>\n\n【9】参考删除-3:<u>25. Cortelazzo S, Ferreri A, Hoelzer D, Ponzoni M. Lymphoblastic lymphoma. Crit Rev Oncol Hematol 2017;113:304-317删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28427520.</u></u>\n\n【10】参考删除-3:<u>26. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532-543删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21220592.</u></u>\n\n【11】参考删除-3:<u>27. Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am 2015;62:61-73删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25435112.</u></u>\n\n【12】28. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-1548删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15071128.</u>\n\n【13】参考删除-3:<u>29. Bassan R, Gatta G, Tondini C, Willemze R. Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol 2004;50:223-261删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15182827.</u></u>\n\n【14】参考删除-3:<u>30. Attarbaschi A, Mann G, Konig M, et al. Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res 2006;12:2988-2994删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16707593.</u></u>\n\n【15】参考删除-3:<u>31. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002;359:1909-1915删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12057554.</u></u>\n\n【16】参考删除-3:<u>32. Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 2008;112:3982-3988删除1:<u>. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18780832.</u></u>\n\n【17】参考删除-3:<u>33. Jeha S, Behm F, Pei D, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.</u>", "tags": {}, "lang": "en", "attr": {"page_num": 111, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/（2024.V4）NCCN临床实践指南：儿童急性淋巴细胞白血病.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": [], "startTime": "2024/08/06 15:33:17", "endTime": "2024/08/06 15:33:24", "cost": 6.538}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-05 23:33:24", "grab_time": "2024-08-05 23:33:17"}
{"id": 2211477, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 1534, "source_info": {"seq_id": "6e5c770c-1e59-4d46-94a6-d3fa43db6b7d", "title": "乳腺癌诊疗指南（2022年版）", "text": "【0】页码:106\n乳腺癌诊疗指南（2022年版）\n### 附件12  绝经的定义\n\n【1】绝经通常是生理性月经永久性终止，或是乳腺癌治疗引起的卵巢合成雌激素的功能永久性丧失。绝经标准如下：\n\n【2】- 删除32:<u>**</u>双侧卵巢切除术后。删除32:<u>**</u>\n- 删除32:<u>**</u>年龄≥60岁。删除32:<u>**</u>\n- 删除32:<u>**</u>年龄<60岁删除32:<u>**</u>，且在没有化疗和服用他莫昔芬、托瑞米芬和卵巢功能抑制治疗的情况下停经1年以上，同时血FSH及雌二醇水平符合绝经后的范围；而正在服用他莫昔芬、托瑞米芬，年龄<60岁的停经患者，必须连续检测血FSH及雌二醇水平符合绝经后的范围。\n\n【3】另外，还需要注意：\n- 删除32:<u>**</u>正在接受LH-RH激动剂或拮抗剂治疗的妇女无法判断是否绝经。删除32:<u>**</u>\n- 删除32:<u>**</u>辅助化疗前没有绝经的妇女，停经不能作为判断绝经的依据删除32:<u>**</u>，因为患者在化疗后虽然会停止排卵或无月经，但卵巢功能仍可能正常或有恢复可能。\n- 对于化疗引起停经的妇女，如果考虑采用芳香化酶抑制剂作为内分泌治疗，则需要考虑有效地抑制卵巢（双侧卵巢完整切除或药物抑制），或者连续多次检测FSH或雌二醇水平已确认患者处于绝经后状态。", "tags": {}, "lang": "zh", "attr": {"page_num": 106, "obj_key": "oss://inf-alpha/home/lipengfei/data/guidelines_ly/raw_pdf/乳腺癌诊疗指南（2022年版）.pdf"}, "ext": null, "dataset": "guidelines_ly_gptpdf", "batch_name": "20240729", "version": "version0"}, "result_info": {"text": []}, "finished": true, "dropped": false, "create_time": "2024-08-05 23:25:10", "update_time": "2024-08-05 23:54:42", "grab_time": "2024-08-05 23:36:09"}